<SEC-DOCUMENT>0000899923-23-000011.txt : 20230301
<SEC-HEADER>0000899923-23-000011.hdr.sgml : 20230301
<ACCEPTANCE-DATETIME>20230301082528
ACCESSION NUMBER:		0000899923-23-000011
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		116
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230301
DATE AS OF CHANGE:		20230301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MYRIAD GENETICS INC
		CENTRAL INDEX KEY:			0000899923
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				870494517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26642
		FILM NUMBER:		23689886

	BUSINESS ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
		BUSINESS PHONE:		801-584-3600

	MAIL ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mygn-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:6db69074-e648-4be3-ae6d-ea77b2ae08c9,g:6dbaf31c-e8bf-47fc-986c-d695276c3aba,d:7e0793090cf84227944277d460d39a4d--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:mygn="http://www.myriad.com/20221231" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mygn-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF80L2ZyYWc6MDc2YzIxZWQ4YzlmNGFmZjk5ZjE4Nzk1NWVhY2RhNGMvdGFibGU6OTM5OTNmNDVkYzcyNDA4YTkxZmNhMTczZGM4YTQyMjQvdGFibGVyYW5nZTo5Mzk5M2Y0NWRjNzI0MDhhOTFmY2ExNzNkYzhhNDIyNF80LTEtMS0xLTExOTQ4Mg_9e6da5c2-1a1e-4a6f-98e6-500b91c39f37">false</ix:nonNumeric><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF80L2ZyYWc6MDc2YzIxZWQ4YzlmNGFmZjk5ZjE4Nzk1NWVhY2RhNGMvdGFibGU6OTM5OTNmNDVkYzcyNDA4YTkxZmNhMTczZGM4YTQyMjQvdGFibGVyYW5nZTo5Mzk5M2Y0NWRjNzI0MDhhOTFmY2ExNzNkYzhhNDIyNF81LTEtMS0xLTExOTQ4Mg_367f6a40-3641-47b5-9323-cd9325224223">2022</ix:nonNumeric><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF80L2ZyYWc6MDc2YzIxZWQ4YzlmNGFmZjk5ZjE4Nzk1NWVhY2RhNGMvdGFibGU6OTM5OTNmNDVkYzcyNDA4YTkxZmNhMTczZGM4YTQyMjQvdGFibGVyYW5nZTo5Mzk5M2Y0NWRjNzI0MDhhOTFmY2ExNzNkYzhhNDIyNF82LTEtMS0xLTExOTQ4Mg_0ba702f8-bdf7-474c-98d6-260f9749022a">FY</ix:nonNumeric><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF80L2ZyYWc6MDc2YzIxZWQ4YzlmNGFmZjk5ZjE4Nzk1NWVhY2RhNGMvdGFibGU6OTM5OTNmNDVkYzcyNDA4YTkxZmNhMTczZGM4YTQyMjQvdGFibGVyYW5nZTo5Mzk5M2Y0NWRjNzI0MDhhOTFmY2ExNzNkYzhhNDIyNF83LTEtMS0xLTExOTQ4Mg_5aafb855-4b47-4efe-b6fd-ff3ee89e6c7c">0000899923</ix:nonNumeric><ix:nonNumeric contextRef="i6fc8057f2387410d80b503300dd4c3c9_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfODUzMw_6379236e-7018-4cbe-9f98-2974e673bf30">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i27f9832c214f44bfb3307e6c592c3894_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfODY3Nw_ce7f7168-4bc2-4449-b270-c38ee0a58400">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="id126768d0af64211a663a5ba94eb3c2c_I20221231" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzE4MA_55b83f90-88ae-4e25-9b41-229696ec6103">P1Y</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzYvZnJhZzo5OGVmNDA3YmY4OWM0NzlmOTJlMzIwMmRlYmEzMGY3Mi90ZXh0cmVnaW9uOjk4ZWY0MDdiZjg5YzQ3OWY5MmUzMjAyZGViYTMwZjcyXzMy_2096e0ca-861b-4248-b81f-591a49b41118">1</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mygn-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f732cf8e70f4da79cc772ea647eba95_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i3b8e0501187143259a1544d7c2a53414_I20230223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ifb254f1abbe54bc896976a7ef3e19442_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29d9f082f6304b3c901b8a69a382c99f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i308b88139f674cb09b58fa82ee43d092_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i794c44e7bf5b45689f334a7dc2a6cc11_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i543bcad925584a75897772999efa4e3e_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc254773edfa4835899bcbe4c0b57775_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bb3d6305f96409c9f4239ce2e6f890c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i934fd4ad46814c4e88f3d8113c493def_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i329f9f45afc549329c841d2e34c6be5d_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f216fe61ee54eeab8ab464958d1e5bb_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08037acddedf4c3da96bc71cd005937c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia45b75059eff4573892e8f756ab08faf_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if291edff4ba84c7e9d38f402671ad107_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb0d838f44dc45f69885b845511ca96e_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if96afdd71e74449aa558f9c0f8968925_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie25ada1ec48a4df091a03bd92db62e3f_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i096822e4050c4c89aecf816ec0a1d89f_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9a92e11e87c4f21a1205b712b3e7a98_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie36c513fa3954843802b82eee7bd4d66_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1006f75c61d2402e941a615d921b10a0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7925e43c913402583ad8467548fcdd9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34a7c6b200aa410a99aba1eb920e920b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideeefc606008446e85d0fd21a9515813_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf7c181e8dc344e5a21614f9c861ac4e_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0799c2a014e447128b2001beef5c11fb_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d4b33f1ee7a42a89b6ffb0a263cc108_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabdc282dcf2544e6a44fbcf258a6191b_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3e0eff6e7f44b0e9bfbf56d9460dba8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide959bef58984d0c800d66085fe2ee2e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aa3dfbc1c6545a0b140ae9c08b0c24b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9056eb749ddd4517883d1f3860b7f895_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id83f26d989d54298a0d5f2d84eba7095_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f2f31965b52467a95929f7baa16f7d7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if31c2aa3a1bd42508fa6f5053cec3008_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d7ca27f075d4f19be69a74e81087fd1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbacf682032e4d0d92179fdcbdcc44c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcbf5fe2793a4a75ace02762c09dba60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07ccaab8fd444e1e96d9d0b927e5739d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82f354105f424032836cdf535b931213_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3575a755df04fc38d5dbd355577687f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie86ab0c9deac4c1cb5e311bc6ccc3e05_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4cbbd0e273544ccb20f9d106126ecc3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i368576ec62ee45cca0320cd56f18e01f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f255485789b4a73b043e3b00f87031c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5215658c5cd475abde0249738d23319_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic40f1f5963e54a2cbe900fef28214a42_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6915ee2f4e247fea81a5a54115ece38_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i87dfdf9848204b5bb02322c598155b03_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41f829e207b542b5b614a6ac506833bf_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec639d3cfaee463ba8e594bc6bb5ce4b_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fc8057f2387410d80b503300dd4c3c9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a04aadd840a46c4a950e132f342709c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27f9832c214f44bfb3307e6c592c3894_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d40dec02733475a840d3032148ea124_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id126768d0af64211a663a5ba94eb3c2c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fa41121b7d143cfbc8e91a9ced3020a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4321aa8ac0974d02ac5b95ed298d955b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fe93ba93efe459db6badb7752b80b87_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7ae454902ce4cceb0fb07cad24d3c8c_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0152bd259b6948b0bc3b7e357d1fc445_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e94095aa8954df29cb417ee209e2fff_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4e8e7880267470bbc22e12957f39118_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i446a798869a940bcb0840713d8d197d5_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i088a89f8c55a4830ae8f287603af0a85_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71764f1445be4ec3b1d8f1ae335382fc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf7ecebc2a4a4743b808a47645131aae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ba2f4fd98b0498cab6a8cd62a52550e_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i608839facd584950806bdce9ed6b7161_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60681fe10dbc48539edaa19296f641ae_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i162851a888574726bbc3d4a48c455909_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c62e82c4b0646a5bfc481b48968354c_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie73cf1f18b64415697365cb853c1fc55_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75b0f8fc04374becb000201e80f83824_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba570416299441d585bdbe522d386ebb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i236ed4b1de894f8198c2d79df713cacf_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66122a21283042e5b1642886306f936f_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i908c0e65a6164625a7ffbc02d881c4b4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9caac20c6a643a08ddbe9107e60ff80_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9bef53171a3408ebbb6bb19f0a61b94_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a9a17ae382543bfb59eee6cb07b076b_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28c0950a478b45b8a240f2704954aa73_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c7a502434884775af9bab6a939e30b9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9ced64cb3044b06a122bd28bfff5d43_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48f46e422d5d477f8d00d83b4afb9715_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5d8ea4dde274fe09e92affa3ca98896_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia63cb40eed4a4bcdb75e61ac29fd3ce1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0d0673d53164492ae8fdf1825d7cc9d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f2792c0364546bc85db617aec3476eb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9ce5e2d04954ed79bbdbdf2f86c31be_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i912da28c3ce14d5fab748b5b779eddcb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78aec82de9644c62815efaae24c0f234_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i968b103643364f408ebde53bd855f7d4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28401cefd42342bba22f821ee9e35aca_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28171e2c0157437f901e8ac487ced4c5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8433607b2fd04ed895116661af183b0b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a1ac302b8d049b5bd17bf6490234668_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cffa2ae4f264f0fbe8bd94485d5382d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if753bf4c43f64a0c8907e6861712cbfd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i857664e374a749be8f04a47ced6ef989_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i474e84aa7269419cb39f79e96b3c61b4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2708618e4b62400ba3acf94032086aa2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife78b8cec88a4dc7b70010cc79af31d4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69ab00712f2643a8801797ff591de929_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50d11802ef0a4bf2934928e07af86a9e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib210a719b53c402c8f0246ea4d23a748_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10e8721d20f74d5b9979734f2dfaaccb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4097e0cabf84d8bb42c8e84583e28d8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i030ec43c8bcc435dbf4851b0831df548_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7677472fc774c0ba9acaa9a151d2429_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06e7851a35894a76b2c28ad9ef85560e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice489849d4474ba488f5e3ef419a245d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i899daa04a5384ab09446e722067496aa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e9b90c162674cfe89cd17b243422a63_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94d4c8e8d9344b66817f27a942c9a7e5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10158fbf9e4e44dfbc25c01cdd6f88cc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id233c4026cd0475ead24a770126edd58_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e280ffa520e4589adc014530a498776_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i512678e2e28d43929c1f1c4039a3643b_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7d58fcd3a8a47c38f913ca273d9e241_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae97bd45a73e4d6b901011f4c036e632_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0196c4e720841a6bf4668d9ae0d9976_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dcbd3ba88b14b8cb9f6afb24c8af942_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dcc457344ff41b99f24941ed96867bb_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11ab72b1aa84417b9db57840fd5421d7_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3b7bb1fac6041bd8446301c256d5875_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9fa0c093df9436380086f024d36dc1a_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i693d5f7bcfb9431498131ea693785506_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib834f1b2fee94f00991b25d7ec3f8343_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01d6d35e2fa543c586adcc726885b4d6_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8440650c7814ce6946c100b1a08a2f6_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2438f843e5643799b35cc8647fde1bf_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i255d2253a7a94a53b1e5268006eec230_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81bb19aea32d467b970e042769acd6f2_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i569b535e97d84810b0407243c35fc225_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27a4954bb37f4c87a40da845b26d61d1_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b140020e5bb4309b28dbcafa95601f1_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ae24aee3b354ce6bbf7be3fb4302b94_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i138bed0fe82b4330903b41329c9addd9_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09ebb20a8a124362bcd7a8357aa29fd5_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03a43431da5647adb236a2611029b943_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icabe0b5ad1bd43baaa10f6239519e5e3_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3dd9a90cd904e9bbf3710d2fa7182e9_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d51d292699e4dd78ccb0056227a5ce1_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78a52daf7ef347be82dc84982294aa48_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15b05f5f12104bbea82045fddddc48f0_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14388d06b3b646bd940f87caf35842b0_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i258e4de3fb8c414ab710d4649d307805_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id55bccb976bc4a4e842f7029e06bddf5_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35dea8de7d5247b6af91e476fc730262_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8042ff618ec94c0b90363a2a23ccd745_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81b11dfa14ea4846bee1b74c8a4f62a1_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7251f8f8dbe2418b8cb8bcc34820beed_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22b6ad0c0a184276b026278ab2492214_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">mygn:PerformanceObligationEstimatedTransactionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67176840186a45f8b5451e8e62e7f69f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">mygn:PerformanceObligationEstimatedTransactionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4259e411c05a49db8fc3dba108adcb2a_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">mygn:PerformanceObligationEstimatedTransactionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if83d47ed8afd45349ebc0526f0253b99_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2d0848b372c49e7879916eea4a55d95_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia75f79427aab4f40a89a2217f2dc3335_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0da8029be334899949f916d03b47e6e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieecccfa51e634b24b60447c9f26442d1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea4bf30af38941b3b6938c631d1ce22e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33fcfcc4292d45c6b97cc255ecd96967_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0e18392f2264c7ba9f8a25badbde19f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic37ece6897254048a406c0b1fa7f3ad7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a9bed5c63e84983966641b7a24d4bd5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffb0ffff83b34e97a987ed8e7389d515_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06c8acb8e4034c26bb0e7099f0eb44f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae9580cce4d64144acfc341401d74a31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fa40776bd48450d8df11ae05f802a71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>mygn:position</xbrli:measure></xbrli:unit><xbrli:context id="i823a913a8ad749ad8b995c1f537650c7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:SividonDiagnosticsGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0aaca7c4dbe24675bb0115e449ba69fc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac2403f7ee104879ad98b6a6781a824e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4956a5a0ff064149afbcc9ba2dfdc7e7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f3a3fbe29f8436db24dface84e90cf7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i054731a368194949b2bfc357f58a8920_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if505b51f5d2949a79b80bf083731f945_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b9734be1f184d3ab68c6b578ec56321_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic347427564244bcc8e0ff3d8c35f4333_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1a379dc7f4c475caaaa883ad45060a9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52834bd336224beaa3d88ac9bf176567_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0531632a6ded481b8155d92ceea1b3ea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8957a860dc7c44a8943b3e806ea2d496_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75e1560d14dc4c37a9651815e98123dd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if528d1eea02f4c89b8cc2f9410d179e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabee9b04bba344d0a4676474f9fd0aa9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f4ee512990746498f686969e753a8f7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fa11b5293574a56b95e476c81a3cbca_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d313c46b56f4ea4811041efe14780de_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8776fe30d4b443b885e41cdae0f9a864_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a42cd3883284fccba2c6f45fdec7c5c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2617796d6b8d481c94ef7401da39b8d8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic168d5bc29fe42c6a375be189bffb89f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibae6823d4dfc48c78710aeb85ccacafb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53c84ffe4852490b9b62069255f02f88_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f6de559c7f84f1ba22b6bde6e9505dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba93170941f54ad4a6e9bd9506cadfec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf95e9b463a9489fba6e904f9b508bc0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1f7a81ab4d546fa8363f6765db2ca47_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f4577ae6fc24714b12a9f4dae881ad9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia38de968e38b4dd0ad1104298f2e258f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0493540df994c2f871795b87f29a7bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdb7ac3fc3ba484292b559015692e497_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1763682428bf431f830915fa01ba4076_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cba5a8d0243495aaf7a24002f234432_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic69437fe4efd4416859e92172cc5790f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie95b38d0545844f98dede4b82126203f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e7d1835e2e34202be5a79f205d84bd9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b14cf32d8ca4635ae65df760ee25e81_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife394a441cff404aaae4b092a3d3bb46_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe950e801781495697dc7289c421c614_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id59c003282bb4959a9f3ab119e181c6c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1174c90b6ee4dc5b6d409ab036a9e96_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30e651fc58854e6d9587d0fd1ace6220_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie511c7937db0407398aaef7ccbbae95e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i524f05cde0ab49718e7546d04f102aa5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50667905e6f44ea3bbc5d72c01cf8826_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d017fae949f44c49fe499f702ad7561_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b01cebc763e4599b78408e1e92b66b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a85a5fe1cfa49c0aaf2a1f85c315776_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bbbaf79da6c4e839df3a413fd2c8433_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d090498adec48f5a5d9ada3ace9a11f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87c0d4d014b8431486ad3d3075f0ca84_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ed990c23f164e939a73f7223c4d3011_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncAndMyriadAutoimmuneBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5e94090de30419c96fa1c05060afd64_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">mygn:MyriadAutoimmuneReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39965e7109344a238233c9caa866cfb3_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">mygn:ClinicReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id82e3f3eeb68492399f4153822f134df_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if437534e60cb4439b2cd0da6651519aa_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3c2906fb217491a8423ba010a090290_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7975a4442d44d779f0f1bf53782120d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife7424d471c047f29674554074fafb8c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i082547e446854663944c1f7d21ca67bf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6ebe315d6824fd7a89d2f7c74efcf31_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88103ecea9f2472aad40efe4318bcd91_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aef28d53f8c47c8ab1d99d12cdd400f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id72ef2bad75948119bfd502da5931067_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcc890f9cd184879a64c08e82dcbbc8f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73af76a4fce548948796425f49a1806c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43ae1240cef14457931c317f4fd211b4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23aeff032bf24bb8a9d3d3bb253094dc_I20161223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia162acc4f40848918e001774e6a4f960_I20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7185e4956c746a9b0f45493392d399d_I20210222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib45bd6e5ec9a4ed7a463e74534d19bab_I20210221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i674b5e2ec7a24dd2868cf183995d5ed4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33356f53153c4a03be9389d7449cf3f6_I20220725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i843f20e91d9b42f9abab257be67b0fba_I20220726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf8301cef485443f9fbd8a975ee8e8bf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f459a7b8fd94d27b059f67e4c1866ff_D20220726-20220726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-26</xbrli:startDate><xbrli:endDate>2022-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i262a62b1f2d845acbe48f9be412ca7bf_D20220726-20220726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-26</xbrli:startDate><xbrli:endDate>2022-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa57fda02bc54eccb40407c480ef96e1_D20200401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60ba3c848587432396a389bd552eb846_D20200401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58d539dc7d304c43a5fbc7a02678e86e_D20220726-20220726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-26</xbrli:startDate><xbrli:endDate>2022-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93a2ffa60cb1493fa939b40a6cd3610e_D20220726-20220726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-26</xbrli:startDate><xbrli:endDate>2022-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e2a786776cf421188638389979b41f0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f7f76edb655468cb01a3ed28231577b_I20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d254d84e7e9429fb9eb353fa0fe6727_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9757cc95b46f40a8a4d1310a7a341adf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i801883d593c048cf8de2e2c90f49176b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12ca3a8a2ca341308119fa4fbac76272_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mygn:OptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mygn:NonEmployeeDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i662ff17b6ca34e25bba3e0323f9e924c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17cec0855d2440f9801f4db7e5a729b9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01fda04e6cb14149830711083c57c751_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a3e0bd95e204ba5951ebd463f3b3a4c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i552292b1ed264bf49d505c379dad4c2b_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaafdb3a4d0da4dec918d7e953639a791_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie26285660df14abb951924a100df85e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5d419cf4013469c83dd80d51c5ee579_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26ec50a211f240d3938bde3431435c8b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dae6418ac5148938050aacb2ef5d508_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i968d2e2144e34ee4916a9183d20c0063_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00d66009a0f2488699d68deb116f85b0_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6b55a5a308740858d157bc072e2ecaf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6834607b2374e2b81387c6f893f406a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2868dacc9996425d84f6678061f8071d_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e2d7d18c84e44c5a8a95712783d775b_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if34523c4b068408ca1452aea7567d7b8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f6f6d3b79734ce2bdb563e220afb94c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66dd3e15c00846fc81665b366c136737_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id15d2c557b414206ada2d552b9b565a4_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia04b5d1b8fa24d0fad862d180d2bd154_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87a0fc790ba34918898f41f810a4a2f1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa289b04ec1840778fdb19aca12b8a05_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff363386463e4c7b99ce076eeb84919c_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i249245e4ff6941f7be7f6d734b685a95_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86e699f1c66445bca22715a30a1f46ed_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58532a67b1154bc58a0b382ff6c515d4_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4d1d3c76ec0427db381fbba56a23a6d_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab27d0ec33e742d2977386c29c6a64ab_D20210923-20210923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-23</xbrli:startDate><xbrli:endDate>2021-09-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15344703477a40f5b457a744eeee71b2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3580a51b82cc466099d9eb0a57c378cd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f908585f461487aa148598b903a4f33_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id374269cc21d403aa573e11a92743d26_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc16948f5d7e4bd8969f02b7c60c2fc4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8481cd3af014407fa42d2b6f5b5acbdf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc38c0d48fe34cf9a4096e501b238ec1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7acceb782b124009867513e1e395eb09_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8265cfaa4f6249e280c2c2cf4edf2b88_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94684063e7f148b8b931a967f3ea2e9d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie05625b5ce714586b315182123a0066c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e56caf70d6447518290386f81719ca9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94ef8507bf234538b9ed98fb0e389325_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bbddf290d464aadaa27acb940277180_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3a2d7f8de3c427785c15b09085c84d6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83f4a6d86c4f4eb39c69c44ec0b4f2fd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5f72eb0018746c886b57ce4f50c4db8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i491a5a05cb774a8fb1c3c42b73443667_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaef3f6c95fd94ce4b015ac7e3db94ae4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">mygn:OtherStateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibea3c187441f480487b44a951451baba_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">mygn:OtherStateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if40585f71c3c463a9840bdd7070fc047_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2f519e64bc04789a7526a6bd09819a6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9e7946b9ce6498cab7885f8d675da90_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb59e7c4e69149dd82d0501e71e1ce19_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf9dfcf78da842f5bad9f364f2105f81_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i532ba0950b96453a85caae716fac82b6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1da4606ad7ed41209dfcdca23de08ed6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic667a4f90d994acbb20e3e566f84f92e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea7482a897494be892bc46b821925654_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if99355023d8f4ac5ab1b42964f050f9e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06d164c0b6e04a459e6a33b952092ab4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6df636aa6bd446ed8b2aea33d99d66a4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78b35c2904e342a2a22d1151ef8b25d8_D20201221-20201221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mygn:RaygenIncVersusMyriadWomensHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-21</xbrli:startDate><xbrli:endDate>2020-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>mygn:patent</xbrli:measure></xbrli:unit><xbrli:context id="i7ec137fde2704324b8c089d57adb90e5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="mygn:LeaseArrangementAxis">mygn:WestSaltLakeCityLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ib7c0bca71a544a8293274a98d8342a84_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="mygn:LeaseArrangementAxis">mygn:WestSaltLakeCityLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d8e9e97f965410eb1e1d5fb7d188a69_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mygn:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d0e08156cb641f29dd07ca3ce93941c_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabf0e35c76ce4737b597d4d31b6103bb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0f83e0a22104fedb4e475de48140594_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03e3d05930c246f797d9ab7061985860_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e82739b44cd45d7b099f422b6ae33cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c8aad575c1d41c389544f11390b9d59_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0a06975e9204301b5cb15099574bcee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>mygn:segment</xbrli:measure></xbrli:unit><xbrli:context id="i871418f253134efc9cceceeafbb4c291_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic41e7d1ebb214f6792a964d2daa1b432_I20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd5b839397f4403ca413620e5ce1dffc_I20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i789e41c2063b4e77b952b8700cc045f7_I20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75436f77b2804ab3bbcc97fe20a6f36c_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a2ff25d850940a7bc40bed0d8065631_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i673ce123e2a44d4598692c845966f939_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42ace60aa6e54d01b61af32b6f5812e2_D20221101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32039b626a934562bee22c0bff60b59d_D20210528-20210528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadMyPathLLCLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-28</xbrli:startDate><xbrli:endDate>2021-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if94a3c16ec0f40b79d3e7cd2713c4a83_D20210701-20210701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i754115245e57408994525a98aed1283a_D20210913-20210913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadAutoimmuneAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-13</xbrli:startDate><xbrli:endDate>2021-09-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11ee8a7e07b6457b867d5750561f27de_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ba75a9ef71348d3b90148f91f146b36_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadMyPathLLCLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b99a13c827f4f10ad3b6af0f22ddd25_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie73f9b8455314405972aa71faee08793_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000899923</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadAutoimmuneAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i7e0793090cf84227944277d460d39a4d_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODc1_174f10c1-07d5-4dd2-815e-e9c1b8600c26">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.387%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGFibGU6MmZjNzk3NGZlMGM5NDk0OGJlYmRjYmRjMGViZGY2ODkvdGFibGVyYW5nZToyZmM3OTc0ZmUwYzk0OTQ4YmViZGNiZGMwZWJkZjY4OV8wLTAtMS0xLTExOTQ4Mg_f17b2fd9-a7a7-4dda-aad3-0589860aafdb">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8yNTY_1df8d337-7eab-4c53-bca0-ae101843eced"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8yNTY_5bfe4b09-a388-4cbe-ade7-627ae7282c06">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.387%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGFibGU6OTZmMmZkNWYwZWY0NGVlYjgxMjQ2YjZmYzMyY2UxZTAvdGFibGVyYW5nZTo5NmYyZmQ1ZjBlZjQ0ZWViODEyNDZiNmZjMzJjZTFlMF8wLTAtMS0xLTExOTQ4Mg_2bd001a3-a377-4727-8b93-3c7dd01b72be">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from ______ to ______</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number:&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODgw_98d58e3e-0950-479b-a2d1-b28d02e2a91c">0-26642</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODgx_4ed75881-27c6-4721-aa58-922d373e9ef0">MYRIAD GENETICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODg2_d41a59eb-5edf-4d6c-a64d-acec68bf1312">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of incorporation or organization)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODc3_415ee600-ed51-4b20-854a-57dac6cfcd13">320 Wakara Way</ix:nonNumeric>, <ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODc4_63f3b5c3-270a-47e9-8d53-3f26e9eeaa8c">Salt Lake City</ix:nonNumeric>, <ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODkw_55a173c4-eccb-4996-baac-93c1829f7f4e">UT</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODcy_9e325ac9-ef1e-46f2-95d6-0bcc9a13091a">87-0494517</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODY2_642dc0ad-8079-4af6-8562-ce4c2662d485">84108</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant's telephone number, including area code: (<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODg3_2cc5c72b-67cd-4155-aa24-d2414ec047be">801</ix:nonNumeric>) <ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODcz_7037ba08-da59-4bf7-a06a-07e17b51a3a3">584-3600</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:36.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGFibGU6Zjk1YjhlYThhNzQ4NDliZmJhNWIzZjY4NDhiYzI4YTgvdGFibGVyYW5nZTpmOTViOGVhOGE3NDg0OWJmYmE1YjNmNjg0OGJjMjhhOF8xLTAtMS0xLTExOTQ4Mg_1412e05b-f270-4ee8-a0cb-ec63fb3e200d">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGFibGU6Zjk1YjhlYThhNzQ4NDliZmJhNWIzZjY4NDhiYzI4YTgvdGFibGVyYW5nZTpmOTViOGVhOGE3NDg0OWJmYmE1YjNmNjg0OGJjMjhhOF8xLTItMS0xLTExOTQ4Mg_e9861f66-5111-4330-a867-03511efc32da">MYGN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGFibGU6Zjk1YjhlYThhNzQ4NDliZmJhNWIzZjY4NDhiYzI4YTgvdGFibGVyYW5nZTpmOTViOGVhOGE3NDg0OWJmYmE1YjNmNjg0OGJjMjhhOF8xLTQtMS0xLTExOTQ4Mg_9bfbb968-f9ea-4cb4-8f8e-889bda813243">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Exchange Act: None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_______________________________________________________________</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODcx_77191452-6149-43e7-be14-4cd46b938044">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODg4_cfe3f34d-ce86-498f-97ac-8e8c3f82dea6">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODky_59d72004-c636-49e3-85b0-a445ca9682ce">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODY1_ec483ddb-2091-4dbf-bcfb-c428d36d1f51">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.&#160;&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:20.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.731%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGFibGU6NGFiNWMwNTM3OWZhNDEzOGFlMzBhNTM1NGEyMmY3MDMvdGFibGVyYW5nZTo0YWI1YzA1Mzc5ZmE0MTM4YWUzMGE1MzU0YTIyZjcwM18wLTAtMS0xLTExOTQ4Mg_fe75e693-3d55-448b-b429-1d51cee49a23">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGFibGU6NGFiNWMwNTM3OWZhNDEzOGFlMzBhNTM1NGEyMmY3MDMvdGFibGVyYW5nZTo0YWI1YzA1Mzc5ZmE0MTM4YWUzMGE1MzU0YTIyZjcwM18xLTQtMS0xLTExOTQ4Mg_ea281924-36d5-42b6-8d7d-5b8555c62828">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGFibGU6NGFiNWMwNTM3OWZhNDEzOGFlMzBhNTM1NGEyMmY3MDMvdGFibGVyYW5nZTo0YWI1YzA1Mzc5ZmE0MTM4YWUzMGE1MzU0YTIyZjcwM18yLTEtMS0xLTExOTQ4Mg_7363ee06-5d09-47f2-88fa-0fc31073f68a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. &#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODkz_3ef1ff41-ce27-4fae-9695-212b75eb0fbc">&#9746;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8yNDczOTAxMTYyOTUzOA_9048c7c2-87a9-4fb4-b07e-10cac83cd4c5">&#9746;</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of the registrant's common stock held by non-affiliates of the registrant (without admitting that any person whose shares are not included in such calculation is an affiliate), computed by reference to the price at which the common stock was last sold on June 30</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> was $<ix:nonFraction unitRef="usd" contextRef="i7f732cf8e70f4da79cc772ea647eba95_I20220630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zMzg5_e08d47ac-a4c4-438f-984e-78caf5c4e75f">1,465,095,487</ix:nonFraction>.&#160;&#160;</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of February&#160;23, 2023 the registrant had <ix:nonFraction unitRef="shares" contextRef="i3b8e0501187143259a1544d7c2a53414_I20230223" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zNDIz_d3e3c9e4-0692-47fb-9604-88c3703d616c">81,223,713</ix:nonFraction> shares of common stock outstanding.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODc5_777e7edb-ef91-4759-8e04-1c590685bf93" escape="true">The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K:&#160;&#160;Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant's Proxy Statement, to be filed no later than 120 days following December&#160;31, 2022, for the Annual Meeting of Stockholders expected to be held on June 1, 2023.</ix:nonNumeric></span></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_16">PART I</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_19">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_19">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_22">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_22">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_22">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_25">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_25">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_25">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_28">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_28">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_28">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_31">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_31">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_31">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_34">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_34">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_34">54</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_37">PART II</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_40">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_40">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_40">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_43">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">[Reserved]</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_43">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_46">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_46">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_46">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_64">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_64">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_64">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_67">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_67">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_67">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_154">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_154">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_154">104</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_157">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_157">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_157">104</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_160">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_160">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_160">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_163">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_163">106</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_166">PART III</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_169">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_169">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_169">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_172">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_172">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_172">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_175">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_175">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_175">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_178">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_178">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_178">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_181">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_181">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_181">107</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_184">PART IV</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_187">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_187">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_187">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_190">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_190">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_190">111</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_193">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e0793090cf84227944277d460d39a4d_193">112</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Statement Regarding Forward-Looking Statements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Securities and Exchange Commission encourages companies to disclose forward-looking information so that investors can better understand a company&#8217;s future prospects and make informed investment decisions. This Annual Report on Form 10&#8209;K contains such &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Words such as &#8220;may,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;expects,&#8221; &#8220;projects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seek,&#8221; &#8220;could,&#8221; &#8220;continue,&#8221; &#8220;likely,&#8221; &#8220;will,&#8221; &#8220;strategy&#8221; and &#8220;goal&#8221; and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify forward-looking statements. All forward-looking statements are management&#8217;s present expectations of future events and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. These risks include, but are not limited to: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that sales and profit margins of our existing tests may decline or that we may not be able to operate our business on a profitable basis; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our ability to achieve certain revenue growth targets and generate sufficient revenue from our existing product portfolio or in launching and commercializing new tests to be profitable; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to changes in governmental or private insurers&#8217; coverage and reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to increased competition and the development of new competing tests; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that we may be unable to develop or achieve commercial success for additional tests in a timely manner, or at all; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that we may not successfully develop new markets or channels for our tests, including our ability to successfully generate substantial revenue outside the United States; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that licenses to the technology underlying our tests and any future tests are terminated or cannot be maintained on satisfactory terms; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to delays or other problems with constructing and operating our laboratory testing facilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to public concern over genetic testing in general or our tests in particular;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our ability to obtain new corporate collaborations or licenses and acquire or develop new technologies or businesses on satisfactory terms, if at all; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license, acquire or develop; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that we are not able to secure additional financing to fund our business, if needed, in a timely manner or on favorable terms, if it all;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our projections about the potential market opportunity for our current and future products; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk of patent-infringement claims or challenges to the validity of our patents; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to changes in intellectual property laws covering our tests, or patents or enforcement, in the United States and foreign countries; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to security breaches, loss of data and other disruptions, including from cyberattacks;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks of new, changing and competitive technologies in the United States and internationally and that we may not be able to keep pace with the rapid technology changes in our industry, or properly leverage new technologies to achieve or sustain competitive advantages in our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our inability to achieve and maintain effective disclosure controls and procedures and internal control over financial reporting; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to current and future investigations, claims or lawsuits, including derivative claims, product or professional liability claims, and risks related to the amount of our insurance coverage limits and scope of insurance coverage with respect thereto; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors discussed under the heading &#8220;Risk Factors&#8221; contained in Item 1A of this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Annual Report on Form 10-K or in any document incorporated by reference might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Annual Report on Form 10-K. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. All forward-looking statements in this Annual Report on Form 10-K attributable to us or to any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;We,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Myriad&#8221; and the &#8220;Company&#8221; as used in this Annual Report on Form 10&#8209;K refer to Myriad Genetics, Inc., a Delaware corporation, and its subsidiaries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, ColarisAP, MyRisk, Myriad myRisk, MyRisk Hereditary Cancer, myChoice, Tumor BRACAnalysis CDx, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, SneakPeek, SneakPeek Early Gender DNA Test, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are registered trademarks or trademarks of Myriad. Solely for convenience, trademarks, trade names and service marks referred to in this Annual Report on Form 10-K may appear without the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8482; or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. </span></div><div style="text-align:justify"><span><br/></span></div><div id="i7e0793090cf84227944277d460d39a4d_13"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Market, Industry and Other Data</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K may contain estimates, forecasts, projections and other information concerning our industry, our business and relevant markets, including data regarding the estimated size of relevant markets, patient populations, and the perceptions and preferences of patients and physicians regarding certain therapies, as well as data regarding market research and estimates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources that we believe to be reliable. In some cases, we may not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i7e0793090cf84227944277d460d39a4d_19"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview and Mission </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. We provide insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. We develop and offer tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower health care costs. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business Strategy</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personalized genetic data, digital, and virtual consumer trends are converging to change traditional models of care. We believe significant growth opportunities exist to help patient populations with pressing health care needs through innovative genetic and precision medicine solutions and services. Our focus is on organic growth, deployment of capital, including through opportunistic acquisitions, and the launch of new products. We are focusing our efforts in three key areas where we have specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. We believe our path to organic growth is driven by articulating our clinical differentiation, advancing a new commercial model in our Oncology and Women's Health businesses to reach a broader set of physicians and patients, raising awareness with patients who we believe would benefit from testing, and innovation that improves clinical outcomes, ease of use, and access. By investing in tech-enabled commercial tools, new laboratory facilities, and advanced automation, we believe we will be able to reduce complexity and cost. With a foundation of financial, commercial, operational, and technological strength, we plan to launch new products and capabilities in 2023, such as our unified ordering portal, FirstGene, and, on a research use only basis, Precise minimal residual disease (MRD), which we expect will help accelerate our growth. We intend to develop and enhance our products to support growth, improve patient and provider experience, and reach more patients of all backgrounds. We are committed to disciplined management of a key set of initiatives to fulfill our mission and drive long-term growth and profitability. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Testing</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our tests are designed to analyze genes and their expression levels to assess an individual&#8217;s risk for developing disease, determine a patient&#8217;s likelihood of responding to a particular drug, assess a patient&#8217;s risk of disease progression, or identify factors which could lead to serious conditions in pregnancy. We focus our efforts in the following three key areas where we have specialized products, capabilities, and expertise:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Oncology:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Clarifying cancer treatment with genetic insights and companion diagnostic tests that are designed to work with corresponding drugs and treatments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Women's Health:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Providing genetic insights for women of all ancestries, assessing cancer risk, and offering prenatal testing solutions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mental Health:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Providing genetic insights to help physicians understand how genetic alterations impact patient response to anti-depressants and other drugs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tests are included in the key areas outlined above:</span></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%;text-decoration:underline">Oncology </span></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%;text-decoration:underline">Women's Health </span></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%;text-decoration:underline">Mental Health </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MyRisk</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MyRisk</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GeneSight</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BRACAnalysis CDx</span></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prequel</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MyChoice CDx</span></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foresight</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolaris</span></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SneakPeek</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EndoPredict</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precise Tumor</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Descriptions of our tests are as follows: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MyRisk&#8482; Hereditary Cancer Test:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DNA sequencing test for assessing the risks for hereditary cancers. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our MyRisk test is designed to determine a patient&#8217;s hereditary cancer risk for breast, ovarian, colorectal, endometrial, melanoma, pancreatic, prostate, and gastric cancers. The test analyzes 48 separate genes to look for deleterious mutations that put a patient at a substantially higher risk than the general population for developing one or more of these cancers. All 48 genes in the panel are well documented in clinical literature for the role they play in hereditary cancer and have been shown to have actionable clinical interventions for the patient to facilitate earlier cancer detection, lower disease risk or reduce risk of cancer recurrence. The MyRisk Genetic Test Result and MyRisk Management Tool</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> summarize medical society guidelines for managing a patient with a genetic mutation in view of their personal and family history of cancer. MyRisk also includes RiskScore</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for all ancestries. RiskScore incorporates the patient&#8217;s own clinical risk factors, family history, and unique genetic, ancestry-informed breast cancer risk markers and provides a personalized five-year and lifetime assessment of the risk of developing breast cancer&#8212;regardless of ancestry.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BRACAnalysis CDx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Germline Companion Diagnostic Test:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DNA sequencing test to help determine the most beneficial therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results of our BRACAnalysis CDx test are used as an aid to identify patients who are eligible for treatment with U.S. Food and Drug Administration (FDA) approved poly-ADP ribose polymerase (PARP) inhibitors. Currently, we are the only laboratory with an FDA-approved test for this indication and have received approvals from the FDA in ovarian cancer, metastatic breast cancer, pancreatic cancer, and advanced prostate cancer. The test is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein coding regions and intron/exon boundaries of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genes using genomic DNA obtained from whole blood specimens collected in ethylenediaminetetraacetic acid (EDTA).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MyChoice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> CDx Companion Diagnostic Test: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">tumor test that determines homologous recombination deficiency (HRD) status in patients with ovarian cancer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This FDA-approved test helps provide information on the magnitude of benefit for PARP inhibitor therapy. HRD status is determined using two independent methods: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> status that encompasses sequence variants and large rearrangements, and Genomic Instability Status (GIS) encompassing loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions across the entire genome. We believe that the combination of these methods is a more comprehensive way to measure HRD status, versus either one alone.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prolaris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Prostate Cancer Prognostic Test:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RNA expression tumor analysis for assessing the aggressiveness of prostate cancer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Prolaris test is a gene expression assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that can be safely monitored through active surveillance, or a more aggressive form of the disease that may warrant aggressive intervention such as a radical prostatectomy or radiation therapy. The Prolaris test was developed to improve physicians&#8217; ability to predict disease outcome and thereby to optimize patient treatment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EndoPredict</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Breast Cancer Prognostic Test:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RNA expression test for assessing the aggressiveness of breast cancer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The EndoPredict test is a next-generation RNA expression test used to determine which women with breast cancer may benefit from chemotherapy. EndoPredict predicts the likelihood of metastases to help guide treatment decisions for chemotherapy and extended endocrine therapy. EndoPredict has been shown to accurately predict risk of distant recurrence in Her 2-, ER+, node negative, and node positive breast cancer patients with no confusing intermediate results in 13 published clinical studies with more than 2,200 patients and is Conformit&#232; Europ&#235;enne (CE) marked, which signifies European certification for clinical use.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Precise&#8482; Tumor Molecular Profile Test:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a tumor profile test offered as part of Precise&#8482; Oncology Solutions,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a comprehensive solution for advanced precision oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Precise</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Oncology Solutions combines</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our leading germline hereditary cancer tests (MyRisk/BRACAnalysis CDx), our HRD companion diagnostic test (MyChoice CDx), and a comprehensive genetic tumor panel performed by Intermountain Precision Genomics, a service of Intermountain Healthcare. We believe Precise Oncology Solutions will help providers determine a clear, integrated, and personalized treatment plan for patients with cancer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prequel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Prenatal Screen:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a non-invasive prenatal screening (NIPS) test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Prequel test uses whole genome sequencing to assess for trisomies and monosomies in all 23 chromosomal pairs including the sex chromosomes, along with microdeletions associated with common genetic diseases. Prequel has a low test failure rate at less than 1 in 1,000 patients and has been validated in multiple clinical studies to be highly accurate. Prequel uses AMPLIFY&#8482; technology that raises NIPS test performance most significantly for the types of patients who have traditionally had test failures on standard NIPS tests due to certain clinical factors.  AMPLIFY is the only NIPS technology that substantially reduces low fetal fraction test failures in order to allow for equity in care across all patients, regardless of body mass index (BMI), race, or ethnicity.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foresight</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Carrier Screen:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foresight test screens for carrier status of up to 176 genes associated with serious and prevalent inherited conditions. The test has been shown to have a detection rate of 99% across all ethnicities. Studies have shown that with prior knowledge of recessive genetic conditions, 76% of patients took preventive actions such as in-vitro fertilization with pre-implantation genetic testing to reduce the risk of having an affected offspring.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SneakPeek</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Early Gender DNA Test:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a non-invasive blood test that predicts the gender of a fetus as early as six weeks. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innovative cell free DNA technology and precise algorithms in the SneakPeek test are used to screen for a single, Y chromosome marker in the material blood sample. If Y chromosome markers are found in the mother's blood, the baby is male. If no Y chromosome markers are detected, the baby is female. The SneakPeek test is able to determine fetal sex as early as six weeks of gestation with 99% accuracy. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GeneSight</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Psychotropic Mental Health Medication Test:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit/hyperactivity disorder (ADHD) and other mental health conditions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GeneSight test provides healthcare professionals with information about which medications may require dose adjustments, may be less likely to work for a patient, or may have an increased risk of side effects based on a patient's genetic makeup. Genesight covers 64 medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. Because genes influence the way a person&#8217;s body responds to specific medications, the medications may work differently for each person. Using DNA gathered with a simple cheek swab, the GeneSight test analyzes a patient&#8217;s genes and provides individualized information to help healthcare providers select medications that better match the patient&#8217;s genetic variations. Multiple clinical studies have shown that when clinicians used the GeneSight test to help guide treatment decisions in major depressive disorders, patients were more likely to respond to treatment compared to standard of care.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Marketing</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our tests primarily through our own sales force and marketing efforts in the United States, Japan, Germany, and France, and we service additional global accounts through indirect sales channels. Our U.S. sales force is comprised of approximately 500 individuals across our dedicated sales channels. We continue to optimize our sales and marketing channels through increased digital marketing, direct to patient marketing, enhanced virtual sales tools, and inside sales teams to drive efficiency in our sales model. For example, in 2022, we focused more on digital engagement and inside sales with our GeneSight test, which contributed to 36% year-over-year growth in product revenue. Our inside sales team focuses on a broader base of leads, freeing up the field sales team to target high potential clinical leads. We plan to integrate elements of this new sales and marketing model into our Women's Health channels and eventually into our other product lines, which we believe can be more cost effective in terms of customer acquisition costs. Additionally, our recent acquisition of Gateway Genomics, LLC (Gateway), which offers a home-test prenatal kit, may provide us with greater direct to consumer access and create opportunities to cross-sell our other Women's Health products. We believe we will be better able to execute on our strategies and fulfill our mission by engaging with providers and patients in new ways.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products stem from expert and innovative investigation into the biological underpinnings of serious human disease. We plan to continue to use our proprietary DNA sequencing and RNA expression technologies, including our supporting bioinformatics and robotic technologies, in an effort to efficiently discover and validate important biomarkers. We embed these biomarkers along with relevant clinical information in complex, proprietary tests that are highly accurate and informative, and intended to help physicians better manage their patients&#8217; health care. We believe that our technologies provide us with a significant competitive advantage and the potential for the continued development of numerous product opportunities. For the year ended December&#160;31, 2022, the year ended December&#160;31, 2021, the six-month transition period ended December&#160;31, 2020, and the fiscal year ended June 30, 2020, we incurred research and development expense of $85.4 million, $81.9 million, $35.8 million and $77.2 million, respectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Industry and Competition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare is evolving to be more patient-centered and value-based. Patients, healthcare providers, payors and health systems are looking to apply the power of genetic insights, molecular diagnostics, and precision medicine to advance care, improve access, and lower cost. We believe key industry trends include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">accelerating shifts in consumer engagement, early detection, home-based care models, the rise of low-cost sequencing, telemedicine, and virtual care; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption in the way outpatient care is delivered as a result of the COVID-19 pandemic, coupled with broadened awareness of the vital role of diagnostic testing; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanding access to genetic insights, particularly among underserved populations with increased focus on health equity, reducing disparities in health care outcomes, and ensuring increased access for challenged communities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">broader, more innovative use of large data sets and analytics; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">growth in personalized medicine </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the interest in new partnership models to advance companion diagnostics and serve patients with specific treatments based on their own genetic makeup and biology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these market trends create new opportunities to position us for organic growth and commercial success through the launch of new products and the enhancement of existing products. Our focus is on articulating the clinical differentiation of our products and our commitment to being a reliable testing partner to patients and providers and innovative science that improves health outcomes, access for all, and ease of experience in the testing process. We expect to use our ability to innovate not only in research, development, and technology, but also in go-to-market approaches, commercial capabilities, and tech-enabled applications to adapt quickly to customer preferences and market dynamics. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncology</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In oncology, we offer testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. Our competitors in the oncology market include Invitae Corporation, Ambry Genetics Corporation, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Exact Sciences Corporation, Foundation Medicine, Inc. and other commercial and academic laboratories.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health, and enable healthcare providers to better detect, treat, and prevent disease. We believe that the key opportunities to grow our Oncology business are our expansion of companion diagnostics, market expansion through new clinical guidelines, and providing new offerings. For example, in the first quarter of 2022, we launched the Precise Tumor Molecular Profile Test in partnership with Intermountain Precision Genomics and Illumina and as part of Precise Oncology Solutions, a differentiated, comprehensive solution for advanced precision oncology. In March 2022, we received FDA approval for the BRACAnalysis CDx test for use as a companion diagnostic to identify patients with germline BRCA-mutated (gRBCAm) HER2 negative, high-risk early-stage breast cancer who may benefit from Lynparza (olaparib). We currently offer our FDA-approved BRACAnalysis CDx test as a companion diagnostic for the prediction of response to PARP inhibitors. Currently, we are the only laboratory with an FDA-approved germline test for this indication and have received approvals from the FDA in ovarian cancer, metastatic breast cancer, pancreatic cancer, and advanced prostate cancer. In August 2022, we received approval from the Japanese regulatory agencies for the use of BRACAnalysis Diagnostic System as a companion diagnostic to identify patients with germline BRCA-mutated (gBRCAm) and HER2-negative high-risk recurrent breast cancer who may benefit from Lynparza (olaparib).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late 2023, we also plan to add, also in partnership with Intermountain Precision Genomics, a new liquid biopsy therapy selection test called Precise Liquid to the comprehensive Precise Oncology Solutions offering. We are also developing Precise MRD, a monitoring test based on whole genome sequencing to deeply interrogate tumors, detect cancer recurrence earlier, and help guide treatment decisions. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Women&#8217;s Health </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the women&#8217;s health market, we serve women assessing their genetic predisposition to cancer, offer prenatal tests for the assessment of fetal chromosomal disorders, and screen prospective parents for recessive genetic conditions that can be passed on to their offspring. We also offer the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. We compete with multiple companies, including large national reference laboratories, specialty laboratories, academic/university laboratories, and kit-based products with our MyRisk, Foresight, Prequel and SneakPeek tests. Our competitors include Invitae Corporation, Natera, Inc., Ambry Genetics Corporation, a subsidiary of Konica Minolta Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, and Peekaboo Early Detection Gender DNA Test. We compete mainly based on our test breadth and accuracy, equity in care capability, and our commercial scale. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We see opportunities to improve both our economics and the customer experience on these products. We remain focused on the reimbursement for carrier screening and finding streamlined patient payment models. We are expanding new sales and marketing channels to interact with patients and allow customers greater access to our products. For example, with our recent acquisition of Gateway and its home-based SneakPeek Early Gender DNA Test, we have greater access to consumers who are pregnant and opportunities to convert these customers into prenatal testing patients as well as cancer screening patients.  We also plan to improve customer experience with our new online unified ordering portal to engage with patients and physicians, our cost estimators across our product lines, our remote in-market customer service teams, and artificial intelligence-based tools for interacting with patients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to further simplify and advance prenatal care with the launch of FirstGene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482;, a comprehensive prenatal screening test.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> FirstGene combines the power of our Prequel NIPS with AMPLIFY technology with our Foresight Carrier Screen into a new 4-in-1 prenatal offering for NIPS, carrier screen, fetal recessive status, and feto-maternal blood compatibility. This new test, which is expected to launch in the third quarter of 2023, is designed to streamline the testing process and simplify workflow with a single maternal blood draw while providing early insight on the fetus with improved sensitivity for all pregnancies, helping to reduce unnecessary amniocentesis. We recently announced our support for the recent guideline update by the American College of Medical Genetics and Genomics (ACMG), which reaffirmed the clinical value of NIPS to screen for a range of chromosomal abnormalities. ACMG continues to recommend offering screening for common trisomies (on chromosomes 13, 18, and 21) in all pregnancies, and recently updated guidance that provides a strong recommendation for offering screening for sex-chromosome aneuploidies (SCAs) and conditional support for offering screening for 22q microdeletion syndrome. As part of the NIPS within FirstGene, both SCAs and 22q are expected to be available as additional opt-in screening.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mental Health </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In mental health, we help physicians understand how genetic alterations may impact patient response to antidepressants and other drugs. We believe our GeneSight Psychotropic Mental Health Medication Test meets a significant unmet clinical need and is a leading product to help physicians anticipate patient response to psychotropic drugs, the selection of which has historically been done through trial and error based approaches. The test is clinically proven to improve response rates in patients compared to standard of care. Our competitors in this market include Genomind, Quest Diagnostics Incorporated, and Laboratory Corporation of America Holdings. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key opportunities to grow our business in this market include growing awareness of pharmacogenomic opportunities for mental health treatment and driving physician adoption and utilization of our product to help guide treatment options. We are broadening access to GeneSight among front-line providers of mental health treatment, including primary care physicians and nurse practitioners who treat the majority of patients suffering from depression and anxiety, and through the expansion of sales and digital marketing capabilities. Moving forward, we are exploring the extension of GeneSight in other indications as well as other areas such as postpartum depression through our Women's Health business. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically experienced seasonality in our testing business. The quarter ended December 31st is generally strong as we typically experience an increase in volumes from patients who have met their annual insurance deductible. Conversely, in the quarter ended March 31st we typically experience a decrease in volumes due to the annual reset of patient deductibles. Additionally, the volume of testing is negatively impacted by the summer season, which is generally reflected in the quarter ended September 30th. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mission is to advance health and well-being for all by empowering individuals with vital insights to help them take control of their health and enabling healthcare providers to better detect, treat and prevent disease. We believe the success of our mission depends, in part, on our ability to attract and retain qualified personnel. Our key human capital management objectives are to recruit, retain and motivate the exceptional people needed to carry out our mission. To support these objectives and help our employees balance their work and personal lives, we maintain a flexible work environment and competitive compensation and benefits programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we have approximately 2,600 full-time equivalent employees. Most of our employees are engaged directly in customer experience, research, technology, development, production, and sales and marketing.&#160;Our employees are not covered by a collective bargaining agreement, and we consider our relations with our employees to be good.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversity, Equity and Inclusion (DE&amp;I)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DE&amp;I objective is to make Myriad a place where all employees have a sense of belonging. Myriad supports a culture of diversity, equity, and inclusion aligned with our company mission, vision, and values to drive company performance by creating opportunities and experiences for learning, development, and a sense of belonging for all employees. Our DE&amp;I plan is focused on our people, mission, and community. We have three employee-led resource groups (ERGs) that represent and support three diverse communities in our workforce: the Pride Alliance Group, the Black Employees at Myriad Group and the Women's Leadership Group. These ERGs mentor, foster, encourage, and inspire employees in all stages of their careers by providing access to senior leadership, peer groups, mentoring, and other valuable resources to help them pursue their career ambitions. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, 62% of our employees are women and women hold 46% of Myriad leadership roles (vice president and above).  One third of the members of our Board of Directors are women, including the chairperson, and 44% of our Board members come from diverse gender, ethnic, and cultural backgrounds.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation, Health, Wellness, Family Resources, and Other Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation program is designed to attract and reward talented individuals who possess the skills necessary to support our business objectives, assist in the achievement of our strategic goals and create long-term value for our stockholders. We provide competitive salaries, stock ownership opportunities, and enhanced incentive and bonus programs. We also provide an expansive benefit offering including medical, dental and vision health care coverage, insurance and disability coverage, 401(k) investment plans with Company matching, tax advantaged savings accounts, paid time off and leaves of absence, parental leave, family formation benefits, employee assistance programs, community outreach programs, training and development opportunities, and wellness programs. We provide added work life balance to our employees through hybrid work arrangements. We also provide free mental health resources for employees and their dependents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Career Development and Training</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer several career development and training opportunities to our employees, including a curriculum of Company-sponsored technical, business and leadership courses, on-the-job training and a support network to all new employees, and tuition reimbursement for approved external training and educational pursuits.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oversight and Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly conduct surveys to seek feedback from our employees on a variety of topics, including employee engagement, Company strengths and focus areas, and culture drivers. The results are reviewed by our Board of Directors, the Compensation and Human Capital Committee and senior leadership, who analyze areas of progress or deterioration and prioritize actions and activities in response to this feedback to drive meaningful improvements in employee engagement. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Social Responsibility and Community</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Myriad, corporate responsibility plays an important role in our approach to developing valuable and transformative diagnostic tests across major diseases to improve patients' lives. We believe that our corporate social responsibility programs build greater value for our patients, healthcare professionals and stockholders, support and improve the communities where we live and work, and empower our employees to become more engaged in the well-being of their own communities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The corporate social responsibility programs at Myriad align with a clearly defined set of strategic priorities including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Philanthropy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We provide financial support to nonprofit organizations and share the expertise of our employees in the communities where we operate.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Advocacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We collaborate with and support key patient advocacy and support organizations where we can make a positive difference in addressing complex health challenges, providing and improving the quality of life for patients.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Scholarship</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We provide financial support for academic scholarship and education at both the undergraduate and post-graduate levels and contribute to advancing education and training for women and minorities in medicine and science.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Patient Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We are working to improve overall health care quality and increase access to diagnostic testing for uninsured and underinsured populations by offering robust financial assistance and free testing to those in need.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Environmental</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: As described further below, we have created a Green Team to foster environmental and sustainability stewardship. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental and Sustainability</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to do business in ways that protect both the health and safety of our employees and the world in which we operate by establishing, promoting, maintaining and improving a culture of sustainability and environmental responsibility. In order to achieve our objectives, we have increased our focus on environmental and sustainability efforts by adopting a Sustainability Strategy and Vision Statement that we are working towards fully implementing. The Nominating, Environmental, Social and Governance Committee of our Board of Directors is responsible for reviewing and evaluating our environmental, climate, safety, social and other corporate responsibility strategies, practices, and initiatives. We have also formed an internal Environmental, Social, and Governance (ESG) Committee, led by our President and Chief Executive Officer, and created a Green Team in an effort to develop and maintain sustainable business practices. For more information on our approach to sustainability, please refer to our 2021 Environmental, Social and Governance Report, which is available on our website. Our 2022 Environmental, Social and Governance Report is expected to be released later this year.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or have license rights to various issued patents and patent applications in the United States and foreign countries. These patents and patent applications relate to a variety of subject matter, including diagnostic biomarkers, gene expression signatures, assays, assay reagents, informatics and data analytics, methods for determining genetic predisposition, methods for disease diagnosis, methods for determining disease progression, methods for determining disease treatment, and general molecular diagnostic techniques. For some of the patent assets, we hold rights through exclusive or non-exclusive license agreements. Material issued patent assets relating to our tests that generate material revenue are described in the table below, along with any related pending applications. These issued patents are expected to begin expiring on the respective dates noted below and any related applications, if issued as patents and depending on term adjustments or terminal disclaimers, if applicable, are expected to have similar expiration timeframes. These patents and applications contain multiple claims including but not limited to those claims described below.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.971%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%;text-decoration:underline">Test</span></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%;text-decoration:underline">Patent Assets</span></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%;text-decoration:underline">Expiration</span></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%;text-decoration:underline">Claims</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Prolaris Prostate Cancer Prognostic Test</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We own or hold an exclusive license to one or more issued patents and pending patent applications in the U.S. and other jurisdictions relating to Prolaris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing.</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These issued U.S. patents have terms expected to begin expiring in 2030.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims relating to biomarkers, kits, systems and methods for detecting, diagnosing, prognosing and selecting therapy for prostate cancer.</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">EndoPredict Breast Cancer Prognostic Test</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We own or hold an exclusive license to one or more issued patents and pending patent applications in the U.S., Europe and other jurisdictions relating to EndoPredict</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing.</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These issued patents have terms expected to begin expiring in 2031.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims relating to biomarkers, kits, systems and methods for prognosing and selecting therapy for breast cancer.</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">MyChoice CDx Companion Diagnostic Test</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We own or hold an exclusive license to one or more issued patents and pending patent applications in the U.S. and other jurisdictions relating to MyChoice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CDx testing.</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These issued patents have terms expected to expire in 2031.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims relating to biomarkers, kits, systems and methods for detecting homologous recombination deficiency and selecting therapy based on such detection.</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">GeneSight Psychotropic Mental Health Medication Test</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We own or hold an exclusive license to one or more issued patents and pending patent applications in the U.S. and other jurisdictions relating to GeneSight</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing.</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These issued patents have terms expected to begin expiring in 2024.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims relating to biomarkers, kits, systems and methods for detecting single nucleotide polymorphisms and selecting and/or optimizing therapy based on such detection.</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Foresight Carrier Screen</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We own or hold an exclusive license to one or more issued patents and pending patent applications in the U.S. and other jurisdictions that relate to laboratory and informatic methods used to enhance Foresight</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing.</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These issued patents have terms expected to begin expiring in 2032.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims relating to systems and methods for detecting genetic sequences.</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Prequel Prenatal Screen</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We own or hold a license to one or more issued patents and pending patent applications in the U.S. and other jurisdictions that relate to laboratory and informatic methods used to enhance Prequel&#8482; testing.</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These issued patents have terms expected to begin expiring in 2032.</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims relating to systems and methods for detecting genetic sequences.</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek patent protection in the United States and major foreign jurisdictions for these and other inventions which we believe are patentable and where we believe our interests would be best served by seeking patent protection. However, any patents issued to us or our licensors may not afford meaningful protection for our products or technology or may be subsequently circumvented, invalidated or narrowed or found unenforceable. Any patent applications which we have filed, or will file, or to which we have licensed or will license rights may not issue, and patents that do issue may not contain commercially valuable claims. In addition, others may obtain patents having claims which cover aspects of our tests or processes which are necessary for or useful to the development, use or performance of our products. Should any other group obtain patent protection with respect to our discoveries, our commercialization of our tests could be limited or prohibited.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Others may offer genomic laboratory testing services which may infringe patents we control. We may seek to negotiate a license to use our patent rights or decide to seek enforcement of our patent rights through litigation. Patent litigation is expensive, the outcome is often uncertain and we may not be able to enforce our patent rights against others.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our tests and processes may also conflict with patents which have been or may be granted to competitors, academic institutions or others. In addition, third parties could bring legal actions against us seeking to invalidate our owned or licensed patents, claiming damages, or seeking to enjoin clinical testing, development and marketing of our tests or processes. If any of these actions are successful, in addition to any potential liability for damages, we could lose patent coverage for our tests, be required to cease the infringing activity or obtain a license in order to continue to develop or market the relevant test or process. We may not prevail in any such action, and any license required under any such patent may not be made available on acceptable terms, if at all. Our failure to maintain patent protection for our tests and processes or to obtain a license to any technology that we may require to commercialize our tests and technologies could have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely upon unpatented proprietary technology, and in the future may determine in some cases that our interests would be better served by protecting certain technologies as trade secrets or through confidentiality agreements rather than patents or licenses. These include some of our genomic, proteomic, RNA expression, mutation analysis, robotic and bioinformatic technologies which may be used in discovering and characterizing new biomarkers and ultimately used in the development or analysis of tests. We also maintain a database of gene mutations and their status as either harmful or benign for some of our tests. To further protect our trade secrets and other proprietary information, we require that our employees and consultants enter into confidentiality and invention assignment agreements. However, those confidentiality and invention assignment agreements may not provide us with adequate protection. We may not be able to protect our rights to such unpatented proprietary technology and others may independently develop substantially equivalent technologies. If we are unable to obtain strong proprietary rights to our processes or tests, competitors may be able to market competing processes and tests.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to license agreements which give us the rights to use certain technologies in the research, development, testing processes, and commercialization of our tests.  These licenses generally end on the expiration of the last to expire patent rights covered by the applicable license agreement. We may not be able to continue to license these technologies on commercially reasonable terms, if at all.  In addition, each license may be terminated by the licensor in the event of an uncured breach by us of any material term of the applicable license agreement. Patents underlying our license agreements may not afford meaningful protection for our technology or tests or may be subsequently circumvented, invalidated or narrowed, or found unenforceable. Our failure to maintain rights to this technology could have a material adverse effect on our business. The table below lists important licenses to technology that is incorporated into tests that generate material revenue:</span></div><div style="margin-top:3pt;text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%;text-decoration:underline">Entity</span></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%;text-decoration:underline">Subject</span></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%;text-decoration:underline">Royalties</span></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%;text-decoration:underline">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Mayo Foundation for Medical Education and Research (Mayo)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exclusive world-wide license to certain rights of Mayo in intellectual property relating to our GeneSight testing.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We pay Mayo a royalty based on net sales of our GeneSight test.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not anticipate that this license will expire until 2024.</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">University of Texas M.D. Anderson Cancer Center (UTMDACC)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exclusive world-wide right to certain rights of UTMDACC in intellectual property relating to our MyChoice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> HRD testing.</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We pay UTMDACC a royalty based on net sales of our MyChoice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> HRD test.</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not anticipate that this license will expire until 2032.</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Children&#8217;s Medical Center in Boston (CMCC)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exclusive world-wide right to certain rights of CMCC in intellectual property relating to our MyChoice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> HRD testing.</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We pay CMCC a royalty based on net sales of our MyChoice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> HRD test.</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not anticipate that this license will expire until 2032.</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Institut Curie and INSERM (INSERM)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exclusive world-wide right to certain rights of INSERM in intellectual property relating to our MyChoice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> HRD testing.</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We pay INSERM a royalty based on net sales of our MyChoice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> HRD test.</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not anticipate that this license will expire until 2032.</span></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Illumina, Inc.</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-exclusive license to certain rights held by or licensed to Illumina to intellectual property relating to non-invasive prenatal screening and the Prequel test.</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We pay Illumina a royalty based on the volume of Prequel testing administered by us.</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">License runs for the term of the Illumina agreement and, in any event, expires upon expiration of the last to expire patent right covered by the Illumina agreement.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are regulated by federal, state and foreign governmental authorities.  Failure to comply with the applicable laws and regulations can subject us to repayment of amounts previously paid to us, significant civil and criminal penalties, loss of licensure, certification, or accreditation, or exclusion from state and federal health care programs. The significant areas of regulation are summarized below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Laboratory Improvement Amendments of 1988 and State Regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our clinical laboratories must hold certain federal, state and local licenses, certifications, and permits to conduct our business.  Laboratories in the United States that perform testing on human specimens for the purpose of providing information for the diagnosis, prevention, or treatment of disease are subject to the Clinical Laboratory Improvement Amendments of 1988 (CLIA).  CLIA requires such laboratories to be certified by the federal government and mandates compliance with various operational, personnel, facilities administration, quality and proficiency testing requirements intended to ensure that testing services are accurate, reliable and timely.  CLIA certification also is a prerequisite to be eligible to bill state and federal health care programs, as well as many private third-party payors, for laboratory testing services. Our laboratories in Salt Lake City, Utah, Mason, Ohio, and South San Francisco, California are CLIA certified to perform high complexity tests.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLIA requires each of our certified laboratories to enroll in an approved proficiency testing program if performing testing in any category for which proficiency testing is required.  Each of our laboratories periodically tests specimens received from an outside proficiency testing organization and then submits the results back to that organization for evaluation.  If one of our laboratories fails to achieve a passing score on a proficiency test, then it may lose its right to perform testing.  Further, failure to comply with other proficiency testing regulations, such as the prohibition on referral of a proficiency testing specimen to another laboratory for analysis, can result in revocation of the laboratory&#8217;s CLIA certification.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of CLIA certification, each of our laboratories is subject to survey and inspection every other year, in addition to being subject to additional random inspections.  The biennial survey is conducted by the Centers for Medicare &amp; Medicaid Services (CMS), a CMS agent (typically a state agency), or a CMS-approved accreditation organization.  Because our laboratories are accredited by the College of American Pathologists (CAP), which is a CMS-approved accreditation organization, they are typically subject to CAP rather than CMS inspections.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our laboratories are licensed by the appropriate state agencies in the states in which they operate, if such licensure is required.  In addition, our laboratories hold state licenses or permits, as applicable, from various states, including, but not limited to, California, New York, Pennsylvania, Rhode Island and Maryland, to the extent that they accept specimens from one or more of these states, each of which requires out-of-state laboratories to obtain licensure.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a laboratory is out of compliance with state laws or regulations governing licensed laboratories or with CLIA, penalties may include suspension, limitation or revocation of the license or CLIA certificate, assessment of financial penalties or fines, or imprisonment.  Loss of a laboratory&#8217;s CLIA certificate or state license may also result in the inability to receive payments from state and federal health care programs as well as private third-party payors. We believe that we are in material compliance with CLIA and all applicable licensing laws and regulations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Food and Drug Administration</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, in vitro diagnostic (IVD) products are subject to regulation by the FDA as medical devices to the extent that they are intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease. They are subject to premarket review and post-market controls that will differ depending on how the FDA classifies a specific IVD, which is further defined in FDA&#8217;s implementing regulations as a device intended for use in the collection, preparation, and examination of specimens taken from the human body. For certain types of tests known as laboratory developed tests (LDTs)&#8212;which are in vitro diagnostic tests that are designed, manufactured and used within a single laboratory&#8212;FDA regulation is less clear than for IVDs. Historically, FDA has exercised enforcement discretion for LDTs, which means that FDA generally has not enforced premarket review and other applicable FDA requirements. However, as LDTs have increased in complexity, the FDA has taken a risk-based approach to their regulation. Congress has also signaled interest in clarifying the regulatory landscape for LDTs. Most recently, reform entitled the Verifying Accurate, Leading-edge IVCT Development (VALID) Act has received bipartisan congressional support as revisions continue to be made to the bill. If enacted, clinical laboratories that develop and offer LDTs and traditional IVD medical device manufacturers would be subjected to the same regulatory oversight. The VALID Act defines both LDTs and IVDs as in vitro clinical tests (IVCT) and would establish a new regulatory framework separate and apart from the medical device framework under the Food, Drug and Cosmetic Act (FDCA) for the review and oversight of IVCTs. The proposed regulatory framework adopts various concepts from the FDCA, utilizing a risk-based approach that aims to ensure that all marketed IVCTs have a reasonable assurance of both analytical and clinical validity, and includes a proposed future user fee program for IVCTs. The VALID Act would also create a new system for clinical laboratories and hospitals to submit their clinical tests electronically to the FDA for approval, among other potentially significant changes to current regulatory requirements applicable to the lab industry as a whole. This system is aimed at reducing the amount of time that it takes for the agency to approve such tests, and it establishes a new program to expedite the development of diagnostic tests that can be used to address a current unmet need for patients. It is unclear whether the VALID Act will be passed by Congress in its current form or signed into law by the President; if enacted, however, it is expected to require clinical laboratories to spend significant time, resources, and money towards ensuring compliance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In Vitro Diagnostics as Medical Devices</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information that must be submitted to the FDA in order to obtain clearance or approval to market a new IVD varies depending on how the device is classified by the FDA. Medical devices are classified into one of three classes on the basis of the controls deemed by the FDA to be necessary to reasonably ensure their safety and effectiveness. Class I devices are subject to general controls, including labeling, and adherence to the FDA&#8217;s quality system regulations, which are device-specific good manufacturing practices. Class II devices are subject to premarket notification, general controls and sometimes special controls, such as performance standards and post-market surveillance. Class III devices are subject to most of the previously identified requirements as well as to premarket approval. All Class I devices are exempt from premarket review, most Class II devices require 510(k) clearance, and all Class III devices must receive premarket approval before they can be sold in the United States. If a previously unclassified new medical device does not qualify for the 510(k) pathway because no predicate device to which it is substantially equivalent can be identified, the device is automatically classified into Class III. However, if such a device would be considered low or moderate risk, it may be eligible for the De Novo classification process. The De Novo classification process allows a device developer to request that the novel medical device be reclassified as either a Class I or Class II device, rather than having it regulated as a high-risk Class III device subject to the premarket approval requirements. The payment of a fee, typically adjusted annually, to the FDA is usually required when a 510(k) notification, premarket approval application, or De Novo classification request is submitted.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">510(k) Premarket Notification and De Novo Classification</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A 510(k) notification requires the sponsor to demonstrate that an IVD is substantially equivalent to another marketed device, termed a &#8220;predicate device,&#8221; that is legally marketed in the United States and for which a premarket approval (PMA) application was not required. A device is substantially equivalent to a predicate device if it has the same intended use and technological characteristics as the predicate; or has the same intended use but different technological characteristics, where the information submitted to the FDA does not raise new questions of safety and effectiveness and demonstrates that the device is at least as safe and effective as the legally marketed device. Clinical trials are almost always required to support a PMA application and are sometimes required for a De Novo classification request or a 510(k) premarket notification.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA determines that the applicant&#8217;s device is substantially equivalent to the identified predicate device(s), the agency will issue a 510(k) clearance letter that authorizes commercial marketing of the device for one or more specific indications for use. Requests for additional data, including clinical data, will increase the time necessary to review the notice. If the FDA believes that the IVD is not substantially equivalent to a predicate device, it will issue a &#8220;Not Substantially Equivalent&#8221; letter, stating that the new device may not be commercially distributed and designating the device as a Class III device, which will require the submission and approval of a PMA application before the new device may be marketed. Alternatively, the applicant may be able to submit a De Novo classification request to have it regulated as a Class I or Class II device. The FDA recently issued a final rule to formally codify requirements for the procedures and criteria for product developers to follow when preparing a De Novo classification request. The new Do Novo regulations became effective on January 3, 2022. Among other things, if the manufacturer seeks reclassification into Class II, the classification request must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the device. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an alternative to the De Novo classification process, the manufacturer could also file a reclassification petition seeking to change the automatic Class III designation of a novel post-amendment device under Section 513(f)(3) of the FDCA. The FDA can also initiate reclassification of an existing device type on its own initiative, and it recently issued a final rule to clarify the administrative process through which the agency reclassifies a medical device. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a new medical device receives 510(k) clearance from the FDA, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, requires a new 510(k) clearance or could require the submission of a PMA application. The FDA continues to reevaluate the 510(k) pathway and other medical device programs and has taken what it describes as a risk-based approach to develop innovative regulatory policy to propose a more &#8220;contemporary&#8221; approach to the life cycle oversight of medical devices and IVDs. We cannot predict what if any additional regulatory changes will occur or how they will affect our current or future products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Premarket Approval</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PMA process is more complex, costly and time consuming than the 510(k) process. As with a De Novo classification request, a PMA application must be supported by more detailed and comprehensive scientific evidence, including clinical data, to demonstrate the safety and efficacy of the IVD for its intended purpose. If the device is determined to present a &#8220;significant risk,&#8221; the sponsor may not begin a clinical trial until it submits an investigational device exemption (IDE) to the FDA and obtains approval to begin the trial. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the PMA application is submitted, the FDA has 45 days to make a threshold determination that the PMA application is sufficiently complete to permit a substantive review. If the PMA application is complete, the FDA will file the PMA. The FDA is subject to a performance goal review time for a PMA application that is 180 days from the date of filing, although in practice this review time is longer. Questions from the FDA, requests for additional data including additional clinical data and referrals to advisory committees may delay the process considerably. The total process may take several years and there is no guarantee that the PMA application will ever be approved. Even if approved, the FDA may limit the indications for which the device may be marketed. New PMA applications or PMA supplements may be required for modifications to the manufacturing process, labeling, device specifications, materials or design of a device that is approved through the PMA process.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation of Companion Diagnostic Devices</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a sponsor or the FDA believes that a diagnostic test is essential for the safe and effective use of a corresponding therapeutic product, the sponsor of the therapeutic product will typically work with a collaborator to develop an IVD companion diagnostic device. The FDA has issued a final guidance document entitled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In Vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Companion Diagnostic Devices&#8221; that is intended to assist companies developing in vitro companion diagnostic devices and companies developing therapeutic products that depend on the use of a specific in vitro companion diagnostic for the safe and effective use of the product. In the guidance, the FDA defined an IVD companion diagnostic device as a device that provides information that is essential for the safe and effective use of a corresponding therapeutic product. The FDA also noted that in some cases, if evidence is sufficient to conclude that the IVD companion diagnostic device is appropriate for use with a class of therapeutic products, the intended use/indications for use should name the therapeutic class, rather than each specific product within the class. In April 2020, FDA published another final guidance entitled &#8220;Developing and Labeling In Vitro Companion Diagnostic Devices for a Specific Group or Class of Oncology Therapeutic Products&#8221; that expands on the idea of a class of therapeutic products. The more recent guidance describes considerations for the development and labeling of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companion diagnostic devices to support the indicated uses of multiple drug or biological oncology products, when appropriate. The FDA expects that the therapeutic sponsor will address the need for an approved or cleared IVD companion diagnostic device in its therapeutic product development plan and that, in most cases, the therapeutic product and its corresponding IVD companion diagnostic will be developed contemporaneously. To that end, the FDA has also issued draft guidance entitled &#8220;Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product&#8221; to serve as a practical guide to assist therapeutic product sponsors and IVD sponsors in developing a therapeutic product and an accompanying IVD companion diagnostic, as well as draft guidance entitled &#8220;Developing and Labeling In Vitro Companion Diagnostic Devices for a Specific Group or Class of Oncology Therapeutic Products&#8221; to facilitate class labeling on diagnostic tests for oncology therapeutic products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has indicated that it will apply a risk-based approach to determine the regulatory pathway for IVD companion diagnostic devices, as it does with all medical devices. This means that the regulatory pathway will depend on the level of risk to patients, based on the intended use of the IVD companion diagnostic device and the controls necessary to provide a reasonable assurance of safety and effectiveness.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the companion diagnostic test will be used to make critical treatment decisions such as patient selection, treatment assignment, or treatment arm, it will likely be considered a significant risk device for which a clinical trial will be required. The sponsor of the IVD companion diagnostic device will be required to comply with the FDA&#8217;s IDE requirements that apply to clinical trials of significant risk devices. If the diagnostic test and the therapeutic drug are studied together to support their respective approvals, the clinical trial must meet both the IDE and investigational new drug application (IND) requirements. We expect that any IVD companion diagnostic device developed for use with drug products will utilize the PMA pathway and that a clinical trial performed under an IDE will have to be completed before the PMA application may be submitted.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing companion diagnostic tests for use with drug products in development by pharmaceutical companies, such as our collaborations with pharmaceutical companies on PARP inhibitors for the treatment of ovarian, breast and other cancers.  The FDA has also introduced the concept of a complementary diagnostic that it defines as a test that is not required but which provides significant information about the use of a drug.  A complementary test can help guide treatment strategy and identify which patients are likely to derive the greatest benefit from therapy, and if approved by the FDA, information regarding the IVD will be included in the therapeutic product labeling. Although the FDA has not yet issued any written guidance regarding complementary diagnostics, it has approved some complementary diagnostics, including a supplementary premarket approval for BRACAnalysis CDx and MyChoice CDx as complementary diagnostic tests in ovarian cancer patients associated with enhanced progression-free survival (PFS) when used with the PARP inhibitor Zejula&#8482; (niraparib).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2014, we first obtained premarket approval for BRACAnalysis CDx, which is used as a companion diagnostic test to identify ovarian cancer patients who may benefit from AstraZeneca&#8217;s PARP inhibitor Lynparza&#8482; (olaparib). Since then, other indications for BRACAnalysis CDx in ovarian, breast, prostate and pancreatic cancer have received supplemental PMA approval as a companion diagnostic for Lynparza. The MyChoice CDx test has also received approvals as a companion diagnostic test. The premarket approval process for companion or complementary diagnostics is a complex, costly and time-consuming procedure.  Approvals must be supported by valid scientific evidence, submitted as part of a PMA application, which typically requires extensive data, including quality technical, preclinical, clinical and manufacturing data to demonstrate to the FDA&#8217;s satisfaction the safety and effectiveness of the companion diagnostic. We are currently collaborating with several bio-pharmaceutical companies for additional indications and geographical commercialization opportunities for BRACAnalysis CDx and MyChoice CDx as companion diagnostics with other drugs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ongoing Post-Market Regulatory Requirements in the United States</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any products sold by us pursuant to FDA clearances or approvals will be subject to pervasive and continuing regulation by the FDA. In particular, after a medical device is placed on the market, applicable regulatory requirements include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with the FDA&#8217;s Quality System Regulation (QSR), which requires manufacturers to follow stringent design, testing, control, documentation, record maintenance, including maintenance of complaint and related investigation files, and other quality assurance controls during the manufacturing process;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">labeling and advertising regulations, which prohibit the promotion of FDA-regulated medical products for uncleared, or unapproved uses, or &#8220;off-label&#8221; uses, and impose other restrictions on labeling; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">medical device reporting obligations, which require that manufacturers investigate and report to the FDA adverse events, including deaths, or serious injuries that may have been or were caused by a medical device and malfunctions in the device that would likely cause or contribute to a death or serious injury if it were to recur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, device manufacturers are required to register their establishments and list their devices with the FDA and are subject to periodic inspections by the FDA and certain state agencies. Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA and other enforcement agencies, which may include sanctions, including but not limited to, warning letters; fines, injunctions and civil penalties; recall or seizure of the device; operating restrictions, partial suspension or total shutdown of production; refusal to grant 510(k) clearance or approval of PMAs of new devices; withdrawal of clearance or approval; and civil or criminal prosecution.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Regulation of In Vitro Diagnostics and Companion Diagnostic Devices Outside the United States</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products intended for use in IVD applications require regulatory approvals in many other countries and geographic areas, some of which also provide for approval of companion diagnostics.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Union</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union (EU), IVD medical devices historically were regulated under the EU Directive 98/79/EC of the European Parliament and of the Council on in vitro diagnostic medical devices (the Directive). IVDs were not subject to pre-market authorization by a National Competent Authority (NCA) under the Directive, but instead had to comply with essential requirements based on conformity with harmonized standards. For certain IVDs, compliance with the essential requirements was subject to assessment by a Notified Body. Notified bodies are entities designated by the relevant NCAs and are responsible for assessing the conformity of IVDs before they are placed on the EU market. Under the Directive, the majority of IVDs could be placed on the market as a result of the manufacturer self-certifying the IVD as being in conformity with the essential requirements, without the involvement of a Notified Body.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Directive was replaced by the Regulation (EU) 2017/746 of the European Parliament and of the Council on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diagnostic medical devices (IVDR) that entered into force in May 2017, and which initially included a 5-year transition period until its original effective date of May 26, 2022. Unlike the Directive, which specifies certain requirements that must be achieved by each Member State and permits each Member State to decide how to transpose the Directive into national law to meet those requirements, the IVDR has direct binding legal force throughout every Member State without the need for national implementation. The major goals of the IVDR are to standardize diagnostic procedures within the EU, increase reliability of diagnostic analysis and enhance patient safety. Under the IVDR, IVDs are subject to additional legal regulatory requirements as compared to the Directive. Among other things, the IVDR introduces a new risk-based classification for IVDs and specifies CDx and genetic tests as Class C products (second highest risk). Under the IVDR, Class C IVDs require assessment by a Notified Body for certification and audit of the manufacturer's quality management system before they can be placed on the market. The IVDR also obligates laboratories located outside the EU to comply with the IVDR if testing specimens from European citizens. Compliance with the IVDR may be expensive and time-consuming.  Manufacturers will need to provide significant evidence to demonstrate that a device performs safely and effectively.  Performance data may require the conduct of additional clinical investigations or performance studies, with additional and more strict requirements under the IVDR. As noted above, the vast majority of IVDs under the Directive are self-certified, so many device manufacturers have not previously been subject to the Notified Body audits that will occur under the IVDR and will have to revise their Quality Management System (QMS) and Technical Documentation which will now be reviewed by the Notified Bodies. Companion diagnostic IVDs may also be reviewed by the competent medicinal product authorities, usually the European Medicines Agency, as part of a consultation process that will be part of the conformity assessment procedure. There will also be a greater emphasis on post-market surveillance and submission of post-market performance follow-up reports. Due to multiple challenges to the IVDR being ready for full application by the May 2022 implementation date, Regulation (EU) 2022/112 of the Parliament and of the Council was published on 25 January 2022 allowing for a delay to the application of the IVDR by amending the transition provision for certain </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diagnostic medical devices. For products classified as Class C under the IVDR, the transition period allows for legacy devices with a valid declaration of conformity drawn up prior to May 26, 2022 to continue to be placed on the market until May 26, 2026. However, certain IVDR requirements, including post-market surveillance, market surveillance, vigilance, and registration of economic operators and devices remained effective on the May 26, 2022 implementation date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United Kingdom</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The withdrawal of the United Kingdom (UK) from the EU has had ramifications for IVD manufacturers. Among other things, IVD manufacturers have to follow new procedures in the UK including appointment of a UK Responsible Person to manage their compliance efforts in the UK.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK Medicine and Healthcare products Regulatory Agency (MHRA) issued guidance on the regulation of IVDs in the UK following Brexit, and changed the applicable legislation in the UK to take account of the fact that the UK is not a free-standing regulatory regime. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in these provisions, MHRA will continue to recognize CE marks until July 2024.  Companies wishing to place IVDs on the UK market have been required to register with MHRA since January 1, 2021, but are still able to sell CE-IVD marked products in Great Britain, which is defined as England, Scotland and Wales, until July 2024. From approximately July 2024, when new legislation is intended to come into force, companies selling in the UK will have to obtain a new marking called a UK Conformity Assessed mark (UKCA) in order to place a diagnostic device into commerce in Great Britain. This mark, which can be obtained now, is not recognized in EU countries, meaning that companies that wish to sell in the UK and the EU will have to seek both a UKCA and CE-IVD mark in the future. The EU legislative framework applies in Northern Ireland, meaning that companies can still, and will still be able to, sell tests in Northern Ireland under applicable EU IVD regulations including the current IVDR.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Japan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IVDs are regulated in Japan by the Pharmaceutical and Medical Devices Agency (PMDA) and are assigned to one of three classes depending on the perceived level of risk. Those in the least risky class may be registered and marketed after filing a pre-market submission, while those in the middle class are subject to pre-market certification by a registered certification body.  The riskiest IVDs must be approved. Submissions may be made only by marketing authorization holders, which must satisfy specific requirements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant revisions to Japanese regulations of medical devices, IVDs and other health care products are ongoing. The first round of changes to Japan&#8217;s Pharmaceuticals and Medical Devices Act took effect September 1, 2020 and August 2021, with additional revisions coming into force in December 2022. Some of those changes will affect IVDs, including the ability to qualify for fast track designation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Additional International Regulation </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market, directly or through distributors, some of our tests outside of the United States and are subject to foreign regulatory requirements governing laboratory licensure, human clinical testing, use of tissue, privacy and data security, and marketing approval for our tests. These requirements vary by jurisdiction, differ from those in the United States and may require us to implement additional compliance measures or perform additional pre-clinical or clinical testing. In many countries outside of the United States, coverage, pricing and reimbursement approvals are also required. We are also required to maintain accurate information on and control over sales and distributors&#8217; activities that may fall within the purview of the Foreign Corrupt Practices Act, its books and records provisions and its anti-bribery provisions, as well the UK Bribery Act and other anti-corruption laws.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">HIPAA and Other Privacy Laws</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996 (HIPAA), which applies to health plans, healthcare clearing houses, and healthcare providers that conduct certain health care transactions electronically (Covered Entities) contains provisions that address the privacy and security of individually identifiable health information (called &#8220;protected health information&#8221; under HIPAA), the standardization of identifying numbers used in the healthcare system and the standardization of certain health care transactions. HIPAA's privacy regulations protect health information by limiting its use and disclosure to certain purposes, such as treatment or payment, without patient authorization. HIPAA also gives patients certain rights including the right to access their medical records and the right to an accounting of certain disclosures of protected health information. HIPAA's privacy rule also limits many disclosures of protected health information to the minimum amount necessary to accomplish an intended purpose. The HIPAA security standards require the adoption of administrative, physical, and technical safeguards for the protection of protected health information and the adoption of written security policies and procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Information Technology for Economic and Clinical Health Act (HITECH) expanded and strengthened HIPAA, created new targets for enforcement, imposed new penalties for noncompliance and established new breach notification requirements for Covered Entities. Under HITECH&#8217;s breach notification requirements, Covered Entities must report breaches of protected health information that has not been encrypted or otherwise secured in accordance with guidance from the Secretary of the U.S. Department of Health and Human Services. Required breach notices must be made as soon as is reasonably practicable, but no later than 60 days following discovery of the breach. Reports must be made to affected individuals and to the Secretary and, in some cases depending on the size of the breach, they must be reported through local and national media. Breach reports can lead to investigation, enforcement, civil monetary penalties and civil litigation, including class action lawsuits and enforcement by state.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently subject to the HIPAA regulations and maintain an active compliance program that is designed to meet requirements of the privacy and security rules and to identify privacy and security incidents and other issues in a timely fashion so that we may remediate, mitigate harm and report if required by law. However, even if we take steps to comply with HIPAA, we may be subject to complaints and investigation at the federal and/or state level. In the event of a breach, even if we mitigate harm and make required reports on a timely basis, we may still be subject to penalties for the underlying breach.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the federal privacy and security regulations, there are a number of state laws regarding the privacy and security of health information and personal data that can be applicable to our clinical laboratories, as further discussed in the "Risk Factor" section below.  Many states have also implemented genetic testing laws imposing specific patient consent requirements and protecting genetic information by limiting the disclosure of such information. State requirements are particularly stringent regarding predictive genetic tests, due to the risk of genetic discrimination against healthy patients identified through testing as being at risk for disease. Compliance with health information privacy and security statutes and regulations, including genetic testing and genetic information privacy laws in all jurisdictions, both state and federal, can be challenging as these laws often change, and we may not be able to maintain compliance in all jurisdictions where we do business. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Transparency Laws and Regulations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A federal law known as the Physician Payments Sunshine Act requires medical device manufacturers to track and report to CMS certain payments and other transfers of value made to covered recipients, which include physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse-midwives who are not bona fide employees of the manufacturer, as well as teaching hospitals, and ownership or investment interests held by physicians and their immediate family members. Manufacturers must report data for the previous calendar year by the 90th day of the then-current calendar year. CMS then publishes the data on a publicly available website no later than June 30th. There are also state &#8220;sunshine&#8221; laws that require manufacturers to provide reports to state governments on pricing and marketing information. Several states have enacted legislation requiring medical device manufacturers to, among other things, establish marketing compliance programs, file periodic reports with the state, and make periodic public disclosures on sales and marketing activities, and such laws may also prohibit or limit certain other sales and marketing practices. These laws may adversely affect our sales, marketing, and other activities by imposing administrative and compliance burdens on us. If we fail to track and report as required by these laws or to otherwise comply with these laws, we could be subject to the penalty provisions of the pertinent state and federal authorities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Reimbursement and Billing</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement and billing for diagnostic services is highly complex. Laboratories must bill various payors, such as private third-party payors, including managed care organizations (MCO), and state and federal health care programs, such as Medicare and Medicaid, and each may have different billing requirements. Additionally, the audit requirements imposed by these payors, as well as our internal compliance policies and procedures, add further complexity to the billing process. Other factors that complicate billing include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">variability in coverage and information requirements among various payors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">patient financial assistance programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">missing, incomplete or inaccurate billing information provided by ordering physicians;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">billings to payors with whom we do not have contracts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">disputes with payors as to which party is responsible for payment; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">disputes with payors as to the appropriate level of reimbursement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the reimbursement arrangement and applicable law, the party that reimburses us for our tests may be:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a third party who provides coverage to the patient, such as an MCO;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a state or federal health care program; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the patient.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presently, approximately 63% of our revenue comes from private third-party payors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2014, Congress passed the Protecting Access to Medicare Act of 2014 (PAMA), which included substantial changes to the way in which CMS pays for clinical laboratory services under Medicare&#8217;s Clinical Laboratory Fee Schedule (CLFS). PAMA took effect on January 1, 2018 and requires applicable laboratories to report to CMS private insurer payment rates and volumes for their tests. CMS uses the data reported and the Healthcare Common Procedure Coding System code associated with the test to calculate a weighted median payment rate for each test, which is used to establish revised Medicare CLFS reimbursement rates for tests that are considered to be clinical diagnostic laboratory tests (CDLTs), subject to certain phase-in limits. For tests furnished on or after January 1, 2019, Medicare payments for CDLTs are based on reported private payor rates. For a CDLT that is assigned a new or substantially revised current procedural terminology (CPT) code, the initial payment rate is assigned using the gap-fill methodology, as under prior law. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the test falls into the category of new advanced diagnostic laboratory test (ADLT) instead of a CDLT, the test will be paid based on an actual list charge for an initial period of three quarters before being shifted to the weighted median private payor rate reported by the laboratory performing the ADLT. Laboratories offering ADLTs are subject to recoupment if the actual list charge exceeds the weighted median private payor rate by a certain amount. Accordingly, if newly developed tests receive Medicare coverage in the future, the reimbursement rate we receive for such tests may be affected by payment rates made by private payors for such tests.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2019, the President signed the Further Consolidated Appropriations Act, which included the Laboratory Access for Beneficiaries Act (LAB Act). The LAB Act delayed until the first quarter of 2021 reporting of payment data under PAMA for CDLTs that are not ADLTs. The Coronavirus Aid, Relief, and Economic Security Act (CARES Act), which Congress passed in March 2020, again delayed the reporting by an additional year, this time until the first quarter of 2022. Then, on December 10, 2021, Congress passed the Protecting Medicare and American Farmers from Sequester Cuts Act, which included a provision that further delayed the next PAMA reporting period for CDLTs that are not ADLTs to January 1, 2023 through March 31, 2023. The Consolidated Appropriations Act, 2023 enacted on December 29, 2022 again delayed the next PAMA reporting period to January 1, 2024 through March 31, 2024. New CLFS rates for CDLTs will be established based on that data beginning in 2025, subject to phase-in limits. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS&#8217;s methodology under PAMA (as well as the willingness of commercial insurers to recognize the value of diagnostic testing and pay for that testing accordingly) renders commercial insurer payment levels even more significant. This calculation methodology has resulted in significant reductions in reimbursement, even though CMS imposed caps on those reductions. For example, PAMA (as amended) includes provisions that limit the amount by which payment for testing may be reduced. For example, for 2018 through 2020, a test price could not be reduced by more than 10% per year. Reductions for 2023 through 2025 are limited to 15%. The CARES Act delayed for one year the 15% cut that was scheduled to take effect on January 1, 2021, and the Protecting Medicare and American Farmers from Sequester Cuts Act further delayed those cuts until 2023. The Consolidated Appropriations Act, 2023, again delayed the cuts until 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The subsequent data reporting period for CDLTs that are not ADLTs will occur in three-year cycles, with the next cycle beginning in 2027. Given the many uncertainties built into PAMA&#8217;s price-setting process, we cannot predict how payments we receive under the CLFS, and thus our revenue, may change from year to year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The No Surprises Act was signed into law on December 27, 2020, as part of the Consolidated Appropriations Act, 2021.  The Department of Health and Human Services, the Department of Treasury, and the Department of Labor have since released &#8220;Tri-Agency&#8221; regulations to implement the No Surprises Act, which became effective on January 1, 2022.  The law and regulations generally apply to group health plans and health insurance issuers offering group or individual health insurance coverage for plan years starting January 1, 2022, and to certain health care providers and facilities.  For non-emergency services provided by an out-of-network provider (such as a laboratory) during a visit at an in-network facility (which includes a hospital but not a physician office), the No Surprises Act requires the non-emergency services provider to hold a patient harmless for amounts beyond the in-network cost-sharing requirement.  In other words, balance billing generally is prohibited.  Because these billing requirements do not apply to patient specimens collected in a physician office, Myriad is impacted primarily when a patient&#8217;s specimen is collected at an in-network hospital, and Myriad is an out-of-network provider under the patient&#8217;s insurance plan.  Out-of-network rates for covered services are determined by a state All-Payer Model Agreement, a specified state law, an agreed-upon amount, or, if none apply, an amount determined by an independent dispute resolution entity.  The cost-sharing amount is limited to an amount determined by an All-Payor Model Agreement, a specified state law, or, if neither applies, the lesser of the billed charge or the &#8220;qualifying payment amount,&#8221; which is generally the plan or issuer&#8217;s median contracted rate for the same or similar service in the specific geographic area.  Non-covered services are not impacted by these rules.  In addition, providers, including Myriad, must post consumer notices on their website about the applicability of the law. Providers, including physician offices, must provide a good faith estimate of the cost of the service when requested by a patient who is uninsured or seeking to forgo insurance and pay cash instead.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Federal and State Fraud and Abuse Laws</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A variety of state and federal laws prohibit fraud and abuse involving state and federal health care programs, such as Medicare and Medicaid. These laws are interpreted broadly and enforced aggressively by various state and federal agencies, including CMS, the Department of Justice, the Office of Inspector General for the Department of Health and Human Services (OIG), and various state agencies. In addition, the Medicare and Medicaid programs increasingly use a variety of contractors to review claims data and to identify improper payments as well as fraud and abuse. Any overpayments must be repaid within 60 days of identification unless a favorable decision is obtained on appeal. In some cases, these overpayments can be used as the basis for an extrapolation by which the error rate is applied to a larger set of claims, which can result in even higher repayments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Anti-Kickback Laws</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for or recommending of an item or service that is reimbursable, in whole or in part, by a federal health care program. &#8220;Remuneration&#8221; is broadly interpreted to include anything of monetary value, such as, for example, cash payments, gifts or gift certificates, discounts, or the furnishing of services, supplies or equipment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognizing the potential breadth of interpretation of the Anti-Kickback Statute and the fact that it may technically prohibit many innocuous or beneficial arrangements within the healthcare industry, the OIG has promulgated safe harbors intended to protect such arrangements. Compliance with all requirements of a safe harbor immunizes the parties to the business arrangement from prosecution under the Anti-Kickback Statute. The failure of a business arrangement to fit within a safe harbor does not necessarily mean that the arrangement is illegal or that enforcement agencies will pursue prosecution. Still, in the absence of an applicable safe harbor, a violation of the Anti-Kickback Statute may occur even if only one purpose of an arrangement is to induce referrals. The penalties for violating the Anti-Kickback Statute can be severe. These sanctions include criminal and civil penalties, imprisonment and possible exclusion from federal health care programs. Many states have adopted laws similar to the Anti-Kickback Statute, and some apply to items and services reimbursable by any payor, including private third-party payors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in October 2018, the Eliminating Kickbacks in Recovery Act of 2018 (EKRA), was enacted as part of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (the SUPPORT Act). EKRA is an all-payor anti-kickback law that makes it a criminal offense to pay any remuneration to induce referrals to, or in exchange for, patients using the services of a recovery home, a substance use clinical treatment facility, or laboratory. Although it appears that EKRA was intended to reach patient brokering and similar arrangements to induce patronage of substance use recovery and treatment, the language in EKRA is broadly written. Further, certain of EKRA&#8217;s exceptions are inconsistent with the Anti-Kickback Statute regulations. Significantly, EKRA permits the U.S. Department of Justice to issue regulations clarifying EKRA&#8217;s exceptions or adding additional exceptions, but such regulations have not yet been issued. Further, there is no agency guidance and little court precedent to indicate how and to what extent EKRA will be applied and enforced.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Physician Self-Referral Bans</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal ban on physician self-referrals, commonly known as the Stark Law, prohibits, subject to certain exceptions, physician referrals of Medicare patients to an entity providing certain designated health services, which include laboratory services, if the physician or an immediate family member of the physician has any financial relationship with the entity. Several Stark Law exceptions are relevant to arrangements involving clinical laboratories, including but not limited to: (1) fair market value compensation for the provision of items or services; (2) payments by physicians to a laboratory for clinical laboratory services; (3) space and equipment rental arrangements that satisfy certain requirements; and (4) personal services arrangements. Penalties for violating the Stark Law include the return of funds received for all prohibited referrals, fines, civil monetary penalties and possible exclusion from federal health care programs. In addition to the Stark Law, many states have their own self-referral bans, which may extend to all self-referrals, regardless of the payor.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">State and Federal Prohibitions on False Claims</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment to the federal government. Under the False Claims Act, a person acts knowingly if he or she has actual knowledge of the information or acts in deliberate ignorance or in reckless disregard of the truth or falsity of the information. Specific intent to defraud is not required. The qui tam provisions of the False Claims Act allow a private individual to bring an action on behalf of the federal government and to share in any amounts paid by the defendant to the government in connection with the action.  Penalties include payment of up to three times the actual damages sustained by the government, plus civil penalties of between $5,500 and $11,000 for each false claim, as well as possible exclusion from federal health care programs. However, the civil penalty amounts are adjusted annually for inflation. In addition, various states have enacted similar laws modeled after the False Claims Act that apply to items and services reimbursed under Medicaid and other state health care programs, and, in several states, such laws apply to claims submitted to any payor. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Civil Monetary Penalties Law</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Civil Monetary Penalties Law (the CMP Law), prohibits, among other things, (1) the offering or transfer of remuneration to a Medicare or state health care program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies; (2) employing or contracting with an individual or entity that the provider knows or should know is excluded from participation in a federal health care program; (3) billing for services requested by an unlicensed physician or an excluded provider; and (4) billing for medically unnecessary services. The penalties for violating the CMP Law include exclusion, substantial fines, and payment of up to three times the amount billed, depending on the nature of the offense.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other U.S. Regulatory Requirements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to laws and regulations related to the protection of the environment, the health and safety of employees and the handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials. For example, the U.S. Occupational Safety and Health Administration (OSHA) has established extensive requirements relating specifically to workplace safety for healthcare employers in the United States. This includes requirements to develop and implement multi-faceted programs to protect workers from exposure to blood-borne pathogens, including preventing or minimizing any exposure through needle stick injuries. For purposes of transportation, some biological materials and laboratory supplies are classified as hazardous materials and are subject to regulation by one or more of the following agencies: the U.S. Department of Transportation, the U.S. Public Health Service, the United States Postal Service, the Office of Foreign Assets Control, and the International Air Transport Association. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our laboratories are subject to federal, state and local regulations relating to the handling and disposal of regulated medical waste, radioactive materials, hazardous waste and biohazardous waste, including chemical and biological agents and compounds, blood and bone marrow samples, and other human tissue. Typically, we use outside vendors who are contractually obligated to comply with applicable laws and regulations to dispose of such waste. These vendors are licensed or otherwise qualified to handle and dispose of such waste.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our advertising for laboratory services and LDTs that are not FDA-approved is subject to federal truth-in-advertising laws enforced by the Federal Trade Commission (FTC), as well as certain state laws. Under the Federal Trade Commission Act, or FTC Act, the FTC is empowered, among other things, to prevent unfair methods of competition and unfair or deceptive acts or practices in or affecting commerce. The FTC has very broad enforcement authority, and failure to abide by the substantive requirements of the FTC Act and other consumer protection laws can result in administrative or judicial penalties, including civil penalties, injunctions affecting the manner in which we would be able to market services or certain products in the future, or criminal prosecution.</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in Fiscal Year</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2021, we changed our fiscal year end from the last day of June to a calendar fiscal year. The six month period that commenced on July 1, 2020 and ended on December 31, 2020 was a transition period and is referred to in this Annual Report on Form 10-K as the "transition period."  References in this Annual Report on Form 10-K to &#8220;fiscal year&#8221; refer to years ended June 30th or December 31st, as applicable. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a Delaware corporation with our principal executive offices located at 320 Wakara Way, Salt Lake City, Utah 84108. Our telephone number is (801) 584-3600 and our website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.myriad.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We make available free of charge through the Investor Relations section of our website our Code of Conduct, our Audit and Finance Committee and other committee charters and our other corporate governance policies, as well as our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission. The Securities and Exchange Commission maintains an internet site (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the Securities and Exchange Commission. We include our website address in this Annual Report on Form 10-K only as an inactive textual reference and do not intend it to be an active link to our website.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;RISK FACTORS </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors Summary</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the principal risks that could adversely affect our business, operations, and financial results: </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Our Strategy</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to generate sufficient revenue from our existing tests or develop new tests to be profitable.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our strategic growth plan may not achieve the anticipated results, and we may not be able to achieve or maintain revenue growth or operate our business on a profitable basis.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our financial condition and results of operations could be further adversely affected by the ongoing coronavirus pandemic or any other adverse public health development.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not generate sufficient cash flow from operations and are unable to secure additional funding, we may have to reduce our operations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to debt covenants that impose operating and financial restrictions on us and if we are not able to comply with them, it could have a material adverse impact on our operations and liquidity.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our current operating plan changes and we find that our existing capital resources will not meet our needs, we may find it necessary to raise additional funding, which may not be available.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are currently subject to, and in the future may be subject to, securities class action lawsuits and stockholder derivative actions, as well as product or professional liability claims. These, and potential similar or related litigation, could result in substantial losses and have a material adverse effect on our business, cash position, operating results or financial condition.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An inability to attract and retain experienced and qualified personnel, including key management personnel, could adversely affect our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have acquired and we may continue to acquire technologies, assets or other businesses that could cause us to incur significant expense and expose us to a number of unanticipated operational and financial risks, which could adversely affect our financial condition, results of operations and business prospects. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our SneakPeek Early Gender DNA Test does not perform as expected, we may not realize the expected benefits of our acquisition of Gateway.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Security breaches, loss of data and other disruptions, including from cyberattacks, could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability, which could adversely affect our business and our reputation.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we experience a significant disruption in our information technology systems, our business operations and financial condition could be adversely affected. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Each of our tests is processed in a single one of our laboratory facilities, and any loss or prolonged interruption of our ability to use these laboratories or failure to maintain their operation in compliance with applicable regulations would seriously harm our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on a limited number of third parties, or, in some cases, single-source suppliers, for equipment, reagents and other supplies. If these supplies become unavailable or are disrupted, including as a result of COVID-19 or another disease and responses to it, then we may not be able to successfully perform our research or operate our business on a timely basis or at all.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our international business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ethical, legal and social concerns related to the use of genetic information could reduce demand for our tests.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on commercial courier delivery services to transport biological materials to our facilities in a timely and cost-efficient manner and if these delivery services are disrupted, our business will be harmed.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face risks associated with currency exchange rate fluctuations, which could adversely affect our operating results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Development and Commercialization of Our Tests and Test Candidates</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our tests in development may not be clinically effective or may never achieve significant commercial market acceptance and our test offerings that we have recently launched or acquired may not be commercially successful.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not compete effectively with scientific and commercial competitors, we may not be able to successfully commercialize our tests, increase our revenue or achieve and sustain profitability.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our current research collaborators or scientific advisors terminate their relationships with us or develop relationships with a competitor, our ability to discover genes, proteins, and biomarkers, and to validate and commercialize tests could be adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reimbursement</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the government and third-party payors fail to provide coverage and adequate payment for our existing and future tests, if any, our revenue and prospects for profitability will be harmed.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to comply with laws and regulations related to submission of claims for our services could result in significant monetary damages and penalties and exclusion from the Medicare and Medicaid programs and corresponding foreign reimbursement programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are not able to protect our proprietary technology, others could compete against us more directly, which would harm our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are subject to litigation or other proceedings arising from a claim of infringement of the intellectual property of a third party, we might incur significant costs and delays in test introduction or we could be prevented from using technologies incorporated in our tests.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to comply with our obligations under license or technology agreements with third parties, we could lose license rights that are critical to our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to claims that we or our employees have wrongfully used or disclosed alleged trade secrets.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to adequately protect our trademarks, service marks, trade names and trade dress, we may lose goodwill and brand equity associated with our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to comply with the complex federal, state, local and foreign laws and regulations that apply to our business, we could suffer consequences that could materially and adversely affect our operating results and financial condition.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our actual or perceived failure to comply with data protection laws and regulations could lead to government enforcement actions, private litigation, and/or adverse publicity and could negatively affect our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may from time to time be subject to government investigation(s), the unfavorable outcome of which may have a material adverse effect on our financial condition, results of operations and cash flows. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in health care policy could increase our costs, decrease our revenues and impact sales of and reimbursement for our tests.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business could be harmed by the loss, suspension, or other restriction on a license, certification, or accreditation, or by the imposition of a fine or penalties, under CLIA, its implementing regulations, or other state, federal and foreign laws and regulations affecting licensure or certification, or by future changes in these laws or regulations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in the way that the FDA regulates tests performed by laboratories like ours could result in delay or additional expense in offering our tests and tests that we may develop in the future.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA regulation of our GeneSight Psychotropic test could be disruptive to our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Companion and complementary diagnostic tests require FDA approval, and we may not be able to secure such approval in a timely manner or at all. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our companion diagnostic tests are subject to ongoing regulatory compliance obligations and continued regulatory review and the failure to comply with such obligations could result in regulatory enforcement and/or penalties.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business involves environmental risks that may result in liability for us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stock price is highly volatile, and our stock may lose all or a significant part of its value.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to achieve and maintain effective disclosure controls and procedures and internal control over financial reporting could adversely affect our results of operations, our stock price and investor confidence in us.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anti-takeover provisions of Delaware law, provisions in our charter and bylaws and re-adoption of our stockholders&#8217; rights plan, or poison pill, could make a third-party acquisition of us difficult.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Future sales and issuances of our common stock would result in dilution of the percentage ownership of our stockholders and could cause the price of our common stock to decline.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We do not intend to pay dividends on our common stock so any returns will be limited to changes in the value of our common stock.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our restated bylaws provide that a state court located within the State of Delaware is the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Our Strategy</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to generate sufficient revenue from our existing tests or develop new tests to be profitable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our future success is dependent upon our ability to successfully market our existing tests to additional patients within the United States, to expand into new markets within and outside the United States, and to develop and commercialize new tests. However, we may not be able to generate sufficient revenue, from our existing tests and launching and commercializing new tests, to be profitable. The demand for our existing tests may decrease or may not continue to increase at historical rates due to sales of new tests that may replace or cannibalize our existing product portfolio, or for other reasons such as the introduction of competing testing products by competitors. For example, because most of our tests are only utilized once per patient, we will need to sell our products to new patients or develop new tests in order to continue to generate revenue. Our average reimbursement rate per test may also decline, which may cause our revenues to decrease. Our pipeline of new test candidates, such as FirstGene and Precise MRD, are in various stages of development, some of which may take many more years to develop, and must undergo extensive clinical validation. We may be unable to discover or develop any additional tests through the utilization of our technologies or technologies we license or acquire from others. Even if we develop tests for commercial use, we may not be able to develop tests that:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">meet applicable regulatory standards, in a timely manner or at all;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully compete with other technologies and tests;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">avoid infringing the proprietary rights of others;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">are adequately reimbursed by third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">can be performed at commercial levels or at reasonable cost; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">can be successfully marketed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must generate significant revenue to achieve profitability. Even if we succeed in marketing our existing tests to physicians for use in new patients and in developing and commercializing any additional tests, we may not be able to generate sufficient revenue to be profitable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our strategic growth plan may not achieve the anticipated results, and we may not be able to achieve or maintain revenue growth or operate our business on a profitable basis.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently executing upon a strategic growth plan in which we intend to accelerate growth through launching new tests, utilizing a unified ordering portal to improve access and ease of use for patients and providers, expanding reimbursement coverage for our tests, enhancing our commercial capabilities and deploying a new commercial model in our Women's Health and Oncology businesses. Our future performance and growth depends on the success of our growth plan, including management's ability to execute upon that plan and the ability of our employees to respond quickly and effectively to strategic projects and changes in our operations and business practices. The implementation of our strategic growth plan has resulted, and is expected to continue to result, in changes to business priorities and operations, capital allocation priorities, operational and organizational structures, and increased demands on management. The execution of our strategic growth plan may take longer than anticipated, and we may not realize, in full or part, our anticipated growth targets in our testing volumes and revenue, or such growth may be realized more slowly than anticipated. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our business operated profitably and provided a cash contribution to our funding and operational needs. However, in recent years we have not operated our business profitably, and we may not be able to operate our business on a profitable basis in the future. Potential events or factors that may have a significant impact on our ability to achieve our growth targets and achieve and/or maintain revenue growth and profitability for our business include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efforts of third-party payors to limit or decrease the amounts that they are willing to pay for our tests, recoup amounts already paid, or institute burdensome administrative requirements for reimbursement, such as prior authorization requirements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased costs of reagents and other consumables required for testing;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased personnel and facility costs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to hire competent, trained staff, including laboratory directors required to review and approve all reports we issue in our business, and sales personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to obtain necessary equipment or reagents to perform testing;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to increase production capacity to meet demand increases;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to expand into new markets within or outside the United States;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to execute on our strategic growth plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased licensing or royalty costs, and our ability to maintain and enforce the intellectual property rights underlying our tests and services;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in intellectual propriety law applicable to our patents or enforcement in the United States and foreign countries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expiration of the patents covering our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of outstanding or new litigation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential obsolescence of our tests;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to obtain or increase commercial acceptance of our tests;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased competition and loss of market share;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">global or local economic conditions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased regulatory requirements; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">material litigation costs, settlements, and judgments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to achieve our growth targets and achieve and/or maintain revenue growth and profitability for our business could have a material adverse effect on our business, prospects, financial condition, results of operations, cash flows, as well as the trading price of our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our financial condition and results of operations could be further adversely affected by the ongoing coronavirus pandemic or any other adverse public health development.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any further outbreaks of COVID-19 (including its variant strains) or any other outbreak of contagious disease or adverse public health development, could have a further material and adverse effect on our business operations, financial condition, or results of operations. For example, government public health officials and businesses have implemented, and may continue to implement,  restrictions to curb the spread of COVID-19, which has limited, and may continue to limit, patients&#8217; access to our products, and has caused, and may continue to cause, patients to elect to defer certain testing, each of which has impeded, and may continue to impede, our progress in returning to profitability and recovering from the earlier effects of the COVID-19 pandemic. Such adverse effects have included, and may continue to include, diversion or prioritization of health care resources away from the conduct of testing, and disruptions or restrictions affecting the ability of our laboratories to process our tests. Future surges in COVID-19 cases or any other outbreak of contagious disease and related employee absences may strain our workforce and impact our ability to process tests in a timely way due to reduced staff availability.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that COVID-19 or another disease affects individuals and businesses around the globe, we may experience further disruptions from time to time that could severely impact our business, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased volume of testing as a result of disruptions to health care providers and limitations on the ability of providers to administer tests, including the suspension of non-emergency appointments and services;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions or restrictions on the ability of our customers, our collaborators&#8217;, or our suppliers&#8217; personnel to travel, including as a result of shelter-in-place or stay-at-home orders from state and local governments, and temporary closures of our facilities or the facilities of our collaborators or suppliers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on employee resources that would otherwise be focused on the development of our products, processing our tests, and the conduct of our clinical trials, including because of sickness of employees or their families or requirements imposed on employees to avoid contact with large groups of people; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or access.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the continued spread of COVID-19 or the spread of another disease globally could continue to adversely affect our manufacturing and supply chain. Parts of our direct and indirect supply chain are located overseas and both international and domestic components have been, and may continue to be, subject to disruption as a result of COVID-19 or another disease and responses to it. If the supplies and components necessary to manufacture our products become unavailable or are disrupted as a result of COVID-19 or the spread of another disease and responses to it, then we may not be able to successfully perform our research, sell our tests, or operate our business on a timely basis or at all. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 continues to affect our business, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration, spread and severity of COVID-19 outbreaks, the rate of vaccination and efficacy of approved vaccines against COVID-19 and its variant strains, actions taken to contain COVID-19 or treat its impact, new information that may emerge concerning the health effects of COVID-19, and how quickly and to what extent normal economic and operating conditions resume, any of which could have a further adverse effect on our business and financial condition. Even after the COVID-19 pandemic subsides or becomes endemic, we may continue to experience an adverse impact to our business as a result of its global economic impact, including from increased inflation, delayed economic recovery and any recession that has occurred or may occur in the future. In addition, difficult macroeconomic conditions, such as inflation, decreases in per capita income and level of disposable income and related health insurance coverage, increased and prolonged unemployment or a decline in consumer confidence as a result of the pandemic, could have a material adverse effect on the demand for some or all of our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not generate sufficient cash flow from operations and are unable to secure additional funding, we may have to reduce our operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we anticipate that our existing cash, cash equivalents and marketable securities, future cash flow from operations, and in certain circumstances, amounts available for borrowing under our Amended Facility (as defined below) will be sufficient to fund our current operations for the foreseeable future, changes could occur that would consume available capital resources more quickly than we currently expect and we may need or want to raise additional financing. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2016, we entered into a senior secured revolving credit facility as borrower, with the lenders from time to time party thereto, which was amended on July 31, 2018, May 1, 2020, February 22, 2021 and July 26, 2022 (the "Amended Facility"). As of December 31, 2022, we have no outstanding borrowings under our Amended Facility and our revolving commitment amount was $150.0 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Facility restricts our ability to make future borrowings if unrestricted cash, cash equivalents and marketable securities exceed $150.0 million, unless such borrowings are used in connection with certain permitted acquisitions. Unrestricted cash, cash equivalents and marketable securities totaled $169.7 million as of December 31, 2022. As our total unrestricted cash, cash equivalents, and marketable securities under the Amended Facility exceeded $150.0 million as of December 31, 2022, we are currently unable to make future borrowings under the Amended Facility unless related to a permitted acquisition. In addition, our Amended Facility expires on July 31, 2023, and there is no guarantee that the Amended Facility will be extended or that we will be able to secure additional funding or other financing options in a timely manner or on favorable terms, if at all. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to financial covenants as part of our Amended Facility that could limit our ability to incur additional indebtedness. Without additional funds, we may be forced to delay, scale back or eliminate some of our sales and marketing activities, research and development activities, or other operations, and potentially delay development of our tests in an effort to provide sufficient funds to continue our operations. If any of these events occur, our ability to achieve our development and commercialization goals could be adversely affected. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors that are currently unknown to us, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and cost of development, clinical testing and pre-market studies of any new tests that we may develop or acquire;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, results, and costs to develop additional tests;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to operate our business on a profitable basis;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our current issued patents, and defending intellectual property-related claims;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into collaborations, licensing or other arrangements favorable to us;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of acquiring technologies or businesses, and our ability to successfully integrate and achieve the expected benefits of our business development activities and acquisitions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, cost and results of our international efforts;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of expanding our sales and marketing functions and commercial operation facilities in the United States and in new markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of any litigation against us; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs to satisfy our current and future obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to debt covenants that impose operating and financial restrictions on us and if we are not able to comply with them, it could have a material adverse impact on our operations and liquidity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covenants in the Amended Facility impose operating and financial restrictions on us. These restrictions may prohibit or place limitations on, among other things, our ability to incur additional indebtedness, create certain types of liens, and complete mergers, consolidations, or change in control transactions. Under the Amended Facility, a change in control of the Company, which means that a stockholder or a group of stockholders is or becomes the beneficial owner, directly or indirectly, of more than 35% of the total voting power of the voting stock of the Company, would require mandatory prepayment of any outstanding debt. The Amended Facility may also prohibit or place limitations on our ability to sell assets, pay dividends or provide other distributions to stockholders. These restrictions could also limit our ability to take advantage of business opportunities. We are also required to comply with certain financial covenants, including a minimum liquidity covenant, under the Amended Facility. If we are unable to comply with these financial covenants in the Amended Facility, we may be in default under the agreement. A default would result in an increase in the rate of interest and limits on our ability to incur certain additional indebtedness and it could potentially cause any loan repayment to be accelerated, any of which could have a material adverse impact on our operations and liquidity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our current operating plan changes and we find that our existing capital resources will not meet our needs, we may find it necessary to raise additional funding, which may not be available.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our existing capital resources and expected net cash to be generated from sales of our tests will enable us to maintain our currently planned operations for the foreseeable future. However, we base this expectation on our current operating plan, which may change. We have incurred, and will continue to incur, significant costs in the development and marketing of current and prospective tests. Our ongoing efforts to develop tests and expand our business, which may be through internally developed products, partnerships, in-licensing and mergers and acquisitions, will require substantial cash resources. In addition, we have incurred, and may continue to incur, substantial costs in defending and settling legal proceedings. We may also be required to pay an additional $32.5 million to the former equity and vested incentive unit holders of Gateway, if certain revenue, volume and earnings targets set forth in the acquisition agreement are achieved. If adequate funds are not available, we may be required to raise additional funds. Sources of potential additional capital resources may include, but are not limited to, public or private equity financings, expanding or supplementing our Amended Facility, or selling convertible or non-convertible debt securities. This additional funding, if necessary, may not be available to us on reasonable terms, or at all.  If we issue shares of stock or other securities to acquire new companies or technologies, the ownership interests of our existing stockholders may be significantly diluted and the price of our common stock may decrease.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of our potential long-term capital requirements, we may access the public or private equity or debt markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time. Under Securities and Exchange Commission rules, we currently qualify as a well-known seasoned issuer (WKSI), and can at any time file a registration statement registering securities to be sold to the public which would become effective and available for use upon filing.  If additional funds are raised by issuing equity or equity-based securities, existing stockholders may suffer significant dilution. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances, partnerships and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or tests or grant licenses on terms that are not favorable to us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently subject to, and in the future may be subject to, securities class action lawsuits and stockholder derivative actions, as well as product or professional liability claims. These, and potential similar or related litigation, could result in substantial losses and have a material adverse effect on our business, cash position, operating results or financial condition. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently subject to a variety of litigation, including a securities class action lawsuit filed in the United States District Court for the District of Utah, and stockholder derivative actions filed in the Delaware Court of Chancery and the United States District Court for the District of Delaware. We also may be subject to future securities class action and stockholder derivative claims. Such litigation may adversely impact our business, cash position, results of operations or financial condition and divert management's time and attention from our business. We cannot predict the outcome of these lawsuits, nor can we predict the amount of time and expense that will be required to resolve these lawsuits and the expense of resolving these lawsuits may be in amounts significantly above our insurance coverage. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the marketing, sale and use of our tests could subject us to liability for errors in, misunderstandings of, or inappropriate reliance on, information we provide to clinicians, geneticists or patients, and lead to claims against us if someone were to allege that a test failed to perform as it was designed or marketed, if we failed to provide a correct test result to a patient, if we failed to correctly interpret the test results, if we failed to update the test results due to a reclassification of the variants according to new published guidelines, or if the ordering physician or patient were to misinterpret test results or improperly rely on them when making a clinical decision. We could also be subject to claims, lawsuits or liability if the biological materials we receive for analysis were not properly attributed to the correct patient or if we failed to maintain custody of or properly track the biological materials. A product liability or professional liability claim could result in substantial damages and be costly and time-consuming for us to defend. For example, on January 24, 2022, we paid $14.0 million to settle a lawsuit that alleged negligence, breach of contract and associated torts in connection with an alleged error in testing performed by us in 2004. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain liability insurance for certain claims, including director and officer's insurance and insurance for errors and omissions, we cannot assure you that such insurance would fully protect us from the financial impact of defending against outstanding or future claims or any judgments, fines or settlement costs arising out of any outstanding or future claims. Any claim, including the securities class action and stockholders derivative claims or an errors and omissions liability claim, brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. If we were successfully sued for product or professional liability claims or in connection with current or future securities class action and stockholder derivative claims, we could face substantial losses that exceed our insurance coverage and our other resources. For example, although we maintain director and officer's insurance coverage and continue to engage in defense of the outstanding securities class action and stockholder derivative claims, our insurance coverage will only cover up to an aggregate of $20.0 million of liability in certain circumstances after we have paid a significant deductible. If we are not successful in our defense of these litigations, we could be forced to make significant payments to or other settlements with our stockholders and their lawyers outside of our insurance coverage, and such payments or settlement arrangements could have a material adverse effect on our business, cash position, operating results or financial condition. Additionally, any lawsuit could cause injury to our reputation or cause us to suspend sales of our tests. The occurrence of any of these events could have a materially adverse effect on our reputation, cash position, and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An inability to attract and retain experienced and qualified personnel, including key management personnel, could adversely affect our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the specialized scientific nature of our business, we are highly dependent upon our ability to attract and retain highly qualified and experienced personnel, including key management personnel. Competition for these personnel is intense, especially for management, sales, scientific, medical, information technology, research and development and other technical personnel. We may not be able to attract or retain qualified personnel in the future due to the competition for qualified personnel among life science and technology businesses as well as universities and public and private research institutions. We have from time to time experienced, and we expect to continue to experience, difficulty in hiring and retaining employees with appropriate qualifications. Our compensation arrangements, such as our short-term incentive and equity award programs, may not be successful in attracting new employees and retaining and motivating our existing employees. Our agreements with our employees generally provide for employment that can be terminated by either party without cause at any time, subject to specified notice requirements. Further, the non-competition provision that certain key employees are subject to may not be enforceable under certain state laws, particularly California, or federal laws or such provisions may be prohibitively expensive to enforce. Our growth and commercial activities have placed a greater workload and strain on our existing employees, increasing the risk that our employees experience fatigue or burnout or terminate their employment with us. In addition, inflation has had, and we expect that it will continue to have, an impact on the costs that we incur to attract and retain qualified personnel, and may make it more difficult for us to attract and retain such personnel.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success also depends on the skills, experience and performance of key members of our senior management team, who are critical to directing and managing our growth and development in the future. The loss of any member of our senior management team may cause us to experience difficulties in competing effectively, developing our technologies, and implementing our business strategies. Furthermore, the loss of the services of or failure to recruit key scientific and technical personnel and other qualified personnel who are necessary to operate our business would adversely affect our business and it may have a material adverse effect on our business as a whole. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have acquired and we may continue to acquire technologies, assets or other businesses that could cause us to incur significant expense and expose us to a number of unanticipated operational and financial risks, which could adversely affect our financial condition, results of operations and business prospects. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to organic growth, we intend to continue to pursue growth through the acquisition of technology, assets or other businesses that may enable us to enhance our technologies and capabilities, expand our geographic market and sales channels, add experienced management personnel and increase our test offerings. For example, on November 1, 2022, we acquired Gateway, which markets and sells the SneakPeek Early Gender DNA Test. However, these acquisitions may not generate a positive return on our investment. Additionally, we may be unable to implement our growth strategy if we cannot identify suitable acquisition candidates, reach agreement on potential acquisitions on acceptable terms, successfully integrate personnel or assets that we acquire or for other reasons. We may also experience increased expenses, distraction of our management, and personnel and customer uncertainty as a result of our acquisition activities. Our acquisition efforts may involve certain risks, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have difficulty integrating operations and systems of any acquired business;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">key personnel and customers of the acquired company may terminate their relationships with the acquired company as a result of the acquisition;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be successful in launching newly acquired tests, or if those tests are launched, they may not prove successful in the marketplace;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience additional financial and accounting challenges and complexities in areas such as tax planning and financial reporting;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may assume or be held liable for risks and liabilities as a result of our acquisitions, including for legal, compliance, recoupment, and environmental-related costs and liabilities, some of which we may not discover during our due diligence;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may incur significant additional operating expenses;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience inconsistencies in standards, controls, procedures, policies and compensation structures;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may encounter risks and limitations on our ability to consolidate our corporate and administrative infrastructures;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ongoing business may be disrupted or receive insufficient management attention; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to realize synergies, the cost savings or other financial and operational benefits we anticipated, or such synergies, savings or benefits may take longer than we expected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of negotiating acquisitions and integrating acquired tests, services, technologies, personnel or businesses might result in operating difficulties and expenditures and might require significant management attention that would otherwise be available for ongoing development of our business, whether or not any such transaction is ever consummated. Moreover, we might never realize the anticipated benefits of any acquisition such as increase in our scale, diversification, cash flows and operational efficiency and meaningful accretion to our diluted earnings per share. Future acquisitions could result in the use of our available cash and marketable securities, potentially dilutive issuances of equity securities, the need to incur additional debt, contingent liabilities, or impairment expenses related to goodwill, and impairment or amortization expenses related to other intangible assets, which could harm our financial condition. In addition, if we are unable to integrate any acquired businesses, tests or technologies effectively, our business, financial condition and results of operations may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also seek to divest assets from time to time, including but not limited to, large capital equipment, diagnostic tests, intellectual property, business units, or corporate affiliates. For example, we divested Myriad RBM, Inc., which provided pharmaceutical and clinical services, on July 1, 2021, and we completed the sale of select operating assets and intellectual property, including the Vectra test, from the Myriad Autoimmune business unit, on September 13, 2021. The prices that we receive for such assets may not be high and, in some cases, have been and may be lower than the amount we invested in or paid for such assets. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our SneakPeek Early Gender DNA Test does not perform as expected, we may not realize the expected benefits of our acquisition of Gateway.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2022, we acquired Gateway, a personal genomics company and developer of consumer genetic tests that gives families insight into their future children. Gateway offers and sells the SneakPeek Early Gender DNA Test in the U.S. direct to consumers via sneakpeektest.com and Amazon.com and through various clinical channels, such as OBGYN offices, midwives, birth centers and ultrasound clinics and laboratories. The SneakPeek Early Gender DNA Test is also sold internationally through distributors in the United Kingdom, Canada, Australia and certain other countries. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SneakPeek Early Gender DNA Test competes against other gender DNA tests and other methods of determining fetal sex (such as non-invasive prenatal testing and ultrasounds) based on a variety of factors, including accuracy, how early the sex of the fetus can be determined, price, ease of use, convenience, and the speed in which test results are delivered. We believe that the SneakPeek Early Gender DNA Test currently outperforms competing tests and methods of fetal sex determination on a number of these factors, including accuracy, ease of sample collection with the at-home SNAP blood collection device, and the test's ability to reveal a baby&#8217;s sex at six weeks into pregnancy, the earliest method available. However, there can be no guarantee that the SneakPeek Early Gender DNA Test will continue to outperform other early fetal sex determination tests in these areas or that we will be able to continue to enhance and improve the SneakPeek Early Gender DNA Test in ways that would allow it to remain the market-leading early fetal sex determination test. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our acquisition of Gateway depends in part on the continued growth of the SneakPeek Early Gender DNA Test, including our ability to sell the SneakPeek Early Gender DNA Test in retail stores while continuing to increase sales volumes in existing channels, and our ability to cross-sell our Prequel prenatal screening test to SneakPeek Early Gender DNA Test customers. Historically, we have limited experience with marketing non-clinical, consumer products directly to consumers or with retail-based marketing strategies, and there can be no guarantee that we will be successful in doing so.  In addition, we may not be able to continue to grow the SneakPeek Early Gender DNA Test at the rate at which it was growing prior to our acquisition of Gateway, and we may not be successful at selling the SneakPeek Early Gender DNA Test in retail stores. We may also face a number of obstacles to cross-sell our Prequel prenatal screening test to SneakPeek Early Gender DNA Test customers, including persuading physicians of our SneakPeek Early Gender DNA Test customers to use our Prequel prenatal screening test and navigating patient consent and data privacy laws. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security breaches, loss of data and other disruptions, including from cyberattacks, could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability, which could adversely affect our business and our reputation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect and store sensitive data, including legally protected patient health information, credit card information, personally identifiable information about our employees and customers, intellectual property, and proprietary business information, including that of our customers, payors and collaboration partners. We manage and maintain our applications and data utilizing on-site, remote, or cloud-based systems. These applications and data encompass a wide variety of business-critical information including research and development information, commercial information and business and financial information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The secure processing, storage, maintenance and transmission of this critical information are vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure has been, and may continue to be, vulnerable to attacks by hackers, or viruses, malware, including ransomware, breaches or interruptions due to employee error, malfeasance or other disruptions, or lapses in compliance with privacy and security mandates. Any such malicious cyberattack, virus, breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, held for ransom, lost or stolen. We have measures in place that are designed to prevent, and if necessary, to detect and respond to such cybersecurity incidents and breaches of privacy and security mandates. While we have experienced unauthorized accesses to our information technology systems and infrastructure in the past, which may occur again in the future, our security measures have been able to detect, respond to and prevent any material adverse effect to our information systems and business operations from such breaches. However, in the future, any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, such as HIPAA, government enforcement actions and civil or even criminal penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to process samples, provide test results, bill payors or patients, provide customer support services, conduct research and development activities, process and prepare company financial information, and manage various general and administrative aspects of our business, and may damage our reputation, any of which could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we face increased cybersecurity risks and potential disruption to our technology infrastructure due to the number of employees that are working remotely as a result of remote work policies and other hybrid work arrangements. Increased levels of remote access create additional opportunities for cybercriminals to exploit vulnerabilities, and employees may be more susceptible to phishing and social engineering attempts. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience a significant disruption in our information technology systems, our business operations and financial condition could be adversely affected. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information technology (IT) and communication systems are an important part of our business operations. These IT and communications systems support a variety of functions, including sample processing, tracking, quality control, customer service and support, billing, research and development activities, and various general and administrative activities. The availability of our products and services and fulfillment of our customer contracts depends on the continuing operation of our IT and communication systems. Our IT and communication systems may be susceptible to damage, disruptions or shutdowns due to power outages, hardware failures, computer viruses, attacks by computer hackers, telecommunication failures, user errors, catastrophes or other unforeseen events. Our IT and communication systems also may experience interruptions, delays or cessations of service or produce errors in connection with system implementation, integration, upgrades or system migration work that takes place from time to time. If we were to experience a prolonged system disruption in the IT and communication systems that involve our interactions with customers, providers or suppliers, it could result in the loss of sales and customers and significant incremental costs, which could adversely affect our business. In addition, security breaches of our IT systems could result in the misappropriation or unauthorized disclosure of confidential information belonging to us or to our employees, partners, customers or suppliers, which could result in our suffering significant financial or reputational damage</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Each of our tests is processed in a single one of our laboratory facilities, and any loss or prolonged interruption of our ability to use these laboratories or failure to maintain their operation in compliance with applicable regulations would seriously harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a CLIA-certified facility in Salt Lake City, Utah to perform most of our tests; a CLIA-certified laboratory in South San Francisco, California to perform our Foresight and Prequel tests; a single laboratory facility in Cologne, Germany to perform and produce our EndoPredict test kits; a CLIA-certified laboratory in Mason, Ohio to perform our GeneSight test; and a laboratory in La Jolla, California to perform our SneakPeek Early Gender DNA test. We also plan to open new laboratories in South San Francisco, California, San Diego, California and west Salt Lake City, Utah. Our laboratories and the equipment we use to perform our tests would be difficult to replace and may require significant lead time to replace and qualify for use if they become inoperable. Some of our laboratories are located near active earthquake fault lines and in a region affected by wildfires and flooding. We currently have no backup or redundant facility to perform each of our tests. In the event any of our testing facilities were to lose its CLIA certification or other required certifications or licenses or were affected by a pandemic or man-made or natural disaster, such as an earthquake, severe weather, flooding, rising sea levels, other physical effects of climate change, power outages or contamination, we would be unable to continue our business, with respect to the tests performed at the particular facility or overall, at current levels to meet customer demands for a significant period of time. Although we maintain insurance on these facilities, including business interruption insurance, it may not be adequate to protect us from all potential losses if these facilities were damaged or destroyed. In addition, any interruption in our business would result in a loss of goodwill, including damage to our reputation. If our business were interrupted, it would seriously harm our business. The inability to open the planned facilities in South San Francisco, California, San Diego, California and west Salt Lake City, Utah, delays in opening such facilities or the failure to obtain any required permits, licenses, or certifications could result in increased costs, limit our ability to keep up with the demand for our products, and prevent us from realizing the intended benefits of these new facilities and our future laboratories.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on a limited number of third parties, or, in some cases, single-source suppliers, for equipment, reagents and other supplies. If these supplies become unavailable or are disrupted, including as a result of COVID-19 or another disease and responses to it, then we may not be able to successfully perform our research or operate our business on a timely basis or at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on a small number of suppliers, or, in some cases, single-source suppliers, to provide our gene sequencing equipment, content enrichment equipment, multiplex protein analysis equipment, robots, and specialty reagents and other laboratory supplies required in connection with our testing and research and development activities. We believe that currently there are limited alternative suppliers of the equipment, robots, reagents and certain other supplies that we use in our business. The equipment, robots, reagents or other supplies may not remain available in commercial quantities at acceptable costs. If we are unable to obtain when needed additional or alternative equipment or robots, or an adequate supply of reagents or other ingredients or supplies at commercially reasonable rates, our ability to continue to identify genes and perform testing would be adversely affected. In addition, the loss of a single-source supplier or the failure to perform by a single-source supplier could have a disruptive effect on our business, including our ability to perform testing, and could adversely affect our results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the continued spread of COVID-19 or the spread of another disease globally could further adversely affect our manufacturing and supply chain. Parts of our direct and indirect supply chain are located overseas and both international and domestic components have been, and may continue to be, subject to disruption as a result of COVID-19 or another disease and  responses to it. We have experienced and may continue to experience a shortage of certain laboratory supplies and equipment, and we may experience a suspension of services from other laboratories or third parties as a result of COVID&#8209;19 or another disease and responses to it. Political, administrative, legislative, legal or regulatory actions in response to COVID&#8209;19 or another disease could create additional supply shortages, disruptions or other uncertainties affecting our research and business. If the supplies and components necessary to manufacture our products become unavailable or are disrupted, including as a result of COVID-19 or another disease and responses to it, then we may not be able to successfully perform our research or operate our business on a timely basis or at all. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our international business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we operate in international markets and have active sales operations in Germany, France, and Japan and production operations in Germany. We also distribute our SneakPeek Early Gender DNA Test through distributors in the United Kingdom, Australia, Canada and certain other countries. We may establish additional operations or acquire additional properties outside the United States in order to advance our international sales. Doing business internationally involves a number of risks, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">multiple, conflicting and changing laws and regulations such as tax laws, export and import restrictions, employment laws, data privacy laws such as the EU GDPR, regulatory requirements and other governmental approvals, permits and licenses; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by us to obtain regulatory approvals or adequate reimbursement for the use of our tests in various countries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ineffective marketing campaigns leading to failure in establishing a viable, profitable, and sustainable presence in our international markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty in staffing and managing foreign operations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">managing multiple payor reimbursement regimes, government payors and self-pay systems;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexities and difficulties in obtaining protection and enforcing our intellectual property;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">logistics and regulations associated with shipping patient samples, including infrastructure conditions, customs and transportation delays, including compliance with the Office of Foreign Assets Control and other international trade sanctions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limits in our ability to penetrate international markets if we are not able to process tests locally;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable and exposure to foreign currency exchange rate fluctuations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political and economic instability, including wars, terrorism, and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors&#8217; activities that may fall within the purview of the U.S. Foreign Corrupt Practice Act, UK Bribery Act, anti-boycott laws and other anti-corruption laws; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to the disruptions caused by COVID-19 or another disease and responses to it.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could significantly harm our international operations and, consequently, our revenues and results of operations. In addition, any failure to comply with applicable legal and regulatory obligations could impact us in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges, seizure of shipments, and restrictions on certain business activities. Also, the failure to comply with applicable legal and regulatory obligations could result in the disruption of our distribution and sales activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our international operations could be affected by changes in laws, trade regulations, labor and employment regulations, and procedures and actions affecting approval, production, pricing, reimbursement and marketing of tests, as well as by inter-governmental disputes. Any of these changes could adversely affect our business. Our success internationally will depend, in part, on our ability to develop and implement policies and strategies that are effective in anticipating and managing these and other risks in the countries in which we do business. Failure to manage these and other risks may have a material adverse effect on our operations in any particular country and on our business as a whole.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ethical, legal and social concerns related to the use of genetic information could reduce demand for our tests.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genetic testing has raised ethical, legal and social issues regarding privacy rights and the appropriate uses of the resulting information. Governmental authorities could, for social or other purposes, limit or regulate the use of genetic information or genetic testing or prohibit testing for genetic predisposition to certain conditions, particularly for those that have no known cure. Similarly, these concerns may lead patients to refuse to use, or clinicians to be reluctant to order, genomic tests even if permissible; they may also refuse genetic testing due to concerns regarding eligibility for life or other insurance. Ethical and social concerns may also influence U.S. and foreign patent offices and courts with regard to patent protection for technology relevant to our business. Although the Genetic Information Non-discrimination Act has criminalized the disallowance of health insurance on the basis of genetic information, modification or retraction of this federal law could reduce public demand for genetic testing. These and other ethical, legal and social concerns may limit market acceptance of our tests or reduce the potential markets for our tests, either of which could have an adverse effect on our business, financial condition or results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on commercial courier delivery services to transport biological materials to our facilities in a timely and cost-efficient manner and if these delivery services are disrupted, our business will be harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our core business depends on our ability to quickly and reliably deliver test results to our customers. We typically receive biological material for analysis at our laboratory facilities within days of collection from the patient. Disruptions in delivery service, whether due to errors by the courier service, labor disruptions, bad weather, natural disasters, terrorist acts or threats or other reasons, some of which we have experienced in the past, could adversely affect specimen integrity, our ability to process or store samples in a timely manner and to service our customers, and ultimately our reputation and our business. In addition, if we are unable to continue to obtain expedited delivery services on commercially reasonable terms, our operating results may be adversely affected. We also rely on commercial courier delivery services to transport our SneakPeek Early Gender DNA Test directly to customers and any disruptions in delivery service could adversely affect our ability obtain and process samples in a timely manner and to service our customers.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks associated with currency exchange rate fluctuations, which could adversely affect our operating results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a portion of our revenues and pay a portion of our expenses in currencies other than the U.S. dollar, such as the Euro, the Swiss franc, the Japanese yen, and the British pound. As a result, we are at risk for exchange rate fluctuations between such foreign currencies and the U.S. dollar, which could affect the results of our operations. If the U.S. dollar strengthens against foreign currencies, the translation of these foreign currency denominated transactions will result in decreased revenues and operating expenses. During the year ended December 31, 2022, our revenues were negatively impacted by approximately $10.4&#160;million due to foreign currency fluctuations. We may not be able to offset adverse foreign currency impact with increased revenues. We do not currently utilize hedging strategies to mitigate foreign currency risk and even if we were to implement hedging strategies to mitigate foreign currency risk, these strategies might not eliminate our exposure to foreign exchange rate fluctuations and would involve costs and risks of their own, such as ongoing management time and expertise, external costs to implement the strategies and potential accounting implications.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Development and Commercialization of Our Tests and Test Candidates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our tests in development may not be clinically effective or may never achieve significant commercial market acceptance and our test offerings that we have recently launched or acquired may not be commercially successful.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not succeed in achieving significant commercial market acceptance of our test offerings that we have launched or acquired in recent years or are currently developing. Our ability to successfully develop and commercialize our current tests, as well as any future tests that we may develop or acquire, depend on several factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to convince the medical community and consumers of the utility of our tests and their potential advantages over existing tests or other competing products or services;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to market current and future products in new and existing channels, such as the launch of our SneakPeek Early Gender DNA Test in retail stores; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to collaborate with biotechnology and pharmaceutical companies to develop and commercialize companion diagnostic tests for their therapeutic drugs and drug candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the agreement by third-party payors to reimburse our tests, the scope and extent of which will affect patients&#8217; willingness or ability to pay for our tests and will likely heavily influence physicians&#8217; decisions to recommend our tests; and/or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of physicians to utilize our diagnostic tests, which can be difficult to interpret as our tests only predict as to a probability, not certainty, that a tested individual will develop the disease, will benefit from a particular therapy or has an aggressive form of the disease that the test is intended to predict.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors present obstacles to commercial acceptance of our tests, which we would have to spend substantial time and money to overcome, if we can do so at all. Our inability to successfully do so would harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may experience research and development and regulatory challenges that could delay or prevent the development and commercialization of new test offerings, such as FirstGene and Precise MRD. The tests we enhance or develop may not be clinically effective in clinical trials or commercially, or may not ultimately meet our desired target product profile, be offered at acceptable cost and with the test performance metrics necessary to address the relevant clinical need or commercial opportunity. We also may experience difficulties completing the clinical development of any new or enhanced product, or establishing or maintaining the collaborative relations that may be essential to our clinical development and commercialization efforts. Clinical development requires large numbers of patient specimens and, for certain products, require large, prospective, and controlled clinical trials. We may not be able to enroll patients or collect a sufficient number of appropriate specimens in a timely manner, or we may experience delays during clinical development due to slower than anticipated enrollment, or due to changes in study design or other unforeseen circumstances, or we may be unable to afford or manage the large-sized clinical trials that some of our planned future products may require. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the publication of clinical data in peer-reviewed journals is an important step in commercializing and obtaining reimbursement for tests such as ours, and our inability to control when, if ever, results are published may delay or limit our ability to derive sufficient revenues from any test that is the subject of a study. Peer-reviewed publications regarding our tests may be limited by many factors, including delays in the completion of, poor design of, or lack of compelling data from, clinical studies, as well as delays in the review, acceptance and publication process. If our tests or the technology underlying our current or future tests do not receive sufficient favorable exposure in peer-reviewed publications, the rate of clinician adoption of our tests and positive reimbursement coverage determinations for our tests could be negatively affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not compete effectively with scientific and commercial competitors, we may not be able to successfully commercialize our tests, increase our revenue or achieve and sustain profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical laboratory and genetics testing fields are intense, highly competitive and characterized by rapid technological change, frequent new product introductions, reimbursement challenges, emerging competition, intellectual property disputes and litigation, price competition, aggressive marketing practices, evolving industry standards, and changing customer preferences. Our competitors in the United States and abroad are numerous and include, among others, major diagnostic companies, reference laboratories, molecular diagnostic firms, direct-to-consumer genetic companies, low-priced competitors, clinical laboratories, universities and other research institutions. Some of our competitors and potential competitors have larger customer bases, greater brand recognition and market penetration, better selling and marketing capabilities, more experience with third-party payors and considerably greater financial, technical, marketing and other resources than we do, which has allowed and may continue to allow these competitors to discover important genes and determine their function before we do, respond more quickly to changes in customer preferences, devote greater resources to the development, promotion and sale of their tests than we do, sell their tests at prices designed to win significant levels of market share, or obtain reimbursement from more third-party payors and at higher prices than we do. We could be adversely affected if we do not discover genes, proteins or biomarkers and characterize their function, develop tests based on these discoveries, obtain required regulatory and other approvals and launch these tests and their related services before our competitors. We may also not be able to keep pace with the rapid technological changes in our industry, or properly leverage new technologies to achieve or sustain competitive advantages in our tests, systems and processes. We also expect to encounter significant competition with respect to any tests that we may develop or commercialize. Those companies that bring to market new tests before we do may achieve a significant competitive advantage in marketing and commercializing their tests. We may not be able to develop additional tests successfully and we or our licensors may not obtain or enforce patents covering these tests that provide protection against our competitors. Moreover, our competitors may succeed in developing tests that circumvent our technologies or tests. Furthermore, our competitors may succeed in developing technologies or tests that are more effective or less costly than those developed by us or that would render our technologies or tests less competitive or obsolete. Increased competition and cost-saving initiatives on the part of governmental entities and third-party payors are likely to result in pricing pressures, which could harm our sales, profitability or ability to gain market share. We expect competition to intensify in the fields in which we are involved as technical advances in these fields occur and become more widely known and changes in intellectual property laws generate challenges to our intellectual property position.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our current research collaborators or scientific advisors terminate their relationships with us or develop relationships with a competitor, our ability to discover genes, proteins, and biomarkers, and to validate and commercialize tests could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with research collaborators at academic and other institutions who conduct research at our request. These research collaborators are not our employees. As a result, we have limited control over their activities and, except as otherwise required by our collaboration agreements, can expect only limited amounts of their time to be dedicated to our activities. Our ability to discover genes, proteins, and biomarkers involved in human disease and validate and commercialize tests will depend in part on the continuation of these collaborations. If any of these collaborations are terminated, we may not be able to enter into other acceptable collaborations. In addition, our existing collaborations may not be successful.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research collaborators and scientific advisors may have relationships with other commercial entities, some of which could compete with us. Our research collaborators and scientific advisors sign agreements which provide for the confidentiality of our proprietary information. We may not, however, be able to maintain the confidentiality of our technology and other confidential information related to all collaborations. The dissemination of our confidential information to third parties could have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reimbursement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the government and third-party payors fail to provide coverage and adequate payment for our existing and future tests, if any, our revenue and prospects for profitability will be harmed. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both domestic and foreign markets, sales of our tests or any future tests will depend in large part, upon the availability of reimbursement from third-party payors. Such third-party payors include state and federal health care programs such as Medicare, managed care organizations, private health insurers and other organizations. These third-party payors are increasingly attempting to contain health care costs by demanding price discounts and limiting both coverage regarding which tests they will pay for and the amounts that they will pay for existing and new tests. We have experienced coverage limitations and price reductions for many of our products, including for our GeneSight Psychotropic Mental Health Medication Test, and we may continue to experience future coverage limitations and price reductions from CMS, managed care organizations, and other third-party payors. The fact that a test has been approved for reimbursement in the past, for any particular indication or in any particular jurisdiction, does not guarantee that such a test will be approved or remain approved for reimbursement, that the reimbursement amount approved for such test will not be reduced in the future, or that similar or additional tests will be approved for reimbursement in the future. Historically, we have not received reimbursement from third-party payors or payment from patients for many of our tests. Moreover, there can be no assurance that any new tests we have launched or may launch will be reimbursed at rates that are comparable to the rates that we historically obtained for our existing product portfolio. As a result, third-party payors may not cover or provide adequate payment for our current or future tests to enable us to maintain past levels of revenue or profitability with respect to such tests. Further, third-party reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in product development. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under PAMA, Medicare reimbursement for any given test is based on the weighted-median of the payments made by private payors for such test, rendering private payor payment levels even more significant. As a result, future Medicare payments may fluctuate more often and become subject to the willingness of private payors to recognize the value of tests generally and any given test individually. On December 10, 2021, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Congress passed the Protecting Medicare and American Farmers from Sequester Cuts Act, which included a provision that delays the next PAMA reporting period for clinical laboratory tests that are not advanced diagnostic tests to January 1, 2023 through March 31, 2023. The Consolidated Appropriations Act, 2023, enacted on December 29, 2022, delayed the next PAMA reporting period for clinical laboratory tests that are not advanced diagnostic tests to January 1, 2024 through March 31, 2024. In addition, the next round of rate cuts will not be implemented until 2024, with tests receiving cuts of up to 15 percent a year from 2024 through 2026. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any declines in average selling prices of our products due to pricing pressures may have an adverse impact on our business, results of operations and financial condition. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors may also dispute our billing or coding and may decide to deny payment or recoup payment for testing that they contend to have been not medically necessary, against their coverage determinations, or for which they have otherwise overpaid, and we may be required to refund reimbursements already received. We have also experienced delays or denials of coverage for failure to adequately comply with procedural requirements imposed by third-party payors to obtain reimbursement. We also periodically receive and respond to requests for recoupment from third-party payors in the ordinary course of business. When a third-party payor denies payment for testing, we often are not able to collect payment from the patient, and therefore, we do not receive any revenue from our testing. In addition, if a third-party payor successfully proves that payment for prior testing was in breach of contract or otherwise contrary to law, they may recoup payment, which amounts could be significant and would impact our results of operations. We may also continue to negotiate and settle with third-party payers in order to resolve allegations of overpayment. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors, such as commercial health insurers and government payors and programs, may also adopt requirements, programs or policies that may restrict or adversely affect our business. For example, in September 2022, the California Department of Public Health (CDPH) promulgated certain regulatory amendments to the California Prenatal Screening (PNS) Program that made the PNS Program the exclusive means of obtaining cfDNA trisomy screening in California. These regulatory amendments set a price that participating laboratories would receive for each cfDNA test that was substantially lower than laboratories had previously charged, and prohibited laboratories that did not contract with CDPH from participating in the PNS Program and from offering or performing cfDNA trisomy screening in California. As we are not currently a participating laboratory under the PNS Program, we would be prohibited from offering or performing our Prequel screening test in California. On September 16, 2022, we filed jointly with Laboratory Corporation of America Holdings (Labcorp) a writ petition in the Superior Court of the State of California, County of San Francisco, against the CDPH and its Director challenging CDPH&#8217;s ability to make the PNS Program the exclusive means of obtaining cfDNA trisomy screening in California. On September 16, 2022, we also moved jointly with Labcorp for a preliminary injunction to enjoin the implementation and enforcement of the new exclusivity regulation. On November 2, 2022, the Superior Court granted our motion for a preliminary injunction, which allowed us to continue to offer our Prequel screening test in California.  On December 17, 2022, we filed jointly with Labcorp a motion for judgment on our writ, through which we are seeking a permanent injunction to enjoin the implementation and enforcement of the new exclusivity regulation.  A hearing on that motion is scheduled for March 21, 2023.  CDPH has also commenced the process of appealing the preliminary injunction, though no hearing date has been set, and that appeal may be mooted by the Superior Court&#8217;s decision on our motion for judgment on the writ prior to any hearing.  Pending the outcome of this ongoing litigation, we cannot be certain that we will be able to continue offering or performing our Prequel screening test in California. If the exclusivity regulation is ultimately determined to be valid and we are either not able to offer our Prequel screening test in California at all, or must do so through the PNS Program at lower rates than we currently charge, our financial and operating results will likely be adversely affected. In addition, although the implementation and enforcement of the exclusivity regulation has been preliminarily enjoined, the possibility that we may be unable to continue to offer our Prequel screening test in California has had a chilling effect on sales of our Prequel screening test in California.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. and foreign governments continue to propose and pass legislation designed to reduce the cost of health care.  For example, in some foreign markets, the government controls the pricing of many health care products. We expect that there will continue to be federal and state proposals to implement governmental controls or impose health care requirements. In addition, the Medicare program and increasing emphasis on managed care in the United States will continue to put pressure on product pricing. Cost control initiatives could decrease the price that we would receive for any tests in the future, which would limit our revenue and profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to comply with laws and regulations related to submission of claims for our services could result in significant monetary damages and penalties and exclusion from the Medicare and Medicaid programs and corresponding foreign reimbursement programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to laws and regulations governing the submission of claims for payment for our services, such as those relating to: coverage of our services under Medicare, Medicaid and other state, federal and foreign health care programs; the amounts that we may bill for our services; and the party to which we must submit claims. Our failure to comply with applicable laws and regulations could result in our inability to receive payment for our services or in attempts by state and federal health care programs, such as Medicare and Medicaid, to recover payments already made. Submission of claims in violation of these laws and regulations can result in recoupment of payments already received, substantial civil monetary penalties, and exclusion from state and federal health care programs, and can subject us to liability under the federal False Claims Act and similar laws. The failure to report and return an overpayment to the Medicare or Medicaid program within 60 days of identifying its existence can give rise to liability under the False Claims Act. Further, a government agency could attempt to hold us liable for causing the improper submission of claims by another entity for services that we performed if we were found to have knowingly participated in the arrangement at issue.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to protect our proprietary technology, others could compete against us more directly, which would harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, our patent portfolio included issued patents owned or licensed by us and numerous patent applications in the United States and other countries with claims protecting our intellectual property rights. Our commercial success will depend, in part, on our ability to obtain additional patents and licenses and protect our existing patent position, both in the United States and in other countries, for compositions, processes, methods and other inventions that we believe are patentable. Our ability to preserve our trade secrets, proprietary data bases and other intellectual property is also important to our long-term success. If our intellectual property is not adequately protected, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. Patents may also issue to third parties which could interfere with our ability to bring our tests to market. The laws of some foreign countries do not protect our proprietary rights to the same extent as U.S. laws, and we may encounter significant problems in protecting our proprietary rights in these countries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of diagnostic companies, including our patent position, are generally highly uncertain and involve complex legal and factual questions, and, therefore, any patents issued to us may be challenged, deemed unenforceable, invalidated or circumvented. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies and any future tests are covered by valid and enforceable patents or are effectively maintained as trade secrets. Our patent applications may never issue as patents, and the claims of any issued patents may not afford meaningful protection for our technology or tests. In addition, any patents issued to us or our licensors may be challenged, and subsequently narrowed, invalidated or circumvented.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where necessary, we may initiate litigation to enforce our patent or other intellectual property rights. Any such litigation may require us to spend a substantial amount of time and money and could distract management from our day-to-day operations. Moreover, there is no assurance that we will be successful in any such litigation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors were the first to make the inventions covered by each of our patent applications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors were the first to file patent applications for these inventions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not independently develop similar or alternative technologies or duplicate any of our technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our or our licensors&#8217; patent applications will result in issued patents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our or our licensors&#8217; patents will be valid or enforceable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patents issued to us or our licensors and collaborators will provide a basis for commercially viable tests, will provide us with any competitive advantages or will not be challenged by third parties;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will develop additional proprietary technologies or tests that are patentable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others will not have an adverse effect on our business; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our patents or patents that we license from others will survive legal challenges and remain valid and enforceable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a third party files a patent application with claims to subject matter we have invented, the U.S. Patent and Trademark Office (USPTO) may declare interference between competing patent applications. If an interference is declared, we may not prevail in the interference. If the other party prevails in the interference, we may be precluded from commercializing services or tests based on the invention or may be required to seek a license. A license may not be available to us on commercially acceptable terms, if at all. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secrets to protect our proprietary technologies and databases, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and others to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy if unauthorized disclosure of confidential information occurs. In addition, others may independently discover our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive position.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are subject to litigation or other proceedings arising from a claim of infringement of the intellectual property of a third party, we might incur significant costs and delays in test introduction or we could be prevented from using technologies incorporated in our tests.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our tests may also conflict with patents that have been or may be granted to others. Our industry includes many organizations that have or are seeking to discern biomarkers and develop genomic, proteomic and other technologies. To the extent any patents are issued or have been issued to those organizations, the risk increases that the sale of our tests currently being marketed or under development may give rise to claims of patent infringement. Others may have filed and in the future are likely to file patent applications covering biomarkers that are similar or identical to our tests. Any of these patent applications may have priority over our patent applications and these entities or persons could bring legal proceedings against us seeking damages or seeking to enjoin us from testing or marketing our tests. Patent litigation is costly, and even if we prevail, the cost of such litigation could have a material adverse effect on us. If the other parties in any such actions are successful, in addition to any liability for damages, we could be required to cease the infringing activity or obtain a license. Any license required may not be available to us on commercially acceptable terms, if at all. Our failure to obtain a license to any technology that we may require to commercialize our tests could have a material adverse effect on our business. In addition, we could experience delays in product introductions or sales growth while we attempt to develop non-infringing alternatives. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that there has been, and may continue to be, significant litigation in the industry regarding patent and other intellectual property rights. On December 21, 2020, Ravgen, Inc. filed a lawsuit against us and our wholly owned subsidiary, Myriad Women's Health, in the U.S. District Court for the District of Delaware, alleging infringement of two patents relating to blood collection tubes and non-invasive prenatal testing analysis. This litigation and any other intellectual property litigation that we may become involved with in the future could consume a substantial portion of our managerial and financial resources. If any such litigation is resolved adversely to us, we could be required to pay damages, cease the infringing activity or pay an ongoing licensing fee for our prenatal tests, each of which could have a material adverse effect on our financial condition, results of operations or cash flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, third parties may claim that the branding of our products infringes the trademarks, service marks, trade names or otherwise misappropriates or dilutes those third parties&#8217; rights.  If we are found to be liable or to have infringed upon those third parties' rights, we may be required to pay damages and rebrand the infringing products.  Rebranding can be expensive and time-consuming and may lead to the loss of brand equity or goodwill associated with the rebranded products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under license or technology agreements with third parties, we could lose license rights that are critical to our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We license intellectual property that is important to our business, including licenses underlying the technology in our tests, and in the future, we may enter into additional agreements that provide us with licenses to valuable intellectual property or technology. These licenses impose various royalty payments, milestones, and other obligations on us. If we fail to comply with any of these obligations, the licensor may have the right to terminate the license. Termination by the licensor would cause us to lose valuable rights, and could prevent us from distributing our current tests, or inhibit our ability to commercialize future test candidates. Our business would suffer if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to prevent infringement by third parties, if the licensed patents or other rights are found to be invalid, unenforceable or infringe upon third party patents, or if we are unable to enter into necessary licenses on acceptable terms.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees have wrongfully used or disclosed alleged trade secrets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is commonplace in our industry, we employ individuals who were previously employed at universities or genetic testing, diagnostic, biotechnology or other health care companies, including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees or consultants have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of a former employer or other third parties. Litigation may be necessary to defend against these claims, and if we are unsuccessful, we could be required to pay substantial damages and could lose rights to important intellectual property. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to adequately protect our trademarks, service marks, trade names and trade dress, we may lose goodwill and brand equity associated with our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered and unregistered trademarks, service marks, or trade names could be infringed by third parties.  Enforcing our rights against such third parties can be expensive and distracting.  If we fail to effectively enforce such rights against third parties, our trademark, service mark or trade name rights, and the associated goodwill and brand equity, could be lost.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file applications for registration of various marks associated with our brands in the United States and foreign jurisdictions.  We may fail to successfully register these marks.  Additionally, once a mark is registered, we may fail to pay all fees and attend to all formalities required to maintain the registration.  Failure to obtain or maintain registration of our marks could make those marks harder to enforce and reduce the liability of an infringer even if we are able to successfully enforce such rights.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with the complex federal, state, local and foreign laws and regulations that apply to our business, we could suffer consequences that could materially and adversely affect our operating results and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to extensive federal, state, local and foreign laws and regulations, all of which are subject to change. These laws and regulations currently include, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical Laboratory Improvement Amendments of 1988, which requires that laboratories obtain certification from the federal government, and state licensure laws;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. Food and Drug Administration laws and regulations that apply to medical devices such as our companion diagnostics;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health Insurance Portability and Accountability Act of 1996 (HIPAA), which imposes comprehensive federal standards with respect to the privacy and security of protected health information and requirements for the use of certain standardized electronic transactions; amendments to HIPAA under HITECH, which strengthened and expanded HIPAA privacy and security compliance requirements, increased penalties for violators, extended enforcement authority to state attorneys general and imposed requirements for breach notification;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws regulating genetic testing and protecting the privacy of genetic test results, as well as state laws protecting the privacy and security of health information and personal data and mandating reporting of breaches to affected individuals and state regulators;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for, or recommending of an item or service that is reimbursable, in whole or in part, by a federal health care program;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Eliminating Kickbacks in Recovery Act of 2018 (EKRA), which is an all-payor anti-kickback prohibition on, among other things, knowingly and willfully paying or offering any remuneration directly or indirectly to induce a referral of an individual to a clinical laboratory;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal physician self-referral prohibition (Stark Law or the Physician Self-Referral Law), which, absent an exception, prohibits a physician from making a referral for certain designated health services, including clinical laboratory services, if the physician or an immediate family member of the physician has an applicable financial relationship with the entity providing the designated health services; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal False Claims Act, which imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment to the federal government;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state health care program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other federal and state fraud and abuse laws, such as anti-kickback laws, prohibitions on self-referral, and false claims acts, which may extend to services reimbursable by any third-party payor, including private insurers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act, which requires medical device manufactures to track and report to the federal government certain payments and other transfers of value made to physicians, other health care professionals, teaching hospitals and ownership or investment interests held by physicians and their immediate family members;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Section 216 of the federal Protecting Access to Medicare Act of 2014, which requires the Centers for Medicare &amp; Medicaid Services (CMS) to set Medicare rates for clinical laboratory testing based on private payor data reported by applicable laboratories;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits companies and their intermediaries from making payments in violation of law to non-U.S. government officials for the purpose of obtaining or retaining business or securing any other improper advantage;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws that impose reporting and other compliance-related requirements; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">similar foreign laws and regulations that apply to us in the countries in which we operate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to or affected by current or future federal, state, local and foreign laws and regulations, including laws relating to reproductive health care, which could restrict our business, reduce demand for our products, and adversely affect our operations, revenue, and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a clinical laboratory, our business practices may face heightened scrutiny from government enforcement agencies such as the Department of Justice, the Office of Inspector General for the Department of Health and Human Services (OIG), and CMS. The OIG has issued fraud alerts in recent years, including a fraud alert relating to speaker programs in November 2020, that identify certain arrangements between medical device and drug companies and referring physicians as implicating the Anti-Kickback Statute. Moreover, the provision of payments or other items of value by a clinical laboratory to a referral source could be prohibited under the federal self-referral prohibition, commonly known as the Stark Law or the Physician Self-Referral Law, unless the arrangement meets all criteria of an applicable exception. The government has actively enforced these laws against clinical laboratories in recent years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These laws and regulations are complex and are subject to interpretation by the courts and by government agencies. Our failure to comply could lead to civil or criminal penalties, exclusion from participation in state and federal health care programs, or prohibitions or restrictions on our laboratories&#8217; ability to provide or receive payment for our services. We believe that we are in material compliance with all statutory and regulatory requirements, but there is a risk that one or more government agencies could take a contrary position, or that a private party could file suit under the qui tam provisions of the federal False Claims Act or a similar state law. Such occurrences, regardless of their outcome, could damage our reputation and adversely affect important business relationships with third parties, including managed care organizations, and other private third-party payors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The growth of our business and our expansion outside of the United States may increase the potential of violating similar foreign laws or our internal policies and procedures. The risk of us being found in violation of these or other laws and regulations is further increased by the fact that many have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Any of the foregoing consequences could seriously harm our business and our financial results.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our actual or perceived failure to comply with data protection laws and regulations could lead to government enforcement actions, private litigation and/or adverse publicity and could negatively affect our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to domestic and international data protection laws and regulations that address privacy and data security and may affect our collection, use, storage, and transfer of personal information. The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been an increasing focus on privacy and data security issues with the potential to affect our business. In the U.S., numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws and federal and state consumer protection laws govern the collection, use, disclosure and protection of health-related and other personal information. Failure to comply with data protection laws and regulations, where applicable, could result in government enforcement actions, which could include civil or criminal penalties, private litigation and/or adverse publicity and could negatively affect our operating results and business. For example, California has enacted the California Consumer Privacy Act, or CCPA, which went into effect in January of 2020. The CCPA establishes a new privacy framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for California residents, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches. Additionally in 2020, California voters passed the California Privacy Rights Act, or CPRA, effective January 1, 2023. The CPRA significantly amends the CCPA, potentially resulting in further uncertainty, additional costs and expenses in an effort to comply and additional potential for harm and liability for failure to comply. Among other things, the CPRA established a new regulatory authority, the California Privacy Protection Agency, which is tasked with enacting new regulations under the CPRA and will have expanded enforcement authority. Effective in 2023, Virginia, Colorado, Connecticut, and Utah will have similar data protection laws, and other U.S. states have proposals under consideration, increasing the regulatory compliance risk.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous other countries have, or are developing, laws governing the collection, use and transmission of personal information as well. For example, the European Union&#8217;s General Data Protection Regulation (GDPR), became effective in 2018 and imposed a broad data protection framework that expanded the scope of EU data protection law, including to non-EU entities meeting the jurisdictional requirements that process, or control the processing of, personal data relating to individuals located in the EU, including clinical trial data. The GDPR sets out a number of requirements for controllers and/or processors, as applicable, that must be complied with when handling the personal data of EU based data subjects, including: providing expanded disclosures about how their personal data will be used; higher standards for organizations to demonstrate that they have obtained valid consent or have another legal basis in place to justify their data processing activities; the obligation to appoint data protection officers in certain circumstances; new rights for individuals to be &#8220;forgotten&#8221; and rights to data portability, as well as enhanced current rights (e.g., access requests); the principal of accountability and demonstrating compliance through policies, procedures, training and audit; and a new mandatory data breach regime. In particular, medical or health data, genetic data and biometric data are all classified as &#8220;special category&#8221; data under the GDPR and afford greater protection and require additional compliance obligations. Further, EU member states have a broad right to impose additional conditions&#8212;including restrictions&#8212;on these data categories. This is because the GDPR allows EU member states to derogate from the requirements of the GDPR mainly in regard to specific processing situations (including special category data and processing for scientific or statistical purposes).  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR is applicable to part of our business and has increased our responsibility and liability in relation to personal data that we process, and we may be required to put in place additional procedures to comply. The GDPR is complex and regulatory guidance continues to evolve. Furthermore, national GDPR variations, including the fields of clinical study and other health-related information may raise our costs of compliance and result in greater legal risks.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to evolving GDPR requirements on data export, because we transfer data to third countries outside of the EU that are not deemed &#8220;adequate.&#8221; The GDPR only permits exports of personal data outside of the EU to &#8220;non-adequate&#8221; countries where there is a suitable data transfer mechanism in place to safeguard personal data (e.g., the EU Commission approved Standard Contractual Clauses). On July 16, 2020, the Court of Justice of the EU, or the CJEU, issued a landmark opinion in the case Maximilian Schrems vs. Facebook (Case C-311/18) (Schrems II). This decision calls into question certain data transfer mechanisms as between the EU member states and the U.S. The CJEU is the highest court in Europe and the Schrems II decision heightens the burden to assess U.S. national security laws on their business, and future actions of EU data protection authorities are difficult to predict at this time. Consequently, there is some risk of any data transfers from the EU being halted. If we have to rely on third parties to carry out services for us, including processing personal data on our behalf, we are required under GDPR to enter into contractual arrangements to flow down or help ensure that these third parties only process such data according to our instructions and have sufficient security measures in place. Any security breach or non-compliance with our contractual terms or breach of applicable law by such third parties could result in enforcement actions, litigation, fines and penalties or adverse publicity and could cause customers to lose trust in us, which would have an adverse impact on our reputation and business. Any contractual arrangements requiring the processing of personal data from the EU to us in the U.S. will require greater scrutiny and assessments as required under Schrems II and may have an adverse impact on cross-border transfers of personal data, or increase costs of compliance. The GDPR provides an enforcement authority to impose large penalties for noncompliance, including the potential for fines of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable data privacy and data protection laws may conflict with each other, and by complying with the laws or regulations of one jurisdiction, we may find that we are violating the laws or regulations of another jurisdiction. Despite our efforts, we may not have fully complied in the past and may not in the future. That could require us to incur significant expenses, which could significantly affect our business. Failure to comply with data protection laws may expose us to risk of enforcement actions taken by data protection authorities or other regulatory agencies, private rights of action in some jurisdictions, and potential significant penalties if we are found to be non-compliant.  Furthermore, the number of government investigations related to data security incidents and privacy violations continue to increase and government investigations typically require significant resources and generate negative publicity, which could harm our business and reputation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may from time to time be subject to government investigation(s), the unfavorable outcome of which may have a material adverse effect on our financial condition, results of operations and cash flows.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may from time to time be subject to government investigations, which may divert management resources and attention, cause us to incur substantial costs, and/or result in negative publicity, and any unfavorable outcome arising from such investigation may have a material adverse effect on our financial condition, results of operations and cash flows. For example, in June 2016, our wholly-owned subsidiary, Crescendo Bioscience, LLC (formerly known as Crescendo Bioscience, Inc.) (CBI), received a subpoena from the Office of Inspector General of the Department of Health and Human Services requesting that CBI produce documents relating to entities that received payment from CBI for the collection and processing of blood specimens for testing, including a named unrelated company, healthcare providers and other third-party entities. On January 30, 2020, the U.S. District Court for the Northern District of California unsealed a qui tam complaint, filed on April 16, 2016 against CBI, alleging violations of the federal and California False Claims Acts and the California Insurance Fraud Prevention Act (CIFPA). On January 22, 2020, after a multi-year investigation into CBI&#8217;s and the Company&#8217;s alleged conduct, the United States declined to intervene. On January 27, 2020, the State of California likewise filed its notice of declination. On April 1, 2022, we settled the qui tam lawsuit pursuant to which we paid a total of $45.25 million to the United States and the State of California and $2.75 million to relator's counsel. The qui tam lawsuit was formally dismissed by the U.S. District Court for the Northern District of California on May 4, 2022. We may be subject to future claims or investigations under the Federal False Claims Act or a similar state law, and any unfavorable outcome arising from such claims or investigation could have a material adverse effect on our financial condition, results of operations and cash flows. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in health care policy could increase our costs, decrease our revenues and impact sales of and reimbursement for our tests. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, collectively called the ACA, became law. This law substantially changed the way health care is financed by both government and private third-party payors and continues to significantly impact our business and operations in ways we cannot currently predict. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and as a result, certain sections of the ACA have not been fully implemented or were effectively repealed. However, following several years of litigation in the federal courts, in June 2021, the U.S. Supreme Court upheld the ACA when it dismissed a legal challenge to the ACA&#8217;s constitutionality. Further legislative and regulatory changes under the ACA remain possible. The federal administration under President Biden has signaled that it plans to build on the ACA and expand the number of people who are eligible for health insurance subsidies under it. Future changes or additions to the ACA or the Medicare and Medicaid programs, such as changes stemming from other health care reform measures, especially with regard to health care access, financing or other legislation in individual states, could have a material adverse effect on the health care industry in the United States. The uncertainty around the future of the ACA, and in particular the impact to reimbursement levels and the number of insured individuals, may lead to delay in the purchasing decisions of our customers, which may in turn negatively impact our product sales. Further, if reimbursement levels are inadequate, our business and results of operations could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the ACA, there will continue to be proposals by legislators at both the federal and state levels, regulators and private third-party payors to reduce costs while expanding individual health care benefits. Certain of these changes could impose additional limitations on the prices we will be able to charge for our tests or the amounts of reimbursement available for our tests from governmental agencies or private third-party payors.  Any future changes to legal or regulatory requirements or new cost containment initiatives could have a materially adverse effect on our business, financial condition, results of operation, and cash flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be harmed by the loss, suspension, or other restriction on a license, certification, or accreditation, or by the imposition of a fine or penalties, under CLIA, its implementing regulations, or other state, federal and foreign laws and regulations affecting licensure or certification, or by future changes in these laws or regulations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The diagnostic testing industry is subject to extensive laws and regulations, many of which have not been interpreted by the courts. CLIA requires virtually all laboratories to be certified by the federal government and mandates compliance with various operational, personnel, facilities administration, quality and proficiency testing requirements intended to ensure that testing services are accurate, reliable and timely. CLIA certification is also a prerequisite to be eligible to bill state and federal health care programs, as well as many private third-party payors, for laboratory testing services. As a condition of CLIA certification, each of our laboratories is subject to survey and inspection every other year, in addition to being subject to additional random inspections. The biennial survey is conducted by CMS, a CMS agent (typically a state agency), or, if the laboratory holds a CLIA certificate of accreditation, a CMS-approved accreditation organization. Sanctions for failure to comply with CLIA requirements, including proficiency testing violations, may include suspension, revocation, or limitation of a laboratory&#8217;s CLIA certificate, which is necessary to conduct business, as well as the imposition of significant fines or criminal penalties. In addition, we are subject to regulation under state laws and regulations governing laboratory licensure. Some states have enacted state licensure laws that are more stringent than CLIA. We are also subject to laws and regulations governing our reference laboratory in Germany. Changes in state or foreign licensure laws that affect our ability to offer and provide diagnostic services across state or foreign country lines could materially and adversely affect our business. In addition, state and foreign requirements for laboratory certification may be costly or difficult to meet and could affect our ability to receive specimens from certain states or foreign countries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing licensure, or our failure to renew a CLIA certificate, a state or foreign license, or accreditation, could have a material adverse effect on our business. If the CLIA certificate of any one of our laboratories is revoked, CMS could seek revocation of the CLIA certificates of our other laboratories based on their common ownership or operation, even though they are separately certified.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in the way that the FDA regulates tests performed by laboratories like ours could result in delay or additional expense in offering our tests and tests that we may develop in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the FDA has exercised enforcement discretion with respect to most LDTs and has generally not required laboratories that furnish LDTs to comply with the agency&#8217;s requirements for medical devices (e.g., establishment registration, device listing, quality systems regulations, premarket clearance or premarket approval, and post-market controls). As of December 31, 2022, none of our products other than MyChoice CDx and BRACAnalysis CDx are marketed by us under the FDA's requirements for medical devices. In recent years, however, the FDA publicly announced its intention to regulate certain LDTs and issued two draft guidance documents that set forth a proposed phased-in risk-based regulatory framework that would apply varying levels of FDA oversight to LDTs. However, these guidance documents were not finalized, and the framework was abandoned and replaced by an informal discussion paper reflecting some of the feedback that FDA had received on the proposed LDT regulation. The FDA acknowledged that the January 2017 discussion paper does not represent the formal position of the FDA and is not enforceable. Nevertheless, the FDA wanted to share its synthesis of the feedback that it had received in the hope that it might advance public discussion on future LDT oversight. Notwithstanding the discussion paper, the FDA continues to exercise enforcement discretion and may attempt to regulate certain LDTs on a case-by-case basis at any time, which could result in delay or additional expense in offering our tests and tests that we may develop in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to potential enforcement priority changes from the FDA, for several years bipartisan members of Congress have been negotiating legislation with the FDA and industry stakeholders to regulate in vitro clinical tests including LDTs under a shared FDA/CMS framework. Most recently, reform legislation entitled the Verifying Accurate, Leading-edge IVCT Development (VALID) Act has received increasing congressional support.  If enacted, the VALID Act would codify into law the term &#8220;in vitro clinical test&#8221; (IVCT) to create a new medical product category separate from medical devices that includes products currently regulated as in vitro diagnostics (IVDs) as well as LDTs.  The framework would give the FDA the authority to ensure IVCTs are both analytically and clinically valid.  CMS would retain the authority to ensure the quality of operations within laboratories.  All LDTs on the market prior to enactment of the legislation would be grandfathered and not subject to the new regulation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is unclear whether the VALID Act will be passed by Congress in its current form or signed into law by the President. Until the FDA finalizes its regulatory position regarding LDTs through formal notice-and-comment rulemaking, or the VALID Act or other legislation is passed reforming the federal government&#8217;s regulation of LDTs, it is unknown how the FDA may attempt to regulate our tests in the future and what testing and data may be required to support any required clearance or approval of our tests by the agency. If the VALID Act is implemented as drafted, or if the FDA were to promulgate regulations governing the development and marketing of LDTs, it could have a materially adverse impact on our results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA regulation of our GeneSight Psychotropic test could be disruptive to our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described further above, the FDA has long claimed authority to regulate laboratory-developed tests but has exercised its &#8220;enforcement discretion&#8221; to limit enforcement of in vitro diagnostic regulatory requirements on this category of products. The FDA has from time to time appeared to increase its attention to the marketing of pharmacogenetic tests. For example, in late 2018, the FDA issued a safety communication regarding &#8220;genetic tests that claim results can be used to help physicians identify which antidepressant medication would have increased effectiveness or side effects compared to other antidepressant medications.&#8221; This safety communication explained that the FDA had reached out to several firms marketing such pharmacogenetic tests where the FDA believed the relationship between genetic variations and a medication&#8217;s effects had not been established, including a warning letter to Inova Genomics Laboratory.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2019, we provided the FDA with clinical evidence and other information to support our GeneSight Psychotropic test. Later that year, the FDA requested changes to the GeneSight test offering. Although we disagreed that changes to the test were required, we submitted a proposal regarding the reporting of GeneSight test results to healthcare providers that we believed addressed the FDA&#8217;s principal concerns and would not affect the benefits that we believe are provided by the GeneSight test.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since submitting our proposal to the FDA, we engaged with our trade association in their efforts to defend the offering of pharmacogenomic tests as LDTs and to monitor broader developments across the stakeholder community. In response to public letters from the national laboratory trade association and patient groups, on February 20, 2020, the FDA announced a new &#8220;collaboration between FDA&#8217;s Center for Devices and Radiological Health and Center for Drug Evaluation and Research intended to provide the agency&#8217;s view of the state of the current science in pharmacogenetics.&#8221; Although the announcement again asserted that some pharmacogenetic test offerings may be potentially dangerous, the agency also acknowledged that pharmacogenetic testing &#8220;offers promise for informing the selection or dosing of some medications for certain individuals.&#8221; In conjunction with the announcement, the FDA also released an updated &#8220;Table of Pharmacogenetic Associations,&#8221; which lists gene-drug interactions that the agency believes are supported by FDA-approved drug labeling and/or &#8220;sufficient scientific evidence based on published literature.&#8221; The Table has been updated periodically since that time. Based on our discussions with the agency and these developments, we have not implemented our proposal to the FDA regarding the GeneSight test. While we see these developments as signaling a positive shift in the FDA&#8217;s approach to regulating pharmacogenetic tests, we cannot predict with certainty the outcome of this matter or its timing, or whether the ultimate form of the GeneSight Psychotropic Mental Health Medication test offering, if it must be changed, will have an adverse effect on our revenues from the test.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Companion and complementary diagnostic tests require FDA approval, and we may not be able to secure such approval in a timely manner or at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our companion and complementary diagnostic products, marketing, sales and development activities and manufacturing processes are subject to extensive and rigorous regulation by the FDA pursuant to the federal Food, Drug, and Cosmetic Act (FDCA), by comparable agencies in foreign countries, and by other regulatory agencies and governing bodies. Under the FDCA, companion diagnostics must receive FDA clearance or approval before they can be commercially marketed in the U.S. The process of obtaining marketing approval or clearance from the FDA or by comparable agencies in foreign countries for new products could:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">take a significant period of time;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the expenditure of substantial resources;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">involve rigorous pre-clinical testing, as well as increased post-market surveillance;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require changes to products; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">result in limitations on the indicated uses of products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have successfully received FDA approval for some tests (e.g., our BRACAnalysis CDx and MyChoice CDx tests), we cannot predict whether or when we will be able to obtain FDA approval for other companion diagnostics that we are developing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our companion diagnostic tests are subject to ongoing regulatory compliance obligations and continued regulatory review and the failure to comply with such obligations could result in regulatory enforcement and/or penalties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companion diagnostic tests such as BRACAnalysis CDx and MyChoice CDx are subject to ongoing FDA and comparable foreign regulatory authority requirements for manufacturing, labeling, packaging, storage, distribution, quality, safety, sale, marketing, advertising, promotion, sampling, record-keeping, export, import, conduct of post-marketing studies and submission of safety, efficacy or other post-market information. In addition, we are subject to continued compliance with regulatory requirements applicable to medical devices and in vitro diagnostics. The FDA or other regulatory authorities may take regulatory enforcement or other legal action or may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur with our marketed products. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained,  and be subject to financial penalties or administrative action.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves environmental risks that may result in liability for us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our research and development activities, we are subject to federal, state and local laws, rules, regulations and policies governing the use, generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain materials, including hazardous materials, biological specimens, chemicals and waste. The cost of compliance with these laws and regulations may become significant and could negatively affect our operating results. Although we believe that we have complied with the applicable laws, regulations and policies in all material respects and have not been required to correct any material noncompliance, we may be required to incur significant costs to comply with environmental and health and safety regulations in the future. Although we believe that our safety procedures for handling and disposing of controlled materials comply with the standards prescribed by state and federal regulations, accidental contamination or injury from these materials may occur. In the event of such an occurrence, we could be held liable for any damages that result and any such liability could exceed our resources or any applicable insurance coverage we may have. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price is highly volatile, and our stock may lose all or a significant part of its value.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market prices for securities of relevant testing companies have been volatile. This volatility has significantly affected the market prices for these securities for reasons frequently unrelated to the operating performance of the specific companies. These broad market fluctuations may adversely affect the market price of our common stock. The market price for our common stock has fluctuated significantly since public trading commenced in October 1995, and it is likely that the market price will continue to fluctuate in the future. In the year ended December 31, 2022, our stock price ranged from $13.92 per share to $28.45 per share.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general has experienced extreme price and volume fluctuations. Events or factors that may have a significant impact on our business and on the market price of our common stock include the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">major market events, such as the market&#8217;s reaction to the COVID-19 pandemic generally and its specific impact on the Company;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any of our recently launched tests and any new test candidates to achieve commercial success;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to achieve and sustain revenue growth or margins in our business;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems and changes in governmental or private insurer reimbursement levels for our tests;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new commercial tests or technological innovations by competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of the licenses underlying our tests;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or other problems with operating our laboratory facilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any of our research and development programs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in intellectual property laws or the enforcement, validity or expiration of our patents in the United States and foreign countries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patents or other proprietary rights involving us directly or otherwise affecting the industry as a whole;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">missing or changing the financial guidance we provide;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of analysts to initiate or maintain coverage of our company; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative publicity, including misinformation, about our company, our tests or the industry in which we operate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the government regulatory approval process for our existing and new tests;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet estimates or recommendations by securities analysts that cover our common stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issuance of new securities analysts reports or changes in estimates or recommendations by securities analysts relating to our common stock or the securities of our competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern over our approved tests and any test candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation, including the outcome of existing and new litigation against us;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government and regulatory investigations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional funds if and when needed;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future sales or anticipated sales of our common stock by us or our stockholders;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and amount of any repurchases of our common stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market conditions, including as a result of changes in the rate of inflation and interest rates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seasonal slowness in sales, particularly in the quarters ending September 30th and March 31st, the effects of which may be difficult to understand during periods of growth;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general perception of the industry and our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic, health care and diagnostic trends, disasters or crises and other external factors; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">period-to-period fluctuations in our financial results.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other external factors may cause the market price and demand for our common stock to fluctuate substantially, which may limit or prevent investors from readily selling their shares of common stock and may otherwise negatively affect the liquidity of our common stock. In addition, securities class action litigation such as the current stockholder suit pending against the Company discussed elsewhere in this Annual Report on Form 10-K and certain related matters may affect the market price and demand for our common stock. Such litigation may cause us to incur substantial costs defending the lawsuit regardless of the outcome and could also divert the time and attention of our management. We also may decide to settle lawsuits on unfavorable terms, including above any insurance coverage that may be available. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our offerings or business practices. Furthermore, during the course of litigation, there could be negative public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a material adverse effect on the market price of our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our inability to achieve and maintain effective disclosure controls and procedures and internal control over financial reporting could adversely affect our results of operations, our stock price and investor confidence in us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 404 of the Sarbanes-Oxley Act of 2002 requires that companies evaluate and report on the effectiveness of their internal control over financial reporting. Failure to have effective internal control over financial reporting and disclosure controls and procedures could impair our ability to produce accurate financial statements on a timely basis and could lead to a restatement of our financial statements. If, as a result of the ineffectiveness of our internal control over financial reporting and disclosure controls and procedures, we cannot provide reliable financial statements, our business decision processes may be adversely affected, our business and results of operations could be harmed, investors could lose confidence in our reported financial information, and our ability to obtain additional financing, or additional financing on favorable terms, could be adversely affected. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we determined that our internal controls over financing reporting were effective as of December 31, 2022, we may in the future identify internal control deficiencies that could rise to the level of a material weakness or uncover other errors in financial reporting. During the course of our evaluation of these material weaknesses, we may identify areas requiring improvement and may be required to design additional enhanced processes and controls to address issues identified through this review. There can be no assurance that such remediation efforts will be successful, that our internal control over financial reporting will be effective as a result of these efforts or that any such future deficiencies identified may not be material weaknesses that would be required to be reported in future periods. In addition, we cannot assure you that our independent registered public accounting firm will be able to attest that such internal controls are effective when they are required to do so.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to remediate any future material weaknesses and maintain effective disclosure controls and procedures or internal control over financial reporting, you may not be able to rely on the integrity of our financial results, which could result in inaccurate or late reporting of our financial results, as well as delays or the inability to meet our reporting obligations or to comply with the rules and regulations of the Securities and Exchange Commission. Any of these could result in delisting actions by the Nasdaq Stock Market, investigation and sanctions by regulatory authorities, stockholder investigations and lawsuits, and could adversely affect our business and the trading price of our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions of Delaware law, provisions in our charter and bylaws and re-adoption of our stockholders&#8217; rights plan, or poison pill, could make a third-party acquisition of us difficult.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we are a Delaware corporation, the anti-takeover provisions of Delaware law could make it more difficult for a third party to acquire control of us, even if the change in control would be beneficial to stockholders. We are subject to the provisions of Section 203 of the General Corporation Law of Delaware, which prohibits us from engaging in certain business combinations, unless the business combination is approved in a prescribed manner. In addition, our restated certificate of incorporation and restated bylaws also contain certain provisions that may make a third-party acquisition of us difficult, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a classified Board of Directors, with three classes of directors each serving a staggered three-year term;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of the Board of Directors to issue preferred stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a 70% super-majority stockholder vote to amend our bylaws and certain provisions of our certificate of incorporation; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of our stockholders to call a special meeting or act by written consent.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, we implemented a stockholders&#8217; rights plan, also called a poison pill, which could make it uneconomical for a third party to acquire the Company on a hostile basis. Although the plan expired in July 2011, our Board of Directors could adopt a new plan at any time. The provisions in a stockholders&#8217; rights plan, as well as Section 203, may discourage certain types of transactions in which our stockholders might otherwise receive a premium for their shares over the then-current market price, and may limit the ability of our stockholders to approve transactions that they think may be in their best interests.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of our common stock would result in dilution of the percentage ownership of our stockholders and could cause the price of our common stock to decline.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may issue additional securities or sell common stock, convertible securities or other securities in one or more transactions at prices and in a manner we determine. We also plan to continue to grant equity awards that convert into our common stock to employees and directors pursuant to our equity incentive plan. If we sell or issue common stock, convertible securities or other equity securities, or common stock is issued pursuant to equity incentive plans, holders of our common stock may be materially diluted. In addition, we may issue common stock or other equity securities in connection with an acquisition or other strategic transaction, which would cause dilution to our existing stockholders. New investors in such transactions could gain rights, preferences and privileges senior to those of holders of our common stock. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock so any returns will be limited to changes in the value of our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently intend to retain any future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of our Amended Facility restrict our ability to pay dividends. Any determination to pay dividends in the future will be at the discretion of our Board of Directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our Board of Directors may deem relevant. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for the foreseeable future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. If few analysts continue coverage of us, the trading of our stock would likely decrease. Even if we do maintain sufficient analyst coverage, there can be no assurance that analysts will provide favorable coverage. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our restated bylaws provide that a state court located within the State of Delaware is the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restated bylaws provide that a state court located within the State of Delaware (or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware) is the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our restated certificate of incorporation or our restated bylaws, or any action asserting a claim against us governed by the internal affairs doctrine. This exclusive forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees and may discourage these types of lawsuits. Alternatively, if a court were to find the exclusive forum provision contained in our restated bylaws to be inapplicable or unenforceable in an action, we might incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, financial condition and results of operations.</span></div><div id="i7e0793090cf84227944277d460d39a4d_25"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters and facilities are located in Salt Lake City, Utah. We currently lease a total of approximately 364,445 square feet of building space in Salt Lake City dedicated to research and development, administration and our laboratory that has received federal certification under CLIA. Activities related to our Oncology and Women&#8217;s Health businesses are performed at this location.&#160;&#160;The leases on our existing Salt Lake City facilities have terms of ten to fifteen years, expiring from 2027 through 2038, and provide for renewal options for up to ten additional years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently lease a total of approximately 111,635 square feet of building space in South San Francisco, California dedicated to administration, research and development and the CLIA-certified laboratory for our Women&#8217;s Health business.&#160;The leases on our existing South San Francisco facilities have terms of seven to ten years, expiring from 2025 through 2033, and provide for renewal options for up to ten additional years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also lease a space in Mason, Ohio, with approximately 24,000 total square feet, which will expire in August 2024. Our GeneSight test is performed at this location in a CLIA-certified laboratory.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also lease several small office locations, including our manufacturing facility located in Cologne, Germany. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing facilities and equipment are well maintained and in good working condition. We believe our current facilities and those planned in South San Francisco and San Diego, California and west Salt Lake City, Utah will provide adequate capacity for the foreseeable future. For more information on our leased properties, see "Note 13-Leases in the Notes to Consolidated Financial Statements."</span></div><div id="i7e0793090cf84227944277d460d39a4d_31"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information regarding certain current legal proceedings, see "Note 12--Commitments and Contingencies in the Notes to Consolidated Financial Statements."</span></div><div id="i7e0793090cf84227944277d460d39a4d_34"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i7e0793090cf84227944277d460d39a4d_40"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the Nasdaq Global Select Market under the symbol "MYGN."&#160;&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholders</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February&#160;23, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were approximately 96 holders of record of our common stock. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees on their behalf.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future. In addition, the terms of our Amended Facility restrict our ability to pay dividends. Any future determination related to our dividend policy will be made at the discretion of our Board of Directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our Board of Directors may deem relevant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unregistered Sales of Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Bo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ard of Directors has previously authorized us to repurchase up to $200.0 million of our outstanding common stock, of which $110.7 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is still available to repurchase as of December&#160;31, 2022. We are authorized to complete the repurchase through open market transactions or through an accelerated share repurchase program, in each case to be executed at management&#8217;s discretion based on business and market conditions, stock price, trading restrictions, acquisition activity and other factors. The repurchase program may be suspended or discontinued at any time without prior notice.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No stock repurchases were made under our stock repurchase program during the year ended December&#160;31, 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph set forth below compares the annual percentage change in our cumulative total stockholder return on our common stock during a period commencing on December 31, 2017 and ending on December&#160;31, 2022 (as measured by dividing (A) the difference between our share price at the end and the beginning of the measurement period by (B) our share price at the beginning of the measurement period) with the cumulative total return of the Nasdaq Composite Index (IXIC) and the Nasdaq Health Care Index (IXHC) during such period.&#160;&#160;We have not paid any cash dividends on our common stock, and we do not include cash dividends in the representation of our performance.&#160;&#160;The price of a share of common stock is based upon the closing price per share as quoted on the Nasdaq Global Select Market on the last trading day of the year shown.&#160;&#160;The graph lines merely connect year-end values and do not reflect fluctuations between those dates.&#160;&#160;The comparison assumes $100 was invested on December 31, 2017 in our common stock and in each of the foregoing indices.&#160;&#160;The comparisons shown in the graph below are based upon historical data. We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our common stock.</span></div><div style="margin-top:12pt;text-align:center"><img src="mygn-20221231_g1.jpg" alt="mygn-20221231_g1.jpg" style="height:376px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.765%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">12/31/2017</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">12/31/2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">12/31/2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">12/31/2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">12/31/2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">12/31/2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Myriad Genetics, Inc.</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.63</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.27</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.55</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.35</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.24</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NASDAQ Composite Index (IXIC)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.97</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.69</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.63</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.61</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NASDAQ Health Care Index (IXHC)</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.83</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.58</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.81</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.25</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.35</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note:&#160;&#160;Information used on the graph was obtained from the CRSP Total Return Indexes, a source believed to be reliable, but we are not responsible for any errors or omission in such information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance graph shall not be deemed to be incorporated by reference by means of any general statement incorporating by reference this Annual Report on Form 10-K into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate such information by reference, and shall not otherwise be deemed filed under such acts.</span></div><div id="i7e0793090cf84227944277d460d39a4d_43"></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;[RESERVED]</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span><br/></span></div><div id="i7e0793090cf84227944277d460d39a4d_46"></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This section of Management's Discussion and Analysis discusses year-to-year comparisons between the year ended December 31, 2022 and the year ended December 31, 2021. Discussions of comparisons between the year ended December 31, 2021 and the year ended December 31, 2020 that are not included in this Annual Report on Form 10-K can be found in "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Item 7 of Part II of our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on February 25, 2022. The following discussion and analysis should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes thereto included elsewhere in this Annual Report on Form 10-K. Unless otherwise noted, all of the financial information in this Annual Report on Form 10-K is consolidated financial information for the Company.</span></div><div id="i7e0793090cf84227944277d460d39a4d_49"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We develop and offer genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower health care costs. Our mission is to advance health and well-being for all, empower individuals with vital insights and enable healthcare providers to better detect, treat and prevent disease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personalized genetic data, digital, and virtual consumer trends are converging to change traditional models of care. We believe significant growth opportunities exist to help patient populations with pressing health care needs through innovative solutions and services. Our focus is on organic growth, deployment of capital, including through opportunistic acquisitions, and the launch of new products. We are focusing our efforts in three key areas where we have specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. We believe our path to organic growth is driven by articulating our clinical differentiation, advancing a new commercial model in our Oncology and Women's Health businesses to reach a broader set of physicians and patients, raising awareness with patients who we believe would benefit from testing, and innovation that improves clinical outcomes, ease of use, and access. By investing in tech-enabled commercial tools, new lab facilities, and advanced automation, we believe we will be able to reduce complexity and cost. With a foundation of financial, commercial, operational and technological strength, we plan to launch new products and capabilities in 2023, such as our unified ordering portal, FirstGene, and, on a research use only basis, Precise MRD, which we expect will help accelerate our growth. We intend to develop and enhance our products to support growth, improve patient and provider experience, and reach more patients of all backgrounds. We are committed to disciplined management of a key set of initiatives to fulfill our mission and drive long-term growth and profitability. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated revenues consist primarily of sales of tests through our wholly-owned subsidiaries.&#160;&#160;During the year ended December&#160;31, 2022, we reported total revenues of $678.4 million, net loss attributable to Myriad Genetics, Inc. stockholders of $112.0 million and basic and diluted loss per share of $1.39.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Updates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, we took meaningful steps to fulfill our mission and execute our strategic transformation and growth plan. These steps included the following: </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the acquisition of Gateway Genomics, LLC (Gateway), a personal genomics company and developer of consumer genetic tests that gives families insight into their future children; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the launch of Precise Oncology Solutions, a comprehensive offering designed to help oncologists determine effective and personalized treatment plans for individual patients; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the appointment of several new leaders to our management team, including a new Chief Commercial Officer, Chief Operating Officer, Chief Scientific Officer, and Chief Marketing Officer, as part of our ongoing enhancement of our executive leadership team; and </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">total revenue grew 6% year-over-year, excluding contributions from divested businesses. Pharmacogenomics volume growth continued to lead our portfolio, reporting 35% volume growth year-over-year, and hereditary cancer test volumes rebounded in the second half of the year, generating 10% volume growth in the second half of the year ended December 31, 2022 as compared to the second half of the year ended December 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically experienced seasonality in our testing business. The quarter ended December 31st is generally strong as we typically experience an increase in volumes from patients who have met their annual insurance deductible. Conversely, in the quarter ended March 31st we typically experience a decrease in volumes due to the annual reset of patient deductibles. Additionally, the volume of testing is negatively impacted by the summer season, which is generally reflected in the quarter ended September 30th.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Consolidated Operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Testing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our tests are designed to analyze genes and their expression levels to assess an individual&#8217;s risk for developing disease, determine a patient&#8217;s likelihood of responding to a particular drug, assess a patient&#8217;s risk of disease progression, or identify factors which could lead to serious conditions in pregnancy. Revenue is recognized when the communication of test results has occurred. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On July 1, 2021, we divested Myriad RBM, Inc., which provided pharmaceutical and clinical services. As a result, we ceased providing pharmaceutical and clinical services as of that date and no longer generate revenue from these services. Through Myriad RBM, Inc., we provided biomarker discovery, pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries utilizing our multiplexed immunoassay technology. We also divested other clinical operations in February 2020.  Revenue for these services was recognized at the completion of the pharmaceutical and clinical services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs and Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel-related costs for each category of Costs and Expenses include salaries, bonuses, employee benefit costs, employer payroll taxes, and stock-based compensation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Testing Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cost of testing revenue consists primarily of costs related to laboratory supplies, personnel-related costs, and overhead costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Other Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cost of other revenue consists primarily of costs related to laboratory supplies and personnel-related costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of personnel-related costs and laboratory supplies, which includes costs incurred in formulating, improving, validating and creating alternative or modified processes related to and expanding the use of our current test offerings and costs incurred in the discovery, development and validation of our pipeline of test candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General, and Administrative Expense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Selling, general, and administrative expenses include costs associated with managing and growing our businesses. Selling, general, and administrative expenses consist primarily of personnel-related costs and third-party costs for sales, marketing, customer service, billing and collection, legal, finance and accounting, information technology, and human resources.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Charges Pending Settlement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Legal charges pending settlement includes accruals related to potential legal settlements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Long-Lived Asset Impairment Charges.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Goodwill and long-lived asset impairment charges include the impairment loss recognized on our goodwill or long-lived assets, including impairments recognized on intangible assets and right-of-use (ROU) lease assets. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) includes interest income earned on our cash, cash equivalents, and restricted cash held in short-term interest-bearing accounts; interest expense associated with our debt and amortization of deferred financing costs and original issue discount costs; gains or losses on the sale of assets or businesses; and foreign currency gains and losses, realized gain or loss on marketable securities, and other nonrecurring income and expenses.</span></div><div id="i7e0793090cf84227944277d460d39a4d_52"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.264%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total Revenue</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Testing revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total testing revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.2)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Test revenues for the year ended December&#160;31, 2022 increased $12.0 million compared to the prior year. Revenue from Pharmacogenomics increased $33.9 million compared to the prior year due primarily to a 35% increase in volume. Prenatal revenues increased $9.6 million due primarily to the acquisition of Gateway and an increase of 7% in average reimbursement per test excluding Gateway. Tumor Profiling revenues increased due to volume increases in our Prolaris and MyChoice CDx products, partially offset by a decrease in international revenue due to changes in foreign exchange rates and a one-time milestone revenue earned in the prior year. Autoimmune revenues decreased $27.9 million compared to the prior year due to the sale of the Myriad Autoimmune business on September 13, 2021. Hereditary Cancer revenues decreased $10.8 million due primarily to changes in foreign exchange rates. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue for the year ended December 31, 2022 declined $24.2 million compared to the year ended December 31, 2021, due to the sale of Myriad RBM, Inc. on July 1, 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of testing revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of testing revenue as a % of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of other revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of other revenue as a % of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of testing revenue as a percentage of revenue increased from 27.9% to 29.8% during the year ended December 31, 2022 compared to the year ended December 31, 2021.&#160;&#160;The increase was primarily driven by the shift in the product mix for the current period and an increase in compensation costs due to an increase in the number of employees and an increase in the average cost per employee during the 2022 period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of other revenue as a percentage of revenue was 49.2% for the year ended December 31, 2021. The sale of Myriad RBM, Inc. was completed on July 1, 2021, and as a result, there were no corresponding costs during the current period. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense as a % of total revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense for the year ended December 31, 2022 increased by $3.5 million compared to the prior year primarily due to an increase in compensation expense and information technology related costs, partially offset by a decrease in clinical trial costs and costs incurred in the 2022 period related to our strategic transformation initiatives as compared to the prior year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General, and Administrative Expense</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense as a % of total revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expense decreased by $23.1 million for the year ended December 31, 2022 compared to the prior year due primarily to a $23.9 million decrease in legal expenses, which was driven in part by the receipt of insurance proceeds for certain legal matters of $12.0 million in 2022 and a decrease in litigation expenses during 2022. Additionally, costs from our strategic transformation initiative decreased by $11.6 million in 2022 due to a decrease in retention and severance costs as well as related consulting costs. The remaining decrease in selling, general, and administrative expenses in 2022 is due to a $9.7 million decrease in amortization expense due to intangible assets sold in the divestitures in the prior year and a $8.8 million decrease in bonus and commission expenses. The decreases were partially offset by a $17.4 million increase in sales and marketing expenses due to more in-person sales and marketing events and travel-related expenses in 2022, a $7.6 million increase in wages and other compensation expenses, a $5.5 million increase in consulting expenses, and a $3.3 million increase in information and technology expenses.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Charges Pending Settlement</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.746%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal charges pending settlement</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal charges pending settlement as a % of total revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal charges pending settlement decreased for the year ended December 31, 2022 compared to the prior year due to $62.0 million of accruals related to potential legal settlements recorded in the prior year, including $48.0 million in connection with the qui tam lawsuit against Crescendo Bioscience, LLC and the Company and $14.0 million in connection with the Abelli lawsuit. These amounts were subsequently paid in connection with the settlement of these cases in April 2022 and January 2022, respectively. There were no corresponding legal charges pending settlement in the year ended December 31, 2022. </span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Long-lived Asset Impairment Charges</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.746%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and long-lived asset impairment charges</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and long-lived asset impairment charges as a % of total revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and long-lived asset impairment charges increased for the year ended December 31, 2022 compared to the prior year  primarily due to the Company recognizing a $13.0 million impairment to ROU assets and a $3.9 million impairment to the related leasehold improvements in the current year as a result our decision to no longer use certain leased facilities in order to consolidate space. During the prior period, the Company recognized a $1.8 million impairment to ROU assets as a result of the voluntary early termination of certain lease agreements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) decreased for the year ended December 31, 2022 compared to the prior year due primarily to the $121.0&#160;million net gain recognized on the sale of Myriad RBM, Inc. and the $31.2&#160;million net gain recognized on the sale of the Myriad myPath, LLC laboratory in the prior period, partially offset by charges in the prior period, including losses of $5.2&#160;million and $6.5&#160;million for a non-cancelable purchase commitment and inventory, respectively, recognized in connection with certain divestiture transactions, as well as a $3.4&#160;million decrease in interest expense in the current period. The interest expense in the prior period is related to the debt outstanding at that time, which was repaid in full on July 30, 2021. There was no debt outstanding during the year ended December 31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Benefit </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our tax rate is the product of a U.S. federal effective rate of 21.0% and a blended state income tax rate of approximately 3.4%. Certain significant or unusual items are separately recognized during the period in which they occur and can be a source of variability in the effective tax rates from period to period.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit for the year ended December 31, 2022 was $(28.6) million, and our effective tax rate was (20.3)%. For the year ended December 31, 2022, our effective tax rate differs from the U.S. federal statutory rate primarily due to disallowed executive compensation expenses, stock compensation, change in valuation allowance, and research and development credits. For the year ended December&#160;31, 2021, our effective tax rate differs from the U.S. federal statutory rate primarily due to disallowed executive compensation expenses, differences between the book and tax basis of assets divested, the tax impact of the CARES Act, stock compensation, and release of a valuation allowance.</span></div><div id="i7e0793090cf84227944277d460d39a4d_55"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are our cash, cash equivalents and marketable investment securities, our cash flows from operations, and, in certain circumstances as discussed below, amounts available for borrowing under our Amended Facility. Our capital deployment strategy focuses on use of resources in the key areas of research and development, technology and acquisitions. We believe that investing organically through research and development and new product development or acquisitively to support our business strategy provides the best return on invested capita</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">l. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing capital resources will be sufficient to meet our projected operating requirements for the foreseeable future. In addition, our capital resources and cash on hand may be used for acquisitions or other strategic investments. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All previously outstanding borrowings under our Amended Facility, which matures on July 31, 2023, were repaid on July 30, 2021 using cash generated from divestitures and as such, we have no outstanding borrowings as of December&#160;31, 2022. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available capital resources, however, may be consumed more rapidly than currently expected, or may be insufficient for our business needs for many reasons, including as a result of our operational cash needs, capital expenditures, and litigation related costs not covered by, or above the limits set forth in, our insurance. As a result, we may need or want to raise additional financing. We may not be able to secure such financing in a timely manner or on favorable terms, if at all. The current rising interest rate environment, together with recessionary headwinds, could make any potential financing more difficult or expensive to obtain. In addition, as of December 31, 2022, our borrowing limit under the Amended Facility has decreased to $150.0 million, and we remain subject to financial covenants under our Amended Facility, which could limit our ability to incur additional indebtedness under the Amended Facility or otherwise or impact our decision to pursue other financing. Without additional funds, we may be forced to delay the build-out of our new laboratories, scale back or eliminate some of our sales and marketing efforts, research and development activities, or other operations, or delay development of our tests in an effort to provide sufficient funds to continue our operations. If any of these events occurs, our ability to achieve our development and commercialization goals could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Facility restricts our ability to make future borrowings if unrestricted cash, cash equivalents and marketable securities exceed $150.0&#160;million, unless such borrowings are in connection with certain permitted acquisitions. Unrestricted cash, cash equivalents, and marketable securities totaled $169.7 million as of December&#160;31, 2022. Our revolving commitment amount under the Amended Facility is $150.0 million as of December 31, 2022. As our total unrestricted cash, cash equivalents, and marketable securities exceeded $150.0&#160;million as of December&#160;31, 2022, we are currently unable to make borrowings under the Amended Facility unless related to a permitted acquisition. In addition, we are subject to a minimum liquidity covenant, which requires us to maintain liquidity of $150.0 million. Liquidity is defined under the Amended Facility as the sum of our unrestricted cash, cash equivalents and marketable investment securities plus the aggregate undrawn and available amount of the revolving commitments under the Amended Facility. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into purchase commitments or other agreements that may materially impact our liquidity position in future periods.  In February 2022, we entered into a non-cancelable operating lease for approximately 230,000 square feet in west Salt Lake City, Utah. The lease has a term of 15 years, which, along with rent payments, is expected to commence in the third quarter of 2023. Total future rent payments under the lease are approximately $78.0&#160;million. We also entered into a non-cancelable operating lease for approximately 63,000 square feet of leased space in South San Francisco, California. The lease has a term of 10 years and, along with rent payments, is expected to commence in the third quarter of 2023. Total future rent payments under the lease are approximately $58.8 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the technical nature of our business and our focus on science, research, and development, we are highly dependent upon our ability to attract and retain highly qualified and experienced management, scientific, and technical personnel. Competition and increased compensation for such personnel and other qualified personnel have increased the difficulty and cost of hiring and retaining qualified personnel. Loss of the services of or failure to recruit additional key management, scientific, and technical personnel and other qualified personnel who are necessary to operate our business would adversely affect our  business, and it may have a material adverse effect on our business as a whole. Additionally, disruptions to our supply chain could cause shortages of critical materials required to conduct our business, which may have a material adverse effect on our business as a whole. In addition, inflation has had, and we expect it will continue to have, an impact on the costs we incur to attract and retain qualified personnel, costs to generate sales and produce diagnostic testing results, and costs of lab supplies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the balances of cash, cash equivalents, and marketable investment securities as of December 31, 2022 and 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:64.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.4&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable investment securities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397.8&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in cash, cash equivalents, and marketable investment securities as of December&#160;31, 2022 compared to December 31, 2021 was primarily driven by $106.3 million in cash used by operations, which included legal settlement payments of $62.0 million, as well as $57.2 million in cash used for our acquisition of Gateway, $45.3 million in cash used for capital expenditures, and $4.3 million in cash used for the payment of withholding tax in connection with the issuance of common stock, net of proceeds from the issuance of common stock. The Company also had restricted cash of $9.5 million and $1.4 million as of December 31, 2022 and 2021, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the condensed cash flow statement:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by (used in) operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of foreign exchange rates on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash  at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December 31, 2022, the decrease in cash flows from operating activities was primarily due to the change in the balance of prepaid taxes due to the receipt of an $89.0 million U.S. federal tax refund in the prior year and an $81.2 million decrease in accrued liabilities during the current year, which was primarily driven by legal settlement payments of $62.0 million in 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December 31, 2022, the decrease in cash flows provided by investing activities as compared to the prior year was primarily due to the receipt of $379.1 million in cash proceeds from divestitures in the prior year, with no corresponding proceeds in the current period and the acquisition of Gateway, net of cash acquired, for $57.2 million, partially offset by a $67.1 million increase in proceeds from marketable investment securities in the current period.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December 31, 2022, the decrease in cash flows used in financing activities as compared to the prior year was primarily due to the use of $226.4 million in cash for repayments of the outstanding debt balances under the Amended Facility during the prior year, partially offset by a decrease of $84.6 million in proceeds from the exercise of stock options, net of shares exchanged for payroll withholding tax in the current year as compared to the prior year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effects of Inflation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation has had, and may continue to have, an impact on the labor costs we incur to attract and retain qualified personnel, costs to generate sales and produce testing results, and costs of laboratory supplies. Inflationary costs have impacted our profitability and continue to adversely affect our business, financial condition and results of operations. In addition, increased inflation has had, and may continue to have, an effect on interest rates. Increased interest rates may adversely affect our borrowing rate and our ability to obtain, or the terms under which we can obtain, additional funding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Program</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has previously authorized us to repurchase up to $200.0 million of our outstanding common stock. We may repurchase our common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by our management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity, and other factors.  As of December&#160;31, 2022, we are authorized to repurchase up to $110.7 million under our current share repurchase authorization.  See &#8220;Part II, Item 5. Market For Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities &#8211; Issuer Purchases of Equity Securities&#8221; above.</span></div><div id="i7e0793090cf84227944277d460d39a4d_58"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting estimates are those policies which are both important to the portrayal of a company&#8217;s financial condition and results and require management&#8217;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our critical accounting estimates are as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">revenue recognition;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">goodwill; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">purchase accounting; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">income taxes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;Revenue is recognized when, or as, performance obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to a customer. We exclude sales, use, value-added, and other taxes we collect on behalf of third parties from revenue. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or services to a customer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenue primarily by performing genetic testing. We perform our obligation under a contract with a customer by processing those tests and communicating the test results to customers, in exchange for consideration from the customer. Revenue from the sale of tests is recorded at the estimated transaction price. We have determined that the communication of test results indicates transfer of control for revenue recognition purposes. We have the right to bill our customers upon the completion of performance obligations and thus do not record contract assets.&#160;Occasionally customers make payments prior to our performance of our contractual obligations.&#160;When this occurs, we record a contract liability as deferred revenue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgments are required in determining the transaction price in connection with satisfying performance obligations under the revenue standard. In determining the transaction price, we estimate the expected amount of consideration as revenue. We apply this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which we will be entitled.&#160;&#160;An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. We consider all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. To determine our estimated transaction price, we apply the expected value method for sales where we have a large number of contracts with similar characteristics. We then consider the probability of the variable consideration for each possible scenario. We have significant experience with historical collection patterns and use this experience to estimate transaction prices. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimate of revenue is affected by assumptions in payor mix and in payor behavior such as changes in payor collections, current customer contractual requirements, and experience with ultimate collection from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. We reserve certain amounts in accrued liabilities in the Consolidated Balance Sheets in anticipation of request for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Consolidated Statements of Operations and Comprehensive Loss.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill.&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We test goodwill for impairment on an annual basis and in the interim by reporting unit if events and circumstances indicate that goodwill may be impaired.&#160;&#160;The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators and competition. Impairment of goodwill is evaluated on a qualitative basis before calculating the fair value of the reporting unit. If the qualitative assessment suggests that impairment is more likely than not, a quantitative impairment analysis is performed.&#160;&#160;The quantitative analysis involves comparison of the fair value of a reporting unit with its carrying amount.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of a reporting unit requires judgment in estimating future cash flows, discount rates, residual growth rates and other factors. In making these judgments, we evaluate the financial health of our business, including such factors as industry performance, market saturation and opportunity, changes in technology and operating cash flows, and other relevant entity-specific events.&#160;Changes in our forecasts or decreases in the value of our common stock could cause book value of reporting units to exceed their fair values.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we have recorded goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $286.8 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million on our Consolidated Balance Sheets. This goodwill is attributable to the Myriad Mental Health, Myriad International, Myriad Women's Health, and Gateway reporting units. We qualitatively evaluated our reporting units for impairmen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The factors that are considered in the qualitative analysis include macroeconomic conditions, industry and market considerations, revenue growth rates, current and financial performance, other factors that would have a negative effect on earnings and cash flows, and other relevant entity-specific events and information. Significant judgment is required in assessing the weight of the qualitative factors. We noted no indicators of impairment during the year ended December&#160;31, 2022. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairment testing requires us to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, and other financial assumptions, which are based upon our long-term plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both debt and equity, including a risk premium. While we use the best available information to prepare our cash flows and discount rate assumptions, actual future cash flows and/or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, our overall methodology used has remained unchanged.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Accounting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We account for acquisitions of entities that include inputs and processes and have the ability to create outputs as business combinations. The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. Significant judgment is often required in estimating the fair value of assets acquired, particularly intangible assets. We base the estimated fair value of identifiable intangible assets acquired in a business combination on third-party valuations that use information and assumptions provided by our management, which consider our estimates of inputs and assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, estimated cost savings, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under Accounting Standards Codification (ASC) 480 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a liability is recognized equal to the fair value of the contingent payments we expect to make as of the acquisition date. This liability is remeasured each reporting period and changes in the fair value are recorded in change in fair value of contingent consideration in our Consolidated Statements of Operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;Our income tax provision is based on income before taxes and is computed using the liability method in accordance with ASC 740 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using tax rates projected to be in effect for the year in which the differences are expected to reverse.&#160;&#160;Significant estimates are required in determining our provision for income taxes.&#160;&#160;Some of these estimates are based on interpretations of existing tax laws or regulations, or the expected results from any future tax examinations.&#160;&#160;Various internal and external factors may have favorable or unfavorable effects on our future provision for income taxes.&#160;&#160;Those factors include, but are not limited to, changes in tax laws, regulations and/or rates, the results of any future tax examinations, changing interpretations of existing tax laws or regulations, changes in estimates of prior years&#8217; items, past levels of research and development spending, acquisitions, changes in our corporate structure, and changes in overall levels of income before taxes all of which may result in periodic revisions to our provision for income taxes.&#160;&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing our provision for income taxes, including our effective tax rate and analysis of potential uncertain tax positions, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowance we deem necessary to offset deferred tax assets.&#160;&#160;If we do not maintain taxable income from operations in future periods, we may increase the valuation allowance for our deferred tax assets and record material adjustments to our income tax expense.&#160;&#160;Our judgment and tax strategies are subject to audit by various taxing authorities.&#160;&#160;While we believe we have provided adequately for our uncertain income tax positions in our consolidated financial statements, an adverse determination by these taxing authorities could have a material adverse effect on our consolidated financial condition, results of operations or cash flows.&#160;Interest and penalties on income tax items are included as a component of overall income tax expense.</span></div><div id="i7e0793090cf84227944277d460d39a4d_61"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Note 1 to the Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for a description of recent accounting pronouncements.</span></div><div id="i7e0793090cf84227944277d460d39a4d_64"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rates and foreign currency exchange risks. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an investment portfolio in accordance with our written investment policy. The primary objectives of our investment policy are to preserve principal, maintain proper liquidity to meet operating needs and maximize yields. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments consist of debt securities of various types and maturities of five years or less, with an average maturity of 2.1 years. These securities are classified as available-for-sale. Available-for-sale securities are recorded on the balance sheet at fair market value with unrealized gains or losses reported as part of Accumulated other comprehensive loss. Realized gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. A decline in the market value of any available-for-sale security below cost that is deemed other-than-temporary results in a charge to earnings and establishes a new cost basis for the security.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our investment policy guidelines are intended to ensure the preservation of principal, market conditions can result in high levels of uncertainty.&#160;Our ability to trade or redeem the securities in which we invest, including certain corporate bonds, may become difficult.&#160;Valuation and pricing of these securities can also become variable and subject to uncertainty. As of December&#160;31, 2022, we had $2.7&#160;million in unrealized losses in our investment portfolio. We do not utilize derivative financial instruments to manage our interest rate risks.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be exposed to fluctuations in foreign currencies with regard to certain agreements with service providers. While our expenses are predominantly denominated in U.S. dollars, approximately 10% of our revenues are denominated in other currencies, primarily in Japanese yen. A hypothetical 10% change in the value of the Japanese yen relative to the U.S. dollar would result in a 1% change in our revenues. Although we also have certain operations denominated in Euros, Swiss francs, and British pounds, among other currencies, those operations are subject to less overall market risk due to the revenue and expenses being denominated in the same currency. During the year ended December 31, 2022, our revenues were negatively impacted by approximately $10.4 million due to foreign currency fluctuations. We do not currently utilize hedging strategies to mitigate foreign currency risk. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_67">Index to Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_70">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: <ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF82Ny9mcmFnOjM1NzgyYzFiNDEwYjQxNDA4ZTJkNzY2OWVlZGNhYjhlL3RhYmxlOjQ3NzYxYzA4ZDU3YTRmYTM5YmY4YzE3YWYyYzUxYTMwL3RhYmxlcmFuZ2U6NDc3NjFjMDhkNTdhNGZhMzliZjhjMTdhZjJjNTFhMzBfMi0wLTEtMS0xMTk0ODIvdGV4dHJlZ2lvbjo0YzIzYzdlOGFkMWY0NTFlOTNhNDczMGIzYWIzZWY2OF83MQ_7017c1db-c854-442a-bdfe-01cd16dcbecd">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_70">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_73">Consolidated Balance Sheets as of December 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_73">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_76">Consolidated Statements of Operations for the Year</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_76">s</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_76"> Ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_76">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_76"> and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_76"> 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_76">, the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_76">Transition Period </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_76">Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_76">December 31, 2020, and for the Year</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_76"> Ended June 30, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_76">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_79">Consolidated Statements of Comprehensive </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_79">Loss</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_79"> for the Year</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_79">s</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_79"> Ended December 31, 2022</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_79"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_79">2021,</a></span></div><div style="text-indent:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_79">the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_79">Transition Period Ended December 31, 2020 and for the Year</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_79"> Ended June 30, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_79">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_82">Consolidated Statements of Stockholders' Equity for the Years Ended December 31, 2022 and 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_82">, </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_82">the</a></span></div><div style="padding-left:13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_82">Transition Period </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_82">Ended December 31, 2020 and for the Year</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_82"> Ended June 30, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_82">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_85">Consolidated Statements of Cash Flows for the Year</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_85">s</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_85"> Ended December 31,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_85"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_85">202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_85">2 and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_85"> 2021, the Transition Period </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_85">Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_85">December 31, 2020 and for the Year</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_85"> Ended June 30, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_85">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_88">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_88">75</a></span></div></td></tr></table></div><div style="margin-top:3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Myriad Genetics, Inc.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Myriad Genetics, Inc. and subsidiaries (the Company) as of December&#160;31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, stockholders' equity and cash flows for the years ended December 31, 2022 and 2021, the six month period ended December&#160;31, 2020 and the year in the period ended June 30, 2020, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for the years ended December 31, 2022 and 2021, the six month period ended December&#160;31, 2020 and the year in the period ended June 30, 2020, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December&#160;31, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated March&#160;1, 2023 expressed an unqualified opinion thereon.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.572%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 84.25pt 2px 1pt;text-align:justify;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Measurement of testing revenue</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December&#160;31, 2022, the Company&#8217;s testing revenue was $678.4 million. As discussed in Note 1 of the consolidated financial statements, management estimates the expected amount of consideration to be received as testing revenue and revenue is recognized when the performance obligation is complete. </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Auditing the measurement of the Company&#8217;s testing revenue was complex and judgmental due to the significant estimation required in determining the amount that will be collected for each test. In particular, the estimate of revenue is affected by assumptions related to payors such as changes in payor mix, payor collections, current customer contractual requirements, and experience with ultimate collection from third-party payors.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.572%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company&#8217;s revenue recognition process. For example, we tested controls over management&#8217;s review of the significant assumptions above and inputs used in calculating the estimated amount that would be collected for each test and tested management&#8217;s controls to compare actual payments received to previously forecasted activity. We also tested controls used by management to compare the current and historical data used in making the estimates for completeness and accuracy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures over the Company&#8217;s testing revenue included, among others, assessing valuation methodologies and models and testing the significant assumptions above and the underlying data used by the Company in its analysis. We agreed transactions selected for testing back to the actual customer contract terms. We compared the significant assumptions above and inputs used by management to changes in the Company&#8217;s contracted rates, third-party payor collection trends, and other relevant factors. We assessed the historical accuracy of the cash collections used in the Company&#8217;s revenue models, and assessed the completeness of adjustments to estimates of future cash collections as a result of significant contract amendments, changes in collection trends and changes in payor behavior. </span></div><div style="text-align:justify"><span><br/></span></div></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83MC9mcmFnOjg4ZmI2ZDUyYjgzNjQ5MWU4OWRiMDI5YTZhZDUzM2M4L3RleHRyZWdpb246ODhmYjZkNTJiODM2NDkxZTg5ZGIwMjlhNmFkNTMzYzhfMzYwNQ_953e7a16-5856-40b6-9314-701ebefefdef">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2006.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83MC9mcmFnOjg4ZmI2ZDUyYjgzNjQ5MWU4OWRiMDI5YTZhZDUzM2M4L3RleHRyZWdpb246ODhmYjZkNTJiODM2NDkxZTg5ZGIwMjlhNmFkNTMzYzhfMzYwNA_4ca6624b-31c7-49c3-9bb8-56f564fa0875">Salt Lake City, UT</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;1, 2023</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions, except per share amounts)</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:63.937%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.085%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfNC0xLTEtMS0xMTk0ODI_b3256974-a115-4cbd-980a-6c4b5b8d1420">56.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfNC0zLTEtMS0xMTk0ODI_06765e56-e9b9-410a-907a-7a674c2dae25">257.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfNS0xLTEtMS0xMTk0ODI_44a7a48a-05db-4777-bec6-f945e0620b2a">58.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfNS0zLTEtMS0xMTk0ODI_e6aded1a-f189-4e6c-b158-8a1ef6053c43">81.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfNi0xLTEtMS0xMTk0ODI_4c5264c0-b7a9-465e-bea5-1c4b70c60207">101.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfNi0zLTEtMS0xMTk0ODI_1a4f9b0a-ca4c-44f3-a29a-450508739ff2">91.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfNy0xLTEtMS0xMTk0ODI_928e64ed-2476-4e36-a4f8-938c7464ca6a">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfNy0zLTEtMS0xMTk0ODI_60806859-d50d-426d-8ea5-6ac058f936b6">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:PrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfOC0xLTEtMS0xMTk0ODI_6fde0f72-2558-4f0e-930d-94ff43789041">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:PrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfOC0zLTEtMS0xMTk0ODI_be42c83f-3237-4627-83c0-8aa5a7330441">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfOS0xLTEtMS0xMTk0ODI_2b7a9029-2ccb-4285-80f7-db884ff9baf3">20.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfOS0zLTEtMS0xMTk0ODI_27ce5862-fb0b-4e8b-b2a1-26c8a059ac8b">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTAtMS0xLTEtMTE5NDgy_d87d5b99-60b0-48c6-aa78-75b816c85d62">274.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTAtMy0xLTEtMTE5NDgy_ddff78d1-efb4-4eda-8fa9-1675f48b6a3d">484.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTEtMS0xLTEtMTE5NDgy_c4a3069e-4778-44d7-bb48-f350b9e36e91">103.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTEtMy0xLTEtMTE5NDgy_e62dfb5e-d9c9-4f80-9c84-442173a0887b">81.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTItMS0xLTEtMTE5NDgy_0a5b359d-1cfd-4ac4-9f99-cea73bc4dac3">54.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTItMy0xLTEtMTE5NDgy_cd922227-a6f9-4b9a-8253-58aeb1706d08">59.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTMtMS0xLTEtMTE5NDgy_046ada57-0b70-4ce4-8652-724cfd8a720b">83.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTMtMy0xLTEtMTE5NDgy_2c2135f8-fd84-4bef-b183-ac3b6e60b4dd">43.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTQtMS0xLTEtMTE5NDgy_7917c73a-055b-406f-956c-74ee649577fc">379.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTQtMy0xLTEtMTE5NDgy_c3a0e19a-3912-4f69-bd1a-334aa1301d18">404.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTUtMS0xLTEtMTE5NDgy_105b8973-1084-485c-94b6-4113174f6c71">286.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTUtMy0xLTEtMTE5NDgy_2c054fa8-8660-4b36-8c3e-36533d8e97ad">239.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTYtMS0xLTEtMTE5NDgy_7d07bbb3-a44c-4319-a7fc-baae3529ae93">15.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTYtMy0xLTEtMTE5NDgy_67b69988-8ef0-46d1-bb85-51f4e1937b1f">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTctMS0xLTEtMTE5NDgy_af8add20-7c06-49f5-8bd9-629bcf516352">1,198.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTctMy0xLTEtMTE5NDgy_5bec5532-17a6-4b70-8df1-8e7bf0af7ff1">1,320.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjAtMS0xLTEtMTE5NDgy_8b1e2720-08ec-4da9-9379-3ac27f896bba">28.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjAtMy0xLTEtMTE5NDgy_e165287b-e400-491b-93c7-3dd72b9a9362">29.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjEtMS0xLTEtMTE5NDgy_260c359f-a951-423f-b586-cacbefe17034">94.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjEtMy0xLTEtMTE5NDgy_b6b7ef62-1d8b-4b8f-8257-b7f7d5adb42d">161.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current maturities of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjItMS0xLTEtMTE5NDgy_8bafa683-f0f5-411b-9c6a-9ca05ac018a5">14.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjItMy0xLTEtMTE5NDgy_c97d51b1-8ee4-4ba6-8c4a-86afc9b2c318">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjQtMS0xLTEtMTE5NDgy_c7c6c55c-2de9-46f7-9c67-1a764c9f8e1a">137.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjQtMy0xLTEtMTE5NDgy_4b32eb39-b2e4-4b20-a879-76221ddc91c6">204.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="mygn:UnrecognizedTaxBenefitsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjUtMS0xLTEtMTE5NDgy_6d51149d-e545-409c-84f4-40e9c9d1705a">26.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="mygn:UnrecognizedTaxBenefitsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjUtMy0xLTEtMTE5NDgy_b2693a00-dc99-43fb-94c9-07f599bf7fae">27.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjYtMS0xLTEtMTE5NDgy_f8323905-0486-4cd4-8118-28c47b33c4a2">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjYtMy0xLTEtMTE5NDgy_392d7f6b-f7d6-42ee-8dc8-d8d8dd5cf2e8">35.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjgtMS0xLTEtMTE5NDgy_b7cea601-291a-4bf5-80f3-468b45d8ea03">130.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjgtMy0xLTEtMTE5NDgy_c61b0b3b-96c7-4e78-869a-bfd01695520a">79.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjktMS0xLTEtMTE5NDgy_16f05521-edac-41f3-962a-a83cb8c83dfe">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjktMy0xLTEtMTE5NDgy_2f8838f0-a0de-4815-9ddd-0ba8bf785f53">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzAtMS0xLTEtMTE5NDgy_952b21c4-be8e-43eb-a781-942e61423251">312.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzAtMy0xLTEtMTE5NDgy_fa1c012a-1a7b-4856-bc3b-5d2bee4f6c32">352.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzEtMS0xLTEtMTE5NDgy_9ec4c75c-2963-4e2d-8912-144f2c10e481"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzEtMy0xLTEtMTE5NDgy_07f1508e-f38e-4e7f-af64-6f3c209c3d22"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzMtMC0xLTEtMTE5NDgyL3RleHRyZWdpb246MTQ3ZDRiODU1ZDEwNGUyZmIyNGRiM2IyMjZjZDE2NmJfMTg_4dd9341f-205f-466b-8f85-f75b04ec5864"><ix:nonFraction unitRef="usdPerShare" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzMtMC0xLTEtMTE5NDgyL3RleHRyZWdpb246MTQ3ZDRiODU1ZDEwNGUyZmIyNGRiM2IyMjZjZDE2NmJfMTg_81d19498-8e19-423b-9a35-effa6e107401">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzMtMC0xLTEtMTE5NDgyL3RleHRyZWdpb246MTQ3ZDRiODU1ZDEwNGUyZmIyNGRiM2IyMjZjZDE2NmJfMzI_696b133f-9e7a-4b19-8e83-8a910b4ff113">81.2</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzMtMC0xLTEtMTE5NDgyL3RleHRyZWdpb246MTQ3ZDRiODU1ZDEwNGUyZmIyNGRiM2IyMjZjZDE2NmJfMzk_e2bac127-66bc-48d9-96d6-f150e1bf3b63">80.0</ix:nonFraction> shares outstanding at December 31, 2022 and 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzMtMS0xLTEtMTE5NDgy_34ef816f-c57b-4931-9a11-bfd233f27b7f">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzMtMy0xLTEtMTE5NDgy_8edcd9ef-ad24-4107-b00b-ab96c91f8083">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzQtMS0xLTEtMTE5NDgy_9537e0c5-6ceb-4a24-bb31-9883f69a02ae">1,260.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzQtMy0xLTEtMTE5NDgy_b9793d2c-ae3f-439f-8fda-54f9f100393e">1,226.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzUtMS0xLTEtMTE5NDgy_ab5113b3-6014-453b-a4bc-11a3393acbef">8.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzUtMy0xLTEtMTE5NDgy_d6c23a9e-d84a-44c7-87fe-0e26c65171cd">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzYtMS0xLTEtMTE5NDgy_d295d998-1572-4c82-995f-9c39f906ae2b">366.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzYtMy0xLTEtMTE5NDgy_5175735b-b0ee-4ebb-9589-11223183901e">254.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Myriad Genetics, Inc. stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzctMS0xLTEtMTE5NDgy_b0669e84-df85-4c27-a846-e7099641a449">885.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzctMy0xLTEtMTE5NDgy_74a04ba2-cfb5-44bf-a999-b111ce20470c">967.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:MinorityInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzgtMS0xLTEtMTE5NDgy_bba71d23-f2df-41df-8edb-62978af3f7c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:MinorityInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzgtMy0xLTEtMTE5NDgy_261b4ed6-02a0-4f6b-8ed3-6a280bfc1fd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzktMS0xLTEtMTE5NDgy_78772fdd-79de-4eb1-a989-79a910fa8364">885.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzktMy0xLTEtMTE5NDgy_9324f7f3-c9c7-4c96-b0e2-d5bc1a16b5b6">967.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfNDAtMS0xLTEtMTE5NDgy_defa40e9-eeff-4ee9-ba77-5cab452a564a">1,198.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfNDAtMy0xLTEtMTE5NDgy_b425cd17-c10f-459a-aedc-0857d8fc98d9">1,320.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:11pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions, except per share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Testing revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i308b88139f674cb09b58fa82ee43d092_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMi0xLTEtMS0xMTk0ODI_1727a502-8918-4f6a-9cd1-501791e7f076">678.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794c44e7bf5b45689f334a7dc2a6cc11_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMi0zLTEtMS0xMTk2NDU_e1cc0da2-c881-472e-8439-dcde51fe2084">666.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i543bcad925584a75897772999efa4e3e_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMi0zLTEtMS0xMTk0ODI_d25ee0ad-1ed0-48e0-ba06-07c6434a2126">279.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc254773edfa4835899bcbe4c0b57775_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMi01LTEtMS0xMTk0ODI_1ef5f909-2dcc-4950-b907-4fffc9f877e1">586.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb3d6305f96409c9f4239ce2e6f890c_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMy0xLTEtMS0xMTk0ODI_4368ec98-27ef-4d8b-886b-4ff3db5a9135">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934fd4ad46814c4e88f3d8113c493def_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMy0zLTEtMS0xMTk2NDU_a4d21ab8-42b8-40fb-87a3-cd56d87ed583">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i329f9f45afc549329c841d2e34c6be5d_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMy0zLTEtMS0xMTk0ODI_089557b7-96ab-45f4-bf84-9652aafcb77c">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f216fe61ee54eeab8ab464958d1e5bb_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMy01LTEtMS0xMTk0ODI_d630c8bf-15c7-473f-9628-2af8753104f6">51.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNC0xLTEtMS0xMTk0ODI_83342bea-9317-4af2-bcc1-4f41197c8b67">678.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNC0zLTEtMS0xMTk2NDU_e560925f-8f81-45b6-9406-52dcf6e1a43a">690.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNC0zLTEtMS0xMTk0ODI_f4d389d9-ed40-4c60-96a8-24886f700429">299.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNC01LTEtMS0xMTk0ODI_eff355b8-1693-4f9f-984a-affc8ea0b2af">638.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of testing revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i308b88139f674cb09b58fa82ee43d092_D20220101-20221231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNi0xLTEtMS0xMTk0ODI_c2e73016-db87-46d5-9de2-a27e67d6aaac">202.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794c44e7bf5b45689f334a7dc2a6cc11_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNi0zLTEtMS0xMTk2NDU_b72adaf3-16fd-4a1c-971f-f1bc9e7be6ba">185.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i543bcad925584a75897772999efa4e3e_D20200701-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNi0zLTEtMS0xMTk0ODI_689c4ef6-8da9-459f-b293-f0c15679c7a4">82.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc254773edfa4835899bcbe4c0b57775_D20190701-20200630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNi01LTEtMS0xMTk0ODI_12754d67-52e1-42a2-acfa-135c52cdc825">157.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb3d6305f96409c9f4239ce2e6f890c_D20220101-20221231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNy0xLTEtMS0xMTk0ODI_247a37de-238e-4006-bc6d-14829614bafa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934fd4ad46814c4e88f3d8113c493def_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNy0zLTEtMS0xMTk2NDU_0bdf99e7-2a24-42d9-9e10-f9dc48cb9393">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i329f9f45afc549329c841d2e34c6be5d_D20200701-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNy0zLTEtMS0xMTk0ODI_4524f132-6213-4bcd-abd2-c676e2589c3a">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f216fe61ee54eeab8ab464958d1e5bb_D20190701-20200630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNy01LTEtMS0xMTk0ODI_4b8e9e7e-0591-4db5-b8ac-afd618185ed1">28.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfOC0xLTEtMS0xMTk0ODI_e6af646d-4eb1-48b0-8fde-5e2af9fe8b65">85.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfOC0zLTEtMS0xMTk2NDU_260a388d-5da2-4308-b51a-524f6ae4e8f5">81.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfOC0zLTEtMS0xMTk0ODI_6dae71f7-3ddf-449a-92b6-423be427b9c5">35.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfOC01LTEtMS0xMTk0ODI_9621c50e-34d3-4e01-9308-32bda875500e">77.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfOS0xLTEtMS0xMTk0ODI_a9936adf-71c5-49f9-ad51-f154b6d3ffbe">514.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfOS0zLTEtMS0xMTk2NDU_11a6cf1a-9926-479e-be74-42c2c087a0a3">537.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfOS0zLTEtMS0xMTk0ODI_8064bbfd-2646-4c65-818d-d9809bdac75f">260.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfOS01LTEtMS0xMTk0ODI_2df2b891-a90a-46d9-9705-7ceaa513cbd6">507.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal charges pending settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTAtMS0xLTEtMTE5NDgy_cab5f7e4-4927-42d0-bf0d-c6dfebe43f7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTAtMy0xLTEtMTE5NjQ1_a7a4d2d6-18e3-47b9-9271-163da3b9be2d">62.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTAtMy0xLTEtMTE5NDgy_b0a98e40-4b05-41e9-be36-19b8665ab857">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTAtNS0xLTEtMTE5NDgy_5451f93b-65bc-4ffb-adc1-5ecbd668bdf8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and long-lived asset impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTEtMS0xLTEtMTE5NDgy_eb76ffc0-7a92-41d8-ba06-bac027e33223">16.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTEtMy0xLTEtMTE5NjQ1_9ad2fcb2-1b95-4fa6-b754-fb2ef0eaaeed">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTEtMy0xLTEtMTE5NDgy_5be3750f-1e82-4eb2-bdbf-f79264ec4ea6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTEtNS0xLTEtMTE5NDgy_1201c102-1137-4e8d-807f-623fde1eaa11">99.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTItMS0xLTEtMTE5NDgy_e37a88b9-8618-4e9f-9caa-11a219e4ca9f">819.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTItMy0xLTEtMTE5NjQ1_5b812798-065a-47b5-bf32-6eb349aa4374">881.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTItMy0xLTEtMTE5NDgy_649d44d3-bd16-4f87-969c-20b75e4cab23">387.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTItNS0xLTEtMTE5NDgy_b96fcdb8-8618-4614-bf03-0c343ccc301a">870.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTMtMS0xLTEtMTE5NDgy_e437c895-fffe-4b28-a4e7-713218202a26">140.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTMtMy0xLTEtMTE5NjQ1_1e8492c1-5d00-488a-820d-2c6d9a559f2c">190.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTMtMy0xLTEtMTE5NDgy_b9f30141-13bf-4223-a06b-565ef82a263b">87.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTMtNS0xLTEtMTE5NDgy_92ff13ea-c119-47d3-b9c6-3ea2d14a3874">231.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTUtMS0xLTEtMTE5NDgy_1c9cbc23-69a5-452b-8d54-9ca997409639">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTUtMy0xLTEtMTE5NjQ1_ed6004f7-4dde-4a24-bf33-03c96bfd0bc0">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTUtMy0xLTEtMTE5NDgy_6baabb4b-592c-44de-88e9-7a9a35d20685">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTUtNS0xLTEtMTE5NDgy_7887a337-118e-4b1f-9e4a-9d801f42b4d2">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTYtMS0xLTEtMTE5NDgy_9ee63a66-eb8e-416f-848b-cbf14cf87c38">3.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTYtMy0xLTEtMTE5NjQ1_7ebe4ecb-ccf8-4789-ab8f-fbb15e651461">6.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTYtMy0xLTEtMTE5NDgy_dabb6be2-3e75-4d7c-a9d6-25f2124869a4">5.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTYtNS0xLTEtMTE5NDgy_36367197-4706-4dbe-a778-46f9eb32e87e">10.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTctMS0xLTEtMTE5NDgy_ef77723c-ce3c-4d59-8410-199b65fbfea3">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTctMy0xLTEtMTE5NjQ1_e1cda9a6-49ee-4d4a-9428-e77f7935cf41">139.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTctMy0xLTEtMTE5NDgy_664fca9b-dc00-43c8-9d6d-8fe2cc98cca6">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTctNS0xLTEtMTE5NDgy_fb3022be-efa0-4904-848b-f8eef72a81c3">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTgtMS0xLTEtMTE5NDgy_3f11e4b5-dbc1-4634-abad-9d887059d48a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTgtMy0xLTEtMTE5NjQ1_23538cbd-ba91-4770-a24b-c24c4017afe6">133.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTgtMy0xLTEtMTE5NDgy_2b84cea3-debb-485e-a0f0-146cb05d2f15">6.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTgtNS0xLTEtMTE5NDgy_cd66515a-65b2-4b36-8d51-a7469daa8dc0">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTktMS0xLTEtMTE5NDgy_c285f1ec-f188-4c02-abdd-1733e5a1b716">140.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTktMy0xLTEtMTE5NjQ1_9f1ea06c-dcbd-4abe-b653-a8a967420468">57.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTktMy0xLTEtMTE5NDgy_3838d99b-1180-4493-b15a-91564449e763">94.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTktNS0xLTEtMTE5NDgy_f4bbc17f-205a-44b4-904a-1fd4bcc3d83f">223.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjAtMS0xLTEtMTE5NDgy_9315049f-f790-4011-85c1-ebbca62f56ad">28.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjAtMy0xLTEtMTE5NjQ1_fc9be6b1-012f-4c57-81c8-1489c960f73c">29.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjAtMy0xLTEtMTE5NDgy_4cf93d23-9349-4148-99bb-f7f8ffda600a">41.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjAtNS0xLTEtMTE5NDgy_6b223b93-3745-4b08-964a-355da94a9a5c">23.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjEtMS0xLTEtMTE5NDgy_c6739b4b-cce3-4667-9062-93afd5db22be">112.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjEtMy0xLTEtMTE5NjQ1_f688c8ef-73d7-446b-9e12-178eebc5c217">27.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjEtMy0xLTEtMTE5NDgy_40d5fe26-0e48-42a5-ad28-37fb7ee5c3fc">53.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjEtNS0xLTEtMTE5NDgy_2c510593-40d4-48d1-8644-4075a9da9718">199.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjItMS0xLTEtMTE5NDgy_984a7b00-348e-4b6f-9f7c-a4047d9322b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjItMy0xLTEtMTE5NjQ1_4128ad71-60e0-4ca6-b8d4-00597c0e33ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjItMy0xLTEtMTE5NDgy_2f4980b9-1555-47cd-80cf-a7086b56210e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjItNS0xLTEtMTE5NDgy_d21d94db-6e73-4007-8953-84ff49b5d198">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Myriad Genetics, Inc. stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjMtMS0xLTEtMTE5NDgy_826b370a-0161-46c9-b183-6bb3da4bd0bc">112.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjMtMy0xLTEtMTE5NjQ1_463f5647-b2ba-43a6-a277-310ceacad057">27.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjMtMy0xLTEtMTE5NDgy_6bda40bf-3ec6-4c8f-8263-353593c239fc">53.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjMtNS0xLTEtMTE5NDgy_ca274bf6-5014-47f1-8b95-806e93354213">199.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjUtMS0xLTEtMTE5NDgy_2266dfff-42da-4371-b66c-cab7ed27ef89"><ix:nonFraction unitRef="usdPerShare" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjUtMS0xLTEtMTE5NDgy_58d5a657-0a30-4ac7-bf08-636b82af42e5">1.39</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjUtMy0xLTEtMTE5NjU1_5c4f6bc9-3282-45be-8ca7-e17c85be494c"><ix:nonFraction unitRef="usdPerShare" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjUtMy0xLTEtMTE5NjU1_6aafd6e3-ac94-436e-86db-42f864022fbb">0.35</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjUtMy0xLTEtMTE5NDgy_154f8540-c46c-496b-8454-b8e378f50679"><ix:nonFraction unitRef="usdPerShare" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjUtMy0xLTEtMTE5NDgy_4e42e51d-671d-495e-a882-45b4ec4d3c30">0.71</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjUtNS0xLTEtMTE5NDgy_6a09231e-cb3e-47ba-b197-6c85727a2e98"><ix:nonFraction unitRef="usdPerShare" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjUtNS0xLTEtMTE5NDgy_b55d1dbd-8677-4958-8fb6-2771c783cbb3">2.69</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjgtMS0xLTEtMTE5NDgy_2bff41ac-0be9-4c29-b40d-22bd66b1a6e9"><ix:nonFraction unitRef="shares" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjgtMS0xLTEtMTE5NDgy_b73cd936-f23e-4e09-92b5-7d650b1bf820">80.6</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjgtMy0xLTEtMTE5NjU1_07ed678d-370d-471f-a3b6-a77dd9421948"><ix:nonFraction unitRef="shares" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjgtMy0xLTEtMTE5NjU1_a3762f6e-1f86-4cda-8d81-c31794cf49ab">78.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjgtMy0xLTEtMTE5NDgy_543f5a27-3b46-4f6e-96dc-74595d00c10c"><ix:nonFraction unitRef="shares" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjgtMy0xLTEtMTE5NDgy_fab66984-b79a-42d2-9626-99c47728056d">75.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjgtNS0xLTEtMTE5NDgy_170ab698-7b08-41b5-b02d-a18466b1d0ca"><ix:nonFraction unitRef="shares" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjgtNS0xLTEtMTE5NDgy_8acd9b65-f2c0-4937-b7c1-ec0397e8a941">74.3</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Myriad Genetics, Inc. stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfMi0xLTEtMS0xMTk0ODI_77223730-56f2-4772-a12c-e1999f98a4b0">112.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfMi0zLTEtMS0xMTk4ODk_dc79b9c6-8439-4e50-b726-7fd5c1ec0fa8">27.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfMi0zLTEtMS0xMTk0ODI_133f07ac-e045-45ef-be56-d9c656411187">53.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfMi01LTEtMS0xMTk0ODI_a543f623-9cce-44e1-a9d5-63ed842b28b0">199.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on available-for-sale securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfMy0xLTEtMS0xMTk0ODI_6e76b6f4-62ed-48cb-9f5b-67af11946816">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfMy0zLTEtMS0xMTk4ODk_5880cd78-186f-4e0e-95cf-101b0d4e2cd6">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfMy0zLTEtMS0xMTk0ODI_1d805ae2-cf22-46b6-97fb-9c1beb858dfb">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfMy01LTEtMS0xMTk0ODI_accff228-5da1-4796-ba96-8f47beb1b470">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in foreign currency translation adjustment, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfNS0xLTEtMS0xMTk0ODI_3ba851aa-2075-4771-a8da-6c3ba1720c46">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfNS0zLTEtMS0xMTk4ODk_34e5e745-c86a-4070-a45e-7bb272af7a44">1.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfNS0zLTEtMS0xMTk0ODI_d1690a02-2ea9-4d1d-97a3-5b49949bc966">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfNS01LTEtMS0xMTk0ODI_8e401923-8374-4233-bfe3-d9665b64c9e2">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfNi0xLTEtMS0xMTk0ODI_cefcd8e0-6c5e-4479-a282-edc343f31e8a">115.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfNi0zLTEtMS0xMTk4ODk_6577c53a-6d2c-4775-8d02-a78f821e7b83">30.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfNi0zLTEtMS0xMTk0ODI_1c28c0b8-2555-42ab-b955-e64c0e16da3c">50.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfNi01LTEtMS0xMTk0ODI_6f20b2ce-9858-4dac-925b-8e71c4de4df6">199.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br/>stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings<br/>(accumulated<br/>deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Myriad<br/>Genetics, Inc.<br/>Stockholders&#8217;<br/>equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BALANCES AT JUNE 30, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08037acddedf4c3da96bc71cd005937c_I20190630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfNy0xLTEtMS0xMTk0ODI_c61eabdf-c2e7-4723-86bf-b49263c3b28b">0.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45b75059eff4573892e8f756ab08faf_I20190630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfNy0zLTEtMS0xMTk0ODI_d9db1288-b953-42bc-b636-f06f8456d404">1,068.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if291edff4ba84c7e9d38f402671ad107_I20190630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfNy01LTEtMS0xMTk0ODI_c3712028-a756-4480-be9a-01479d116dc5">5.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb0d838f44dc45f69885b845511ca96e_I20190630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfNy03LTEtMS0xMTk0ODI_e0bf6c5a-f617-49de-8a0f-fc02b30b8384">25.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96afdd71e74449aa558f9c0f8968925_I20190630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfNy05LTEtMS0xMTk0ODI_90934f43-76af-4e9e-b6cc-04481b230128">1,088.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie25ada1ec48a4df091a03bd92db62e3f_D20190701-20200630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfOC0zLTEtMS0xMTk0ODI_24e036bd-d8c9-43d1-ad39-65790339021e">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfOC05LTEtMS0xMTk0ODI_4ca3b15e-3168-4e87-ad2e-96cda10821fd">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based payment expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie25ada1ec48a4df091a03bd92db62e3f_D20190701-20200630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfOS0zLTEtMS0xMTk0ODI_9c0d7520-67d2-4114-81ec-daea7b79abef">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfOS05LTEtMS0xMTk0ODI_b2811f13-b498-4887-8423-1bb83c858fcd">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i096822e4050c4c89aecf816ec0a1d89f_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTAtNy0xLTEtMTE5NDgy_40cded4b-04e9-4443-a030-df4a0c691a99">199.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTAtOS0xLTEtMTE5NDgy_d06a352a-b9ba-416c-93a3-76e9a78e7562">199.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification out of accumulated other comprehensive loss upon the deconsolidation of a subsidiary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a92e11e87c4f21a1205b712b3e7a98_D20190701-20200630" decimals="-5" name="mygn:ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTEtNS0xLTEtMTE5NDgy_62a8f450-0859-489a-9a11-9aee5ccbf7c1">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="mygn:ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTEtOS0xLTEtMTE5NDgy_1dbf2bbe-bd5e-4a05-a4d2-df9e9d58cc2d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a92e11e87c4f21a1205b712b3e7a98_D20190701-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTItNS0xLTEtMTE5NDgy_ac9d2dc1-7747-478a-b058-83a0a86d8594">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTItOS0xLTEtMTE5NDgy_b72d9a4b-8542-4723-a63c-bf80ad2d8d12">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BALANCES AT JUNE 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36c513fa3954843802b82eee7bd4d66_I20200630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTMtMS0xLTEtMTE5NDgy_ec68198b-1215-4063-960b-2bb0506327f0">0.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1006f75c61d2402e941a615d921b10a0_I20200630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTMtMy0xLTEtMTE5NDgy_4e3437fd-f115-4805-903c-dfcd4f68bf56">1,096.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7925e43c913402583ad8467548fcdd9_I20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTMtNS0xLTEtMTE5NDgy_5ae12629-c3a7-4db2-a6dd-fbeba90777bd">5.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34a7c6b200aa410a99aba1eb920e920b_I20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTMtNy0xLTEtMTE5NDgy_5a29d642-ee50-446a-ab58-70c77507cbcd">173.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideeefc606008446e85d0fd21a9515813_I20200630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTMtOS0xLTEtMTE5NDgy_d0e9870f-87b2-48de-9587-a0eae4624eb4">918.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf7c181e8dc344e5a21614f9c861ac4e_D20200701-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTQtMS0xLTEtMTE5NDgy_b77e8bed-ef0d-4939-8a08-1d428b6d5074">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0799c2a014e447128b2001beef5c11fb_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTQtMy0xLTEtMTE5NDgy_993d25ea-4857-48d0-9207-8b132e53eeff">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTQtOS0xLTEtMTE5NDgy_7d8f94d8-7c3d-4cb7-ad1b-2e0942e64281">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based payment expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0799c2a014e447128b2001beef5c11fb_D20200701-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTUtMy0xLTEtMTE5NDgy_4cc8e708-cc8e-486b-b791-46f916fb96f1">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTUtOS0xLTEtMTE5NDgy_d500ce47-3fa0-4a0e-83b7-d52de96756dd">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d4b33f1ee7a42a89b6ffb0a263cc108_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTYtNy0xLTEtMTE5NDgy_d12c0097-66f5-4fef-a0ed-9972ca3384a7">53.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTYtOS0xLTEtMTE5NDgy_459264e3-451b-46e8-812c-93bb54be6ffc">53.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabdc282dcf2544e6a44fbcf258a6191b_D20200701-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTctNS0xLTEtMTE5NDgy_c2675013-88c6-452d-8064-d59a831c16d9">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTctOS0xLTEtMTE5NDgy_f8e9252b-e367-4c8d-8b58-9eae1b9b7130">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BALANCES AT DECEMBER 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3e0eff6e7f44b0e9bfbf56d9460dba8_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTgtMS0xLTEtMTE5NDgy_f230299f-5ae8-43cb-a3ff-3d6e348231fd">0.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide959bef58984d0c800d66085fe2ee2e_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTgtMy0xLTEtMTE5NDgy_906731a6-ce9e-41cc-a135-c410684a4104">1,109.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6aa3dfbc1c6545a0b140ae9c08b0c24b_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTgtNS0xLTEtMTE5NDgy_7f719223-415d-429c-97e5-9088ba4d74d4">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9056eb749ddd4517883d1f3860b7f895_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTgtNy0xLTEtMTE5NDgy_3cf08ed6-be30-4076-9a7d-a1a9427d98ea">227.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTgtOS0xLTEtMTE5NDgy_668f38c8-3968-4bca-a8aa-a8229d76f998">881.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f2f31965b52467a95929f7baa16f7d7_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTktMy0xLTEtMTE5NDgy_a06da79a-4c1e-47cb-a767-1c73fc30c29e">80.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTktOS0xLTEtMTE5NDgy_0f0fb328-72a3-44b8-9b9b-49c127966c3c">80.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based payment expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f2f31965b52467a95929f7baa16f7d7_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjAtMy0xLTEtMTE5NDgy_8f439677-8798-4a71-baff-e4dd9992125c">36.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjAtOS0xLTEtMTE5NDgy_5fa5116b-fa90-4cd4-b60b-6fd9e06e8271">36.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if31c2aa3a1bd42508fa6f5053cec3008_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjEtNy0xLTEtMTE5NDgy_4f06c159-905b-40bc-9b2c-bfb20472cd6f">27.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjEtOS0xLTEtMTE5NDgy_81a572d6-d283-4fda-9cb7-66305ba2fd30">27.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d7ca27f075d4f19be69a74e81087fd1_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjItNS0xLTEtMTE5NDgy_4a0c29fb-0c04-477e-a02f-f1a7dbb8b0be">2.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjItOS0xLTEtMTE5NDgy_c759467b-25ff-4fd4-aa61-eeeab1d88afb">2.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BALANCES AT DECEMBER 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbacf682032e4d0d92179fdcbdcc44c7_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjMtMS0xLTEtMTE5NDgy_e01539ca-17a2-4b6f-a793-bd9f4698bff6">0.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcbf5fe2793a4a75ace02762c09dba60_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjMtMy0xLTEtMTE5NDgy_882a2f92-cd2d-4903-9614-5a4dc7ad0c29">1,226.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07ccaab8fd444e1e96d9d0b927e5739d_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjMtNS0xLTEtMTE5NDgy_f666b48c-0dce-440d-bc1d-85cc0fd2f2b0">5.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82f354105f424032836cdf535b931213_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjMtNy0xLTEtMTE5NDgy_f4a83e9e-546a-4865-b494-c8dac5b55fdc">254.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjMtOS0xLTEtMTE5NDgy_a55bd698-0a65-481d-ba12-b96e87a3df6a">967.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3575a755df04fc38d5dbd355577687f_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjQtMy0xLTEtMTIwMTkz_4175f721-150f-4510-a2a9-9c9119cd0243">4.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjQtOS0xLTEtMTIwMTkz_2792fe30-3b80-46ae-a90b-a8fb8ce2efb2">4.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based payment expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3575a755df04fc38d5dbd355577687f_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjUtMy0xLTEtMTIwMTkz_2319c23d-6361-4388-ac8a-40eba073792e">38.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjUtOS0xLTEtMTIwMTkz_3c39d7a6-7fa8-417b-9b62-4cddb9913677">38.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie86ab0c9deac4c1cb5e311bc6ccc3e05_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjYtNy0xLTEtMTIwMTkz_f8c9d8be-d6ef-44e2-a383-455e9ec8fba9">112.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjYtOS0xLTEtMTIwMTkz_bdfaada5-62cc-4ba8-a810-4209f4d99b71">112.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4cbbd0e273544ccb20f9d106126ecc3_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjctNS0xLTEtMTIwMTkz_7a7e20ad-acc7-413a-ac9c-0ef42f72cb09">3.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjctOS0xLTEtMTIwMTkz_b3a63d0b-5d13-4d0b-8fc9-37ce67c96a6c">3.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BALANCES AT DECEMBER 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i368576ec62ee45cca0320cd56f18e01f_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjgtMS0xLTEtMTIwMTkz_728bca4d-98ce-4808-8e39-f878f458bfa8">0.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f255485789b4a73b043e3b00f87031c_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjgtMy0xLTEtMTIwMTkz_9cccd47c-0729-4a9e-aae0-c1a5b784cd48">1,260.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5215658c5cd475abde0249738d23319_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjgtNS0xLTEtMTIwMTkz_e79bfb67-6875-4f8f-bf42-bb3ec6b77923">8.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic40f1f5963e54a2cbe900fef28214a42_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjgtNy0xLTEtMTIwMTkz_bac86c68-5074-4f1a-83f3-ff6ddcd6df22">366.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjgtOS0xLTEtMTIwMTkz_4aa3c9f0-df83-45aa-9cd6-1f1bbe622bfc">885.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYRIAD GENETICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Myriad Genetics, Inc. stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMy0xLTEtMS0xMTk0ODI_4baf4c6d-b39c-4b05-acc1-2bcf58c7a127">112.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMy0zLTEtMS0xMjAwMTc_37baeceb-2346-4eca-9de3-23a020ad1e5c">27.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMy0zLTEtMS0xMTk0ODI_0459f151-7b6b-403b-b136-9d2b22e2536a">53.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMy01LTEtMS0xMTk0ODI_e44bb5c4-51e0-4483-b67b-7b442e6c80ff">199.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNS0xLTEtMS0xMTk0ODI_4b10909b-f888-476d-adfe-1360dfc46aea">52.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNS0zLTEtMS0xMjAwMTc_db452f0d-3eda-43b5-94f0-8b124f65d1cd">62.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNS0zLTEtMS0xMTk0ODI_07c1daa5-2098-4589-90e7-b329983eb1ee">35.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNS01LTEtMS0xMTk0ODI_4c57408a-521d-47fa-86dd-8f148e1c2119">72.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="mygn:NonCashInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNi0xLTEtMS0xMTk0ODI_c8df760c-5de1-4cc1-be44-da6bb7f2ab53">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="mygn:NonCashInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNi0zLTEtMS0xMjAwMTc_64571302-4bd7-4956-bc4d-8e1c0c74fb31">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="mygn:NonCashInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNi0zLTEtMS0xMTk0ODI_4c8905d1-0310-4816-a59a-9735a7ec4ec4">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="mygn:NonCashInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNi01LTEtMS0xMTk0ODI_bc7c5862-80ac-4179-9a64-ce9e5372b4c7">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNy0xLTEtMS0xMTk0ODI_15043f57-e749-4974-ac90-0dfb93ae2f3e">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNy0zLTEtMS0xMjAwMTc_325f380b-6235-49b0-bd8b-6ccf6b97fd90">12.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNy0zLTEtMS0xMTk0ODI_a80d96f4-fe26-4963-b57d-5427ccd75012">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNy01LTEtMS0xMTk0ODI_b575cbf8-305d-4964-a207-b02a78aae67f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tenant improvement allowance received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromTenantAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOC0xLTEtMS0xMjA1NDc_1079add2-2dc4-4c05-97e1-16bd6d9aaaf9">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsForProceedsFromTenantAllowance" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOC0zLTEtMS0xMjA1NTQ_b88d9d53-a3a8-483d-8af2-1f530e57dab8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:PaymentsForProceedsFromTenantAllowance" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOC01LTEtMS0xMjA1NjE_7b1a6486-229a-4e81-8b73-dc0ebe9f7631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:PaymentsForProceedsFromTenantAllowance" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOC03LTEtMS0xMjA1Njk_e644b045-0327-403d-b8b9-4142966ae1c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOC0xLTEtMS0xMTk0ODI_9782f347-3067-4447-82e0-8dccab927104">38.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOC0zLTEtMS0xMjAwMTc_98379634-601f-4708-8db2-afa558710cdb">36.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOC0zLTEtMS0xMTk0ODI_d315b48c-62d1-4df8-9ea7-7ca242cef87d">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOC01LTEtMS0xMTk0ODI_b4800048-fe46-48f5-a527-fadbada03c8b">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOS0xLTEtMS0xMTk0ODI_25f9f6a6-db04-4d47-aa8f-118060c5ce31">30.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOS0zLTEtMS0xMjAwMTc_d026fe1f-855b-411f-b5f2-1e85e924d508">32.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOS0zLTEtMS0xMTk0ODI_e5b89fba-5955-4ae2-9068-63a87ef787e2">44.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOS01LTEtMS0xMTk0ODI_0e9d912f-cc51-4b2a-aa47-bf8ab90705d2">55.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="mygn:IncreaseDecreaseInUnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTAtMS0xLTEtMTE5NDgy_d9100e71-7b5f-4fac-bccc-6f6c3757c35a">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="mygn:IncreaseDecreaseInUnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTAtMy0xLTEtMTIwMDE3_76a3b6cd-f3c0-4c68-a0dd-ed4ddae1ea28">2.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="mygn:IncreaseDecreaseInUnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTAtMy0xLTEtMTE5NDgy_cd0cbbd3-6906-48a0-91e3-bfeeda65be5b">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="mygn:IncreaseDecreaseInUnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTAtNS0xLTEtMTE5NDgy_b4361c9d-d425-4bb4-829a-1105c70101ce">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash impact of foreign currency transactions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTEtMS0xLTEtMTE5NDgy_9cb9a883-9dd8-457a-8a19-7f325afe3882">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTEtMy0xLTEtMTIwMDE3_7c72ebef-49e4-4dc0-9606-10eb6bf8b016">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTEtMy0xLTEtMTE5NDgy_4e5704b1-8b33-402e-a223-fb14443fb9a2">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTEtNS0xLTEtMTE5NDgy_85f83679-8ab8-4a20-ae40-239453b6a233">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTItMS0xLTEtMTE5NDgy_deeb039e-de18-41da-a3eb-b45e8bfe66a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTItMy0xLTEtMTIwMDE3_2d604017-313a-4ccc-b2e3-5d266c07f120">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTItMy0xLTEtMTE5NDgy_24c5c7e7-7d6a-4974-b609-34018883b38a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTItNS0xLTEtMTE5NDgy_149042e5-145b-4cb6-bd51-5c044dd94bd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment of goodwill and long-lived assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTMtMS0xLTEtMTE5NDgy_4d7608b3-82d9-4a89-8dee-e981990892de">16.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTMtMy0xLTEtMTIwMDE3_cabaa1d3-777f-4c51-84ba-8ad33923dbb5">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTMtMy0xLTEtMTE5NDgy_a8c73344-53ad-4171-9c79-c23bbd529415">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTMtNS0xLTEtMTE5NDgy_5a1e98dd-91c6-4d19-9967-dcb3e6b91868">99.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of businesses and assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTQtMS0xLTEtMTE5NDgy_958e626d-25f5-4d09-a857-d890d04699ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTQtMy0xLTEtMTIwMDE3_11112c90-235f-4439-9a3d-ee6cac25dd84">162.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTQtMy0xLTEtMTE5NDgy_fbea5537-ebe8-4e44-a714-17b4e48a04ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTQtNS0xLTEtMTE5NDgy_31869041-3fc7-4b41-8f58-f9ebfce3feb6">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTctMS0xLTEtMTE5NDgy_13a13612-4d41-4cc4-bdec-ed99bb3803c1">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTctMy0xLTEtMTIwMDE3_bd3b4c92-56fa-4669-866a-8ac7e999b5d8">6.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTctMy0xLTEtMTE5NDgy_5abc9f4a-a2ed-4e7f-b922-8fec4d0764c5">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTctNS0xLTEtMTE5NDgy_536419d7-bdf9-46bc-a009-5495f4214202">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTgtMS0xLTEtMTE5NDgy_c27b4abb-b40c-49f1-8b11-3905fa349c4d">10.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTgtMy0xLTEtMTIwMDE3_8f9ad9f0-ff98-4cfe-ac2c-208cf37a7ad5">8.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTgtMy0xLTEtMTE5NDgy_797943b3-f5cd-414c-a82d-663ceb8a54a7">21.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTgtNS0xLTEtMTE5NDgy_9472f177-565c-48e3-b1fa-c9c4f18a738b">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTktMS0xLTEtMTE5NDgy_274b3e88-3863-4a2d-83e6-3ab8f328e0f6">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTktMy0xLTEtMTIwMDE3_8083781f-c9e6-4562-97c7-aca0a6eec488">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTktMy0xLTEtMTE5NDgy_938130e3-af24-4a24-86f5-1768a4354d0e">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTktNS0xLTEtMTE5NDgy_e69dac93-8bc7-4191-81a1-14b8cf2c49ae">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjAtMS0xLTEtMTE5NDgy_d7f1f109-2c8d-45c4-a54b-bb54fc831755">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjAtMy0xLTEtMTIwMDE3_3eca1f0b-6bfe-4ddd-89eb-49c03203fd76">89.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjAtMy0xLTEtMTE5NDgy_988d6d30-ed4f-4fb0-96c8-171727d75d3e">108.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjAtNS0xLTEtMTE5NDgy_09403347-e0c0-4e03-adca-21730c103460">25.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjEtMS0xLTEtMTE5NDgy_3ba3f5d8-e7c9-4315-bcea-6db44cec0cf3">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjEtMy0xLTEtMTIwMDE3_c4614faf-229b-438d-9446-082345e59c38">3.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjEtMy0xLTEtMTE5NDgy_a931e6c6-798b-431e-9187-c4d49227bba4">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjEtNS0xLTEtMTE5NDgy_89f1315c-f945-4261-bddc-36f6bf530ceb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjItMS0xLTEtMTE5NDgy_56c77673-a0c7-46c3-ae30-519de1d4dd22">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjItMy0xLTEtMTIwMDE3_bfb321f2-6c97-4bae-8009-bf5a48fcb56a">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjItMy0xLTEtMTE5NDgy_aad5f92b-2847-4cd3-91b8-4ba9b87488c5">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjItNS0xLTEtMTE5NDgy_f6dd12b9-7192-4017-9994-6060b9a48177">10.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjMtMS0xLTEtMTE5NDgy_1f0b8ad7-cb1c-4410-8516-b3be6a7bd299">81.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjMtMy0xLTEtMTIwMDE3_ddb286e1-8a8b-483a-9236-ddc80c7cfe19">65.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjMtMy0xLTEtMTE5NDgy_e1c1e02d-ccf1-4f69-919c-8e93ff88b9a9">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjMtNS0xLTEtMTE5NDgy_a0f0322b-ea7c-44e8-a7cb-b7a5ff0cf17f">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjQtMS0xLTEtMTE5NDgy_6242798a-cb53-4e90-ba16-5b2a9fe0bb82">5.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjQtMy0xLTEtMTIwMDE3_1fbc92be-17f6-421f-9e5b-d3e05f584c9e">26.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjQtMy0xLTEtMTE5NDgy_37b6e147-c795-4a3b-ab1c-c10a66925b1c">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjQtNS0xLTEtMTE5NDgy_55d4ad0d-45e0-470e-8335-8690f10feb7f">30.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjUtMS0xLTEtMTE5NDgy_ac91b254-5354-4a1b-be8c-74f9d966c453">106.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjUtMy0xLTEtMTIwMDE3_23544151-3a97-419c-925d-15fa28109295">18.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjUtMy0xLTEtMTE5NDgy_d8e41dbb-9db2-4b6b-a8f5-974dc8afd6df">73.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjUtNS0xLTEtMTE5NDgy_fba6f6d0-9870-41ac-8bba-da2780ed618c">60.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjctMS0xLTEtMTE5NDgy_ecfd911c-36e9-497a-bfe1-0a54e5817fde">45.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjctMy0xLTEtMTIwMDc1_6f77738c-8738-4978-bb61-6a7bb7f33b1f">18.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjctMy0xLTEtMTE5NDgy_b031169e-f36d-445b-86b8-27fd45bde90f">7.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjctNS0xLTEtMTE5NDgy_3257b54f-5b27-43bc-a007-9a969b503f21">10.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjgtMS0xLTEtMTE5NDgy_2d74b717-c1d2-4c01-92d8-d100860608a8">57.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjgtMy0xLTEtMTIwMDE3_cb17a7f4-83a7-4169-8b04-3a38281e9cb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjgtMy0xLTEtMTE5NDgy_4490f5ea-d852-4191-89b2-9bd7b213acc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjgtNS0xLTEtMTE5NDgy_873c55bf-5c9d-4c4a-b6a0-a9e1f53ecba3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of business and assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjktMS0xLTEtMTE5NDgy_147857fc-5e1a-4bc6-970e-b6b88a37c347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjktMy0xLTEtMTIwMDE3_e1b16a10-85f7-4aac-8864-2a8ff29dd7ac">379.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjktMy0xLTEtMTE5NDgy_239b77c3-7cf0-4e07-bbcc-eda49d491622">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjktNS0xLTEtMTE5NDgy_aaa4b426-c8a9-4834-b1e0-ffd0923e9a53">21.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzAtMS0xLTEtMTE5NDgy_c18bf938-9600-453b-8e93-1ddac496f297">103.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzAtMy0xLTEtMTIwMDE3_b9655243-4d3b-4c75-acb8-d8b3e66dbf43">147.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzAtMy0xLTEtMTE5NDgy_c7ae5a71-76c8-4d17-a275-b5e00a7a7e90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzAtNS0xLTEtMTE5NDgy_a058c67c-f43f-48ec-93d9-859835e98c0b">60.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from maturities and sales of marketable investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzEtMS0xLTEtMTE5NDgy_4b725e54-baa5-452d-860d-c9d88756150b">128.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzEtMy0xLTEtMTIwMDE3_d4d6ef23-d533-4140-9ed6-2d7a8e986f85">61.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzEtMy0xLTEtMTE5NDgy_4d9b7ada-a34a-44ab-8d8c-dd61bdb81e5e">35.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzEtNS0xLTEtMTE5NDgy_37332b3c-62f5-48d6-a3b5-5fe54ad9d21b">69.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzItMS0xLTEtMTE5NDgy_3116e574-e583-44d0-a8e1-a41da2d96077">77.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzItMy0xLTEtMTIwMDE3_8885afd6-8f18-4e2f-9e36-c078e67a6ff7">274.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzItMy0xLTEtMTE5NDgy_b273c36e-5aa6-428e-b8e8-bda1ccea00de">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzItNS0xLTEtMTE5NDgy_fea61aeb-e816-4df0-aa77-07cfcff4637f">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from common stock issued under stock-based compensation plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzQtMS0xLTEtMTE5NDgy_7073069c-3aaa-402a-a2ee-0ebb3f8cf05f">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzQtMy0xLTEtMTIwMDgw_73154266-6566-4f95-a47f-09dea52d4a22">91.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzQtMy0xLTEtMTE5NDgy_16e322d8-0b54-48e6-8d6c-852723ce2f96">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzQtNS0xLTEtMTE5NDgy_38b59cc1-44cf-44b5-84fb-6d64f1ee9c43">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of tax withheld for common stock issued under stock-based compensation plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzUtMS0xLTEtMTE5NDgy_09d85f23-65a6-4f2b-bb51-bc10f8d78149">10.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzUtMy0xLTEtMTIwMDE3_d53d20db-192b-441c-9d60-e48e1bf296cb">11.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzUtMy0xLTEtMTE5NDgy_a3acfe72-d394-4255-aea5-361cdaadc7a7">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzUtNS0xLTEtMTE5NDgy_c89396db-b287-44bc-a527-7d70fd03b2c0">9.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of contingent consideration recognized at acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzYtMS0xLTEtMTE5NDgy_9aa6666f-ea90-4932-88dd-d1439405b4ab">3.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzYtMy0xLTEtMTIwMDE3_138a49bc-7e87-4a4e-b58f-c7104e8b3de9">3.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzYtMy0xLTEtMTE5NDgy_1651bf61-6aa1-4ede-9421-01b048b70ed8">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzYtNS0xLTEtMTE5NDgy_68cd2f08-4da8-470b-8d78-c130d1194aa7">3.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fees associated with refinancing of revolving credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsOfDebtRestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzgtMS0xLTEtMTE5NDgy_5a40ea3e-59fa-4d0d-80f5-20db914e2de1">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsOfDebtRestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzgtMy0xLTEtMTIwMDE3_13f7549a-0b08-485e-9c5b-f14c144cf977">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:PaymentsOfDebtRestructuringCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzgtMy0xLTEtMTE5NDgy_11be7f8c-3fa9-4eca-8b96-acdf03cf92b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:PaymentsOfDebtRestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzgtNS0xLTEtMTE5NDgy_6ef7f0f6-7fda-4acd-bac3-c4842d85cafd">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzktMS0xLTEtMTE5NDgy_7081fa6c-e009-4cf6-9b40-ff450e6df2cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzktMy0xLTEtMTIwMDE3_0a1af685-60af-4e87-b40d-aef446baae0b">226.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzktMy0xLTEtMTE5NDgy_43898358-3a84-4b88-938b-326d3f447ef5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzktNS0xLTEtMTE5NDgy_67756df2-4960-441a-a6a2-1288d2091de5">8.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDEtMS0xLTEtMTE5NDgy_d7dcf911-aed8-44ba-a1c4-50146c1c6eea">8.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDEtMy0xLTEtMTIwMDE3_7983b398-e312-4d26-b3de-92b3a97c5648">150.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDEtMy0xLTEtMTE5NDgy_ec4ae8f5-f704-47d4-a62c-8fde239453be">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDEtNS0xLTEtMTE5NDgy_78ef95e6-6148-49fe-ab71-e44de9c93b25">10.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of foreign exchange rates on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDItMS0xLTEtMTE5NDgy_e63194b5-dda8-45d9-82a2-ce33b61a1eaa">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDItMy0xLTEtMTIwMDE3_2314ecd5-24da-44dc-b169-64e360cfd13a">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDItMy0xLTEtMTE5NDgy_89db4ec5-dbe9-40d4-9fd7-5a4e48dcdc3d">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDItNS0xLTEtMTE5NDgy_c1b1755d-ccd4-405c-914d-afb5b73833ff">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDMtMS0xLTEtMTE5NDgy_425c90c8-516f-4646-a5d3-6acb9c0a7778">192.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDMtMy0xLTEtMTIwMDE3_5cd000c8-feb7-4465-a4ee-f66a3bcc785b">141.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDMtMy0xLTEtMTE5NDgy_fb7b73f8-f545-406d-9ecb-a4897debd8f0">46.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDMtNS0xLTEtMTE5NDgy_ce1d13d5-2392-4780-84ca-dbcc94a7eeec">70.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDQtMS0xLTEtMTE5NDgy_e7e7293f-98a4-45e6-a5ef-62d2bf1e2294">258.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDQtMy0xLTEtMTIwMDE3_4a7e724b-50e9-4fb8-9f05-187aef1b592e">117.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideeefc606008446e85d0fd21a9515813_I20200630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDQtMy0xLTEtMTE5NDgy_983b1917-4fab-469c-9af3-6ab821e6dcf2">163.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96afdd71e74449aa558f9c0f8968925_I20190630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDQtNS0xLTEtMTE5NDgy_56097fb2-22f1-413e-bff7-e9d37529a6c5">93.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDUtMS0xLTEtMTE5NDgy_99636816-1b8b-4393-90bc-dd79303e047e">66.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDUtMy0xLTEtMTIwMDE3_eef84b9d-78f6-46c4-b722-c419fd326eca">258.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDUtMy0xLTEtMTE5NDgy_f6944932-eebd-48c2-9cf3-0994184cdfd1">117.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideeefc606008446e85d0fd21a9515813_I20200630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDUtNS0xLTEtMTE5NDgy_9e6a9a6a-7fb5-456e-99a6-8ec845993820">163.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div id="i7e0793090cf84227944277d460d39a4d_88"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except per share data)</span></div><div id="i7e0793090cf84227944277d460d39a4d_91"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1NzI_5a480fd2-4e9f-4606-917d-944aaa1cc5bd" continuedAt="i4c87c138434247d397c558c46476ea0d" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i4c87c138434247d397c558c46476ea0d" continuedAt="i39d3584509cf48daa43ee92ba530027b"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1Nzk_a1baa0cc-784c-47a1-984f-2891d1cc6ff4" continuedAt="iaf1e2c9a8091410e8b724800c1f9907b" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Financial Statement Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad Genetics, Inc. (together with its subsidiaries, the&#160;"Company" or "Myriad") is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Myriad develops and offers tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower health care costs. The Company generates revenue by performing tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 17, by providing pharmaceutical and clinical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company currently operates as a single reporting segment.&#160;The Company&#8217;s principal executive office is located in Salt Lake City, Utah.  </span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaf1e2c9a8091410e8b724800c1f9907b">The accompanying consolidated financial statements for the Company have been prepared in accordance with United States ("U.S.") generally accepted accounting principles (&#8220;GAAP&#8221;) for financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP.</ix:continuation>&#160;&#160;</span></div><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1ODk_01015d65-a949-4b6d-84b7-01176b9a007e" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates and assumptions include revenue recognition estimates for the average expected reimbursement per test, valuation allowances for deferred income tax assets, certain accrued liabilities, stock-based compensation, purchase accounting, and impairment analysis of goodwill and long-lived assets. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1NzM_017b4b42-618f-4ab8-83eb-b4b11cd36cf2" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders' equity, or cash flows from operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1ODg_24807161-48ec-4fb8-ab13-40264793f1a1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company&#8217;s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related health care programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately <ix:nonFraction unitRef="number" contextRef="ia6915ee2f4e247fea81a5a54115ece38_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNTQ5NzU1ODQyNjIz_4ada0769-d5b8-412f-92ab-8717be53c44e">14</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i87dfdf9848204b5bb02322c598155b03_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDY1Nw_7d60dfda-f596-4f77-b910-f78c6e5979fb">17</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i41f829e207b542b5b614a6ac506833bf_D20200701-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDY2MQ_5c457732-400c-439d-b828-91a2857ee3e3">16</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="iec639d3cfaee463ba8e594bc6bb5ce4b_D20190701-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDY2NQ_22212659-f7c6-4f1b-ba5e-8239d91d9b01">15</ix:nonFraction>% of total revenue for the years ended December 31, 2022 and 2021, the six-month transition period ended December&#160;31, 2020, and the fiscal year ended June 30, 2020, respectively. Concentrations of credit risk are mitigated due to the number of the Company&#8217;s customers as well as their dispersion across many geographic regions. No payor accounted for&#160;more than 10%&#160;of accounts receivable at&#160;December&#160;31, 2022 or December&#160;31, 2021.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1ODc_7e8227cb-300d-4ef1-a8b2-4d785c16a871" continuedAt="i644da57421fe438a8c5485f49c1bafe1" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i644da57421fe438a8c5485f49c1bafe1">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents primarily consist of cash and money market deposits with financial institutions.</ix:continuation>  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="i39d3584509cf48daa43ee92ba530027b" continuedAt="iba1e2aa551d840de8aca8b2af108e7ae"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDk0NzgwMjM5MDA5Mw_064956f3-6320-4220-bdec-887638fde99b" continuedAt="i8182ac3782504239aa5c137a857fcab3" escape="true">Restricted Cash</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8182ac3782504239aa5c137a857fcab3" continuedAt="icc638f60c19244e5bf26084dff522bb0">In certain circumstances, the Company is required to maintain cash deposit with certain banks with respect to contractual or other legal obligations, and therefore the use of these cash deposits for general operational purposes is restricted.</ix:continuation> As of December 31, 2022, restricted cash was approximately $<ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDM5ODA0NjU3NDg3Mg_a1018d9f-1de5-4b2e-8d22-56518abf031c">9.5</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDM5ODA0NjU3NTI1OQ_b39be357-827c-427c-a972-efbca50cd64c">2.0</ix:nonFraction> million was recognized as a current asset and $<ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDM5ODA0NjU3NTI2NA_f4538f3f-998a-45e7-993e-276c03d2019c">7.5</ix:nonFraction> million was recognized as a long-term asset. As of December 31, 2021, restricted cash was approximately $<ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDM5ODA0NjU3NTI3Nw_34a123c4-2398-4222-a8dc-b27bcc6e797a">1.4</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDM5ODA0NjU3NTMxMA_542de38f-bf4d-4fda-bd5f-d08e060d50c4">1.0</ix:nonFraction> million was recognized as a current asset and $<ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDM5ODA0NjU3NTM2NQ_0268a7b9-b22c-49f9-af7e-b83b1027e9db">0.4</ix:nonFraction> million was recognized as a long-term asset.<ix:continuation id="icc638f60c19244e5bf26084dff522bb0"> The restricted cash amounts are largely comprised of cash held in escrow related to the Company's acquisition of Gateway Genomics, LLC ("Gateway") during the year ended December 31, 2022 and certain divestitures during the year ended December 31, 2021. The current and long-term portions are included in Prepaid expenses and other current assets and Other assets, respectively, on the Consolidated Balance Sheets.</ix:continuation>  </span></div><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDk0NzgwMjM5MDA5NA_53b2009e-02f6-4f6a-9c8f-b077041a11a4" escape="true"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDk0NzgwMjM5MDA5NA_e9364c66-4387-4548-9d40-cafe8311dcfe" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Consolidated Balance Sheets that agrees to the amounts included in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfMi0xLTEtMS0xNDYwMzU_8f1eb1cb-3409-4f5a-8e76-d7403aa9f63a">56.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfMi0zLTEtMS0xNDYwMzU_0b630af4-bb69-46f9-b1d1-92b2e6eb5b12">257.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfMi01LTEtMS0xNDYwODY_4bcb8c62-28df-4c54-bf03-d75e78da515c">117.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideeefc606008446e85d0fd21a9515813_I20200630" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfMi03LTEtMS0xNDYxMTI_ab5eaba1-5a45-4273-8823-a716b3c8ef8f">163.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfMy0xLTEtMS0xNDYwMzU_149750d2-0045-4dda-938c-56a40de212b2">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfMy0zLTEtMS0xNDYwMzU_74c5839e-b390-46d7-a360-258a74c4eff6">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfMy01LTEtMS0xNDYwODY_0bb84b66-0c30-450a-b3f8-953d0ac5249a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideeefc606008446e85d0fd21a9515813_I20200630" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfMy03LTEtMS0xNDYxMTI_039a7476-8f40-4ad2-83d7-ffa61453371d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfNC0xLTEtMS0xNDYwMzU_5f399f1a-ac9d-4942-ac41-0301398f7421">66.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfNC0zLTEtMS0xNDYwMzU_bd3e3df0-433e-4b66-be01-22813ba4257e">258.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfNC01LTEtMS0xNDYwODY_22bbaf61-a966-449c-b627-a7fd18a291b2">117.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideeefc606008446e85d0fd21a9515813_I20200630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfNC03LTEtMS0xNDYxMTI_2b79ea45-f925-45cf-b0cb-d81f66c05175">163.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1NzY_77f5abbd-cc19-4ea3-b304-295b4f4dfaa1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Investment Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has classified its marketable investment securities, all of which are debt securities, as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in Accumulated other comprehensive loss in Stockholders&#8217; equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The Company&#8217;s cash equivalents consist of short-term, highly liquid investments that are readily convertible to known amounts of cash.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. Losses are charged against Other income (expense) when a decline in fair value is determined to be other than temporary. The Company reviews several factors to determine whether a loss is other than temporary. These factors include but are not limited to: (i) the extent to which the fair value is less than cost and the cause for the fair value decline, (ii) the financial condition and near term prospects of the issuer, (iii) the length of time a security is in an unrealized loss position and (iv) the Company&#8217;s ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. There were no other-than-temporary impairments recognized during the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020 or during the fiscal year ended June 30, 2020.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1OTA_1fbe4e3f-79eb-4149-8f77-834e549e63e2" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of supplies such as reagents, plates and testing kits, which are consumed when providing test results, and therefore the Company does not maintain finished goods inventory. Inventories are stated at the lower of cost or market and costs are determined on a first-in, first-out basis.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its inventories for excess quantities and obsolescence.&#160;&#160;Inventories that are considered excess or obsolete are expensed.&#160;&#160;&#160;In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels. The valuation of inventories requires the use of estimates as to the amounts of current inventories that will be sold. These estimates are dependent on management&#8217;s assessment of current and expected orders from the Company&#8217;s customers.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1NjY_451e4c4f-7880-4e47-9bd3-a18a85b2f609" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Accounts Receivable</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable represents estimated receivables from customers for revenue recognized related to genetic tests. The Company does not have any off-balance-sheet credit exposure related to its customers and does not require collateral.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="iba1e2aa551d840de8aca8b2af108e7ae" continuedAt="i75b99c3a8f01458bbc9ab7fe58198d2c"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1ODM_72d1b98b-8e04-43d3-8917-0e4a2024cf14" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method based on the lesser of estimated useful lives of the related assets or lease terms. Equipment items have depreciable lives of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfODUzMw_6379236e-7018-4cbe-9f98-2974e673bf30">five</span> to <ix:nonNumeric contextRef="i2a04aadd840a46c4a950e132f342709c_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfODUzOQ_63ebc7ec-e0bf-4986-996a-1a8489df3225">seven years</ix:nonNumeric>. Leasehold improvements are depreciated over the shorter of the estimated useful lives or the associated lease terms, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfODY3Nw_ce7f7168-4bc2-4449-b270-c38ee0a58400">one</span> to <ix:nonNumeric contextRef="i7d40dec02733475a840d3032148ea124_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfODY4Mw_3cc9915d-5bcc-4e56-a6f2-bb5e47e3cdd0">fifteen years</ix:nonNumeric>. Repairs and maintenance costs are charged to expense as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDk0NzgwMjM4NDE2OQ_90c0581c-a918-4feb-a1a0-f7ce21601877" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acts as lessee in its lease agreements, which include operating leases for corporate offices, laboratory space, warehouse space, vehicles and certain laboratory and office equipment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is, or contains, a lease at inception. The Company records the present value of lease payments as right-of-use (&#8220;ROU&#8221;) assets and lease liabilities on the Consolidated Balance Sheets. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of lease liabilities as either current or non-current is based on the expected timing of payments due under the Company&#8217;s obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of the Company&#8217;s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The leases have remaining lease terms of <ix:nonNumeric contextRef="id126768d0af64211a663a5ba94eb3c2c_I20221231" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNTQ5NzU1ODgwNzEw_38f941a0-fb4f-4690-bf7e-d36067da9126">1</ix:nonNumeric> year to <ix:nonNumeric contextRef="i4fa41121b7d143cfbc8e91a9ced3020a_I20221231" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNTQ5NzU1ODgwNzE0_5e029a6f-9da1-40a7-91c0-60f889d90f47">15</ix:nonNumeric> years, some of which include options to extend the lease term for up to <ix:nonNumeric contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNTQ5NzU1ODgwNzIx_dae0ed03-45f4-465f-ab6e-17d589586cb1">10</ix:nonNumeric> years. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has taken advantage of certain practical expedients offered to registrants at adoption of Accounting Standards Codification ("ASC") 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis and is not included in the recognized ROU assets and lease liabilities. Further, as a practical expedient, all lease contracts are accounted for as one single lease component, as opposed to separating lease and non-lease components to allocate the consideration within a single lease contract.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1NzE_485a4dc8-8e4e-4877-adaa-4e45f7e4f86f" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Other Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible and other long-lived assets are comprised of acquired licenses and technology. Acquired intangible assets are recorded at fair value and amortized over the shorter of the contractual life or the estimated useful life. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred to develop internal-use technology, including certain implementation costs incurred in cloud computing arrangements and hosting arrangements that include an internal-use software license. The Company's cloud computing arrangements or hosting arrangements are primarily service contracts related to information technology. Implementation and development costs for internal-use technology are capitalized as part of Other assets in the Consolidated Balance Sheets. After the implementation of the internal-use cloud computing software or other internal-use technology, the capitalized costs are amortized on a straight-line basis over the estimated useful life of the asset. Costs incurred during the post implementation stage of the project are expensed as incurred. As of December&#160;31, 2022 and 2021, the Company had unamortized software costs of $<ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTAyNzU_bb6d44ec-e7b2-4637-9d1b-d3f479f360ee">7.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTAyODI_a184a079-b6a3-4115-a06e-3ea78c514c7b">6.7</ix:nonFraction> million, respectively. For the years ended December 31, 2022 and 2021, amortization expense for capitalized software costs was $<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTAzNjg_b663f3ff-bd22-44f7-aedf-97a13c5e8239">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNTQ5NzU1ODU0MDUw_925c3527-c782-4fa5-915b-2c845785c9ee">0.2</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually reviews and monitors long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="i75b99c3a8f01458bbc9ab7fe58198d2c" continuedAt="ia651bdc9d1064216bec10ffb68bbc2b9"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1Njk_5045bbca-50d4-4c9a-bb3f-51d15c3770ed" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment by reporting unit on an annual basis as of October 1 and in the interim if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators and competition.&#160;&#160;Impairment of goodwill is first assessed using a qualitative approach.&#160;If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed.&#160;The quantitative analysis involves a comparison of the fair value of the reporting unit with its carrying amount.&#160;If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.&#160;If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDk0NzgwMjM4NDE3MQ_bf1e38e5-68a4-4b4b-b66a-4540b833f2f2" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Acquisitions</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for acquisitions of entities that include inputs and processes and have the ability to create outputs as business combinations. The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on third-party valuations that use information and assumptions provided by the Company's management, which consider the Company's estimates of inputs and assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, estimated cost savings, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognizes a liability equal to the fair value of the contingent payments expected to be made as of the acquisition date. This liability is remeasured each reporting period and the changes in the fair value are recognized in Selling, general, and administrative expenses in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs associated with acquisitions are expensed as incurred in Selling, general, and administrative expenses in the Consolidated Statements of Operations. Results of operations and cash flows of acquired companies are included in the operating results from the date of acquisition.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1Nzc_fb33aab9-3ca3-4a5b-a5b6-9d5c3cf97ac7" continuedAt="i489c88f12bba4338a1e82f2ee3ade3fb" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily generates revenue by performing genetic testing. Testing revenues are primarily derived from the following categories of products: Hereditary Cancer (MyRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight, Prequel, and SneakPeek), and Pharmacogenomics (GeneSight). The Company previously provided pharmaceutical services and clinical services prior to the sale of Myriad RBM, Inc. in July 2021 and Privatklinik Dr. Robert Schindlbeck GmbH &amp; Co. KG in February 2020. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 and the Myriad Autoimmune business in September 2021, the associated revenue from such businesses was included within Testing revenues. See Note 17 for a discussion of these divestitures. Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results or the completion of pharmaceutical and clinical services indicates transfer of control for revenue recognition purposes.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="ia651bdc9d1064216bec10ffb68bbc2b9" continuedAt="i76c69c82b5c949788bf176ce11a3ef4e"><ix:continuation id="i489c88f12bba4338a1e82f2ee3ade3fb" continuedAt="i7269edb0c35343b796a7e43a9eab7b95"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1Njg_694a17f5-c76d-4241-8671-fb7021504918" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents detail regarding the composition of the Company&#8217;s total revenue by product type for the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020, and the fiscal year ended June 30, 2020:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Testing revenues:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4321aa8ac0974d02ac5b95ed298d955b_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMy0xLTEtMS0xMjQ2MTA_d6c4d04b-f7ba-4428-b6a0-389853713d06">305.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe93ba93efe459db6badb7752b80b87_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMy0xLTEtMS0xMTk0ODI_eac8d55f-0f33-4da0-919c-f196c675e34e">316.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7ae454902ce4cceb0fb07cad24d3c8c_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMy0zLTEtMS0xMTk0ODI_a5796bc8-7a3a-49c4-8f77-59cffc6a68d5">159.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0152bd259b6948b0bc3b7e357d1fc445_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMy01LTEtMS0xMTk0ODI_2a6f61ed-3c0e-4cc0-ac9e-c39f6bbe1b6f">347.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e94095aa8954df29cb417ee209e2fff_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNC0xLTEtMS0xMjQ2MTA_8307aaa3-0219-49c6-abb4-bcaae61253b8">128.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4e8e7880267470bbc22e12957f39118_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNC0xLTEtMS0xMTk0ODI_7033eb7e-4e44-4a93-b791-695a922ccd2d">120.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i446a798869a940bcb0840713d8d197d5_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNC0zLTEtMS0xMTk0ODI_a711a428-17ac-4310-84b1-e172654c89f6">33.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088a89f8c55a4830ae8f287603af0a85_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNC01LTEtMS0xMTk0ODI_1c5a7045-c5d8-42a2-b3d2-8353a9714745">48.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71764f1445be4ec3b1d8f1ae335382fc_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNS0xLTEtMS0xMjQ2MTA_62fb8507-fc37-4f32-b9c1-7252c57d3e4a">116.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf7ecebc2a4a4743b808a47645131aae_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNS0xLTEtMS0xMTk0ODI_2fa6f6b3-2659-4785-9279-67f96e1a41ff">106.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ba2f4fd98b0498cab6a8cd62a52550e_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNS0zLTEtMS0xMTk0ODI_91fd846f-732d-4ec9-8514-1c64f571b478">37.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608839facd584950806bdce9ed6b7161_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNS01LTEtMS0xMTk0ODI_8b5878c4-70d6-426a-b745-e409da37cb93">76.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60681fe10dbc48539edaa19296f641ae_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNi0xLTEtMS0xMjQ2MTA_5756be58-7522-418f-aa49-b695e3f5e5fc">127.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i162851a888574726bbc3d4a48c455909_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNi0xLTEtMS0xMTk0ODI_c4174785-52b3-41af-9777-de4fb9fcefde">93.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c62e82c4b0646a5bfc481b48968354c_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNi0zLTEtMS0xMTk0ODI_65b64ab3-0c16-4986-ad9a-363cd1e9ec46">29.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie73cf1f18b64415697365cb853c1fc55_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNi01LTEtMS0xMTk0ODI_3d1236e1-a5e9-409c-92d0-d10fc6268604">74.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b0f8fc04374becb000201e80f83824_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNy0xLTEtMS0xMjQ2MTA_9d205445-c342-4c74-bbf5-72d637155c3b">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba570416299441d585bdbe522d386ebb_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNy0xLTEtMS0xMTk0ODI_d982b48b-4904-4d17-a210-b8304ae4cded">28.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i236ed4b1de894f8198c2d79df713cacf_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNy0zLTEtMS0xMTk0ODI_f6dcd384-555b-4c33-95f0-2a0d24739769">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66122a21283042e5b1642886306f936f_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNy01LTEtMS0xMTk0ODI_33d86bcf-9916-4265-b3aa-4df37612b10c">39.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i908c0e65a6164625a7ffbc02d881c4b4_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfOC0xLTEtMS0xMjQ2MTc_340652f1-b19c-4631-b9d2-54e7b308b38f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9caac20c6a643a08ddbe9107e60ff80_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfOC0xLTEtMS0xMTk0ODI_7bb1cace-fc0b-4025-9727-14fbdc2f591f">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9bef53171a3408ebbb6bb19f0a61b94_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfOC0zLTEtMS0xMTk0ODI_8891e05d-4e56-402a-90bb-5375d22c32f0">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a9a17ae382543bfb59eee6cb07b076b_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfOC01LTEtMS0xMTk0ODI_428a516e-5dcd-49e9-9f04-295d8a39e7e9">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total testing revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i308b88139f674cb09b58fa82ee43d092_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfOS0xLTEtMS0xMjQ2MTc_29fd42ed-cc11-4e00-b815-c11912e541e6">678.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794c44e7bf5b45689f334a7dc2a6cc11_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfOS0xLTEtMS0xMTk0ODI_17d45b86-bfee-451f-a450-1043cb7f84cd">666.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i543bcad925584a75897772999efa4e3e_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfOS0zLTEtMS0xMTk0ODI_be6fab49-558e-42b3-a806-607f09fede56">279.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc254773edfa4835899bcbe4c0b57775_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfOS01LTEtMS0xMTk0ODI_9349aa4e-2adf-421f-9d2e-5057e6fad209">586.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb3d6305f96409c9f4239ce2e6f890c_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMTAtMS0xLTEtMTI0NjE3_8f2f3364-941d-437d-8d5c-141702f4ad1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934fd4ad46814c4e88f3d8113c493def_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMTAtMS0xLTEtMTE5NDgy_7bf7a00a-bdb0-4b40-8d62-c7358475e6eb">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i329f9f45afc549329c841d2e34c6be5d_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMTAtMy0xLTEtMTE5NDgy_dc5ef455-16a8-44da-b7fc-ffb0a16d2150">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f216fe61ee54eeab8ab464958d1e5bb_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMTAtNS0xLTEtMTE5NDgy_c2baf0cd-62b9-4aaf-a3db-a1277cfc3db5">51.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMTEtMS0xLTEtMTI0NjE3_6588e4e5-0fa3-4336-b969-a27537a2198f">678.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMTEtMS0xLTEtMTE5NDgy_14ed904f-6abb-4185-a30c-e1ae72745fb6">690.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMTEtMy0xLTEtMTE5NDgy_be089e80-e47b-4679-95bc-80de1ab8cace">299.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMTEtNS0xLTEtMTE5NDgy_311e986d-7b3c-4ef0-82d3-f43ad9667612">638.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1NzQ_02963077-a1a0-4886-918c-a726e11ff763" continuedAt="i95e222524c83490098f53705ba7b1adf" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the following tables reconcile revenue by geographical region, either U.S. or rest of world ("RoW"), to total revenue:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Testing revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i28c0950a478b45b8a240f2704954aa73_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNC0xLTEtMS0xMTk0ODI_a9aae6d2-8c6a-4473-89b3-aabd9f48a4fe">263.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0c7a502434884775af9bab6a939e30b9_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNC0zLTEtMS0xMTk0ODI_d7a62e00-b4f8-4358-be18-af581795e162">42.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4321aa8ac0974d02ac5b95ed298d955b_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNC01LTEtMS0xMTk0ODI_68c6873e-51c7-4211-a98b-35cb11f0ec7c">305.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if9ced64cb3044b06a122bd28bfff5d43_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNC04LTEtMS0xMTk0ODI_1ee02b84-5d9b-475c-a07a-51fd5df381a6">271.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i48f46e422d5d477f8d00d83b4afb9715_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNC0xMC0xLTEtMTE5NDgy_e32a9e95-916a-4484-998a-cfdfcef501f3">45.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3fe93ba93efe459db6badb7752b80b87_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNC0xMi0xLTEtMTE5NDgy_353f4b31-2344-4d10-9b4f-bad55f712264">316.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib5d8ea4dde274fe09e92affa3ca98896_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNS0xLTEtMS0xMTk0ODI_1f49f66b-cee7-4c14-96bf-3304d3b26140">84.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63cb40eed4a4bcdb75e61ac29fd3ce1_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNS0zLTEtMS0xMTk0ODI_a56e3f05-ecc9-4eb6-ad50-878b6c4d5d4a">44.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4e94095aa8954df29cb417ee209e2fff_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNS01LTEtMS0xMTk0ODI_ba9fcdb1-5852-40ac-a395-86f0950dffe4">128.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia0d0673d53164492ae8fdf1825d7cc9d_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNS04LTEtMS0xMTk0ODI_223dea6c-5995-4243-a1d5-f5e29d9a17dd">80.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f2792c0364546bc85db617aec3476eb_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNS0xMC0xLTEtMTE5NDgy_fdd22d1e-b9cc-4a55-9a11-12ef22af246d">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4e8e7880267470bbc22e12957f39118_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNS0xMi0xLTEtMTE5NDgy_692b3cab-c526-413c-83e0-2dcd776acc82">120.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie9ce5e2d04954ed79bbdbdf2f86c31be_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNi0xLTEtMS0xMTk0ODI_2807e530-fa2b-4c27-96be-5125e64f2489">115.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i912da28c3ce14d5fab748b5b779eddcb_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNi0zLTEtMS0xMTk0ODI_688a4b68-18d4-4e5d-8ece-e7c39d64f638">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i71764f1445be4ec3b1d8f1ae335382fc_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNi01LTEtMS0xMTk0ODI_083d3661-22e6-49b9-99d4-9f8110a5a77a">116.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i78aec82de9644c62815efaae24c0f234_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNi04LTEtMS0xMTk0ODI_0dc05b9a-f650-40d1-aabd-47ca7188f249">106.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i968b103643364f408ebde53bd855f7d4_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNi0xMC0xLTEtMTE5NDgy_34138695-52af-453e-843e-0978d8636c59">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf7ecebc2a4a4743b808a47645131aae_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNi0xMi0xLTEtMTE5NDgy_07b697c4-e21a-4f0b-b0d7-90a190f959b1">106.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i28401cefd42342bba22f821ee9e35aca_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNy0xLTEtMS0xMTk0ODI_cebe9d6b-99f4-4a86-afab-715d567d44f5">127.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28171e2c0157437f901e8ac487ced4c5_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNy0zLTEtMS0xMTk0ODI_e3498964-30a5-45df-bc41-a8b34f059cbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i60681fe10dbc48539edaa19296f641ae_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNy01LTEtMS0xMTk0ODI_63710efe-7bdd-4212-9714-fb7f05cdac03">127.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8433607b2fd04ed895116661af183b0b_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNy04LTEtMS0xMTk0ODI_44a51c05-a047-4d97-9cff-980336d0cff7">93.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a1ac302b8d049b5bd17bf6490234668_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNy0xMC0xLTEtMTE5NDgy_983809ae-eb1d-4499-b7b6-0ccaf66cc2d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i162851a888574726bbc3d4a48c455909_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNy0xMi0xLTEtMTE5NDgy_35aa701e-9ff0-4f89-ae6b-86c52b871507">93.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7cffa2ae4f264f0fbe8bd94485d5382d_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOC0xLTEtMS0xMTk0ODI_94772c1b-6642-4ad0-823c-22d94c2ae63b">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if753bf4c43f64a0c8907e6861712cbfd_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOC0zLTEtMS0xMTk0ODI_c359e5e7-70f3-401c-8064-2fb93e3b2d4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i75b0f8fc04374becb000201e80f83824_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOC01LTEtMS0xMTk0ODI_093dc9b7-6d55-4ba5-9061-2427fdac0009">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i857664e374a749be8f04a47ced6ef989_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOC04LTEtMS0xMTk0ODI_b6327522-0a1e-43fc-8e66-c5661570fb89">28.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i474e84aa7269419cb39f79e96b3c61b4_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOC0xMC0xLTEtMTE5NDgy_f2794e1c-8a05-40f9-93bb-54e6a7101600">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iba570416299441d585bdbe522d386ebb_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOC0xMi0xLTEtMTE5NDgy_65cba125-1f01-46e9-921d-5e61b21fe2c7">28.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2708618e4b62400ba3acf94032086aa2_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOS0xLTEtMS0xMTk0ODI_ef7d503d-6f86-4028-8880-5494424eced0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife78b8cec88a4dc7b70010cc79af31d4_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOS0zLTEtMS0xMTk0ODI_5adec7de-c418-455d-8758-5f81bb05412a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i908c0e65a6164625a7ffbc02d881c4b4_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOS01LTEtMS0xMTk0ODI_cea279e5-df8a-4752-a6bd-fd816e468b6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i69ab00712f2643a8801797ff591de929_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOS04LTEtMS0xMTk0ODI_28ecd563-23b7-43a6-bf02-7aadfa1e4f5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i50d11802ef0a4bf2934928e07af86a9e_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOS0xMC0xLTEtMTE5NDgy_587e1751-67cd-48b1-a4a9-c148cd6a77d8">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie9caac20c6a643a08ddbe9107e60ff80_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOS0xMi0xLTEtMTE5NDgy_749eecb6-96c5-4589-87bb-be5bc613cf1e">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total testing revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib210a719b53c402c8f0246ea4d23a748_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTAtMS0xLTEtMTE5NDgy_cf2beeeb-8983-458c-9ae0-f352c107cc9c">591.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i10e8721d20f74d5b9979734f2dfaaccb_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTAtMy0xLTEtMTE5NDgy_1024f8e1-19d7-4922-b7a7-ca7d3ad827a6">86.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i308b88139f674cb09b58fa82ee43d092_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTAtNS0xLTEtMTE5NDgy_e57bef9d-3b5b-4be8-9899-a49d7a1aeafd">678.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic4097e0cabf84d8bb42c8e84583e28d8_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTAtOC0xLTEtMTE5NDgy_d14d9c1c-3d2b-46ae-961e-34cde78220e5">579.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i030ec43c8bcc435dbf4851b0831df548_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTAtMTAtMS0xLTExOTQ4Mg_443d8609-290c-4d78-a92e-488be9cc76af">86.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i794c44e7bf5b45689f334a7dc2a6cc11_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTAtMTItMS0xLTExOTQ4Mg_93d0f943-62b9-41cf-b589-a3cf6d401c00">666.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7677472fc774c0ba9acaa9a151d2429_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTEtMS0xLTEtMTE5NDgy_b68ea131-9bd7-43ca-94df-b462be1875d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06e7851a35894a76b2c28ad9ef85560e_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTEtMy0xLTEtMTE5NDgy_ed0d7653-708f-4f0d-950f-e8bfc89a5346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bb3d6305f96409c9f4239ce2e6f890c_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTEtNS0xLTEtMTE5NDgy_df6c8d5a-c3ec-43de-beff-868854fe79fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ice489849d4474ba488f5e3ef419a245d_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTEtOC0xLTEtMTE5NDgy_f27ad8d1-f210-4d8e-84eb-f64208f99e69">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i899daa04a5384ab09446e722067496aa_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTEtMTAtMS0xLTExOTQ4Mg_0561f6b4-a9c0-4d15-9d3f-1f92387142a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934fd4ad46814c4e88f3d8113c493def_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTEtMTItMS0xLTExOTQ4Mg_43e0b603-bb7e-46a2-ae88-017c3f98905d">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e9b90c162674cfe89cd17b243422a63_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTItMS0xLTEtMTE5NDgy_8b9d470b-b406-4bc1-b5ad-65cbd5345193">591.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i94d4c8e8d9344b66817f27a942c9a7e5_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTItMy0xLTEtMTE5NDgy_d7de1a75-e039-4882-be3b-018298941baa">86.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTItNS0xLTEtMTE5NDgy_9055525a-3ee7-4a9f-af06-2ec482294229">678.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i10158fbf9e4e44dfbc25c01cdd6f88cc_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTItOC0xLTEtMTE5NDgy_a4601c9d-f617-4052-9501-d539485e5ef2">603.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id233c4026cd0475ead24a770126edd58_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTItMTAtMS0xLTExOTQ4Mg_4eaeb613-eedc-4cd3-a432-a1431c09d2e9">86.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTItMTItMS0xLTExOTQ4Mg_a0d932ab-6b88-4640-b126-85c500e957e5">690.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="margin-top:5pt;text-align:right"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="i76c69c82b5c949788bf176ce11a3ef4e" continuedAt="ie0f94d8cd97f43d19b23a21235a87600"><ix:continuation id="i7269edb0c35343b796a7e43a9eab7b95" continuedAt="i0ac53a50f91649559c301a3fe5aad702"><div style="margin-top:5pt;text-align:justify"><ix:continuation id="i95e222524c83490098f53705ba7b1adf"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Testing revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7e280ffa520e4589adc014530a498776_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNC0xLTEtMS0xMTk0ODI_f1ce55e6-8840-4d93-952b-0e83ece5f448">140.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i512678e2e28d43929c1f1c4039a3643b_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNC0zLTEtMS0xMTk0ODI_2e5b09f8-dc35-4b23-97c6-f7f663865e02">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7ae454902ce4cceb0fb07cad24d3c8c_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNC01LTEtMS0xMTk0ODI_8bd67a54-3b43-4f56-9ce9-15dc0812bb5d">159.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7d58fcd3a8a47c38f913ca273d9e241_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNC04LTEtMS0xMTk0ODI_76aaa2ca-25c7-4223-9242-65ad2dc0789d">329.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae97bd45a73e4d6b901011f4c036e632_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNC0xMC0xLTEtMTE5NDgy_56f393f5-81a1-4a01-8b74-186522b5a3d1">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0152bd259b6948b0bc3b7e357d1fc445_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNC0xMi0xLTEtMTE5NDgy_04e40b04-17ec-4ca0-9e96-d912a2d30418">347.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0196c4e720841a6bf4668d9ae0d9976_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNS0xLTEtMS0xMTk0ODI_a28c0358-3b0e-45dd-9cad-21ea84b62a30">28.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dcbd3ba88b14b8cb9f6afb24c8af942_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNS0zLTEtMS0xMTk0ODI_4b7bcd0e-2238-41ea-8751-b3b9dff4f328">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i446a798869a940bcb0840713d8d197d5_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNS01LTEtMS0xMTk0ODI_ea40fba8-444c-4dc8-977d-5a33ddcd04c6">33.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4dcc457344ff41b99f24941ed96867bb_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNS04LTEtMS0xMTk0ODI_84f6d6f3-d2d6-4cba-9a5b-c665b0c89aa0">39.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ab72b1aa84417b9db57840fd5421d7_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNS0xMC0xLTEtMTE5NDgy_455ca001-a22e-4a99-8a9a-128257d19b20">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i088a89f8c55a4830ae8f287603af0a85_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNS0xMi0xLTEtMTE5NDgy_07b846c6-7805-42d8-8016-c2abb7a81419">48.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id3b7bb1fac6041bd8446301c256d5875_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNi0xLTEtMS0xMTk0ODI_f3d07711-ac1b-49ab-a9e0-20ffda5c192c">37.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9fa0c093df9436380086f024d36dc1a_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNi0zLTEtMS0xMTk0ODI_ce1720ed-e3a5-4931-968b-bb53f47972ee">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ba2f4fd98b0498cab6a8cd62a52550e_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNi01LTEtMS0xMTk0ODI_6d87bc85-1ad7-4f35-a1b9-98d52084030e">37.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i693d5f7bcfb9431498131ea693785506_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNi04LTEtMS0xMTk0ODI_8381bbb7-b431-4c6c-b51b-aa98208a023d">76.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib834f1b2fee94f00991b25d7ec3f8343_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNi0xMC0xLTEtMTE5NDgy_c5660a0b-fdee-4690-8ea4-1c6e352d89a3">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i608839facd584950806bdce9ed6b7161_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNi0xMi0xLTEtMTE5NDgy_e7539c74-6cd9-4c6d-8e0f-d11ac20e7493">76.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i01d6d35e2fa543c586adcc726885b4d6_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNy0xLTEtMS0xMTk0ODI_c2c725f0-aa05-4614-9ada-485a0b97396f">29.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8440650c7814ce6946c100b1a08a2f6_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNy0zLTEtMS0xMTk0ODI_fc695aaa-7710-4b56-a9ab-71b7a21297e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1c62e82c4b0646a5bfc481b48968354c_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNy01LTEtMS0xMTk0ODI_b6875f8c-c79b-4f51-a1ee-39bf4834ee3a">29.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia2438f843e5643799b35cc8647fde1bf_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNy04LTEtMS0xMTk0ODI_f4f9208f-b64d-410d-a504-e35259b3d63f">74.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i255d2253a7a94a53b1e5268006eec230_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNy0xMC0xLTEtMTE5NDgy_9b7eecd4-eb98-4851-8ce6-e331cd5b47ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie73cf1f18b64415697365cb853c1fc55_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNy0xMi0xLTEtMTE5NDgy_2e381192-479b-4be0-b833-3a21f0f3a327">74.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i81bb19aea32d467b970e042769acd6f2_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOC0xLTEtMS0xMTk0ODI_0b1d155e-7f03-4187-aa5e-1723a6699b83">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i569b535e97d84810b0407243c35fc225_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOC0zLTEtMS0xMTk0ODI_539bc31a-da4c-47e4-ab04-159d3226ad93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i236ed4b1de894f8198c2d79df713cacf_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOC01LTEtMS0xMTk0ODI_8d049451-74ea-43ec-b372-33e0d84c24ee">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i27a4954bb37f4c87a40da845b26d61d1_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOC04LTEtMS0xMTk0ODI_e7d5ff55-a27f-49b9-85ed-dd21e064dffd">39.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b140020e5bb4309b28dbcafa95601f1_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOC0xMC0xLTEtMTE5NDgy_3dc62286-4178-491f-a273-f8a6c8e10eb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i66122a21283042e5b1642886306f936f_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOC0xMi0xLTEtMTE5NDgy_740fc651-5f53-4442-87c5-759572b4007d">39.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ae24aee3b354ce6bbf7be3fb4302b94_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOS0xLTEtMS0xMTk0ODI_f2249fa8-a9ad-4900-9f60-224c3eb6c0a4">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i138bed0fe82b4330903b41329c9addd9_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOS0zLTEtMS0xMTk0ODI_5b6fc796-ae6f-43f0-9d92-98728487bb3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia9bef53171a3408ebbb6bb19f0a61b94_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOS01LTEtMS0xMTk0ODI_2748824d-ad53-43c7-b7f0-ae433564dbcc">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i09ebb20a8a124362bcd7a8357aa29fd5_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOS04LTEtMS0xMTk0ODI_85a817fa-9ef5-4866-b81c-b654da508990">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i03a43431da5647adb236a2611029b943_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOS0xMC0xLTEtMTE5NDgy_9c42d103-7279-40a5-8c65-0bc3fb01666e">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6a9a17ae382543bfb59eee6cb07b076b_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOS0xMi0xLTEtMTE5NDgy_ce79b58f-aefe-487d-975f-2c4456b85ddf">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total testing revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icabe0b5ad1bd43baaa10f6239519e5e3_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTAtMS0xLTEtMTE5NDgy_49c55467-87b2-4cd2-a971-f85057a6497e">255.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id3dd9a90cd904e9bbf3710d2fa7182e9_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTAtMy0xLTEtMTE5NDgy_489beb41-5d4c-4a15-8e08-0a84c14d6afe">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i543bcad925584a75897772999efa4e3e_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTAtNS0xLTEtMTE5NDgy_145265ea-fd4d-4fa9-9708-453869f43f3b">279.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2d51d292699e4dd78ccb0056227a5ce1_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTAtOC0xLTEtMTE5NDgy_02a016c4-be90-4a97-a79a-1712d7d3af76">559.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i78a52daf7ef347be82dc84982294aa48_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTAtMTAtMS0xLTExOTQ4Mg_db2fe34f-beb4-49eb-b1bd-2abdc896d0bf">27.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc254773edfa4835899bcbe4c0b57775_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTAtMTItMS0xLTExOTQ4Mg_45be8ce3-dc98-405a-b73c-9132c6d3d8ef">586.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i15b05f5f12104bbea82045fddddc48f0_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTEtMS0xLTEtMTE5NDgy_350d2abc-178b-4a58-b205-a0c9dfa9651c">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i14388d06b3b646bd940f87caf35842b0_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTEtMy0xLTEtMTE5NDgy_92504d29-9e55-47bf-956f-e6dc4aa4bd7b">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i329f9f45afc549329c841d2e34c6be5d_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTEtNS0xLTEtMTE5NDgy_6689c3e6-0d60-457a-9208-04995094a7f6">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i258e4de3fb8c414ab710d4649d307805_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTEtOC0xLTEtMTE5NDgy_22225e59-b499-4bb0-a4f8-c5a9a9c3e310">36.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id55bccb976bc4a4e842f7029e06bddf5_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTEtMTAtMS0xLTExOTQ4Mg_617efee0-dbad-4d7c-82f2-41e549ed7c6d">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f216fe61ee54eeab8ab464958d1e5bb_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTEtMTItMS0xLTExOTQ4Mg_8f4a2a3a-4b22-4b2c-b515-5d528aa39b96">51.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i35dea8de7d5247b6af91e476fc730262_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTItMS0xLTEtMTE5NDgy_0b5f0802-42db-48d4-8641-14536ced2bee">275.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8042ff618ec94c0b90363a2a23ccd745_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTItMy0xLTEtMTE5NDgy_bac0199e-ab3c-4404-af88-61e504166908">24.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTItNS0xLTEtMTE5NDgy_f744d1a6-988c-42a6-9ecf-bcad6139a4b9">299.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i81b11dfa14ea4846bee1b74c8a4f62a1_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTItOC0xLTEtMTE5NDgy_a5f68be3-3579-46d3-b9c4-751090e0a417">596.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7251f8f8dbe2418b8cb8bcc34820beed_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTItMTAtMS0xLTExOTQ4Mg_b9ad1d94-e855-4f03-abba-4aae0eb6ca03">42.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTItMTItMS0xLTExOTQ4Mg_99d0c50d-c4cf-44d3-93a4-da998fe005de">638.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performs its obligation under a contract with a customer by processing tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets.&#160;Occasionally, customers make payments prior to the Company's performance of its contractual obligations.&#160;When this occurs, the Company records a contract liability as Deferred revenue in the Consolidated Balance Sheets. During the fiscal year ended June 30, 2020, the Company received approximat</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ely $<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="mygn:CARESActOf2020MedicarePaymentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTQ1ODY_7b56c27a-a2db-49a6-bdbd-d82e09591199">29.7</ix:nonFraction>&#160;million in a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dvance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments were applied against services performed beginning in April 2021 and continued until the funds previously received were fully earned, which occurred during the quarter ended March 31, 2022. <ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1NzA_d2004589-535e-4714-8f48-2abe7b97657f" continuedAt="ib392e1009880483ea2d210d039654c1b" escape="true">A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><ix:continuation id="ib392e1009880483ea2d210d039654c1b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfMi0xLTEtMS0xMTk0ODI_14d37523-5e8e-4898-a039-2e5219c8c765">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfMi0zLTEtMS0xMTk0ODI_6280c499-e6f3-4fb3-a023-fc1b1e30256c">32.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideeefc606008446e85d0fd21a9515813_I20200630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfMi01LTEtMS0xMTk0ODI_101325dc-447c-48b7-9049-cf5e52d53353">32.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96afdd71e74449aa558f9c0f8968925_I20190630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfMi03LTEtMS0xMTk0ODI_616a3c23-24de-49c6-ba89-0616823ecac8">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfMy0xLTEtMS0xMTk0ODI_3bae7189-634f-46d8-ad46-2be0041e113d">4.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfMy0zLTEtMS0xMTk0ODI_8843d2db-5205-4da8-a01a-fca2c6c34587">40.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfMy01LTEtMS0xMTk0ODI_c2c50274-38db-474a-8650-47481a5d0d52">6.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfMy03LTEtMS0xMTk0ODI_6fc490ff-1789-40a7-931a-cc29d920a137">7.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="mygn:ContractWithCustomerLiabilityPrepayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNC0xLTEtMS0xMTk0ODI_0f09bc65-f143-4bf8-a308-4be28c48784e">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="mygn:ContractWithCustomerLiabilityPrepayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNC0zLTEtMS0xMTk0ODI_77930c2d-8481-40af-bc36-e6904ea37dfc">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="mygn:ContractWithCustomerLiabilityPrepayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNC01LTEtMS0xMTk0ODI_9490427a-7380-4fc7-95b3-ebd0905360a9">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="mygn:ContractWithCustomerLiabilityPrepayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNC03LTEtMS0xMTk0ODI_a8ed490b-dcc7-43a8-8db9-2d58af947105">37.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="mygn:ContractWithCustomerLiabilityDivestitures" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNS0xLTEtMS0xMTk0ODI_de556112-4bc2-4e38-aba5-3fb46bd0374b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="mygn:ContractWithCustomerLiabilityDivestitures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNS0zLTEtMS0xMTk0ODI_7b4559e1-8c83-4a48-874b-f2704b78cdd7">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="mygn:ContractWithCustomerLiabilityDivestitures" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNS01LTEtMS0xMTk0ODI_7401107c-cc4d-4b22-a2dd-dbf2332e3872">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="mygn:ContractWithCustomerLiabilityDivestitures" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNS03LTEtMS0xMTk0ODI_5b162a15-a61f-4c3d-9768-96e27a654bd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNi0xLTEtMS0xMTk0ODI_11baf338-528b-42f5-ba47-d100fee7f861">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNi0zLTEtMS0xMTk0ODI_29eed256-b386-40d2-991a-23b13f091c67">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNi01LTEtMS0xMTk0ODI_6280c499-e6f3-4fb3-a023-fc1b1e30256c">32.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideeefc606008446e85d0fd21a9515813_I20200630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNi03LTEtMS0xMTk0ODI_d92ae8c2-263f-45ba-a2c2-f8b58d4c4613">32.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company&#8217;s right to payment is in an amount that directly corresponds with the value of the Company&#8217;s performance to date. In determining the transaction price, the Company includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="ie0f94d8cd97f43d19b23a21235a87600" continuedAt="i4b01d80495a64dc698f91c8578e2cfac"><ix:continuation id="i0ac53a50f91649559c301a3fe5aad702"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with ultimate collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenue in the Consolidated Statements of Operations and Comprehensive Loss. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash collections for certain tests delivered may differ from rates estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third-party payors. As a result of this new information, the Company updates its estimate of the amounts to be recognized for previously delivered tests. During the year ended December&#160;31, 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTA5OTUxMTY2MTE4Mg_c7ad3283-056e-413f-a5a9-1bec64219a42">22.1</ix:nonFraction> million in revenue, which resulted in a $<ix:nonFraction unitRef="usdPerShare" contextRef="i22b6ad0c0a184276b026278ab2492214_D20220101-20221231" decimals="2" name="mygn:IncreaseDecreaseInEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTA5OTUxMTY2MTIyMA_f2d984a6-5258-461a-be21-0295937c4853">0.21</ix:nonFraction> impact to loss per share for tests in which the performance obligation of delivering the test results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. During the year ended December&#160;31, 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTc1ODE_b7d525fb-ec1f-4f40-8271-0e7c496e14ad">15.9</ix:nonFraction> million in revenue which resulted in a $<ix:nonFraction unitRef="usdPerShare" contextRef="i67176840186a45f8b5451e8e62e7f69f_D20210101-20211231" decimals="2" name="mygn:IncreaseDecreaseInEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTc2MTU_88bab5a1-c5ee-4d98-aed1-e7fb196885b1">0.15</ix:nonFraction> impact to loss per share for tests in which the performance obligation of delivering the test results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. Additionally, during the year ended December&#160;31, 2021, revenue of $<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="mygn:ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTc5MDU_869f28da-39bf-4f1a-924d-799bf78de892">6.8</ix:nonFraction> million was recognized due to expanded coverage for the Company's Prolaris test, for which revenue was fully constrained in a prior period. During the transition period ended December 31, 2020, the impact to revenue and loss per share for tests in which the performance obligation of delivering the test results was met in the prior period was immaterial. During the fiscal year ended June 30, 2020, the Company recognized a $<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTgwODM_e1803c54-7df3-4961-ae13-d50672c54035">9.9</ix:nonFraction> million decrease in revenue, which resulted in a $(<ix:nonFraction unitRef="usdPerShare" contextRef="i4259e411c05a49db8fc3dba108adcb2a_D20190701-20200630" decimals="2" sign="-" name="mygn:IncreaseDecreaseInEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTgxMjc_22726ada-0aab-456a-9c2b-7a6e0cea5528">0.10</ix:nonFraction>) impact to loss per share for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third-party payors. In addition, during the fiscal year ended June 30, 2020, the Company identified an error related to prior periods for Medicare claims and reduced revenue and recorded an accrued liability for a total of $<ix:nonFraction unitRef="usd" contextRef="if83d47ed8afd45349ebc0526f0253b99_I20200630" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTg3Mzg_1ae33bfa-f54e-4a4b-91b9-9b608f279e1c"><ix:nonFraction unitRef="usd" contextRef="ie2d0848b372c49e7879916eea4a55d95_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTg3Mzg_4c9e61f7-7045-4a57-9510-ea21f1d7cf35">4.7</ix:nonFraction></ix:nonFraction> million that will be refunded to Medicare. The impact of correcting the error during that period and the impact to all prior periods was concluded to be immaterial. The correction of the error in the fiscal year ended June 30, 2020 resulted in an impact to loss per share for the fiscal year ended June 30, 2020 of $(<ix:nonFraction unitRef="usdPerShare" contextRef="ie2d0848b372c49e7879916eea4a55d95_D20190701-20200630" decimals="2" sign="-" name="mygn:IncreaseDecreaseInEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTkwNDU_2a46987c-af3e-430e-8a46-762aa4fb1ba0">0.05</ix:nonFraction>).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company has elected to exclude from the measurement of transaction price, all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a customer for sales tax, value added tax, and certain other taxes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, <ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="INF" name="us-gaap:CapitalizedContractCostGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTk4MTI_6460ce29-18bb-4054-b323-a6f9dadb7ebb">no</ix:nonFraction> costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year.</span></div></ix:continuation><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1ODQ_7c5eeb6c-d0f4-4410-b7e7-7ad22f84a2e0" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Payment Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the fair value compensation cost relating to stock-based payment transactions in accordance with ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation &#8211; Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee&#8217;s requisite service period, which is generally the vesting period. The fair value of restricted stock units (RSUs) and performance restricted stock units (PSUs) that do not have market conditions is based on the number of shares granted and the quoted price of the Company&#8217;s common stock on the grant date. The fair value of PSU awards that have market conditions is determined using the Monte Carlo Method. For PSUs, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company estimates the likelihood of achievement of the performance conditions at the end of each period. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeitures are recognized as a reduction of compensation expense in earnings in the period in which they occur. The fair value of shares issued under the Company's Employee Stock Purchase Plan is calculated using the Black-Scholes option-pricing model, based on assumptions including the risk-free interest rate, expected life, expected dividend yield and expected volatility. The average risk-free interest rate is determined using the U.S. Treasury rate. We determine the expected life based on the offering period of the Employee Stock Purchase Plan. The expected volatility is determined using the weighted average of daily historical volatility of the price of the Company's common stock.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="i4b01d80495a64dc698f91c8578e2cfac" continuedAt="i24beb0c506834e21a8331a65846fbae3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="mygn:OtherIncomeExpensePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1ODU_d3d6126f-3d67-4a1e-a3c1-68cd377715ec" continuedAt="i675c51dbf5974344b221801cad166a18" escape="true">Other Income (Expense)</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i675c51dbf5974344b221801cad166a18">The Company recognizes the gain or loss on its divestitures as Other income (expense) in the Consolidated Statement of Operations. During the year ended December&#160;31, 2021, the Company recognized a net gain on divestitures of $<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNTQ5NzU1ODQzNjkz_11112c90-235f-4439-9a3d-ee6cac25dd84">162.0</ix:nonFraction> million. See Note 17 for additional information regarding these divestitures. In addition, during the fiscal year ended June 30, 2020, the Company received approximately $<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="mygn:CARESActOf2020ProviderReliefFundAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjIyMDk_d11cb9dc-5036-4c6a-94e2-21401a7a1812">14.6</ix:nonFraction> million from the Provider Relief Fund under the CARES Act to reimburse the Company for health care related expenses or lost revenues that were attributable to COVID-19, which was recognized as a component of Other income (expense) in the Consolidated Statements of Operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1ODY_d4d1e194-ec36-4e3f-b197-77b70b2ac14b" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal, state, and foreign income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company&#8217;s filings, including the positions taken therein, are subject to audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the Company's consolidated financial condition, results of operations or cash flows.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1ODI_41bc9283-3c1f-42d5-a427-d08ab2a603ea" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (EPS) is computed based on the weighted-average number of shares of common stock outstanding.&#160;&#160;Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding.</span></div><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1NjU_340333f1-a600-4b14-bf2a-61a499c62ee5" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding used to compute basic EPS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfMy0xLTEtMS0xMTk0ODI_de58c89a-1169-4153-a7f0-58c8bd1e0677">80.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfMy0zLTEtMS0xMTk0ODI_0d9a1e81-777d-49bb-86e6-e1c8f2260fd5">78.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfMy01LTEtMS0xMTk0ODI_ee119907-5823-4d25-ac2f-3e630ebf3c4a">75.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfMy03LTEtMS0xMTk0ODI_cbcc44b3-e17a-44bd-b5de-d1b0d913eaa2">74.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfNC0xLTEtMS0xMTk0ODI_e22eb89e-8232-4dd0-bd31-52d7f96ea462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfNC0zLTEtMS0xMTk0ODI_24b55a8d-1d06-4ae0-be22-6c46967e4937">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfNC01LTEtMS0xMTk0ODI_519525dc-f51d-461e-8f78-ef9f353d4033">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfNC03LTEtMS0xMTk0ODI_746c5edc-30f7-4d5c-9133-6164a3cd91eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfNS0xLTEtMS0xMTk0ODI_40558196-ba3a-45a2-bbfd-d579cd020de8">80.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfNS0zLTEtMS0xMTk0ODI_6d3062a4-ad12-4346-9e2f-eaa85bb1bab2">78.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfNS01LTEtMS0xMTk0ODI_2c030741-ade4-49fc-99bc-d589563b1656">75.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfNS03LTEtMS0xMTk0ODI_e41f53b7-9e1b-4d63-b010-c16eb2ac8f1a">74.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain outstanding options and RSUs were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. <ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1Njc_08fc8a98-24c7-40d5-bd51-77c66fac64c4" continuedAt="i8912d0acccae4238bd72cb541129c1a4" escape="true">These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows:</ix:nonNumeric></span></div><div style="text-align:justify"><ix:continuation id="i8912d0acccae4238bd72cb541129c1a4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive options and RSUs excluded from EPS computation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmVjOGI0ZjQyYjViNjQ1M2E4ZjFmMTNmMGFlZDY4NjA2L3RhYmxlcmFuZ2U6ZWM4YjRmNDJiNWI2NDUzYThmMWYxM2YwYWVkNjg2MDZfMi0xLTEtMS0xMTk0ODI_274c63a1-abfb-4ab0-92e1-08b623456a20">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmVjOGI0ZjQyYjViNjQ1M2E4ZjFmMTNmMGFlZDY4NjA2L3RhYmxlcmFuZ2U6ZWM4YjRmNDJiNWI2NDUzYThmMWYxM2YwYWVkNjg2MDZfMi0zLTEtMS0xMTk0ODI_6b7ebc43-8301-480f-9d49-ea2345725d85">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmVjOGI0ZjQyYjViNjQ1M2E4ZjFmMTNmMGFlZDY4NjA2L3RhYmxlcmFuZ2U6ZWM4YjRmNDJiNWI2NDUzYThmMWYxM2YwYWVkNjg2MDZfMi01LTEtMS0xMTk0ODI_0d4f7554-93a2-416c-8c4f-552da94ae188">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmVjOGI0ZjQyYjViNjQ1M2E4ZjFmMTNmMGFlZDY4NjA2L3RhYmxlcmFuZ2U6ZWM4YjRmNDJiNWI2NDUzYThmMWYxM2YwYWVkNjg2MDZfMi03LTEtMS0xMTk0ODI_a7e2ffbb-6028-4b9a-b196-be0fd0ef72db">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="i24beb0c506834e21a8331a65846fbae3"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1ODE_b197243b-dcb2-42d3-a8e7-d294e6bf8e5c" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company&#8217;s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive loss as a separate component of Stockholders&#8217; equity.</span></div><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1Nzg_fc6fa889-53ff-455d-b7e7-0c8736f6b6a1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the cumulative translation adjustments included in Accumulated other comprehensive loss (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmJmNGE0N2I5OGY4MDQwZmI4MjJiZjBlYTI3ZTVjOGEzL3RhYmxlcmFuZ2U6YmY0YTQ3Yjk4ZjgwNDBmYjgyMmJmMGVhMjdlNWM4YTNfMC0xLTEtMS0xMTk0ODI_84a770c0-0382-423f-83f4-ec80656239a4">4.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmJmNGE0N2I5OGY4MDQwZmI4MjJiZjBlYTI3ZTVjOGEzL3RhYmxlcmFuZ2U6YmY0YTQ3Yjk4ZjgwNDBmYjgyMmJmMGVhMjdlNWM4YTNfMS0xLTEtMS0xMTk0ODI_28707e46-9da3-408d-b1c7-b0188471cc4f">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmJmNGE0N2I5OGY4MDQwZmI4MjJiZjBlYTI3ZTVjOGEzL3RhYmxlcmFuZ2U6YmY0YTQ3Yjk4ZjgwNDBmYjgyMmJmMGVhMjdlNWM4YTNfMi0xLTEtMS0xMTk0ODI_3380b7d5-5674-4c47-a60b-eb57a7b60207">6.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1NzU_d91426a3-038d-48d7-91b7-f984d5db6468" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies and adopted by the Company as of the specified effective date. During the year ended December 31, 2022, there have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the FASB that have or are expected to have a material impact on the Company's consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i7e0793090cf84227944277d460d39a4d_94"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNjE2_be301806-b267-4a7f-8e93-badc487717a9" continuedAt="i52f2091e08cf425581c959ab56d3e5f3" escape="true">MARKETABLE INVESTMENT SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i52f2091e08cf425581c959ab56d3e5f3" continuedAt="idb63f3329ff348138b86ff7ac181326e"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNjE0_6dd6c77f-338d-4ca7-a762-6994568f0a73" continuedAt="i6aff8ec17d8b45829fedbae3406de8be" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value debt securities classified as available-for-sale securities by major security type and class of security at December&#160;31, 2022 and December&#160;31, 2021 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75f79427aab4f40a89a2217f2dc3335_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfMy0xLTEtMS0xMTk0ODI_7faef468-d895-483b-933c-79df6355b678">53.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75f79427aab4f40a89a2217f2dc3335_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfMy03LTEtMS0xMTk0ODI_67478596-fcf4-446f-9ad3-19eb89a41e4a">53.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0da8029be334899949f916d03b47e6e_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfNC0xLTEtMS0xMTk0ODI_301f8b07-e5ee-4ca8-8b47-f2f62f1a7c23">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0da8029be334899949f916d03b47e6e_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfNC03LTEtMS0xMTk0ODI_c5422795-f6c6-473a-8bf4-454a80d26c0d">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfNS0xLTEtMS0xMTk0ODI_14644990-01a1-4ccb-a8fa-55eadfad8b74">56.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfNS03LTEtMS0xMTk0ODI_d7fbcb4f-d990-4ffa-8d95-c1bce3189036">56.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieecccfa51e634b24b60447c9f26442d1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfNy0xLTEtMS0xMTk0ODI_b4ea1a13-52d8-4a79-b128-feee16bdbba1">66.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieecccfa51e634b24b60447c9f26442d1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfNy0zLTEtMS0xMTk0ODI_eab52196-d158-4c50-8ecf-2fa9a9519efa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieecccfa51e634b24b60447c9f26442d1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfNy01LTEtMS0xMTk0ODI_a1c8fa66-448d-4a55-be0b-9475850871d4">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieecccfa51e634b24b60447c9f26442d1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfNy03LTEtMS0xMTk0ODI_b2f15b3d-8c40-46ce-babe-4a964f66bda8">65.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea4bf30af38941b3b6938c631d1ce22e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfOC0xLTEtMS0xMTk0ODI_f51023fe-06eb-4147-80ce-b66315d0f731">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea4bf30af38941b3b6938c631d1ce22e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfOC0zLTEtMS0xMTk0ODI_99600a84-02ae-4f43-8df4-494f965b3c18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea4bf30af38941b3b6938c631d1ce22e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfOC01LTEtMS0xMTk0ODI_d325999f-719c-4071-9ba4-13e958c992ab">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea4bf30af38941b3b6938c631d1ce22e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfOC03LTEtMS0xMTk0ODI_cbaffeb4-9961-4600-8d16-3119311ddb10">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33fcfcc4292d45c6b97cc255ecd96967_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfOS0xLTEtMS0xMTk0ODI_5a176c94-dc80-4f97-aa32-4307d8461ea7">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33fcfcc4292d45c6b97cc255ecd96967_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfOS0zLTEtMS0xMTk0ODI_1228b742-fa60-4594-b882-73b2476df64c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33fcfcc4292d45c6b97cc255ecd96967_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfOS01LTEtMS0xMTk0ODI_8b48cb8d-df76-49ea-901a-a32505840ed7">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33fcfcc4292d45c6b97cc255ecd96967_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfOS03LTEtMS0xMTk0ODI_3f9d4147-9734-4670-8c9c-90643f4947fb">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e18392f2264c7ba9f8a25badbde19f_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfMTAtMS0xLTEtMTE5NDgy_a725fecd-6e12-4d63-893a-5a3c198cca75">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e18392f2264c7ba9f8a25badbde19f_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfMTAtMy0xLTEtMTE5NDgy_c9fdb3d9-242b-4bea-aa21-0facf8dba9bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0e18392f2264c7ba9f8a25badbde19f_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfMTAtNS0xLTEtMTE5NDgy_f8810309-8cd9-45e9-9541-f1bf9d1400ad">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e18392f2264c7ba9f8a25badbde19f_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfMTAtNy0xLTEtMTE5NDgy_3e3f696d-3e4f-490e-94f3-2dd3c982c88e">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="mygn:InvestmentsAndCashAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfMTEtMS0xLTEtMTE5NDgy_1d40ee6a-d424-4307-8ec8-fc886cfd9421">172.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfMTEtMy0xLTEtMTE5NDgy_e949e4f3-e701-4ec2-b676-61ffc439a85e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfMTEtNS0xLTEtMTE5NDgy_f6009565-99b7-4ddb-b379-a3a3b8784f5a">2.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:InvestmentsAndCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfMTEtNy0xLTEtMTE5NDgy_a57e8f6e-1a19-4266-acd4-f6f4a55bf69d">169.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="idb63f3329ff348138b86ff7ac181326e"><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i6aff8ec17d8b45829fedbae3406de8be"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37ece6897254048a406c0b1fa7f3ad7_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfMy0xLTEtMS0xMTk0ODI_584bfcc4-0938-4f3d-832b-63b6f14a5fed">194.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37ece6897254048a406c0b1fa7f3ad7_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfMy03LTEtMS0xMTk0ODI_1148d15b-4778-4598-9817-37d508d60604">194.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9bed5c63e84983966641b7a24d4bd5_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfNC0xLTEtMS0xMTk0ODI_fa9d1a00-8dd8-49f0-8b5c-93a5c635e50d">63.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9bed5c63e84983966641b7a24d4bd5_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfNC03LTEtMS0xMTk0ODI_96598fc2-7c0d-45f9-92b4-6839bf4860ab">63.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfNS0xLTEtMS0xMTk0ODI_2fe60af4-cd79-4c11-8e27-9e20240238d0">257.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfNS03LTEtMS0xMTk0ODI_8a2a50ca-441c-4d71-88c4-c9e2359ea935">257.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb0ffff83b34e97a987ed8e7389d515_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfNy0xLTEtMS0xMTk0ODI_afd67bf4-049b-4f3a-a25e-3200ab5756ac">105.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb0ffff83b34e97a987ed8e7389d515_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfNy0zLTEtMS0xMTk0ODI_e594d13b-0350-47c6-b29a-578c9347fb6a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffb0ffff83b34e97a987ed8e7389d515_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfNy01LTEtMS0xMTk0ODI_5584b335-78bb-47fd-a202-ea6ce875aa4c">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb0ffff83b34e97a987ed8e7389d515_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfNy03LTEtMS0xMTk0ODI_f9674e8f-c6d4-4bc7-8490-1fa6f05245a1">105.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06c8acb8e4034c26bb0e7099f0eb44f5_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfOC0xLTEtMS0xMTk0ODI_fbafe362-7b29-47bd-b682-d68965a6c68d">16.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06c8acb8e4034c26bb0e7099f0eb44f5_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfOC0zLTEtMS0xMTk0ODI_647bc425-2064-4303-a116-81b56b1bebfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06c8acb8e4034c26bb0e7099f0eb44f5_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfOC01LTEtMS0xMTk0ODI_d78ecc11-7d7b-4281-b9fd-65d895d09b3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06c8acb8e4034c26bb0e7099f0eb44f5_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfOC03LTEtMS0xMTk0ODI_d3131803-6554-4116-b515-f5b76cf0f7ff">16.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae9580cce4d64144acfc341401d74a31_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfOS0xLTEtMS0xMTk0ODI_3b778d76-e2b9-4394-a23d-e92ef1f4465d">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae9580cce4d64144acfc341401d74a31_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfOS0zLTEtMS0xMTk0ODI_ba0638dc-b533-477f-843d-4eb822006416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae9580cce4d64144acfc341401d74a31_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfOS01LTEtMS0xMTk0ODI_7388fa71-a00d-4857-b565-a637925e871c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae9580cce4d64144acfc341401d74a31_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfOS03LTEtMS0xMTk0ODI_5ba770c8-6aac-473f-b3ff-e57f49a25119">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa40776bd48450d8df11ae05f802a71_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfMTAtMS0xLTEtMTE5NDgy_4f601390-a585-4190-ad6c-5c5dca6bc227">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa40776bd48450d8df11ae05f802a71_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfMTAtMy0xLTEtMTE5NDgy_2bcf3ed8-c18c-4db1-bbee-bb0ea07c3b63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa40776bd48450d8df11ae05f802a71_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfMTAtNS0xLTEtMTE5NDgy_50782ae5-a982-4c12-b615-7c1242070ac0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa40776bd48450d8df11ae05f802a71_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfMTAtNy0xLTEtMTE5NDgy_fffea6d9-9fdd-432a-b086-59825aaac431">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="mygn:InvestmentsAndCashAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfMTEtMS0xLTEtMTE5NDgy_27f4c5cc-b738-4a18-8250-960059bfec01">397.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfMTEtMy0xLTEtMTE5NDgy_69b741ab-204b-4f7a-91f5-7e89dc6799bb">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfMTEtNS0xLTEtMTE5NDgy_dfe93dc6-5f91-4f6b-9ee9-80493619cdb9">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:InvestmentsAndCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfMTEtNy0xLTEtMTE5NDgy_bb4f53c3-2312-48a7-8ce7-5db31128d3fb">397.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNjE1_35792114-5a42-4389-b444-4b1c4bdfe9c1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and maturities of debt securities classified as available-for-sale are as follows at December&#160;31, 2022:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75f79427aab4f40a89a2217f2dc3335_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfMS0xLTEtMS0xMTk0ODI_e98807a8-ad40-4989-a041-bac91b297cf3">53.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75f79427aab4f40a89a2217f2dc3335_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfMS0zLTEtMS0xMTk0ODI_f7449ddd-1a1b-4def-b2d5-34945f6808f8">53.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0da8029be334899949f916d03b47e6e_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfMi0xLTEtMS0xMTk0ODI_22a685dd-edc4-4482-bc4f-f53540ac0751">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0da8029be334899949f916d03b47e6e_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfMi0zLTEtMS0xMTk0ODI_946b95d1-75bc-4758-b84b-76b6b1c67d40">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfNC0xLTEtMS0xMTk0ODI_ebb7f2eb-cd9a-45a3-bccd-ba44717a81e4">58.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfNC0zLTEtMS0xMTk0ODI_9a82b475-042b-4fff-95c1-17bad00ea52e">58.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfNS0xLTEtMS0xMTk0ODI_8ded9e9d-a296-438d-bc92-b760d45f3c88">56.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfNS0zLTEtMS0xMTk0ODI_5c1d6798-324d-4703-8c31-b176f9d84e92">54.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfNi0xLTEtMS0xMTk0ODI_d1d2b119-cf44-47a1-9991-37e404054ea3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfNi0zLTEtMS0xMTk0ODI_bd9799fe-92ec-48bb-836d-edaed64d0cc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="mygn:InvestmentsAndCashAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfNy0xLTEtMS0xMTk0ODI_ab7559b5-821b-4d17-86d2-0058c9775231">172.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:InvestmentsAndCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfNy0zLTEtMS0xMTk0ODI_49e0173f-c922-40aa-b392-8da97bd8ecd0">169.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2022 and 2021, the transition period ended December 31, 2020, and the fiscal year ended June 30, 2020, the Company sold $<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNTQ5NzU1ODE3Nzgx_4972544c-a727-4498-9528-81283f41e119">28.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNTQ5NzU1ODE3Nzk2_283753cf-f81d-4b83-9c8b-9083a56fe038">8.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNDM5ODA0NjUxNTY4MQ_67177035-80aa-4988-8b22-8f727b5c9cd2">1.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNDM5ODA0NjUxNTY4NQ_96ce8b53-c37c-438e-b349-99487bdec213">3.4</ix:nonFraction> million of investments, respectively. The amount of gross realized gains and realized losses upon sales of investments were insignificant in all periods presented. As of December&#160;31, 2022, the Company had <span id="i98f7445d1c2e464ba5eec17b1b0524ad_4604"></span><ix:nonFraction unitRef="position" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNTQ5NzU1ODE2Njc3_eea11a09-08d5-4143-9589-ece27e52c76f">118</ix:nonFraction> available-for-sale debt securities in a gross unrealized loss position of $<ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfMjE5OTAyMzI2MDM3OQ_e1ad7706-8364-4e22-8a37-0905d898b4ee">2.7</ix:nonFraction> million, with a fair market value of $<ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNTQ5NzU1ODE2NzUx_f8cc6099-f48d-4b06-b2f9-150bf3a61a2e">111.6</ix:nonFraction> million. As of December&#160;31, 2021, the Company had <ix:nonFraction unitRef="position" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNTQ5NzU1ODE3MzU0_ba2d0ca3-bf5b-4f73-b92f-6a265a6bac65">100</ix:nonFraction> available-for-sale debt securities in a gross unrealized loss position of $<ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfMjE5OTAyMzI2MDM4NQ_41329496-e130-49b2-98de-9efbc2e88deb">0.2</ix:nonFraction> million, with a fair market value of $<ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNTQ5NzU1ODE3NDI4_d8d48fdc-c637-4a11-8c5d-efa3d273d731">77.7</ix:nonFraction> million. As of December 31, 2022 and December 31, 2021, the expected losses were determined to be immaterial and as such, the Company did not record an allowance for credit losses. The Company does not intend to sell these available-for-sale debt securities, and it is not more likely than not that it will be required to sell these securities prior to recovery of their amortized cost basis. Additional information relating to fair value of marketable investment securities can be found in Note 3.</span></div></ix:continuation><div id="i7e0793090cf84227944277d460d39a4d_97"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RleHRyZWdpb246MDUzYjcwZWZlZjU5NGUzZTljNmQzNDNkMjIwOGU3ZjZfMzE0Mw_6190ff23-761f-4765-ab22-4aa2693038cc" continuedAt="i75a9abe7b9754995b6f222b67b30ec3b" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i75a9abe7b9754995b6f222b67b30ec3b" continuedAt="ie1c446bafbe84ef6b023e2c28277136f"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RleHRyZWdpb246MDUzYjcwZWZlZjU5NGUzZTljNmQzNDNkMjIwOGU3ZjZfMzE0NA_e51511fc-d5eb-4a25-a635-3d8b770ca4a7" continuedAt="ic8b68a9aa409468195096d75154204e2" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&#160;Some of the Company&#8217;s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;unobservable inputs.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="ie1c446bafbe84ef6b023e2c28277136f" continuedAt="i72151dada3564f9dbde18ebe8886e395"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic8b68a9aa409468195096d75154204e2">All of the Company&#8217;s financial instruments are valued using quoted prices in active markets or based on other observable inputs.&#160;&#160;For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information.&#160;&#160;For Level 3 contingent consideration related to the acquisitions of Sividon Diagnostics GmbH ("Sividon") and Gateway, the Company reassesses the fair value of each expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected contingent consideration liability.&#160;&#160;This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the expected measurement periods of approximately <ix:nonNumeric contextRef="i823a913a8ad749ad8b995c1f537650c7_D20220101-20221231" name="mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RleHRyZWdpb246MDUzYjcwZWZlZjU5NGUzZTljNmQzNDNkMjIwOGU3ZjZfMTg5Mg_105b542b-9202-4819-9904-e88a1488fea2">12.5</ix:nonNumeric> and <ix:nonNumeric contextRef="i0aaca7c4dbe24675bb0115e449ba69fc_D20220101-20221231" name="mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RleHRyZWdpb246MDUzYjcwZWZlZjU5NGUzZTljNmQzNDNkMjIwOGU3ZjZfNDM5ODA0NjUxNDQ2Nw_ceff012b-1495-4e9c-bf41-a7bae56a91db">2.3</ix:nonNumeric> years for Sividon and Gateway, respectively, utilizing various potential pay-out scenarios.&#160;&#160;Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the contingent consideration itself, the related projections, and the overall business.&#160;&#160;The contingent consideration liabilities are classified as components of Accrued liabilities and Other long-term liabilities in the Consolidated Balance Sheets.&#160;Changes to contingent consideration liabilities are reflected in Selling, general, and administrative expense in the Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company&#8217;s financial statements.</ix:continuation></span></div><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RleHRyZWdpb246MDUzYjcwZWZlZjU5NGUzZTljNmQzNDNkMjIwOGU3ZjZfMzE0NQ_85fff0c3-c72e-4359-8cc6-23a2a95ab384" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (a)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac2403f7ee104879ad98b6a6781a824e_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfMi0xLTEtMS0xMTk0ODI_8b77093d-f792-41f6-9562-d5d481a643a6">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4956a5a0ff064149afbcc9ba2dfdc7e7_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfMi0zLTEtMS0xMTk0ODI_26df4cab-2c67-4240-a7ee-9a5d07693c00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f3a3fbe29f8436db24dface84e90cf7_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfMi01LTEtMS0xMTk0ODI_46a44e6e-af15-44ef-96e0-9c1723adb9ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i054731a368194949b2bfc357f58a8920_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfMi03LTEtMS0xMTk0ODI_44b27f06-9557-4ff5-90df-0f90132123ef">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if505b51f5d2949a79b80bf083731f945_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfMy0xLTEtMS0xMTk0ODI_14a0d25f-5955-47b3-afa5-57b8ab59d10b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b9734be1f184d3ab68c6b578ec56321_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfMy0zLTEtMS0xMTk0ODI_3eee3a93-42eb-4666-9de4-9bd65763ad52">65.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic347427564244bcc8e0ff3d8c35f4333_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfMy01LTEtMS0xMTk0ODI_f3b3eefc-fe07-4a61-94a4-00a1921664cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieecccfa51e634b24b60447c9f26442d1_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfMy03LTEtMS0xMTk0ODI_56d98a02-f41d-483a-8fbf-25e938541900">65.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a379dc7f4c475caaaa883ad45060a9_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNC0xLTEtMS0xMTk0ODI_9eaaba73-9a8e-4568-9fb3-a20adcb83469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52834bd336224beaa3d88ac9bf176567_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNC0zLTEtMS0xMTk0ODI_3a6ccd71-e02b-4cce-b2d8-755d0f02a54c">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0531632a6ded481b8155d92ceea1b3ea_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNC01LTEtMS0xMTk0ODI_0e96a9a3-c03a-4104-a562-748df37fa10d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea4bf30af38941b3b6938c631d1ce22e_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNC03LTEtMS0xMTk0ODI_f37333ee-793d-4874-9e1b-4e101ed86baa">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8957a860dc7c44a8943b3e806ea2d496_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNS0xLTEtMS0xMTk0ODI_3b298753-7aaa-415e-9c7d-e09334d0db0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e1560d14dc4c37a9651815e98123dd_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNS0zLTEtMS0xMTk0ODI_ea412d18-35dc-4280-9b9b-822c5aec287b">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if528d1eea02f4c89b8cc2f9410d179e9_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNS01LTEtMS0xMTk0ODI_402fdfd5-5333-4d38-8aa7-e3a9999ecbbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33fcfcc4292d45c6b97cc255ecd96967_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNS03LTEtMS0xMTk0ODI_1c1ed4a1-364b-4581-b940-1b55cbd37155">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabee9b04bba344d0a4676474f9fd0aa9_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNi0xLTEtMS0xMTk0ODI_c8855641-84b5-4c10-b9ec-08b559428a1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f4ee512990746498f686969e753a8f7_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNi0zLTEtMS0xMTk0ODI_80262068-b41d-4fdc-ae0e-96e77d3efa26">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fa11b5293574a56b95e476c81a3cbca_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNi01LTEtMS0xMTk0ODI_1339a9f0-1e2d-47bd-b421-db287b3956bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e18392f2264c7ba9f8a25badbde19f_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNi03LTEtMS0xMTk0ODI_0d290b86-25fa-4ac0-b8cf-1f0a1a289683">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d313c46b56f4ea4811041efe14780de_I20221231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNy0xLTEtMS0xMTk0ODI_6dc89f55-2df0-4cfe-aa31-838d6f0bcb3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8776fe30d4b443b885e41cdae0f9a864_I20221231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNy0zLTEtMS0xMTk0ODI_d76f14dd-3c7d-463f-a4e7-fb8b18d526e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a42cd3883284fccba2c6f45fdec7c5c_I20221231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNy01LTEtMS0xMTk0ODI_034c02ad-54ff-4315-8b2d-97ea5d82a68d">6.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2617796d6b8d481c94ef7401da39b8d8_I20221231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNy03LTEtMS0xMTk0ODI_a3e44081-4d0b-4e91-b4b7-04a212022fe9">6.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic168d5bc29fe42c6a375be189bffb89f_I20221231" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfOC0xLTEtMS0xMTk0ODI_c07afe53-2b50-4891-a66c-251b64584158">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibae6823d4dfc48c78710aeb85ccacafb_I20221231" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfOC0zLTEtMS0xMTk0ODI_02bc0067-fdff-43be-a1ea-119ba09a7f39">112.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53c84ffe4852490b9b62069255f02f88_I20221231" decimals="-5" sign="-" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfOC01LTEtMS0xMTk0ODI_47863386-ab2f-4a9c-b3c5-40371c57ab9f">6.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfOC03LTEtMS0xMTk0ODI_080bf46a-44c6-4561-942b-d9ddd6ef9103">109.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (a)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f6de559c7f84f1ba22b6bde6e9505dc_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfMi0xLTEtMS0xMTk0ODI_be04f438-4a28-45f1-97bf-bbb7b7fe9a97">63.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba93170941f54ad4a6e9bd9506cadfec_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfMi0zLTEtMS0xMTk0ODI_1f41a778-5a9e-4683-9b3c-8b504709a5a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf95e9b463a9489fba6e904f9b508bc0_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfMi01LTEtMS0xMTk0ODI_adc379b3-be30-4708-b28b-234f1fd93b68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1f7a81ab4d546fa8363f6765db2ca47_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfMi03LTEtMS0xMTk0ODI_ce9ea390-f7c9-470a-91e6-452706791a8b">63.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f4577ae6fc24714b12a9f4dae881ad9_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfMy0xLTEtMS0xMTk0ODI_3c7a17ec-3c49-4819-95fe-d863937c99e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia38de968e38b4dd0ad1104298f2e258f_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfMy0zLTEtMS0xMTk0ODI_640c1ad2-654e-4984-bcf1-d07a6eb0a844">105.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0493540df994c2f871795b87f29a7bc_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfMy01LTEtMS0xMTk0ODI_d1ece127-b4f4-46fa-8721-695736d41721">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb0ffff83b34e97a987ed8e7389d515_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfMy03LTEtMS0xMTk0ODI_30f9a2fc-6dbb-4749-bdf6-fd22814acf75">105.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb7ac3fc3ba484292b559015692e497_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNC0xLTEtMS0xMTk0ODI_f4f3ce53-36d4-4d21-b710-00618c1d3aaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1763682428bf431f830915fa01ba4076_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNC0zLTEtMS0xMTk0ODI_7ffc7497-6afb-4cf8-9646-3ed8e489388a">16.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cba5a8d0243495aaf7a24002f234432_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNC01LTEtMS0xMTk0ODI_41846e50-b933-4c73-a969-15e8bdf3c89b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06c8acb8e4034c26bb0e7099f0eb44f5_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNC03LTEtMS0xMTk0ODI_f934f5ad-849a-4502-8cc8-5fa940a038b9">16.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic69437fe4efd4416859e92172cc5790f_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNS0xLTEtMS0xMTk0ODI_81ca80b1-733d-4b29-ad4d-923a0aeb33e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie95b38d0545844f98dede4b82126203f_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNS0zLTEtMS0xMTk0ODI_6515a699-a27f-4d43-83c6-10192aad5ddf">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e7d1835e2e34202be5a79f205d84bd9_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNS01LTEtMS0xMTk0ODI_ba0f9104-add1-454f-8432-f2036f284ea8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae9580cce4d64144acfc341401d74a31_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNS03LTEtMS0xMTk0ODI_09eeae55-fcd8-47f1-8227-56d68a9bfd31">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b14cf32d8ca4635ae65df760ee25e81_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNi0xLTEtMS0xMTk0ODI_e49f650a-7d6b-4c73-867a-62dcd131014c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife394a441cff404aaae4b092a3d3bb46_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNi0zLTEtMS0xMTk0ODI_850c8bb0-0623-4d69-8dde-77cb337e8d87">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe950e801781495697dc7289c421c614_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNi01LTEtMS0xMTk0ODI_aa221f46-188d-408e-bb03-c2e115c6ccb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa40776bd48450d8df11ae05f802a71_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNi03LTEtMS0xMTk0ODI_130b2ce1-0899-4b37-b47f-2478bd2b49cd">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id59c003282bb4959a9f3ab119e181c6c_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNy0xLTEtMS0xMTk0ODI_6f1453fe-03a4-404d-8311-73ca1858d253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1174c90b6ee4dc5b6d409ab036a9e96_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNy0zLTEtMS0xMTk0ODI_1ea5ee00-cfc3-4f7e-93d5-958d45763c2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30e651fc58854e6d9587d0fd1ace6220_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNy01LTEtMS0xMTk0ODI_b676e1e1-ce6b-4ace-aa46-3a84284e24ef">8.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie511c7937db0407398aaef7ccbbae95e_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNy03LTEtMS0xMTk0ODI_5cb6428c-3d2d-45e7-bffc-0d0da6cce8ec">8.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524f05cde0ab49718e7546d04f102aa5_I20211231" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfOC0xLTEtMS0xMTk0ODI_61ec6d67-95e8-4ce0-a526-977b4343fa4b">63.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50667905e6f44ea3bbc5d72c01cf8826_I20211231" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfOC0zLTEtMS0xMTk0ODI_4ce34a94-e8fe-4ea6-b6eb-43a6caa8a6c8">140.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d017fae949f44c49fe499f702ad7561_I20211231" decimals="-5" sign="-" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfOC01LTEtMS0xMTk0ODI_69e54f98-c82f-44a6-b02f-8e8e9103a7f9">8.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:FairValueNetAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfOC03LTEtMS0xMTk0ODI_94f527ba-4efb-436b-8fbb-6eeec9296598">195.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.03pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="i72151dada3564f9dbde18ebe8886e395"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RleHRyZWdpb246MDUzYjcwZWZlZjU5NGUzZTljNmQzNDNkMjIwOGU3ZjZfMzE0Ng_442d278c-f2f1-49c7-96dc-c94c09a5e8e1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the change in the fair value of the contingent consideration during the periods presented:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMS0xLTEtMS0xMTk0ODI_5e494e48-380d-485d-bc85-d770539bd074">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMS0zLTEtMS0xMTk0ODI_1b03c53a-53aa-47db-bd04-272d7d4153de">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideeefc606008446e85d0fd21a9515813_I20200630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMS01LTEtMS0xMTk0ODI_bbda7076-b7d9-4c80-a91b-19d30e8bbd8d">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96afdd71e74449aa558f9c0f8968925_I20190630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMS03LTEtMS0xMTk0ODI_7d1a8abe-3f73-41af-85cb-c20bd4708796">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMi0xLTEtMS0xMTk0ODI_305f3ce4-c485-4b6a-b146-81934b35ebf8">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMi0zLTEtMS0xMTk0ODI_02a1562f-bea5-43d8-9c14-b03a1b5447a4">3.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMi01LTEtMS0xMTk0ODI_e01a4e5a-aa1f-409d-b22e-cb924e6d7e38">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMi03LTEtMS0xMTk0ODI_f2702178-3a1f-4853-a8e5-e4a028f4737e">3.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration recognized at acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMy0xLTEtMS0xMzM5MjE_d7dd2c69-a707-4070-97fb-50a1a81cf478">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMy0zLTEtMS0xMzM5MjE_7607a9dd-6504-48d8-9bce-83ce03f52e07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMy01LTEtMS0xMzM5MjE_cec13f6f-99f2-46c0-aa68-d773d5725abe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMy03LTEtMS0xMzM5MjE_4f52a823-c59d-4d43-8c93-26fcef50a7e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" name="mygn:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMy0wLTEtMS0xMTk0ODI_0360defe-fb8a-48dd-a915-4a3693d24d9e">Change in fair value recognized in the statement of operations</ix:nonNumeric></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMy0xLTEtMS0xMTk0ODI_ea3547e9-e800-469a-b68b-227b006a14b5">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMy0zLTEtMS0xMTk0ODI_4e24a8fd-466a-40dd-af7e-5ddc61752f10">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMy01LTEtMS0xMTk0ODI_ede3eb44-8995-479c-91f0-fa59729cdab8">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMy03LTEtMS0xMTk0ODI_0ff86c96-0d6b-4c8e-8a6a-94e8b95e876e">2.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustments recognized in other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfNC0xLTEtMS0xMTk0ODI_b1ff1adf-4f59-43bd-8b7c-7cc6ea6bc7b4">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfNC0zLTEtMS0xMTk0ODI_dd821c4b-8639-4300-9fe6-d45a7e7b1ed7">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfNC01LTEtMS0xMTk0ODI_bb4d4592-e238-4fd8-908c-589d10717f4a">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfNC03LTEtMS0xMTk0ODI_4ddd1a21-d2e3-4495-8ac9-72a81bb9ed6a">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfNS0xLTEtMS0xMTk0ODI_28f9bcc6-2f7f-45a5-af3b-94e7cfbe44e5">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfNS0zLTEtMS0xMTk0ODI_0ed75eee-be3e-47a3-a386-178e7519a721">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfNS01LTEtMS0xMTk0ODI_cbbb9b1e-92cf-464e-afa7-07532cba0d2c">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideeefc606008446e85d0fd21a9515813_I20200630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfNS03LTEtMS0xMTk0ODI_8aa89679-b3b3-4358-96f7-331136e07e68">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i7e0793090cf84227944277d460d39a4d_100"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90ZXh0cmVnaW9uOjkzYjU4NWYzMTQzMTRlZDJiM2Y1MTkxM2FiZWU1OTljXzMxOQ_ee5d7ae3-fd3f-4fe5-bb7a-23d92f5377dc" continuedAt="ic30fb2d12deb4cc09b46057028d197ab" escape="true">PROPERTY, PLANT AND EQUIPMENT, NET</ix:nonNumeric></span></div><ix:continuation id="ic30fb2d12deb4cc09b46057028d197ab"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90ZXh0cmVnaW9uOjkzYjU4NWYzMTQzMTRlZDJiM2Y1MTkxM2FiZWU1OTljXzMyMA_3920fffd-5d52-41bc-b89f-1e7689d60752" continuedAt="ife0cc5aa84324ca5943a7718112aaac4" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The property, plant and equipment at December&#160;31, 2022 and December&#160;31, 2021 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b01cebc763e4599b78408e1e92b66b8_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTo1YjgzZTc5NjI0NmU0OGQyOTFjODAyMDdjMmVlNWI5Ni90YWJsZXJhbmdlOjViODNlNzk2MjQ2ZTQ4ZDI5MWM4MDIwN2MyZWU1Yjk2XzItMS0xLTEtMTE5NDgy_592675cd-45f5-4887-b5e5-26bede22d775">67.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a85a5fe1cfa49c0aaf2a1f85c315776_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTo1YjgzZTc5NjI0NmU0OGQyOTFjODAyMDdjMmVlNWI5Ni90YWJsZXJhbmdlOjViODNlNzk2MjQ2ZTQ4ZDI5MWM4MDIwN2MyZWU1Yjk2XzItMy0xLTEtMTE5NDgy_b13d65df-ba92-4b8f-92ac-60a5d6939cc8">38.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bbbaf79da6c4e839df3a413fd2c8433_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTo1YjgzZTc5NjI0NmU0OGQyOTFjODAyMDdjMmVlNWI5Ni90YWJsZXJhbmdlOjViODNlNzk2MjQ2ZTQ4ZDI5MWM4MDIwN2MyZWU1Yjk2XzMtMS0xLTEtMTE5NDgy_5b0c64b9-21e3-43fd-831b-fad098d951e2">124.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d090498adec48f5a5d9ada3ace9a11f_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTo1YjgzZTc5NjI0NmU0OGQyOTFjODAyMDdjMmVlNWI5Ni90YWJsZXJhbmdlOjViODNlNzk2MjQ2ZTQ4ZDI5MWM4MDIwN2MyZWU1Yjk2XzMtMy0xLTEtMTE5NDgy_70a37e35-681a-495e-9efc-2309ee7b4e10">112.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTo1YjgzZTc5NjI0NmU0OGQyOTFjODAyMDdjMmVlNWI5Ni90YWJsZXJhbmdlOjViODNlNzk2MjQ2ZTQ4ZDI5MWM4MDIwN2MyZWU1Yjk2XzQtMS0xLTEtMTE5NDgy_2d61734c-0ef6-48f9-9231-adb4bb9da542">192.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTo1YjgzZTc5NjI0NmU0OGQyOTFjODAyMDdjMmVlNWI5Ni90YWJsZXJhbmdlOjViODNlNzk2MjQ2ZTQ4ZDI5MWM4MDIwN2MyZWU1Yjk2XzQtMy0xLTEtMTE5NDgy_c1435257-4f7f-442d-acdc-43aa023df44b">150.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTo1YjgzZTc5NjI0NmU0OGQyOTFjODAyMDdjMmVlNWI5Ni90YWJsZXJhbmdlOjViODNlNzk2MjQ2ZTQ4ZDI5MWM4MDIwN2MyZWU1Yjk2XzUtMS0xLTEtMTE5NDgy_a444551a-7ad9-46db-a574-9dbae4934de2">109.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTo1YjgzZTc5NjI0NmU0OGQyOTFjODAyMDdjMmVlNWI5Ni90YWJsZXJhbmdlOjViODNlNzk2MjQ2ZTQ4ZDI5MWM4MDIwN2MyZWU1Yjk2XzUtMy0xLTEtMTE5NDgy_05ef87bc-7b09-4a38-9dfc-4a591489ea1a">106.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTo1YjgzZTc5NjI0NmU0OGQyOTFjODAyMDdjMmVlNWI5Ni90YWJsZXJhbmdlOjViODNlNzk2MjQ2ZTQ4ZDI5MWM4MDIwN2MyZWU1Yjk2XzYtMS0xLTEtMTE5NDgy_b120f902-960f-490f-abc7-77797e743fca">83.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTo1YjgzZTc5NjI0NmU0OGQyOTFjODAyMDdjMmVlNWI5Ni90YWJsZXJhbmdlOjViODNlNzk2MjQ2ZTQ4ZDI5MWM4MDIwN2MyZWU1Yjk2XzYtMy0xLTEtMTE5NDgy_b5e53c9f-2afd-46d0-a7b2-d1acdba3d0cd">43.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company ceased the use of certain leased Salt Lake City facilities and one of its South San Francisco facilities. As a result, the Company recognized a $<ix:nonFraction unitRef="usd" contextRef="i87c0d4d014b8431486ad3d3075f0ca84_D20220101-20221231" decimals="-5" name="us-gaap:OtherAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90ZXh0cmVnaW9uOjkzYjU4NWYzMTQzMTRlZDJiM2Y1MTkxM2FiZWU1OTljXzExNTQ0ODcyMDkyODc0_b749a5e8-968a-4fd0-8629-09f1b5930d6b">3.9</ix:nonFraction> million impairment on the property, plant and equipment associated with the leases, which consisted primarily of leasehold improvements.  See Note 13 for further discussion. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company completed the sales of Myriad RBM, Inc. and the Myriad Autoimmune business, which resulted in the disposition of $<ix:nonFraction unitRef="usd" contextRef="i2ed990c23f164e939a73f7223c4d3011_D20210101-20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentDisposals" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90ZXh0cmVnaW9uOjkzYjU4NWYzMTQzMTRlZDJiM2Y1MTkxM2FiZWU1OTljXzIxMQ_24c572fa-3b96-4e5b-92bc-4ea2e04587b4">3.1</ix:nonFraction> million of property, plant and equipment. See Note 17 for additional information regarding these divestitures. </span></div><ix:continuation id="ife0cc5aa84324ca5943a7718112aaac4"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded depreciation during the respective periods as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTpmOWE3MGUyMTBkNDM0ZDExYWY2Mjg2NTk5MzU2ZGQyNC90YWJsZXJhbmdlOmY5YTcwZTIxMGQ0MzRkMTFhZjYyODY1OTkzNTZkZDI0XzItMS0xLTEtMTE5NDgy_7e6da233-0db7-4ada-87bb-03f15dac9924">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTpmOWE3MGUyMTBkNDM0ZDExYWY2Mjg2NTk5MzU2ZGQyNC90YWJsZXJhbmdlOmY5YTcwZTIxMGQ0MzRkMTFhZjYyODY1OTkzNTZkZDI0XzItMy0xLTEtMTE5NDgy_b78e0b2c-c719-47a4-b60c-6538eacb0db7">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTpmOWE3MGUyMTBkNDM0ZDExYWY2Mjg2NTk5MzU2ZGQyNC90YWJsZXJhbmdlOmY5YTcwZTIxMGQ0MzRkMTFhZjYyODY1OTkzNTZkZDI0XzItNS0xLTEtMTE5NDgy_c150999b-3af1-483a-aa37-a761c5e9090f">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTpmOWE3MGUyMTBkNDM0ZDExYWY2Mjg2NTk5MzU2ZGQyNC90YWJsZXJhbmdlOmY5YTcwZTIxMGQ0MzRkMTFhZjYyODY1OTkzNTZkZDI0XzItNy0xLTEtMTE5NDgy_727502ee-93c8-4d5f-88d7-785358ba8d8c">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzQyNDU_40bed2b9-d275-47ff-9900-e494b0b56055" continuedAt="i7862f5e71aad4e9b9c742299d216684c" escape="true">GOODWILL AND INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="i7862f5e71aad4e9b9c742299d216684c" continuedAt="i47b975ee1e37498d9c97a6423f9f1653"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzQyNDY_7cd30b75-8639-4e70-a040-fb15a655552a" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of goodwill for the year ended December&#160;31, 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTpjZTM3NGNjYTUyMjY0Y2Y2OGEyYzVjYjJlZTk5NzJjOS90YWJsZXJhbmdlOmNlMzc0Y2NhNTIyNjRjZjY4YTJjNWNiMmVlOTk3MmM5XzEtMS0xLTEtMTE5NDgy_de1e25c5-f4c0-48e1-8858-3c82eabf257f">239.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired (see Note 16)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTpjZTM3NGNjYTUyMjY0Y2Y2OGEyYzVjYjJlZTk5NzJjOS90YWJsZXJhbmdlOmNlMzc0Y2NhNTIyNjRjZjY4YTJjNWNiMmVlOTk3MmM5XzItMS0xLTEtMTM0MDYx_1334c3db-ae57-4f5a-a077-0f55c0667149">48.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTpjZTM3NGNjYTUyMjY0Y2Y2OGEyYzVjYjJlZTk5NzJjOS90YWJsZXJhbmdlOmNlMzc0Y2NhNTIyNjRjZjY4YTJjNWNiMmVlOTk3MmM5XzMtMS0xLTEtMTE5NDgy_242534e0-9e48-4319-a3be-f05db6ea112d">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTpjZTM3NGNjYTUyMjY0Y2Y2OGEyYzVjYjJlZTk5NzJjOS90YWJsZXJhbmdlOmNlMzc0Y2NhNTIyNjRjZjY4YTJjNWNiMmVlOTk3MmM5XzQtMS0xLTEtMTE5NDgy_3356db1a-edbe-431a-9c25-613014993600">286.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2022, the Company acquired Gateway. In connection therewith, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzU0OTc1NTgyMDQ5MA_1334c3db-ae57-4f5a-a077-0f55c0667149">48.7</ix:nonFraction> million of goodwill. See Note 16 for additional information on this acquisition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed goodwill for impairment as part of its annual goodwill testing in accordance with the appropriate guidance (see Note 1) and determined none of its reporting units were impaired as of the annual testing date. The Company did <ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzM5NQ_9df03175-d4e3-4f54-8781-6a5af98397fd"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzM5NQ_a1aef03f-7abd-491d-8cea-33727dd365db"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzM5NQ_bdb9aeae-abc1-4e6b-a0a2-a4a35ae64763">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t record an impairment of goodwill for the years ended December 31, 2022 and 2021, or the transition period ended December 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended June 30, 2020, as a result of the effect of COVID-19 on expected future cash flows and a corresponding decline in the Company's market capitalization and enterprise value, the Company performed an interim quantitative impairment review of goodwill for the Myriad Mental Health, Myriad Autoimmune and Myriad International reporting units as of March 31, 2020. Based on this analysis, the Company recognized a goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="ia5e94090de30419c96fa1c05060afd64_D20200101-20200331" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzEwMDY_cdd94d13-dca6-4cc2-af49-6528b15bdbf8">80.7</ix:nonFraction>&#160;million related to the goodwill from the Myriad Autoimmune reporting unit. The goodwill impairment charge is reflected in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations. On July 1, 2021, the Company completed the sale of Myriad RBM, Inc., and as a result the goodwill attributable to the Myriad RBM reporting unit is no longer held by the Company. In addition, on September 13, 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">select operating assets and intellectual property, including the Vectra</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> test, from the Myriad Autoimmune business unit were sold. As a result of this divestiture, the goodwill attributable to the Myriad Autoimmune reporting unit is no longer held by the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended June 30, 2020, the Company also recognized a $<ix:nonFraction unitRef="usd" contextRef="i39965e7109344a238233c9caa866cfb3_D20190701-20200630" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzE3NjM_7b129449-1c95-4c38-9354-f90f6b605808">1.3</ix:nonFraction> million impairment charge for goodwill allocated to the Clinic asset group that is included in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets have primarily consisted of amortizable assets of developed technologies, customer relationships, and trademarks as well as a non-amortizable intangible asset of in-process research and development.&#160;On November 1, 2022, the Company acquired Gateway. As part of the acquisition, the Company acquired customer relationships, trademarks, and developed technologies of $<ix:nonFraction unitRef="usd" contextRef="id82e3f3eeb68492399f4153822f134df_D20221101-20221101" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzQzOTgwNDY1MjE2MjA_9de1c87a-d79a-4636-9472-9862732c8b74">1.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if437534e60cb4439b2cd0da6651519aa_D20221101-20221101" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzQzOTgwNDY1MjE2Mjg_f6a3442e-add3-4e5b-8ef2-2a2b122a19c5">6.1</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ic3c2906fb217491a8423ba010a090290_D20221101-20221101" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzU0OTc1NTgyMTkxOA_f6d0a627-1a2b-4a31-bf8f-42a4b4ee96cf">10.1</ix:nonFraction> million, respectively. See Note 16 for additional information on this acquisition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's developed technologies have estimated remaining useful lives of <ix:nonNumeric contextRef="ic7975a4442d44d779f0f1bf53782120d_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzI4NTk_9d2860b4-9b04-4ab8-979e-330ed74794e6">8</ix:nonNumeric> and <ix:nonNumeric contextRef="ife7424d471c047f29674554074fafb8c_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzI4NjY_d330aa62-920c-4234-818d-57694f787765">13</ix:nonNumeric> years. The Company's trademarks and customer relationships acquired have an estimated remaining useful life of approximately <ix:nonNumeric contextRef="i082547e446854663944c1f7d21ca67bf_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzU0OTc1NTgxOTg4MA_93a615f5-7c94-4b38-a10b-191a57b4369b">10</ix:nonNumeric> years. Prior to the sale of Myriad RBM, Inc., the estimated useful life of acquired in-process research and development was also evaluated in conjunction with the annual impairment analysis of intangible assets.&#160;The classification of the acquired in-process research and development as an indefinite lived asset was deemed appropriate during prior years as the related research and development was not yet complete nor had it been abandoned. During the fiscal year ended June 30, 2020, the Company decided to abandon the development of one of its in-process research and development intangible assets, and as a result the Company recognized a charge of $<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzM1MTU_004e9700-34ca-4c5e-9d39-eb5068a5b21c">17.7</ix:nonFraction> million, which is reflected in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations. The Company concluded there was <ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzM2Njg_a39e3b8e-6c2f-4852-8d58-6d9d051b31b4"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzM2Njg_a886a3f2-e5e9-4b7a-bfa6-0845dfd6b5e4"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzM2Njg_f4ebfc12-ed61-4235-b0f7-9a76c7270049">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of long-lived intangible assets for the years ended December 31, 2022 and 2021 or the transition period ended December 31, 2020.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="i47b975ee1e37498d9c97a6423f9f1653"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzQyNDc_068752ff-5aab-4a41-beda-57e48f7dff59" escape="true"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzQyNDc_dd9a2c96-65c7-4988-8d75-4c2a64a45f9f" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the amounts reported as intangible assets (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2022:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Carrying Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Useful Life <br/>(in Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Useful Life <br/>(in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ebe315d6824fd7a89d2f7c74efcf31_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzEtMS0xLTEtMTE5NDgy_7b3b6726-a0da-4b64-b1fd-b6f34335c7ab">625.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6ebe315d6824fd7a89d2f7c74efcf31_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzEtMy0xLTEtMTE5NDgy_6c2a4cb3-d447-4d3f-bc46-02db3fe256d4">252.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ebe315d6824fd7a89d2f7c74efcf31_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzEtNS0xLTEtMTE5NDgy_b6b6abe0-693b-4ee4-90da-b1ea5411cf44">372.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88103ecea9f2472aad40efe4318bcd91_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzEtNy0xLTEtMTQyODU0_8f548b5a-170a-49da-b2f8-b907279f5dad">14.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88103ecea9f2472aad40efe4318bcd91_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzEtOS0xLTEtMTQyODU0_d264b9f6-80a9-458f-961f-cd59dc952545">9.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aef28d53f8c47c8ab1d99d12cdd400f_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzItMS0xLTEtMTMyNjk0_35d9e91b-5f3e-4b92-98ad-cd630c556282">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aef28d53f8c47c8ab1d99d12cdd400f_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzItMy0xLTEtMTMyNjk0_3bd753fb-cd5c-4287-a0b2-cd6db42c4938">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aef28d53f8c47c8ab1d99d12cdd400f_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzItNS0xLTEtMTMyNjk0_04ea54ac-9ba3-4715-abe9-691fb56eaffb">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i082547e446854663944c1f7d21ca67bf_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzItNy0xLTEtMTQyODU0_14a67255-9c85-4e3d-bb8b-37549c2cdde9">10.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i082547e446854663944c1f7d21ca67bf_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzItOS0xLTEtMTQyODU0_f1b7cfb8-d148-4153-a5c2-e2d7d449269e">9.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id72ef2bad75948119bfd502da5931067_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzMtMS0xLTEtMTMyNjk0_5783a88c-d851-44be-a67d-a52f2a6eb74a">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id72ef2bad75948119bfd502da5931067_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzMtMy0xLTEtMTMyNjk0_3c47259d-71a0-4aa7-843e-c764f30d294f">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id72ef2bad75948119bfd502da5931067_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzMtNS0xLTEtMTMyNjk0_a5f70b1c-71de-42fc-bfde-e60caa9ba89d">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idcc890f9cd184879a64c08e82dcbbc8f_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzMtNy0xLTEtMTQyODU0_ba78d70e-7b28-4b7d-9d92-9e36bca85b64">10.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idcc890f9cd184879a64c08e82dcbbc8f_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzMtOS0xLTEtMTQyODU0_6e5f1419-9d7d-4bcb-9c05-735adfab8692">9.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzItMS0xLTEtMTE5NDgy_d3f3d058-6b22-464d-a0bc-255991b1922f">632.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzItMy0xLTEtMTE5NDgy_c806868d-5214-400c-a212-aed03dbc1e24">253.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzItNS0xLTEtMTE5NDgy_90b3d44f-822e-466b-8a69-99cc6b41ae13">379.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzQtNy0xLTEtMTQyODU0_752c514d-69c5-44f8-9575-b4b28942deb4">14.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzQtOS0xLTEtMTQyODU0_277be4ee-6ad9-487c-9fb4-2a503a84be80">9.1</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Carrying Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Useful Life <br/>(in Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Useful Life <br/>(in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73af76a4fce548948796425f49a1806c_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTphMDc2YjYzMDc4MDc0NmNkYjUwZGFmNTlhMzUzMTZhYy90YWJsZXJhbmdlOmEwNzZiNjMwNzgwNzQ2Y2RiNTBkYWY1OWEzNTMxNmFjXzEtMS0xLTEtMTE5NDgy_7e68df1f-e6ab-4d57-8918-e02bc0df7f34">616.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73af76a4fce548948796425f49a1806c_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTphMDc2YjYzMDc4MDc0NmNkYjUwZGFmNTlhMzUzMTZhYy90YWJsZXJhbmdlOmEwNzZiNjMwNzgwNzQ2Y2RiNTBkYWY1OWEzNTMxNmFjXzEtMy0xLTEtMTE5NDgy_2b8f4ced-784c-4707-b1f7-bb21cda95bf5">212.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73af76a4fce548948796425f49a1806c_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTphMDc2YjYzMDc4MDc0NmNkYjUwZGFmNTlhMzUzMTZhYy90YWJsZXJhbmdlOmEwNzZiNjMwNzgwNzQ2Y2RiNTBkYWY1OWEzNTMxNmFjXzEtNS0xLTEtMTE5NDgy_cf415c96-8ba7-484a-8d9c-82a14fa74c0b">404.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i43ae1240cef14457931c317f4fd211b4_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTphMDc2YjYzMDc4MDc0NmNkYjUwZGFmNTlhMzUzMTZhYy90YWJsZXJhbmdlOmEwNzZiNjMwNzgwNzQ2Y2RiNTBkYWY1OWEzNTMxNmFjXzEtNy0xLTEtMTQyODcw_f67738cf-4c8e-4852-804b-a65409242f88">14.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i43ae1240cef14457931c317f4fd211b4_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTphMDc2YjYzMDc4MDc0NmNkYjUwZGFmNTlhMzUzMTZhYy90YWJsZXJhbmdlOmEwNzZiNjMwNzgwNzQ2Y2RiNTBkYWY1OWEzNTMxNmFjXzEtOS0xLTEtMTQyODcw_708e97f7-6049-4dea-a792-aae97af47963">10.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTphMDc2YjYzMDc4MDc0NmNkYjUwZGFmNTlhMzUzMTZhYy90YWJsZXJhbmdlOmEwNzZiNjMwNzgwNzQ2Y2RiNTBkYWY1OWEzNTMxNmFjXzctMS0xLTEtMTE5NDgy_3e461a05-5f97-4930-b9de-22d4b7e2e564">616.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTphMDc2YjYzMDc4MDc0NmNkYjUwZGFmNTlhMzUzMTZhYy90YWJsZXJhbmdlOmEwNzZiNjMwNzgwNzQ2Y2RiNTBkYWY1OWEzNTMxNmFjXzctMy0xLTEtMTE5NDgy_a88d18c2-cea3-4b79-8f8e-fb41a96d5a12">212.5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTphMDc2YjYzMDc4MDc0NmNkYjUwZGFmNTlhMzUzMTZhYy90YWJsZXJhbmdlOmEwNzZiNjMwNzgwNzQ2Y2RiNTBkYWY1OWEzNTMxNmFjXzctNS0xLTEtMTE5NDgy_f35cb530-d5b3-45ac-b1fb-eca2516fe749">404.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTphMDc2YjYzMDc4MDc0NmNkYjUwZGFmNTlhMzUzMTZhYy90YWJsZXJhbmdlOmEwNzZiNjMwNzgwNzQ2Y2RiNTBkYWY1OWEzNTMxNmFjXzctNy0xLTEtMTQyODc4_5f71135f-c006-43c3-9cf7-d4a07ae9c58f">14.6</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTphMDc2YjYzMDc4MDc0NmNkYjUwZGFmNTlhMzUzMTZhYy90YWJsZXJhbmdlOmEwNzZiNjMwNzgwNzQ2Y2RiNTBkYWY1OWEzNTMxNmFjXzctOS0xLTEtMTQyODc4_1fe90849-6eed-4209-99c6-fc1a708c3a89">10.2</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzQyNDk_b89fae9a-b860-48c1-ae20-b4de8363d145" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded amortization during the respective periods for these intangible assets as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTowOTkwN2RjYTBhMDE0MmUxOTBhMTgyMThhODhkNTRiMS90YWJsZXJhbmdlOjA5OTA3ZGNhMGEwMTQyZTE5MGExODIxOGE4OGQ1NGIxXzItMS0xLTEtMTE5NDgy_3ec5ed25-c192-4c46-97af-d82fe2d104ed">41.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTowOTkwN2RjYTBhMDE0MmUxOTBhMTgyMThhODhkNTRiMS90YWJsZXJhbmdlOjA5OTA3ZGNhMGEwMTQyZTE5MGExODIxOGE4OGQ1NGIxXzItMy0xLTEtMTE5NDgy_4953c6c4-6c98-42b7-9ef6-2a3bafe73632">50.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTowOTkwN2RjYTBhMDE0MmUxOTBhMTgyMThhODhkNTRiMS90YWJsZXJhbmdlOjA5OTA3ZGNhMGEwMTQyZTE5MGExODIxOGE4OGQ1NGIxXzItNS0xLTEtMTE5NDgy_79a3e9e5-fb57-4a08-9f60-fc0e1e1e9dca">30.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTowOTkwN2RjYTBhMDE0MmUxOTBhMTgyMThhODhkNTRiMS90YWJsZXJhbmdlOjA5OTA3ZGNhMGEwMTQyZTE5MGExODIxOGE4OGQ1NGIxXzItNy0xLTEtMTE5NDgy_34ab52f5-69b7-4da1-a248-a06690b41d16">61.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzQyNDg_55d60bc3-a8d2-42d5-81f5-4f9ae27436c2" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense of intangible assets as of December&#160;31, 2022 is estimated to be as follows (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortization Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo2NDI4MjY5ZWFjNTc0NzhlODY0MmI3MDM4MjkwOTdjZC90YWJsZXJhbmdlOjY0MjgyNjllYWM1NzQ3OGU4NjQyYjcwMzgyOTA5N2NkXzEtMS0xLTEtMTE5NDgy_8f396fa1-d677-43e1-8cda-2815ca593c87">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo2NDI4MjY5ZWFjNTc0NzhlODY0MmI3MDM4MjkwOTdjZC90YWJsZXJhbmdlOjY0MjgyNjllYWM1NzQ3OGU4NjQyYjcwMzgyOTA5N2NkXzItMS0xLTEtMTE5NDgy_f6049e3c-a929-4c92-997e-17721019ecda">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo2NDI4MjY5ZWFjNTc0NzhlODY0MmI3MDM4MjkwOTdjZC90YWJsZXJhbmdlOjY0MjgyNjllYWM1NzQ3OGU4NjQyYjcwMzgyOTA5N2NkXzMtMS0xLTEtMTE5NDgy_0503b4bf-1100-4ea1-a403-e06fb0e66046">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo2NDI4MjY5ZWFjNTc0NzhlODY0MmI3MDM4MjkwOTdjZC90YWJsZXJhbmdlOjY0MjgyNjllYWM1NzQ3OGU4NjQyYjcwMzgyOTA5N2NkXzQtMS0xLTEtMTE5NDgy_daa301f2-0b96-4c18-b7f2-d6b3624bf0d6">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo2NDI4MjY5ZWFjNTc0NzhlODY0MmI3MDM4MjkwOTdjZC90YWJsZXJhbmdlOjY0MjgyNjllYWM1NzQ3OGU4NjQyYjcwMzgyOTA5N2NkXzUtMS0xLTEtMTE5NDgy_98b962a5-b2e0-4aab-9efd-38ce8f4aec02">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo2NDI4MjY5ZWFjNTc0NzhlODY0MmI3MDM4MjkwOTdjZC90YWJsZXJhbmdlOjY0MjgyNjllYWM1NzQ3OGU4NjQyYjcwMzgyOTA5N2NkXzYtMS0xLTEtMTE5NDgy_4d3d8f5e-b708-4454-98a8-27f828a363d6">165.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo2NDI4MjY5ZWFjNTc0NzhlODY0MmI3MDM4MjkwOTdjZC90YWJsZXJhbmdlOjY0MjgyNjllYWM1NzQ3OGU4NjQyYjcwMzgyOTA5N2NkXzctMS0xLTEtMTE5NDgy_db3e5702-06fc-451f-a704-6c1b55697fee">379.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i7e0793090cf84227944277d460d39a4d_106"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90ZXh0cmVnaW9uOjJmYWUxM2ZlZGEwNTRjZDhiMmU5MjNiODg3ZGMwMzA1XzI4_e8113f23-6942-4a31-9410-10ea5f8ceb3d" continuedAt="ie97bbb91e75649a394985a832dbe5f06" escape="true">ACCRUED LIABILITIES</ix:nonNumeric></span></div><ix:continuation id="ie97bbb91e75649a394985a832dbe5f06"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90ZXh0cmVnaW9uOjJmYWUxM2ZlZGEwNTRjZDhiMmU5MjNiODg3ZGMwMzA1XzI5_8fdb4878-aefe-4889-9728-f10f6e7cd7ca" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accrued liabilities at December&#160;31, 2022 and December&#160;31, 2021 were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzItMS0xLTEtMTE5NDgy_5074a502-31af-4679-8bf7-a170fbb12c2e">41.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzItMy0xLTEtMTE5NDgy_4fa1c6ac-0748-4119-8c3b-55d32a5b1b37">52.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal charges pending settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:LitigationReserveCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzMtMS0xLTEtMTE5NDgy_0a0814e3-9a53-4e2d-956e-c938f3cc2321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:LitigationReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzMtMy0xLTEtMTE5NDgy_7b990666-e189-43bb-b286-ec97fb3959cd">62.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzQtMS0xLTEtMTE5NDgy_4bde8203-14f7-4160-9056-3498d8409d53">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzQtMy0xLTEtMTE5NDgy_00839af3-910a-40c7-9287-7979ae7b03ac">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refunds payable and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="mygn:RefundsPayableAndReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzUtMS0xLTEtMTE5NDgy_22ed16d3-6aa7-41ee-bb8f-0322efe4b1e5">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="mygn:RefundsPayableAndReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzUtMy0xLTEtMTE5NDgy_032d38d4-fb6d-4b1a-b4f7-51ac5fb0d281">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzYtMS0xLTEtMTE5NDgy_84b94c29-9423-459f-89e8-4215fb793118">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzYtMy0xLTEtMTE5NDgy_d069404e-2573-436b-a231-369123f9c71d">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzctMS0xLTEtMTM2NzQx_d300ee4a-bb28-49e9-87d5-f5721f0522c0">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzctMy0xLTEtMTM2NzQx_8c2a045d-e029-445e-8b16-3283749913e2">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzctMS0xLTEtMTE5NDgy_66c1c387-5fd5-4c24-b101-dc29312fe131">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzctMy0xLTEtMTE5NDgy_bc9df50c-0f5c-45eb-b847-15b48ef137a3">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzgtMS0xLTEtMTE5NDgy_307dbb12-5aad-4fe6-afbc-84e3b5f4c762">23.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzgtMy0xLTEtMTE5NDgy_960060e0-adc6-4738-b9f4-ddac05ea8a51">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzktMS0xLTEtMTE5NDgy_222881fb-b317-462d-8dd3-a9cc563098c8">94.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzktMy0xLTEtMTE5NDgy_7f0c8a17-415d-4f6f-9cd9-168f7bd9e62c">161.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzQ0MjA_3ec65fcb-9a33-45de-adb7-a07d6c9bb97b" continuedAt="id1f7aa9238ef4d0484a81e01a1964179" escape="true">LONG-TERM DEBT</ix:nonNumeric></span></div><ix:continuation id="id1f7aa9238ef4d0484a81e01a1964179" continuedAt="i53a9aab7abdd48af84c68da8263f3e6f"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2016, the Company entered into a senior secured revolving credit facility (the &#8220;Facility&#8221;) as borrower, with the lenders from time to time party thereto. On July 31, 2018, the Company entered into Amendment No. 1 to the Facility, which effected an &#8220;amend and extend&#8221; transaction with respect to the Facility by which the maturity date thereof was extended to July 31, 2023 (the "Maturity Date") and the maximum aggregate principal commitment was increased from $<ix:nonFraction unitRef="usd" contextRef="i23aeff032bf24bb8a9d3d3bb253094dc_I20161223" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzQ2Nw_3eec56b8-5624-430e-a7d6-115de2494c02">300.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="ia162acc4f40848918e001774e6a4f960_I20180731" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzQ3Mw_74bc735a-ab31-45e7-9064-a228198cd811">350.0</ix:nonFraction> million.&#160;&#160;On May 1, 2020, the Company entered into Amendment No. 2 to the Facility, which waived the Company&#8217;s compliance with certain covenants and modified the interest rate and other terms during the modification period from March 31, 2020 through June 30, 2021 (as modified, the "Modification Period&#8221;). This amendment included a modification to the leverage covenant and the interest coverage ratio covenant, which were waived through March 31, 2021, as well as revisions to certain negative covenants of the Facility during the Modification Period. On February 22, 2021, the Company entered into Amendment No. 3 to the Facility, which waived compliance with the leverage ratio and the interest coverage ratio covenants through the quarter ended March 31, 2022 and also lowered the minimum liquidity covenant (which was added by Amendment No. 2) to $<ix:nonFraction unitRef="usd" contextRef="ia7185e4956c746a9b0f45493392d399d_I20210222" decimals="-6" name="mygn:DebtCovenantLiquidityCovenantMinimum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgxNDg0NDU_f3a739a7-a276-412a-ade0-21444c1845c6">150</ix:nonFraction>&#160;million, and made it applicable through such quarter. Amendment No. 3 also restricted the Company from borrowing under the Facility if unrestricted cash, cash equivalents and marketable investment securities exceed $<ix:nonFraction unitRef="usd" contextRef="ia7185e4956c746a9b0f45493392d399d_I20210222" decimals="-5" name="mygn:DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgxNDg0NTk_0e0d1af6-dca9-42e2-ba95-e03e4584da48">150.0</ix:nonFraction>&#160;million, unless such borrowings are in connection with permitted acquisitions, decreased the maximum aggregate principal commitment from $<ix:nonFraction unitRef="usd" contextRef="ib45bd6e5ec9a4ed7a463e74534d19bab_I20210221" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzk0MA_cccbd8b3-b05e-47c7-a6b5-41390c0753fb">350.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="ia7185e4956c746a9b0f45493392d399d_I20210222" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzk0Ng_39649a42-b749-4240-9c99-be785621039c">300.0</ix:nonFraction>&#160;million, with a further reduction in the maximum aggregate principal commitment from $<ix:nonFraction unitRef="usd" contextRef="ia7185e4956c746a9b0f45493392d399d_I20210222" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzEwMjY_79595b45-b079-46d1-8899-d1003f073c2f">300.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i674b5e2ec7a24dd2868cf183995d5ed4_I20210930" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzEwMzI_07d946cb-092e-44ae-9fa6-568674cd4e68">250.0</ix:nonFraction>&#160;million by September 30, 2021, extended the Modification Period for an additional year through June 30, 2022, and revised certain negative covenants in connection with the extension. The amendments were accounted for as modifications pursuant to guidance in ASC 470-50, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On July 26, 2022, the Company entered into Amendment No. 4 to the Facility (the "Amended Facility"), which extended the Modification Period through the Maturity Date, decreased the maximum aggregate principal commitment from $<ix:nonFraction unitRef="usd" contextRef="i33356f53153c4a03be9389d7449cf3f6_I20220725" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMDE0MA_b3c83b34-c0ec-445b-9ead-a5e41b308733">250.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i843f20e91d9b42f9abab257be67b0fba_I20220726" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMDE1Ng_66cfe280-da7d-45b4-8ed2-63ba599c5c76">200.0</ix:nonFraction>&#160;million, with a further reduction to $<ix:nonFraction unitRef="usd" contextRef="icf8301cef485443f9fbd8a975ee8e8bf_I20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMDE3Mg_8808841d-461d-4b24-846f-e47a8de7324a">150.0</ix:nonFraction>&#160;million as of December 31, 2022, waived compliance with the leverage ratio and interest coverage ratio covenants through the Maturity Date, and provided for monthly reporting of the Company's liquidity if the total revolving credit exposure is greater than $<ix:nonFraction unitRef="usd" contextRef="i8f459a7b8fd94d27b059f67e4c1866ff_D20220726-20220726" decimals="-5" name="mygn:LineOfCreditFacilityCreditExposureThreshold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMDE4OA_58a5c49a-2d0a-4815-a757-4e05db9ce060">0</ix:nonFraction>, without giving effect to the dollar amount of any letter of credit exposure not in excess of $<ix:nonFraction unitRef="usd" contextRef="i262a62b1f2d845acbe48f9be412ca7bf_D20220726-20220726" decimals="-5" name="mygn:LineOfCreditFacilityCreditExposureThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMDE5Mg_ca2b4c6e-86f7-4e51-8845-cfbeeab0a49d">5.0</ix:nonFraction>&#160;million. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covenants in the Amended Facility impose operating and financial restrictions on the Company. These restrictions may prohibit or place limitations on, among other things, the Company&#8217;s ability to incur additional indebtedness under the Amended Facility or otherwise, create certain types of liens, and complete mergers, consolidations, or change in control transactions. The Amended Facility may also prohibit or place limitations on the Company&#8217;s ability to sell assets, pay dividends or provide other distributions to stockholders. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Facility contains customary loan terms, interest rates, representations and warranties, and affirmative and negative covenants, subject to customary limitations, exceptions and exclusions. The Amended Facility also contains certain customary events of default. Amendment No. 2 modified the Facility to increase the interest rate to be fixed at a spread of LIBOR plus <ix:nonFraction unitRef="number" contextRef="iaa57fda02bc54eccb40407c480ef96e1_D20200401-20210630" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMjA5MQ_96d7494f-4505-454c-a501-57d9fab65ae0">350</ix:nonFraction> basis points on drawn balances and the undrawn fee was increased to <ix:nonFraction unitRef="number" contextRef="i60ba3c848587432396a389bd552eb846_D20200401-20210630" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMjA5OQ_c1ed27eb-5a48-405a-af1b-40ee0d4dda00">50</ix:nonFraction> basis points during the Modification Period. Amendment No. 4 replaced the option to make Eurodollar borrowings, which bore interest by reference to the LIBOR rate, with term benchmark loans, which will bear interest by reference to the secured overnight financing rate ("SOFR"). Amendment No. 4 did not modify the applicable margins and undrawn fee amounts. The interest rate for term benchmark loans continues to be fixed at a spread of SOFR plus <ix:nonFraction unitRef="number" contextRef="i58d539dc7d304c43a5fbc7a02678e86e_D20220726-20220726" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMjExNA_76236f30-c733-47ba-9c8a-e804c5de5eff">350</ix:nonFraction> basis points on drawn balances and undrawn fees continue to be <ix:nonFraction unitRef="number" contextRef="i93a2ffa60cb1493fa939b40a6cd3610e_D20220726-20220726" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMjEwNg_e3279773-2b24-4b04-bc54-e94531293cea">50</ix:nonFraction> basis points. The SOFR floor was revised to <ix:nonFraction unitRef="number" contextRef="i58d539dc7d304c43a5fbc7a02678e86e_D20220726-20220726" decimals="2" name="mygn:DebtInstrumentFloorPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMjEyNA_a70fd8b5-e641-435f-a63e-226a29e848d7">0.0</ix:nonFraction>%. The Company was in compliance with all applicable financial covenants at December&#160;31, 2022. </span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i53a9aab7abdd48af84c68da8263f3e6f">During the year ended December 31, 2021, the Company made principal repayments totaling $<ix:nonFraction unitRef="usd" contextRef="i1e2a786776cf421188638389979b41f0_D20210101-20211231" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMzY5MA_7337cd07-4c83-4e65-a808-9c060018671a">226.4</ix:nonFraction> million to pay off the remaining outstanding balances on the Amended Facility. As a result, the Company had <ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="INF" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzQyNzI_74a343e3-8d93-459c-9bcf-0900bd543c7c">no</ix:nonFraction> outstanding balances under the Amended Facility as of December 31, 2022.</ix:continuation> </span></div><div id="i7e0793090cf84227944277d460d39a4d_112"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTIvZnJhZzphZTdjYjM3MDVkZDE0MmYxYmE5ZDM0ZWU0M2M2ZjdhNi90ZXh0cmVnaW9uOmFlN2NiMzcwNWRkMTQyZjFiYTlkMzRlZTQzYzZmN2E2XzYwOA_72a09403-c7d9-43b4-9ccb-428caa7a5fd6" continuedAt="i7070f282620841629950b65db68f336f" escape="true">OTHER LONG-TERM LIABILITIES</ix:nonNumeric></span></div><ix:continuation id="i7070f282620841629950b65db68f336f" continuedAt="ifa168be405834523a3f18e1dba467c65"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTIvZnJhZzphZTdjYjM3MDVkZDE0MmYxYmE5ZDM0ZWU0M2M2ZjdhNi90ZXh0cmVnaW9uOmFlN2NiMzcwNWRkMTQyZjFiYTlkMzRlZTQzYzZmN2E2XzYwOQ_3976446c-a13e-4616-baa6-b1fe7023371b" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's other long-term liabilities at December&#160;31, 2022 and December&#160;31, 2021 were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTIvZnJhZzphZTdjYjM3MDVkZDE0MmYxYmE5ZDM0ZWU0M2M2ZjdhNi90YWJsZTo1YmEzY2FiMGFlNmI0MTE2YmYwYmE5ZDg1MjZmYzIxZi90YWJsZXJhbmdlOjViYTNjYWIwYWU2YjQxMTZiZjBiYTlkODUyNmZjMjFmXzItMS0xLTEtMTE5NDgy_52747532-b7c7-4a55-ad03-a0665cce1d58">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTIvZnJhZzphZTdjYjM3MDVkZDE0MmYxYmE5ZDM0ZWU0M2M2ZjdhNi90YWJsZTo1YmEzY2FiMGFlNmI0MTE2YmYwYmE5ZDg1MjZmYzIxZi90YWJsZXJhbmdlOjViYTNjYWIwYWU2YjQxMTZiZjBiYTlkODUyNmZjMjFmXzItMy0xLTEtMTE5NDgy_0b8d88d7-ccff-4445-94bf-e98c8be64b05">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTIvZnJhZzphZTdjYjM3MDVkZDE0MmYxYmE5ZDM0ZWU0M2M2ZjdhNi90YWJsZTo1YmEzY2FiMGFlNmI0MTE2YmYwYmE5ZDg1MjZmYzIxZi90YWJsZXJhbmdlOjViYTNjYWIwYWU2YjQxMTZiZjBiYTlkODUyNmZjMjFmXzMtMS0xLTEtMTE5NDgy_865848ec-9cc0-41bc-8370-253b704088e0">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTIvZnJhZzphZTdjYjM3MDVkZDE0MmYxYmE5ZDM0ZWU0M2M2ZjdhNi90YWJsZTo1YmEzY2FiMGFlNmI0MTE2YmYwYmE5ZDg1MjZmYzIxZi90YWJsZXJhbmdlOjViYTNjYWIwYWU2YjQxMTZiZjBiYTlkODUyNmZjMjFmXzMtMy0xLTEtMTE5NDgy_27269305-a385-43a9-80c6-6f2dff4de86d">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTIvZnJhZzphZTdjYjM3MDVkZDE0MmYxYmE5ZDM0ZWU0M2M2ZjdhNi90YWJsZTo1YmEzY2FiMGFlNmI0MTE2YmYwYmE5ZDg1MjZmYzIxZi90YWJsZXJhbmdlOjViYTNjYWIwYWU2YjQxMTZiZjBiYTlkODUyNmZjMjFmXzQtMS0xLTEtMTE5NDgy_68ad3d13-3ae8-43ab-9ae2-3d96c3784a0f">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTIvZnJhZzphZTdjYjM3MDVkZDE0MmYxYmE5ZDM0ZWU0M2M2ZjdhNi90YWJsZTo1YmEzY2FiMGFlNmI0MTE2YmYwYmE5ZDg1MjZmYzIxZi90YWJsZXJhbmdlOjViYTNjYWIwYWU2YjQxMTZiZjBiYTlkODUyNmZjMjFmXzQtMy0xLTEtMTE5NDgy_8ea171cc-43c0-4ab2-a711-763874681151">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifa168be405834523a3f18e1dba467c65">The Company&#8217;s balance of other long-term liabilities as of December&#160;31, 2022 and 2021 consisted primarily of the long-term portion of contingent consideration related to the acquisitions of Sividon and Gateway and restricted cash related to the acquisition of Gateway. See Note 16 for additional information on the Gateway acquisition.</ix:continuation></span></div><div id="i7e0793090cf84227944277d460d39a4d_115"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzE2NjI_ba050c0f-42f8-4bde-9e37-da976a98275d" continuedAt="i500ede6d092f48e98d28a556919a5e24" escape="true">PREFERRED AND COMMON STOCKHOLDERS' EQUITY</ix:nonNumeric></span></div><ix:continuation id="i500ede6d092f48e98d28a556919a5e24"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzkx_82eb1e80-b928-4914-be60-d008f04691ad"><ix:nonFraction unitRef="shares" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzkx_b4031ec7-cefe-4609-ae5f-f0e7ae706388">5.0</ix:nonFraction></ix:nonFraction> million shares of preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzEzMQ_3b31072b-e2a6-474d-a8d2-5956f3ac9d0f"><ix:nonFraction unitRef="usdPerShare" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzEzMQ_d9a7c5f4-8788-42e1-a9f9-d0b0935ea5e3">0.01</ix:nonFraction></ix:nonFraction> per share.&#160;There were <ix:nonFraction unitRef="shares" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzE1Ng_0804a2c9-9652-43e6-b163-427bfbe946ef"><ix:nonFraction unitRef="shares" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzE1Ng_8b74d96c-10ad-43ed-8517-eae3e14a4b6c">no</ix:nonFraction></ix:nonFraction> shares of preferred stock outstanding at December&#160;31, 2022 and December&#160;31, 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzI0NA_2eca74f6-6ab3-4f76-9bf8-4f8269e7ba87"><ix:nonFraction unitRef="shares" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzI0NA_436402ed-06ef-4cc5-ab50-60636281d170">150.0</ix:nonFraction></ix:nonFraction> million shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzI4MQ_2e2d644b-6c9c-44a2-b3c9-e824dbefc857"><ix:nonFraction unitRef="usdPerShare" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzI4MQ_69cbed33-4520-4ee4-913b-92a0b15e7e16">0.01</ix:nonFraction></ix:nonFraction> per share. There were <ix:nonFraction unitRef="shares" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzU0OTc1NTgxNjM4NA_544291e6-000f-4298-bda9-dadd5e537fb7"><ix:nonFraction unitRef="shares" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzU0OTc1NTgxNjM4NA_b18a1e92-626c-4aa4-821d-cf98f4765546">81.2</ix:nonFraction></ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzU0OTc1NTgxNjM3OQ_130e4922-7e4c-41cb-9093-1ad0d825b580"><ix:nonFraction unitRef="shares" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzU0OTc1NTgxNjM3OQ_eafbadca-ef1e-419f-aec8-192b2fb222d8">80.0</ix:nonFraction></ix:nonFraction>&#160;million shares of common stock issued and outstanding at December&#160;31, 2022 and 2021, respectively.</span></div><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzE2NjA_f7149403-4f72-4e77-aa9e-f62a43645e61" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shares of common stock issued and outstanding</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning common stock issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzItMS0xLTEtMTE5NDgy_04938b83-ad93-40e6-987b-64a1fb202d7b"><ix:nonFraction unitRef="shares" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzItMS0xLTEtMTE5NDgy_df127af9-5a09-4bd5-916f-6c8f13bbd613">80.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzItMy0xLTEtMTE5NDgy_9d44d667-3abd-4703-bbad-77ce7ed59124"><ix:nonFraction unitRef="shares" contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzItMy0xLTEtMTE5NDgy_c5067c5c-949c-4b82-b463-198ca0b27774">75.4</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ideeefc606008446e85d0fd21a9515813_I20200630" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzItNS0xLTEtMTE5NDgy_026d6b23-adc2-4a12-b5b6-d7e169391e9d"><ix:nonFraction unitRef="shares" contextRef="ideeefc606008446e85d0fd21a9515813_I20200630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzItNS0xLTEtMTE5NDgy_d867a1c5-2af1-4a23-9b93-2e36424ebd02">74.7</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if96afdd71e74449aa558f9c0f8968925_I20190630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzItNy0xLTEtMTE5NDgy_800dc614-21b1-4644-858f-a059ae450405"><ix:nonFraction unitRef="shares" contextRef="if96afdd71e74449aa558f9c0f8968925_I20190630" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzItNy0xLTEtMTE5NDgy_8c26711f-be0b-4141-8b39-87ed53791b75">73.5</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzMtMS0xLTEtMTE5NDgy_9f6490fe-f4c1-49f5-b2e2-bb8248d4b221">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzMtMy0xLTEtMTE5NDgy_f6aa58bf-33b6-4d08-8348-1a5221be1a4a">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzMtNS0xLTEtMTE5NDgy_7a48dde0-b64d-4252-a123-cac2a7243a18">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzMtNy0xLTEtMTE5NDgy_a696a1aa-cc1c-40a8-b0f4-07e3ec3fd145">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued and outstanding at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzUtMS0xLTEtMTE5NDgy_a811f2ff-3e8c-4bb9-bcb4-17ebf347340e"><ix:nonFraction unitRef="shares" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzUtMS0xLTEtMTE5NDgy_f2f9ee8c-e396-43aa-832f-d2da3ff53bd3">81.2</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzUtMy0xLTEtMTE5NDgy_a79afe66-5bd6-4259-8255-1e2bbdee5aee"><ix:nonFraction unitRef="shares" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzUtMy0xLTEtMTE5NDgy_ab97c595-3716-4e8b-9a51-e5c75b626595">80.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzUtNS0xLTEtMTE5NDgy_7f2a8769-aa27-4f30-b56b-aa1c376df6f5"><ix:nonFraction unitRef="shares" contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzUtNS0xLTEtMTE5NDgy_b2da25d5-27f2-49c7-a1ef-6fed4baa20ea">75.4</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ideeefc606008446e85d0fd21a9515813_I20200630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzUtNy0xLTEtMTE5NDgy_7d13b29f-ebab-46a1-ae7d-448e4d4f16e9"><ix:nonFraction unitRef="shares" contextRef="ideeefc606008446e85d0fd21a9515813_I20200630" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzUtNy0xLTEtMTE5NDgy_dbb70726-7cb3-44e2-80cd-0724fdf85e1e">74.7</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchase Program</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company&#8217;s Board of Directors authorized a share repurchase program of $<ix:nonFraction unitRef="usd" contextRef="i3f7f76edb655468cb01a3ed28231577b_I20160630" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzUyNw_21677560-0090-448a-bdc7-10f3b3e9adaa">200.0</ix:nonFraction> million of the Company&#8217;s outstanding common stock. The Company may repurchase its common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company&#8217;s management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.&#160;&#160;As of December&#160;31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzk4NQ_50e985db-2af3-4a41-bbc1-68712f22dfec">110.7</ix:nonFraction> million remaining on its current share repurchase authorization. <ix:nonFraction unitRef="shares" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzU0OTc1NTgxNDE0MzU_4e01c85a-82b8-4807-8c20-2449e194d0ce"><ix:nonFraction unitRef="shares" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzU0OTc1NTgxNDE0MzU_7d1e6b35-81bd-4af2-8749-4cc27c585afa">No</ix:nonFraction></ix:nonFraction> shares were repurchased during the years ended December&#160;31, 2022 and 2021 under this authorization.</span></div></ix:continuation><div id="i7e0793090cf84227944277d460d39a4d_118"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzYyODI_c0c737f7-77b2-48b1-b020-b48eea34f6a1" continuedAt="ic494268f6d6949b5b26815cff0699f75" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="ic494268f6d6949b5b26815cff0699f75" continuedAt="i5d717397ce33423fbd621db7acdc0155"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2017, the Company&#8217;s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the &#8220;2017 Plan&#8221;).&#160;&#160;The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee of the Board of Directors, to make grants of restricted and unrestricted stock and stock unit awards to employees, consultants and directors.&#160;Stockholders have approved amendments to the 2017 Plan increasing the shares available to grant. As of December&#160;31, 2022, the Company had <ix:nonFraction unitRef="shares" contextRef="i5d254d84e7e9429fb9eb353fa0fe6727_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzYwOQ_452befe7-9cd7-4ab1-909b-faef8cdb43d9">1.9</ix:nonFraction> million shares of common stock available for grant under the 2017 Plan. If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued or reacquired shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. To the extent that awards outstanding under the Company's prior equity plans expire or are cancelled without delivery of shares of common stock, the shares of common stock underlying these awards also will be available for issuance pursuant to the 2017 Plan. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares, terms, and vesting periods are generally determined by the Company&#8217;s Board of Directors or a committee thereof on an award-by-award basis. RSUs granted to employees generally vest either ratably over <ix:nonNumeric contextRef="i9757cc95b46f40a8a4d1310a7a341adf_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzEzNTU_1dfe03b6-76b5-4ae5-b12f-1157d6d0d26a">four years</ix:nonNumeric> or as a cliff vesting after <ix:nonNumeric contextRef="i801883d593c048cf8de2e2c90f49176b_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzY1OTcwNjk3NzY4ODY_999692c9-6653-474a-9c31-29b12008bee2">three years</ix:nonNumeric> either on the anniversary of the date on which the RSUs were granted or during the month in which such anniversary dates occur. The number of PSUs awarded to certain employees may be increased or may be reduced based on certain additional performance and market metrics. RSUs granted to non-employee directors vest in full upon the earlier of the completion of <ix:nonNumeric contextRef="i12ca3a8a2ca341308119fa4fbac76272_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzE3MTE_003f0a3f-1aca-4e4b-92f2-0d3627b3de5f">one year</ix:nonNumeric> of service following the date of the grant or the date of the next annual meeting of stockholders following such grant. Options granted to the Company's President and Chief Executive Officer as an inducement to his employment expire <ix:nonNumeric contextRef="i662ff17b6ca34e25bba3e0323f9e924c_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzIwNjY_c6c7b032-2bfe-4173-b89d-17999c8a5b2e">seven years</ix:nonNumeric> from the grant date. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="i5d717397ce33423fbd621db7acdc0155" continuedAt="i4b91fc87fb5c4f898c2b39d643437159"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance and market conditions associated with PSU awards granted during the year ended December&#160;31, 2022 include vesting that is based on revenue targets (<ix:nonFraction unitRef="number" contextRef="i17cec0855d2440f9801f4db7e5a729b9_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzU0OTc1NTgyMTcwMg_ea69948f-b9c4-4c39-8db6-cb289c62de76">34</ix:nonFraction>% weighting), adjusted earnings per share targets (<ix:nonFraction unitRef="number" contextRef="i01fda04e6cb14149830711083c57c751_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzU0OTc1NTgyMTcyMA_07d63a66-8139-49f2-96e8-c2656fcb2232">33</ix:nonFraction>% weighting), and relative total stockholder return (<ix:nonFraction unitRef="number" contextRef="i8a3e0bd95e204ba5951ebd463f3b3a4c_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzU0OTc1NTgyMTcxMQ_37a0f053-f5a5-4c6f-86f0-e3f41c462062">33</ix:nonFraction>% weighting) measured against the Nasdaq Health Care Index (IXHC) using the 20-trading day averages at the beginning and end of the measurement period. The measurement period for these awards is January 1, 2022 through December 31, 2024. The Company estimates the likelihood of achievement of performance conditions at the end of each period. The portion of the awards pertaining to relative total stockholder return represent market conditions and, accordingly, the estimated fair value of such awards are recognized over the performance period. The Company has also assessed that as of December&#160;31, 2022, the performance conditions for the remaining two performance targets (revenue and adjusted earnings per share) are considered probable of being achieved and, accordingly, these portions of the awards are also being expensed over the performance period. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the transition period ended December 31, 2020, the Company granted stock-based awards to the Company's President and Chief Executive Officer as an inducement material to his commencement of employment and entry into an employment agreement with the Company. The inducement awards are included in the tables presented below. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzYyODY_be660370-760a-4599-a48e-29a6b7314ebf" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the Company's equity plans, and inducement awards for the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual<br/>life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzEtMS0xLTEtMTE5NDgy_b1eac592-d987-4a83-9595-bdd37ca8f34b">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzEtMy0xLTEtMTE5NDgy_dc411cda-51c7-45cb-8324-7bea17f107b8">20.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzQtMS0xLTEtMTE5NDgy_29509e59-1bac-4245-bcde-c24557d902d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzQtMy0xLTEtMTE5NDgy_f93086c0-8171-4b8d-8d46-29cab4bcb1d3">26.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzUtMS0xLTEtMTE5NDgy_96875192-b468-495e-8eee-01a0b9989b38">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzUtMy0xLTEtMTE5NDgy_f0407905-339a-4484-a47c-e26b7a09e556">26.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzYtMS0xLTEtMTE5NDgy_7119daeb-f2ed-4e42-8f9a-2cb7f859f4b1">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzYtMy0xLTEtMTE5NDgy_674a242e-b0d8-43cd-966c-58fe0bfb7941">13.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzYtNS0xLTEtMTE5NDgy_a7b6fb9b-7e27-492c-8785-91e49c54cdc5">4.62</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzctMS0xLTEtMTE5NDgy_e69a23ac-9ab8-4da8-be97-216976f2e6bb">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzctMy0xLTEtMTE5NDgy_3e109ccc-5918-4d87-a87b-5b0b47de5b3a">13.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzctNS0xLTEtMTE5NDgy_0e369235-856c-4fbf-8d48-41d22d5e7666">4.62</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzgtMS0xLTEtMTE5NDgy_d001743f-c22c-4943-afe9-2ca7558a511b">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzgtMy0xLTEtMTE5NDgy_2d576a49-b6e1-410d-aa9c-50667a8452eb">13.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzgtNS0xLTEtMTE5NDgy_c13a8905-f9c9-4b3d-80c8-fd0cd57e736c">4.62</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzMyMTA_7346fdad-0184-4fdc-b0e9-81bd4860b793"><ix:nonFraction unitRef="shares" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzMyMTA_78e87407-5919-4c48-83f8-832b8c254582"><ix:nonFraction unitRef="shares" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzMyMTA_8cc65dcf-af48-4f8e-911b-eae3b5ad79d3">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> options granted during the years ended December 31, 2022 and 2021 and June&#160;30, 2020. During the transition period ended December&#160;31, 2020, <ix:nonFraction unitRef="shares" contextRef="i552292b1ed264bf49d505c379dad4c2b_D20200701-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzMzMTg_851d9579-9705-4278-b40c-e076cac2672a">0.7</ix:nonFraction>&#160;million options were granted to the Company's President and Chief Executive Officer, with a weighted average grant fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="iaafdb3a4d0da4dec918d7e953639a791_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzM0NDI_c1c0204a-06f9-4f51-976e-e685871d28bc"><ix:nonFraction unitRef="usdPerShare" contextRef="i552292b1ed264bf49d505c379dad4c2b_D20200701-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzM0NDI_f27fd73c-413f-4c98-ac6d-316d3a8c814a">13.38</ix:nonFraction></ix:nonFraction> and as of December 31, 2022, these were the only options outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzYyODA_fbc5261c-5117-4f88-9f2b-dab028f62d62" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU awards activity under the Company's equity plans and inducement awards, including PSU awards for the year ended December&#160;31, 2022, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(number of shares in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>grant date<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs unvested and outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie26285660df14abb951924a100df85e5_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTpjYTlhM2QwYzhhYjM0NzY3YmUzMWZkMDg3NmIzMjNiNC90YWJsZXJhbmdlOmNhOWEzZDBjOGFiMzQ3NjdiZTMxZmQwODc2YjMyM2I0XzItMS0xLTEtMTE5NDgy_32b72b63-2025-4536-81c4-63b00b670e68">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie26285660df14abb951924a100df85e5_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTpjYTlhM2QwYzhhYjM0NzY3YmUzMWZkMDg3NmIzMjNiNC90YWJsZXJhbmdlOmNhOWEzZDBjOGFiMzQ3NjdiZTMxZmQwODc2YjMyM2I0XzItMy0xLTEtMTE5NDgy_9e13ea08-d603-4c16-b781-c1f8345a25b7">24.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5d419cf4013469c83dd80d51c5ee579_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTpjYTlhM2QwYzhhYjM0NzY3YmUzMWZkMDg3NmIzMjNiNC90YWJsZXJhbmdlOmNhOWEzZDBjOGFiMzQ3NjdiZTMxZmQwODc2YjMyM2I0XzMtMS0xLTEtMTE5NDgy_a006d099-4bc9-495d-89f8-92605eab14b4">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id5d419cf4013469c83dd80d51c5ee579_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTpjYTlhM2QwYzhhYjM0NzY3YmUzMWZkMDg3NmIzMjNiNC90YWJsZXJhbmdlOmNhOWEzZDBjOGFiMzQ3NjdiZTMxZmQwODc2YjMyM2I0XzMtMy0xLTEtMTE5NDgy_9d19f7e0-4c67-49a0-a31a-15d7c05cc160">25.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id5d419cf4013469c83dd80d51c5ee579_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTpjYTlhM2QwYzhhYjM0NzY3YmUzMWZkMDg3NmIzMjNiNC90YWJsZXJhbmdlOmNhOWEzZDBjOGFiMzQ3NjdiZTMxZmQwODc2YjMyM2I0XzUtMS0xLTEtMTE5NDgy_78a8c62a-9002-4fc6-99a4-d4ca91674ca8">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id5d419cf4013469c83dd80d51c5ee579_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTpjYTlhM2QwYzhhYjM0NzY3YmUzMWZkMDg3NmIzMjNiNC90YWJsZXJhbmdlOmNhOWEzZDBjOGFiMzQ3NjdiZTMxZmQwODc2YjMyM2I0XzUtMy0xLTEtMTE5NDgy_35bf4e3b-516d-4c63-a3c5-b64db2543527">25.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id5d419cf4013469c83dd80d51c5ee579_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTpjYTlhM2QwYzhhYjM0NzY3YmUzMWZkMDg3NmIzMjNiNC90YWJsZXJhbmdlOmNhOWEzZDBjOGFiMzQ3NjdiZTMxZmQwODc2YjMyM2I0XzYtMS0xLTEtMTE5NDgy_ce704cea-4a0b-4985-87c0-6dea5e015cbb">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id5d419cf4013469c83dd80d51c5ee579_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTpjYTlhM2QwYzhhYjM0NzY3YmUzMWZkMDg3NmIzMjNiNC90YWJsZXJhbmdlOmNhOWEzZDBjOGFiMzQ3NjdiZTMxZmQwODc2YjMyM2I0XzYtMy0xLTEtMTE5NDgy_fda59d35-f0cd-490f-becf-6bb1358cb103">26.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs unvested and outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26ec50a211f240d3938bde3431435c8b_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTpjYTlhM2QwYzhhYjM0NzY3YmUzMWZkMDg3NmIzMjNiNC90YWJsZXJhbmdlOmNhOWEzZDBjOGFiMzQ3NjdiZTMxZmQwODc2YjMyM2I0XzctMS0xLTEtMTE5NDgy_09188190-01df-4ca1-b22b-07a9dbe5f00a">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i26ec50a211f240d3938bde3431435c8b_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTpjYTlhM2QwYzhhYjM0NzY3YmUzMWZkMDg3NmIzMjNiNC90YWJsZXJhbmdlOmNhOWEzZDBjOGFiMzQ3NjdiZTMxZmQwODc2YjMyM2I0XzctMy0xLTEtMTE5NDgy_d217099f-d431-4b54-9685-b391f65e7319">25.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value of RSUs granted during the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020, and the fiscal year ended June&#160;30, 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="id5d419cf4013469c83dd80d51c5ee579_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzM5NTU_9d19f7e0-4c67-49a0-a31a-15d7c05cc160">25.78</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i3dae6418ac5148938050aacb2ef5d508_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzM5NTk_9ff50eba-5eaf-4786-a3e5-f012ba3960cb">29.83</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i968d2e2144e34ee4916a9183d20c0063_D20200701-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzM5NjM_18032661-3c6f-4503-9838-baf7ce91c807">13.69</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i00d66009a0f2488699d68deb116f85b0_D20190701-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzM5NzA_01c353e4-2759-4cd1-9824-b4a2d9b2c8d4">27.96</ix:nonFraction>, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs that vested during the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020, and the fiscal year ended June&#160;30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="id5d419cf4013469c83dd80d51c5ee579_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzQxMzQ_cf4dc6d3-1a4c-4bdb-832f-73caf4f4d44f">31.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3dae6418ac5148938050aacb2ef5d508_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzQxMzg_0ea32ffa-5941-4435-928b-209404ede194">22.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i968d2e2144e34ee4916a9183d20c0063_D20200701-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzQxNDI_5f6a79b8-89ce-4705-b355-6584406737c8">29.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i00d66009a0f2488699d68deb116f85b0_D20190701-20200630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzQxNDk_f9ee4d93-8d97-460d-b9e3-46f30e3f330d">32.4</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="i4b91fc87fb5c4f898c2b39d643437159" continuedAt="i93d71a11189b474abe0ab3a46ff0f98f"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzYyODc_975da954-a2f8-4dcc-95a1-d21c911dfff7" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized and included in the Consolidated Statements of Operations was allocated as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of testing revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6b55a5a308740858d157bc072e2ecaf_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzItMS0xLTEtMTE5NDgy_6df75644-431e-47e7-89b4-2378e9680abf">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6834607b2374e2b81387c6f893f406a_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzItMy0xLTEtMTI1ODkx_26ccee6f-65dc-4d4a-8051-fa45d5cc0657">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2868dacc9996425d84f6678061f8071d_D20200701-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzItMy0xLTEtMTE5NDgy_3e095612-097b-4a5e-b780-81adcc2fad84">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e2d7d18c84e44c5a8a95712783d775b_D20190701-20200630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzItNS0xLTEtMTE5NDgy_df4b664d-156c-49ee-b5a7-ad4fcf8c44b8">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34523c4b068408ca1452aea7567d7b8_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzMtMS0xLTEtMTE5NDgy_4da7501b-159f-4a8d-b7f5-82c1906d8f30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f6f6d3b79734ce2bdb563e220afb94c_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzMtMy0xLTEtMTI1ODkx_881f6f03-ee84-4801-9eec-5f904069c57a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66dd3e15c00846fc81665b366c136737_D20200701-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzMtMy0xLTEtMTE5NDgy_1738d55b-5093-43aa-b046-d616631d690e">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id15d2c557b414206ada2d552b9b565a4_D20190701-20200630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzMtNS0xLTEtMTE5NDgy_5ff8d111-7537-4cfd-85c7-8660845e63bc">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04b5d1b8fa24d0fad862d180d2bd154_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzQtMS0xLTEtMTE5NDgy_e58c27dd-d11c-4f04-b94f-346dd9117fd5">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a0fc790ba34918898f41f810a4a2f1_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzQtMy0xLTEtMTI1ODkx_ff4d583a-7388-452e-bf70-da942406f19b">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa289b04ec1840778fdb19aca12b8a05_D20200701-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzQtMy0xLTEtMTE5NDgy_b28f5540-d7a2-4948-8663-dc062f2dcb78">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff363386463e4c7b99ce076eeb84919c_D20190701-20200630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzQtNS0xLTEtMTE5NDgy_47a53478-7cb6-4f51-9cb9-44e7e4cb6d04">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i249245e4ff6941f7be7f6d734b685a95_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzUtMS0xLTEtMTE5NDgy_fc56b9ae-26ec-4669-b359-24888e3b2162">31.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86e699f1c66445bca22715a30a1f46ed_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzUtMy0xLTEtMTI1ODkx_6c9d028f-a300-4d8e-8625-e6142756ac8f">30.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58532a67b1154bc58a0b382ff6c515d4_D20200701-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzUtMy0xLTEtMTE5NDgy_f30e36b3-429a-4920-9736-84b46e1b5135">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d1d3c76ec0427db381fbba56a23a6d_D20190701-20200630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzUtNS0xLTEtMTE5NDgy_16b78b87-8c6b-4d9d-b5c7-229dfd039550">18.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzYtMS0xLTEtMTE5NDgy_51d0eb12-0596-4e82-8db9-0e44b13c85d4">38.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzYtMy0xLTEtMTI1ODkx_d109a3ca-d4cd-405c-9b87-904e413f5c16">36.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzYtMy0xLTEtMTE5NDgy_a887cd56-10a1-4577-a420-c3ca42838063">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzYtNS0xLTEtMTE5NDgy_1291d413-8490-402e-8b3e-4d244c1a6dab">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzQzMTc_f60c8a90-2cb5-452c-8393-e528b6eaefd9">64.3</ix:nonFraction> million of total unrecognized stock-based compensation expense that will be recognized over a weighted-average period of <ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzQ0MzM_e07cd6fb-c4f0-43e4-96ce-246d067d2de4">2.0</ix:nonNumeric> years. The Company recognizes forfeitures as they occur.</span></div><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="mygn:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzYyODg_b0f7456d-8537-4300-83a4-3371e8aecbb7" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of options outstanding</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MDU5YzUxY2UyMjE0ZmE3ODhhZTdkYjkwMWFhNzc3MS90YWJsZXJhbmdlOjUwNTljNTFjZTIyMTRmYTc4OGFlN2RiOTAxYWE3NzcxXzEtMS0xLTEtMTE5NDgy_1abd2c78-f988-470b-8ba1-2cc149a8d903">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of options fully vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MDU5YzUxY2UyMjE0ZmE3ODhhZTdkYjkwMWFhNzc3MS90YWJsZXJhbmdlOjUwNTljNTFjZTIyMTRmYTc4OGFlN2RiOTAxYWE3NzcxXzItMS0xLTEtMTE5NDgy_646b9d6a-3413-44b9-a4ba-f03839d262a8">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of RSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26ec50a211f240d3938bde3431435c8b_I20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MDU5YzUxY2UyMjE0ZmE3ODhhZTdkYjkwMWFhNzc3MS90YWJsZXJhbmdlOjUwNTljNTFjZTIyMTRmYTc4OGFlN2RiOTAxYWE3NzcxXzMtMS0xLTEtMTE5NDgy_3a47a385-1abf-49dd-bca4-5489b7e576c3">54.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzYyODQ_bf73b0b2-60cd-464b-bcd1-33e1cf0e27f0" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic value of options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5MGM5NjU1MmZjNjA0MmZjYThlNzI2NjU3Mjc1NDQ1NC90YWJsZXJhbmdlOjkwYzk2NTUyZmM2MDQyZmNhOGU3MjY2NTcyNzU0NDU0XzItMS0xLTEtMTE5NDgy_551e6d52-5342-415a-8f3e-b05c9a3d8f6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5MGM5NjU1MmZjNjA0MmZjYThlNzI2NjU3Mjc1NDQ1NC90YWJsZXJhbmdlOjkwYzk2NTUyZmM2MDQyZmNhOGU3MjY2NTcyNzU0NDU0XzItMy0xLTEtMTE5NDgy_8bf6a082-3705-4dd0-b7a2-d0323c39d8de">29.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5MGM5NjU1MmZjNjA0MmZjYThlNzI2NjU3Mjc1NDQ1NC90YWJsZXJhbmdlOjkwYzk2NTUyZmM2MDQyZmNhOGU3MjY2NTcyNzU0NDU0XzItNS0xLTEtMTE5NDgy_a2881182-b3ff-49c7-bcfb-9077f8802c10">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5MGM5NjU1MmZjNjA0MmZjYThlNzI2NjU3Mjc1NDQ1NC90YWJsZXJhbmdlOjkwYzk2NTUyZmM2MDQyZmNhOGU3MjY2NTcyNzU0NDU0XzItNy0xLTEtMTE5NDgy_3e64fa4b-287f-48fa-9302-32417faacb95">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an Employee Stock Purchase Plan that was initially approved by stockholders in 2012 and was amended and approved by the Board of Directors of the Company on September 23, 2021 and the stockholders on June 2, 2022 (the &#8220;Amended and Restated 2012 Purchase Plan&#8221;), under which <ix:nonFraction unitRef="shares" contextRef="iab27d0ec33e742d2977386c29c6a64ab_D20210923-20210923" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzUxNTM_7df693bf-5996-4222-ba91-cc1db50a0bcb">4.0</ix:nonFraction>&#160;million shares of common stock were authorized. Shares are issued under the Amended and Restated 2012 Purchase Plan twice yearly at the end of each offering period and the number of shares that may be purchased by any participant during an offering period is limited to <ix:nonFraction unitRef="shares" contextRef="iab27d0ec33e742d2977386c29c6a64ab_D20210923-20210923" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzU3Mzc_4e1fa98a-a834-46b4-aed4-73a5ec2144b3">5,000</ix:nonFraction> shares. As of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i15344703477a40f5b457a744eeee71b2_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzU4NzY_56befbef-38c7-4f9e-8cd6-e78e8a775643">1.7</ix:nonFraction> million shares of common stock were available for issuance under the Amended and Restated Purchase Plan. <ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzYyODU_72366ec9-d720-4692-8925-801ec73b0557" continuedAt="i4918b8e20f3049c4bbabcf16f7b086c1" escape="true">Shares purchased under, and compensation expense associated with, the Amended and Restated 2012 Purchase Plan for the periods reported are as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><ix:continuation id="i4918b8e20f3049c4bbabcf16f7b086c1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under the plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15344703477a40f5b457a744eeee71b2_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTphYjhiYTc2YjE3YTA0MGI0YWNmMzJmMzE0M2IxNWY1Zi90YWJsZXJhbmdlOmFiOGJhNzZiMTdhMDQwYjRhY2YzMmYzMTQzYjE1ZjVmXzItMS0xLTEtMTE5NDgy_5e977b1f-0ae7-4bed-aa34-53b541ee7af4">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3580a51b82cc466099d9eb0a57c378cd_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTphYjhiYTc2YjE3YTA0MGI0YWNmMzJmMzE0M2IxNWY1Zi90YWJsZXJhbmdlOmFiOGJhNzZiMTdhMDQwYjRhY2YzMmYzMTQzYjE1ZjVmXzItMy0xLTEtMTE5NDgy_1aa00bbb-814c-47a8-ac54-e807361b63d8">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f908585f461487aa148598b903a4f33_D20200701-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTphYjhiYTc2YjE3YTA0MGI0YWNmMzJmMzE0M2IxNWY1Zi90YWJsZXJhbmdlOmFiOGJhNzZiMTdhMDQwYjRhY2YzMmYzMTQzYjE1ZjVmXzItNS0xLTEtMTE5NDgy_c2832ad3-0a03-422f-ac30-318cdc3663ed">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id374269cc21d403aa573e11a92743d26_D20190701-20200630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTphYjhiYTc2YjE3YTA0MGI0YWNmMzJmMzE0M2IxNWY1Zi90YWJsZXJhbmdlOmFiOGJhNzZiMTdhMDQwYjRhY2YzMmYzMTQzYjE1ZjVmXzItNy0xLTEtMTE5NDgy_7fd62c6d-0e67-4698-8b29-33a77d280195">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan compensation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15344703477a40f5b457a744eeee71b2_D20220101-20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTphYjhiYTc2YjE3YTA0MGI0YWNmMzJmMzE0M2IxNWY1Zi90YWJsZXJhbmdlOmFiOGJhNzZiMTdhMDQwYjRhY2YzMmYzMTQzYjE1ZjVmXzMtMS0xLTEtMTE5NDgy_5d9d4bf3-1401-46c3-a6ea-de0848b181b9">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3580a51b82cc466099d9eb0a57c378cd_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTphYjhiYTc2YjE3YTA0MGI0YWNmMzJmMzE0M2IxNWY1Zi90YWJsZXJhbmdlOmFiOGJhNzZiMTdhMDQwYjRhY2YzMmYzMTQzYjE1ZjVmXzMtMy0xLTEtMTE5NDgy_56ea7fce-bf28-4411-89a5-5dc4e667aaca">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f908585f461487aa148598b903a4f33_D20200701-20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTphYjhiYTc2YjE3YTA0MGI0YWNmMzJmMzE0M2IxNWY1Zi90YWJsZXJhbmdlOmFiOGJhNzZiMTdhMDQwYjRhY2YzMmYzMTQzYjE1ZjVmXzMtNS0xLTEtMTE5NDgy_853a1ec3-f028-472f-ba5e-f799a1d26793">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id374269cc21d403aa573e11a92743d26_D20190701-20200630" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTphYjhiYTc2YjE3YTA0MGI0YWNmMzJmMzE0M2IxNWY1Zi90YWJsZXJhbmdlOmFiOGJhNzZiMTdhMDQwYjRhY2YzMmYzMTQzYjE1ZjVmXzMtNy0xLTEtMTE5NDgy_badc267d-0bdd-435c-acfc-4f872fc8d05d">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="i93d71a11189b474abe0ab3a46ff0f98f"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzYyODE_16355df4-9d13-41f5-80dc-8114b262ee79" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of shares issued under the Amended and Restated 2012 Purchase Plan that was in effect for each period reported was calculated using the Black&#8209;Scholes option-pricing model using the weighted-average assumptions below. Each of these inputs is subjective and its determination generally requires significant judgment.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15344703477a40f5b457a744eeee71b2_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzItMS0xLTEtMTE5NDgy_3bc0ef30-e814-4e70-929d-db14086d4cdd">1.4</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3580a51b82cc466099d9eb0a57c378cd_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzItMy0xLTEtMTE5NDgy_7046b411-f330-4be7-b687-54397153c636">0.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f908585f461487aa148598b903a4f33_D20200701-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzItNS0xLTEtMTE5NDgy_47140b4a-5d4d-46b7-99aa-13b70feb477a">0.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id374269cc21d403aa573e11a92743d26_D20190701-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzItNy0xLTEtMTE5NDgy_ba9f8442-cdee-453c-b9e1-33db497dd628">1.8</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15344703477a40f5b457a744eeee71b2_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzMtMS0xLTEtMTE5NDgy_cfa02a30-c743-4845-836f-2eddd27033ae">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3580a51b82cc466099d9eb0a57c378cd_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzMtMy0xLTEtMTE5NDgy_ae973ac7-553b-4242-b22e-760f30b4ba54">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f908585f461487aa148598b903a4f33_D20200701-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzMtNS0xLTEtMTE5NDgy_48bd4bca-7009-4cb6-8af4-9185648c0b09">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id374269cc21d403aa573e11a92743d26_D20190701-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzMtNy0xLTEtMTE5NDgy_bc9da06d-505f-4e64-bb83-0d8c2eb05002">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i15344703477a40f5b457a744eeee71b2_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzQtMS0xLTEtMTE5NDgy_b36361f4-4117-4e04-8ff5-66d1c0383982">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3580a51b82cc466099d9eb0a57c378cd_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzQtMy0xLTEtMTE5NDgy_09e41ad8-5caa-4ea9-972b-408b64ed635f">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0f908585f461487aa148598b903a4f33_D20200701-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzQtNS0xLTEtMTE5NDgy_bc3eadb9-59c4-491e-a6be-a62b8ad982de">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id374269cc21d403aa573e11a92743d26_D20190701-20200630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzQtNy0xLTEtMTE5NDgy_d802015d-5dfe-4b77-9837-773648b414b9">0.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15344703477a40f5b457a744eeee71b2_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzUtMS0xLTEtMTE5NDgy_489d570d-b4cd-4715-a983-2900fd5010b2">53</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3580a51b82cc466099d9eb0a57c378cd_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzUtMy0xLTEtMTE5NDgy_37b19809-d6e8-4873-97e5-b0de29cf29f2">60</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f908585f461487aa148598b903a4f33_D20200701-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzUtNS0xLTEtMTE5NDgy_30688d11-7e76-4f81-bd90-733a2d74bdf0">94</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id374269cc21d403aa573e11a92743d26_D20190701-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzUtNy0xLTEtMTE5NDgy_6a20ac8e-37eb-4912-8a01-ca669b216a8b">99</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i7e0793090cf84227944277d460d39a4d_121"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90ZXh0cmVnaW9uOmQ2YWEyZWE4YThhYzRlNzNhMzIzMGEwNDQ2ZjMyNDA4XzU0NDU_891f56d1-f0e4-4ae8-a50e-7084e134a393" continuedAt="ic54150df7f6c4edd999db8e701cd25b4" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="ic54150df7f6c4edd999db8e701cd25b4" continuedAt="if131f3bf06f84dcfb7b50643d8b2a69b"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90ZXh0cmVnaW9uOmQ2YWEyZWE4YThhYzRlNzNhMzIzMGEwNDQ2ZjMyNDA4XzU0NDY_cabd2040-e198-4422-8694-7d0fc9f0aaab" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit consists of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzMtMS0xLTEtMTE5NDgy_f79e7f62-3eda-44cd-93b7-303fc9dfe531">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzMtMy0xLTEtMTE5NDgy_79a7a370-a4e4-4491-b4ce-27e55d9c0694">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzMtNS0xLTEtMTE5NDgy_a2deae49-20b3-4aeb-a5f5-c3892ab3144a">75.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzMtNy0xLTEtMTE5NDgy_1bfd5123-a080-40a5-bd0d-a6b8b9fad774">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzQtMS0xLTEtMTE5NDgy_9273a71c-f1a5-4028-8b3c-ad5d3bbcd3e4">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzQtMy0xLTEtMTE5NDgy_926a7782-d0c0-4f74-aa0e-196786363d5a">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzQtNS0xLTEtMTE5NDgy_cf6ef515-3bea-4d8f-988f-2271881a6337">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzQtNy0xLTEtMTE5NDgy_541e11d5-6e8b-4b30-8cf7-f96601fe32ca">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzUtMS0xLTEtMTE5NDgy_a5479cd6-394c-476a-b520-b60b59d78012">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzUtMy0xLTEtMTE5NDgy_b95badab-ae52-4687-be72-feb430a66463">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzUtNS0xLTEtMTE5NDgy_fb7cfce2-e1c9-42a4-8b13-d8402307612c">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzUtNy0xLTEtMTE5NDgy_c2ebece7-a672-4a18-9c8b-c0e41ae0f945">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzYtMS0xLTEtMTE5NDgy_442da0a0-c922-4ab9-9862-6c60578a015a">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzYtMy0xLTEtMTE5NDgy_41797bb2-8276-482b-9e23-f8bac9249b9b">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzYtNS0xLTEtMTE5NDgy_a10ad688-e0ae-49ce-bf92-ba4789d274c1">76.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzYtNy0xLTEtMTE5NDgy_c431f681-aa18-43b8-b508-714f56fc587e">32.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzgtMS0xLTEtMTE5NDgy_85fe8b1b-7f05-44da-b919-5807f2c67a4c">25.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzgtMy0xLTEtMTE5NDgy_539a03f2-047a-4106-957d-a4d67da8ebc2">33.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzgtNS0xLTEtMTE5NDgy_131986ee-fa59-47e7-9882-93fdc61abd57">39.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzgtNy0xLTEtMTE5NDgy_c559dcde-1797-4d01-aaaa-744ddb48c859">51.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzktMS0xLTEtMTE5NDgy_e6ef0fca-b930-4c12-b53b-9bc1047cbbcd">4.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzktMy0xLTEtMTE5NDgy_1edcbbf8-69bf-4c80-a263-3b5642d4b4be">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzktNS0xLTEtMTE5NDgy_bc20ec9b-cad4-4fd7-8a5e-5a20d23650e5">3.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzktNy0xLTEtMTE5NDgy_c1da0116-4c64-4b55-bfa1-97a8e6148467">4.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEwLTEtMS0xLTExOTQ4Mg_b26c89e7-d595-424b-a7f5-040946b94afe">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEwLTMtMS0xLTExOTQ4Mg_fc99a652-88ee-4461-bd1b-5fad068b2958">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEwLTUtMS0xLTExOTQ4Mg_0a0a6223-1e8b-4042-a5c8-64448e3e2b8e">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEwLTctMS0xLTExOTQ4Mg_9ac4dc96-487c-4897-bd9d-5166b00f11a3">3.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzExLTEtMS0xLTExOTQ4Mg_93cadb49-3dd4-461c-b24a-60b3da3f253b">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzExLTMtMS0xLTExOTQ4Mg_71ebe5b4-6fb0-49a3-8fcb-7b40f42a8820">3.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzExLTUtMS0xLTExOTQ4Mg_ea3ea483-a162-4df8-9c59-71927ea70b93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzExLTctMS0xLTExOTQ4Mg_f833580e-ce26-479a-8fd3-3d546c15941c">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEyLTEtMS0xLTExOTQ4Mg_74323e1d-50ba-4cf8-ab71-86796b69dd9e">30.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEyLTMtMS0xLTExOTQ4Mg_02fc30e3-0911-43bc-9f2f-dfa1baea437a">31.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEyLTUtMS0xLTExOTQ4Mg_1cbf5e87-b9a5-495c-9be4-1b8b87f52618">35.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEyLTctMS0xLTExOTQ4Mg_f8e6911a-f228-42c1-a3a8-2537723f05fb">55.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEzLTEtMS0xLTExOTQ4Mg_8ba5356a-4f23-496f-87df-8c4d8a9392fb">28.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEzLTMtMS0xLTExOTQ4Mg_8555e2be-be80-44f4-92e7-6e4fd94479a9">29.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEzLTUtMS0xLTExOTQ4Mg_80999957-61a5-400a-9468-e2f4e2a608d0">41.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEzLTctMS0xLTExOTQ4Mg_ffd88beb-b924-46fe-9a74-c3557e528413">23.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90ZXh0cmVnaW9uOmQ2YWEyZWE4YThhYzRlNzNhMzIzMGEwNDQ2ZjMyNDA4XzU0NDc_8cefeb64-076b-421e-b424-e43a4c720738" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income taxes consists of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzItMS0xLTEtMTE5NDgy_4f6f0696-d86f-4ae8-abfe-b45ccf503ab0">141.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzItMy0xLTEtMTE5NDgy_baf57618-fdf0-4adf-ab10-dba914c2f68b">53.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzItNS0xLTEtMTE5NDgy_3e9a287d-1b3a-4d9c-9faf-63df163240f2">101.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzItNy0xLTEtMTE5NDgy_d7b7d8ea-9cd1-4a98-a8be-5809ccc69d63">240.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzMtMS0xLTEtMTE5NDgy_5b9360f9-ecfd-4ba6-b2f9-20b93c993851">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzMtMy0xLTEtMTE5NDgy_e590f33a-a0e6-44a7-8984-a6e7afc61a50">3.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzMtNS0xLTEtMTE5NDgy_32abbabb-1da9-49f3-aee5-e2f780d76d06">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzMtNy0xLTEtMTE5NDgy_ee30bc1c-e52e-40f7-82d4-92e43bc863f9">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzQtMS0xLTEtMTE5NDgy_6adbac88-bc2b-4d54-95f0-a3cb05049db1">140.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzQtMy0xLTEtMTE5NDgy_7a163311-e2e7-4226-a27a-db381a7276e1">57.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzQtNS0xLTEtMTE5NDgy_5e3b1ee2-3cee-4c37-9778-f7e74a966061">94.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzQtNy0xLTEtMTE5NDgy_77bff06a-6a10-45eb-b0fe-747328221b65">223.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="if131f3bf06f84dcfb7b50643d8b2a69b" continuedAt="i8bb2880ebd504549b0262c7457973bb4"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90ZXh0cmVnaW9uOmQ2YWEyZWE4YThhYzRlNzNhMzIzMGEwNDQ2ZjMyNDA4XzU0NDk_c397577e-dd54-43af-b68b-b0caeaf20ecd" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between income taxes at the statutory federal income tax rate and income taxes reported in the Consolidated Statements of Operations were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.404%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.880%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax expense at the statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzItMS0xLTEtMTE5NDgy_215215b1-f95a-481b-9ded-fade1f09b07a">29.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzItMy0xLTEtMTE5NDgy_19d06bf4-f597-4bb2-9a8d-a05ccd87d03f">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzItNS0xLTEtMTE5NDgy_71e5db84-eb8e-4f64-80f5-89c8f520e233">12.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzItNy0xLTEtMTE5NDgy_a83ba05a-41c4-492d-bf7d-602db2577b29">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzItOS0xLTEtMTE5NDgy_64687b0b-bfde-4f3b-9ffd-ee1a5fe52008">19.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzItMTEtMS0xLTExOTQ4Mg_ca90184b-fab6-4351-a8a7-652cd4f4ac23">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzItMTMtMS0xLTExOTQ4Mg_cc34c2ce-4742-4c84-8662-d9b8ce024194">46.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzItMTUtMS0xLTExOTQ4Mg_2c23675e-98d4-426d-b7f4-01017aa94239">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzMtMS0xLTEtMTE5NDgy_d564473f-45eb-4310-bb72-09abffccdc0a">3.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzMtMy0xLTEtMTE5NDgy_de9f4aa0-38e6-4089-a101-daf8424db832">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzMtNS0xLTEtMTE5NDgy_17936bef-c8b3-494f-803d-e6dcf0d2a524">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzMtNy0xLTEtMTE5NDgy_2dc883f9-38c9-46c8-880e-0c2f9c2a88f5">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzMtOS0xLTEtMTE5NDgy_cd8fb898-1658-4ae6-bb99-cba394f77456">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzMtMTEtMS0xLTExOTQ4Mg_dd865833-ea3d-42ec-a36e-2867ea8bdb4d">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzMtMTMtMS0xLTExOTQ4Mg_823be6c6-136f-4b7d-9d01-3d5e4073dc61">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzMtMTUtMS0xLTExOTQ4Mg_e4e93169-75f7-4c7c-81a3-0bd5acbba320">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzQtMS0xLTEtMTE5NDgy_0af79d7d-5ee5-4ad2-9094-b775c27e9dc0">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzQtMy0xLTEtMTE5NDgy_1e9e9687-6128-4d88-b4fa-5c78a460dd30">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzQtNS0xLTEtMTE5NDgy_d1e60565-c0b1-40d6-b0e2-d2404d0d40a1">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzQtNy0xLTEtMTE5NDgy_da8a789b-4a98-457f-9bb1-91a4c4193e9a">4.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzQtOS0xLTEtMTE5NDgy_65fa9998-9548-4f62-a0c1-d02f1086aaf8">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzQtMTEtMS0xLTExOTQ4Mg_2d47a399-6f27-4e47-97ec-58b6b4d68bcd">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzQtMTMtMS0xLTExOTQ4Mg_f2cace01-b294-4d99-bca6-fc60d799cb85">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzQtMTUtMS0xLTExOTQ4Mg_91ed3e18-d0f3-4a19-9be2-f12e5bffe5fd">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzUtMS0xLTEtMTE5NDgy_41d11f14-8392-4593-a6ce-eee6464f3ad3">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzUtMy0xLTEtMTE5NDgy_97726a53-34ba-4a96-9cef-e0fc368b8826">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzUtNS0xLTEtMTE5NDgy_e5933cf6-48c1-4fef-b71d-fdae1c3685a0">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzUtNy0xLTEtMTE5NDgy_3cb4b6ce-ee5d-424b-96fd-1689eb0a6314">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzUtOS0xLTEtMTE5NDgy_d87a1810-ceef-4fbb-9fce-5a88a3a0eed3">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzUtMTEtMS0xLTExOTQ4Mg_5369899e-0917-421c-9046-581ac3af2dce">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzUtMTMtMS0xLTExOTQ4Mg_4036c3f2-7c37-48de-8b84-ee7196c1075a">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzUtMTUtMS0xLTExOTQ4Mg_e87d0163-c2f7-459c-b82e-0e9988cd5a43">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incentive stock option and employee stock purchase plan expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzYtMS0xLTEtMTE5NDgy_018851de-58e9-4456-8b90-2a5056172c5e">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzYtMy0xLTEtMTE5NDgy_434690cf-58ea-4794-8439-15761418457e">1.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzYtNS0xLTEtMTE5NDgy_4b63ba6f-c97d-4566-b3d0-0bb141249275">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzYtNy0xLTEtMTE5NDgy_4668848a-8ae8-43c2-8415-1ee06480e662">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzYtOS0xLTEtMTE5NDgy_96c3bc3d-e81a-4942-98ba-6943eb86d64a">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzYtMTEtMS0xLTExOTQ4Mg_36abf3fd-9061-4200-8b7a-200435bdb14f">2.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzYtMTMtMS0xLTExOTQ4Mg_3bf80863-122d-4881-9f88-23b80a5e0de0">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzYtMTUtMS0xLTExOTQ4Mg_c406a2ec-50ec-474d-a4bb-f846712254ae">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzctMS0xLTEtMTE5NDgy_cd919999-8a86-4ef5-943e-97231591971b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzctMy0xLTEtMTE5NDgy_70465747-e989-49c9-91e1-f9673b1262a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzctNS0xLTEtMTE5NDgy_43960434-2c05-4024-b63f-886b001223f5">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzctNy0xLTEtMTE5NDgy_2b63ca22-6b85-42ef-8ac9-b86b5a9f38d6">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzctOS0xLTEtMTE5NDgy_10e1763b-13da-44a0-9422-8909d5865031">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzctMTEtMS0xLTExOTQ4Mg_b3ee335f-86f3-4286-bc0c-14e0983e3c7b">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzctMTMtMS0xLTExOTQ4Mg_9b84a52b-7759-4a24-9cbd-f7cfdabb9520">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzctMTUtMS0xLTExOTQ4Mg_8c28b352-3cf8-4b3d-b7f6-4670a5793759">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzgtMS0xLTEtMTE5NDgy_8e8d1a2c-c2a0-4cb4-b1ad-03eb09537ca1">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzgtMy0xLTEtMTE5NDgy_32a059b9-30d8-4f8f-a843-549827636bd3">1.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzgtNS0xLTEtMTE5NDgy_25cf384d-063d-4520-a17a-28354cc3b7d8">3.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzgtNy0xLTEtMTE5NDgy_5d224606-9275-42cf-b739-552c992bf0e5">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzgtOS0xLTEtMTE5NDgy_40236b98-9269-47e2-aaef-0cdc0572e1ad">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzgtMTEtMS0xLTExOTQ4Mg_a9f3abfe-9b12-4dcd-960f-e8d7292e45ed">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzgtMTMtMS0xLTExOTQ4Mg_c21aa163-d06f-4359-8f1f-1d8d9f83adf4">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzgtMTUtMS0xLTExOTQ4Mg_c7097e2b-4450-410b-b09a-f8d88fe0a041">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARES Act</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="mygn:IncomeTaxReconciliationCARESAct" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzktMS0xLTEtMTE5NDgy_4df2c7f6-8890-449d-8f07-498709531e7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationCARESAct" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzktMy0xLTEtMTE5NDgy_484658ed-5b7f-4b06-81a8-9ce3c4d08309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="mygn:IncomeTaxReconciliationCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzktNS0xLTEtMTE5NDgy_a531f153-c939-464b-a118-6dc19e103e15">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="3" sign="-" name="mygn:EffectiveIncomeTaxRateReconciliationCARESAct" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzktNy0xLTEtMTE5NDgy_10627ca0-2196-4346-9c9c-871ddcd89942">4.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="mygn:IncomeTaxReconciliationCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzktOS0xLTEtMTE5NDgy_8831c927-8163-4df1-8cc2-8ba94a60bdcd">20.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationCARESAct" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzktMTEtMS0xLTExOTQ4Mg_10f28eb7-496e-4366-9181-d6e9704f7556">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="mygn:IncomeTaxReconciliationCARESAct" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzktMTMtMS0xLTEyMjM0OA_b9ec247d-90ef-4d7a-a354-58ad3d29a6c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationCARESAct" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzktMTUtMS0xLTEyMjM0OA_821157df-2519-4550-927a-07d494f3a023">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible meals and entertainment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEwLTEtMS0xLTExOTQ4Mg_c23cf641-27b8-441f-9c50-0ec58b2c0dd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEwLTMtMS0xLTExOTQ4Mg_4c1b3518-4742-48f3-9b7f-725f9c68077c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEwLTUtMS0xLTExOTQ4Mg_5983dd33-5599-41b8-b751-196d74ebc2aa">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEwLTctMS0xLTExOTQ4Mg_984f946b-f9d2-4fd2-91ec-6021f159bcbb">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEwLTktMS0xLTExOTQ4Mg_5e171e90-fbe2-491d-bb4a-7a7b3567065f">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEwLTExLTEtMS0xMTk0ODI_970c3da5-d2b2-4e4a-85d0-856ab060531b">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEwLTEzLTEtMS0xMTk0ODI_dfe0db37-284c-4d07-a886-209dc99ccc95">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEwLTE1LTEtMS0xMTk0ODI_9a1ff73f-37ce-4f97-be67-2d1bcaa6310c">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible officer compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzExLTEtMS0xLTExOTQ4Mg_983ddf14-e55e-463c-92ea-068d9be4ad0f">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="3" sign="-" name="mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzExLTMtMS0xLTExOTQ4Mg_9f0e8616-2143-4529-99a1-1721a9617356">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzExLTUtMS0xLTExOTQ4Mg_d6b685fb-f736-4da1-8027-a75f5e010a46">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="3" sign="-" name="mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzExLTctMS0xLTExOTQ4Mg_74e2ff00-31f7-45b5-aeb8-962808adbfc4">5.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzExLTktMS0xLTExOTQ4Mg_130761fc-2858-42f8-b5d1-2748d81b979d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="3" sign="-" name="mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzExLTExLTEtMS0xMTk0ODI_a76b0365-9beb-4aeb-84dd-c74f3f8ebeb9">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzExLTEzLTEtMS0xMTk0ODI_7c095ea2-0b41-448e-bc85-9066145a7f93">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="3" sign="-" name="mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzExLTE1LTEtMS0xMTk0ODI_46e8fedf-bc52-4947-ac94-173772635fbc">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="mygn:IncomeTaxReconciliationAssetImpairment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEyLTEtMS0xLTExOTQ4Mg_6e58b68e-7eb5-4f41-9ae2-c1e28d81a1ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEyLTMtMS0xLTExOTQ4Mg_57c9bebb-df0c-4f84-a34a-4bfb1aa334c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="mygn:IncomeTaxReconciliationAssetImpairment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEyLTUtMS0xLTExOTQ4Mg_c5e2fce5-91e9-4d80-8017-342f6882fabc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEyLTctMS0xLTExOTQ4Mg_1b1187dd-15a2-40e2-aed1-ec387d776518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="mygn:IncomeTaxReconciliationAssetImpairment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEyLTktMS0xLTExOTQ4Mg_68c43be5-93d6-483f-8f31-eb24afd52aee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEyLTExLTEtMS0xMTk0ODI_46cb1226-0fd4-4d67-97a7-d4a774769896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="mygn:IncomeTaxReconciliationAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEyLTEzLTEtMS0xMTk0ODI_2eabfc46-71e5-4b59-bf7b-c703a0e384c4">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="3" sign="-" name="mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEyLTE1LTEtMS0xMTk0ODI_3f3b7c5e-c893-477c-85c9-4ba38771e3df">5.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible legal settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEzLTEtMS0xLTExOTQ4Mg_18abb214-c53d-4737-a7ee-d38f3a788936">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEzLTMtMS0xLTExOTQ4Mg_38efb359-2294-42d1-b38d-79534bcb643b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEzLTUtMS0xLTExOTQ4Mg_e6d56b95-e8ec-47f8-9303-fd08c7b50447">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="3" sign="-" name="mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEzLTctMS0xLTExOTQ4Mg_eebd3963-29e6-4217-8b5e-495f2d20388b">4.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEzLTktMS0xLTExOTQ4Mg_7f4de322-b602-4d93-8e6e-ec62f680c1ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEzLTExLTEtMS0xMTk0ODI_4b67d23c-8918-413d-b69e-c64efd318bdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEzLTEzLTEtMS0xMTk0ODI_513daed9-b437-4244-b590-02a6d4ec57a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEzLTE1LTEtMS0xMTk0ODI_c62426de-b6f0-48d7-9643-56e379387b45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, dispositions, and contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE0LTEtMS0xLTExOTQ4Mg_bb5a2e92-f26d-472b-a60f-751477f224ee">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE0LTMtMS0xLTExOTQ4Mg_87c1dd16-bd93-41dc-8972-9d4a9d4d8082">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE0LTUtMS0xLTExOTQ4Mg_064e695c-3b32-4ca6-9578-52ef9c4511b0">23.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE0LTctMS0xLTExOTQ4Mg_a5a1b1fb-2cf2-44b9-befb-81e972639af5">40.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE0LTktMS0xLTExOTQ4Mg_9ee9f2b1-7167-4bfd-b11a-37ba94fd75f8">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="3" sign="-" name="mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE0LTExLTEtMS0xMTk0ODI_840d0dd2-943e-49b7-be7a-066ebdc32e22">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE0LTEzLTEtMS0xMTk0ODI_ac744d4a-3939-453e-9072-515845c659a9">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="3" name="mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE0LTE1LTEtMS0xMTk0ODI_6a033e90-9fd3-46d2-854f-251e47125540">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE2LTEtMS0xLTExOTQ4Mg_781e6882-26c5-4efc-a97b-3753760f8289">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE2LTMtMS0xLTExOTQ4Mg_898a9b8f-b8e8-49d4-b72b-85d77734e745">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE2LTUtMS0xLTExOTQ4Mg_24c2e134-d387-47da-b8c9-a2661cd4eb43">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE2LTctMS0xLTExOTQ4Mg_bc13da6f-c80c-434b-9f4e-b03bf51cbac2">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE2LTktMS0xLTExOTQ4Mg_44769f86-1b35-4346-b6fd-9604af68ebd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE2LTExLTEtMS0xMTk0ODI_73187cde-9443-4036-be4e-bfebe433aed6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE2LTEzLTEtMS0xMTk0ODI_d5bfdea2-1f48-408b-a8e3-a9762de500a4">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE2LTE1LTEtMS0xMTk0ODI_96384bb1-9fc5-450f-a97f-474914e35f10">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax benefit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE3LTEtMS0xLTExOTQ4Mg_eb15e1fe-4bc0-4d00-ae35-f6a66b7c4314">28.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE3LTMtMS0xLTExOTQ4Mg_b7f39e33-b93b-46f6-8e34-d496739756df">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE3LTUtMS0xLTExOTQ4Mg_1d6fb008-0d49-401f-a3a3-e05b9bba4d38">29.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE3LTctMS0xLTExOTQ4Mg_4edc0781-1fe6-49d8-8b39-e8032905291b">52.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE3LTktMS0xLTExOTQ4Mg_75b93543-3d86-4ad8-8fdd-612211a109e9">41.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE3LTExLTEtMS0xMTk0ODI_b9a56e9c-d799-4166-959e-47efeb4188b4">43.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE3LTEzLTEtMS0xMTk0ODI_32348eb8-86cf-4d5d-8724-254bae47e69b">23.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE3LTE1LTEtMS0xMTk0ODI_ceddd18a-7600-4052-a14d-2ecbe0b9e048">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="i8bb2880ebd504549b0262c7457973bb4" continuedAt="i3f4c87ec226248279aad35a29b22b225"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90ZXh0cmVnaW9uOmQ2YWEyZWE4YThhYzRlNzNhMzIzMGEwNDQ2ZjMyNDA4XzU0NTA_b29144b1-9de9-4958-93e6-0c457afeb060" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s deferred tax assets and liabilities were comprised of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzMtMS0xLTEtMTE5NDgy_a00994cf-fa71-4d98-9812-57aadb19c464">66.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzMtMy0xLTEtMTE5NDgy_dc1fa3b7-df81-4813-87d0-08af16d96fa0">67.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzQtMS0xLTEtMTE5NDgy_9526da02-dfa1-402b-9119-861de196802f">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzQtMy0xLTEtMTE5NDgy_fe7d99d2-342d-4acf-94bb-8d9b594a9c5b">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzUtMS0xLTEtMTE5NDgy_82dbe4de-2db0-4427-b147-391d191a74fe">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzUtMy0xLTEtMTE5NDgy_9372e021-d1b6-4e9f-bff5-da70cbb18212">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzYtMS0xLTEtMTE5NDgy_d23ac52f-8dc9-45da-8cdc-3eb8369b3a40">19.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzYtMy0xLTEtMTE5NDgy_d68f9ad4-9f0d-417c-ad0b-36b5388ce06d">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="mygn:DeferredTaxAssetsLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzctMS0xLTEtMTE5NDgy_375eff3f-6a15-4488-a4a2-60cf91e30f87">35.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="mygn:DeferredTaxAssetsLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzctMy0xLTEtMTE5NDgy_f33ebfbb-d606-4a9d-9bae-0086a8e87bef">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 capitalized costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="mygn:DeferredTaxAssetResearchAndExperimentalExpenseCapitalization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzgtMS0xLTEtMTM0NDIw_4eb3aa3d-b9f4-486d-bfdb-f626086ebb67">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="mygn:DeferredTaxAssetResearchAndExperimentalExpenseCapitalization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzgtMy0xLTEtMTM0NDMz_febfe4a2-7d8d-498e-bf8e-1bb32d13e4ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzgtMS0xLTEtMTE5NDgy_83732c24-c39b-43a4-a453-6549633bb027">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzgtMy0xLTEtMTE5NDgy_5a75baef-88fb-493b-b9c7-05bc28e89326">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzktMS0xLTEtMTE5NDgy_b509e4ae-5c46-4f87-87c3-48b6d3696091">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzktMy0xLTEtMTE5NDgy_dcac148b-cda9-4145-866c-0fb8108eeae2">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzEwLTEtMS0xLTExOTQ4Mg_a6e514a3-2487-4862-bf15-d5374130bcec">160.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzEwLTMtMS0xLTExOTQ4Mg_8bf1046b-345e-4a62-a98a-55950e7a4f8f">131.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzExLTEtMS0xLTExOTQ4Mg_1b145362-8ac3-4dda-8eeb-384710a0fdcf">42.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzExLTMtMS0xLTExOTQ4Mg_95d83cb4-a050-4d4e-b241-71840c8dfdb3">38.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzEyLTEtMS0xLTExOTQ4Mg_c48659ce-0ac6-4850-9eee-7dd24c87717b">118.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzEyLTMtMS0xLTExOTQ4Mg_5a95d6a0-5335-4a82-94bc-1e39c1d539dc">92.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzE0LTEtMS0xLTExOTQ4Mg_f9fb6a2d-7d77-445e-8750-701b1dba48e4">93.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzE0LTMtMS0xLTExOTQ4Mg_98ca9e53-83cb-448e-ae5b-4ac7796a0cea">104.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="mygn:DeferredTaxLiabilitiesLeaseRightOfUseAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzE1LTEtMS0xLTExOTQ4Mg_9839d82e-213a-4274-af90-ee63c2e3e197">25.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="mygn:DeferredTaxLiabilitiesLeaseRightOfUseAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzE1LTMtMS0xLTExOTQ4Mg_2ab4a3dc-f1e6-4818-8754-18013476d28c">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzE2LTEtMS0xLTExOTQ4Mg_84efaeac-d3b5-4533-8f07-e6bbfd4e1783">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzE2LTMtMS0xLTExOTQ4Mg_43099fe0-7f5c-4af9-99a0-496394702b8d">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzE3LTEtMS0xLTExOTQ4Mg_ee9c1b98-3a0f-463d-ac39-dccbaac02ada">122.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzE3LTMtMS0xLTExOTQ4Mg_3affb99c-5dc7-4d29-9f22-93be1eab0738">128.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzE4LTEtMS0xLTExOTQ4Mg_8d995d8c-0ca6-4595-b8bf-c16971f496e8">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzE4LTMtMS0xLTExOTQ4Mg_fdfb18d1-6536-4267-8f08-a513ba38bd66">35.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act (TCJA), passed in 2017, amended Section 174 of the Internal Revenue Code to require that specific research and experimental (R&amp;E) expenditures be capitalized and amortized over five years for U.S. R&amp;E expenditures or 15 years for non-US R&amp;E expenditures beginning in the Company&#8217;s fiscal year ended December 31, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although Congress has considered legislation that would defer, modify or repeal the capitalization and amortization requirement, there is no assurance that the provision will be deferred, repealed or otherwise modified.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the requirement is not modified, the Company may be required to utilize some of its federal and state tax attributes and there may be increases to state cash taxes or tax expense.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred a cumulative three-year loss. Pursuant to ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the negative evidence of a cumulative loss may be difficult to overcome. However, the Company will have significant future taxable income resulting from the reversal of taxable temporary differences. Primarily due to the availability of such expected future taxable income, the Company concluded that it is more likely than not that the benefits of the majority of its deferred income tax assets will be realized. However, for certain deferred tax assets a valuation allowance has been established, primarily due to limitations imposed by Section 382 of the Internal Revenue Code and certain jurisdictional limitations. For the year ended December&#160;31, 2022, the Company's valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" sign="-" name="mygn:ValuationAllowanceIncreaseDecreaseDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90ZXh0cmVnaW9uOmQ2YWEyZWE4YThhYzRlNzNhMzIzMGEwNDQ2ZjMyNDA4XzQ5NDc4MDIzMzA5ODc_f8474021-bcba-43a1-a37f-669a41af8c53">3.9</ix:nonFraction>&#160;million, primarily due to the anticipated inability to utilize deferred tax assets related to state attributes and credits. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="i3f4c87ec226248279aad35a29b22b225"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90ZXh0cmVnaW9uOmQ2YWEyZWE4YThhYzRlNzNhMzIzMGEwNDQ2ZjMyNDA4XzU0NTE_580ab83e-8710-4d12-8f8c-542d57f37948" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the Company had the following net operating loss and research credit carryforwards (tax effected), with their respective expiration periods. Certain carryforwards are subject to the limitations of Section 382 and 383 of the Internal Revenue Code as indicated (in millions):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carryforwards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Subject to<br/>sections 382, 383</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expires<br/>beginning in year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Through</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal net operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc16948f5d7e4bd8969f02b7c60c2fc4_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzEtMi0xLTEtMTE5NDgy_78b2fac5-2368-4383-80fb-e1e5ee270f5b">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8481cd3af014407fa42d2b6f5b5acbdf_D20220101-20221231" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzEtNC0xLTEtMTE5NDgy_ea7968bb-1ccd-44d2-a159-f4a1654f9fc2">Yes</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idc38c0d48fe34cf9a4096e501b238ec1_D20220101-20221231" name="mygn:OperatingLossCarryforwardsExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzEtNi0xLTEtMTE5NDgy_799f8663-33da-44d9-941c-8cf16e52aba5">2033</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal capital loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acceb782b124009867513e1e395eb09_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzItMi0xLTEtMTE5NDgy_e9a87ada-4191-4a4c-9116-6f375468e78b">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8265cfaa4f6249e280c2c2cf4edf2b88_D20220101-20221231" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzItNC0xLTEtMTE5NDgy_f161cdf1-1aa0-4257-a505-a1db848b8abc">No</ix:nonNumeric> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i94684063e7f148b8b931a967f3ea2e9d_D20220101-20221231" name="mygn:TaxCreditCarryforwardsExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzItNi0xLTEtMTE5NDgy_542b76a2-05d6-48d7-9147-d2423bde757b">2026</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie05625b5ce714586b315182123a0066c_D20220101-20221231" name="mygn:TaxCreditCarryforwardsExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzItOC0xLTEtMTE5NDgy_8549c862-6ebf-4a7d-9d37-ffecee0acb9f">2026</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utah net operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e56caf70d6447518290386f81719ca9_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzMtMi0xLTEtMTE5NDgy_531609d8-8a2e-4a05-b5b4-bfd51e3edf01">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i94ef8507bf234538b9ed98fb0e389325_D20220101-20221231" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzMtNC0xLTEtMTE5NDgy_12989380-cb8f-448f-80d8-4e11eedc9a52">No</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0bbddf290d464aadaa27acb940277180_D20220101-20221231" name="mygn:OperatingLossCarryforwardsExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzMtNi0xLTEtMTE5NDgy_bf3736c2-3faf-41e5-b1e2-6fd6a30f0e73">2023</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California net operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3a2d7f8de3c427785c15b09085c84d6_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzQtMi0xLTEtMTE5NDgy_4f0420aa-3a86-473f-b29f-ea13b80a56ce">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i83f4a6d86c4f4eb39c69c44ec0b4f2fd_D20220101-20221231" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzQtNC0xLTEtMTE5NDgy_e1676122-9485-4f0b-bf31-9f57fc45d83d">Yes</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib5f72eb0018746c886b57ce4f50c4db8_D20220101-20221231" name="mygn:OperatingLossCarryforwardsExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzQtNi0xLTEtMTE5NDgy_87fea002-66b5-4df3-b3ff-ac08e1b2e1e4">2029</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i491a5a05cb774a8fb1c3c42b73443667_D20220101-20221231" name="mygn:OperatingLossCarryforwardsExpirationYear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzQtOC0xLTEtMTE5NDgy_7cfa04a6-9089-4fac-b613-0754e799cca4">2041</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other state net operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaef3f6c95fd94ce4b015ac7e3db94ae4_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzUtMi0xLTEtMTE5NDgy_5dedb442-5564-413a-8149-0c8384881d31">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibea3c187441f480487b44a951451baba_D20220101-20221231" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzUtNC0xLTEtMTE5NDgy_2a8533a3-8353-4022-9373-d744be6c66f4">Yes</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign net operating losses (various jurisdictions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if40585f71c3c463a9840bdd7070fc047_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzYtMi0xLTEtMTE5NDgy_2a823a0d-8492-4745-89b0-93bc88a3e81c">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id2f519e64bc04789a7526a6bd09819a6_D20220101-20221231" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzYtNC0xLTEtMTE5NDgy_070fca1b-e916-4647-899a-60634bf745b0">No</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal research credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9e7946b9ce6498cab7885f8d675da90_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzctMi0xLTEtMTE5NDgy_2cbcd692-1d45-45f9-9ea7-598c99727990">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifb59e7c4e69149dd82d0501e71e1ce19_D20220101-20221231" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzctNC0xLTEtMTE5NDgy_94491ebc-2fc8-48b1-ad56-cc3c5eb7b639">Yes</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaf9dfcf78da842f5bad9f364f2105f81_D20220101-20221231" name="mygn:TaxCreditCarryforwardsExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzctNi0xLTEtMTE5NDgy_f754668d-5426-4149-a607-7f2f52e71e01">2027</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i532ba0950b96453a85caae716fac82b6_D20220101-20221231" name="mygn:TaxCreditCarryforwardsExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzctOC0xLTEtMTE5NDgy_8f913600-d509-49e7-863e-2237e025a691">2042</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utah research credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1da4606ad7ed41209dfcdca23de08ed6_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzgtMi0xLTEtMTE5NDgy_c5659152-16c7-45a1-8c0c-0e8fbb6932e3">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic667a4f90d994acbb20e3e566f84f92e_D20220101-20221231" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzgtNC0xLTEtMTE5NDgy_7087c8a6-702f-4cc7-b2e6-51ee7e6ee0b7">No</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iea7482a897494be892bc46b821925654_D20220101-20221231" name="mygn:TaxCreditCarryforwardsExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzgtNi0xLTEtMTE5NDgy_523e072f-4eb0-4004-9d1d-412b8a8606af">2023</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if99355023d8f4ac5ab1b42964f050f9e_D20220101-20221231" name="mygn:TaxCreditCarryforwardsExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzgtOC0xLTEtMTE5NDgy_dc574225-339e-482a-a138-6a00a7585ae2">2036</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California research credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06d164c0b6e04a459e6a33b952092ab4_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzktMi0xLTEtMTE5NDgy_4a2f35ec-62c7-475a-921d-d0f6f5d57067">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6df636aa6bd446ed8b2aea33d99d66a4_D20220101-20221231" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzktNC0xLTEtMTE5NDgy_61d3ceae-67ef-4a15-8933-fabaa3dace21">No</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the cumulative losses that have been incurred to date in foreign operations, the changes of the Tax Cuts and Jobs Act and the election to treat its foreign subsidiaries as disregarded entities, no deferred taxes related to the Company&#8217;s foreign operations have been recorded. For those foreign entities for which an election has been made to be treated as disregarded for U.S. tax purposes, the appropriate U.S. jurisdiction deferred tax assets and liabilities have been recorded.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement criteria as set forth in ASC 740. As of December&#160;31, 2022, the Company had net unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90ZXh0cmVnaW9uOmQ2YWEyZWE4YThhYzRlNzNhMzIzMGEwNDQ2ZjMyNDA4XzU0OTc1NTgxOTg2Nw_bd544ac0-64e7-47da-9f89-17b668fac928">31.9</ix:nonFraction> million. <ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90ZXh0cmVnaW9uOmQ2YWEyZWE4YThhYzRlNzNhMzIzMGEwNDQ2ZjMyNDA4XzU0NDg_ac7935d9-c8be-4a17-82a2-9a33ff3fb93d" continuedAt="icfca2001040e4a5db5dbcd3d883a0b62" escape="true">The Company&#8217;s gross unrecognized tax benefits as of the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020 and the fiscal year ended June 30, 2020, and the changes in those balances are as follows:&#160;</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><ix:continuation id="icfca2001040e4a5db5dbcd3d883a0b62"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:52.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at the beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzItMS0xLTEtMTE5NDgy_d0b52d32-3328-4e28-ab68-7a5577d741b6">32.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzItMy0xLTEtMTIyOTEx_065d3a56-c266-4e8a-89c6-2b56f7b109ab">37.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideeefc606008446e85d0fd21a9515813_I20200630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzItMy0xLTEtMTE5NDgy_35619275-a9fe-400a-ab13-4d3622880620">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96afdd71e74449aa558f9c0f8968925_I20190630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzItNS0xLTEtMTE5NDgy_feef172d-7036-468c-b336-508dcaa30c15">21.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzMtMS0xLTEtMTE5NDgy_7787263d-983a-43f6-9ebb-ded50feedc2f">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzMtMy0xLTEtMTIyOTEx_541ee85e-f441-445f-9395-4085bc203168">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzMtMy0xLTEtMTE5NDgy_720e09f2-4ce5-4606-ad46-d85d96d20b9e">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzMtNS0xLTEtMTE5NDgy_1e2e01fd-c24c-4833-b0b9-2c34926c5fec">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzQtMS0xLTEtMTE5NDgy_0f34f6b9-6e53-4a3a-acfb-96e1fbc5efbc">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzQtMy0xLTEtMTIyOTEx_d4543420-0528-4e84-af39-7bc15b5a9153">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzQtMy0xLTEtMTE5NDgy_2955d16b-1a9e-4d17-a727-4d67223db650">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzQtNS0xLTEtMTE5NDgy_a3fccb7a-c49d-458f-bfa1-9d302ad75647">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzYtMS0xLTEtMTE5NDgy_f326d196-2ee0-49c8-a651-76a732066882">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzYtMy0xLTEtMTIyOTEx_6ecdda79-674f-4f03-a258-03b56b36a534">2.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzYtMy0xLTEtMTE5NDgy_ca0da84b-0b25-466b-8e06-dbf587218650">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzYtNS0xLTEtMTE5NDgy_9a3f8cbe-e35b-4f5c-af64-c5ece7460186">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzctMS0xLTEtMTE5NDgy_18d200bf-5da8-441f-bed8-d78d21863aa5">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzctMy0xLTEtMTIyOTEx_ec0dc735-cef3-4867-858a-6147c3b58607">5.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzctMy0xLTEtMTE5NDgy_42afc3d9-a3a3-40cd-a808-1066435d0dd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzctNS0xLTEtMTE5NDgy_b26a2ccc-81e9-4095-aabd-af78fdf5f4b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - statute lapse</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzgtMS0xLTEtMTE5NDgy_7088797c-c97f-4d92-ae30-9d9801cdeade">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzgtMy0xLTEtMTIyOTEx_bc34d245-fdd8-40c5-ad42-9abdee04d9a7">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzgtMy0xLTEtMTE5NDgy_bcf5e0b3-f23f-48c4-ad57-50c5f0c06f46">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzgtNS0xLTEtMTE5NDgy_ff4c1734-5922-495b-99c3-63e9336139a3">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzktMS0xLTEtMTE5NDgy_bd544ac0-64e7-47da-9f89-17b668fac928">31.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzktMy0xLTEtMTIyOTEx_16914b94-3d76-4f55-8bb8-a2145709fda2">32.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzktMy0xLTEtMTE5NDgy_cac0c874-de9e-423c-af59-920b16604d02">37.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideeefc606008446e85d0fd21a9515813_I20200630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzktNS0xLTEtMTE5NDgy_c8e35ba4-5457-4bf6-91ac-5de6da1be2cb">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and penalties in year-end balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzEwLTEtMS0xLTExOTQ4Mg_ad4368b9-08ba-4534-b1ac-b51c6ddb712f">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzEwLTMtMS0xLTEyMjkxMQ_8452b122-1695-4193-a9e4-79b93efb27ab">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzEwLTMtMS0xLTExOTQ4Mg_4184eb11-989e-4f1a-b770-04e255b3f713">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideeefc606008446e85d0fd21a9515813_I20200630" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzEwLTUtMS0xLTExOTQ4Mg_b7fddfa0-981e-41f5-bd62-cc0deef9c7e9">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties related to uncertain tax positions are included as a component of Income tax benefit and all other interest and penalties are included as a component of Other income (expense) in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files U.S. federal, foreign and state income tax returns in jurisdictions with various statutes of limitations. The Company is currently under audit by the state of California for years ended June 30, 2017 and 2018.&#160;&#160;Annual tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjQvZnJhZzo2N2RjOTI1NDk5YjI0YmI1YmFmMjY0NTdhMDE5YjczNy90ZXh0cmVnaW9uOjY3ZGM5MjU0OTliMjRiYjViYWYyNjQ1N2EwMTliNzM3XzEwMTIz_c376c0d5-f5fe-401f-87ac-8176274789c5" continuedAt="i1c1cb2044c6d44e586874398035ee63b" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i1c1cb2044c6d44e586874398035ee63b" continuedAt="i8d460079c4664a02a9a88f72a040534a"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved from time to time in various disputes, claims and legal actions, including class actions and other litigation, including the matters described below, arising in the ordinary course of business. Such actions may include allegations of negligence, product or professional liability or other legal claims, and could involve claims for substantial compensatory and punitive damages or claims for indeterminate amounts of damages. The Company is also involved, from time to time, in investigations by governmental agencies regarding its business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of the government or private payors. The Company has received subpoenas from time to time related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations or other laws.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to defend its current litigation matters, but cannot provide any assurance as to the ultimate outcome or that an adverse resolution would not have a material adverse effect on its financial condition, results of operations or cash flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses legal contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. When evaluating legal contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the proceedings may be in early stages, there may be uncertainty as to the outcome of pending appeals or motions, there may be significant factual issues to be resolved, and there may be complex or novel legal theories to be presented. In addition, damages may not be specified or the damage amounts claimed may be unsupported, exaggerated or unrelated to possible outcomes, and therefore, such amounts are not a reliable indicator of potential liability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company has not recorded any material accrual for loss contingencies associated with legal proceedings or other matters or determined that an unfavorable outcome is probable and reasonably estimable in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. However, it is possible that the ultimate resolution of legal proceedings or other matters, if unfavorable, may be material to the Company's results of operations, financial condition or cash flows. Further, in the event that damages from an unfavorable resolution of one or more of these proceedings exceed the aggregate amount of the coverage limits of the Company&#8217;s insurance, or if the Company&#8217;s insurance carriers disclaim coverage, the amounts payable by the Company could also have a material adverse impact on the Company&#8217;s results of operations, financial condition or cash flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Class Action</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 27, 2019, a class action complaint was filed in the U.S. District Court for the District of Utah, against the Company, its former President and Chief Executive Officer, Mark C. Capone, and its Chief Financial Officer, R. Bryan Riggsbee (Defendants). On February 21, 2020, the plaintiff filed an amended class action complaint, which added the Company's former Executive Vice President of Clinical Development, Bryan M. Dechairo, as an additional Defendant. This action, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">In re Myriad Genetics, Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (No. 2:19-cv-00707-DBB), is premised upon allegations that the Defendants made false and misleading statements regarding the Company's business, operations, and acquisitions.&#160;&#160;The lead plaintiff seeks the payment of damages allegedly sustained by it and the purported class by reason of the allegations set forth in the amended complaint, plus interest, and legal and other costs and fees.&#160;On March 16, 2021, the U.S. District Court for the District of Utah denied the Company's motion to dismiss.&#160;On December 1, 2021, the U.S. District Court for the District of Utah granted plaintiff's motion for class certification. The parties currently are engaged in discovery.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Derivative Actions </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2021, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Company's former President and Chief Executive Officer, Mark C. Capone, its Chief Financial Officer, R. Bryan Riggsbee, its former Executive Vice President of Clinical Development, Bryan M. Dechairo, and certain of the Company's current and former directors, Lawrence C. Best, Walter Gilbert, John T. Henderson, Heiner Dreismann, Dennis Langer, Lee N. Newcomer, S. Louise Phanstiel, and Colleen F. Reitan (collectively, the Individual Defendants), and the Company, as nominal defendant. The complaint is premised upon similar allegations as set forth in the securities class action, including that the Individual Defendants made false and misleading statements regarding the Company's business and operations. The plaintiff, Donna Hickock, asserts breach of fiduciary duty and unjust enrichment claims against the Individual Defendants and seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches, or disgorgement or restitution, from each of the Individual Defendants, plus interest. Plaintiff Hickock also seeks legal and other costs and fees relating to this action. On November 19, 2021, this action was stayed by the Delaware Court of Chancery pending the resolution of the securities class action lawsuit. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="i8d460079c4664a02a9a88f72a040534a"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and the Hickock stockholder derivative action. The plaintiff, Esther Kogus, asserts that the Individual Defendants breached their fiduciary duties and also asserts unjust enrichment and aiding and abetting breaches of fiduciary duty claims against the Individual Defendants. Plaintiff Kogus seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches and claims, and restitution from the Individual Defendants. On behalf of herself, plaintiff Kogus seeks legal and other costs and fees relating to this action.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2022, the Delaware Court of Chancery consolidated the Hickock and Kogus derivative actions and stayed the consolidated action.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2021, a stockholder derivative complaint was filed in the U.S. District Court in the District of Delaware against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and Hickock stockholder derivative action. The plaintiff, Karen Marcey, asserts that the Individual Defendants violated U.S. securities laws and breached their fiduciary duties, and also asserts unjust enrichment, waste of corporate assets and insider trading claims against all or some of the Individual Defendants. Plaintiff Marcey seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged violations and restitution from the Individual Defendants, plus interest and, on behalf of herself, legal and other costs and fees relating to this action. On January 4, 2022, this action was stayed by the U.S. District Court for the District of Delaware pending the resolution of the securities class action lawsuit. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 21, 2020, Ravgen, Inc. filed a lawsuit against the Company and its wholly owned subsidiary, Myriad Women's Health, Inc., in the U.S. District Court for the District of Delaware, alleging infringement of <ix:nonFraction unitRef="patent" contextRef="i78b35c2904e342a2a22d1151ef8b25d8_D20201221-20201221" decimals="INF" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjQvZnJhZzo2N2RjOTI1NDk5YjI0YmI1YmFmMjY0NTdhMDE5YjczNy90ZXh0cmVnaW9uOjY3ZGM5MjU0OTliMjRiYjViYWYyNjQ1N2EwMTliNzM3XzIxOTkwMjMyOTkwMDY_3fd6d84f-b594-4183-a139-24f96c6cd70a">two</ix:nonFraction> Ravgen-owned patents. The lawsuit seeks monetary damages, enhancement of those damages for willfulness, injunctive relief, and recovery of attorney's fees and costs. Various third parties have filed challenges to the validity of the asserted patents with the U.S. Patent and Trademark Office, which challenges have been instituted for review. On March 14, 2022, the case was stayed pending the outcome of the first of these validity challenges. On February 13, 2022, the court lifted the stay and litigation of the case has resumed. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2022, a purported class action lawsuit was filed against the Company in the U.S. District Court in the Northern District of California by Ashley Carroll. Plaintiff alleges, among other things, that the Company made false statements about the accuracy of its Prequel prenatal screening test. The complaint seeks unspecified monetary damages and injunctive relief. On April 1, 2022, the Company filed a motion to dismiss the lawsuit. On May 2, 2022, the plaintiff amended her complaint. On June 2, 2022, the Company filed a motion to dismiss the amended complaint. On July 26, 2022, the court granted and denied in part the Company's motion to dismiss the amended complaint. As part of the court's order, plaintiff was granted leave to file a second amended complaint. The plaintiff filed a second amended complaint on August 16, 2022. On September 6, 2022, the Company filed a motion to dismiss the second amended complaint. On November 9, 2022, the Court granted and denied in part the Company's motion to dismiss the second amended complaint.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments.</span></div></ix:continuation><div id="i7e0793090cf84227944277d460d39a4d_127"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzQ5MTc_8de37a19-8f91-4003-ac69-1c374ef98117" continuedAt="i94c93c26f0b342a1a00f7e4fc79fcc2b" escape="true">LEASES </ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i94c93c26f0b342a1a00f7e4fc79fcc2b" continuedAt="i798750ea1159422a980ddb5379c478e8">The Company leases certain office spaces and research and development laboratory facilities, vehicles, and office equipment with remaining lease terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzE4MA_55b83f90-88ae-4e25-9b41-229696ec6103">one</span> to <ix:nonNumeric contextRef="i4fa41121b7d143cfbc8e91a9ced3020a_I20221231" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzE4Ng_07d02409-f5e3-4814-bf7b-4e336c3a5d86">fifteen years</ix:nonNumeric>. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options, which allows the Company to, at its election, renew or extend the lease for a fixed period of time. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. During the twelve months ended December&#160;31, 2022, in an effort to reduce its real estate footprint, the Company ceased the use of certain of its leased Salt Lake City facilities and one of its South San Francisco facilities. As a result, the Company recorded an impairment charge on ROU assets of $<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzExNTQ0ODcyMTAzNTI0_6f51713d-3c2e-4721-ba14-ff67898fb8f3">13.0</ix:nonFraction> million and an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i87c0d4d014b8431486ad3d3075f0ca84_D20220101-20221231" decimals="-5" name="us-gaap:OtherAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzExNTQ0ODcyMTAzNTMx_b749a5e8-968a-4fd0-8629-09f1b5930d6b">3.9</ix:nonFraction> million on the related property, plant and equipment, which consisted primarily of leasehold improvements. The total $<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzEwOTk1MTE2MzkyMTc_bf84b7cd-01fe-41df-a896-fdfd05e0668b">16.9</ix:nonFraction> million impairment is included in Goodwill and long-lived asset impairment charges in the Consolidated Statement of Operations.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="i798750ea1159422a980ddb5379c478e8"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the year ended December&#160;31, 2022, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzI0Nzg_d0ca7cc5-2740-4dde-85ce-18ff38c98a4d">22.1</ix:nonFraction> million in lease costs which are included in operating expenses in the Consolidated Statements of Operations in relation to these operating leases. Of such lease costs, $<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzI2NDI_ceb8755e-c4c5-49d2-975d-0c8ef10e8491">3.2</ix:nonFraction>&#160;million was variable lease expense, which was not included in the measurement of the Company's operating ROU assets and lease liabilities. The variable rent expense is comprised primarily of the Company's proportionate share of operating expenses, property taxes, and insurance and is classified as lease expense due to the Company's election to not separate lease and non-lease components. For the year ended December&#160;31, 2021, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyMTQwMg_761300f8-080f-4f2a-bc97-8b3647a711a5">20.7</ix:nonFraction> million in lease costs which are included in operating expenses in the Consolidated Statements of Operations in relation to these operating leases. Of such lease costs, $<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyMTQxMA_868ec9f0-6310-4311-bd53-ec3c6caf18d5">3.2</ix:nonFraction> million was variable lease expense, which was not included in the measurement of the Company's operating ROU assets and lease liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, the Company entered into a non-cancelable operating lease for approximately <ix:nonFraction unitRef="sqft" contextRef="i7ec137fde2704324b8c089d57adb90e5_I20220331" decimals="-3" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyMzU1Ng_59d2187e-d72b-4856-af09-ba94b334c9b4">230,000</ix:nonFraction> square feet in west Salt Lake City, Utah. The lease has a term of <ix:nonNumeric contextRef="i7ec137fde2704324b8c089d57adb90e5_I20220331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyMzU0Ng_3f965ca1-9971-4109-9bbb-19171171f5f6">15</ix:nonNumeric> years, which, along with rent payments, are expected to commence in the third quarter of 2023. The Company will take possession of the leased facility in phases, which began in the three months ended June 30, 2022. As a result, the Company has recognized the related lease balances for the phase, or portion, of the leased facility that the Company has taken possession of, and will recognize the additional phases of the leased facility as possession occurs. As of December&#160;31, 2022, the Company has recognized an approximately $<ix:nonFraction unitRef="usd" contextRef="ib7c0bca71a544a8293274a98d8342a84_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyNDU1OA_c7f075ae-6805-4348-936f-02dc87701431"><ix:nonFraction unitRef="usd" contextRef="ib7c0bca71a544a8293274a98d8342a84_I20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyNDU1OA_d39e3d0f-1deb-496b-b081-8e9c66e40ade">13.9</ix:nonFraction></ix:nonFraction> million ROU asset and corresponding lease liability, net of tenant improvement allowance not yet received. Total future rent payments under the lease are approximately $<ix:nonFraction unitRef="usd" contextRef="ib7c0bca71a544a8293274a98d8342a84_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyMzYyOQ_769a8af0-cb0c-4075-a884-8cefc8914993">78.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also took possession of a lease for approximately <ix:nonFraction unitRef="sqft" contextRef="i0d8e9e97f965410eb1e1d5fb7d188a69_I20221231" decimals="-3" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyNDQ2NA_b7b519a8-d749-4860-a321-94f8383ae6d4">63,000</ix:nonFraction> square feet in South San Francisco, California with a term of <ix:nonNumeric contextRef="i0d8e9e97f965410eb1e1d5fb7d188a69_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyNDQ4MA_fcae1aab-f849-40b1-aec7-0b5648a42b88">10</ix:nonNumeric> years, which, along with rent payments, are expected to commence in the third quarter of 2023. As a result, the Company recognized the related ROU asset and lease liability, net of tenant improvement allowance not yet received, of $<ix:nonFraction unitRef="usd" contextRef="i0d8e9e97f965410eb1e1d5fb7d188a69_I20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyNDU3Nw_847ea305-2b6f-41e3-bf75-fc10c2c04a65"><ix:nonFraction unitRef="usd" contextRef="i0d8e9e97f965410eb1e1d5fb7d188a69_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyNDU3Nw_fb158110-c4d0-4cb7-86bc-490138ff318a">30.7</ix:nonFraction></ix:nonFraction> million in the Consolidated Balance Sheets as of December&#160;31, 2022. Total future rent payments under the lease are approximately $<ix:nonFraction unitRef="usd" contextRef="i0d8e9e97f965410eb1e1d5fb7d188a69_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgxNDk3NDI_ba641039-c5fa-4521-b152-8ffdfcee8604">58.8</ix:nonFraction>&#160;million. </span></div><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzQ5MTY_aba30366-2683-4ce1-991c-a756021576bd" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the maturities of the Company&#8217;s operating lease liabilities were as follows (in millions):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzEtMS0xLTEtMTE5NDgy_076dbad9-4f71-4fe5-bec5-caa8ea95224e">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzItMS0xLTEtMTE5NDgy_a3c290e8-2834-47e4-bc8d-86af6e03faf4">23.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzMtMS0xLTEtMTE5NDgy_4d6ecbf4-b2af-4b09-8eb4-e4784ed69802">17.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzQtMS0xLTEtMTE5NDgy_f5315cba-9799-4b04-af90-ba10e54466a2">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzUtMS0xLTEtMTE5NDgy_712d24ca-0089-4e69-a571-b925cbe319fd">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzYtMS0xLTEtMTE5NDgy_07c89ac0-a8fb-48ad-9191-c708eccb5343">92.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzctMS0xLTEtMTE5NDgy_f613d85c-417b-4b88-9a8a-ebb0929d3955">185.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzgtMS0xLTEtMTE5NDgy_f899fa32-b5b5-4d07-81a0-2a00b174ea35">18.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="mygn:OperatingLeaseLiabilityIncludingLeasesNotYetCommenced" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzktMS0xLTEtMTE5NDgy_2861381d-ab4f-4ec4-be7c-68e9764419d2">166.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: leases not yet commenced</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="mygn:OperatingLeaseLiabilityLeasesNotYetCommenced" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzEwLTEtMS0xLTExOTQ4Mg_b7eed224-ac8e-497b-8122-76d67470480b">21.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current maturities of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzExLTEtMS0xLTExOTQ4Mg_0ff69279-6703-4f03-9bc0-353046dee16b">14.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzEyLTEtMS0xLTExOTQ4Mg_bcfbf851-d71d-4c5c-a751-1bdbf6389288">130.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the weighted average remaining lease term is <ix:nonNumeric contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzQxMTM_49c256f1-58a1-474a-851e-b736ca1fd5c7">10.3</ix:nonNumeric> years and the weighted average discount rate used to determine the operating lease liability was <ix:nonFraction unitRef="number" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzQyMDc_7a03031c-12ab-43e4-8fab-cca24dbde347">5.87</ix:nonFraction>%. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company's leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating the Company&#8217;s incremental borrowing rates, the Company gives consideration to its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary. The lease term used may reflect any option to extend or terminate the lease when it is reasonably certain the Company will exercise such options. Lease expenses for the Company's operating leases are recognized on a straight-line basis over the lease term.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzAvZnJhZzpkNzUzNmNlODNiZDk0YTMwOTVlYzJkZWIzYmIwYTZiMS90ZXh0cmVnaW9uOmQ3NTM2Y2U4M2JkOTRhMzA5NWVjMmRlYjNiYjBhNmIxXzQ0OQ_5ed7bde7-b92f-4ffc-8d2a-f7925539fcbe" continuedAt="i18887337c7244cacb930705f673b1895" escape="true">EMPLOYEE DEFERRED SAVINGS PLAN</ix:nonNumeric></span></div><ix:continuation id="i18887337c7244cacb930705f673b1895"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a deferred savings plan which qualifies under Section&#160;401(k) of the Internal Revenue Code. Substantially all of the Company&#8217;s U.S. employees are covered by the plan. The Company makes matching contributions of <ix:nonFraction unitRef="number" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzAvZnJhZzpkNzUzNmNlODNiZDk0YTMwOTVlYzJkZWIzYmIwYTZiMS90ZXh0cmVnaW9uOmQ3NTM2Y2U4M2JkOTRhMzA5NWVjMmRlYjNiYjBhNmIxXzI2Ng_78f8221f-961a-4468-bed0-3c05616565c4">50</ix:nonFraction>% of each employee&#8217;s contribution with the employer&#8217;s contribution not to exceed <ix:nonFraction unitRef="number" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzAvZnJhZzpkNzUzNmNlODNiZDk0YTMwOTVlYzJkZWIzYmIwYTZiMS90ZXh0cmVnaW9uOmQ3NTM2Y2U4M2JkOTRhMzA5NWVjMmRlYjNiYjBhNmIxXzM0OA_83bda8b3-3788-46f8-a1c3-7a3214d4add4">4</ix:nonFraction>% of the employee&#8217;s compensation. </span></div><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:DefinedContributionPlanDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzAvZnJhZzpkNzUzNmNlODNiZDk0YTMwOTVlYzJkZWIzYmIwYTZiMS90ZXh0cmVnaW9uOmQ3NTM2Y2U4M2JkOTRhMzA5NWVjMmRlYjNiYjBhNmIxXzQ1MA_1ffb82a2-f568-412e-917c-dd38f04c0317" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s recorded contributions to the plan are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred savings plan contributions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzAvZnJhZzpkNzUzNmNlODNiZDk0YTMwOTVlYzJkZWIzYmIwYTZiMS90YWJsZTozNDgwN2UyMWUzZDc0NjZhYWNjZGQyNzg3MGRkYjg0OS90YWJsZXJhbmdlOjM0ODA3ZTIxZTNkNzQ2NmFhY2NkZDI3ODcwZGRiODQ5XzItMS0xLTEtMTE5NDgy_51f97f28-c642-4927-accd-90c1486afb7d">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzAvZnJhZzpkNzUzNmNlODNiZDk0YTMwOTVlYzJkZWIzYmIwYTZiMS90YWJsZTozNDgwN2UyMWUzZDc0NjZhYWNjZGQyNzg3MGRkYjg0OS90YWJsZXJhbmdlOjM0ODA3ZTIxZTNkNzQ2NmFhY2NkZDI3ODcwZGRiODQ5XzItMy0xLTEtMTIxNTAz_23860edf-7a3f-4658-a14b-4a22109fcc8c">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzAvZnJhZzpkNzUzNmNlODNiZDk0YTMwOTVlYzJkZWIzYmIwYTZiMS90YWJsZTozNDgwN2UyMWUzZDc0NjZhYWNjZGQyNzg3MGRkYjg0OS90YWJsZXJhbmdlOjM0ODA3ZTIxZTNkNzQ2NmFhY2NkZDI3ODcwZGRiODQ5XzItMy0xLTEtMTE5NDgy_4500463c-e8dd-4330-beb2-d4e43b73060e">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d0e08156cb641f29dd07ca3ce93941c_D20200701-20210630" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzAvZnJhZzpkNzUzNmNlODNiZDk0YTMwOTVlYzJkZWIzYmIwYTZiMS90YWJsZTozNDgwN2UyMWUzZDc0NjZhYWNjZGQyNzg3MGRkYjg0OS90YWJsZXJhbmdlOjM0ODA3ZTIxZTNkNzQ2NmFhY2NkZDI3ODcwZGRiODQ5XzItNS0xLTEtMTE5NDgy_9a58222a-33c3-45dc-a908-d73de5148bdc">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i7e0793090cf84227944277d460d39a4d_133"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90ZXh0cmVnaW9uOjVjM2M3NmU3OWI4ZTQ0NDA4YWEyYWRmYzY1NWYzOWYwXzEyOTI_f4234307-403d-403c-bdb6-17ca33e21ff7" continuedAt="i661118cae033442dbcda526cf7153840" escape="true">SEGMENT AND RELATED INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i661118cae033442dbcda526cf7153840"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business is aligned with how the chief operating decision maker ("CODM") reviews performance and makes decisions in managing the Company. On July 1, 2021, the Company completed the divestiture of Myriad RBM, Inc., and, as a result, now operates a single reporting segment. Prior to the sale, the Myriad RBM, Inc. operating segment was included in the Company&#8217;s previously reported "other" segment. The Company&#8217;s remaining operations have been aggregated into a single reporting segment, which primarily provides testing that helps assess an individual&#8217;s risk for developing disease or disease progression and guides treatment decisions across medical specialties where genetic insights can significantly improve patient health care and lower health care costs, and includes corporate services such as finance, human resources, legal and information technology. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. The CODM evaluates segment performance based on operating income (loss).</span></div><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90ZXh0cmVnaW9uOjVjM2M3NmU3OWI4ZTQ0NDA4YWEyYWRmYzY1NWYzOWYwXzEyOTQ_e5411f65-a68b-41fb-bb35-b4acc9624773" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles assets by geographical region to total assets:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Net equipment, leasehold improvements and property:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf0e35c76ce4737b597d4d31b6103bb_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzMtMS0xLTEtMTE5NDgy_331f453b-bec9-438b-8dd3-62822ddb840e">81.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0f83e0a22104fedb4e475de48140594_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzMtMy0xLTEtMTE5NDgy_f5272903-f430-48c1-b5f6-605b685c8ee9">41.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e3d05930c246f797d9ab7061985860_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzQtMS0xLTEtMTE5NDgy_f1ccc482-77ce-4054-8deb-4d451ff75a11">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e82739b44cd45d7b099f422b6ae33cf_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzQtMy0xLTEtMTE5NDgy_61d604e6-c775-4295-a64e-fdb3637bcfb8">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c8aad575c1d41c389544f11390b9d59_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzUtMS0xLTEtMTE5NDgy_e77d07e6-21cb-4356-b95c-bc15f9f309e3">83.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0a06975e9204301b5cb15099574bcee_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzUtMy0xLTEtMTE5NDgy_5342beb5-69d4-4312-87b6-8203370d0d46">43.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf0e35c76ce4737b597d4d31b6103bb_I20221231" decimals="-5" name="mygn:AssetsLessCashCashEquivalentsAndInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzctMS0xLTEtMTE5NDgy_13f80ca2-b1b0-47e1-b31a-97dd884a3274">983.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0f83e0a22104fedb4e475de48140594_I20211231" decimals="-5" name="mygn:AssetsLessCashCashEquivalentsAndInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzctMy0xLTEtMTE5NDgy_784e1caf-5268-4be5-b6c3-b05c806ef1fd">870.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e3d05930c246f797d9ab7061985860_I20221231" decimals="-5" name="mygn:AssetsLessCashCashEquivalentsAndInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzgtMS0xLTEtMTE5NDgy_5ee04cde-e08c-4a7f-a3ca-86cdd4272e9f">45.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e82739b44cd45d7b099f422b6ae33cf_I20211231" decimals="-5" name="mygn:AssetsLessCashCashEquivalentsAndInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzgtMy0xLTEtMTE5NDgy_593abc11-a377-42d8-89d4-057dd6fdc4df">51.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c8aad575c1d41c389544f11390b9d59_I20221231" decimals="-5" name="mygn:AssetsLessCashCashEquivalentsAndInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzktMS0xLTEtMTE5NDgy_ae939da5-d33d-40b2-acc0-b2b4b66d57a9">1,029.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0a06975e9204301b5cb15099574bcee_I20211231" decimals="-5" name="mygn:AssetsLessCashCashEquivalentsAndInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzktMy0xLTEtMTE5NDgy_8c2017bf-f284-4276-94ac-b3c9017d74fd">921.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable investment securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzEwLTEtMS0xLTExOTQ4Mg_e141f250-4060-437c-af21-9457bfb8524e">169.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzEwLTMtMS0xLTExOTQ4Mg_54d94bd1-9bf2-426a-8f78-4e91f3f816e9">398.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzExLTEtMS0xLTExOTQ4Mg_a39428e0-7b41-4792-943d-1b69073145ac">1,198.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzExLTMtMS0xLTExOTQ4Mg_3c55e5f2-89b9-4bcd-8ba7-a0efaf0688ec">1,320.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i7e0793090cf84227944277d460d39a4d_142"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzkxOA_8a66adcf-ab74-430d-9d5a-cd23ba700fee" continuedAt="idc844a6d044d4cb19ad322e83ee59f7d" escape="true">BUSINESS ACQUISITION</ix:nonNumeric></span></div><ix:continuation id="idc844a6d044d4cb19ad322e83ee59f7d" continuedAt="i96411c7a4ffb4bb4a81d3d0b63c0df87"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2022, the Company acquired all of the membership interests of Gateway, a San Diego-based personal genomics company and developer of consumer genetic tests that give families insight into their future children.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair value of the consideration transferred was $<ix:nonFraction unitRef="usd" contextRef="i871418f253134efc9cceceeafbb4c291_D20221101-20221101" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzQ5NDc4MDIzNDI2MTY_529d2386-09ee-4f96-ae45-db9ae952e7d4">68.7</ix:nonFraction>&#160;million. Cash consideration amounted to $<ix:nonFraction unitRef="usd" contextRef="i871418f253134efc9cceceeafbb4c291_D20221101-20221101" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMxOTI_e9999dfa-554a-4f20-97c0-da2809dd3b33">66.6</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="i871418f253134efc9cceceeafbb4c291_D20221101-20221101" decimals="-5" name="mygn:BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzczMTc_63ebee01-1dee-48fa-9769-0c7f11e3b5c4">8.5</ix:nonFraction>&#160;million was deposited for general representation and warranty and working capital adjustment purposes in an escrow account, legally owned by the Company. The remaining consideration included contingent cash consideration with a fair value of $<ix:nonFraction unitRef="usd" contextRef="i871418f253134efc9cceceeafbb4c291_D20221101-20221101" decimals="-5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMyMDc_1ecb331d-4976-4f51-beeb-7a93faba9f53">2.1</ix:nonFraction>&#160;million. The contingent consideration is classified as a liability and has a maximum value of up to $<ix:nonFraction unitRef="usd" contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMyMjE_ecc0c80b-bfca-4cf2-879f-d5d8846bb4e1">32.5</ix:nonFraction>&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on the achievement of certain performance-based targets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The acquisition date fair value of the contingent consideration was based on the Monte Carlo Method, utilizing various pay-out scenarios that factor in forecasted revenue, earnings before interest, taxes, depreciation and amortization ("EBITDA"), and Prequel and FirstGene test volumes that directly result from the sale of the SneakPeek Gender DNA Test relative to targets for fiscal 2023 and 2024.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="i96411c7a4ffb4bb4a81d3d0b63c0df87" continuedAt="ia19c624f246d4c04abcbdc19f6109712"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition is being accounted for under the acquisition method of accounting in accordance with ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The consideration transferred was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date. Management estimated the fair value of tangible and intangible assets and liabilities in accordance with the applicable accounting guidance for business combinations and utilized the services of third-party valuation consultants. The significant assumptions used in the model to estimate the value of the intangible assets included projected cash flows, discount rates, net working capital and long-term growth rate. The initial allocation of the consideration transferred is based on a preliminary valuation and is subject to adjustments. Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible), liabilities assumed, as well as tax-related matters. During the measurement period, the Company may record adjustments to the provisional amounts recognized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management estimated that consideration paid exceeded the fair value of the net assets acquired. Therefore, goodwill of $<ix:nonFraction unitRef="usd" contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMyMzY_246540dc-5151-4fe1-8a92-6c70d271300a">48.7</ix:nonFraction>&#160;million was recorded. The goodwill recognized is primarily attributable to the expected synergies to be achieved from the business combination and is deductible for income tax purposes. <ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzQ5NDc4MDIzNDM2ODQ_dfd529f5-0441-4586-84d7-75e08db8b714" continuedAt="ied83aaa32f4a49639d1cb9917c90262f" escape="true">The following table summarizes the estimated fair value of identified assets acquired and liabilities assumed at the date of acquisition. </ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><ix:continuation id="ied83aaa32f4a49639d1cb9917c90262f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable assets acquired</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzEtMS0xLTEtMTMwMzI2_742e18ea-9702-461f-88be-0d77d2ee6250">1,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzItMS0xLTEtMTMwMzI2_5c0d7a40-6031-4e61-884b-f3a76fdbb59f">1,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic41e7d1ebb214f6792a964d2daa1b432_I20221101" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzUtMS0xLTEtMTM2NTk5_a44ada57-c1f1-4d78-9854-df32917d19b7">10,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd5b839397f4403ca413620e5ce1dffc_I20221101" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzYtMS0xLTEtMTM2NTk5_b0b9da08-2ca4-4f23-af91-76af01ae93fb">6,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i789e41c2063b4e77b952b8700cc045f7_I20221101" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzctMS0xLTEtMTM2NTk5_980b1114-4148-47c1-a82c-d833b1affaa5">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzgtMS0xLTEtMTM3MjUz_06629387-8092-4387-8741-be982eb0bbb3">17,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzUtMS0xLTEtMTMwMzI2_5620d883-9649-4554-8a7b-a4fdb5095d34">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzExLTEtMS0xLTEzODU2OA_c73d8fee-d585-41ff-8385-a48219b00427">20,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzYtMS0xLTEtMTMwMzI2_0fe2a4d5-e3c1-462a-9d27-df501923a848">246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzctMS0xLTEtMTMwMzI2_de105a3b-a595-4e6b-b1f2-74dd176780e5">693</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzgtMS0xLTEtMTMwMzI2_f1ff2b79-3016-45ed-a228-dbe7ec255567">939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzE2LTEtMS0xLTEzODU3OA_198fabf5-8c5e-426c-9087-2ebc304e798f">19,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzExLTEtMS0xLTEzNjQ3MA_1e2e6adc-0784-4eb2-a617-052f5b67ccad">48,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of Purchase Price</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzExLTEtMS0xLTEzMDMyNg_9bf6daee-48fc-44c6-8463-e85506f69bc7">68,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Identifiable Intangible Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the identifiable intangible assets and related useful lives were determined using an income approach discounting expected future cash flows to present value at a discount rate of <ix:nonFraction unitRef="number" contextRef="i75436f77b2804ab3bbcc97fe20a6f36c_D20221101-20221101" decimals="3" name="mygn:BusinessCombinationIntangibleAssetsMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMyOTQ_64c2382b-b7dc-43ec-b51a-a3dc94ede252">15.5</ix:nonFraction>%. The discount rate was based on the estimated internal rate of return for the acquisition and represents the rate that market participants might use to value the intangible assets. The Company will amortize the intangible assets on a straight-line basis over their estimated useful lives. The estimated useful life of the customer relationships and trademarks is <ix:nonNumeric contextRef="id82e3f3eeb68492399f4153822f134df_D20221101-20221101" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMzMDA_38d7e33a-56b5-42fb-8849-d72a77914614"><ix:nonNumeric contextRef="if437534e60cb4439b2cd0da6651519aa_D20221101-20221101" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMzMDA_c0422a72-3c37-45c0-956b-45d348da1995">10</ix:nonNumeric></ix:nonNumeric> years and the estimated useful life of the developed technology is <ix:nonNumeric contextRef="ic3c2906fb217491a8423ba010a090290_D20221101-20221101" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMzMTQ_ff13d72a-c0e9-4168-a27e-2e5d89c6006b">8</ix:nonNumeric> years. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transactions Separate From the Business Acquisition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the business acquisition, the Company also recognized certain transactions which were accounted for separately from the acquisition of assets and assumptions of liabilities in the business acquisition. Compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i7a2ff25d850940a7bc40bed0d8065631_D20220101-20221231" decimals="-5" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMzMjc_dffe71b0-852e-4bca-9b6a-02b1497ce391">1.9</ix:nonFraction>&#160;million was paid at the closing of the transaction pursuant to a retention arrangement with Gateway employees that was negotiated in connection with their retention by the Company. Receipt of the additional amounts available under the retention arrangement is contingent upon future service from the employees and the achievement of certain performance-based targets related to revenue and EBITDA. The $<ix:nonFraction unitRef="usd" contextRef="i7a2ff25d850940a7bc40bed0d8065631_D20220101-20221231" decimals="-5" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMzNDE_96de7982-b9df-462d-b87d-027e7340f314">1.9</ix:nonFraction>&#160;million of compensation expense is recognized in Selling, general, and administrative expense in the Consolidated Statement of Operations for the year ended December 31, 2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="ia19c624f246d4c04abcbdc19f6109712"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i7a2ff25d850940a7bc40bed0d8065631_D20220101-20221231" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMzNTU_7a72a39e-b923-445c-b4f1-d7c5923764a4">3.1</ix:nonFraction>&#160;million of acquisition-related costs in connection with the acquisition of Gateway, which has been recognized as an expense in Selling, general, and administrative expense in the Consolidated Statement of Operations in the period incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro Forma Information (Unaudited)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma results presented below include the effects of Gateway acquisition as if it had been consummated as of January 1, 2021, with adjustments to give effect to pro forma events that are directly attributable to the acquisition, which includes adjustments related to the amortization of acquired intangible assets, interest income and expense, and depreciation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma results do not reflect any operating efficiency or potential cost savings that may result from the consolidation of Gateway with the Company. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operation of the combined company would have been if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations and are not necessarily indicative of results that might have been achieved had the acquisition been consummated as of January 1, 2021. The Company did not have any material, nonrecurring pro forma adjustments directly attributable to the business acquisition included in the reported pro forma earnings.</span></div><div style="margin-top:5pt;text-align:justify"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzQ5NDc4MDIzNDM2ODU_b74bfa6c-83f8-4e52-8090-1dcc6b1aa504" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a2ff25d850940a7bc40bed0d8065631_D20220101-20221231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTpiOTQ4YThkNjJhNDY0OWNjOWVkYTY4MDdmZjFmYmQxOC90YWJsZXJhbmdlOmI5NDhhOGQ2MmE0NjQ5Y2M5ZWRhNjgwN2ZmMWZiZDE4XzMtMS0xLTEtMTMwMzYy_170bf0db-3825-48b7-bbb0-12db48fba014">695,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i673ce123e2a44d4598692c845966f939_D20210101-20211231" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTpiOTQ4YThkNjJhNDY0OWNjOWVkYTY4MDdmZjFmYmQxOC90YWJsZXJhbmdlOmI5NDhhOGQ2MmE0NjQ5Y2M5ZWRhNjgwN2ZmMWZiZDE4XzMtMy0xLTEtMTMwMzYy_c037e776-afc5-43a1-9555-97cc471be93b">709,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a2ff25d850940a7bc40bed0d8065631_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTpiOTQ4YThkNjJhNDY0OWNjOWVkYTY4MDdmZjFmYmQxOC90YWJsZXJhbmdlOmI5NDhhOGQ2MmE0NjQ5Y2M5ZWRhNjgwN2ZmMWZiZDE4XzQtMS0xLTEtMTMwMzYy_68b9b4bd-5847-44f8-bbe0-18ef73349762">112,185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i673ce123e2a44d4598692c845966f939_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTpiOTQ4YThkNjJhNDY0OWNjOWVkYTY4MDdmZjFmYmQxOC90YWJsZXJhbmdlOmI5NDhhOGQ2MmE0NjQ5Y2M5ZWRhNjgwN2ZmMWZiZDE4XzQtMy0xLTEtMTMwMzYy_0b4d14e3-8f8a-45c7-ad5a-ef4c39cf35e6">28,686</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue and net loss from Gateway included in the Company's Consolidated Statements of Operations since the acquisition date through December 31, 2022 is $<ix:nonFraction unitRef="usd" contextRef="i42ace60aa6e54d01b61af32b6f5812e2_D20221101-20221231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzQzOTgwNDY1MjgzODk_147483a9-4b84-42c3-9483-ac08cf85aeca">3.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i42ace60aa6e54d01b61af32b6f5812e2_D20221101-20221231" decimals="-5" sign="-" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzQzOTgwNDY1Mjg0MDQ_a3ddcba4-904e-4a56-884d-5eef2c43d6a7">2.8</ix:nonFraction> million, respectively. Of the $<ix:nonFraction unitRef="usd" contextRef="i42ace60aa6e54d01b61af32b6f5812e2_D20221101-20221231" decimals="-5" sign="-" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzQzOTgwNDY1MjkxNTM_a3ddcba4-904e-4a56-884d-5eef2c43d6a7">2.8</ix:nonFraction> million net loss recognized, $<ix:nonFraction unitRef="usd" contextRef="i7a2ff25d850940a7bc40bed0d8065631_D20220101-20221231" decimals="-5" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzQzOTgwNDY1MjkxNjg_96de7982-b9df-462d-b87d-027e7340f314">1.9</ix:nonFraction>&#160;million is the compensation expense paid at the closing of the transaction discussed above.</span></div></ix:continuation><div id="i7e0793090cf84227944277d460d39a4d_139"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzE4NDQ_6cd37162-86cc-47a5-8a6f-fc796b45155f" continuedAt="ifbffe0256f8047bbb64aa65fcd1584c9" escape="true">DIVESTITURES</ix:nonNumeric></span></div><ix:continuation id="ifbffe0256f8047bbb64aa65fcd1584c9" continuedAt="id7e3a9652163455b90f79491dbcb725d"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 28, 2021, the Company completed the sale of the Myriad myPath, LLC laboratory to Castle Biosciences, Inc. for cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i32039b626a934562bee22c0bff60b59d_D20210528-20210528" decimals="-5" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzE2MQ_ea8babfc-7f80-4197-af3f-7fa220962fa4">32.5</ix:nonFraction>&#160;million. The transaction was accounted for as a sale of assets and the Company recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="i32039b626a934562bee22c0bff60b59d_D20210528-20210528" decimals="-5" name="mygn:GainLossOnDispositionOfAssetsNetOfTransactionFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzI1Ng_67ae0b38-2c6b-4219-b355-2804db1c24c5">31.2</ix:nonFraction>&#160;million, net of transaction costs of $<ix:nonFraction unitRef="usd" contextRef="i32039b626a934562bee22c0bff60b59d_D20210528-20210528" decimals="-5" name="mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzI4OA_f9f9a31b-0b69-4fdf-89d0-e04fc62c214a">1.3</ix:nonFraction>&#160;million, in Other income (expense) in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021, the Company completed the sale of Myriad RBM, Inc., then a wholly owned subsidiary of the Company, to IQVIA RDS, Inc., for cash consideration of $<ix:nonFraction unitRef="usd" contextRef="if94a3c16ec0f40b79d3e7cd2713c4a83_D20210701-20210701" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzUzNg_6897c532-6c9e-477c-b104-63c804155230">197.0</ix:nonFraction>&#160;million. The transaction was accounted for as a sale of a business and the Company recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="if94a3c16ec0f40b79d3e7cd2713c4a83_D20210701-20210701" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzYzNQ_4b1b247b-b133-4e25-8cf9-94c02da5957e">121.0</ix:nonFraction>&#160;million, net of transaction costs of $<ix:nonFraction unitRef="usd" contextRef="if94a3c16ec0f40b79d3e7cd2713c4a83_D20210701-20210701" decimals="-5" name="mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzY2Nw_cca63351-d690-4aa3-9007-933085b41dd2">4.8</ix:nonFraction>&#160;million, in Other income (expense) in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 13, 2021, the Company completed the sale of select operating assets and intellectual property, including the Vectra test, from the Myriad Autoimmune business unit to Laboratory Corporation of America Holdings for cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i754115245e57408994525a98aed1283a_D20210913-20210913" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzEwMDI_525feefb-464b-4409-a5ea-bfca0c2ce0e1">150.0</ix:nonFraction>&#160;million. The transaction was accounted for as a sale of a business and the Company recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="i754115245e57408994525a98aed1283a_D20210913-20210913" decimals="-5" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzExMDE_9c5a6bf1-c7b8-46e4-b19c-d1e52bf8fb99">0.6</ix:nonFraction>&#160;million, net of transaction costs of $<ix:nonFraction unitRef="usd" contextRef="i754115245e57408994525a98aed1283a_D20210913-20210913" decimals="-5" name="mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzExMzM_25e581f4-8391-4725-8dfb-6410848f60a8">4.4</ix:nonFraction>&#160;million, in Other income (expense) in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating results of these businesses do not qualify for reporting as discontinued operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the divestiture transactions, the Company recognized losses of $<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:InventoryFirmPurchaseCommitmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzE0MTA_1fdc811c-388d-4092-8746-29e4f91678c4">5.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzE0MTc_afd48829-6ff7-4790-a3b0-766bade2087d">6.5</ix:nonFraction>&#160;million for a non-cancelable inventory purchase commitment and inventory, respectively, during the year ended December 31, 2021, as t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company no longer had use for the goods. Both of these losses are included in Other income (expense) in the Consolidated Statements of Operations for the year ended December, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><ix:continuation id="id7e3a9652163455b90f79491dbcb725d"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzE4NDU_63a42862-9ea4-4635-8654-74f067d14cd8" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the amounts recognized in Other income (expense) for the year ended December 31, 2021:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of Myriad RBM, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ee8a7e07b6457b867d5750561f27de_D20210101-20211231" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90YWJsZTpkMjI2YWFjOTdkNDc0NWJkODVhNWNlZTVkNmM0MGUwZi90YWJsZXJhbmdlOmQyMjZhYWM5N2Q0NzQ1YmQ4NWE1Y2VlNWQ2YzQwZTBmXzEtMS0xLTEtMTE5NDgy_7fd79b2d-61c6-4c4b-bc52-7fb351f06ae2">121.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of the Myriad myPath, LLC laboratory</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ba75a9ef71348d3b90148f91f146b36_D20210101-20211231" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90YWJsZTpkMjI2YWFjOTdkNDc0NWJkODVhNWNlZTVkNmM0MGUwZi90YWJsZXJhbmdlOmQyMjZhYWM5N2Q0NzQ1YmQ4NWE1Y2VlNWQ2YzQwZTBmXzItMS0xLTEtMTE5NDgy_552bd60d-398f-496f-b936-5bbf8b2e73bb">31.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b99a13c827f4f10ad3b6af0f22ddd25_D20210101-20211231" decimals="-5" sign="-" name="mygn:DisposalGroupNotDiscontinuedOperationGainLossOnInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90YWJsZTpkMjI2YWFjOTdkNDc0NWJkODVhNWNlZTVkNmM0MGUwZi90YWJsZXJhbmdlOmQyMjZhYWM5N2Q0NzQ1YmQ4NWE1Y2VlNWQ2YzQwZTBmXzMtMS0xLTEtMTE5NDgy_7b768c2f-feda-48ac-875b-586b81414096">11.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on sale of Myriad Autoimmune assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie73f9b8455314405972aa71faee08793_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90YWJsZTpkMjI2YWFjOTdkNDc0NWJkODVhNWNlZTVkNmM0MGUwZi90YWJsZXJhbmdlOmQyMjZhYWM5N2Q0NzQ1YmQ4NWE1Y2VlNWQ2YzQwZTBmXzQtMS0xLTEtMTE5NDgy_e78f5daa-e9f1-434e-8f9d-1ec2ac05a90a">0.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b99a13c827f4f10ad3b6af0f22ddd25_D20210101-20211231" decimals="-5" sign="-" name="mygn:DisposalGroupNotDiscontinuedOperationGainLossOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90YWJsZTpkMjI2YWFjOTdkNDc0NWJkODVhNWNlZTVkNmM0MGUwZi90YWJsZXJhbmdlOmQyMjZhYWM5N2Q0NzQ1YmQ4NWE1Y2VlNWQ2YzQwZTBmXzUtMS0xLTEtMTE5NDgy_e1f7c9b6-ef3b-44b2-a04c-e001e9658934">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90YWJsZTpkMjI2YWFjOTdkNDc0NWJkODVhNWNlZTVkNmM0MGUwZi90YWJsZXJhbmdlOmQyMjZhYWM5N2Q0NzQ1YmQ4NWE1Y2VlNWQ2YzQwZTBmXzYtMS0xLTEtMTE5NDgy_392d293a-007f-40a7-8c12-b46e5e0d68ca">139.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i7e0793090cf84227944277d460d39a4d_148"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90ZXh0cmVnaW9uOmNlOTdjNWQyZGM4ZjRkMTRiZTUzYTNkYWY5NjM2YTk5XzQ0_12b8d58a-427f-48cb-ba79-433c8c51ddbf" continuedAt="ia59fd1a1059f448686ec3aa682c77b48" escape="true">SUPPLEMENTAL CASH FLOW INFORMATION</ix:nonNumeric></span></div><ix:continuation id="ia59fd1a1059f448686ec3aa682c77b48"><ix:nonNumeric contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90ZXh0cmVnaW9uOmNlOTdjNWQyZGM4ZjRkMTRiZTUzYTNkYWY5NjM2YTk5XzQ1_eed38525-992f-477c-913b-b9ac3cfd8098" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's supplemental cash flow information for the respective periods are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzItMS0xLTEtMTE5NDgy_84457a13-0952-45bd-9955-905ebeeb513d">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzItMy0xLTEtMTE5NDgy_0b1847c7-1b4f-4721-88fc-0ba6978da1e8">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzItNS0xLTEtMTE5NDgy_f7bdb96c-e4b1-485d-b646-d61173edb497">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzItNy0xLTEtMTE5NDgy_26fafe26-c948-4999-bafb-8073673346f2">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzMtMS0xLTEtMTE5NDgy_d7135b41-1fce-4926-9ad8-81be84300c53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzMtMy0xLTEtMTE5NDgy_5205b386-4937-4e3d-8d14-1d38b8344a8c">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzMtNS0xLTEtMTE5NDgy_2ae8339b-b0d1-437d-b965-08f6bef8706f">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzMtNy0xLTEtMTE5NDgy_ff0d851c-13cb-4653-8449-1dc38e4fa8f8">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received for income tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromIncomeTaxRefunds" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzQtMS0xLTEtMTE5NDgy_eb050973-a8dc-40a9-9beb-0b817853e59a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIncomeTaxRefunds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzQtMy0xLTEtMTE5NDgy_9ce88cb8-c5dd-499e-b8f8-c02a134ff8e9">90.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:ProceedsFromIncomeTaxRefunds" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzQtNS0xLTEtMTE5NDgy_9a99f300-87aa-470b-820c-f3c4a1c0367a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:ProceedsFromIncomeTaxRefunds" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzQtNy0xLTEtMTE5NDgy_e2bc1272-1baa-431a-a8a3-7cc4a313c338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of operating lease right-of-use assets and lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzctMS0xLTEtMTE5NDgy_82c9a9d7-3734-4884-9c8f-d884e41adbae">46.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzctMy0xLTEtMTE5NDgy_15e1c3ce-f150-4348-a8ce-a4f9b3e57753">41.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzctNS0xLTEtMTE5NDgy_e27e3b88-ee03-4ae4-b327-bc1d24da5a2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzctNy0xLTEtMTE5NDgy_728827a7-7458-4c4e-a901-0ee49762c920">74.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="mygn:OperatingLeaseLiabilityEstablished" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzgtMS0xLTEtMTE5NDgy_7782f3a9-705e-4533-8ff8-1221f656c4d1">46.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="mygn:OperatingLeaseLiabilityEstablished" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzgtMy0xLTEtMTE5NDgy_3545ae74-42b4-439f-b72e-8e77ef19a942">48.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="mygn:OperatingLeaseLiabilityEstablished" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzgtNS0xLTEtMTE5NDgy_4a8c4f68-962e-41c4-8c4b-38a3c6becb7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="mygn:OperatingLeaseLiabilityEstablished" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzgtNy0xLTEtMTE5NDgy_8f1d7a80-ea76-45aa-99f4-c6d47945336e">78.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant improvement allowance not yet received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="mygn:TenantImprovementAllowanceNotYetReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzktMS0xLTEtMTMzMzk2_3a8eaf65-f369-44f5-8440-56c539338bb0">22.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="mygn:TenantImprovementAllowanceNotYetReceived" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzktMy0xLTEtMTMzNDA0_ceeddabc-6b53-4c47-bd55-277f6bad4906">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="mygn:TenantImprovementAllowanceNotYetReceived" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzktNS0xLTEtMTMzNDEy_8ff060db-8bf2-4d09-a639-65d748755521">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="mygn:TenantImprovementAllowanceNotYetReceived" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzktNy0xLTEtMTMzNDIw_b91fa1be-9a9c-400d-88bc-5a4e16e51b54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment in accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzEwLTEtMS0xLTEzMzM5Ng_fbeca70a-6c77-47ab-878c-2ad3e401840f">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzEwLTMtMS0xLTEzMzQwNA_21eaaf6e-df9e-4a93-927b-96d23ede0e97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzEwLTUtMS0xLTEzMzQxMg_d54ab61b-3023-4325-89e1-af2b58b92372">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzEwLTctMS0xLTEzMzQyMA_441dcb0b-5396-4d52-a94d-7fbc0a93bcba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities and other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231" decimals="-5" name="mygn:LeaseRelatedExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzktMS0xLTEtMTE5NDgy_a193b642-cf07-40e0-be37-c2e7dfa9930e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231" decimals="-5" name="mygn:LeaseRelatedExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzktMy0xLTEtMTE5NDgy_6540a3e2-5985-49ba-885d-5b211b93e04f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231" decimals="-5" name="mygn:LeaseRelatedExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzktNS0xLTEtMTE5NDgy_a842de92-06b1-4035-99ba-bf5ca5b3626d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630" decimals="-5" name="mygn:LeaseRelatedExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzktNy0xLTEtMTE5NDgy_cbd81926-8f42-470b-b149-15005817d118">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i7e0793090cf84227944277d460d39a4d_157"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures (Disclosure Controls) within the meaning of Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our Disclosure Controls are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act, such as this Annual Report on Form 10-K, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Our Disclosure Controls are also designed to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our Disclosure Controls, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily applied its judgment in evaluating and implementing possible controls and procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this Annual Report on Form 10-K, we evaluated the effectiveness of the design and operation of our Disclosure Controls, which was done under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. Based on the evaluation of our Disclosure Controls, our Chief Executive Officer and Chief Financial Officer have concluded that, as of December&#160;31, 2022, our Disclosure Controls were effective to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the Securities and Exchange Commission's rules and forms and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a&#8209;15(f) and 15d&#8209;15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of the Company's internal control over financial reporting as of December&#160;31, 2022, using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework (2013). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have evaluated the effectiveness of our internal control over financial reporting as of the end of the period covered by this Annual Report on Form 10-K, with the participation of our Chief Executive Officer and Chief Financial Officer, as well as other key members of our management. Based on this assessment, management concluded that, as of December&#160;31, 2022, the Company's internal control over financial reporting was effective.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of December&#160;31, 2022 has been audited by Ernst &amp; Young LLP, an independent registered public accounting firm, as stated in their report included elsewhere herein.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Remediation of Previously Reported Material Weakness</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discrete Tax Transaction</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The material weakness in our internal control over financial reporting related to our income tax provision process identified in connection with the preparation of our condensed consolidated quarterly financial statements as of September 30, 2021 has been remediated. Specifically, we did not provide adequate review and control with respect to the completeness and accuracy of inputs used in the income tax provision and related accrual. While the control deficiency did not result in a misstatement of our previously issued consolidated financial statements, the control deficiency could have resulted in a misstatement of the income tax related accounts or disclosures that would have resulted in a material misstatement of our annual or interim consolidated financial statements that would not have been prevented or detected on a timely basis. This material weakness has been remediated as of March 31, 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To improve our internal control over financial reporting and remediate this prior period material weakness, we designed and implemented enhanced controls over the review of information underlying discrete transactions in the income tax provision.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Information Technology General Controls ("ITGCs")</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The material weakness in our internal control over financial reporting related to general information technology controls for information systems identified in connection with the preparation of the financial statements as of December 31, 2021 has been remediated. Specifically, the material weakness resulted from the aggregation of control deficiencies related to systems supporting the Company's internal control processes. Our IT-dependent business process controls were also deemed ineffective because they could have been adversely impacted. While the control deficiency did not result in a misstatement to the consolidated financial statement, the material weakness could have resulted in a misstatement impacting account balances or disclosures that would have resulted in a material misstatement to the consolidated financial statements that would not have been prevented or detected on a timely basis. This material weakness has been remediated as of December 31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To improve our internal control over financial reporting and remediate this prior period material weakness, we took the following actions:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We conducted additional training for our IT personnel to ensure a clear understanding of risk assessment, controls and monitoring activities related to automated processes and systems and ITGCs related to financial reporting.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We implemented improved IT policies, procedures and control activities for key systems which impact our financial reporting.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We increased resources dedicated to monitoring ITGCs related to financial reporting, including additional personnel with the appropriate level of knowledge, experience and training, to ensure compliance with policies and procedures.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We hired a third-party to assist with the implementation of, and to review and provide feedback on, our remediation plan. In addition, the third-party advised us on best practices to further strengthen our IT control environment.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. &#160;&#160;&#160;&#160;Change in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as discussed above under "Remediation of Previously Reported Material Weakness," there were no changes in our internal control over financial reporting that occurred during the quarter or year ended December&#160;31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Myriad Genetics, Inc.&#160;&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Myriad Genetics, Inc. and subsidiaries&#8217; internal control over financial reporting as of December&#160;31, 2022, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Myriad Genetics, Inc. and subsidiaries (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2022, based on the COSO criteria.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of Myriad Genetics, Inc. and subsidiaries as of December&#160;31, 2022 and 2021, and the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity and cash flows for the years ended December&#160;31, 2022 and 2021, the six month period ended December&#160;31, 2020 and the year in the period ended June 30, 2020, and the related notes and our report dated March&#160;1, 2023 expressed an unqualified opinion thereon. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salt Lake City, UT</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;1, 2023</span></div><div id="i7e0793090cf84227944277d460d39a4d_160"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i7e0793090cf84227944277d460d39a4d_163"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C.&#160;&#160;&#160;&#160;DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i7e0793090cf84227944277d460d39a4d_169"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Management and Corporate Governance,&#8221; and &#8220;Corporate Code of Conduct&#8221; in our Proxy Statement for the 2023 Annual Meeting of Stockholders expected to be held on June 1, 2023.</span></div><div id="i7e0793090cf84227944277d460d39a4d_172"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Compensation Discussion and Analysis,&#8221; "Pay Versus Performance," &#8220;Management and Corporate Governance &#8211; Committees of the Board of Directors and Meetings &#8211; Compensation and Human Capital Committee Interlocks and Insider Participation,&#8221; &#8220;Compensation and Human Capital Committee Report</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and &#8220;Management and Corporate Governance &#8211; Board&#8217;s Role in the Oversight of Risk Management&#8221; in our Proxy Statement for the 2023 Annual Meeting of Stockholders expected to be held on June 1, 2023.</span></div><div id="i7e0793090cf84227944277d460d39a4d_175"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Compensation Discussion and Analysis - Equity Compensation Plan Information&#8221; in our Proxy Statement for the 2023 Annual Meeting of Stockholders expected to be held on June 1, 2023.</span></div><div id="i7e0793090cf84227944277d460d39a4d_178"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the caption &#8220;Certain Relationships and Related Person Transactions&#8221; and &#8220;Management and Corporate Governance &#8211; Director Independence&#8221; in our Proxy Statement for the 2023 Annual Meeting of Stockholders expected to be held </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 1, 2023.</span></div><div id="i7e0793090cf84227944277d460d39a4d_181"></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto in the proposal entitled &#8220;Selection of Independent Registered Public Accounting Firm&#8221; in our Proxy Statement for the 2023 Annual Meeting of the Stockholders expected to be held on June 1, 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_184"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i7e0793090cf84227944277d460d39a4d_187"></div><div style="-sec-extract:summary;margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.&#160;&#160;&#160;&#160;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The following documents are included as part of this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Index to Consolidated Financial Statements&#8221; under Part II, Item 8 to this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Financial Statement Schedules</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial statement schedules have not been included because they are not applicable, or the information is included in financial statements or notes thereto.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed with this<br/>Report</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by<br/>Reference herein<br/>from Form or<br/>Schedule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC File/<br/>Registration<br/>Number</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000119312511223211/dex31.htm">Restated Certificate of Incorporation, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 3.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2011</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000119312520269801/d102302dex31.htm">Restated By-Laws</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 3.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/15/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000899923/000119312511223211/dex41.htm">Specimen </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000899923/000119312511223211/dex41.htm">C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000899923/000119312511223211/dex41.htm">ommon </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000899923/000119312511223211/dex41.htm">S</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000899923/000119312511223211/dex41.htm">tock </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000899923/000119312511223211/dex41.htm">C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000899923/000119312511223211/dex41.htm">ertificate</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 4.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2011</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000089992321000021/mygn-20201231xexx42.htm">Description of Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-KT (Exhibit 4.2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/16/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Agreements</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/0000927016-96-001627.txt">Lease Agreement, dated October 12, 1995, between the Registrant and Boyer Research Park Associates V, by its general partner, the Boyer Company</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/8/1996</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000899923/000119312516576683/d173578dex101.htm">Amendment to Phase I Lease Agreement, dated February 3, 2016, between the Registrant and HCPI/UTAH II, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/4/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/0000927356-98-001556.txt">Lease Agreement-Research Park Building Phase II, dated March 6, 1998, between the Registrant and Research Park Associated VI, by its general partner, the Boyer Company, L.C.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 10.44)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/24/1998</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/000119312516576683/d173578dex102.htm">Amendment to Phase II Lease Agreement, dated February 3, 2016, between Myriad Genetics, Inc. and HCPI/UTAH II, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/4/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/000092735601500159/dex101.txt">Lease Agreement, dated March 31, 2001, between the Registrant and Boyer Research Park Associates VI, by its general partner, The Boyer Company, L.C.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/15/2001</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/000119312516576683/d173578dex103.htm">Amendment to Phase III Lease Agreement, dated February 3, 2016, between Myriad Genetics, Inc. and HCPI/UTAH II, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/4/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/000119312508186392/dex1032.htm">Lease Agreement, dated March 11, 2008, between the Registrant and Boyer Research Park Associates IX, by its general partner, The Boyer Company, L.C.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 10.32)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/28/2008</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/000119312510107257/dex104.htm">Amendment to Lease Agreement, dated February 12, 2010 between the Registrant and Boyer Research Park Associates IX, L.C.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/5/2010</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed with this<br/>Report</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by<br/>Reference herein<br/>from Form or<br/>Schedule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC File/<br/>Registration<br/>Number</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/000156459019031849/mygn-ex106_159.htm">Lease Agreement, dated January 31, 2019 between the Registrant and Boyer Research Park Associates X, L.C., by its Manager, The Boyer Company, L.C.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K (Exhibit 10.6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/13/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Agreements with Executive Officers and Directors</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000089992322000140/directorcompensationpolicy.htm">Non-Employee Director Compensation Policy+</a></span></div><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit<br/>10.2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/2/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/000119312509181226/dex1034.htm">Form of director and executive officer indemnification agreement+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 10.34)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/25/2009</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000119312520269801/d102302dex101.htm">Form of Severance and Change in Control Agreement+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K   (Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/15/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000162828020016036/exhibit101-diazemploym.htm">Executive Employment Agreement between the Registrant and Paul J. Diaz dated July 24, 2020+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit<br/>10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000162828020016036/exhibit102-diazpsuagre.htm">Performance-Based Restricted Stock Unit Agreement between Registrant and Paul J. Diaz dated October 8, 2020+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit<br/>10.2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000162828020016036/exhibit103-diazrsuagre.htm">Restricted Stock Unit Agreement between the Registrant and Paul J. Diaz dated August 13, 2020+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit<br/>10.3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000162828020016036/exhibit104-diazperform.htm">Performance-Based Non-Qualified Stock Option Agreement between the Registrant and Paul J. Diaz dated August 13, 2020+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit<br/>10.4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000162828020016036/exhibit105-diaztimexba.htm">Non-Qualified Stock Option Agreement between the Registrant and Paul J. Diaz dated August 13, 2020+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit<br/>10.5)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000162828020016036/exhibit106-diazformofs.htm">Form of Separation and Release Agreement between the Registrant and Paul J. Diaz+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit<br/>10.6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity Compensation Plans</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000119312516783506/d308192dex101.htm">2010 Employee, Director and Consultant Equity Incentive Plan, as amended+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/2/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000119312511019910/dex103.htm">Form of Stock Option Agreement under the 2010 Equity Incentive Plan+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit<br/>10.3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/1/2011</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000119312511019910/dex104.htm">Form of Director Stock Option Agreement under the 2010 Equity Incentive Plan+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit<br/>10.4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/1/2011</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000089992320000006/exhibit1012017employee.htm">2017 Employee, Director and Consultant Equity Incentive Plan, as amended+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/7/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000156459020040011/mygn-ex1011_355.htm">Form of Restricted Stock Unit Agreement under the 2017 Equity Incentive Plan+</a></span></div><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 10.11)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/13/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed with this<br/>Report</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by<br/>Reference herein<br/>from Form or<br/>Schedule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC File/<br/>Registration<br/>Number</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000089992322000085/ex101-espp.htm">Amended and Restated 2012 Employee Stock Purchase </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000089992322000085/ex101-espp.htm">Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000089992322000085/ex101-espp.htm"> +</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000089992322000085/ex101-espp.htm"> </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/2/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/899923/000156459017024444/mygn-ex102_44.htm">2013 Executive Incentive Plan, as amended+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 10.2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/1/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Credit Agreement</span></td></tr><tr style="height:6pt"><td colspan="33" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000089992322000112/creditagreementforamendmen.htm">Amendment No. 4, dated July 26, 2022, to the Credit Agreement, dated December 23, 2016, among the Company, the lenders from time to time party thereto, and JPMorgan Chase Bank, N.A., as administrative agent, as amended July 31, 2018, May 1, 2020, and February 22, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000089992322000112/creditagreementforamendmen.htm"> (which includes the full Credit Agreement, as amended, in Exhibit A thereto)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/899923/000089992322000112/creditagreementforamendmen.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/27/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-26642</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Exhibits</span></td></tr><tr style="height:6pt"><td colspan="33" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mygn-20221231ex211.htm">List of Subsidiaries of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mygn-20221231xexx231.htm">Consent of Independent Registered Public Accounting Firm (Ernst &amp; Young LLP)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Power of Attorney (included in the signature page hereto)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mygn-20221231xexx311.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mygn-20221231xexx312.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mygn-20221231xexx32.htm">Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from Myriad Genetics, Inc.&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii)&#160;Consolidated Statements of Operations (iii) Consolidated Statements of Comprehensive Loss, (iv) Consolidated Statements of Stockholders&#8217; Equity, (v)&#160;Consolidated Statements of Cash Flows, and (vi)&#160;Notes to Consolidated Financial Statements. Inline XBRL Instance Document &#8211; Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(+)&#160;&#160;&#160;&#160;Management contract or compensatory plan arrangement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><div id="i7e0793090cf84227944277d460d39a4d_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March&#160;1, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MYRIAD GENETICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Paul J. Diaz</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paul J. Diaz</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">President and Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Power of Attorney</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Paul J. Diaz and R. Bryan Riggsbee and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated below and on the dates indicated.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7e0793090cf84227944277d460d39a4d_7">Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signatures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Paul J. Diaz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paul J. Diaz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ R. Bryan Riggsbee</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">R. Bryan Riggsbee</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer (Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Natalie Munk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Natalie Munk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ S. Louise Phanstiel</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair of the Board</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">S. Louise Phanstiel</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Paul Bisaro</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paul Bisaro</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Heiner Dreismann</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Heiner Dreismann, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Rashmi Kumar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rashmi Kumar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Lee N. Newcomer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lee N. Newcomer, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Colleen F. Reitan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Colleen F. Reitan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Daniel M. Skovronsky</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Daniel M. Skovronsky, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Daniel K. Spiegelman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Daniel K. Spiegelman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>mygn-20221231ex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i389a2a0a9bbc4e158701b17d38caf19f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Exhibit 21.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">LIST OF SUBSIDIARIES OF MYRIAD GENETICS, INC.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.987%"><tr><td style="width:1.0%"></td><td style="width:25.206%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Company Name</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Jurisdiction of Incorporation</font></div></td></tr><tr style="height:8pt"><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Genetic Laboratories, Inc.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Assurex Health, Inc.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Crescendo Bioscience, LLC</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">2</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Gateway Genomics, LLC</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Women&#8217;s Health, Inc</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Delaware</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad GmbH</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">4</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Germany</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Services GmbH</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">3</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Germany</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Genetics Espana SL</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Spain</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Genetics SAS</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">3</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">France</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Genetics S.r.l.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Italy</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Genetics GmbH </font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">3</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Switzerland</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Genetics LTD</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">3</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">United Kingdom</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Genetics Canada Corp</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">3</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Canada</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Genetics B.V.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Netherlands</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Genetics Australia PTY LTD</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">3</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Australia</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad International GmbH</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">4</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Germany</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Assurex Health, Ltd</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">5</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Canada</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Myriad Genetics GK</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Japan</font></div></td></tr><tr style="height:8pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1 &#8211; A wholly-owned subsidiary of Myriad Genetics, Inc., a Delaware corporation.  </font></div><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">2 &#8211; Crescendo Bioscience, LLC is owned by Myriad Genetics, Inc. and Myriad Genetics GK.</font></div><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3 &#8211; A wholly-owned subsidiary of Myriad Genetics B.V.</font></div><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4 &#8211; A wholly-owned subsidiary of Myriad Services GmbH </font></div><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5 &#8211; A majority owned subsidiary of Assurex Health, Inc.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>mygn-20221231xexx231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0533a0a303134b098e5dfca54c125545_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:118%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">We consent to the incorporation by reference in the following Registration Statements of Myriad Genetics, Inc.&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:9.75pt">Registration Statements on Form S-8 (File No.&#8217;. 333-185325 and 333-26541) pertaining to the Myriad Genetics, Inc. Amended and Restated 2012 Employee Stock Purchase Plan, </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:9.75pt">Registration Statement on Form S-8 (File No. 333-245718) pertaining to the Myriad Genetics, Inc. Non-Qualified Stock Option Agreement, Performance-Based Non-Qualified Stock Option Agreement, Restricted Stock Unit Agreement, and Performance-Based Restricted Stock Unit Agreement, </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:9.75pt">Registration Statement on Form S-8 (File No. 333-222913, File No. 333-229574, File No. 333-236324, File No. 333-254337) pertaining to the Myriad Genetics, Inc. 2017 Employee, Director and Consultant Equity Incentive Plan, as amended,</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:9.75pt">Registration Statements on Form S-8 (File No.&#8217;s 333-171994, 333-179281, 333-185325, 333-193767, 333-209354 and 333-215959) pertaining to the Myriad Genetics, Inc. 2010 Employee, Director and Consultant Equity Incentive Plan, as amended, and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:9.75pt">Registration Statements on Form S-8 (File No.&#8217;s 333-115409, 333-120398, 333-131653, 333-140830, 333-150792, 333-157130 and 333-164670) pertaining to the Myriad Genetics, Inc. 2003 Employee, Director and Consultant Stock Option Plan, as amended&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">of our reports dated March 1, 2023 with respect to the consolidated financial statements of Myriad Genetics, Inc. and the effectiveness of internal control over financial reporting of Myriad Genetics, Inc. included in this Annual Report (Form 10-K) of Myriad Genetics, Inc. for the year ended December 31, 2022. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Salt Lake City, UT</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 1, 2023</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>mygn-20221231xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i618e69bf6a314e499a25daccdd3f2969_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SARBANES-OXLEY SECTION 302 CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Paul J. Diaz, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form 10-K of Myriad Genetics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 1, 2023</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Paul J. Diaz</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Diaz</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>mygn-20221231xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie950e7cec6404362902c3daad026d15c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SARBANES-OXLEY SECTION 302 CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, R. Bryan Riggsbee, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form 10-K of Myriad Genetics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 1, 2023</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; R. Bryan Riggsbee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Bryan Riggsbee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>mygn-20221231xexx32.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib79423a3ab0a46798c09678b307f909e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Myriad Genetics, Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Annual Report on Form 10-K for the year ended December 31, 2022 (the &#8220;Form 10-K&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 1, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 1, 2023</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Paul J. Diaz</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; R. Bryan Riggsbee</font></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul J. Diaz</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. Bryan Riggsbee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>mygn-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6db69074-e648-4be3-ae6d-ea77b2ae08c9,g:6dbaf31c-e8bf-47fc-986c-d695276c3aba-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mygn="http://www.myriad.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.myriad.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mygn-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mygn-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mygn-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mygn-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.myriad.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.myriad.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.myriad.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.myriad.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.myriad.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000006 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000007 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.myriad.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableInvestmentSecurities" roleURI="http://www.myriad.com/role/MarketableInvestmentSecurities">
        <link:definition>0000010 - Disclosure - Marketable Investment Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.myriad.com/role/FairValueMeasurements">
        <link:definition>0000011 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNet" roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNet">
        <link:definition>0000012 - Disclosure - Property, Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssets">
        <link:definition>0000013 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilities" roleURI="http://www.myriad.com/role/AccruedLiabilities">
        <link:definition>0000014 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.myriad.com/role/LongTermDebt">
        <link:definition>0000015 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLongTermLiabilities" roleURI="http://www.myriad.com/role/OtherLongTermLiabilities">
        <link:definition>0000016 - Disclosure - Other Long-Term Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquity" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquity">
        <link:definition>0000017 - Disclosure - Preferred and Common Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.myriad.com/role/StockBasedCompensation">
        <link:definition>0000018 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.myriad.com/role/IncomeTaxes">
        <link:definition>0000019 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.myriad.com/role/CommitmentsandContingencies">
        <link:definition>0000020 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.myriad.com/role/Leases">
        <link:definition>0000021 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeDeferredSavingsPlan" roleURI="http://www.myriad.com/role/EmployeeDeferredSavingsPlan">
        <link:definition>0000022 - Disclosure - Employee Deferred Savings Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandRelatedInformation" roleURI="http://www.myriad.com/role/SegmentandRelatedInformation">
        <link:definition>0000023 - Disclosure - Segment and Related Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisition" roleURI="http://www.myriad.com/role/BusinessAcquisition">
        <link:definition>0000024 - Disclosure - Business Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Divestitures" roleURI="http://www.myriad.com/role/Divestitures">
        <link:definition>0000025 - Disclosure - Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformation" roleURI="http://www.myriad.com/role/SupplementalCashFlowInformation">
        <link:definition>0000026 - Disclosure - Supplemental Cash Flow Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000027 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000028 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableInvestmentSecuritiesTables" roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesTables">
        <link:definition>0000029 - Disclosure - Marketable Investment Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.myriad.com/role/FairValueMeasurementsTables">
        <link:definition>0000030 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetTables" roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetTables">
        <link:definition>0000031 - Disclosure - Property, Plant and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>0000032 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.myriad.com/role/AccruedLiabilitiesTables">
        <link:definition>0000033 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLongTermLiabilitiesTables" roleURI="http://www.myriad.com/role/OtherLongTermLiabilitiesTables">
        <link:definition>0000034 - Disclosure - Other Long-Term Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquityTables" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables">
        <link:definition>0000035 - Disclosure - Preferred and Common Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.myriad.com/role/StockBasedCompensationTables">
        <link:definition>0000036 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.myriad.com/role/IncomeTaxesTables">
        <link:definition>0000037 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.myriad.com/role/LeasesTables">
        <link:definition>0000038 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeDeferredSavingsPlanTables" roleURI="http://www.myriad.com/role/EmployeeDeferredSavingsPlanTables">
        <link:definition>0000039 - Disclosure - Employee Deferred Savings Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandRelatedInformationTables" roleURI="http://www.myriad.com/role/SegmentandRelatedInformationTables">
        <link:definition>0000040 - Disclosure - Segment and Related Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionTables" roleURI="http://www.myriad.com/role/BusinessAcquisitionTables">
        <link:definition>0000041 - Disclosure - Business Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresTables" roleURI="http://www.myriad.com/role/DivestituresTables">
        <link:definition>0000042 - Disclosure - Divestitures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationTables" roleURI="http://www.myriad.com/role/SupplementalCashFlowInformationTables">
        <link:definition>0000043 - Disclosure - Supplemental Cash Flow Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000044 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesRestrictedCashDetails" roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRestrictedCashDetails">
        <link:definition>0000045 - Disclosure - Organization and Summary of Significant Accounting Policies - Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails" roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails">
        <link:definition>0000046 - Disclosure - Organization and Summary of Significant Accounting Policies - Revenue by Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails" roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails">
        <link:definition>0000047 - Disclosure - Organization and Summary of Significant Accounting Policies - Revenue by Geographical Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails" roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails">
        <link:definition>0000048 - Disclosure - Organization and Summary of Significant Accounting Policies - Reconciliation of Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails" roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails">
        <link:definition>0000049 - Disclosure - Organization and Summary of Significant Accounting Policies - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesForeignCurrencyCumulativeTranslationAdjustmentsDetails" roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesForeignCurrencyCumulativeTranslationAdjustmentsDetails">
        <link:definition>0000050 - Disclosure - Organization and Summary of Significant Accounting Policies - Foreign Currency Cumulative Translation Adjustments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails">
        <link:definition>0000051 - Disclosure - Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails">
        <link:definition>0000052 - Disclosure - Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableInvestmentSecuritiesNarrativeDetails" roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails">
        <link:definition>0000053 - Disclosure - Marketable Investment Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>0000054 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" roleURI="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails">
        <link:definition>0000055 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails" roleURI="http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails">
        <link:definition>0000056 - Disclosure - Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetBalancesDetails" roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails">
        <link:definition>0000057 - Disclosure - Property, Plant and Equipment, Net - Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetNarrativeDetails" roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails">
        <link:definition>0000058 - Disclosure - Property, Plant and Equipment, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetDepreciationExpenseDetails" roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails">
        <link:definition>0000059 - Disclosure - Property, Plant and Equipment, Net - Depreciation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails">
        <link:definition>0000060 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>0000061 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsIntangibleAssetsDetails" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails">
        <link:definition>0000062 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails">
        <link:definition>0000063 - Disclosure - Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails" roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails">
        <link:definition>0000064 - Disclosure - Goodwill and Intangible Assets - Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesDetails" roleURI="http://www.myriad.com/role/AccruedLiabilitiesDetails">
        <link:definition>0000065 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtDetails" roleURI="http://www.myriad.com/role/LongTermDebtDetails">
        <link:definition>0000066 - Disclosure - Long Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLongTermLiabilitiesDetails" roleURI="http://www.myriad.com/role/OtherLongTermLiabilitiesDetails">
        <link:definition>0000067 - Disclosure - Other Long-Term Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquityNarrativeDetails" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails">
        <link:definition>0000068 - Disclosure - Preferred and Common Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PreferredandCommonStockholdersEquitySharesofCommonStockIssuedandOutstandingDetails" roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquitySharesofCommonStockIssuedandOutstandingDetails">
        <link:definition>0000069 - Disclosure - Preferred and Common Stockholders' Equity - Shares of Common Stock Issued and Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>0000070 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionsActivityDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails">
        <link:definition>0000071 - Disclosure - Stock-Based Compensation - Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockUnitsActivityDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails">
        <link:definition>0000072 - Disclosure - Stock-Based Compensation - Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>0000073 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAggregateIntrinsicValueDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails">
        <link:definition>0000074 - Disclosure - Stock-Based Compensation - Aggregate Intrinsic Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationIntrinsicValueofOptionsExercisedDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationIntrinsicValueofOptionsExercisedDetails">
        <link:definition>0000075 - Disclosure - Stock-Based Compensation - Intrinsic Value of Options Exercised (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails">
        <link:definition>0000076 - Disclosure - Stock-Based Compensation - Shares Purchased and Compensation Expenses for ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationValuationAssumptionsforESPPDetails" roleURI="http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails">
        <link:definition>0000077 - Disclosure - Stock-Based Compensation - Valuation Assumptions for ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxBenefitDetails" roleURI="http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails">
        <link:definition>0000078 - Disclosure - Income Taxes - Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesLossBeforeIncomeTaxesDetails" roleURI="http://www.myriad.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails">
        <link:definition>0000079 - Disclosure - Income Taxes - Loss Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails" roleURI="http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails">
        <link:definition>0000080 - Disclosure - Income Taxes - Statutory Federal Income Tax Rate and Income Taxes Reported (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>0000081 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.myriad.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000082 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails" roleURI="http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails">
        <link:definition>0000083 - Disclosure - Income Taxes - Net Operating Loss and Research Credit Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitsDetails" roleURI="http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails">
        <link:definition>0000084 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.myriad.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000085 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.myriad.com/role/LeasesNarrativeDetails">
        <link:definition>0000086 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>0000087 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>0000087 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeDeferredSavingsPlanNarrativeDetails" roleURI="http://www.myriad.com/role/EmployeeDeferredSavingsPlanNarrativeDetails">
        <link:definition>0000088 - Disclosure - Employee Deferred Savings Plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeDeferredSavingsPlanContributionstoPlanDetails" roleURI="http://www.myriad.com/role/EmployeeDeferredSavingsPlanContributionstoPlanDetails">
        <link:definition>0000089 - Disclosure - Employee Deferred Savings Plan - Contributions to Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandRelatedInformationNarrativeDetails" roleURI="http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails">
        <link:definition>0000090 - Disclosure - Segment and Related Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandRelatedInformationAssetsbyGeographicalRegionDetails" roleURI="http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails">
        <link:definition>0000091 - Disclosure - Segment and Related Information - Assets by Geographical Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionNarrativeDetails" roleURI="http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails">
        <link:definition>0000092 - Disclosure - Business Acquisition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails" roleURI="http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails">
        <link:definition>0000093 - Disclosure - Business Acquisition - Schedule of Estimated Fair Value of Identified Assets acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionScheduleofProFormaInformationDetails" roleURI="http://www.myriad.com/role/BusinessAcquisitionScheduleofProFormaInformationDetails">
        <link:definition>0000094 - Disclosure - Business Acquisition - Schedule of Pro Forma Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresNarrativeDetails" roleURI="http://www.myriad.com/role/DivestituresNarrativeDetails">
        <link:definition>0000095 - Disclosure - Divestitures - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresOtherIncomeDetails" roleURI="http://www.myriad.com/role/DivestituresOtherIncomeDetails">
        <link:definition>0000096 - Disclosure - Divestitures - Other Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationDetails" roleURI="http://www.myriad.com/role/SupplementalCashFlowInformationDetails">
        <link:definition>0000097 - Disclosure - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced" abstract="false" name="OperatingLeaseLiabilityIncludingLeasesNotYetCommenced" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_LeaseRelatedExpendituresIncurredButNotYetPaid" abstract="false" name="LeaseRelatedExpendituresIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_MyriadAutoimmuneAssetsMember" abstract="true" name="MyriadAutoimmuneAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" abstract="false" name="ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityCurrentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" abstract="false" name="DisposalGroupNotDiscontinuedOperationGainLossOnInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_UnrecognizedTaxBenefitsNet" abstract="false" name="UnrecognizedTaxBenefitsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" abstract="false" name="DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod" abstract="false" name="ValuationAllowanceIncreaseDecreaseDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_EarningsPerShareBasicAndDilutedEPSAbstract" abstract="true" name="EarningsPerShareBasicAndDilutedEPSAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mygn_MyriadMyPathLLCLaboratoryMember" abstract="true" name="MyriadMyPathLLCLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_OtherIncomeExpensePolicyPolicyTextBlock" abstract="false" name="OtherIncomeExpensePolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mygn_MyriadRBMIncMember" abstract="true" name="MyriadRBMIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_ContractWithCustomerLiabilityDivestitures" abstract="false" name="ContractWithCustomerLiabilityDivestitures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_AutoimmuneMember" abstract="true" name="AutoimmuneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" abstract="false" name="EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mygn_SouthSanFranciscoCaliforniaMember" abstract="true" name="SouthSanFranciscoCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_InvestmentsAndCashAmortizedCost" abstract="false" name="InvestmentsAndCashAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" abstract="false" name="FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mygn_LineOfCreditFacilityCreditExposureThreshold" abstract="false" name="LineOfCreditFacilityCreditExposureThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" abstract="false" name="GainLossOnDispositionOfAssetsNetOfTransactionFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_PharmacogenomicsMember" abstract="true" name="PharmacogenomicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_ContractWithCustomerLiabilityPrepayments" abstract="false" name="ContractWithCustomerLiabilityPrepayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" abstract="false" name="IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_DeferredTaxAssetsLeaseLiabilities" abstract="false" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_ScheduleOfIntangibleAssetsTable" abstract="true" name="ScheduleOfIntangibleAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" abstract="false" name="DisposalGroupNotDiscontinuedOperationTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" abstract="false" name="DisposalGroupNotDiscontinuedOperationGainLossOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" abstract="false" name="EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" abstract="false" name="IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_RefundsPayableAndReserveCurrent" abstract="false" name="RefundsPayableAndReserveCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_AssetsLessCashCashEquivalentsAndInvestments" abstract="false" name="AssetsLessCashCashEquivalentsAndInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember" abstract="true" name="MyriadRBMIncAndMyriadAutoimmuneBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_IncomeTaxReconciliationCARESAct" abstract="false" name="IncomeTaxReconciliationCARESAct" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_ClinicReportingUnitMember" abstract="true" name="ClinicReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments" abstract="false" name="BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_LeaseArrangementDomain" abstract="true" name="LeaseArrangementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" abstract="false" name="StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization" abstract="false" name="DeferredTaxAssetResearchAndExperimentalExpenseCapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_EmployeeStockPurchasePlanTwentyTwelveMember" abstract="true" name="EmployeeStockPurchasePlanTwentyTwelveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_GoodwillAndIntangibleAssetsLineItems" abstract="true" name="GoodwillAndIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" abstract="false" name="ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_GatewayGenomicsLLCMember" abstract="true" name="GatewayGenomicsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock" abstract="false" name="ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment" abstract="false" name="EffectiveIncomeTaxRateReconciliationAssetImpairment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mygn_TestingRevenueMember" abstract="true" name="TestingRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" abstract="true" name="TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_IncomeTaxReconciliationAssetImpairment" abstract="false" name="IncomeTaxReconciliationAssetImpairment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_CARESActOf2020ProviderReliefFundAmount" abstract="false" name="CARESActOf2020ProviderReliefFundAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_SividonDiagnosticsGmbHMember" abstract="true" name="SividonDiagnosticsGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_LeaseArrangementAxis" abstract="true" name="LeaseArrangementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="mygn_RaygenIncVersusMyriadWomensHealthIncMember" abstract="true" name="RaygenIncVersusMyriadWomensHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mygn_HereditaryCancerTestingMember" abstract="true" name="HereditaryCancerTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_IncreaseDecreaseInEarningsLossPerShare" abstract="false" name="IncreaseDecreaseInEarningsLossPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mygn_NonEmployeeDirectorMember" abstract="true" name="NonEmployeeDirectorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" abstract="false" name="EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mygn_TumorProfilingMember" abstract="true" name="TumorProfilingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_OperatingLossCarryforwardsExpirationYear" abstract="false" name="OperatingLossCarryforwardsExpirationYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:gYearItemType"/>
  <xs:element id="mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mygn_WestSaltLakeCityLeaseMember" abstract="true" name="WestSaltLakeCityLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_GoodwillAndIntangibleAssetsTable" abstract="true" name="GoodwillAndIntangibleAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement" abstract="false" name="IncomeTaxReconciliationNonDeductibleLegalSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_OtherStateMember" abstract="true" name="OtherStateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_OptionsAndRestrictedStockUnitsMember" abstract="true" name="OptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" abstract="false" name="IncreaseDecreaseInUnrecognizedTaxBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_EffectiveIncomeTaxRateReconciliationCARESAct" abstract="false" name="EffectiveIncomeTaxRateReconciliationCARESAct" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mygn_DebtInstrumentFloorPercentage" abstract="false" name="DebtInstrumentFloorPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mygn_TenantImprovementAllowanceNotYetReceived" abstract="false" name="TenantImprovementAllowanceNotYetReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_PerformanceObligationEstimatedTransactionPriceMember" abstract="true" name="PerformanceObligationEstimatedTransactionPriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_PrenatalTestingMember" abstract="true" name="PrenatalTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_TaxCreditCarryforwardsExpirationDate" abstract="false" name="TaxCreditCarryforwardsExpirationDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:gYearItemType"/>
  <xs:element id="mygn_CARESActOf2020MedicarePaymentAmount" abstract="false" name="CARESActOf2020MedicarePaymentAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_DebtCovenantLiquidityCovenantMinimum" abstract="false" name="DebtCovenantLiquidityCovenantMinimum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_OperatingLeaseLiabilityEstablished" abstract="false" name="OperatingLeaseLiabilityEstablished" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_AmendmentToCreditAgreementMember" abstract="true" name="AmendmentToCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_IntangibleAssetsLineItems" abstract="true" name="IntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mygn_BusinessCombinationIntangibleAssetsMeasurementInput" abstract="false" name="BusinessCombinationIntangibleAssetsMeasurementInput" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mygn_OtherTestingMember" abstract="true" name="OtherTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_OperatingLeaseLiabilityLeasesNotYetCommenced" abstract="false" name="OperatingLeaseLiabilityLeasesNotYetCommenced" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_MyriadAutoimmuneReportingUnitMember" abstract="true" name="MyriadAutoimmuneReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_CostOfTestingMember" abstract="true" name="CostOfTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_CostOfOtherRevenueMember" abstract="true" name="CostOfOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" abstract="false" name="ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mygn_NonCashInterestExpense" abstract="false" name="NonCashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>mygn-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6db69074-e648-4be3-ae6d-ea77b2ae08c9,g:6dbaf31c-e8bf-47fc-986c-d695276c3aba-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mygn-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_758abd7a-a857-4aab-9f5c-36b1dd036a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_13006007-899f-4f0d-a713-bcf39575e9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_758abd7a-a857-4aab-9f5c-36b1dd036a08" xlink:to="loc_us-gaap_AccountsPayableCurrent_13006007-899f-4f0d-a713-bcf39575e9cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4eba88bb-55bc-406d-8c31-dd4b4bd5bcc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_758abd7a-a857-4aab-9f5c-36b1dd036a08" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4eba88bb-55bc-406d-8c31-dd4b4bd5bcc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_86978fb3-210a-4df5-9479-3e07b069d1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_758abd7a-a857-4aab-9f5c-36b1dd036a08" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_86978fb3-210a-4df5-9479-3e07b069d1c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d138107f-147d-48c6-8adc-21a9b096bbb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_eee2aa97-267a-4ac7-971e-6fbcf7b5a2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d138107f-147d-48c6-8adc-21a9b096bbb8" xlink:to="loc_us-gaap_CommonStockValue_eee2aa97-267a-4ac7-971e-6fbcf7b5a2aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_fc78d60f-d624-4b34-86e8-e45ad83cebd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d138107f-147d-48c6-8adc-21a9b096bbb8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_fc78d60f-d624-4b34-86e8-e45ad83cebd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c267f86b-bdd2-4c5d-ac6d-a28598e3d512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d138107f-147d-48c6-8adc-21a9b096bbb8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c267f86b-bdd2-4c5d-ac6d-a28598e3d512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a090ff3d-6bef-42f9-b668-9e37257e2cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d138107f-147d-48c6-8adc-21a9b096bbb8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a090ff3d-6bef-42f9-b668-9e37257e2cd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e063b6bf-f010-4417-9506-9201efa50718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2469c20e-3b1b-4d68-841f-53fae7d39fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e063b6bf-f010-4417-9506-9201efa50718" xlink:to="loc_us-gaap_LiabilitiesCurrent_2469c20e-3b1b-4d68-841f-53fae7d39fd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_UnrecognizedTaxBenefitsNet_6ed3ea2f-dc1f-4fb0-acc8-563913d74b74" xlink:href="mygn-20221231.xsd#mygn_UnrecognizedTaxBenefitsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e063b6bf-f010-4417-9506-9201efa50718" xlink:to="loc_mygn_UnrecognizedTaxBenefitsNet_6ed3ea2f-dc1f-4fb0-acc8-563913d74b74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_acd5cb5d-3bd8-4c98-a27a-56f970298fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e063b6bf-f010-4417-9506-9201efa50718" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_acd5cb5d-3bd8-4c98-a27a-56f970298fdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_38f2e553-3c7f-4bf8-a7ca-3a337ddb5e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e063b6bf-f010-4417-9506-9201efa50718" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_38f2e553-3c7f-4bf8-a7ca-3a337ddb5e73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f41e3148-0f80-47a0-bff1-3e0beb718b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e063b6bf-f010-4417-9506-9201efa50718" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f41e3148-0f80-47a0-bff1-3e0beb718b32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d0aefc9b-c259-4ba6-af88-527b9733ec8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3486b6e5-e3ac-4832-80bc-4b1b4a072e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d0aefc9b-c259-4ba6-af88-527b9733ec8e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3486b6e5-e3ac-4832-80bc-4b1b4a072e82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_6c3e3cdc-8b0e-4f6e-b070-a1c5b9a53552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d0aefc9b-c259-4ba6-af88-527b9733ec8e" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_6c3e3cdc-8b0e-4f6e-b070-a1c5b9a53552" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2c7dab67-22d9-45ef-93b2-d28af922d264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d0aefc9b-c259-4ba6-af88-527b9733ec8e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2c7dab67-22d9-45ef-93b2-d28af922d264" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1bcf2a00-c71d-40df-8ab9-1ddb79a531e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d0aefc9b-c259-4ba6-af88-527b9733ec8e" xlink:to="loc_us-gaap_InventoryNet_1bcf2a00-c71d-40df-8ab9-1ddb79a531e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_c158ba69-f3fa-4341-98d5-d0a9459e1be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d0aefc9b-c259-4ba6-af88-527b9733ec8e" xlink:to="loc_us-gaap_PrepaidTaxes_c158ba69-f3fa-4341-98d5-d0a9459e1be0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ffcb41e8-f311-4632-8b07-a660ee2d38cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d0aefc9b-c259-4ba6-af88-527b9733ec8e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ffcb41e8-f311-4632-8b07-a660ee2d38cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_98940a02-933c-4330-be80-fc6eb97c27aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_053da591-4021-466b-85c9-053290f5c802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_98940a02-933c-4330-be80-fc6eb97c27aa" xlink:to="loc_us-gaap_Liabilities_053da591-4021-466b-85c9-053290f5c802" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_70ee96d5-6849-4ea4-9e84-3de922539a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_98940a02-933c-4330-be80-fc6eb97c27aa" xlink:to="loc_us-gaap_CommitmentsAndContingencies_70ee96d5-6849-4ea4-9e84-3de922539a75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_de4179df-929a-4e1d-bfe8-5063e1aca78f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_98940a02-933c-4330-be80-fc6eb97c27aa" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_de4179df-929a-4e1d-bfe8-5063e1aca78f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f7f45e4c-478a-4737-8442-cc90802c01bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_838f062e-5f3c-4fec-b546-267721ba2bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7f45e4c-478a-4737-8442-cc90802c01bc" xlink:to="loc_us-gaap_AssetsCurrent_838f062e-5f3c-4fec-b546-267721ba2bca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_788b725d-03b5-4c55-90a0-04287f393c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7f45e4c-478a-4737-8442-cc90802c01bc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_788b725d-03b5-4c55-90a0-04287f393c1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_8902a5e6-933f-41b7-be05-ce4f4a6ba4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7f45e4c-478a-4737-8442-cc90802c01bc" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_8902a5e6-933f-41b7-be05-ce4f4a6ba4bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_db7aed72-9995-4a39-98ea-91527d39c306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7f45e4c-478a-4737-8442-cc90802c01bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_db7aed72-9995-4a39-98ea-91527d39c306" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5bb12688-1152-4d79-b229-7e648bff514c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7f45e4c-478a-4737-8442-cc90802c01bc" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5bb12688-1152-4d79-b229-7e648bff514c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_aa3dac5d-495b-4cdf-80f0-9ac11eace2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7f45e4c-478a-4737-8442-cc90802c01bc" xlink:to="loc_us-gaap_Goodwill_aa3dac5d-495b-4cdf-80f0-9ac11eace2d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e2ac4dfb-b7c0-4aaf-9e9d-4926061c1116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7f45e4c-478a-4737-8442-cc90802c01bc" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e2ac4dfb-b7c0-4aaf-9e9d-4926061c1116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_06ddd964-bbc5-4573-a1e4-cc45abefce97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2e978446-d41a-4bdc-bcc2-1b8b95913244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_06ddd964-bbc5-4573-a1e4-cc45abefce97" xlink:to="loc_us-gaap_StockholdersEquity_2e978446-d41a-4bdc-bcc2-1b8b95913244" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_016a42fb-2003-4530-87cd-e56e44391aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_06ddd964-bbc5-4573-a1e4-cc45abefce97" xlink:to="loc_us-gaap_MinorityInterest_016a42fb-2003-4530-87cd-e56e44391aa4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="mygn-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e4e452f7-af9e-4366-a281-64520aa38897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fffff9a2-7ec1-42b6-b845-fd57e654751c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e4e452f7-af9e-4366-a281-64520aa38897" xlink:to="loc_us-gaap_OperatingIncomeLoss_fffff9a2-7ec1-42b6-b845-fd57e654751c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_204aed28-6b69-46fd-943c-db85a27c7f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e4e452f7-af9e-4366-a281-64520aa38897" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_204aed28-6b69-46fd-943c-db85a27c7f9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b5c51aa7-3a2c-46ed-89ac-a90af422ebb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_86d229a1-982b-4e34-9b59-34797cff853e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b5c51aa7-3a2c-46ed-89ac-a90af422ebb2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_86d229a1-982b-4e34-9b59-34797cff853e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e40b59ac-ae15-444a-8a7c-a8ce55e5d240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b5c51aa7-3a2c-46ed-89ac-a90af422ebb2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e40b59ac-ae15-444a-8a7c-a8ce55e5d240" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_da699643-d723-4cac-ab79-81ae5771ab6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b5c51aa7-3a2c-46ed-89ac-a90af422ebb2" xlink:to="loc_us-gaap_LitigationSettlementExpense_da699643-d723-4cac-ab79-81ae5771ab6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_d28ccd58-da6a-4cdd-ba05-70d7b3a88683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b5c51aa7-3a2c-46ed-89ac-a90af422ebb2" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_d28ccd58-da6a-4cdd-ba05-70d7b3a88683" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_84f5e066-2513-478d-bc30-e57a424e64ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b5c51aa7-3a2c-46ed-89ac-a90af422ebb2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_84f5e066-2513-478d-bc30-e57a424e64ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_151384e4-e6c1-4da5-89e5-a100780f543c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_52815ef9-f998-4c40-86e9-e7c45caf9122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_151384e4-e6c1-4da5-89e5-a100780f543c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_52815ef9-f998-4c40-86e9-e7c45caf9122" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_92b5a8d3-9353-4a1e-bd4b-f3a31287f9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_151384e4-e6c1-4da5-89e5-a100780f543c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_92b5a8d3-9353-4a1e-bd4b-f3a31287f9d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_66c1a8ba-a9c5-4ec4-8918-394cfbdcfa07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3cc58159-c1c7-47c6-8dfa-200d3b1dc452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_66c1a8ba-a9c5-4ec4-8918-394cfbdcfa07" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3cc58159-c1c7-47c6-8dfa-200d3b1dc452" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_9a0bcaa7-14f9-49c7-afc0-cc847827523f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_66c1a8ba-a9c5-4ec4-8918-394cfbdcfa07" xlink:to="loc_us-gaap_InvestmentIncomeInterest_9a0bcaa7-14f9-49c7-afc0-cc847827523f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4b01cde7-c825-461a-9a99-4744090c7068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_66c1a8ba-a9c5-4ec4-8918-394cfbdcfa07" xlink:to="loc_us-gaap_InterestExpense_4b01cde7-c825-461a-9a99-4744090c7068" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f97d5e0a-7e50-4a3c-8a04-0d74e75d191f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d1d87672-dfc7-442c-805f-6dc2134cff58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f97d5e0a-7e50-4a3c-8a04-0d74e75d191f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d1d87672-dfc7-442c-805f-6dc2134cff58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_071f05b6-584a-4e48-9919-5c3b81c6b272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f97d5e0a-7e50-4a3c-8a04-0d74e75d191f" xlink:to="loc_us-gaap_CostsAndExpenses_071f05b6-584a-4e48-9919-5c3b81c6b272" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5075bd83-72e5-4d6c-88d7-e7121a096b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_af05b8d8-ac3c-4f65-82c4-cfcc595c7eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5075bd83-72e5-4d6c-88d7-e7121a096b06" xlink:to="loc_us-gaap_ProfitLoss_af05b8d8-ac3c-4f65-82c4-cfcc595c7eb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_882f5ee9-8044-4d73-830b-6c92086af05c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5075bd83-72e5-4d6c-88d7-e7121a096b06" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_882f5ee9-8044-4d73-830b-6c92086af05c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="mygn-20221231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9d13b45c-c197-49e1-8c3e-6f6db9e80f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d3ea0053-13d4-40af-87cb-800272c2ce11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9d13b45c-c197-49e1-8c3e-6f6db9e80f6d" xlink:to="loc_us-gaap_NetIncomeLoss_d3ea0053-13d4-40af-87cb-800272c2ce11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_91aa2fcb-96c7-4652-a9ea-4fb43d2a299c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9d13b45c-c197-49e1-8c3e-6f6db9e80f6d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_91aa2fcb-96c7-4652-a9ea-4fb43d2a299c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8b36ef69-41a5-43fa-ad83-85679f5f922d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9d13b45c-c197-49e1-8c3e-6f6db9e80f6d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8b36ef69-41a5-43fa-ad83-85679f5f922d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mygn-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_45913f27-1088-4123-8c62-754f0e098179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2dfbf6d3-1258-433e-b7a5-e1bd5038c9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_45913f27-1088-4123-8c62-754f0e098179" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2dfbf6d3-1258-433e-b7a5-e1bd5038c9f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8fcea9ec-fce3-4e48-a11a-cd640e29da0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_45913f27-1088-4123-8c62-754f0e098179" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8fcea9ec-fce3-4e48-a11a-cd640e29da0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e600464d-49c8-4ab2-aa7e-cae248955bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_45913f27-1088-4123-8c62-754f0e098179" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e600464d-49c8-4ab2-aa7e-cae248955bc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3de2a867-5482-4db6-a7fa-0c1abb834110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_45913f27-1088-4123-8c62-754f0e098179" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3de2a867-5482-4db6-a7fa-0c1abb834110" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0367e8da-0a25-4ddc-bb51-a6c37df1c555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_6232f073-9222-4c82-b93e-881e046227b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0367e8da-0a25-4ddc-bb51-a6c37df1c555" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_6232f073-9222-4c82-b93e-881e046227b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_11936b4b-df7b-4870-8636-698d98dbaa50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0367e8da-0a25-4ddc-bb51-a6c37df1c555" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_11936b4b-df7b-4870-8636-698d98dbaa50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_0fc78c86-6d93-4c84-b62f-7d73ea5cc13e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0367e8da-0a25-4ddc-bb51-a6c37df1c555" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_0fc78c86-6d93-4c84-b62f-7d73ea5cc13e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_13beef62-04c5-429d-87dd-9c4b34eedda7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0367e8da-0a25-4ddc-bb51-a6c37df1c555" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_13beef62-04c5-429d-87dd-9c4b34eedda7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_4b2d054d-6d1c-4f44-8383-ab5b911697d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0367e8da-0a25-4ddc-bb51-a6c37df1c555" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_4b2d054d-6d1c-4f44-8383-ab5b911697d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_914d9cd4-fb57-4e17-bfe4-be1b0b47b821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0b94464e-1477-453a-b38f-b0b0302bcc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_914d9cd4-fb57-4e17-bfe4-be1b0b47b821" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_0b94464e-1477-453a-b38f-b0b0302bcc7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ba72903c-1776-49e0-ba98-cd72a14a0b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_914d9cd4-fb57-4e17-bfe4-be1b0b47b821" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ba72903c-1776-49e0-ba98-cd72a14a0b46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_83401ef9-f9f6-4821-a396-1a12d8bd66d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_914d9cd4-fb57-4e17-bfe4-be1b0b47b821" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_83401ef9-f9f6-4821-a396-1a12d8bd66d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts_74eef5b2-3d7c-4f1b-9b88-121bed24528c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtRestructuringCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_914d9cd4-fb57-4e17-bfe4-be1b0b47b821" xlink:to="loc_us-gaap_PaymentsOfDebtRestructuringCosts_74eef5b2-3d7c-4f1b-9b88-121bed24528c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_bc41dbf5-542a-4d3e-8238-9af5109eda6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_914d9cd4-fb57-4e17-bfe4-be1b0b47b821" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_bc41dbf5-542a-4d3e-8238-9af5109eda6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1cbc11f2-4cf1-4210-a46e-62dddb878268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:to="loc_us-gaap_NetIncomeLoss_1cbc11f2-4cf1-4210-a46e-62dddb878268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_cded892c-dda7-4ea1-8c52-fde99286bf69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:to="loc_us-gaap_DepreciationAndAmortization_cded892c-dda7-4ea1-8c52-fde99286bf69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonCashInterestExpense_f0550614-62b1-431d-ab51-0b2d9059a01b" xlink:href="mygn-20221231.xsd#mygn_NonCashInterestExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:to="loc_mygn_NonCashInterestExpense_f0550614-62b1-431d-ab51-0b2d9059a01b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_346f93b6-d791-4e38-bf01-a64b57a40f81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_346f93b6-d791-4e38-bf01-a64b57a40f81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_14cd8381-ace2-40a5-9d99-a177115485d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:to="loc_us-gaap_ShareBasedCompensation_14cd8381-ace2-40a5-9d99-a177115485d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_035e9ce4-552e-485b-b4d7-0129c11f9867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_035e9ce4-552e-485b-b4d7-0129c11f9867" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_47d9d72d-76f7-4d06-8698-d395b0eff646" xlink:href="mygn-20221231.xsd#mygn_IncreaseDecreaseInUnrecognizedTaxBenefits"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:to="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_47d9d72d-76f7-4d06-8698-d395b0eff646" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7575588f-2b8e-4577-b935-95d26bf71c10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7575588f-2b8e-4577-b935-95d26bf71c10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_dbcc0f3f-9579-42bf-986e-fbf8d79f07c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:to="loc_us-gaap_InventoryWriteDown_dbcc0f3f-9579-42bf-986e-fbf8d79f07c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_44d63451-24d8-4527-8dd5-eb18af1e8f15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_44d63451-24d8-4527-8dd5-eb18af1e8f15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_30ff1b20-c157-4354-b498-8ec3441a6e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_30ff1b20-c157-4354-b498-8ec3441a6e88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_1aa9911b-4cd6-48ae-ae5a-2f8f08be890a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_1aa9911b-4cd6-48ae-ae5a-2f8f08be890a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_321ca879-f0f4-4a08-8aa4-dad7b1614dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_321ca879-f0f4-4a08-8aa4-dad7b1614dfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8b8af501-d4a2-47bf-838a-7011d25bbc48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8b8af501-d4a2-47bf-838a-7011d25bbc48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1b2252a8-0e74-4d0d-b13f-aa3d470fc46c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1b2252a8-0e74-4d0d-b13f-aa3d470fc46c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_217c5f40-cd4d-4109-97c6-beacc25a7d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_217c5f40-cd4d-4109-97c6-beacc25a7d4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f6a65bed-5cb2-4db2-b537-499fc01631fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f6a65bed-5cb2-4db2-b537-499fc01631fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f2ea74e1-269c-4760-a028-fca776dfe34c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f2ea74e1-269c-4760-a028-fca776dfe34c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5972beb7-c384-4d9b-9619-625ee89ea0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5972beb7-c384-4d9b-9619-625ee89ea0fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0a2d0cc8-14d6-489e-b37b-5e9bf5ae779c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84fc0757-4697-4e18-a93d-389473ee065e" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0a2d0cc8-14d6-489e-b37b-5e9bf5ae779c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_06d585e5-1d75-4918-84e2-19102a4a9e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_80361d94-f8b4-4ec8-9aed-07087835f09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_06d585e5-1d75-4918-84e2-19102a4a9e0b" xlink:to="loc_us-gaap_RestrictedCash_80361d94-f8b4-4ec8-9aed-07087835f09b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7d716848-eeaf-4570-9932-5a9f374c2cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_06d585e5-1d75-4918-84e2-19102a4a9e0b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7d716848-eeaf-4570-9932-5a9f374c2cad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cd5f6458-2252-44bb-94df-16b22ee1bcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_533999a8-f087-4878-8354-f04b6e69de28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cd5f6458-2252-44bb-94df-16b22ee1bcf7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_533999a8-f087-4878-8354-f04b6e69de28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_f5a45f49-2613-4ae6-8903-d8af2fdfc717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cd5f6458-2252-44bb-94df-16b22ee1bcf7" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_f5a45f49-2613-4ae6-8903-d8af2fdfc717" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b8854770-5689-40c5-9525-6f8214450567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1e6d84e2-53d3-4667-8fff-214ae2e8d2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b8854770-5689-40c5-9525-6f8214450567" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1e6d84e2-53d3-4667-8fff-214ae2e8d2f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d2083d75-f8d0-4566-8558-8e0527fcc82d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b8854770-5689-40c5-9525-6f8214450567" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d2083d75-f8d0-4566-8558-8e0527fcc82d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3c1f43bb-32b1-4e3d-8936-bd9c9c423ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b8854770-5689-40c5-9525-6f8214450567" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3c1f43bb-32b1-4e3d-8936-bd9c9c423ae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_357ef593-25b5-4c3b-95ce-a442e48672ad" xlink:href="mygn-20221231.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_60b85e1e-323d-4300-9cce-48eeb491dfb2" xlink:href="mygn-20221231.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_357ef593-25b5-4c3b-95ce-a442e48672ad" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_60b85e1e-323d-4300-9cce-48eeb491dfb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_6553fe91-0a22-4de4-9834-7d06f7d49a2e" xlink:href="mygn-20221231.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_357ef593-25b5-4c3b-95ce-a442e48672ad" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_6553fe91-0a22-4de4-9834-7d06f7d49a2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_bb3ebaf5-1b92-4b96-87fc-bfbcf5334908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_357ef593-25b5-4c3b-95ce-a442e48672ad" xlink:to="loc_us-gaap_InvestmentsAndCash_bb3ebaf5-1b92-4b96-87fc-bfbcf5334908" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_7d381933-fabb-4b53-bafb-35366e1f9b0b" xlink:href="mygn-20221231.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5c669606-e150-42fe-b860-229110bf193f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_7d381933-fabb-4b53-bafb-35366e1f9b0b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5c669606-e150-42fe-b860-229110bf193f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_6a6af4ef-2726-4046-bbfd-224d06a8c3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_7d381933-fabb-4b53-bafb-35366e1f9b0b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_6a6af4ef-2726-4046-bbfd-224d06a8c3cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_f408518f-aa39-4fd7-9bac-8a4223af84dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_7d381933-fabb-4b53-bafb-35366e1f9b0b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_f408518f-aa39-4fd7-9bac-8a4223af84dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_18e43b1e-0d2c-4e88-9931-4d78fbd61255" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost_7d381933-fabb-4b53-bafb-35366e1f9b0b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_18e43b1e-0d2c-4e88-9931-4d78fbd61255" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_03857412-2d8d-4c20-959a-28123e44d06f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ad38b690-ad5a-4481-9b2c-c57d1d354ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_03857412-2d8d-4c20-959a-28123e44d06f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ad38b690-ad5a-4481-9b2c-c57d1d354ef1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_90f190ee-0317-4f09-a200-4341789f2cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_03857412-2d8d-4c20-959a-28123e44d06f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_90f190ee-0317-4f09-a200-4341789f2cb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_065e4d2b-425b-4902-86f1-7835bd2a68b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_03857412-2d8d-4c20-959a-28123e44d06f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_065e4d2b-425b-4902-86f1-7835bd2a68b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_5befbc02-a433-4aa2-b9b9-62268208b39e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentsAndCash_03857412-2d8d-4c20-959a-28123e44d06f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_5befbc02-a433-4aa2-b9b9-62268208b39e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_35c09c63-336e-4170-8f3f-b40138d63433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_95f41be4-afb6-48c2-8cdd-724516529cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueNetAssetLiability_35c09c63-336e-4170-8f3f-b40138d63433" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_95f41be4-afb6-48c2-8cdd-724516529cb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_125d8707-8b54-4b13-bf25-7b894ab13b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueNetAssetLiability_35c09c63-336e-4170-8f3f-b40138d63433" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_125d8707-8b54-4b13-bf25-7b894ab13b79" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#PropertyPlantandEquipmentNetBalancesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c3b1bc6b-d314-4e65-a32b-b5c75f3d1606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8e7f9853-7f4e-46aa-b6d9-88454eafa50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c3b1bc6b-d314-4e65-a32b-b5c75f3d1606" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8e7f9853-7f4e-46aa-b6d9-88454eafa50a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d5cf56eb-0741-474a-9502-6068bad1c4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c3b1bc6b-d314-4e65-a32b-b5c75f3d1606" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d5cf56eb-0741-474a-9502-6068bad1c4b6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_191a40bc-7418-4330-9a88-5b6f63a4b78c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_63d40287-dae0-4411-b5b5-4efbe5b4e696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_191a40bc-7418-4330-9a88-5b6f63a4b78c" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_63d40287-dae0-4411-b5b5-4efbe5b4e696" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f698fea7-e9fd-4932-8f85-47061684f86e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_191a40bc-7418-4330-9a88-5b6f63a4b78c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f698fea7-e9fd-4932-8f85-47061684f86e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6f2941ba-11c5-45a7-a6f8-2fe590498d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_cba1bdc5-1511-4896-8918-c3938cfa1840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6f2941ba-11c5-45a7-a6f8-2fe590498d2d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_cba1bdc5-1511-4896-8918-c3938cfa1840" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a45d060f-36ee-4a53-874a-8fca9767f08f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6f2941ba-11c5-45a7-a6f8-2fe590498d2d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a45d060f-36ee-4a53-874a-8fca9767f08f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2001ba82-2433-4eb8-8f94-5610d8af74f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c461bc6f-fb62-41b3-8d12-b3c57c22092b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2001ba82-2433-4eb8-8f94-5610d8af74f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c461bc6f-fb62-41b3-8d12-b3c57c22092b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_65823a61-06ff-4090-a9b7-90a398a4be92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2001ba82-2433-4eb8-8f94-5610d8af74f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_65823a61-06ff-4090-a9b7-90a398a4be92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_48e89319-42a4-48a0-aa9e-cd72b1279457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2001ba82-2433-4eb8-8f94-5610d8af74f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_48e89319-42a4-48a0-aa9e-cd72b1279457" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_734c64d7-c40b-4942-9aec-811c145a5176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2001ba82-2433-4eb8-8f94-5610d8af74f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_734c64d7-c40b-4942-9aec-811c145a5176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_163a3304-fa44-4527-b538-f4cef61bbe00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2001ba82-2433-4eb8-8f94-5610d8af74f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_163a3304-fa44-4527-b538-f4cef61bbe00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_81125d85-542f-4d2b-9ddd-d19feadf12cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2001ba82-2433-4eb8-8f94-5610d8af74f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_81125d85-542f-4d2b-9ddd-d19feadf12cf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#AccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e3e6114b-a52d-4089-89ad-bdefbeceb7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ede845f9-28fb-41aa-a9bd-6c5370360aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e3e6114b-a52d-4089-89ad-bdefbeceb7c8" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ede845f9-28fb-41aa-a9bd-6c5370360aa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_a1864dec-d8f5-40c1-ad4b-ffd6b37dbc59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e3e6114b-a52d-4089-89ad-bdefbeceb7c8" xlink:to="loc_us-gaap_LitigationReserveCurrent_a1864dec-d8f5-40c1-ad4b-ffd6b37dbc59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_ce17c06f-5421-46f1-a75d-3cd9a45fb543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e3e6114b-a52d-4089-89ad-bdefbeceb7c8" xlink:to="loc_us-gaap_TaxesPayableCurrent_ce17c06f-5421-46f1-a75d-3cd9a45fb543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RefundsPayableAndReserveCurrent_906e04b7-82ff-4335-a21a-1fe05287ac6d" xlink:href="mygn-20221231.xsd#mygn_RefundsPayableAndReserveCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e3e6114b-a52d-4089-89ad-bdefbeceb7c8" xlink:to="loc_mygn_RefundsPayableAndReserveCurrent_906e04b7-82ff-4335-a21a-1fe05287ac6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7b9f1b31-1a8c-49e1-b88e-07b1587ba99f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e3e6114b-a52d-4089-89ad-bdefbeceb7c8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7b9f1b31-1a8c-49e1-b88e-07b1587ba99f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_38fd1f73-a17a-4bdc-a4aa-c95b4c2995b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e3e6114b-a52d-4089-89ad-bdefbeceb7c8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_38fd1f73-a17a-4bdc-a4aa-c95b4c2995b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_96b775ad-bb09-4f70-a62c-cc64f36b4b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e3e6114b-a52d-4089-89ad-bdefbeceb7c8" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_96b775ad-bb09-4f70-a62c-cc64f36b4b79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_5f20358b-e335-40fe-bf85-d4a25d84a192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e3e6114b-a52d-4089-89ad-bdefbeceb7c8" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_5f20358b-e335-40fe-bf85-d4a25d84a192" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OtherLongTermLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#OtherLongTermLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/OtherLongTermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_cdd016ba-9642-40d0-968d-20a76c5edea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ce455cbd-80f5-4477-a9b0-172651aec602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_cdd016ba-9642-40d0-968d-20a76c5edea7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ce455cbd-80f5-4477-a9b0-172651aec602" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_56a8c0df-ff58-460a-9eb7-66e4b4187d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_cdd016ba-9642-40d0-968d-20a76c5edea7" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_56a8c0df-ff58-460a-9eb7-66e4b4187d44" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#IncomeTaxesIncomeTaxBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_746fe29e-87a1-4c53-bd25-dcdb679ea184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3a4b0395-e7c2-404e-a2a9-697868ed5bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_746fe29e-87a1-4c53-bd25-dcdb679ea184" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3a4b0395-e7c2-404e-a2a9-697868ed5bc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_673144f0-775f-4942-b59b-467783d12e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_746fe29e-87a1-4c53-bd25-dcdb679ea184" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_673144f0-775f-4942-b59b-467783d12e3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_25386746-8b59-424d-860c-561f7042d003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e5d02df9-c787-44d6-ad14-75bdcb12d366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_25386746-8b59-424d-860c-561f7042d003" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e5d02df9-c787-44d6-ad14-75bdcb12d366" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2d64bfb4-074b-4cf5-9184-0f8c3370f01b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_25386746-8b59-424d-860c-561f7042d003" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2d64bfb4-074b-4cf5-9184-0f8c3370f01b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a9ced80d-1dfb-4bf7-b38c-8ba37aefb29f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_25386746-8b59-424d-860c-561f7042d003" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a9ced80d-1dfb-4bf7-b38c-8ba37aefb29f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_827a32f4-24cf-4739-91e2-ade685aef463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_25386746-8b59-424d-860c-561f7042d003" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_827a32f4-24cf-4739-91e2-ade685aef463" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_07dcb2c4-7c3d-461b-9cd2-50ad3ec8a3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_4a013bb7-ba5e-4265-b617-e7f2a38448f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_07dcb2c4-7c3d-461b-9cd2-50ad3ec8a3c9" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_4a013bb7-ba5e-4265-b617-e7f2a38448f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_9487ada5-3d53-479d-9210-0b760ce1e8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_07dcb2c4-7c3d-461b-9cd2-50ad3ec8a3c9" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_9487ada5-3d53-479d-9210-0b760ce1e8ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9b0f6d76-da5a-4dfc-a1a7-c97620893deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_07dcb2c4-7c3d-461b-9cd2-50ad3ec8a3c9" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9b0f6d76-da5a-4dfc-a1a7-c97620893deb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#IncomeTaxesLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fe6d9018-1606-4b62-aa68-fb61ea8660cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6edf5f26-a5be-4b91-b81f-9f4a506b9d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fe6d9018-1606-4b62-aa68-fb61ea8660cb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6edf5f26-a5be-4b91-b81f-9f4a506b9d0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_911488cd-3fb2-4973-ad3c-4f9195325029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fe6d9018-1606-4b62-aa68-fb61ea8660cb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_911488cd-3fb2-4973-ad3c-4f9195325029" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8bb91d43-0bba-4368-9105-e338cd781703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b021b541-209a-4ba8-83f0-4437d7efbce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8bb91d43-0bba-4368-9105-e338cd781703" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b021b541-209a-4ba8-83f0-4437d7efbce9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_82bd4f03-8348-4f8e-bfbf-092661cd6841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8bb91d43-0bba-4368-9105-e338cd781703" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_82bd4f03-8348-4f8e-bfbf-092661cd6841" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_7a4d111c-e0d3-4d9c-a0a3-92320d9253a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8bb91d43-0bba-4368-9105-e338cd781703" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_7a4d111c-e0d3-4d9c-a0a3-92320d9253a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_cacb45ee-122f-48a1-bedd-b8424652b871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8bb91d43-0bba-4368-9105-e338cd781703" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_cacb45ee-122f-48a1-bedd-b8424652b871" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_2b18dc24-db47-433b-ba24-986aa64c20e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8bb91d43-0bba-4368-9105-e338cd781703" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_2b18dc24-db47-433b-ba24-986aa64c20e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_f45b4794-45ee-4ece-8291-f61cb64dd1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8bb91d43-0bba-4368-9105-e338cd781703" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_f45b4794-45ee-4ece-8291-f61cb64dd1f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_83c84a37-15b3-4fe6-a48d-ff1254ab089a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8bb91d43-0bba-4368-9105-e338cd781703" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_83c84a37-15b3-4fe6-a48d-ff1254ab089a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationCARESAct_ce303206-9c31-45e5-a242-1eea259b86bb" xlink:href="mygn-20221231.xsd#mygn_IncomeTaxReconciliationCARESAct"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8bb91d43-0bba-4368-9105-e338cd781703" xlink:to="loc_mygn_IncomeTaxReconciliationCARESAct_ce303206-9c31-45e5-a242-1eea259b86bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_21f3159d-38ea-482d-92f1-0ba209b792b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8bb91d43-0bba-4368-9105-e338cd781703" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_21f3159d-38ea-482d-92f1-0ba209b792b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation_131b1f8f-e75e-4942-95e1-dce19019ace2" xlink:href="mygn-20221231.xsd#mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8bb91d43-0bba-4368-9105-e338cd781703" xlink:to="loc_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation_131b1f8f-e75e-4942-95e1-dce19019ace2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationAssetImpairment_150e49d2-945b-463f-a321-c457af4233ec" xlink:href="mygn-20221231.xsd#mygn_IncomeTaxReconciliationAssetImpairment"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8bb91d43-0bba-4368-9105-e338cd781703" xlink:to="loc_mygn_IncomeTaxReconciliationAssetImpairment_150e49d2-945b-463f-a321-c457af4233ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement_f53b314d-99ee-45d5-8fc5-8193a0acf092" xlink:href="mygn-20221231.xsd#mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8bb91d43-0bba-4368-9105-e338cd781703" xlink:to="loc_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement_f53b314d-99ee-45d5-8fc5-8193a0acf092" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration_245c3771-2a30-4758-9efb-f966bfc9084c" xlink:href="mygn-20221231.xsd#mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8bb91d43-0bba-4368-9105-e338cd781703" xlink:to="loc_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration_245c3771-2a30-4758-9efb-f966bfc9084c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b340b56e-782f-41fd-8f24-75a90c1f2967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8bb91d43-0bba-4368-9105-e338cd781703" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b340b56e-782f-41fd-8f24-75a90c1f2967" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_31410c23-4b37-469a-8007-50b4c5f1422f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a9f62b33-7ddc-45e8-b0ce-79afe3755341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_31410c23-4b37-469a-8007-50b4c5f1422f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a9f62b33-7ddc-45e8-b0ce-79afe3755341" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_027fa43c-8d3d-461f-b200-138150f30240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_31410c23-4b37-469a-8007-50b4c5f1422f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_027fa43c-8d3d-461f-b200-138150f30240" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_8e4d1949-9cd9-4180-88a0-c8bb59417139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_31410c23-4b37-469a-8007-50b4c5f1422f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_8e4d1949-9cd9-4180-88a0-c8bb59417139" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_3d9196bf-9d2e-4231-97a6-4ab0602ab2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_31410c23-4b37-469a-8007-50b4c5f1422f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_3d9196bf-9d2e-4231-97a6-4ab0602ab2eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_52d459b1-c970-4768-b514-54b8dbfce919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_31410c23-4b37-469a-8007-50b4c5f1422f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_52d459b1-c970-4768-b514-54b8dbfce919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_a98ada39-58c2-4f7b-9560-b7dfc43dfa0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_31410c23-4b37-469a-8007-50b4c5f1422f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_a98ada39-58c2-4f7b-9560-b7dfc43dfa0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_66233ce9-5699-4b6a-aa60-5f11dc64be4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_31410c23-4b37-469a-8007-50b4c5f1422f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_66233ce9-5699-4b6a-aa60-5f11dc64be4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationCARESAct_05900c88-578f-4490-90da-c72a17a9406b" xlink:href="mygn-20221231.xsd#mygn_EffectiveIncomeTaxRateReconciliationCARESAct"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_31410c23-4b37-469a-8007-50b4c5f1422f" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationCARESAct_05900c88-578f-4490-90da-c72a17a9406b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_d43efb00-1939-4cc8-ab09-afba75b6e44b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_31410c23-4b37-469a-8007-50b4c5f1422f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_d43efb00-1939-4cc8-ab09-afba75b6e44b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation_8c9a28d0-fdab-4ff6-81b7-43e2f3784b19" xlink:href="mygn-20221231.xsd#mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_31410c23-4b37-469a-8007-50b4c5f1422f" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation_8c9a28d0-fdab-4ff6-81b7-43e2f3784b19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment_6344917a-42ea-438f-94bb-c1e49acd6246" xlink:href="mygn-20221231.xsd#mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_31410c23-4b37-469a-8007-50b4c5f1422f" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment_6344917a-42ea-438f-94bb-c1e49acd6246" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements_6f6ac309-51fc-41c2-81a8-f926dabd8d14" xlink:href="mygn-20221231.xsd#mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_31410c23-4b37-469a-8007-50b4c5f1422f" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements_6f6ac309-51fc-41c2-81a8-f926dabd8d14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration_e34cc64a-8856-4d6f-8f64-a0926a2d7741" xlink:href="mygn-20221231.xsd#mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_31410c23-4b37-469a-8007-50b4c5f1422f" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration_e34cc64a-8856-4d6f-8f64-a0926a2d7741" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4cb456de-3c6f-4a92-a4b3-9b71d00ecd47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_31410c23-4b37-469a-8007-50b4c5f1422f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4cb456de-3c6f-4a92-a4b3-9b71d00ecd47" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_151e243c-8334-49c6-8961-689584d7ff7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_16ec8bd6-0bf9-4640-8b0b-f7100afc73ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_151e243c-8334-49c6-8961-689584d7ff7a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_16ec8bd6-0bf9-4640-8b0b-f7100afc73ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization_316bff36-08fa-4a93-acae-f17fcf1d7b40" xlink:href="mygn-20221231.xsd#mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_151e243c-8334-49c6-8961-689584d7ff7a" xlink:to="loc_mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization_316bff36-08fa-4a93-acae-f17fcf1d7b40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_b48148da-71f7-4bdc-be89-422a836b7ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_151e243c-8334-49c6-8961-689584d7ff7a" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_b48148da-71f7-4bdc-be89-422a836b7ac3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_26c67402-0fdd-49f9-a16a-24a26ed90914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_151e243c-8334-49c6-8961-689584d7ff7a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_26c67402-0fdd-49f9-a16a-24a26ed90914" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_32eda053-0e78-488e-a776-ae36bfd147b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_151e243c-8334-49c6-8961-689584d7ff7a" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_32eda053-0e78-488e-a776-ae36bfd147b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DeferredTaxAssetsLeaseLiabilities_a7eb9d9b-d801-449c-ae97-18134649d374" xlink:href="mygn-20221231.xsd#mygn_DeferredTaxAssetsLeaseLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_151e243c-8334-49c6-8961-689584d7ff7a" xlink:to="loc_mygn_DeferredTaxAssetsLeaseLiabilities_a7eb9d9b-d801-449c-ae97-18134649d374" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_528a2b69-5c86-484f-9dac-1bcc2002ced1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_151e243c-8334-49c6-8961-689584d7ff7a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_528a2b69-5c86-484f-9dac-1bcc2002ced1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_cc32f18c-bd66-4624-8204-59777be1ba40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_151e243c-8334-49c6-8961-689584d7ff7a" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_cc32f18c-bd66-4624-8204-59777be1ba40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_b76cb42c-8fc2-42ae-bc33-27f9dc1622f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_81023e9e-a1ce-4f3e-8656-32bfbc2a0136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_b76cb42c-8fc2-42ae-bc33-27f9dc1622f8" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_81023e9e-a1ce-4f3e-8656-32bfbc2a0136" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_bd0d8a9b-2b84-4ebd-bda4-4abe2210d23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_b76cb42c-8fc2-42ae-bc33-27f9dc1622f8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_bd0d8a9b-2b84-4ebd-bda4-4abe2210d23e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_86c806a0-ec77-456f-acd8-7b2a534345c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6f2193d3-751b-4a99-a79c-3a4604763246" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_86c806a0-ec77-456f-acd8-7b2a534345c5" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_6f2193d3-751b-4a99-a79c-3a4604763246" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5c6725fd-daee-42e2-abf6-6078b68611b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_86c806a0-ec77-456f-acd8-7b2a534345c5" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5c6725fd-daee-42e2-abf6-6078b68611b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_c43d60df-14d1-45f7-9a5d-f8c868a601ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_f4d3c429-756a-463e-b4e6-4a7e6f026d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c43d60df-14d1-45f7-9a5d-f8c868a601ed" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_f4d3c429-756a-463e-b4e6-4a7e6f026d67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets_fd87b8a2-806b-48a4-a991-50a131cb8a40" xlink:href="mygn-20221231.xsd#mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c43d60df-14d1-45f7-9a5d-f8c868a601ed" xlink:to="loc_mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets_fd87b8a2-806b-48a4-a991-50a131cb8a40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_26f613a3-5f0d-4664-8bbb-1348644d2417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_c43d60df-14d1-45f7-9a5d-f8c868a601ed" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_26f613a3-5f0d-4664-8bbb-1348644d2417" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c8fc2f41-9b0c-4b27-9bea-799a8426e79d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dc19c581-bfad-4ce4-b6b6-0c2c992662e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c8fc2f41-9b0c-4b27-9bea-799a8426e79d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dc19c581-bfad-4ce4-b6b6-0c2c992662e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c5b307aa-49da-42e1-ba0f-af346bdc027a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c8fc2f41-9b0c-4b27-9bea-799a8426e79d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c5b307aa-49da-42e1-ba0f-af346bdc027a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4c8d0575-1885-460e-88b5-a37c0e7cecac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c8fc2f41-9b0c-4b27-9bea-799a8426e79d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4c8d0575-1885-460e-88b5-a37c0e7cecac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_191da82e-b928-4be4-a05d-72416ebad01d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c8fc2f41-9b0c-4b27-9bea-799a8426e79d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_191da82e-b928-4be4-a05d-72416ebad01d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_062b8bdc-2150-4fb1-9acb-e773ce608008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c8fc2f41-9b0c-4b27-9bea-799a8426e79d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_062b8bdc-2150-4fb1-9acb-e773ce608008" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ec2b2ffa-c17c-4d67-9fca-a32c3d329f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c8fc2f41-9b0c-4b27-9bea-799a8426e79d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ec2b2ffa-c17c-4d67-9fca-a32c3d329f3f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="mygn-20221231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fde7e5f9-866c-407a-99e2-f26f9eba7f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_291549eb-cda5-4318-a0de-8e57727ca9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fde7e5f9-866c-407a-99e2-f26f9eba7f66" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_291549eb-cda5-4318-a0de-8e57727ca9b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced_bb2b1d1d-9a20-4190-8ed0-6d1d181f4726" xlink:href="mygn-20221231.xsd#mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fde7e5f9-866c-407a-99e2-f26f9eba7f66" xlink:to="loc_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced_bb2b1d1d-9a20-4190-8ed0-6d1d181f4726" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_ef08c7ed-9e81-4405-827e-27404e6a09b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_2bc1ef25-a0cf-46d2-98a2-e2981e982715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_ef08c7ed-9e81-4405-827e-27404e6a09b1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_2bc1ef25-a0cf-46d2-98a2-e2981e982715" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_662d3e7d-0ec7-4dce-bd0d-8a7e049d5c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_ef08c7ed-9e81-4405-827e-27404e6a09b1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_662d3e7d-0ec7-4dce-bd0d-8a7e049d5c6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1076f2e3-bfe5-40cc-a9f9-750ffa1b9896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_ef08c7ed-9e81-4405-827e-27404e6a09b1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1076f2e3-bfe5-40cc-a9f9-750ffa1b9896" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3534abf5-4d9c-41eb-9c22-b90ed16f8c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_ef08c7ed-9e81-4405-827e-27404e6a09b1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3534abf5-4d9c-41eb-9c22-b90ed16f8c51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_38e0e9e5-1f81-42b5-8243-7737307a9d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_932775bb-9884-498d-8eeb-eeb3939b132f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_38e0e9e5-1f81-42b5-8243-7737307a9d99" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_932775bb-9884-498d-8eeb-eeb3939b132f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2e467848-f054-4c02-ba80-2e9851e85051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_38e0e9e5-1f81-42b5-8243-7737307a9d99" xlink:to="loc_us-gaap_Goodwill_2e467848-f054-4c02-ba80-2e9851e85051" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_75ffe382-f23b-4567-98d4-d77b88147e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5abfbf27-8a02-44c7-a685-6ed4cd8dbe12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_75ffe382-f23b-4567-98d4-d77b88147e90" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_5abfbf27-8a02-44c7-a685-6ed4cd8dbe12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_76d9c868-1fb8-4d96-a6d8-2472ee9c5294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_75ffe382-f23b-4567-98d4-d77b88147e90" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_76d9c868-1fb8-4d96-a6d8-2472ee9c5294" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/DivestituresOtherIncomeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#DivestituresOtherIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.myriad.com/role/DivestituresOtherIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_587454c2-35fd-4a7c-a546-8d83a62e63c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_0d69afff-63f2-4ba6-b4e0-289c7bf3e2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_587454c2-35fd-4a7c-a546-8d83a62e63c0" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_0d69afff-63f2-4ba6-b4e0-289c7bf3e2ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_59e1d5e3-7726-46e0-bc22-43f06e9c41eb" xlink:href="mygn-20221231.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_587454c2-35fd-4a7c-a546-8d83a62e63c0" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_59e1d5e3-7726-46e0-bc22-43f06e9c41eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_81895897-5aab-4041-9c6f-0402f6d0bc7b" xlink:href="mygn-20221231.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_587454c2-35fd-4a7c-a546-8d83a62e63c0" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_81895897-5aab-4041-9c6f-0402f6d0bc7b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>mygn-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6db69074-e648-4be3-ae6d-ea77b2ae08c9,g:6dbaf31c-e8bf-47fc-986c-d695276c3aba-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="mygn-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="i1d1af9bb826145a1814aa5a6c733b9c5_ConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_994076c8-c36c-4a11-9469-c9f0b9a41c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_994076c8-c36c-4a11-9469-c9f0b9a41c3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_3e3129e5-7b82-483a-b225-6da63829ef86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_3e3129e5-7b82-483a-b225-6da63829ef86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_55155670-23cc-4c04-b9bb-d7cf73a5645b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3e3129e5-7b82-483a-b225-6da63829ef86" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_55155670-23cc-4c04-b9bb-d7cf73a5645b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_de0f3036-5ad9-4bd0-809e-b15b000d274d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3e3129e5-7b82-483a-b225-6da63829ef86" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_de0f3036-5ad9-4bd0-809e-b15b000d274d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_bf93e2a5-cd15-45fc-81f9-30ba04fbf65d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3e3129e5-7b82-483a-b225-6da63829ef86" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_bf93e2a5-cd15-45fc-81f9-30ba04fbf65d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_3e69b03d-5701-4889-8d32-3ab7fbc9e21e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3e3129e5-7b82-483a-b225-6da63829ef86" xlink:to="loc_us-gaap_LitigationSettlementExpense_3e69b03d-5701-4889-8d32-3ab7fbc9e21e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_f7d265f7-6e3b-4c2b-924d-5ee1ac6fb6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3e3129e5-7b82-483a-b225-6da63829ef86" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_f7d265f7-6e3b-4c2b-924d-5ee1ac6fb6a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b6fe5b78-72c2-4311-8d6d-91e7f4067933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3e3129e5-7b82-483a-b225-6da63829ef86" xlink:to="loc_us-gaap_CostsAndExpenses_b6fe5b78-72c2-4311-8d6d-91e7f4067933" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c56e0f99-2294-489d-952b-48338a82b57f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_OperatingIncomeLoss_c56e0f99-2294-489d-952b-48338a82b57f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c599485b-3b35-4a18-accb-bc17568ab9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c599485b-3b35-4a18-accb-bc17568ab9d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4f36a4f6-7892-4eb1-b2d5-8ded93183019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c599485b-3b35-4a18-accb-bc17568ab9d3" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4f36a4f6-7892-4eb1-b2d5-8ded93183019" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_dc9e6743-db70-4d50-a4f3-a51263db73ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c599485b-3b35-4a18-accb-bc17568ab9d3" xlink:to="loc_us-gaap_InterestExpense_dc9e6743-db70-4d50-a4f3-a51263db73ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c90ebd7f-47a1-449d-93b1-4a7efeae2f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c599485b-3b35-4a18-accb-bc17568ab9d3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c90ebd7f-47a1-449d-93b1-4a7efeae2f8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b7302ee1-6280-4a64-a58a-c77a8ccc2321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c599485b-3b35-4a18-accb-bc17568ab9d3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_b7302ee1-6280-4a64-a58a-c77a8ccc2321" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_78428e0e-4de0-438d-9190-c6f103d72885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_78428e0e-4de0-438d-9190-c6f103d72885" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5a5ff4f5-f692-49e4-9111-37e6c9b9494c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5a5ff4f5-f692-49e4-9111-37e6c9b9494c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_21c6b9fd-92ea-4e44-a71d-da383c01f4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_ProfitLoss_21c6b9fd-92ea-4e44-a71d-da383c01f4c8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_36cc1799-1642-4e73-b1bb-f8a6f459ee3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_36cc1799-1642-4e73-b1bb-f8a6f459ee3b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_42de9e7b-e256-4f5d-8ecc-f69c831b212c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_NetIncomeLoss_42de9e7b-e256-4f5d-8ecc-f69c831b212c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EarningsPerShareBasicAndDilutedEPSAbstract_9c7bb729-3075-437a-80b3-549603d1e2e8" xlink:href="mygn-20221231.xsd#mygn_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_mygn_EarningsPerShareBasicAndDilutedEPSAbstract_9c7bb729-3075-437a-80b3-549603d1e2e8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d4b4607c-1c93-421d-acbf-62fd6fec5713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_EarningsPerShareBasicAndDilutedEPSAbstract_9c7bb729-3075-437a-80b3-549603d1e2e8" xlink:to="loc_us-gaap_EarningsPerShareBasic_d4b4607c-1c93-421d-acbf-62fd6fec5713" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_57118798-2bad-4630-a96a-6c76a563cae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_EarningsPerShareBasicAndDilutedEPSAbstract_9c7bb729-3075-437a-80b3-549603d1e2e8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_57118798-2bad-4630-a96a-6c76a563cae1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d867ae04-4581-4b94-9ba0-7f4529f730cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d867ae04-4581-4b94-9ba0-7f4529f730cd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_391052f6-3fc0-4b53-a96b-5fe1630f0fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d867ae04-4581-4b94-9ba0-7f4529f730cd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_391052f6-3fc0-4b53-a96b-5fe1630f0fd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2d69efbe-7770-46a7-baa6-59da39170508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d867ae04-4581-4b94-9ba0-7f4529f730cd" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2d69efbe-7770-46a7-baa6-59da39170508" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cfd67334-68a1-40ef-aeb1-21b965d2d9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_StatementTable_cfd67334-68a1-40ef-aeb1-21b965d2d9c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a66ea91f-cc02-42a8-a43a-78daf6503739" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cfd67334-68a1-40ef-aeb1-21b965d2d9c2" xlink:to="loc_srt_ProductOrServiceAxis_a66ea91f-cc02-42a8-a43a-78daf6503739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a66ea91f-cc02-42a8-a43a-78daf6503739_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a66ea91f-cc02-42a8-a43a-78daf6503739" xlink:to="loc_srt_ProductsAndServicesDomain_a66ea91f-cc02-42a8-a43a-78daf6503739_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e3b3df6f-19dc-4460-8320-ca8e8d431f4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a66ea91f-cc02-42a8-a43a-78daf6503739" xlink:to="loc_srt_ProductsAndServicesDomain_e3b3df6f-19dc-4460-8320-ca8e8d431f4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TestingRevenueMember_a8323883-aa93-4984-8ad7-69a668559c63" xlink:href="mygn-20221231.xsd#mygn_TestingRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e3b3df6f-19dc-4460-8320-ca8e8d431f4e" xlink:to="loc_mygn_TestingRevenueMember_a8323883-aa93-4984-8ad7-69a668559c63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_d6735b23-b635-4ff5-9c33-63efd88b1f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e3b3df6f-19dc-4460-8320-ca8e8d431f4e" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_d6735b23-b635-4ff5-9c33-63efd88b1f5a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="mygn-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i54b51e130b7140ed8747810ee90f1558_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f9c4f90f-fcc6-4504-a41b-376df01ef962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b82d13bc-bb0f-4260-938e-f692461fa89c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f9c4f90f-fcc6-4504-a41b-376df01ef962" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b82d13bc-bb0f-4260-938e-f692461fa89c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_948dbcd5-f3ff-4e79-aab7-a4964e169718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b82d13bc-bb0f-4260-938e-f692461fa89c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_948dbcd5-f3ff-4e79-aab7-a4964e169718" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2cbcb730-8973-4a03-8139-7ef269c46a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b82d13bc-bb0f-4260-938e-f692461fa89c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2cbcb730-8973-4a03-8139-7ef269c46a25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fa33e3a9-e207-4bca-b5bf-2fad7bfc3ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b82d13bc-bb0f-4260-938e-f692461fa89c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fa33e3a9-e207-4bca-b5bf-2fad7bfc3ad0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_21fd8021-b371-44f3-9bed-8aac3e9561a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b82d13bc-bb0f-4260-938e-f692461fa89c" xlink:to="loc_us-gaap_NetIncomeLoss_21fd8021-b371-44f3-9bed-8aac3e9561a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_90052b74-7160-4f9d-8540-ef37d0829824" xlink:href="mygn-20221231.xsd#mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b82d13bc-bb0f-4260-938e-f692461fa89c" xlink:to="loc_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_90052b74-7160-4f9d-8540-ef37d0829824" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e7267612-2c31-429f-8c7c-8d424cf66194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b82d13bc-bb0f-4260-938e-f692461fa89c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e7267612-2c31-429f-8c7c-8d424cf66194" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6f209ef5-1e10-4189-bee2-7ec522378ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_75ea43cf-1e38-494e-81ee-bd3bf5d43814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f9c4f90f-fcc6-4504-a41b-376df01ef962" xlink:to="loc_us-gaap_StatementTable_75ea43cf-1e38-494e-81ee-bd3bf5d43814" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fdc946b4-0600-4f1a-a5e4-c0c404de1b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_75ea43cf-1e38-494e-81ee-bd3bf5d43814" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fdc946b4-0600-4f1a-a5e4-c0c404de1b95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fdc946b4-0600-4f1a-a5e4-c0c404de1b95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fdc946b4-0600-4f1a-a5e4-c0c404de1b95" xlink:to="loc_us-gaap_EquityComponentDomain_fdc946b4-0600-4f1a-a5e4-c0c404de1b95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8db71410-9317-416f-b6f3-5f083b892b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fdc946b4-0600-4f1a-a5e4-c0c404de1b95" xlink:to="loc_us-gaap_EquityComponentDomain_8db71410-9317-416f-b6f3-5f083b892b34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f743625a-47b6-41db-9c84-ed623a4b20a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8db71410-9317-416f-b6f3-5f083b892b34" xlink:to="loc_us-gaap_CommonStockMember_f743625a-47b6-41db-9c84-ed623a4b20a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2239bf0b-a761-4e04-8e34-2f420bb12185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8db71410-9317-416f-b6f3-5f083b892b34" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2239bf0b-a761-4e04-8e34-2f420bb12185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_17692eed-5a1d-4e43-be57-9a1a23fafc19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8db71410-9317-416f-b6f3-5f083b892b34" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_17692eed-5a1d-4e43-be57-9a1a23fafc19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_119592a9-731f-4a83-9517-fd26ec54072a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8db71410-9317-416f-b6f3-5f083b892b34" xlink:to="loc_us-gaap_RetainedEarningsMember_119592a9-731f-4a83-9517-fd26ec54072a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="ib723e9d701724f20a88bf0c2ba2e47bb_OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:href="mygn-20221231.xsd#mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ce899eaa-9518-44e7-92a5-53ad59c85885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ce899eaa-9518-44e7-92a5-53ad59c85885" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_a6f3786a-56a8-4c20-9bf8-b74a279d1828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_RestrictedCash_a6f3786a-56a8-4c20-9bf8-b74a279d1828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_86b93bd7-458b-4445-a6b2-a0bf925d5c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_RestrictedCashCurrent_86b93bd7-458b-4445-a6b2-a0bf925d5c39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_3177800a-db15-4041-a654-f6979f54b8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_3177800a-db15-4041-a654-f6979f54b8ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_88872db8-4a53-4c7d-859f-0b9bcf09a57b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_88872db8-4a53-4c7d-859f-0b9bcf09a57b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_91cf6519-7003-46f7-8c55-f059699c9f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_91cf6519-7003-46f7-8c55-f059699c9f8f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_6fb454a8-a405-4456-93ff-e836c25452a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_6fb454a8-a405-4456-93ff-e836c25452a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet_d4771102-06ac-4bbc-96da-65224b62fe61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareNet_d4771102-06ac-4bbc-96da-65224b62fe61" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_687e74fb-7d87-412f-a1ca-1afe05242421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_687e74fb-7d87-412f-a1ca-1afe05242421" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CARESActOf2020MedicarePaymentAmount_7cb33f23-60b4-4838-bfbb-fa8618aca006" xlink:href="mygn-20221231.xsd#mygn_CARESActOf2020MedicarePaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_mygn_CARESActOf2020MedicarePaymentAmount_7cb33f23-60b4-4838-bfbb-fa8618aca006" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_35a34e6d-6ff5-4f68-a502-932dd1cdf47c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_35a34e6d-6ff5-4f68-a502-932dd1cdf47c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInEarningsLossPerShare_bc59d4c9-94e9-460f-9d14-58b23e957322" xlink:href="mygn-20221231.xsd#mygn_IncreaseDecreaseInEarningsLossPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_mygn_IncreaseDecreaseInEarningsLossPerShare_bc59d4c9-94e9-460f-9d14-58b23e957322" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained_2cbc45cc-d332-439f-8ad0-98ba680d8b38" xlink:href="mygn-20221231.xsd#mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained_2cbc45cc-d332-439f-8ad0-98ba680d8b38" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_63a6cfeb-a14a-4424-a55d-b16d5b0405d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_63a6cfeb-a14a-4424-a55d-b16d5b0405d4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9e76634c-b4cd-46db-862d-3834fb126e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9e76634c-b4cd-46db-862d-3834fb126e95" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_22a28291-0a51-4804-b530-f7181a7f2f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_CapitalizedContractCostGross_22a28291-0a51-4804-b530-f7181a7f2f14" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_faec4ec3-4a48-4098-97a5-8c484250607e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_faec4ec3-4a48-4098-97a5-8c484250607e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CARESActOf2020ProviderReliefFundAmount_282911d9-2abe-4645-8c71-7423a90d82e5" xlink:href="mygn-20221231.xsd#mygn_CARESActOf2020ProviderReliefFundAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_mygn_CARESActOf2020ProviderReliefFundAmount_282911d9-2abe-4645-8c71-7423a90d82e5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_b7e98ada-60ee-45ab-9bb6-203b7f4c5afd" xlink:href="mygn-20221231.xsd#mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_b7e98ada-60ee-45ab-9bb6-203b7f4c5afd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b973a670-6dac-45f3-ac55-28273d8a5fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_b7e98ada-60ee-45ab-9bb6-203b7f4c5afd" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b973a670-6dac-45f3-ac55-28273d8a5fc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b973a670-6dac-45f3-ac55-28273d8a5fc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b973a670-6dac-45f3-ac55-28273d8a5fc3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b973a670-6dac-45f3-ac55-28273d8a5fc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_469dff97-4ed7-467b-a3ec-a844f774c241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b973a670-6dac-45f3-ac55-28273d8a5fc3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_469dff97-4ed7-467b-a3ec-a844f774c241" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember_a9bc661c-13da-4e94-b631-a8001246bb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_469dff97-4ed7-467b-a3ec-a844f774c241" xlink:to="loc_us-gaap_GovernmentContractsConcentrationRiskMember_a9bc661c-13da-4e94-b631-a8001246bb5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_5df08029-a7a4-42ee-b8f9-094bf2f44c1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_b7e98ada-60ee-45ab-9bb6-203b7f4c5afd" xlink:to="loc_srt_MajorCustomersAxis_5df08029-a7a4-42ee-b8f9-094bf2f44c1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5df08029-a7a4-42ee-b8f9-094bf2f44c1b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_5df08029-a7a4-42ee-b8f9-094bf2f44c1b" xlink:to="loc_srt_NameOfMajorCustomerDomain_5df08029-a7a4-42ee-b8f9-094bf2f44c1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_52028d2e-9f5e-46bc-8261-5a2220156b2a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_5df08029-a7a4-42ee-b8f9-094bf2f44c1b" xlink:to="loc_srt_NameOfMajorCustomerDomain_52028d2e-9f5e-46bc-8261-5a2220156b2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MedicareMember_bdf3f927-d944-42ec-a834-304be94f650b" xlink:href="mygn-20221231.xsd#mygn_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_52028d2e-9f5e-46bc-8261-5a2220156b2a" xlink:to="loc_mygn_MedicareMember_bdf3f927-d944-42ec-a834-304be94f650b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5e18d3f0-6afe-4c45-8c80-c1010a1cb914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_b7e98ada-60ee-45ab-9bb6-203b7f4c5afd" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5e18d3f0-6afe-4c45-8c80-c1010a1cb914" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5e18d3f0-6afe-4c45-8c80-c1010a1cb914_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5e18d3f0-6afe-4c45-8c80-c1010a1cb914" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5e18d3f0-6afe-4c45-8c80-c1010a1cb914_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b17ba749-71f9-4e76-b8a7-bd055d747248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5e18d3f0-6afe-4c45-8c80-c1010a1cb914" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b17ba749-71f9-4e76-b8a7-bd055d747248" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_c8913ae1-5941-464a-98e8-7815aebb8023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b17ba749-71f9-4e76-b8a7-bd055d747248" xlink:to="loc_us-gaap_SalesRevenueNetMember_c8913ae1-5941-464a-98e8-7815aebb8023" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60947fe4-869b-4af0-99c9-d4783a0b4cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_b7e98ada-60ee-45ab-9bb6-203b7f4c5afd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60947fe4-869b-4af0-99c9-d4783a0b4cc5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60947fe4-869b-4af0-99c9-d4783a0b4cc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60947fe4-869b-4af0-99c9-d4783a0b4cc5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60947fe4-869b-4af0-99c9-d4783a0b4cc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79ee98d9-2b6c-4126-ae51-c1ef87776e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60947fe4-869b-4af0-99c9-d4783a0b4cc5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79ee98d9-2b6c-4126-ae51-c1ef87776e65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_eb9bec1b-d0f6-4abb-87f4-1a5d3609c304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79ee98d9-2b6c-4126-ae51-c1ef87776e65" xlink:to="loc_us-gaap_EquipmentMember_eb9bec1b-d0f6-4abb-87f4-1a5d3609c304" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_529e6536-48dd-45cf-8c17-fd7013bfa54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79ee98d9-2b6c-4126-ae51-c1ef87776e65" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_529e6536-48dd-45cf-8c17-fd7013bfa54f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_2cbb0c8c-0e92-4a5e-847b-ba07f3429e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_b7e98ada-60ee-45ab-9bb6-203b7f4c5afd" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_2cbb0c8c-0e92-4a5e-847b-ba07f3429e77" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_2cbb0c8c-0e92-4a5e-847b-ba07f3429e77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_2cbb0c8c-0e92-4a5e-847b-ba07f3429e77" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_2cbb0c8c-0e92-4a5e-847b-ba07f3429e77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_6f779fc0-2200-4cc1-a884-40c7d333264a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_2cbb0c8c-0e92-4a5e-847b-ba07f3429e77" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_6f779fc0-2200-4cc1-a884-40c7d333264a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember_7fa351af-1ec4-4324-a80e-e685dc8ed925" xlink:href="mygn-20221231.xsd#mygn_PerformanceObligationEstimatedTransactionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_6f779fc0-2200-4cc1-a884-40c7d333264a" xlink:to="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember_7fa351af-1ec4-4324-a80e-e685dc8ed925" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_d880abd0-549c-483f-86f4-65e3df8e625b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_b7e98ada-60ee-45ab-9bb6-203b7f4c5afd" xlink:to="loc_srt_RestatementAxis_d880abd0-549c-483f-86f4-65e3df8e625b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_d880abd0-549c-483f-86f4-65e3df8e625b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_d880abd0-549c-483f-86f4-65e3df8e625b" xlink:to="loc_srt_RestatementDomain_d880abd0-549c-483f-86f4-65e3df8e625b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_97e6e560-0a82-4d70-a446-c3d455b8bdf2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_d880abd0-549c-483f-86f4-65e3df8e625b" xlink:to="loc_srt_RestatementDomain_97e6e560-0a82-4d70-a446-c3d455b8bdf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_06034cac-46bf-4ae5-8b62-8910df5f75ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_97e6e560-0a82-4d70-a446-c3d455b8bdf2" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_06034cac-46bf-4ae5-8b62-8910df5f75ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ad445909-8545-40b1-a6f8-0d7cc78b58e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_b7e98ada-60ee-45ab-9bb6-203b7f4c5afd" xlink:to="loc_srt_RangeAxis_ad445909-8545-40b1-a6f8-0d7cc78b58e8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ad445909-8545-40b1-a6f8-0d7cc78b58e8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ad445909-8545-40b1-a6f8-0d7cc78b58e8" xlink:to="loc_srt_RangeMember_ad445909-8545-40b1-a6f8-0d7cc78b58e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_592a9d6c-2c46-493e-a8e5-81c142cd5560" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ad445909-8545-40b1-a6f8-0d7cc78b58e8" xlink:to="loc_srt_RangeMember_592a9d6c-2c46-493e-a8e5-81c142cd5560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_876d0cc3-0fbb-4c9d-bbee-4a33f3feced2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_592a9d6c-2c46-493e-a8e5-81c142cd5560" xlink:to="loc_srt_MinimumMember_876d0cc3-0fbb-4c9d-bbee-4a33f3feced2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2a014d37-6e51-4ef3-8281-216d113ad8f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_592a9d6c-2c46-493e-a8e5-81c142cd5560" xlink:to="loc_srt_MaximumMember_2a014d37-6e51-4ef3-8281-216d113ad8f0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails" xlink:type="extended" id="i3802fab404e245a7afa73b4a4e9f39ce_OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_655b0f9e-3efa-4fa9-b695-43f88e3a76c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3aac0dce-4dd0-403a-ba5e-be497483d6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_655b0f9e-3efa-4fa9-b695-43f88e3a76c7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3aac0dce-4dd0-403a-ba5e-be497483d6cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_90ee2f66-024d-46b7-a3a0-03ef8d91db68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_655b0f9e-3efa-4fa9-b695-43f88e3a76c7" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_90ee2f66-024d-46b7-a3a0-03ef8d91db68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a2fc7cf6-db41-4a99-af60-ee278f9308cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_90ee2f66-024d-46b7-a3a0-03ef8d91db68" xlink:to="loc_srt_ProductOrServiceAxis_a2fc7cf6-db41-4a99-af60-ee278f9308cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a2fc7cf6-db41-4a99-af60-ee278f9308cf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a2fc7cf6-db41-4a99-af60-ee278f9308cf" xlink:to="loc_srt_ProductsAndServicesDomain_a2fc7cf6-db41-4a99-af60-ee278f9308cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_748a01ca-3df3-4030-8980-342db3c5c98e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a2fc7cf6-db41-4a99-af60-ee278f9308cf" xlink:to="loc_srt_ProductsAndServicesDomain_748a01ca-3df3-4030-8980-342db3c5c98e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TestingRevenueMember_275fea63-cff4-4a73-956b-3d665dac8d69" xlink:href="mygn-20221231.xsd#mygn_TestingRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_748a01ca-3df3-4030-8980-342db3c5c98e" xlink:to="loc_mygn_TestingRevenueMember_275fea63-cff4-4a73-956b-3d665dac8d69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_HereditaryCancerTestingMember_add142ec-67fb-42eb-8b01-b7855f91f316" xlink:href="mygn-20221231.xsd#mygn_HereditaryCancerTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TestingRevenueMember_275fea63-cff4-4a73-956b-3d665dac8d69" xlink:to="loc_mygn_HereditaryCancerTestingMember_add142ec-67fb-42eb-8b01-b7855f91f316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TumorProfilingMember_702d4ce5-f431-4238-8d26-d6fa40bc741f" xlink:href="mygn-20221231.xsd#mygn_TumorProfilingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TestingRevenueMember_275fea63-cff4-4a73-956b-3d665dac8d69" xlink:to="loc_mygn_TumorProfilingMember_702d4ce5-f431-4238-8d26-d6fa40bc741f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PrenatalTestingMember_c853b366-3269-4e8b-8691-b213364b2655" xlink:href="mygn-20221231.xsd#mygn_PrenatalTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TestingRevenueMember_275fea63-cff4-4a73-956b-3d665dac8d69" xlink:to="loc_mygn_PrenatalTestingMember_c853b366-3269-4e8b-8691-b213364b2655" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmacogenomicsMember_1fba5d6c-961d-47b5-968c-a2acfda27eca" xlink:href="mygn-20221231.xsd#mygn_PharmacogenomicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TestingRevenueMember_275fea63-cff4-4a73-956b-3d665dac8d69" xlink:to="loc_mygn_PharmacogenomicsMember_1fba5d6c-961d-47b5-968c-a2acfda27eca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AutoimmuneMember_934aa0e1-f2b0-42c0-9d4a-559b5b93bb19" xlink:href="mygn-20221231.xsd#mygn_AutoimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TestingRevenueMember_275fea63-cff4-4a73-956b-3d665dac8d69" xlink:to="loc_mygn_AutoimmuneMember_934aa0e1-f2b0-42c0-9d4a-559b5b93bb19" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OtherTestingMember_d96332e1-d351-4dec-9ce4-181f81562285" xlink:href="mygn-20221231.xsd#mygn_OtherTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TestingRevenueMember_275fea63-cff4-4a73-956b-3d665dac8d69" xlink:to="loc_mygn_OtherTestingMember_d96332e1-d351-4dec-9ce4-181f81562285" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_e6a1b578-d1f1-4784-bc1d-937fa6cc73c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_748a01ca-3df3-4030-8980-342db3c5c98e" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_e6a1b578-d1f1-4784-bc1d-937fa6cc73c6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails" xlink:type="extended" id="ic1efcb826fed4bad92f14e6ab616431e_OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_639810eb-2f42-4a4a-aec3-12373004a2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8f575034-146d-45fd-adf0-32c9aba89fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_639810eb-2f42-4a4a-aec3-12373004a2b8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8f575034-146d-45fd-adf0-32c9aba89fed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_846adcd2-c3c1-4389-a6b5-3c0e2f861d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_639810eb-2f42-4a4a-aec3-12373004a2b8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_846adcd2-c3c1-4389-a6b5-3c0e2f861d08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e5f6dbd5-9ef3-4adb-ba49-fbd3d7e49b1c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_846adcd2-c3c1-4389-a6b5-3c0e2f861d08" xlink:to="loc_srt_StatementGeographicalAxis_e5f6dbd5-9ef3-4adb-ba49-fbd3d7e49b1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e5f6dbd5-9ef3-4adb-ba49-fbd3d7e49b1c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e5f6dbd5-9ef3-4adb-ba49-fbd3d7e49b1c" xlink:to="loc_srt_SegmentGeographicalDomain_e5f6dbd5-9ef3-4adb-ba49-fbd3d7e49b1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e10587cb-c16a-4d17-a6b3-a03d34f9629b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e5f6dbd5-9ef3-4adb-ba49-fbd3d7e49b1c" xlink:to="loc_srt_SegmentGeographicalDomain_e10587cb-c16a-4d17-a6b3-a03d34f9629b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_62b3182f-fa9e-46df-ae4c-c78e1655f6fd" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e10587cb-c16a-4d17-a6b3-a03d34f9629b" xlink:to="loc_country_US_62b3182f-fa9e-46df-ae4c-c78e1655f6fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_826e386d-ed1f-4f45-afca-f027d13da416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e10587cb-c16a-4d17-a6b3-a03d34f9629b" xlink:to="loc_us-gaap_NonUsMember_826e386d-ed1f-4f45-afca-f027d13da416" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b4309dd8-37ac-4d2a-9e27-32d87d2e9962" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_846adcd2-c3c1-4389-a6b5-3c0e2f861d08" xlink:to="loc_srt_ProductOrServiceAxis_b4309dd8-37ac-4d2a-9e27-32d87d2e9962" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b4309dd8-37ac-4d2a-9e27-32d87d2e9962_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b4309dd8-37ac-4d2a-9e27-32d87d2e9962" xlink:to="loc_srt_ProductsAndServicesDomain_b4309dd8-37ac-4d2a-9e27-32d87d2e9962_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7cd135a5-4f67-4964-a88e-e7e75adb8e5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b4309dd8-37ac-4d2a-9e27-32d87d2e9962" xlink:to="loc_srt_ProductsAndServicesDomain_7cd135a5-4f67-4964-a88e-e7e75adb8e5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TestingRevenueMember_5d37f3e7-56ce-4ca5-b8bc-bdcba514a4d0" xlink:href="mygn-20221231.xsd#mygn_TestingRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7cd135a5-4f67-4964-a88e-e7e75adb8e5d" xlink:to="loc_mygn_TestingRevenueMember_5d37f3e7-56ce-4ca5-b8bc-bdcba514a4d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_HereditaryCancerTestingMember_ce483dec-f693-45dd-ba82-189be11c74fd" xlink:href="mygn-20221231.xsd#mygn_HereditaryCancerTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TestingRevenueMember_5d37f3e7-56ce-4ca5-b8bc-bdcba514a4d0" xlink:to="loc_mygn_HereditaryCancerTestingMember_ce483dec-f693-45dd-ba82-189be11c74fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TumorProfilingMember_b4db2618-c80a-44cd-b72a-af7ddcb8c6c0" xlink:href="mygn-20221231.xsd#mygn_TumorProfilingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TestingRevenueMember_5d37f3e7-56ce-4ca5-b8bc-bdcba514a4d0" xlink:to="loc_mygn_TumorProfilingMember_b4db2618-c80a-44cd-b72a-af7ddcb8c6c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PrenatalTestingMember_7bef2883-a7fb-4c08-a2e0-fc4dbe3c70b5" xlink:href="mygn-20221231.xsd#mygn_PrenatalTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TestingRevenueMember_5d37f3e7-56ce-4ca5-b8bc-bdcba514a4d0" xlink:to="loc_mygn_PrenatalTestingMember_7bef2883-a7fb-4c08-a2e0-fc4dbe3c70b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmacogenomicsMember_576f1b50-629e-4e03-92b3-a34e11e68653" xlink:href="mygn-20221231.xsd#mygn_PharmacogenomicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TestingRevenueMember_5d37f3e7-56ce-4ca5-b8bc-bdcba514a4d0" xlink:to="loc_mygn_PharmacogenomicsMember_576f1b50-629e-4e03-92b3-a34e11e68653" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AutoimmuneMember_645ee1f6-147f-4dfa-90a8-f9035c193562" xlink:href="mygn-20221231.xsd#mygn_AutoimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TestingRevenueMember_5d37f3e7-56ce-4ca5-b8bc-bdcba514a4d0" xlink:to="loc_mygn_AutoimmuneMember_645ee1f6-147f-4dfa-90a8-f9035c193562" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OtherTestingMember_5d4d9fbd-d517-48eb-9d7d-b01fb5cd86b2" xlink:href="mygn-20221231.xsd#mygn_OtherTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_TestingRevenueMember_5d37f3e7-56ce-4ca5-b8bc-bdcba514a4d0" xlink:to="loc_mygn_OtherTestingMember_5d4d9fbd-d517-48eb-9d7d-b01fb5cd86b2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_208cb738-93fb-416d-aa68-a303da8dd824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7cd135a5-4f67-4964-a88e-e7e75adb8e5d" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_208cb738-93fb-416d-aa68-a303da8dd824" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="extended" id="ieaee7f012ba7450cb968ae49cab43461_MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0174a32d-ac50-472c-996f-3ca27832d3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_551b3abb-8180-4b4e-af42-c7e730bd3c56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0174a32d-ac50-472c-996f-3ca27832d3ac" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_551b3abb-8180-4b4e-af42-c7e730bd3c56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bbe09526-eb4c-4e5e-b4bc-dc9363714a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_551b3abb-8180-4b4e-af42-c7e730bd3c56" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bbe09526-eb4c-4e5e-b4bc-dc9363714a77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8ecb5fb7-aaae-45db-a339-90e86d796e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_551b3abb-8180-4b4e-af42-c7e730bd3c56" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8ecb5fb7-aaae-45db-a339-90e86d796e7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b28d1892-8cce-4c81-bff5-4eb0a43c1ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0174a32d-ac50-472c-996f-3ca27832d3ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b28d1892-8cce-4c81-bff5-4eb0a43c1ca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_461201d8-e429-4057-9ba8-045b2e9e13fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b28d1892-8cce-4c81-bff5-4eb0a43c1ca8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_461201d8-e429-4057-9ba8-045b2e9e13fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_01985cdf-4c8b-453d-a2f4-c4d43982667f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b28d1892-8cce-4c81-bff5-4eb0a43c1ca8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_01985cdf-4c8b-453d-a2f4-c4d43982667f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6a620d7e-c2c9-45ee-9461-712023740d47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b28d1892-8cce-4c81-bff5-4eb0a43c1ca8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6a620d7e-c2c9-45ee-9461-712023740d47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ef981df4-2b15-4b3b-8937-a01c495204cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b28d1892-8cce-4c81-bff5-4eb0a43c1ca8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ef981df4-2b15-4b3b-8937-a01c495204cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCashAbstract_ac5b49c5-5ccc-4b1c-abb9-4ffe9fe9b33d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCashAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0174a32d-ac50-472c-996f-3ca27832d3ac" xlink:to="loc_us-gaap_InvestmentsAndCashAbstract_ac5b49c5-5ccc-4b1c-abb9-4ffe9fe9b33d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_74d56516-0625-41f3-b15e-4f393bd6606f" xlink:href="mygn-20221231.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_ac5b49c5-5ccc-4b1c-abb9-4ffe9fe9b33d" xlink:to="loc_mygn_InvestmentsAndCashAmortizedCost_74d56516-0625-41f3-b15e-4f393bd6606f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_75f3008e-e69c-4501-8ab5-67d888208fa7" xlink:href="mygn-20221231.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_ac5b49c5-5ccc-4b1c-abb9-4ffe9fe9b33d" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_75f3008e-e69c-4501-8ab5-67d888208fa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_1e5e774e-4c77-4444-bbd4-cd1df83a8b72" xlink:href="mygn-20221231.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_ac5b49c5-5ccc-4b1c-abb9-4ffe9fe9b33d" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_1e5e774e-4c77-4444-bbd4-cd1df83a8b72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_e61826fe-c999-4850-b4b1-80bbfb500b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_ac5b49c5-5ccc-4b1c-abb9-4ffe9fe9b33d" xlink:to="loc_us-gaap_InvestmentsAndCash_e61826fe-c999-4850-b4b1-80bbfb500b9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e80378b9-c64d-4ab0-9bf5-64750c16e40f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0174a32d-ac50-472c-996f-3ca27832d3ac" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e80378b9-c64d-4ab0-9bf5-64750c16e40f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_124337a6-f506-4256-81da-f87d146264bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e80378b9-c64d-4ab0-9bf5-64750c16e40f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_124337a6-f506-4256-81da-f87d146264bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_124337a6-f506-4256-81da-f87d146264bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_124337a6-f506-4256-81da-f87d146264bb" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_124337a6-f506-4256-81da-f87d146264bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2496d826-aaa0-4a57-8c76-1e96bcbe4b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_124337a6-f506-4256-81da-f87d146264bb" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2496d826-aaa0-4a57-8c76-1e96bcbe4b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_5831f0ea-e0ea-4587-abba-229b60461dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2496d826-aaa0-4a57-8c76-1e96bcbe4b9e" xlink:to="loc_us-gaap_CashMember_5831f0ea-e0ea-4587-abba-229b60461dd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_850b3e7b-d987-4a50-8d4c-a9b39a38eef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2496d826-aaa0-4a57-8c76-1e96bcbe4b9e" xlink:to="loc_us-gaap_CashEquivalentsMember_850b3e7b-d987-4a50-8d4c-a9b39a38eef7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e2537c7f-2f2d-4e66-a2d2-17a804d7e0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e80378b9-c64d-4ab0-9bf5-64750c16e40f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e2537c7f-2f2d-4e66-a2d2-17a804d7e0b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e2537c7f-2f2d-4e66-a2d2-17a804d7e0b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e2537c7f-2f2d-4e66-a2d2-17a804d7e0b4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e2537c7f-2f2d-4e66-a2d2-17a804d7e0b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fa69a9d-34aa-45cb-8fb9-e4ee378b6da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e2537c7f-2f2d-4e66-a2d2-17a804d7e0b4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fa69a9d-34aa-45cb-8fb9-e4ee378b6da1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6f4261ef-1769-4f09-a364-8d5ea81ce886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fa69a9d-34aa-45cb-8fb9-e4ee378b6da1" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6f4261ef-1769-4f09-a364-8d5ea81ce886" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_a26fba97-2bdd-404e-a9e1-0377e8b05a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fa69a9d-34aa-45cb-8fb9-e4ee378b6da1" xlink:to="loc_us-gaap_MunicipalBondsMember_a26fba97-2bdd-404e-a9e1-0377e8b05a5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_a17798f6-16b4-48ad-9712-bfbafedcad45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fa69a9d-34aa-45cb-8fb9-e4ee378b6da1" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_a17798f6-16b4-48ad-9712-bfbafedcad45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_567cd004-3ef3-4dae-9230-800a8ad5181d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fa69a9d-34aa-45cb-8fb9-e4ee378b6da1" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_567cd004-3ef3-4dae-9230-800a8ad5181d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="extended" id="i88c4a5ce715e4cdca1db65fd0ffe326b_MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1355c23a-d793-4e65-9649-c558b33c7e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1203f1a8-943b-4171-b831-1518e0114cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1355c23a-d793-4e65-9649-c558b33c7e26" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1203f1a8-943b-4171-b831-1518e0114cfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_83b21426-85f9-4831-a11f-966eec630800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1203f1a8-943b-4171-b831-1518e0114cfd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_83b21426-85f9-4831-a11f-966eec630800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_769ab64a-3883-480a-aef1-a9e50c8c90b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1203f1a8-943b-4171-b831-1518e0114cfd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_769ab64a-3883-480a-aef1-a9e50c8c90b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_cef02607-7f1c-460d-967e-a79d9e805cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1203f1a8-943b-4171-b831-1518e0114cfd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_cef02607-7f1c-460d-967e-a79d9e805cd0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_b02b73aa-e2ea-4c38-9f81-a8867cdfaff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1203f1a8-943b-4171-b831-1518e0114cfd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_b02b73aa-e2ea-4c38-9f81-a8867cdfaff9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_ae78e6ba-e68e-4248-a7b2-383a0a5f4df7" xlink:href="mygn-20221231.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1203f1a8-943b-4171-b831-1518e0114cfd" xlink:to="loc_mygn_InvestmentsAndCashAmortizedCost_ae78e6ba-e68e-4248-a7b2-383a0a5f4df7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_be8d7d5c-642e-4cb9-8a3b-7df694621004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1355c23a-d793-4e65-9649-c558b33c7e26" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_be8d7d5c-642e-4cb9-8a3b-7df694621004" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c0e4dbba-1cbb-4045-a66f-3df1d88d4c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_be8d7d5c-642e-4cb9-8a3b-7df694621004" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c0e4dbba-1cbb-4045-a66f-3df1d88d4c13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8447a85b-337f-457d-80db-d85332203973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_be8d7d5c-642e-4cb9-8a3b-7df694621004" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8447a85b-337f-457d-80db-d85332203973" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6d125e2c-1109-44f3-9b4b-83c6a6afaef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_be8d7d5c-642e-4cb9-8a3b-7df694621004" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6d125e2c-1109-44f3-9b4b-83c6a6afaef1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_7be43ae3-efae-4020-a77f-8d3218752a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_be8d7d5c-642e-4cb9-8a3b-7df694621004" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_7be43ae3-efae-4020-a77f-8d3218752a6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_dc2d3519-ed88-4ce4-9dac-4a2a292defbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_be8d7d5c-642e-4cb9-8a3b-7df694621004" xlink:to="loc_us-gaap_InvestmentsAndCash_dc2d3519-ed88-4ce4-9dac-4a2a292defbd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_72df08c6-a21c-4243-a752-caec789381ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1355c23a-d793-4e65-9649-c558b33c7e26" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_72df08c6-a21c-4243-a752-caec789381ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_7bb7fd07-a6cc-4368-b7c7-aeeb0e2aa7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_72df08c6-a21c-4243-a752-caec789381ad" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_7bb7fd07-a6cc-4368-b7c7-aeeb0e2aa7d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7bb7fd07-a6cc-4368-b7c7-aeeb0e2aa7d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_7bb7fd07-a6cc-4368-b7c7-aeeb0e2aa7d8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7bb7fd07-a6cc-4368-b7c7-aeeb0e2aa7d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_84ba4e5f-05d8-4f55-94a3-e19ae126a3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_7bb7fd07-a6cc-4368-b7c7-aeeb0e2aa7d8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_84ba4e5f-05d8-4f55-94a3-e19ae126a3d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_10a1a099-3d54-47d2-ab5e-b8c0f7773d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_84ba4e5f-05d8-4f55-94a3-e19ae126a3d9" xlink:to="loc_us-gaap_CashMember_10a1a099-3d54-47d2-ab5e-b8c0f7773d35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_78d8d9c3-e76c-4f7f-bc34-56bdcb034d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_84ba4e5f-05d8-4f55-94a3-e19ae126a3d9" xlink:to="loc_us-gaap_CashEquivalentsMember_78d8d9c3-e76c-4f7f-bc34-56bdcb034d34" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i0897b3be280a4a1ba4425324b7b56638_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6d003e0c-1241-4872-8b83-adfeef993081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_fef3cf7a-33bf-4b4f-9ea3-11fdfb55b0a9" xlink:href="mygn-20221231.xsd#mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6d003e0c-1241-4872-8b83-adfeef993081" xlink:to="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_fef3cf7a-33bf-4b4f-9ea3-11fdfb55b0a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_82d8806d-2d9b-463b-8d0b-d3e900c8cb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6d003e0c-1241-4872-8b83-adfeef993081" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_82d8806d-2d9b-463b-8d0b-d3e900c8cb9a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d774272-0840-4bbd-89ec-4b23b4bba5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_82d8806d-2d9b-463b-8d0b-d3e900c8cb9a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d774272-0840-4bbd-89ec-4b23b4bba5a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0d774272-0840-4bbd-89ec-4b23b4bba5a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d774272-0840-4bbd-89ec-4b23b4bba5a2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0d774272-0840-4bbd-89ec-4b23b4bba5a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c47425ef-f082-4816-b9be-1b49ac60c05f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d774272-0840-4bbd-89ec-4b23b4bba5a2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c47425ef-f082-4816-b9be-1b49ac60c05f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3fe4d4ff-2241-40d1-aa39-4f374bf47875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c47425ef-f082-4816-b9be-1b49ac60c05f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3fe4d4ff-2241-40d1-aa39-4f374bf47875" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_86c43667-be4a-474a-9143-13886f70c467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_82d8806d-2d9b-463b-8d0b-d3e900c8cb9a" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_86c43667-be4a-474a-9143-13886f70c467" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_86c43667-be4a-474a-9143-13886f70c467_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_86c43667-be4a-474a-9143-13886f70c467" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_86c43667-be4a-474a-9143-13886f70c467_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_31962395-6157-4acd-8efd-db9f17366aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_86c43667-be4a-474a-9143-13886f70c467" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_31962395-6157-4acd-8efd-db9f17366aac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_77a2ff87-30d1-4849-bf0c-9f6988a25ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_31962395-6157-4acd-8efd-db9f17366aac" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_77a2ff87-30d1-4849-bf0c-9f6988a25ecd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_35039d31-a732-4fb4-ba0c-bef5567b0cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_82d8806d-2d9b-463b-8d0b-d3e900c8cb9a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_35039d31-a732-4fb4-ba0c-bef5567b0cbb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_35039d31-a732-4fb4-ba0c-bef5567b0cbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_35039d31-a732-4fb4-ba0c-bef5567b0cbb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_35039d31-a732-4fb4-ba0c-bef5567b0cbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0dd0416-c12d-4481-81ff-46c19b91234a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_35039d31-a732-4fb4-ba0c-bef5567b0cbb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0dd0416-c12d-4481-81ff-46c19b91234a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_SividonDiagnosticsGmbHMember_e47f124d-75de-4273-9c1e-c4ca70c82dce" xlink:href="mygn-20221231.xsd#mygn_SividonDiagnosticsGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0dd0416-c12d-4481-81ff-46c19b91234a" xlink:to="loc_mygn_SividonDiagnosticsGmbHMember_e47f124d-75de-4273-9c1e-c4ca70c82dce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GatewayGenomicsLLCMember_d72fe40c-1b5e-4798-8a83-c9a2f3847b63" xlink:href="mygn-20221231.xsd#mygn_GatewayGenomicsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0dd0416-c12d-4481-81ff-46c19b91234a" xlink:to="loc_mygn_GatewayGenomicsLLCMember_d72fe40c-1b5e-4798-8a83-c9a2f3847b63" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended" id="ib60f773f1ca0447abac16dee046ef025_FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1462be07-1308-4083-a5e6-0cc0eaa02132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b4f3ed45-de0c-4a7f-8bf2-578aff55046a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1462be07-1308-4083-a5e6-0cc0eaa02132" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b4f3ed45-de0c-4a7f-8bf2-578aff55046a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_47c6b464-732f-4e5a-9277-cb208229a05c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1462be07-1308-4083-a5e6-0cc0eaa02132" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_47c6b464-732f-4e5a-9277-cb208229a05c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_b778e207-5105-4c43-bb43-c4c14dcec606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1462be07-1308-4083-a5e6-0cc0eaa02132" xlink:to="loc_us-gaap_FairValueNetAssetLiability_b778e207-5105-4c43-bb43-c4c14dcec606" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_26db28e8-1cbb-4f02-939c-d07673a4604b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1462be07-1308-4083-a5e6-0cc0eaa02132" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_26db28e8-1cbb-4f02-939c-d07673a4604b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c351bc8b-dfe0-4b98-8c50-47a63f924080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_26db28e8-1cbb-4f02-939c-d07673a4604b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c351bc8b-dfe0-4b98-8c50-47a63f924080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c351bc8b-dfe0-4b98-8c50-47a63f924080_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c351bc8b-dfe0-4b98-8c50-47a63f924080" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c351bc8b-dfe0-4b98-8c50-47a63f924080_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c5b50fca-b39a-44a5-aacc-ab5817384d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c351bc8b-dfe0-4b98-8c50-47a63f924080" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c5b50fca-b39a-44a5-aacc-ab5817384d7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5bbe9f00-5260-4840-b580-fa05967bed20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c5b50fca-b39a-44a5-aacc-ab5817384d7f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5bbe9f00-5260-4840-b580-fa05967bed20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b5964a38-7205-49d4-af3d-c147f957690a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c5b50fca-b39a-44a5-aacc-ab5817384d7f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b5964a38-7205-49d4-af3d-c147f957690a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9033e973-557d-4632-b39d-28db529f6c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c5b50fca-b39a-44a5-aacc-ab5817384d7f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9033e973-557d-4632-b39d-28db529f6c31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_3834e677-b35d-44a7-99b3-7e972fe6c8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_26db28e8-1cbb-4f02-939c-d07673a4604b" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_3834e677-b35d-44a7-99b3-7e972fe6c8e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_3834e677-b35d-44a7-99b3-7e972fe6c8e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_3834e677-b35d-44a7-99b3-7e972fe6c8e0" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_3834e677-b35d-44a7-99b3-7e972fe6c8e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2a5e3c0e-03d7-4d30-bcda-730d5b5ae357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_3834e677-b35d-44a7-99b3-7e972fe6c8e0" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2a5e3c0e-03d7-4d30-bcda-730d5b5ae357" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContingentConsiderationMember_e1de25f5-df10-4cf4-8eaf-5d292197eac3" xlink:href="mygn-20221231.xsd#mygn_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2a5e3c0e-03d7-4d30-bcda-730d5b5ae357" xlink:to="loc_mygn_ContingentConsiderationMember_e1de25f5-df10-4cf4-8eaf-5d292197eac3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4cfef9e3-1535-4941-bdcb-788a0bd3813c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_26db28e8-1cbb-4f02-939c-d07673a4604b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4cfef9e3-1535-4941-bdcb-788a0bd3813c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cfef9e3-1535-4941-bdcb-788a0bd3813c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4cfef9e3-1535-4941-bdcb-788a0bd3813c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cfef9e3-1535-4941-bdcb-788a0bd3813c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_03bef79c-2650-4b67-9b45-0e2a64feef94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4cfef9e3-1535-4941-bdcb-788a0bd3813c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_03bef79c-2650-4b67-9b45-0e2a64feef94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b291dda5-50ad-48f1-81cc-e145469dba53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_03bef79c-2650-4b67-9b45-0e2a64feef94" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b291dda5-50ad-48f1-81cc-e145469dba53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d00980c4-d3e2-4b97-a4af-7fef403249c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_03bef79c-2650-4b67-9b45-0e2a64feef94" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d00980c4-d3e2-4b97-a4af-7fef403249c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_e8d3d2cf-c944-4f1e-92c5-00049bafcdba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_03bef79c-2650-4b67-9b45-0e2a64feef94" xlink:to="loc_us-gaap_MunicipalBondsMember_e8d3d2cf-c944-4f1e-92c5-00049bafcdba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_80c4b77a-214a-4347-ae56-ca050e99c6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_03bef79c-2650-4b67-9b45-0e2a64feef94" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_80c4b77a-214a-4347-ae56-ca050e99c6b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1edb3edb-f19e-477f-aa44-eea391be00d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_03bef79c-2650-4b67-9b45-0e2a64feef94" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1edb3edb-f19e-477f-aa44-eea391be00d4" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#PropertyPlantandEquipmentNetBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="extended" id="i00ab96ab454d41bf9c8f493de8f5234f_PropertyPlantandEquipmentNetBalancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c3789c9d-a7b0-42dc-a497-fc9a125b04b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ef3d19b1-2219-4552-81dc-5bf122f4676f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c3789c9d-a7b0-42dc-a497-fc9a125b04b7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ef3d19b1-2219-4552-81dc-5bf122f4676f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_02bff3dc-cc12-413c-aa4a-3d9d944b0645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c3789c9d-a7b0-42dc-a497-fc9a125b04b7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_02bff3dc-cc12-413c-aa4a-3d9d944b0645" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0b7f3f09-4d54-4c7c-9524-0e70c397a917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c3789c9d-a7b0-42dc-a497-fc9a125b04b7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0b7f3f09-4d54-4c7c-9524-0e70c397a917" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_237752f7-feda-4434-9e54-6d897b6edcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c3789c9d-a7b0-42dc-a497-fc9a125b04b7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_237752f7-feda-4434-9e54-6d897b6edcfe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd7d33ab-0362-4d9c-ae5a-49c12a551ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_237752f7-feda-4434-9e54-6d897b6edcfe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd7d33ab-0362-4d9c-ae5a-49c12a551ce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dd7d33ab-0362-4d9c-ae5a-49c12a551ce6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd7d33ab-0362-4d9c-ae5a-49c12a551ce6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dd7d33ab-0362-4d9c-ae5a-49c12a551ce6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d977911-0a96-472c-9e80-a2971e4d75b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd7d33ab-0362-4d9c-ae5a-49c12a551ce6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d977911-0a96-472c-9e80-a2971e4d75b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2faa001b-0509-4a78-9de8-3bca32649587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d977911-0a96-472c-9e80-a2971e4d75b1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2faa001b-0509-4a78-9de8-3bca32649587" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_a77bea5a-f314-49e2-98a2-f7773032b5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d977911-0a96-472c-9e80-a2971e4d75b1" xlink:to="loc_us-gaap_EquipmentMember_a77bea5a-f314-49e2-98a2-f7773032b5ac" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#PropertyPlantandEquipmentNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails" xlink:type="extended" id="idb04cf33ae694407b15a42fd5cdba1d5_PropertyPlantandEquipmentNetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3b2ce311-8bf6-4a5c-8c00-c3eb31578520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_9b4dfa03-d8cd-402e-8fc5-026f63aab36d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3b2ce311-8bf6-4a5c-8c00-c3eb31578520" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_9b4dfa03-d8cd-402e-8fc5-026f63aab36d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_eb642b71-6fd0-47be-8354-c663e06654e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3b2ce311-8bf6-4a5c-8c00-c3eb31578520" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_eb642b71-6fd0-47be-8354-c663e06654e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_709d4804-32a1-40e0-a05b-967bd7144285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3b2ce311-8bf6-4a5c-8c00-c3eb31578520" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_709d4804-32a1-40e0-a05b-967bd7144285" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e2e262e7-1003-40bf-adf9-d1d6e465b527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_709d4804-32a1-40e0-a05b-967bd7144285" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e2e262e7-1003-40bf-adf9-d1d6e465b527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2e262e7-1003-40bf-adf9-d1d6e465b527_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e2e262e7-1003-40bf-adf9-d1d6e465b527" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2e262e7-1003-40bf-adf9-d1d6e465b527_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1173433-da16-4bed-857f-8923d9367498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e2e262e7-1003-40bf-adf9-d1d6e465b527" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1173433-da16-4bed-857f-8923d9367498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2949861b-2915-4ae9-ab9c-032c542ca37b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1173433-da16-4bed-857f-8923d9367498" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2949861b-2915-4ae9-ab9c-032c542ca37b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3fcb1975-4e26-4c01-84ca-c42d4c167d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_709d4804-32a1-40e0-a05b-967bd7144285" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3fcb1975-4e26-4c01-84ca-c42d4c167d2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3fcb1975-4e26-4c01-84ca-c42d4c167d2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3fcb1975-4e26-4c01-84ca-c42d4c167d2a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3fcb1975-4e26-4c01-84ca-c42d4c167d2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_43b1d46c-87c2-4f3e-a94f-e9d0e0e3af11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3fcb1975-4e26-4c01-84ca-c42d4c167d2a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_43b1d46c-87c2-4f3e-a94f-e9d0e0e3af11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember_88aa4477-2390-4f50-a096-b047221c6b06" xlink:href="mygn-20221231.xsd#mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_43b1d46c-87c2-4f3e-a94f-e9d0e0e3af11" xlink:to="loc_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember_88aa4477-2390-4f50-a096-b047221c6b06" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended" id="ia950abe86b14433e8e6a971322a61a3c_GoodwillandIntangibleAssetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GoodwillAndIntangibleAssetsLineItems_fd67abe9-94c3-46c2-9a6a-4278d24512f7" xlink:href="mygn-20221231.xsd#mygn_GoodwillAndIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_71e01e7f-293a-45fe-9274-cd042003f772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_fd67abe9-94c3-46c2-9a6a-4278d24512f7" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_71e01e7f-293a-45fe-9274-cd042003f772" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_301afc55-2041-4a71-b3e7-e05f9650c5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_fd67abe9-94c3-46c2-9a6a-4278d24512f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_301afc55-2041-4a71-b3e7-e05f9650c5e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_bd1ff8f9-3059-4861-a951-f8ab09acc05e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_fd67abe9-94c3-46c2-9a6a-4278d24512f7" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_bd1ff8f9-3059-4861-a951-f8ab09acc05e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c14a6b6d-61dd-428a-8f07-c5eeaf3b45e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_fd67abe9-94c3-46c2-9a6a-4278d24512f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c14a6b6d-61dd-428a-8f07-c5eeaf3b45e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3a82e845-78aa-4f20-859f-0f068dd78cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_fd67abe9-94c3-46c2-9a6a-4278d24512f7" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3a82e845-78aa-4f20-859f-0f068dd78cb3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GoodwillAndIntangibleAssetsTable_ca5eeef3-1483-4c1d-a81a-06f9a97fabe6" xlink:href="mygn-20221231.xsd#mygn_GoodwillAndIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_fd67abe9-94c3-46c2-9a6a-4278d24512f7" xlink:to="loc_mygn_GoodwillAndIntangibleAssetsTable_ca5eeef3-1483-4c1d-a81a-06f9a97fabe6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_6bcd925d-0bb9-4029-9bea-d4cfc9476cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_ca5eeef3-1483-4c1d-a81a-06f9a97fabe6" xlink:to="loc_us-gaap_ReportingUnitAxis_6bcd925d-0bb9-4029-9bea-d4cfc9476cad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_6bcd925d-0bb9-4029-9bea-d4cfc9476cad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_6bcd925d-0bb9-4029-9bea-d4cfc9476cad" xlink:to="loc_us-gaap_ReportingUnitDomain_6bcd925d-0bb9-4029-9bea-d4cfc9476cad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_05fab207-64ed-4498-8be3-e11ac5030a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_6bcd925d-0bb9-4029-9bea-d4cfc9476cad" xlink:to="loc_us-gaap_ReportingUnitDomain_05fab207-64ed-4498-8be3-e11ac5030a94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneReportingUnitMember_8e569515-8fcd-45ff-8a0b-8957839eb356" xlink:href="mygn-20221231.xsd#mygn_MyriadAutoimmuneReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_05fab207-64ed-4498-8be3-e11ac5030a94" xlink:to="loc_mygn_MyriadAutoimmuneReportingUnitMember_8e569515-8fcd-45ff-8a0b-8957839eb356" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ClinicReportingUnitMember_93d265e0-d9fe-45be-b7f6-b279550745e2" xlink:href="mygn-20221231.xsd#mygn_ClinicReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_05fab207-64ed-4498-8be3-e11ac5030a94" xlink:to="loc_mygn_ClinicReportingUnitMember_93d265e0-d9fe-45be-b7f6-b279550745e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9bd6b3f5-a137-480c-a710-7e178bb12850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_ca5eeef3-1483-4c1d-a81a-06f9a97fabe6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9bd6b3f5-a137-480c-a710-7e178bb12850" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9bd6b3f5-a137-480c-a710-7e178bb12850_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9bd6b3f5-a137-480c-a710-7e178bb12850" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9bd6b3f5-a137-480c-a710-7e178bb12850_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2308a00a-e16b-4df5-b4f5-0209aa4612fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9bd6b3f5-a137-480c-a710-7e178bb12850" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2308a00a-e16b-4df5-b4f5-0209aa4612fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_95ef9d02-f0b3-462a-976c-db43ceed4eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2308a00a-e16b-4df5-b4f5-0209aa4612fb" xlink:to="loc_us-gaap_CustomerRelationshipsMember_95ef9d02-f0b3-462a-976c-db43ceed4eb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_8831a73b-e69d-4e5d-95b5-a9d24130f206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2308a00a-e16b-4df5-b4f5-0209aa4612fb" xlink:to="loc_us-gaap_TrademarksMember_8831a73b-e69d-4e5d-95b5-a9d24130f206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_49bd794c-7287-4c1d-a5c2-6873d947078f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2308a00a-e16b-4df5-b4f5-0209aa4612fb" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_49bd794c-7287-4c1d-a5c2-6873d947078f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9d45c98f-ce9b-4b9c-a430-a6f26e63fa4a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_ca5eeef3-1483-4c1d-a81a-06f9a97fabe6" xlink:to="loc_srt_RangeAxis_9d45c98f-ce9b-4b9c-a430-a6f26e63fa4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9d45c98f-ce9b-4b9c-a430-a6f26e63fa4a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9d45c98f-ce9b-4b9c-a430-a6f26e63fa4a" xlink:to="loc_srt_RangeMember_9d45c98f-ce9b-4b9c-a430-a6f26e63fa4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e7d50727-fbc9-40c9-b8f2-6b98930c11a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9d45c98f-ce9b-4b9c-a430-a6f26e63fa4a" xlink:to="loc_srt_RangeMember_e7d50727-fbc9-40c9-b8f2-6b98930c11a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cebd0602-42b1-4f5f-9153-8498beab401f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e7d50727-fbc9-40c9-b8f2-6b98930c11a6" xlink:to="loc_srt_MinimumMember_cebd0602-42b1-4f5f-9153-8498beab401f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_afde65da-9123-4e94-96be-5e846f813cfa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e7d50727-fbc9-40c9-b8f2-6b98930c11a6" xlink:to="loc_srt_MaximumMember_afde65da-9123-4e94-96be-5e846f813cfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3402e051-768d-4ba9-9c89-11e8fcc2716b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_ca5eeef3-1483-4c1d-a81a-06f9a97fabe6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3402e051-768d-4ba9-9c89-11e8fcc2716b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3402e051-768d-4ba9-9c89-11e8fcc2716b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3402e051-768d-4ba9-9c89-11e8fcc2716b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3402e051-768d-4ba9-9c89-11e8fcc2716b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b7177732-7082-40cd-8c89-fc1b64e8cd31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3402e051-768d-4ba9-9c89-11e8fcc2716b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b7177732-7082-40cd-8c89-fc1b64e8cd31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GatewayGenomicsLLCMember_5f44d381-dddd-4799-9f5f-5b40490c22f5" xlink:href="mygn-20221231.xsd#mygn_GatewayGenomicsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b7177732-7082-40cd-8c89-fc1b64e8cd31" xlink:to="loc_mygn_GatewayGenomicsLLCMember_5f44d381-dddd-4799-9f5f-5b40490c22f5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended" id="ia84625581dd842e4b4b302e73848c846_GoodwillandIntangibleAssetsIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IntangibleAssetsLineItems_23b33d50-3d0d-4a7f-a574-dca57d3c6bfc" xlink:href="mygn-20221231.xsd#mygn_IntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_714eb63c-3c97-4fee-b8ab-c1b732021774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_23b33d50-3d0d-4a7f-a574-dca57d3c6bfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_714eb63c-3c97-4fee-b8ab-c1b732021774" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0702ebdf-2381-4c92-9a45-c67b6f36e4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_23b33d50-3d0d-4a7f-a574-dca57d3c6bfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0702ebdf-2381-4c92-9a45-c67b6f36e4e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_88f226ac-265c-466f-9f26-82a8f5c3b30e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_23b33d50-3d0d-4a7f-a574-dca57d3c6bfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_88f226ac-265c-466f-9f26-82a8f5c3b30e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9724dbb8-bcd9-4710-92e3-26aaae1744ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_23b33d50-3d0d-4a7f-a574-dca57d3c6bfc" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9724dbb8-bcd9-4710-92e3-26aaae1744ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_82fc14f8-7591-4a44-9a02-afa8e297bc49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_23b33d50-3d0d-4a7f-a574-dca57d3c6bfc" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_82fc14f8-7591-4a44-9a02-afa8e297bc49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5c229cc7-6c79-4630-ab2f-a8d9a4246525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_23b33d50-3d0d-4a7f-a574-dca57d3c6bfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5c229cc7-6c79-4630-ab2f-a8d9a4246525" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_e48a0a08-d709-4018-a53a-d1e26ed23264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_IntangibleAssetsLineItems_23b33d50-3d0d-4a7f-a574-dca57d3c6bfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_e48a0a08-d709-4018-a53a-d1e26ed23264" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfIntangibleAssetsTable_e26026a9-7d77-46ac-945a-5d7db39a6afe" xlink:href="mygn-20221231.xsd#mygn_ScheduleOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mygn_IntangibleAssetsLineItems_23b33d50-3d0d-4a7f-a574-dca57d3c6bfc" xlink:to="loc_mygn_ScheduleOfIntangibleAssetsTable_e26026a9-7d77-46ac-945a-5d7db39a6afe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_89f3df63-7610-4f37-b178-442ea7f2dc11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_e26026a9-7d77-46ac-945a-5d7db39a6afe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_89f3df63-7610-4f37-b178-442ea7f2dc11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89f3df63-7610-4f37-b178-442ea7f2dc11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_89f3df63-7610-4f37-b178-442ea7f2dc11" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89f3df63-7610-4f37-b178-442ea7f2dc11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_967b94ef-9285-4795-ac37-550fb74886d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_89f3df63-7610-4f37-b178-442ea7f2dc11" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_967b94ef-9285-4795-ac37-550fb74886d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_cd9382c2-0df3-4789-af65-1ced9d6172f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_967b94ef-9285-4795-ac37-550fb74886d2" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_cd9382c2-0df3-4789-af65-1ced9d6172f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_f979f6c3-a8c8-4435-a785-9dde0c04860f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_967b94ef-9285-4795-ac37-550fb74886d2" xlink:to="loc_us-gaap_CustomerRelationshipsMember_f979f6c3-a8c8-4435-a785-9dde0c04860f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_9891c634-2e5e-45a0-874c-f29975877b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_967b94ef-9285-4795-ac37-550fb74886d2" xlink:to="loc_us-gaap_TrademarksMember_9891c634-2e5e-45a0-874c-f29975877b39" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LongTermDebtDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#LongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/LongTermDebtDetails" xlink:type="extended" id="ia1bc4efcfae0429097078f4a09c0a206_LongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e0dfb500-3ad7-426c-a8d0-edb713960ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e0dfb500-3ad7-426c-a8d0-edb713960ff1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantLiquidityCovenantMinimum_3d4ce350-c2fd-47e7-9db5-fd631ce6be17" xlink:href="mygn-20221231.xsd#mygn_DebtCovenantLiquidityCovenantMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:to="loc_mygn_DebtCovenantLiquidityCovenantMinimum_3d4ce350-c2fd-47e7-9db5-fd631ce6be17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_74487311-919a-40d2-800c-5858e99b40ae" xlink:href="mygn-20221231.xsd#mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:to="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_74487311-919a-40d2-800c-5858e99b40ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LineOfCreditFacilityCreditExposureThreshold_35a0d509-917b-447f-957d-dd438e4ec894" xlink:href="mygn-20221231.xsd#mygn_LineOfCreditFacilityCreditExposureThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:to="loc_mygn_LineOfCreditFacilityCreditExposureThreshold_35a0d509-917b-447f-957d-dd438e4ec894" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5f7f9aa6-075c-4cce-b8ff-7fc0d668f21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5f7f9aa6-075c-4cce-b8ff-7fc0d668f21a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_2824cbe4-2b77-4c2f-a1a3-6325b571aea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_2824cbe4-2b77-4c2f-a1a3-6325b571aea8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtInstrumentFloorPercentage_3a4a8609-f03e-48d9-bebc-0949c9fe3492" xlink:href="mygn-20221231.xsd#mygn_DebtInstrumentFloorPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:to="loc_mygn_DebtInstrumentFloorPercentage_3a4a8609-f03e-48d9-bebc-0949c9fe3492" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_f9a2373d-d12d-4a75-9389-122564ccfa23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_f9a2373d-d12d-4a75-9389-122564ccfa23" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6cf8d965-3965-4f3a-8ca3-ddcbd2fa6c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:to="loc_us-gaap_LongTermDebt_6cf8d965-3965-4f3a-8ca3-ddcbd2fa6c8a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_282c35aa-5f57-482e-b663-bad409e86704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:to="loc_us-gaap_DebtInstrumentTable_282c35aa-5f57-482e-b663-bad409e86704" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b97cadfa-1d88-4c04-8710-022bdec9d9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_282c35aa-5f57-482e-b663-bad409e86704" xlink:to="loc_us-gaap_CreditFacilityAxis_b97cadfa-1d88-4c04-8710-022bdec9d9f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b97cadfa-1d88-4c04-8710-022bdec9d9f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_b97cadfa-1d88-4c04-8710-022bdec9d9f1" xlink:to="loc_us-gaap_CreditFacilityDomain_b97cadfa-1d88-4c04-8710-022bdec9d9f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5edd3e38-42af-4eb4-917d-be5d94c70b83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_b97cadfa-1d88-4c04-8710-022bdec9d9f1" xlink:to="loc_us-gaap_CreditFacilityDomain_5edd3e38-42af-4eb4-917d-be5d94c70b83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_4b7d8e7c-5a51-4c80-b6e2-986f9160d85a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5edd3e38-42af-4eb4-917d-be5d94c70b83" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_4b7d8e7c-5a51-4c80-b6e2-986f9160d85a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_c43f5fbc-4b2f-4ae0-8ab5-707758a96db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5edd3e38-42af-4eb4-917d-be5d94c70b83" xlink:to="loc_us-gaap_LetterOfCreditMember_c43f5fbc-4b2f-4ae0-8ab5-707758a96db4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9d38f430-0966-4fb2-87fd-03c4fb5493f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_282c35aa-5f57-482e-b663-bad409e86704" xlink:to="loc_us-gaap_DebtInstrumentAxis_9d38f430-0966-4fb2-87fd-03c4fb5493f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9d38f430-0966-4fb2-87fd-03c4fb5493f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9d38f430-0966-4fb2-87fd-03c4fb5493f9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9d38f430-0966-4fb2-87fd-03c4fb5493f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1b684ee4-dabe-4a38-9d53-36c6c9b883e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9d38f430-0966-4fb2-87fd-03c4fb5493f9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1b684ee4-dabe-4a38-9d53-36c6c9b883e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AmendmentToCreditAgreementMember_2c68df65-a6ee-4d4e-b413-04a8a2a6c752" xlink:href="mygn-20221231.xsd#mygn_AmendmentToCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1b684ee4-dabe-4a38-9d53-36c6c9b883e8" xlink:to="loc_mygn_AmendmentToCreditAgreementMember_2c68df65-a6ee-4d4e-b413-04a8a2a6c752" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_3cb6ddb7-5e41-49f9-982a-8cd1a2f4a259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_282c35aa-5f57-482e-b663-bad409e86704" xlink:to="loc_us-gaap_VariableRateAxis_3cb6ddb7-5e41-49f9-982a-8cd1a2f4a259" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_3cb6ddb7-5e41-49f9-982a-8cd1a2f4a259_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_3cb6ddb7-5e41-49f9-982a-8cd1a2f4a259" xlink:to="loc_us-gaap_VariableRateDomain_3cb6ddb7-5e41-49f9-982a-8cd1a2f4a259_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_830e204b-d2aa-405f-a4c8-7b3cfe42b037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_3cb6ddb7-5e41-49f9-982a-8cd1a2f4a259" xlink:to="loc_us-gaap_VariableRateDomain_830e204b-d2aa-405f-a4c8-7b3cfe42b037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_e6f51795-3131-4fdc-b092-46f83ef10749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_830e204b-d2aa-405f-a4c8-7b3cfe42b037" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_e6f51795-3131-4fdc-b092-46f83ef10749" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_3ed7879d-4509-45ff-b7a7-16f365f29a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_830e204b-d2aa-405f-a4c8-7b3cfe42b037" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_3ed7879d-4509-45ff-b7a7-16f365f29a4e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="icd0edb43501146f2b30710921aac39e5_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c035046b-2d72-42fc-9fe3-156822441907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c035046b-2d72-42fc-9fe3-156822441907" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_eac1c2b5-383e-424e-a3d8-eb7f3f12599f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_eac1c2b5-383e-424e-a3d8-eb7f3f12599f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2a37a73c-66bf-43b0-a843-97ebf048ecc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2a37a73c-66bf-43b0-a843-97ebf048ecc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_afc63fa4-b14e-4dbd-b031-b23f33f88cce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_afc63fa4-b14e-4dbd-b031-b23f33f88cce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_03920eed-8b8c-4a79-b291-6ae2d7c25106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_03920eed-8b8c-4a79-b291-6ae2d7c25106" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_51b1947d-6543-45ad-87a9-7c3f649dd920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_51b1947d-6543-45ad-87a9-7c3f649dd920" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0ecb7bd8-9dda-4c20-b345-f3849aa3fe11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0ecb7bd8-9dda-4c20-b345-f3849aa3fe11" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7d4280d7-e779-49ff-a11e-3a90a7a759f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7d4280d7-e779-49ff-a11e-3a90a7a759f6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_680c9c68-465b-41b8-be91-363fe986ad4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_680c9c68-465b-41b8-be91-363fe986ad4b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_10e7ff19-1892-42fd-b6f9-ecdf071fc31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_10e7ff19-1892-42fd-b6f9-ecdf071fc31b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_135b0ef8-c098-472f-92d6-4e60ce743df2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_135b0ef8-c098-472f-92d6-4e60ce743df2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f36c0715-62a0-4614-8958-6d8a587c79ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f36c0715-62a0-4614-8958-6d8a587c79ec" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_c70472b6-8b9b-4e23-b6c0-12d93fa1c85d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_c70472b6-8b9b-4e23-b6c0-12d93fa1c85d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1f863037-15bc-4ab8-833c-96b28e9fb527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1f863037-15bc-4ab8-833c-96b28e9fb527" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2f7eec3-7e7e-45ef-8835-05cb9d82e061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2f7eec3-7e7e-45ef-8835-05cb9d82e061" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c27c5ff7-316d-4ff9-84a7-7e374b594a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2f7eec3-7e7e-45ef-8835-05cb9d82e061" xlink:to="loc_us-gaap_AwardTypeAxis_c27c5ff7-316d-4ff9-84a7-7e374b594a03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c27c5ff7-316d-4ff9-84a7-7e374b594a03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c27c5ff7-316d-4ff9-84a7-7e374b594a03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c27c5ff7-316d-4ff9-84a7-7e374b594a03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ecab2f59-b822-411d-a3bc-8e21f29414ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c27c5ff7-316d-4ff9-84a7-7e374b594a03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ecab2f59-b822-411d-a3bc-8e21f29414ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OptionsAndRestrictedStockUnitsMember_6e444ed1-1e21-4726-b525-8cbffba1dc75" xlink:href="mygn-20221231.xsd#mygn_OptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ecab2f59-b822-411d-a3bc-8e21f29414ba" xlink:to="loc_mygn_OptionsAndRestrictedStockUnitsMember_6e444ed1-1e21-4726-b525-8cbffba1dc75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_336ebe5d-82eb-4f96-b92a-ad5b60038249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OptionsAndRestrictedStockUnitsMember_6e444ed1-1e21-4726-b525-8cbffba1dc75" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_336ebe5d-82eb-4f96-b92a-ad5b60038249" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_605025dc-ba54-44b7-914a-1f2bea6bcc98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_OptionsAndRestrictedStockUnitsMember_6e444ed1-1e21-4726-b525-8cbffba1dc75" xlink:to="loc_us-gaap_EmployeeStockOptionMember_605025dc-ba54-44b7-914a-1f2bea6bcc98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_a91b3b26-dc22-4442-a739-7ffcd43b0685" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2f7eec3-7e7e-45ef-8835-05cb9d82e061" xlink:to="loc_srt_TitleOfIndividualAxis_a91b3b26-dc22-4442-a739-7ffcd43b0685" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a91b3b26-dc22-4442-a739-7ffcd43b0685_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_a91b3b26-dc22-4442-a739-7ffcd43b0685" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a91b3b26-dc22-4442-a739-7ffcd43b0685_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f264869c-07be-4f08-9cf8-664b524e3b6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_a91b3b26-dc22-4442-a739-7ffcd43b0685" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f264869c-07be-4f08-9cf8-664b524e3b6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonEmployeeDirectorMember_b352194b-bad9-4859-8b03-6312bd9ab166" xlink:href="mygn-20221231.xsd#mygn_NonEmployeeDirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f264869c-07be-4f08-9cf8-664b524e3b6d" xlink:to="loc_mygn_NonEmployeeDirectorMember_b352194b-bad9-4859-8b03-6312bd9ab166" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_782a228b-f0d9-4106-8e7e-44271d11128d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f264869c-07be-4f08-9cf8-664b524e3b6d" xlink:to="loc_srt_ChiefExecutiveOfficerMember_782a228b-f0d9-4106-8e7e-44271d11128d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_29d1fbea-b3c9-475e-a098-6dae20001c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2f7eec3-7e7e-45ef-8835-05cb9d82e061" xlink:to="loc_us-gaap_VestingAxis_29d1fbea-b3c9-475e-a098-6dae20001c4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_29d1fbea-b3c9-475e-a098-6dae20001c4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_29d1fbea-b3c9-475e-a098-6dae20001c4b" xlink:to="loc_us-gaap_VestingDomain_29d1fbea-b3c9-475e-a098-6dae20001c4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a17a5b61-2b45-4cff-9892-ffe7cf277c43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_29d1fbea-b3c9-475e-a098-6dae20001c4b" xlink:to="loc_us-gaap_VestingDomain_a17a5b61-2b45-4cff-9892-ffe7cf277c43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2921b120-7b73-427f-8a64-706d57866d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a17a5b61-2b45-4cff-9892-ffe7cf277c43" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2921b120-7b73-427f-8a64-706d57866d90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_8d1636bf-a4ab-4bfa-ad05-341327604299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a17a5b61-2b45-4cff-9892-ffe7cf277c43" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_8d1636bf-a4ab-4bfa-ad05-341327604299" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_65698cbc-4ff1-4f58-abf1-9df509a9b5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a17a5b61-2b45-4cff-9892-ffe7cf277c43" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_65698cbc-4ff1-4f58-abf1-9df509a9b5b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f5eae624-e9e7-443b-89dd-8662bcd6a295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2f7eec3-7e7e-45ef-8835-05cb9d82e061" xlink:to="loc_us-gaap_PlanNameAxis_f5eae624-e9e7-443b-89dd-8662bcd6a295" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f5eae624-e9e7-443b-89dd-8662bcd6a295_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f5eae624-e9e7-443b-89dd-8662bcd6a295" xlink:to="loc_us-gaap_PlanNameDomain_f5eae624-e9e7-443b-89dd-8662bcd6a295_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b747f5a3-7c05-42bb-b555-99441120fa51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f5eae624-e9e7-443b-89dd-8662bcd6a295" xlink:to="loc_us-gaap_PlanNameDomain_b747f5a3-7c05-42bb-b555-99441120fa51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_66a52c0d-efa7-40dd-b762-970ef1e7aecc" xlink:href="mygn-20221231.xsd#mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b747f5a3-7c05-42bb-b555-99441120fa51" xlink:to="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_66a52c0d-efa7-40dd-b762-970ef1e7aecc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_4b13e64d-eeb3-4bb9-a4c4-bf1a4fc414ca" xlink:href="mygn-20221231.xsd#mygn_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b747f5a3-7c05-42bb-b555-99441120fa51" xlink:to="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_4b13e64d-eeb3-4bb9-a4c4-bf1a4fc414ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cfe6dafe-4a1f-4a41-adf4-896174ed4170" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2f7eec3-7e7e-45ef-8835-05cb9d82e061" xlink:to="loc_srt_RangeAxis_cfe6dafe-4a1f-4a41-adf4-896174ed4170" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cfe6dafe-4a1f-4a41-adf4-896174ed4170_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cfe6dafe-4a1f-4a41-adf4-896174ed4170" xlink:to="loc_srt_RangeMember_cfe6dafe-4a1f-4a41-adf4-896174ed4170_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5acf4fb9-f73f-433f-a5ef-ee06bbfcb939" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cfe6dafe-4a1f-4a41-adf4-896174ed4170" xlink:to="loc_srt_RangeMember_5acf4fb9-f73f-433f-a5ef-ee06bbfcb939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fc883e70-60bd-4be7-8a98-7c26dd00f12e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5acf4fb9-f73f-433f-a5ef-ee06bbfcb939" xlink:to="loc_srt_MaximumMember_fc883e70-60bd-4be7-8a98-7c26dd00f12e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9157e35c-c22b-4263-8f6c-45bb85aa05d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5acf4fb9-f73f-433f-a5ef-ee06bbfcb939" xlink:to="loc_srt_MinimumMember_9157e35c-c22b-4263-8f6c-45bb85aa05d5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#StockBasedCompensationRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="extended" id="i6fc4d444ec9f4a7e96ff7d47741e47c7_StockBasedCompensationRestrictedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dfd1b2e8-eb97-43c4-95bb-a1b22d5450b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daec2046-f0f9-4e2a-96dd-d9ef11529e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dfd1b2e8-eb97-43c4-95bb-a1b22d5450b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daec2046-f0f9-4e2a-96dd-d9ef11529e0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00236bfc-47bf-4633-9890-49f1e7b2c714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daec2046-f0f9-4e2a-96dd-d9ef11529e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00236bfc-47bf-4633-9890-49f1e7b2c714" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_154323ec-1f27-4e5a-9b88-6f3f9e4d1141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daec2046-f0f9-4e2a-96dd-d9ef11529e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_154323ec-1f27-4e5a-9b88-6f3f9e4d1141" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d0e719fc-58c2-43f5-b390-32a299335713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daec2046-f0f9-4e2a-96dd-d9ef11529e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d0e719fc-58c2-43f5-b390-32a299335713" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b90052e8-31db-4a7b-889e-d33c4f800260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daec2046-f0f9-4e2a-96dd-d9ef11529e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b90052e8-31db-4a7b-889e-d33c4f800260" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d51a5d0e-f4a8-4d82-998b-c48c1f889039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e569e0a-4f8e-4142-9e2a-7e70c33ce39a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dfd1b2e8-eb97-43c4-95bb-a1b22d5450b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e569e0a-4f8e-4142-9e2a-7e70c33ce39a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fdff026c-b184-41da-b96a-4279cfae0670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e569e0a-4f8e-4142-9e2a-7e70c33ce39a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fdff026c-b184-41da-b96a-4279cfae0670" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2596e83d-f496-46eb-978c-ed2ff2166a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e569e0a-4f8e-4142-9e2a-7e70c33ce39a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2596e83d-f496-46eb-978c-ed2ff2166a6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_865e7a45-be5c-46a8-ae85-fc6d3650e183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e569e0a-4f8e-4142-9e2a-7e70c33ce39a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_865e7a45-be5c-46a8-ae85-fc6d3650e183" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9df9567a-f61d-4d73-824b-ae87db962677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e569e0a-4f8e-4142-9e2a-7e70c33ce39a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9df9567a-f61d-4d73-824b-ae87db962677" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_71d75de7-40f8-43e1-b82f-30b98bcda165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cfd06ef-e200-4f04-934a-feb945f536a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dfd1b2e8-eb97-43c4-95bb-a1b22d5450b2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cfd06ef-e200-4f04-934a-feb945f536a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9e9d9cc6-e70e-4257-85e5-565d3ed57ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cfd06ef-e200-4f04-934a-feb945f536a5" xlink:to="loc_us-gaap_AwardTypeAxis_9e9d9cc6-e70e-4257-85e5-565d3ed57ceb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e9d9cc6-e70e-4257-85e5-565d3ed57ceb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9e9d9cc6-e70e-4257-85e5-565d3ed57ceb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e9d9cc6-e70e-4257-85e5-565d3ed57ceb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72ec8ac-6f3d-4628-99da-c845a2c4ce04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9e9d9cc6-e70e-4257-85e5-565d3ed57ceb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72ec8ac-6f3d-4628-99da-c845a2c4ce04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_915bb6f7-f2fb-4637-ab29-324f590db935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72ec8ac-6f3d-4628-99da-c845a2c4ce04" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_915bb6f7-f2fb-4637-ab29-324f590db935" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="i1b9b00cdcac44914bf8bf3929bbb7a53_StockBasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0a638636-7607-4c02-910d-c1a607ab4132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7ef13e20-1090-4e5a-b3f4-45b176eb1c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0a638636-7607-4c02-910d-c1a607ab4132" xlink:to="loc_us-gaap_ShareBasedCompensation_7ef13e20-1090-4e5a-b3f4-45b176eb1c2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_69953c85-2560-4b26-8a10-952772dd583a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0a638636-7607-4c02-910d-c1a607ab4132" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_69953c85-2560-4b26-8a10-952772dd583a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8b325eef-87b9-4c91-a58e-e43b479f1696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_69953c85-2560-4b26-8a10-952772dd583a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8b325eef-87b9-4c91-a58e-e43b479f1696" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8b325eef-87b9-4c91-a58e-e43b479f1696_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8b325eef-87b9-4c91-a58e-e43b479f1696" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8b325eef-87b9-4c91-a58e-e43b479f1696_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6e0d700e-a72a-4442-b6a5-f3edb56647a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8b325eef-87b9-4c91-a58e-e43b479f1696" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6e0d700e-a72a-4442-b6a5-f3edb56647a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfTestingMember_92f4a788-0bc0-42f4-8471-9432083128ba" xlink:href="mygn-20221231.xsd#mygn_CostOfTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6e0d700e-a72a-4442-b6a5-f3edb56647a5" xlink:to="loc_mygn_CostOfTestingMember_92f4a788-0bc0-42f4-8471-9432083128ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfOtherRevenueMember_6475478e-b715-4abf-946b-34d7ae0e83c6" xlink:href="mygn-20221231.xsd#mygn_CostOfOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6e0d700e-a72a-4442-b6a5-f3edb56647a5" xlink:to="loc_mygn_CostOfOtherRevenueMember_6475478e-b715-4abf-946b-34d7ae0e83c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9fc43f89-72dc-4d04-a635-421cda62fba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6e0d700e-a72a-4442-b6a5-f3edb56647a5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9fc43f89-72dc-4d04-a635-421cda62fba9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_62dede1d-908c-454c-af47-b76c1ac217f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6e0d700e-a72a-4442-b6a5-f3edb56647a5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_62dede1d-908c-454c-af47-b76c1ac217f3" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#StockBasedCompensationAggregateIntrinsicValueDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails" xlink:type="extended" id="i8c62ac226c8841079270972a1d162caf_StockBasedCompensationAggregateIntrinsicValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6ab1cc10-e147-435f-9ddc-c4d90555bc74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3a3b4071-585b-450a-ae74-28cf9937e132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6ab1cc10-e147-435f-9ddc-c4d90555bc74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3a3b4071-585b-450a-ae74-28cf9937e132" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8fcf452e-041e-4337-83a4-ef416102f1af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6ab1cc10-e147-435f-9ddc-c4d90555bc74" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8fcf452e-041e-4337-83a4-ef416102f1af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_d7a0cecf-d8c6-45fc-b950-5fb171743dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6ab1cc10-e147-435f-9ddc-c4d90555bc74" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_d7a0cecf-d8c6-45fc-b950-5fb171743dcf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da7559a8-4c0d-4014-8996-cb05b8ba9b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6ab1cc10-e147-435f-9ddc-c4d90555bc74" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da7559a8-4c0d-4014-8996-cb05b8ba9b9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_77ade6f0-a32e-4e0d-b28d-ad0de2e03310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da7559a8-4c0d-4014-8996-cb05b8ba9b9e" xlink:to="loc_us-gaap_AwardTypeAxis_77ade6f0-a32e-4e0d-b28d-ad0de2e03310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77ade6f0-a32e-4e0d-b28d-ad0de2e03310_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_77ade6f0-a32e-4e0d-b28d-ad0de2e03310" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77ade6f0-a32e-4e0d-b28d-ad0de2e03310_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aadc66e7-3f86-49e4-b6b8-71a6852d9aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_77ade6f0-a32e-4e0d-b28d-ad0de2e03310" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aadc66e7-3f86-49e4-b6b8-71a6852d9aa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_15bad476-43c6-4b28-9b3b-e6f0beb50166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aadc66e7-3f86-49e4-b6b8-71a6852d9aa4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_15bad476-43c6-4b28-9b3b-e6f0beb50166" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails" xlink:type="extended" id="i07934721946a482ea349da6fc01b5e65_StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa311370-28b0-496d-9b51-f6384850858f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_38d97bc8-560a-43d6-bc72-e517dea4a988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa311370-28b0-496d-9b51-f6384850858f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_38d97bc8-560a-43d6-bc72-e517dea4a988" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_ccb73009-8695-4bc9-8cf4-35da14c0258f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa311370-28b0-496d-9b51-f6384850858f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_ccb73009-8695-4bc9-8cf4-35da14c0258f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2650224-98b1-4891-af60-2ce9ce79be61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa311370-28b0-496d-9b51-f6384850858f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2650224-98b1-4891-af60-2ce9ce79be61" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_06a67027-7b4f-4b53-a142-09ad25976587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2650224-98b1-4891-af60-2ce9ce79be61" xlink:to="loc_us-gaap_PlanNameAxis_06a67027-7b4f-4b53-a142-09ad25976587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_06a67027-7b4f-4b53-a142-09ad25976587_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_06a67027-7b4f-4b53-a142-09ad25976587" xlink:to="loc_us-gaap_PlanNameDomain_06a67027-7b4f-4b53-a142-09ad25976587_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_46beeb42-04f8-43b9-a3a1-f78f6be37234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_06a67027-7b4f-4b53-a142-09ad25976587" xlink:to="loc_us-gaap_PlanNameDomain_46beeb42-04f8-43b9-a3a1-f78f6be37234" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_36a67a41-ff1b-42b0-bceb-064f43f32b31" xlink:href="mygn-20221231.xsd#mygn_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_46beeb42-04f8-43b9-a3a1-f78f6be37234" xlink:to="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_36a67a41-ff1b-42b0-bceb-064f43f32b31" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#StockBasedCompensationValuationAssumptionsforESPPDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails" xlink:type="extended" id="ie1f5f03d20c84d868fdcbec67541ca6b_StockBasedCompensationValuationAssumptionsforESPPDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52d53e60-8c1c-4fcf-b086-f427f8cb3f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_75494499-6b51-4e95-a3e6-582ad764c916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52d53e60-8c1c-4fcf-b086-f427f8cb3f4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_75494499-6b51-4e95-a3e6-582ad764c916" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_398ddb61-98fb-49c5-bc89-fad77b4a24bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_75494499-6b51-4e95-a3e6-582ad764c916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_398ddb61-98fb-49c5-bc89-fad77b4a24bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4b3cbfe3-64ca-46e8-b867-8232bd53ccb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_75494499-6b51-4e95-a3e6-582ad764c916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4b3cbfe3-64ca-46e8-b867-8232bd53ccb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_31d73bc8-bce0-453c-bbe6-ad023f19ffaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_75494499-6b51-4e95-a3e6-582ad764c916" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_31d73bc8-bce0-453c-bbe6-ad023f19ffaa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ba2b0d80-5042-49e3-9e93-74c30398c5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_75494499-6b51-4e95-a3e6-582ad764c916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ba2b0d80-5042-49e3-9e93-74c30398c5c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9604dfa-5ac2-4dd4-b950-242f9357b2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52d53e60-8c1c-4fcf-b086-f427f8cb3f4e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9604dfa-5ac2-4dd4-b950-242f9357b2c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_cc795f5b-6193-4afd-9486-e41dff4190be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9604dfa-5ac2-4dd4-b950-242f9357b2c9" xlink:to="loc_us-gaap_PlanNameAxis_cc795f5b-6193-4afd-9486-e41dff4190be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cc795f5b-6193-4afd-9486-e41dff4190be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_cc795f5b-6193-4afd-9486-e41dff4190be" xlink:to="loc_us-gaap_PlanNameDomain_cc795f5b-6193-4afd-9486-e41dff4190be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6e5f03f0-02fa-436c-9a43-b3943707ee0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_cc795f5b-6193-4afd-9486-e41dff4190be" xlink:to="loc_us-gaap_PlanNameDomain_6e5f03f0-02fa-436c-9a43-b3943707ee0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_7367d35e-cd01-4394-ba3c-1f7e8f24993d" xlink:href="mygn-20221231.xsd#mygn_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6e5f03f0-02fa-436c-9a43-b3943707ee0f" xlink:to="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_7367d35e-cd01-4394-ba3c-1f7e8f24993d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails" xlink:type="extended" id="i40067512fce0472ca815887e8e40aa38_IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_4660d414-3553-460a-9f84-69563a590ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_d51e49b4-59ce-46f6-9285-b09b931c68cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4660d414-3553-460a-9f84-69563a590ca9" xlink:to="loc_us-gaap_OperatingLossCarryforwards_d51e49b4-59ce-46f6-9285-b09b931c68cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_a0c312a9-7810-4936-b78f-aafd17cb287e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4660d414-3553-460a-9f84-69563a590ca9" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_a0c312a9-7810-4936-b78f-aafd17cb287e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_a70578cd-3a21-4f73-9c3f-fe7898fc426f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4660d414-3553-460a-9f84-69563a590ca9" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_a70578cd-3a21-4f73-9c3f-fe7898fc426f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_25230850-1d34-46a9-bba7-abd6bd415339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4660d414-3553-460a-9f84-69563a590ca9" xlink:to="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_25230850-1d34-46a9-bba7-abd6bd415339" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLossCarryforwardsExpirationYear_48da84a9-4aad-49bf-9c2e-788cc80faada" xlink:href="mygn-20221231.xsd#mygn_OperatingLossCarryforwardsExpirationYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4660d414-3553-460a-9f84-69563a590ca9" xlink:to="loc_mygn_OperatingLossCarryforwardsExpirationYear_48da84a9-4aad-49bf-9c2e-788cc80faada" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TaxCreditCarryforwardsExpirationDate_8b6639d9-5765-487a-83d8-c013f6803098" xlink:href="mygn-20221231.xsd#mygn_TaxCreditCarryforwardsExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4660d414-3553-460a-9f84-69563a590ca9" xlink:to="loc_mygn_TaxCreditCarryforwardsExpirationDate_8b6639d9-5765-487a-83d8-c013f6803098" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_d119ece1-2be6-4161-9b0a-072f61189844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4660d414-3553-460a-9f84-69563a590ca9" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_d119ece1-2be6-4161-9b0a-072f61189844" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_425a1c08-4ed9-4695-ba0a-aa9a8bff08ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d119ece1-2be6-4161-9b0a-072f61189844" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_425a1c08-4ed9-4695-ba0a-aa9a8bff08ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_425a1c08-4ed9-4695-ba0a-aa9a8bff08ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_425a1c08-4ed9-4695-ba0a-aa9a8bff08ff" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_425a1c08-4ed9-4695-ba0a-aa9a8bff08ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_801c673c-d00a-4a7e-9a14-d6b739f6b1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_425a1c08-4ed9-4695-ba0a-aa9a8bff08ff" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_801c673c-d00a-4a7e-9a14-d6b739f6b1d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_971fc3c7-c2f5-4938-82b2-72b1654e5eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_801c673c-d00a-4a7e-9a14-d6b739f6b1d5" xlink:to="loc_us-gaap_DomesticCountryMember_971fc3c7-c2f5-4938-82b2-72b1654e5eeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1c7fea2c-a1f1-4624-9f9d-959509e34881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_801c673c-d00a-4a7e-9a14-d6b739f6b1d5" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1c7fea2c-a1f1-4624-9f9d-959509e34881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_1df8a7e3-1995-476c-b271-3fbfac403dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_801c673c-d00a-4a7e-9a14-d6b739f6b1d5" xlink:to="loc_us-gaap_ForeignCountryMember_1df8a7e3-1995-476c-b271-3fbfac403dd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_11e381ee-0e96-4bd2-b847-16163e303670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d119ece1-2be6-4161-9b0a-072f61189844" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_11e381ee-0e96-4bd2-b847-16163e303670" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_11e381ee-0e96-4bd2-b847-16163e303670_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_11e381ee-0e96-4bd2-b847-16163e303670" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_11e381ee-0e96-4bd2-b847-16163e303670_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_1b00ebc3-7719-4220-aafc-e93d3142720e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_11e381ee-0e96-4bd2-b847-16163e303670" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_1b00ebc3-7719-4220-aafc-e93d3142720e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_0bbd3929-a63c-4d00-aab9-252b99fbb364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_1b00ebc3-7719-4220-aafc-e93d3142720e" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_0bbd3929-a63c-4d00-aab9-252b99fbb364" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_UT_dfa78cab-8b18-4b51-ad42-ef9c40cc5fdc" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_UT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_1b00ebc3-7719-4220-aafc-e93d3142720e" xlink:to="loc_stpr_UT_dfa78cab-8b18-4b51-ad42-ef9c40cc5fdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_c3daf7e2-0ec3-4630-a143-bf4c910edbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_1b00ebc3-7719-4220-aafc-e93d3142720e" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_c3daf7e2-0ec3-4630-a143-bf4c910edbf9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OtherStateMember_b0d80cf1-1fb4-44e9-af99-e5358aec70f4" xlink:href="mygn-20221231.xsd#mygn_OtherStateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_1b00ebc3-7719-4220-aafc-e93d3142720e" xlink:to="loc_mygn_OtherStateMember_b0d80cf1-1fb4-44e9-af99-e5358aec70f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_01749470-b2a0-4860-9d5d-694703705db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d119ece1-2be6-4161-9b0a-072f61189844" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_01749470-b2a0-4860-9d5d-694703705db4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_01749470-b2a0-4860-9d5d-694703705db4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_01749470-b2a0-4860-9d5d-694703705db4" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_01749470-b2a0-4860-9d5d-694703705db4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_bb78ac63-074d-4c0e-83ea-d02e3a68f297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_01749470-b2a0-4860-9d5d-694703705db4" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_bb78ac63-074d-4c0e-83ea-d02e3a68f297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_ed60641a-3ddf-4da2-af7a-3a3efb5fd67c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_bb78ac63-074d-4c0e-83ea-d02e3a68f297" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_ed60641a-3ddf-4da2-af7a-3a3efb5fd67c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_691cdd57-228f-4688-a86d-794eb29d1442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_bb78ac63-074d-4c0e-83ea-d02e3a68f297" xlink:to="loc_us-gaap_ResearchMember_691cdd57-228f-4688-a86d-794eb29d1442" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_99a197a4-8ca0-4dfa-8272-71e3e127af4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d119ece1-2be6-4161-9b0a-072f61189844" xlink:to="loc_srt_RangeAxis_99a197a4-8ca0-4dfa-8272-71e3e127af4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_99a197a4-8ca0-4dfa-8272-71e3e127af4e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_99a197a4-8ca0-4dfa-8272-71e3e127af4e" xlink:to="loc_srt_RangeMember_99a197a4-8ca0-4dfa-8272-71e3e127af4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74b82b55-a582-4463-b9c9-fdaa96922aca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_99a197a4-8ca0-4dfa-8272-71e3e127af4e" xlink:to="loc_srt_RangeMember_74b82b55-a582-4463-b9c9-fdaa96922aca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_42dcda5a-7e24-4e2b-819f-7976f9c08dd1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_74b82b55-a582-4463-b9c9-fdaa96922aca" xlink:to="loc_srt_MinimumMember_42dcda5a-7e24-4e2b-819f-7976f9c08dd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ffe0eb16-0c3e-4bb2-8b62-811cedbae8a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_74b82b55-a582-4463-b9c9-fdaa96922aca" xlink:to="loc_srt_MaximumMember_ffe0eb16-0c3e-4bb2-8b62-811cedbae8a7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="if3a5d1486bfd47839d879b4dacf6f811_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_3d34a39f-6c5f-4e9f-9428-b256bfac648e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_a13ab0b5-f58b-4669-9cb3-acbaa71ca7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_3d34a39f-6c5f-4e9f-9428-b256bfac648e" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_a13ab0b5-f58b-4669-9cb3-acbaa71ca7d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_388487fd-60e0-49db-b5fc-8f897b5aa662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_3d34a39f-6c5f-4e9f-9428-b256bfac648e" xlink:to="loc_us-gaap_LossContingenciesTable_388487fd-60e0-49db-b5fc-8f897b5aa662" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_2d5c470f-df51-4094-ba0e-975735a185be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_388487fd-60e0-49db-b5fc-8f897b5aa662" xlink:to="loc_srt_LitigationCaseAxis_2d5c470f-df51-4094-ba0e-975735a185be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2d5c470f-df51-4094-ba0e-975735a185be_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_2d5c470f-df51-4094-ba0e-975735a185be" xlink:to="loc_srt_LitigationCaseTypeDomain_2d5c470f-df51-4094-ba0e-975735a185be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c7aae0ef-c35d-47f4-97c9-242e15afa75a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_2d5c470f-df51-4094-ba0e-975735a185be" xlink:to="loc_srt_LitigationCaseTypeDomain_c7aae0ef-c35d-47f4-97c9-242e15afa75a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RaygenIncVersusMyriadWomensHealthIncMember_ccccbcde-0152-4035-8244-6cb5965988ca" xlink:href="mygn-20221231.xsd#mygn_RaygenIncVersusMyriadWomensHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c7aae0ef-c35d-47f4-97c9-242e15afa75a" xlink:to="loc_mygn_RaygenIncVersusMyriadWomensHealthIncMember_ccccbcde-0152-4035-8244-6cb5965988ca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/LeasesNarrativeDetails" xlink:type="extended" id="ie690068a1df1412b88fd79aa10035137_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_dbb56727-39d2-445e-b0eb-4916d38a79af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_dbb56727-39d2-445e-b0eb-4916d38a79af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_98152c9c-4687-4356-bc27-ba5c2d4d9469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_98152c9c-4687-4356-bc27-ba5c2d4d9469" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_13e68d75-3bb6-4dc5-8604-99b1fbcf3b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_13e68d75-3bb6-4dc5-8604-99b1fbcf3b6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_fbf6306d-ca79-48dd-9f1d-4d4061c309c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_AssetImpairmentCharges_fbf6306d-ca79-48dd-9f1d-4d4061c309c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_20466cc7-79cf-430e-9edc-54db704de203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_LeaseCost_20466cc7-79cf-430e-9edc-54db704de203" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_e1a0a271-0a1e-4ccf-b872-1a45759c938c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_VariableLeaseCost_e1a0a271-0a1e-4ccf-b872-1a45759c938c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_00e24faa-28f2-48f8-a706-51c02394a39a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_00e24faa-28f2-48f8-a706-51c02394a39a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_00fe0799-0c22-4a41-8197-8c5fafab0232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_00fe0799-0c22-4a41-8197-8c5fafab0232" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0799ada7-2188-4058-9a34-e1409058b62d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0799ada7-2188-4058-9a34-e1409058b62d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a5b06dc3-8daa-41f1-8cb7-f13b5e74015a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_OperatingLeaseLiability_a5b06dc3-8daa-41f1-8cb7-f13b5e74015a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3f8e3afb-5ee9-4414-aa20-6c6170dc1807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3f8e3afb-5ee9-4414-aa20-6c6170dc1807" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0de27956-70cf-40af-bbe0-613405d2a9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0de27956-70cf-40af-bbe0-613405d2a9d2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2680661c-d507-44da-8297-50049473abc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2680661c-d507-44da-8297-50049473abc2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_89860aa0-55c8-4087-a67b-f0f006b97a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_89860aa0-55c8-4087-a67b-f0f006b97a17" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e09f1cf4-7eeb-4c39-8e23-3379319148d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_89860aa0-55c8-4087-a67b-f0f006b97a17" xlink:to="loc_srt_RangeAxis_e09f1cf4-7eeb-4c39-8e23-3379319148d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e09f1cf4-7eeb-4c39-8e23-3379319148d7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e09f1cf4-7eeb-4c39-8e23-3379319148d7" xlink:to="loc_srt_RangeMember_e09f1cf4-7eeb-4c39-8e23-3379319148d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_893d46e5-ca45-4a11-bce5-6535bfa321af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e09f1cf4-7eeb-4c39-8e23-3379319148d7" xlink:to="loc_srt_RangeMember_893d46e5-ca45-4a11-bce5-6535bfa321af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c6e09305-4b72-4f84-b433-50b2edd0bdc1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_893d46e5-ca45-4a11-bce5-6535bfa321af" xlink:to="loc_srt_MinimumMember_c6e09305-4b72-4f84-b433-50b2edd0bdc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_94c3eff4-f414-4eb4-998c-088032177d24" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_893d46e5-ca45-4a11-bce5-6535bfa321af" xlink:to="loc_srt_MaximumMember_94c3eff4-f414-4eb4-998c-088032177d24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f0969a8b-91ab-45c6-a88d-dd64a1c34ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_89860aa0-55c8-4087-a67b-f0f006b97a17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f0969a8b-91ab-45c6-a88d-dd64a1c34ae6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f0969a8b-91ab-45c6-a88d-dd64a1c34ae6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f0969a8b-91ab-45c6-a88d-dd64a1c34ae6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f0969a8b-91ab-45c6-a88d-dd64a1c34ae6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4214743b-77c8-4c3f-af98-1fe11513a108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f0969a8b-91ab-45c6-a88d-dd64a1c34ae6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4214743b-77c8-4c3f-af98-1fe11513a108" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_f80f9fc9-b623-4938-a008-8e503fef8dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4214743b-77c8-4c3f-af98-1fe11513a108" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_f80f9fc9-b623-4938-a008-8e503fef8dde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementAxis_fde15bfc-3106-41b5-8546-fc8651725ae1" xlink:href="mygn-20221231.xsd#mygn_LeaseArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_89860aa0-55c8-4087-a67b-f0f006b97a17" xlink:to="loc_mygn_LeaseArrangementAxis_fde15bfc-3106-41b5-8546-fc8651725ae1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementDomain_fde15bfc-3106-41b5-8546-fc8651725ae1_default" xlink:href="mygn-20221231.xsd#mygn_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mygn_LeaseArrangementAxis_fde15bfc-3106-41b5-8546-fc8651725ae1" xlink:to="loc_mygn_LeaseArrangementDomain_fde15bfc-3106-41b5-8546-fc8651725ae1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementDomain_9ec2cf79-39c8-473b-b9f1-5640bfb6c449" xlink:href="mygn-20221231.xsd#mygn_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mygn_LeaseArrangementAxis_fde15bfc-3106-41b5-8546-fc8651725ae1" xlink:to="loc_mygn_LeaseArrangementDomain_9ec2cf79-39c8-473b-b9f1-5640bfb6c449" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_WestSaltLakeCityLeaseMember_c404682b-0273-4e64-8d3c-8407d0585c49" xlink:href="mygn-20221231.xsd#mygn_WestSaltLakeCityLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mygn_LeaseArrangementDomain_9ec2cf79-39c8-473b-b9f1-5640bfb6c449" xlink:to="loc_mygn_WestSaltLakeCityLeaseMember_c404682b-0273-4e64-8d3c-8407d0585c49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_53d5d69d-f670-4207-ab1a-349f6230d0df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_89860aa0-55c8-4087-a67b-f0f006b97a17" xlink:to="loc_srt_StatementGeographicalAxis_53d5d69d-f670-4207-ab1a-349f6230d0df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_53d5d69d-f670-4207-ab1a-349f6230d0df_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_53d5d69d-f670-4207-ab1a-349f6230d0df" xlink:to="loc_srt_SegmentGeographicalDomain_53d5d69d-f670-4207-ab1a-349f6230d0df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a7d65e03-f2ca-4c17-9ce1-5e66f6298765" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_53d5d69d-f670-4207-ab1a-349f6230d0df" xlink:to="loc_srt_SegmentGeographicalDomain_a7d65e03-f2ca-4c17-9ce1-5e66f6298765" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_SouthSanFranciscoCaliforniaMember_c720cfe1-1a25-4f70-b478-30f0b79b2639" xlink:href="mygn-20221231.xsd#mygn_SouthSanFranciscoCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a7d65e03-f2ca-4c17-9ce1-5e66f6298765" xlink:to="loc_mygn_SouthSanFranciscoCaliforniaMember_c720cfe1-1a25-4f70-b478-30f0b79b2639" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails" xlink:type="extended" id="ie2dd003e0f7149749bef0d73c45fe6da_SegmentandRelatedInformationAssetsbyGeographicalRegionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_13419860-fa21-4e38-a9a8-d8a9972e55b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4abbf92e-2075-45b4-b785-69c86eaa43de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_13419860-fa21-4e38-a9a8-d8a9972e55b7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4abbf92e-2075-45b4-b785-69c86eaa43de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AssetsLessCashCashEquivalentsAndInvestments_2b6ac6a0-50b0-4d37-a9e3-2e2f798b8b86" xlink:href="mygn-20221231.xsd#mygn_AssetsLessCashCashEquivalentsAndInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_13419860-fa21-4e38-a9a8-d8a9972e55b7" xlink:to="loc_mygn_AssetsLessCashCashEquivalentsAndInvestments_2b6ac6a0-50b0-4d37-a9e3-2e2f798b8b86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_063651a2-fcb2-4c3e-952d-9904e35ece89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_13419860-fa21-4e38-a9a8-d8a9972e55b7" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_063651a2-fcb2-4c3e-952d-9904e35ece89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6023e46b-71cd-4e15-aec9-5870e98aeba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_13419860-fa21-4e38-a9a8-d8a9972e55b7" xlink:to="loc_us-gaap_Assets_6023e46b-71cd-4e15-aec9-5870e98aeba8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ca44a301-ce4a-4646-b2e8-5bf4f6e2c208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_13419860-fa21-4e38-a9a8-d8a9972e55b7" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ca44a301-ce4a-4646-b2e8-5bf4f6e2c208" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_5e44cf05-8712-47e0-9d64-002c6bb7f9f4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ca44a301-ce4a-4646-b2e8-5bf4f6e2c208" xlink:to="loc_srt_ConsolidationItemsAxis_5e44cf05-8712-47e0-9d64-002c6bb7f9f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_5e44cf05-8712-47e0-9d64-002c6bb7f9f4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_5e44cf05-8712-47e0-9d64-002c6bb7f9f4" xlink:to="loc_srt_ConsolidationItemsDomain_5e44cf05-8712-47e0-9d64-002c6bb7f9f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_58ba1f83-852a-42a2-883e-6a4bd6961e26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_5e44cf05-8712-47e0-9d64-002c6bb7f9f4" xlink:to="loc_srt_ConsolidationItemsDomain_58ba1f83-852a-42a2-883e-6a4bd6961e26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableGeographicalComponentsMember_13a2a000-25bd-4ad1-b6cc-aa041a6d919d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ReportableGeographicalComponentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_58ba1f83-852a-42a2-883e-6a4bd6961e26" xlink:to="loc_srt_ReportableGeographicalComponentsMember_13a2a000-25bd-4ad1-b6cc-aa041a6d919d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7d10b54b-d8eb-425f-ba4a-7cf10bec513b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ca44a301-ce4a-4646-b2e8-5bf4f6e2c208" xlink:to="loc_srt_StatementGeographicalAxis_7d10b54b-d8eb-425f-ba4a-7cf10bec513b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7d10b54b-d8eb-425f-ba4a-7cf10bec513b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_7d10b54b-d8eb-425f-ba4a-7cf10bec513b" xlink:to="loc_srt_SegmentGeographicalDomain_7d10b54b-d8eb-425f-ba4a-7cf10bec513b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b5bfe39c-f7bb-4196-9140-9f9b2e124490" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_7d10b54b-d8eb-425f-ba4a-7cf10bec513b" xlink:to="loc_srt_SegmentGeographicalDomain_b5bfe39c-f7bb-4196-9140-9f9b2e124490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1a739ad2-b60f-437f-ba84-f5d1a5bb3028" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b5bfe39c-f7bb-4196-9140-9f9b2e124490" xlink:to="loc_country_US_1a739ad2-b60f-437f-ba84-f5d1a5bb3028" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_d3a90844-9eff-4985-8573-ac3499f377d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b5bfe39c-f7bb-4196-9140-9f9b2e124490" xlink:to="loc_us-gaap_NonUsMember_d3a90844-9eff-4985-8573-ac3499f377d8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#BusinessAcquisitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails" xlink:type="extended" id="i7921d79c77f04ca5b6cf49108a6fb4c1_BusinessAcquisitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2bce25e9-90c8-44e8-b215-cbe1f490a580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2bce25e9-90c8-44e8-b215-cbe1f490a580" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_c44ad0f5-59a9-43e2-a90e-c745458dcaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_c44ad0f5-59a9-43e2-a90e-c745458dcaa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments_d88b7b77-3ed8-46c8-8502-6c24d883b09f" xlink:href="mygn-20221231.xsd#mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments_d88b7b77-3ed8-46c8-8502-6c24d883b09f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_21845732-07e4-432d-afc5-274b2bdf047d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_21845732-07e4-432d-afc5-274b2bdf047d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4870579e-cca1-48f8-b875-87f4f7c20cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4870579e-cca1-48f8-b875-87f4f7c20cea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a5ffdcca-67b3-4e41-a557-9033f9f5b105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_Goodwill_a5ffdcca-67b3-4e41-a557-9033f9f5b105" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_BusinessCombinationIntangibleAssetsMeasurementInput_d4957d75-2df2-43e4-b8f8-560304b2afb8" xlink:href="mygn-20221231.xsd#mygn_BusinessCombinationIntangibleAssetsMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_mygn_BusinessCombinationIntangibleAssetsMeasurementInput_d4957d75-2df2-43e4-b8f8-560304b2afb8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1ea1175c-0fb9-4953-beb8-0df978d9a831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1ea1175c-0fb9-4953-beb8-0df978d9a831" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_d3dccef2-27c2-4887-8a17-ba7ebb2a48c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_d3dccef2-27c2-4887-8a17-ba7ebb2a48c1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_e51dd0b7-154e-4c70-87d7-ceb6f53787ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_e51dd0b7-154e-4c70-87d7-ceb6f53787ce" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_ea807466-2dcc-4ce0-8a41-5d6ac884e532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_ea807466-2dcc-4ce0-8a41-5d6ac884e532" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_f3323395-ede8-4a4a-99cf-d6dcd7bec540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_f3323395-ede8-4a4a-99cf-d6dcd7bec540" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed4c0138-b6b3-4136-a97b-c729fae2a41e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed4c0138-b6b3-4136-a97b-c729fae2a41e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3cd9a2ca-b8cf-4b4a-946b-80c1e10333d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed4c0138-b6b3-4136-a97b-c729fae2a41e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3cd9a2ca-b8cf-4b4a-946b-80c1e10333d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3cd9a2ca-b8cf-4b4a-946b-80c1e10333d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3cd9a2ca-b8cf-4b4a-946b-80c1e10333d3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3cd9a2ca-b8cf-4b4a-946b-80c1e10333d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_960f3f0c-8846-4a28-94a3-fd62da6a1466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3cd9a2ca-b8cf-4b4a-946b-80c1e10333d3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_960f3f0c-8846-4a28-94a3-fd62da6a1466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GatewayGenomicsLLCMember_730ce2d0-8cf0-4c1c-ab6c-f813788498de" xlink:href="mygn-20221231.xsd#mygn_GatewayGenomicsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_960f3f0c-8846-4a28-94a3-fd62da6a1466" xlink:to="loc_mygn_GatewayGenomicsLLCMember_730ce2d0-8cf0-4c1c-ab6c-f813788498de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8fd1ad77-3ecd-4f06-b113-420c1eaf3605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed4c0138-b6b3-4136-a97b-c729fae2a41e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8fd1ad77-3ecd-4f06-b113-420c1eaf3605" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8fd1ad77-3ecd-4f06-b113-420c1eaf3605_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8fd1ad77-3ecd-4f06-b113-420c1eaf3605" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8fd1ad77-3ecd-4f06-b113-420c1eaf3605_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_176b947d-8fc8-494a-8947-b280da1b94d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8fd1ad77-3ecd-4f06-b113-420c1eaf3605" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_176b947d-8fc8-494a-8947-b280da1b94d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_0e7c1e87-7e1b-40fa-a41d-9fc80064d6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_176b947d-8fc8-494a-8947-b280da1b94d0" xlink:to="loc_us-gaap_CustomerRelationshipsMember_0e7c1e87-7e1b-40fa-a41d-9fc80064d6d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_610c9596-7971-4594-abf6-8d27f32e8f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_176b947d-8fc8-494a-8947-b280da1b94d0" xlink:to="loc_us-gaap_TrademarksMember_610c9596-7971-4594-abf6-8d27f32e8f07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_285fec43-93f2-4818-b117-8739f01f47c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_176b947d-8fc8-494a-8947-b280da1b94d0" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_285fec43-93f2-4818-b117-8739f01f47c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_09b97f66-acb3-45b1-aa11-0b31dcc31b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed4c0138-b6b3-4136-a97b-c729fae2a41e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_09b97f66-acb3-45b1-aa11-0b31dcc31b84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_09b97f66-acb3-45b1-aa11-0b31dcc31b84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_09b97f66-acb3-45b1-aa11-0b31dcc31b84" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_09b97f66-acb3-45b1-aa11-0b31dcc31b84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_96a12e82-b0bc-4f5f-b53a-b9a73550a4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_09b97f66-acb3-45b1-aa11-0b31dcc31b84" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_96a12e82-b0bc-4f5f-b53a-b9a73550a4bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_1683ea34-cdeb-44ca-878d-d6719d65fca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_96a12e82-b0bc-4f5f-b53a-b9a73550a4bb" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_1683ea34-cdeb-44ca-878d-d6719d65fca0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="ie2b08789a26d4806bf3c58614d25d2b3_BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_b9d5aa9b-e58f-4105-b3ce-583594dd00f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_b9d5aa9b-e58f-4105-b3ce-583594dd00f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_4bf3f7dd-7f06-4cb4-a903-26768c2dee9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_4bf3f7dd-7f06-4cb4-a903-26768c2dee9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9683bc96-7dcc-4017-9af1-dfa9227ce80d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9683bc96-7dcc-4017-9af1-dfa9227ce80d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_e0d82079-3f8b-4fc3-a57d-f881ad81eb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_e0d82079-3f8b-4fc3-a57d-f881ad81eb9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_dca59acc-3a4d-4f18-8f9c-eeba59eaf1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_dca59acc-3a4d-4f18-8f9c-eeba59eaf1d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e14fe5ef-6833-4bd8-afd9-438d93bcff09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_Goodwill_e14fe5ef-6833-4bd8-afd9-438d93bcff09" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_41174f36-45ce-4b34-86d6-43739b92d7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_41174f36-45ce-4b34-86d6-43739b92d7db" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_aa0cdd06-b36a-45a5-94ab-f8a0c243d694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_aa0cdd06-b36a-45a5-94ab-f8a0c243d694" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_79403f80-16cc-4e55-bba2-32d2ec2c8164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_79403f80-16cc-4e55-bba2-32d2ec2c8164" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_19c4a9f8-01a5-4558-83d3-3de0e304012c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_19c4a9f8-01a5-4558-83d3-3de0e304012c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e9b78a4b-0897-477e-aa2a-dfe80b949198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e9b78a4b-0897-477e-aa2a-dfe80b949198" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_417f28c6-b8a9-40e9-99db-98e9b5e583b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_417f28c6-b8a9-40e9-99db-98e9b5e583b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9bfff989-90e7-45aa-a893-e87cf51b565d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_417f28c6-b8a9-40e9-99db-98e9b5e583b9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9bfff989-90e7-45aa-a893-e87cf51b565d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9bfff989-90e7-45aa-a893-e87cf51b565d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9bfff989-90e7-45aa-a893-e87cf51b565d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9bfff989-90e7-45aa-a893-e87cf51b565d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b3819e51-829b-465e-90f0-c7a06cf13937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9bfff989-90e7-45aa-a893-e87cf51b565d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b3819e51-829b-465e-90f0-c7a06cf13937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GatewayGenomicsLLCMember_132c5d88-03de-4c46-8ce1-67987e57153a" xlink:href="mygn-20221231.xsd#mygn_GatewayGenomicsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b3819e51-829b-465e-90f0-c7a06cf13937" xlink:to="loc_mygn_GatewayGenomicsLLCMember_132c5d88-03de-4c46-8ce1-67987e57153a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_db8cc861-44db-47bd-86ec-3819025d9ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_417f28c6-b8a9-40e9-99db-98e9b5e583b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_db8cc861-44db-47bd-86ec-3819025d9ec5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db8cc861-44db-47bd-86ec-3819025d9ec5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_db8cc861-44db-47bd-86ec-3819025d9ec5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_db8cc861-44db-47bd-86ec-3819025d9ec5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d5ba4fbf-f2c9-4d08-b858-2f69bf292875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_db8cc861-44db-47bd-86ec-3819025d9ec5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d5ba4fbf-f2c9-4d08-b858-2f69bf292875" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_95dac8b8-7ff3-48ea-bbc1-0ead75dd1c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d5ba4fbf-f2c9-4d08-b858-2f69bf292875" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_95dac8b8-7ff3-48ea-bbc1-0ead75dd1c65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_231d6b9c-88c5-4643-851c-3399917df3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d5ba4fbf-f2c9-4d08-b858-2f69bf292875" xlink:to="loc_us-gaap_TrademarksMember_231d6b9c-88c5-4643-851c-3399917df3ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_3f51b702-b51f-4838-9ccd-b256ff2d6da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d5ba4fbf-f2c9-4d08-b858-2f69bf292875" xlink:to="loc_us-gaap_CustomerRelationshipsMember_3f51b702-b51f-4838-9ccd-b256ff2d6da4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/BusinessAcquisitionScheduleofProFormaInformationDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#BusinessAcquisitionScheduleofProFormaInformationDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/BusinessAcquisitionScheduleofProFormaInformationDetails" xlink:type="extended" id="ib6a6e25a3b1e430282a2268f404d7fed_BusinessAcquisitionScheduleofProFormaInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_05305ef6-0cdc-47b8-9bcf-75684cd31de2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_21b9527f-49f2-4c11-a739-ba33b5f8ef03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05305ef6-0cdc-47b8-9bcf-75684cd31de2" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_21b9527f-49f2-4c11-a739-ba33b5f8ef03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_f2b10c2f-7490-47b2-b910-f5c115181c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05305ef6-0cdc-47b8-9bcf-75684cd31de2" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_f2b10c2f-7490-47b2-b910-f5c115181c4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7b955e78-b7b4-4f43-9946-86dbef8dc624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05305ef6-0cdc-47b8-9bcf-75684cd31de2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7b955e78-b7b4-4f43-9946-86dbef8dc624" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b22d3a60-516e-4e6e-9264-5491b4f4b03a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7b955e78-b7b4-4f43-9946-86dbef8dc624" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b22d3a60-516e-4e6e-9264-5491b4f4b03a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b22d3a60-516e-4e6e-9264-5491b4f4b03a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b22d3a60-516e-4e6e-9264-5491b4f4b03a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b22d3a60-516e-4e6e-9264-5491b4f4b03a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6715be7c-a86e-4375-8631-d3ebf21b4240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b22d3a60-516e-4e6e-9264-5491b4f4b03a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6715be7c-a86e-4375-8631-d3ebf21b4240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GatewayGenomicsLLCMember_bcce656b-3b47-467f-813b-00e427573705" xlink:href="mygn-20221231.xsd#mygn_GatewayGenomicsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6715be7c-a86e-4375-8631-d3ebf21b4240" xlink:to="loc_mygn_GatewayGenomicsLLCMember_bcce656b-3b47-467f-813b-00e427573705" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/DivestituresNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#DivestituresNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/DivestituresNarrativeDetails" xlink:type="extended" id="idd69569c00d34f7fa6c298319b83b5b4_DivestituresNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e718d16e-ef2f-4aca-a0e2-543b728370f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_cf728fc5-be17-4d04-8058-372807dd73fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e718d16e-ef2f-4aca-a0e2-543b728370f4" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_cf728fc5-be17-4d04-8058-372807dd73fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_1f78323f-f8c6-420d-adbb-4d3f58a09c61" xlink:href="mygn-20221231.xsd#mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e718d16e-ef2f-4aca-a0e2-543b728370f4" xlink:to="loc_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_1f78323f-f8c6-420d-adbb-4d3f58a09c61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_bc7942fb-71cd-4073-8d57-e9b97d4560d1" xlink:href="mygn-20221231.xsd#mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e718d16e-ef2f-4aca-a0e2-543b728370f4" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_bc7942fb-71cd-4073-8d57-e9b97d4560d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_34f8fc13-672c-4d2b-abcd-af678d8d6e83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e718d16e-ef2f-4aca-a0e2-543b728370f4" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_34f8fc13-672c-4d2b-abcd-af678d8d6e83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_f733db8a-51ab-42dd-90c2-c95ba941d6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e718d16e-ef2f-4aca-a0e2-543b728370f4" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_f733db8a-51ab-42dd-90c2-c95ba941d6ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_f58c648a-44db-462a-bdde-792f9417e346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e718d16e-ef2f-4aca-a0e2-543b728370f4" xlink:to="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_f58c648a-44db-462a-bdde-792f9417e346" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_9fa621cd-638f-4d8f-9e55-d693f5e0760d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e718d16e-ef2f-4aca-a0e2-543b728370f4" xlink:to="loc_us-gaap_InventoryWriteDown_9fa621cd-638f-4d8f-9e55-d693f5e0760d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_094c74e6-1b3e-44b9-a22a-af55e61d5b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e718d16e-ef2f-4aca-a0e2-543b728370f4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_094c74e6-1b3e-44b9-a22a-af55e61d5b6d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_dc491346-cf6e-4811-975f-7109efbf078a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_094c74e6-1b3e-44b9-a22a-af55e61d5b6d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_dc491346-cf6e-4811-975f-7109efbf078a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_dc491346-cf6e-4811-975f-7109efbf078a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_dc491346-cf6e-4811-975f-7109efbf078a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_dc491346-cf6e-4811-975f-7109efbf078a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7980b61e-4f96-4baa-88e3-330d647fb820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_dc491346-cf6e-4811-975f-7109efbf078a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7980b61e-4f96-4baa-88e3-330d647fb820" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_aedeeb64-e2ce-45b4-8425-b8ee6149d0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_7980b61e-4f96-4baa-88e3-330d647fb820" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_aedeeb64-e2ce-45b4-8425-b8ee6149d0e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1c9c78ce-3e86-4bad-9975-d7784d3c73a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_094c74e6-1b3e-44b9-a22a-af55e61d5b6d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1c9c78ce-3e86-4bad-9975-d7784d3c73a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1c9c78ce-3e86-4bad-9975-d7784d3c73a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1c9c78ce-3e86-4bad-9975-d7784d3c73a3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1c9c78ce-3e86-4bad-9975-d7784d3c73a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c2afda6d-d636-4c4a-8f64-c8153e20bad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1c9c78ce-3e86-4bad-9975-d7784d3c73a3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c2afda6d-d636-4c4a-8f64-c8153e20bad6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadMyPathLLCLaboratoryMember_b844ff48-4402-4de5-a66d-acd67fac60bd" xlink:href="mygn-20221231.xsd#mygn_MyriadMyPathLLCLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c2afda6d-d636-4c4a-8f64-c8153e20bad6" xlink:to="loc_mygn_MyriadMyPathLLCLaboratoryMember_b844ff48-4402-4de5-a66d-acd67fac60bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncMember_a7115391-d00c-468d-8d83-d50d76e38802" xlink:href="mygn-20221231.xsd#mygn_MyriadRBMIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c2afda6d-d636-4c4a-8f64-c8153e20bad6" xlink:to="loc_mygn_MyriadRBMIncMember_a7115391-d00c-468d-8d83-d50d76e38802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneAssetsMember_bd4b5934-c0ae-42e2-8f43-2372068623d5" xlink:href="mygn-20221231.xsd#mygn_MyriadAutoimmuneAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c2afda6d-d636-4c4a-8f64-c8153e20bad6" xlink:to="loc_mygn_MyriadAutoimmuneAssetsMember_bd4b5934-c0ae-42e2-8f43-2372068623d5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.myriad.com/role/DivestituresOtherIncomeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#DivestituresOtherIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.myriad.com/role/DivestituresOtherIncomeDetails" xlink:type="extended" id="i05718f80d83c433a87f6d27239296a8c_DivestituresOtherIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ed597d1f-3d03-4421-b093-1def7b7138bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_88a696d3-dd2c-480c-9f05-cab2dffe315d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ed597d1f-3d03-4421-b093-1def7b7138bc" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_88a696d3-dd2c-480c-9f05-cab2dffe315d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_a9fbf3ff-38ac-49e5-87c8-3e781a4be32d" xlink:href="mygn-20221231.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ed597d1f-3d03-4421-b093-1def7b7138bc" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_a9fbf3ff-38ac-49e5-87c8-3e781a4be32d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_846b7d65-9d24-4460-b78c-7fe4054c4ed7" xlink:href="mygn-20221231.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ed597d1f-3d03-4421-b093-1def7b7138bc" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_846b7d65-9d24-4460-b78c-7fe4054c4ed7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_54eb770d-0a59-4338-98fd-a9bffbec80c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ed597d1f-3d03-4421-b093-1def7b7138bc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_54eb770d-0a59-4338-98fd-a9bffbec80c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_82f1499d-033c-48ff-bdfa-8cf3d74d68d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ed597d1f-3d03-4421-b093-1def7b7138bc" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_82f1499d-033c-48ff-bdfa-8cf3d74d68d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fd966ad4-6ef2-4d6a-b52c-93ade7b8463b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_82f1499d-033c-48ff-bdfa-8cf3d74d68d3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fd966ad4-6ef2-4d6a-b52c-93ade7b8463b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fd966ad4-6ef2-4d6a-b52c-93ade7b8463b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fd966ad4-6ef2-4d6a-b52c-93ade7b8463b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fd966ad4-6ef2-4d6a-b52c-93ade7b8463b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f1931d5d-7e40-4747-8933-6d96e89a250c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fd966ad4-6ef2-4d6a-b52c-93ade7b8463b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f1931d5d-7e40-4747-8933-6d96e89a250c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncMember_862072e5-7a5f-46c7-82ca-9736858315b9" xlink:href="mygn-20221231.xsd#mygn_MyriadRBMIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f1931d5d-7e40-4747-8933-6d96e89a250c" xlink:to="loc_mygn_MyriadRBMIncMember_862072e5-7a5f-46c7-82ca-9736858315b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadMyPathLLCLaboratoryMember_d73e5fea-7713-4d47-b8a2-40fd4d60f5cd" xlink:href="mygn-20221231.xsd#mygn_MyriadMyPathLLCLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f1931d5d-7e40-4747-8933-6d96e89a250c" xlink:to="loc_mygn_MyriadMyPathLLCLaboratoryMember_d73e5fea-7713-4d47-b8a2-40fd4d60f5cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneAssetsMember_5af22a45-71d0-48c9-a1de-d9721bd82b3d" xlink:href="mygn-20221231.xsd#mygn_MyriadAutoimmuneAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f1931d5d-7e40-4747-8933-6d96e89a250c" xlink:to="loc_mygn_MyriadAutoimmuneAssetsMember_5af22a45-71d0-48c9-a1de-d9721bd82b3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_fbb2752b-c289-4fa3-9628-02868bb22805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_82f1499d-033c-48ff-bdfa-8cf3d74d68d3" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_fbb2752b-c289-4fa3-9628-02868bb22805" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_fbb2752b-c289-4fa3-9628-02868bb22805_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_fbb2752b-c289-4fa3-9628-02868bb22805" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_fbb2752b-c289-4fa3-9628-02868bb22805_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_fa3533e5-c675-47a6-8979-7dbcaa76ce5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_fbb2752b-c289-4fa3-9628-02868bb22805" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_fa3533e5-c675-47a6-8979-7dbcaa76ce5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_62cea367-eb2a-4301-8cd0-e6bd9db108cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_fa3533e5-c675-47a6-8979-7dbcaa76ce5b" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_62cea367-eb2a-4301-8cd0-e6bd9db108cc" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>mygn-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6db69074-e648-4be3-ae6d-ea77b2ae08c9,g:6dbaf31c-e8bf-47fc-986c-d695276c3aba-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_5142c327-b891-444f-be65-5b7fd199a90a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_160ce9fd-5c0f-4cfc-985d-cc42ed7a2ce8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IncomeTaxReconciliationCARESAct_6069f0f3-6804-490b-afa5-b28c59d5209a_terseLabel_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationCARESAct_label_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation CARES Act</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationCARESAct_documentation_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationCARESAct" xlink:href="mygn-20221231.xsd#mygn_IncomeTaxReconciliationCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IncomeTaxReconciliationCARESAct" xlink:to="lab_mygn_IncomeTaxReconciliationCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_b14ad1bd-f5ef-445c-8767-7701b000b822_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f7b1191-caa2-489f-b668-cc5e61ed2002_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8b9e0826-d754-4bbe-a936-7415d7a31e7d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_359c7794-4843-4433-8c2b-0875a9e1d598_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_f00b4386-f2ed-43f2-bd75-08654c054ac9_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_d8051399-9767-4ecc-a023-c07a5f506301_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8cff6980-ab06-4c18-9120-dd43ffb03d0a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_5ab70bcd-53fd-478d-bd9a-10a7145dd2e9_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d858d04e-094d-4e9c-bdbe-6d2956014d1a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_998c29e8-a15f-4796-9e81-9216d1e3f5d0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contributions to the Plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_61819880-e557-497a-9946-629872e91bb1_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of real estate property</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_e2f1b14e-5634-4ffe-a48e-1de56b8bf139_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_LeaseArrangementAxis_194a0447-6540-4a43-8ec7-73176ec2a6ef_terseLabel_en-US" xlink:label="lab_mygn_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Axis]</link:label>
    <link:label id="lab_mygn_LeaseArrangementAxis_label_en-US" xlink:label="lab_mygn_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Axis]</link:label>
    <link:label id="lab_mygn_LeaseArrangementAxis_documentation_en-US" xlink:label="lab_mygn_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementAxis" xlink:href="mygn-20221231.xsd#mygn_LeaseArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_LeaseArrangementAxis" xlink:to="lab_mygn_LeaseArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a05e39b0-2df4-4567-ad35-a9f6ba8684de_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_73538bd1-bc07-460f-86cd-1de4b435a441_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_14bb4740-8740-4d2b-be90-b6f9bb2f978c_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtRestructuringCosts_e8e9f8a9-a76e-48ab-a95b-18692c5dada6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees associated with refinancing of revolving credit facility</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtRestructuringCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtRestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:to="lab_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_41be7495-7ce0-47b6-ab9f-273604312a2e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_53c5d187-a70b-4baa-8469-ee4546d66daf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_e1e4c0d8-9e02-4703-b99e-4fb34d0f446e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-amortizable Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_840330d7-db33-49a0-8d3f-3cfd6a8d78b1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_88241e0d-6e24-4756-91d0-7b65160a3920_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate principal commitment</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_9d3edff9-e009-4382-956b-3e4c2a2e6aac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2c7702e3-a5bd-478c-b68a-13e219667189_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_4563972b-a0a1-4475-be86-1a0ebbeeab88_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due after five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8911aaf-fa0d-4d07-8032-85c80c336530_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_TaxCreditCarryforwardsExpirationDate_71c0f19f-92fa-4da6-903b-355aa51223f0_terseLabel_en-US" xlink:label="lab_mygn_TaxCreditCarryforwardsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit, expiration in year</link:label>
    <link:label id="lab_mygn_TaxCreditCarryforwardsExpirationDate_label_en-US" xlink:label="lab_mygn_TaxCreditCarryforwardsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforwards Expiration Date</link:label>
    <link:label id="lab_mygn_TaxCreditCarryforwardsExpirationDate_documentation_en-US" xlink:label="lab_mygn_TaxCreditCarryforwardsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforwards Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TaxCreditCarryforwardsExpirationDate" xlink:href="mygn-20221231.xsd#mygn_TaxCreditCarryforwardsExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_TaxCreditCarryforwardsExpirationDate" xlink:to="lab_mygn_TaxCreditCarryforwardsExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_87fe512f-3de1-421f-bb0d-6d890a28836f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_08db359e-b8b8-4456-b403-a097251ec2f8_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_5c0a0d03-cb40-4f7c-900e-5a6e42757d8d_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b3eb02b3-24e9-4332-bb28-ed9819148e0b_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization_c3c5c02d-904c-40c6-92f6-c467657c801c_terseLabel_en-US" xlink:label="lab_mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Section 174 capitalized costs</link:label>
    <link:label id="lab_mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization_label_en-US" xlink:label="lab_mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Research And Experimental Expense Capitalization</link:label>
    <link:label id="lab_mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization_documentation_en-US" xlink:label="lab_mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Research And Experimental Expense Capitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization" xlink:href="mygn-20221231.xsd#mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization" xlink:to="lab_mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_deff43e6-936f-46aa-90b2-5cb1bfd6e38c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_0f207e1f-9a8c-4622-ae05-293c9debfeda_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales of marketable investment securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2867f7c9-a882-4305-9bd7-e857657d9441_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_5cce14f9-7d6f-478d-bf94-136bb5096880_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross decreases - statute lapse</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_c09adb85-30c6-4cf3-b699-3a3acac66fb7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_3029c97a-ec5c-4383-8a20-c9f2c914eda3_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_9ea2a4ff-7e54-4cb8-b335-c98f050db747_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_df5af7cb-fce1-4f78-9679-c7c96c4127a6_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetAssetLiability_4762b1a7-8381-4419-8d01-f199adceaa2e_totalLabel_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FairValueNetAssetLiability_label_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Asset (Liability)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiability" xlink:to="lab_us-gaap_FairValueNetAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ad4f0779-bed8-46d0-a56b-8998c06d7670_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Myriad Genetics, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_874c1899-b609-47b3-a540-5d5946bb0977_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Myriad Genetics, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1af0d2cb-08cb-4ddb-91f2-18a35abe234d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_d84d953f-fed8-4b46-bee9-542bedfc1f36_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_5fb07225-c6f7-43ee-8e90-b18fa6095139_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_2416e98d-4ff2-44f0-a1a8-8d68ff724fda_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions for ESPP</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_620397b0-58f8-4b9d-a1de-212db7a88f8e_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_eaa7ac67-6374-48a5-9bc5-312db16b50af_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_09394520-f19a-40e4-830b-86e28ce8a112_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive options and RSUs excluded from EPS computation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_60a66d1d-5ef9-41eb-9f5a-372d53b7a74c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5c10b127-9248-4ea0-8c91-bb314809098f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_7a9c4e27-5406-4805-8613-9d13a08b7ed2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MyriadMyPathLLCLaboratoryMember_c5ca92c1-36d7-4e16-9256-303bf25478b5_terseLabel_en-US" xlink:label="lab_mygn_MyriadMyPathLLCLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad myPath LLC laboratory</link:label>
    <link:label id="lab_mygn_MyriadMyPathLLCLaboratoryMember_2ff573db-e8cf-4a76-84c4-c8f8acc34849_verboseLabel_en-US" xlink:label="lab_mygn_MyriadMyPathLLCLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of the Myriad myPath, LLC laboratory</link:label>
    <link:label id="lab_mygn_MyriadMyPathLLCLaboratoryMember_label_en-US" xlink:label="lab_mygn_MyriadMyPathLLCLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad My Path LLC Laboratory [Member]</link:label>
    <link:label id="lab_mygn_MyriadMyPathLLCLaboratoryMember_documentation_en-US" xlink:label="lab_mygn_MyriadMyPathLLCLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad My Path LLC Laboratory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadMyPathLLCLaboratoryMember" xlink:href="mygn-20221231.xsd#mygn_MyriadMyPathLLCLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MyriadMyPathLLCLaboratoryMember" xlink:to="lab_mygn_MyriadMyPathLLCLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b115aa42-497b-4a15-9d69-9770c3eea152_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_9a179112-3bc7-4cbc-aeae-a788b8089f2b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_827c470b-3c7e-4bda-8c3c-735dce779b83_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_d6357270-5623-4328-81b5-328ba76ab6ce_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_01b47530-04bf-49cf-ac70-146aa7484847_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross increases - current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_fd67b6b2-4f12-4d9b-a7d2-926a1203396e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting weight (in percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_7f24963d-682c-42ec-831b-2a348aff92b3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_704c480f-b463-42cc-9609-c4a535bebe18_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_831fac86-1dcb-4299-96b2-b8cd0a2ac2d9_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense for capitalized software</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_51cd791c-527e-449a-be99-3e41acc70cd5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_3f2f0adf-bd77-4054-9089-3d31b1187e94_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_8683e2e5-1f19-4b4b-9014-b2820533d56b_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_f4381bf2-0515-4828-90d9-75e527870b6d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_bf8b2e62-ddb3-402f-93c1-0ec47108980d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_PharmacogenomicsMember_384faf15-3e26-460a-9877-94427c600982_terseLabel_en-US" xlink:label="lab_mygn_PharmacogenomicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacogenomics</link:label>
    <link:label id="lab_mygn_PharmacogenomicsMember_label_en-US" xlink:label="lab_mygn_PharmacogenomicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacogenomics [Member]</link:label>
    <link:label id="lab_mygn_PharmacogenomicsMember_documentation_en-US" xlink:label="lab_mygn_PharmacogenomicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacogenomics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmacogenomicsMember" xlink:href="mygn-20221231.xsd#mygn_PharmacogenomicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_PharmacogenomicsMember" xlink:to="lab_mygn_PharmacogenomicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OperatingLeaseLiabilityEstablished_30f8c809-1115-4e29-b7d3-aefa02d2a6e9_negatedLabel_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityEstablished" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_mygn_OperatingLeaseLiabilityEstablished_label_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityEstablished" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability Established</link:label>
    <link:label id="lab_mygn_OperatingLeaseLiabilityEstablished_documentation_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityEstablished" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability Established</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseLiabilityEstablished" xlink:href="mygn-20221231.xsd#mygn_OperatingLeaseLiabilityEstablished"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OperatingLeaseLiabilityEstablished" xlink:to="lab_mygn_OperatingLeaseLiabilityEstablished" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ec75d15b-458f-438c-9d51-bca2af6d5572_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_9dfcfd80-24aa-49f7-9234-bffa450e526d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_70c0a784-ed1b-4059-b289-d803bb214922_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityDivestitures_6a20531a-6b3c-4844-9bad-ffb310e56f81_negatedTerseLabel_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityDivestitures" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityDivestitures_label_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityDivestitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Divestitures</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityDivestitures_documentation_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityDivestitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Divestitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityDivestitures" xlink:href="mygn-20221231.xsd#mygn_ContractWithCustomerLiabilityDivestitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ContractWithCustomerLiabilityDivestitures" xlink:to="lab_mygn_ContractWithCustomerLiabilityDivestitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_db212b97-f957-4eb8-99bb-fcf2097ea51e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_802a48ee-17d3-444b-8438-4e5203227c1f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_03298ca2-8a42-411c-b4e0-58872453b5b0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e67e90d2-8cac-494b-89a2-406008c8ed83_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_85285308-c1a3-4413-8129-85530733d493_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_46c7c481-820b-4750-a313-4e5e9e8f61ec_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, separately recognized transactions, expenses and losses recognized</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember_a22cf241-2873-40bb-baf1-e37891082bc3_terseLabel_en-US" xlink:label="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Obligation Estimate</link:label>
    <link:label id="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember_label_en-US" xlink:label="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Obligation Estimated Transaction Price [Member]</link:label>
    <link:label id="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember_documentation_en-US" xlink:label="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Obligation Estimated Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:href="mygn-20221231.xsd#mygn_PerformanceObligationEstimatedTransactionPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:to="lab_mygn_PerformanceObligationEstimatedTransactionPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_8dbad064-8e1d-40ac-8991-1121f548df2f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_f818e6ad-14d8-4cb6-baf5-e80175c0b5d4_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross decreases - settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_6f617fdd-993d-46f6-80c3-fa89e17b9967_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OtherTestingMember_143d1e9f-5c84-4726-8a7d-195b5e4f934b_terseLabel_en-US" xlink:label="lab_mygn_OtherTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mygn_OtherTestingMember_label_en-US" xlink:label="lab_mygn_OtherTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Testing [Member]</link:label>
    <link:label id="lab_mygn_OtherTestingMember_documentation_en-US" xlink:label="lab_mygn_OtherTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic other testing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OtherTestingMember" xlink:href="mygn-20221231.xsd#mygn_OtherTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OtherTestingMember" xlink:to="lab_mygn_OtherTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa8e454b-441f-4894-87be-e8a518e8e130_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b63063c9-5484-4dad-b297-b18ba2a5770a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current maturities of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_97f9bd2e-d1dc-47aa-b5bb-550486a8ebef_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current maturities of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration_d0e7375a-adee-4440-8714-95ccddfa079d_terseLabel_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, dispositions, and contingent consideration</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration_label_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Acquisitions, Dispositions, And Contingent Consideration</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration_documentation_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Acquisitions, Dispositions, And Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:href="mygn-20221231.xsd#mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:to="lab_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_f3322b5c-d410-4311-8806-4ea478dfa86f_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Establishment of operating lease right-of-use assets and lease liabilities</link:label>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_2a42db2f-180e-485c-a3b0-81faf855b07d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, pro forma information, revenue of acquiree since acquisition date, actual</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_db2ee665-b37c-4f0a-a089-6e45bc503479_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_4415701a-9b34-40d8-be51-c6f0977934fa_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod_9eed7003-0ec8-4299-9120-13f6b49a3ef5_negatedTerseLabel_en-US" xlink:label="lab_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in valuation allowance</link:label>
    <link:label id="lab_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod_label_en-US" xlink:label="lab_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Increase (Decrease) During Period</link:label>
    <link:label id="lab_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod_documentation_en-US" xlink:label="lab_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Increase (Decrease) During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod" xlink:href="mygn-20221231.xsd#mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod" xlink:to="lab_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLimitationsOnUse_0609af3b-dd85-4925-a323-218de1db5b30_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit subject to sections 382,383</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLimitationsOnUse_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Limitations on Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="lab_us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_a35a8c2c-8b73-4e67-aab4-260f623d83f3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_c2f94c2c-1387-426f-8a07-590d3d69efbb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company matching contribution, maximum as percentage of employee compensation</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_CARESActOf2020ProviderReliefFundAmount_6b50e449-ec3f-4de9-a9ec-3b0848a698e3_terseLabel_en-US" xlink:label="lab_mygn_CARESActOf2020ProviderReliefFundAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider fund relief under CARES Act</link:label>
    <link:label id="lab_mygn_CARESActOf2020ProviderReliefFundAmount_label_en-US" xlink:label="lab_mygn_CARESActOf2020ProviderReliefFundAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C A R E S Act Of2020 Provider Relief Fund Amount</link:label>
    <link:label id="lab_mygn_CARESActOf2020ProviderReliefFundAmount_documentation_en-US" xlink:label="lab_mygn_CARESActOf2020ProviderReliefFundAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act of 2020 Provider Relief Fund amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CARESActOf2020ProviderReliefFundAmount" xlink:href="mygn-20221231.xsd#mygn_CARESActOf2020ProviderReliefFundAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_CARESActOf2020ProviderReliefFundAmount" xlink:to="lab_mygn_CARESActOf2020ProviderReliefFundAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_55276379-d70f-41b6-9f26-68a4189a0594_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_daa8395d-a6d6-427e-b1c8-37f8ca0ebb45_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_b85930b3-91b9-41b8-bab9-683651e8df12_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance received</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Tenant Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_fedaed00-2cf5-43e0-b8ef-89c3c6d8f540_terseLabel_en-US" xlink:label="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</link:label>
    <link:label id="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_label_en-US" xlink:label="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</link:label>
    <link:label id="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_documentation_en-US" xlink:label="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:href="mygn-20221231.xsd#mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_fd759a71-976d-4b0d-a6b0-2ada0ee7e143_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d25c8782-af47-4d42-b066-10790d7215aa_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_1567578e-7e54-4b8c-a1fc-665359f85976_terseLabel_en-US" xlink:label="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on sale of assets adjusted for transaction fees</link:label>
    <link:label id="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_label_en-US" xlink:label="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition of Assets, Net Of Transaction Fees</link:label>
    <link:label id="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_documentation_en-US" xlink:label="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition of Assets, Net Of Transaction Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" xlink:href="mygn-20221231.xsd#mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" xlink:to="lab_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_e77ec1ea-bc6d-43f2-9444-0e91f127d8f9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4d0be4be-583a-4645-8d75-a98fd4f5a4f7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dbf02178-0716-4607-a93d-474b52a567d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_2fcf2060-b715-4fd6-8835-3c73c6d9880f_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_TumorProfilingMember_85a0ecd3-e34f-4c62-9dfa-ca39d3a1a8ef_terseLabel_en-US" xlink:label="lab_mygn_TumorProfilingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tumor Profiling</link:label>
    <link:label id="lab_mygn_TumorProfilingMember_label_en-US" xlink:label="lab_mygn_TumorProfilingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tumor Profiling [Member]</link:label>
    <link:label id="lab_mygn_TumorProfilingMember_documentation_en-US" xlink:label="lab_mygn_TumorProfilingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tumor Profiling</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TumorProfilingMember" xlink:href="mygn-20221231.xsd#mygn_TumorProfilingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_TumorProfilingMember" xlink:to="lab_mygn_TumorProfilingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e5a5dda-fdfe-4832-a77f-241c593ea4c7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_91a6dc9b-a7ed-4499-89c4-37fd328a58b3_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4930b7d8-fe8d-4642-ac57-0bb5542edf04_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_10b13b4a-bb9f-41d1-bfe3-075a452021b3_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationCARESAct_2111105b-55aa-4d90-b2f8-248269f02fe0_terseLabel_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationCARESAct_label_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation CARES Act</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationCARESAct_documentation_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationCARESAct" xlink:href="mygn-20221231.xsd#mygn_EffectiveIncomeTaxRateReconciliationCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_EffectiveIncomeTaxRateReconciliationCARESAct" xlink:to="lab_mygn_EffectiveIncomeTaxRateReconciliationCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_2367c99b-fb5d-4121-a913-85b5cc8e34e9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e49b77da-477e-4af9-8fb0-1738593aa63f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_219d35d4-99a9-4814-bd23-1d84c930cce4_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ec568203-ee37-4b99-8eeb-f4a7eaafba54_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_042f8de3-475e-422e-904e-69467edabbd1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_e3db08cf-38cc-4fc9-b1b7-f539bce034c1_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_73495cfb-5929-4a86-8599-15ee897a9c62_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8924e703-e12c-4faf-88c0-93180e5515a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_61f97c7e-9ba8-42db-9be3-31ae3b0e51e5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_acf3be62-8aa8-4464-8111-99e58f3231ad_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_AmendmentToCreditAgreementMember_8e0b1029-65b1-4e0d-a033-11976a9ab369_terseLabel_en-US" xlink:label="lab_mygn_AmendmentToCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended facility</link:label>
    <link:label id="lab_mygn_AmendmentToCreditAgreementMember_label_en-US" xlink:label="lab_mygn_AmendmentToCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment To Credit Agreement [Member]</link:label>
    <link:label id="lab_mygn_AmendmentToCreditAgreementMember_documentation_en-US" xlink:label="lab_mygn_AmendmentToCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment to Credit Agreement [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AmendmentToCreditAgreementMember" xlink:href="mygn-20221231.xsd#mygn_AmendmentToCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_AmendmentToCreditAgreementMember" xlink:to="lab_mygn_AmendmentToCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7f842628-27f1-4fbb-96d8-43f28f7ab9ee_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_10c11a8f-8e65-4648-a16e-966977ddd297_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_84a070f6-a36c-40b0-ba63-92a161fe7abe_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs unvested and outstanding, beginning (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_768c39b3-aa0b-4cbc-8be2-d5a4752ccaf8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs unvested and outstanding, ending (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_7a42e20d-7def-4a5b-a990-f8bc27d6639e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LONG-TERM DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_c5be8709-56e4-443a-bb0d-21aa115c46e0_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMPLOYEE DEFERRED SAVINGS PLAN</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_528a6dd6-a800-4c12-a2ce-d827db12af72_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_27550df5-6510-434e-a0ce-c6626e6e78e3_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5b87fb83-f664-4362-94c6-7c572c9731b4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_HereditaryCancerTestingMember_3272f55f-a6d4-4262-83fc-60dfe21a4cf8_terseLabel_en-US" xlink:label="lab_mygn_HereditaryCancerTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hereditary Cancer</link:label>
    <link:label id="lab_mygn_HereditaryCancerTestingMember_label_en-US" xlink:label="lab_mygn_HereditaryCancerTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hereditary Cancer Testing [Member]</link:label>
    <link:label id="lab_mygn_HereditaryCancerTestingMember_documentation_en-US" xlink:label="lab_mygn_HereditaryCancerTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic hereditary cancer testing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_HereditaryCancerTestingMember" xlink:href="mygn-20221231.xsd#mygn_HereditaryCancerTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_HereditaryCancerTestingMember" xlink:to="lab_mygn_HereditaryCancerTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_01771d87-d426-4da3-bad4-51fd2cd939b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_d1d6d7b7-4c85-4aa5-9d65-470054f0c05a_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross decreases - prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_c1121cc3-4839-4500-a027-0e96032be7e1_negatedTerseLabel_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized holding losses</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="mygn-20221231.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c8ad12af-97c1-4abc-a343-d35be51f7189_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_8fd29eca-5455-4755-aaf5-f41dcfcb352a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER LONG-TERM LIABILITIES</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_0179240a-0951-4882-b9c1-34d343ba5222_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technologies</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_841c7cbe-7af8-4ea1-ace1-c376219481ad_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation_28c4af53-71e9-4c04-b123-61de460bcb8c_terseLabel_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible officer compensation</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation_label_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Nondeductible Expense Officers Compensation</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation_documentation_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation nondeductible expense officers compensation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" xlink:href="mygn-20221231.xsd#mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" xlink:to="lab_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_9e1bf9e9-43f6-4647-aac9-3d7a1f2dca4e_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_942337fa-63b8-4cca-871f-870c98263f98_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_741b84df-14e1-4ae3-8630-3b28ca8f184c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Deferred Revenue Balances</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_50b22bbd-a7bf-46d0-bb00-51620a20afa1_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e872a47b-12f5-4699-8e9a-12603d71d99c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement levels based on EPS Targets</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_fbf8774c-d34a-409d-988f-546cca828b96_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net identifiable assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MyriadAutoimmuneAssetsMember_e018aaa4-c211-401c-8e5b-1ce88ba40825_terseLabel_en-US" xlink:label="lab_mygn_MyriadAutoimmuneAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad Autoimmune Assets</link:label>
    <link:label id="lab_mygn_MyriadAutoimmuneAssetsMember_39d24565-7d57-4d13-baa7-18a8e2037b6b_verboseLabel_en-US" xlink:label="lab_mygn_MyriadAutoimmuneAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on sale of Myriad Autoimmune assets</link:label>
    <link:label id="lab_mygn_MyriadAutoimmuneAssetsMember_label_en-US" xlink:label="lab_mygn_MyriadAutoimmuneAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad Autoimmune Assets [Member]</link:label>
    <link:label id="lab_mygn_MyriadAutoimmuneAssetsMember_documentation_en-US" xlink:label="lab_mygn_MyriadAutoimmuneAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad Autoimmune Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneAssetsMember" xlink:href="mygn-20221231.xsd#mygn_MyriadAutoimmuneAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MyriadAutoimmuneAssetsMember" xlink:to="lab_mygn_MyriadAutoimmuneAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_19ee7513-fff9-4a61-90dc-39353e433974_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cumulative Translation Adjustments Included in Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_99fa25bf-de80-4b51-9c4f-a89c4e57d092_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_1d35a6d2-d926-42e8-8d30-46c5e07810d6_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndCashAbstract_44b0f9cb-7a91-4fb6-a5f9-f26d8b45586b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCashAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total:</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCashAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Cash [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCashAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract" xlink:to="lab_us-gaap_InvestmentsAndCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_f5011713-6e42-4546-b67f-bcc2d4f840a1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_1f1c43e0-2ab1-49f4-a4c1-649981e58668_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ebb7a050-4eac-4c89-ba9c-df550bedbce2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9379b26a-4373-420d-bb28-29280b4b1de6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_435d8f1b-8716-4746-9709-9f6be7f2999b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_31747497-8dfd-4d2d-9ebd-fa531098e5a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relative Total Stockholders Return</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_9d05aa16-c7b9-4cf4-99fb-4f363409c0cc_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b8f3eabd-7962-4627-8d3c-7d2ae4bdd6a0_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8c5e3b3d-aa35-4852-8a9b-927a0743e969_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2162c186-be6c-41c0-8d77-1c86f71e9936_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_d0042f73-d57a-48da-bee6-cc8893bdbdf6_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_c848928b-2e7e-4cb9-b601-0271589d36f7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements_874bfe62-91d4-4568-baa5-f9ace0d6e8c0_terseLabel_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible legal settlement</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements_label_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Non Deductible Legal Settlements</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements_documentation_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation non deductible legal settlements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" xlink:href="mygn-20221231.xsd#mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" xlink:to="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_9d90c75f-0ede-49f3-ab5a-a30b5e112f0c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3c131e3d-e1fd-4ffb-9f33-75f95eb02c35_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_f023f1b1-1b96-4edc-99b7-f87870d5b055_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_4f17d2cc-8764-471f-a1e6-fcad330a0821_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a172b16-1fb4-4473-94ce-5daddf03e2a0_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_564884cf-de66-4018-872f-df44894023d3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3b1811e9-adff-4436-b0d3-a92486086cea_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_242c3514-c084-4329-b14a-283171cc3828_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_f6682bfe-1362-4a65-a8ab-3f2d474dd96c_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of business</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Interest in Consolidated Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_55d58979-14e4-4fc8-8b60-8432184b144b_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_05ec5658-cf84-4996-9cbf-4c344a9c7440_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_8a7a62b4-5ed9-4aa0-b914-06d045693c0f_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_a3859f71-d8eb-48be-bc48-0c64148fa054_verboseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_8c0daf18-0a45-4edf-95aa-9497f7fd7eb2_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_abffaaf3-b600-4d11-afb7-f3fb8e211ef7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_ec4d8000-63ac-47a3-b660-d50ed7826221_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0adca5f4-482e-4b7b-b1ee-a01e27e9f002_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_636ba35d-f832-44ca-8b0c-5b8e6e704132_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_eabde61c-74db-4b0f-99b1-71f5247c3232_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period for recognition (years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_00164e03-d40c-455d-8302-2dfcec00df3f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, unrealized loss position, accumulated loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ad3a592e-ed4d-41ad-8758-e808b2e36fce_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted average remaining contractual life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_41f24c47-6342-4d4a-ab90-25a6132824bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amortizable Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_a14b8238-ab4e-4022-8ef2-8427ca9c10f8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash purchase price paid</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_13dcca3c-4b96-4c08-8107-2b17f3880698_verboseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_a946dece-851e-4650-9ef7-ab56ca385836_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_5d0ffcba-29da-4151-9080-d6443c9aae9a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MyriadRBMIncMember_a44d9295-8cd8-4933-b8d8-0560ac497ef8_terseLabel_en-US" xlink:label="lab_mygn_MyriadRBMIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad RBM, Inc.</link:label>
    <link:label id="lab_mygn_MyriadRBMIncMember_262a8037-8639-4617-95a9-7f3b8593ab99_verboseLabel_en-US" xlink:label="lab_mygn_MyriadRBMIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of Myriad RBM, Inc.</link:label>
    <link:label id="lab_mygn_MyriadRBMIncMember_label_en-US" xlink:label="lab_mygn_MyriadRBMIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad RBM, Inc [Member]</link:label>
    <link:label id="lab_mygn_MyriadRBMIncMember_documentation_en-US" xlink:label="lab_mygn_MyriadRBMIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad RBM, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncMember" xlink:href="mygn-20221231.xsd#mygn_MyriadRBMIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MyriadRBMIncMember" xlink:to="lab_mygn_MyriadRBMIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4b87241a-0cfe-41ff-9397-15a9cdc99e54_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_e4b82f14-2895-4176-a6ec-25b9f52a8767_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_2177d770-31e2-418a-8643-e57d906c4055_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_2a53fc92-f839-469f-b935-b731b323518c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation adjustments recognized in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_TestingRevenueMember_ad2f8b77-42e3-40f2-b66a-3a5d27e8959c_terseLabel_en-US" xlink:label="lab_mygn_TestingRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Testing revenue</link:label>
    <link:label id="lab_mygn_TestingRevenueMember_label_en-US" xlink:label="lab_mygn_TestingRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Testing Revenue [Member]</link:label>
    <link:label id="lab_mygn_TestingRevenueMember_documentation_en-US" xlink:label="lab_mygn_TestingRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic testing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TestingRevenueMember" xlink:href="mygn-20221231.xsd#mygn_TestingRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_TestingRevenueMember" xlink:to="lab_mygn_TestingRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2656d208-57d0-4ffc-ba35-1ae082999ca5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_20a38799-95e0-4095-bf21-daea48ab73d6_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DeferredTaxAssetsLeaseLiabilities_107eaa44-d4ea-4c74-89c1-f0a9432f86df_terseLabel_en-US" xlink:label="lab_mygn_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_mygn_DeferredTaxAssetsLeaseLiabilities_label_en-US" xlink:label="lab_mygn_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:label id="lab_mygn_DeferredTaxAssetsLeaseLiabilities_documentation_en-US" xlink:label="lab_mygn_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets lease right-of-use asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DeferredTaxAssetsLeaseLiabilities" xlink:href="mygn-20221231.xsd#mygn_DeferredTaxAssetsLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_mygn_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_2352cafe-4b9e-4ce9-998d-79c83f80a4e8_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input, expected term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48d6eaac-c08d-4dbe-a3ad-de535cfddbaa_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e63f55bb-e581-4e7d-b1f1-f2e8469e5fd1_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c969f36b-2e56-4130-aff2-f6c0cc23c258_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d73b1a62-8043-4f6a-9c4a-a41826c53a4a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_37b5e17b-75f5-4842-9c38-141db70f51b9_negatedLabel_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_label_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract, Revenue Recognized</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_documentation_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:href="mygn-20221231.xsd#mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:to="lab_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_LineOfCreditFacilityCreditExposureThreshold_33ac27b4-d205-4b45-98a6-c0aac3092f12_terseLabel_en-US" xlink:label="lab_mygn_LineOfCreditFacilityCreditExposureThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, credit exposure threshold</link:label>
    <link:label id="lab_mygn_LineOfCreditFacilityCreditExposureThreshold_label_en-US" xlink:label="lab_mygn_LineOfCreditFacilityCreditExposureThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Credit Exposure Threshold</link:label>
    <link:label id="lab_mygn_LineOfCreditFacilityCreditExposureThreshold_documentation_en-US" xlink:label="lab_mygn_LineOfCreditFacilityCreditExposureThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Credit Exposure Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LineOfCreditFacilityCreditExposureThreshold" xlink:href="mygn-20221231.xsd#mygn_LineOfCreditFacilityCreditExposureThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_LineOfCreditFacilityCreditExposureThreshold" xlink:to="lab_mygn_LineOfCreditFacilityCreditExposureThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_3bf32449-cee4-494c-861c-50342bafbdc5_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_c5821aa5-df3f-424e-a966-a385460463f2_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_5f9e7c76-bad7-47a2-9a65-380b812aae02_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_f15ecbd1-b1ce-4fd6-aaba-08179c41a476_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9a7888e0-867a-48dd-b305-0818960efb6c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_8373e852-8308-4ba2-aff7-601fa8a8bc48_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_d741e662-2693-424c-bde8-2527e5b146b5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_fe63ae1f-e1dd-4c57-b5d5-81c27ecf58fd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d70334ef-e98b-429e-95aa-d46b7dfba1df_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_18642c03-9d7f-4bc9-908d-6f668d289daf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_2a4887a8-ffa8-4d52-a5f8-198fcdf6bcf0_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_9fd348b6-d2ce-41af-a389-eee0ea0a32db_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_bd82c82a-81fb-4ae5-86b8-d62a8fa7956c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a376ca0a-61dc-450f-ab12-8ccb3827c64f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1825c11b-ba34-4e45-aae9-1efe1d28f00d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_f12dfd17-93b7-44df-99d9-32fe7af947bf_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7372b6ad-bd00-4c06-89a2-1831a8adfe4b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_5ef5ed3d-824c-48ae-84a4-24db8f76d164_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, Weighted average remaining contractual life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_5fec46b4-c977-4651-9f63-9095c0d0d3d2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_48598764-17c1-412a-a5b6-6e28610246a7_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross increases - prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9613131d-1977-4353-a50d-56db907c7ff2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, Weighted average remaining contractual life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ClinicReportingUnitMember_d8e7eb07-d873-4546-b8bf-12b48b7a9577_terseLabel_en-US" xlink:label="lab_mygn_ClinicReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinic reporting unit</link:label>
    <link:label id="lab_mygn_ClinicReportingUnitMember_label_en-US" xlink:label="lab_mygn_ClinicReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinic Reporting Unit [Member]</link:label>
    <link:label id="lab_mygn_ClinicReportingUnitMember_documentation_en-US" xlink:label="lab_mygn_ClinicReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinic Reporting Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ClinicReportingUnitMember" xlink:href="mygn-20221231.xsd#mygn_ClinicReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ClinicReportingUnitMember" xlink:to="lab_mygn_ClinicReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_d979fe88-3f5b-48fa-a956-6f1c765f7fd1_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5ec48a5c-8bb4-406e-9d5f-dadde4bd3071_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_e08b097e-1554-497d-98e6-3d470aa34d5d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_737c61fd-44c3-4a52-95be-3048173118a6_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_f1865389-0646-48ac-94c5-db98b96dc04c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credit</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a4dfb101-a45f-4aa8-b2b4-8b22f2faef4d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_e561e7c7-b6a5-49ac-aefd-8f636594e885_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7b15f6dd-8bc9-406f-9727-5e936d0e365b_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_5bffcd14-c61a-4370-8d2a-a979a2d5f383_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Operating Loss and Research Credit Carryforwards (Tax Effected)</link:label>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_RefundsPayableAndReserveCurrent_5359c29f-a0b5-430e-bffa-fbff02fcc436_terseLabel_en-US" xlink:label="lab_mygn_RefundsPayableAndReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refunds payable and reserves</link:label>
    <link:label id="lab_mygn_RefundsPayableAndReserveCurrent_label_en-US" xlink:label="lab_mygn_RefundsPayableAndReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refunds Payable And Reserve, Current</link:label>
    <link:label id="lab_mygn_RefundsPayableAndReserveCurrent_documentation_en-US" xlink:label="lab_mygn_RefundsPayableAndReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refunds Payable And Reserve, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RefundsPayableAndReserveCurrent" xlink:href="mygn-20221231.xsd#mygn_RefundsPayableAndReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_RefundsPayableAndReserveCurrent" xlink:to="lab_mygn_RefundsPayableAndReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_5a1ccce2-8441-4a94-bb6d-757cae15ae00_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_d6404800-2de2-47a8-aa37-2972d7b6b918_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_24189c2a-33e3-4b82-9901-4d7bddbbec8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MedicareMember_6e20f3bd-efe0-45fa-8950-3821a3f21e6f_terseLabel_en-US" xlink:label="lab_mygn_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_mygn_MedicareMember_label_en-US" xlink:label="lab_mygn_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_mygn_MedicareMember_documentation_en-US" xlink:label="lab_mygn_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MedicareMember" xlink:href="mygn-20221231.xsd#mygn_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MedicareMember" xlink:to="lab_mygn_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_824c2e3d-448d-45e8-81da-e9f823d9199f_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_58235790-a112-4c27-b8d8-338afaa93e25_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_10cd4071-30cc-47ad-a48b-96bb1a7c9828_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_10690aa1-2469-43cf-a341-a503c2344efa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BUSINESS ACQUISITION</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_ae545850-9bc1-45da-8d2c-56899e9e3f36_terseLabel_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immaterial Prior Period Medicare Claims</link:label>
    <link:label id="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_label_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Error Correction, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:to="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OperatingLossCarryforwardsExpirationYear_a27db734-aacd-44fc-b9e0-c14cf883d040_terseLabel_en-US" xlink:label="lab_mygn_OperatingLossCarryforwardsExpirationYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss, expiration in year</link:label>
    <link:label id="lab_mygn_OperatingLossCarryforwardsExpirationYear_label_en-US" xlink:label="lab_mygn_OperatingLossCarryforwardsExpirationYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label id="lab_mygn_OperatingLossCarryforwardsExpirationYear_documentation_en-US" xlink:label="lab_mygn_OperatingLossCarryforwardsExpirationYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiration Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLossCarryforwardsExpirationYear" xlink:href="mygn-20221231.xsd#mygn_OperatingLossCarryforwardsExpirationYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OperatingLossCarryforwardsExpirationYear" xlink:to="lab_mygn_OperatingLossCarryforwardsExpirationYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6703a78b-6100-4432-8a66-72dd00dd3204_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_221e0413-75a1-4cf2-960d-7799941f3da0_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of Purchase Price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_37b4a1ce-9d09-4199-b086-05756c768ca1_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fc8e6be0-7906-4ad9-8e9c-2783a14aa184_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f2f032ab-26b9-420c-9fe9-534de2e29cb7_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_a4534940-a9f1-465e-9fd0-be1e54806029_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (in percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_4f8eaa00-e953-47d7-8424-61638d1e7f15_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_b3787877-1399-47c4-8a81-d11f07a02d19_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_cba06d60-3a05-44db-a0c4-93db5c6de88c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MARKETABLE INVESTMENT SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_762ce9c2-c3be-4ca1-a549-d73987afcfb9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_SouthSanFranciscoCaliforniaMember_e552130f-9ff9-4d6b-8d41-affaa3f6cbf7_terseLabel_en-US" xlink:label="lab_mygn_SouthSanFranciscoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South San Francisco, California</link:label>
    <link:label id="lab_mygn_SouthSanFranciscoCaliforniaMember_label_en-US" xlink:label="lab_mygn_SouthSanFranciscoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South San Francisco, California [Member]</link:label>
    <link:label id="lab_mygn_SouthSanFranciscoCaliforniaMember_documentation_en-US" xlink:label="lab_mygn_SouthSanFranciscoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South San Francisco, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_SouthSanFranciscoCaliforniaMember" xlink:href="mygn-20221231.xsd#mygn_SouthSanFranciscoCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_SouthSanFranciscoCaliforniaMember" xlink:to="lab_mygn_SouthSanFranciscoCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7604f801-8e1e-4366-806d-a60cc39f35bd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_79128cef-b6c9-4a62-8595-e864e2f75b9c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of RSUs outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_e3066f19-ff57-4794-9427-40b4bbe412a3_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_GoodwillAndIntangibleAssetsTable_1cd360ec-3ec8-44a0-9248-5c5f2d09295d_terseLabel_en-US" xlink:label="lab_mygn_GoodwillAndIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill And Intangible Assets [Table]</link:label>
    <link:label id="lab_mygn_GoodwillAndIntangibleAssetsTable_label_en-US" xlink:label="lab_mygn_GoodwillAndIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill And Intangible Assets [Table]</link:label>
    <link:label id="lab_mygn_GoodwillAndIntangibleAssetsTable_documentation_en-US" xlink:label="lab_mygn_GoodwillAndIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GoodwillAndIntangibleAssetsTable" xlink:href="mygn-20221231.xsd#mygn_GoodwillAndIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable" xlink:to="lab_mygn_GoodwillAndIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_0fded6eb-ccfd-4fd6-8da4-4a8c208b7ef4_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8e5270dd-5dc3-4ea2-9ccd-e2112be72fa6_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying amount, total</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_62edfd87-ac03-4b06-bcab-25cec0d7b417_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_45f9ce13-32e4-459d-935d-f4004a6972f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Carrying Amount of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_c4ae217d-b835-4100-a30b-1a68339bbda1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fa3dd5c1-7b1f-4c89-8976-79a9cb603010_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_b8c39831-00cd-42c0-8b38-d60c7617a67a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of restricted stock units that vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_660a2a40-6c88-45b1-a11c-b25d306550cf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_d07902b8-7c6d-44c6-9903-afa8cf42819f_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized costs incurred to obtain or fulfill contract</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostGross" xlink:to="lab_us-gaap_CapitalizedContractCostGross" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_AssetsLessCashCashEquivalentsAndInvestments_c5c958e5-d46d-4b1f-a57b-d6ef28a3d9e1_verboseLabel_en-US" xlink:label="lab_mygn_AssetsLessCashCashEquivalentsAndInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_mygn_AssetsLessCashCashEquivalentsAndInvestments_label_en-US" xlink:label="lab_mygn_AssetsLessCashCashEquivalentsAndInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Less Cash, Cash Equivalents, And Investments</link:label>
    <link:label id="lab_mygn_AssetsLessCashCashEquivalentsAndInvestments_documentation_en-US" xlink:label="lab_mygn_AssetsLessCashCashEquivalentsAndInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Less Cash, Cash Equivalents, And Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AssetsLessCashCashEquivalentsAndInvestments" xlink:href="mygn-20221231.xsd#mygn_AssetsLessCashCashEquivalentsAndInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_AssetsLessCashCashEquivalentsAndInvestments" xlink:to="lab_mygn_AssetsLessCashCashEquivalentsAndInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_dfc8dec2-1f81-4d12-9f59-be2273cad300_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_dd9a0d4b-30eb-4bef-a824-6ebaa25a318a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_409604e8-f7c5-4d23-a550-d5113fb831c0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_592830db-d4d7-407f-9889-be20ccc8054f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Myriad Genetics, Inc. stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_022f88f3-9115-458e-a1f8-ba9357098dc2_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7b650e96-4701-42fa-8ffc-08b05be1ada9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_fbdd767f-f8fd-4991-b4ab-4a140452e169_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, Due after five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock_c994e901-2622-4da8-bf65-aad17b3ba781_terseLabel_en-US" xlink:label="lab_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Aggregate Intrinsic Value</link:label>
    <link:label id="lab_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock_label_en-US" xlink:label="lab_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Compensation Arrangement By Share-Based Payment Award, Aggregate Intrinsic Value [Table Text Block]</link:label>
    <link:label id="lab_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock_documentation_en-US" xlink:label="lab_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Compensation Arrangement By Share-Based Payment Award, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock" xlink:href="mygn-20221231.xsd#mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock" xlink:to="lab_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_904924c9-6bfa-47c4-add8-fd4a44405164_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_7b7db6a6-36c1-4afc-872f-eb9de3d337ce_terseLabel_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on inventory</link:label>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_label_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) On Inventory</link:label>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_documentation_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) On Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" xlink:href="mygn-20221231.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" xlink:to="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_9696a813-7db1-4a57-9901-54af20df1a2f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_59b5d040-bb5d-441a-8784-c35f02f467d5_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_2d19f698-e083-4cf5-b908-1ecd49374e83_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible meals and entertainment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_966dc51e-4115-4a70-ab12-d8b780993d77_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_afe4ff81-a9e8-4160-bbfb-ddc3987f51ff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_225b2f89-b231-46de-85d2-2cd77edcfc03_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_827d4eda-2b63-455a-a282-125966d8bd2a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b230f2b1-e7a4-48cb-8502-a195a9462cd2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b68aed96-b9cf-4a76-8fa3-6346b0da29e5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Fair Value of Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_a2e2239a-70df-44c5-94d6-5bbf803114fa_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_a63508c9-1977-45d9-b461-c413a224004c_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_13990356-3252-4f6f-a0a6-5b522829afcf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment sold</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_4d679bb1-fb2d-41c6-b745-41c437f370cf_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_5304469f-fdee-42fd-ab02-e448fdbb7802_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_CARESActOf2020MedicarePaymentAmount_104a5343-cf5e-4ccb-a750-510f944384bd_terseLabel_en-US" xlink:label="lab_mygn_CARESActOf2020MedicarePaymentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Medicare payments to provide relief from economic impacts of COVID-19</link:label>
    <link:label id="lab_mygn_CARESActOf2020MedicarePaymentAmount_label_en-US" xlink:label="lab_mygn_CARESActOf2020MedicarePaymentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Of 2020 Medicare Payment Amount</link:label>
    <link:label id="lab_mygn_CARESActOf2020MedicarePaymentAmount_documentation_en-US" xlink:label="lab_mygn_CARESActOf2020MedicarePaymentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act of 2020 medicare payment amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CARESActOf2020MedicarePaymentAmount" xlink:href="mygn-20221231.xsd#mygn_CARESActOf2020MedicarePaymentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_CARESActOf2020MedicarePaymentAmount" xlink:to="lab_mygn_CARESActOf2020MedicarePaymentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_64e4c6de-d900-40a8-971d-d482de5d333f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_91395077-4432-4d62-9958-84c0acc881bd_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital loss</link:label>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_label_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLossCarryforwardMember" xlink:to="lab_us-gaap_CapitalLossCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_d21235e4-fa79-41ba-9f82-39b213557560_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_91c4f19a-3b73-45be-9fbe-7a21e128487c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c1351e31-3b7d-410d-a62c-d60683b51246_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e4ac049c-b961-4f8e-9194-8d9b1c7c7742_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_0b44ff01-01fc-47a2-a307-68bdcd6abdeb_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_cd967c26-d896-4f15-97e8-465a0a6006be_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7606fda3-8f4b-4dd1-b32d-b17b83ec529d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_b8024ad6-acc7-40ae-986d-36a14ebf0c4b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_7c81397c-9dbe-4d04-ba5a-d4377cd484c4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_51598f50-d7a9-474c-90ca-7c2ae55338da_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Investment Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_30298b1d-75e9-416c-9512-fddbd065890a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_e361069a-b379-493a-9584-cd9ce05c0d86_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and marketable investment securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_c9a6049d-1a67-483e-b6a0-17c3f8f91f15_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Other Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6e79dd80-d777-4641-9216-d6941ee00703_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_3d243e66-994b-426e-9dee-d89a3377513f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease extension term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_12ce9596-7fe3-428a-97b5-df508232f45c_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable investment securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_befd4e84-754c-41b6-ba1b-8746f02e3561_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_46f113ce-99c3-4741-ab07-85f2475ed9df_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_69791cf0-cb47-42a7-a804-ca3a4b09d195_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_5fff0115-4349-4d25-936e-0c4460fa11e1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4e3f4192-2ee6-41bf-a369-2b5f16be4508_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_022d3589-eea8-4153-a024-066e564e75b7_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ed051760-b70d-4cdd-8abb-a08af3f41501_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration recognized at acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_3b4b1ea7-c480-4ebf-b30d-8005adf7f006_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_13f3fa50-8b8d-4a6d-ae47-2c193c7e782c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Geographical Region</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_fc28db7f-b8e1-4110-8ca5-69c8116ec85a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4cab0d27-875e-4b84-b6e3-4db9b7d541eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_3ebef56e-0db9-4de1-9048-02d11bea5236_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares purchased under the plans (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_42b97640-a938-495b-9bbc-673d50c46041_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_01204c4d-41da-47c9-a888-e9d80c06cbff_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal agency issues</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_81ec8d75-fc30-4ceb-8e2c-f890b961b41d_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal agency issues</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_331243b1-1d67-474a-a43e-8a2c717f1a91_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_f089731e-cd24-456d-8c7b-e190e1ab1f1d_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DebtInstrumentFloorPercentage_114c1b39-f5e6-4752-8d5a-9445983d45eb_terseLabel_en-US" xlink:label="lab_mygn_DebtInstrumentFloorPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR floor (percent)</link:label>
    <link:label id="lab_mygn_DebtInstrumentFloorPercentage_label_en-US" xlink:label="lab_mygn_DebtInstrumentFloorPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Floor Percentage</link:label>
    <link:label id="lab_mygn_DebtInstrumentFloorPercentage_documentation_en-US" xlink:label="lab_mygn_DebtInstrumentFloorPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Floor Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtInstrumentFloorPercentage" xlink:href="mygn-20221231.xsd#mygn_DebtInstrumentFloorPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DebtInstrumentFloorPercentage" xlink:to="lab_mygn_DebtInstrumentFloorPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_a6c12510-756c-4a92-ab26-1ef2d125d2bd_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9d3adb3d-18c4-41c0-ae3b-bf18787bd8fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_b7b8a635-e0d8-4068-b5b0-b1eba06559a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes:</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_92cb6d9a-a0ee-49ca-97d3-bec302a5b8fa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_WestSaltLakeCityLeaseMember_0f01a8e3-756e-4a62-9d97-a8f0d5e7d4fa_terseLabel_en-US" xlink:label="lab_mygn_WestSaltLakeCityLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">West Salt Lake City Lease</link:label>
    <link:label id="lab_mygn_WestSaltLakeCityLeaseMember_label_en-US" xlink:label="lab_mygn_WestSaltLakeCityLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">West Salt Lake City Lease [Member]</link:label>
    <link:label id="lab_mygn_WestSaltLakeCityLeaseMember_documentation_en-US" xlink:label="lab_mygn_WestSaltLakeCityLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">West Salt Lake City Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_WestSaltLakeCityLeaseMember" xlink:href="mygn-20221231.xsd#mygn_WestSaltLakeCityLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_WestSaltLakeCityLeaseMember" xlink:to="lab_mygn_WestSaltLakeCityLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_1f5c84ab-195f-42fc-beca-db7f489c44d1_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_70235b40-8ddb-4c4e-b5bf-d26e9a51b5ab_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_509db93f-7877-45b7-b9af-05ac8825f33b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recorded Amortization for Intangible Assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_fa44b562-6a95-4a2a-bc1c-bb3b280f71a8_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0e1b1508-fff7-4504-a71e-d2c63dec2237_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_0393fb81-b7c7-435b-95c2-e1ff7a20b69a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_382a9998-62e8-44b3-8f8a-74cb7beaf018_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1481f74e-a47b-45b9-90f6-7a28c0d3a253_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs unvested and outstanding, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0ca4d9b9-ea69-459d-93e1-0e019690f694_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs unvested and outstanding, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_ae046ae3-a34b-4df2-aa51-bf88cacce963_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments_8729b3b2-80d6-4277-a971-bf14dbf9b458_terseLabel_en-US" xlink:label="lab_mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty and working capital adjustment</link:label>
    <link:label id="lab_mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments_label_en-US" xlink:label="lab_mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Warranty And Working Capital Adjustments</link:label>
    <link:label id="lab_mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments_documentation_en-US" xlink:label="lab_mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Warranty And Working Capital Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments" xlink:href="mygn-20221231.xsd#mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments" xlink:to="lab_mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_addb3866-2cf7-4682-a622-0c5c85bde7e7_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_a75f1d10-6368-4dc0-919d-85ea95f2ffc5_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_0be27df4-8d5f-4736-9502-0a4b8219249d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying amount, amortizable</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_47360028-737f-442f-9e87-0dd4037466e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_930ad744-d113-49e1-b46f-ccd5fecbd683_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IncomeTaxReconciliationAssetImpairment_947a791f-d4c6-4d9c-bde1-05216a47e450_terseLabel_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationAssetImpairment_label_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Asset Impairment</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationAssetImpairment_documentation_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation asset impairment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationAssetImpairment" xlink:href="mygn-20221231.xsd#mygn_IncomeTaxReconciliationAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IncomeTaxReconciliationAssetImpairment" xlink:to="lab_mygn_IncomeTaxReconciliationAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_f0e3cdbf-5b1e-4136-bc72-686576cab746_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_GatewayGenomicsLLCMember_b2aa2943-c31c-44d5-872a-9cb06c6d806f_terseLabel_en-US" xlink:label="lab_mygn_GatewayGenomicsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gateway Genomics, LLC</link:label>
    <link:label id="lab_mygn_GatewayGenomicsLLCMember_label_en-US" xlink:label="lab_mygn_GatewayGenomicsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gateway Genomics, LLC [Member]</link:label>
    <link:label id="lab_mygn_GatewayGenomicsLLCMember_documentation_en-US" xlink:label="lab_mygn_GatewayGenomicsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gateway Genomics, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GatewayGenomicsLLCMember" xlink:href="mygn-20221231.xsd#mygn_GatewayGenomicsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_GatewayGenomicsLLCMember" xlink:to="lab_mygn_GatewayGenomicsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_72b9b88b-8906-4544-9d4f-a32fa56ea695_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_44fd3da5-a7f1-4f66-847b-876c41e6e83e_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_98b0660b-b435-4b93-93cc-9be0f1403c5f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized holding losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_3bb7459e-22b2-42a6-b580-840588d67cae_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_631ece1d-07b5-45cc-b4ba-8086321ba824_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss subject to sections 382,383</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Limitations on Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dfe9c7d1-0537-480f-ad49-42d45e675989_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_CostOfOtherRevenueMember_4438d2bc-8eb7-4112-8252-97487f0d00cc_terseLabel_en-US" xlink:label="lab_mygn_CostOfOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of other revenue</link:label>
    <link:label id="lab_mygn_CostOfOtherRevenueMember_label_en-US" xlink:label="lab_mygn_CostOfOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Other Revenue [Member]</link:label>
    <link:label id="lab_mygn_CostOfOtherRevenueMember_documentation_en-US" xlink:label="lab_mygn_CostOfOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primary financial statement caption in which the reported facts about the cost of pharmaceutical and clinical services expense have been included.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfOtherRevenueMember" xlink:href="mygn-20221231.xsd#mygn_CostOfOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_CostOfOtherRevenueMember" xlink:to="lab_mygn_CostOfOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_375a0e01-b789-4af8-afc0-a011e08e4131_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_a089d2fe-1026-4ac0-aece-13443b065333_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_PrenatalTestingMember_db5959fb-1916-4c0c-b15e-f2c6016aa6a7_terseLabel_en-US" xlink:label="lab_mygn_PrenatalTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prenatal</link:label>
    <link:label id="lab_mygn_PrenatalTestingMember_label_en-US" xlink:label="lab_mygn_PrenatalTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prenatal Testing [Member]</link:label>
    <link:label id="lab_mygn_PrenatalTestingMember_documentation_en-US" xlink:label="lab_mygn_PrenatalTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular diagnostic Prenatal testing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PrenatalTestingMember" xlink:href="mygn-20221231.xsd#mygn_PrenatalTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_PrenatalTestingMember" xlink:to="lab_mygn_PrenatalTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_60475cdc-cfe4-4d48-bf99-f4f842bccb8a_negatedLabel_en-US" xlink:label="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_label_en-US" xlink:label="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Unrecognized Tax Benefits</link:label>
    <link:label id="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_documentation_en-US" xlink:label="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in unrecognized tax benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:href="mygn-20221231.xsd#mygn_IncreaseDecreaseInUnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:to="lab_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6f650501-d57a-421c-af7a-6e581bfcc62f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_dde6106e-c675-43d8-8148-ae8ca277a64f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained_1c39cd3a-d7f9-4a21-89b5-ffdffe1e3426_terseLabel_en-US" xlink:label="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized due to expanded local coverage determination for which revenue was previously constrained</link:label>
    <link:label id="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained_label_en-US" xlink:label="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Adjustment To Revenue For Expanded Coverage, Previously Constrained</link:label>
    <link:label id="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained_documentation_en-US" xlink:label="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Adjustment To Revenue For Expanded Coverage, Previously Constrained</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" xlink:href="mygn-20221231.xsd#mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" xlink:to="lab_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_030a0a47-7c6d-4506-8d65-d6ab7d2eba4b_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_3033d4a8-1af8-4c97-bc1d-244ffe149d94_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bcfca7aa-d235-4c85-8bd9-b9ce677c4dde_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_88c40cc1-70fd-448c-8266-d137e5d0ae0a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock option and employee stock purchase plan expense</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_eb352ca3-3cf2-4090-ae9b-0516376e3b53_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9330b1ff-6f50-41d4-8644-c1ad7c8a972e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_a6084ac6-6616-412f-a94e-0dca39713725_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_227914cd-cf23-4546-b002-f98ece968ef1_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_NonEmployeeDirectorMember_8a797581-0b5c-4318-8979-bfc8f70c88f9_terseLabel_en-US" xlink:label="lab_mygn_NonEmployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee Director</link:label>
    <link:label id="lab_mygn_NonEmployeeDirectorMember_label_en-US" xlink:label="lab_mygn_NonEmployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Director [Member]</link:label>
    <link:label id="lab_mygn_NonEmployeeDirectorMember_documentation_en-US" xlink:label="lab_mygn_NonEmployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non employee director.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonEmployeeDirectorMember" xlink:href="mygn-20221231.xsd#mygn_NonEmployeeDirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_NonEmployeeDirectorMember" xlink:to="lab_mygn_NonEmployeeDirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_7863526b-9a8a-4712-bcfb-2356a65470f9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_94aa62bc-4f79-415b-95a1-ac9e1593cd98_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_CostOfTestingMember_0be1a091-80fb-4d57-a2ec-d766f8b79d0d_terseLabel_en-US" xlink:label="lab_mygn_CostOfTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of testing revenue</link:label>
    <link:label id="lab_mygn_CostOfTestingMember_label_en-US" xlink:label="lab_mygn_CostOfTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Testing [Member]</link:label>
    <link:label id="lab_mygn_CostOfTestingMember_documentation_en-US" xlink:label="lab_mygn_CostOfTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primary financial statement caption in which the reported facts about the cost of molecular diagnostic testing expense have been included.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfTestingMember" xlink:href="mygn-20221231.xsd#mygn_CostOfTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_CostOfTestingMember" xlink:to="lab_mygn_CostOfTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_6e8af2a8-2efa-4e4c-9dd4-1fed6df6e027_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_c444b346-7822-47de-92b3-f16a389edeb6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_e19c12dc-5b1c-494a-a8d2-11bb6554ebd3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_64a14a1a-b7d0-4a15-9bd7-65e19afef2c6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_eb4a5dba-4bbc-49a9-999d-77c864637e60_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e8a56adb-3070-402e-b054-be0f9c66bddc_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_64c7c819-6320-4f83-a5dd-14d591ec6c5e_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_8ab95387-1203-49f4-b5af-3dcb9120e62b_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_0588ac0f-025d-4fd0-bd30-736dbef3852d_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount at end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_de75974e-02fd-401e-af28-10f2a7c92056_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and long-lived asset impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_61f07918-160e-49ac-a861-4e8c436d9229_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill and long-lived assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_586ead15-c556-4d9c-aa05-8519c06b5d69_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_daa754eb-35c8-4edc-8762-3f987bd70914_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_09b131e5-d9d5-4626-81a3-7d41611fc087_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_9953c7d0-1790-46df-bd4b-506c0df6ac76_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_757e4efa-dd8d-4714-bd64-307eeda8f218_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_54523f10-bc45-4820-981a-7daac91801e6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GOODWILL AND INTANGIBLE ASSETS</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e1f0021e-41fa-47e3-a427-60779e17067b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_74ee985a-0e1a-4895-96bb-f270d5291847_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_67fb6ec3-e01c-498b-a66c-73a94201851c_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentContractsConcentrationRiskMember_121f6195-98bc-4648-9d55-b18761e6bfb6_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Contracts Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GovernmentContractsConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Contracts Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:to="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_b14f68cf-0a71-420d-9c7a-ee7a962c3198_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1d314614-3b8f-4667-ae4e-5b1408761c95_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_fa1ab550-6134-4244-9c64-3191e9d02a47_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6515a614-8865-4e47-85c9-801c75b5bf79_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8d923448-63c3-49cd-a2cc-e3c0715b3c7a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_deb66115-0a63-4440-a5d4-2fa17bd44a42_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bc67c591-f586-4596-b346-1b3f6ab48238_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_0723ba1d-fcc7-4020-a0ce-76f851d21118_terseLabel_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized holding gains</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="mygn-20221231.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_60ddb9ad-0429-4ecf-b66e-4de31ad6672c_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1a310513-b04d-4061-838d-8b5b6c7eb7ce_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_c2df9b1c-7e2f-41d2-93bf-65cee8bed726_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_2f9dd552-ea11-4bd4-97f8-0b9c4a5fbf40_verboseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_bad35c1b-8e33-4f86-b9e6-05acd744680e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, non current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_67e9189d-7c08-46d8-8f20-609a6fe8f121_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_3f4dde6a-5f95-49fe-8a8e-82a1fd4333ae_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5beb8579-cd74-428f-b24d-fbbc98d0a6c9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_83af6438-f328-41fe-8bd5-c027d7150cd7_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b7368ea5-472a-4eb5-80b7-6f18994a6770_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_90dfa944-08aa-4374-887c-dfb7c655c42c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Other Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a1ba0c3f-b05d-4823-ac8c-3bbadeeb92c6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_92b89422-5975-471c-abfa-2865e853e984_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares per participant per offering period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_9e1805fb-acb4-4506-8831-68194a6256a0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_449cb0bd-e7e2-4bd7-8a0b-b3af02e37043_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_fb2ccb9e-c859-4476-8990-942db323b4b0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_cb270a26-c54b-4d91-8863-182c5aedf739_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_79044fac-da06-4932-90bb-8ef7f55af993_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value, 81.2 and 80.0 shares outstanding at December 31, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_08a3930b-d43b-477c-a740-cc2a9c4a5913_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4019151b-bcc0-4719-ab10-1b96a6b54a11_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_837a8996-4221-491c-bd9b-90b771e9a9dc_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue increase (decrease) due to changes in estimated transaction price due to contractual adjustments</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_b27723d9-63da-4a72-a62f-0c1dfbc7a6eb_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents allegedly infringed</link:label>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:to="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a59829c7-e0fe-4116-9472-79eacd19c075_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eefc04e3-529d-4d64-a581-d6e32d0b76b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ba0cda28-b94b-47d3-9b54-6f4a5027e557_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Dilutive Common Shares</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9b906080-49c5-46b2-8e93-ec076a33e53d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options fully vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_481b08ad-667b-4919-b672-b42e35800cdb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IncreaseDecreaseInEarningsLossPerShare_87da828b-0ed8-43eb-b49c-dde00344af72_terseLabel_en-US" xlink:label="lab_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in earnings (loss) per share (in dollars per share)</link:label>
    <link:label id="lab_mygn_IncreaseDecreaseInEarningsLossPerShare_label_en-US" xlink:label="lab_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Earnings Loss Per Share</link:label>
    <link:label id="lab_mygn_IncreaseDecreaseInEarningsLossPerShare_documentation_en-US" xlink:label="lab_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in earnings (loss) per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:href="mygn-20221231.xsd#mygn_IncreaseDecreaseInEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:to="lab_mygn_IncreaseDecreaseInEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_667cfab0-d24e-41f8-b933-83c0ea7e22a1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1cf2885e-33ef-43dd-a0fa-1d33d5a5293e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b3987e0-3a1c-471d-85b4-1e139cd4af3a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_fcedce04-b83b-4e6e-94bf-cfd7dd097c6c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in foreign currency translation adjustment, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_94a5cb3a-38b3-4bb9-8533-feb6b3d6c556_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DebtCovenantLiquidityCovenantMinimum_96c9d834-0010-4aa7-ab2c-9f822db1259c_terseLabel_en-US" xlink:label="lab_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum liquidity covenant</link:label>
    <link:label id="lab_mygn_DebtCovenantLiquidityCovenantMinimum_label_en-US" xlink:label="lab_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Liquidity Covenant Minimum</link:label>
    <link:label id="lab_mygn_DebtCovenantLiquidityCovenantMinimum_documentation_en-US" xlink:label="lab_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Liquidity Covenant Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:href="mygn-20221231.xsd#mygn_DebtCovenantLiquidityCovenantMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:to="lab_mygn_DebtCovenantLiquidityCovenantMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8cdcafd2-3c13-470c-a117-32cb9b84c3cc_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c18040e2-ff4d-439b-9384-0a7f41ddb80d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_763bf357-a546-4e8e-a656-ba8ce4ebc908_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_7f3aa060-4f95-4467-879c-0e524eb7c194_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_84821416-db97-4527-b9a4-3544de246ad0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_7602196a-05cb-41c0-aeb2-34ac5d975bff_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_04fc0058-a6a7-46c6-bdc3-374fc5bb083b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration recognized at acquisition</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_89986f72-008a-4465-a70c-f65fc4ffb1a8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_08112f58-e44d-4669-85bc-fd664bc8d5cf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue - beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_16c978bf-f6f8-4c82-b829-45770265cdc2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue - ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_da6911f0-5cc0-49b8-9ab5-2792373f5573_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_094361b1-2d4d-4c79-bcea-21ac59ca5242_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_94a5e273-23c7-44cc-ac0a-6fd5f41ee39e_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d8325cf4-6ab7-4169-8963-d302791a8046_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9a03c518-1997-49d2-918d-f3b029a193ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash impact of foreign currency transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_92b75258-d290-47d0-9384-a21d62077744_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_91a87cfb-a2f5-4eba-b075-a52de8cd6015_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_26076edd-35fb-452c-9073-cd83fc75f0b6_terseLabel_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_label_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c0c4f38f-def7-4668-9d2d-5aadc2c8f9d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityPrepayments_2c84c1a7-d116-4d52-8215-9715c1482598_terseLabel_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayments</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityPrepayments_label_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Liability Prepayments</link:label>
    <link:label id="lab_mygn_ContractWithCustomerLiabilityPrepayments_documentation_en-US" xlink:label="lab_mygn_ContractWithCustomerLiabilityPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability, prepayments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityPrepayments" xlink:href="mygn-20221231.xsd#mygn_ContractWithCustomerLiabilityPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ContractWithCustomerLiabilityPrepayments" xlink:to="lab_mygn_ContractWithCustomerLiabilityPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_54152f26-e9d7-4e70-981e-8047f760425a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, in unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b28d81f2-6877-47cc-a4e9-7c4c306bbb0f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, gross unrealized loss, fair market value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ada4c459-18c4-41ef-b12c-3292ed779de9_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0de7e095-1b88-49eb-bac9-f620902b5fc2_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated remaining useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1d8a0dfe-9dd7-4d9a-a695-a87439394efc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Useful Life (in Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_38a783a7-9bfd-41cf-87ac-948ec5f47fb3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease terms</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c825729d-508d-4fb3-8fac-971833448519_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_fc82a0fe-4281-42c1-9781-9d27e0720251_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_840e6e82-f9f3-4d6c-8101-6eb1865add2a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Useful Life (in Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_60dd966f-f431-4571-8bd6-7601e53d6f57_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, contingent cash fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_88f45cfb-1ff2-4e11-9d4c-02a2a0c51c02_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_616cff2c-0358-4103-b68a-22effa73a36f_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_51038496-293c-4aab-b43e-6f36986d844d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill acquired (see Note 16)</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_592f76b7-681c-49bd-a013-e8790236776c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock issued under stock-based compensation plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_17476d78-7259-4502-b621-8aa9ddfa3d59_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_7c252a93-33cd-4809-af9b-43b5b5f1a3ec_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_69a63f2a-486f-4ea5-be0a-4f589e807ea6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized holding gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_47d7aa78-6e18-411a-aa62-011a7a64b649_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f5a36acf-0bbb-42b7-bc52-0b94772579b0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_32d9257e-cf6c-4c7c-8b95-ab94144e609a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_c99bca24-74c9-43fe-acf9-c2a4b5749b45_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible meals and entertainment</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7a6ed66c-c5ee-4b08-9291-28ff59a8ad02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life (years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6a436c0e-97c0-42da-86ec-9a634e74f4b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes_9927a4cc-b75f-47ed-8add-2fc057f63f73_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_673d7c1a-ed98-493f-9ca7-59df88cfa9b0_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_a71a4512-b4ba-4848-b9c5-97969b4d443f_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">President and Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_8077df0f-7b12-4235-ae7f-151f1a5a9632_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undrawn fee (percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets_e133837d-8bd8-4c56-b1b5-1494a8b0e161_terseLabel_en-US" xlink:label="lab_mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease right-of-use assets</link:label>
    <link:label id="lab_mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets_label_en-US" xlink:label="lab_mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Lease Right-Of-Use Assets</link:label>
    <link:label id="lab_mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:href="mygn-20221231.xsd#mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:to="lab_mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_494f7bf8-5dde-4775-971e-e8d0db54f8ed_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax expense at the statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward_eea0886d-d69e-4b4e-af57-7d7ff8535cf0_terseLabel_en-US" xlink:label="lab_mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract with Customer, Liability, Current [Roll Forward]</link:label>
    <link:label id="lab_mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward_label_en-US" xlink:label="lab_mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract with Customer, Liability, Current [Roll Forward]</link:label>
    <link:label id="lab_mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward_documentation_en-US" xlink:label="lab_mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward" xlink:href="mygn-20221231.xsd#mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward" xlink:to="lab_mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_c30ee86a-43cb-4b24-81fc-b532c1cb3265_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss due to abandonment of facility</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2f1c3d08-45c0-4b58-a16e-ef941cb16bc1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_867e7a8f-e80f-4fa2-8961-0c2bbc3dce24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intrinsic Value of Options Exercised</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_56abb1f3-1212-4361-b5d3-16bc559c99f1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_6d791349-0010-4172-9b78-7debba92e787_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_843e6ae8-65fa-44d0-9191-905ece635680_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Fair Value of Identified Assets acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1d586757-e666-4839-9084-f4c30ca4a560_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70ac8b8a-3be1-465d-b5fa-c97074bd4815_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_0dee7e4a-c451-463a-b987-becbf779b4d5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_RaygenIncVersusMyriadWomensHealthIncMember_5b3a9a21-3472-4eeb-9846-d2a44d0133d0_terseLabel_en-US" xlink:label="lab_mygn_RaygenIncVersusMyriadWomensHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raygen, Inc Versus Myriad Women's Health, Inc.</link:label>
    <link:label id="lab_mygn_RaygenIncVersusMyriadWomensHealthIncMember_label_en-US" xlink:label="lab_mygn_RaygenIncVersusMyriadWomensHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raygen, Inc Versus Myriad Women's Health, Inc. [Member]</link:label>
    <link:label id="lab_mygn_RaygenIncVersusMyriadWomensHealthIncMember_documentation_en-US" xlink:label="lab_mygn_RaygenIncVersusMyriadWomensHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raygen, Inc Versus Myriad Women's Health, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RaygenIncVersusMyriadWomensHealthIncMember" xlink:href="mygn-20221231.xsd#mygn_RaygenIncVersusMyriadWomensHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_RaygenIncVersusMyriadWomensHealthIncMember" xlink:to="lab_mygn_RaygenIncVersusMyriadWomensHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_2bb415d1-f487-473a-aa0b-242eca0bced6_terseLabel_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_label_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) Other</link:label>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_documentation_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" xlink:href="mygn-20221231.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" xlink:to="lab_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_68f509f4-3103-4f94-b514-b294a2d9e01a_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal charges pending settlement</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a2655774-b623-4a24-ac67-1a1b254e4ce9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5eaa7e14-0a16-42d5-9234-d4cc62d7b5b7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b20fc5f3-2d98-4295-a0d1-53db71ca11ba_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Financial Statement Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2cbc1f6c-fd47-4658-b65d-b3acdffe933f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign exchange rates on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_594b1a77-0392-41c1-8044-642dd3c85729_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_966beada-f58d-4cb4-8908-bde20626e603_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0063c98f-9ee1-4197-bb62-8e56d7330a24_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_86a2920f-5dbb-4e69-9e64-e967930736e9_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL CASH FLOW INFORMATION</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IntangibleAssetsLineItems_5a09a9fc-2fa2-43f7-8522-eaaccea4240e_terseLabel_en-US" xlink:label="lab_mygn_IntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Line Items]</link:label>
    <link:label id="lab_mygn_IntangibleAssetsLineItems_label_en-US" xlink:label="lab_mygn_IntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Line Items]</link:label>
    <link:label id="lab_mygn_IntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_mygn_IntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IntangibleAssetsLineItems" xlink:href="mygn-20221231.xsd#mygn_IntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IntangibleAssetsLineItems" xlink:to="lab_mygn_IntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_956aaff8-b2f8-49a7-b7b5-0f19aa836021_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for income tax receivables</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Income Tax Refunds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_911e6b4a-c279-436e-b5cb-3fb5d8ef4848_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Amortization Expense of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_39028234-9e4b-43d6-aff9-2326221545b7_terseLabel_en-US" xlink:label="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Purchase Plan</link:label>
    <link:label id="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_label_en-US" xlink:label="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Twenty Twelve [Member]</link:label>
    <link:label id="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_documentation_en-US" xlink:label="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Twenty Twelve [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:href="mygn-20221231.xsd#mygn_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:to="lab_mygn_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_78bb8bf3-ea3c-45ba-adc6-c8be372e0832_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value recognized in the statement of operations</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_7f70c174-81b2-4893-bd87-7f1e3fd52764_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_42258ddf-d4eb-4196-a93a-132418d9fe78_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_8f415675-337d-4854-b486-537be969b610_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6ffbcfe0-1f65-4896-8bd4-b455e9568cfd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisposals_fa9b8ed8-772c-4ee4-a5fa-3f4b61a57353_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment sold and deconsolidated</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisposals_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Disposals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_8fe0b3de-d431-4d0f-819b-fa56c6935ecb_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on sale of subsidiary</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_16bed565-c8ae-4665-b306-9145886aec24_terseLabel_en-US" xlink:label="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Plan</link:label>
    <link:label id="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_label_en-US" xlink:label="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Employee Director And Consultant Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand seventeen employee director and consultant equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:href="mygn-20221231.xsd#mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:to="lab_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_64780f6c-3177-439a-b85e-bc24fc577c40_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_f5701d62-c7e9-4302-a014-98bc26e5721e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balances</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_af9e7051-e0fc-488c-a3ac-48feca4c7703_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_3f5dd97d-531a-4696-852e-9b0d72be456a_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_df1899a6-1920-4ef8-86eb-5f980945abf3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_92da02af-87d8-46f8-af74-105dd6102e46_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2e70af53-5838-46a0-a7a7-884480a6e388_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0725980d-5580-4816-8098-688893257755_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b00f7cd5-37be-49e2-b68f-b24ff3eda5bd_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_def1b015-fcf4-4e63-8f07-a10894536915_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ContingentConsiderationMember_18d8d9c4-6a53-4419-af15-e1c0b16ad74a_terseLabel_en-US" xlink:label="lab_mygn_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_mygn_ContingentConsiderationMember_label_en-US" xlink:label="lab_mygn_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_mygn_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_mygn_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContingentConsiderationMember" xlink:href="mygn-20221231.xsd#mygn_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ContingentConsiderationMember" xlink:to="lab_mygn_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_InvestmentsAndCashAmortizedCost_cdb236a8-bfac-4dc8-8d25-94d126918c9b_totalLabel_en-US" xlink:label="lab_mygn_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAmortizedCost_label_en-US" xlink:label="lab_mygn_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Amortized Cost</link:label>
    <link:label id="lab_mygn_InvestmentsAndCashAmortizedCost_documentation_en-US" xlink:label="lab_mygn_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost" xlink:href="mygn-20221231.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_InvestmentsAndCashAmortizedCost" xlink:to="lab_mygn_InvestmentsAndCashAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_104d827c-bd0d-474a-bdb7-bab0b3f6c06e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_cc38b998-dcdd-43a7-b4ad-b931c2d8e665_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_eb3761dc-d5bb-41e5-b827-708a4f797e91_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ac1a5b4c-5c18-432b-9c44-ce9590332738_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_90c4c28d-2b90-4174-9ad1-c17cb2a6e0c3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_44973120-a35f-46dc-9a3f-d8ccf9d172c2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_dc7334d5-4e18-4b63-af0b-c7e0a7db81db_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_b3bd10ab-b288-43a4-883c-4bb8a6fc7234_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ReportableGeographicalComponentsMember_8fe18704-79f4-4a57-8895-358001feeb72_terseLabel_en-US" xlink:label="lab_srt_ReportableGeographicalComponentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable geographical components</link:label>
    <link:label id="lab_srt_ReportableGeographicalComponentsMember_label_en-US" xlink:label="lab_srt_ReportableGeographicalComponentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Geographical Components [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableGeographicalComponentsMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ReportableGeographicalComponentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ReportableGeographicalComponentsMember" xlink:to="lab_srt_ReportableGeographicalComponentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_541ad3e6-ac8d-4af8-9273-cc8434d2cc05_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d4fe22ae-4f43-4251-9dd7-55c41fdf4070_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREFERRED AND COMMON STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_e9bf929a-83d3-4d4d-82bd-2e1db77b94b5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_48441e10-4c63-49a9-b0d6-7f72dc792596_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under the plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_537020d3-6435-4042-b4b6-ecad147e9a8b_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net, amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_079f5eb9-80f4-4529-bfec-96f83addddd2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_db1b5d18-b475-4bb9-9ed0-83f5d556e66f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_2bc73e6d-42a6-4a2c-bee1-3575826def4b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_03cacf4f-b09f-4532-b4c5-cb26050065be_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable investment securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_TenantImprovementAllowanceNotYetReceived_9dd55659-fa19-4c23-98d4-56d36aa47794_terseLabel_en-US" xlink:label="lab_mygn_TenantImprovementAllowanceNotYetReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance not yet received</link:label>
    <link:label id="lab_mygn_TenantImprovementAllowanceNotYetReceived_label_en-US" xlink:label="lab_mygn_TenantImprovementAllowanceNotYetReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance Not Yet Received</link:label>
    <link:label id="lab_mygn_TenantImprovementAllowanceNotYetReceived_documentation_en-US" xlink:label="lab_mygn_TenantImprovementAllowanceNotYetReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance Not Yet Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TenantImprovementAllowanceNotYetReceived" xlink:href="mygn-20221231.xsd#mygn_TenantImprovementAllowanceNotYetReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_TenantImprovementAllowanceNotYetReceived" xlink:to="lab_mygn_TenantImprovementAllowanceNotYetReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_82828091-159d-4254-a426-6d3501dd3a61_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on non-cancelable purchase commitment</link:label>
    <link:label id="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss_label_en-US" xlink:label="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Firm Purchase Commitment, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:to="lab_us-gaap_InventoryFirmPurchaseCommitmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1f6018ae-1438-4fd4-b1b3-fe5212434b30_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_299c4e35-1ecd-41ef-b7ef-a694b4eb12e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_64a5be71-75f3-4bdd-95d5-c1bedab1eefd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT, NET</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_0858a163-7810-4b1f-9106-cf7dd5980b38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease_2bf89fbf-7b00-43df-9013-217d95999b73_verboseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period translation adjustments</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease" xlink:to="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4234935e-95c0-4493-b184-7b24f11c0bc0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_be05bf4c-7ac0-471d-b01d-0dbfe82eb620_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0fb4d835-277f-4ca2-839c-c206581d30af_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_b216afcd-7023-47c0-bcea-c5153097bb7e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Long-Term Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OtherIncomeExpensePolicyPolicyTextBlock_bd267f55-d575-4046-ba8b-3d45ebd717a9_terseLabel_en-US" xlink:label="lab_mygn_OtherIncomeExpensePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:label id="lab_mygn_OtherIncomeExpensePolicyPolicyTextBlock_label_en-US" xlink:label="lab_mygn_OtherIncomeExpensePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense) Policy [Policy Text Block]</link:label>
    <link:label id="lab_mygn_OtherIncomeExpensePolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_mygn_OtherIncomeExpensePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income policy text block.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OtherIncomeExpensePolicyPolicyTextBlock" xlink:href="mygn-20221231.xsd#mygn_OtherIncomeExpensePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OtherIncomeExpensePolicyPolicyTextBlock" xlink:to="lab_mygn_OtherIncomeExpensePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_f195e0cf-3f37-4625-8f00-bad8945310e5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_984372b9-b959-4757-8a74-c5f162c496a5_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_2526667a-a48a-40a4-9d2f-b80b51dab8d8_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_df73965b-a687-4913-906a-e0a8e5cff3e6_terseLabel_en-US" xlink:label="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period for earn out liability</link:label>
    <link:label id="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_label_en-US" xlink:label="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input, Term</link:label>
    <link:label id="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_documentation_en-US" xlink:label="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:href="mygn-20221231.xsd#mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:to="lab_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced_aeeafcef-259e-4392-a9eb-5ed3e8318a1c_negatedTerseLabel_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: leases not yet commenced</link:label>
    <link:label id="lab_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced_label_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Leases Not Yet Commenced</link:label>
    <link:label id="lab_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced_documentation_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Leases Not Yet Commenced</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced" xlink:href="mygn-20221231.xsd#mygn_OperatingLeaseLiabilityLeasesNotYetCommenced"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced" xlink:to="lab_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_8c8165fa-1ae1-469e-b448-0271240c18c7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_a62d93f0-a683-4707-b3a6-7924c9116fdd_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_0adde367-07cf-4d84-a8e7-dc687249c81f_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_05ea643b-019f-4cf6-8d64-47b83a19743c_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_b1793b97-df0a-499a-bdfb-d1ba2d553741_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_15f9f3c0-6000-4de8-86f0-b5ad8bcb7cbb_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal repayment</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_5004d4f2-b958-48a4-847e-d0365a7da366_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_7a09f4d7-92d8-4cce-8567-92738213f3cb_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_798a5aa3-0f9e-445d-a59c-dc5fa5b17022_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_bc659127-8c13-4ed8-a8ee-8689faec5bed_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_eaf03c4c-0e5f-4eca-bfc3-1eb145565431_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_98c96517-a588-4ff2-bbf6-5b1658449ed7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT AND RELATED INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward_18ebbb8f-01ae-4a53-8c5a-f39d5ea9dfc1_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Translation Adjustment Summary [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward_label_en-US" xlink:label="lab_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Translation Adjustment Summary [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CumulativeTranslationAdjustmentSummaryRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward" xlink:to="lab_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MyriadAutoimmuneReportingUnitMember_a0551718-5a58-469a-9c60-760c84a8aced_terseLabel_en-US" xlink:label="lab_mygn_MyriadAutoimmuneReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad Autoimmune reporting unit</link:label>
    <link:label id="lab_mygn_MyriadAutoimmuneReportingUnitMember_label_en-US" xlink:label="lab_mygn_MyriadAutoimmuneReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad Autoimmune Reporting Unit [Member]</link:label>
    <link:label id="lab_mygn_MyriadAutoimmuneReportingUnitMember_documentation_en-US" xlink:label="lab_mygn_MyriadAutoimmuneReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad Autoimmune Reporting Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneReportingUnitMember" xlink:href="mygn-20221231.xsd#mygn_MyriadAutoimmuneReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MyriadAutoimmuneReportingUnitMember" xlink:to="lab_mygn_MyriadAutoimmuneReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_57b1b53f-bd8a-4ba9-88fe-c4f040476534_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Payment Expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_a99ff0d4-0071-424e-9fa2-e9a58a006410_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3619b1b7-0175-45cd-870b-7df9d672e4e8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_8d4c1654-b9b7-4cfc-98f4-a977e136832f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock option and employee stock purchase plan expense</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7474ef00-8fe1-4b18-bf90-dd451a8f1dc3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_60334c96-db0a-4f79-81fa-bab9577c7262_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_bd168d53-667d-49e7-b936-30d4334a9c67_terseLabel_en-US" xlink:label="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum unrestricted cash and cash equivalents threshold per covenant</link:label>
    <link:label id="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_label_en-US" xlink:label="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum</link:label>
    <link:label id="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_documentation_en-US" xlink:label="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:href="mygn-20221231.xsd#mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:to="lab_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_819d06ca-b9a6-4981-8795-171b65075df3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28079009-0e5f-4e99-8d75-aaf7b347dd67_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_52c19d00-0127-4199-91b9-d16cee23e842_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_a4b0e1a5-e94c-4d3f-807b-6e5853e70723_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_NonCashInterestExpense_c6e87562-666b-4c15-b767-51059c22f5c4_terseLabel_en-US" xlink:label="lab_mygn_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_mygn_NonCashInterestExpense_label_en-US" xlink:label="lab_mygn_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense</link:label>
    <link:label id="lab_mygn_NonCashInterestExpense_documentation_en-US" xlink:label="lab_mygn_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash interest expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonCashInterestExpense" xlink:href="mygn-20221231.xsd#mygn_NonCashInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_NonCashInterestExpense" xlink:to="lab_mygn_NonCashInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_937c6557-0176-4553-a476-673c6ca98fab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares Purchased and Compensation Expenses for ESPP</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_a6dcf5e2-120d-495c-83b3-7c32a182ca2a_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of businesses and assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_6326b808-aa5c-4ba9-aa4e-304bfee8a9e7_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on divestiture</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced_b8d73d47-de79-4040-ab9c-de3698cb2e62_terseLabel_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of future lease payments</link:label>
    <link:label id="lab_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced_label_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Including Leases Not Yet Commenced</link:label>
    <link:label id="lab_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced_documentation_en-US" xlink:label="lab_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Including Leases Not Yet Commenced</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced" xlink:href="mygn-20221231.xsd#mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced" xlink:to="lab_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_52ff320d-efb3-48ea-9ea7-e7a035d2eefa_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_546bb559-69cf-4a33-8546-b21abdff42ca_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_f95092cd-e21c-4d97-b045-86abd33f1521_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_2949a2ff-82aa-431e-936a-e05223840d72_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation_9355ae1d-a552-4d95-9921-b0092679847a_terseLabel_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible officer compensation</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation_label_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Non Deductible Officer Compensation</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation_documentation_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation non-deductible officer compensation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" xlink:href="mygn-20221231.xsd#mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" xlink:to="lab_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_561771c2-8e46-4fd3-8fe6-c20de1d4bcf0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_6f91bf6f-292b-4a42-88d0-9a39bac2c4a0_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_76c14212-787a-404c-89b4-5e6d5ba8567f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_4ac8bdcc-3100-4ebd-9cb1-84a0c9d415cb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of business and assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sales of Business, Affiliate and Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndCash_e5417f32-206d-407f-b3bb-8f671aa3fcf3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_80a233f3-8b78-4fdb-9727-a137256d0487_totalLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, Estimated fair value</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCash" xlink:to="lab_us-gaap_InvestmentsAndCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_2505af19-06df-4138-8212-6e1ae5c892a6_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fa6c619a-02ca-4db8-83a1-a4851225b444_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_503c9f45-fd20-4b1a-8517-57c50076978f_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding used to compute basic EPS (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_09cdd9af-9948-4a73-9134-5e9b61e23861_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c76c06ad-029c-4408-a26d-9c3acd09ccce_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_9737cc0c-a410-402a-99dc-197fd3cec6be_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_1910cd53-f473-4755-acbb-e17d1c532f9a_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, pro forma information, loss of acquiree since acquisition date, actual</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_eee610aa-112d-4f43-ab78-ef702448049c_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_28d4c3e1-cad6-45dc-b9b8-1a7b5b3cd888_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OptionsAndRestrictedStockUnitsMember_0f7a97c4-fb97-4965-a06c-361f73934495_terseLabel_en-US" xlink:label="lab_mygn_OptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options and RSUs</link:label>
    <link:label id="lab_mygn_OptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_mygn_OptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_mygn_OptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_mygn_OptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options and Restricted Stock Units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OptionsAndRestrictedStockUnitsMember" xlink:href="mygn-20221231.xsd#mygn_OptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OptionsAndRestrictedStockUnitsMember" xlink:to="lab_mygn_OptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_bd0d2cf3-641c-43e4-974d-863d77a838fd_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ccfc8798-e4e3-447e-81a8-d6ab9311cbc9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fca27730-bfb0-4cc4-884b-99ee6e1a5e23_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_52833934-ea76-42b8-a7d1-d972fa29f690_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_cdf135a2-72c3-4d64-8c9e-db3a313376fc_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives (in years)</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_6aa2ad72-6451-4f18-a881-0fdecaa5ab83_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_99fb72a5-eae6-421b-8e03-e00be941a63d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_GoodwillAndIntangibleAssetsLineItems_61a1384a-e16d-465e-90cd-841b8a281190_terseLabel_en-US" xlink:label="lab_mygn_GoodwillAndIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill And Intangible Assets [Line Items]</link:label>
    <link:label id="lab_mygn_GoodwillAndIntangibleAssetsLineItems_label_en-US" xlink:label="lab_mygn_GoodwillAndIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill And Intangible Assets [Line Items]</link:label>
    <link:label id="lab_mygn_GoodwillAndIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_mygn_GoodwillAndIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GoodwillAndIntangibleAssetsLineItems" xlink:href="mygn-20221231.xsd#mygn_GoodwillAndIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems" xlink:to="lab_mygn_GoodwillAndIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_ba1a3ed1-f925-45ea-adbd-ef749f9e9028_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_3539690f-3e77-4071-a041-c2adad7b36b7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2b323cd3-a8ca-4e22-9259-302d06637fda_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2025ee19-60ed-4852-b756-cb7a69d0f0c1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduced revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_498c1262-4bef-4479-9214-306f9e2dfb8c_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_SividonDiagnosticsGmbHMember_8281c9ab-66ad-4c4b-9b0c-1643d9abf062_terseLabel_en-US" xlink:label="lab_mygn_SividonDiagnosticsGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sividon Diagnostics GmbH</link:label>
    <link:label id="lab_mygn_SividonDiagnosticsGmbHMember_label_en-US" xlink:label="lab_mygn_SividonDiagnosticsGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sividon Diagnostics GmbH [Member]</link:label>
    <link:label id="lab_mygn_SividonDiagnosticsGmbHMember_documentation_en-US" xlink:label="lab_mygn_SividonDiagnosticsGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sividon Diagnostics GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_SividonDiagnosticsGmbHMember" xlink:href="mygn-20221231.xsd#mygn_SividonDiagnosticsGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_SividonDiagnosticsGmbHMember" xlink:to="lab_mygn_SividonDiagnosticsGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_782fb975-8e74-4406-8bad-2084e0a631f9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company matching contribution as percentage of employee contribution</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration_7289b37f-9c7e-43be-994f-48fb909de8f3_terseLabel_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, dispositions, and contingent consideration</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration_label_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Acquisitions, Dispositions, And Contingent Consideration</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration_documentation_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Acquisitions, Dispositions, And Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:href="mygn-20221231.xsd#mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:to="lab_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_EarningsPerShareBasicAndDilutedEPSAbstract_7f609c02-a1bd-4850-8454-1d27673cfc2d_terseLabel_en-US" xlink:label="lab_mygn_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_mygn_EarningsPerShareBasicAndDilutedEPSAbstract_label_en-US" xlink:label="lab_mygn_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic And Diluted EPS [Abstract]</link:label>
    <link:label id="lab_mygn_EarningsPerShareBasicAndDilutedEPSAbstract_documentation_en-US" xlink:label="lab_mygn_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic And Diluted EPS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:href="mygn-20221231.xsd#mygn_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:to="lab_mygn_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_3def48c6-58dc-4489-9b35-cd7627099892_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_26bca0c4-4fa7-438b-b9c1-7b7020f8c61c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_b9940f93-3097-4e06-9a1c-486b9cceada5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_a47f0bfc-b433-4108-a9d7-d614461b5c40_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_63dc365d-f98f-453c-9360-8ac1cbd1b6ab_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_a27e649e-6f2c-44e3-87d5-39bf543c6099_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment charge</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_2ab1a7c9-eeec-43ae-a81e-fb846df4ed15_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e1c6572e-2439-4a52-b5df-ab506683e425_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7ca8cdc8-011a-4bce-9369-b17fb57e1adc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal of Subsidiary [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_66323f3c-5e61-41ef-a76d-12993f216b5c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_0c3ab10d-fc89-4b4d-b0b2-2a0150385eab_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_1fe395f6-fc93-40b8-9473-5166c49dbf9c_terseLabel_en-US" xlink:label="lab_mygn_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, recurring basis, unobservable input reconciliation, gain (loss), statement of income</link:label>
    <link:label id="lab_mygn_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_label_en-US" xlink:label="lab_mygn_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag</link:label>
    <link:label id="lab_mygn_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_documentation_en-US" xlink:label="lab_mygn_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:href="mygn-20221231.xsd#mygn_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:to="lab_mygn_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_b38e40a8-4cff-4e97-b92a-2e22adc0c02e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f5a624a3-9677-4cfa-90da-c6ff6c393506_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_adb75b91-f6a3-4f62-be9d-d87e02fff6a9_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2a381d88-f8a3-4814-9f4f-fa09495cecee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of tax withheld for common stock issued under stock-based compensation plans</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d563c3d4-c8f0-4a6e-9831-61905437d331_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0b4bb20b-d47a-42e3-afd4-4ba5ee3fe3b4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_0ea16d42-7ec7-4cfc-916c-1dd79e18bc56_terseLabel_en-US" xlink:label="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
    <link:label id="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_label_en-US" xlink:label="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
    <link:label id="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_documentation_en-US" xlink:label="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:href="mygn-20221231.xsd#mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="lab_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_625519ee-bde8-4976-ab06-3dad726adf6b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_1e24817e-9161-47ea-91be-1500c0e50168_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, remaining repurchase authorization</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_26bf3ac2-c447-4abb-bda6-35e7e350bc4c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_ad304469-4684-4d58-b009-f84a205cd920_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of world</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_bf32930d-aaff-4004-901c-fafb2b61e209_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_fd983f59-a49d-42e1-b135-5f7cc8d989e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Shares of Common Stock Issued and Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Outstanding Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b399494e-5ef8-49c8-b42e-7366106effb9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_67653f53-8e59-49e3-9aa2-cc7664f23a4d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Loss Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_05ec7dd2-b1cb-449c-86cd-695033e633f9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid_55bdfd8e-72db-4d91-ba10-3cd526781849_terseLabel_en-US" xlink:label="lab_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities and other long-term liabilities</link:label>
    <link:label id="lab_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Related Expenditures Incurred But Not Yet Paid</link:label>
    <link:label id="lab_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Related Expenditures Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid" xlink:href="mygn-20221231.xsd#mygn_LeaseRelatedExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid" xlink:to="lab_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a39659d3-ccde-4cb1-bfb7-f82a0c167934_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Expense [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_15cb7ba3-88fc-4886-9fd0-4680bd7a868e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_77d81062-4bd9-45da-9b42-a7f12028290e_verboseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_57a28422-6093-4e14-b168-1a5569b1b62b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and penalties in year-end balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e447251d-5bde-4459-9905-da62c118826e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_e72c4d7e-351f-488f-84be-fb055a49378f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4c6fdb9c-db2d-4876-a85f-9f08686d5b0d_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: amounts representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_220c2a0a-452d-4347-b31e-af139c012720_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable investment securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_1b6c160c-9e2b-4819-92d9-7c4a26fcadba_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_214e5618-5cc5-4802-b804-e31d9a89ea26_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_795c9ca7-7013-4fc5-a4c2-a79a18b804f8_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_f0b82938-3275-41a2-a26f-407b145a754f_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net, total</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_f59e6dda-22de-470a-ae3a-3fcf1451dfd6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance based on Nasdaq Healthcare Provider Index</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8f8c646f-7aac-4fb6-bf74-8b149bcfbe33_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service period for award vesting (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_17dc8ba0-e4eb-406d-b153-d061ee0fdcdc_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based payment expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_e6c908d2-f636-496a-af94-03cadf69bd97_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_87068ce1-9e65-4412-88b3-fab62277d0a5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f078f5c6-d283-4052-b9c5-ef8e3a393dc8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_86a90e15-73bc-44d0-93d2-8156dd9b3cba_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_59930c47-ffe4-4499-a06f-4663e250e0f1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_8a270d4c-7f65-45c1-8c2c-35816ea74d52_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan compensation expense</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1720a9a9-6e8d-4c6f-9db2-c51d35254313_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_962f7aed-4204-45c8-b6ca-ba26214de548_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_0ad626a9-96b1-4287-a6c5-be742bf11706_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits at the beginning of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_2007f8c1-6b56-4507-b44f-4ef0d1fe8966_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits at end of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_410fd156-add2-40ce-aaa2-71f1f3a5ad0d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_0c454714-cc62-4917-84b8-ef9866ffd398_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_b2854834-b972-4779-b080-50be33ee02ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement_f81ea5eb-0bac-4e70-b61e-f580a1428daf_terseLabel_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible legal settlement</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement_label_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Non Deductible Legal Settlement</link:label>
    <link:label id="lab_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement_documentation_en-US" xlink:label="lab_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation non-deductible legal settlement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement" xlink:href="mygn-20221231.xsd#mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement" xlink:to="lab_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetImpairmentCharges_c722eb49-15fc-475e-aca5-c3634732c2d8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charge</link:label>
    <link:label id="lab_us-gaap_OtherAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetImpairmentCharges" xlink:to="lab_us-gaap_OtherAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_4666172a-bbc3-4772-b020-8ba0e1b9754e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DIVESTITURES</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_44b9cda2-c91d-4677-a63b-94371c41f3e1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_eadbd09a-ddad-4ee2-8a71-87a4e6927994_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_c1b71ee4-9062-4a4a-8e2d-72c0a781c21b_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds and notes</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_3a93907e-ff43-4d1d-8d32-9a95e8b1a70d_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds and notes</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_8fcee7f1-a8f3-4744-9f94-8313325a831d_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_baa04c7a-122a-4346-b8d0-fa6d3262947c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_389ad040-eead-49d1-8f36-767e24a1d5df_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_UnrecognizedTaxBenefitsNet_c176a26c-3bec-4217-8a61-ef7541a0536f_terseLabel_en-US" xlink:label="lab_mygn_UnrecognizedTaxBenefitsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_mygn_UnrecognizedTaxBenefitsNet_label_en-US" xlink:label="lab_mygn_UnrecognizedTaxBenefitsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net</link:label>
    <link:label id="lab_mygn_UnrecognizedTaxBenefitsNet_documentation_en-US" xlink:label="lab_mygn_UnrecognizedTaxBenefitsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_UnrecognizedTaxBenefitsNet" xlink:href="mygn-20221231.xsd#mygn_UnrecognizedTaxBenefitsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_UnrecognizedTaxBenefitsNet" xlink:to="lab_mygn_UnrecognizedTaxBenefitsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_1dc6050a-c67a-40db-aa2c-c1fd4de626df_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_f9f0ca8f-9203-4d69-a4d9-cd511bc872a9_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_3beb852f-8af9-467b-a191-ea65ed4c3e70_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5cc3c1f7-c92e-44b4-a339-70d0ce34f5ba_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_b90c500e-6c0b-45dc-9291-70db9dc2e846_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_9612765d-b0f5-4af9-b049-d471c7749d48_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_7241ad8d-28be-42d4-b488-a01bb07a17b5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_be73da68-fb33-4c22-a167-79a72a2f2ae2_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_11bdceb5-49a2-4ebf-b1dc-7c58d353b7c6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_48741f7f-2ad5-47ef-8224-fa631ed8405d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_UT_f4431ba0-2c29-4596-97ad-d486d875cc91_terseLabel_en-US" xlink:label="lab_stpr_UT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Utah</link:label>
    <link:label id="lab_stpr_UT_label_en-US" xlink:label="lab_stpr_UT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UTAH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_UT" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_UT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_UT" xlink:to="lab_stpr_UT" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4c4131d6-6c7c-479a-ba2f-3d54d3cb8990_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_a00a4610-f747-4099-8c5a-aa304a163e25_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred savings plan contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment_80447d33-3e89-49be-a89f-bc3ac00fc787_terseLabel_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment_label_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Asset Impairment</link:label>
    <link:label id="lab_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment_documentation_en-US" xlink:label="lab_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation asset impairment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment" xlink:href="mygn-20221231.xsd#mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment" xlink:to="lab_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_eb2d29e1-514a-41b9-a87d-4ef8aedcdfa1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4c7efac8-2099-4bf0-b089-428b2d35a433_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6d01b6f9-94bf-4e4a-b087-0b9060509bb2_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_cf8a9aed-3228-4ea5-9703-ba941c14a1a1_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets by Geographical Region</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_aa1fc823-b0a0-4509-8a5f-ec948fd792b4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_aa58612f-99bf-47ac-aeb4-43f74c26278d_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_2eb4587d-2b95-427f-aff1-9f57cbe5fba6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Type</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_364ff106-53e0-4a00-8e27-04b21535e591_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_AuditInformationAbstract_label_en-US" xlink:label="lab_mygn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_mygn_AuditInformationAbstract_documentation_en-US" xlink:label="lab_mygn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AuditInformationAbstract" xlink:href="mygn-20221231.xsd#mygn_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_AuditInformationAbstract" xlink:to="lab_mygn_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_6c99f457-d49d-4c71-95f6-195f6e56e0b8_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_2bf5541f-ca03-45ee-91b2-fed8251b2628_verboseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2a88f13a-ddee-42be-af2f-5551dd3a5858_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_023b93c2-f0c5-48d9-93ec-9ffc4f711164_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Differences Between Statutory Federal Income Tax Rate and Income Taxes Reported</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_135a8398-a617-4c40-bd10-06149e403d6b_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal charges pending settlement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_42f336fa-2606-44f0-b02e-62220f1826ab_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_607656ed-f907-4497-8b7e-2e017973124d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6aaa1e48-6af9-432d-a3c1-53bff8a1ec1e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive stock option and RSUs (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ScheduleOfIntangibleAssetsTable_a4bbc577-648f-4aeb-ac71-a5bcfa1c94a3_terseLabel_en-US" xlink:label="lab_mygn_ScheduleOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Intangible Assets [Table]</link:label>
    <link:label id="lab_mygn_ScheduleOfIntangibleAssetsTable_label_en-US" xlink:label="lab_mygn_ScheduleOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Intangible Assets [Table]</link:label>
    <link:label id="lab_mygn_ScheduleOfIntangibleAssetsTable_documentation_en-US" xlink:label="lab_mygn_ScheduleOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfIntangibleAssetsTable" xlink:href="mygn-20221231.xsd#mygn_ScheduleOfIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable" xlink:to="lab_mygn_ScheduleOfIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6f64a0cd-6578-4019-9983-debf5fb49b5a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_564b96d7-d06a-4b2e-864a-a41c6ec95a3b_verboseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_8b1099a2-9deb-4e33-b2a1-1aabab8f5222_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_27848f25-24d3-42b9-be34-7ae0c89d247f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_88375a2d-f88b-489b-8134-396548e56660_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6fdcfa83-0ea5-4d27-93eb-88b1fcb39a44_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e24e0958-c3cf-4d1c-bfee-ca1cd9ad394f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_2bc28822-a0ff-437e-976e-354e076bdffa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_7991df65-ad1d-4c8d-9d2e-355457e4aa00_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7314d505-5d69-4314-a280-3cc8895769bf_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liability for Medicare refund</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_64d18838-b030-4d29-aa67-e3656104360d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_37572bea-f9ad-4d3f-a984-7073507c7f36_terseLabel_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_label_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Transaction Costs</link:label>
    <link:label id="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_documentation_en-US" xlink:label="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" xlink:href="mygn-20221231.xsd#mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" xlink:to="lab_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_d9dd2010-d2c3-4b86-a636-490641c8bd2e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareNet_4ab86806-c163-44bf-8ba5-4b1ee1c1b813_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized software costs</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareNet_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareNet" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_AutoimmuneMember_1c13816d-5f2c-4089-8374-c7752801ea30_terseLabel_en-US" xlink:label="lab_mygn_AutoimmuneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Autoimmune</link:label>
    <link:label id="lab_mygn_AutoimmuneMember_label_en-US" xlink:label="lab_mygn_AutoimmuneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Autoimmune [Member]</link:label>
    <link:label id="lab_mygn_AutoimmuneMember_documentation_en-US" xlink:label="lab_mygn_AutoimmuneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Autoimmune</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AutoimmuneMember" xlink:href="mygn-20221231.xsd#mygn_AutoimmuneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_AutoimmuneMember" xlink:to="lab_mygn_AutoimmuneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_73a300da-e73d-4b12-9683-05e398b9b03f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_OtherStateMember_6433834d-8e7e-441b-b263-12362d6cd833_terseLabel_en-US" xlink:label="lab_mygn_OtherStateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mygn_OtherStateMember_label_en-US" xlink:label="lab_mygn_OtherStateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other State [Member]</link:label>
    <link:label id="lab_mygn_OtherStateMember_documentation_en-US" xlink:label="lab_mygn_OtherStateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other State.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OtherStateMember" xlink:href="mygn-20221231.xsd#mygn_OtherStateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_OtherStateMember" xlink:to="lab_mygn_OtherStateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_45cc1c72-c6e5-4bcb-820f-33d77c5fd876_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_73f02e66-196e-4c09-9932-9df101f07ce6_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_90084e63-f8ae-4ada-b1ac-eadf64fcd8d3_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember_c97ba350-1946-4382-9a78-98025db6db31_terseLabel_en-US" xlink:label="lab_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad RBM, Inc. and Myriad Autoimmune business</link:label>
    <link:label id="lab_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember_label_en-US" xlink:label="lab_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad RBM, Inc. And Myriad Autoimmune Business [Member]</link:label>
    <link:label id="lab_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember_documentation_en-US" xlink:label="lab_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad RBM, Inc. And Myriad Autoimmune Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember" xlink:href="mygn-20221231.xsd#mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember" xlink:to="lab_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_1b134f19-ebe4-47c0-aae6-88273ac0edea_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_277a007a-1364-40eb-9dc2-42520adfd744_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax expense at the statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_368b09d8-1f0e-4fa5-b378-58e6adc7d917_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9311cd2d-54cd-4331-962e-00684fc1e77a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_36822dd6-85d6-4514-8ad2-a3654e401758_terseLabel_en-US" xlink:label="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of accumulated other comprehensive loss upon the deconsolidation of a subsidiary</link:label>
    <link:label id="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_label_en-US" xlink:label="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification From Accumulated Other Comprehensive Loss, Deconsolidation Of Subsidiary</link:label>
    <link:label id="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_documentation_en-US" xlink:label="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification From Accumulated Other Comprehensive Loss, Deconsolidation Of Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" xlink:href="mygn-20221231.xsd#mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" xlink:to="lab_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_09edee58-1786-44a2-9949-11e0531f6739_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_2a3cf5c5-e75f-46b9-a7d0-e718ec219b70_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6b07a802-70d0-4822-b6c6-b0efabcfbf7a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4276a853-a991-49b9-bfe3-517d678351d0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_68a25f25-263d-4784-a833-e49ca0c84a8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_54a05691-bb40-4532-8a5c-ba6101fa38ad_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans_b8457025-e56a-4e39-b592-dfa04c9b495c_terseLabel_en-US" xlink:label="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plans (in shares)</link:label>
    <link:label id="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans</link:label>
    <link:label id="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans_documentation_en-US" xlink:label="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:href="mygn-20221231.xsd#mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:to="lab_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_d9694052-6530-49de-a7cf-00709a97698c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_264cfa30-887f-45ad-baeb-8a303f508ce6_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_fea039e5-4263-4efb-b015-df3fec84e7aa_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_99d9cfcb-3cc1-4253-82f7-dc5209882c53_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and long-lived asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_08f7d3cb-e6c2-400f-86fd-7f12b10e4aeb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_d0970bbc-cbb7-4a99-8185-da070ce73f93_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_LeaseArrangementDomain_e7333400-6b73-4461-878a-82061697516b_terseLabel_en-US" xlink:label="lab_mygn_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Domain]</link:label>
    <link:label id="lab_mygn_LeaseArrangementDomain_label_en-US" xlink:label="lab_mygn_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Domain]</link:label>
    <link:label id="lab_mygn_LeaseArrangementDomain_documentation_en-US" xlink:label="lab_mygn_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementDomain" xlink:href="mygn-20221231.xsd#mygn_LeaseArrangementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_LeaseArrangementDomain" xlink:to="lab_mygn_LeaseArrangementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ff8fe427-7bf9-49f3-9069-9c95926dc0f9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_mygn_BusinessCombinationIntangibleAssetsMeasurementInput_68cd798a-4b11-46e8-8077-4e22e6772c8d_terseLabel_en-US" xlink:label="lab_mygn_BusinessCombinationIntangibleAssetsMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated net cash flows discount rate</link:label>
    <link:label id="lab_mygn_BusinessCombinationIntangibleAssetsMeasurementInput_label_en-US" xlink:label="lab_mygn_BusinessCombinationIntangibleAssetsMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Intangible Assets, Measurement Input</link:label>
    <link:label id="lab_mygn_BusinessCombinationIntangibleAssetsMeasurementInput_documentation_en-US" xlink:label="lab_mygn_BusinessCombinationIntangibleAssetsMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Intangible Assets, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_BusinessCombinationIntangibleAssetsMeasurementInput" xlink:href="mygn-20221231.xsd#mygn_BusinessCombinationIntangibleAssetsMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mygn_BusinessCombinationIntangibleAssetsMeasurementInput" xlink:to="lab_mygn_BusinessCombinationIntangibleAssetsMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6d269c70-3f60-46c5-a036-df9de328b45e_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_165e7f1c-f5ab-40d9-b73d-fe2235a70bbe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_d4753613-0811-4d06-8bee-c4731b0b933b_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>mygn-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6db69074-e648-4be3-ae6d-ea77b2ae08c9,g:6dbaf31c-e8bf-47fc-986c-d695276c3aba-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.myriad.com/role/Cover" xlink:type="simple" xlink:href="mygn-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6c7bf1df-6e66-4b73-95f7-691ed71f2b0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_DocumentType_6c7bf1df-6e66-4b73-95f7-691ed71f2b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_26327ca4-ff76-4e72-b68f-ba994acf1e4f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_DocumentAnnualReport_26327ca4-ff76-4e72-b68f-ba994acf1e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_947feab3-9656-48f6-b0f1-6f67a5dc3484" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_DocumentPeriodEndDate_947feab3-9656-48f6-b0f1-6f67a5dc3484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f3152ac1-d435-405c-94eb-c3fd75157459" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_CurrentFiscalYearEndDate_f3152ac1-d435-405c-94eb-c3fd75157459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_9db20fa3-9bd3-4e60-9418-332e6b581946" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_DocumentTransitionReport_9db20fa3-9bd3-4e60-9418-332e6b581946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5e5deafd-b50c-4a49-8195-75e1963d7d16" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_EntityFileNumber_5e5deafd-b50c-4a49-8195-75e1963d7d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_741b0c4b-b5c6-40b5-8e11-3b842800dfa6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_EntityRegistrantName_741b0c4b-b5c6-40b5-8e11-3b842800dfa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7f615fba-f840-4e03-a767-3f458714119b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7f615fba-f840-4e03-a767-3f458714119b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3f93c464-d467-4117-90a0-b30b0062d36a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_EntityTaxIdentificationNumber_3f93c464-d467-4117-90a0-b30b0062d36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_69860126-ad0b-4abe-8344-95ac0f26a926" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_EntityAddressAddressLine1_69860126-ad0b-4abe-8344-95ac0f26a926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c0bddb16-817c-42ca-9154-1a5a81b6962d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_EntityAddressCityOrTown_c0bddb16-817c-42ca-9154-1a5a81b6962d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_87978c55-b218-4954-8153-edc628383150" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_EntityAddressStateOrProvince_87978c55-b218-4954-8153-edc628383150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f80bd77f-cd17-49a7-bece-f5e30efb296f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_EntityAddressPostalZipCode_f80bd77f-cd17-49a7-bece-f5e30efb296f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_27d056c2-1bc1-4a85-b79d-3e34038b35fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_CityAreaCode_27d056c2-1bc1-4a85-b79d-3e34038b35fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_16b1ca02-3a71-4805-abc2-e1e6b7fd982d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_LocalPhoneNumber_16b1ca02-3a71-4805-abc2-e1e6b7fd982d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_fec11ac1-2f19-44d2-b8d6-501987b732e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_Security12bTitle_fec11ac1-2f19-44d2-b8d6-501987b732e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8c26d4c1-9ef4-49bf-a48a-43286ef46623" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_TradingSymbol_8c26d4c1-9ef4-49bf-a48a-43286ef46623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0f28a820-08f3-4e3f-9385-de59ec476f41" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_SecurityExchangeName_0f28a820-08f3-4e3f-9385-de59ec476f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_7be1d6f4-72f8-4a0b-b865-904eed9fcbf0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_7be1d6f4-72f8-4a0b-b865-904eed9fcbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_7cf23d4f-8cbc-4c46-96e5-403d638aa0a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_EntityVoluntaryFilers_7cf23d4f-8cbc-4c46-96e5-403d638aa0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_f1dfb3bf-91b5-4375-aea3-838fffc0bee4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_EntityCurrentReportingStatus_f1dfb3bf-91b5-4375-aea3-838fffc0bee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6f19f74b-a948-434b-b792-0c7f966d33c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_EntityInteractiveDataCurrent_6f19f74b-a948-434b-b792-0c7f966d33c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_aedaa076-1ac5-429d-aa6c-37b6c45862fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_EntityFilerCategory_aedaa076-1ac5-429d-aa6c-37b6c45862fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_78960d26-7a40-4d44-81f5-86ba8c6f6a83" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_EntitySmallBusiness_78960d26-7a40-4d44-81f5-86ba8c6f6a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_723990c5-3364-44c1-a362-8f0306bed997" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_EntityEmergingGrowthCompany_723990c5-3364-44c1-a362-8f0306bed997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_5d22c16a-8a42-4cd6-a27b-61749f51efef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_IcfrAuditorAttestationFlag_5d22c16a-8a42-4cd6-a27b-61749f51efef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_da3295d9-faf8-4ab9-9194-e89395d24a6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_EntityShellCompany_da3295d9-faf8-4ab9-9194-e89395d24a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_324fec6a-38ce-43a5-9b82-98ea5a23c256" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_EntityPublicFloat_324fec6a-38ce-43a5-9b82-98ea5a23c256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9dc2df5c-db7f-4a08-a1ca-a3f3ae0d2585" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9dc2df5c-db7f-4a08-a1ca-a3f3ae0d2585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_0df92f7f-8e49-4936-a617-56012184443c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_0df92f7f-8e49-4936-a617-56012184443c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d700be07-f45c-4b3b-92ed-1e877cde6efd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_AmendmentFlag_d700be07-f45c-4b3b-92ed-1e877cde6efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_cdbb80f5-34e5-4525-9bce-073d8872643e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_DocumentFiscalYearFocus_cdbb80f5-34e5-4525-9bce-073d8872643e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d9c64891-0ce9-4f14-9725-3c17c9ad0a1d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d9c64891-0ce9-4f14-9725-3c17c9ad0a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f0f696f2-b217-4543-ab5d-bd89a5231d35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d66971d8-e361-47a4-b6b6-f9a02d23c964" xlink:to="loc_dei_EntityCentralIndexKey_f0f696f2-b217-4543-ab5d-bd89a5231d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/AuditInformation" xlink:type="simple" xlink:href="mygn-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AuditInformationAbstract_65acd2bf-a7d8-4022-8ee7-ab2b6fc922a1" xlink:href="mygn-20221231.xsd#mygn_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_2dd2478f-09d8-4e0c-ba7a-ff49be1aafc1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_AuditInformationAbstract_65acd2bf-a7d8-4022-8ee7-ab2b6fc922a1" xlink:to="loc_dei_AuditorName_2dd2478f-09d8-4e0c-ba7a-ff49be1aafc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_eba05ef3-bec3-4e38-a207-480fabed1d4c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_AuditInformationAbstract_65acd2bf-a7d8-4022-8ee7-ab2b6fc922a1" xlink:to="loc_dei_AuditorLocation_eba05ef3-bec3-4e38-a207-480fabed1d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_23429b55-e39d-4a95-8ae4-2b82093529b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_AuditInformationAbstract_65acd2bf-a7d8-4022-8ee7-ab2b6fc922a1" xlink:to="loc_dei_AuditorFirmId_23429b55-e39d-4a95-8ae4-2b82093529b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mygn-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_313acf1e-f7c0-4126-9a77-87df988e421d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d1e213c0-9ca1-4372-893f-57bab5c19bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_313acf1e-f7c0-4126-9a77-87df988e421d" xlink:to="loc_us-gaap_AssetsAbstract_d1e213c0-9ca1-4372-893f-57bab5c19bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d1833f9f-4077-448e-b0aa-edd851c874dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d1e213c0-9ca1-4372-893f-57bab5c19bd2" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d1833f9f-4077-448e-b0aa-edd851c874dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b859850e-e4ea-4a7d-9c6f-2a8b19a2cdde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d1833f9f-4077-448e-b0aa-edd851c874dd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b859850e-e4ea-4a7d-9c6f-2a8b19a2cdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_7f403bd4-162d-468b-8ba8-3a713d57ba12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d1833f9f-4077-448e-b0aa-edd851c874dd" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_7f403bd4-162d-468b-8ba8-3a713d57ba12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f1876201-d8d3-4dd6-81b3-9704eb25a69f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d1833f9f-4077-448e-b0aa-edd851c874dd" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f1876201-d8d3-4dd6-81b3-9704eb25a69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_22578a8e-0e1d-4f1d-a259-88201c917216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d1833f9f-4077-448e-b0aa-edd851c874dd" xlink:to="loc_us-gaap_InventoryNet_22578a8e-0e1d-4f1d-a259-88201c917216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_bc9be3e7-a802-4bb8-b756-0e19144eee64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d1833f9f-4077-448e-b0aa-edd851c874dd" xlink:to="loc_us-gaap_PrepaidTaxes_bc9be3e7-a802-4bb8-b756-0e19144eee64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_98821dfc-fac4-4630-b5f9-5aa297a729e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d1833f9f-4077-448e-b0aa-edd851c874dd" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_98821dfc-fac4-4630-b5f9-5aa297a729e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6be8c1db-f3b6-4bfd-8bec-3bc31ad20085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d1833f9f-4077-448e-b0aa-edd851c874dd" xlink:to="loc_us-gaap_AssetsCurrent_6be8c1db-f3b6-4bfd-8bec-3bc31ad20085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3976ab4b-27dc-499b-b5c0-e69d623362cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d1e213c0-9ca1-4372-893f-57bab5c19bd2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3976ab4b-27dc-499b-b5c0-e69d623362cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_996d9e7b-4d95-4efa-8a25-0d68774243d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d1e213c0-9ca1-4372-893f-57bab5c19bd2" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_996d9e7b-4d95-4efa-8a25-0d68774243d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_95ea4f9d-f1d5-4662-9353-d2b4c9750466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d1e213c0-9ca1-4372-893f-57bab5c19bd2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_95ea4f9d-f1d5-4662-9353-d2b4c9750466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7b5d935b-5d05-4058-9055-193c86ef731c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d1e213c0-9ca1-4372-893f-57bab5c19bd2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7b5d935b-5d05-4058-9055-193c86ef731c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9deb8e3e-297d-44e0-b502-6e28b249be85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d1e213c0-9ca1-4372-893f-57bab5c19bd2" xlink:to="loc_us-gaap_Goodwill_9deb8e3e-297d-44e0-b502-6e28b249be85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5fb44f72-1204-4d5a-9968-c05e952a90ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d1e213c0-9ca1-4372-893f-57bab5c19bd2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5fb44f72-1204-4d5a-9968-c05e952a90ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_bffd645f-defe-4234-b358-ce7e7c6b2907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d1e213c0-9ca1-4372-893f-57bab5c19bd2" xlink:to="loc_us-gaap_Assets_bffd645f-defe-4234-b358-ce7e7c6b2907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b25a10c2-39ed-4827-b3fc-cf6eee10758d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_313acf1e-f7c0-4126-9a77-87df988e421d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b25a10c2-39ed-4827-b3fc-cf6eee10758d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_949ea5cc-e490-4d70-803d-50aee3768dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b25a10c2-39ed-4827-b3fc-cf6eee10758d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_949ea5cc-e490-4d70-803d-50aee3768dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b1e64d4c-31c3-4ab8-a39b-50f9acde3643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_949ea5cc-e490-4d70-803d-50aee3768dcb" xlink:to="loc_us-gaap_AccountsPayableCurrent_b1e64d4c-31c3-4ab8-a39b-50f9acde3643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_00eeaad3-1336-478d-bcce-601449a19a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_949ea5cc-e490-4d70-803d-50aee3768dcb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_00eeaad3-1336-478d-bcce-601449a19a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4c5f5f49-d0f7-4f2d-aee6-fd668fb73fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_949ea5cc-e490-4d70-803d-50aee3768dcb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4c5f5f49-d0f7-4f2d-aee6-fd668fb73fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ef41b4a5-6307-4848-ad1c-db6895dec499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_949ea5cc-e490-4d70-803d-50aee3768dcb" xlink:to="loc_us-gaap_LiabilitiesCurrent_ef41b4a5-6307-4848-ad1c-db6895dec499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_UnrecognizedTaxBenefitsNet_f63324b1-f1ea-48c3-8495-85ffa7004b17" xlink:href="mygn-20221231.xsd#mygn_UnrecognizedTaxBenefitsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b25a10c2-39ed-4827-b3fc-cf6eee10758d" xlink:to="loc_mygn_UnrecognizedTaxBenefitsNet_f63324b1-f1ea-48c3-8495-85ffa7004b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4a12e03e-5876-4e71-b831-888eca4e350a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b25a10c2-39ed-4827-b3fc-cf6eee10758d" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4a12e03e-5876-4e71-b831-888eca4e350a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c94772cf-cdc0-4a80-9a0a-46a910e61bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b25a10c2-39ed-4827-b3fc-cf6eee10758d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c94772cf-cdc0-4a80-9a0a-46a910e61bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4b087d2b-c139-4046-a2cd-e31c5493d804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b25a10c2-39ed-4827-b3fc-cf6eee10758d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4b087d2b-c139-4046-a2cd-e31c5493d804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_49148fb0-5cc8-444f-b5dd-eb0c141990eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b25a10c2-39ed-4827-b3fc-cf6eee10758d" xlink:to="loc_us-gaap_Liabilities_49148fb0-5cc8-444f-b5dd-eb0c141990eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_87d6d41f-87f9-4b63-b18f-1a57e81043c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b25a10c2-39ed-4827-b3fc-cf6eee10758d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_87d6d41f-87f9-4b63-b18f-1a57e81043c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_cc7e5174-1be3-41e4-be1c-cdc42b1f09fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b25a10c2-39ed-4827-b3fc-cf6eee10758d" xlink:to="loc_us-gaap_StockholdersEquityAbstract_cc7e5174-1be3-41e4-be1c-cdc42b1f09fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e655c003-fc09-4297-9134-23f2fb432510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cc7e5174-1be3-41e4-be1c-cdc42b1f09fc" xlink:to="loc_us-gaap_CommonStockValue_e655c003-fc09-4297-9134-23f2fb432510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e7cdf991-1681-4c51-a3fd-f0a9251449d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cc7e5174-1be3-41e4-be1c-cdc42b1f09fc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e7cdf991-1681-4c51-a3fd-f0a9251449d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fca3ffaa-5c81-4ad6-81ab-ff50c7dd15bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cc7e5174-1be3-41e4-be1c-cdc42b1f09fc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fca3ffaa-5c81-4ad6-81ab-ff50c7dd15bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7deeadb5-f978-4183-b824-5309e794a148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cc7e5174-1be3-41e4-be1c-cdc42b1f09fc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7deeadb5-f978-4183-b824-5309e794a148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1c6601ee-b276-40f5-855c-acdddcae9c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cc7e5174-1be3-41e4-be1c-cdc42b1f09fc" xlink:to="loc_us-gaap_StockholdersEquity_1c6601ee-b276-40f5-855c-acdddcae9c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_f76916e3-b168-42af-a9bd-d31f0c058ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cc7e5174-1be3-41e4-be1c-cdc42b1f09fc" xlink:to="loc_us-gaap_MinorityInterest_f76916e3-b168-42af-a9bd-d31f0c058ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e5b3d83c-5737-472a-974b-73ee8abe2609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cc7e5174-1be3-41e4-be1c-cdc42b1f09fc" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e5b3d83c-5737-472a-974b-73ee8abe2609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_648add0e-96bb-40a8-8d83-de3a3b118e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b25a10c2-39ed-4827-b3fc-cf6eee10758d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_648add0e-96bb-40a8-8d83-de3a3b118e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="mygn-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c0693b17-d906-46ee-a021-66ba34037764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2e49b8d6-3ec7-4a09-9948-6e167520a0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0693b17-d906-46ee-a021-66ba34037764" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2e49b8d6-3ec7-4a09-9948-6e167520a0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_179f2add-82b4-4649-8368-b82fa7630335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0693b17-d906-46ee-a021-66ba34037764" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_179f2add-82b4-4649-8368-b82fa7630335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="mygn-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_be5ca5f1-8953-4f0c-b869-603b83e6c307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cfd67334-68a1-40ef-aeb1-21b965d2d9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5ca5f1-8953-4f0c-b869-603b83e6c307" xlink:to="loc_us-gaap_StatementTable_cfd67334-68a1-40ef-aeb1-21b965d2d9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a66ea91f-cc02-42a8-a43a-78daf6503739" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cfd67334-68a1-40ef-aeb1-21b965d2d9c2" xlink:to="loc_srt_ProductOrServiceAxis_a66ea91f-cc02-42a8-a43a-78daf6503739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e3b3df6f-19dc-4460-8320-ca8e8d431f4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a66ea91f-cc02-42a8-a43a-78daf6503739" xlink:to="loc_srt_ProductsAndServicesDomain_e3b3df6f-19dc-4460-8320-ca8e8d431f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TestingRevenueMember_a8323883-aa93-4984-8ad7-69a668559c63" xlink:href="mygn-20221231.xsd#mygn_TestingRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e3b3df6f-19dc-4460-8320-ca8e8d431f4e" xlink:to="loc_mygn_TestingRevenueMember_a8323883-aa93-4984-8ad7-69a668559c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_d6735b23-b635-4ff5-9c33-63efd88b1f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e3b3df6f-19dc-4460-8320-ca8e8d431f4e" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_d6735b23-b635-4ff5-9c33-63efd88b1f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cfd67334-68a1-40ef-aeb1-21b965d2d9c2" xlink:to="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_994076c8-c36c-4a11-9469-c9f0b9a41c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_994076c8-c36c-4a11-9469-c9f0b9a41c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_3e3129e5-7b82-483a-b225-6da63829ef86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_3e3129e5-7b82-483a-b225-6da63829ef86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_55155670-23cc-4c04-b9bb-d7cf73a5645b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3e3129e5-7b82-483a-b225-6da63829ef86" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_55155670-23cc-4c04-b9bb-d7cf73a5645b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_de0f3036-5ad9-4bd0-809e-b15b000d274d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3e3129e5-7b82-483a-b225-6da63829ef86" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_de0f3036-5ad9-4bd0-809e-b15b000d274d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_bf93e2a5-cd15-45fc-81f9-30ba04fbf65d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3e3129e5-7b82-483a-b225-6da63829ef86" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_bf93e2a5-cd15-45fc-81f9-30ba04fbf65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_3e69b03d-5701-4889-8d32-3ab7fbc9e21e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3e3129e5-7b82-483a-b225-6da63829ef86" xlink:to="loc_us-gaap_LitigationSettlementExpense_3e69b03d-5701-4889-8d32-3ab7fbc9e21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_f7d265f7-6e3b-4c2b-924d-5ee1ac6fb6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3e3129e5-7b82-483a-b225-6da63829ef86" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_f7d265f7-6e3b-4c2b-924d-5ee1ac6fb6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b6fe5b78-72c2-4311-8d6d-91e7f4067933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_3e3129e5-7b82-483a-b225-6da63829ef86" xlink:to="loc_us-gaap_CostsAndExpenses_b6fe5b78-72c2-4311-8d6d-91e7f4067933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c56e0f99-2294-489d-952b-48338a82b57f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_OperatingIncomeLoss_c56e0f99-2294-489d-952b-48338a82b57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c599485b-3b35-4a18-accb-bc17568ab9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c599485b-3b35-4a18-accb-bc17568ab9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4f36a4f6-7892-4eb1-b2d5-8ded93183019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c599485b-3b35-4a18-accb-bc17568ab9d3" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4f36a4f6-7892-4eb1-b2d5-8ded93183019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_dc9e6743-db70-4d50-a4f3-a51263db73ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c599485b-3b35-4a18-accb-bc17568ab9d3" xlink:to="loc_us-gaap_InterestExpense_dc9e6743-db70-4d50-a4f3-a51263db73ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c90ebd7f-47a1-449d-93b1-4a7efeae2f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c599485b-3b35-4a18-accb-bc17568ab9d3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c90ebd7f-47a1-449d-93b1-4a7efeae2f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b7302ee1-6280-4a64-a58a-c77a8ccc2321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c599485b-3b35-4a18-accb-bc17568ab9d3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_b7302ee1-6280-4a64-a58a-c77a8ccc2321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_78428e0e-4de0-438d-9190-c6f103d72885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_78428e0e-4de0-438d-9190-c6f103d72885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5a5ff4f5-f692-49e4-9111-37e6c9b9494c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5a5ff4f5-f692-49e4-9111-37e6c9b9494c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_21c6b9fd-92ea-4e44-a71d-da383c01f4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_ProfitLoss_21c6b9fd-92ea-4e44-a71d-da383c01f4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_36cc1799-1642-4e73-b1bb-f8a6f459ee3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_36cc1799-1642-4e73-b1bb-f8a6f459ee3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_42de9e7b-e256-4f5d-8ecc-f69c831b212c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_NetIncomeLoss_42de9e7b-e256-4f5d-8ecc-f69c831b212c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EarningsPerShareBasicAndDilutedEPSAbstract_9c7bb729-3075-437a-80b3-549603d1e2e8" xlink:href="mygn-20221231.xsd#mygn_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_mygn_EarningsPerShareBasicAndDilutedEPSAbstract_9c7bb729-3075-437a-80b3-549603d1e2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d4b4607c-1c93-421d-acbf-62fd6fec5713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_EarningsPerShareBasicAndDilutedEPSAbstract_9c7bb729-3075-437a-80b3-549603d1e2e8" xlink:to="loc_us-gaap_EarningsPerShareBasic_d4b4607c-1c93-421d-acbf-62fd6fec5713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_57118798-2bad-4630-a96a-6c76a563cae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_EarningsPerShareBasicAndDilutedEPSAbstract_9c7bb729-3075-437a-80b3-549603d1e2e8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_57118798-2bad-4630-a96a-6c76a563cae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d867ae04-4581-4b94-9ba0-7f4529f730cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6bc12a23-877d-4a7b-b972-3bc494b9156f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d867ae04-4581-4b94-9ba0-7f4529f730cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_391052f6-3fc0-4b53-a96b-5fe1630f0fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d867ae04-4581-4b94-9ba0-7f4529f730cd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_391052f6-3fc0-4b53-a96b-5fe1630f0fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2d69efbe-7770-46a7-baa6-59da39170508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_d867ae04-4581-4b94-9ba0-7f4529f730cd" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2d69efbe-7770-46a7-baa6-59da39170508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="mygn-20221231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_631c17d7-c6e6-4433-af7c-084045fdd7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_334acf76-2d3c-4007-9f96-3b68f864f6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_631c17d7-c6e6-4433-af7c-084045fdd7a3" xlink:to="loc_us-gaap_NetIncomeLoss_334acf76-2d3c-4007-9f96-3b68f864f6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e8523100-4267-4e04-80b7-b19904c6b6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_631c17d7-c6e6-4433-af7c-084045fdd7a3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e8523100-4267-4e04-80b7-b19904c6b6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_076f084d-bfb7-417b-a394-f65dba39c0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_631c17d7-c6e6-4433-af7c-084045fdd7a3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_076f084d-bfb7-417b-a394-f65dba39c0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_06e62184-5900-4ff6-95b3-67a658422d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_631c17d7-c6e6-4433-af7c-084045fdd7a3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_06e62184-5900-4ff6-95b3-67a658422d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="mygn-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_07031d3d-43a4-4136-be9a-e7ed2719ae5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_75ea43cf-1e38-494e-81ee-bd3bf5d43814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_07031d3d-43a4-4136-be9a-e7ed2719ae5f" xlink:to="loc_us-gaap_StatementTable_75ea43cf-1e38-494e-81ee-bd3bf5d43814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fdc946b4-0600-4f1a-a5e4-c0c404de1b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_75ea43cf-1e38-494e-81ee-bd3bf5d43814" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fdc946b4-0600-4f1a-a5e4-c0c404de1b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8db71410-9317-416f-b6f3-5f083b892b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fdc946b4-0600-4f1a-a5e4-c0c404de1b95" xlink:to="loc_us-gaap_EquityComponentDomain_8db71410-9317-416f-b6f3-5f083b892b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f743625a-47b6-41db-9c84-ed623a4b20a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8db71410-9317-416f-b6f3-5f083b892b34" xlink:to="loc_us-gaap_CommonStockMember_f743625a-47b6-41db-9c84-ed623a4b20a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2239bf0b-a761-4e04-8e34-2f420bb12185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8db71410-9317-416f-b6f3-5f083b892b34" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2239bf0b-a761-4e04-8e34-2f420bb12185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_17692eed-5a1d-4e43-be57-9a1a23fafc19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8db71410-9317-416f-b6f3-5f083b892b34" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_17692eed-5a1d-4e43-be57-9a1a23fafc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_119592a9-731f-4a83-9517-fd26ec54072a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8db71410-9317-416f-b6f3-5f083b892b34" xlink:to="loc_us-gaap_RetainedEarningsMember_119592a9-731f-4a83-9517-fd26ec54072a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f9c4f90f-fcc6-4504-a41b-376df01ef962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_75ea43cf-1e38-494e-81ee-bd3bf5d43814" xlink:to="loc_us-gaap_StatementLineItems_f9c4f90f-fcc6-4504-a41b-376df01ef962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b82d13bc-bb0f-4260-938e-f692461fa89c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f9c4f90f-fcc6-4504-a41b-376df01ef962" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b82d13bc-bb0f-4260-938e-f692461fa89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_948dbcd5-f3ff-4e79-aab7-a4964e169718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b82d13bc-bb0f-4260-938e-f692461fa89c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_948dbcd5-f3ff-4e79-aab7-a4964e169718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2cbcb730-8973-4a03-8139-7ef269c46a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b82d13bc-bb0f-4260-938e-f692461fa89c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2cbcb730-8973-4a03-8139-7ef269c46a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fa33e3a9-e207-4bca-b5bf-2fad7bfc3ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b82d13bc-bb0f-4260-938e-f692461fa89c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fa33e3a9-e207-4bca-b5bf-2fad7bfc3ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_21fd8021-b371-44f3-9bed-8aac3e9561a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b82d13bc-bb0f-4260-938e-f692461fa89c" xlink:to="loc_us-gaap_NetIncomeLoss_21fd8021-b371-44f3-9bed-8aac3e9561a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_90052b74-7160-4f9d-8540-ef37d0829824" xlink:href="mygn-20221231.xsd#mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b82d13bc-bb0f-4260-938e-f692461fa89c" xlink:to="loc_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary_90052b74-7160-4f9d-8540-ef37d0829824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e7267612-2c31-429f-8c7c-8d424cf66194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b82d13bc-bb0f-4260-938e-f692461fa89c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e7267612-2c31-429f-8c7c-8d424cf66194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6f209ef5-1e10-4189-bee2-7ec522378ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b82d13bc-bb0f-4260-938e-f692461fa89c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6f209ef5-1e10-4189-bee2-7ec522378ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mygn-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_efd916e3-e1fe-47b8-b4d9-a9fa9abab098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9df7b46d-a740-445a-ac70-26e0bf6a2ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_efd916e3-e1fe-47b8-b4d9-a9fa9abab098" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9df7b46d-a740-445a-ac70-26e0bf6a2ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dfaea964-7070-4d97-8d44-f25489470085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9df7b46d-a740-445a-ac70-26e0bf6a2ef6" xlink:to="loc_us-gaap_NetIncomeLoss_dfaea964-7070-4d97-8d44-f25489470085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ba47e5e2-220d-4234-9ef0-49f4b8bfd7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9df7b46d-a740-445a-ac70-26e0bf6a2ef6" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ba47e5e2-220d-4234-9ef0-49f4b8bfd7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_f34c713d-56d1-454a-a07c-4846413f46f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ba47e5e2-220d-4234-9ef0-49f4b8bfd7c4" xlink:to="loc_us-gaap_DepreciationAndAmortization_f34c713d-56d1-454a-a07c-4846413f46f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonCashInterestExpense_eadc1acc-0476-4ace-ace8-8dd795a61e62" xlink:href="mygn-20221231.xsd#mygn_NonCashInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ba47e5e2-220d-4234-9ef0-49f4b8bfd7c4" xlink:to="loc_mygn_NonCashInterestExpense_eadc1acc-0476-4ace-ace8-8dd795a61e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1c4a56fc-fe4d-4b7b-8896-049fd9059620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ba47e5e2-220d-4234-9ef0-49f4b8bfd7c4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1c4a56fc-fe4d-4b7b-8896-049fd9059620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_a4128f13-3172-4556-a3c3-a9324481f561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ba47e5e2-220d-4234-9ef0-49f4b8bfd7c4" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_a4128f13-3172-4556-a3c3-a9324481f561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_30757161-f955-41a5-a6ce-1e5801b8c1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ba47e5e2-220d-4234-9ef0-49f4b8bfd7c4" xlink:to="loc_us-gaap_ShareBasedCompensation_30757161-f955-41a5-a6ce-1e5801b8c1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_d7c697c4-cb64-4c05-94ba-81415d83c2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ba47e5e2-220d-4234-9ef0-49f4b8bfd7c4" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_d7c697c4-cb64-4c05-94ba-81415d83c2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_0cb2163b-83ff-4b43-9e88-431ed2fec74d" xlink:href="mygn-20221231.xsd#mygn_IncreaseDecreaseInUnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ba47e5e2-220d-4234-9ef0-49f4b8bfd7c4" xlink:to="loc_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits_0cb2163b-83ff-4b43-9e88-431ed2fec74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_77703729-dd22-43c6-9081-8fdfd91c2a74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ba47e5e2-220d-4234-9ef0-49f4b8bfd7c4" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_77703729-dd22-43c6-9081-8fdfd91c2a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_e7fa5203-cd3b-42e2-8b07-7038a68587fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ba47e5e2-220d-4234-9ef0-49f4b8bfd7c4" xlink:to="loc_us-gaap_InventoryWriteDown_e7fa5203-cd3b-42e2-8b07-7038a68587fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_985d5fdc-1c7f-465b-ba5d-1b52b5f6d19b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ba47e5e2-220d-4234-9ef0-49f4b8bfd7c4" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_985d5fdc-1c7f-465b-ba5d-1b52b5f6d19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_108aa8dd-991e-4bd2-8fa2-071d75b70626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ba47e5e2-220d-4234-9ef0-49f4b8bfd7c4" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_108aa8dd-991e-4bd2-8fa2-071d75b70626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f1ce442e-322d-4398-95a4-6d1b1b263b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ba47e5e2-220d-4234-9ef0-49f4b8bfd7c4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f1ce442e-322d-4398-95a4-6d1b1b263b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_1a2b6900-9821-4483-8f77-5a2cee97baa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f1ce442e-322d-4398-95a4-6d1b1b263b42" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_1a2b6900-9821-4483-8f77-5a2cee97baa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c3d9869c-8c18-4f7e-bad3-55a2d47bce00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f1ce442e-322d-4398-95a4-6d1b1b263b42" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c3d9869c-8c18-4f7e-bad3-55a2d47bce00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_62b8ec4c-7907-488c-8957-cb0a0151a237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f1ce442e-322d-4398-95a4-6d1b1b263b42" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_62b8ec4c-7907-488c-8957-cb0a0151a237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_788aae62-8457-4761-abd4-d4eb532cf60e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f1ce442e-322d-4398-95a4-6d1b1b263b42" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_788aae62-8457-4761-abd4-d4eb532cf60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_286785d3-028c-4d8e-8d13-81da6f46ab13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f1ce442e-322d-4398-95a4-6d1b1b263b42" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_286785d3-028c-4d8e-8d13-81da6f46ab13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0ebef0f2-5a3a-4613-a436-b0577325c771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f1ce442e-322d-4398-95a4-6d1b1b263b42" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0ebef0f2-5a3a-4613-a436-b0577325c771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_fadd5c2f-5582-484b-a296-5435969f2e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f1ce442e-322d-4398-95a4-6d1b1b263b42" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_fadd5c2f-5582-484b-a296-5435969f2e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_94c560c8-6b30-4830-b27d-fb075953369c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f1ce442e-322d-4398-95a4-6d1b1b263b42" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_94c560c8-6b30-4830-b27d-fb075953369c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fe5e6c1a-e2ed-416d-80ff-c4b5682d728d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ba47e5e2-220d-4234-9ef0-49f4b8bfd7c4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fe5e6c1a-e2ed-416d-80ff-c4b5682d728d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_826ac994-9a22-4e29-a23c-929b7f8f79c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_efd916e3-e1fe-47b8-b4d9-a9fa9abab098" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_826ac994-9a22-4e29-a23c-929b7f8f79c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_963361c8-f0f6-49bd-b6f0-b7444e53dbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_826ac994-9a22-4e29-a23c-929b7f8f79c0" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_963361c8-f0f6-49bd-b6f0-b7444e53dbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_fc9490e3-8ca6-4497-a312-2473617d7b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_826ac994-9a22-4e29-a23c-929b7f8f79c0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_fc9490e3-8ca6-4497-a312-2473617d7b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_9b74d406-e950-4e14-ba26-1ab373f3f5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_826ac994-9a22-4e29-a23c-929b7f8f79c0" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_9b74d406-e950-4e14-ba26-1ab373f3f5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f4050c07-1461-405e-a20e-9f32e0e85211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_826ac994-9a22-4e29-a23c-929b7f8f79c0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f4050c07-1461-405e-a20e-9f32e0e85211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_4e732b51-60e6-46ce-89b8-9842cadad6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_826ac994-9a22-4e29-a23c-929b7f8f79c0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_4e732b51-60e6-46ce-89b8-9842cadad6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e051baec-ba1f-4685-a494-2cb9c315fb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_826ac994-9a22-4e29-a23c-929b7f8f79c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e051baec-ba1f-4685-a494-2cb9c315fb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7446c27c-efa5-40c4-8fff-3f22ec040036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_efd916e3-e1fe-47b8-b4d9-a9fa9abab098" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7446c27c-efa5-40c4-8fff-3f22ec040036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b850bbee-ae15-4b4e-b699-343aa3da6bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7446c27c-efa5-40c4-8fff-3f22ec040036" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b850bbee-ae15-4b4e-b699-343aa3da6bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4c543e88-a56b-4c9d-957d-e21f461140d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7446c27c-efa5-40c4-8fff-3f22ec040036" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4c543e88-a56b-4c9d-957d-e21f461140d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_5021802a-9257-4cc6-a75d-71c618cca8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7446c27c-efa5-40c4-8fff-3f22ec040036" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_5021802a-9257-4cc6-a75d-71c618cca8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts_b8db0c03-2bd5-4c2a-a04e-837403250eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtRestructuringCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7446c27c-efa5-40c4-8fff-3f22ec040036" xlink:to="loc_us-gaap_PaymentsOfDebtRestructuringCosts_b8db0c03-2bd5-4c2a-a04e-837403250eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_a0e325c6-b24b-4c12-aecf-5feb25190c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7446c27c-efa5-40c4-8fff-3f22ec040036" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_a0e325c6-b24b-4c12-aecf-5feb25190c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1f1ff9ff-7fdf-42c7-bc4d-a24252e86e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7446c27c-efa5-40c4-8fff-3f22ec040036" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1f1ff9ff-7fdf-42c7-bc4d-a24252e86e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b05e89f6-5b9c-4850-a4a5-dd3dddbeddc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_efd916e3-e1fe-47b8-b4d9-a9fa9abab098" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b05e89f6-5b9c-4850-a4a5-dd3dddbeddc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5839138a-aa0f-4baf-b43d-c7fe652ee4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_efd916e3-e1fe-47b8-b4d9-a9fa9abab098" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5839138a-aa0f-4baf-b43d-c7fe652ee4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52496136-7984-4b60-b71f-872bcf32cb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_efd916e3-e1fe-47b8-b4d9-a9fa9abab098" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52496136-7984-4b60-b71f-872bcf32cb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7c109b83-193a-46a9-8a5d-513c6fb89c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_efd916e3-e1fe-47b8-b4d9-a9fa9abab098" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7c109b83-193a-46a9-8a5d-513c6fb89c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mygn-20221231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0d48a9c9-7f5c-40a5-9cc9-e97c48e6de2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_7aa2cc91-c42a-4e34-a316-2775c57809a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d48a9c9-7f5c-40a5-9cc9-e97c48e6de2b" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_7aa2cc91-c42a-4e34-a316-2775c57809a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecurities" xlink:type="simple" xlink:href="mygn-20221231.xsd#MarketableInvestmentSecurities"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4d6b1e96-697a-4f29-90bd-0fca1968596b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_757fa21e-e005-44ff-afec-9508c165ae7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4d6b1e96-697a-4f29-90bd-0fca1968596b" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_757fa21e-e005-44ff-afec-9508c165ae7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="mygn-20221231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_acedb9d5-ea1c-4ebd-815f-4c36d48e9f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ab507a11-cc58-4cd4-a561-6fe1418ecd28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_acedb9d5-ea1c-4ebd-815f-4c36d48e9f1e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ab507a11-cc58-4cd4-a561-6fe1418ecd28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNet" xlink:type="simple" xlink:href="mygn-20221231.xsd#PropertyPlantandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5503a0b6-6ace-4656-84a3-2f00e8cc0756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_db523292-5b43-489b-80df-874f9e4fcf6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5503a0b6-6ace-4656-84a3-2f00e8cc0756" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_db523292-5b43-489b-80df-874f9e4fcf6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="mygn-20221231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4982e71f-b059-4d2b-9393-147a4cb38722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_6294c8c1-d89e-4f7c-9d66-6738cb6809e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4982e71f-b059-4d2b-9393-147a4cb38722" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_6294c8c1-d89e-4f7c-9d66-6738cb6809e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="mygn-20221231.xsd#AccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_c1ba6f0a-2332-4657-b8ef-7369bf931a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e12e1df2-9f81-4193-a3e6-2460538c62a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c1ba6f0a-2332-4657-b8ef-7369bf931a6f" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e12e1df2-9f81-4193-a3e6-2460538c62a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LongTermDebt" xlink:type="simple" xlink:href="mygn-20221231.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3c0e2beb-4345-4ad5-9efe-438bad77fc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_59e5f562-55b9-42a2-b0c3-e0d895dbdfd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3c0e2beb-4345-4ad5-9efe-438bad77fc8c" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_59e5f562-55b9-42a2-b0c3-e0d895dbdfd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OtherLongTermLiabilities" xlink:type="simple" xlink:href="mygn-20221231.xsd#OtherLongTermLiabilities"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OtherLongTermLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_6bc54f54-2be0-43d2-b1c2-f4766f0c9454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_c9cd755d-9d0f-4685-a796-7b699c586ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_6bc54f54-2be0-43d2-b1c2-f4766f0c9454" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_c9cd755d-9d0f-4685-a796-7b699c586ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquity" xlink:type="simple" xlink:href="mygn-20221231.xsd#PreferredandCommonStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c70448ee-eb86-419d-b7fc-11c1469ecaed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ccf26228-bc69-4d24-b8c4-a0728c17e33f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c70448ee-eb86-419d-b7fc-11c1469ecaed" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ccf26228-bc69-4d24-b8c4-a0728c17e33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mygn-20221231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5c010668-d1e4-4e20-b5d8-e219455c07da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1eb01993-d93a-4c07-b94f-318711e656d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5c010668-d1e4-4e20-b5d8-e219455c07da" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1eb01993-d93a-4c07-b94f-318711e656d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mygn-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5a0ce075-edf2-45cd-815b-3906ae6d9e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_986379eb-840e-4c30-9a3f-251d34af04f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5a0ce075-edf2-45cd-815b-3906ae6d9e3f" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_986379eb-840e-4c30-9a3f-251d34af04f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mygn-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e1b65321-abff-4ec7-adaa-ff660ea2c7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3941db3a-02fb-4139-a56e-ba07645550b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e1b65321-abff-4ec7-adaa-ff660ea2c7c5" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3941db3a-02fb-4139-a56e-ba07645550b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/Leases" xlink:type="simple" xlink:href="mygn-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a062fe79-df7a-4b1f-a4d5-9c7800db6f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_449cdbc3-dd9b-46af-a605-8ec9810059a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a062fe79-df7a-4b1f-a4d5-9c7800db6f6c" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_449cdbc3-dd9b-46af-a605-8ec9810059a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/EmployeeDeferredSavingsPlan" xlink:type="simple" xlink:href="mygn-20221231.xsd#EmployeeDeferredSavingsPlan"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/EmployeeDeferredSavingsPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b1744f1a-122f-4a6c-90b6-5ab4ebe02063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_c3d8787e-a524-4e0b-8189-17ad26b59884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b1744f1a-122f-4a6c-90b6-5ab4ebe02063" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_c3d8787e-a524-4e0b-8189-17ad26b59884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SegmentandRelatedInformation" xlink:type="simple" xlink:href="mygn-20221231.xsd#SegmentandRelatedInformation"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SegmentandRelatedInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_81772640-ed3a-40ac-a88d-7b6bda79bd92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_b66e7e06-8daf-42c4-a532-c961ee8e80c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_81772640-ed3a-40ac-a88d-7b6bda79bd92" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_b66e7e06-8daf-42c4-a532-c961ee8e80c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/BusinessAcquisition" xlink:type="simple" xlink:href="mygn-20221231.xsd#BusinessAcquisition"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/BusinessAcquisition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3042aba0-c7d4-4715-ba1a-3038ecb59f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_ea21623f-c983-421e-94b4-7c1863765e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3042aba0-c7d4-4715-ba1a-3038ecb59f22" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_ea21623f-c983-421e-94b4-7c1863765e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/Divestitures" xlink:type="simple" xlink:href="mygn-20221231.xsd#Divestitures"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/Divestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0af7f0dc-0869-4894-abeb-81485f352dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_d9ae3960-605b-4924-b14d-58c47538c50c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0af7f0dc-0869-4894-abeb-81485f352dcf" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_d9ae3960-605b-4924-b14d-58c47538c50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SupplementalCashFlowInformation" xlink:type="simple" xlink:href="mygn-20221231.xsd#SupplementalCashFlowInformation"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SupplementalCashFlowInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_97261e7c-eeb5-442a-830f-7ba500e8d592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_601e1de3-fd51-42ca-8b14-a7ca2d956834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_97261e7c-eeb5-442a-830f-7ba500e8d592" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_601e1de3-fd51-42ca-8b14-a7ca2d956834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mygn-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f8fca7ec-bfa4-4645-b9f8-851b3322f0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f8fca7ec-bfa4-4645-b9f8-851b3322f0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_5093b07b-ae9c-45c0-b86c-cc35766695d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_UseOfEstimates_5093b07b-ae9c-45c0-b86c-cc35766695d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_de121038-7060-43f6-970b-345cf7e667d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_de121038-7060-43f6-970b-345cf7e667d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_7161ac1a-20d9-4530-8bd5-84e4ebc039b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_7161ac1a-20d9-4530-8bd5-84e4ebc039b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ae246772-4dba-45b7-b109-ae28d66c3a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ae246772-4dba-45b7-b109-ae28d66c3a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_13ba4a50-1fb4-4575-9fa9-16a65a199936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_13ba4a50-1fb4-4575-9fa9-16a65a199936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_a6399a9e-9024-439e-aa50-cca98e992fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_a6399a9e-9024-439e-aa50-cca98e992fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_ecc6d7b7-6782-4e25-91ab-d48d5f062fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_ecc6d7b7-6782-4e25-91ab-d48d5f062fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_4133ee92-98ab-45fb-9a97-867b8d2baa3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_4133ee92-98ab-45fb-9a97-867b8d2baa3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b16a0bc7-1915-47f9-90c0-52af63ca1ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b16a0bc7-1915-47f9-90c0-52af63ca1ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_a1da71aa-cde8-4e56-86ca-e08fb279d754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_a1da71aa-cde8-4e56-86ca-e08fb279d754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_668e5a5a-1427-4f6a-9665-ebec73a74a31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_668e5a5a-1427-4f6a-9665-ebec73a74a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_0905baa3-bee0-4f22-97b1-44b8a15e1040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_0905baa3-bee0-4f22-97b1-44b8a15e1040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_db8f160a-8a27-4c4d-b772-5430990de4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_db8f160a-8a27-4c4d-b772-5430990de4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c96e9cf8-8460-4769-813e-c367b27e71bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c96e9cf8-8460-4769-813e-c367b27e71bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3fe11b52-02b9-4239-bbdb-b61fc1f19e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3fe11b52-02b9-4239-bbdb-b61fc1f19e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OtherIncomeExpensePolicyPolicyTextBlock_db788fea-2c70-4686-a3cd-2a7048ca77b8" xlink:href="mygn-20221231.xsd#mygn_OtherIncomeExpensePolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_mygn_OtherIncomeExpensePolicyPolicyTextBlock_db788fea-2c70-4686-a3cd-2a7048ca77b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_b84d5c0e-9515-457d-86a5-b76a2313489d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_b84d5c0e-9515-457d-86a5-b76a2313489d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_ca1d4c93-5e3c-4052-8d40-a120f43a424c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_ca1d4c93-5e3c-4052-8d40-a120f43a424c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_65d0e06c-0aa6-4596-aa42-8d0fc59cc95d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_65d0e06c-0aa6-4596-aa42-8d0fc59cc95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1a0cd695-6c40-4df1-b467-2b295b86bc34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1a0cd695-6c40-4df1-b467-2b295b86bc34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_899c8ac8-c4d2-45fc-8042-e1896d927d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7974f20-bacf-4a7e-905d-65501d3e86c7" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_899c8ac8-c4d2-45fc-8042-e1896d927d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mygn-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c3d665ea-34bd-4830-830a-eab0c45aec01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_98f50b91-728e-48ff-810b-0d120c16c4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3d665ea-34bd-4830-830a-eab0c45aec01" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_98f50b91-728e-48ff-810b-0d120c16c4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_49595d51-bf63-4cbe-b4ae-ddc1916d3e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3d665ea-34bd-4830-830a-eab0c45aec01" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_49595d51-bf63-4cbe-b4ae-ddc1916d3e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_4d46385b-f9b9-4286-b5de-8866fcb47b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3d665ea-34bd-4830-830a-eab0c45aec01" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_4d46385b-f9b9-4286-b5de-8866fcb47b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_461edb3c-b562-49ec-9ab3-ed74f6e19c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3d665ea-34bd-4830-830a-eab0c45aec01" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_461edb3c-b562-49ec-9ab3-ed74f6e19c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_18ff1d41-e5db-47f7-9818-1ba26052d64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3d665ea-34bd-4830-830a-eab0c45aec01" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_18ff1d41-e5db-47f7-9818-1ba26052d64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_e96fd670-6aec-41e7-8c78-df449260e089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3d665ea-34bd-4830-830a-eab0c45aec01" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_e96fd670-6aec-41e7-8c78-df449260e089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_969e5dae-d5fd-4f16-ba08-67fdb3a33202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3d665ea-34bd-4830-830a-eab0c45aec01" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_969e5dae-d5fd-4f16-ba08-67fdb3a33202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_0fb02514-3abc-488b-8711-2be55eca0100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3d665ea-34bd-4830-830a-eab0c45aec01" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_0fb02514-3abc-488b-8711-2be55eca0100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesTables" xlink:type="simple" xlink:href="mygn-20221231.xsd#MarketableInvestmentSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_871303d3-e6f8-4193-905c-c06b38c8eb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_869fb102-54b3-4451-b009-61c4930aa6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_871303d3-e6f8-4193-905c-c06b38c8eb5a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_869fb102-54b3-4451-b009-61c4930aa6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_28b99c35-6b37-4063-a806-a58fae43b9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_871303d3-e6f8-4193-905c-c06b38c8eb5a" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_28b99c35-6b37-4063-a806-a58fae43b9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="mygn-20221231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1983ac6d-992a-455b-816e-376ab2824e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_2b73e8e5-967d-4906-b1a1-6e5ad44af5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1983ac6d-992a-455b-816e-376ab2824e38" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_2b73e8e5-967d-4906-b1a1-6e5ad44af5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2c9e7f28-634d-4af7-a191-e5c48d1edb96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1983ac6d-992a-455b-816e-376ab2824e38" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2c9e7f28-634d-4af7-a191-e5c48d1edb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetTables" xlink:type="simple" xlink:href="mygn-20221231.xsd#PropertyPlantandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_02450172-e677-43d2-9331-ac8ffa3f8dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_59a42913-290f-4807-bc57-75a2dc8eb391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_02450172-e677-43d2-9331-ac8ffa3f8dcc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_59a42913-290f-4807-bc57-75a2dc8eb391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="mygn-20221231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24f647f8-ed5d-4b0d-bd63-6b3755203671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_457854b1-7902-40d6-976c-970b0e9bcea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24f647f8-ed5d-4b0d-bd63-6b3755203671" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_457854b1-7902-40d6-976c-970b0e9bcea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_fac1ab67-6e2d-4080-8b46-222ed6bb9ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24f647f8-ed5d-4b0d-bd63-6b3755203671" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_fac1ab67-6e2d-4080-8b46-222ed6bb9ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_8b8bdefc-6404-43ab-9ba1-52dfe5b7fc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24f647f8-ed5d-4b0d-bd63-6b3755203671" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_8b8bdefc-6404-43ab-9ba1-52dfe5b7fc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_ffe15952-d68d-4197-9d93-4da93c3313b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24f647f8-ed5d-4b0d-bd63-6b3755203671" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_ffe15952-d68d-4197-9d93-4da93c3313b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_de492b6d-d383-4167-8547-e4aad9c29b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24f647f8-ed5d-4b0d-bd63-6b3755203671" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_de492b6d-d383-4167-8547-e4aad9c29b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="mygn-20221231.xsd#AccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_82561ce7-7582-469e-bc30-6abc11e0d55f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_97c4018e-e824-4343-9246-617ee7b2f4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_82561ce7-7582-469e-bc30-6abc11e0d55f" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_97c4018e-e824-4343-9246-617ee7b2f4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OtherLongTermLiabilitiesTables" xlink:type="simple" xlink:href="mygn-20221231.xsd#OtherLongTermLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OtherLongTermLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_3bc22d98-90ed-4eec-bbfc-8960468a756c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_31e7183c-a123-4051-98e6-19585f9927df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_3bc22d98-90ed-4eec-bbfc-8960468a756c" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_31e7183c-a123-4051-98e6-19585f9927df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables" xlink:type="simple" xlink:href="mygn-20221231.xsd#PreferredandCommonStockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3d9dd9fa-b505-4e75-8974-e276b1c4ae4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_a9cfe7ea-8bca-451b-80af-21da9ba38247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3d9dd9fa-b505-4e75-8974-e276b1c4ae4a" xlink:to="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_a9cfe7ea-8bca-451b-80af-21da9ba38247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mygn-20221231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c45fe58e-1c76-47e6-a094-5da35b321f81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3f1d1c4f-cbcd-4bf5-a7f7-73fe89ca3dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c45fe58e-1c76-47e6-a094-5da35b321f81" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3f1d1c4f-cbcd-4bf5-a7f7-73fe89ca3dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_cb61f902-0395-490f-9f69-ea8999fe0fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c45fe58e-1c76-47e6-a094-5da35b321f81" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_cb61f902-0395-490f-9f69-ea8999fe0fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1f235fe3-1933-4f1f-93a1-38fef0e40d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c45fe58e-1c76-47e6-a094-5da35b321f81" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1f235fe3-1933-4f1f-93a1-38fef0e40d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock_3f9cb2b5-8a97-43c1-91d7-debbaf99e2e2" xlink:href="mygn-20221231.xsd#mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c45fe58e-1c76-47e6-a094-5da35b321f81" xlink:to="loc_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock_3f9cb2b5-8a97-43c1-91d7-debbaf99e2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_001fe42b-b438-4d41-a2aa-ba86721920f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c45fe58e-1c76-47e6-a094-5da35b321f81" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_001fe42b-b438-4d41-a2aa-ba86721920f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_1ac7ee78-70d5-4e84-9d2d-ed8d5b76b1af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c45fe58e-1c76-47e6-a094-5da35b321f81" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_1ac7ee78-70d5-4e84-9d2d-ed8d5b76b1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_eddeb82a-acb9-4191-a9ff-128807c6d28e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c45fe58e-1c76-47e6-a094-5da35b321f81" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_eddeb82a-acb9-4191-a9ff-128807c6d28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mygn-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_84b95dc7-5710-4071-adb4-f5a90396894d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0dfad865-5de3-42a0-90c0-9b23c84db3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84b95dc7-5710-4071-adb4-f5a90396894d" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0dfad865-5de3-42a0-90c0-9b23c84db3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_491cce8e-7d2c-49ef-941e-15194982106f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84b95dc7-5710-4071-adb4-f5a90396894d" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_491cce8e-7d2c-49ef-941e-15194982106f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_74cbdc1f-b0f6-49f7-8e48-4840cffbec53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84b95dc7-5710-4071-adb4-f5a90396894d" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_74cbdc1f-b0f6-49f7-8e48-4840cffbec53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_985fe7dd-dfff-476d-acd2-feb9e70b0275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84b95dc7-5710-4071-adb4-f5a90396894d" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_985fe7dd-dfff-476d-acd2-feb9e70b0275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_ede72c2f-acde-4131-ba3f-1243f80ef1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84b95dc7-5710-4071-adb4-f5a90396894d" xlink:to="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_ede72c2f-acde-4131-ba3f-1243f80ef1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_77b75559-8e25-4e90-8e7a-854579c81662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84b95dc7-5710-4071-adb4-f5a90396894d" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_77b75559-8e25-4e90-8e7a-854579c81662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LeasesTables" xlink:type="simple" xlink:href="mygn-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fd9cd3ce-11e7-4c5a-bf92-6d57dd341ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_aee4cd1c-74cc-4e7b-bb7a-a66cee3123d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fd9cd3ce-11e7-4c5a-bf92-6d57dd341ad2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_aee4cd1c-74cc-4e7b-bb7a-a66cee3123d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/EmployeeDeferredSavingsPlanTables" xlink:type="simple" xlink:href="mygn-20221231.xsd#EmployeeDeferredSavingsPlanTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/EmployeeDeferredSavingsPlanTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_780280b6-781a-4143-9024-83abee61f055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_058490b0-a08b-420c-950b-159fa98cb507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_780280b6-781a-4143-9024-83abee61f055" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_058490b0-a08b-420c-950b-159fa98cb507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SegmentandRelatedInformationTables" xlink:type="simple" xlink:href="mygn-20221231.xsd#SegmentandRelatedInformationTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SegmentandRelatedInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_97d73b77-69a1-4d0d-916d-4d1549796065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_3a69444e-294b-41b8-979b-0fa9c46b3854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_97d73b77-69a1-4d0d-916d-4d1549796065" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_3a69444e-294b-41b8-979b-0fa9c46b3854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/BusinessAcquisitionTables" xlink:type="simple" xlink:href="mygn-20221231.xsd#BusinessAcquisitionTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/BusinessAcquisitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4db9584a-b2b2-4e8d-ab60-0183733ef53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_62c8f606-9e7d-4f46-bc8b-7abfed5b140f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4db9584a-b2b2-4e8d-ab60-0183733ef53f" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_62c8f606-9e7d-4f46-bc8b-7abfed5b140f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_e1207504-5b90-4723-8c6c-e1edafba61e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4db9584a-b2b2-4e8d-ab60-0183733ef53f" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_e1207504-5b90-4723-8c6c-e1edafba61e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/DivestituresTables" xlink:type="simple" xlink:href="mygn-20221231.xsd#DivestituresTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/DivestituresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0ea784b0-88a4-47f3-b3a6-c8c36802115d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_79838ee5-74ad-4e72-be65-9370356be75b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0ea784b0-88a4-47f3-b3a6-c8c36802115d" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_79838ee5-74ad-4e72-be65-9370356be75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SupplementalCashFlowInformationTables" xlink:type="simple" xlink:href="mygn-20221231.xsd#SupplementalCashFlowInformationTables"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SupplementalCashFlowInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_d10760e5-b469-4741-9c5d-7ba94b12140d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_c1b8406e-30b4-43a8-9aec-462576d3c228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_d10760e5-b469-4741-9c5d-7ba94b12140d" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_c1b8406e-30b4-43a8-9aec-462576d3c228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e15b1a98-756c-4362-b65f-96fe20d8fc1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_b7e98ada-60ee-45ab-9bb6-203b7f4c5afd" xlink:href="mygn-20221231.xsd#mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e15b1a98-756c-4362-b65f-96fe20d8fc1d" xlink:to="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_b7e98ada-60ee-45ab-9bb6-203b7f4c5afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b973a670-6dac-45f3-ac55-28273d8a5fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_b7e98ada-60ee-45ab-9bb6-203b7f4c5afd" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b973a670-6dac-45f3-ac55-28273d8a5fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_469dff97-4ed7-467b-a3ec-a844f774c241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b973a670-6dac-45f3-ac55-28273d8a5fc3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_469dff97-4ed7-467b-a3ec-a844f774c241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember_a9bc661c-13da-4e94-b631-a8001246bb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_469dff97-4ed7-467b-a3ec-a844f774c241" xlink:to="loc_us-gaap_GovernmentContractsConcentrationRiskMember_a9bc661c-13da-4e94-b631-a8001246bb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_5df08029-a7a4-42ee-b8f9-094bf2f44c1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_b7e98ada-60ee-45ab-9bb6-203b7f4c5afd" xlink:to="loc_srt_MajorCustomersAxis_5df08029-a7a4-42ee-b8f9-094bf2f44c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_52028d2e-9f5e-46bc-8261-5a2220156b2a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_5df08029-a7a4-42ee-b8f9-094bf2f44c1b" xlink:to="loc_srt_NameOfMajorCustomerDomain_52028d2e-9f5e-46bc-8261-5a2220156b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MedicareMember_bdf3f927-d944-42ec-a834-304be94f650b" xlink:href="mygn-20221231.xsd#mygn_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_52028d2e-9f5e-46bc-8261-5a2220156b2a" xlink:to="loc_mygn_MedicareMember_bdf3f927-d944-42ec-a834-304be94f650b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5e18d3f0-6afe-4c45-8c80-c1010a1cb914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_b7e98ada-60ee-45ab-9bb6-203b7f4c5afd" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5e18d3f0-6afe-4c45-8c80-c1010a1cb914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b17ba749-71f9-4e76-b8a7-bd055d747248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5e18d3f0-6afe-4c45-8c80-c1010a1cb914" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b17ba749-71f9-4e76-b8a7-bd055d747248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_c8913ae1-5941-464a-98e8-7815aebb8023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b17ba749-71f9-4e76-b8a7-bd055d747248" xlink:to="loc_us-gaap_SalesRevenueNetMember_c8913ae1-5941-464a-98e8-7815aebb8023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60947fe4-869b-4af0-99c9-d4783a0b4cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_b7e98ada-60ee-45ab-9bb6-203b7f4c5afd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60947fe4-869b-4af0-99c9-d4783a0b4cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79ee98d9-2b6c-4126-ae51-c1ef87776e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60947fe4-869b-4af0-99c9-d4783a0b4cc5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79ee98d9-2b6c-4126-ae51-c1ef87776e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_eb9bec1b-d0f6-4abb-87f4-1a5d3609c304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79ee98d9-2b6c-4126-ae51-c1ef87776e65" xlink:to="loc_us-gaap_EquipmentMember_eb9bec1b-d0f6-4abb-87f4-1a5d3609c304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_529e6536-48dd-45cf-8c17-fd7013bfa54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79ee98d9-2b6c-4126-ae51-c1ef87776e65" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_529e6536-48dd-45cf-8c17-fd7013bfa54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_2cbb0c8c-0e92-4a5e-847b-ba07f3429e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_b7e98ada-60ee-45ab-9bb6-203b7f4c5afd" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_2cbb0c8c-0e92-4a5e-847b-ba07f3429e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_6f779fc0-2200-4cc1-a884-40c7d333264a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_2cbb0c8c-0e92-4a5e-847b-ba07f3429e77" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_6f779fc0-2200-4cc1-a884-40c7d333264a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember_7fa351af-1ec4-4324-a80e-e685dc8ed925" xlink:href="mygn-20221231.xsd#mygn_PerformanceObligationEstimatedTransactionPriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_6f779fc0-2200-4cc1-a884-40c7d333264a" xlink:to="loc_mygn_PerformanceObligationEstimatedTransactionPriceMember_7fa351af-1ec4-4324-a80e-e685dc8ed925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_d880abd0-549c-483f-86f4-65e3df8e625b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_b7e98ada-60ee-45ab-9bb6-203b7f4c5afd" xlink:to="loc_srt_RestatementAxis_d880abd0-549c-483f-86f4-65e3df8e625b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_97e6e560-0a82-4d70-a446-c3d455b8bdf2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_d880abd0-549c-483f-86f4-65e3df8e625b" xlink:to="loc_srt_RestatementDomain_97e6e560-0a82-4d70-a446-c3d455b8bdf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_06034cac-46bf-4ae5-8b62-8910df5f75ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_97e6e560-0a82-4d70-a446-c3d455b8bdf2" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_06034cac-46bf-4ae5-8b62-8910df5f75ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ad445909-8545-40b1-a6f8-0d7cc78b58e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_b7e98ada-60ee-45ab-9bb6-203b7f4c5afd" xlink:to="loc_srt_RangeAxis_ad445909-8545-40b1-a6f8-0d7cc78b58e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_592a9d6c-2c46-493e-a8e5-81c142cd5560" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ad445909-8545-40b1-a6f8-0d7cc78b58e8" xlink:to="loc_srt_RangeMember_592a9d6c-2c46-493e-a8e5-81c142cd5560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_876d0cc3-0fbb-4c9d-bbee-4a33f3feced2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_592a9d6c-2c46-493e-a8e5-81c142cd5560" xlink:to="loc_srt_MinimumMember_876d0cc3-0fbb-4c9d-bbee-4a33f3feced2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2a014d37-6e51-4ef3-8281-216d113ad8f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_592a9d6c-2c46-493e-a8e5-81c142cd5560" xlink:to="loc_srt_MaximumMember_2a014d37-6e51-4ef3-8281-216d113ad8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:href="mygn-20221231.xsd#mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_b7e98ada-60ee-45ab-9bb6-203b7f4c5afd" xlink:to="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ce899eaa-9518-44e7-92a5-53ad59c85885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ce899eaa-9518-44e7-92a5-53ad59c85885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_a6f3786a-56a8-4c20-9bf8-b74a279d1828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_RestrictedCash_a6f3786a-56a8-4c20-9bf8-b74a279d1828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_86b93bd7-458b-4445-a6b2-a0bf925d5c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_RestrictedCashCurrent_86b93bd7-458b-4445-a6b2-a0bf925d5c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_3177800a-db15-4041-a654-f6979f54b8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_3177800a-db15-4041-a654-f6979f54b8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_88872db8-4a53-4c7d-859f-0b9bcf09a57b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_88872db8-4a53-4c7d-859f-0b9bcf09a57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_91cf6519-7003-46f7-8c55-f059699c9f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_91cf6519-7003-46f7-8c55-f059699c9f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_6fb454a8-a405-4456-93ff-e836c25452a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_6fb454a8-a405-4456-93ff-e836c25452a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet_d4771102-06ac-4bbc-96da-65224b62fe61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareNet_d4771102-06ac-4bbc-96da-65224b62fe61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_687e74fb-7d87-412f-a1ca-1afe05242421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_687e74fb-7d87-412f-a1ca-1afe05242421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CARESActOf2020MedicarePaymentAmount_7cb33f23-60b4-4838-bfbb-fa8618aca006" xlink:href="mygn-20221231.xsd#mygn_CARESActOf2020MedicarePaymentAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_mygn_CARESActOf2020MedicarePaymentAmount_7cb33f23-60b4-4838-bfbb-fa8618aca006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_35a34e6d-6ff5-4f68-a502-932dd1cdf47c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_35a34e6d-6ff5-4f68-a502-932dd1cdf47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncreaseDecreaseInEarningsLossPerShare_bc59d4c9-94e9-460f-9d14-58b23e957322" xlink:href="mygn-20221231.xsd#mygn_IncreaseDecreaseInEarningsLossPerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_mygn_IncreaseDecreaseInEarningsLossPerShare_bc59d4c9-94e9-460f-9d14-58b23e957322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained_2cbc45cc-d332-439f-8ad0-98ba680d8b38" xlink:href="mygn-20221231.xsd#mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained_2cbc45cc-d332-439f-8ad0-98ba680d8b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_63a6cfeb-a14a-4424-a55d-b16d5b0405d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_63a6cfeb-a14a-4424-a55d-b16d5b0405d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9e76634c-b4cd-46db-862d-3834fb126e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9e76634c-b4cd-46db-862d-3834fb126e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_22a28291-0a51-4804-b530-f7181a7f2f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_CapitalizedContractCostGross_22a28291-0a51-4804-b530-f7181a7f2f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_faec4ec3-4a48-4098-97a5-8c484250607e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_faec4ec3-4a48-4098-97a5-8c484250607e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CARESActOf2020ProviderReliefFundAmount_282911d9-2abe-4645-8c71-7423a90d82e5" xlink:href="mygn-20221231.xsd#mygn_CARESActOf2020ProviderReliefFundAmount"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_d69a23bc-a774-46ea-9ae1-56f92ed0dd6f" xlink:to="loc_mygn_CARESActOf2020ProviderReliefFundAmount_282911d9-2abe-4645-8c71-7423a90d82e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_408c02a6-bb8c-4e4b-b172-a6a3678eddfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ea254d08-00c8-420e-874d-a4ceb376893a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_408c02a6-bb8c-4e4b-b172-a6a3678eddfd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ea254d08-00c8-420e-874d-a4ceb376893a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_8bca7d63-bd40-4203-affa-657cb0606959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_408c02a6-bb8c-4e4b-b172-a6a3678eddfd" xlink:to="loc_us-gaap_RestrictedCash_8bca7d63-bd40-4203-affa-657cb0606959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6a6f1efd-926b-45d6-af21-9673ce5d2dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_408c02a6-bb8c-4e4b-b172-a6a3678eddfd" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6a6f1efd-926b-45d6-af21-9673ce5d2dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4dd900f9-e0eb-4a22-90ab-99e6841045f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_90ee2f66-024d-46b7-a3a0-03ef8d91db68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4dd900f9-e0eb-4a22-90ab-99e6841045f1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_90ee2f66-024d-46b7-a3a0-03ef8d91db68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a2fc7cf6-db41-4a99-af60-ee278f9308cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_90ee2f66-024d-46b7-a3a0-03ef8d91db68" xlink:to="loc_srt_ProductOrServiceAxis_a2fc7cf6-db41-4a99-af60-ee278f9308cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_748a01ca-3df3-4030-8980-342db3c5c98e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a2fc7cf6-db41-4a99-af60-ee278f9308cf" xlink:to="loc_srt_ProductsAndServicesDomain_748a01ca-3df3-4030-8980-342db3c5c98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TestingRevenueMember_275fea63-cff4-4a73-956b-3d665dac8d69" xlink:href="mygn-20221231.xsd#mygn_TestingRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_748a01ca-3df3-4030-8980-342db3c5c98e" xlink:to="loc_mygn_TestingRevenueMember_275fea63-cff4-4a73-956b-3d665dac8d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_HereditaryCancerTestingMember_add142ec-67fb-42eb-8b01-b7855f91f316" xlink:href="mygn-20221231.xsd#mygn_HereditaryCancerTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TestingRevenueMember_275fea63-cff4-4a73-956b-3d665dac8d69" xlink:to="loc_mygn_HereditaryCancerTestingMember_add142ec-67fb-42eb-8b01-b7855f91f316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TumorProfilingMember_702d4ce5-f431-4238-8d26-d6fa40bc741f" xlink:href="mygn-20221231.xsd#mygn_TumorProfilingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TestingRevenueMember_275fea63-cff4-4a73-956b-3d665dac8d69" xlink:to="loc_mygn_TumorProfilingMember_702d4ce5-f431-4238-8d26-d6fa40bc741f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PrenatalTestingMember_c853b366-3269-4e8b-8691-b213364b2655" xlink:href="mygn-20221231.xsd#mygn_PrenatalTestingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TestingRevenueMember_275fea63-cff4-4a73-956b-3d665dac8d69" xlink:to="loc_mygn_PrenatalTestingMember_c853b366-3269-4e8b-8691-b213364b2655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmacogenomicsMember_1fba5d6c-961d-47b5-968c-a2acfda27eca" xlink:href="mygn-20221231.xsd#mygn_PharmacogenomicsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TestingRevenueMember_275fea63-cff4-4a73-956b-3d665dac8d69" xlink:to="loc_mygn_PharmacogenomicsMember_1fba5d6c-961d-47b5-968c-a2acfda27eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AutoimmuneMember_934aa0e1-f2b0-42c0-9d4a-559b5b93bb19" xlink:href="mygn-20221231.xsd#mygn_AutoimmuneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TestingRevenueMember_275fea63-cff4-4a73-956b-3d665dac8d69" xlink:to="loc_mygn_AutoimmuneMember_934aa0e1-f2b0-42c0-9d4a-559b5b93bb19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OtherTestingMember_d96332e1-d351-4dec-9ce4-181f81562285" xlink:href="mygn-20221231.xsd#mygn_OtherTestingMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TestingRevenueMember_275fea63-cff4-4a73-956b-3d665dac8d69" xlink:to="loc_mygn_OtherTestingMember_d96332e1-d351-4dec-9ce4-181f81562285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_e6a1b578-d1f1-4784-bc1d-937fa6cc73c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_748a01ca-3df3-4030-8980-342db3c5c98e" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_e6a1b578-d1f1-4784-bc1d-937fa6cc73c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_655b0f9e-3efa-4fa9-b695-43f88e3a76c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_90ee2f66-024d-46b7-a3a0-03ef8d91db68" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_655b0f9e-3efa-4fa9-b695-43f88e3a76c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3aac0dce-4dd0-403a-ba5e-be497483d6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_655b0f9e-3efa-4fa9-b695-43f88e3a76c7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3aac0dce-4dd0-403a-ba5e-be497483d6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_17e9471d-87fb-457d-8b22-b65c1e4b2ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_846adcd2-c3c1-4389-a6b5-3c0e2f861d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_17e9471d-87fb-457d-8b22-b65c1e4b2ddb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_846adcd2-c3c1-4389-a6b5-3c0e2f861d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e5f6dbd5-9ef3-4adb-ba49-fbd3d7e49b1c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_846adcd2-c3c1-4389-a6b5-3c0e2f861d08" xlink:to="loc_srt_StatementGeographicalAxis_e5f6dbd5-9ef3-4adb-ba49-fbd3d7e49b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e10587cb-c16a-4d17-a6b3-a03d34f9629b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e5f6dbd5-9ef3-4adb-ba49-fbd3d7e49b1c" xlink:to="loc_srt_SegmentGeographicalDomain_e10587cb-c16a-4d17-a6b3-a03d34f9629b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_62b3182f-fa9e-46df-ae4c-c78e1655f6fd" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e10587cb-c16a-4d17-a6b3-a03d34f9629b" xlink:to="loc_country_US_62b3182f-fa9e-46df-ae4c-c78e1655f6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_826e386d-ed1f-4f45-afca-f027d13da416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e10587cb-c16a-4d17-a6b3-a03d34f9629b" xlink:to="loc_us-gaap_NonUsMember_826e386d-ed1f-4f45-afca-f027d13da416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b4309dd8-37ac-4d2a-9e27-32d87d2e9962" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_846adcd2-c3c1-4389-a6b5-3c0e2f861d08" xlink:to="loc_srt_ProductOrServiceAxis_b4309dd8-37ac-4d2a-9e27-32d87d2e9962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7cd135a5-4f67-4964-a88e-e7e75adb8e5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b4309dd8-37ac-4d2a-9e27-32d87d2e9962" xlink:to="loc_srt_ProductsAndServicesDomain_7cd135a5-4f67-4964-a88e-e7e75adb8e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TestingRevenueMember_5d37f3e7-56ce-4ca5-b8bc-bdcba514a4d0" xlink:href="mygn-20221231.xsd#mygn_TestingRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7cd135a5-4f67-4964-a88e-e7e75adb8e5d" xlink:to="loc_mygn_TestingRevenueMember_5d37f3e7-56ce-4ca5-b8bc-bdcba514a4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_HereditaryCancerTestingMember_ce483dec-f693-45dd-ba82-189be11c74fd" xlink:href="mygn-20221231.xsd#mygn_HereditaryCancerTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TestingRevenueMember_5d37f3e7-56ce-4ca5-b8bc-bdcba514a4d0" xlink:to="loc_mygn_HereditaryCancerTestingMember_ce483dec-f693-45dd-ba82-189be11c74fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TumorProfilingMember_b4db2618-c80a-44cd-b72a-af7ddcb8c6c0" xlink:href="mygn-20221231.xsd#mygn_TumorProfilingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TestingRevenueMember_5d37f3e7-56ce-4ca5-b8bc-bdcba514a4d0" xlink:to="loc_mygn_TumorProfilingMember_b4db2618-c80a-44cd-b72a-af7ddcb8c6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PrenatalTestingMember_7bef2883-a7fb-4c08-a2e0-fc4dbe3c70b5" xlink:href="mygn-20221231.xsd#mygn_PrenatalTestingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TestingRevenueMember_5d37f3e7-56ce-4ca5-b8bc-bdcba514a4d0" xlink:to="loc_mygn_PrenatalTestingMember_7bef2883-a7fb-4c08-a2e0-fc4dbe3c70b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_PharmacogenomicsMember_576f1b50-629e-4e03-92b3-a34e11e68653" xlink:href="mygn-20221231.xsd#mygn_PharmacogenomicsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TestingRevenueMember_5d37f3e7-56ce-4ca5-b8bc-bdcba514a4d0" xlink:to="loc_mygn_PharmacogenomicsMember_576f1b50-629e-4e03-92b3-a34e11e68653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AutoimmuneMember_645ee1f6-147f-4dfa-90a8-f9035c193562" xlink:href="mygn-20221231.xsd#mygn_AutoimmuneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TestingRevenueMember_5d37f3e7-56ce-4ca5-b8bc-bdcba514a4d0" xlink:to="loc_mygn_AutoimmuneMember_645ee1f6-147f-4dfa-90a8-f9035c193562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OtherTestingMember_5d4d9fbd-d517-48eb-9d7d-b01fb5cd86b2" xlink:href="mygn-20221231.xsd#mygn_OtherTestingMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_TestingRevenueMember_5d37f3e7-56ce-4ca5-b8bc-bdcba514a4d0" xlink:to="loc_mygn_OtherTestingMember_5d4d9fbd-d517-48eb-9d7d-b01fb5cd86b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_208cb738-93fb-416d-aa68-a303da8dd824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7cd135a5-4f67-4964-a88e-e7e75adb8e5d" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_208cb738-93fb-416d-aa68-a303da8dd824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_639810eb-2f42-4a4a-aec3-12373004a2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_846adcd2-c3c1-4389-a6b5-3c0e2f861d08" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_639810eb-2f42-4a4a-aec3-12373004a2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8f575034-146d-45fd-adf0-32c9aba89fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_639810eb-2f42-4a4a-aec3-12373004a2b8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8f575034-146d-45fd-adf0-32c9aba89fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4c50b0bb-e9c3-4c08-ba5f-f1a4c5f69f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_b2acdd09-b240-435a-aebe-9a791c889a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c50b0bb-e9c3-4c08-ba5f-f1a4c5f69f3d" xlink:to="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_b2acdd09-b240-435a-aebe-9a791c889a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward_f3205e56-4c21-4890-8dd1-4e0f4dce42e9" xlink:href="mygn-20221231.xsd#mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_b2acdd09-b240-435a-aebe-9a791c889a34" xlink:to="loc_mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward_f3205e56-4c21-4890-8dd1-4e0f4dce42e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c15b68c0-456e-4960-91f1-b9ce7a3d027d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward_f3205e56-4c21-4890-8dd1-4e0f4dce42e9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c15b68c0-456e-4960-91f1-b9ce7a3d027d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_b0918c23-180d-4d8e-920b-9ff7af4549a7" xlink:href="mygn-20221231.xsd#mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward_f3205e56-4c21-4890-8dd1-4e0f4dce42e9" xlink:to="loc_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_b0918c23-180d-4d8e-920b-9ff7af4549a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityPrepayments_5675f21e-88dd-4e1f-a886-ca1d0cc2d3b7" xlink:href="mygn-20221231.xsd#mygn_ContractWithCustomerLiabilityPrepayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward_f3205e56-4c21-4890-8dd1-4e0f4dce42e9" xlink:to="loc_mygn_ContractWithCustomerLiabilityPrepayments_5675f21e-88dd-4e1f-a886-ca1d0cc2d3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContractWithCustomerLiabilityDivestitures_b9493946-97a2-428b-bf9c-c8e71db303d0" xlink:href="mygn-20221231.xsd#mygn_ContractWithCustomerLiabilityDivestitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward_f3205e56-4c21-4890-8dd1-4e0f4dce42e9" xlink:to="loc_mygn_ContractWithCustomerLiabilityDivestitures_b9493946-97a2-428b-bf9c-c8e71db303d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_eab8ec56-4c23-4f89-bc05-db1200efb144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward_f3205e56-4c21-4890-8dd1-4e0f4dce42e9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_eab8ec56-4c23-4f89-bc05-db1200efb144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7c973257-c22f-4efa-9314-73389ba0da3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_886cfc1e-0bf7-4823-a26f-32ba933519ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c973257-c22f-4efa-9314-73389ba0da3b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_886cfc1e-0bf7-4823-a26f-32ba933519ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_f81c2d8b-dbce-4ab4-807b-a93072175fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c973257-c22f-4efa-9314-73389ba0da3b" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_f81c2d8b-dbce-4ab4-807b-a93072175fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_50fb00f6-3da4-4276-aa05-18d8b97734fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c973257-c22f-4efa-9314-73389ba0da3b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_50fb00f6-3da4-4276-aa05-18d8b97734fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_eaa65e99-740f-459b-8038-884cc4168da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c973257-c22f-4efa-9314-73389ba0da3b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_eaa65e99-740f-459b-8038-884cc4168da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesForeignCurrencyCumulativeTranslationAdjustmentsDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesForeignCurrencyCumulativeTranslationAdjustmentsDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesForeignCurrencyCumulativeTranslationAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d483516d-a3b6-4508-bae4-8ffcdc81b6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward_e51b66ee-4712-4b58-9925-dffd9581fe15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CumulativeTranslationAdjustmentSummaryRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d483516d-a3b6-4508-bae4-8ffcdc81b6d3" xlink:to="loc_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward_e51b66ee-4712-4b58-9925-dffd9581fe15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_9bf7fae4-3cf8-4955-91ad-e93c70282293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward_e51b66ee-4712-4b58-9925-dffd9581fe15" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_9bf7fae4-3cf8-4955-91ad-e93c70282293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease_a10a2462-1c1b-4737-9b9e-54cfb58c37a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward_e51b66ee-4712-4b58-9925-dffd9581fe15" xlink:to="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease_a10a2462-1c1b-4737-9b9e-54cfb58c37a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_63595a7a-ac36-4e52-90eb-295970129746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward_e51b66ee-4712-4b58-9925-dffd9581fe15" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_63595a7a-ac36-4e52-90eb-295970129746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bc0e5fdd-e01a-441f-9983-9d313da4edd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e80378b9-c64d-4ab0-9bf5-64750c16e40f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bc0e5fdd-e01a-441f-9983-9d313da4edd6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e80378b9-c64d-4ab0-9bf5-64750c16e40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_124337a6-f506-4256-81da-f87d146264bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e80378b9-c64d-4ab0-9bf5-64750c16e40f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_124337a6-f506-4256-81da-f87d146264bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2496d826-aaa0-4a57-8c76-1e96bcbe4b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_124337a6-f506-4256-81da-f87d146264bb" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2496d826-aaa0-4a57-8c76-1e96bcbe4b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_5831f0ea-e0ea-4587-abba-229b60461dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2496d826-aaa0-4a57-8c76-1e96bcbe4b9e" xlink:to="loc_us-gaap_CashMember_5831f0ea-e0ea-4587-abba-229b60461dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_850b3e7b-d987-4a50-8d4c-a9b39a38eef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2496d826-aaa0-4a57-8c76-1e96bcbe4b9e" xlink:to="loc_us-gaap_CashEquivalentsMember_850b3e7b-d987-4a50-8d4c-a9b39a38eef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e2537c7f-2f2d-4e66-a2d2-17a804d7e0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e80378b9-c64d-4ab0-9bf5-64750c16e40f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e2537c7f-2f2d-4e66-a2d2-17a804d7e0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fa69a9d-34aa-45cb-8fb9-e4ee378b6da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e2537c7f-2f2d-4e66-a2d2-17a804d7e0b4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fa69a9d-34aa-45cb-8fb9-e4ee378b6da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6f4261ef-1769-4f09-a364-8d5ea81ce886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fa69a9d-34aa-45cb-8fb9-e4ee378b6da1" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6f4261ef-1769-4f09-a364-8d5ea81ce886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_a26fba97-2bdd-404e-a9e1-0377e8b05a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fa69a9d-34aa-45cb-8fb9-e4ee378b6da1" xlink:to="loc_us-gaap_MunicipalBondsMember_a26fba97-2bdd-404e-a9e1-0377e8b05a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_a17798f6-16b4-48ad-9712-bfbafedcad45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fa69a9d-34aa-45cb-8fb9-e4ee378b6da1" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_a17798f6-16b4-48ad-9712-bfbafedcad45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_567cd004-3ef3-4dae-9230-800a8ad5181d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fa69a9d-34aa-45cb-8fb9-e4ee378b6da1" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_567cd004-3ef3-4dae-9230-800a8ad5181d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0174a32d-ac50-472c-996f-3ca27832d3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e80378b9-c64d-4ab0-9bf5-64750c16e40f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0174a32d-ac50-472c-996f-3ca27832d3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_551b3abb-8180-4b4e-af42-c7e730bd3c56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0174a32d-ac50-472c-996f-3ca27832d3ac" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_551b3abb-8180-4b4e-af42-c7e730bd3c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bbe09526-eb4c-4e5e-b4bc-dc9363714a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_551b3abb-8180-4b4e-af42-c7e730bd3c56" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bbe09526-eb4c-4e5e-b4bc-dc9363714a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8ecb5fb7-aaae-45db-a339-90e86d796e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_551b3abb-8180-4b4e-af42-c7e730bd3c56" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8ecb5fb7-aaae-45db-a339-90e86d796e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b28d1892-8cce-4c81-bff5-4eb0a43c1ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0174a32d-ac50-472c-996f-3ca27832d3ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b28d1892-8cce-4c81-bff5-4eb0a43c1ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_461201d8-e429-4057-9ba8-045b2e9e13fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b28d1892-8cce-4c81-bff5-4eb0a43c1ca8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_461201d8-e429-4057-9ba8-045b2e9e13fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_01985cdf-4c8b-453d-a2f4-c4d43982667f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b28d1892-8cce-4c81-bff5-4eb0a43c1ca8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_01985cdf-4c8b-453d-a2f4-c4d43982667f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6a620d7e-c2c9-45ee-9461-712023740d47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b28d1892-8cce-4c81-bff5-4eb0a43c1ca8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6a620d7e-c2c9-45ee-9461-712023740d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ef981df4-2b15-4b3b-8937-a01c495204cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_b28d1892-8cce-4c81-bff5-4eb0a43c1ca8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ef981df4-2b15-4b3b-8937-a01c495204cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCashAbstract_ac5b49c5-5ccc-4b1c-abb9-4ffe9fe9b33d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCashAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0174a32d-ac50-472c-996f-3ca27832d3ac" xlink:to="loc_us-gaap_InvestmentsAndCashAbstract_ac5b49c5-5ccc-4b1c-abb9-4ffe9fe9b33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_74d56516-0625-41f3-b15e-4f393bd6606f" xlink:href="mygn-20221231.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_ac5b49c5-5ccc-4b1c-abb9-4ffe9fe9b33d" xlink:to="loc_mygn_InvestmentsAndCashAmortizedCost_74d56516-0625-41f3-b15e-4f393bd6606f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_75f3008e-e69c-4501-8ab5-67d888208fa7" xlink:href="mygn-20221231.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_ac5b49c5-5ccc-4b1c-abb9-4ffe9fe9b33d" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax_75f3008e-e69c-4501-8ab5-67d888208fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_1e5e774e-4c77-4444-bbd4-cd1df83a8b72" xlink:href="mygn-20221231.xsd#mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_ac5b49c5-5ccc-4b1c-abb9-4ffe9fe9b33d" xlink:to="loc_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax_1e5e774e-4c77-4444-bbd4-cd1df83a8b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_e61826fe-c999-4850-b4b1-80bbfb500b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAndCashAbstract_ac5b49c5-5ccc-4b1c-abb9-4ffe9fe9b33d" xlink:to="loc_us-gaap_InvestmentsAndCash_e61826fe-c999-4850-b4b1-80bbfb500b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_375ad1ef-7288-48aa-b6ba-b2dbb00c01b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_72df08c6-a21c-4243-a752-caec789381ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_375ad1ef-7288-48aa-b6ba-b2dbb00c01b1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_72df08c6-a21c-4243-a752-caec789381ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_7bb7fd07-a6cc-4368-b7c7-aeeb0e2aa7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_72df08c6-a21c-4243-a752-caec789381ad" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_7bb7fd07-a6cc-4368-b7c7-aeeb0e2aa7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_84ba4e5f-05d8-4f55-94a3-e19ae126a3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_7bb7fd07-a6cc-4368-b7c7-aeeb0e2aa7d8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_84ba4e5f-05d8-4f55-94a3-e19ae126a3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_10a1a099-3d54-47d2-ab5e-b8c0f7773d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_84ba4e5f-05d8-4f55-94a3-e19ae126a3d9" xlink:to="loc_us-gaap_CashMember_10a1a099-3d54-47d2-ab5e-b8c0f7773d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_78d8d9c3-e76c-4f7f-bc34-56bdcb034d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_84ba4e5f-05d8-4f55-94a3-e19ae126a3d9" xlink:to="loc_us-gaap_CashEquivalentsMember_78d8d9c3-e76c-4f7f-bc34-56bdcb034d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1355c23a-d793-4e65-9649-c558b33c7e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_72df08c6-a21c-4243-a752-caec789381ad" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1355c23a-d793-4e65-9649-c558b33c7e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1203f1a8-943b-4171-b831-1518e0114cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1355c23a-d793-4e65-9649-c558b33c7e26" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1203f1a8-943b-4171-b831-1518e0114cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_83b21426-85f9-4831-a11f-966eec630800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1203f1a8-943b-4171-b831-1518e0114cfd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_83b21426-85f9-4831-a11f-966eec630800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_769ab64a-3883-480a-aef1-a9e50c8c90b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1203f1a8-943b-4171-b831-1518e0114cfd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_769ab64a-3883-480a-aef1-a9e50c8c90b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_cef02607-7f1c-460d-967e-a79d9e805cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1203f1a8-943b-4171-b831-1518e0114cfd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_cef02607-7f1c-460d-967e-a79d9e805cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_b02b73aa-e2ea-4c38-9f81-a8867cdfaff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1203f1a8-943b-4171-b831-1518e0114cfd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_b02b73aa-e2ea-4c38-9f81-a8867cdfaff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_InvestmentsAndCashAmortizedCost_ae78e6ba-e68e-4248-a7b2-383a0a5f4df7" xlink:href="mygn-20221231.xsd#mygn_InvestmentsAndCashAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1203f1a8-943b-4171-b831-1518e0114cfd" xlink:to="loc_mygn_InvestmentsAndCashAmortizedCost_ae78e6ba-e68e-4248-a7b2-383a0a5f4df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_be8d7d5c-642e-4cb9-8a3b-7df694621004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1355c23a-d793-4e65-9649-c558b33c7e26" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_be8d7d5c-642e-4cb9-8a3b-7df694621004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c0e4dbba-1cbb-4045-a66f-3df1d88d4c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_be8d7d5c-642e-4cb9-8a3b-7df694621004" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c0e4dbba-1cbb-4045-a66f-3df1d88d4c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8447a85b-337f-457d-80db-d85332203973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_be8d7d5c-642e-4cb9-8a3b-7df694621004" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8447a85b-337f-457d-80db-d85332203973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6d125e2c-1109-44f3-9b4b-83c6a6afaef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_be8d7d5c-642e-4cb9-8a3b-7df694621004" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6d125e2c-1109-44f3-9b4b-83c6a6afaef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_7be43ae3-efae-4020-a77f-8d3218752a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_be8d7d5c-642e-4cb9-8a3b-7df694621004" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_7be43ae3-efae-4020-a77f-8d3218752a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_dc2d3519-ed88-4ce4-9dac-4a2a292defbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_be8d7d5c-642e-4cb9-8a3b-7df694621004" xlink:to="loc_us-gaap_InvestmentsAndCash_dc2d3519-ed88-4ce4-9dac-4a2a292defbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#MarketableInvestmentSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_488d389d-bf38-4a62-96c5-48f9c7a4154d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4ff27350-3297-4829-9c64-68112498e915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_488d389d-bf38-4a62-96c5-48f9c7a4154d" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4ff27350-3297-4829-9c64-68112498e915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_e6f3647a-78b8-45e4-9418-89c3d099c4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_488d389d-bf38-4a62-96c5-48f9c7a4154d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_e6f3647a-78b8-45e4-9418-89c3d099c4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_253b856f-7120-4ccb-91e5-6f9c56d80981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_488d389d-bf38-4a62-96c5-48f9c7a4154d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_253b856f-7120-4ccb-91e5-6f9c56d80981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_63ace9c6-4995-44c3-a0d4-ba5f9c418d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_488d389d-bf38-4a62-96c5-48f9c7a4154d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_63ace9c6-4995-44c3-a0d4-ba5f9c418d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_65b7e489-39be-4b30-894b-45d52a0a911d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_82d8806d-2d9b-463b-8d0b-d3e900c8cb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_65b7e489-39be-4b30-894b-45d52a0a911d" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_82d8806d-2d9b-463b-8d0b-d3e900c8cb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d774272-0840-4bbd-89ec-4b23b4bba5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_82d8806d-2d9b-463b-8d0b-d3e900c8cb9a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d774272-0840-4bbd-89ec-4b23b4bba5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c47425ef-f082-4816-b9be-1b49ac60c05f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d774272-0840-4bbd-89ec-4b23b4bba5a2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c47425ef-f082-4816-b9be-1b49ac60c05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3fe4d4ff-2241-40d1-aa39-4f374bf47875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c47425ef-f082-4816-b9be-1b49ac60c05f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3fe4d4ff-2241-40d1-aa39-4f374bf47875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_86c43667-be4a-474a-9143-13886f70c467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_82d8806d-2d9b-463b-8d0b-d3e900c8cb9a" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_86c43667-be4a-474a-9143-13886f70c467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_31962395-6157-4acd-8efd-db9f17366aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_86c43667-be4a-474a-9143-13886f70c467" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_31962395-6157-4acd-8efd-db9f17366aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_77a2ff87-30d1-4849-bf0c-9f6988a25ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_31962395-6157-4acd-8efd-db9f17366aac" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_77a2ff87-30d1-4849-bf0c-9f6988a25ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_35039d31-a732-4fb4-ba0c-bef5567b0cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_82d8806d-2d9b-463b-8d0b-d3e900c8cb9a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_35039d31-a732-4fb4-ba0c-bef5567b0cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0dd0416-c12d-4481-81ff-46c19b91234a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_35039d31-a732-4fb4-ba0c-bef5567b0cbb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0dd0416-c12d-4481-81ff-46c19b91234a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_SividonDiagnosticsGmbHMember_e47f124d-75de-4273-9c1e-c4ca70c82dce" xlink:href="mygn-20221231.xsd#mygn_SividonDiagnosticsGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0dd0416-c12d-4481-81ff-46c19b91234a" xlink:to="loc_mygn_SividonDiagnosticsGmbHMember_e47f124d-75de-4273-9c1e-c4ca70c82dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GatewayGenomicsLLCMember_d72fe40c-1b5e-4798-8a83-c9a2f3847b63" xlink:href="mygn-20221231.xsd#mygn_GatewayGenomicsLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0dd0416-c12d-4481-81ff-46c19b91234a" xlink:to="loc_mygn_GatewayGenomicsLLCMember_d72fe40c-1b5e-4798-8a83-c9a2f3847b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6d003e0c-1241-4872-8b83-adfeef993081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_82d8806d-2d9b-463b-8d0b-d3e900c8cb9a" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6d003e0c-1241-4872-8b83-adfeef993081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_fef3cf7a-33bf-4b4f-9ea3-11fdfb55b0a9" xlink:href="mygn-20221231.xsd#mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_6d003e0c-1241-4872-8b83-adfeef993081" xlink:to="loc_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm_fef3cf7a-33bf-4b4f-9ea3-11fdfb55b0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e5cd4845-5319-4002-a10e-ff0ae99c05c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_26db28e8-1cbb-4f02-939c-d07673a4604b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e5cd4845-5319-4002-a10e-ff0ae99c05c6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_26db28e8-1cbb-4f02-939c-d07673a4604b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c351bc8b-dfe0-4b98-8c50-47a63f924080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_26db28e8-1cbb-4f02-939c-d07673a4604b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c351bc8b-dfe0-4b98-8c50-47a63f924080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c5b50fca-b39a-44a5-aacc-ab5817384d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c351bc8b-dfe0-4b98-8c50-47a63f924080" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c5b50fca-b39a-44a5-aacc-ab5817384d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5bbe9f00-5260-4840-b580-fa05967bed20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c5b50fca-b39a-44a5-aacc-ab5817384d7f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5bbe9f00-5260-4840-b580-fa05967bed20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b5964a38-7205-49d4-af3d-c147f957690a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c5b50fca-b39a-44a5-aacc-ab5817384d7f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b5964a38-7205-49d4-af3d-c147f957690a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9033e973-557d-4632-b39d-28db529f6c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c5b50fca-b39a-44a5-aacc-ab5817384d7f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9033e973-557d-4632-b39d-28db529f6c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_3834e677-b35d-44a7-99b3-7e972fe6c8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_26db28e8-1cbb-4f02-939c-d07673a4604b" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_3834e677-b35d-44a7-99b3-7e972fe6c8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2a5e3c0e-03d7-4d30-bcda-730d5b5ae357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_3834e677-b35d-44a7-99b3-7e972fe6c8e0" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2a5e3c0e-03d7-4d30-bcda-730d5b5ae357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ContingentConsiderationMember_e1de25f5-df10-4cf4-8eaf-5d292197eac3" xlink:href="mygn-20221231.xsd#mygn_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2a5e3c0e-03d7-4d30-bcda-730d5b5ae357" xlink:to="loc_mygn_ContingentConsiderationMember_e1de25f5-df10-4cf4-8eaf-5d292197eac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4cfef9e3-1535-4941-bdcb-788a0bd3813c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_26db28e8-1cbb-4f02-939c-d07673a4604b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4cfef9e3-1535-4941-bdcb-788a0bd3813c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_03bef79c-2650-4b67-9b45-0e2a64feef94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4cfef9e3-1535-4941-bdcb-788a0bd3813c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_03bef79c-2650-4b67-9b45-0e2a64feef94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b291dda5-50ad-48f1-81cc-e145469dba53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_03bef79c-2650-4b67-9b45-0e2a64feef94" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b291dda5-50ad-48f1-81cc-e145469dba53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d00980c4-d3e2-4b97-a4af-7fef403249c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_03bef79c-2650-4b67-9b45-0e2a64feef94" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d00980c4-d3e2-4b97-a4af-7fef403249c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_e8d3d2cf-c944-4f1e-92c5-00049bafcdba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_03bef79c-2650-4b67-9b45-0e2a64feef94" xlink:to="loc_us-gaap_MunicipalBondsMember_e8d3d2cf-c944-4f1e-92c5-00049bafcdba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_80c4b77a-214a-4347-ae56-ca050e99c6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_03bef79c-2650-4b67-9b45-0e2a64feef94" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_80c4b77a-214a-4347-ae56-ca050e99c6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1edb3edb-f19e-477f-aa44-eea391be00d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_03bef79c-2650-4b67-9b45-0e2a64feef94" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1edb3edb-f19e-477f-aa44-eea391be00d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1462be07-1308-4083-a5e6-0cc0eaa02132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_26db28e8-1cbb-4f02-939c-d07673a4604b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1462be07-1308-4083-a5e6-0cc0eaa02132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b4f3ed45-de0c-4a7f-8bf2-578aff55046a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1462be07-1308-4083-a5e6-0cc0eaa02132" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b4f3ed45-de0c-4a7f-8bf2-578aff55046a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_47c6b464-732f-4e5a-9277-cb208229a05c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1462be07-1308-4083-a5e6-0cc0eaa02132" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_47c6b464-732f-4e5a-9277-cb208229a05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_b778e207-5105-4c43-bb43-c4c14dcec606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1462be07-1308-4083-a5e6-0cc0eaa02132" xlink:to="loc_us-gaap_FairValueNetAssetLiability_b778e207-5105-4c43-bb43-c4c14dcec606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f7605b8f-1ca1-46b4-9562-4969a8b5ade8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5facf41c-37fa-44fa-b156-150b1ad84642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f7605b8f-1ca1-46b4-9562-4969a8b5ade8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5facf41c-37fa-44fa-b156-150b1ad84642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9e19d73c-3ee3-4db9-ab2c-65028e7dc057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5facf41c-37fa-44fa-b156-150b1ad84642" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9e19d73c-3ee3-4db9-ab2c-65028e7dc057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_881ef66c-6a52-432d-96e2-e28682f0c4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5facf41c-37fa-44fa-b156-150b1ad84642" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_881ef66c-6a52-432d-96e2-e28682f0c4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_cb17183a-df30-4ca1-8566-2e1a7f6e5f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5facf41c-37fa-44fa-b156-150b1ad84642" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_cb17183a-df30-4ca1-8566-2e1a7f6e5f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_44e14f90-0364-499b-a871-6445c5feb235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5facf41c-37fa-44fa-b156-150b1ad84642" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_44e14f90-0364-499b-a871-6445c5feb235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_efedb44b-6ece-4dfe-bb09-627a516463e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5facf41c-37fa-44fa-b156-150b1ad84642" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_efedb44b-6ece-4dfe-bb09-627a516463e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_aae54745-29ee-438a-b946-e8ad98300fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5facf41c-37fa-44fa-b156-150b1ad84642" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_aae54745-29ee-438a-b946-e8ad98300fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_6d093718-1eab-4a1f-9a4b-0348fdd65249" xlink:href="mygn-20221231.xsd#mygn_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f7605b8f-1ca1-46b4-9562-4969a8b5ade8" xlink:to="loc_mygn_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_6d093718-1eab-4a1f-9a4b-0348fdd65249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#PropertyPlantandEquipmentNetBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e66e4f37-59cc-46c4-88ab-e64626318267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_237752f7-feda-4434-9e54-6d897b6edcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e66e4f37-59cc-46c4-88ab-e64626318267" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_237752f7-feda-4434-9e54-6d897b6edcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd7d33ab-0362-4d9c-ae5a-49c12a551ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_237752f7-feda-4434-9e54-6d897b6edcfe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd7d33ab-0362-4d9c-ae5a-49c12a551ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d977911-0a96-472c-9e80-a2971e4d75b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd7d33ab-0362-4d9c-ae5a-49c12a551ce6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d977911-0a96-472c-9e80-a2971e4d75b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2faa001b-0509-4a78-9de8-3bca32649587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d977911-0a96-472c-9e80-a2971e4d75b1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2faa001b-0509-4a78-9de8-3bca32649587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_a77bea5a-f314-49e2-98a2-f7773032b5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d977911-0a96-472c-9e80-a2971e4d75b1" xlink:to="loc_us-gaap_EquipmentMember_a77bea5a-f314-49e2-98a2-f7773032b5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c3789c9d-a7b0-42dc-a497-fc9a125b04b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_237752f7-feda-4434-9e54-6d897b6edcfe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c3789c9d-a7b0-42dc-a497-fc9a125b04b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ef3d19b1-2219-4552-81dc-5bf122f4676f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c3789c9d-a7b0-42dc-a497-fc9a125b04b7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ef3d19b1-2219-4552-81dc-5bf122f4676f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_02bff3dc-cc12-413c-aa4a-3d9d944b0645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c3789c9d-a7b0-42dc-a497-fc9a125b04b7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_02bff3dc-cc12-413c-aa4a-3d9d944b0645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0b7f3f09-4d54-4c7c-9524-0e70c397a917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c3789c9d-a7b0-42dc-a497-fc9a125b04b7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0b7f3f09-4d54-4c7c-9524-0e70c397a917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#PropertyPlantandEquipmentNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_90f4f616-4ed8-407e-8d8d-c92b23400584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_709d4804-32a1-40e0-a05b-967bd7144285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_90f4f616-4ed8-407e-8d8d-c92b23400584" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_709d4804-32a1-40e0-a05b-967bd7144285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e2e262e7-1003-40bf-adf9-d1d6e465b527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_709d4804-32a1-40e0-a05b-967bd7144285" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e2e262e7-1003-40bf-adf9-d1d6e465b527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1173433-da16-4bed-857f-8923d9367498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e2e262e7-1003-40bf-adf9-d1d6e465b527" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1173433-da16-4bed-857f-8923d9367498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2949861b-2915-4ae9-ab9c-032c542ca37b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1173433-da16-4bed-857f-8923d9367498" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2949861b-2915-4ae9-ab9c-032c542ca37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3fcb1975-4e26-4c01-84ca-c42d4c167d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_709d4804-32a1-40e0-a05b-967bd7144285" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3fcb1975-4e26-4c01-84ca-c42d4c167d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_43b1d46c-87c2-4f3e-a94f-e9d0e0e3af11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3fcb1975-4e26-4c01-84ca-c42d4c167d2a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_43b1d46c-87c2-4f3e-a94f-e9d0e0e3af11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember_88aa4477-2390-4f50-a096-b047221c6b06" xlink:href="mygn-20221231.xsd#mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_43b1d46c-87c2-4f3e-a94f-e9d0e0e3af11" xlink:to="loc_mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember_88aa4477-2390-4f50-a096-b047221c6b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3b2ce311-8bf6-4a5c-8c00-c3eb31578520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_709d4804-32a1-40e0-a05b-967bd7144285" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3b2ce311-8bf6-4a5c-8c00-c3eb31578520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_9b4dfa03-d8cd-402e-8fc5-026f63aab36d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3b2ce311-8bf6-4a5c-8c00-c3eb31578520" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_9b4dfa03-d8cd-402e-8fc5-026f63aab36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_eb642b71-6fd0-47be-8354-c663e06654e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3b2ce311-8bf6-4a5c-8c00-c3eb31578520" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_eb642b71-6fd0-47be-8354-c663e06654e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#PropertyPlantandEquipmentNetDepreciationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2c81910e-162a-40ae-bd4a-1430832a8d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b79dd357-6db4-470b-8366-d851711f82e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2c81910e-162a-40ae-bd4a-1430832a8d1e" xlink:to="loc_us-gaap_Depreciation_b79dd357-6db4-470b-8366-d851711f82e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4e5afa24-ca39-4dc4-86b5-47bf9ce24d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_ddf0a032-f62c-46af-847a-9f7b8b41f88a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4e5afa24-ca39-4dc4-86b5-47bf9ce24d35" xlink:to="loc_us-gaap_GoodwillRollForward_ddf0a032-f62c-46af-847a-9f7b8b41f88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5f0ef217-6ed0-414a-bec4-174952c94f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ddf0a032-f62c-46af-847a-9f7b8b41f88a" xlink:to="loc_us-gaap_Goodwill_5f0ef217-6ed0-414a-bec4-174952c94f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_a8c1346f-59a6-4c64-ab34-ced15295ef06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ddf0a032-f62c-46af-847a-9f7b8b41f88a" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_a8c1346f-59a6-4c64-ab34-ced15295ef06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_c9a03e3d-9b26-48ab-8bde-01ba4d815c76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ddf0a032-f62c-46af-847a-9f7b8b41f88a" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_c9a03e3d-9b26-48ab-8bde-01ba4d815c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_54453754-c43f-4d53-8f5e-35f2ee86bf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ddf0a032-f62c-46af-847a-9f7b8b41f88a" xlink:to="loc_us-gaap_Goodwill_54453754-c43f-4d53-8f5e-35f2ee86bf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_94cc2c90-994c-4a4b-a8ad-64ae3df27f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GoodwillAndIntangibleAssetsTable_ca5eeef3-1483-4c1d-a81a-06f9a97fabe6" xlink:href="mygn-20221231.xsd#mygn_GoodwillAndIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_94cc2c90-994c-4a4b-a8ad-64ae3df27f6e" xlink:to="loc_mygn_GoodwillAndIntangibleAssetsTable_ca5eeef3-1483-4c1d-a81a-06f9a97fabe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_6bcd925d-0bb9-4029-9bea-d4cfc9476cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_ca5eeef3-1483-4c1d-a81a-06f9a97fabe6" xlink:to="loc_us-gaap_ReportingUnitAxis_6bcd925d-0bb9-4029-9bea-d4cfc9476cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_05fab207-64ed-4498-8be3-e11ac5030a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_6bcd925d-0bb9-4029-9bea-d4cfc9476cad" xlink:to="loc_us-gaap_ReportingUnitDomain_05fab207-64ed-4498-8be3-e11ac5030a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneReportingUnitMember_8e569515-8fcd-45ff-8a0b-8957839eb356" xlink:href="mygn-20221231.xsd#mygn_MyriadAutoimmuneReportingUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_05fab207-64ed-4498-8be3-e11ac5030a94" xlink:to="loc_mygn_MyriadAutoimmuneReportingUnitMember_8e569515-8fcd-45ff-8a0b-8957839eb356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ClinicReportingUnitMember_93d265e0-d9fe-45be-b7f6-b279550745e2" xlink:href="mygn-20221231.xsd#mygn_ClinicReportingUnitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_05fab207-64ed-4498-8be3-e11ac5030a94" xlink:to="loc_mygn_ClinicReportingUnitMember_93d265e0-d9fe-45be-b7f6-b279550745e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9bd6b3f5-a137-480c-a710-7e178bb12850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_ca5eeef3-1483-4c1d-a81a-06f9a97fabe6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9bd6b3f5-a137-480c-a710-7e178bb12850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2308a00a-e16b-4df5-b4f5-0209aa4612fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9bd6b3f5-a137-480c-a710-7e178bb12850" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2308a00a-e16b-4df5-b4f5-0209aa4612fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_95ef9d02-f0b3-462a-976c-db43ceed4eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2308a00a-e16b-4df5-b4f5-0209aa4612fb" xlink:to="loc_us-gaap_CustomerRelationshipsMember_95ef9d02-f0b3-462a-976c-db43ceed4eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_8831a73b-e69d-4e5d-95b5-a9d24130f206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2308a00a-e16b-4df5-b4f5-0209aa4612fb" xlink:to="loc_us-gaap_TrademarksMember_8831a73b-e69d-4e5d-95b5-a9d24130f206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_49bd794c-7287-4c1d-a5c2-6873d947078f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2308a00a-e16b-4df5-b4f5-0209aa4612fb" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_49bd794c-7287-4c1d-a5c2-6873d947078f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9d45c98f-ce9b-4b9c-a430-a6f26e63fa4a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_ca5eeef3-1483-4c1d-a81a-06f9a97fabe6" xlink:to="loc_srt_RangeAxis_9d45c98f-ce9b-4b9c-a430-a6f26e63fa4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e7d50727-fbc9-40c9-b8f2-6b98930c11a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9d45c98f-ce9b-4b9c-a430-a6f26e63fa4a" xlink:to="loc_srt_RangeMember_e7d50727-fbc9-40c9-b8f2-6b98930c11a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cebd0602-42b1-4f5f-9153-8498beab401f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e7d50727-fbc9-40c9-b8f2-6b98930c11a6" xlink:to="loc_srt_MinimumMember_cebd0602-42b1-4f5f-9153-8498beab401f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_afde65da-9123-4e94-96be-5e846f813cfa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e7d50727-fbc9-40c9-b8f2-6b98930c11a6" xlink:to="loc_srt_MaximumMember_afde65da-9123-4e94-96be-5e846f813cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3402e051-768d-4ba9-9c89-11e8fcc2716b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_ca5eeef3-1483-4c1d-a81a-06f9a97fabe6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3402e051-768d-4ba9-9c89-11e8fcc2716b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b7177732-7082-40cd-8c89-fc1b64e8cd31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3402e051-768d-4ba9-9c89-11e8fcc2716b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b7177732-7082-40cd-8c89-fc1b64e8cd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GatewayGenomicsLLCMember_5f44d381-dddd-4799-9f5f-5b40490c22f5" xlink:href="mygn-20221231.xsd#mygn_GatewayGenomicsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b7177732-7082-40cd-8c89-fc1b64e8cd31" xlink:to="loc_mygn_GatewayGenomicsLLCMember_5f44d381-dddd-4799-9f5f-5b40490c22f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GoodwillAndIntangibleAssetsLineItems_fd67abe9-94c3-46c2-9a6a-4278d24512f7" xlink:href="mygn-20221231.xsd#mygn_GoodwillAndIntangibleAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsTable_ca5eeef3-1483-4c1d-a81a-06f9a97fabe6" xlink:to="loc_mygn_GoodwillAndIntangibleAssetsLineItems_fd67abe9-94c3-46c2-9a6a-4278d24512f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_71e01e7f-293a-45fe-9274-cd042003f772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_fd67abe9-94c3-46c2-9a6a-4278d24512f7" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_71e01e7f-293a-45fe-9274-cd042003f772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_301afc55-2041-4a71-b3e7-e05f9650c5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_fd67abe9-94c3-46c2-9a6a-4278d24512f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_301afc55-2041-4a71-b3e7-e05f9650c5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_bd1ff8f9-3059-4861-a951-f8ab09acc05e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_fd67abe9-94c3-46c2-9a6a-4278d24512f7" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_bd1ff8f9-3059-4861-a951-f8ab09acc05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c14a6b6d-61dd-428a-8f07-c5eeaf3b45e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_fd67abe9-94c3-46c2-9a6a-4278d24512f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c14a6b6d-61dd-428a-8f07-c5eeaf3b45e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3a82e845-78aa-4f20-859f-0f068dd78cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_GoodwillAndIntangibleAssetsLineItems_fd67abe9-94c3-46c2-9a6a-4278d24512f7" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3a82e845-78aa-4f20-859f-0f068dd78cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_87c33541-22cf-40ab-af21-80d1b6d62009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ScheduleOfIntangibleAssetsTable_e26026a9-7d77-46ac-945a-5d7db39a6afe" xlink:href="mygn-20221231.xsd#mygn_ScheduleOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_87c33541-22cf-40ab-af21-80d1b6d62009" xlink:to="loc_mygn_ScheduleOfIntangibleAssetsTable_e26026a9-7d77-46ac-945a-5d7db39a6afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_89f3df63-7610-4f37-b178-442ea7f2dc11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_e26026a9-7d77-46ac-945a-5d7db39a6afe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_89f3df63-7610-4f37-b178-442ea7f2dc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_967b94ef-9285-4795-ac37-550fb74886d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_89f3df63-7610-4f37-b178-442ea7f2dc11" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_967b94ef-9285-4795-ac37-550fb74886d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_cd9382c2-0df3-4789-af65-1ced9d6172f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_967b94ef-9285-4795-ac37-550fb74886d2" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_cd9382c2-0df3-4789-af65-1ced9d6172f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_f979f6c3-a8c8-4435-a785-9dde0c04860f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_967b94ef-9285-4795-ac37-550fb74886d2" xlink:to="loc_us-gaap_CustomerRelationshipsMember_f979f6c3-a8c8-4435-a785-9dde0c04860f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_9891c634-2e5e-45a0-874c-f29975877b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_967b94ef-9285-4795-ac37-550fb74886d2" xlink:to="loc_us-gaap_TrademarksMember_9891c634-2e5e-45a0-874c-f29975877b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IntangibleAssetsLineItems_23b33d50-3d0d-4a7f-a574-dca57d3c6bfc" xlink:href="mygn-20221231.xsd#mygn_IntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_ScheduleOfIntangibleAssetsTable_e26026a9-7d77-46ac-945a-5d7db39a6afe" xlink:to="loc_mygn_IntangibleAssetsLineItems_23b33d50-3d0d-4a7f-a574-dca57d3c6bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_714eb63c-3c97-4fee-b8ab-c1b732021774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_23b33d50-3d0d-4a7f-a574-dca57d3c6bfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_714eb63c-3c97-4fee-b8ab-c1b732021774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0702ebdf-2381-4c92-9a45-c67b6f36e4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_23b33d50-3d0d-4a7f-a574-dca57d3c6bfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0702ebdf-2381-4c92-9a45-c67b6f36e4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_88f226ac-265c-466f-9f26-82a8f5c3b30e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_23b33d50-3d0d-4a7f-a574-dca57d3c6bfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_88f226ac-265c-466f-9f26-82a8f5c3b30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9724dbb8-bcd9-4710-92e3-26aaae1744ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_23b33d50-3d0d-4a7f-a574-dca57d3c6bfc" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9724dbb8-bcd9-4710-92e3-26aaae1744ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_82fc14f8-7591-4a44-9a02-afa8e297bc49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_23b33d50-3d0d-4a7f-a574-dca57d3c6bfc" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_82fc14f8-7591-4a44-9a02-afa8e297bc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5c229cc7-6c79-4630-ab2f-a8d9a4246525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_23b33d50-3d0d-4a7f-a574-dca57d3c6bfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5c229cc7-6c79-4630-ab2f-a8d9a4246525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_e48a0a08-d709-4018-a53a-d1e26ed23264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_IntangibleAssetsLineItems_23b33d50-3d0d-4a7f-a574-dca57d3c6bfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_e48a0a08-d709-4018-a53a-d1e26ed23264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8aa41ef5-64b2-4e52-816a-65e3041f672a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_0fe6d644-c60b-41ee-94e3-821d7c7c91af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8aa41ef5-64b2-4e52-816a-65e3041f672a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_0fe6d644-c60b-41ee-94e3-821d7c7c91af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_eab6fdd9-72cc-487d-a24c-0a46074ee34b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e0a15862-6b6f-43cf-8431-2d5f979cf69b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_eab6fdd9-72cc-487d-a24c-0a46074ee34b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e0a15862-6b6f-43cf-8431-2d5f979cf69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7d956ddf-95f0-4fab-8667-4e3789af9359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e0a15862-6b6f-43cf-8431-2d5f979cf69b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7d956ddf-95f0-4fab-8667-4e3789af9359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_86a6cc10-4da9-45ce-bdb9-16feb75aa962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e0a15862-6b6f-43cf-8431-2d5f979cf69b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_86a6cc10-4da9-45ce-bdb9-16feb75aa962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2348da91-0f3a-41a8-aeed-4e7cf32f0384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e0a15862-6b6f-43cf-8431-2d5f979cf69b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2348da91-0f3a-41a8-aeed-4e7cf32f0384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_9cee0ba5-384d-426a-a74b-e04e74d1c8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e0a15862-6b6f-43cf-8431-2d5f979cf69b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_9cee0ba5-384d-426a-a74b-e04e74d1c8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4e0e7936-f75a-49e9-8243-386490771255" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e0a15862-6b6f-43cf-8431-2d5f979cf69b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4e0e7936-f75a-49e9-8243-386490771255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_3387bf93-ede6-47ae-94ff-6caf1102c306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e0a15862-6b6f-43cf-8431-2d5f979cf69b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_3387bf93-ede6-47ae-94ff-6caf1102c306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e1c94603-6eb3-4b0c-a662-259b49114055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e0a15862-6b6f-43cf-8431-2d5f979cf69b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e1c94603-6eb3-4b0c-a662-259b49114055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#AccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_27bb7ee9-7556-45d8-9147-7510774af271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4906549b-b178-4dc9-a18d-1be1e21736f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_27bb7ee9-7556-45d8-9147-7510774af271" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4906549b-b178-4dc9-a18d-1be1e21736f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_1f76e808-9d44-4bbf-9991-e3cb8a029299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_27bb7ee9-7556-45d8-9147-7510774af271" xlink:to="loc_us-gaap_LitigationReserveCurrent_1f76e808-9d44-4bbf-9991-e3cb8a029299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_4b99b1e8-1a18-469a-9227-319c210026dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_27bb7ee9-7556-45d8-9147-7510774af271" xlink:to="loc_us-gaap_TaxesPayableCurrent_4b99b1e8-1a18-469a-9227-319c210026dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RefundsPayableAndReserveCurrent_dc66cb89-6c36-42f7-ab05-ffe2ce9b8919" xlink:href="mygn-20221231.xsd#mygn_RefundsPayableAndReserveCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_27bb7ee9-7556-45d8-9147-7510774af271" xlink:to="loc_mygn_RefundsPayableAndReserveCurrent_dc66cb89-6c36-42f7-ab05-ffe2ce9b8919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_135fbb3c-2400-4f60-a204-b7cbfca4304c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_27bb7ee9-7556-45d8-9147-7510774af271" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_135fbb3c-2400-4f60-a204-b7cbfca4304c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_eea074fb-5719-4240-8ed0-f4d83e116e22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_27bb7ee9-7556-45d8-9147-7510774af271" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_eea074fb-5719-4240-8ed0-f4d83e116e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_90a8cf9b-46d4-49be-8645-e5702b990d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_27bb7ee9-7556-45d8-9147-7510774af271" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_90a8cf9b-46d4-49be-8645-e5702b990d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_34018e27-2e48-475d-bd84-90a69bff983e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_27bb7ee9-7556-45d8-9147-7510774af271" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_34018e27-2e48-475d-bd84-90a69bff983e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_154b8ff5-898f-46e8-b60a-88d55737226d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_27bb7ee9-7556-45d8-9147-7510774af271" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_154b8ff5-898f-46e8-b60a-88d55737226d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LongTermDebtDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#LongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/LongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_35292268-ed4a-4a71-ae21-75fcd0bdd584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_282c35aa-5f57-482e-b663-bad409e86704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_35292268-ed4a-4a71-ae21-75fcd0bdd584" xlink:to="loc_us-gaap_DebtInstrumentTable_282c35aa-5f57-482e-b663-bad409e86704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b97cadfa-1d88-4c04-8710-022bdec9d9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_282c35aa-5f57-482e-b663-bad409e86704" xlink:to="loc_us-gaap_CreditFacilityAxis_b97cadfa-1d88-4c04-8710-022bdec9d9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5edd3e38-42af-4eb4-917d-be5d94c70b83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_b97cadfa-1d88-4c04-8710-022bdec9d9f1" xlink:to="loc_us-gaap_CreditFacilityDomain_5edd3e38-42af-4eb4-917d-be5d94c70b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_4b7d8e7c-5a51-4c80-b6e2-986f9160d85a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5edd3e38-42af-4eb4-917d-be5d94c70b83" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_4b7d8e7c-5a51-4c80-b6e2-986f9160d85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_c43f5fbc-4b2f-4ae0-8ab5-707758a96db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5edd3e38-42af-4eb4-917d-be5d94c70b83" xlink:to="loc_us-gaap_LetterOfCreditMember_c43f5fbc-4b2f-4ae0-8ab5-707758a96db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9d38f430-0966-4fb2-87fd-03c4fb5493f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_282c35aa-5f57-482e-b663-bad409e86704" xlink:to="loc_us-gaap_DebtInstrumentAxis_9d38f430-0966-4fb2-87fd-03c4fb5493f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1b684ee4-dabe-4a38-9d53-36c6c9b883e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9d38f430-0966-4fb2-87fd-03c4fb5493f9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1b684ee4-dabe-4a38-9d53-36c6c9b883e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AmendmentToCreditAgreementMember_2c68df65-a6ee-4d4e-b413-04a8a2a6c752" xlink:href="mygn-20221231.xsd#mygn_AmendmentToCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1b684ee4-dabe-4a38-9d53-36c6c9b883e8" xlink:to="loc_mygn_AmendmentToCreditAgreementMember_2c68df65-a6ee-4d4e-b413-04a8a2a6c752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_3cb6ddb7-5e41-49f9-982a-8cd1a2f4a259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_282c35aa-5f57-482e-b663-bad409e86704" xlink:to="loc_us-gaap_VariableRateAxis_3cb6ddb7-5e41-49f9-982a-8cd1a2f4a259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_830e204b-d2aa-405f-a4c8-7b3cfe42b037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_3cb6ddb7-5e41-49f9-982a-8cd1a2f4a259" xlink:to="loc_us-gaap_VariableRateDomain_830e204b-d2aa-405f-a4c8-7b3cfe42b037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_e6f51795-3131-4fdc-b092-46f83ef10749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_830e204b-d2aa-405f-a4c8-7b3cfe42b037" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_e6f51795-3131-4fdc-b092-46f83ef10749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_3ed7879d-4509-45ff-b7a7-16f365f29a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_830e204b-d2aa-405f-a4c8-7b3cfe42b037" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_3ed7879d-4509-45ff-b7a7-16f365f29a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_282c35aa-5f57-482e-b663-bad409e86704" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e0dfb500-3ad7-426c-a8d0-edb713960ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e0dfb500-3ad7-426c-a8d0-edb713960ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantLiquidityCovenantMinimum_3d4ce350-c2fd-47e7-9db5-fd631ce6be17" xlink:href="mygn-20221231.xsd#mygn_DebtCovenantLiquidityCovenantMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:to="loc_mygn_DebtCovenantLiquidityCovenantMinimum_3d4ce350-c2fd-47e7-9db5-fd631ce6be17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_74487311-919a-40d2-800c-5858e99b40ae" xlink:href="mygn-20221231.xsd#mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:to="loc_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum_74487311-919a-40d2-800c-5858e99b40ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LineOfCreditFacilityCreditExposureThreshold_35a0d509-917b-447f-957d-dd438e4ec894" xlink:href="mygn-20221231.xsd#mygn_LineOfCreditFacilityCreditExposureThreshold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:to="loc_mygn_LineOfCreditFacilityCreditExposureThreshold_35a0d509-917b-447f-957d-dd438e4ec894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5f7f9aa6-075c-4cce-b8ff-7fc0d668f21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5f7f9aa6-075c-4cce-b8ff-7fc0d668f21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_2824cbe4-2b77-4c2f-a1a3-6325b571aea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_2824cbe4-2b77-4c2f-a1a3-6325b571aea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DebtInstrumentFloorPercentage_3a4a8609-f03e-48d9-bebc-0949c9fe3492" xlink:href="mygn-20221231.xsd#mygn_DebtInstrumentFloorPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:to="loc_mygn_DebtInstrumentFloorPercentage_3a4a8609-f03e-48d9-bebc-0949c9fe3492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_f9a2373d-d12d-4a75-9389-122564ccfa23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_f9a2373d-d12d-4a75-9389-122564ccfa23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6cf8d965-3965-4f3a-8ca3-ddcbd2fa6c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ace6d109-e55d-4ada-8b0a-7a2ca5f2d809" xlink:to="loc_us-gaap_LongTermDebt_6cf8d965-3965-4f3a-8ca3-ddcbd2fa6c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/OtherLongTermLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#OtherLongTermLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/OtherLongTermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_76c6ca05-8ac7-49d4-9037-d7d4c7e09129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_81c98d72-3234-4e40-ae5a-70a8e12e28dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_76c6ca05-8ac7-49d4-9037-d7d4c7e09129" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_81c98d72-3234-4e40-ae5a-70a8e12e28dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_1105eebe-12d7-4164-93be-79a74664b761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_76c6ca05-8ac7-49d4-9037-d7d4c7e09129" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_1105eebe-12d7-4164-93be-79a74664b761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_049c4a27-5997-4922-bde2-8716b5797461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_76c6ca05-8ac7-49d4-9037-d7d4c7e09129" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_049c4a27-5997-4922-bde2-8716b5797461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#PreferredandCommonStockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9a1689df-aa8e-4707-8f0a-9ec3b547739e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8c97b75e-dd6d-4b36-bffd-0434c2cecbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a1689df-aa8e-4707-8f0a-9ec3b547739e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8c97b75e-dd6d-4b36-bffd-0434c2cecbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8d296c82-0938-4b40-bea2-04f34ec861b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a1689df-aa8e-4707-8f0a-9ec3b547739e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8d296c82-0938-4b40-bea2-04f34ec861b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2085b999-5f72-492e-b6ad-b18c57dc6886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a1689df-aa8e-4707-8f0a-9ec3b547739e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2085b999-5f72-492e-b6ad-b18c57dc6886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fbbb48ca-e2a9-40df-b62b-20706ce3dc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a1689df-aa8e-4707-8f0a-9ec3b547739e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fbbb48ca-e2a9-40df-b62b-20706ce3dc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_bb5c1c6c-800b-46dd-b51e-fd28332719ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a1689df-aa8e-4707-8f0a-9ec3b547739e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_bb5c1c6c-800b-46dd-b51e-fd28332719ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e9c3d0f6-f48d-412e-b45e-fd7ba12e2e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a1689df-aa8e-4707-8f0a-9ec3b547739e" xlink:to="loc_us-gaap_CommonStockSharesIssued_e9c3d0f6-f48d-412e-b45e-fd7ba12e2e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0e8abdef-2ffc-47f0-9294-58f8fe0439f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a1689df-aa8e-4707-8f0a-9ec3b547739e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0e8abdef-2ffc-47f0-9294-58f8fe0439f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_883af674-61e5-4e28-b0de-0443fbf71559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a1689df-aa8e-4707-8f0a-9ec3b547739e" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_883af674-61e5-4e28-b0de-0443fbf71559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_f090691b-d027-4f0f-9e7b-376a12abf48b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a1689df-aa8e-4707-8f0a-9ec3b547739e" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_f090691b-d027-4f0f-9e7b-376a12abf48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_fb676e67-0346-46bc-836e-11b203f20ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9a1689df-aa8e-4707-8f0a-9ec3b547739e" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_fb676e67-0346-46bc-836e-11b203f20ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/PreferredandCommonStockholdersEquitySharesofCommonStockIssuedandOutstandingDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#PreferredandCommonStockholdersEquitySharesofCommonStockIssuedandOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/PreferredandCommonStockholdersEquitySharesofCommonStockIssuedandOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3a371c60-ed3e-4b81-8f5c-277d6dfc85ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e78956cf-9519-4173-a58a-8435a85a6b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3a371c60-ed3e-4b81-8f5c-277d6dfc85ba" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e78956cf-9519-4173-a58a-8435a85a6b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b76cbc4d-1585-4122-91e6-af1967b43625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e78956cf-9519-4173-a58a-8435a85a6b7b" xlink:to="loc_us-gaap_CommonStockSharesIssued_b76cbc4d-1585-4122-91e6-af1967b43625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f7ad220d-cc55-43e2-991d-68a0869ec9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e78956cf-9519-4173-a58a-8435a85a6b7b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f7ad220d-cc55-43e2-991d-68a0869ec9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans_e91facf3-b10d-4df2-9431-c1df1f8338fd" xlink:href="mygn-20221231.xsd#mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e78956cf-9519-4173-a58a-8435a85a6b7b" xlink:to="loc_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans_e91facf3-b10d-4df2-9431-c1df1f8338fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_538bc5fd-aa69-4892-bd40-3cccbe11e023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e78956cf-9519-4173-a58a-8435a85a6b7b" xlink:to="loc_us-gaap_CommonStockSharesIssued_538bc5fd-aa69-4892-bd40-3cccbe11e023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7d3d1d26-51e7-4f3a-85da-eda6aa552636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e78956cf-9519-4173-a58a-8435a85a6b7b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7d3d1d26-51e7-4f3a-85da-eda6aa552636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ba93445c-32a6-4775-9618-d5d1f3d0e774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2f7eec3-7e7e-45ef-8835-05cb9d82e061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ba93445c-32a6-4775-9618-d5d1f3d0e774" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2f7eec3-7e7e-45ef-8835-05cb9d82e061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c27c5ff7-316d-4ff9-84a7-7e374b594a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2f7eec3-7e7e-45ef-8835-05cb9d82e061" xlink:to="loc_us-gaap_AwardTypeAxis_c27c5ff7-316d-4ff9-84a7-7e374b594a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ecab2f59-b822-411d-a3bc-8e21f29414ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c27c5ff7-316d-4ff9-84a7-7e374b594a03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ecab2f59-b822-411d-a3bc-8e21f29414ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OptionsAndRestrictedStockUnitsMember_6e444ed1-1e21-4726-b525-8cbffba1dc75" xlink:href="mygn-20221231.xsd#mygn_OptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ecab2f59-b822-411d-a3bc-8e21f29414ba" xlink:to="loc_mygn_OptionsAndRestrictedStockUnitsMember_6e444ed1-1e21-4726-b525-8cbffba1dc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_336ebe5d-82eb-4f96-b92a-ad5b60038249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OptionsAndRestrictedStockUnitsMember_6e444ed1-1e21-4726-b525-8cbffba1dc75" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_336ebe5d-82eb-4f96-b92a-ad5b60038249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_605025dc-ba54-44b7-914a-1f2bea6bcc98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_OptionsAndRestrictedStockUnitsMember_6e444ed1-1e21-4726-b525-8cbffba1dc75" xlink:to="loc_us-gaap_EmployeeStockOptionMember_605025dc-ba54-44b7-914a-1f2bea6bcc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_a91b3b26-dc22-4442-a739-7ffcd43b0685" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2f7eec3-7e7e-45ef-8835-05cb9d82e061" xlink:to="loc_srt_TitleOfIndividualAxis_a91b3b26-dc22-4442-a739-7ffcd43b0685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f264869c-07be-4f08-9cf8-664b524e3b6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_a91b3b26-dc22-4442-a739-7ffcd43b0685" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f264869c-07be-4f08-9cf8-664b524e3b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_NonEmployeeDirectorMember_b352194b-bad9-4859-8b03-6312bd9ab166" xlink:href="mygn-20221231.xsd#mygn_NonEmployeeDirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f264869c-07be-4f08-9cf8-664b524e3b6d" xlink:to="loc_mygn_NonEmployeeDirectorMember_b352194b-bad9-4859-8b03-6312bd9ab166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_782a228b-f0d9-4106-8e7e-44271d11128d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f264869c-07be-4f08-9cf8-664b524e3b6d" xlink:to="loc_srt_ChiefExecutiveOfficerMember_782a228b-f0d9-4106-8e7e-44271d11128d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_29d1fbea-b3c9-475e-a098-6dae20001c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2f7eec3-7e7e-45ef-8835-05cb9d82e061" xlink:to="loc_us-gaap_VestingAxis_29d1fbea-b3c9-475e-a098-6dae20001c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a17a5b61-2b45-4cff-9892-ffe7cf277c43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_29d1fbea-b3c9-475e-a098-6dae20001c4b" xlink:to="loc_us-gaap_VestingDomain_a17a5b61-2b45-4cff-9892-ffe7cf277c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2921b120-7b73-427f-8a64-706d57866d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a17a5b61-2b45-4cff-9892-ffe7cf277c43" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2921b120-7b73-427f-8a64-706d57866d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_8d1636bf-a4ab-4bfa-ad05-341327604299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a17a5b61-2b45-4cff-9892-ffe7cf277c43" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_8d1636bf-a4ab-4bfa-ad05-341327604299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_65698cbc-4ff1-4f58-abf1-9df509a9b5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a17a5b61-2b45-4cff-9892-ffe7cf277c43" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_65698cbc-4ff1-4f58-abf1-9df509a9b5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f5eae624-e9e7-443b-89dd-8662bcd6a295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2f7eec3-7e7e-45ef-8835-05cb9d82e061" xlink:to="loc_us-gaap_PlanNameAxis_f5eae624-e9e7-443b-89dd-8662bcd6a295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b747f5a3-7c05-42bb-b555-99441120fa51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f5eae624-e9e7-443b-89dd-8662bcd6a295" xlink:to="loc_us-gaap_PlanNameDomain_b747f5a3-7c05-42bb-b555-99441120fa51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_66a52c0d-efa7-40dd-b762-970ef1e7aecc" xlink:href="mygn-20221231.xsd#mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b747f5a3-7c05-42bb-b555-99441120fa51" xlink:to="loc_mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember_66a52c0d-efa7-40dd-b762-970ef1e7aecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_4b13e64d-eeb3-4bb9-a4c4-bf1a4fc414ca" xlink:href="mygn-20221231.xsd#mygn_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b747f5a3-7c05-42bb-b555-99441120fa51" xlink:to="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_4b13e64d-eeb3-4bb9-a4c4-bf1a4fc414ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cfe6dafe-4a1f-4a41-adf4-896174ed4170" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2f7eec3-7e7e-45ef-8835-05cb9d82e061" xlink:to="loc_srt_RangeAxis_cfe6dafe-4a1f-4a41-adf4-896174ed4170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5acf4fb9-f73f-433f-a5ef-ee06bbfcb939" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cfe6dafe-4a1f-4a41-adf4-896174ed4170" xlink:to="loc_srt_RangeMember_5acf4fb9-f73f-433f-a5ef-ee06bbfcb939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fc883e70-60bd-4be7-8a98-7c26dd00f12e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5acf4fb9-f73f-433f-a5ef-ee06bbfcb939" xlink:to="loc_srt_MaximumMember_fc883e70-60bd-4be7-8a98-7c26dd00f12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9157e35c-c22b-4263-8f6c-45bb85aa05d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5acf4fb9-f73f-433f-a5ef-ee06bbfcb939" xlink:to="loc_srt_MinimumMember_9157e35c-c22b-4263-8f6c-45bb85aa05d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2f7eec3-7e7e-45ef-8835-05cb9d82e061" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c035046b-2d72-42fc-9fe3-156822441907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c035046b-2d72-42fc-9fe3-156822441907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_eac1c2b5-383e-424e-a3d8-eb7f3f12599f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_eac1c2b5-383e-424e-a3d8-eb7f3f12599f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2a37a73c-66bf-43b0-a843-97ebf048ecc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2a37a73c-66bf-43b0-a843-97ebf048ecc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_afc63fa4-b14e-4dbd-b031-b23f33f88cce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_afc63fa4-b14e-4dbd-b031-b23f33f88cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_03920eed-8b8c-4a79-b291-6ae2d7c25106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_03920eed-8b8c-4a79-b291-6ae2d7c25106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_51b1947d-6543-45ad-87a9-7c3f649dd920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_51b1947d-6543-45ad-87a9-7c3f649dd920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0ecb7bd8-9dda-4c20-b345-f3849aa3fe11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0ecb7bd8-9dda-4c20-b345-f3849aa3fe11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7d4280d7-e779-49ff-a11e-3a90a7a759f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7d4280d7-e779-49ff-a11e-3a90a7a759f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_680c9c68-465b-41b8-be91-363fe986ad4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_680c9c68-465b-41b8-be91-363fe986ad4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_10e7ff19-1892-42fd-b6f9-ecdf071fc31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_10e7ff19-1892-42fd-b6f9-ecdf071fc31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_135b0ef8-c098-472f-92d6-4e60ce743df2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_135b0ef8-c098-472f-92d6-4e60ce743df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f36c0715-62a0-4614-8958-6d8a587c79ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f36c0715-62a0-4614-8958-6d8a587c79ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_c70472b6-8b9b-4e23-b6c0-12d93fa1c85d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_c70472b6-8b9b-4e23-b6c0-12d93fa1c85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1f863037-15bc-4ab8-833c-96b28e9fb527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6b0932-d4b3-4e9d-a982-26910ddf149f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1f863037-15bc-4ab8-833c-96b28e9fb527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#StockBasedCompensationStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_588bb267-a182-4cbb-973f-436f812232f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cbd5d7ab-d47f-4a8f-b8f6-30e88b6f4b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_588bb267-a182-4cbb-973f-436f812232f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cbd5d7ab-d47f-4a8f-b8f6-30e88b6f4b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_de31704e-2b5f-4e71-b0a8-d9c397f87d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cbd5d7ab-d47f-4a8f-b8f6-30e88b6f4b7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_de31704e-2b5f-4e71-b0a8-d9c397f87d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_96ff39ba-c7f3-40ea-9ce5-dd87d3da2acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cbd5d7ab-d47f-4a8f-b8f6-30e88b6f4b7d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_96ff39ba-c7f3-40ea-9ce5-dd87d3da2acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_6cf2b546-2b11-4e44-a455-3939996ef916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cbd5d7ab-d47f-4a8f-b8f6-30e88b6f4b7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_6cf2b546-2b11-4e44-a455-3939996ef916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ad1de376-e6f8-4466-b3b3-ebbab9aa2634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cbd5d7ab-d47f-4a8f-b8f6-30e88b6f4b7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ad1de376-e6f8-4466-b3b3-ebbab9aa2634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_023a4687-bf1a-4f8b-967a-fb8e753731f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_588bb267-a182-4cbb-973f-436f812232f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_023a4687-bf1a-4f8b-967a-fb8e753731f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_330e4a46-cb65-4d20-9d9e-f23f3c71d525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_588bb267-a182-4cbb-973f-436f812232f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_330e4a46-cb65-4d20-9d9e-f23f3c71d525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30bdb9c9-92a1-476d-af2d-64267cea395f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_588bb267-a182-4cbb-973f-436f812232f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30bdb9c9-92a1-476d-af2d-64267cea395f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4e5fc498-816d-48d0-b6d2-813975c47539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30bdb9c9-92a1-476d-af2d-64267cea395f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4e5fc498-816d-48d0-b6d2-813975c47539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_bb6b03f9-529f-44ed-8ce1-2c939aff0a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30bdb9c9-92a1-476d-af2d-64267cea395f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_bb6b03f9-529f-44ed-8ce1-2c939aff0a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_e03fdc1f-51f8-4f0c-8716-25210dc0b328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30bdb9c9-92a1-476d-af2d-64267cea395f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_e03fdc1f-51f8-4f0c-8716-25210dc0b328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5c765758-4fef-41bb-933f-1d1b824e3b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_30bdb9c9-92a1-476d-af2d-64267cea395f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5c765758-4fef-41bb-933f-1d1b824e3b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4ad3b223-5304-4773-84e3-61d1158e5526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_588bb267-a182-4cbb-973f-436f812232f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4ad3b223-5304-4773-84e3-61d1158e5526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_660991bd-a9bf-447b-9174-e8fc7255c7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_588bb267-a182-4cbb-973f-436f812232f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_660991bd-a9bf-447b-9174-e8fc7255c7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_92140324-f26c-4649-89a1-a94e34ce60b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_588bb267-a182-4cbb-973f-436f812232f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_92140324-f26c-4649-89a1-a94e34ce60b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_0c0c5a0a-894e-402d-80ec-51af1ee4ec2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_92140324-f26c-4649-89a1-a94e34ce60b8" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_0c0c5a0a-894e-402d-80ec-51af1ee4ec2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_610a8c14-ac83-4075-b4b6-a4b0e105c712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_92140324-f26c-4649-89a1-a94e34ce60b8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_610a8c14-ac83-4075-b4b6-a4b0e105c712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_a3c4a73b-b1cc-46bb-99fb-6adc0fe11584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_92140324-f26c-4649-89a1-a94e34ce60b8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_a3c4a73b-b1cc-46bb-99fb-6adc0fe11584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#StockBasedCompensationRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9c4287fe-c073-47cc-99bb-d7e4f71e6522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cfd06ef-e200-4f04-934a-feb945f536a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9c4287fe-c073-47cc-99bb-d7e4f71e6522" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cfd06ef-e200-4f04-934a-feb945f536a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9e9d9cc6-e70e-4257-85e5-565d3ed57ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cfd06ef-e200-4f04-934a-feb945f536a5" xlink:to="loc_us-gaap_AwardTypeAxis_9e9d9cc6-e70e-4257-85e5-565d3ed57ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72ec8ac-6f3d-4628-99da-c845a2c4ce04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9e9d9cc6-e70e-4257-85e5-565d3ed57ceb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72ec8ac-6f3d-4628-99da-c845a2c4ce04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_915bb6f7-f2fb-4637-ab29-324f590db935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b72ec8ac-6f3d-4628-99da-c845a2c4ce04" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_915bb6f7-f2fb-4637-ab29-324f590db935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dfd1b2e8-eb97-43c4-95bb-a1b22d5450b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cfd06ef-e200-4f04-934a-feb945f536a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dfd1b2e8-eb97-43c4-95bb-a1b22d5450b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daec2046-f0f9-4e2a-96dd-d9ef11529e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dfd1b2e8-eb97-43c4-95bb-a1b22d5450b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daec2046-f0f9-4e2a-96dd-d9ef11529e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00236bfc-47bf-4633-9890-49f1e7b2c714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daec2046-f0f9-4e2a-96dd-d9ef11529e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00236bfc-47bf-4633-9890-49f1e7b2c714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_154323ec-1f27-4e5a-9b88-6f3f9e4d1141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daec2046-f0f9-4e2a-96dd-d9ef11529e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_154323ec-1f27-4e5a-9b88-6f3f9e4d1141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d0e719fc-58c2-43f5-b390-32a299335713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daec2046-f0f9-4e2a-96dd-d9ef11529e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d0e719fc-58c2-43f5-b390-32a299335713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b90052e8-31db-4a7b-889e-d33c4f800260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daec2046-f0f9-4e2a-96dd-d9ef11529e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b90052e8-31db-4a7b-889e-d33c4f800260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d51a5d0e-f4a8-4d82-998b-c48c1f889039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_daec2046-f0f9-4e2a-96dd-d9ef11529e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d51a5d0e-f4a8-4d82-998b-c48c1f889039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e569e0a-4f8e-4142-9e2a-7e70c33ce39a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dfd1b2e8-eb97-43c4-95bb-a1b22d5450b2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e569e0a-4f8e-4142-9e2a-7e70c33ce39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fdff026c-b184-41da-b96a-4279cfae0670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e569e0a-4f8e-4142-9e2a-7e70c33ce39a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fdff026c-b184-41da-b96a-4279cfae0670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2596e83d-f496-46eb-978c-ed2ff2166a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e569e0a-4f8e-4142-9e2a-7e70c33ce39a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2596e83d-f496-46eb-978c-ed2ff2166a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_865e7a45-be5c-46a8-ae85-fc6d3650e183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e569e0a-4f8e-4142-9e2a-7e70c33ce39a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_865e7a45-be5c-46a8-ae85-fc6d3650e183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9df9567a-f61d-4d73-824b-ae87db962677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e569e0a-4f8e-4142-9e2a-7e70c33ce39a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9df9567a-f61d-4d73-824b-ae87db962677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_71d75de7-40f8-43e1-b82f-30b98bcda165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e569e0a-4f8e-4142-9e2a-7e70c33ce39a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_71d75de7-40f8-43e1-b82f-30b98bcda165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3274365d-777a-4009-b654-36d0f2ae973c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_69953c85-2560-4b26-8a10-952772dd583a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3274365d-777a-4009-b654-36d0f2ae973c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_69953c85-2560-4b26-8a10-952772dd583a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8b325eef-87b9-4c91-a58e-e43b479f1696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_69953c85-2560-4b26-8a10-952772dd583a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8b325eef-87b9-4c91-a58e-e43b479f1696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6e0d700e-a72a-4442-b6a5-f3edb56647a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8b325eef-87b9-4c91-a58e-e43b479f1696" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6e0d700e-a72a-4442-b6a5-f3edb56647a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfTestingMember_92f4a788-0bc0-42f4-8471-9432083128ba" xlink:href="mygn-20221231.xsd#mygn_CostOfTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6e0d700e-a72a-4442-b6a5-f3edb56647a5" xlink:to="loc_mygn_CostOfTestingMember_92f4a788-0bc0-42f4-8471-9432083128ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_CostOfOtherRevenueMember_6475478e-b715-4abf-946b-34d7ae0e83c6" xlink:href="mygn-20221231.xsd#mygn_CostOfOtherRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6e0d700e-a72a-4442-b6a5-f3edb56647a5" xlink:to="loc_mygn_CostOfOtherRevenueMember_6475478e-b715-4abf-946b-34d7ae0e83c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9fc43f89-72dc-4d04-a635-421cda62fba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6e0d700e-a72a-4442-b6a5-f3edb56647a5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9fc43f89-72dc-4d04-a635-421cda62fba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_62dede1d-908c-454c-af47-b76c1ac217f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6e0d700e-a72a-4442-b6a5-f3edb56647a5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_62dede1d-908c-454c-af47-b76c1ac217f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0a638636-7607-4c02-910d-c1a607ab4132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_69953c85-2560-4b26-8a10-952772dd583a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0a638636-7607-4c02-910d-c1a607ab4132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7ef13e20-1090-4e5a-b3f4-45b176eb1c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0a638636-7607-4c02-910d-c1a607ab4132" xlink:to="loc_us-gaap_ShareBasedCompensation_7ef13e20-1090-4e5a-b3f4-45b176eb1c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#StockBasedCompensationAggregateIntrinsicValueDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4b4cde23-263f-4861-b406-c37c263b5afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da7559a8-4c0d-4014-8996-cb05b8ba9b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4b4cde23-263f-4861-b406-c37c263b5afe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da7559a8-4c0d-4014-8996-cb05b8ba9b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_77ade6f0-a32e-4e0d-b28d-ad0de2e03310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da7559a8-4c0d-4014-8996-cb05b8ba9b9e" xlink:to="loc_us-gaap_AwardTypeAxis_77ade6f0-a32e-4e0d-b28d-ad0de2e03310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aadc66e7-3f86-49e4-b6b8-71a6852d9aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_77ade6f0-a32e-4e0d-b28d-ad0de2e03310" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aadc66e7-3f86-49e4-b6b8-71a6852d9aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_15bad476-43c6-4b28-9b3b-e6f0beb50166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aadc66e7-3f86-49e4-b6b8-71a6852d9aa4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_15bad476-43c6-4b28-9b3b-e6f0beb50166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6ab1cc10-e147-435f-9ddc-c4d90555bc74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da7559a8-4c0d-4014-8996-cb05b8ba9b9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6ab1cc10-e147-435f-9ddc-c4d90555bc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3a3b4071-585b-450a-ae74-28cf9937e132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6ab1cc10-e147-435f-9ddc-c4d90555bc74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3a3b4071-585b-450a-ae74-28cf9937e132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8fcf452e-041e-4337-83a4-ef416102f1af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6ab1cc10-e147-435f-9ddc-c4d90555bc74" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8fcf452e-041e-4337-83a4-ef416102f1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_d7a0cecf-d8c6-45fc-b950-5fb171743dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6ab1cc10-e147-435f-9ddc-c4d90555bc74" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_d7a0cecf-d8c6-45fc-b950-5fb171743dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationIntrinsicValueofOptionsExercisedDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#StockBasedCompensationIntrinsicValueofOptionsExercisedDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationIntrinsicValueofOptionsExercisedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_183c9d94-7eca-48ea-8d86-050a3ac198d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a3d18346-8bb4-42f2-935d-7c8dec72a235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_183c9d94-7eca-48ea-8d86-050a3ac198d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a3d18346-8bb4-42f2-935d-7c8dec72a235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8af0531f-397b-4008-a815-ff31bd6d7710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2650224-98b1-4891-af60-2ce9ce79be61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8af0531f-397b-4008-a815-ff31bd6d7710" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2650224-98b1-4891-af60-2ce9ce79be61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_06a67027-7b4f-4b53-a142-09ad25976587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2650224-98b1-4891-af60-2ce9ce79be61" xlink:to="loc_us-gaap_PlanNameAxis_06a67027-7b4f-4b53-a142-09ad25976587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_46beeb42-04f8-43b9-a3a1-f78f6be37234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_06a67027-7b4f-4b53-a142-09ad25976587" xlink:to="loc_us-gaap_PlanNameDomain_46beeb42-04f8-43b9-a3a1-f78f6be37234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_36a67a41-ff1b-42b0-bceb-064f43f32b31" xlink:href="mygn-20221231.xsd#mygn_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_46beeb42-04f8-43b9-a3a1-f78f6be37234" xlink:to="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_36a67a41-ff1b-42b0-bceb-064f43f32b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa311370-28b0-496d-9b51-f6384850858f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2650224-98b1-4891-af60-2ce9ce79be61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa311370-28b0-496d-9b51-f6384850858f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_38d97bc8-560a-43d6-bc72-e517dea4a988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa311370-28b0-496d-9b51-f6384850858f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_38d97bc8-560a-43d6-bc72-e517dea4a988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_ccb73009-8695-4bc9-8cf4-35da14c0258f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa311370-28b0-496d-9b51-f6384850858f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_ccb73009-8695-4bc9-8cf4-35da14c0258f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#StockBasedCompensationValuationAssumptionsforESPPDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_76d2593b-9a05-458f-a2fa-b8a02073185f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9604dfa-5ac2-4dd4-b950-242f9357b2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_76d2593b-9a05-458f-a2fa-b8a02073185f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9604dfa-5ac2-4dd4-b950-242f9357b2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_cc795f5b-6193-4afd-9486-e41dff4190be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9604dfa-5ac2-4dd4-b950-242f9357b2c9" xlink:to="loc_us-gaap_PlanNameAxis_cc795f5b-6193-4afd-9486-e41dff4190be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6e5f03f0-02fa-436c-9a43-b3943707ee0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_cc795f5b-6193-4afd-9486-e41dff4190be" xlink:to="loc_us-gaap_PlanNameDomain_6e5f03f0-02fa-436c-9a43-b3943707ee0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_7367d35e-cd01-4394-ba3c-1f7e8f24993d" xlink:href="mygn-20221231.xsd#mygn_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6e5f03f0-02fa-436c-9a43-b3943707ee0f" xlink:to="loc_mygn_EmployeeStockPurchasePlanTwentyTwelveMember_7367d35e-cd01-4394-ba3c-1f7e8f24993d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52d53e60-8c1c-4fcf-b086-f427f8cb3f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9604dfa-5ac2-4dd4-b950-242f9357b2c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52d53e60-8c1c-4fcf-b086-f427f8cb3f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_75494499-6b51-4e95-a3e6-582ad764c916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52d53e60-8c1c-4fcf-b086-f427f8cb3f4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_75494499-6b51-4e95-a3e6-582ad764c916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_398ddb61-98fb-49c5-bc89-fad77b4a24bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_75494499-6b51-4e95-a3e6-582ad764c916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_398ddb61-98fb-49c5-bc89-fad77b4a24bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4b3cbfe3-64ca-46e8-b867-8232bd53ccb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_75494499-6b51-4e95-a3e6-582ad764c916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4b3cbfe3-64ca-46e8-b867-8232bd53ccb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_31d73bc8-bce0-453c-bbe6-ad023f19ffaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_75494499-6b51-4e95-a3e6-582ad764c916" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_31d73bc8-bce0-453c-bbe6-ad023f19ffaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ba2b0d80-5042-49e3-9e93-74c30398c5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_75494499-6b51-4e95-a3e6-582ad764c916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ba2b0d80-5042-49e3-9e93-74c30398c5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#IncomeTaxesIncomeTaxBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0cc8c21c-ff74-4273-bbd1-c07505d23d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f5ae87ab-95f9-42b3-a627-46863468c014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0cc8c21c-ff74-4273-bbd1-c07505d23d00" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f5ae87ab-95f9-42b3-a627-46863468c014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f91a9bf6-a7f3-482b-9488-419a0adfca89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f5ae87ab-95f9-42b3-a627-46863468c014" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f91a9bf6-a7f3-482b-9488-419a0adfca89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a92778fa-476b-4d28-871b-006fe012ff2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f5ae87ab-95f9-42b3-a627-46863468c014" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a92778fa-476b-4d28-871b-006fe012ff2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_86e0dae8-e7b4-41f6-a945-795be7443f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f5ae87ab-95f9-42b3-a627-46863468c014" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_86e0dae8-e7b4-41f6-a945-795be7443f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ee1a2506-c260-4e14-8d43-e5ee92575260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f5ae87ab-95f9-42b3-a627-46863468c014" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ee1a2506-c260-4e14-8d43-e5ee92575260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25688f7e-3709-4465-b83a-a0b1681bbb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0cc8c21c-ff74-4273-bbd1-c07505d23d00" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25688f7e-3709-4465-b83a-a0b1681bbb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_07021e32-0bc7-43ca-8e17-3f2ede851bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25688f7e-3709-4465-b83a-a0b1681bbb4e" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_07021e32-0bc7-43ca-8e17-3f2ede851bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_cca9557c-4944-49ec-b24f-8590c8bd49bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25688f7e-3709-4465-b83a-a0b1681bbb4e" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_cca9557c-4944-49ec-b24f-8590c8bd49bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_61157524-8150-4ab9-8c1b-5c349bd13ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25688f7e-3709-4465-b83a-a0b1681bbb4e" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_61157524-8150-4ab9-8c1b-5c349bd13ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9c7b378a-b8d2-4906-8cdd-c903decdece2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25688f7e-3709-4465-b83a-a0b1681bbb4e" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9c7b378a-b8d2-4906-8cdd-c903decdece2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_122af678-114e-4e68-a4e5-ff92d19d1a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_25688f7e-3709-4465-b83a-a0b1681bbb4e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_122af678-114e-4e68-a4e5-ff92d19d1a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bfdfd31d-2afa-48ae-9b03-38c1a8eabd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0cc8c21c-ff74-4273-bbd1-c07505d23d00" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bfdfd31d-2afa-48ae-9b03-38c1a8eabd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#IncomeTaxesLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_63c888db-4434-4375-8252-52c33705ea9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_16163f98-144d-4c5d-8066-d9b414f94a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_63c888db-4434-4375-8252-52c33705ea9c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_16163f98-144d-4c5d-8066-d9b414f94a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a85ba5a2-fa78-47b2-bda6-80fc21f9ea09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_16163f98-144d-4c5d-8066-d9b414f94a91" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a85ba5a2-fa78-47b2-bda6-80fc21f9ea09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_73900bbc-a6c8-4ec2-a7f1-9c4b16ee870b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_16163f98-144d-4c5d-8066-d9b414f94a91" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_73900bbc-a6c8-4ec2-a7f1-9c4b16ee870b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_85a28d59-d0d7-4922-8eac-8345adec64ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_16163f98-144d-4c5d-8066-d9b414f94a91" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_85a28d59-d0d7-4922-8eac-8345adec64ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2d4804f3-9e6a-481d-aa3f-1536a12c1ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_515d052b-05d4-4794-9a00-3807d4fa4084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2d4804f3-9e6a-481d-aa3f-1536a12c1ec3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_515d052b-05d4-4794-9a00-3807d4fa4084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_e7bdb047-aa14-4f18-8dcc-e588e117668b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_515d052b-05d4-4794-9a00-3807d4fa4084" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_e7bdb047-aa14-4f18-8dcc-e588e117668b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2f5267f6-0e94-4f02-b1b7-146da6ae7a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_515d052b-05d4-4794-9a00-3807d4fa4084" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2f5267f6-0e94-4f02-b1b7-146da6ae7a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_9af34394-586a-4fc5-b747-bf00cd6ae7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_515d052b-05d4-4794-9a00-3807d4fa4084" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_9af34394-586a-4fc5-b747-bf00cd6ae7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_df99c8f7-2964-433e-9b19-5e9c2a51206f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_515d052b-05d4-4794-9a00-3807d4fa4084" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_df99c8f7-2964-433e-9b19-5e9c2a51206f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_22466477-f160-4e59-a910-ffa06a4ef747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_515d052b-05d4-4794-9a00-3807d4fa4084" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_22466477-f160-4e59-a910-ffa06a4ef747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_7147d8d2-dce1-487b-a73e-04bb0bea1350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_515d052b-05d4-4794-9a00-3807d4fa4084" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_7147d8d2-dce1-487b-a73e-04bb0bea1350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_edfc9b27-d63d-4296-b383-b78ee8611b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_515d052b-05d4-4794-9a00-3807d4fa4084" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_edfc9b27-d63d-4296-b383-b78ee8611b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationCARESAct_3e1c7eaa-f514-4930-af55-c1bd22ddfeaa" xlink:href="mygn-20221231.xsd#mygn_IncomeTaxReconciliationCARESAct"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_515d052b-05d4-4794-9a00-3807d4fa4084" xlink:to="loc_mygn_IncomeTaxReconciliationCARESAct_3e1c7eaa-f514-4930-af55-c1bd22ddfeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_fa6152ed-71f6-4b1d-8c40-7abbcc8aa6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_515d052b-05d4-4794-9a00-3807d4fa4084" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_fa6152ed-71f6-4b1d-8c40-7abbcc8aa6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation_7c5acd80-bc5e-4680-a0dc-86af5ef39390" xlink:href="mygn-20221231.xsd#mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_515d052b-05d4-4794-9a00-3807d4fa4084" xlink:to="loc_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation_7c5acd80-bc5e-4680-a0dc-86af5ef39390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationAssetImpairment_c83e409a-3d10-4296-98f6-9f20b082ac39" xlink:href="mygn-20221231.xsd#mygn_IncomeTaxReconciliationAssetImpairment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_515d052b-05d4-4794-9a00-3807d4fa4084" xlink:to="loc_mygn_IncomeTaxReconciliationAssetImpairment_c83e409a-3d10-4296-98f6-9f20b082ac39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement_8ff28c3e-885d-4add-922e-58c6f39bff0b" xlink:href="mygn-20221231.xsd#mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_515d052b-05d4-4794-9a00-3807d4fa4084" xlink:to="loc_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement_8ff28c3e-885d-4add-922e-58c6f39bff0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration_3a4998af-418b-4b77-95f2-9d4324efdbaf" xlink:href="mygn-20221231.xsd#mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_515d052b-05d4-4794-9a00-3807d4fa4084" xlink:to="loc_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration_3a4998af-418b-4b77-95f2-9d4324efdbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_f44a7856-aaac-4477-897c-26ce50c2db95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_515d052b-05d4-4794-9a00-3807d4fa4084" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_f44a7856-aaac-4477-897c-26ce50c2db95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6806e48f-360c-4a1f-aa4c-476414a3c70d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_515d052b-05d4-4794-9a00-3807d4fa4084" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6806e48f-360c-4a1f-aa4c-476414a3c70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_25c63f9a-b6e0-4bfc-9add-bf6dab02099f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2d4804f3-9e6a-481d-aa3f-1536a12c1ec3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_25c63f9a-b6e0-4bfc-9add-bf6dab02099f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e0431a6c-4398-43b7-a5a3-3384322b9b20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_25c63f9a-b6e0-4bfc-9add-bf6dab02099f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e0431a6c-4398-43b7-a5a3-3384322b9b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a9cb700a-a158-4551-8b11-d183b01a9f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_25c63f9a-b6e0-4bfc-9add-bf6dab02099f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a9cb700a-a158-4551-8b11-d183b01a9f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_c8353761-2ebf-41fc-bccf-8cbce65c1257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_25c63f9a-b6e0-4bfc-9add-bf6dab02099f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_c8353761-2ebf-41fc-bccf-8cbce65c1257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_cae92140-5260-40cf-ad9a-46c100a22c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_25c63f9a-b6e0-4bfc-9add-bf6dab02099f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_cae92140-5260-40cf-ad9a-46c100a22c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_830eb144-d6b0-4fe8-a4dc-2eb330c5443f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_25c63f9a-b6e0-4bfc-9add-bf6dab02099f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_830eb144-d6b0-4fe8-a4dc-2eb330c5443f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_af92dc8d-7f09-469b-a797-82d40bf16bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_25c63f9a-b6e0-4bfc-9add-bf6dab02099f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_af92dc8d-7f09-469b-a797-82d40bf16bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6794c975-1daf-4536-afa8-2b2b013109b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_25c63f9a-b6e0-4bfc-9add-bf6dab02099f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6794c975-1daf-4536-afa8-2b2b013109b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationCARESAct_915aa861-2075-4cbf-8940-1e6a451cbece" xlink:href="mygn-20221231.xsd#mygn_EffectiveIncomeTaxRateReconciliationCARESAct"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_25c63f9a-b6e0-4bfc-9add-bf6dab02099f" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationCARESAct_915aa861-2075-4cbf-8940-1e6a451cbece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_f0001386-a2a5-4c18-b180-a8184cb56cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_25c63f9a-b6e0-4bfc-9add-bf6dab02099f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_f0001386-a2a5-4c18-b180-a8184cb56cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation_4b74b46b-b95c-4ec9-a509-d77bd56d02a4" xlink:href="mygn-20221231.xsd#mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_25c63f9a-b6e0-4bfc-9add-bf6dab02099f" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation_4b74b46b-b95c-4ec9-a509-d77bd56d02a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment_e5b6c4b9-c0e3-43a9-af88-8437f5293893" xlink:href="mygn-20221231.xsd#mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_25c63f9a-b6e0-4bfc-9add-bf6dab02099f" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment_e5b6c4b9-c0e3-43a9-af88-8437f5293893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements_2f161a97-797a-4a4c-a8a2-65431a2577e8" xlink:href="mygn-20221231.xsd#mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_25c63f9a-b6e0-4bfc-9add-bf6dab02099f" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements_2f161a97-797a-4a4c-a8a2-65431a2577e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration_f187a0e6-55d3-4704-b261-b068e1396293" xlink:href="mygn-20221231.xsd#mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_25c63f9a-b6e0-4bfc-9add-bf6dab02099f" xlink:to="loc_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration_f187a0e6-55d3-4704-b261-b068e1396293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4f6c5680-0429-45c7-b652-8f866b827e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_25c63f9a-b6e0-4bfc-9add-bf6dab02099f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4f6c5680-0429-45c7-b652-8f866b827e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_763b9eac-bfb1-46ee-acb1-3146a41a4023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_25c63f9a-b6e0-4bfc-9add-bf6dab02099f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_763b9eac-bfb1-46ee-acb1-3146a41a4023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4a03685f-c15d-4a67-8b00-29a38521ee30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_101d211b-86cc-4c06-bada-6e1da3471c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4a03685f-c15d-4a67-8b00-29a38521ee30" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_101d211b-86cc-4c06-bada-6e1da3471c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e4078227-eb8e-4259-a69e-f4e8f45da426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_101d211b-86cc-4c06-bada-6e1da3471c51" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e4078227-eb8e-4259-a69e-f4e8f45da426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_f4f109db-1fdb-4588-9057-3b366073a512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_101d211b-86cc-4c06-bada-6e1da3471c51" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_f4f109db-1fdb-4588-9057-3b366073a512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_79f209a5-0a0d-44de-8fca-a085e5688b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_101d211b-86cc-4c06-bada-6e1da3471c51" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_79f209a5-0a0d-44de-8fca-a085e5688b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_913ce5a4-dae0-4b49-a157-7aadf7af8e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_101d211b-86cc-4c06-bada-6e1da3471c51" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_913ce5a4-dae0-4b49-a157-7aadf7af8e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DeferredTaxAssetsLeaseLiabilities_bdcf9968-fc82-44f9-a950-23bbfc7e05f9" xlink:href="mygn-20221231.xsd#mygn_DeferredTaxAssetsLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_101d211b-86cc-4c06-bada-6e1da3471c51" xlink:to="loc_mygn_DeferredTaxAssetsLeaseLiabilities_bdcf9968-fc82-44f9-a950-23bbfc7e05f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization_c512603b-88b5-4451-84f2-afb26ed9973b" xlink:href="mygn-20221231.xsd#mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_101d211b-86cc-4c06-bada-6e1da3471c51" xlink:to="loc_mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization_c512603b-88b5-4451-84f2-afb26ed9973b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_a317d139-ba27-4800-ba5b-113bed50c28e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_101d211b-86cc-4c06-bada-6e1da3471c51" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_a317d139-ba27-4800-ba5b-113bed50c28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_886da995-c385-471f-b393-6ff3091bd448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_101d211b-86cc-4c06-bada-6e1da3471c51" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_886da995-c385-471f-b393-6ff3091bd448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_678bdb8b-e0c3-4915-80e7-520d0ce2565d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_101d211b-86cc-4c06-bada-6e1da3471c51" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_678bdb8b-e0c3-4915-80e7-520d0ce2565d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_df2e72c0-5dca-460f-ba4d-ea587bb9ee6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_101d211b-86cc-4c06-bada-6e1da3471c51" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_df2e72c0-5dca-460f-ba4d-ea587bb9ee6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_839c0b15-5106-45f5-aacd-58cb8b44cc97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_101d211b-86cc-4c06-bada-6e1da3471c51" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_839c0b15-5106-45f5-aacd-58cb8b44cc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a5fc6a58-0790-4d9c-b2bd-b8a63c00b60a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4a03685f-c15d-4a67-8b00-29a38521ee30" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a5fc6a58-0790-4d9c-b2bd-b8a63c00b60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_defaff99-a00b-4738-bd0f-88ebecee0414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a5fc6a58-0790-4d9c-b2bd-b8a63c00b60a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_defaff99-a00b-4738-bd0f-88ebecee0414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets_46f10080-9ead-4bbd-853f-a11852357d1a" xlink:href="mygn-20221231.xsd#mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a5fc6a58-0790-4d9c-b2bd-b8a63c00b60a" xlink:to="loc_mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets_46f10080-9ead-4bbd-853f-a11852357d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_d44c877d-3f91-4912-a618-b8270ecaf91e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a5fc6a58-0790-4d9c-b2bd-b8a63c00b60a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_d44c877d-3f91-4912-a618-b8270ecaf91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_0d832ab2-f855-4780-bfef-603a15e49194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a5fc6a58-0790-4d9c-b2bd-b8a63c00b60a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_0d832ab2-f855-4780-bfef-603a15e49194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_28e106c9-196d-49c3-af7a-21d5f5e0b1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_a5fc6a58-0790-4d9c-b2bd-b8a63c00b60a" xlink:to="loc_us-gaap_DeferredTaxLiabilities_28e106c9-196d-49c3-af7a-21d5f5e0b1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fb517248-0b8b-4c2a-a3d9-4443db4e312e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod_bf87eb48-cc3f-432c-a10b-225dd5ab9091" xlink:href="mygn-20221231.xsd#mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb517248-0b8b-4c2a-a3d9-4443db4e312e" xlink:to="loc_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod_bf87eb48-cc3f-432c-a10b-225dd5ab9091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_dbc9f93e-53c8-436f-9775-47dc7857bb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb517248-0b8b-4c2a-a3d9-4443db4e312e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_dbc9f93e-53c8-436f-9775-47dc7857bb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ceb3a41a-16b0-4f35-a5c9-fe978a431d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_d119ece1-2be6-4161-9b0a-072f61189844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ceb3a41a-16b0-4f35-a5c9-fe978a431d1e" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_d119ece1-2be6-4161-9b0a-072f61189844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_425a1c08-4ed9-4695-ba0a-aa9a8bff08ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d119ece1-2be6-4161-9b0a-072f61189844" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_425a1c08-4ed9-4695-ba0a-aa9a8bff08ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_801c673c-d00a-4a7e-9a14-d6b739f6b1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_425a1c08-4ed9-4695-ba0a-aa9a8bff08ff" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_801c673c-d00a-4a7e-9a14-d6b739f6b1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_971fc3c7-c2f5-4938-82b2-72b1654e5eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_801c673c-d00a-4a7e-9a14-d6b739f6b1d5" xlink:to="loc_us-gaap_DomesticCountryMember_971fc3c7-c2f5-4938-82b2-72b1654e5eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1c7fea2c-a1f1-4624-9f9d-959509e34881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_801c673c-d00a-4a7e-9a14-d6b739f6b1d5" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1c7fea2c-a1f1-4624-9f9d-959509e34881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_1df8a7e3-1995-476c-b271-3fbfac403dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_801c673c-d00a-4a7e-9a14-d6b739f6b1d5" xlink:to="loc_us-gaap_ForeignCountryMember_1df8a7e3-1995-476c-b271-3fbfac403dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_11e381ee-0e96-4bd2-b847-16163e303670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d119ece1-2be6-4161-9b0a-072f61189844" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_11e381ee-0e96-4bd2-b847-16163e303670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_1b00ebc3-7719-4220-aafc-e93d3142720e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_11e381ee-0e96-4bd2-b847-16163e303670" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_1b00ebc3-7719-4220-aafc-e93d3142720e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_0bbd3929-a63c-4d00-aab9-252b99fbb364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_1b00ebc3-7719-4220-aafc-e93d3142720e" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_0bbd3929-a63c-4d00-aab9-252b99fbb364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_UT_dfa78cab-8b18-4b51-ad42-ef9c40cc5fdc" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_UT"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_1b00ebc3-7719-4220-aafc-e93d3142720e" xlink:to="loc_stpr_UT_dfa78cab-8b18-4b51-ad42-ef9c40cc5fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_c3daf7e2-0ec3-4630-a143-bf4c910edbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_1b00ebc3-7719-4220-aafc-e93d3142720e" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_c3daf7e2-0ec3-4630-a143-bf4c910edbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OtherStateMember_b0d80cf1-1fb4-44e9-af99-e5358aec70f4" xlink:href="mygn-20221231.xsd#mygn_OtherStateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_1b00ebc3-7719-4220-aafc-e93d3142720e" xlink:to="loc_mygn_OtherStateMember_b0d80cf1-1fb4-44e9-af99-e5358aec70f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_01749470-b2a0-4860-9d5d-694703705db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d119ece1-2be6-4161-9b0a-072f61189844" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_01749470-b2a0-4860-9d5d-694703705db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_bb78ac63-074d-4c0e-83ea-d02e3a68f297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_01749470-b2a0-4860-9d5d-694703705db4" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_bb78ac63-074d-4c0e-83ea-d02e3a68f297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_ed60641a-3ddf-4da2-af7a-3a3efb5fd67c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_bb78ac63-074d-4c0e-83ea-d02e3a68f297" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_ed60641a-3ddf-4da2-af7a-3a3efb5fd67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_691cdd57-228f-4688-a86d-794eb29d1442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_bb78ac63-074d-4c0e-83ea-d02e3a68f297" xlink:to="loc_us-gaap_ResearchMember_691cdd57-228f-4688-a86d-794eb29d1442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_99a197a4-8ca0-4dfa-8272-71e3e127af4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d119ece1-2be6-4161-9b0a-072f61189844" xlink:to="loc_srt_RangeAxis_99a197a4-8ca0-4dfa-8272-71e3e127af4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74b82b55-a582-4463-b9c9-fdaa96922aca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_99a197a4-8ca0-4dfa-8272-71e3e127af4e" xlink:to="loc_srt_RangeMember_74b82b55-a582-4463-b9c9-fdaa96922aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_42dcda5a-7e24-4e2b-819f-7976f9c08dd1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_74b82b55-a582-4463-b9c9-fdaa96922aca" xlink:to="loc_srt_MinimumMember_42dcda5a-7e24-4e2b-819f-7976f9c08dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ffe0eb16-0c3e-4bb2-8b62-811cedbae8a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_74b82b55-a582-4463-b9c9-fdaa96922aca" xlink:to="loc_srt_MaximumMember_ffe0eb16-0c3e-4bb2-8b62-811cedbae8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_4660d414-3553-460a-9f84-69563a590ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d119ece1-2be6-4161-9b0a-072f61189844" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_4660d414-3553-460a-9f84-69563a590ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_d51e49b4-59ce-46f6-9285-b09b931c68cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4660d414-3553-460a-9f84-69563a590ca9" xlink:to="loc_us-gaap_OperatingLossCarryforwards_d51e49b4-59ce-46f6-9285-b09b931c68cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_a0c312a9-7810-4936-b78f-aafd17cb287e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4660d414-3553-460a-9f84-69563a590ca9" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_a0c312a9-7810-4936-b78f-aafd17cb287e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_a70578cd-3a21-4f73-9c3f-fe7898fc426f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4660d414-3553-460a-9f84-69563a590ca9" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_a70578cd-3a21-4f73-9c3f-fe7898fc426f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_25230850-1d34-46a9-bba7-abd6bd415339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4660d414-3553-460a-9f84-69563a590ca9" xlink:to="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_25230850-1d34-46a9-bba7-abd6bd415339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLossCarryforwardsExpirationYear_48da84a9-4aad-49bf-9c2e-788cc80faada" xlink:href="mygn-20221231.xsd#mygn_OperatingLossCarryforwardsExpirationYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4660d414-3553-460a-9f84-69563a590ca9" xlink:to="loc_mygn_OperatingLossCarryforwardsExpirationYear_48da84a9-4aad-49bf-9c2e-788cc80faada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TaxCreditCarryforwardsExpirationDate_8b6639d9-5765-487a-83d8-c013f6803098" xlink:href="mygn-20221231.xsd#mygn_TaxCreditCarryforwardsExpirationDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4660d414-3553-460a-9f84-69563a590ca9" xlink:to="loc_mygn_TaxCreditCarryforwardsExpirationDate_8b6639d9-5765-487a-83d8-c013f6803098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#IncomeTaxesUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fb354f1c-fd47-4342-9c6c-14ff6f21ad35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8fc26a0d-1744-480b-b0a4-de84ca9ff198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb354f1c-fd47-4342-9c6c-14ff6f21ad35" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8fc26a0d-1744-480b-b0a4-de84ca9ff198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_4b34450c-6a2e-4c61-89b4-b8937073ef63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8fc26a0d-1744-480b-b0a4-de84ca9ff198" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_4b34450c-6a2e-4c61-89b4-b8937073ef63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7e8fc21d-9988-47d3-a876-c1b8acacc15d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8fc26a0d-1744-480b-b0a4-de84ca9ff198" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_7e8fc21d-9988-47d3-a876-c1b8acacc15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_80f1fa4e-0fe4-421d-917b-743d844ffc45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8fc26a0d-1744-480b-b0a4-de84ca9ff198" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_80f1fa4e-0fe4-421d-917b-743d844ffc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_8a952767-d843-4b1b-9a0a-29f14c0022a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8fc26a0d-1744-480b-b0a4-de84ca9ff198" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_8a952767-d843-4b1b-9a0a-29f14c0022a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_078fe30e-757d-45ad-80f0-510664fb1a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8fc26a0d-1744-480b-b0a4-de84ca9ff198" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_078fe30e-757d-45ad-80f0-510664fb1a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_22951b2e-ad0e-4b76-b37f-b2e082bc4f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8fc26a0d-1744-480b-b0a4-de84ca9ff198" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_22951b2e-ad0e-4b76-b37f-b2e082bc4f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_ba0d694e-a525-437c-a30d-fa2f61192db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8fc26a0d-1744-480b-b0a4-de84ca9ff198" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_ba0d694e-a525-437c-a30d-fa2f61192db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_92c0e258-6522-4b64-94ff-87a17f5cbcec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb354f1c-fd47-4342-9c6c-14ff6f21ad35" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_92c0e258-6522-4b64-94ff-87a17f5cbcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7c84eff1-3a6f-4a20-bd2d-89565b650ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_388487fd-60e0-49db-b5fc-8f897b5aa662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7c84eff1-3a6f-4a20-bd2d-89565b650ef7" xlink:to="loc_us-gaap_LossContingenciesTable_388487fd-60e0-49db-b5fc-8f897b5aa662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_2d5c470f-df51-4094-ba0e-975735a185be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_388487fd-60e0-49db-b5fc-8f897b5aa662" xlink:to="loc_srt_LitigationCaseAxis_2d5c470f-df51-4094-ba0e-975735a185be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c7aae0ef-c35d-47f4-97c9-242e15afa75a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_2d5c470f-df51-4094-ba0e-975735a185be" xlink:to="loc_srt_LitigationCaseTypeDomain_c7aae0ef-c35d-47f4-97c9-242e15afa75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_RaygenIncVersusMyriadWomensHealthIncMember_ccccbcde-0152-4035-8244-6cb5965988ca" xlink:href="mygn-20221231.xsd#mygn_RaygenIncVersusMyriadWomensHealthIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c7aae0ef-c35d-47f4-97c9-242e15afa75a" xlink:to="loc_mygn_RaygenIncVersusMyriadWomensHealthIncMember_ccccbcde-0152-4035-8244-6cb5965988ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_3d34a39f-6c5f-4e9f-9428-b256bfac648e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_388487fd-60e0-49db-b5fc-8f897b5aa662" xlink:to="loc_us-gaap_LossContingenciesLineItems_3d34a39f-6c5f-4e9f-9428-b256bfac648e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_a13ab0b5-f58b-4669-9cb3-acbaa71ca7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_3d34a39f-6c5f-4e9f-9428-b256bfac648e" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_a13ab0b5-f58b-4669-9cb3-acbaa71ca7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cc38086e-5461-4809-8909-6aa16a44f8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_89860aa0-55c8-4087-a67b-f0f006b97a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cc38086e-5461-4809-8909-6aa16a44f8b0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_89860aa0-55c8-4087-a67b-f0f006b97a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e09f1cf4-7eeb-4c39-8e23-3379319148d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_89860aa0-55c8-4087-a67b-f0f006b97a17" xlink:to="loc_srt_RangeAxis_e09f1cf4-7eeb-4c39-8e23-3379319148d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_893d46e5-ca45-4a11-bce5-6535bfa321af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e09f1cf4-7eeb-4c39-8e23-3379319148d7" xlink:to="loc_srt_RangeMember_893d46e5-ca45-4a11-bce5-6535bfa321af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c6e09305-4b72-4f84-b433-50b2edd0bdc1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_893d46e5-ca45-4a11-bce5-6535bfa321af" xlink:to="loc_srt_MinimumMember_c6e09305-4b72-4f84-b433-50b2edd0bdc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_94c3eff4-f414-4eb4-998c-088032177d24" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_893d46e5-ca45-4a11-bce5-6535bfa321af" xlink:to="loc_srt_MaximumMember_94c3eff4-f414-4eb4-998c-088032177d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f0969a8b-91ab-45c6-a88d-dd64a1c34ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_89860aa0-55c8-4087-a67b-f0f006b97a17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f0969a8b-91ab-45c6-a88d-dd64a1c34ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4214743b-77c8-4c3f-af98-1fe11513a108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f0969a8b-91ab-45c6-a88d-dd64a1c34ae6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4214743b-77c8-4c3f-af98-1fe11513a108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_f80f9fc9-b623-4938-a008-8e503fef8dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4214743b-77c8-4c3f-af98-1fe11513a108" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_f80f9fc9-b623-4938-a008-8e503fef8dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementAxis_fde15bfc-3106-41b5-8546-fc8651725ae1" xlink:href="mygn-20221231.xsd#mygn_LeaseArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_89860aa0-55c8-4087-a67b-f0f006b97a17" xlink:to="loc_mygn_LeaseArrangementAxis_fde15bfc-3106-41b5-8546-fc8651725ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseArrangementDomain_9ec2cf79-39c8-473b-b9f1-5640bfb6c449" xlink:href="mygn-20221231.xsd#mygn_LeaseArrangementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_LeaseArrangementAxis_fde15bfc-3106-41b5-8546-fc8651725ae1" xlink:to="loc_mygn_LeaseArrangementDomain_9ec2cf79-39c8-473b-b9f1-5640bfb6c449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_WestSaltLakeCityLeaseMember_c404682b-0273-4e64-8d3c-8407d0585c49" xlink:href="mygn-20221231.xsd#mygn_WestSaltLakeCityLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mygn_LeaseArrangementDomain_9ec2cf79-39c8-473b-b9f1-5640bfb6c449" xlink:to="loc_mygn_WestSaltLakeCityLeaseMember_c404682b-0273-4e64-8d3c-8407d0585c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_53d5d69d-f670-4207-ab1a-349f6230d0df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_89860aa0-55c8-4087-a67b-f0f006b97a17" xlink:to="loc_srt_StatementGeographicalAxis_53d5d69d-f670-4207-ab1a-349f6230d0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a7d65e03-f2ca-4c17-9ce1-5e66f6298765" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_53d5d69d-f670-4207-ab1a-349f6230d0df" xlink:to="loc_srt_SegmentGeographicalDomain_a7d65e03-f2ca-4c17-9ce1-5e66f6298765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_SouthSanFranciscoCaliforniaMember_c720cfe1-1a25-4f70-b478-30f0b79b2639" xlink:href="mygn-20221231.xsd#mygn_SouthSanFranciscoCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a7d65e03-f2ca-4c17-9ce1-5e66f6298765" xlink:to="loc_mygn_SouthSanFranciscoCaliforniaMember_c720cfe1-1a25-4f70-b478-30f0b79b2639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_89860aa0-55c8-4087-a67b-f0f006b97a17" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_dbb56727-39d2-445e-b0eb-4916d38a79af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_dbb56727-39d2-445e-b0eb-4916d38a79af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_98152c9c-4687-4356-bc27-ba5c2d4d9469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_98152c9c-4687-4356-bc27-ba5c2d4d9469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_13e68d75-3bb6-4dc5-8604-99b1fbcf3b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_13e68d75-3bb6-4dc5-8604-99b1fbcf3b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_fbf6306d-ca79-48dd-9f1d-4d4061c309c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_AssetImpairmentCharges_fbf6306d-ca79-48dd-9f1d-4d4061c309c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_20466cc7-79cf-430e-9edc-54db704de203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_LeaseCost_20466cc7-79cf-430e-9edc-54db704de203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_e1a0a271-0a1e-4ccf-b872-1a45759c938c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_VariableLeaseCost_e1a0a271-0a1e-4ccf-b872-1a45759c938c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_00e24faa-28f2-48f8-a706-51c02394a39a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_00e24faa-28f2-48f8-a706-51c02394a39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_00fe0799-0c22-4a41-8197-8c5fafab0232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_00fe0799-0c22-4a41-8197-8c5fafab0232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0799ada7-2188-4058-9a34-e1409058b62d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0799ada7-2188-4058-9a34-e1409058b62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a5b06dc3-8daa-41f1-8cb7-f13b5e74015a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_OperatingLeaseLiability_a5b06dc3-8daa-41f1-8cb7-f13b5e74015a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3f8e3afb-5ee9-4414-aa20-6c6170dc1807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3f8e3afb-5ee9-4414-aa20-6c6170dc1807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0de27956-70cf-40af-bbe0-613405d2a9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0de27956-70cf-40af-bbe0-613405d2a9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2680661c-d507-44da-8297-50049473abc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_216bb24f-4948-47de-a308-ee3f19ad1dd0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2680661c-d507-44da-8297-50049473abc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6b5255a7-1124-44e8-9f47-160abf90ab22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f842734d-7f45-4ee7-9371-a7443618aa18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6b5255a7-1124-44e8-9f47-160abf90ab22" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f842734d-7f45-4ee7-9371-a7443618aa18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7cae7548-c4a0-487f-8100-49b314cd46b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f842734d-7f45-4ee7-9371-a7443618aa18" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7cae7548-c4a0-487f-8100-49b314cd46b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d03ab262-f463-4e52-8fc9-c6e0928a4b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f842734d-7f45-4ee7-9371-a7443618aa18" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d03ab262-f463-4e52-8fc9-c6e0928a4b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_cdaa0fa9-4b65-437e-80c0-9386656570c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f842734d-7f45-4ee7-9371-a7443618aa18" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_cdaa0fa9-4b65-437e-80c0-9386656570c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_90cc38e8-6c31-41f7-82e8-10c4e334a793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f842734d-7f45-4ee7-9371-a7443618aa18" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_90cc38e8-6c31-41f7-82e8-10c4e334a793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2c8cea3a-23ae-4dc4-ba2b-892a220ca43c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f842734d-7f45-4ee7-9371-a7443618aa18" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2c8cea3a-23ae-4dc4-ba2b-892a220ca43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ec5d428a-4d55-42be-bff8-2c2f932be3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f842734d-7f45-4ee7-9371-a7443618aa18" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ec5d428a-4d55-42be-bff8-2c2f932be3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3443d464-0903-4de8-84a6-ca03d6f10824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f842734d-7f45-4ee7-9371-a7443618aa18" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3443d464-0903-4de8-84a6-ca03d6f10824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_765888f3-0321-4fc3-9e42-387c4e5d99b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f842734d-7f45-4ee7-9371-a7443618aa18" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_765888f3-0321-4fc3-9e42-387c4e5d99b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced_0d4a3298-f0c3-4a32-b5b1-8bffdac92845" xlink:href="mygn-20221231.xsd#mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f842734d-7f45-4ee7-9371-a7443618aa18" xlink:to="loc_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced_0d4a3298-f0c3-4a32-b5b1-8bffdac92845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced_b82bb322-e469-4874-a415-b7df5603bf6d" xlink:href="mygn-20221231.xsd#mygn_OperatingLeaseLiabilityLeasesNotYetCommenced"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f842734d-7f45-4ee7-9371-a7443618aa18" xlink:to="loc_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced_b82bb322-e469-4874-a415-b7df5603bf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a670b984-7157-4375-87e4-3bc4bf2aca98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f842734d-7f45-4ee7-9371-a7443618aa18" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a670b984-7157-4375-87e4-3bc4bf2aca98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f12288e3-9c8b-4ef5-a579-c083dbbed863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_f842734d-7f45-4ee7-9371-a7443618aa18" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f12288e3-9c8b-4ef5-a579-c083dbbed863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="mygn-20221231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.myriad.com/role/EmployeeDeferredSavingsPlanNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#EmployeeDeferredSavingsPlanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/EmployeeDeferredSavingsPlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d7869e88-4360-46d9-b8c8-dafd086d7199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_f3e5a8db-45e7-4ad8-b947-808d82e4e164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d7869e88-4360-46d9-b8c8-dafd086d7199" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_f3e5a8db-45e7-4ad8-b947-808d82e4e164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_4273d6bf-6c9f-421e-8443-ce2f7b8105bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d7869e88-4360-46d9-b8c8-dafd086d7199" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_4273d6bf-6c9f-421e-8443-ce2f7b8105bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/EmployeeDeferredSavingsPlanContributionstoPlanDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#EmployeeDeferredSavingsPlanContributionstoPlanDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/EmployeeDeferredSavingsPlanContributionstoPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9c66989d-ac3e-4ece-a196-7f182d082ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_0bc26f33-5c0d-4637-bdb9-0598a360b0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9c66989d-ac3e-4ece-a196-7f182d082ada" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_0bc26f33-5c0d-4637-bdb9-0598a360b0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#SegmentandRelatedInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_898e8974-bf21-473b-bba1-0ecf093b7413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_834d032c-7e17-4ce9-9909-1b384af19381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_898e8974-bf21-473b-bba1-0ecf093b7413" xlink:to="loc_us-gaap_NumberOfReportableSegments_834d032c-7e17-4ce9-9909-1b384af19381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_40409d55-b638-4304-8c48-cf1e388478de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ca44a301-ce4a-4646-b2e8-5bf4f6e2c208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_40409d55-b638-4304-8c48-cf1e388478de" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ca44a301-ce4a-4646-b2e8-5bf4f6e2c208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_5e44cf05-8712-47e0-9d64-002c6bb7f9f4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ca44a301-ce4a-4646-b2e8-5bf4f6e2c208" xlink:to="loc_srt_ConsolidationItemsAxis_5e44cf05-8712-47e0-9d64-002c6bb7f9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_58ba1f83-852a-42a2-883e-6a4bd6961e26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_5e44cf05-8712-47e0-9d64-002c6bb7f9f4" xlink:to="loc_srt_ConsolidationItemsDomain_58ba1f83-852a-42a2-883e-6a4bd6961e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableGeographicalComponentsMember_13a2a000-25bd-4ad1-b6cc-aa041a6d919d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ReportableGeographicalComponentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_58ba1f83-852a-42a2-883e-6a4bd6961e26" xlink:to="loc_srt_ReportableGeographicalComponentsMember_13a2a000-25bd-4ad1-b6cc-aa041a6d919d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7d10b54b-d8eb-425f-ba4a-7cf10bec513b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ca44a301-ce4a-4646-b2e8-5bf4f6e2c208" xlink:to="loc_srt_StatementGeographicalAxis_7d10b54b-d8eb-425f-ba4a-7cf10bec513b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b5bfe39c-f7bb-4196-9140-9f9b2e124490" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_7d10b54b-d8eb-425f-ba4a-7cf10bec513b" xlink:to="loc_srt_SegmentGeographicalDomain_b5bfe39c-f7bb-4196-9140-9f9b2e124490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1a739ad2-b60f-437f-ba84-f5d1a5bb3028" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b5bfe39c-f7bb-4196-9140-9f9b2e124490" xlink:to="loc_country_US_1a739ad2-b60f-437f-ba84-f5d1a5bb3028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_d3a90844-9eff-4985-8573-ac3499f377d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b5bfe39c-f7bb-4196-9140-9f9b2e124490" xlink:to="loc_us-gaap_NonUsMember_d3a90844-9eff-4985-8573-ac3499f377d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_13419860-fa21-4e38-a9a8-d8a9972e55b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ca44a301-ce4a-4646-b2e8-5bf4f6e2c208" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_13419860-fa21-4e38-a9a8-d8a9972e55b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4abbf92e-2075-45b4-b785-69c86eaa43de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_13419860-fa21-4e38-a9a8-d8a9972e55b7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4abbf92e-2075-45b4-b785-69c86eaa43de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_AssetsLessCashCashEquivalentsAndInvestments_2b6ac6a0-50b0-4d37-a9e3-2e2f798b8b86" xlink:href="mygn-20221231.xsd#mygn_AssetsLessCashCashEquivalentsAndInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_13419860-fa21-4e38-a9a8-d8a9972e55b7" xlink:to="loc_mygn_AssetsLessCashCashEquivalentsAndInvestments_2b6ac6a0-50b0-4d37-a9e3-2e2f798b8b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_063651a2-fcb2-4c3e-952d-9904e35ece89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_13419860-fa21-4e38-a9a8-d8a9972e55b7" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_063651a2-fcb2-4c3e-952d-9904e35ece89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6023e46b-71cd-4e15-aec9-5870e98aeba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_13419860-fa21-4e38-a9a8-d8a9972e55b7" xlink:to="loc_us-gaap_Assets_6023e46b-71cd-4e15-aec9-5870e98aeba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#BusinessAcquisitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_44fb55b5-7834-4461-bee6-a5d3d353b92c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed4c0138-b6b3-4136-a97b-c729fae2a41e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_44fb55b5-7834-4461-bee6-a5d3d353b92c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed4c0138-b6b3-4136-a97b-c729fae2a41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3cd9a2ca-b8cf-4b4a-946b-80c1e10333d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed4c0138-b6b3-4136-a97b-c729fae2a41e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3cd9a2ca-b8cf-4b4a-946b-80c1e10333d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_960f3f0c-8846-4a28-94a3-fd62da6a1466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3cd9a2ca-b8cf-4b4a-946b-80c1e10333d3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_960f3f0c-8846-4a28-94a3-fd62da6a1466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GatewayGenomicsLLCMember_730ce2d0-8cf0-4c1c-ab6c-f813788498de" xlink:href="mygn-20221231.xsd#mygn_GatewayGenomicsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_960f3f0c-8846-4a28-94a3-fd62da6a1466" xlink:to="loc_mygn_GatewayGenomicsLLCMember_730ce2d0-8cf0-4c1c-ab6c-f813788498de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8fd1ad77-3ecd-4f06-b113-420c1eaf3605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed4c0138-b6b3-4136-a97b-c729fae2a41e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8fd1ad77-3ecd-4f06-b113-420c1eaf3605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_176b947d-8fc8-494a-8947-b280da1b94d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8fd1ad77-3ecd-4f06-b113-420c1eaf3605" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_176b947d-8fc8-494a-8947-b280da1b94d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_0e7c1e87-7e1b-40fa-a41d-9fc80064d6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_176b947d-8fc8-494a-8947-b280da1b94d0" xlink:to="loc_us-gaap_CustomerRelationshipsMember_0e7c1e87-7e1b-40fa-a41d-9fc80064d6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_610c9596-7971-4594-abf6-8d27f32e8f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_176b947d-8fc8-494a-8947-b280da1b94d0" xlink:to="loc_us-gaap_TrademarksMember_610c9596-7971-4594-abf6-8d27f32e8f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_285fec43-93f2-4818-b117-8739f01f47c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_176b947d-8fc8-494a-8947-b280da1b94d0" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_285fec43-93f2-4818-b117-8739f01f47c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_09b97f66-acb3-45b1-aa11-0b31dcc31b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed4c0138-b6b3-4136-a97b-c729fae2a41e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_09b97f66-acb3-45b1-aa11-0b31dcc31b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_96a12e82-b0bc-4f5f-b53a-b9a73550a4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_09b97f66-acb3-45b1-aa11-0b31dcc31b84" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_96a12e82-b0bc-4f5f-b53a-b9a73550a4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_1683ea34-cdeb-44ca-878d-d6719d65fca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_96a12e82-b0bc-4f5f-b53a-b9a73550a4bb" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_1683ea34-cdeb-44ca-878d-d6719d65fca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ed4c0138-b6b3-4136-a97b-c729fae2a41e" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2bce25e9-90c8-44e8-b215-cbe1f490a580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2bce25e9-90c8-44e8-b215-cbe1f490a580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_c44ad0f5-59a9-43e2-a90e-c745458dcaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_c44ad0f5-59a9-43e2-a90e-c745458dcaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments_d88b7b77-3ed8-46c8-8502-6c24d883b09f" xlink:href="mygn-20221231.xsd#mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments_d88b7b77-3ed8-46c8-8502-6c24d883b09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_21845732-07e4-432d-afc5-274b2bdf047d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_21845732-07e4-432d-afc5-274b2bdf047d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4870579e-cca1-48f8-b875-87f4f7c20cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4870579e-cca1-48f8-b875-87f4f7c20cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a5ffdcca-67b3-4e41-a557-9033f9f5b105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_Goodwill_a5ffdcca-67b3-4e41-a557-9033f9f5b105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_BusinessCombinationIntangibleAssetsMeasurementInput_d4957d75-2df2-43e4-b8f8-560304b2afb8" xlink:href="mygn-20221231.xsd#mygn_BusinessCombinationIntangibleAssetsMeasurementInput"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_mygn_BusinessCombinationIntangibleAssetsMeasurementInput_d4957d75-2df2-43e4-b8f8-560304b2afb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1ea1175c-0fb9-4953-beb8-0df978d9a831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_1ea1175c-0fb9-4953-beb8-0df978d9a831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_d3dccef2-27c2-4887-8a17-ba7ebb2a48c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_d3dccef2-27c2-4887-8a17-ba7ebb2a48c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_e51dd0b7-154e-4c70-87d7-ceb6f53787ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_e51dd0b7-154e-4c70-87d7-ceb6f53787ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_ea807466-2dcc-4ce0-8a41-5d6ac884e532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_ea807466-2dcc-4ce0-8a41-5d6ac884e532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_f3323395-ede8-4a4a-99cf-d6dcd7bec540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0b0586c0-17f2-414d-b126-71d1909c7865" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_f3323395-ede8-4a4a-99cf-d6dcd7bec540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7cf0cad8-50e8-4368-8fd4-f1a323b95c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_417f28c6-b8a9-40e9-99db-98e9b5e583b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7cf0cad8-50e8-4368-8fd4-f1a323b95c9b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_417f28c6-b8a9-40e9-99db-98e9b5e583b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9bfff989-90e7-45aa-a893-e87cf51b565d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_417f28c6-b8a9-40e9-99db-98e9b5e583b9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9bfff989-90e7-45aa-a893-e87cf51b565d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b3819e51-829b-465e-90f0-c7a06cf13937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9bfff989-90e7-45aa-a893-e87cf51b565d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b3819e51-829b-465e-90f0-c7a06cf13937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GatewayGenomicsLLCMember_132c5d88-03de-4c46-8ce1-67987e57153a" xlink:href="mygn-20221231.xsd#mygn_GatewayGenomicsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b3819e51-829b-465e-90f0-c7a06cf13937" xlink:to="loc_mygn_GatewayGenomicsLLCMember_132c5d88-03de-4c46-8ce1-67987e57153a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_db8cc861-44db-47bd-86ec-3819025d9ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_417f28c6-b8a9-40e9-99db-98e9b5e583b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_db8cc861-44db-47bd-86ec-3819025d9ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d5ba4fbf-f2c9-4d08-b858-2f69bf292875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_db8cc861-44db-47bd-86ec-3819025d9ec5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d5ba4fbf-f2c9-4d08-b858-2f69bf292875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_95dac8b8-7ff3-48ea-bbc1-0ead75dd1c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d5ba4fbf-f2c9-4d08-b858-2f69bf292875" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_95dac8b8-7ff3-48ea-bbc1-0ead75dd1c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_231d6b9c-88c5-4643-851c-3399917df3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d5ba4fbf-f2c9-4d08-b858-2f69bf292875" xlink:to="loc_us-gaap_TrademarksMember_231d6b9c-88c5-4643-851c-3399917df3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_3f51b702-b51f-4838-9ccd-b256ff2d6da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d5ba4fbf-f2c9-4d08-b858-2f69bf292875" xlink:to="loc_us-gaap_CustomerRelationshipsMember_3f51b702-b51f-4838-9ccd-b256ff2d6da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_417f28c6-b8a9-40e9-99db-98e9b5e583b9" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_b9d5aa9b-e58f-4105-b3ce-583594dd00f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_b9d5aa9b-e58f-4105-b3ce-583594dd00f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_4bf3f7dd-7f06-4cb4-a903-26768c2dee9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_4bf3f7dd-7f06-4cb4-a903-26768c2dee9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9683bc96-7dcc-4017-9af1-dfa9227ce80d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9683bc96-7dcc-4017-9af1-dfa9227ce80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_e0d82079-3f8b-4fc3-a57d-f881ad81eb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_e0d82079-3f8b-4fc3-a57d-f881ad81eb9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_dca59acc-3a4d-4f18-8f9c-eeba59eaf1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_dca59acc-3a4d-4f18-8f9c-eeba59eaf1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e14fe5ef-6833-4bd8-afd9-438d93bcff09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_Goodwill_e14fe5ef-6833-4bd8-afd9-438d93bcff09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_41174f36-45ce-4b34-86d6-43739b92d7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_41174f36-45ce-4b34-86d6-43739b92d7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_aa0cdd06-b36a-45a5-94ab-f8a0c243d694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_aa0cdd06-b36a-45a5-94ab-f8a0c243d694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_79403f80-16cc-4e55-bba2-32d2ec2c8164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_79403f80-16cc-4e55-bba2-32d2ec2c8164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_19c4a9f8-01a5-4558-83d3-3de0e304012c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_19c4a9f8-01a5-4558-83d3-3de0e304012c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e9b78a4b-0897-477e-aa2a-dfe80b949198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_702d6358-1f89-49a6-9f64-d7d0756b51c8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e9b78a4b-0897-477e-aa2a-dfe80b949198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/BusinessAcquisitionScheduleofProFormaInformationDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#BusinessAcquisitionScheduleofProFormaInformationDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/BusinessAcquisitionScheduleofProFormaInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9c8f04e1-4d4a-434c-a6a7-52f7d70a4760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7b955e78-b7b4-4f43-9946-86dbef8dc624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9c8f04e1-4d4a-434c-a6a7-52f7d70a4760" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7b955e78-b7b4-4f43-9946-86dbef8dc624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b22d3a60-516e-4e6e-9264-5491b4f4b03a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7b955e78-b7b4-4f43-9946-86dbef8dc624" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b22d3a60-516e-4e6e-9264-5491b4f4b03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6715be7c-a86e-4375-8631-d3ebf21b4240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b22d3a60-516e-4e6e-9264-5491b4f4b03a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6715be7c-a86e-4375-8631-d3ebf21b4240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GatewayGenomicsLLCMember_bcce656b-3b47-467f-813b-00e427573705" xlink:href="mygn-20221231.xsd#mygn_GatewayGenomicsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6715be7c-a86e-4375-8631-d3ebf21b4240" xlink:to="loc_mygn_GatewayGenomicsLLCMember_bcce656b-3b47-467f-813b-00e427573705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_05305ef6-0cdc-47b8-9bcf-75684cd31de2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7b955e78-b7b4-4f43-9946-86dbef8dc624" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_05305ef6-0cdc-47b8-9bcf-75684cd31de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_21b9527f-49f2-4c11-a739-ba33b5f8ef03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05305ef6-0cdc-47b8-9bcf-75684cd31de2" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_21b9527f-49f2-4c11-a739-ba33b5f8ef03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_f2b10c2f-7490-47b2-b910-f5c115181c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_05305ef6-0cdc-47b8-9bcf-75684cd31de2" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_f2b10c2f-7490-47b2-b910-f5c115181c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/DivestituresNarrativeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#DivestituresNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/DivestituresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9c5603fc-f6ef-4106-abbd-170b2792bd21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_094c74e6-1b3e-44b9-a22a-af55e61d5b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9c5603fc-f6ef-4106-abbd-170b2792bd21" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_094c74e6-1b3e-44b9-a22a-af55e61d5b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_dc491346-cf6e-4811-975f-7109efbf078a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_094c74e6-1b3e-44b9-a22a-af55e61d5b6d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_dc491346-cf6e-4811-975f-7109efbf078a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7980b61e-4f96-4baa-88e3-330d647fb820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_dc491346-cf6e-4811-975f-7109efbf078a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7980b61e-4f96-4baa-88e3-330d647fb820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_aedeeb64-e2ce-45b4-8425-b8ee6149d0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_7980b61e-4f96-4baa-88e3-330d647fb820" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_aedeeb64-e2ce-45b4-8425-b8ee6149d0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1c9c78ce-3e86-4bad-9975-d7784d3c73a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_094c74e6-1b3e-44b9-a22a-af55e61d5b6d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1c9c78ce-3e86-4bad-9975-d7784d3c73a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c2afda6d-d636-4c4a-8f64-c8153e20bad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1c9c78ce-3e86-4bad-9975-d7784d3c73a3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c2afda6d-d636-4c4a-8f64-c8153e20bad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadMyPathLLCLaboratoryMember_b844ff48-4402-4de5-a66d-acd67fac60bd" xlink:href="mygn-20221231.xsd#mygn_MyriadMyPathLLCLaboratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c2afda6d-d636-4c4a-8f64-c8153e20bad6" xlink:to="loc_mygn_MyriadMyPathLLCLaboratoryMember_b844ff48-4402-4de5-a66d-acd67fac60bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncMember_a7115391-d00c-468d-8d83-d50d76e38802" xlink:href="mygn-20221231.xsd#mygn_MyriadRBMIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c2afda6d-d636-4c4a-8f64-c8153e20bad6" xlink:to="loc_mygn_MyriadRBMIncMember_a7115391-d00c-468d-8d83-d50d76e38802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneAssetsMember_bd4b5934-c0ae-42e2-8f43-2372068623d5" xlink:href="mygn-20221231.xsd#mygn_MyriadAutoimmuneAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c2afda6d-d636-4c4a-8f64-c8153e20bad6" xlink:to="loc_mygn_MyriadAutoimmuneAssetsMember_bd4b5934-c0ae-42e2-8f43-2372068623d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e718d16e-ef2f-4aca-a0e2-543b728370f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_094c74e6-1b3e-44b9-a22a-af55e61d5b6d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e718d16e-ef2f-4aca-a0e2-543b728370f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_cf728fc5-be17-4d04-8058-372807dd73fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e718d16e-ef2f-4aca-a0e2-543b728370f4" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_cf728fc5-be17-4d04-8058-372807dd73fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_1f78323f-f8c6-420d-adbb-4d3f58a09c61" xlink:href="mygn-20221231.xsd#mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e718d16e-ef2f-4aca-a0e2-543b728370f4" xlink:to="loc_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees_1f78323f-f8c6-420d-adbb-4d3f58a09c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_bc7942fb-71cd-4073-8d57-e9b97d4560d1" xlink:href="mygn-20221231.xsd#mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e718d16e-ef2f-4aca-a0e2-543b728370f4" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts_bc7942fb-71cd-4073-8d57-e9b97d4560d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_34f8fc13-672c-4d2b-abcd-af678d8d6e83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e718d16e-ef2f-4aca-a0e2-543b728370f4" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries_34f8fc13-672c-4d2b-abcd-af678d8d6e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_f733db8a-51ab-42dd-90c2-c95ba941d6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e718d16e-ef2f-4aca-a0e2-543b728370f4" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_f733db8a-51ab-42dd-90c2-c95ba941d6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_f58c648a-44db-462a-bdde-792f9417e346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFirmPurchaseCommitmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e718d16e-ef2f-4aca-a0e2-543b728370f4" xlink:to="loc_us-gaap_InventoryFirmPurchaseCommitmentLoss_f58c648a-44db-462a-bdde-792f9417e346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_9fa621cd-638f-4d8f-9e55-d693f5e0760d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e718d16e-ef2f-4aca-a0e2-543b728370f4" xlink:to="loc_us-gaap_InventoryWriteDown_9fa621cd-638f-4d8f-9e55-d693f5e0760d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/DivestituresOtherIncomeDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#DivestituresOtherIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/DivestituresOtherIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e2a8b3bf-c854-43b1-90ba-d01f598861aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_82f1499d-033c-48ff-bdfa-8cf3d74d68d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e2a8b3bf-c854-43b1-90ba-d01f598861aa" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_82f1499d-033c-48ff-bdfa-8cf3d74d68d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fd966ad4-6ef2-4d6a-b52c-93ade7b8463b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_82f1499d-033c-48ff-bdfa-8cf3d74d68d3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fd966ad4-6ef2-4d6a-b52c-93ade7b8463b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f1931d5d-7e40-4747-8933-6d96e89a250c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fd966ad4-6ef2-4d6a-b52c-93ade7b8463b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f1931d5d-7e40-4747-8933-6d96e89a250c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadRBMIncMember_862072e5-7a5f-46c7-82ca-9736858315b9" xlink:href="mygn-20221231.xsd#mygn_MyriadRBMIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f1931d5d-7e40-4747-8933-6d96e89a250c" xlink:to="loc_mygn_MyriadRBMIncMember_862072e5-7a5f-46c7-82ca-9736858315b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadMyPathLLCLaboratoryMember_d73e5fea-7713-4d47-b8a2-40fd4d60f5cd" xlink:href="mygn-20221231.xsd#mygn_MyriadMyPathLLCLaboratoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f1931d5d-7e40-4747-8933-6d96e89a250c" xlink:to="loc_mygn_MyriadMyPathLLCLaboratoryMember_d73e5fea-7713-4d47-b8a2-40fd4d60f5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_MyriadAutoimmuneAssetsMember_5af22a45-71d0-48c9-a1de-d9721bd82b3d" xlink:href="mygn-20221231.xsd#mygn_MyriadAutoimmuneAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f1931d5d-7e40-4747-8933-6d96e89a250c" xlink:to="loc_mygn_MyriadAutoimmuneAssetsMember_5af22a45-71d0-48c9-a1de-d9721bd82b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_fbb2752b-c289-4fa3-9628-02868bb22805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_82f1499d-033c-48ff-bdfa-8cf3d74d68d3" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_fbb2752b-c289-4fa3-9628-02868bb22805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_fa3533e5-c675-47a6-8979-7dbcaa76ce5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_fbb2752b-c289-4fa3-9628-02868bb22805" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_fa3533e5-c675-47a6-8979-7dbcaa76ce5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_62cea367-eb2a-4301-8cd0-e6bd9db108cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_fa3533e5-c675-47a6-8979-7dbcaa76ce5b" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_62cea367-eb2a-4301-8cd0-e6bd9db108cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ed597d1f-3d03-4421-b093-1def7b7138bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_82f1499d-033c-48ff-bdfa-8cf3d74d68d3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ed597d1f-3d03-4421-b093-1def7b7138bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_88a696d3-dd2c-480c-9f05-cab2dffe315d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ed597d1f-3d03-4421-b093-1def7b7138bc" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_88a696d3-dd2c-480c-9f05-cab2dffe315d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_a9fbf3ff-38ac-49e5-87c8-3e781a4be32d" xlink:href="mygn-20221231.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ed597d1f-3d03-4421-b093-1def7b7138bc" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory_a9fbf3ff-38ac-49e5-87c8-3e781a4be32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_846b7d65-9d24-4460-b78c-7fe4054c4ed7" xlink:href="mygn-20221231.xsd#mygn_DisposalGroupNotDiscontinuedOperationGainLossOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ed597d1f-3d03-4421-b093-1def7b7138bc" xlink:to="loc_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther_846b7d65-9d24-4460-b78c-7fe4054c4ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_54eb770d-0a59-4338-98fd-a9bffbec80c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ed597d1f-3d03-4421-b093-1def7b7138bc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_54eb770d-0a59-4338-98fd-a9bffbec80c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.myriad.com/role/SupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="mygn-20221231.xsd#SupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.myriad.com/role/SupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_6dc64922-c9ba-43f7-9df2-7c9b8d92c912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_d30f79ee-b197-49ce-bc41-14fa55155d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_6dc64922-c9ba-43f7-9df2-7c9b8d92c912" xlink:to="loc_us-gaap_IncomeTaxesPaid_d30f79ee-b197-49ce-bc41-14fa55155d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_fd54cf6b-fdde-4aae-b82c-aecfe2cc640d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_6dc64922-c9ba-43f7-9df2-7c9b8d92c912" xlink:to="loc_us-gaap_InterestPaidNet_fd54cf6b-fdde-4aae-b82c-aecfe2cc640d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_0b7f2df4-b814-4e13-be88-afce36e41bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_6dc64922-c9ba-43f7-9df2-7c9b8d92c912" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_0b7f2df4-b814-4e13-be88-afce36e41bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0854ae6a-4285-4b55-9fa7-e3d20816ec7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_6dc64922-c9ba-43f7-9df2-7c9b8d92c912" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0854ae6a-4285-4b55-9fa7-e3d20816ec7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_ec4899da-508c-4fb9-a04c-f9f82d8fcf76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0854ae6a-4285-4b55-9fa7-e3d20816ec7d" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_ec4899da-508c-4fb9-a04c-f9f82d8fcf76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_27389061-c1dc-49e9-a978-bc6bc93278da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_ec4899da-508c-4fb9-a04c-f9f82d8fcf76" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_27389061-c1dc-49e9-a978-bc6bc93278da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_OperatingLeaseLiabilityEstablished_6e6b775c-71af-4db7-960a-8bddfb2d0324" xlink:href="mygn-20221231.xsd#mygn_OperatingLeaseLiabilityEstablished"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_ec4899da-508c-4fb9-a04c-f9f82d8fcf76" xlink:to="loc_mygn_OperatingLeaseLiabilityEstablished_6e6b775c-71af-4db7-960a-8bddfb2d0324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_TenantImprovementAllowanceNotYetReceived_7e7b4a81-550d-4caa-b63a-23928860e25c" xlink:href="mygn-20221231.xsd#mygn_TenantImprovementAllowanceNotYetReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_ec4899da-508c-4fb9-a04c-f9f82d8fcf76" xlink:to="loc_mygn_TenantImprovementAllowanceNotYetReceived_7e7b4a81-550d-4caa-b63a-23928860e25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_02aeb30c-2239-4e13-885d-a0fbc72cc4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_ec4899da-508c-4fb9-a04c-f9f82d8fcf76" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_02aeb30c-2239-4e13-885d-a0fbc72cc4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid_38cc1326-dcc1-4876-9492-824cf2fd8ff0" xlink:href="mygn-20221231.xsd#mygn_LeaseRelatedExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_ec4899da-508c-4fb9-a04c-f9f82d8fcf76" xlink:to="loc_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid_38cc1326-dcc1-4876-9492-824cf2fd8ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>mygn-20221231_g1.jpg
<TEXT>
begin 644 mygn-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 4:"4,# 2(  A$! Q$!_\0
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?
M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B
M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_
M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")
MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_
M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y
MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBBB@#T#X?\ _(&F_P"O
MAO\ T%:Z:N9^'_\ R!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/A__ ,@:;_KX;_T%
M:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'_ /R!IO\ KX;_ -!6
MNFKF?A__ ,@:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#QFBBB@#T#X?_P#(&F_Z^&_]!6NFKF?A
M_P#\@:;_ *^&_P#05KIJ "BBB@ HHHH **** "BBN=^(?AF]\9^"M7T/3]7F
MT&[OH?)34K<$R09(R5 93G&1U'6@!=3^(GA31=0^P:AXFT>POL[?LMU?Q1RY
MZXVLP-;L%Q'=0I-#(LT4BADDC8,K ]"".HKYTT_]@CX7V^BM:WL>JZCJ#J=^
MIR7K)+N/5E51LZ],J??-<7^QC?ZMX'^+'Q#^%D^H2:EH^CM)-:O(<B-DF$9V
M\_+O#@E1QE3[Y /K;4M:T_1D1]0OK:Q1SA&N9EC#'T&XC-4/^$Z\-_\ 0P:5
M_P"!L7_Q5?)_[?.G0ZUXZ^$6FW6XVMW=W$$JJV#M>6V5L>AP:]!_X8)^%'_/
MIJO_ ('M_A0!]#V]Q%=P1SP2I-#(H=)(V#*RGD$$=15/6O$6E>&[47.KZG9Z
M5;$[1->W"0IGTRQ JGH.B:5\._!]GIEF#:Z/H]H(T\QBQ2*->I)Y)P,FOCWX
M)?#F#]K[QIXJ^(?C][G4O#]O=M8Z7I/GO$B# 8+E""H1&3A2-S,2?< ^RM!\
M5:+XJMVGT76+#6(%QF2PN4G49&1DH3VK4KX;^/WPML_V3?%/A/XC_#TW6EZ:
MUZME?Z9]H>6-Q@OLRY+%75) 0Q."%(P>GVYI]]#JFGVU[;-OM[B)9HVQC*L
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MNTA+%8@[1O&">=JNG&>SX' P #ZGHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVY]<2=/PS7M'PF:1OA7X-,W^N.BV1?\ WO(3/ZU\K?M/_$G3/VC/$'A#X6^
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MCO0!]:5\@_L\[E_;0^,*Q@" QW!;;TW?:(L?CRU>L-^U]\*U\(_V]_PE%O\
MZD2?V;@_;-V,^7Y77=GC/W??'->=_L1^%]1UBZ\<?%'5[62UF\4W[M:(_&8C
M(TCLOJI=@H/_ $S- 'U51110 4444 %07UP]K:2S1PM<.@R(UZM[=*GHH YG
M_A*M1_Z %U_X]_\ $4?\)5J/_0 NO_'O_B*Z:B@#F?\ A*M1_P"@!=?^/?\
MQ%'_  E6H_\ 0 NO_'O_ (BNFHH YG_A*M1_Z %U_P"/?_$4?\)5J/\ T +K
M_P >_P#B*Z:B@#F?^$JU'_H 77_CW_Q%'_"5:C_T +K_ ,>_^(KIJ* .9_X2
MK4?^@!=?^/?_ !%'_"5:C_T +K_Q[_XBNFHH YG_ (2K4?\ H 77_CW_ ,11
M_P )5J/_ $ +K_Q[_P"(KIJ* .9_X2K4?^@!=?\ CW_Q%'_"5:C_ - "Z_\
M'O\ XBNFHH YG_A*M1_Z %U_X]_\11_PE6H_] "Z_P#'O_B*Z:B@#F?^$JU'
M_H 77_CW_P 11_PE6H_] "Z_\>_^(KIJ* .9_P"$JU'_ * %U_X]_P#$4?\
M"5:C_P! "Z_\>_\ B*Z:B@#F?^$JU'_H 77_ (]_\11_PE6H_P#0 NO_ ![_
M .(KIJ* .9_X2K4?^@!=?^/?_$4?\)5J/_0 NO\ Q[_XBNFHH YG_A*M1_Z
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M_P 11_PE6H_] "Z_\>_^(KIJ* .9_P"$JU'_ * %U_X]_P#$4?\ "5:C_P!
M"Z_\>_\ B*Z:B@#F?^$JU'_H 77_ (]_\11_PE6H_P#0 NO_ ![_ .(KIJ*
M.9_X2K4?^@!=?^/?_$4?\)5J/_0 NO\ Q[_XBNFHH YG_A*M1_Z %U_X]_\
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M6H_] "Z_\>_^(KIJ* .9_P"$JU'_ * %U_X]_P#$4?\ "5:C_P! "Z_\>_\
MB*Z:B@#F?^$JU'_H 77_ (]_\11_PE6H_P#0 NO_ ![_ .(KIJ* .9_X2K4?
M^@!=?^/?_$4?\)5J/_0 NO\ Q[_XBNFHH YG_A*M1_Z %U_X]_\ $4?\)5J/
M_0 NO_'O_B*Z:B@#F?\ A*M1_P"@!=?^/?\ Q%'_  E6H_\ 0 NO_'O_ (BN
MFHH YG_A*M1_Z %U_P"/?_$4?\)5J/\ T +K_P >_P#B*Z:B@#F?^$JU'_H
M77_CW_Q%'_"5:C_T +K_ ,>_^(KIJ* .9_X2K4?^@!=?^/?_ !%'_"5:C_T
M+K_Q[_XBNFHH YG_ (2K4?\ H 77_CW_ ,11_P )5J/_ $ +K_Q[_P"(KIJ*
M .9_X2K4?^@!=?\ CW_Q%'_"5:C_ - "Z_\ 'O\ XBNFHH YG_A*M1_Z %U_
MX]_\11_PE6H_] "Z_P#'O_B*Z:B@#F?^$JU'_H 77_CW_P 11_PE6H_] "Z_
M\>_^(KIJ* .9_P"$JU'_ * %U_X]_P#$4?\ "5:C_P! "Z_\>_\ B*Z:B@#F
M?^$JU'_H 77_ (]_\11_PE6H_P#0 NO_ ![_ .(KIJ* .9_X2K4?^@!=?^/?
M_$4?\)5J/_0 NO\ Q[_XBNFHH YG_A*M1_Z %U_X]_\ $4?\)5J/_0 NO_'O
M_B*Z:B@#F?\ A*M1_P"@!=?^/?\ Q%'_  E6H_\ 0 NO_'O_ (BNFHH YG_A
M*M1_Z %U_P"/?_$4?\)5J/\ T +K_P >_P#B*Z:B@#F?^$JU'_H 77_CW_Q%
M'_"5:C_T +K_ ,>_^(KIJ* .9_X2K4?^@!=?^/?_ !%'_"5:C_T +K_Q[_XB
MNFHH YG_ (2K4?\ H 77_CW_ ,11_P )5J/_ $ +K_Q[_P"(KIJ* .9_X2K4
M?^@!=?\ CW_Q%'_"5:C_ - "Z_\ 'O\ XBNFHH YG_A*M1_Z %U_X]_\11_P
ME6H_] "Z_P#'O_B*Z:B@#F?^$JU'_H 77_CW_P 11_PE6H_] "Z_\>_^(KIJ
M* .9_P"$JU'_ * %U_X]_P#$4?\ "5:C_P! "Z_\>_\ B*Z:B@#F?^$JU'_H
M 77_ (]_\11_PE6H_P#0 NO_ ![_ .(KIJ* .9_X2K4?^@!=?^/?_$4?\)5J
M/_0 NO\ Q[_XBNFHH YG_A*M1_Z %U_X]_\ $4?\)5J/_0 NO_'O_B*Z:B@#
MF?\ A*M1_P"@!=?^/?\ Q%'_  E6H_\ 0 NO_'O_ (BNFHH YG_A*M1_Z %U
M_P"/?_$4?\)5J/\ T +K_P >_P#B*Z:B@#F?^$JU'_H 77_CW_Q%'_"5:C_T
M +K_ ,>_^(KIJ* .9_X2K4?^@!=?^/?_ !%'_"5:C_T +K_Q[_XBNFHH YG_
M (2K4?\ H 77_CW_ ,11_P )5J/_ $ +K_Q[_P"(KIJ* .9_X2K4?^@!=?\
MCW_Q%'_"5:C_ - "Z_\ 'O\ XBNFHH YG_A*M1_Z %U_X]_\11_PE6H_] "Z
M_P#'O_B*Z:B@#F?^$JU'_H 77_CW_P 11_PE6H_] "Z_\>_^(KIJ* .9_P"$
MJU'_ * %U_X]_P#$4?\ "5:C_P! "Z_\>_\ B*Z:B@#F?^$JU'_H 77_ (]_
M\11_PE6H_P#0 NO_ ![_ .(KIJ* .9_X2K4?^@!=?^/?_$4?\)5J/_0 NO\
MQ[_XBNFHH YG_A*M1_Z %U_X]_\ $4?\)5J/_0 NO_'O_B*Z:B@#F?\ A*M1
M_P"@!=?^/?\ Q%'_  E6H_\ 0 NO_'O_ (BNFHH YG_A*M1_Z %U_P"/?_$4
M?\)5J/\ T +K_P >_P#B*Z:B@#F?^$JU'_H 77_CW_Q%'_"5:C_T +K_ ,>_
M^(KIJ* .9_X2K4?^@!=?^/?_ !%'_"5:C_T +K_Q[_XBNFHH YG_ (2K4?\
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M/?\ Q%'_  E6H_\ 0 NO_'O_ (BNFHH YG_A*M1_Z %U_P"/?_$4?\)5J/\
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M5J/_ $ +K_Q[_P"(KIJ* .9_X2K4?^@!=?\ CW_Q%'_"5:C_ - "Z_\ 'O\
MXBNFHH YG_A*M1_Z %U_X]_\11_PE6H_] "Z_P#'O_B*Z:B@#F?^$JU'_H 7
M7_CW_P 11_PE6H_] "Z_\>_^(KIJ* .9_P"$JU'_ * %U_X]_P#$4?\ "5:C
M_P! "Z_\>_\ B*Z:B@#F?^$JU'_H 77_ (]_\11_PE6H_P#0 NO_ ![_ .(K
MIJ* .9_X2K4?^@!=?^/?_$4?\)5J/_0 NO\ Q[_XBNFHH YG_A*M1_Z %U_X
M]_\ $4?\)5J/_0 NO_'O_B*Z:B@#F?\ A*M1_P"@!=?^/?\ Q%'_  E6H_\
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MLR_"N'4OMZ^!='\_=NVM!F+.2?\ 5D[._I7I<,,=M#'##&L44:A$C0 *J@8
M '04^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH \9HHHH ] ^'_P#R!IO^OAO_ $%:Z:N9^'__ "!IO^OAO_05
MKIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /&:*** /0/A__P @:;_KX;_T%:Z:N9^'_P#R!IO^OAO_ $%:Z:@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#QFBBB@#T#X?_ /(&F_Z^&_\ 05KIJYGX?_\ (&F_Z^&_]!6NFH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \
M9HHHH ] ^'__ "!IO^OAO_05KIJYGX?_ /(&F_Z^&_\ 05KIJ "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&:***
M /0/A_\ \@:;_KX;_P!!6NFKF?A__P @:;_KX;_T%:Z:@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **\\\<_'3PMX'\R%[O^T]17C['9$.0?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5NFG:@8[+Q!&O,><)<@=63W]5_$<9QZI7ZYA<71QM)5J$KQ?]6?F?C>,P=;
MUG0KQM)?U=>04445UG&%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'C-%%% 'H'P__P"0--_U\-_Z"M=-7,_#_P#Y TW_ %\-_P"@K734 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%9?B#Q-I7A6Q-YJ]_!86_9IFP6/HHZL?8 FHE.-.+E-V2+A"522A!7;Z(
MU*HZQKFG^'[%[S4[R&QM4ZRSN%'T&>I]A7@7CG]JL#S+;PK8Y[?;[Y?U6/\
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M?JNJ?F?D68Y;B,KK.C77H^C7D+1117IGE!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'C-%%% 'H'P_P#^0--_U\-_Z"M=-7,_#_\ Y TW_7PW_H*U
MTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445
MSGB[XA>'_ MOYFL:E%;.1E+<'=*_T0<_CT]ZRJ5848N=22275Z&M*E4KS5.E
M%RD^BU9T=8GBCQIHG@RS^TZSJ,-BF,JKMEW_ -U!RWX"OG;QU^U+JFJ>9;>&
MK4:3;GC[5. \Y'L/NK_X\?<5XIJ6IW>L7DEW?74UY<R'+S3N79OJ37PV8<64
M*-X8./.^[T7^;_#U/O\ +N#\16M/&RY%V6K_ ,E^/H>[^.OVJ;JZ\RU\+6?V
M2/I]NO%#2'W5.@_'/T%>&ZSKNH^(KY[S4[V:^NFZRSN6/T&>@]A6]X*^%GB3
MQ](ITO3V^RYPUY/^[@7_ ($>OT7)]J^A/ W[,>@Z#Y=SKDIUV\'/E$%+=3_N
M]6_$X/I7R\<-F_$$E.HWR=WI'Y+K\D_4^LEB<FX<BX4TN?LM9/U?3YM>2/G+
MP?\ #OQ!XZN/+T?3I;B,'#W##9"GU<\?AU]J^@? W[+>E:5Y=SXDN3JUR.?L
ML!*0*?<\,_Z#VKV^UM8;&WC@MH8[>",;4BB4*JCT ' J6OM<OX7P>$M.M^\E
MY[?=_G<^%S'BO&XR\*'[N/EO]_\ E8K:?IMII-G':V-K#9VT8PD,"!$7Z 59
MHHK[!)15EL?%.3D[O<****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "O*_C%\#[/XA6[ZCIXCLO$$:\28PEP .%D]_1OP.1C'JE%<F*PE'&T
MG1KQO%_U=>9V83&5L#65>A*TE_5GY'YY:MI-YH6HSV&H6TEI>0-LDAD&"I_S
MW[U['\%?C]+X7,&A^(I7GTCA(+MLL]K['NR?J.W' ]M^*OPCTWXF:;E]MGK$
M*XM[Y5Y_W']5_4=1W!^.O%'A;4_!NL3:9JMLUM=1'ZJZ]F4]P?6OR/%8/&\-
MXE5Z#O![/H_*7]>:\OV3"8W \3X5X>NK36ZZK^]%_P!=GY_?UO<17=O'/!(D
MT,BATDC8,K*1D$$=0:DKX[^#OQPO/A[.FG:@9+WP^[<Q]7MR3RR>WJOXCGK]
M<Z3JUGKFGP7]A<1W=G.N^.:,Y5A_GMVK]*RK-Z&:4N:&DENNW^:\S\NS?)J^
M4U>6>L'M+O\ Y/R+=%%%>Z> %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X
MS1110!Z!\/\ _D#3?]?#?^@K735S/P__ .0--_U\-_Z"M=-0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !117$^./C%X8\!!X[Z^%Q?+_RXVF)
M)<^AYPO_  (BL*V(I8:#J5I**[LZ*&'K8J:IT(N4NR.VKD_&GQ2\-^ HV_M7
M4$%SC*V<'[R=O^ CI]6P/>OF_P =?M)^)/$WF6^E8T"Q;C_1VS.P]Y.W_ 0/
MJ:\EEE>>1I)':21CN9F.22>Y-? YAQ=3A>&"CS/N]ODM_OL?H>7<&U)VGCI<
MJ_E6_P WLOE<]F\<_M/:[KWF6VA1#0[,\>=D/<,/][HOX#(]:\<NKR>_N)+B
MYFDN+B0[GEE<LS'U)/)KOO WP+\4^./+F2T_LS3FY^V7H* CU5?O-^6/>OH;
MP-^SWX7\'^7/<0_VWJ*\^?>*"BGU6/H/QR?>OGZ>79MGLU5KMJ/>6B^2_P E
M\SZ.KF63\/P=+#I.7:.K^<O\W?R/FWP/\&_$_CPI+96)MK!O^7Z[S'%CU7C+
M?\!!KZ%\"_LV^&_"_EW&I@Z_?KSFX7$"GVC[_P# B?H*]; "@ # %+7W67\-
MX+!6E-<\N[V^2V^^Y\!F/$^.QUX0?LX=EO\ -[_=8;'&D,:QQJJ(HPJJ,  =
M@*=117U9\@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %<K\0OAQI/Q(T<V>HQ[)TR;>\C'[R%O4>H/=>A^N".JHK&
MM1IXBFZ56-XO=&U&M4P]15:4K26S1\%^// .K?#S6FT_5(<!LM#<)DQS+_>4
M_P QU%;/PJ^+NI_#/40%+7>CS-FXLF;C_?3T;]#W[$?8'B_P?I?CC19=,U:W
M$T#\JPX>)NSH>Q'_ -8Y%?''Q/\ A5JGPSU3R[@&YTV9C]FOD7"O_LM_=;V_
M+-?DF9Y3B<CK+&8.3Y%UZKR?E_PS/V3*LXPV?47@L;%<[Z=)>:[/R^:\OLSP
MOXITWQCH\.IZ5<K<VLHZCAD;NK#L1Z5K5\(_#SXD:M\-]8%[ITGF0/@7%G(?
MW<R^A]".S#D?3(/V5X#\?:3\0]%74-+ER1A9K=^)(6_NL/Y'H:^YR;/*6:0Y
M)^[46Z[^:_RZ'P.>9!5RJ?M(>]2>S[>3_P ^ITE%%%?4'R84444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^&93^%>1?L,_#'3M!^$]KXNGMDG\0:_)+/)>2C?*L2R,BH&/0':6..N[GH,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44A.!D\"O,
MO'/[07A?P=YD$$_]M:@O'V>R8%%/^U)]T?ADCTKDQ.*H8.'M*\U%>?\ 6IV8
M7!XC&3]GAX.3\OU[?,].KSWQU\<O"_@?S(9+O^TM17(^QV1#L#Z.WW5_$Y]J
M^;?'/QV\4^-O,@:Z_LO3FX^R6)*!AZ,WWF_/'M7GL<;S2+'&C.['"JHR2?0"
MOS_'\7;PP,/^WG^B_P _N/T;+^#=JF/G_P!NK]7_ )?>>G>.?VAO%'C#S(+6
M;^P]/;CR;-CYC#T:3J?PP/:O,.7;NS$_4FO6O O[-OB3Q/Y=QJ@&@V#8/^D+
MF=A[1]O^!$?0U]"^!_@WX8\!A);*Q%S?K_R_7>))<^J\87_@(%>11R;-,YFJ
MV*DTN\OTC_PR/9KYWE.20=#"14GVC^LO^'9\W>!OV>_%'C#RY[F'^Q-/;GS[
MQ2'8?[,?4_C@'UKZ&\#? OPMX'\N9+3^T]17G[9>@.0?]E?NK^6?>O0Z*^^R
M_A_!8"TE'FEW>OW+9?GYGYYF/$6.S"\7+DAVCI][W?Y>04445](?+A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !5#7-"L/$FESZ=J5LEW9SKM>.0<?4>A'8CD5?HJ91C.+C)7
M3*C*4)*479H^,OB]\%K_ .'%XUW:[[W0)6Q'<XRT)/1),=#Z-T/L>*X_P?XR
MU3P/K46IZ3<&"=>'0\I*O=''<'_ZXP:^]KRS@U&UEM;J&.XMIE*212*&5E/4
M$'K7RE\:/@+/X+:;6=#22ZT(G=)%RTEI]?5/]KJ._J?RK.<AJ8"?US 7Y5K9
M;Q\UY?EZ'Z[D?$-/,(?4<PMS/2[VEY/S_/U/?OAA\5-+^)FE^9;D6VI0J/M-
MBS99/]I?[RGU_/%=M7Y[:'KM_P"&]4@U'3;E[2\@;<DL9Y^A]0>X/!KZ^^$/
MQIL/B1:+:7.RRU^)<R6V?EE ZO'GJ/5>H]QS7T.1\00QR6'Q+M4_"7_!\ON[
M'S6?<-SR]O$857I=>\?^!Y_?W/2Z***^V/A0HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MQFBBB@#T#X?_ /(&F_Z^&_\ 05KIJYGX?_\ (&F_Z^&_]!6NFH **** "BBB
M@ HHHH ***X;XV>.-3^'/POUWQ!HNF/K&JVL2BVM4C9\N[J@8JO)5=VX@=E/
M(ZT <3^TM\?/^%8Z/%X=\.JVI>/];'D:;8VZ[WBWG:)F4>_W1_$P] :O_LQ_
M! _!7P&T.H.+GQ/JT@N]6N=V_,G.V,-W" GGNS,>]?)/P2^+!^'_ (FU3QGX
MM\"^*?%WCK4)&)U*2WPENAXQ&"O!(XSQA<*H SGZ:^%_[5W_  LKQQIWAW_A
M ?$.C?;/,_TZ[C_<Q;8V?YC@8!VX^I% 'G<+?9?^"C4_FOC[3IN(@3Z6(X'_
M 'PQK[ KY8_:J^'/BK1/B)X6^+W@;2VU;4]& AO[*!"\DD8+;6V+\S J[HVW
MD J>@)&7XD_;.U/QUX7N="\#_#_Q(?%M_$ULIE@#1VC,-ID!7)8KGC<% ZG@
M8H Y#]E6W;4/AC^T%=V[92\@F2%AQSY-R0<_\#%>J_\ !/V=)O@*Z(V6BU>X
M1QZ';&V/R8?G7:_LS?!4_"'X0P:#JT4,NJ:@TEUJ:+AUWN OEY[A4"J>V=Q'
M6OGSP/X@\2_L3^,?$>@:SX7U/7/ 6I71N;#4-.CWE3T4@GY=Q0!61B#E 1QU
M /3O^"@5PD/P%1';#2ZO;H@]3MD;'Y*?RKVOX46KV/PM\'6S_?AT:SC;C'(@
M0'^5?*GBK4O$O[:WC;PUI=CX7U/P]\.=)N1=WU]JB>6;CL0,<;MNY552V-Y)
M..GTC\=O'&N?##X6:EK?A;1DU?5+4PI#9F%Y(U4NJEBD9#$!2>A&..PH P/V
MOX7F_9O\:K&<,((6/T%Q$3^@-2_LDSI<?LY^"'C;<HM9$)]UFD4C\P:T?",E
M]\=/@+$OB[2O[&OO$&G307EF(G3RBQ= ZJ_S#@*XR>,CD]:^;/A'\8O$W[)E
MC>> O'_@_5[W3+:XDDTW4-+A$BLK$E@A8A70D[A@@J68$9X !T/_  4*07D'
MPVT]#_I%SJ4P1<9SQ$I/YL/SI/VBF^R_MG?!Z>5]L+I;1+D\;C<RC]2RTSPW
MIOBC]JKX[>'O&FK^&KOPYX \,'S;*'4D*O=2AMX(!'S%G"%L94+'MR3U[?\
M;&^$&N^.-&\/^+/"%LUSXI\+W/VF*&$9EEBRK?(/XF5T5@O4Y;&20" ?1E?(
M'[.J"\_;,^,5Y$=T42W$#''\7VF,8_.-JN0_MT7EQH/V&+X;>(9?''E^5]A2
MV)M_/Q@GC]YC/.W;GMGO7:?LA_!S6OASX;UOQ!XLCV>+?$UU]LND;!DB3+%5
M;' 8L[L0/[R@\B@#W^BBB@ HHHH *@OEN&LY1:LJW&/D+=,U/10!S/D>*/\
MGXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_
M !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_
M !-'D>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-1
M0!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>
M*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>
M*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU
M_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU
M_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q
M-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q
M-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!
MS/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/
M^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/
M^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?
MR'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?
MR'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_ !-=
M-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'
MD>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/
MD>*/^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\
MGXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>*/\
MGXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_
M !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_
M !-'D>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-1
M0!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>
M*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>
M*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU
M_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU
M_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q
M-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q
M-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!
MS/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/
M^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/
M^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?
MR'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?
MR'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_ !-=
M-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'
MD>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/
MD>*/^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\
MGXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>*/\
MGXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_
M !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_
M !-'D>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-1
M0!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>
M*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>
M*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU
M_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU
M_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q
M-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q
M-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!
MS/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/^?BU_(?_ !-'D>*/
M^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?R'_Q-=-10!S/D>*/
M^?BU_(?_ !-'D>*/^?BU_(?_ !-=-10!S/D>*/\ GXM?R'_Q-'D>*/\ GXM?
MR'_Q-=#<W4-G;O/<2I!#&-SR2,%51ZDGI7CWCG]IO0/#_F6VB1G7;T<>8IV6
MZG_>ZM_P$8/K7#B\=AL##GQ$U'\WZ+=GH8/ 8K'SY,-!R?X+U>R.^D3Q+#&S
MO=VB(HRS-@ #U)Q7EGC#]H9/#,CVUG?V^M7:\'[( 8E/N^,'_@.:\0\:_%;Q
M+X^D8:IJ#"T)R+*W_=P#_@(^]]6R:YK3M-N]7O([2QM9KRYD.$A@0N[?0"OS
MS'<6U*C]G@(6\WJ_DO\ ._H?I&7\'TJ2]KF$[VZ+1?-[_=;U.M\9_&+Q3XX1
MH+_46AL6_P"7.U'EQD>C8Y;_ ($37'6MK-?7$<%M#)<3R':D42EF8^@ Y)KV
M_P "_LMZKJGEW/B2Z&DVQP?LL!#SL/0G[J?^/'V%?0'@_P"'GA_P+;^7H^G1
M6\A&'N&&Z9_]YSS^'3VKAPW#^8YI/V^-DXI]9:OY+I\['?BN(LLRF'L,#%2:
MZ1TC\WU^5_4^:O"7[,WB?6XTN-3$>CV[<^5*V9B/]T?=_'GVKVCP;\)W\"*&
MTFULDN<8-W,!),?^!%>/H,"O4:*_0<!DF"R^SIPO+N]7_P #Y'YSF&?8[,KQ
MJSM'^5:+_@_,YGR/%'_/Q:_D/_B:/(\4?\_%K^0_^)KIJ*]X^>.9\CQ1_P _
M%K^0_P#B:/(\4?\ /Q:_D/\ XFNFHH YGR/%'_/Q:_D/_B:/(\4?\_%K^0_^
M)KIJ* .9\CQ1_P _%K^0_P#B:/(\4?\ /Q:_D/\ XFNFHH YGR/%'_/Q:_D/
M_B:/(\4?\_%K^0_^)KIJ* .9\CQ1_P _%K^0_P#B:/(\4?\ /Q:_D/\ XFNF
MHH YGR/%'_/Q:_D/_B:/(\4?\_%K^0_^)KIJ* .9\CQ1_P _%K^0_P#B:/(\
M4?\ /Q:_D/\ XFNFHH YGR/%'_/Q:_D/_B:/(\4?\_%K^0_^)KIJ* .9\CQ1
M_P _%K^0_P#B:/(\4?\ /Q:_D/\ XFNFHH YGR/%'_/Q:_D/_B:/(\4?\_%K
M^0_^)KIJ* .9\CQ1_P _%K^0_P#B:/(\4?\ /Q:_D/\ XFNFHH YGR/%'_/Q
M:_D/_B:/(\4?\_%K^0_^)KIJ* .9\CQ1_P _%K^0_P#B:/(\4?\ /Q:_D/\
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MU<S\/_\ D#3?]?#?^@K734 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5S/P_P#^0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOU?S/S;'9IB\QE?$S;7;HOE_3"BBBO3/*"BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /&:*** /0/A_\ \@:;_KX;_P!!6NFKF?A_
M_P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*ZN*O1P7N0[_ &G_ )+\?R&11)!&D<:+'&@"JBC 4#H /2GT45]X?GP4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >,T444 >@?#_P#Y TW_ %\-
M_P"@K735S/P__P"0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,_IYBE1KZ5?PEZ>?E]WE\?GW#M3+6Z]#WJ7XQ]?+L_O\^[HHHK[ ^+"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/A_\ \@:;_KX;_P!!6NFK
MF?A__P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ K-\0>(M-\+:7+J&JWD=E:1]9)#
MU/H!U)]AS7!?%#X\:-X 66RM2NJZV./LL;?)"?61AT_W1S].M?*GC#QSK/CS
M4C>ZQ>-<.,^7$/ECB'HB]!_,]R:^0S;B.AE]Z5'WZGX+U?Z+\#[/)^&<1F-J
MM;W*?XOT7ZO\3TGXH?M':GXH\[3_  _YFDZ6<JT^<7$P^H^X/8<^_:O'+>WF
MO+B.&")YYY&"I'&I9F8]  .IKJ/ 'PQUSXC7WDZ9;[;9#B:]FR(HOJ>Y_P!D
M<_AS7U?\-_@WH7PWA66WC^W:J5Q)J$ZC?[A!_ /ISZDU\3ALOS'B*K[>O*T.
M[V](K^EW=S[S%9CEO#='ZOAXWGV6_K)_T^RL>4_"_P#9EDN/)U+Q=F&+ADTN
M-OF;_KHPZ?[HY]2.E?1EC8VVF6<5K:01VMM$NV.&%0JJ/0 =*GHK]0R_+,-E
MM/DH1UZOJ_Z^X_)\QS3%9I4Y\1+3HELO1?KN%%%%>J>0%%%% !1110 4444
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MN(EB;8;&.T^C[^OG^?KOYG$'#+PM\5@E>'6/;S7E^7IM[71117WY^=A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 >,T444 >@?#_P#Y TW_ %\-_P"@K735S/P_
M_P"0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS2?-7EHMDME_7=A1117L'BA1110 4444 %%%% !1110 4444 %%%% !1110
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MBB@#T#X?_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?!+XT:+\<O!B:]I"O;2QOY%Y8S$&2VE !*DC[RD$$,.H/8@@=^JA5"@ *!@
M#BOCO]DN%?!O[3'Q@\(V8\O31))<11+]U%CN"$'X+/C\* /L6BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGK0=$V3:H[ZU=#G;(-D(/^Z#S^)(]J]0M;6"QMT@MH8[>!!A8XE"JH] !TH
M\/\ "?[-2+LG\17^\]?LED<#Z,Y'\A^->P:!X7TGPO:^1I5A#91]"8U^9O\
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MF-"W0W%B=R_BC'(_ GZ4 >Y45A^'?&^A>+(PVE:G!=/C)B#;9!]4.&'Y5N4
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBBB@#T#X?_\
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M/F@^,/$OPOU73_ E^VG>(Y&B,,T<_D.5#J759/X25SSQZ9YH QOVM-/DU/\
M9U\;PQHTC+:).0HR<1RI(3] %)_"JO['NIQ:I^SEX.:)@3##-;NN>59)Y 0?
MR!_&NJ^%_A;7H?A%IF@>/;D:QK4EI);ZE*TOF^:KLXVE\?,=C*I/<@\GK7SO
MX9^$/QS_ &<=2U33_AP-)\7^%+N<SPVNJ2A&B)P,LIDCPV,9*L0VT' /% $W
M[>RC7M>^%7AJW7S[Z^U*0B).6P6AC7CW+'_ODU'^TVRZ'^UQ\&]8N 4M)&M[
M;S6X7(NF!Y]O.4GZBNJ^%OP#\<>(OBQ!\3?BUJ%G+JUBFS3='L"&BMNH!)'
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M/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\
M"C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5
MTU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7
M_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;
MK_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_
M //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_
M .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% '
M,_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_P
MH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=
M-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=
M?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_
M +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO
M_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06
MW_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S
M/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\
M"C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5
MTU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7
M_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;
MK_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_
M //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_
M .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% '
M,_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_P
MH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=
M-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=
M?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_
M +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO
M_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06
MW_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S
M/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\
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M>KZTN&!89@@/^PIZD?WC^ %>NUU95PM=JOF'_@/^;_1??T./-^+;)T,M_P#
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MA_A7344 <S_P@MO_ ,_MU_WT/\*/^$%M_P#G]NO^^A_A7344 <S_ ,(+;_\
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MT/\ "NFHH YG_A!;?_G]NO\ OH?X4?\ ""V__/[=?]]#_"NFHH YG_A!;?\
MY_;K_OH?X4?\(+;_ //[=?\ ?0_PKIJ* .9_X06W_P"?VZ_[Z'^%'_""V_\
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M:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CN+B*T@
MDGGD2&&-2SR2,%55'4DGH*Y?Q_\ $W0_AS8>=J=QNN7&8;*$@S2_0=A_M'C^
M5?)_Q(^,FN_$>9HKB3[#I0;,>GP,=GL7/\9^O'H!7S>:9[ALL3@_>J?RK]>W
MYGT^4\/XK-&II<M/^9_HNOY>9ZO\4/VFX[?SM-\(8FE^Z^J2+E5_ZYJ>O^\>
M/0'K7SG?7]SJEY-=WD\ES<S-ODFE8LS'U)-7/#GAG5/%NJ1Z?I-G)>W3\[8Q
MPH_O,>BCW/%?4/PO_9STSPGY.HZ[Y>K:LN&6/&;> ^P/WS[GCT'>OSN-/,N)
M:W-)V@OE%>G=_CW/TJ57*^%Z/+%7F_G*7KV7X=D>2?"_]GW5_&WDW^J>9I&B
MMA@[+^^F'^PIZ _WCQZ U]3^%O".D^"]+2PT>RCL[<<MM&6D/]YFZL?K6Q17
MZ7EF38;*X_NU>?63W_X"/R[-,[Q6:R_>NT.D5M\^[_I6"BBBO=/GPHHHH **
M** "BBB@ HHHH **K:AJ5II-J]S>W,-I;K]Z69PBC\37E/BS]HW2-,WPZ);O
MJTXX\Z3,<(_/YF_(?6@#UXD*"3P*X'Q9\;/#/A??$MU_:EXO_+"RPX!]W^Z/
MS)]J^>/%GQ.\1>,BRW]^RVK?\NEO^[B^A ^]_P ")KF+>WENIDBAC>:5SA8X
MU+,Q] !0!Z/XL^/?B/Q%OALW71;1N-EJ<R$>\AY_[YQ7F\DKS2-)([22,<LS
M'))]2:]-\)_L_P#B'7MDVH;=$M3S_I W3$>R#I_P(BO9_"?P9\,^$]DJ6?\
M:%XO/VF]PY!]0OW1^6?>@#YW\)_"GQ)XPV26=@T%HW_+W=?NX\>HSRW_  $&
MO:/"?[.NB:1LFUB9]8N!SY?,<(/T!R?Q./:O6J* (+&QMM-MDM[2WBM;=!A8
MH4"J/H!4]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBBB@#T#X?_
M /(&F_Z^&_\ 05KIJYGX?_\ (&F_Z^&_]!6NFH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6#*&4Y!Y!% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'C-%%% 'H'P_\ ^0--_P!?#?\ H*UT
MU<S\/_\ D#3?]?#?^@K734 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\-_Z"M=-7,_#_P#Y TW_ %\-_P"@K734 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY%#*P]P: /ANQU"ZTNY6XL[F:TG7[LL+E&'XBO2O#/[0GB31=L>H"+6;<?\
M/8;)<>SJ/Y@UZOXF^ GA?7MTEM"^CW!YW69^3/NAXQ],5Y/XF_9[\2:+NDL#
M%K-N/^>!V2X]T/\ 0F@#UGPS\>O"^O;([F=](N3QLO!A,^SCC'UQ7H=O<17<
M*302I-$XRLD;!E(]B*^&K[3[K3+AK>\MY;6=?O13(48?@:O:#XJUCPQ-YNEZ
MC<639R5C?Y6^JG@_B* /MNBOGCPS^TMJ%KLBUS3X[Z/H;BU_=R?4J?E)^FVO
M6/#/Q8\,>*MB6NIQP7#?\NUW^ZDSZ#/!/T)H Z^BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/A_\ \@:;_KX;_P!!6NFK
MF?A__P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVNFP]3;P$23'V)^ZOZU[/X5^'/A_P:JG3=/C6X YNI?GE/\ P(]/H,"NEHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW0Q$#[1]/^^LUZ/'$D,:QQHL<:C"JHP /0"GT4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN\I\N7Z;6Y/X9KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_%WC#RY5L#IEDW/VG4,QC'J%QN/Y8]Z]R\'_ +,/AK0MDVKR2Z[=+SMD_=P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#7BS<U]ID2W#?\O-O^ZDSZDCK^.:\G\3?LT7<&Z70M26Z7J+>\&Q_H''!/U
MH W?#/[2FEWFR+6[&73I.AGM_P![%]2/O#\,UZGH?B32_$EOY^EW\%]&/O>2
MX)7_ 'AU'XU\<^(/!VM>%9=FJZ;<68S@2,N8V^CCY3^!K7^$LVH0_$+11IQ?
MS'N%64)T,.?WF?;;D_A0!]@T444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &30I<1M'*BR1L,
M,CC((]"*HZ7X<TG1)))-.TRSL7D^^UM L9;V.!6C10 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C-
M%%% 'H'P_P#^0--_U\-_Z"M=-7,_#_\ Y TW_7PW_H*UTU !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 45#=WD&GV\EQ=3QVT$8
MR\LSA%4>I)X%>4>,?VF/"_AWS(=,\S7KM>/]'.R$'WD/7_@(-<6*QN&P4>;$
M34?ZZ+=G?A,#BL=+DPU-R]-OF]D>NURWB[XG>&O!"L-6U6&*<#(M8SYDQ_X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C-%%% 'H'P_\ ^0--
M_P!?#?\ H*UTU<S\/_\ D#3?]?#?^@K734 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !114=Q<16<+S3RI#"@RTDC!54>I)Z4MM6-7>B)**\H\8?M)>
M%/#>^*QD?7KM>-MGQ$#[R'C'NNZO#?&'[1/BWQ1OBM[E=$LVX\JQRKD>\A^;
M/TQ]*^9QO$6 P=XJ7/+M'7\=CZG \-9AC;2<.2/>6GX;GU+XL^(WAWP3&3K&
MJ0VTN,BW4[YF^B+D_CC%>(>,/VKYI/,@\-:6(5Z"\O\ YF^HC!P/Q)^E?/DL
MKSR-)([22,<LS'))]2:Z[P?\)/%/C?8^G:7(MJW_ "^7/[J''J&/WO\ @(-?
M$5^(\RS"?LL''EO_ "ZR^_\ R2/O,/PSEF6P]MC9\UNLG:/W?YMF3XD\::YX
MPN/.UG4[B_;.561_D7_=0?*OX"J.E:/?ZY>+:Z=9SWURW2*WC+M]<#M7TMX/
M_95TG3]DWB*_DU2;J;:VS%#]"WWF_#;7IG]H>$/AK8_95ET[1(5&3!'M5V]R
MH^9C[\UKA>%L9BI>UQL^6_\ V]+_ "_'Y&6+XMP6#C[+ PYK?]NQ_P _P7J?
M/O@[]EO7M7\N?7;F+1;8\F%<2SD?0':OYDCTKW'P?\$_"7@O9):Z:MY>+_R]
MWV)9,^HR-JG_ '0*YO7OVD]#L=R:797.IR#I(^(8S^)RW_CHKSC7OV@/%6L;
MDMI8=*A/&+6/+X_WFR?RQ7W6"R+ X&SA"\N[U?\ DODCX#'9_F&/NJE2T>T=
M%_F_FSZ?O+^VTV SW=Q%:PKUDF<(H_$UP>O?'CPEHN]8KR34YE_@LDW#_OHX
M7\B:^7-2U:^UBX\^_O)[V;_GI<2%S^9-1VEG<:A.L%K!)<S-]V.%"['Z 5[Y
M\Z>P:]^TOJEUN32--M[%.@DN&,K_ % X _6O.->\?>(?$VX:EJ]S/&W6$/LC
M_P"^%POZ5T.@_ OQ;KFUGL5TR%O^6E\^P_\ ?(RWYBO1]!_9GTVWVOJ^J3WC
M=3%;*(D^A)R2/RH ^>*Z70?AOXE\2[&L-'N7B;I-(OEQ_7<V ?PKZIT'X>^'
M/#.TZ=I%M#*O29U\R3_OMLG]:Z*@#YZT']F:_FVOK&JPVJ]3#:*9&^FXX _(
MUZ/H/P/\(Z'M8Z>=1F7_ ):7S>9G_@/"_I7?44 16UK#9PK#;PQP1+TCC4*H
M^@%2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3V;3-+^$OPMPYFBUO4X_^6CXNGW#T 'EJ?R/O4.O?M-N0T>BZ.J#^&:^?/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!K45D_\ "5Z3_P _B_\ ?+?X4?\ "5Z3_P _B_\ ?+?X4 :U%9/_  E>D_\
M/XO_ 'RW^%'_  E>D_\ /XO_ 'RW^% &M163_P )7I/_ #^+_P!\M_A1_P )
M7I/_ #^+_P!\M_A0!K45D_\ "5Z3_P _B_\ ?+?X4?\ "5Z3_P _B_\ ?+?X
M4 :U%9/_  E>D_\ /XO_ 'RW^%'_  E>D_\ /XO_ 'RW^% &M163_P )7I/_
M #^+_P!\M_A1_P )7I/_ #^+_P!\M_A0!K45D_\ "5Z3_P _B_\ ?+?X4?\
M"5Z3_P _B_\ ?+?X4 :U%9/_  E>D_\ /XO_ 'RW^%'_  E>D_\ /XO_ 'RW
M^% &M163_P )7I/_ #^+_P!\M_A1_P )7I/_ #^+_P!\M_A0!K45D_\ "5Z3
M_P _B_\ ?+?X4?\ "5Z3_P _B_\ ?+?X4 :U%9/_  E>D_\ /XO_ 'RW^%'_
M  E>D_\ /XO_ 'RW^% &M163_P )7I/_ #^+_P!\M_A1_P )7I/_ #^+_P!\
MM_A0!K45D_\ "5Z3_P _B_\ ?+?X4C>+=(12S7J*H&22&P/TH UZ*\Q\5?M$
M>#_#:.L-X^L78X$-BN1GW<X4?@2?:O$O%_[2GBKQ(SP:6$T*U;@+;?/,1[R$
M<?\  0*^<QF?X'!OEYN>7:.O_ _$^FP7#N/QJY^3DCWEI_P?PL?4'B;QIH?@
MZV\_6=3M[!2,JLC9=O\ =0?,WX"O%/&'[6$,>^#PUI9F;H+O4/E7ZB-3D_B1
M]*^?9K>_U2X>XNI))IY#EYKARSL?4D\FIHM%1>9'+>R\5X-3&YYF6F%H^RB^
MKW_']$?0T\#D&5ZXNM[6:Z+;\/U?R+GBOXB>(O&TA;6-5GNH\Y%N#LB7Z(,#
M\<9K#ALYION1L1ZG@5N16D,/W(U!]>IJ:L:7"<ZTO:8ZNY-]M?Q?^1M6XPIT
M8>RR^@HI;7T_\E7^9DPZ*QP9' 'HO-:=G#'8D-#&HD'_ "T8!F^HST/N,&MC
M2_"NJZP1]ELI&0_\M'^1/^^C@5WV@_!&*XVOK'B&VM%ZF*UC:5_ID@ '\Z^I
MPN1Y?@]:=)-]WJ_QV^1\EB\_S'&W52JTNRT7X;_,\PN+F:ZD,D\KS2'J\C%B
M?Q-6-+T74-;G\G3[*XO9?[MO$SD?7 XKZ.T'X;_#S0]K,HU*8?\ +2^+./\
MOD +^E=U:Z_H5C L-M-!;PK]V.*,JH^@ KWCY\^>=!_9[\4:MM>\6WTF(\_Z
M1)N?'LJY_4BO1M!_9NT"PVOJ=W<ZK(.J@^3&?P'S?^/5Z-_PE>D_\_B_]\M_
MA1_PE>D_\_B_]\M_A0 :)X3T;PVH&F:9:V1QC?%& Y^K=3^)K6K)_P"$KTG_
M )_%_P"^6_PH_P"$KTG_ )_%_P"^6_PH UJ*R?\ A*])_P"?Q?\ OEO\*/\
MA*])_P"?Q?\ OEO\* -:BLG_ (2O2?\ G\7_ +Y;_"C_ (2O2?\ G\7_ +Y;
M_"@#6HK)_P"$KTG_ )_%_P"^6_PH_P"$KTG_ )_%_P"^6_PH UJ*R?\ A*])
M_P"?Q?\ OEO\*/\ A*])_P"?Q?\ OEO\* -:BLG_ (2O2?\ G\7_ +Y;_"C_
M (2O2?\ G\7_ +Y;_"@#6HK)_P"$KTG_ )_%_P"^6_PH_P"$KTG_ )_%_P"^
M6_PH UJ*R?\ A*])_P"?Q?\ OEO\*/\ A*])_P"?Q?\ OEO\* -:BLG_ (2O
M2?\ G\7_ +Y;_"C_ (2O2?\ G\7_ +Y;_"@#6HK)_P"$KTG_ )_%_P"^6_PH
M_P"$KTG_ )_%_P"^6_PH UJ*R?\ A*])_P"?Q?\ OEO\*/\ A*])_P"?Q?\
MOEO\* -:BLG_ (2O2?\ G\7_ +Y;_"C_ (2O2?\ G\7_ +Y;_"@#6HK)_P"$
MKTG_ )_%_P"^6_PH_P"$KTG_ )_%_P"^6_PH UJ*R?\ A*])_P"?Q?\ OEO\
M*/\ A*])_P"?Q?\ OEO\* -:BLG_ (2O2?\ G\7_ +Y;_"C_ (2O2?\ G\7_
M +Y;_"@#6HK)_P"$KTG_ )_%_P"^6_PH_P"$KTG_ )_%_P"^6_PH UJ*R?\
MA*])_P"?Q?\ OEO\*/\ A*])_P"?Q?\ OEO\* -:BLG_ (2O2?\ G\7_ +Y;
M_"C_ (2O2?\ G\7_ +Y;_"@#6HK)_P"$KTG_ )_%_P"^6_PH_P"$KTG_ )_%
M_P"^6_PH UJ*R?\ A*])_P"?Q?\ OEO\*/\ A*])_P"?Q?\ OEO\* -:BLG_
M (2O2?\ G\7_ +Y;_"C_ (2O2?\ G\7_ +Y;_"@#6HK)_P"$KTG_ )_%_P"^
M6_PH_P"$KTG_ )_%_P"^6_PH UJ*R?\ A*])_P"?Q?\ OEO\*/\ A*])_P"?
MQ?\ OEO\* -:BLG_ (2O2?\ G\7_ +Y;_"C_ (2O2?\ G\7_ +Y;_"@#6HK)
M_P"$KTG_ )_%_P"^6_PH_P"$KTG_ )_%_P"^6_PH UJ*R?\ A*])_P"?Q?\
MOEO\*/\ A*])_P"?Q?\ OEO\* -:BLG_ (2O2?\ G\7_ +Y;_"C_ (2O2?\
MG\7_ +Y;_"@#6HK)_P"$KTG_ )_%_P"^6_PH_P"$KTG_ )_%_P"^6_PH UJ*
MR?\ A*])_P"?Q?\ OEO\*/\ A*])_P"?Q?\ OEO\* -:BLG_ (2O2?\ G\7_
M +Y;_"C_ (2O2?\ G\7_ +Y;_"@#6HK)_P"$KTG_ )_%_P"^6_PH_P"$KTG_
M )_%_P"^6_PH UJ*R?\ A*])_P"?Q?\ OEO\*/\ A*])_P"?Q?\ OEO\* -:
MBLG_ (2O2?\ G\7_ +Y;_"C_ (2O2?\ G\7_ +Y;_"@#6HK)_P"$KTG_ )_%
M_P"^6_PH_P"$KTG_ )_%_P"^6_PH UJ*R?\ A*])_P"?Q?\ OEO\*/\ A*])
M_P"?Q?\ OEO\* -:BLG_ (2O2?\ G\7_ +Y;_"C_ (2O2?\ G\7_ +Y;_"@#
M6HK)_P"$KTG_ )_%_P"^6_PH_P"$KTG_ )_%_P"^6_PH UJ*R?\ A*])_P"?
MQ?\ OEO\*/\ A*])_P"?Q?\ OEO\* -:BLG_ (2O2?\ G\7_ +Y;_"C_ (2O
M2?\ G\7_ +Y;_"@#6HK)_P"$KTG_ )_%_P"^6_PH_P"$KTG_ )_%_P"^6_PH
M UJ*R?\ A*])_P"?Q?\ OEO\*/\ A*])_P"?Q?\ OEO\* -:BLG_ (2O2?\
MG\7_ +Y;_"C_ (2O2?\ G\7_ +Y;_"@#6HK)_P"$KTG_ )_%_P"^6_PH_P"$
MKTG_ )_%_P"^6_PH UJ*R?\ A*])_P"?Q?\ OEO\*/\ A*])_P"?Q?\ OEO\
M* -:BLG_ (2O2?\ G\7_ +Y;_"C_ (2O2?\ G\7_ +Y;_"@#6HK)_P"$KTG_
M )_%_P"^6_PH_P"$KTG_ )_%_P"^6_PH UJ*R?\ A*])_P"?Q?\ OEO\*/\
MA*])_P"?Q?\ OEO\* -:BLG_ (2O2?\ G\7_ +Y;_"C_ (2O2?\ G\7_ +Y;
M_"@#6HK)_P"$KTG_ )_%_P"^6_PH_P"$KTG_ )_%_P"^6_PH UJ*R?\ A*])
M_P"?Q?\ OEO\*/\ A*])_P"?Q?\ OEO\* -:BLG_ (2O2?\ G\7_ +Y;_"C_
M (2O2?\ G\7_ +Y;_"@#6HK)_P"$KTG_ )_%_P"^6_PH_P"$KTG_ )_%_P"^
M6_PH UJ*R?\ A*])_P"?Q?\ OEO\*/\ A*])_P"?Q?\ OEO\* -:BLG_ (2O
M2?\ G\7_ +Y;_"C_ (2O2?\ G\7_ +Y;_"@#6HK)_P"$KTG_ )_%_P"^6_PH
M_P"$KTG_ )_%_P"^6_PH UJ*R?\ A*])_P"?Q?\ OEO\*/\ A*])_P"?Q?\
MOEO\* -:BLG_ (2O2?\ G\7_ +Y;_"C_ (2O2?\ G\7_ +Y;_"@#6HK)_P"$
MKTG_ )_%_P"^6_PH_P"$KTG_ )_%_P"^6_PH UJ*R?\ A*])_P"?Q?\ OEO\
M*/\ A*])_P"?Q?\ OEO\* -:BLG_ (2O2?\ G\7_ +Y;_"C_ (2O2?\ G\7_
M +Y;_"@#6HK)_P"$KTG_ )_%_P"^6_PH_P"$KTG_ )_%_P"^6_PH UJ*R?\
MA*])_P"?Q?\ OEO\*/\ A*])_P"?Q?\ OEO\* -:BLG_ (2O2?\ G\7_ +Y;
M_"C_ (2O2?\ G\7_ +Y;_"@#6HK)_P"$KTG_ )_%_P"^6_PH_P"$KTG_ )_%
M_P"^6_PH UJ*R?\ A*])_P"?Q?\ OEO\*/\ A*])_P"?Q?\ OEO\* -:BLG_
M (2O2?\ G\7_ +Y;_"C_ (2O2?\ G\7_ +Y;_"@#6HK)_P"$KTG_ )_%_P"^
M6_PH_P"$KTG_ )_%_P"^6_PH UJ*R?\ A*])_P"?Q?\ OEO\*/\ A*])_P"?
MQ?\ OEO\* -:BLG_ (2O2?\ G\7_ +Y;_"C_ (2O2?\ G\7_ +Y;_"@#6HK)
M_P"$KTG_ )_%_P"^6_PH_P"$KTG_ )_%_P"^6_PH UJ*R?\ A*])_P"?Q?\
MOEO\*/\ A*])_P"?Q?\ OEO\* -:BLG_ (2O2?\ G\7_ +Y;_"C_ (2O2?\
MG\7_ +Y;_"@#6HK)_P"$KTG_ )_%_P"^6_PH_P"$KTG_ )_%_P"^6_PH UJ*
MR?\ A*])_P"?Q?\ OEO\*/\ A*])_P"?Q?\ OEO\* -:BLG_ (2O2?\ G\7_
M +Y;_"C_ (2O2?\ G\7_ +Y;_"@#6HK)_P"$KTG_ )_%_P"^6_PH_P"$KTG_
M )_%_P"^6_PH UJ*R?\ A*])_P"?Q?\ OEO\*/\ A*])_P"?Q?\ OEO\* -:
MBLG_ (2O2?\ G\7_ +Y;_"C_ (2O2?\ G\7_ +Y;_"@#6HK)_P"$KTG_ )_%
M_P"^6_PH_P"$KTG_ )_%_P"^6_PH UJ*R?\ A*])_P"?Q?\ OEO\*/\ A*])
M_P"?Q?\ OEO\* -:BLG_ (2O2?\ G\7_ +Y;_"C_ (2O2?\ G\7_ +Y;_"@#
M6HK)_P"$KTG_ )_%_P"^6_PH_P"$KTG_ )_%_P"^6_PH UJ*R?\ A*])_P"?
MQ?\ OEO\*/\ A*])_P"?Q?\ OEO\* -:BLG_ (2O2?\ G\7_ +Y;_"C_ (2O
M2?\ G\7_ +Y;_"@#6HK)_P"$KTG_ )_%_P"^6_PH_P"$KTG_ )_%_P"^6_PH
M UJ*R?\ A*])_P"?Q?\ OEO\*/\ A*])_P"?Q?\ OEO\* -:BLG_ (2O2?\
MG\7_ +Y;_"C_ (2O2?\ G\7_ +Y;_"@#6HK)_P"$KTG_ )_%_P"^6_PH_P"$
MKTG_ )_%_P"^6_PH UJ*R?\ A*])_P"?Q?\ OEO\*/\ A*])_P"?Q?\ OEO\
M* -:BLVW\1Z;=3)#%=*\CG"J%//Z5I4 %%%% !1110 4444 >,T444 >@?#_
M /Y TW_7PW_H*UTU<S\/_P#D#3?]?#?^@K734 %%%% !1110 4444 %%%4M:
ML)-5T>_LH;N6PEN;>2%+J XDA9E(#J?[P)R/<4 ?.G_!0;_D@]O_ -AFW_\
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MQ7$VY?$>I9Z?-<,P_(YHYJW6*^__ ( <M#I-_=_P3Z\_X1_3?^?&#_O@4?\
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M&T6,O!X7\.1WS]!>7L>R//J$')'U*UY#X@\0Z]XNE+:E>A(B>+>!0D8_X"N
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MC_A']-_Y\8/^^!6A10!G_P#"/Z;_ ,^,'_? H_X1_3?^?&#_ +X%:%% &?\
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M_P"$?TW_ )\8/^^!6A10!G_\(_IO_/C!_P!\"C_A']-_Y\8/^^!6A10!G_\
M"/Z;_P ^,'_? H_X1_3?^?&#_O@5H44 9_\ PC^F_P#/C!_WP*/^$?TW_GQ@
M_P"^!6A10!G_ /"/Z;_SXP?]\"C_ (1_3?\ GQ@_[X%:%% &?_PC^F_\^,'_
M 'P*/^$?TW_GQ@_[X%:%% &?_P (_IO_ #XP?]\"C_A']-_Y\8/^^!6A10!G
M_P#"/Z;_ ,^,'_? H_X1_3?^?&#_ +X%:%% &?\ \(_IO_/C!_WP*/\ A']-
M_P"?&#_O@5H44 9__"/Z;_SXP?\ ? H_X1_3?^?&#_O@5H44 9__  C^F_\
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MC_A']-_Y\8/^^!6A10!G_P#"/Z;_ ,^,'_? H_X1_3?^?&#_ +X%:%% &?\
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M_P"$?TW_ )\8/^^!6A10!G_\(_IO_/C!_P!\"C_A']-_Y\8/^^!6A10!G_\
M"/Z;_P ^,'_? H_X1_3?^?&#_O@5H44 9_\ PC^F_P#/C!_WP*/^$?TW_GQ@
M_P"^!6A10!G_ /"/Z;_SXP?]\"C_ (1_3?\ GQ@_[X%:%% &?_PC^F_\^,'_
M 'P*/^$?TW_GQ@_[X%:%% &?_P (_IO_ #XP?]\"C_A']-_Y\8/^^!6A10!G
M_P#"/Z;_ ,^,'_? H_X1_3?^?&#_ +X%:%% &?\ \(_IO_/C!_WP*/\ A']-
M_P"?&#_O@5H44 9__"/Z;_SXP?\ ? H_X1_3?^?&#_O@5H44 9__  C^F_\
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MC_A']-_Y\8/^^!6A10!G_P#"/Z;_ ,^,'_? H_X1_3?^?&#_ +X%:%% &?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"6MY^^/UPW /T KL8XUC1410B*,!5& !3J* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /&:*** /0/A_\ \@:;_KX;_P!!6NFKF?A_
M_P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!-JUUI$C=$O[-Q^;(&4?G7QMKW[-7Q-\.[OM/A"_G4'[UB%NL^^(BQ_2O/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#QFBBB@#T#X?\ _(&F_P"OAO\ T%:Z:N9^'_\ R!IO^OAO_05KIJ "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AN[.W
MOX6AN8([B%NL<R!E/X&IJ*>VP'GVO?L__#GQ)N^V^#M+#,,%[6'[,Q]]T6TY
M]Z\XU[]AOX?ZGN:PN-6T=\?*L-PLL8^H=2Q_[Z%?1%%>A2S'&4?X=62^?Z'+
M/"T*GQ07W'QQJ7_!/V82N;#QI&T>,JMSIY!!]"1)^N/PK#NOV!O%:9^S>)-&
MF^7CS1+'SZ<*W'O^E?<=%>G'B',8[SO\E_D<;RO"O[/XL^!+O]A?XB6V?+N]
M"NOES^YNY!D^GS1#G]*QKO\ 8T^*-OGR](M+K S^YOXAGV^9AS7Z*45T1XFQ
MT=U%_+_@F3R?#/O]Y^:5W^RO\5++=YGA&X;:,GR;F"3_ -!D.:Q[OX!_$:RW
M>9X*UIMHR?)LWD_]!!S7ZBT5TQXJQ7VJ<?Q_S,GDM'I)_@?E#>?#+QCI^[[5
MX3URVVC+>=ILR8^N5K'O-%U#3]WVJPNK;;][SH63&>F<BOUVHKHCQ9/[5%??
M_P  R>21Z5/P_P""?CY17Z[WFCZ?J&_[58VUSNQN\Z%7SCIG(]JQKSX9^#]0
MW?:O"FB7.[&[SM.A?..F<K[5T1XLA]JB_O\ ^ 9/))=*GX?\$_*&BOU%O/@)
M\.;[=YG@K15W<GR;-(ORV@8_"L>\_99^%E]N\SPC;KN.3Y-Q/'^6UQBNF/%6
M%^U3E^'^9B\EK=)+\3\XK7Q!JECC[-J5Y;\;?W4[KQZ<'I6Q:_%3QI8_\>WB
M_7K?C;^ZU.=>/3ANE?=EY^QK\+;G=Y>C75KDY'DW\QQ[#<QK'N_V&/AU<Y\N
MZUVUR<_N;N,X]OFC-7_K%EM3XXOYI?YLG^R\7'X9+[SY#M?V@?B19_ZOQIK#
M<8_>W+2?^A9K9M?VK/BK:?<\73-QC][:6\G_ *%&:^BKS]@;PF^?LOB/68?F
MX\X0R<>G"+S[UCW?_!/RS?/V7QM/#\W'G::LG'IQ*O/O^E']J9)4^.*^</\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>C+>"^Y'A-W^Q;\,;C/EV.H6ORX_<WSG!]?FSS^E8]W^PCX GR8=3\06S;<
M+<PLN?4@Q9_6OHZBNB.;8^.U:7WF3P.&?_+M'RQ>?L!^''S]E\4ZI#QQYT,<
MG/KQMX]JQKO_ ()]H<FU\<LO'"S:7G)^HF_I7V!171'/<QCM5_!?Y&+RW"/[
M'XO_ #/B>[_8!UY-WV7Q9ITW'R^=;21Y/O@MBL:[_8-\>0[C!J_A^X4#@&>9
M&/X>5C]:^\:*Z8\1YA'>2?R1D\JPKZ/[S\]KS]BCXF6V[R[;3;O'3R;T#=]-
MP'ZUC7G[(_Q6L]Q_X1?ST7'S0WULV?H/,S^E?I%171'BC&K>,7\G_F9/)\.]
MF_Z^1^8EY^SC\3+'?YG@W4FVXSY*++U]-I.?PK'O/@[X\L-WG^"_$$:KU?\
MLR8KS_M!<5^J=%=$>*L1]JG'\3)Y+2Z39^2=YX/U[3]WVK1-1MMIPWG6DB8^
MN165)&\,C)(C(Z\%6&"/PK]@:CFMXKF/9-&DJ==KJ"/R-=$>+)?:H_\ DW_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_#7]NYU\JS\<:3O'W?[3TM<'ZO$3^94_1:^HO!GQ"\.?$+3_ +9X=UBUU6$
M;Q"_SQY[.APRGZ@5\/C,MQ6!?[Z&G?=?>?14,71Q'\.6O;J=%1117F'8%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XS1110!Z!\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >,T444 >@?#_P#Y TW_ %\-_P"@K735S/P__P"0--_U\-_Z"M=-0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 <QXJ^&/A/QLK?V[X=T[4G88\Z:W7S1])
M-P_ UXWXL_8;\":UODT>YU'P],?NI'+Y\(^JOEC_ -]BOHNBN^AC\5AOX-1K
MYZ?=L<U3#4:WQP3/@_Q7^PIXSTG>^B:EIVOQ#[J,QMIF_P" ME?_ !^O&_%?
MPB\:>!]YUOPSJ5C$G6X,!>'_ +^+E?UK]5**^BH<48NGI5BI+[G^&GX'E5,G
MH2^!M?C_ %]Y^/E=5X5^*WC#P/M&A^)-2TZ)>EO'<,8?QC.5/XBOTB\5_!/P
M)XVWMK'A;3KF9_O7$<7DS'ZR1[6_6O&O%?[!_A34M\F@ZUJ&B2GI'.%NHA]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'F_[^-EOUKKJ**\&I4G5?-4DV_/4].,8P5HJR"BBBLR@HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&
M:*** /0/A_\ \@:;_KX;_P!!6NFKF?A__P @:;_KX;_T%:Z:@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KF/%7PQ\)^-E;^W?#NG:D[#'G36Z^:/I(!N'X&NGHJ
MX5)TWS0=GY$RC&2M)7/G3Q9^PWX$UK?)H]SJ/AZ8_=2.7SX1]5?+'_OL5XUX
MK_84\9Z3O?1-2T[7XA]U&8VTS?\  6RO_C]?>%%>[0S['T-.?F7GK^._XGFU
M,MPU3[-O33_@'Y5^*_A%XT\#[SK?AG4K&).MP8"\/_?Q<K^M<A7[!UQ'BOX)
M^!/&V]M8\+:=<S/]ZXCB\F8_62/:WZU]%0XKZ8BE\T_T?^9Y=3)?^?4_O_K]
M#\W?"OQ6\8>!]HT/Q)J6G1+TMX[AC#^,9RI_$5[+X4_;H\;Z/LCUJQTWQ!"/
MO.4-M,?^!)\H_P"^*]8\5_L'^%-2WR:#K6H:)*>D<X6ZB'T!VM^;&O&_%?[$
M?Q!T+?)I9T_Q#".0+6?RI<>ZR;1GV#&O2^NY+F/\6UWW5G]__!./ZOF&%^"]
MO+7\/^ >X^%/VZ/!&L;(]:L=1\/RG[SM&+F%?^!)\Q_[XKV7PK\5/!_C@(-#
M\2:;J,K=(([A1-^,9PP_$5^8WB?X?^)O!<A37=!U#2AG >ZMG1&_W6(VG\#7
M/@D<C@UC5X:P==<^'FU^*_KYFD,VQ%-\M6-_P?\ 7R/V#IKNL:,[L%11DLQP
M /6ORX\+_'/Q]X,54TGQ7J4$*C"PS2^?$OT20,H_ 5D^*OB1XI\;N3KWB#4-
M44G/E7%PQC'T3.T?@*\N/"E;GM*JN7T=_N_X)VO.J?+I!W_K^MC]%_%O[17P
MZ\%[UO\ Q3937"];>Q8W,F?0B/.T_P"\17BWBW]OK2[??'X:\,W5ZW1;C4I5
MA7Z[$W$C\17Q;7>>$_@3X^\;;&TGPMJ$D+]+BXC^SQ$>H>3:I_ UZ]/A_+L(
MN?$ROZNR_3\S@EFF*KOEI*WHKLZWQ;^U]\2O%.](M6BT.W;_ )8Z5"(S_P!]
MMN<?@PKR/5M:U'7KMKK4[^ZU&Y;K-=S-*Y_X$Q)KZ9\)?L$^(+[9)XB\06.E
M1GDPV4;7,GT).U0?H6KVGPC^QI\./#6R2[LKKQ!<+SOU*X.S/LB;5(]FS5O-
M\IP"Y:"3?]U?KI^8E@<;BG>J_O?Z'Y\Z?IMWJUTEK8VLUY<O]V&WC,CM] !D
MUZOX2_9/^)?BS8XT$Z/;M_RVU:008^J<R?\ CM?HAH7AG2/"]K]FT?2[/2K?
M_GG9VZ1*?J% S6G7BXCBJK+2A32]=?\ +]3OI9+!:U97]-#Y%\(_L"6T>R7Q
M/XHEF/\ %;:5"$ _[:/G/_? KVGPC^S/\-_!NQ[7PS;7MPO_ "\:EFZ8GUP^
M5!^@%>HT5\WB,VQN)_B57;LM%^!ZU+!8>C\,%^?YD<%O%:PI##&D,2#"QQJ%
M51Z #I4E%%>2=P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.(_ARU[=3IJ***\L[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ@K15D%%%%9E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M07MXEA:R7$N?+C&3M&30!/17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
M='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!
M_C1_PGFF_P!V?_O@?XT ='17.?\ ">:;_=G_ .^!_C1_PGFF_P!V?_O@?XT
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M7.?\)YIO]V?_ +X'^-'_  GFF_W9_P#O@?XU(SHZ*YS_ (3S3?[L_P#WP/\
M&C_A/--_NS_]\#_&@#HZ*YS_ (3S3?[L_P#WP/\ &C_A/--_NS_]\#_&@#HZ
M*YS_ (3S3?[L_P#WP/\ &C_A/--_NS_]\#_&@#HZ*YS_ (3S3?[L_P#WP/\
M&C_A/--_NS_]\#_&@#HZ*YS_ (3S3?[L_P#WP/\ &C_A/--_NS_]\#_&@#HZ
M*YS_ (3S3?[L_P#WP/\ &C_A/--_NS_]\#_&@#HZ*YS_ (3S3?[L_P#WP/\
M&C_A/--_NS_]\#_&@#HZ*YS_ (3S3?[L_P#WP/\ &C_A/--_NS_]\#_&@#HZ
M*YS_ (3S3?[L_P#WP/\ &C_A/--_NS_]\#_&@#HZ*YS_ (3S3?[L_P#WP/\
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M8V-MI=G!9V=O%:6D"".*"! B1J!@*JC@ #L* )Z*** "BBB@ I" PP1D4M%
M$?D1_P#/-?\ OD4>1'_SS7_OD5)10!'Y$?\ SS7_ +Y%'D1_\\U_[Y%244 1
M^1'_ ,\U_P"^11Y$?_/-?^^14E% $?D1_P#/-?\ OD4>1'_SS7_OD5)10!'Y
M$?\ SS7_ +Y%'D1_\\U_[Y%244 1^1'_ ,\U_P"^11Y$?_/-?^^14E% $?D1
M_P#/-?\ OD4>1'_SS7_OD5)10!'Y$?\ SS7_ +Y%'D1_\\U_[Y%244 1^1'_
M ,\U_P"^11Y$?_/-?^^14E% $?D1_P#/-?\ OD4>1'_SS7_OD5)10!'Y$?\
MSS7_ +Y%'D1_\\U_[Y%244 1^1'_ ,\U_P"^11Y$?_/-?^^14E% $?D1_P#/
M-?\ OD4>1'_SS7_OD5)10!'Y$?\ SS7_ +Y%'D1_\\U_[Y%244 1^1'_ ,\U
M_P"^11Y$?_/-?^^14E% $?D1_P#/-?\ OD4>1'_SS7_OD5)10!'Y$?\ SS7_
M +Y%'D1_\\U_[Y%244 1^1'_ ,\U_P"^11Y$?_/-?^^14E% $?D1_P#/-?\
MOD4>1'_SS7_OD5)10!'Y$?\ SS7_ +Y%'D1_\\U_[Y%244 1^1'_ ,\U_P"^
M11Y$?_/-?^^14E% $?D1_P#/-?\ OD4>1'_SS7_OD5)10!'Y$?\ SS7_ +Y%
M'D1_\\U_[Y%244 1^1'_ ,\U_P"^11Y$?_/-?^^14E% $?D1_P#/-?\ OD4>
M1'_SS7_OD5)10!'Y$?\ SS7_ +Y%'D1_\\U_[Y%244 1^1'_ ,\U_P"^11Y$
M?_/-?^^14E% $?D1_P#/-?\ OD4>1'_SS7_OD5)10!'Y$?\ SS7_ +Y%'D1_
M\\U_[Y%244 1^1'_ ,\U_P"^11Y$?_/-?^^14E% $?D1_P#/-?\ OD4>1'_S
MS7_OD5)10!'Y$?\ SS7_ +Y%'D1_\\U_[Y%244 1^1'_ ,\U_P"^11Y$?_/-
M?^^14E% $?D1_P#/-?\ OD4>1'_SS7_OD5)10!'Y$?\ SS7_ +Y%'D1_\\U_
M[Y%244 1^1'_ ,\U_P"^11Y$?_/-?^^14E% $?D1_P#/-?\ OD4>1'_SS7_O
MD5)10!'Y$?\ SS7_ +Y%'D1_\\U_[Y%244 1^1'_ ,\U_P"^11Y$?_/-?^^1
M4E% $?D1_P#/-?\ OD4>1'_SS7_OD5)10!'Y$?\ SS7_ +Y%'D1_\\U_[Y%2
M44 1^1'_ ,\U_P"^11Y$?_/-?^^14E% $?D1_P#/-?\ OD4>1'_SS7_OD5)1
M0!'Y$?\ SS7_ +Y%'D1_\\U_[Y%244 1^1'_ ,\U_P"^11Y$?_/-?^^14E%
M$?D1_P#/-?\ OD4>1'_SS7_OD5)10!'Y$?\ SS7_ +Y%'D1_\\U_[Y%244 1
M^1'_ ,\U_P"^11Y$?_/-?^^14E% $?D1_P#/-?\ OD4>1'_SS7_OD5)10!'Y
M$?\ SS7_ +Y%'D1_\\U_[Y%244 1^1'_ ,\U_P"^11Y$?_/-?^^14E% $?D1
M_P#/-?\ OD4>1'_SS7_OD5)10!'Y$?\ SS7_ +Y%'D1_\\U_[Y%244 1^1'_
M ,\U_P"^11Y$?_/-?^^14E% $?D1_P#/-?\ OD4>1'_SS7_OD5)10!'Y$?\
MSS7_ +Y%'D1_\\U_[Y%244 1^1'_ ,\U_P"^11Y$?_/-?^^14E% $?D1_P#/
M-?\ OD4>1'_SS7_OD5)10!'Y$?\ SS7_ +Y%'D1_\\U_[Y%244 1^1'_ ,\U
M_P"^11Y$?_/-?^^14E% $?D1_P#/-?\ OD4>1'_SS7_OD5)10!'Y$?\ SS7_
M +Y%'D1_\\U_[Y%244 1^1'_ ,\U_P"^11Y$?_/-?^^14E% $?D1_P#/-?\
MOD4>1'_SS7_OD5)10!'Y$?\ SS7_ +Y%'D1_\\U_[Y%244 1^1'_ ,\U_P"^
M11Y$?_/-?^^14E% $?D1_P#/-?\ OD4>1'_SS7_OD5)10!'Y$?\ SS7_ +Y%
M'D1_\\U_[Y%244 1^1'_ ,\U_P"^11Y$?_/-?^^14E% $?D1_P#/-?\ OD4>
M1'_SS7_OD5)10!'Y$?\ SS7_ +Y%'D1_\\U_[Y%244 1^1'_ ,\U_P"^11Y$
M?_/-?^^14E% $?D1_P#/-?\ OD4>1'_SS7_OD5)10!'Y$?\ SS7_ +Y%'D1_
M\\U_[Y%244 1^1'_ ,\U_P"^11Y$?_/-?^^14E% $?D1_P#/-?\ OD4>1'_S
MS7_OD5)10!'Y$?\ SS7_ +Y%'D1_\\U_[Y%244 1^1'_ ,\U_P"^11Y$?_/-
M?^^14E% $?D1_P#/-?\ OD4>1'_SS7_OD5)10!'Y$?\ SS7_ +Y%'D1_\\U_
M[Y%244 1^1'_ ,\U_P"^11Y$?_/-?^^14E% $?D1_P#/-?\ OD4>1'_SS7_O
MD5)10!'Y$?\ SS7_ +Y%'D1_\\U_[Y%244 1^1'_ ,\U_P"^11Y$?_/-?^^1
M4E% $?D1_P#/-?\ OD4>1'_SS7_OD5)10!'Y$?\ SS7_ +Y%'D1_\\U_[Y%2
M44 1^1'_ ,\U_P"^11Y$?_/-?^^14E% $?D1_P#/-?\ OD4>1'_SS7_OD5)1
M0!'Y$?\ SS7_ +Y%'D1_\\U_[Y%244 1^1'_ ,\U_P"^11Y$?_/-?^^14E%
M$?D1_P#/-?\ OD4>1'_SS7_OD5)10!'Y$?\ SS7_ +Y%'D1_\\U_[Y%244 1
M^1'_ ,\U_P"^11Y$?_/-?^^14E% $?D1_P#/-?\ OD4>1'_SS7_OD5)10!'Y
M$?\ SS7_ +Y%'D1_\\U_[Y%244 1^1'_ ,\U_P"^11Y$?_/-?^^14E% $?D1
M_P#/-?\ OD4>1'_SS7_OD5)10!'Y$?\ SS7_ +Y%'D1_\\U_[Y%244 1^1'_
M ,\U_P"^11Y$?_/-?^^14E% $?D1_P#/-?\ OD4>1'_SS7_OD5)10!'Y$?\
MSS7_ +Y%'D1_\\U_[Y%244 1^1'_ ,\U_P"^11Y$?_/-?^^14E% $?D1_P#/
M-?\ OD4>1'_SS7_OD5)10!'Y$?\ SS7_ +Y%'D1_\\U_[Y%244 1^1'_ ,\U
M_P"^11Y$?_/-?^^14E% $?D1_P#/-?\ OD4>1'_SS7_OD5)10!'Y$?\ SS7_
M +Y%'D1_\\U_[Y%244 1^1'_ ,\U_P"^11Y$?_/-?^^14E% $?D1_P#/-?\
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MFL=2LX+^RF&V2WN8Q)&X]U(P:^LP7$F*P]HU_?C^/W_Y_>>)B,IHU=:?NO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2S;+<TBJ6)23[2_1_P##,\&>!Q>#?/1=UY?JO^'/IGX:?M7>!/B)Y5M)??\
M"/:J_'V/5"$5F]$E^ZWL"03Z5[(&# $'(/0U^0=Y9W&GW4MM=026UQ$VV2&9
M"CH1V(/(->W?LS_&_P 4^%/'WA[P]_:%QJ&@:C=Q6+Z?.QD6(2,%#QYY3:3G
M X(!R.X\O,.&HQA*MA):+6S_ $?^?WG9A<VE*2IUU\U_D?H?1117Y^?3A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!XS1110!Z!\/_\ D#3?]?#?^@K735S/P_\ ^0--_P!?#?\ H*UTU !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ''?$#X1^$OB=:^5XAT
M:WO)0NU+M1LN(_\ =D7#8]LX]17%_#7]E+P3\,?$RZ]8G4-2OX<FV.HS(ZVY
M((RH5%R<$C+9QVP>:]EHKMAC<33I.C&HU%]+Z'/+#TI35245==0HHHKB.@**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /&:*** /0/A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH \9HHHH ] ^'_ /R!IO\ KX;_ -!6NFKF?A__ ,@:;_KX;_T%:Z:@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#QFBBB@#T#X?_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&:
M*** /0/A_P#\@:;_ *^&_P#05KIJYGX?_P#(&F_Z^&_]!6NFH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \9HHHH
M ] ^'_\ R!IO^OAO_05KIJYGX?\ _(&F_P"OAO\ T%:Z:@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBBB@#T#
MX?\ _(&F_P"OAO\ T%:Z:N9^'_\ R!IO^OAO_05KIJ "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/A__
M ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'_ /R!
MIO\ KX;_ -!6NFKF?A__ ,@:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBBB@#T#X?_P#(&F_Z
M^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M (N@#IJ*YG[?XH_Z!MK_ -]#_P"+H^W^*/\ H&VO_?0_^+H Z:BN9^W^*/\
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M[?XH_P"@;:_]]#_XNC[?XH_Z!MK_ -]#_P"+H Z:BN9^W^*/^@;:_P#?0_\
MBZ/M_BC_ *!MK_WT/_BZ .FHKF?M_BC_ *!MK_WT/_BZ/M_BC_H&VO\ WT/_
M (N@#IJ*YG[?XH_Z!MK_ -]#_P"+H^W^*/\ H&VO_?0_^+H Z:BN9^W^*/\
MH&VO_?0_^+H^W^*/^@;:_P#?0_\ BZ .FHKD[GQ%K6E>7-J%C!';%]I,9RQX
M)P/F/I764 %%%% !1110 4444 >,T444 >@?#_\ Y TW_7PW_H*UTU<S\/\
M_D#3?]?#?^@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7,_$#_ ) T/_7PO_H+5TU07EC!J$8CN(EE
M0'<%;U]?UH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#'\7?\B[>?1?_ $(59T'_ ) MC_UP3^0JU<6T5Y"T,R"2-NJMT/>G0Q)!
M$D<:A$0;54=@* 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !535_\ D$WO_7!__035NFR1K-&T;C<C JRGN#0!C>#?^1=MOJ__ *$:VZBM
M;6*SA6&",1QKT5>@[U+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7,^&/^0]KO\ UV_]F:NFJ"WL8+6::6*)4DF.78=6/^30!/1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ',VG_(^7O\ U[C^
M25TU0+8P)=M=")1<,-K2=R../T%3T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5S.I?\ (\:9_P!<3_)ZZ:H)+&"2ZCN6B5IXQA9.X'/^
M)H GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F?B!
M_P @:'_KX7_T%JZ:H+RQ@U",1W$2RH#N"MZ^OZU/0 4444 %%%% !1110!XS
M1110!Z!\/_\ D#3?]?#?^@K735S/P_\ ^0--_P!?#?\ H*UTU !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@$\]JYCXW?%+QM\.[S2H_"GP]NO&L%U'(T\UM(P\AE(PI"HW4$G)]*3]D_\
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MDCY,4:S^?M8CH5C1FP?[X]:^QZ /$OVP_B0WPY^!^L-;3&'4]7(TNU*-A@9
M?,88Y&(P_/8XJ'PCJ5O^S'^S/HUWKT-]J%W;01O/;0Y>>6ZN'SY0R>S2;?HO
M<\'SGXR?\7N_:Z\&> D_?Z)X7C_M+4T_A+G;(RMZ@@0)[>8U?6LS1K&SRE5C
M3YRSXPN.<\],4 ?*VI?M)?&RUT^77Q\&'MO#L2&9TN)G-RL8&2Q'## R3^[X
M_"O9/@1\<]'^/'A%]8TR"2QNK:3R+VPF8,\$F,C!'WE(Z-@9P> 0:H>-?VHO
MAGX/T:YNQXKTO6[E8R8;#2+I+J6=^=J#RRP!)XRV ,\UYI^P;\,]>\%^$O$F
MN:Y82Z4=?N8GMK*92CB*,/\ /L/*AC(0,\X7/0B@#W'XG?%SPM\(=#.I^)M3
MCLD;(@MU^>>X8#[L:#D]N>@R,D5Y-\ OVK+SXW?%36?#3>&O[#TZUTY[^!YY
M6-RP$D**'7  W"7=QTXY/6O8-?\ A;X5\5>+--\2:QHUOJ>KZ;$8;26Z!=(@
M6W9"$[=P/(8C([5\W_!G_D_7XI_]@J7_ -&V= 'UW67XI\16GA#PUJNN7[[+
M+3K62ZF/?:BEB![G&!6I7S/^W7XRN;/X>:1X)TK,FL>++^.U2%#\S1(RD@?6
M1HE]P6H P?V3]8N-#^&_Q"^,OBV>ZF75;F:[,:DOB&$NS>6I..9'9 . /+'(
M%3M^U%\7/$T)U;PK\&KN7P]CS(Y;WS#+/'V9  N<\<*'^IKZ*\ ^![+P+X T
M7PM#''-::?9I:L&4%92%^=B#_>;<Q^M=)0!XY^SS^TII?QXMM0M3I\NA>(]-
MP;O3)GW_ "DE=Z-@$@$8((!4D#N"=OXZ?'31/@1X535=4CDOKRZ<Q6.FP,%D
MN9 ,GD_=49&6P<9'!) /@7[,\<?BO]KGXK>*M%"GP]&DUKY\7W)9))XR&!'!
M#>3(^?<>M3?%9$\=?MX?#_P_>_OM.TNS%R(&7<@D6.:XR0?4I$/P% %W4/VG
M_C-X<TN3Q)K7P=^S^%XQYDN)G2>*/^\W4J .YC '>OH7X5_$[1OB]X+LO$NA
MNYM+C*/#, )()%^]&X'<>W!!!'6NINK6&^M9K:XB6:WF1HY(W&5=2,$$>A!K
MY#_8!N)-'U3XH>%"Y-OINHQ/"N>^Z:-S^44?Y4 >P_&G]ISPK\'=VG$OK_BE
MQ^YT/3SNER1D&1@#Y8^N6P<A2*?^S'\;;WX]> K_ ,07VF0:5-;:G)8"&WD9
MU95BB<-D]_WA'X5NWGPM\*^&%\7^(]/T:WBU[5+>XFNM0<&29B8SD*S$[%/]
MU<"O&?\ @G3_ ,D3UO\ [&&?_P!)K:@#Z'\>>.-)^&_A'4_$FMS&#3=/B\R0
MJ,LQ) 5%&>69B% ]2*^?--_:,^,?CW31K_@SX11S^&G):&;4-019IT&1N52R
M$YQ_"&'8$UZ3^U)\.-4^*?P7UK1-%^?5 T=U!!G'GF-PQCR>,D9QGC.*\L^"
M?[7G@OPS\+[/0O&#W'AKQ!X9L8[&?3YK5]]QY2B-?+ 'WCA<JVT@DG[H) !Z
M5\ ?VC+'XV-JNF7.DW'ASQ3I!Q?:5<MN*C<5+*2 >&&"" 02.O6O8J^7?V5_
M!>N>(/B=XU^,&L:7+H%IXB5H=-T^<%9'A9T?S67MQ''@_P 1+$<8)^HJ "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I:SK5AX=TNYU+5+R#3]
M/MDWS75S((XXU]2QX%7:P/''@71/B-X?ET/Q#9?VAI<LD<LEN9&0,4<.N2I!
MQD#C/- 'S9XD_;RL9?'FBZ-X2T%M5T:\ODLGUB]+PI*2Z*WDKC)"A@<M@\C@
M=3]95\8_MEZ/8>'_ !]\#M.TRRM]/L+>^D2&VM8Q''&OGVO 4# K[.H \!^*
MW[3&L^'/'E]X)\#> ]1\9>(;%8FO)5#+;VWF(LB9*@YRK#DE1D]37(:-^V3X
MB\(>+M/T+XL^!)/"4=\P6/4H6;RER0-Q5LAD&?F97./0U]5)#'&TCHBJTAW.
MRC!8X R?7@ ?A7R3_P %"[JWU;PWX)\+VD2W7B._U;S;6% #)LV-&1[!GDC
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DLJ01O)(ZQQH"S.QP%
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MIRK%;6L8CC09@Z 4 ?95%%8GC;Q7:>!?!^L^(;X_Z+IEI)=.N<%MJDA1[DX
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MRR1G_@-?1G@'6I/$G@7PYJTQS+?Z;;73G_:>)6/ZF@#>HHHH **** "BBB@
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MOQ"T[X5^!=5\4ZK'/-8Z>B%XK90TCL[K&B@$@<LZCD\9KYL_X)P_\D[\5_\
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M_P#D#3?]?#?^@K735S/P_P#^0--_U\-_Z"M=-0 4444 %%%% !1110 4444
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M4B&6Y8<;F=G9L''"^E?0- !1110 4444 %%%% !1110 4444 %%%% !1110
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M'.3U *OPW4>)O^"@'C[4[9?,MM/L3%)(O*K(D5O 03ZY5^/8^E?7]>-_LU_
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MPSZ;I^EZ'()K+P_IC!T9P0W."P"EE4L2S$A=O YKZJH **** "BBB@ HHHH
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MUSCE<[B1W.WTKS3P5X)_:5^'GAJRT'0+'PEI^F6B[8XD\LDGNS'JS$\DGDT
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M_.0?=053_@%>,_'C_B]?[57@;X<Q_OM'T ?VGJJ?PY($A5O8HL2C_KL:^N:
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M<5\X:#\&_C7^SCK&K6OPP.D^*_"=].;B*PU20*T3' RP+Q_,% !96PP4$@=
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M/@7HFE_&35OB4]Y?7VNW]N+9(;ET,%LNU%/E@*"#M0#DG[S>M>CT44 %%%%
M!1110 5YQ\4/@7HGQ;\2>%=5UR\OO*\/7!N8=/A=!!.Q9&_> J21E%'!'&1W
MS7H]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9N"N/N$F1?FZX!Q69'_P3[\(KIB2'Q/XA'B,*'.K+.F/.Q]X)MSC/;=G_:H
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MU2U8J\A4A9<L""0&.P(" Q#$G'0 ^PO-3S#'O7S,;MF><>N/2GU\LS?\$]?
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MSXD_\&]Q_P#%U]A?\,&> /\ H,>)/_ FW_\ C%'_  P9X _Z#'B3_P ";?\
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M?%\6O^O.;_T=;UU_[#_@.XT'X877BS5=TFN>+;IM0FFD^^T0+"//^\3(^?\
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M5]&?\,G^$?\ H(ZU_P!_X?\ XU1_PR?X1_Z".M?]_P"'_P"-4O\ 5_.?YO\
MR8/]8\C_ )/_ "0^<_\ A9/B[_H:=:_\&$W_ ,51_P +)\7?]#3K7_@PF_\
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M2\:?#.V\8>.K!_$^O>(#)=-->W,I,<98@=&&6;&XL<GYL#&.>$U3X1Q?!O\
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MG-_Z.MZSOVL-/UCX0_'CP?\ &/3[-[S2H1':WWEKG8PW(RD]O,B<JI/=3[4
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M>&/^?_5O^_T7_P ;H \'_P"$^\3_ /0QZM_X'2__ !5'_"?>)_\ H8]6_P#
MZ7_XJO>/^&:/#'_/_JW_ '^B_P#C='_#-'AC_G_U;_O]%_\ &Z /!_\ A/O$
M_P#T,>K?^!TO_P 51_PGWB?_ *&/5O\ P.E_^*KWC_AFCPQ_S_ZM_P!_HO\
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MLR?4+SDU!#^QG\)K?P_?Z5%X9"F\38U\]Q))<Q'J&C=R=A!]!@]"""17MU%
M'S/\)?@[\6/@?X\TW1]/\10>)_AC)(XEBO&"S62;6(*JW*G=@81BIR25';Z8
MHHH RO$WA71_&FCS:3KNFVVJZ=-]^WNHPZD]B,]".Q'([5XY_P ,0?"#[?\
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M4A.8969HY8O7;(A# 'N,X.!D&O.M&_8E^$>CWWVH^'IK]E;<D=Y>RO&OMM#
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MBBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'_\ R!IO^OAO_05KIJYGX?\
M_(&F_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#QFBBB@#T#X?\ _(&F_P"OAO\ T%:Z:N9^'_\
MR!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** /&:*** .X\#ZA:VFDRI/<PPN9R0LD@4XVKSR:Z'^V
MM/\ ^?\ M?\ O\O^->67BA;R< 8 D8 #ZU#0!ZS_ &UI_P#S_P!K_P!_E_QH
M_MK3_P#G_M?^_P O^->344 >L_VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^->
M344 >L_VUI__ #_VO_?Y?\:/[:T__G_M?^_R_P"->344 >L_VUI__/\ VO\
MW^7_ !H_MK3_ /G_ +7_ +_+_C7DU% 'K/\ ;6G_ //_ &O_ '^7_&C^VM/_
M .?^U_[_ "_XUY-10!ZS_;6G_P#/_:_]_E_QH_MK3_\ G_M?^_R_XUY-10!Z
MS_;6G_\ /_:_]_E_QH_MK3_^?^U_[_+_ (UY-10!ZS_;6G_\_P#:_P#?Y?\
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MQH_MK3_^?^U_[_+_ (UY-10!ZS_;6G_\_P#:_P#?Y?\ &C^VM/\ ^?\ M?\
MO\O^->344 >L_P!M:?\ \_\ :_\ ?Y?\:/[:T_\ Y_[7_O\ +_C7DU% 'K/]
MM:?_ ,_]K_W^7_&C^VM/_P"?^U_[_+_C7DU% 'K/]M:?_P _]K_W^7_&C^VM
M/_Y_[7_O\O\ C7DU% 'K/]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XU
MY-10!ZS_ &UI_P#S_P!K_P!_E_QH_MK3_P#G_M?^_P O^->344 >L_VUI_\
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M_P#G_M?^_P O^->344 >L_VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^->344
M>L_VUI__ #_VO_?Y?\:/[:T__G_M?^_R_P"->344 >L_VUI__/\ VO\ W^7_
M !H_MK3_ /G_ +7_ +_+_C7DU% 'K/\ ;6G_ //_ &O_ '^7_&C^VM/_ .?^
MU_[_ "_XUY-10!ZS_;6G_P#/_:_]_E_QH_MK3_\ G_M?^_R_XUY-10!ZS_;6
MG_\ /_:_]_E_QH_MK3_^?^U_[_+_ (UY-10!ZS_;6G_\_P#:_P#?Y?\ &C^V
MM/\ ^?\ M?\ O\O^->344 >L_P!M:?\ \_\ :_\ ?Y?\:/[:T_\ Y_[7_O\
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M_P"->344 >L_VUI__/\ VO\ W^7_ !H_MK3_ /G_ +7_ +_+_C7DU% 'K/\
M;6G_ //_ &O_ '^7_&C^VM/_ .?^U_[_ "_XUY-10!ZS_;6G_P#/_:_]_E_Q
MH_MK3_\ G_M?^_R_XUY-10!ZS_;6G_\ /_:_]_E_QH_MK3_^?^U_[_+_ (UY
M-10!ZS_;6G_\_P#:_P#?Y?\ &C^VM/\ ^?\ M?\ O\O^->344 >L_P!M:?\
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M "_XUY-10!ZS_;6G_P#/_:_]_E_QH_MK3_\ G_M?^_R_XUY-10!ZS_;6G_\
M/_:_]_E_QH_MK3_^?^U_[_+_ (UY-10!ZS_;6G_\_P#:_P#?Y?\ &C^VM/\
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MZS_;6G_\_P#:_P#?Y?\ &C^VM/\ ^?\ M?\ O\O^->344 >L_P!M:?\ \_\
M:_\ ?Y?\:/[:T_\ Y_[7_O\ +_C7DU% 'K/]M:?_ ,_]K_W^7_&C^VM/_P"?
M^U_[_+_C7DU% 'K/]M:?_P _]K_W^7_&C^VM/_Y_[7_O\O\ C7DU% 'K/]M:
M?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XUY-10!ZS_ &UI_P#S_P!K_P!_
ME_QH_MK3_P#G_M?^_P O^->344 >L_VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\
MO^->344 >L_VUI__ #_VO_?Y?\:/[:T__G_M?^_R_P"->344 >L_VUI__/\
MVO\ W^7_ !H_MK3_ /G_ +7_ +_+_C7DU% 'K/\ ;6G_ //_ &O_ '^7_&C^
MVM/_ .?^U_[_ "_XUY-10!ZS_;6G_P#/_:_]_E_QH_MK3_\ G_M?^_R_XUY-
M10!ZS_;6G_\ /_:_]_E_QH_MK3_^?^U_[_+_ (UY-10!ZS_;6G_\_P#:_P#?
MY?\ &C^VM/\ ^?\ M?\ O\O^->344 >L_P!M:?\ \_\ :_\ ?Y?\:/[:T_\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670503828160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 23, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-26642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MYRIAD GENETICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0494517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">320 Wakara Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Salt Lake City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">584-3600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MYGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,465,095,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,223,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K:&#160;&#160;Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant's Proxy Statement, to be filed no later than 120 days following December&#160;31, 2022, for the Annual Meeting of Stockholders expected to be held on June 1, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000899923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670503818016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Salt Lake City, UT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670503013536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 56.9<span></span>
</td>
<td class="nump">$ 257.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable investment securities</a></td>
<td class="nump">58.0<span></span>
</td>
<td class="nump">81.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable</a></td>
<td class="nump">101.6<span></span>
</td>
<td class="nump">91.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">20.1<span></span>
</td>
<td class="nump">15.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">17.6<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">20.4<span></span>
</td>
<td class="nump">21.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">274.6<span></span>
</td>
<td class="nump">484.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">103.9<span></span>
</td>
<td class="nump">81.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable investment securities</a></td>
<td class="nump">54.8<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">83.4<span></span>
</td>
<td class="nump">43.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangibles, net</a></td>
<td class="nump">379.7<span></span>
</td>
<td class="nump">404.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">286.8<span></span>
</td>
<td class="nump">239.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">15.5<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,198.7<span></span>
</td>
<td class="nump">1,320.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">28.8<span></span>
</td>
<td class="nump">29.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">94.3<span></span>
</td>
<td class="nump">161.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of operating lease liabilities</a></td>
<td class="nump">14.1<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">137.2<span></span>
</td>
<td class="nump">204.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_UnrecognizedTaxBenefitsNet', window );">Unrecognized tax benefits</a></td>
<td class="nump">26.8<span></span>
</td>
<td class="nump">27.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Long-term deferred taxes</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">35.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">130.9<span></span>
</td>
<td class="nump">79.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">14.5<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">312.9<span></span>
</td>
<td class="nump">352.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 81.2 and 80.0 shares outstanding at December 31, 2022 and 2021, respectively</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,260.1<span></span>
</td>
<td class="nump">1,226.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(8.9)<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(366.2)<span></span>
</td>
<td class="num">(254.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Myriad Genetics, Inc. stockholders' equity</a></td>
<td class="nump">885.8<span></span>
</td>
<td class="nump">967.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">885.8<span></span>
</td>
<td class="nump">967.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,198.7<span></span>
</td>
<td class="nump">$ 1,320.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_UnrecognizedTaxBenefitsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_UnrecognizedTaxBenefitsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670503152192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">81.2<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">74.7<span></span>
</td>
<td class="nump">73.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502290144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 299.8<span></span>
</td>
<td class="nump">$ 678.4<span></span>
</td>
<td class="nump">$ 690.6<span></span>
</td>
<td class="nump">$ 638.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">35.8<span></span>
</td>
<td class="nump">85.4<span></span>
</td>
<td class="nump">81.9<span></span>
</td>
<td class="nump">77.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative expense</a></td>
<td class="nump">260.4<span></span>
</td>
<td class="nump">514.7<span></span>
</td>
<td class="nump">537.8<span></span>
</td>
<td class="nump">507.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Legal charges pending settlement</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">62.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill and long-lived asset impairment charges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">16.9<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">99.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">387.6<span></span>
</td>
<td class="nump">819.0<span></span>
</td>
<td class="nump">881.1<span></span>
</td>
<td class="nump">870.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(87.8)<span></span>
</td>
<td class="num">(140.6)<span></span>
</td>
<td class="num">(190.5)<span></span>
</td>
<td class="num">(231.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(5.8)<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="num">(6.6)<span></span>
</td>
<td class="num">(10.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">139.3<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(6.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">133.4<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(94.1)<span></span>
</td>
<td class="num">(140.6)<span></span>
</td>
<td class="num">(57.1)<span></span>
</td>
<td class="num">(223.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(41.0)<span></span>
</td>
<td class="num">(28.6)<span></span>
</td>
<td class="num">(29.9)<span></span>
</td>
<td class="num">(23.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(53.1)<span></span>
</td>
<td class="num">(112.0)<span></span>
</td>
<td class="num">(27.2)<span></span>
</td>
<td class="num">(199.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Myriad Genetics, Inc. stockholders</a></td>
<td class="num">$ (53.1)<span></span>
</td>
<td class="num">$ (112.0)<span></span>
</td>
<td class="num">$ (27.2)<span></span>
</td>
<td class="num">$ (199.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_EarningsPerShareBasicAndDilutedEPSAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="num">$ (1.39)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (2.69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="num">$ (1.39)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (2.69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">80.6<span></span>
</td>
<td class="nump">78.0<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">80.6<span></span>
</td>
<td class="nump">78.0<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_TestingRevenueMember', window );">Testing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 279.6<span></span>
</td>
<td class="nump">$ 678.4<span></span>
</td>
<td class="nump">$ 666.4<span></span>
</td>
<td class="nump">$ 586.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs and expenses</a></td>
<td class="nump">82.6<span></span>
</td>
<td class="nump">202.0<span></span>
</td>
<td class="nump">185.7<span></span>
</td>
<td class="nump">157.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">51.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs and expenses</a></td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 11.9<span></span>
</td>
<td class="nump">$ 28.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_EarningsPerShareBasicAndDilutedEPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic And Diluted EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_EarningsPerShareBasicAndDilutedEPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_TestingRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_TestingRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670501944736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Myriad Genetics, Inc. stockholders</a></td>
<td class="num">$ (53.1)<span></span>
</td>
<td class="num">$ (112.0)<span></span>
</td>
<td class="num">$ (27.2)<span></span>
</td>
<td class="num">$ (199.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities, net of tax</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Change in foreign currency translation adjustment, net of tax</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (50.2)<span></span>
</td>
<td class="num">$ (115.8)<span></span>
</td>
<td class="num">$ (30.0)<span></span>
</td>
<td class="num">$ (199.4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670501073760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Retained earnings (accumulated deficit)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2019</a></td>
<td class="nump">$ 1,088.9<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 1,068.0<span></span>
</td>
<td class="num">$ (5.4)<span></span>
</td>
<td class="nump">$ 25.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based payment expense</a></td>
<td class="nump">25.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(199.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(199.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary', window );">Reclassification out of accumulated other comprehensive loss upon the deconsolidation of a subsidiary</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">918.2<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1,096.6<span></span>
</td>
<td class="num">(5.2)<span></span>
</td>
<td class="num">(173.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</a></td>
<td class="num">(1.9)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based payment expense</a></td>
<td class="nump">14.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(53.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">881.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1,109.5<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(227.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</a></td>
<td class="nump">80.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based payment expense</a></td>
<td class="nump">36.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(27.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(2.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">967.8<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1,226.3<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
<td class="num">(254.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax</a></td>
<td class="num">(4.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based payment expense</a></td>
<td class="nump">38.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(112.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(112.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(3.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 885.8<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 1,260.1<span></span>
</td>
<td class="num">$ (8.9)<span></span>
</td>
<td class="num">$ (366.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification From Accumulated Other Comprehensive Loss, Deconsolidation Of Subsidiary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502428992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Myriad Genetics, Inc. stockholders</a></td>
<td class="num">$ (53.1)<span></span>
</td>
<td class="num">$ (112.0)<span></span>
</td>
<td class="num">$ (27.2)<span></span>
</td>
<td class="num">$ (199.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">35.8<span></span>
</td>
<td class="nump">52.7<span></span>
</td>
<td class="nump">62.8<span></span>
</td>
<td class="nump">72.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">6.4<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
<td class="nump">12.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Tenant improvement allowance received</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">14.9<span></span>
</td>
<td class="nump">38.1<span></span>
</td>
<td class="nump">36.3<span></span>
</td>
<td class="nump">25.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="nump">44.2<span></span>
</td>
<td class="num">(30.8)<span></span>
</td>
<td class="num">(32.1)<span></span>
</td>
<td class="num">(55.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">7.1<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Non-cash impact of foreign currency transactions</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Loss on inventory</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of goodwill and long-lived assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">16.9<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">99.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Gain on sale of businesses and assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(162.0)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="num">(6.6)<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade accounts receivable</a></td>
<td class="num">(21.4)<span></span>
</td>
<td class="num">(10.3)<span></span>
</td>
<td class="num">(8.8)<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="num">(108.4)<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">89.9<span></span>
</td>
<td class="nump">25.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="num">(10.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(81.2)<span></span>
</td>
<td class="nump">65.7<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(5.0)<span></span>
</td>
<td class="num">(26.6)<span></span>
</td>
<td class="nump">30.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(73.7)<span></span>
</td>
<td class="num">(106.3)<span></span>
</td>
<td class="nump">18.6<span></span>
</td>
<td class="nump">60.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="num">(7.9)<span></span>
</td>
<td class="num">(45.3)<span></span>
</td>
<td class="num">(18.0)<span></span>
</td>
<td class="num">(10.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(57.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets', window );">Proceeds from sale of business and assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">379.1<span></span>
</td>
<td class="nump">21.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable investment securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(103.2)<span></span>
</td>
<td class="num">(147.8)<span></span>
</td>
<td class="num">(60.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities and sales of marketable investment securities</a></td>
<td class="nump">35.9<span></span>
</td>
<td class="nump">128.2<span></span>
</td>
<td class="nump">61.1<span></span>
</td>
<td class="nump">69.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">28.0<span></span>
</td>
<td class="num">(77.5)<span></span>
</td>
<td class="nump">274.4<span></span>
</td>
<td class="nump">19.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from common stock issued under stock-based compensation plans</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">91.8<span></span>
</td>
<td class="nump">13.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of tax withheld for common stock issued under stock-based compensation plans</a></td>
<td class="num">(3.8)<span></span>
</td>
<td class="num">(10.6)<span></span>
</td>
<td class="num">(11.5)<span></span>
</td>
<td class="num">(9.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration recognized at acquisition</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtRestructuringCosts', window );">Fees associated with refinancing of revolving credit facility</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of revolving credit facility</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(226.4)<span></span>
</td>
<td class="num">(8.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="num">(150.6)<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rates on cash, cash equivalents, and restricted cash</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(46.7)<span></span>
</td>
<td class="num">(192.4)<span></span>
</td>
<td class="nump">141.8<span></span>
</td>
<td class="nump">70.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of the period</a></td>
<td class="nump">163.7<span></span>
</td>
<td class="nump">258.8<span></span>
</td>
<td class="nump">117.0<span></span>
</td>
<td class="nump">93.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of the period</a></td>
<td class="nump">$ 117.0<span></span>
</td>
<td class="nump">$ 66.4<span></span>
</td>
<td class="nump">$ 258.8<span></span>
</td>
<td class="nump">$ 163.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IncreaseDecreaseInUnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IncreaseDecreaseInUnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670507948416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Financial Statement Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad Genetics, Inc. (together with its subsidiaries, the&#160;"Company" or "Myriad") is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Myriad develops and offers tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower health care costs. The Company generates revenue by performing tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 17, by providing pharmaceutical and clinical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company currently operates as a single reporting segment.&#160;The Company&#8217;s principal executive office is located in Salt Lake City, Utah.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements for the Company have been prepared in accordance with United States ("U.S.") generally accepted accounting principles (&#8220;GAAP&#8221;) for financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP.&#160;&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates and assumptions include revenue recognition estimates for the average expected reimbursement per test, valuation allowances for deferred income tax assets, certain accrued liabilities, stock-based compensation, purchase accounting, and impairment analysis of goodwill and long-lived assets. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders' equity, or cash flows from operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company&#8217;s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related health care programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately 14%, 17%, 16%, and 15% of total revenue for the years ended December 31, 2022 and 2021, the six-month transition period ended December&#160;31, 2020, and the fiscal year ended June 30, 2020, respectively. Concentrations of credit risk are mitigated due to the number of the Company&#8217;s customers as well as their dispersion across many geographic regions. No payor accounted for&#160;more than 10%&#160;of accounts receivable at&#160;December&#160;31, 2022 or December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents primarily consist of cash and money market deposits with financial institutions.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, the Company is required to maintain cash deposit with certain banks with respect to contractual or other legal obligations, and therefore the use of these cash deposits for general operational purposes is restricted. As of December 31, 2022, restricted cash was approximately $9.5 million, of which $2.0 million was recognized as a current asset and $7.5 million was recognized as a long-term asset. As of December 31, 2021, restricted cash was approximately $1.4 million, of which $1.0 million was recognized as a current asset and $0.4 million was recognized as a long-term asset. The restricted cash amounts are largely comprised of cash held in escrow related to the Company's acquisition of Gateway Genomics, LLC ("Gateway") during the year ended December 31, 2022 and certain divestitures during the year ended December 31, 2021. The current and long-term portions are included in Prepaid expenses and other current assets and Other assets, respectively, on the Consolidated Balance Sheets.  </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Consolidated Balance Sheets that agrees to the amounts included in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Investment Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has classified its marketable investment securities, all of which are debt securities, as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in Accumulated other comprehensive loss in Stockholders&#8217; equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The Company&#8217;s cash equivalents consist of short-term, highly liquid investments that are readily convertible to known amounts of cash.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. Losses are charged against Other income (expense) when a decline in fair value is determined to be other than temporary. The Company reviews several factors to determine whether a loss is other than temporary. These factors include but are not limited to: (i) the extent to which the fair value is less than cost and the cause for the fair value decline, (ii) the financial condition and near term prospects of the issuer, (iii) the length of time a security is in an unrealized loss position and (iv) the Company&#8217;s ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. There were no other-than-temporary impairments recognized during the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020 or during the fiscal year ended June 30, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of supplies such as reagents, plates and testing kits, which are consumed when providing test results, and therefore the Company does not maintain finished goods inventory. Inventories are stated at the lower of cost or market and costs are determined on a first-in, first-out basis.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its inventories for excess quantities and obsolescence.&#160;&#160;Inventories that are considered excess or obsolete are expensed.&#160;&#160;&#160;In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels. The valuation of inventories requires the use of estimates as to the amounts of current inventories that will be sold. These estimates are dependent on management&#8217;s assessment of current and expected orders from the Company&#8217;s customers.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Accounts Receivable</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable represents estimated receivables from customers for revenue recognized related to genetic tests. The Company does not have any off-balance-sheet credit exposure related to its customers and does not require collateral.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method based on the lesser of estimated useful lives of the related assets or lease terms. Equipment items have depreciable lives of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfODUzMw_6379236e-7018-4cbe-9f98-2974e673bf30">five</span> to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful lives or the associated lease terms, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfODY3Nw_ce7f7168-4bc2-4449-b270-c38ee0a58400">one</span> to fifteen years. Repairs and maintenance costs are charged to expense as incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acts as lessee in its lease agreements, which include operating leases for corporate offices, laboratory space, warehouse space, vehicles and certain laboratory and office equipment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is, or contains, a lease at inception. The Company records the present value of lease payments as right-of-use (&#8220;ROU&#8221;) assets and lease liabilities on the Consolidated Balance Sheets. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of lease liabilities as either current or non-current is based on the expected timing of payments due under the Company&#8217;s obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of the Company&#8217;s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The leases have remaining lease terms of 1 year to 15 years, some of which include options to extend the lease term for up to 10 years. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has taken advantage of certain practical expedients offered to registrants at adoption of Accounting Standards Codification ("ASC") 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis and is not included in the recognized ROU assets and lease liabilities. Further, as a practical expedient, all lease contracts are accounted for as one single lease component, as opposed to separating lease and non-lease components to allocate the consideration within a single lease contract.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Other Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible and other long-lived assets are comprised of acquired licenses and technology. Acquired intangible assets are recorded at fair value and amortized over the shorter of the contractual life or the estimated useful life. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred to develop internal-use technology, including certain implementation costs incurred in cloud computing arrangements and hosting arrangements that include an internal-use software license. The Company's cloud computing arrangements or hosting arrangements are primarily service contracts related to information technology. Implementation and development costs for internal-use technology are capitalized as part of Other assets in the Consolidated Balance Sheets. After the implementation of the internal-use cloud computing software or other internal-use technology, the capitalized costs are amortized on a straight-line basis over the estimated useful life of the asset. Costs incurred during the post implementation stage of the project are expensed as incurred. As of December&#160;31, 2022 and 2021, the Company had unamortized software costs of $7.1 million and $6.7 million, respectively. For the years ended December 31, 2022 and 2021, amortization expense for capitalized software costs was $1.2 million and $0.2 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually reviews and monitors long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment by reporting unit on an annual basis as of October 1 and in the interim if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators and competition.&#160;&#160;Impairment of goodwill is first assessed using a qualitative approach.&#160;If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed.&#160;The quantitative analysis involves a comparison of the fair value of the reporting unit with its carrying amount.&#160;If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.&#160;If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Acquisitions</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for acquisitions of entities that include inputs and processes and have the ability to create outputs as business combinations. The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on third-party valuations that use information and assumptions provided by the Company's management, which consider the Company's estimates of inputs and assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, estimated cost savings, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognizes a liability equal to the fair value of the contingent payments expected to be made as of the acquisition date. This liability is remeasured each reporting period and the changes in the fair value are recognized in Selling, general, and administrative expenses in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs associated with acquisitions are expensed as incurred in Selling, general, and administrative expenses in the Consolidated Statements of Operations. Results of operations and cash flows of acquired companies are included in the operating results from the date of acquisition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily generates revenue by performing genetic testing. Testing revenues are primarily derived from the following categories of products: Hereditary Cancer (MyRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight, Prequel, and SneakPeek), and Pharmacogenomics (GeneSight). The Company previously provided pharmaceutical services and clinical services prior to the sale of Myriad RBM, Inc. in July 2021 and Privatklinik Dr. Robert Schindlbeck GmbH &amp; Co. KG in February 2020. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 and the Myriad Autoimmune business in September 2021, the associated revenue from such businesses was included within Testing revenues. See Note 17 for a discussion of these divestitures. Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results or the completion of pharmaceutical and clinical services indicates transfer of control for revenue recognition purposes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents detail regarding the composition of the Company&#8217;s total revenue by product type for the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020, and the fiscal year ended June 30, 2020:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:50.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Testing revenues:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total testing revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the following tables reconcile revenue by geographical region, either U.S. or rest of world ("RoW"), to total revenue:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Testing revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">263.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">305.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">271.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total testing revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">591.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">678.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">579.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">666.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">591.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">678.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">603.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">690.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Testing revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">329.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">347.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total testing revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">255.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">279.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">559.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">586.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">275.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">299.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">596.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">638.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performs its obligation under a contract with a customer by processing tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets.&#160;Occasionally, customers make payments prior to the Company's performance of its contractual obligations.&#160;When this occurs, the Company records a contract liability as Deferred revenue in the Consolidated Balance Sheets. During the fiscal year ended June 30, 2020, the Company received approximat</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ely $29.7&#160;million in a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dvance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments were applied against services performed beginning in April 2021 and continued until the funds previously received were fully earned, which occurred during the quarter ended March 31, 2022. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company&#8217;s right to payment is in an amount that directly corresponds with the value of the Company&#8217;s performance to date. In determining the transaction price, the Company includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with ultimate collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenue in the Consolidated Statements of Operations and Comprehensive Loss. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash collections for certain tests delivered may differ from rates estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third-party payors. As a result of this new information, the Company updates its estimate of the amounts to be recognized for previously delivered tests. During the year ended December&#160;31, 2022, the Company recognized $22.1 million in revenue, which resulted in a $0.21 impact to loss per share for tests in which the performance obligation of delivering the test results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. During the year ended December&#160;31, 2021, the Company recognized $15.9 million in revenue which resulted in a $0.15 impact to loss per share for tests in which the performance obligation of delivering the test results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. Additionally, during the year ended December&#160;31, 2021, revenue of $6.8 million was recognized due to expanded coverage for the Company's Prolaris test, for which revenue was fully constrained in a prior period. During the transition period ended December 31, 2020, the impact to revenue and loss per share for tests in which the performance obligation of delivering the test results was met in the prior period was immaterial. During the fiscal year ended June 30, 2020, the Company recognized a $9.9 million decrease in revenue, which resulted in a $(0.10) impact to loss per share for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third-party payors. In addition, during the fiscal year ended June 30, 2020, the Company identified an error related to prior periods for Medicare claims and reduced revenue and recorded an accrued liability for a total of $4.7 million that will be refunded to Medicare. The impact of correcting the error during that period and the impact to all prior periods was concluded to be immaterial. The correction of the error in the fiscal year ended June 30, 2020 resulted in an impact to loss per share for the fiscal year ended June 30, 2020 of $(0.05).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company has elected to exclude from the measurement of transaction price, all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a customer for sales tax, value added tax, and certain other taxes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Payment Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the fair value compensation cost relating to stock-based payment transactions in accordance with ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation &#8211; Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee&#8217;s requisite service period, which is generally the vesting period. The fair value of restricted stock units (RSUs) and performance restricted stock units (PSUs) that do not have market conditions is based on the number of shares granted and the quoted price of the Company&#8217;s common stock on the grant date. The fair value of PSU awards that have market conditions is determined using the Monte Carlo Method. For PSUs, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company estimates the likelihood of achievement of the performance conditions at the end of each period. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeitures are recognized as a reduction of compensation expense in earnings in the period in which they occur. The fair value of shares issued under the Company's Employee Stock Purchase Plan is calculated using the Black-Scholes option-pricing model, based on assumptions including the risk-free interest rate, expected life, expected dividend yield and expected volatility. The average risk-free interest rate is determined using the U.S. Treasury rate. We determine the expected life based on the offering period of the Employee Stock Purchase Plan. The expected volatility is determined using the weighted average of daily historical volatility of the price of the Company's common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the gain or loss on its divestitures as Other income (expense) in the Consolidated Statement of Operations. During the year ended December&#160;31, 2021, the Company recognized a net gain on divestitures of $162.0 million. See Note 17 for additional information regarding these divestitures. In addition, during the fiscal year ended June 30, 2020, the Company received approximately $14.6 million from the Provider Relief Fund under the CARES Act to reimburse the Company for health care related expenses or lost revenues that were attributable to COVID-19, which was recognized as a component of Other income (expense) in the Consolidated Statements of Operations. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal, state, and foreign income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company&#8217;s filings, including the positions taken therein, are subject to audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the Company's consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (EPS) is computed based on the weighted-average number of shares of common stock outstanding.&#160;&#160;Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding used to compute basic EPS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain outstanding options and RSUs were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive options and RSUs excluded from EPS computation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company&#8217;s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive loss as a separate component of Stockholders&#8217; equity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the cumulative translation adjustments included in Accumulated other comprehensive loss (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies and adopted by the Company as of the specified effective date. During the year ended December 31, 2022, there have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the FASB that have or are expected to have a material impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670504570688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Investment Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">MARKETABLE INVESTMENT SECURITIES</a></td>
<td class="text">MARKETABLE INVESTMENT SECURITIES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value debt securities classified as available-for-sale securities by major security type and class of security at December&#160;31, 2022 and December&#160;31, 2021 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and maturities of debt securities classified as available-for-sale are as follows at December&#160;31, 2022:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2022 and 2021, the transition period ended December 31, 2020, and the fiscal year ended June 30, 2020, the Company sold $28.4 million, $8.3 million, $1.6 million, and $3.4 million of investments, respectively. The amount of gross realized gains and realized losses upon sales of investments were insignificant in all periods presented. As of December&#160;31, 2022, the Company had <span id="i98f7445d1c2e464ba5eec17b1b0524ad_4604"/>118 available-for-sale debt securities in a gross unrealized loss position of $2.7 million, with a fair market value of $111.6 million. As of December&#160;31, 2021, the Company had 100 available-for-sale debt securities in a gross unrealized loss position of $0.2 million, with a fair market value of $77.7 million. As of December 31, 2022 and December 31, 2021, the expected losses were determined to be immaterial and as such, the Company did not record an allowance for credit losses. The Company does not intend to sell these available-for-sale debt securities, and it is not more likely than not that it will be required to sell these securities prior to recovery of their amortized cost basis. Additional information relating to fair value of marketable investment securities can be found in Note 3.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505408112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&#160;Some of the Company&#8217;s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;unobservable inputs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s financial instruments are valued using quoted prices in active markets or based on other observable inputs.&#160;&#160;For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information.&#160;&#160;For Level 3 contingent consideration related to the acquisitions of Sividon Diagnostics GmbH ("Sividon") and Gateway, the Company reassesses the fair value of each expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected contingent consideration liability.&#160;&#160;This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the expected measurement periods of approximately 12.5 and 2.3 years for Sividon and Gateway, respectively, utilizing various potential pay-out scenarios.&#160;&#160;Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the contingent consideration itself, the related projections, and the overall business.&#160;&#160;The contingent consideration liabilities are classified as components of Accrued liabilities and Other long-term liabilities in the Consolidated Balance Sheets.&#160;Changes to contingent consideration liabilities are reflected in Selling, general, and administrative expense in the Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (a)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (a)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.03pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the change in the fair value of the contingent consideration during the periods presented:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration recognized at acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recognized in the statement of operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustments recognized in other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505322656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT, NET</a></td>
<td class="text">PROPERTY, PLANT AND EQUIPMENT, NET<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The property, plant and equipment at December&#160;31, 2022 and December&#160;31, 2021 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company ceased the use of certain leased Salt Lake City facilities and one of its South San Francisco facilities. As a result, the Company recognized a $3.9 million impairment on the property, plant and equipment associated with the leases, which consisted primarily of leasehold improvements.  See Note 13 for further discussion. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company completed the sales of Myriad RBM, Inc. and the Myriad Autoimmune business, which resulted in the disposition of $3.1 million of property, plant and equipment. See Note 17 for additional information regarding these divestitures. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded depreciation during the respective periods as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670622104160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND INTANGIBLE ASSETS</a></td>
<td class="text">GOODWILL AND INTANGIBLE ASSETS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of goodwill for the year ended December&#160;31, 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.836%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired (see Note 16)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2022, the Company acquired Gateway. In connection therewith, the Company recognized $48.7 million of goodwill. See Note 16 for additional information on this acquisition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed goodwill for impairment as part of its annual goodwill testing in accordance with the appropriate guidance (see Note 1) and determined none of its reporting units were impaired as of the annual testing date. The Company did not record an impairment of goodwill for the years ended December 31, 2022 and 2021, or the transition period ended December 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended June 30, 2020, as a result of the effect of COVID-19 on expected future cash flows and a corresponding decline in the Company's market capitalization and enterprise value, the Company performed an interim quantitative impairment review of goodwill for the Myriad Mental Health, Myriad Autoimmune and Myriad International reporting units as of March 31, 2020. Based on this analysis, the Company recognized a goodwill impairment charge of $80.7&#160;million related to the goodwill from the Myriad Autoimmune reporting unit. The goodwill impairment charge is reflected in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations. On July 1, 2021, the Company completed the sale of Myriad RBM, Inc., and as a result the goodwill attributable to the Myriad RBM reporting unit is no longer held by the Company. In addition, on September 13, 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">select operating assets and intellectual property, including the Vectra</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> test, from the Myriad Autoimmune business unit were sold. As a result of this divestiture, the goodwill attributable to the Myriad Autoimmune reporting unit is no longer held by the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended June 30, 2020, the Company also recognized a $1.3 million impairment charge for goodwill allocated to the Clinic asset group that is included in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets have primarily consisted of amortizable assets of developed technologies, customer relationships, and trademarks as well as a non-amortizable intangible asset of in-process research and development.&#160;On November 1, 2022, the Company acquired Gateway. As part of the acquisition, the Company acquired customer relationships, trademarks, and developed technologies of $1.6 million, $6.1 million, and $10.1 million, respectively. See Note 16 for additional information on this acquisition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's developed technologies have estimated remaining useful lives of 8 and 13 years. The Company's trademarks and customer relationships acquired have an estimated remaining useful life of approximately 10 years. Prior to the sale of Myriad RBM, Inc., the estimated useful life of acquired in-process research and development was also evaluated in conjunction with the annual impairment analysis of intangible assets.&#160;The classification of the acquired in-process research and development as an indefinite lived asset was deemed appropriate during prior years as the related research and development was not yet complete nor had it been abandoned. During the fiscal year ended June 30, 2020, the Company decided to abandon the development of one of its in-process research and development intangible assets, and as a result the Company recognized a charge of $17.7 million, which is reflected in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations. The Company concluded there was no impairment of long-lived intangible assets for the years ended December 31, 2022 and 2021 or the transition period ended December 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the amounts reported as intangible assets (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2022:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Carrying Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Useful Life <br/>(in Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Useful Life <br/>(in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Carrying Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Useful Life <br/>(in Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Useful Life <br/>(in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212.5)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded amortization during the respective periods for these intangible assets as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense of intangible assets as of December&#160;31, 2022 is estimated to be as follows (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.906%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortization Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505434736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED LIABILITIES</a></td>
<td class="text">ACCRUED LIABILITIES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accrued liabilities at December&#160;31, 2022 and December&#160;31, 2021 were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal charges pending settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refunds payable and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670508232128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">LONG-TERM DEBT</a></td>
<td class="text">LONG-TERM DEBT<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2016, the Company entered into a senior secured revolving credit facility (the &#8220;Facility&#8221;) as borrower, with the lenders from time to time party thereto. On July 31, 2018, the Company entered into Amendment No. 1 to the Facility, which effected an &#8220;amend and extend&#8221; transaction with respect to the Facility by which the maturity date thereof was extended to July 31, 2023 (the "Maturity Date") and the maximum aggregate principal commitment was increased from $300.0 million to $350.0 million.&#160;&#160;On May 1, 2020, the Company entered into Amendment No. 2 to the Facility, which waived the Company&#8217;s compliance with certain covenants and modified the interest rate and other terms during the modification period from March 31, 2020 through June 30, 2021 (as modified, the "Modification Period&#8221;). This amendment included a modification to the leverage covenant and the interest coverage ratio covenant, which were waived through March 31, 2021, as well as revisions to certain negative covenants of the Facility during the Modification Period. On February 22, 2021, the Company entered into Amendment No. 3 to the Facility, which waived compliance with the leverage ratio and the interest coverage ratio covenants through the quarter ended March 31, 2022 and also lowered the minimum liquidity covenant (which was added by Amendment No. 2) to $150&#160;million, and made it applicable through such quarter. Amendment No. 3 also restricted the Company from borrowing under the Facility if unrestricted cash, cash equivalents and marketable investment securities exceed $150.0&#160;million, unless such borrowings are in connection with permitted acquisitions, decreased the maximum aggregate principal commitment from $350.0&#160;million to $300.0&#160;million, with a further reduction in the maximum aggregate principal commitment from $300.0&#160;million to $250.0&#160;million by September 30, 2021, extended the Modification Period for an additional year through June 30, 2022, and revised certain negative covenants in connection with the extension. The amendments were accounted for as modifications pursuant to guidance in ASC 470-50, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On July 26, 2022, the Company entered into Amendment No. 4 to the Facility (the "Amended Facility"), which extended the Modification Period through the Maturity Date, decreased the maximum aggregate principal commitment from $250.0&#160;million to $200.0&#160;million, with a further reduction to $150.0&#160;million as of December 31, 2022, waived compliance with the leverage ratio and interest coverage ratio covenants through the Maturity Date, and provided for monthly reporting of the Company's liquidity if the total revolving credit exposure is greater than $0, without giving effect to the dollar amount of any letter of credit exposure not in excess of $5.0&#160;million. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covenants in the Amended Facility impose operating and financial restrictions on the Company. These restrictions may prohibit or place limitations on, among other things, the Company&#8217;s ability to incur additional indebtedness under the Amended Facility or otherwise, create certain types of liens, and complete mergers, consolidations, or change in control transactions. The Amended Facility may also prohibit or place limitations on the Company&#8217;s ability to sell assets, pay dividends or provide other distributions to stockholders. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Facility contains customary loan terms, interest rates, representations and warranties, and affirmative and negative covenants, subject to customary limitations, exceptions and exclusions. The Amended Facility also contains certain customary events of default. Amendment No. 2 modified the Facility to increase the interest rate to be fixed at a spread of LIBOR plus 350 basis points on drawn balances and the undrawn fee was increased to 50 basis points during the Modification Period. Amendment No. 4 replaced the option to make Eurodollar borrowings, which bore interest by reference to the LIBOR rate, with term benchmark loans, which will bear interest by reference to the secured overnight financing rate ("SOFR"). Amendment No. 4 did not modify the applicable margins and undrawn fee amounts. The interest rate for term benchmark loans continues to be fixed at a spread of SOFR plus 350 basis points on drawn balances and undrawn fees continue to be 50 basis points. The SOFR floor was revised to 0.0%. The Company was in compliance with all applicable financial covenants at December&#160;31, 2022. </span></div>During the year ended December 31, 2021, the Company made principal repayments totaling $226.4 million to pay off the remaining outstanding balances on the Amended Facility. As a result, the Company had no outstanding balances under the Amended Facility as of December 31, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670622104160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Long-Term Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">OTHER LONG-TERM LIABILITIES</a></td>
<td class="text">OTHER LONG-TERM LIABILITIES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's other long-term liabilities at December&#160;31, 2022 and December&#160;31, 2021 were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The Company&#8217;s balance of other long-term liabilities as of December&#160;31, 2022 and 2021 consisted primarily of the long-term portion of contingent consideration related to the acquisitions of Sividon and Gateway and restricted cash related to the acquisition of Gateway. See Note 16 for additional information on the Gateway acquisition.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670508091264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">PREFERRED AND COMMON STOCKHOLDERS' EQUITY</a></td>
<td class="text">PREFERRED AND COMMON STOCKHOLDERS' EQUITY<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share.&#160;There were no shares of preferred stock outstanding at December&#160;31, 2022 and December&#160;31, 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. There were 81.2&#160;million and 80.0&#160;million shares of common stock issued and outstanding at December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shares of common stock issued and outstanding</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning common stock issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued and outstanding at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchase Program</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company&#8217;s Board of Directors authorized a share repurchase program of $200.0 million of the Company&#8217;s outstanding common stock. The Company may repurchase its common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company&#8217;s management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.&#160;&#160;As of December&#160;31, 2022, the Company had $110.7 million remaining on its current share repurchase authorization. No shares were repurchased during the years ended December&#160;31, 2022 and 2021 under this authorization.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505128528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2017, the Company&#8217;s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the &#8220;2017 Plan&#8221;).&#160;&#160;The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee of the Board of Directors, to make grants of restricted and unrestricted stock and stock unit awards to employees, consultants and directors.&#160;Stockholders have approved amendments to the 2017 Plan increasing the shares available to grant. As of December&#160;31, 2022, the Company had 1.9 million shares of common stock available for grant under the 2017 Plan. If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued or reacquired shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. To the extent that awards outstanding under the Company's prior equity plans expire or are cancelled without delivery of shares of common stock, the shares of common stock underlying these awards also will be available for issuance pursuant to the 2017 Plan. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares, terms, and vesting periods are generally determined by the Company&#8217;s Board of Directors or a committee thereof on an award-by-award basis. RSUs granted to employees generally vest either ratably over four years or as a cliff vesting after three years either on the anniversary of the date on which the RSUs were granted or during the month in which such anniversary dates occur. The number of PSUs awarded to certain employees may be increased or may be reduced based on certain additional performance and market metrics. RSUs granted to non-employee directors vest in full upon the earlier of the completion of one year of service following the date of the grant or the date of the next annual meeting of stockholders following such grant. Options granted to the Company's President and Chief Executive Officer as an inducement to his employment expire seven years from the grant date. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance and market conditions associated with PSU awards granted during the year ended December&#160;31, 2022 include vesting that is based on revenue targets (34% weighting), adjusted earnings per share targets (33% weighting), and relative total stockholder return (33% weighting) measured against the Nasdaq Health Care Index (IXHC) using the 20-trading day averages at the beginning and end of the measurement period. The measurement period for these awards is January 1, 2022 through December 31, 2024. The Company estimates the likelihood of achievement of performance conditions at the end of each period. The portion of the awards pertaining to relative total stockholder return represent market conditions and, accordingly, the estimated fair value of such awards are recognized over the performance period. The Company has also assessed that as of December&#160;31, 2022, the performance conditions for the remaining two performance targets (revenue and adjusted earnings per share) are considered probable of being achieved and, accordingly, these portions of the awards are also being expensed over the performance period. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the transition period ended December 31, 2020, the Company granted stock-based awards to the Company's President and Chief Executive Officer as an inducement material to his commencement of employment and entry into an employment agreement with the Company. The inducement awards are included in the tables presented below. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the Company's equity plans, and inducement awards for the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual<br/>life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no options granted during the years ended December 31, 2022 and 2021 and June&#160;30, 2020. During the transition period ended December&#160;31, 2020, 0.7&#160;million options were granted to the Company's President and Chief Executive Officer, with a weighted average grant fair value of $13.38 and as of December 31, 2022, these were the only options outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU awards activity under the Company's equity plans and inducement awards, including PSU awards for the year ended December&#160;31, 2022, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(number of shares in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>grant date<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs unvested and outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs unvested and outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value of RSUs granted during the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020, and the fiscal year ended June&#160;30, 2020 was $25.78, $29.83, $13.69 and $27.96, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs that vested during the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020, and the fiscal year ended June&#160;30, 2020 was $31.0 million, $22.6 million, $29.1 million and $32.4 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized and included in the Consolidated Statements of Operations was allocated as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of testing revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $64.3 million of total unrecognized stock-based compensation expense that will be recognized over a weighted-average period of 2.0 years. The Company recognizes forfeitures as they occur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of options outstanding</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of options fully vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of RSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic value of options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an Employee Stock Purchase Plan that was initially approved by stockholders in 2012 and was amended and approved by the Board of Directors of the Company on September 23, 2021 and the stockholders on June 2, 2022 (the &#8220;Amended and Restated 2012 Purchase Plan&#8221;), under which 4.0&#160;million shares of common stock were authorized. Shares are issued under the Amended and Restated 2012 Purchase Plan twice yearly at the end of each offering period and the number of shares that may be purchased by any participant during an offering period is limited to 5,000 shares. As of December&#160;31, 2022, 1.7 million shares of common stock were available for issuance under the Amended and Restated Purchase Plan. Shares purchased under, and compensation expense associated with, the Amended and Restated 2012 Purchase Plan for the periods reported are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under the plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan compensation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of shares issued under the Amended and Restated 2012 Purchase Plan that was in effect for each period reported was calculated using the Black&#8209;Scholes option-pricing model using the weighted-average assumptions below. Each of these inputs is subjective and its determination generally requires significant judgment.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670596379904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit consists of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income taxes consists of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140.6)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.1)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94.1)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223.3)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between income taxes at the statutory federal income tax rate and income taxes reported in the Consolidated Statements of Operations were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.880%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax expense at the statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incentive stock option and employee stock purchase plan expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARES Act</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible meals and entertainment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible officer compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible legal settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, dispositions, and contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax benefit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s deferred tax assets and liabilities were comprised of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 capitalized costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act (TCJA), passed in 2017, amended Section 174 of the Internal Revenue Code to require that specific research and experimental (R&amp;E) expenditures be capitalized and amortized over five years for U.S. R&amp;E expenditures or 15 years for non-US R&amp;E expenditures beginning in the Company&#8217;s fiscal year ended December 31, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although Congress has considered legislation that would defer, modify or repeal the capitalization and amortization requirement, there is no assurance that the provision will be deferred, repealed or otherwise modified.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the requirement is not modified, the Company may be required to utilize some of its federal and state tax attributes and there may be increases to state cash taxes or tax expense.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred a cumulative three-year loss. Pursuant to ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the negative evidence of a cumulative loss may be difficult to overcome. However, the Company will have significant future taxable income resulting from the reversal of taxable temporary differences. Primarily due to the availability of such expected future taxable income, the Company concluded that it is more likely than not that the benefits of the majority of its deferred income tax assets will be realized. However, for certain deferred tax assets a valuation allowance has been established, primarily due to limitations imposed by Section 382 of the Internal Revenue Code and certain jurisdictional limitations. For the year ended December&#160;31, 2022, the Company's valuation allowance increased by $3.9&#160;million, primarily due to the anticipated inability to utilize deferred tax assets related to state attributes and credits. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the Company had the following net operating loss and research credit carryforwards (tax effected), with their respective expiration periods. Certain carryforwards are subject to the limitations of Section 382 and 383 of the Internal Revenue Code as indicated (in millions):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carryforwards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Subject to<br/>sections 382, 383</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expires<br/>beginning in year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Through</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal net operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal capital loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utah net operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California net operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other state net operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign net operating losses (various jurisdictions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal research credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utah research credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California research credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the cumulative losses that have been incurred to date in foreign operations, the changes of the Tax Cuts and Jobs Act and the election to treat its foreign subsidiaries as disregarded entities, no deferred taxes related to the Company&#8217;s foreign operations have been recorded. For those foreign entities for which an election has been made to be treated as disregarded for U.S. tax purposes, the appropriate U.S. jurisdiction deferred tax assets and liabilities have been recorded.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement criteria as set forth in ASC 740. As of December&#160;31, 2022, the Company had net unrecognized tax benefits of $31.9 million. The Company&#8217;s gross unrecognized tax benefits as of the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020 and the fiscal year ended June 30, 2020, and the changes in those balances are as follows:&#160;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:52.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.949%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at the beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - statute lapse</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and penalties in year-end balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties related to uncertain tax positions are included as a component of Income tax benefit and all other interest and penalties are included as a component of Other income (expense) in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files U.S. federal, foreign and state income tax returns in jurisdictions with various statutes of limitations. The Company is currently under audit by the state of California for years ended June 30, 2017 and 2018.&#160;&#160;Annual tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505219040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved from time to time in various disputes, claims and legal actions, including class actions and other litigation, including the matters described below, arising in the ordinary course of business. Such actions may include allegations of negligence, product or professional liability or other legal claims, and could involve claims for substantial compensatory and punitive damages or claims for indeterminate amounts of damages. The Company is also involved, from time to time, in investigations by governmental agencies regarding its business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of the government or private payors. The Company has received subpoenas from time to time related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations or other laws.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to defend its current litigation matters, but cannot provide any assurance as to the ultimate outcome or that an adverse resolution would not have a material adverse effect on its financial condition, results of operations or cash flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses legal contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. When evaluating legal contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the proceedings may be in early stages, there may be uncertainty as to the outcome of pending appeals or motions, there may be significant factual issues to be resolved, and there may be complex or novel legal theories to be presented. In addition, damages may not be specified or the damage amounts claimed may be unsupported, exaggerated or unrelated to possible outcomes, and therefore, such amounts are not a reliable indicator of potential liability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company has not recorded any material accrual for loss contingencies associated with legal proceedings or other matters or determined that an unfavorable outcome is probable and reasonably estimable in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. However, it is possible that the ultimate resolution of legal proceedings or other matters, if unfavorable, may be material to the Company's results of operations, financial condition or cash flows. Further, in the event that damages from an unfavorable resolution of one or more of these proceedings exceed the aggregate amount of the coverage limits of the Company&#8217;s insurance, or if the Company&#8217;s insurance carriers disclaim coverage, the amounts payable by the Company could also have a material adverse impact on the Company&#8217;s results of operations, financial condition or cash flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Class Action</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 27, 2019, a class action complaint was filed in the U.S. District Court for the District of Utah, against the Company, its former President and Chief Executive Officer, Mark C. Capone, and its Chief Financial Officer, R. Bryan Riggsbee (Defendants). On February 21, 2020, the plaintiff filed an amended class action complaint, which added the Company's former Executive Vice President of Clinical Development, Bryan M. Dechairo, as an additional Defendant. This action, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">In re Myriad Genetics, Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (No. 2:19-cv-00707-DBB), is premised upon allegations that the Defendants made false and misleading statements regarding the Company's business, operations, and acquisitions.&#160;&#160;The lead plaintiff seeks the payment of damages allegedly sustained by it and the purported class by reason of the allegations set forth in the amended complaint, plus interest, and legal and other costs and fees.&#160;On March 16, 2021, the U.S. District Court for the District of Utah denied the Company's motion to dismiss.&#160;On December 1, 2021, the U.S. District Court for the District of Utah granted plaintiff's motion for class certification. The parties currently are engaged in discovery.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Derivative Actions </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2021, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Company's former President and Chief Executive Officer, Mark C. Capone, its Chief Financial Officer, R. Bryan Riggsbee, its former Executive Vice President of Clinical Development, Bryan M. Dechairo, and certain of the Company's current and former directors, Lawrence C. Best, Walter Gilbert, John T. Henderson, Heiner Dreismann, Dennis Langer, Lee N. Newcomer, S. Louise Phanstiel, and Colleen F. Reitan (collectively, the Individual Defendants), and the Company, as nominal defendant. The complaint is premised upon similar allegations as set forth in the securities class action, including that the Individual Defendants made false and misleading statements regarding the Company's business and operations. The plaintiff, Donna Hickock, asserts breach of fiduciary duty and unjust enrichment claims against the Individual Defendants and seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches, or disgorgement or restitution, from each of the Individual Defendants, plus interest. Plaintiff Hickock also seeks legal and other costs and fees relating to this action. On November 19, 2021, this action was stayed by the Delaware Court of Chancery pending the resolution of the securities class action lawsuit. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and the Hickock stockholder derivative action. The plaintiff, Esther Kogus, asserts that the Individual Defendants breached their fiduciary duties and also asserts unjust enrichment and aiding and abetting breaches of fiduciary duty claims against the Individual Defendants. Plaintiff Kogus seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches and claims, and restitution from the Individual Defendants. On behalf of herself, plaintiff Kogus seeks legal and other costs and fees relating to this action.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2022, the Delaware Court of Chancery consolidated the Hickock and Kogus derivative actions and stayed the consolidated action.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2021, a stockholder derivative complaint was filed in the U.S. District Court in the District of Delaware against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and Hickock stockholder derivative action. The plaintiff, Karen Marcey, asserts that the Individual Defendants violated U.S. securities laws and breached their fiduciary duties, and also asserts unjust enrichment, waste of corporate assets and insider trading claims against all or some of the Individual Defendants. Plaintiff Marcey seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged violations and restitution from the Individual Defendants, plus interest and, on behalf of herself, legal and other costs and fees relating to this action. On January 4, 2022, this action was stayed by the U.S. District Court for the District of Delaware pending the resolution of the securities class action lawsuit. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 21, 2020, Ravgen, Inc. filed a lawsuit against the Company and its wholly owned subsidiary, Myriad Women's Health, Inc., in the U.S. District Court for the District of Delaware, alleging infringement of two Ravgen-owned patents. The lawsuit seeks monetary damages, enhancement of those damages for willfulness, injunctive relief, and recovery of attorney's fees and costs. Various third parties have filed challenges to the validity of the asserted patents with the U.S. Patent and Trademark Office, which challenges have been instituted for review. On March 14, 2022, the case was stayed pending the outcome of the first of these validity challenges. On February 13, 2022, the court lifted the stay and litigation of the case has resumed. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2022, a purported class action lawsuit was filed against the Company in the U.S. District Court in the Northern District of California by Ashley Carroll. Plaintiff alleges, among other things, that the Company made false statements about the accuracy of its Prequel prenatal screening test. The complaint seeks unspecified monetary damages and injunctive relief. On April 1, 2022, the Company filed a motion to dismiss the lawsuit. On May 2, 2022, the plaintiff amended her complaint. On June 2, 2022, the Company filed a motion to dismiss the amended complaint. On July 26, 2022, the court granted and denied in part the Company's motion to dismiss the amended complaint. As part of the court's order, plaintiff was granted leave to file a second amended complaint. The plaintiff filed a second amended complaint on August 16, 2022. On September 6, 2022, the Company filed a motion to dismiss the second amended complaint. On November 9, 2022, the Court granted and denied in part the Company's motion to dismiss the second amended complaint.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505160880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES The Company leases certain office spaces and research and development laboratory facilities, vehicles, and office equipment with remaining lease terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzE4MA_55b83f90-88ae-4e25-9b41-229696ec6103">one</span> to fifteen years. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options, which allows the Company to, at its election, renew or extend the lease for a fixed period of time. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. During the twelve months ended December&#160;31, 2022, in an effort to reduce its real estate footprint, the Company ceased the use of certain of its leased Salt Lake City facilities and one of its South San Francisco facilities. As a result, the Company recorded an impairment charge on ROU assets of $13.0 million and an impairment charge of $3.9 million on the related property, plant and equipment, which consisted primarily of leasehold improvements. The total $16.9 million impairment is included in Goodwill and long-lived asset impairment charges in the Consolidated Statement of Operations.<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the year ended December&#160;31, 2022, the Company incurred $22.1 million in lease costs which are included in operating expenses in the Consolidated Statements of Operations in relation to these operating leases. Of such lease costs, $3.2&#160;million was variable lease expense, which was not included in the measurement of the Company's operating ROU assets and lease liabilities. The variable rent expense is comprised primarily of the Company's proportionate share of operating expenses, property taxes, and insurance and is classified as lease expense due to the Company's election to not separate lease and non-lease components. For the year ended December&#160;31, 2021, the Company incurred $20.7 million in lease costs which are included in operating expenses in the Consolidated Statements of Operations in relation to these operating leases. Of such lease costs, $3.2 million was variable lease expense, which was not included in the measurement of the Company's operating ROU assets and lease liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, the Company entered into a non-cancelable operating lease for approximately 230,000 square feet in west Salt Lake City, Utah. The lease has a term of 15 years, which, along with rent payments, are expected to commence in the third quarter of 2023. The Company will take possession of the leased facility in phases, which began in the three months ended June 30, 2022. As a result, the Company has recognized the related lease balances for the phase, or portion, of the leased facility that the Company has taken possession of, and will recognize the additional phases of the leased facility as possession occurs. As of December&#160;31, 2022, the Company has recognized an approximately $13.9 million ROU asset and corresponding lease liability, net of tenant improvement allowance not yet received. Total future rent payments under the lease are approximately $78.0&#160;million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also took possession of a lease for approximately 63,000 square feet in South San Francisco, California with a term of 10 years, which, along with rent payments, are expected to commence in the third quarter of 2023. As a result, the Company recognized the related ROU asset and lease liability, net of tenant improvement allowance not yet received, of $30.7 million in the Consolidated Balance Sheets as of December&#160;31, 2022. Total future rent payments under the lease are approximately $58.8&#160;million. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the maturities of the Company&#8217;s operating lease liabilities were as follows (in millions):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: leases not yet commenced</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current maturities of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the weighted average remaining lease term is 10.3 years and the weighted average discount rate used to determine the operating lease liability was 5.87%. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company's leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating the Company&#8217;s incremental borrowing rates, the Company gives consideration to its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary. The lease term used may reflect any option to extend or terminate the lease when it is reasonably certain the Company will exercise such options. Lease expenses for the Company's operating leases are recognized on a straight-line basis over the lease term.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505092384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Deferred Savings Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE DEFERRED SAVINGS PLAN</a></td>
<td class="text">EMPLOYEE DEFERRED SAVINGS PLAN<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a deferred savings plan which qualifies under Section&#160;401(k) of the Internal Revenue Code. Substantially all of the Company&#8217;s U.S. employees are covered by the plan. The Company makes matching contributions of 50% of each employee&#8217;s contribution with the employer&#8217;s contribution not to exceed 4% of the employee&#8217;s compensation. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s recorded contributions to the plan are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:50.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred savings plan contributions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505219040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Related Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT AND RELATED INFORMATION</a></td>
<td class="text">SEGMENT AND RELATED INFORMATION<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business is aligned with how the chief operating decision maker ("CODM") reviews performance and makes decisions in managing the Company. On July 1, 2021, the Company completed the divestiture of Myriad RBM, Inc., and, as a result, now operates a single reporting segment. Prior to the sale, the Myriad RBM, Inc. operating segment was included in the Company&#8217;s previously reported "other" segment. The Company&#8217;s remaining operations have been aggregated into a single reporting segment, which primarily provides testing that helps assess an individual&#8217;s risk for developing disease or disease progression and guides treatment decisions across medical specialties where genetic insights can significantly improve patient health care and lower health care costs, and includes corporate services such as finance, human resources, legal and information technology. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. The CODM evaluates segment performance based on operating income (loss).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles assets by geographical region to total assets:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Net equipment, leasehold improvements and property:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable investment securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,320.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505225152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">BUSINESS ACQUISITION</a></td>
<td class="text">BUSINESS ACQUISITION<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2022, the Company acquired all of the membership interests of Gateway, a San Diego-based personal genomics company and developer of consumer genetic tests that give families insight into their future children.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition date fair value of the consideration transferred was $68.7&#160;million. Cash consideration amounted to $66.6&#160;million, of which $8.5&#160;million was deposited for general representation and warranty and working capital adjustment purposes in an escrow account, legally owned by the Company. The remaining consideration included contingent cash consideration with a fair value of $2.1&#160;million. The contingent consideration is classified as a liability and has a maximum value of up to $32.5&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on the achievement of certain performance-based targets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The acquisition date fair value of the contingent consideration was based on the Monte Carlo Method, utilizing various pay-out scenarios that factor in forecasted revenue, earnings before interest, taxes, depreciation and amortization ("EBITDA"), and Prequel and FirstGene test volumes that directly result from the sale of the SneakPeek Gender DNA Test relative to targets for fiscal 2023 and 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition is being accounted for under the acquisition method of accounting in accordance with ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The consideration transferred was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date. Management estimated the fair value of tangible and intangible assets and liabilities in accordance with the applicable accounting guidance for business combinations and utilized the services of third-party valuation consultants. The significant assumptions used in the model to estimate the value of the intangible assets included projected cash flows, discount rates, net working capital and long-term growth rate. The initial allocation of the consideration transferred is based on a preliminary valuation and is subject to adjustments. Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible), liabilities assumed, as well as tax-related matters. During the measurement period, the Company may record adjustments to the provisional amounts recognized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management estimated that consideration paid exceeded the fair value of the net assets acquired. Therefore, goodwill of $48.7&#160;million was recorded. The goodwill recognized is primarily attributable to the expected synergies to be achieved from the business combination and is deductible for income tax purposes. The following table summarizes the estimated fair value of identified assets acquired and liabilities assumed at the date of acquisition. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable assets acquired</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,800&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,914&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(939)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of Purchase Price</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,698&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Identifiable Intangible Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the identifiable intangible assets and related useful lives were determined using an income approach discounting expected future cash flows to present value at a discount rate of 15.5%. The discount rate was based on the estimated internal rate of return for the acquisition and represents the rate that market participants might use to value the intangible assets. The Company will amortize the intangible assets on a straight-line basis over their estimated useful lives. The estimated useful life of the customer relationships and trademarks is 10 years and the estimated useful life of the developed technology is 8 years. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transactions Separate From the Business Acquisition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the business acquisition, the Company also recognized certain transactions which were accounted for separately from the acquisition of assets and assumptions of liabilities in the business acquisition. Compensation expense of $1.9&#160;million was paid at the closing of the transaction pursuant to a retention arrangement with Gateway employees that was negotiated in connection with their retention by the Company. Receipt of the additional amounts available under the retention arrangement is contingent upon future service from the employees and the achievement of certain performance-based targets related to revenue and EBITDA. The $1.9&#160;million of compensation expense is recognized in Selling, general, and administrative expense in the Consolidated Statement of Operations for the year ended December 31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also incurred approximately $3.1&#160;million of acquisition-related costs in connection with the acquisition of Gateway, which has been recognized as an expense in Selling, general, and administrative expense in the Consolidated Statement of Operations in the period incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro Forma Information (Unaudited)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma results presented below include the effects of Gateway acquisition as if it had been consummated as of January 1, 2021, with adjustments to give effect to pro forma events that are directly attributable to the acquisition, which includes adjustments related to the amortization of acquired intangible assets, interest income and expense, and depreciation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma results do not reflect any operating efficiency or potential cost savings that may result from the consolidation of Gateway with the Company. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operation of the combined company would have been if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations and are not necessarily indicative of results that might have been achieved had the acquisition been consummated as of January 1, 2021. The Company did not have any material, nonrecurring pro forma adjustments directly attributable to the business acquisition included in the reported pro forma earnings.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,686)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue and net loss from Gateway included in the Company's Consolidated Statements of Operations since the acquisition date through December 31, 2022 is $3.3 million and $2.8 million, respectively. Of the $2.8 million net loss recognized, $1.9&#160;million is the compensation expense paid at the closing of the transaction discussed above.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670503108256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">DIVESTITURES</a></td>
<td class="text">DIVESTITURES<div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 28, 2021, the Company completed the sale of the Myriad myPath, LLC laboratory to Castle Biosciences, Inc. for cash consideration of $32.5&#160;million. The transaction was accounted for as a sale of assets and the Company recognized a gain of $31.2&#160;million, net of transaction costs of $1.3&#160;million, in Other income (expense) in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021, the Company completed the sale of Myriad RBM, Inc., then a wholly owned subsidiary of the Company, to IQVIA RDS, Inc., for cash consideration of $197.0&#160;million. The transaction was accounted for as a sale of a business and the Company recognized a gain of $121.0&#160;million, net of transaction costs of $4.8&#160;million, in Other income (expense) in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 13, 2021, the Company completed the sale of select operating assets and intellectual property, including the Vectra test, from the Myriad Autoimmune business unit to Laboratory Corporation of America Holdings for cash consideration of $150.0&#160;million. The transaction was accounted for as a sale of a business and the Company recognized a loss of $0.6&#160;million, net of transaction costs of $4.4&#160;million, in Other income (expense) in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating results of these businesses do not qualify for reporting as discontinued operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the divestiture transactions, the Company recognized losses of $5.2&#160;million and $6.5&#160;million for a non-cancelable inventory purchase commitment and inventory, respectively, during the year ended December 31, 2021, as t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company no longer had use for the goods. Both of these losses are included in Other income (expense) in the Consolidated Statements of Operations for the year ended December, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the amounts recognized in Other income (expense) for the year ended December 31, 2021:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of Myriad RBM, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of the Myriad myPath, LLC laboratory</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on sale of Myriad Autoimmune assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505219040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">SUPPLEMENTAL CASH FLOW INFORMATION</a></td>
<td class="text">SUPPLEMENTAL CASH FLOW INFORMATION<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's supplemental cash flow information for the respective periods are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received for income tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of operating lease right-of-use assets and lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant improvement allowance not yet received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment in accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities and other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI https://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502263152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Financial Statement Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Financial Statement Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad Genetics, Inc. (together with its subsidiaries, the&#160;"Company" or "Myriad") is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Myriad develops and offers tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower health care costs. The Company generates revenue by performing tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 17, by providing pharmaceutical and clinical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company currently operates as a single reporting segment.&#160;The Company&#8217;s principal executive office is located in Salt Lake City, Utah.  </span></div>The accompanying consolidated financial statements for the Company have been prepared in accordance with United States ("U.S.") generally accepted accounting principles (&#8220;GAAP&#8221;) for financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates and assumptions include revenue recognition estimates for the average expected reimbursement per test, valuation allowances for deferred income tax assets, certain accrued liabilities, stock-based compensation, purchase accounting, and impairment analysis of goodwill and long-lived assets. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders' equity, or cash flows from operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company&#8217;s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related health care programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately 14%, 17%, 16%, and 15% of total revenue for the years ended December 31, 2022 and 2021, the six-month transition period ended December&#160;31, 2020, and the fiscal year ended June 30, 2020, respectively. Concentrations of credit risk are mitigated due to the number of the Company&#8217;s customers as well as their dispersion across many geographic regions. No payor accounted for&#160;more than 10%&#160;of accounts receivable at&#160;December&#160;31, 2022 or December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsThe Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents primarily consist of cash and money market deposits with financial institutions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">Restricted CashIn certain circumstances, the Company is required to maintain cash deposit with certain banks with respect to contractual or other legal obligations, and therefore the use of these cash deposits for general operational purposes is restricted. The restricted cash amounts are largely comprised of cash held in escrow related to the Company's acquisition of Gateway Genomics, LLC ("Gateway") during the year ended December 31, 2022 and certain divestitures during the year ended December 31, 2021. The current and long-term portions are included in Prepaid expenses and other current assets and Other assets, respectively, on the Consolidated Balance Sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Investment Securities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Investment Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has classified its marketable investment securities, all of which are debt securities, as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in Accumulated other comprehensive loss in Stockholders&#8217; equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The Company&#8217;s cash equivalents consist of short-term, highly liquid investments that are readily convertible to known amounts of cash.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. Losses are charged against Other income (expense) when a decline in fair value is determined to be other than temporary. The Company reviews several factors to determine whether a loss is other than temporary. These factors include but are not limited to: (i) the extent to which the fair value is less than cost and the cause for the fair value decline, (ii) the financial condition and near term prospects of the issuer, (iii) the length of time a security is in an unrealized loss position and (iv) the Company&#8217;s ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. There were no other-than-temporary impairments recognized during the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020 or during the fiscal year ended June 30, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of supplies such as reagents, plates and testing kits, which are consumed when providing test results, and therefore the Company does not maintain finished goods inventory. Inventories are stated at the lower of cost or market and costs are determined on a first-in, first-out basis.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its inventories for excess quantities and obsolescence.&#160;&#160;Inventories that are considered excess or obsolete are expensed.&#160;&#160;&#160;In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels. The valuation of inventories requires the use of estimates as to the amounts of current inventories that will be sold. These estimates are dependent on management&#8217;s assessment of current and expected orders from the Company&#8217;s customers.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade Accounts Receivable</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Accounts Receivable</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable represents estimated receivables from customers for revenue recognized related to genetic tests. The Company does not have any off-balance-sheet credit exposure related to its customers and does not require collateral.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method based on the lesser of estimated useful lives of the related assets or lease terms. Equipment items have depreciable lives of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfODUzMw_6379236e-7018-4cbe-9f98-2974e673bf30">five</span> to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful lives or the associated lease terms, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfODY3Nw_ce7f7168-4bc2-4449-b270-c38ee0a58400">one</span> to fifteen years. Repairs and maintenance costs are charged to expense as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acts as lessee in its lease agreements, which include operating leases for corporate offices, laboratory space, warehouse space, vehicles and certain laboratory and office equipment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is, or contains, a lease at inception. The Company records the present value of lease payments as right-of-use (&#8220;ROU&#8221;) assets and lease liabilities on the Consolidated Balance Sheets. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of lease liabilities as either current or non-current is based on the expected timing of payments due under the Company&#8217;s obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of the Company&#8217;s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The leases have remaining lease terms of 1 year to 15 years, some of which include options to extend the lease term for up to 10 years. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has taken advantage of certain practical expedients offered to registrants at adoption of Accounting Standards Codification ("ASC") 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis and is not included in the recognized ROU assets and lease liabilities. Further, as a practical expedient, all lease contracts are accounted for as one single lease component, as opposed to separating lease and non-lease components to allocate the consideration within a single lease contract.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets and Other Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Other Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible and other long-lived assets are comprised of acquired licenses and technology. Acquired intangible assets are recorded at fair value and amortized over the shorter of the contractual life or the estimated useful life. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred to develop internal-use technology, including certain implementation costs incurred in cloud computing arrangements and hosting arrangements that include an internal-use software license. The Company's cloud computing arrangements or hosting arrangements are primarily service contracts related to information technology. Implementation and development costs for internal-use technology are capitalized as part of Other assets in the Consolidated Balance Sheets. After the implementation of the internal-use cloud computing software or other internal-use technology, the capitalized costs are amortized on a straight-line basis over the estimated useful life of the asset. Costs incurred during the post implementation stage of the project are expensed as incurred. As of December&#160;31, 2022 and 2021, the Company had unamortized software costs of $7.1 million and $6.7 million, respectively. For the years ended December 31, 2022 and 2021, amortization expense for capitalized software costs was $1.2 million and $0.2 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually reviews and monitors long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment by reporting unit on an annual basis as of October 1 and in the interim if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators and competition.&#160;&#160;Impairment of goodwill is first assessed using a qualitative approach.&#160;If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed.&#160;The quantitative analysis involves a comparison of the fair value of the reporting unit with its carrying amount.&#160;If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.&#160;If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Acquisitions</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Acquisitions</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for acquisitions of entities that include inputs and processes and have the ability to create outputs as business combinations. The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on third-party valuations that use information and assumptions provided by the Company's management, which consider the Company's estimates of inputs and assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, estimated cost savings, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognizes a liability equal to the fair value of the contingent payments expected to be made as of the acquisition date. This liability is remeasured each reporting period and the changes in the fair value are recognized in Selling, general, and administrative expenses in the Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs associated with acquisitions are expensed as incurred in Selling, general, and administrative expenses in the Consolidated Statements of Operations. Results of operations and cash flows of acquired companies are included in the operating results from the date of acquisition.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily generates revenue by performing genetic testing. Testing revenues are primarily derived from the following categories of products: Hereditary Cancer (MyRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight, Prequel, and SneakPeek), and Pharmacogenomics (GeneSight). The Company previously provided pharmaceutical services and clinical services prior to the sale of Myriad RBM, Inc. in July 2021 and Privatklinik Dr. Robert Schindlbeck GmbH &amp; Co. KG in February 2020. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 and the Myriad Autoimmune business in September 2021, the associated revenue from such businesses was included within Testing revenues. See Note 17 for a discussion of these divestitures. Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results or the completion of pharmaceutical and clinical services indicates transfer of control for revenue recognition purposes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents detail regarding the composition of the Company&#8217;s total revenue by product type for the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020, and the fiscal year ended June 30, 2020:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:50.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Testing revenues:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total testing revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the following tables reconcile revenue by geographical region, either U.S. or rest of world ("RoW"), to total revenue:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Testing revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">263.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">305.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">271.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total testing revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">591.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">678.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">579.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">666.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">591.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">678.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">603.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">690.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Testing revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">329.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">347.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total testing revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">255.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">279.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">559.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">586.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">275.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">299.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">596.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">638.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performs its obligation under a contract with a customer by processing tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets.&#160;Occasionally, customers make payments prior to the Company's performance of its contractual obligations.&#160;When this occurs, the Company records a contract liability as Deferred revenue in the Consolidated Balance Sheets. During the fiscal year ended June 30, 2020, the Company received approximat</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ely $29.7&#160;million in a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dvance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments were applied against services performed beginning in April 2021 and continued until the funds previously received were fully earned, which occurred during the quarter ended March 31, 2022. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company&#8217;s right to payment is in an amount that directly corresponds with the value of the Company&#8217;s performance to date. In determining the transaction price, the Company includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with ultimate collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenue in the Consolidated Statements of Operations and Comprehensive Loss. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash collections for certain tests delivered may differ from rates estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third-party payors. As a result of this new information, the Company updates its estimate of the amounts to be recognized for previously delivered tests. During the year ended December&#160;31, 2022, the Company recognized $22.1 million in revenue, which resulted in a $0.21 impact to loss per share for tests in which the performance obligation of delivering the test results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. During the year ended December&#160;31, 2021, the Company recognized $15.9 million in revenue which resulted in a $0.15 impact to loss per share for tests in which the performance obligation of delivering the test results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. Additionally, during the year ended December&#160;31, 2021, revenue of $6.8 million was recognized due to expanded coverage for the Company's Prolaris test, for which revenue was fully constrained in a prior period. During the transition period ended December 31, 2020, the impact to revenue and loss per share for tests in which the performance obligation of delivering the test results was met in the prior period was immaterial. During the fiscal year ended June 30, 2020, the Company recognized a $9.9 million decrease in revenue, which resulted in a $(0.10) impact to loss per share for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third-party payors. In addition, during the fiscal year ended June 30, 2020, the Company identified an error related to prior periods for Medicare claims and reduced revenue and recorded an accrued liability for a total of $4.7 million that will be refunded to Medicare. The impact of correcting the error during that period and the impact to all prior periods was concluded to be immaterial. The correction of the error in the fiscal year ended June 30, 2020 resulted in an impact to loss per share for the fiscal year ended June 30, 2020 of $(0.05).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company has elected to exclude from the measurement of transaction price, all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a customer for sales tax, value added tax, and certain other taxes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Payment Expense</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Payment Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the fair value compensation cost relating to stock-based payment transactions in accordance with ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation &#8211; Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee&#8217;s requisite service period, which is generally the vesting period. The fair value of restricted stock units (RSUs) and performance restricted stock units (PSUs) that do not have market conditions is based on the number of shares granted and the quoted price of the Company&#8217;s common stock on the grant date. The fair value of PSU awards that have market conditions is determined using the Monte Carlo Method. For PSUs, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company estimates the likelihood of achievement of the performance conditions at the end of each period. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeitures are recognized as a reduction of compensation expense in earnings in the period in which they occur. The fair value of shares issued under the Company's Employee Stock Purchase Plan is calculated using the Black-Scholes option-pricing model, based on assumptions including the risk-free interest rate, expected life, expected dividend yield and expected volatility. The average risk-free interest rate is determined using the U.S. Treasury rate. We determine the expected life based on the offering period of the Employee Stock Purchase Plan. The expected volatility is determined using the weighted average of daily historical volatility of the price of the Company's common stock.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_OtherIncomeExpensePolicyPolicyTextBlock', window );">Other Income (Expense)</a></td>
<td class="text">Other Income (Expense)The Company recognizes the gain or loss on its divestitures as Other income (expense) in the Consolidated Statement of Operations. During the year ended December&#160;31, 2021, the Company recognized a net gain on divestitures of $162.0 million. See Note 17 for additional information regarding these divestitures. In addition, during the fiscal year ended June 30, 2020, the Company received approximately $14.6 million from the Provider Relief Fund under the CARES Act to reimburse the Company for health care related expenses or lost revenues that were attributable to COVID-19, which was recognized as a component of Other income (expense) in the Consolidated Statements of Operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal, state, and foreign income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company&#8217;s filings, including the positions taken therein, are subject to audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the Company's consolidated financial condition, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (EPS) is computed based on the weighted-average number of shares of common stock outstanding.&#160;&#160;Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding used to compute basic EPS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain outstanding options and RSUs were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive options and RSUs excluded from EPS computation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company&#8217;s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive loss as a separate component of Stockholders&#8217; equity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the cumulative translation adjustments included in Accumulated other comprehensive loss (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies and adopted by the Company as of the specified effective date. During the year ended December 31, 2022, there have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the FASB that have or are expected to have a material impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&#160;Some of the Company&#8217;s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;unobservable inputs.</span></div>All of the Company&#8217;s financial instruments are valued using quoted prices in active markets or based on other observable inputs.&#160;&#160;For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information.&#160;&#160;For Level 3 contingent consideration related to the acquisitions of Sividon Diagnostics GmbH ("Sividon") and Gateway, the Company reassesses the fair value of each expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected contingent consideration liability.&#160;&#160;This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the expected measurement periods of approximately 12.5 and 2.3 years for Sividon and Gateway, respectively, utilizing various potential pay-out scenarios.&#160;&#160;Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the contingent consideration itself, the related projections, and the overall business.&#160;&#160;The contingent consideration liabilities are classified as components of Accrued liabilities and Other long-term liabilities in the Consolidated Balance Sheets.&#160;Changes to contingent consideration liabilities are reflected in Selling, general, and administrative expense in the Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company&#8217;s financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_OtherIncomeExpensePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other income policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_OtherIncomeExpensePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670503887856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Consolidated Balance Sheets that agrees to the amounts included in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Consolidated Balance Sheets that agrees to the amounts included in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenue by Type</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents detail regarding the composition of the Company&#8217;s total revenue by product type for the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020, and the fiscal year ended June 30, 2020:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:50.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Testing revenues:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total testing revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenue by Geographical Region</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the following tables reconcile revenue by geographical region, either U.S. or rest of world ("RoW"), to total revenue:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Testing revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">263.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">305.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">271.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total testing revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">591.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">678.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">579.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">666.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">591.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">678.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">603.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">690.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Testing revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">329.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">347.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total testing revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">255.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">279.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">559.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">586.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">275.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">299.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">596.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">638.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Reconciliation of Deferred Revenue Balances</a></td>
<td class="text">A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding used to compute basic EPS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Dilutive Common Shares</a></td>
<td class="text">These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive options and RSUs excluded from EPS computation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Cumulative Translation Adjustments Included in Accumulated Other Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the cumulative translation adjustments included in Accumulated other comprehensive loss (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Period translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505211952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Investment Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value debt securities classified as available-for-sale securities by major security type and class of security at December&#160;31, 2022 and December&#160;31, 2021 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and maturities of debt securities classified as available-for-sale are as follows at December&#160;31, 2022:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505310016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Fair Value of Financial Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (a)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (a)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.03pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Change in Fair Value of Contingent Consideration</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the change in the fair value of the contingent consideration during the periods presented:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration recognized at acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recognized in the statement of operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustments recognized in other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505214560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment, Net</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The property, plant and equipment at December&#160;31, 2022 and December&#160;31, 2021 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded depreciation during the respective periods as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502857664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Changes in Carrying Amount of Goodwill</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of goodwill for the year ended December&#160;31, 2022 are as follows: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.836%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired (see Note 16)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Amortizable Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the amounts reported as intangible assets (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2022:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Carrying Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Useful Life <br/>(in Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Useful Life <br/>(in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Carrying Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Useful Life <br/>(in Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Useful Life <br/>(in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212.5)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Non-amortizable Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the amounts reported as intangible assets (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2022:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Carrying Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Useful Life <br/>(in Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Useful Life <br/>(in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Carrying Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Useful Life <br/>(in Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Useful Life <br/>(in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212.5)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Recorded Amortization for Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded amortization during the respective periods for these intangible assets as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization Expense of Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense of intangible assets as of December&#160;31, 2022 is estimated to be as follows (in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.906%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortization Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505239648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's accrued liabilities at December&#160;31, 2022 and December&#160;31, 2021 were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal charges pending settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refunds payable and reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505281312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Long-Term Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Schedule of Other Long-Term Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's other long-term liabilities at December&#160;31, 2022 and December&#160;31, 2021 were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505169056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">Summary of Shares of Common Stock Issued and Outstanding</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shares of common stock issued and outstanding</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning common stock issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued and outstanding at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670503805296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the Company's equity plans, and inducement awards for the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual<br/>life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU awards activity under the Company's equity plans and inducement awards, including PSU awards for the year ended December&#160;31, 2022, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(number of shares in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of<br/>shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>grant date<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs unvested and outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs unvested and outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized and included in the Consolidated Statements of Operations was allocated as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of testing revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock', window );">Schedule of Aggregate Intrinsic Value</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of options outstanding</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of options fully vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of RSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock', window );">Schedule of Intrinsic Value of Options Exercised</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic value of options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock', window );">Schedule of Shares Purchased and Compensation Expenses for ESPP</a></td>
<td class="text">Shares purchased under, and compensation expense associated with, the Amended and Restated 2012 Purchase Plan for the periods reported are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased under the plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan compensation expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions for ESPP</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of shares issued under the Amended and Restated 2012 Purchase Plan that was in effect for each period reported was calculated using the Black&#8209;Scholes option-pricing model using the weighted-average assumptions below. Each of these inputs is subjective and its determination generally requires significant judgment.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share-Based Compensation Arrangement By Share-Based Payment Award, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee stock purchase plan activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502232976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Benefit</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit consists of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss Before Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income taxes consists of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140.6)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.1)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94.1)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223.3)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Differences Between Statutory Federal Income Tax Rate and Income Taxes Reported</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between income taxes at the statutory federal income tax rate and income taxes reported in the Consolidated Statements of Operations were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.880%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax expense at the statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incentive stock option and employee stock purchase plan expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARES Act</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible meals and entertainment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible officer compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible legal settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, dispositions, and contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax benefit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s deferred tax assets and liabilities were comprised of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 capitalized costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Schedule of Net Operating Loss and Research Credit Carryforwards (Tax Effected)</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the Company had the following net operating loss and research credit carryforwards (tax effected), with their respective expiration periods. Certain carryforwards are subject to the limitations of Section 382 and 383 of the Internal Revenue Code as indicated (in millions):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carryforwards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Subject to<br/>sections 382, 383</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expires<br/>beginning in year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Through</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal net operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal capital loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utah net operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California net operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other state net operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign net operating losses (various jurisdictions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Various</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal research credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utah research credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California research credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text">The Company&#8217;s gross unrecognized tax benefits as of the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020 and the fiscal year ended June 30, 2020, and the changes in those balances are as follows:&#160;<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:52.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.949%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at the beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases - statute lapse</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and penalties in year-end balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505303744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the maturities of the Company&#8217;s operating lease liabilities were as follows (in millions):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: leases not yet commenced</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current maturities of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505092384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Deferred Savings Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock', window );">Schedule of Contributions to the Plan</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s recorded contributions to the plan are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:50.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred savings plan contributions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505160880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Related Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of Assets by Geographical Region</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles assets by geographical region to total assets:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Net equipment, leasehold improvements and property:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable investment securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,320.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670503956480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Estimated Fair Value of Identified Assets acquired and Liabilities Assumed</a></td>
<td class="text">The following table summarizes the estimated fair value of identified assets acquired and liabilities assumed at the date of acquisition. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable assets acquired</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,800&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,914&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(939)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of Purchase Price</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,698&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Pro Forma Information</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,686)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505225152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Amounts Recognized in Other Income</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the amounts recognized in Other income (expense) for the year ended December 31, 2021:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of Myriad RBM, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of the Myriad myPath, LLC laboratory</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on sale of Myriad Autoimmune assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505092384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Supplemental Cash Flow Information</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's supplemental cash flow information for the respective periods are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six-month Transition Period Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received for income tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of operating lease right-of-use assets and lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant improvement allowance not yet received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment in accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities and other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502632096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareNet', window );">Unamortized software costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="nump">6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Amortization expense for capitalized software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_CARESActOf2020MedicarePaymentAmount', window );">Advance Medicare payments to provide relief from economic impacts of COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Revenue increase (decrease) due to changes in estimated transaction price due to contractual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,100,000<span></span>
</td>
<td class="nump">15,900,000<span></span>
</td>
<td class="num">(9,900,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained', window );">Revenue recognized due to expanded local coverage determination for which revenue was previously constrained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued liability for Medicare refund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,600,000<span></span>
</td>
<td class="nump">19,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Reduced revenues</a></td>
<td class="num">(299,800,000)<span></span>
</td>
<td class="num">(678,400,000)<span></span>
</td>
<td class="num">(690,600,000)<span></span>
</td>
<td class="num">(638,600,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Capitalized costs incurred to obtain or fulfill contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Net gain on divestiture</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 162,000,000.0<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_CARESActOf2020ProviderReliefFundAmount', window );">Provider fund relief under CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Immaterial Prior Period Medicare Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_IncreaseDecreaseInEarningsLossPerShare', window );">Change in earnings (loss) per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued liability for Medicare refund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Reduced revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=mygn_PerformanceObligationEstimatedTransactionPriceMember', window );">Performance Obligation Estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_IncreaseDecreaseInEarningsLossPerShare', window );">Change in earnings (loss) per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember', window );">Government Contracts Concentration Risk | Medicare | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_CARESActOf2020MedicarePaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CARES Act of 2020 medicare payment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_CARESActOf2020MedicarePaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_CARESActOf2020ProviderReliefFundAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CARES Act of 2020 Provider Relief Fund amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_CARESActOf2020ProviderReliefFundAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Adjustment To Revenue For Expanded Coverage, Previously Constrained</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IncreaseDecreaseInEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in earnings (loss) per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IncreaseDecreaseInEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128487-111756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=mygn_PerformanceObligationEstimatedTransactionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=mygn_PerformanceObligationEstimatedTransactionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mygn_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mygn_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670498143648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 56.9<span></span>
</td>
<td class="nump">$ 257.4<span></span>
</td>
<td class="nump">$ 117.0<span></span>
</td>
<td class="nump">$ 163.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 66.4<span></span>
</td>
<td class="nump">$ 258.8<span></span>
</td>
<td class="nump">$ 117.0<span></span>
</td>
<td class="nump">$ 163.7<span></span>
</td>
<td class="nump">$ 93.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670498238176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Revenue by Type (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 299.8<span></span>
</td>
<td class="nump">$ 678.4<span></span>
</td>
<td class="nump">$ 690.6<span></span>
</td>
<td class="nump">$ 638.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_TestingRevenueMember', window );">Testing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">279.6<span></span>
</td>
<td class="nump">678.4<span></span>
</td>
<td class="nump">666.4<span></span>
</td>
<td class="nump">586.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_HereditaryCancerTestingMember', window );">Hereditary Cancer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">159.3<span></span>
</td>
<td class="nump">305.5<span></span>
</td>
<td class="nump">316.3<span></span>
</td>
<td class="nump">347.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_TumorProfilingMember', window );">Tumor Profiling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">33.9<span></span>
</td>
<td class="nump">128.6<span></span>
</td>
<td class="nump">120.9<span></span>
</td>
<td class="nump">48.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_PrenatalTestingMember', window );">Prenatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">37.6<span></span>
</td>
<td class="nump">116.4<span></span>
</td>
<td class="nump">106.8<span></span>
</td>
<td class="nump">76.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_PharmacogenomicsMember', window );">Pharmacogenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">29.8<span></span>
</td>
<td class="nump">127.6<span></span>
</td>
<td class="nump">93.7<span></span>
</td>
<td class="nump">74.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_AutoimmuneMember', window );">Autoimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">18.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">28.2<span></span>
</td>
<td class="nump">39.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_OtherTestingMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 20.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 24.2<span></span>
</td>
<td class="nump">$ 51.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_TestingRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_TestingRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_HereditaryCancerTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_HereditaryCancerTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_TumorProfilingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_TumorProfilingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_PrenatalTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_PrenatalTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_PharmacogenomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_PharmacogenomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_AutoimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_AutoimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_OtherTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_OtherTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670497546064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Revenue by Geographical Region (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 299.8<span></span>
</td>
<td class="nump">$ 678.4<span></span>
</td>
<td class="nump">$ 690.6<span></span>
</td>
<td class="nump">$ 638.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_TestingRevenueMember', window );">Testing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">279.6<span></span>
</td>
<td class="nump">678.4<span></span>
</td>
<td class="nump">666.4<span></span>
</td>
<td class="nump">586.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_HereditaryCancerTestingMember', window );">Hereditary Cancer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">159.3<span></span>
</td>
<td class="nump">305.5<span></span>
</td>
<td class="nump">316.3<span></span>
</td>
<td class="nump">347.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_TumorProfilingMember', window );">Tumor Profiling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">33.9<span></span>
</td>
<td class="nump">128.6<span></span>
</td>
<td class="nump">120.9<span></span>
</td>
<td class="nump">48.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_PrenatalTestingMember', window );">Prenatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">37.6<span></span>
</td>
<td class="nump">116.4<span></span>
</td>
<td class="nump">106.8<span></span>
</td>
<td class="nump">76.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_PharmacogenomicsMember', window );">Pharmacogenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">29.8<span></span>
</td>
<td class="nump">127.6<span></span>
</td>
<td class="nump">93.7<span></span>
</td>
<td class="nump">74.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_AutoimmuneMember', window );">Autoimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">18.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">28.2<span></span>
</td>
<td class="nump">39.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mygn_OtherTestingMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">51.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">275.4<span></span>
</td>
<td class="nump">591.5<span></span>
</td>
<td class="nump">603.7<span></span>
</td>
<td class="nump">596.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Testing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">255.3<span></span>
</td>
<td class="nump">591.5<span></span>
</td>
<td class="nump">579.5<span></span>
</td>
<td class="nump">559.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Hereditary Cancer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">140.9<span></span>
</td>
<td class="nump">263.5<span></span>
</td>
<td class="nump">271.0<span></span>
</td>
<td class="nump">329.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Tumor Profiling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">28.2<span></span>
</td>
<td class="nump">84.5<span></span>
</td>
<td class="nump">80.4<span></span>
</td>
<td class="nump">39.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Prenatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">37.4<span></span>
</td>
<td class="nump">115.6<span></span>
</td>
<td class="nump">106.2<span></span>
</td>
<td class="nump">76.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmacogenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">29.8<span></span>
</td>
<td class="nump">127.6<span></span>
</td>
<td class="nump">93.7<span></span>
</td>
<td class="nump">74.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Autoimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">18.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">28.2<span></span>
</td>
<td class="nump">39.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">20.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">36.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">24.4<span></span>
</td>
<td class="nump">86.9<span></span>
</td>
<td class="nump">86.9<span></span>
</td>
<td class="nump">42.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Testing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">24.3<span></span>
</td>
<td class="nump">86.9<span></span>
</td>
<td class="nump">86.9<span></span>
</td>
<td class="nump">27.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Hereditary Cancer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">18.4<span></span>
</td>
<td class="nump">42.0<span></span>
</td>
<td class="nump">45.3<span></span>
</td>
<td class="nump">17.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Tumor Profiling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">44.1<span></span>
</td>
<td class="nump">40.5<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Prenatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Pharmacogenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Autoimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 15.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_TestingRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_TestingRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_HereditaryCancerTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_HereditaryCancerTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_TumorProfilingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_TumorProfilingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_PrenatalTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_PrenatalTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_PharmacogenomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_PharmacogenomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_AutoimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_AutoimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mygn_OtherTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mygn_OtherTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502873936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Reconciliation of Deferred Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward', window );"><strong>Change In Contract with Customer, Liability, Current [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue - beginning balance</a></td>
<td class="nump">$ 32.8<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="nump">$ 32.7<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized', window );">Revenue recognized</a></td>
<td class="num">(6.1)<span></span>
</td>
<td class="num">(4.9)<span></span>
</td>
<td class="num">(40.5)<span></span>
</td>
<td class="num">(7.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_ContractWithCustomerLiabilityPrepayments', window );">Prepayments</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="nump">37.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_ContractWithCustomerLiabilityDivestitures', window );">Divestitures</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue - ending balance</a></td>
<td class="nump">$ 32.7<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="nump">$ 32.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Contract with Customer, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ContractWithCustomerLiabilityDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Divestitures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ContractWithCustomerLiabilityDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Including New Contract, Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ContractWithCustomerLiabilityPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customer, liability, prepayments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ContractWithCustomerLiabilityPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670506389312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Earnings Per Share (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding used to compute basic EPS (in shares)</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">80.6<span></span>
</td>
<td class="nump">78.0<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive stock option and RSUs (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS (in shares)</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">80.6<span></span>
</td>
<td class="nump">78.0<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive options and RSUs excluded from EPS computation (in shares)</a></td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670501444544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Foreign Currency Cumulative Translation Adjustments (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward', window );"><strong>Cumulative Translation Adjustment Summary [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Beginning balance</a></td>
<td class="num">$ (4.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease', window );">Period translation adjustments</a></td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Ending balance</a></td>
<td class="num">$ (6.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594809&amp;loc=SL116692626-108610<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeTranslationAdjustmentSummaryRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeTranslationAdjustmentSummaryRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cumulative translation adjustment, after tax, from translating foreign currency financial statements into the reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502563104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized cost</a></td>
<td class="nump">$ 56.9<span></span>
</td>
<td class="nump">$ 257.4<span></span>
</td>
<td class="nump">$ 117.0<span></span>
</td>
<td class="nump">$ 163.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="nump">56.9<span></span>
</td>
<td class="nump">257.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndCashAbstract', window );"><strong>Total:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_InvestmentsAndCashAmortizedCost', window );">Amortized cost</a></td>
<td class="nump">172.4<span></span>
</td>
<td class="nump">397.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="num">(2.7)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Estimated fair value</a></td>
<td class="nump">169.7<span></span>
</td>
<td class="nump">397.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">66.7<span></span>
</td>
<td class="nump">105.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="num">(1.6)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">65.1<span></span>
</td>
<td class="nump">105.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">16.3<span></span>
</td>
<td class="nump">16.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">16.0<span></span>
</td>
<td class="nump">16.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Federal agency issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">20.7<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">11.8<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">11.7<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized cost</a></td>
<td class="nump">53.6<span></span>
</td>
<td class="nump">194.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="nump">53.6<span></span>
</td>
<td class="nump">194.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized cost</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">63.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="nump">$ 63.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Accumulated Gross Unrealized Gain, before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Accumulated Gross Unrealized Loss, before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_InvestmentsAndCashAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_InvestmentsAndCashAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670501029008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 56.9<span></span>
</td>
<td class="nump">$ 257.4<span></span>
</td>
<td class="nump">$ 117.0<span></span>
</td>
<td class="nump">$ 163.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Available-for-sale, Due within one year</a></td>
<td class="nump">58.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Available-for-sale, Due after one year through five years</a></td>
<td class="nump">56.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Available-for-sale, Due after five years</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_InvestmentsAndCashAmortizedCost', window );">Amortized cost</a></td>
<td class="nump">172.4<span></span>
</td>
<td class="nump">397.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Estimated fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">56.9<span></span>
</td>
<td class="nump">257.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale, Due within one year</a></td>
<td class="nump">58.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Available-for-sale, Due after one year through five years</a></td>
<td class="nump">54.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Available-for-sale, Due after five years</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Total, Estimated fair value</a></td>
<td class="nump">169.7<span></span>
</td>
<td class="nump">397.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">53.6<span></span>
</td>
<td class="nump">194.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Estimated fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">53.6<span></span>
</td>
<td class="nump">194.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">63.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Estimated fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="nump">$ 63.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_InvestmentsAndCashAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_InvestmentsAndCashAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670506388320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Investment Securities - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Investment sold</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 28.4<span></span>
</td>
<td class="nump">$ 8.3<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Debt securities, available-for-sale, in unrealized loss position | position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Debt securities, available-for-sale, unrealized loss position, accumulated loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.7)<span></span>
</td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Available-for-sale securities, gross unrealized loss, fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111.6<span></span>
</td>
<td class="nump">$ 77.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670504796144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - Level 3 - Measurement input, expected term<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Sividon Diagnostics GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm', window );">Measurement period for earn out liability</a></td>
<td class="text">12 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Gateway Genomics, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm', window );">Measurement period for earn out liability</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Measurement Input, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mygn_SividonDiagnosticsGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mygn_SividonDiagnosticsGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mygn_GatewayGenomicsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mygn_GatewayGenomicsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670501601392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">$ 109.3<span></span>
</td>
<td class="nump">$ 195.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">63.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">65.1<span></span>
</td>
<td class="nump">105.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">16.0<span></span>
</td>
<td class="nump">16.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Federal agency issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">11.7<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mygn_ContingentConsiderationMember', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="num">(6.8)<span></span>
</td>
<td class="num">(8.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">63.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">63.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Federal agency issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="nump">112.8<span></span>
</td>
<td class="nump">140.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">65.1<span></span>
</td>
<td class="nump">105.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">16.0<span></span>
</td>
<td class="nump">16.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Federal agency issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">11.7<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total</a></td>
<td class="num">(6.8)<span></span>
</td>
<td class="num">(8.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Federal agency issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="num">$ (6.8)<span></span>
</td>
<td class="num">$ (8.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mygn_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mygn_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502550624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="nump">$ 13.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payment of contingent consideration</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Consideration recognized at acquisition</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value recognized in the statement of operations</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Translation adjustments recognized in other comprehensive income (loss)</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag', window );">Fair value, recurring basis, unobservable input reconciliation, gain (loss), statement of income</a></td>
<td class="text">Change in fair value recognized in the statement of operations<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502943264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net - Balances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 192.6<span></span>
</td>
<td class="nump">$ 150.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(109.2)<span></span>
</td>
<td class="num">(106.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">83.4<span></span>
</td>
<td class="nump">43.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">67.9<span></span>
</td>
<td class="nump">38.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 124.7<span></span>
</td>
<td class="nump">$ 112.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670504640752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember', window );">Myriad RBM, Inc. and Myriad Autoimmune business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Property, plant and equipment sold and deconsolidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670506287168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net - Depreciation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 11.6<span></span>
</td>
<td class="nump">$ 12.1<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670504658112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 239.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired (see Note 16)</a></td>
<td class="nump">48.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation adjustments</a></td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Carrying amount at end of period</a></td>
<td class="nump">$ 286.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670497325904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated remaining useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 4 months 24 days<span></span>
</td>
<td class="text">14 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount, amortizable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated remaining useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Gateway Genomics, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount, amortizable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated remaining useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks | Gateway Genomics, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Identifiable intangible assets</a></td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount, amortizable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625,000,000.0<span></span>
</td>
<td class="nump">$ 616,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated remaining useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 4 months 24 days<span></span>
</td>
<td class="text">14 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technologies | Gateway Genomics, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 10,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technologies | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated remaining useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technologies | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated remaining useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=mygn_MyriadAutoimmuneReportingUnitMember', window );">Myriad Autoimmune reporting unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=mygn_ClinicReportingUnitMember', window );">Clinic reporting unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_GoodwillAndIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_GoodwillAndIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mygn_GatewayGenomicsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mygn_GatewayGenomicsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=mygn_MyriadAutoimmuneReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=mygn_MyriadAutoimmuneReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=mygn_ClinicReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=mygn_ClinicReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670503933584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (253.0)<span></span>
</td>
<td class="num">$ (212.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total net, amortization</a></td>
<td class="nump">379.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross carrying amount, total</a></td>
<td class="nump">632.7<span></span>
</td>
<td class="nump">616.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net, total</a></td>
<td class="nump">$ 379.7<span></span>
</td>
<td class="nump">$ 404.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Useful Life (in Years)</a></td>
<td class="text">14 years 4 months 24 days<span></span>
</td>
<td class="text">14 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted-Average Remaining Useful Life (in Years)</a></td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">10 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount, amortizable</a></td>
<td class="nump">$ 625.0<span></span>
</td>
<td class="nump">$ 616.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(252.9)<span></span>
</td>
<td class="num">(212.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total net, amortization</a></td>
<td class="nump">$ 372.1<span></span>
</td>
<td class="nump">$ 404.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Useful Life (in Years)</a></td>
<td class="text">14 years 4 months 24 days<span></span>
</td>
<td class="text">14 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted-Average Remaining Useful Life (in Years)</a></td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">10 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount, amortizable</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total net, amortization</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Useful Life (in Years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted-Average Remaining Useful Life (in Years)</a></td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_IntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount, amortizable</a></td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total net, amortization</a></td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Useful Life (in Years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted-Average Remaining Useful Life (in Years)</a></td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505476992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Amortization on Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 30.8<span></span>
</td>
<td class="nump">$ 41.1<span></span>
</td>
<td class="nump">$ 50.7<span></span>
</td>
<td class="nump">$ 61.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502550704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Future Amortization Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Future Amortization Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 42.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">42.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">42.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">42.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">42.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">165.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total net, amortization</a></td>
<td class="nump">$ 379.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502617296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">$ 41.2<span></span>
</td>
<td class="nump">$ 52.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Legal charges pending settlement</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">62.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Accrued taxes payable</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_RefundsPayableAndReserveCurrent', window );">Refunds payable and reserves</a></td>
<td class="nump">19.3<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Short-term contingent consideration</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">$ 32.7<span></span>
</td>
<td class="nump">$ 32.8<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">23.6<span></span>
</td>
<td class="nump">19.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 94.3<span></span>
</td>
<td class="nump">$ 161.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_RefundsPayableAndReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refunds Payable And Reserve, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_RefundsPayableAndReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670496765856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 26, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jul. 25, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Feb. 22, 2021</div></th>
<th class="th"><div>Feb. 21, 2021</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Dec. 23, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Principal repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 226,400,000<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mygn_AmendmentToCreditAgreementMember', window );">Amended facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_LineOfCreditFacilityCreditExposureThreshold', window );">Line of credit facility, credit exposure threshold</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum aggregate principal commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Principal repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Amended facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum aggregate principal commitment</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_DebtCovenantLiquidityCovenantMinimum', window );">Minimum liquidity covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum', window );">Minimum unrestricted cash and cash equivalents threshold per covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Undrawn fee (percent)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Amended facility | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Amended facility | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on rate (percent)</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_DebtInstrumentFloorPercentage', window );">SOFR floor (percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Amended facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_LineOfCreditFacilityCreditExposureThreshold', window );">Line of credit facility, credit exposure threshold</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DebtCovenantLiquidityCovenantMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant, Liquidity Covenant Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DebtCovenantLiquidityCovenantMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DebtInstrumentFloorPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Floor Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DebtInstrumentFloorPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_LineOfCreditFacilityCreditExposureThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Credit Exposure Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_LineOfCreditFacilityCreditExposureThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mygn_AmendmentToCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mygn_AmendmentToCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670503910272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Long-Term Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total other long-term liabilities</a></td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502591936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">81,200,000<span></span>
</td>
<td class="nump">80,000,000.0<span></span>
</td>
<td class="nump">75,400,000<span></span>
</td>
<td class="nump">74,700,000<span></span>
</td>
<td class="nump">73,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">81,200,000<span></span>
</td>
<td class="nump">80,000,000.0<span></span>
</td>
<td class="nump">75,400,000<span></span>
</td>
<td class="nump">74,700,000<span></span>
</td>
<td class="nump">73,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock repurchase program, remaining repurchase authorization</a></td>
<td class="nump">$ 110,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares repurchased (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502510800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stockholders' Equity - Shares of Common Stock Issued and Outstanding (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning common stock issued (in shares)</a></td>
<td class="nump">74.7<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">73.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning common stock outstanding (in shares)</a></td>
<td class="nump">74.7<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">73.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans', window );">Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plans (in shares)</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending common stock issued (in shares)</a></td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">81.2<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="nump">74.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending common stock outstanding (in shares)</a></td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">81.2<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="nump">74.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670498094384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 23, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.38<span></span>
</td>
<td class="nump">$ 20.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember', window );">2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember', window );">2012 Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum number of shares per participant per offering period (in shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued under the plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">President and Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mygn_OptionsAndRestrictedStockUnitsMember', window );">Options and RSUs | Non-Employee Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Service period for award vesting (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.69<span></span>
</td>
<td class="nump">$ 25.78<span></span>
</td>
<td class="nump">$ 29.83<span></span>
</td>
<td class="nump">$ 27.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted stock units that vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.1<span></span>
</td>
<td class="nump">$ 31.0<span></span>
</td>
<td class="nump">$ 22.6<span></span>
</td>
<td class="nump">$ 32.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Service period for award vesting (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Service period for award vesting (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Achievement levels based on EPS Targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting weight (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Relative Total Stockholders Return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting weight (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Performance based on Nasdaq Healthcare Provider Index</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting weight (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | President and Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mygn_OptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mygn_OptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mygn_NonEmployeeDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mygn_NonEmployeeDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502368912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Options Activity (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning (in shares) | shares</a></td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares) | shares</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options canceled or expired (in shares) | shares</a></td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending (in shares) | shares</a></td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest (in shares) | shares</a></td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 20.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">26.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options canceled or expired (in dollars per share) | $ / shares</a></td>
<td class="nump">26.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending (in dollars per share) | $ / shares</a></td>
<td class="nump">13.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">13.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 13.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual life (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted average remaining contractual life (in years)</a></td>
<td class="text">4 years 7 months 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted average remaining contractual life (in years)</a></td>
<td class="text">4 years 7 months 13 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest, Weighted average remaining contractual life (in years)</a></td>
<td class="text">4 years 7 months 13 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502599168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Units Activity (Details) - RSUs - $ / shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs unvested and outstanding, beginning (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs unvested and outstanding, ending (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">RSUs unvested and outstanding, beginning (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSUs granted (in dollars per share)</a></td>
<td class="nump">$ 13.69<span></span>
</td>
<td class="nump">25.78<span></span>
</td>
<td class="nump">$ 29.83<span></span>
</td>
<td class="nump">$ 27.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">RSUs vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">RSUs canceled (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">RSUs unvested and outstanding, ending (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.08<span></span>
</td>
<td class="nump">$ 24.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670498023360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 14.9<span></span>
</td>
<td class="nump">$ 38.1<span></span>
</td>
<td class="nump">$ 36.3<span></span>
</td>
<td class="nump">$ 25.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=mygn_CostOfTestingMember', window );">Cost of testing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=mygn_CostOfOtherRevenueMember', window );">Cost of other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 11.8<span></span>
</td>
<td class="nump">$ 31.2<span></span>
</td>
<td class="nump">$ 30.5<span></span>
</td>
<td class="nump">$ 18.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=mygn_CostOfTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=mygn_CostOfTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=mygn_CostOfOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=mygn_CostOfOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670504557232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation - Aggregate Intrinsic Value (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of options fully vested</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value of RSUs outstanding</a></td>
<td class="nump">$ 54.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502220400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Intrinsic Value of Options Exercised (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 29.2<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670496917120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Shares Purchased and Compensation Expenses for ESPP (Details) - 2012 Purchase Plan - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Shares purchased under the plans (in shares)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Plan compensation expense</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost expensed and capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670501097440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Valuation Assumptions for ESPP (Details) - 2012 Purchase Plan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">94.00%<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670498209312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Benefit (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (75.8)<span></span>
</td>
<td class="num">$ (0.5)<span></span>
</td>
<td class="num">$ (1.9)<span></span>
</td>
<td class="nump">$ 26.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="num">(76.2)<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">32.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">39.1<span></span>
</td>
<td class="num">(25.8)<span></span>
</td>
<td class="num">(33.7)<span></span>
</td>
<td class="num">(51.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(3.4)<span></span>
</td>
<td class="num">(4.8)<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">35.2<span></span>
</td>
<td class="num">(30.5)<span></span>
</td>
<td class="num">(31.7)<span></span>
</td>
<td class="num">(55.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax benefit</a></td>
<td class="num">$ (41.0)<span></span>
</td>
<td class="num">$ (28.6)<span></span>
</td>
<td class="num">$ (29.9)<span></span>
</td>
<td class="num">$ (23.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670496912560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Loss Before Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Income (loss) before income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (101.8)<span></span>
</td>
<td class="num">$ (141.3)<span></span>
</td>
<td class="num">$ (53.8)<span></span>
</td>
<td class="num">$ (240.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
<td class="nump">17.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">$ (94.1)<span></span>
</td>
<td class="num">$ (140.6)<span></span>
</td>
<td class="num">$ (57.1)<span></span>
</td>
<td class="num">$ (223.3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670501701824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Statutory Federal Income Tax Rate and Income Taxes Reported (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal income tax expense at the statutory rate</a></td>
<td class="num">$ (19.8)<span></span>
</td>
<td class="num">$ (29.5)<span></span>
</td>
<td class="num">$ (12.0)<span></span>
</td>
<td class="num">$ (46.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Uncertain tax positions</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Incentive stock option and employee stock purchase plan expense</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_IncomeTaxReconciliationCARESAct', window );">CARES Act</a></td>
<td class="num">(20.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Non-deductible meals and entertainment</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation', window );">Non-deductible officer compensation</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_IncomeTaxReconciliationAssetImpairment', window );">Asset impairment</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement', window );">Non-deductible legal settlement</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration', window );">Acquisitions, dispositions, and contingent consideration</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(23.0)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax benefit</a></td>
<td class="num">$ (41.0)<span></span>
</td>
<td class="num">$ (28.6)<span></span>
</td>
<td class="num">$ (29.9)<span></span>
</td>
<td class="num">$ (23.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax expense at the statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="num">(4.40%)<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies', window );">Uncertain tax positions</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Incentive stock option and employee stock purchase plan expense</a></td>
<td class="num">(2.70%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_EffectiveIncomeTaxRateReconciliationCARESAct', window );">CARES Act</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(4.70%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Non-deductible meals and entertainment</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation', window );">Non-deductible officer compensation</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
<td class="num">(5.80%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment', window );">Asset impairment</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(5.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements', window );">Non-deductible legal settlement</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(4.50%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration', window );">Acquisitions, dispositions, and contingent consideration</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">40.30%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total income tax benefit</a></td>
<td class="nump">43.50%<span></span>
</td>
<td class="nump">20.30%<span></span>
</td>
<td class="nump">52.30%<span></span>
</td>
<td class="nump">10.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Acquisitions, Dispositions, And Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation asset impairment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_EffectiveIncomeTaxRateReconciliationCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation CARES Act</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_EffectiveIncomeTaxRateReconciliationCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation non deductible legal settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation non-deductible officer compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation, Acquisitions, Dispositions, And Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IncomeTaxReconciliationAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation asset impairment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IncomeTaxReconciliationAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IncomeTaxReconciliationCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation CARES Act</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IncomeTaxReconciliationCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation non-deductible legal settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation nondeductible expense officers compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to meals and entertainment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670501526176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 66.6<span></span>
</td>
<td class="nump">$ 67.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation expense</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">19.9<span></span>
</td>
<td class="nump">17.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_DeferredTaxAssetsLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">35.2<span></span>
</td>
<td class="nump">22.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization', window );">Section 174 capitalized costs</a></td>
<td class="nump">21.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses and liabilities</a></td>
<td class="nump">10.8<span></span>
</td>
<td class="nump">14.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">160.9<span></span>
</td>
<td class="nump">131.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(42.4)<span></span>
</td>
<td class="num">(38.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">118.5<span></span>
</td>
<td class="nump">92.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">93.8<span></span>
</td>
<td class="nump">104.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets', window );">Lease right-of-use assets</a></td>
<td class="nump">25.4<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">122.0<span></span>
</td>
<td class="nump">128.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="num">$ (3.5)<span></span>
</td>
<td class="num">$ (35.8)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Research And Experimental Expense Capitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502887488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod', window );">Decrease in valuation allowance</a></td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 31.9<span></span>
</td>
<td class="nump">$ 32.1<span></span>
</td>
<td class="nump">$ 37.6<span></span>
</td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="nump">$ 21.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Increase (Decrease) During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670496780240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Net Operating Loss and Research Credit Carryforwards (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 26.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating loss subject to sections 382,383</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Federal | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss, expiration in year</a></td>
<td class="text">2033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Federal | Capital loss</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit</a></td>
<td class="nump">$ 13.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit subject to sections 382,383</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Federal | Capital loss | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_TaxCreditCarryforwardsExpirationDate', window );">Tax credit, expiration in year</a></td>
<td class="text">2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Federal | Capital loss | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_TaxCreditCarryforwardsExpirationDate', window );">Tax credit, expiration in year</a></td>
<td class="text">2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Federal | Research credit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit</a></td>
<td class="nump">$ 8.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit subject to sections 382,383</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Federal | Research credit | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_TaxCreditCarryforwardsExpirationDate', window );">Tax credit, expiration in year</a></td>
<td class="text">2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Federal | Research credit | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_TaxCreditCarryforwardsExpirationDate', window );">Tax credit, expiration in year</a></td>
<td class="text">2042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Utah</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating loss subject to sections 382,383</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Utah | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss, expiration in year</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Utah | Research credit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit</a></td>
<td class="nump">$ 6.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit subject to sections 382,383</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Utah | Research credit | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_TaxCreditCarryforwardsExpirationDate', window );">Tax credit, expiration in year</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Utah | Research credit | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_TaxCreditCarryforwardsExpirationDate', window );">Tax credit, expiration in year</a></td>
<td class="text">2036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 4.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating loss subject to sections 382,383</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss, expiration in year</a></td>
<td class="text">2029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss, expiration in year</a></td>
<td class="text">2041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California | Research credit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit</a></td>
<td class="nump">$ 4.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit subject to sections 382,383</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 7.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating loss subject to sections 382,383</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 11.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating loss subject to sections 382,383</a></td>
<td class="text">No<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiration Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_TaxCreditCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforwards Expiration Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_TaxCreditCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=stpr_UT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=stpr_UT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=mygn_OtherStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=mygn_OtherStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670591479376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits at the beginning of period</a></td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="nump">$ 32.1<span></span>
</td>
<td class="nump">$ 37.6<span></span>
</td>
<td class="nump">$ 21.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increases - current year tax positions</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Gross increases - prior year tax positions</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Gross decreases - prior year tax positions</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Gross decreases - settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Gross decreases - statute lapse</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits at end of year</a></td>
<td class="nump">37.6<span></span>
</td>
<td class="nump">31.9<span></span>
</td>
<td class="nump">32.1<span></span>
</td>
<td class="nump">23.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest and penalties in year-end balance</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502237872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 21, 2020 </div>
<div>patent</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mygn_RaygenIncVersusMyriadWomensHealthIncMember', window );">Raygen, Inc Versus Myriad Women's Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Number of patents allegedly infringed</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of another entity's patents that the entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPatentsAllegedlyInfringedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mygn_RaygenIncVersusMyriadWomensHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mygn_RaygenIncVersusMyriadWomensHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502793456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> ft&#178; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Loss due to abandonment of facility</a></td>
<td class="nump">$ 13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Goodwill and long-lived asset impairment charges</a></td>
<td class="nump">16.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost</a></td>
<td class="nump">22.1<span></span>
</td>
<td class="nump">$ 20.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">103.9<span></span>
</td>
<td class="nump">$ 81.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">$ 185.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease weighted average remaining lease term</a></td>
<td class="text">10 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease weighted average discount rate</a></td>
<td class="nump">5.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mygn_SouthSanFranciscoCaliforniaMember', window );">South San Francisco, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate property | ft&#178;</a></td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 30.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">30.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">58.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_LeaseArrangementAxis=mygn_WestSaltLakeCityLeaseMember', window );">West Salt Lake City Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">78.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease terms</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease terms</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mygn_SouthSanFranciscoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mygn_SouthSanFranciscoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_LeaseArrangementAxis=mygn_WestSaltLakeCityLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_LeaseArrangementAxis=mygn_WestSaltLakeCityLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670503014048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Operating Lease Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturities of operating lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 20.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">17.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">16.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">92.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">185.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amounts representing interest</a></td>
<td class="num">(18.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced', window );">Present value of future lease payments</a></td>
<td class="nump">166.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced', window );">Less: leases not yet commenced</a></td>
<td class="num">(21.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current maturities of operating lease liabilities</a></td>
<td class="num">(14.1)<span></span>
</td>
<td class="num">$ (13.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">$ 130.9<span></span>
</td>
<td class="nump">$ 79.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Liability, Including Leases Not Yet Commenced</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_OperatingLeaseLiabilityLeasesNotYetCommenced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Liability, Leases Not Yet Commenced</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_OperatingLeaseLiabilityLeasesNotYetCommenced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670508099104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Deferred Savings Plan - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Company matching contribution as percentage of employee contribution</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Company matching contribution, maximum as percentage of employee compensation</a></td>
<td class="nump">4.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505416832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Deferred Savings Plan - Contributions to Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Deferred savings plan contributions</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="nump">$ 8.4<span></span>
</td>
<td class="nump">$ 7.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670505346752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Related Information - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502359136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment and Related Information - Assets by Geographical Region (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">$ 83.4<span></span>
</td>
<td class="nump">$ 43.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and marketable investment securities</a></td>
<td class="nump">169.7<span></span>
</td>
<td class="nump">398.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total</a></td>
<td class="nump">1,198.7<span></span>
</td>
<td class="nump">1,320.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember', window );">Reportable geographical components</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">83.4<span></span>
</td>
<td class="nump">43.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_AssetsLessCashCashEquivalentsAndInvestments', window );">Total</a></td>
<td class="nump">1,029.0<span></span>
</td>
<td class="nump">921.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember', window );">Reportable geographical components | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">81.9<span></span>
</td>
<td class="nump">41.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_AssetsLessCashCashEquivalentsAndInvestments', window );">Total</a></td>
<td class="nump">983.4<span></span>
</td>
<td class="nump">870.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember', window );">Reportable geographical components | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_AssetsLessCashCashEquivalentsAndInvestments', window );">Total</a></td>
<td class="nump">$ 45.6<span></span>
</td>
<td class="nump">$ 51.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_AssetsLessCashCashEquivalentsAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets, Less Cash, Cash Equivalents, And Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_AssetsLessCashCashEquivalentsAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670502842160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisition - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286,800<span></span>
</td>
<td class="nump">$ 286,800<span></span>
</td>
<td class="nump">$ 239,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mygn_GatewayGenomicsLLCMember', window );">Gateway Genomics, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business acquisition consideration</a></td>
<td class="nump">$ 68,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash purchase price paid</a></td>
<td class="nump">66,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments', window );">Warranty and working capital adjustment</a></td>
<td class="nump">8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Business acquisition, contingent cash fair value</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 48,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Business combination, separately recognized transactions, expenses and losses recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, revenue of acquiree since acquisition date, actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, loss of acquiree since acquisition date, actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mygn_GatewayGenomicsLLCMember', window );">Gateway Genomics, LLC | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_BusinessCombinationIntangibleAssetsMeasurementInput', window );">Estimated net cash flows discount rate</a></td>
<td class="nump">15.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mygn_GatewayGenomicsLLCMember', window );">Gateway Genomics, LLC | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful lives (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mygn_GatewayGenomicsLLCMember', window );">Gateway Genomics, LLC | Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful lives (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mygn_GatewayGenomicsLLCMember', window );">Gateway Genomics, LLC | Developed technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful lives (in years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Warranty And Working Capital Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_BusinessCombinationIntangibleAssetsMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Intangible Assets, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_BusinessCombinationIntangibleAssetsMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mygn_GatewayGenomicsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mygn_GatewayGenomicsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670497315888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Acquisition - Schedule of Estimated Fair Value of Identified Assets acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 286,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mygn_GatewayGenomicsLLCMember', window );">Gateway Genomics, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets', window );">Current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(693)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total fair value of Purchase Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mygn_GatewayGenomicsLLCMember', window );">Gateway Genomics, LLC | Developed technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mygn_GatewayGenomicsLLCMember', window );">Gateway Genomics, LLC | Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mygn_GatewayGenomicsLLCMember', window );">Gateway Genomics, LLC | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mygn_GatewayGenomicsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mygn_GatewayGenomicsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670506246976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisition - Schedule of Pro Forma Information (Details) - Gateway Genomics, LLC - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Revenue</a></td>
<td class="nump">$ 695,632<span></span>
</td>
<td class="nump">$ 709,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (112,185)<span></span>
</td>
<td class="num">$ (28,686)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mygn_GatewayGenomicsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mygn_GatewayGenomicsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670501604096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 13, 2021</div></th>
<th class="th"><div>Jul. 01, 2021</div></th>
<th class="th"><div>May 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of Subsidiary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFirmPurchaseCommitmentLoss', window );">Loss on non-cancelable purchase commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Loss on inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by Sale | Myriad myPath LLC laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of Subsidiary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from sale of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees', window );">Net gain on sale of assets adjusted for transaction fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on sale of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by Sale | Myriad RBM, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of Subsidiary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries', window );">Proceeds from sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on sale of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by Sale | Myriad Autoimmune Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of Subsidiary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts', window );">Transaction costs</a></td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries', window );">Proceeds from sale of business</a></td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on sale of subsidiary</a></td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition of Assets, Net Of Transaction Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFirmPurchaseCommitmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss recognized on firm purchase commitment for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4578-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFirmPurchaseCommitmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or the sale of investment in consolidated subsidiaries (generally greater than 50 percent).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadMyPathLLCLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadMyPathLLCLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadAutoimmuneAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadAutoimmuneAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670503065216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures - Other Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 13, 2021</div></th>
<th class="th"><div>Jul. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of Subsidiary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.2)<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 139.3<span></span>
</td>
<td class="nump">$ 16.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of Subsidiary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory', window );">Loss on inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncMember', window );">Gain on sale of Myriad RBM, Inc. | Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of Subsidiary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on sale of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadMyPathLLCLaboratoryMember', window );">Gain on sale of the Myriad myPath, LLC laboratory | Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of Subsidiary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on sale of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadAutoimmuneAssetsMember', window );">Loss on sale of Myriad Autoimmune assets | Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Disposal of Subsidiary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on sale of subsidiary</a></td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Gain (Loss) On Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_DisposalGroupNotDiscontinuedOperationGainLossOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Gain (Loss) Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_DisposalGroupNotDiscontinuedOperationGainLossOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadRBMIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadMyPathLLCLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadMyPathLLCLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadAutoimmuneAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_MyriadAutoimmuneAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140670503068224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Cash received for income tax receivables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Establishment of operating lease right-of-use assets and lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">46.9<span></span>
</td>
<td class="nump">41.8<span></span>
</td>
<td class="nump">74.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_OperatingLeaseLiabilityEstablished', window );">Operating lease liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(46.9)<span></span>
</td>
<td class="num">(48.1)<span></span>
</td>
<td class="num">(78.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_TenantImprovementAllowanceNotYetReceived', window );">Tenant improvement allowance not yet received</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">22.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property, plant and equipment in accounts payable and accrued liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid', window );">Accrued liabilities and other long-term liabilities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_LeaseRelatedExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Related Expenditures Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_LeaseRelatedExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_OperatingLeaseLiabilityEstablished">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability Established</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_OperatingLeaseLiabilityEstablished</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mygn_TenantImprovementAllowanceNotYetReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant Improvement Allowance Not Yet Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mygn_TenantImprovementAllowanceNotYetReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mygn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>mygn-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mygn="http://www.myriad.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mygn-20221231.xsd" xlink:type="simple"/>
    <context id="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7f732cf8e70f4da79cc772ea647eba95_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3b8e0501187143259a1544d7c2a53414_I20230223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2023-02-23</instant>
        </period>
    </context>
    <context id="ifb254f1abbe54bc896976a7ef3e19442_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i29d9f082f6304b3c901b8a69a382c99f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i308b88139f674cb09b58fa82ee43d092_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i794c44e7bf5b45689f334a7dc2a6cc11_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i543bcad925584a75897772999efa4e3e_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibc254773edfa4835899bcbe4c0b57775_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5bb3d6305f96409c9f4239ce2e6f890c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i934fd4ad46814c4e88f3d8113c493def_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i329f9f45afc549329c841d2e34c6be5d_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7f216fe61ee54eeab8ab464958d1e5bb_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i08037acddedf4c3da96bc71cd005937c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ia45b75059eff4573892e8f756ab08faf_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if291edff4ba84c7e9d38f402671ad107_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ifb0d838f44dc45f69885b845511ca96e_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if96afdd71e74449aa558f9c0f8968925_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ie25ada1ec48a4df091a03bd92db62e3f_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i096822e4050c4c89aecf816ec0a1d89f_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib9a92e11e87c4f21a1205b712b3e7a98_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie36c513fa3954843802b82eee7bd4d66_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1006f75c61d2402e941a615d921b10a0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia7925e43c913402583ad8467548fcdd9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i34a7c6b200aa410a99aba1eb920e920b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ideeefc606008446e85d0fd21a9515813_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iaf7c181e8dc344e5a21614f9c861ac4e_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0799c2a014e447128b2001beef5c11fb_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7d4b33f1ee7a42a89b6ffb0a263cc108_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iabdc282dcf2544e6a44fbcf258a6191b_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia3e0eff6e7f44b0e9bfbf56d9460dba8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ide959bef58984d0c800d66085fe2ee2e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6aa3dfbc1c6545a0b140ae9c08b0c24b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9056eb749ddd4517883d1f3860b7f895_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id83f26d989d54298a0d5f2d84eba7095_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f2f31965b52467a95929f7baa16f7d7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if31c2aa3a1bd42508fa6f5053cec3008_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1d7ca27f075d4f19be69a74e81087fd1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifbacf682032e4d0d92179fdcbdcc44c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifcbf5fe2793a4a75ace02762c09dba60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07ccaab8fd444e1e96d9d0b927e5739d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i82f354105f424032836cdf535b931213_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic3575a755df04fc38d5dbd355577687f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie86ab0c9deac4c1cb5e311bc6ccc3e05_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id4cbbd0e273544ccb20f9d106126ecc3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i368576ec62ee45cca0320cd56f18e01f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4f255485789b4a73b043e3b00f87031c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia5215658c5cd475abde0249738d23319_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic40f1f5963e54a2cbe900fef28214a42_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia6915ee2f4e247fea81a5a54115ece38_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i87dfdf9848204b5bb02322c598155b03_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i41f829e207b542b5b614a6ac506833bf_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iec639d3cfaee463ba8e594bc6bb5ce4b_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mygn:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6fc8057f2387410d80b503300dd4c3c9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2a04aadd840a46c4a950e132f342709c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i27f9832c214f44bfb3307e6c592c3894_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7d40dec02733475a840d3032148ea124_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id126768d0af64211a663a5ba94eb3c2c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4fa41121b7d143cfbc8e91a9ced3020a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4321aa8ac0974d02ac5b95ed298d955b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3fe93ba93efe459db6badb7752b80b87_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib7ae454902ce4cceb0fb07cad24d3c8c_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0152bd259b6948b0bc3b7e357d1fc445_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4e94095aa8954df29cb417ee209e2fff_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib4e8e7880267470bbc22e12957f39118_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i446a798869a940bcb0840713d8d197d5_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i088a89f8c55a4830ae8f287603af0a85_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i71764f1445be4ec3b1d8f1ae335382fc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibf7ecebc2a4a4743b808a47645131aae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7ba2f4fd98b0498cab6a8cd62a52550e_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i608839facd584950806bdce9ed6b7161_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i60681fe10dbc48539edaa19296f641ae_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i162851a888574726bbc3d4a48c455909_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1c62e82c4b0646a5bfc481b48968354c_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie73cf1f18b64415697365cb853c1fc55_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i75b0f8fc04374becb000201e80f83824_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iba570416299441d585bdbe522d386ebb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i236ed4b1de894f8198c2d79df713cacf_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i66122a21283042e5b1642886306f936f_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i908c0e65a6164625a7ffbc02d881c4b4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie9caac20c6a643a08ddbe9107e60ff80_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia9bef53171a3408ebbb6bb19f0a61b94_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6a9a17ae382543bfb59eee6cb07b076b_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i28c0950a478b45b8a240f2704954aa73_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0c7a502434884775af9bab6a939e30b9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if9ced64cb3044b06a122bd28bfff5d43_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48f46e422d5d477f8d00d83b4afb9715_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib5d8ea4dde274fe09e92affa3ca98896_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia63cb40eed4a4bcdb75e61ac29fd3ce1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia0d0673d53164492ae8fdf1825d7cc9d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6f2792c0364546bc85db617aec3476eb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie9ce5e2d04954ed79bbdbdf2f86c31be_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i912da28c3ce14d5fab748b5b779eddcb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i78aec82de9644c62815efaae24c0f234_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i968b103643364f408ebde53bd855f7d4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i28401cefd42342bba22f821ee9e35aca_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i28171e2c0157437f901e8ac487ced4c5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8433607b2fd04ed895116661af183b0b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3a1ac302b8d049b5bd17bf6490234668_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7cffa2ae4f264f0fbe8bd94485d5382d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if753bf4c43f64a0c8907e6861712cbfd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i857664e374a749be8f04a47ced6ef989_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i474e84aa7269419cb39f79e96b3c61b4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2708618e4b62400ba3acf94032086aa2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ife78b8cec88a4dc7b70010cc79af31d4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i69ab00712f2643a8801797ff591de929_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i50d11802ef0a4bf2934928e07af86a9e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib210a719b53c402c8f0246ea4d23a748_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i10e8721d20f74d5b9979734f2dfaaccb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic4097e0cabf84d8bb42c8e84583e28d8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i030ec43c8bcc435dbf4851b0831df548_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia7677472fc774c0ba9acaa9a151d2429_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i06e7851a35894a76b2c28ad9ef85560e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ice489849d4474ba488f5e3ef419a245d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i899daa04a5384ab09446e722067496aa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2e9b90c162674cfe89cd17b243422a63_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i94d4c8e8d9344b66817f27a942c9a7e5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i10158fbf9e4e44dfbc25c01cdd6f88cc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id233c4026cd0475ead24a770126edd58_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7e280ffa520e4589adc014530a498776_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i512678e2e28d43929c1f1c4039a3643b_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia7d58fcd3a8a47c38f913ca273d9e241_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iae97bd45a73e4d6b901011f4c036e632_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:HereditaryCancerTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id0196c4e720841a6bf4668d9ae0d9976_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8dcbd3ba88b14b8cb9f6afb24c8af942_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4dcc457344ff41b99f24941ed96867bb_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i11ab72b1aa84417b9db57840fd5421d7_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TumorProfilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id3b7bb1fac6041bd8446301c256d5875_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id9fa0c093df9436380086f024d36dc1a_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i693d5f7bcfb9431498131ea693785506_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib834f1b2fee94f00991b25d7ec3f8343_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PrenatalTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i01d6d35e2fa543c586adcc726885b4d6_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id8440650c7814ce6946c100b1a08a2f6_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia2438f843e5643799b35cc8647fde1bf_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i255d2253a7a94a53b1e5268006eec230_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:PharmacogenomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i81bb19aea32d467b970e042769acd6f2_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i569b535e97d84810b0407243c35fc225_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i27a4954bb37f4c87a40da845b26d61d1_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3b140020e5bb4309b28dbcafa95601f1_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:AutoimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7ae24aee3b354ce6bbf7be3fb4302b94_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i138bed0fe82b4330903b41329c9addd9_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i09ebb20a8a124362bcd7a8357aa29fd5_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i03a43431da5647adb236a2611029b943_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:OtherTestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icabe0b5ad1bd43baaa10f6239519e5e3_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id3dd9a90cd904e9bbf3710d2fa7182e9_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2d51d292699e4dd78ccb0056227a5ce1_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i78a52daf7ef347be82dc84982294aa48_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mygn:TestingRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i15b05f5f12104bbea82045fddddc48f0_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i14388d06b3b646bd940f87caf35842b0_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i258e4de3fb8c414ab710d4649d307805_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id55bccb976bc4a4e842f7029e06bddf5_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i35dea8de7d5247b6af91e476fc730262_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8042ff618ec94c0b90363a2a23ccd745_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i81b11dfa14ea4846bee1b74c8a4f62a1_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7251f8f8dbe2418b8cb8bcc34820beed_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i22b6ad0c0a184276b026278ab2492214_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">mygn:PerformanceObligationEstimatedTransactionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i67176840186a45f8b5451e8e62e7f69f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">mygn:PerformanceObligationEstimatedTransactionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4259e411c05a49db8fc3dba108adcb2a_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">mygn:PerformanceObligationEstimatedTransactionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if83d47ed8afd45349ebc0526f0253b99_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie2d0848b372c49e7879916eea4a55d95_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia75f79427aab4f40a89a2217f2dc3335_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id0da8029be334899949f916d03b47e6e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieecccfa51e634b24b60447c9f26442d1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iea4bf30af38941b3b6938c631d1ce22e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i33fcfcc4292d45c6b97cc255ecd96967_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib0e18392f2264c7ba9f8a25badbde19f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic37ece6897254048a406c0b1fa7f3ad7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a9bed5c63e84983966641b7a24d4bd5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iffb0ffff83b34e97a987ed8e7389d515_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06c8acb8e4034c26bb0e7099f0eb44f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae9580cce4d64144acfc341401d74a31_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6fa40776bd48450d8df11ae05f802a71_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i823a913a8ad749ad8b995c1f537650c7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:SividonDiagnosticsGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0aaca7c4dbe24675bb0115e449ba69fc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iac2403f7ee104879ad98b6a6781a824e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4956a5a0ff064149afbcc9ba2dfdc7e7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6f3a3fbe29f8436db24dface84e90cf7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i054731a368194949b2bfc357f58a8920_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if505b51f5d2949a79b80bf083731f945_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2b9734be1f184d3ab68c6b578ec56321_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic347427564244bcc8e0ff3d8c35f4333_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib1a379dc7f4c475caaaa883ad45060a9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i52834bd336224beaa3d88ac9bf176567_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0531632a6ded481b8155d92ceea1b3ea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8957a860dc7c44a8943b3e806ea2d496_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i75e1560d14dc4c37a9651815e98123dd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if528d1eea02f4c89b8cc2f9410d179e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iabee9b04bba344d0a4676474f9fd0aa9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7f4ee512990746498f686969e753a8f7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4fa11b5293574a56b95e476c81a3cbca_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5d313c46b56f4ea4811041efe14780de_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8776fe30d4b443b885e41cdae0f9a864_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9a42cd3883284fccba2c6f45fdec7c5c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2617796d6b8d481c94ef7401da39b8d8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic168d5bc29fe42c6a375be189bffb89f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibae6823d4dfc48c78710aeb85ccacafb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i53c84ffe4852490b9b62069255f02f88_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6f6de559c7f84f1ba22b6bde6e9505dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba93170941f54ad4a6e9bd9506cadfec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf95e9b463a9489fba6e904f9b508bc0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1f7a81ab4d546fa8363f6765db2ca47_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f4577ae6fc24714b12a9f4dae881ad9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia38de968e38b4dd0ad1104298f2e258f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0493540df994c2f871795b87f29a7bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifdb7ac3fc3ba484292b559015692e497_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1763682428bf431f830915fa01ba4076_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3cba5a8d0243495aaf7a24002f234432_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic69437fe4efd4416859e92172cc5790f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie95b38d0545844f98dede4b82126203f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e7d1835e2e34202be5a79f205d84bd9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b14cf32d8ca4635ae65df760ee25e81_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife394a441cff404aaae4b092a3d3bb46_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibe950e801781495697dc7289c421c614_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id59c003282bb4959a9f3ab119e181c6c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1174c90b6ee4dc5b6d409ab036a9e96_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30e651fc58854e6d9587d0fd1ace6220_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie511c7937db0407398aaef7ccbbae95e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mygn:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i524f05cde0ab49718e7546d04f102aa5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50667905e6f44ea3bbc5d72c01cf8826_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d017fae949f44c49fe499f702ad7561_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b01cebc763e4599b78408e1e92b66b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4a85a5fe1cfa49c0aaf2a1f85c315776_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0bbbaf79da6c4e839df3a413fd2c8433_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7d090498adec48f5a5d9ada3ace9a11f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87c0d4d014b8431486ad3d3075f0ca84_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2ed990c23f164e939a73f7223c4d3011_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncAndMyriadAutoimmuneBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia5e94090de30419c96fa1c05060afd64_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">mygn:MyriadAutoimmuneReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i39965e7109344a238233c9caa866cfb3_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">mygn:ClinicReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id82e3f3eeb68492399f4153822f134df_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="if437534e60cb4439b2cd0da6651519aa_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="ic3c2906fb217491a8423ba010a090290_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="ic7975a4442d44d779f0f1bf53782120d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ife7424d471c047f29674554074fafb8c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i082547e446854663944c1f7d21ca67bf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib6ebe315d6824fd7a89d2f7c74efcf31_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i88103ecea9f2472aad40efe4318bcd91_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9aef28d53f8c47c8ab1d99d12cdd400f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id72ef2bad75948119bfd502da5931067_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idcc890f9cd184879a64c08e82dcbbc8f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i73af76a4fce548948796425f49a1806c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i43ae1240cef14457931c317f4fd211b4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i23aeff032bf24bb8a9d3d3bb253094dc_I20161223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-23</instant>
        </period>
    </context>
    <context id="ia162acc4f40848918e001774e6a4f960_I20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="ia7185e4956c746a9b0f45493392d399d_I20210222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-22</instant>
        </period>
    </context>
    <context id="ib45bd6e5ec9a4ed7a463e74534d19bab_I20210221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-21</instant>
        </period>
    </context>
    <context id="i674b5e2ec7a24dd2868cf183995d5ed4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i33356f53153c4a03be9389d7449cf3f6_I20220725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="i843f20e91d9b42f9abab257be67b0fba_I20220726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="icf8301cef485443f9fbd8a975ee8e8bf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f459a7b8fd94d27b059f67e4c1866ff_D20220726-20220726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-26</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="i262a62b1f2d845acbe48f9be412ca7bf_D20220726-20220726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-26</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="iaa57fda02bc54eccb40407c480ef96e1_D20200401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i60ba3c848587432396a389bd552eb846_D20200401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i58d539dc7d304c43a5fbc7a02678e86e_D20220726-20220726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-26</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="i93a2ffa60cb1493fa939b40a6cd3610e_D20220726-20220726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mygn:AmendmentToCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-26</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="i1e2a786776cf421188638389979b41f0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3f7f76edb655468cb01a3ed28231577b_I20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <instant>2016-06-30</instant>
        </period>
    </context>
    <context id="i5d254d84e7e9429fb9eb353fa0fe6727_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9757cc95b46f40a8a4d1310a7a341adf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i801883d593c048cf8de2e2c90f49176b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i12ca3a8a2ca341308119fa4fbac76272_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mygn:NonEmployeeDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mygn:OptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i662ff17b6ca34e25bba3e0323f9e924c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i17cec0855d2440f9801f4db7e5a729b9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i01fda04e6cb14149830711083c57c751_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8a3e0bd95e204ba5951ebd463f3b3a4c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i552292b1ed264bf49d505c379dad4c2b_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaafdb3a4d0da4dec918d7e953639a791_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie26285660df14abb951924a100df85e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id5d419cf4013469c83dd80d51c5ee579_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i26ec50a211f240d3938bde3431435c8b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3dae6418ac5148938050aacb2ef5d508_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i968d2e2144e34ee4916a9183d20c0063_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i00d66009a0f2488699d68deb116f85b0_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if6b55a5a308740858d157bc072e2ecaf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie6834607b2374e2b81387c6f893f406a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2868dacc9996425d84f6678061f8071d_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5e2d7d18c84e44c5a8a95712783d775b_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if34523c4b068408ca1452aea7567d7b8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6f6f6d3b79734ce2bdb563e220afb94c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i66dd3e15c00846fc81665b366c136737_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id15d2c557b414206ada2d552b9b565a4_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mygn:CostOfOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia04b5d1b8fa24d0fad862d180d2bd154_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i87a0fc790ba34918898f41f810a4a2f1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaa289b04ec1840778fdb19aca12b8a05_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iff363386463e4c7b99ce076eeb84919c_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i249245e4ff6941f7be7f6d734b685a95_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i86e699f1c66445bca22715a30a1f46ed_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i58532a67b1154bc58a0b382ff6c515d4_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4d1d3c76ec0427db381fbba56a23a6d_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iab27d0ec33e742d2977386c29c6a64ab_D20210923-20210923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-23</startDate>
            <endDate>2021-09-23</endDate>
        </period>
    </context>
    <context id="i15344703477a40f5b457a744eeee71b2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3580a51b82cc466099d9eb0a57c378cd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0f908585f461487aa148598b903a4f33_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id374269cc21d403aa573e11a92743d26_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mygn:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibc16948f5d7e4bd8969f02b7c60c2fc4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8481cd3af014407fa42d2b6f5b5acbdf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idc38c0d48fe34cf9a4096e501b238ec1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7acceb782b124009867513e1e395eb09_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8265cfaa4f6249e280c2c2cf4edf2b88_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i94684063e7f148b8b931a967f3ea2e9d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie05625b5ce714586b315182123a0066c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0e56caf70d6447518290386f81719ca9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i94ef8507bf234538b9ed98fb0e389325_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0bbddf290d464aadaa27acb940277180_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib3a2d7f8de3c427785c15b09085c84d6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i83f4a6d86c4f4eb39c69c44ec0b4f2fd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib5f72eb0018746c886b57ce4f50c4db8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i491a5a05cb774a8fb1c3c42b73443667_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaef3f6c95fd94ce4b015ac7e3db94ae4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">mygn:OtherStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibea3c187441f480487b44a951451baba_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">mygn:OtherStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if40585f71c3c463a9840bdd7070fc047_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id2f519e64bc04789a7526a6bd09819a6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia9e7946b9ce6498cab7885f8d675da90_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifb59e7c4e69149dd82d0501e71e1ce19_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaf9dfcf78da842f5bad9f364f2105f81_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i532ba0950b96453a85caae716fac82b6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1da4606ad7ed41209dfcdca23de08ed6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic667a4f90d994acbb20e3e566f84f92e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iea7482a897494be892bc46b821925654_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if99355023d8f4ac5ab1b42964f050f9e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">stpr:UT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i06d164c0b6e04a459e6a33b952092ab4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6df636aa6bd446ed8b2aea33d99d66a4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i78b35c2904e342a2a22d1151ef8b25d8_D20201221-20201221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mygn:RaygenIncVersusMyriadWomensHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-21</startDate>
            <endDate>2020-12-21</endDate>
        </period>
    </context>
    <context id="i7ec137fde2704324b8c089d57adb90e5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="mygn:LeaseArrangementAxis">mygn:WestSaltLakeCityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib7c0bca71a544a8293274a98d8342a84_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="mygn:LeaseArrangementAxis">mygn:WestSaltLakeCityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d8e9e97f965410eb1e1d5fb7d188a69_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mygn:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3d0e08156cb641f29dd07ca3ce93941c_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iabf0e35c76ce4737b597d4d31b6103bb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id0f83e0a22104fedb4e475de48140594_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03e3d05930c246f797d9ab7061985860_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e82739b44cd45d7b099f422b6ae33cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4c8aad575c1d41c389544f11390b9d59_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib0a06975e9204301b5cb15099574bcee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i871418f253134efc9cceceeafbb4c291_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="ic41e7d1ebb214f6792a964d2daa1b432_I20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="ibd5b839397f4403ca413620e5ce1dffc_I20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="i789e41c2063b4e77b952b8700cc045f7_I20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="i75436f77b2804ab3bbcc97fe20a6f36c_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="i7a2ff25d850940a7bc40bed0d8065631_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i673ce123e2a44d4598692c845966f939_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i42ace60aa6e54d01b61af32b6f5812e2_D20221101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mygn:GatewayGenomicsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i32039b626a934562bee22c0bff60b59d_D20210528-20210528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadMyPathLLCLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-28</startDate>
            <endDate>2021-05-28</endDate>
        </period>
    </context>
    <context id="if94a3c16ec0f40b79d3e7cd2713c4a83_D20210701-20210701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="i754115245e57408994525a98aed1283a_D20210913-20210913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadAutoimmuneAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-13</startDate>
            <endDate>2021-09-13</endDate>
        </period>
    </context>
    <context id="i11ee8a7e07b6457b867d5750561f27de_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadRBMIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2ba75a9ef71348d3b90148f91f146b36_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadMyPathLLCLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7b99a13c827f4f10ad3b6af0f22ddd25_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie73f9b8455314405972aa71faee08793_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899923</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mygn:MyriadAutoimmuneAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="position">
        <measure>mygn:position</measure>
    </unit>
    <unit id="patent">
        <measure>mygn:patent</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="segment">
        <measure>mygn:segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF80L2ZyYWc6MDc2YzIxZWQ4YzlmNGFmZjk5ZjE4Nzk1NWVhY2RhNGMvdGFibGU6OTM5OTNmNDVkYzcyNDA4YTkxZmNhMTczZGM4YTQyMjQvdGFibGVyYW5nZTo5Mzk5M2Y0NWRjNzI0MDhhOTFmY2ExNzNkYzhhNDIyNF80LTEtMS0xLTExOTQ4Mg_9e6da5c2-1a1e-4a6f-98e6-500b91c39f37">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF80L2ZyYWc6MDc2YzIxZWQ4YzlmNGFmZjk5ZjE4Nzk1NWVhY2RhNGMvdGFibGU6OTM5OTNmNDVkYzcyNDA4YTkxZmNhMTczZGM4YTQyMjQvdGFibGVyYW5nZTo5Mzk5M2Y0NWRjNzI0MDhhOTFmY2ExNzNkYzhhNDIyNF81LTEtMS0xLTExOTQ4Mg_367f6a40-3641-47b5-9323-cd9325224223">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF80L2ZyYWc6MDc2YzIxZWQ4YzlmNGFmZjk5ZjE4Nzk1NWVhY2RhNGMvdGFibGU6OTM5OTNmNDVkYzcyNDA4YTkxZmNhMTczZGM4YTQyMjQvdGFibGVyYW5nZTo5Mzk5M2Y0NWRjNzI0MDhhOTFmY2ExNzNkYzhhNDIyNF82LTEtMS0xLTExOTQ4Mg_0ba702f8-bdf7-474c-98d6-260f9749022a">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF80L2ZyYWc6MDc2YzIxZWQ4YzlmNGFmZjk5ZjE4Nzk1NWVhY2RhNGMvdGFibGU6OTM5OTNmNDVkYzcyNDA4YTkxZmNhMTczZGM4YTQyMjQvdGFibGVyYW5nZTo5Mzk5M2Y0NWRjNzI0MDhhOTFmY2ExNzNkYzhhNDIyNF83LTEtMS0xLTExOTQ4Mg_5aafb855-4b47-4efe-b6fd-ff3ee89e6c7c">0000899923</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6fc8057f2387410d80b503300dd4c3c9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfODUzMw_6379236e-7018-4cbe-9f98-2974e673bf30">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i27f9832c214f44bfb3307e6c592c3894_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfODY3Nw_ce7f7168-4bc2-4449-b270-c38ee0a58400">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="id126768d0af64211a663a5ba94eb3c2c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzE4MA_55b83f90-88ae-4e25-9b41-229696ec6103">P1Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:NumberOfReportableSegments
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzYvZnJhZzo5OGVmNDA3YmY4OWM0NzlmOTJlMzIwMmRlYmEzMGY3Mi90ZXh0cmVnaW9uOjk4ZWY0MDdiZjg5YzQ3OWY5MmUzMjAyZGViYTMwZjcyXzMy_2096e0ca-861b-4248-b81f-591a49b41118"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <dei:DocumentType
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODc1_174f10c1-07d5-4dd2-815e-e9c1b8600c26">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGFibGU6MmZjNzk3NGZlMGM5NDk0OGJlYmRjYmRjMGViZGY2ODkvdGFibGVyYW5nZToyZmM3OTc0ZmUwYzk0OTQ4YmViZGNiZGMwZWJkZjY4OV8wLTAtMS0xLTExOTQ4Mg_f17b2fd9-a7a7-4dda-aad3-0589860aafdb">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8yNTY_1df8d337-7eab-4c53-bca0-ae101843eced">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8yNTY_5bfe4b09-a388-4cbe-ade7-627ae7282c06">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGFibGU6OTZmMmZkNWYwZWY0NGVlYjgxMjQ2YjZmYzMyY2UxZTAvdGFibGVyYW5nZTo5NmYyZmQ1ZjBlZjQ0ZWViODEyNDZiNmZjMzJjZTFlMF8wLTAtMS0xLTExOTQ4Mg_2bd001a3-a377-4727-8b93-3c7dd01b72be">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODgw_98d58e3e-0950-479b-a2d1-b28d02e2a91c">0-26642</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODgx_4ed75881-27c6-4721-aa58-922d373e9ef0">MYRIAD GENETICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODg2_d41a59eb-5edf-4d6c-a64d-acec68bf1312">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODc3_415ee600-ed51-4b20-854a-57dac6cfcd13">320 Wakara Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODc4_63f3b5c3-270a-47e9-8d53-3f26e9eeaa8c">Salt Lake City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODkw_55a173c4-eccb-4996-baac-93c1829f7f4e">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityTaxIdentificationNumber
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODcy_9e325ac9-ef1e-46f2-95d6-0bcc9a13091a">87-0494517</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressPostalZipCode
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODY2_642dc0ad-8079-4af6-8562-ce4c2662d485">84108</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODg3_2cc5c72b-67cd-4155-aa24-d2414ec047be">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODcz_7037ba08-da59-4bf7-a06a-07e17b51a3a3">584-3600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGFibGU6Zjk1YjhlYThhNzQ4NDliZmJhNWIzZjY4NDhiYzI4YTgvdGFibGVyYW5nZTpmOTViOGVhOGE3NDg0OWJmYmE1YjNmNjg0OGJjMjhhOF8xLTAtMS0xLTExOTQ4Mg_1412e05b-f270-4ee8-a0cb-ec63fb3e200d">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGFibGU6Zjk1YjhlYThhNzQ4NDliZmJhNWIzZjY4NDhiYzI4YTgvdGFibGVyYW5nZTpmOTViOGVhOGE3NDg0OWJmYmE1YjNmNjg0OGJjMjhhOF8xLTItMS0xLTExOTQ4Mg_e9861f66-5111-4330-a867-03511efc32da">MYGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGFibGU6Zjk1YjhlYThhNzQ4NDliZmJhNWIzZjY4NDhiYzI4YTgvdGFibGVyYW5nZTpmOTViOGVhOGE3NDg0OWJmYmE1YjNmNjg0OGJjMjhhOF8xLTQtMS0xLTExOTQ4Mg_9bfbb968-f9ea-4cb4-8f8e-889bda813243">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODcx_77191452-6149-43e7-be14-4cd46b938044">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODg4_cfe3f34d-ce86-498f-97ac-8e8c3f82dea6">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODky_59d72004-c636-49e3-85b0-a445ca9682ce">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODY1_ec483ddb-2091-4dbf-bcfb-c428d36d1f51">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGFibGU6NGFiNWMwNTM3OWZhNDEzOGFlMzBhNTM1NGEyMmY3MDMvdGFibGVyYW5nZTo0YWI1YzA1Mzc5ZmE0MTM4YWUzMGE1MzU0YTIyZjcwM18wLTAtMS0xLTExOTQ4Mg_fe75e693-3d55-448b-b429-1d51cee49a23">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGFibGU6NGFiNWMwNTM3OWZhNDEzOGFlMzBhNTM1NGEyMmY3MDMvdGFibGVyYW5nZTo0YWI1YzA1Mzc5ZmE0MTM4YWUzMGE1MzU0YTIyZjcwM18xLTQtMS0xLTExOTQ4Mg_ea281924-36d5-42b6-8d7d-5b8555c62828">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGFibGU6NGFiNWMwNTM3OWZhNDEzOGFlMzBhNTM1NGEyMmY3MDMvdGFibGVyYW5nZTo0YWI1YzA1Mzc5ZmE0MTM4YWUzMGE1MzU0YTIyZjcwM18yLTEtMS0xLTExOTQ4Mg_7363ee06-5d09-47f2-88fa-0fc31073f68a">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODkz_3ef1ff41-ce27-4fae-9695-212b75eb0fbc">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8yNDczOTAxMTYyOTUzOA_9048c7c2-87a9-4fb4-b07e-10cac83cd4c5">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i7f732cf8e70f4da79cc772ea647eba95_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zMzg5_e08d47ac-a4c4-438f-984e-78caf5c4e75f"
      unitRef="usd">1465095487</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i3b8e0501187143259a1544d7c2a53414_I20230223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zNDIz_d3e3c9e4-0692-47fb-9604-88c3703d616c"
      unitRef="shares">81223713</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xL2ZyYWc6MGFhNDc3MDk4MWJkNDRmZmEwYjdlNGU4OTNmZjczZWEvdGV4dHJlZ2lvbjowYWE0NzcwOTgxYmQ0NGZmYTBiN2U0ZTg5M2ZmNzNlYV8zODc5_777e7edb-ef91-4759-8e04-1c590685bf93">The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K:&#160;&#160;Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant's Proxy Statement, to be filed no later than 120 days following December&#160;31, 2022, for the Annual Meeting of Stockholders expected to be held on June 1, 2023.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF82Ny9mcmFnOjM1NzgyYzFiNDEwYjQxNDA4ZTJkNzY2OWVlZGNhYjhlL3RhYmxlOjQ3NzYxYzA4ZDU3YTRmYTM5YmY4YzE3YWYyYzUxYTMwL3RhYmxlcmFuZ2U6NDc3NjFjMDhkNTdhNGZhMzliZjhjMTdhZjJjNTFhMzBfMi0wLTEtMS0xMTk0ODIvdGV4dHJlZ2lvbjo0YzIzYzdlOGFkMWY0NTFlOTNhNDczMGIzYWIzZWY2OF83MQ_7017c1db-c854-442a-bdfe-01cd16dcbecd">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83MC9mcmFnOjg4ZmI2ZDUyYjgzNjQ5MWU4OWRiMDI5YTZhZDUzM2M4L3RleHRyZWdpb246ODhmYjZkNTJiODM2NDkxZTg5ZGIwMjlhNmFkNTMzYzhfMzYwNQ_953e7a16-5856-40b6-9314-701ebefefdef">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83MC9mcmFnOjg4ZmI2ZDUyYjgzNjQ5MWU4OWRiMDI5YTZhZDUzM2M4L3RleHRyZWdpb246ODhmYjZkNTJiODM2NDkxZTg5ZGIwMjlhNmFkNTMzYzhfMzYwNA_4ca6624b-31c7-49c3-9bb8-56f564fa0875">Salt Lake City, UT</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfNC0xLTEtMS0xMTk0ODI_b3256974-a115-4cbd-980a-6c4b5b8d1420"
      unitRef="usd">56900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfNC0zLTEtMS0xMTk0ODI_06765e56-e9b9-410a-907a-7a674c2dae25"
      unitRef="usd">257400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfNS0xLTEtMS0xMTk0ODI_44a7a48a-05db-4777-bec6-f945e0620b2a"
      unitRef="usd">58000000.0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfNS0zLTEtMS0xMTk0ODI_e6aded1a-f189-4e6c-b158-8a1ef6053c43"
      unitRef="usd">81400000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfNi0xLTEtMS0xMTk0ODI_4c5264c0-b7a9-465e-bea5-1c4b70c60207"
      unitRef="usd">101600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfNi0zLTEtMS0xMTk0ODI_1a4f9b0a-ca4c-44f3-a29a-450508739ff2"
      unitRef="usd">91300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfNy0xLTEtMS0xMTk0ODI_928e64ed-2476-4e36-a4f8-938c7464ca6a"
      unitRef="usd">20100000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfNy0zLTEtMS0xMTk0ODI_60806859-d50d-426d-8ea5-6ac058f936b6"
      unitRef="usd">15300000</us-gaap:InventoryNet>
    <us-gaap:PrepaidTaxes
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfOC0xLTEtMS0xMTk0ODI_6fde0f72-2558-4f0e-930d-94ff43789041"
      unitRef="usd">17600000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfOC0zLTEtMS0xMTk0ODI_be42c83f-3237-4627-83c0-8aa5a7330441"
      unitRef="usd">18400000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfOS0xLTEtMS0xMTk0ODI_2b7a9029-2ccb-4285-80f7-db884ff9baf3"
      unitRef="usd">20400000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfOS0zLTEtMS0xMTk0ODI_27ce5862-fb0b-4e8b-b2a1-26c8a059ac8b"
      unitRef="usd">21000000.0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTAtMS0xLTEtMTE5NDgy_d87d5b99-60b0-48c6-aa78-75b816c85d62"
      unitRef="usd">274600000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTAtMy0xLTEtMTE5NDgy_ddff78d1-efb4-4eda-8fa9-1675f48b6a3d"
      unitRef="usd">484800000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTEtMS0xLTEtMTE5NDgy_c4a3069e-4778-44d7-bb48-f350b9e36e91"
      unitRef="usd">103900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTEtMy0xLTEtMTE5NDgy_e62dfb5e-d9c9-4f80-9c84-442173a0887b"
      unitRef="usd">81800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTItMS0xLTEtMTE5NDgy_0a5b359d-1cfd-4ac4-9f99-cea73bc4dac3"
      unitRef="usd">54800000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTItMy0xLTEtMTE5NDgy_cd922227-a6f9-4b9a-8253-58aeb1706d08"
      unitRef="usd">59000000.0</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTMtMS0xLTEtMTE5NDgy_046ada57-0b70-4ce4-8652-724cfd8a720b"
      unitRef="usd">83400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTMtMy0xLTEtMTE5NDgy_2c2135f8-fd84-4bef-b183-ac3b6e60b4dd"
      unitRef="usd">43500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTQtMS0xLTEtMTE5NDgy_7917c73a-055b-406f-956c-74ee649577fc"
      unitRef="usd">379700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTQtMy0xLTEtMTE5NDgy_c3a0e19a-3912-4f69-bd1a-334aa1301d18"
      unitRef="usd">404100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTUtMS0xLTEtMTE5NDgy_105b8973-1084-485c-94b6-4113174f6c71"
      unitRef="usd">286800000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTUtMy0xLTEtMTE5NDgy_2c054fa8-8660-4b36-8c3e-36533d8e97ad"
      unitRef="usd">239200000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTYtMS0xLTEtMTE5NDgy_7d07bbb3-a44c-4319-a7fc-baae3529ae93"
      unitRef="usd">15500000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTYtMy0xLTEtMTE5NDgy_67b69988-8ef0-46d1-bb85-51f4e1937b1f"
      unitRef="usd">8300000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTctMS0xLTEtMTE5NDgy_af8add20-7c06-49f5-8bd9-629bcf516352"
      unitRef="usd">1198700000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMTctMy0xLTEtMTE5NDgy_5bec5532-17a6-4b70-8df1-8e7bf0af7ff1"
      unitRef="usd">1320700000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjAtMS0xLTEtMTE5NDgy_8b1e2720-08ec-4da9-9379-3ac27f896bba"
      unitRef="usd">28800000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjAtMy0xLTEtMTE5NDgy_e165287b-e400-491b-93c7-3dd72b9a9362"
      unitRef="usd">29600000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjEtMS0xLTEtMTE5NDgy_260c359f-a951-423f-b586-cacbefe17034"
      unitRef="usd">94300000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjEtMy0xLTEtMTE5NDgy_b6b7ef62-1d8b-4b8f-8257-b7f7d5adb42d"
      unitRef="usd">161700000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjItMS0xLTEtMTE5NDgy_8bafa683-f0f5-411b-9c6a-9ca05ac018a5"
      unitRef="usd">14100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjItMy0xLTEtMTE5NDgy_c97d51b1-8ee4-4ba6-8c4a-86afc9b2c318"
      unitRef="usd">13000000.0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjQtMS0xLTEtMTE5NDgy_c7c6c55c-2de9-46f7-9c67-1a764c9f8e1a"
      unitRef="usd">137200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjQtMy0xLTEtMTE5NDgy_4b32eb39-b2e4-4b20-a879-76221ddc91c6"
      unitRef="usd">204300000</us-gaap:LiabilitiesCurrent>
    <mygn:UnrecognizedTaxBenefitsNet
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjUtMS0xLTEtMTE5NDgy_6d51149d-e545-409c-84f4-40e9c9d1705a"
      unitRef="usd">26800000</mygn:UnrecognizedTaxBenefitsNet>
    <mygn:UnrecognizedTaxBenefitsNet
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjUtMy0xLTEtMTE5NDgy_b2693a00-dc99-43fb-94c9-07f599bf7fae"
      unitRef="usd">27900000</mygn:UnrecognizedTaxBenefitsNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjYtMS0xLTEtMTE5NDgy_f8323905-0486-4cd4-8118-28c47b33c4a2"
      unitRef="usd">3500000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjYtMy0xLTEtMTE5NDgy_392d7f6b-f7d6-42ee-8dc8-d8d8dd5cf2e8"
      unitRef="usd">35800000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjgtMS0xLTEtMTE5NDgy_b7cea601-291a-4bf5-80f3-468b45d8ea03"
      unitRef="usd">130900000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjgtMy0xLTEtMTE5NDgy_c61b0b3b-96c7-4e78-869a-bfd01695520a"
      unitRef="usd">79300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjktMS0xLTEtMTE5NDgy_16f05521-edac-41f3-962a-a83cb8c83dfe"
      unitRef="usd">14500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMjktMy0xLTEtMTE5NDgy_2f8838f0-a0de-4815-9ddd-0ba8bf785f53"
      unitRef="usd">5600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzAtMS0xLTEtMTE5NDgy_952b21c4-be8e-43eb-a781-942e61423251"
      unitRef="usd">312900000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzAtMy0xLTEtMTE5NDgy_fa1c012a-1a7b-4856-bc3b-5d2bee4f6c32"
      unitRef="usd">352900000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzEtMS0xLTEtMTE5NDgy_9ec4c75c-2963-4e2d-8912-144f2c10e481"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzEtMy0xLTEtMTE5NDgy_07f1508e-f38e-4e7f-af64-6f3c209c3d22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzMtMC0xLTEtMTE5NDgyL3RleHRyZWdpb246MTQ3ZDRiODU1ZDEwNGUyZmIyNGRiM2IyMjZjZDE2NmJfMTg_4dd9341f-205f-466b-8f85-f75b04ec5864"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzMtMC0xLTEtMTE5NDgyL3RleHRyZWdpb246MTQ3ZDRiODU1ZDEwNGUyZmIyNGRiM2IyMjZjZDE2NmJfMTg_81d19498-8e19-423b-9a35-effa6e107401"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzMtMC0xLTEtMTE5NDgyL3RleHRyZWdpb246MTQ3ZDRiODU1ZDEwNGUyZmIyNGRiM2IyMjZjZDE2NmJfMzI_696b133f-9e7a-4b19-8e83-8a910b4ff113"
      unitRef="shares">81200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzMtMC0xLTEtMTE5NDgyL3RleHRyZWdpb246MTQ3ZDRiODU1ZDEwNGUyZmIyNGRiM2IyMjZjZDE2NmJfMzk_e2bac127-66bc-48d9-96d6-f150e1bf3b63"
      unitRef="shares">80000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzMtMS0xLTEtMTE5NDgy_34ef816f-c57b-4931-9a11-bfd233f27b7f"
      unitRef="usd">800000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzMtMy0xLTEtMTE5NDgy_8edcd9ef-ad24-4107-b00b-ab96c91f8083"
      unitRef="usd">800000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzQtMS0xLTEtMTE5NDgy_9537e0c5-6ceb-4a24-bb31-9883f69a02ae"
      unitRef="usd">1260100000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzQtMy0xLTEtMTE5NDgy_b9793d2c-ae3f-439f-8fda-54f9f100393e"
      unitRef="usd">1226300000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzUtMS0xLTEtMTE5NDgy_ab5113b3-6014-453b-a4bc-11a3393acbef"
      unitRef="usd">-8900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzUtMy0xLTEtMTE5NDgy_d6c23a9e-d84a-44c7-87fe-0e26c65171cd"
      unitRef="usd">-5100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzYtMS0xLTEtMTE5NDgy_d295d998-1572-4c82-995f-9c39f906ae2b"
      unitRef="usd">-366200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzYtMy0xLTEtMTE5NDgy_5175735b-b0ee-4ebb-9589-11223183901e"
      unitRef="usd">-254200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzctMS0xLTEtMTE5NDgy_b0669e84-df85-4c27-a846-e7099641a449"
      unitRef="usd">885800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzctMy0xLTEtMTE5NDgy_74a04ba2-cfb5-44bf-a999-b111ce20470c"
      unitRef="usd">967800000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzgtMS0xLTEtMTE5NDgy_bba71d23-f2df-41df-8edb-62978af3f7c0"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzgtMy0xLTEtMTE5NDgy_261b4ed6-02a0-4f6b-8ed3-6a280bfc1fd4"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzktMS0xLTEtMTE5NDgy_78772fdd-79de-4eb1-a989-79a910fa8364"
      unitRef="usd">885800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfMzktMy0xLTEtMTE5NDgy_9324f7f3-c9c7-4c96-b0e2-d5bc1a16b5b6"
      unitRef="usd">967800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfNDAtMS0xLTEtMTE5NDgy_defa40e9-eeff-4ee9-ba77-5cab452a564a"
      unitRef="usd">1198700000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83My9mcmFnOmJjYzgyNTFjNWMxNjQwZmM4OGY5YWYzZTI3ZDMzMzdiL3RhYmxlOjA3ZDUwNWJmOTZmZTQ4Y2VhZmM3ZjlkMWJkMmM0MzdmL3RhYmxlcmFuZ2U6MDdkNTA1YmY5NmZlNDhjZWFmYzdmOWQxYmQyYzQzN2ZfNDAtMy0xLTEtMTE5NDgy_b425cd17-c10f-459a-aedc-0857d8fc98d9"
      unitRef="usd">1320700000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i308b88139f674cb09b58fa82ee43d092_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMi0xLTEtMS0xMTk0ODI_1727a502-8918-4f6a-9cd1-501791e7f076"
      unitRef="usd">678400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i794c44e7bf5b45689f334a7dc2a6cc11_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMi0zLTEtMS0xMTk2NDU_e1cc0da2-c881-472e-8439-dcde51fe2084"
      unitRef="usd">666400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i543bcad925584a75897772999efa4e3e_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMi0zLTEtMS0xMTk0ODI_d25ee0ad-1ed0-48e0-ba06-07c6434a2126"
      unitRef="usd">279600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc254773edfa4835899bcbe4c0b57775_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMi01LTEtMS0xMTk0ODI_1ef5f909-2dcc-4950-b907-4fffc9f877e1"
      unitRef="usd">586900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5bb3d6305f96409c9f4239ce2e6f890c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMy0xLTEtMS0xMTk0ODI_4368ec98-27ef-4d8b-886b-4ff3db5a9135"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i934fd4ad46814c4e88f3d8113c493def_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMy0zLTEtMS0xMTk2NDU_a4d21ab8-42b8-40fb-87a3-cd56d87ed583"
      unitRef="usd">24200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i329f9f45afc549329c841d2e34c6be5d_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMy0zLTEtMS0xMTk0ODI_089557b7-96ab-45f4-bf84-9652aafcb77c"
      unitRef="usd">20200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f216fe61ee54eeab8ab464958d1e5bb_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMy01LTEtMS0xMTk0ODI_d630c8bf-15c7-473f-9628-2af8753104f6"
      unitRef="usd">51700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNC0xLTEtMS0xMTk0ODI_83342bea-9317-4af2-bcc1-4f41197c8b67"
      unitRef="usd">678400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNC0zLTEtMS0xMTk2NDU_e560925f-8f81-45b6-9406-52dcf6e1a43a"
      unitRef="usd">690600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNC0zLTEtMS0xMTk0ODI_f4d389d9-ed40-4c60-96a8-24886f700429"
      unitRef="usd">299800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNC01LTEtMS0xMTk0ODI_eff355b8-1693-4f9f-984a-affc8ea0b2af"
      unitRef="usd">638600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i308b88139f674cb09b58fa82ee43d092_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNi0xLTEtMS0xMTk0ODI_c2e73016-db87-46d5-9de2-a27e67d6aaac"
      unitRef="usd">202000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i794c44e7bf5b45689f334a7dc2a6cc11_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNi0zLTEtMS0xMTk2NDU_b72adaf3-16fd-4a1c-971f-f1bc9e7be6ba"
      unitRef="usd">185700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i543bcad925584a75897772999efa4e3e_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNi0zLTEtMS0xMTk0ODI_689c4ef6-8da9-459f-b293-f0c15679c7a4"
      unitRef="usd">82600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ibc254773edfa4835899bcbe4c0b57775_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNi01LTEtMS0xMTk0ODI_12754d67-52e1-42a2-acfa-135c52cdc825"
      unitRef="usd">157500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5bb3d6305f96409c9f4239ce2e6f890c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNy0xLTEtMS0xMTk0ODI_247a37de-238e-4006-bc6d-14829614bafa"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i934fd4ad46814c4e88f3d8113c493def_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNy0zLTEtMS0xMTk2NDU_0bdf99e7-2a24-42d9-9e10-f9dc48cb9393"
      unitRef="usd">11900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i329f9f45afc549329c841d2e34c6be5d_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNy0zLTEtMS0xMTk0ODI_4524f132-6213-4bcd-abd2-c676e2589c3a"
      unitRef="usd">8800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7f216fe61ee54eeab8ab464958d1e5bb_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfNy01LTEtMS0xMTk0ODI_4b8e9e7e-0591-4db5-b8ac-afd618185ed1"
      unitRef="usd">28600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfOC0xLTEtMS0xMTk0ODI_e6af646d-4eb1-48b0-8fde-5e2af9fe8b65"
      unitRef="usd">85400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfOC0zLTEtMS0xMTk2NDU_260a388d-5da2-4308-b51a-524f6ae4e8f5"
      unitRef="usd">81900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfOC0zLTEtMS0xMTk0ODI_6dae71f7-3ddf-449a-92b6-423be427b9c5"
      unitRef="usd">35800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfOC01LTEtMS0xMTk0ODI_9621c50e-34d3-4e01-9308-32bda875500e"
      unitRef="usd">77200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfOS0xLTEtMS0xMTk0ODI_a9936adf-71c5-49f9-ad51-f154b6d3ffbe"
      unitRef="usd">514700000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfOS0zLTEtMS0xMTk2NDU_11a6cf1a-9926-479e-be74-42c2c087a0a3"
      unitRef="usd">537800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfOS0zLTEtMS0xMTk0ODI_8064bbfd-2646-4c65-818d-d9809bdac75f"
      unitRef="usd">260400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfOS01LTEtMS0xMTk0ODI_2df2b891-a90a-46d9-9705-7ceaa513cbd6"
      unitRef="usd">507300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTAtMS0xLTEtMTE5NDgy_cab5f7e4-4927-42d0-bf0d-c6dfebe43f7d"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTAtMy0xLTEtMTE5NjQ1_a7a4d2d6-18e3-47b9-9271-163da3b9be2d"
      unitRef="usd">62000000.0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTAtMy0xLTEtMTE5NDgy_b0a98e40-4b05-41e9-be36-19b8665ab857"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTAtNS0xLTEtMTE5NDgy_5451f93b-65bc-4ffb-adc1-5ecbd668bdf8"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTEtMS0xLTEtMTE5NDgy_eb76ffc0-7a92-41d8-ba06-bac027e33223"
      unitRef="usd">16900000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTEtMy0xLTEtMTE5NjQ1_9ad2fcb2-1b95-4fa6-b754-fb2ef0eaaeed"
      unitRef="usd">1800000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTEtMy0xLTEtMTE5NDgy_5be3750f-1e82-4eb2-bdbf-f79264ec4ea6"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTEtNS0xLTEtMTE5NDgy_1201c102-1137-4e8d-807f-623fde1eaa11"
      unitRef="usd">99700000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:CostsAndExpenses
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTItMS0xLTEtMTE5NDgy_e37a88b9-8618-4e9f-9caa-11a219e4ca9f"
      unitRef="usd">819000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTItMy0xLTEtMTE5NjQ1_5b812798-065a-47b5-bf32-6eb349aa4374"
      unitRef="usd">881100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTItMy0xLTEtMTE5NDgy_649d44d3-bd16-4f87-969c-20b75e4cab23"
      unitRef="usd">387600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTItNS0xLTEtMTE5NDgy_b96fcdb8-8618-4614-bf03-0c343ccc301a"
      unitRef="usd">870300000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTMtMS0xLTEtMTE5NDgy_e437c895-fffe-4b28-a4e7-713218202a26"
      unitRef="usd">-140600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTMtMy0xLTEtMTE5NjQ1_1e8492c1-5d00-488a-820d-2c6d9a559f2c"
      unitRef="usd">-190500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTMtMy0xLTEtMTE5NDgy_b9f30141-13bf-4223-a06b-565ef82a263b"
      unitRef="usd">-87800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTMtNS0xLTEtMTE5NDgy_92ff13ea-c119-47d3-b9c6-3ea2d14a3874"
      unitRef="usd">-231700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTUtMS0xLTEtMTE5NDgy_1c9cbc23-69a5-452b-8d54-9ca997409639"
      unitRef="usd">2600000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTUtMy0xLTEtMTE5NjQ1_ed6004f7-4dde-4a24-bf33-03c96bfd0bc0"
      unitRef="usd">700000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTUtMy0xLTEtMTE5NDgy_6baabb4b-592c-44de-88e9-7a9a35d20685"
      unitRef="usd">700000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTUtNS0xLTEtMTE5NDgy_7887a337-118e-4b1f-9e4a-9d801f42b4d2"
      unitRef="usd">3000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTYtMS0xLTEtMTE5NDgy_9ee63a66-eb8e-416f-848b-cbf14cf87c38"
      unitRef="usd">3200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTYtMy0xLTEtMTE5NjQ1_7ebe4ecb-ccf8-4789-ab8f-fbb15e651461"
      unitRef="usd">6600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTYtMy0xLTEtMTE5NDgy_dabb6be2-3e75-4d7c-a9d6-25f2124869a4"
      unitRef="usd">5800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTYtNS0xLTEtMTE5NDgy_36367197-4706-4dbe-a778-46f9eb32e87e"
      unitRef="usd">10800000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTctMS0xLTEtMTE5NDgy_ef77723c-ce3c-4d59-8410-199b65fbfea3"
      unitRef="usd">600000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTctMy0xLTEtMTE5NjQ1_e1cda9a6-49ee-4d4a-9428-e77f7935cf41"
      unitRef="usd">139300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTctMy0xLTEtMTE5NDgy_664fca9b-dc00-43c8-9d6d-8fe2cc98cca6"
      unitRef="usd">-1200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTctNS0xLTEtMTE5NDgy_fb3022be-efa0-4904-848b-f8eef72a81c3"
      unitRef="usd">16200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTgtMS0xLTEtMTE5NDgy_3f11e4b5-dbc1-4634-abad-9d887059d48a"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTgtMy0xLTEtMTE5NjQ1_23538cbd-ba91-4770-a24b-c24c4017afe6"
      unitRef="usd">133400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTgtMy0xLTEtMTE5NDgy_2b84cea3-debb-485e-a0f0-146cb05d2f15"
      unitRef="usd">-6300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTgtNS0xLTEtMTE5NDgy_cd66515a-65b2-4b36-8d51-a7469daa8dc0"
      unitRef="usd">8400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTktMS0xLTEtMTE5NDgy_c285f1ec-f188-4c02-abdd-1733e5a1b716"
      unitRef="usd">-140600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTktMy0xLTEtMTE5NjQ1_9f1ea06c-dcbd-4abe-b653-a8a967420468"
      unitRef="usd">-57100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTktMy0xLTEtMTE5NDgy_3838d99b-1180-4493-b15a-91564449e763"
      unitRef="usd">-94100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMTktNS0xLTEtMTE5NDgy_f4bbc17f-205a-44b4-904a-1fd4bcc3d83f"
      unitRef="usd">-223300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjAtMS0xLTEtMTE5NDgy_9315049f-f790-4011-85c1-ebbca62f56ad"
      unitRef="usd">-28600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjAtMy0xLTEtMTE5NjQ1_fc9be6b1-012f-4c57-81c8-1489c960f73c"
      unitRef="usd">-29900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjAtMy0xLTEtMTE5NDgy_4cf93d23-9349-4148-99bb-f7f8ffda600a"
      unitRef="usd">-41000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjAtNS0xLTEtMTE5NDgy_6b223b93-3745-4b08-964a-355da94a9a5c"
      unitRef="usd">-23700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjEtMS0xLTEtMTE5NDgy_c6739b4b-cce3-4667-9062-93afd5db22be"
      unitRef="usd">-112000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjEtMy0xLTEtMTE5NjQ1_f688c8ef-73d7-446b-9e12-178eebc5c217"
      unitRef="usd">-27200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjEtMy0xLTEtMTE5NDgy_40d5fe26-0e48-42a5-ad28-37fb7ee5c3fc"
      unitRef="usd">-53100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjEtNS0xLTEtMTE5NDgy_2c510593-40d4-48d1-8644-4075a9da9718"
      unitRef="usd">-199600000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjItMS0xLTEtMTE5NDgy_984a7b00-348e-4b6f-9f7c-a4047d9322b7"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjItMy0xLTEtMTE5NjQ1_4128ad71-60e0-4ca6-b8d4-00597c0e33ad"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjItMy0xLTEtMTE5NDgy_2f4980b9-1555-47cd-80cf-a7086b56210e"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjItNS0xLTEtMTE5NDgy_d21d94db-6e73-4007-8953-84ff49b5d198"
      unitRef="usd">-100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjMtMS0xLTEtMTE5NDgy_826b370a-0161-46c9-b183-6bb3da4bd0bc"
      unitRef="usd">-112000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjMtMy0xLTEtMTE5NjQ1_463f5647-b2ba-43a6-a277-310ceacad057"
      unitRef="usd">-27200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjMtMy0xLTEtMTE5NDgy_6bda40bf-3ec6-4c8f-8263-353593c239fc"
      unitRef="usd">-53100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjMtNS0xLTEtMTE5NDgy_ca274bf6-5014-47f1-8b95-806e93354213"
      unitRef="usd">-199500000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjUtMS0xLTEtMTE5NDgy_2266dfff-42da-4371-b66c-cab7ed27ef89"
      unitRef="usdPerShare">-1.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjUtMS0xLTEtMTE5NDgy_58d5a657-0a30-4ac7-bf08-636b82af42e5"
      unitRef="usdPerShare">-1.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjUtMy0xLTEtMTE5NjU1_5c4f6bc9-3282-45be-8ca7-e17c85be494c"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjUtMy0xLTEtMTE5NjU1_6aafd6e3-ac94-436e-86db-42f864022fbb"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjUtMy0xLTEtMTE5NDgy_154f8540-c46c-496b-8454-b8e378f50679"
      unitRef="usdPerShare">-0.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjUtMy0xLTEtMTE5NDgy_4e42e51d-671d-495e-a882-45b4ec4d3c30"
      unitRef="usdPerShare">-0.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjUtNS0xLTEtMTE5NDgy_6a09231e-cb3e-47ba-b197-6c85727a2e98"
      unitRef="usdPerShare">-2.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjUtNS0xLTEtMTE5NDgy_b55d1dbd-8677-4958-8fb6-2771c783cbb3"
      unitRef="usdPerShare">-2.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjgtMS0xLTEtMTE5NDgy_2bff41ac-0be9-4c29-b40d-22bd66b1a6e9"
      unitRef="shares">80600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjgtMS0xLTEtMTE5NDgy_b73cd936-f23e-4e09-92b5-7d650b1bf820"
      unitRef="shares">80600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjgtMy0xLTEtMTE5NjU1_07ed678d-370d-471f-a3b6-a77dd9421948"
      unitRef="shares">78000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjgtMy0xLTEtMTE5NjU1_a3762f6e-1f86-4cda-8d81-c31794cf49ab"
      unitRef="shares">78000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjgtMy0xLTEtMTE5NDgy_543f5a27-3b46-4f6e-96dc-74595d00c10c"
      unitRef="shares">75000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjgtMy0xLTEtMTE5NDgy_fab66984-b79a-42d2-9626-99c47728056d"
      unitRef="shares">75000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjgtNS0xLTEtMTE5NDgy_170ab698-7b08-41b5-b02d-a18466b1d0ca"
      unitRef="shares">74300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83Ni9mcmFnOjYxZjY1OTE4YTY5ZDRjNTM4ZjcyMDdlMDAzYThmOGRhL3RhYmxlOjUwYzYyZDk3MmFlZjQ3NTI4OGM3MDkyMDhmNWZjZDY1L3RhYmxlcmFuZ2U6NTBjNjJkOTcyYWVmNDc1Mjg4YzcwOTIwOGY1ZmNkNjVfMjgtNS0xLTEtMTE5NDgy_8acd9b65-f2c0-4937-b7c1-ec0397e8a941"
      unitRef="shares">74300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfMi0xLTEtMS0xMTk0ODI_77223730-56f2-4772-a12c-e1999f98a4b0"
      unitRef="usd">-112000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfMi0zLTEtMS0xMTk4ODk_dc79b9c6-8439-4e50-b726-7fd5c1ec0fa8"
      unitRef="usd">-27200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfMi0zLTEtMS0xMTk0ODI_133f07ac-e045-45ef-be56-d9c656411187"
      unitRef="usd">-53100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfMi01LTEtMS0xMTk0ODI_a543f623-9cce-44e1-a9d5-63ed842b28b0"
      unitRef="usd">-199500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfMy0xLTEtMS0xMTk0ODI_6e76b6f4-62ed-48cb-9f5b-67af11946816"
      unitRef="usd">-2500000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfMy0zLTEtMS0xMTk4ODk_5880cd78-186f-4e0e-95cf-101b0d4e2cd6"
      unitRef="usd">-1000000.0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfMy0zLTEtMS0xMTk0ODI_1d805ae2-cf22-46b6-97fb-9c1beb858dfb"
      unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfMy01LTEtMS0xMTk0ODI_accff228-5da1-4796-ba96-8f47beb1b470"
      unitRef="usd">700000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfNS0xLTEtMS0xMTk0ODI_3ba851aa-2075-4771-a8da-6c3ba1720c46"
      unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfNS0zLTEtMS0xMTk4ODk_34e5e745-c86a-4070-a45e-7bb272af7a44"
      unitRef="usd">-1800000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfNS0zLTEtMS0xMTk0ODI_d1690a02-2ea9-4d1d-97a3-5b49949bc966"
      unitRef="usd">3400000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfNS01LTEtMS0xMTk0ODI_8e401923-8374-4233-bfe3-d9665b64c9e2"
      unitRef="usd">-600000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfNi0xLTEtMS0xMTk0ODI_cefcd8e0-6c5e-4479-a282-edc343f31e8a"
      unitRef="usd">-115800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfNi0zLTEtMS0xMTk4ODk_6577c53a-6d2c-4775-8d02-a78f821e7b83"
      unitRef="usd">-30000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfNi0zLTEtMS0xMTk0ODI_1c28c0b8-2555-42ab-b955-e64c0e16da3c"
      unitRef="usd">-50200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF83OS9mcmFnOjIyMTRkNjk5MWI0NDQ3MDc5MTg4ZDFlZmJiMDc2NzI5L3RhYmxlOjJmOTk1OGEyZjcyNDQ3Nzg5MDRmNTFkNGFmN2YwOTY0L3RhYmxlcmFuZ2U6MmY5OTU4YTJmNzI0NDc3ODkwNGY1MWQ0YWY3ZjA5NjRfNi01LTEtMS0xMTk0ODI_6f20b2ce-9858-4dac-925b-8e71c4de4df6"
      unitRef="usd">-199400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i08037acddedf4c3da96bc71cd005937c_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfNy0xLTEtMS0xMTk0ODI_c61eabdf-c2e7-4723-86bf-b49263c3b28b"
      unitRef="usd">700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia45b75059eff4573892e8f756ab08faf_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfNy0zLTEtMS0xMTk0ODI_d9db1288-b953-42bc-b636-f06f8456d404"
      unitRef="usd">1068000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if291edff4ba84c7e9d38f402671ad107_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfNy01LTEtMS0xMTk0ODI_c3712028-a756-4480-be9a-01479d116dc5"
      unitRef="usd">-5400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifb0d838f44dc45f69885b845511ca96e_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfNy03LTEtMS0xMTk0ODI_e0bf6c5a-f617-49de-8a0f-fc02b30b8384"
      unitRef="usd">25600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if96afdd71e74449aa558f9c0f8968925_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfNy05LTEtMS0xMTk0ODI_90934f43-76af-4e9e-b6cc-04481b230128"
      unitRef="usd">1088900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie25ada1ec48a4df091a03bd92db62e3f_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfOC0zLTEtMS0xMTk0ODI_24e036bd-d8c9-43d1-ad39-65790339021e"
      unitRef="usd">3400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfOC05LTEtMS0xMTk0ODI_4ca3b15e-3168-4e87-ad2e-96cda10821fd"
      unitRef="usd">3400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie25ada1ec48a4df091a03bd92db62e3f_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfOS0zLTEtMS0xMTk0ODI_9c0d7520-67d2-4114-81ec-daea7b79abef"
      unitRef="usd">25200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfOS05LTEtMS0xMTk0ODI_b2811f13-b498-4887-8423-1bb83c858fcd"
      unitRef="usd">25200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i096822e4050c4c89aecf816ec0a1d89f_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTAtNy0xLTEtMTE5NDgy_40cded4b-04e9-4443-a030-df4a0c691a99"
      unitRef="usd">-199500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTAtOS0xLTEtMTE5NDgy_d06a352a-b9ba-416c-93a3-76e9a78e7562"
      unitRef="usd">-199500000</us-gaap:NetIncomeLoss>
    <mygn:ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary
      contextRef="ib9a92e11e87c4f21a1205b712b3e7a98_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTEtNS0xLTEtMTE5NDgy_62a8f450-0859-489a-9a11-9aee5ccbf7c1"
      unitRef="usd">100000</mygn:ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary>
    <mygn:ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTEtOS0xLTEtMTE5NDgy_1dbf2bbe-bd5e-4a05-a4d2-df9e9d58cc2d"
      unitRef="usd">100000</mygn:ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib9a92e11e87c4f21a1205b712b3e7a98_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTItNS0xLTEtMTE5NDgy_ac9d2dc1-7747-478a-b058-83a0a86d8594"
      unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTItOS0xLTEtMTE5NDgy_b72d9a4b-8542-4723-a63c-bf80ad2d8d12"
      unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie36c513fa3954843802b82eee7bd4d66_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTMtMS0xLTEtMTE5NDgy_ec68198b-1215-4063-960b-2bb0506327f0"
      unitRef="usd">700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1006f75c61d2402e941a615d921b10a0_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTMtMy0xLTEtMTE5NDgy_4e3437fd-f115-4805-903c-dfcd4f68bf56"
      unitRef="usd">1096600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia7925e43c913402583ad8467548fcdd9_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTMtNS0xLTEtMTE5NDgy_5ae12629-c3a7-4db2-a6dd-fbeba90777bd"
      unitRef="usd">-5200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34a7c6b200aa410a99aba1eb920e920b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTMtNy0xLTEtMTE5NDgy_5a29d642-ee50-446a-ab58-70c77507cbcd"
      unitRef="usd">-173900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ideeefc606008446e85d0fd21a9515813_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTMtOS0xLTEtMTE5NDgy_d0e9870f-87b2-48de-9587-a0eae4624eb4"
      unitRef="usd">918200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iaf7c181e8dc344e5a21614f9c861ac4e_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTQtMS0xLTEtMTE5NDgy_b77e8bed-ef0d-4939-8a08-1d428b6d5074"
      unitRef="usd">100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0799c2a014e447128b2001beef5c11fb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTQtMy0xLTEtMTE5NDgy_993d25ea-4857-48d0-9207-8b132e53eeff"
      unitRef="usd">-2000000.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTQtOS0xLTEtMTE5NDgy_7d8f94d8-7c3d-4cb7-ad1b-2e0942e64281"
      unitRef="usd">-1900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0799c2a014e447128b2001beef5c11fb_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTUtMy0xLTEtMTE5NDgy_4cc8e708-cc8e-486b-b791-46f916fb96f1"
      unitRef="usd">14900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTUtOS0xLTEtMTE5NDgy_d500ce47-3fa0-4a0e-83b7-d52de96756dd"
      unitRef="usd">14900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i7d4b33f1ee7a42a89b6ffb0a263cc108_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTYtNy0xLTEtMTE5NDgy_d12c0097-66f5-4fef-a0ed-9972ca3384a7"
      unitRef="usd">-53100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTYtOS0xLTEtMTE5NDgy_459264e3-451b-46e8-812c-93bb54be6ffc"
      unitRef="usd">-53100000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iabdc282dcf2544e6a44fbcf258a6191b_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTctNS0xLTEtMTE5NDgy_c2675013-88c6-452d-8064-d59a831c16d9"
      unitRef="usd">2900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTctOS0xLTEtMTE5NDgy_f8e9252b-e367-4c8d-8b58-9eae1b9b7130"
      unitRef="usd">2900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia3e0eff6e7f44b0e9bfbf56d9460dba8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTgtMS0xLTEtMTE5NDgy_f230299f-5ae8-43cb-a3ff-3d6e348231fd"
      unitRef="usd">800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ide959bef58984d0c800d66085fe2ee2e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTgtMy0xLTEtMTE5NDgy_906731a6-ce9e-41cc-a135-c410684a4104"
      unitRef="usd">1109500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6aa3dfbc1c6545a0b140ae9c08b0c24b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTgtNS0xLTEtMTE5NDgy_7f719223-415d-429c-97e5-9088ba4d74d4"
      unitRef="usd">-2300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9056eb749ddd4517883d1f3860b7f895_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTgtNy0xLTEtMTE5NDgy_3cf08ed6-be30-4076-9a7d-a1a9427d98ea"
      unitRef="usd">-227000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTgtOS0xLTEtMTE5NDgy_668f38c8-3968-4bca-a8aa-a8229d76f998"
      unitRef="usd">881000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6f2f31965b52467a95929f7baa16f7d7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTktMy0xLTEtMTE5NDgy_a06da79a-4c1e-47cb-a767-1c73fc30c29e"
      unitRef="usd">80300000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMTktOS0xLTEtMTE5NDgy_0f0fb328-72a3-44b8-9b9b-49c127966c3c"
      unitRef="usd">80300000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6f2f31965b52467a95929f7baa16f7d7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjAtMy0xLTEtMTE5NDgy_8f439677-8798-4a71-baff-e4dd9992125c"
      unitRef="usd">36500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjAtOS0xLTEtMTE5NDgy_5fa5116b-fa90-4cd4-b60b-6fd9e06e8271"
      unitRef="usd">36500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="if31c2aa3a1bd42508fa6f5053cec3008_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjEtNy0xLTEtMTE5NDgy_4f06c159-905b-40bc-9b2c-bfb20472cd6f"
      unitRef="usd">-27200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjEtOS0xLTEtMTE5NDgy_81a572d6-d283-4fda-9cb7-66305ba2fd30"
      unitRef="usd">-27200000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1d7ca27f075d4f19be69a74e81087fd1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjItNS0xLTEtMTE5NDgy_4a0c29fb-0c04-477e-a02f-f1a7dbb8b0be"
      unitRef="usd">-2800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjItOS0xLTEtMTE5NDgy_c759467b-25ff-4fd4-aa61-eeeab1d88afb"
      unitRef="usd">-2800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifbacf682032e4d0d92179fdcbdcc44c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjMtMS0xLTEtMTE5NDgy_e01539ca-17a2-4b6f-a793-bd9f4698bff6"
      unitRef="usd">800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifcbf5fe2793a4a75ace02762c09dba60_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjMtMy0xLTEtMTE5NDgy_882a2f92-cd2d-4903-9614-5a4dc7ad0c29"
      unitRef="usd">1226300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i07ccaab8fd444e1e96d9d0b927e5739d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjMtNS0xLTEtMTE5NDgy_f666b48c-0dce-440d-bc1d-85cc0fd2f2b0"
      unitRef="usd">-5100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i82f354105f424032836cdf535b931213_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjMtNy0xLTEtMTE5NDgy_f4a83e9e-546a-4865-b494-c8dac5b55fdc"
      unitRef="usd">-254200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjMtOS0xLTEtMTE5NDgy_a55bd698-0a65-481d-ba12-b96e87a3df6a"
      unitRef="usd">967800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic3575a755df04fc38d5dbd355577687f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjQtMy0xLTEtMTIwMTkz_4175f721-150f-4510-a2a9-9c9119cd0243"
      unitRef="usd">-4300000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjQtOS0xLTEtMTIwMTkz_2792fe30-3b80-46ae-a90b-a8fb8ce2efb2"
      unitRef="usd">-4300000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic3575a755df04fc38d5dbd355577687f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjUtMy0xLTEtMTIwMTkz_2319c23d-6361-4388-ac8a-40eba073792e"
      unitRef="usd">38100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjUtOS0xLTEtMTIwMTkz_3c39d7a6-7fa8-417b-9b62-4cddb9913677"
      unitRef="usd">38100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ie86ab0c9deac4c1cb5e311bc6ccc3e05_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjYtNy0xLTEtMTIwMTkz_f8c9d8be-d6ef-44e2-a383-455e9ec8fba9"
      unitRef="usd">-112000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjYtOS0xLTEtMTIwMTkz_bdfaada5-62cc-4ba8-a810-4209f4d99b71"
      unitRef="usd">-112000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id4cbbd0e273544ccb20f9d106126ecc3_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjctNS0xLTEtMTIwMTkz_7a7e20ad-acc7-413a-ac9c-0ef42f72cb09"
      unitRef="usd">-3800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjctOS0xLTEtMTIwMTkz_b3a63d0b-5d13-4d0b-8fc9-37ce67c96a6c"
      unitRef="usd">-3800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i368576ec62ee45cca0320cd56f18e01f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjgtMS0xLTEtMTIwMTkz_728bca4d-98ce-4808-8e39-f878f458bfa8"
      unitRef="usd">800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4f255485789b4a73b043e3b00f87031c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjgtMy0xLTEtMTIwMTkz_9cccd47c-0729-4a9e-aae0-c1a5b784cd48"
      unitRef="usd">1260100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia5215658c5cd475abde0249738d23319_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjgtNS0xLTEtMTIwMTkz_e79bfb67-6875-4f8f-bf42-bb3ec6b77923"
      unitRef="usd">-8900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic40f1f5963e54a2cbe900fef28214a42_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjgtNy0xLTEtMTIwMTkz_bac86c68-5074-4f1a-83f3-ff6ddcd6df22"
      unitRef="usd">-366200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84Mi9mcmFnOjVhZDNhNDM4MzdmODQxNTQ5Yjg0MjdiMDM0MzBmNTdiL3RhYmxlOjE3MTQ4NjZiNzFiMzRkMWE4ZGVlODAxZDk2MTVlMDAwL3RhYmxlcmFuZ2U6MTcxNDg2NmI3MWIzNGQxYThkZWU4MDFkOTYxNWUwMDBfMjgtOS0xLTEtMTIwMTkz_4aa3c9f0-df83-45aa-9cd6-1f1bbe622bfc"
      unitRef="usd">885800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMy0xLTEtMS0xMTk0ODI_4baf4c6d-b39c-4b05-acc1-2bcf58c7a127"
      unitRef="usd">-112000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMy0zLTEtMS0xMjAwMTc_37baeceb-2346-4eca-9de3-23a020ad1e5c"
      unitRef="usd">-27200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMy0zLTEtMS0xMTk0ODI_0459f151-7b6b-403b-b136-9d2b22e2536a"
      unitRef="usd">-53100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMy01LTEtMS0xMTk0ODI_e44bb5c4-51e0-4483-b67b-7b442e6c80ff"
      unitRef="usd">-199500000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNS0xLTEtMS0xMTk0ODI_4b10909b-f888-476d-adfe-1360dfc46aea"
      unitRef="usd">52700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNS0zLTEtMS0xMjAwMTc_db452f0d-3eda-43b5-94f0-8b124f65d1cd"
      unitRef="usd">62800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNS0zLTEtMS0xMTk0ODI_07c1daa5-2098-4589-90e7-b329983eb1ee"
      unitRef="usd">35800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNS01LTEtMS0xMTk0ODI_4c57408a-521d-47fa-86dd-8f148e1c2119"
      unitRef="usd">72000000.0</us-gaap:DepreciationAndAmortization>
    <mygn:NonCashInterestExpense
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNi0xLTEtMS0xMTk0ODI_c8df760c-5de1-4cc1-be44-da6bb7f2ab53"
      unitRef="usd">1700000</mygn:NonCashInterestExpense>
    <mygn:NonCashInterestExpense
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNi0zLTEtMS0xMjAwMTc_64571302-4bd7-4956-bc4d-8e1c0c74fb31"
      unitRef="usd">1500000</mygn:NonCashInterestExpense>
    <mygn:NonCashInterestExpense
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNi0zLTEtMS0xMTk0ODI_4c8905d1-0310-4816-a59a-9735a7ec4ec4"
      unitRef="usd">400000</mygn:NonCashInterestExpense>
    <mygn:NonCashInterestExpense
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNi01LTEtMS0xMTk0ODI_bc7c5862-80ac-4179-9a64-ce9e5372b4c7"
      unitRef="usd">500000</mygn:NonCashInterestExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNy0xLTEtMS0xMTk0ODI_15043f57-e749-4974-ac90-0dfb93ae2f3e"
      unitRef="usd">11700000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNy0zLTEtMS0xMjAwMTc_325f380b-6235-49b0-bd8b-6ccf6b97fd90"
      unitRef="usd">12800000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNy0zLTEtMS0xMTk0ODI_a80d96f4-fe26-4963-b57d-5427ccd75012"
      unitRef="usd">6400000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNy01LTEtMS0xMTk0ODI_b575cbf8-305d-4964-a207-b02a78aae67f"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOC0xLTEtMS0xMjA1NDc_1079add2-2dc4-4c05-97e1-16bd6d9aaaf9"
      unitRef="usd">-18000000.0</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOC0zLTEtMS0xMjA1NTQ_b88d9d53-a3a8-483d-8af2-1f530e57dab8"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOC01LTEtMS0xMjA1NjE_7b1a6486-229a-4e81-8b73-dc0ebe9f7631"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOC03LTEtMS0xMjA1Njk_e644b045-0327-403d-b8b9-4142966ae1c9"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:ShareBasedCompensation
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOC0xLTEtMS0xMTk0ODI_9782f347-3067-4447-82e0-8dccab927104"
      unitRef="usd">38100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOC0zLTEtMS0xMjAwMTc_98379634-601f-4708-8db2-afa558710cdb"
      unitRef="usd">36300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOC0zLTEtMS0xMTk0ODI_d315b48c-62d1-4df8-9ea7-7ca242cef87d"
      unitRef="usd">14900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOC01LTEtMS0xMTk0ODI_b4800048-fe46-48f5-a527-fadbada03c8b"
      unitRef="usd">25200000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOS0xLTEtMS0xMTk0ODI_25f9f6a6-db04-4d47-aa8f-118060c5ce31"
      unitRef="usd">30800000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOS0zLTEtMS0xMjAwMTc_d026fe1f-855b-411f-b5f2-1e85e924d508"
      unitRef="usd">32100000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOS0zLTEtMS0xMTk0ODI_e5b89fba-5955-4ae2-9068-63a87ef787e2"
      unitRef="usd">-44200000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfOS01LTEtMS0xMTk0ODI_0e9d912f-cc51-4b2a-aa47-bf8ab90705d2"
      unitRef="usd">55800000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <mygn:IncreaseDecreaseInUnrecognizedTaxBenefits
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTAtMS0xLTEtMTE5NDgy_d9100e71-7b5f-4fac-bccc-6f6c3757c35a"
      unitRef="usd">1100000</mygn:IncreaseDecreaseInUnrecognizedTaxBenefits>
    <mygn:IncreaseDecreaseInUnrecognizedTaxBenefits
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTAtMy0xLTEtMTIwMDE3_76a3b6cd-f3c0-4c68-a0dd-ed4ddae1ea28"
      unitRef="usd">2600000</mygn:IncreaseDecreaseInUnrecognizedTaxBenefits>
    <mygn:IncreaseDecreaseInUnrecognizedTaxBenefits
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTAtMy0xLTEtMTE5NDgy_cd0cbbd3-6906-48a0-91e3-bfeeda65be5b"
      unitRef="usd">-7100000</mygn:IncreaseDecreaseInUnrecognizedTaxBenefits>
    <mygn:IncreaseDecreaseInUnrecognizedTaxBenefits
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTAtNS0xLTEtMTE5NDgy_b4361c9d-d425-4bb4-829a-1105c70101ce"
      unitRef="usd">-1700000</mygn:IncreaseDecreaseInUnrecognizedTaxBenefits>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTEtMS0xLTEtMTE5NDgy_9cb9a883-9dd8-457a-8a19-7f325afe3882"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTEtMy0xLTEtMTIwMDE3_7c72ebef-49e4-4dc0-9606-10eb6bf8b016"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTEtMy0xLTEtMTE5NDgy_4e5704b1-8b33-402e-a223-fb14443fb9a2"
      unitRef="usd">1000000.0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTEtNS0xLTEtMTE5NDgy_85f83679-8ab8-4a20-ae40-239453b6a233"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InventoryWriteDown
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTItMS0xLTEtMTE5NDgy_deeb039e-de18-41da-a3eb-b45e8bfe66a7"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTItMy0xLTEtMTIwMDE3_2d604017-313a-4ccc-b2e3-5d266c07f120"
      unitRef="usd">6500000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTItMy0xLTEtMTE5NDgy_24c5c7e7-7d6a-4974-b609-34018883b38a"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTItNS0xLTEtMTE5NDgy_149042e5-145b-4cb6-bd51-5c044dd94bd5"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTMtMS0xLTEtMTE5NDgy_4d7608b3-82d9-4a89-8dee-e981990892de"
      unitRef="usd">16900000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTMtMy0xLTEtMTIwMDE3_cabaa1d3-777f-4c51-84ba-8ad33923dbb5"
      unitRef="usd">1800000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTMtMy0xLTEtMTE5NDgy_a8c73344-53ad-4171-9c79-c23bbd529415"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTMtNS0xLTEtMTE5NDgy_5a1e98dd-91c6-4d19-9967-dcb3e6b91868"
      unitRef="usd">99700000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTQtMS0xLTEtMTE5NDgy_958e626d-25f5-4d09-a857-d890d04699ac"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTQtMy0xLTEtMTIwMDE3_11112c90-235f-4439-9a3d-ee6cac25dd84"
      unitRef="usd">162000000.0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTQtMy0xLTEtMTE5NDgy_fbea5537-ebe8-4e44-a714-17b4e48a04ee"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTQtNS0xLTEtMTE5NDgy_31869041-3fc7-4b41-8f58-f9ebfce3feb6"
      unitRef="usd">1000000.0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTctMS0xLTEtMTE5NDgy_13a13612-4d41-4cc4-bdec-ed99bb3803c1"
      unitRef="usd">-1600000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTctMy0xLTEtMTIwMDE3_bd3b4c92-56fa-4669-866a-8ac7e999b5d8"
      unitRef="usd">6600000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTctMy0xLTEtMTE5NDgy_5abc9f4a-a2ed-4e7f-b922-8fec4d0764c5"
      unitRef="usd">-3100000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTctNS0xLTEtMTE5NDgy_536419d7-bdf9-46bc-a009-5495f4214202"
      unitRef="usd">-2800000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTgtMS0xLTEtMTE5NDgy_c27b4abb-b40c-49f1-8b11-3905fa349c4d"
      unitRef="usd">10300000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTgtMy0xLTEtMTIwMDE3_8f9ad9f0-ff98-4cfe-ac2c-208cf37a7ad5"
      unitRef="usd">8800000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTgtMy0xLTEtMTE5NDgy_797943b3-f5cd-414c-a82d-663ceb8a54a7"
      unitRef="usd">21400000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTgtNS0xLTEtMTE5NDgy_9472f177-565c-48e3-b1fa-c9c4f18a738b"
      unitRef="usd">-64000000.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTktMS0xLTEtMTE5NDgy_274b3e88-3863-4a2d-83e6-3ab8f328e0f6"
      unitRef="usd">2900000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTktMy0xLTEtMTIwMDE3_8083781f-c9e6-4562-97c7-aca0a6eec488"
      unitRef="usd">-1600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTktMy0xLTEtMTE5NDgy_938130e3-af24-4a24-86f5-1768a4354d0e"
      unitRef="usd">-2200000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMTktNS0xLTEtMTE5NDgy_e69dac93-8bc7-4191-81a1-14b8cf2c49ae"
      unitRef="usd">-1600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjAtMS0xLTEtMTE5NDgy_d7f1f109-2c8d-45c4-a54b-bb54fc831755"
      unitRef="usd">-700000</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjAtMy0xLTEtMTIwMDE3_3eca1f0b-6bfe-4ddd-89eb-49c03203fd76"
      unitRef="usd">-89900000</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjAtMy0xLTEtMTE5NDgy_988d6d30-ed4f-4fb0-96c8-171727d75d3e"
      unitRef="usd">108400000</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjAtNS0xLTEtMTE5NDgy_09403347-e0c0-4e03-adca-21730c103460"
      unitRef="usd">-25100000</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjEtMS0xLTEtMTE5NDgy_3ba3f5d8-e7c9-4315-bcea-6db44cec0cf3"
      unitRef="usd">900000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjEtMy0xLTEtMTIwMDE3_c4614faf-229b-438d-9446-082345e59c38"
      unitRef="usd">3600000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjEtMy0xLTEtMTE5NDgy_a931e6c6-798b-431e-9187-c4d49227bba4"
      unitRef="usd">2300000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjEtNS0xLTEtMTE5NDgy_89f1315c-f945-4261-bddc-36f6bf530ceb"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjItMS0xLTEtMTE5NDgy_56c77673-a0c7-46c3-ae30-519de1d4dd22"
      unitRef="usd">-3500000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjItMy0xLTEtMTIwMDE3_bfb321f2-6c97-4bae-8009-bf5a48fcb56a"
      unitRef="usd">9200000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjItMy0xLTEtMTE5NDgy_aad5f92b-2847-4cd3-91b8-4ba9b87488c5"
      unitRef="usd">-1200000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjItNS0xLTEtMTE5NDgy_f6dd12b9-7192-4017-9994-6060b9a48177"
      unitRef="usd">-10700000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjMtMS0xLTEtMTE5NDgy_1f0b8ad7-cb1c-4410-8516-b3be6a7bd299"
      unitRef="usd">-81200000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjMtMy0xLTEtMTIwMDE3_ddb286e1-8a8b-483a-9236-ddc80c7cfe19"
      unitRef="usd">65700000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjMtMy0xLTEtMTE5NDgy_e1c1e02d-ccf1-4f69-919c-8e93ff88b9a9"
      unitRef="usd">-200000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjMtNS0xLTEtMTE5NDgy_a0f0322b-ea7c-44e8-a7cb-b7a5ff0cf17f"
      unitRef="usd">4400000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjQtMS0xLTEtMTE5NDgy_6242798a-cb53-4e90-ba16-5b2a9fe0bb82"
      unitRef="usd">-5000000.0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjQtMy0xLTEtMTIwMDE3_1fbc92be-17f6-421f-9e5b-d3e05f584c9e"
      unitRef="usd">-26600000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjQtMy0xLTEtMTE5NDgy_37b6e147-c795-4a3b-ab1c-c10a66925b1c"
      unitRef="usd">-200000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjQtNS0xLTEtMTE5NDgy_55d4ad0d-45e0-470e-8335-8690f10feb7f"
      unitRef="usd">30700000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjUtMS0xLTEtMTE5NDgy_ac91b254-5354-4a1b-be8c-74f9d966c453"
      unitRef="usd">-106300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjUtMy0xLTEtMTIwMDE3_23544151-3a97-419c-925d-15fa28109295"
      unitRef="usd">18600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjUtMy0xLTEtMTE5NDgy_d8e41dbb-9db2-4b6b-a8f5-974dc8afd6df"
      unitRef="usd">-73700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjUtNS0xLTEtMTE5NDgy_fba6f6d0-9870-41ac-8bba-da2780ed618c"
      unitRef="usd">60700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjctMS0xLTEtMTE5NDgy_ecfd911c-36e9-497a-bfe1-0a54e5817fde"
      unitRef="usd">45300000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjctMy0xLTEtMTIwMDc1_6f77738c-8738-4978-bb61-6a7bb7f33b1f"
      unitRef="usd">18000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjctMy0xLTEtMTE5NDgy_b031169e-f36d-445b-86b8-27fd45bde90f"
      unitRef="usd">7900000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjctNS0xLTEtMTE5NDgy_3257b54f-5b27-43bc-a007-9a969b503f21"
      unitRef="usd">10200000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjgtMS0xLTEtMTE5NDgy_2d74b717-c1d2-4c01-92d8-d100860608a8"
      unitRef="usd">57200000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjgtMy0xLTEtMTIwMDE3_cb17a7f4-83a7-4169-8b04-3a38281e9cb2"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjgtMy0xLTEtMTE5NDgy_4490f5ea-d852-4191-89b2-9bd7b213acc7"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjgtNS0xLTEtMTE5NDgy_873c55bf-5c9d-4c4a-b6a0-a9e1f53ecba3"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjktMS0xLTEtMTE5NDgy_147857fc-5e1a-4bc6-970e-b6b88a37c347"
      unitRef="usd">0</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjktMy0xLTEtMTIwMDE3_e1b16a10-85f7-4aac-8864-2a8ff29dd7ac"
      unitRef="usd">379100000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjktMy0xLTEtMTE5NDgy_239b77c3-7cf0-4e07-bbcc-eda49d491622"
      unitRef="usd">0</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMjktNS0xLTEtMTE5NDgy_aaa4b426-c8a9-4834-b1e0-ffd0923e9a53"
      unitRef="usd">21300000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzAtMS0xLTEtMTE5NDgy_c18bf938-9600-453b-8e93-1ddac496f297"
      unitRef="usd">103200000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzAtMy0xLTEtMTIwMDE3_b9655243-4d3b-4c75-acb8-d8b3e66dbf43"
      unitRef="usd">147800000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzAtMy0xLTEtMTE5NDgy_c7ae5a71-76c8-4d17-a275-b5e00a7a7e90"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzAtNS0xLTEtMTE5NDgy_a058c67c-f43f-48ec-93d9-859835e98c0b"
      unitRef="usd">60800000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzEtMS0xLTEtMTE5NDgy_4b725e54-baa5-452d-860d-c9d88756150b"
      unitRef="usd">128200000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzEtMy0xLTEtMTIwMDE3_d4d6ef23-d533-4140-9ed6-2d7a8e986f85"
      unitRef="usd">61100000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzEtMy0xLTEtMTE5NDgy_4d9b7ada-a34a-44ab-8d8c-dd61bdb81e5e"
      unitRef="usd">35900000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzEtNS0xLTEtMTE5NDgy_37332b3c-62f5-48d6-a3b5-5fe54ad9d21b"
      unitRef="usd">69000000.0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzItMS0xLTEtMTE5NDgy_3116e574-e583-44d0-a8e1-a41da2d96077"
      unitRef="usd">-77500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzItMy0xLTEtMTIwMDE3_8885afd6-8f18-4e2f-9e36-c078e67a6ff7"
      unitRef="usd">274400000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzItMy0xLTEtMTE5NDgy_b273c36e-5aa6-428e-b8e8-bda1ccea00de"
      unitRef="usd">28000000.0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzItNS0xLTEtMTE5NDgy_fea61aeb-e816-4df0-aa77-07cfcff4637f"
      unitRef="usd">19300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzQtMS0xLTEtMTE5NDgy_7073069c-3aaa-402a-a2ee-0ebb3f8cf05f"
      unitRef="usd">6300000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzQtMy0xLTEtMTIwMDgw_73154266-6566-4f95-a47f-09dea52d4a22"
      unitRef="usd">91800000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzQtMy0xLTEtMTE5NDgy_16e322d8-0b54-48e6-8d6c-852723ce2f96"
      unitRef="usd">1800000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzQtNS0xLTEtMTE5NDgy_38b59cc1-44cf-44b5-84fb-6d64f1ee9c43"
      unitRef="usd">13300000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzUtMS0xLTEtMTE5NDgy_09d85f23-65a6-4f2b-bb51-bc10f8d78149"
      unitRef="usd">10600000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzUtMy0xLTEtMTIwMDE3_d53d20db-192b-441c-9d60-e48e1bf296cb"
      unitRef="usd">11500000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzUtMy0xLTEtMTE5NDgy_a3acfe72-d394-4255-aea5-361cdaadc7a7"
      unitRef="usd">3800000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzUtNS0xLTEtMTE5NDgy_c89396db-b287-44bc-a527-7d70fd03b2c0"
      unitRef="usd">9800000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzYtMS0xLTEtMTE5NDgy_9aa6666f-ea90-4932-88dd-d1439405b4ab"
      unitRef="usd">3000000.0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzYtMy0xLTEtMTIwMDE3_138a49bc-7e87-4a4e-b58f-c7104e8b3de9"
      unitRef="usd">3300000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzYtMy0xLTEtMTE5NDgy_1651bf61-6aa1-4ede-9421-01b048b70ed8"
      unitRef="usd">100000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzYtNS0xLTEtMTE5NDgy_68cd2f08-4da8-470b-8d78-c130d1194aa7"
      unitRef="usd">3900000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsOfDebtRestructuringCosts
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzgtMS0xLTEtMTE5NDgy_5a40ea3e-59fa-4d0d-80f5-20db914e2de1"
      unitRef="usd">700000</us-gaap:PaymentsOfDebtRestructuringCosts>
    <us-gaap:PaymentsOfDebtRestructuringCosts
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzgtMy0xLTEtMTIwMDE3_13f7549a-0b08-485e-9c5b-f14c144cf977"
      unitRef="usd">1200000</us-gaap:PaymentsOfDebtRestructuringCosts>
    <us-gaap:PaymentsOfDebtRestructuringCosts
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzgtMy0xLTEtMTE5NDgy_11be7f8c-3fa9-4eca-8b96-acdf03cf92b1"
      unitRef="usd">0</us-gaap:PaymentsOfDebtRestructuringCosts>
    <us-gaap:PaymentsOfDebtRestructuringCosts
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzgtNS0xLTEtMTE5NDgy_6ef7f0f6-7fda-4acd-bac3-c4842d85cafd"
      unitRef="usd">1000000.0</us-gaap:PaymentsOfDebtRestructuringCosts>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzktMS0xLTEtMTE5NDgy_7081fa6c-e009-4cf6-9b40-ff450e6df2cd"
      unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzktMy0xLTEtMTIwMDE3_0a1af685-60af-4e87-b40d-aef446baae0b"
      unitRef="usd">226400000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzktMy0xLTEtMTE5NDgy_43898358-3a84-4b88-938b-326d3f447ef5"
      unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfMzktNS0xLTEtMTE5NDgy_67756df2-4960-441a-a6a2-1288d2091de5"
      unitRef="usd">8600000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDEtMS0xLTEtMTE5NDgy_d7dcf911-aed8-44ba-a1c4-50146c1c6eea"
      unitRef="usd">-8000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDEtMy0xLTEtMTIwMDE3_7983b398-e312-4d26-b3de-92b3a97c5648"
      unitRef="usd">-150600000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDEtMy0xLTEtMTE5NDgy_ec4ae8f5-f704-47d4-a62c-8fde239453be"
      unitRef="usd">-2100000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDEtNS0xLTEtMTE5NDgy_78ef95e6-6148-49fe-ab71-e44de9c93b25"
      unitRef="usd">-10000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDItMS0xLTEtMTE5NDgy_e63194b5-dda8-45d9-82a2-ce33b61a1eaa"
      unitRef="usd">-600000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDItMy0xLTEtMTIwMDE3_2314ecd5-24da-44dc-b169-64e360cfd13a"
      unitRef="usd">-600000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDItMy0xLTEtMTE5NDgy_89db4ec5-dbe9-40d4-9fd7-5a4e48dcdc3d"
      unitRef="usd">1100000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDItNS0xLTEtMTE5NDgy_c1b1755d-ccd4-405c-914d-afb5b73833ff"
      unitRef="usd">500000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDMtMS0xLTEtMTE5NDgy_425c90c8-516f-4646-a5d3-6acb9c0a7778"
      unitRef="usd">-192400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDMtMy0xLTEtMTIwMDE3_5cd000c8-feb7-4465-a4ee-f66a3bcc785b"
      unitRef="usd">141800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDMtMy0xLTEtMTE5NDgy_fb7b73f8-f545-406d-9ecb-a4897debd8f0"
      unitRef="usd">-46700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDMtNS0xLTEtMTE5NDgy_ce1d13d5-2392-4780-84ca-dbcc94a7eeec"
      unitRef="usd">70500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDQtMS0xLTEtMTE5NDgy_e7e7293f-98a4-45e6-a5ef-62d2bf1e2294"
      unitRef="usd">258800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDQtMy0xLTEtMTIwMDE3_4a7e724b-50e9-4fb8-9f05-187aef1b592e"
      unitRef="usd">117000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ideeefc606008446e85d0fd21a9515813_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDQtMy0xLTEtMTE5NDgy_983b1917-4fab-469c-9af3-6ab821e6dcf2"
      unitRef="usd">163700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if96afdd71e74449aa558f9c0f8968925_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDQtNS0xLTEtMTE5NDgy_56097fb2-22f1-413e-bff7-e9d37529a6c5"
      unitRef="usd">93200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDUtMS0xLTEtMTE5NDgy_99636816-1b8b-4393-90bc-dd79303e047e"
      unitRef="usd">66400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDUtMy0xLTEtMTIwMDE3_eef84b9d-78f6-46c4-b722-c419fd326eca"
      unitRef="usd">258800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDUtMy0xLTEtMTE5NDgy_f6944932-eebd-48c2-9cf3-0994184cdfd1"
      unitRef="usd">117000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ideeefc606008446e85d0fd21a9515813_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF84NS9mcmFnOjY2NDM3MjI5MGNlZDRhM2ViZGQ0OTE4YjNhYzU1YzQ5L3RhYmxlOjNjMGZlOGRiYzYyYTRmOWRiYTc5MDU0YzBjZDU2MTY5L3RhYmxlcmFuZ2U6M2MwZmU4ZGJjNjJhNGY5ZGJhNzkwNTRjMGNkNTYxNjlfNDUtNS0xLTEtMTE5NDgy_9e6a9a6a-7fb5-456e-99a6-8ec845993820"
      unitRef="usd">163700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1NzI_5a480fd2-4e9f-4606-917d-944aaa1cc5bd">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Financial Statement Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Myriad Genetics, Inc. (together with its subsidiaries, the&#160;"Company" or "Myriad") is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Myriad develops and offers tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower health care costs. The Company generates revenue by performing tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 17, by providing pharmaceutical and clinical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company currently operates as a single reporting segment.&#160;The Company&#x2019;s principal executive office is located in Salt Lake City, Utah.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements for the Company have been prepared in accordance with United States ("U.S.") generally accepted accounting principles (&#x201c;GAAP&#x201d;) for financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates and assumptions include revenue recognition estimates for the average expected reimbursement per test, valuation allowances for deferred income tax assets, certain accrued liabilities, stock-based compensation, purchase accounting, and impairment analysis of goodwill and long-lived assets. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders' equity, or cash flows from operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company&#x2019;s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related health care programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately 14%, 17%, 16%, and 15% of total revenue for the years ended December 31, 2022 and 2021, the six-month transition period ended December&#160;31, 2020, and the fiscal year ended June 30, 2020, respectively. Concentrations of credit risk are mitigated due to the number of the Company&#x2019;s customers as well as their dispersion across many geographic regions. No payor accounted for&#160;more than 10%&#160;of accounts receivable at&#160;December&#160;31, 2022 or December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents primarily consist of cash and money market deposits with financial institutions.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain circumstances, the Company is required to maintain cash deposit with certain banks with respect to contractual or other legal obligations, and therefore the use of these cash deposits for general operational purposes is restricted. As of December 31, 2022, restricted cash was approximately $9.5 million, of which $2.0 million was recognized as a current asset and $7.5 million was recognized as a long-term asset. As of December 31, 2021, restricted cash was approximately $1.4 million, of which $1.0 million was recognized as a current asset and $0.4 million was recognized as a long-term asset. The restricted cash amounts are largely comprised of cash held in escrow related to the Company's acquisition of Gateway Genomics, LLC ("Gateway") during the year ended December 31, 2022 and certain divestitures during the year ended December 31, 2021. The current and long-term portions are included in Prepaid expenses and other current assets and Other assets, respectively, on the Consolidated Balance Sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Consolidated Balance Sheets that agrees to the amounts included in the Consolidated Statement of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Investment Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has classified its marketable investment securities, all of which are debt securities, as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in Accumulated other comprehensive loss in Stockholders&#x2019; equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The Company&#x2019;s cash equivalents consist of short-term, highly liquid investments that are readily convertible to known amounts of cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. Losses are charged against Other income (expense) when a decline in fair value is determined to be other than temporary. The Company reviews several factors to determine whether a loss is other than temporary. These factors include but are not limited to: (i) the extent to which the fair value is less than cost and the cause for the fair value decline, (ii) the financial condition and near term prospects of the issuer, (iii) the length of time a security is in an unrealized loss position and (iv) the Company&#x2019;s ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. There were no other-than-temporary impairments recognized during the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020 or during the fiscal year ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of supplies such as reagents, plates and testing kits, which are consumed when providing test results, and therefore the Company does not maintain finished goods inventory. Inventories are stated at the lower of cost or market and costs are determined on a first-in, first-out basis.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its inventories for excess quantities and obsolescence.&#160;&#160;Inventories that are considered excess or obsolete are expensed.&#160;&#160;&#160;In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels. The valuation of inventories requires the use of estimates as to the amounts of current inventories that will be sold. These estimates are dependent on management&#x2019;s assessment of current and expected orders from the Company&#x2019;s customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable represents estimated receivables from customers for revenue recognized related to genetic tests. The Company does not have any off-balance-sheet credit exposure related to its customers and does not require collateral.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method based on the lesser of estimated useful lives of the related assets or lease terms. Equipment items have depreciable lives of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfODUzMw_6379236e-7018-4cbe-9f98-2974e673bf30"&gt;five&lt;/span&gt; to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful lives or the associated lease terms, which range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfODY3Nw_ce7f7168-4bc2-4449-b270-c38ee0a58400"&gt;one&lt;/span&gt; to fifteen years. Repairs and maintenance costs are charged to expense as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company acts as lessee in its lease agreements, which include operating leases for corporate offices, laboratory space, warehouse space, vehicles and certain laboratory and office equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is, or contains, a lease at inception. The Company records the present value of lease payments as right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities on the Consolidated Balance Sheets. ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of lease liabilities as either current or non-current is based on the expected timing of payments due under the Company&#x2019;s obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of the Company&#x2019;s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The leases have remaining lease terms of 1 year to 15 years, some of which include options to extend the lease term for up to 10 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has taken advantage of certain practical expedients offered to registrants at adoption of Accounting Standards Codification ("ASC") 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis and is not included in the recognized ROU assets and lease liabilities. Further, as a practical expedient, all lease contracts are accounted for as one single lease component, as opposed to separating lease and non-lease components to allocate the consideration within a single lease contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Other Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible and other long-lived assets are comprised of acquired licenses and technology. Acquired intangible assets are recorded at fair value and amortized over the shorter of the contractual life or the estimated useful life. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain costs incurred to develop internal-use technology, including certain implementation costs incurred in cloud computing arrangements and hosting arrangements that include an internal-use software license. The Company's cloud computing arrangements or hosting arrangements are primarily service contracts related to information technology. Implementation and development costs for internal-use technology are capitalized as part of Other assets in the Consolidated Balance Sheets. After the implementation of the internal-use cloud computing software or other internal-use technology, the capitalized costs are amortized on a straight-line basis over the estimated useful life of the asset. Costs incurred during the post implementation stage of the project are expensed as incurred. As of December&#160;31, 2022 and 2021, the Company had unamortized software costs of $7.1 million and $6.7 million, respectively. For the years ended December 31, 2022 and 2021, amortization expense for capitalized software costs was $1.2 million and $0.2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually reviews and monitors long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment by reporting unit on an annual basis as of October 1 and in the interim if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators and competition.&#160;&#160;Impairment of goodwill is first assessed using a qualitative approach.&#160;If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed.&#160;The quantitative analysis involves a comparison of the fair value of the reporting unit with its carrying amount.&#160;If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.&#160;If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for acquisitions of entities that include inputs and processes and have the ability to create outputs as business combinations. The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on third-party valuations that use information and assumptions provided by the Company's management, which consider the Company's estimates of inputs and assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, estimated cost savings, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under ASC 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recognizes a liability equal to the fair value of the contingent payments expected to be made as of the acquisition date. This liability is remeasured each reporting period and the changes in the fair value are recognized in Selling, general, and administrative expenses in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction costs associated with acquisitions are expensed as incurred in Selling, general, and administrative expenses in the Consolidated Statements of Operations. Results of operations and cash flows of acquired companies are included in the operating results from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company primarily generates revenue by performing genetic testing. Testing revenues are primarily derived from the following categories of products: Hereditary Cancer (MyRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight, Prequel, and SneakPeek), and Pharmacogenomics (GeneSight). The Company previously provided pharmaceutical services and clinical services prior to the sale of Myriad RBM, Inc. in July 2021 and Privatklinik Dr. Robert Schindlbeck GmbH &amp;amp; Co. KG in February 2020. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 and the Myriad Autoimmune business in September 2021, the associated revenue from such businesses was included within Testing revenues. See Note 17 for a discussion of these divestitures. Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results or the completion of pharmaceutical and clinical services indicates transfer of control for revenue recognition purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents detail regarding the composition of the Company&#x2019;s total revenue by product type for the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020, and the fiscal year ended June 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Testing revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total testing revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;678.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;678.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the following tables reconcile revenue by geographical region, either U.S. or rest of world ("RoW"), to total revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Testing revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;263.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;271.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;316.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;120.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;115.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;116.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;127.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;127.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total testing revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;591.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;678.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;579.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;666.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;591.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;678.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;603.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;690.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Testing revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;329.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;347.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total testing revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;255.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;279.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;559.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;586.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;596.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;638.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performs its obligation under a contract with a customer by processing tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets.&#160;Occasionally, customers make payments prior to the Company's performance of its contractual obligations.&#160;When this occurs, the Company records a contract liability as Deferred revenue in the Consolidated Balance Sheets. During the fiscal year ended June 30, 2020, the Company received approximat&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ely $29.7&#160;million in a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;dvance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments were applied against services performed beginning in April 2021 and continued until the funds previously received were fully earned, which occurred during the quarter ended March 31, 2022. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue - beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue - ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company&#x2019;s right to payment is in an amount that directly corresponds with the value of the Company&#x2019;s performance to date. In determining the transaction price, the Company includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with ultimate collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenue in the Consolidated Statements of Operations and Comprehensive Loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash collections for certain tests delivered may differ from rates estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third-party payors. As a result of this new information, the Company updates its estimate of the amounts to be recognized for previously delivered tests. During the year ended December&#160;31, 2022, the Company recognized $22.1 million in revenue, which resulted in a $0.21 impact to loss per share for tests in which the performance obligation of delivering the test results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. During the year ended December&#160;31, 2021, the Company recognized $15.9 million in revenue which resulted in a $0.15 impact to loss per share for tests in which the performance obligation of delivering the test results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. Additionally, during the year ended December&#160;31, 2021, revenue of $6.8 million was recognized due to expanded coverage for the Company's Prolaris test, for which revenue was fully constrained in a prior period. During the transition period ended December 31, 2020, the impact to revenue and loss per share for tests in which the performance obligation of delivering the test results was met in the prior period was immaterial. During the fiscal year ended June 30, 2020, the Company recognized a $9.9 million decrease in revenue, which resulted in a $(0.10) impact to loss per share for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third-party payors. In addition, during the fiscal year ended June 30, 2020, the Company identified an error related to prior periods for Medicare claims and reduced revenue and recorded an accrued liability for a total of $4.7 million that will be refunded to Medicare. The impact of correcting the error during that period and the impact to all prior periods was concluded to be immaterial. The correction of the error in the fiscal year ended June 30, 2020 resulted in an impact to loss per share for the fiscal year ended June 30, 2020 of $(0.05).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, the Company has elected to exclude from the measurement of transaction price, all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a customer for sales tax, value added tax, and certain other taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Payment Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the fair value compensation cost relating to stock-based payment transactions in accordance with ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation &#x2013; Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee&#x2019;s requisite service period, which is generally the vesting period. The fair value of restricted stock units (RSUs) and performance restricted stock units (PSUs) that do not have market conditions is based on the number of shares granted and the quoted price of the Company&#x2019;s common stock on the grant date. The fair value of PSU awards that have market conditions is determined using the Monte Carlo Method. For PSUs, t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Company estimates the likelihood of achievement of the performance conditions at the end of each period. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeitures are recognized as a reduction of compensation expense in earnings in the period in which they occur. The fair value of shares issued under the Company's Employee Stock Purchase Plan is calculated using the Black-Scholes option-pricing model, based on assumptions including the risk-free interest rate, expected life, expected dividend yield and expected volatility. The average risk-free interest rate is determined using the U.S. Treasury rate. We determine the expected life based on the offering period of the Employee Stock Purchase Plan. The expected volatility is determined using the weighted average of daily historical volatility of the price of the Company's common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Income (Expense)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the gain or loss on its divestitures as Other income (expense) in the Consolidated Statement of Operations. During the year ended December&#160;31, 2021, the Company recognized a net gain on divestitures of $162.0 million. See Note 17 for additional information regarding these divestitures. In addition, during the fiscal year ended June 30, 2020, the Company received approximately $14.6 million from the Provider Relief Fund under the CARES Act to reimburse the Company for health care related expenses or lost revenues that were attributable to COVID-19, which was recognized as a component of Other income (expense) in the Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal, state, and foreign income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company&#x2019;s filings, including the positions taken therein, are subject to audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the Company's consolidated financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share (EPS) is computed based on the weighted-average number of shares of common stock outstanding.&#160;&#160;Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding used to compute basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding and dilutive securities used to compute diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain outstanding options and RSUs were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive options and RSUs excluded from EPS computation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company&#x2019;s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive loss as a separate component of Stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the cumulative translation adjustments included in Accumulated other comprehensive loss (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Period translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies and adopted by the Company as of the specified effective date. During the year ended December 31, 2022, there have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the FASB that have or are expected to have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1Nzk_a1baa0cc-784c-47a1-984f-2891d1cc6ff4">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Financial Statement Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Myriad Genetics, Inc. (together with its subsidiaries, the&#160;"Company" or "Myriad") is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Myriad develops and offers tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower health care costs. The Company generates revenue by performing tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 17, by providing pharmaceutical and clinical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company currently operates as a single reporting segment.&#160;The Company&#x2019;s principal executive office is located in Salt Lake City, Utah.  &lt;/span&gt;&lt;/div&gt;The accompanying consolidated financial statements for the Company have been prepared in accordance with United States ("U.S.") generally accepted accounting principles (&#x201c;GAAP&#x201d;) for financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1ODk_01015d65-a949-4b6d-84b7-01176b9a007e">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates and assumptions include revenue recognition estimates for the average expected reimbursement per test, valuation allowances for deferred income tax assets, certain accrued liabilities, stock-based compensation, purchase accounting, and impairment analysis of goodwill and long-lived assets. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1NzM_017b4b42-618f-4ab8-83eb-b4b11cd36cf2">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders' equity, or cash flows from operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1ODg_24807161-48ec-4fb8-ab13-40264793f1a1">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company&#x2019;s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related health care programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately 14%, 17%, 16%, and 15% of total revenue for the years ended December 31, 2022 and 2021, the six-month transition period ended December&#160;31, 2020, and the fiscal year ended June 30, 2020, respectively. Concentrations of credit risk are mitigated due to the number of the Company&#x2019;s customers as well as their dispersion across many geographic regions. No payor accounted for&#160;more than 10%&#160;of accounts receivable at&#160;December&#160;31, 2022 or December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia6915ee2f4e247fea81a5a54115ece38_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNTQ5NzU1ODQyNjIz_4ada0769-d5b8-412f-92ab-8717be53c44e"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i87dfdf9848204b5bb02322c598155b03_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDY1Nw_7d60dfda-f596-4f77-b910-f78c6e5979fb"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i41f829e207b542b5b614a6ac506833bf_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDY2MQ_5c457732-400c-439d-b828-91a2857ee3e3"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iec639d3cfaee463ba8e594bc6bb5ce4b_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDY2NQ_22212659-f7c6-4f1b-ba5e-8239d91d9b01"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1ODc_7e8227cb-300d-4ef1-a8b2-4d785c16a871">Cash and Cash EquivalentsThe Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents primarily consist of cash and money market deposits with financial institutions.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDk0NzgwMjM5MDA5Mw_064956f3-6320-4220-bdec-887638fde99b">Restricted CashIn certain circumstances, the Company is required to maintain cash deposit with certain banks with respect to contractual or other legal obligations, and therefore the use of these cash deposits for general operational purposes is restricted. The restricted cash amounts are largely comprised of cash held in escrow related to the Company's acquisition of Gateway Genomics, LLC ("Gateway") during the year ended December 31, 2022 and certain divestitures during the year ended December 31, 2021. The current and long-term portions are included in Prepaid expenses and other current assets and Other assets, respectively, on the Consolidated Balance Sheets.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDM5ODA0NjU3NDg3Mg_a1018d9f-1de5-4b2e-8d22-56518abf031c"
      unitRef="usd">9500000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCashCurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDM5ODA0NjU3NTI1OQ_b39be357-827c-427c-a972-efbca50cd64c"
      unitRef="usd">2000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDM5ODA0NjU3NTI2NA_f4538f3f-998a-45e7-993e-276c03d2019c"
      unitRef="usd">7500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCash
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDM5ODA0NjU3NTI3Nw_34a123c4-2398-4222-a8dc-b27bcc6e797a"
      unitRef="usd">1400000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCashCurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDM5ODA0NjU3NTMxMA_542de38f-bf4d-4fda-bd5f-d08e060d50c4"
      unitRef="usd">1000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDM5ODA0NjU3NTM2NQ_0268a7b9-b22c-49f9-af7e-b83b1027e9db"
      unitRef="usd">400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDk0NzgwMjM5MDA5NA_53b2009e-02f6-4f6a-9c8f-b077041a11a4">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Consolidated Balance Sheets that agrees to the amounts included in the Consolidated Statement of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDk0NzgwMjM5MDA5NA_e9364c66-4387-4548-9d40-cafe8311dcfe">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Consolidated Balance Sheets that agrees to the amounts included in the Consolidated Statement of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfMi0xLTEtMS0xNDYwMzU_8f1eb1cb-3409-4f5a-8e76-d7403aa9f63a"
      unitRef="usd">56900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfMi0zLTEtMS0xNDYwMzU_0b630af4-bb69-46f9-b1d1-92b2e6eb5b12"
      unitRef="usd">257400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfMi01LTEtMS0xNDYwODY_4bcb8c62-28df-4c54-bf03-d75e78da515c"
      unitRef="usd">117000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ideeefc606008446e85d0fd21a9515813_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfMi03LTEtMS0xNDYxMTI_ab5eaba1-5a45-4273-8823-a716b3c8ef8f"
      unitRef="usd">163700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfMy0xLTEtMS0xNDYwMzU_149750d2-0045-4dda-938c-56a40de212b2"
      unitRef="usd">9500000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfMy0zLTEtMS0xNDYwMzU_74c5839e-b390-46d7-a360-258a74c4eff6"
      unitRef="usd">1400000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfMy01LTEtMS0xNDYwODY_0bb84b66-0c30-450a-b3f8-953d0ac5249a"
      unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ideeefc606008446e85d0fd21a9515813_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfMy03LTEtMS0xNDYxMTI_039a7476-8f40-4ad2-83d7-ffa61453371d"
      unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfNC0xLTEtMS0xNDYwMzU_5f399f1a-ac9d-4942-ac41-0301398f7421"
      unitRef="usd">66400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfNC0zLTEtMS0xNDYwMzU_bd3e3df0-433e-4b66-be01-22813ba4257e"
      unitRef="usd">258800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfNC01LTEtMS0xNDYwODY_22bbaf61-a966-449c-b627-a7fd18a291b2"
      unitRef="usd">117000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ideeefc606008446e85d0fd21a9515813_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjc3MzAzZmY4YjVhZjRiYjFhMzFmM2JkYmEwNDg1ZDc5L3RhYmxlcmFuZ2U6NzczMDNmZjhiNWFmNGJiMWEzMWYzYmRiYTA0ODVkNzlfNC03LTEtMS0xNDYxMTI_2b79ea45-f925-45cf-b0cb-d81f66c05175"
      unitRef="usd">163700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1NzY_77f5abbd-cc19-4ea3-b304-295b4f4dfaa1">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Investment Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has classified its marketable investment securities, all of which are debt securities, as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in Accumulated other comprehensive loss in Stockholders&#x2019; equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The Company&#x2019;s cash equivalents consist of short-term, highly liquid investments that are readily convertible to known amounts of cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. Losses are charged against Other income (expense) when a decline in fair value is determined to be other than temporary. The Company reviews several factors to determine whether a loss is other than temporary. These factors include but are not limited to: (i) the extent to which the fair value is less than cost and the cause for the fair value decline, (ii) the financial condition and near term prospects of the issuer, (iii) the length of time a security is in an unrealized loss position and (iv) the Company&#x2019;s ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. There were no other-than-temporary impairments recognized during the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020 or during the fiscal year ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1OTA_1fbe4e3f-79eb-4149-8f77-834e549e63e2">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of supplies such as reagents, plates and testing kits, which are consumed when providing test results, and therefore the Company does not maintain finished goods inventory. Inventories are stated at the lower of cost or market and costs are determined on a first-in, first-out basis.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its inventories for excess quantities and obsolescence.&#160;&#160;Inventories that are considered excess or obsolete are expensed.&#160;&#160;&#160;In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels. The valuation of inventories requires the use of estimates as to the amounts of current inventories that will be sold. These estimates are dependent on management&#x2019;s assessment of current and expected orders from the Company&#x2019;s customers.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1NjY_451e4c4f-7880-4e47-9bd3-a18a85b2f609">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable represents estimated receivables from customers for revenue recognized related to genetic tests. The Company does not have any off-balance-sheet credit exposure related to its customers and does not require collateral.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1ODM_72d1b98b-8e04-43d3-8917-0e4a2024cf14">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method based on the lesser of estimated useful lives of the related assets or lease terms. Equipment items have depreciable lives of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfODUzMw_6379236e-7018-4cbe-9f98-2974e673bf30"&gt;five&lt;/span&gt; to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful lives or the associated lease terms, which range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfODY3Nw_ce7f7168-4bc2-4449-b270-c38ee0a58400"&gt;one&lt;/span&gt; to fifteen years. Repairs and maintenance costs are charged to expense as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i2a04aadd840a46c4a950e132f342709c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfODUzOQ_63ebc7ec-e0bf-4986-996a-1a8489df3225">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7d40dec02733475a840d3032148ea124_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfODY4Mw_3cc9915d-5bcc-4e56-a6f2-bb5e47e3cdd0">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDk0NzgwMjM4NDE2OQ_90c0581c-a918-4feb-a1a0-f7ce21601877">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company acts as lessee in its lease agreements, which include operating leases for corporate offices, laboratory space, warehouse space, vehicles and certain laboratory and office equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is, or contains, a lease at inception. The Company records the present value of lease payments as right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities on the Consolidated Balance Sheets. ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of lease liabilities as either current or non-current is based on the expected timing of payments due under the Company&#x2019;s obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of the Company&#x2019;s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The leases have remaining lease terms of 1 year to 15 years, some of which include options to extend the lease term for up to 10 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has taken advantage of certain practical expedients offered to registrants at adoption of Accounting Standards Codification ("ASC") 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis and is not included in the recognized ROU assets and lease liabilities. Further, as a practical expedient, all lease contracts are accounted for as one single lease component, as opposed to separating lease and non-lease components to allocate the consideration within a single lease contract.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="id126768d0af64211a663a5ba94eb3c2c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNTQ5NzU1ODgwNzEw_38f941a0-fb4f-4690-bf7e-d36067da9126">P1Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i4fa41121b7d143cfbc8e91a9ced3020a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNTQ5NzU1ODgwNzE0_5e029a6f-9da1-40a7-91c0-60f889d90f47">P15Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNTQ5NzU1ODgwNzIx_dae0ed03-45f4-465f-ab6e-17d589586cb1">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1NzE_485a4dc8-8e4e-4877-adaa-4e45f7e4f86f">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Other Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible and other long-lived assets are comprised of acquired licenses and technology. Acquired intangible assets are recorded at fair value and amortized over the shorter of the contractual life or the estimated useful life. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain costs incurred to develop internal-use technology, including certain implementation costs incurred in cloud computing arrangements and hosting arrangements that include an internal-use software license. The Company's cloud computing arrangements or hosting arrangements are primarily service contracts related to information technology. Implementation and development costs for internal-use technology are capitalized as part of Other assets in the Consolidated Balance Sheets. After the implementation of the internal-use cloud computing software or other internal-use technology, the capitalized costs are amortized on a straight-line basis over the estimated useful life of the asset. Costs incurred during the post implementation stage of the project are expensed as incurred. As of December&#160;31, 2022 and 2021, the Company had unamortized software costs of $7.1 million and $6.7 million, respectively. For the years ended December 31, 2022 and 2021, amortization expense for capitalized software costs was $1.2 million and $0.2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually reviews and monitors long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTAyNzU_bb6d44ec-e7b2-4637-9d1b-d3f479f360ee"
      unitRef="usd">7100000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTAyODI_a184a079-b6a3-4115-a06e-3ea78c514c7b"
      unitRef="usd">6700000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTAzNjg_b663f3ff-bd22-44f7-aedf-97a13c5e8239"
      unitRef="usd">1200000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNTQ5NzU1ODU0MDUw_925c3527-c782-4fa5-915b-2c845785c9ee"
      unitRef="usd">200000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1Njk_5045bbca-50d4-4c9a-bb3f-51d15c3770ed">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment by reporting unit on an annual basis as of October 1 and in the interim if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators and competition.&#160;&#160;Impairment of goodwill is first assessed using a qualitative approach.&#160;If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed.&#160;The quantitative analysis involves a comparison of the fair value of the reporting unit with its carrying amount.&#160;If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.&#160;If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNDk0NzgwMjM4NDE3MQ_bf1e38e5-68a4-4b4b-b66a-4540b833f2f2">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for acquisitions of entities that include inputs and processes and have the ability to create outputs as business combinations. The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on third-party valuations that use information and assumptions provided by the Company's management, which consider the Company's estimates of inputs and assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, estimated cost savings, cash flows, discount rates, estimated useful lives and probabilities surrounding the achievement of contingent milestones could result in different purchase price allocations and amortization expense in current and future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under ASC 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recognizes a liability equal to the fair value of the contingent payments expected to be made as of the acquisition date. This liability is remeasured each reporting period and the changes in the fair value are recognized in Selling, general, and administrative expenses in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction costs associated with acquisitions are expensed as incurred in Selling, general, and administrative expenses in the Consolidated Statements of Operations. Results of operations and cash flows of acquired companies are included in the operating results from the date of acquisition.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1Nzc_fb33aab9-3ca3-4a5b-a5b6-9d5c3cf97ac7">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company primarily generates revenue by performing genetic testing. Testing revenues are primarily derived from the following categories of products: Hereditary Cancer (MyRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight, Prequel, and SneakPeek), and Pharmacogenomics (GeneSight). The Company previously provided pharmaceutical services and clinical services prior to the sale of Myriad RBM, Inc. in July 2021 and Privatklinik Dr. Robert Schindlbeck GmbH &amp;amp; Co. KG in February 2020. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 and the Myriad Autoimmune business in September 2021, the associated revenue from such businesses was included within Testing revenues. See Note 17 for a discussion of these divestitures. Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results or the completion of pharmaceutical and clinical services indicates transfer of control for revenue recognition purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents detail regarding the composition of the Company&#x2019;s total revenue by product type for the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020, and the fiscal year ended June 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Testing revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total testing revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;678.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;678.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the following tables reconcile revenue by geographical region, either U.S. or rest of world ("RoW"), to total revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Testing revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;263.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;271.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;316.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;120.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;115.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;116.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;127.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;127.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total testing revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;591.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;678.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;579.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;666.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;591.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;678.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;603.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;690.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Testing revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;329.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;347.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total testing revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;255.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;279.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;559.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;586.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;596.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;638.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performs its obligation under a contract with a customer by processing tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets.&#160;Occasionally, customers make payments prior to the Company's performance of its contractual obligations.&#160;When this occurs, the Company records a contract liability as Deferred revenue in the Consolidated Balance Sheets. During the fiscal year ended June 30, 2020, the Company received approximat&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ely $29.7&#160;million in a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;dvance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments were applied against services performed beginning in April 2021 and continued until the funds previously received were fully earned, which occurred during the quarter ended March 31, 2022. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue - beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue - ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company&#x2019;s right to payment is in an amount that directly corresponds with the value of the Company&#x2019;s performance to date. In determining the transaction price, the Company includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with ultimate collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenue in the Consolidated Statements of Operations and Comprehensive Loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash collections for certain tests delivered may differ from rates estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third-party payors. As a result of this new information, the Company updates its estimate of the amounts to be recognized for previously delivered tests. During the year ended December&#160;31, 2022, the Company recognized $22.1 million in revenue, which resulted in a $0.21 impact to loss per share for tests in which the performance obligation of delivering the test results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. During the year ended December&#160;31, 2021, the Company recognized $15.9 million in revenue which resulted in a $0.15 impact to loss per share for tests in which the performance obligation of delivering the test results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. Additionally, during the year ended December&#160;31, 2021, revenue of $6.8 million was recognized due to expanded coverage for the Company's Prolaris test, for which revenue was fully constrained in a prior period. During the transition period ended December 31, 2020, the impact to revenue and loss per share for tests in which the performance obligation of delivering the test results was met in the prior period was immaterial. During the fiscal year ended June 30, 2020, the Company recognized a $9.9 million decrease in revenue, which resulted in a $(0.10) impact to loss per share for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third-party payors. In addition, during the fiscal year ended June 30, 2020, the Company identified an error related to prior periods for Medicare claims and reduced revenue and recorded an accrued liability for a total of $4.7 million that will be refunded to Medicare. The impact of correcting the error during that period and the impact to all prior periods was concluded to be immaterial. The correction of the error in the fiscal year ended June 30, 2020 resulted in an impact to loss per share for the fiscal year ended June 30, 2020 of $(0.05).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, the Company has elected to exclude from the measurement of transaction price, all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a customer for sales tax, value added tax, and certain other taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1Njg_694a17f5-c76d-4241-8671-fb7021504918">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents detail regarding the composition of the Company&#x2019;s total revenue by product type for the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020, and the fiscal year ended June 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Testing revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total testing revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;678.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;678.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4321aa8ac0974d02ac5b95ed298d955b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMy0xLTEtMS0xMjQ2MTA_d6c4d04b-f7ba-4428-b6a0-389853713d06"
      unitRef="usd">305500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fe93ba93efe459db6badb7752b80b87_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMy0xLTEtMS0xMTk0ODI_eac8d55f-0f33-4da0-919c-f196c675e34e"
      unitRef="usd">316300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7ae454902ce4cceb0fb07cad24d3c8c_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMy0zLTEtMS0xMTk0ODI_a5796bc8-7a3a-49c4-8f77-59cffc6a68d5"
      unitRef="usd">159300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0152bd259b6948b0bc3b7e357d1fc445_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMy01LTEtMS0xMTk0ODI_2a6f61ed-3c0e-4cc0-ac9e-c39f6bbe1b6f"
      unitRef="usd">347400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e94095aa8954df29cb417ee209e2fff_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNC0xLTEtMS0xMjQ2MTA_8307aaa3-0219-49c6-abb4-bcaae61253b8"
      unitRef="usd">128600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4e8e7880267470bbc22e12957f39118_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNC0xLTEtMS0xMTk0ODI_7033eb7e-4e44-4a93-b791-695a922ccd2d"
      unitRef="usd">120900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i446a798869a940bcb0840713d8d197d5_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNC0zLTEtMS0xMTk0ODI_a711a428-17ac-4310-84b1-e172654c89f6"
      unitRef="usd">33900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i088a89f8c55a4830ae8f287603af0a85_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNC01LTEtMS0xMTk0ODI_1c5a7045-c5d8-42a2-b3d2-8353a9714745"
      unitRef="usd">48300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71764f1445be4ec3b1d8f1ae335382fc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNS0xLTEtMS0xMjQ2MTA_62fb8507-fc37-4f32-b9c1-7252c57d3e4a"
      unitRef="usd">116400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf7ecebc2a4a4743b808a47645131aae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNS0xLTEtMS0xMTk0ODI_2fa6f6b3-2659-4785-9279-67f96e1a41ff"
      unitRef="usd">106800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ba2f4fd98b0498cab6a8cd62a52550e_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNS0zLTEtMS0xMTk0ODI_91fd846f-732d-4ec9-8514-1c64f571b478"
      unitRef="usd">37600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i608839facd584950806bdce9ed6b7161_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNS01LTEtMS0xMTk0ODI_8b5878c4-70d6-426a-b745-e409da37cb93"
      unitRef="usd">76700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60681fe10dbc48539edaa19296f641ae_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNi0xLTEtMS0xMjQ2MTA_5756be58-7522-418f-aa49-b695e3f5e5fc"
      unitRef="usd">127600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i162851a888574726bbc3d4a48c455909_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNi0xLTEtMS0xMTk0ODI_c4174785-52b3-41af-9777-de4fb9fcefde"
      unitRef="usd">93700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c62e82c4b0646a5bfc481b48968354c_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNi0zLTEtMS0xMTk0ODI_65b64ab3-0c16-4986-ad9a-363cd1e9ec46"
      unitRef="usd">29800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie73cf1f18b64415697365cb853c1fc55_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNi01LTEtMS0xMTk0ODI_3d1236e1-a5e9-409c-92d0-d10fc6268604"
      unitRef="usd">74100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75b0f8fc04374becb000201e80f83824_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNy0xLTEtMS0xMjQ2MTA_9d205445-c342-4c74-bbf5-72d637155c3b"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba570416299441d585bdbe522d386ebb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNy0xLTEtMS0xMTk0ODI_d982b48b-4904-4d17-a210-b8304ae4cded"
      unitRef="usd">28200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i236ed4b1de894f8198c2d79df713cacf_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNy0zLTEtMS0xMTk0ODI_f6dcd384-555b-4c33-95f0-2a0d24739769"
      unitRef="usd">18000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66122a21283042e5b1642886306f936f_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfNy01LTEtMS0xMTk0ODI_33d86bcf-9916-4265-b3aa-4df37612b10c"
      unitRef="usd">39100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i908c0e65a6164625a7ffbc02d881c4b4_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfOC0xLTEtMS0xMjQ2MTc_340652f1-b19c-4631-b9d2-54e7b308b38f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9caac20c6a643a08ddbe9107e60ff80_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfOC0xLTEtMS0xMTk0ODI_7bb1cace-fc0b-4025-9727-14fbdc2f591f"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9bef53171a3408ebbb6bb19f0a61b94_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfOC0zLTEtMS0xMTk0ODI_8891e05d-4e56-402a-90bb-5375d22c32f0"
      unitRef="usd">1000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a9a17ae382543bfb59eee6cb07b076b_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfOC01LTEtMS0xMTk0ODI_428a516e-5dcd-49e9-9f04-295d8a39e7e9"
      unitRef="usd">1300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i308b88139f674cb09b58fa82ee43d092_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfOS0xLTEtMS0xMjQ2MTc_29fd42ed-cc11-4e00-b815-c11912e541e6"
      unitRef="usd">678400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i794c44e7bf5b45689f334a7dc2a6cc11_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfOS0xLTEtMS0xMTk0ODI_17d45b86-bfee-451f-a450-1043cb7f84cd"
      unitRef="usd">666400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i543bcad925584a75897772999efa4e3e_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfOS0zLTEtMS0xMTk0ODI_be6fab49-558e-42b3-a806-607f09fede56"
      unitRef="usd">279600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc254773edfa4835899bcbe4c0b57775_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfOS01LTEtMS0xMTk0ODI_9349aa4e-2adf-421f-9d2e-5057e6fad209"
      unitRef="usd">586900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5bb3d6305f96409c9f4239ce2e6f890c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMTAtMS0xLTEtMTI0NjE3_8f2f3364-941d-437d-8d5c-141702f4ad1e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i934fd4ad46814c4e88f3d8113c493def_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMTAtMS0xLTEtMTE5NDgy_7bf7a00a-bdb0-4b40-8d62-c7358475e6eb"
      unitRef="usd">24200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i329f9f45afc549329c841d2e34c6be5d_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMTAtMy0xLTEtMTE5NDgy_dc5ef455-16a8-44da-b7fc-ffb0a16d2150"
      unitRef="usd">20200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f216fe61ee54eeab8ab464958d1e5bb_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMTAtNS0xLTEtMTE5NDgy_c2baf0cd-62b9-4aaf-a3db-a1277cfc3db5"
      unitRef="usd">51700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMTEtMS0xLTEtMTI0NjE3_6588e4e5-0fa3-4336-b969-a27537a2198f"
      unitRef="usd">678400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMTEtMS0xLTEtMTE5NDgy_14ed904f-6abb-4185-a30c-e1ae72745fb6"
      unitRef="usd">690600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMTEtMy0xLTEtMTE5NDgy_be089e80-e47b-4679-95bc-80de1ab8cace"
      unitRef="usd">299800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjE1YTQ4Mzc3N2VhMTQ5OGVhMTVjMTIwMTk3N2EyMDNiL3RhYmxlcmFuZ2U6MTVhNDgzNzc3ZWExNDk4ZWExNWMxMjAxOTc3YTIwM2JfMTEtNS0xLTEtMTE5NDgy_311e986d-7b3c-4ef0-82d3-f43ad9667612"
      unitRef="usd">638600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1NzQ_02963077-a1a0-4886-918c-a726e11ff763">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the following tables reconcile revenue by geographical region, either U.S. or rest of world ("RoW"), to total revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Testing revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;263.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;271.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;316.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;120.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;115.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;116.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;127.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;127.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total testing revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;591.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;678.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;579.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;666.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;591.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;678.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;603.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;690.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;RoW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Testing revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hereditary Cancer&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;329.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;347.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tumor Profiling&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prenatal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmacogenomics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Autoimmune&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total testing revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;255.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;279.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;559.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;586.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;299.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;596.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;638.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28c0950a478b45b8a240f2704954aa73_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNC0xLTEtMS0xMTk0ODI_a9aae6d2-8c6a-4473-89b3-aabd9f48a4fe"
      unitRef="usd">263500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c7a502434884775af9bab6a939e30b9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNC0zLTEtMS0xMTk0ODI_d7a62e00-b4f8-4358-be18-af581795e162"
      unitRef="usd">42000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4321aa8ac0974d02ac5b95ed298d955b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNC01LTEtMS0xMTk0ODI_68c6873e-51c7-4211-a98b-35cb11f0ec7c"
      unitRef="usd">305500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9ced64cb3044b06a122bd28bfff5d43_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNC04LTEtMS0xMTk0ODI_1ee02b84-5d9b-475c-a07a-51fd5df381a6"
      unitRef="usd">271000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48f46e422d5d477f8d00d83b4afb9715_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNC0xMC0xLTEtMTE5NDgy_e32a9e95-916a-4484-998a-cfdfcef501f3"
      unitRef="usd">45300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fe93ba93efe459db6badb7752b80b87_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNC0xMi0xLTEtMTE5NDgy_353f4b31-2344-4d10-9b4f-bad55f712264"
      unitRef="usd">316300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5d8ea4dde274fe09e92affa3ca98896_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNS0xLTEtMS0xMTk0ODI_1f49f66b-cee7-4c14-96bf-3304d3b26140"
      unitRef="usd">84500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia63cb40eed4a4bcdb75e61ac29fd3ce1_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNS0zLTEtMS0xMTk0ODI_a56e3f05-ecc9-4eb6-ad50-878b6c4d5d4a"
      unitRef="usd">44100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e94095aa8954df29cb417ee209e2fff_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNS01LTEtMS0xMTk0ODI_ba9fcdb1-5852-40ac-a395-86f0950dffe4"
      unitRef="usd">128600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0d0673d53164492ae8fdf1825d7cc9d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNS04LTEtMS0xMTk0ODI_223dea6c-5995-4243-a1d5-f5e29d9a17dd"
      unitRef="usd">80400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f2792c0364546bc85db617aec3476eb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNS0xMC0xLTEtMTE5NDgy_fdd22d1e-b9cc-4a55-9a11-12ef22af246d"
      unitRef="usd">40500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4e8e7880267470bbc22e12957f39118_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNS0xMi0xLTEtMTE5NDgy_692b3cab-c526-413c-83e0-2dcd776acc82"
      unitRef="usd">120900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9ce5e2d04954ed79bbdbdf2f86c31be_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNi0xLTEtMS0xMTk0ODI_2807e530-fa2b-4c27-96be-5125e64f2489"
      unitRef="usd">115600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i912da28c3ce14d5fab748b5b779eddcb_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNi0zLTEtMS0xMTk0ODI_688a4b68-18d4-4e5d-8ece-e7c39d64f638"
      unitRef="usd">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71764f1445be4ec3b1d8f1ae335382fc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNi01LTEtMS0xMTk0ODI_083d3661-22e6-49b9-99d4-9f8110a5a77a"
      unitRef="usd">116400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78aec82de9644c62815efaae24c0f234_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNi04LTEtMS0xMTk0ODI_0dc05b9a-f650-40d1-aabd-47ca7188f249"
      unitRef="usd">106200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i968b103643364f408ebde53bd855f7d4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNi0xMC0xLTEtMTE5NDgy_34138695-52af-453e-843e-0978d8636c59"
      unitRef="usd">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf7ecebc2a4a4743b808a47645131aae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNi0xMi0xLTEtMTE5NDgy_07b697c4-e21a-4f0b-b0d7-90a190f959b1"
      unitRef="usd">106800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28401cefd42342bba22f821ee9e35aca_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNy0xLTEtMS0xMTk0ODI_cebe9d6b-99f4-4a86-afab-715d567d44f5"
      unitRef="usd">127600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28171e2c0157437f901e8ac487ced4c5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNy0zLTEtMS0xMTk0ODI_e3498964-30a5-45df-bc41-a8b34f059cbb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60681fe10dbc48539edaa19296f641ae_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNy01LTEtMS0xMTk0ODI_63710efe-7bdd-4212-9714-fb7f05cdac03"
      unitRef="usd">127600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8433607b2fd04ed895116661af183b0b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNy04LTEtMS0xMTk0ODI_44a51c05-a047-4d97-9cff-980336d0cff7"
      unitRef="usd">93700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a1ac302b8d049b5bd17bf6490234668_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNy0xMC0xLTEtMTE5NDgy_983809ae-eb1d-4499-b7b6-0ccaf66cc2d7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i162851a888574726bbc3d4a48c455909_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfNy0xMi0xLTEtMTE5NDgy_35aa701e-9ff0-4f89-ae6b-86c52b871507"
      unitRef="usd">93700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7cffa2ae4f264f0fbe8bd94485d5382d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOC0xLTEtMS0xMTk0ODI_94772c1b-6642-4ad0-823c-22d94c2ae63b"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if753bf4c43f64a0c8907e6861712cbfd_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOC0zLTEtMS0xMTk0ODI_c359e5e7-70f3-401c-8064-2fb93e3b2d4c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75b0f8fc04374becb000201e80f83824_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOC01LTEtMS0xMTk0ODI_093dc9b7-6d55-4ba5-9061-2427fdac0009"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i857664e374a749be8f04a47ced6ef989_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOC04LTEtMS0xMTk0ODI_b6327522-0a1e-43fc-8e66-c5661570fb89"
      unitRef="usd">28200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i474e84aa7269419cb39f79e96b3c61b4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOC0xMC0xLTEtMTE5NDgy_f2794e1c-8a05-40f9-93bb-54e6a7101600"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba570416299441d585bdbe522d386ebb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOC0xMi0xLTEtMTE5NDgy_65cba125-1f01-46e9-921d-5e61b21fe2c7"
      unitRef="usd">28200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2708618e4b62400ba3acf94032086aa2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOS0xLTEtMS0xMTk0ODI_ef7d503d-6f86-4028-8880-5494424eced0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife78b8cec88a4dc7b70010cc79af31d4_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOS0zLTEtMS0xMTk0ODI_5adec7de-c418-455d-8758-5f81bb05412a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i908c0e65a6164625a7ffbc02d881c4b4_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOS01LTEtMS0xMTk0ODI_cea279e5-df8a-4752-a6bd-fd816e468b6d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69ab00712f2643a8801797ff591de929_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOS04LTEtMS0xMTk0ODI_28ecd563-23b7-43a6-bf02-7aadfa1e4f5c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50d11802ef0a4bf2934928e07af86a9e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOS0xMC0xLTEtMTE5NDgy_587e1751-67cd-48b1-a4a9-c148cd6a77d8"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9caac20c6a643a08ddbe9107e60ff80_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfOS0xMi0xLTEtMTE5NDgy_749eecb6-96c5-4589-87bb-be5bc613cf1e"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib210a719b53c402c8f0246ea4d23a748_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTAtMS0xLTEtMTE5NDgy_cf2beeeb-8983-458c-9ae0-f352c107cc9c"
      unitRef="usd">591500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10e8721d20f74d5b9979734f2dfaaccb_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTAtMy0xLTEtMTE5NDgy_1024f8e1-19d7-4922-b7a7-ca7d3ad827a6"
      unitRef="usd">86900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i308b88139f674cb09b58fa82ee43d092_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTAtNS0xLTEtMTE5NDgy_e57bef9d-3b5b-4be8-9899-a49d7a1aeafd"
      unitRef="usd">678400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4097e0cabf84d8bb42c8e84583e28d8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTAtOC0xLTEtMTE5NDgy_d14d9c1c-3d2b-46ae-961e-34cde78220e5"
      unitRef="usd">579500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i030ec43c8bcc435dbf4851b0831df548_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTAtMTAtMS0xLTExOTQ4Mg_443d8609-290c-4d78-a92e-488be9cc76af"
      unitRef="usd">86900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i794c44e7bf5b45689f334a7dc2a6cc11_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTAtMTItMS0xLTExOTQ4Mg_93d0f943-62b9-41cf-b589-a3cf6d401c00"
      unitRef="usd">666400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7677472fc774c0ba9acaa9a151d2429_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTEtMS0xLTEtMTE5NDgy_b68ea131-9bd7-43ca-94df-b462be1875d1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06e7851a35894a76b2c28ad9ef85560e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTEtMy0xLTEtMTE5NDgy_ed0d7653-708f-4f0d-950f-e8bfc89a5346"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5bb3d6305f96409c9f4239ce2e6f890c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTEtNS0xLTEtMTE5NDgy_df6c8d5a-c3ec-43de-beff-868854fe79fb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice489849d4474ba488f5e3ef419a245d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTEtOC0xLTEtMTE5NDgy_f27ad8d1-f210-4d8e-84eb-f64208f99e69"
      unitRef="usd">24200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i899daa04a5384ab09446e722067496aa_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTEtMTAtMS0xLTExOTQ4Mg_0561f6b4-a9c0-4d15-9d3f-1f92387142a0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i934fd4ad46814c4e88f3d8113c493def_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTEtMTItMS0xLTExOTQ4Mg_43e0b603-bb7e-46a2-ae88-017c3f98905d"
      unitRef="usd">24200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e9b90c162674cfe89cd17b243422a63_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTItMS0xLTEtMTE5NDgy_8b9d470b-b406-4bc1-b5ad-65cbd5345193"
      unitRef="usd">591500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94d4c8e8d9344b66817f27a942c9a7e5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTItMy0xLTEtMTE5NDgy_d7de1a75-e039-4882-be3b-018298941baa"
      unitRef="usd">86900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTItNS0xLTEtMTE5NDgy_9055525a-3ee7-4a9f-af06-2ec482294229"
      unitRef="usd">678400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10158fbf9e4e44dfbc25c01cdd6f88cc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTItOC0xLTEtMTE5NDgy_a4601c9d-f617-4052-9501-d539485e5ef2"
      unitRef="usd">603700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id233c4026cd0475ead24a770126edd58_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTItMTAtMS0xLTExOTQ4Mg_4eaeb613-eedc-4cd3-a432-a1431c09d2e9"
      unitRef="usd">86900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmMyZGI3ZDI1YmZiODRlMTU4NzBlZDg4NGZkYzU5MDM3L3RhYmxlcmFuZ2U6YzJkYjdkMjViZmI4NGUxNTg3MGVkODg0ZmRjNTkwMzdfMTItMTItMS0xLTExOTQ4Mg_a0d932ab-6b88-4640-b126-85c500e957e5"
      unitRef="usd">690600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e280ffa520e4589adc014530a498776_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNC0xLTEtMS0xMTk0ODI_f1ce55e6-8840-4d93-952b-0e83ece5f448"
      unitRef="usd">140900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i512678e2e28d43929c1f1c4039a3643b_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNC0zLTEtMS0xMTk0ODI_2e5b09f8-dc35-4b23-97c6-f7f663865e02"
      unitRef="usd">18400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7ae454902ce4cceb0fb07cad24d3c8c_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNC01LTEtMS0xMTk0ODI_8bd67a54-3b43-4f56-9ce9-15dc0812bb5d"
      unitRef="usd">159300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7d58fcd3a8a47c38f913ca273d9e241_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNC04LTEtMS0xMTk0ODI_76aaa2ca-25c7-4223-9242-65ad2dc0789d"
      unitRef="usd">329800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae97bd45a73e4d6b901011f4c036e632_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNC0xMC0xLTEtMTE5NDgy_56f393f5-81a1-4a01-8b74-186522b5a3d1"
      unitRef="usd">17600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0152bd259b6948b0bc3b7e357d1fc445_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNC0xMi0xLTEtMTE5NDgy_04e40b04-17ec-4ca0-9e96-d912a2d30418"
      unitRef="usd">347400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0196c4e720841a6bf4668d9ae0d9976_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNS0xLTEtMS0xMTk0ODI_a28c0358-3b0e-45dd-9cad-21ea84b62a30"
      unitRef="usd">28200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8dcbd3ba88b14b8cb9f6afb24c8af942_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNS0zLTEtMS0xMTk0ODI_4b7bcd0e-2238-41ea-8751-b3b9dff4f328"
      unitRef="usd">5700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i446a798869a940bcb0840713d8d197d5_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNS01LTEtMS0xMTk0ODI_ea40fba8-444c-4dc8-977d-5a33ddcd04c6"
      unitRef="usd">33900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4dcc457344ff41b99f24941ed96867bb_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNS04LTEtMS0xMTk0ODI_84f6d6f3-d2d6-4cba-9a5b-c665b0c89aa0"
      unitRef="usd">39200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11ab72b1aa84417b9db57840fd5421d7_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNS0xMC0xLTEtMTE5NDgy_455ca001-a22e-4a99-8a9a-128257d19b20"
      unitRef="usd">9100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i088a89f8c55a4830ae8f287603af0a85_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNS0xMi0xLTEtMTE5NDgy_07b846c6-7805-42d8-8016-c2abb7a81419"
      unitRef="usd">48300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3b7bb1fac6041bd8446301c256d5875_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNi0xLTEtMS0xMTk0ODI_f3d07711-ac1b-49ab-a9e0-20ffda5c192c"
      unitRef="usd">37400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9fa0c093df9436380086f024d36dc1a_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNi0zLTEtMS0xMTk0ODI_ce1720ed-e3a5-4931-968b-bb53f47972ee"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ba2f4fd98b0498cab6a8cd62a52550e_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNi01LTEtMS0xMTk0ODI_6d87bc85-1ad7-4f35-a1b9-98d52084030e"
      unitRef="usd">37600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i693d5f7bcfb9431498131ea693785506_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNi04LTEtMS0xMTk0ODI_8381bbb7-b431-4c6c-b51b-aa98208a023d"
      unitRef="usd">76400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib834f1b2fee94f00991b25d7ec3f8343_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNi0xMC0xLTEtMTE5NDgy_c5660a0b-fdee-4690-8ea4-1c6e352d89a3"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i608839facd584950806bdce9ed6b7161_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNi0xMi0xLTEtMTE5NDgy_e7539c74-6cd9-4c6d-8e0f-d11ac20e7493"
      unitRef="usd">76700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01d6d35e2fa543c586adcc726885b4d6_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNy0xLTEtMS0xMTk0ODI_c2c725f0-aa05-4614-9ada-485a0b97396f"
      unitRef="usd">29800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8440650c7814ce6946c100b1a08a2f6_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNy0zLTEtMS0xMTk0ODI_fc695aaa-7710-4b56-a9ab-71b7a21297e7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c62e82c4b0646a5bfc481b48968354c_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNy01LTEtMS0xMTk0ODI_b6875f8c-c79b-4f51-a1ee-39bf4834ee3a"
      unitRef="usd">29800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2438f843e5643799b35cc8647fde1bf_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNy04LTEtMS0xMTk0ODI_f4f9208f-b64d-410d-a504-e35259b3d63f"
      unitRef="usd">74100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i255d2253a7a94a53b1e5268006eec230_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNy0xMC0xLTEtMTE5NDgy_9b7eecd4-eb98-4851-8ce6-e331cd5b47ee"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie73cf1f18b64415697365cb853c1fc55_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfNy0xMi0xLTEtMTE5NDgy_2e381192-479b-4be0-b833-3a21f0f3a327"
      unitRef="usd">74100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81bb19aea32d467b970e042769acd6f2_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOC0xLTEtMS0xMTk0ODI_0b1d155e-7f03-4187-aa5e-1723a6699b83"
      unitRef="usd">18000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i569b535e97d84810b0407243c35fc225_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOC0zLTEtMS0xMTk0ODI_539bc31a-da4c-47e4-ab04-159d3226ad93"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i236ed4b1de894f8198c2d79df713cacf_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOC01LTEtMS0xMTk0ODI_8d049451-74ea-43ec-b372-33e0d84c24ee"
      unitRef="usd">18000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27a4954bb37f4c87a40da845b26d61d1_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOC04LTEtMS0xMTk0ODI_e7d5ff55-a27f-49b9-85ed-dd21e064dffd"
      unitRef="usd">39100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b140020e5bb4309b28dbcafa95601f1_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOC0xMC0xLTEtMTE5NDgy_3dc62286-4178-491f-a273-f8a6c8e10eb8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66122a21283042e5b1642886306f936f_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOC0xMi0xLTEtMTE5NDgy_740fc651-5f53-4442-87c5-759572b4007d"
      unitRef="usd">39100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ae24aee3b354ce6bbf7be3fb4302b94_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOS0xLTEtMS0xMTk0ODI_f2249fa8-a9ad-4900-9f60-224c3eb6c0a4"
      unitRef="usd">1000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i138bed0fe82b4330903b41329c9addd9_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOS0zLTEtMS0xMTk0ODI_5b6fc796-ae6f-43f0-9d92-98728487bb3f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9bef53171a3408ebbb6bb19f0a61b94_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOS01LTEtMS0xMTk0ODI_2748824d-ad53-43c7-b7f0-ae433564dbcc"
      unitRef="usd">1000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09ebb20a8a124362bcd7a8357aa29fd5_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOS04LTEtMS0xMTk0ODI_85a817fa-9ef5-4866-b81c-b654da508990"
      unitRef="usd">1200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03a43431da5647adb236a2611029b943_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOS0xMC0xLTEtMTE5NDgy_9c42d103-7279-40a5-8c65-0bc3fb01666e"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a9a17ae382543bfb59eee6cb07b076b_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfOS0xMi0xLTEtMTE5NDgy_ce79b58f-aefe-487d-975f-2c4456b85ddf"
      unitRef="usd">1300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icabe0b5ad1bd43baaa10f6239519e5e3_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTAtMS0xLTEtMTE5NDgy_49c55467-87b2-4cd2-a971-f85057a6497e"
      unitRef="usd">255300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3dd9a90cd904e9bbf3710d2fa7182e9_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTAtMy0xLTEtMTE5NDgy_489beb41-5d4c-4a15-8e08-0a84c14d6afe"
      unitRef="usd">24300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i543bcad925584a75897772999efa4e3e_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTAtNS0xLTEtMTE5NDgy_145265ea-fd4d-4fa9-9708-453869f43f3b"
      unitRef="usd">279600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d51d292699e4dd78ccb0056227a5ce1_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTAtOC0xLTEtMTE5NDgy_02a016c4-be90-4a97-a79a-1712d7d3af76"
      unitRef="usd">559800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78a52daf7ef347be82dc84982294aa48_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTAtMTAtMS0xLTExOTQ4Mg_db2fe34f-beb4-49eb-b1bd-2abdc896d0bf"
      unitRef="usd">27100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc254773edfa4835899bcbe4c0b57775_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTAtMTItMS0xLTExOTQ4Mg_45be8ce3-dc98-405a-b73c-9132c6d3d8ef"
      unitRef="usd">586900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15b05f5f12104bbea82045fddddc48f0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTEtMS0xLTEtMTE5NDgy_350d2abc-178b-4a58-b205-a0c9dfa9651c"
      unitRef="usd">20100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14388d06b3b646bd940f87caf35842b0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTEtMy0xLTEtMTE5NDgy_92504d29-9e55-47bf-956f-e6dc4aa4bd7b"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i329f9f45afc549329c841d2e34c6be5d_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTEtNS0xLTEtMTE5NDgy_6689c3e6-0d60-457a-9208-04995094a7f6"
      unitRef="usd">20200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i258e4de3fb8c414ab710d4649d307805_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTEtOC0xLTEtMTE5NDgy_22225e59-b499-4bb0-a4f8-c5a9a9c3e310"
      unitRef="usd">36400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id55bccb976bc4a4e842f7029e06bddf5_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTEtMTAtMS0xLTExOTQ4Mg_617efee0-dbad-4d7c-82f2-41e549ed7c6d"
      unitRef="usd">15300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f216fe61ee54eeab8ab464958d1e5bb_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTEtMTItMS0xLTExOTQ4Mg_8f4a2a3a-4b22-4b2c-b515-5d528aa39b96"
      unitRef="usd">51700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35dea8de7d5247b6af91e476fc730262_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTItMS0xLTEtMTE5NDgy_0b5f0802-42db-48d4-8641-14536ced2bee"
      unitRef="usd">275400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8042ff618ec94c0b90363a2a23ccd745_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTItMy0xLTEtMTE5NDgy_bac0199e-ab3c-4404-af88-61e504166908"
      unitRef="usd">24400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTItNS0xLTEtMTE5NDgy_f744d1a6-988c-42a6-9ecf-bcad6139a4b9"
      unitRef="usd">299800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81b11dfa14ea4846bee1b74c8a4f62a1_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTItOC0xLTEtMTE5NDgy_a5f68be3-3579-46d3-b9c4-751090e0a417"
      unitRef="usd">596200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7251f8f8dbe2418b8cb8bcc34820beed_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTItMTAtMS0xLTExOTQ4Mg_b9ad1d94-e855-4f03-abba-4aae0eb6ca03"
      unitRef="usd">42400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjY4ZThiOWI3Zjg5YTQzMzFhMjhiN2E1MjYwOTQzYWU5L3RhYmxlcmFuZ2U6NjhlOGI5YjdmODlhNDMzMWEyOGI3YTUyNjA5NDNhZTlfMTItMTItMS0xLTExOTQ4Mg_99d0c50d-c4cf-44d3-93a4-da998fe005de"
      unitRef="usd">638600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <mygn:CARESActOf2020MedicarePaymentAmount
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTQ1ODY_7b56c27a-a2db-49a6-bdbd-d82e09591199"
      unitRef="usd">29700000</mygn:CARESActOf2020MedicarePaymentAmount>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1NzA_d2004589-535e-4714-8f48-2abe7b97657f">A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue - beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue - ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfMi0xLTEtMS0xMTk0ODI_14d37523-5e8e-4898-a039-2e5219c8c765"
      unitRef="usd">5200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfMi0zLTEtMS0xMTk0ODI_6280c499-e6f3-4fb3-a023-fc1b1e30256c"
      unitRef="usd">32700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ideeefc606008446e85d0fd21a9515813_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfMi01LTEtMS0xMTk0ODI_101325dc-447c-48b7-9049-cf5e52d53353"
      unitRef="usd">32800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="if96afdd71e74449aa558f9c0f8968925_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfMi03LTEtMS0xMTk0ODI_616a3c23-24de-49c6-ba89-0616823ecac8"
      unitRef="usd">2200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfMy0xLTEtMS0xMTk0ODI_3bae7189-634f-46d8-ad46-2be0041e113d"
      unitRef="usd">4900000</mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfMy0zLTEtMS0xMTk0ODI_8843d2db-5205-4da8-a01a-fca2c6c34587"
      unitRef="usd">40500000</mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfMy01LTEtMS0xMTk0ODI_c2c50274-38db-474a-8650-47481a5d0d52"
      unitRef="usd">6100000</mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfMy03LTEtMS0xMTk0ODI_6fc490ff-1789-40a7-931a-cc29d920a137"
      unitRef="usd">7200000</mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <mygn:ContractWithCustomerLiabilityPrepayments
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNC0xLTEtMS0xMTk0ODI_0f09bc65-f143-4bf8-a308-4be28c48784e"
      unitRef="usd">300000</mygn:ContractWithCustomerLiabilityPrepayments>
    <mygn:ContractWithCustomerLiabilityPrepayments
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNC0zLTEtMS0xMTk0ODI_77930c2d-8481-40af-bc36-e6904ea37dfc"
      unitRef="usd">14000000.0</mygn:ContractWithCustomerLiabilityPrepayments>
    <mygn:ContractWithCustomerLiabilityPrepayments
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNC01LTEtMS0xMTk0ODI_9490427a-7380-4fc7-95b3-ebd0905360a9"
      unitRef="usd">6000000.0</mygn:ContractWithCustomerLiabilityPrepayments>
    <mygn:ContractWithCustomerLiabilityPrepayments
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNC03LTEtMS0xMTk0ODI_a8ed490b-dcc7-43a8-8db9-2d58af947105"
      unitRef="usd">37800000</mygn:ContractWithCustomerLiabilityPrepayments>
    <mygn:ContractWithCustomerLiabilityDivestitures
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNS0xLTEtMS0xMTk0ODI_de556112-4bc2-4e38-aba5-3fb46bd0374b"
      unitRef="usd">0</mygn:ContractWithCustomerLiabilityDivestitures>
    <mygn:ContractWithCustomerLiabilityDivestitures
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNS0zLTEtMS0xMTk0ODI_7b4559e1-8c83-4a48-874b-f2704b78cdd7"
      unitRef="usd">1000000.0</mygn:ContractWithCustomerLiabilityDivestitures>
    <mygn:ContractWithCustomerLiabilityDivestitures
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNS01LTEtMS0xMTk0ODI_7401107c-cc4d-4b22-a2dd-dbf2332e3872"
      unitRef="usd">0</mygn:ContractWithCustomerLiabilityDivestitures>
    <mygn:ContractWithCustomerLiabilityDivestitures
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNS03LTEtMS0xMTk0ODI_5b162a15-a61f-4c3d-9768-96e27a654bd2"
      unitRef="usd">0</mygn:ContractWithCustomerLiabilityDivestitures>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNi0xLTEtMS0xMTk0ODI_11baf338-528b-42f5-ba47-d100fee7f861"
      unitRef="usd">600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNi0zLTEtMS0xMTk0ODI_29eed256-b386-40d2-991a-23b13f091c67"
      unitRef="usd">5200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNi01LTEtMS0xMTk0ODI_6280c499-e6f3-4fb3-a023-fc1b1e30256c"
      unitRef="usd">32700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ideeefc606008446e85d0fd21a9515813_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOjJhNzc3YjZlZDE2NjRkNGU5ODU4ZDQ4NTYwN2I3ODY4L3RhYmxlcmFuZ2U6MmE3NzdiNmVkMTY2NGQ0ZTk4NThkNDg1NjA3Yjc4NjhfNi03LTEtMS0xMTk0ODI_d92ae8c2-263f-45ba-a2c2-f8b58d4c4613"
      unitRef="usd">32800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTA5OTUxMTY2MTE4Mg_c7ad3283-056e-413f-a5a9-1bec64219a42"
      unitRef="usd">22100000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <mygn:IncreaseDecreaseInEarningsLossPerShare
      contextRef="i22b6ad0c0a184276b026278ab2492214_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTA5OTUxMTY2MTIyMA_f2d984a6-5258-461a-be21-0295937c4853"
      unitRef="usdPerShare">0.21</mygn:IncreaseDecreaseInEarningsLossPerShare>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTc1ODE_b7d525fb-ec1f-4f40-8271-0e7c496e14ad"
      unitRef="usd">15900000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <mygn:IncreaseDecreaseInEarningsLossPerShare
      contextRef="i67176840186a45f8b5451e8e62e7f69f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTc2MTU_88bab5a1-c5ee-4d98-aed1-e7fb196885b1"
      unitRef="usdPerShare">0.15</mygn:IncreaseDecreaseInEarningsLossPerShare>
    <mygn:ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTc5MDU_869f28da-39bf-4f1a-924d-799bf78de892"
      unitRef="usd">6800000</mygn:ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTgwODM_e1803c54-7df3-4961-ae13-d50672c54035"
      unitRef="usd">-9900000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <mygn:IncreaseDecreaseInEarningsLossPerShare
      contextRef="i4259e411c05a49db8fc3dba108adcb2a_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTgxMjc_22726ada-0aab-456a-9c2b-7a6e0cea5528"
      unitRef="usdPerShare">-0.10</mygn:IncreaseDecreaseInEarningsLossPerShare>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="if83d47ed8afd45349ebc0526f0253b99_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTg3Mzg_1ae33bfa-f54e-4a4b-91b9-9b608f279e1c"
      unitRef="usd">4700000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2d0848b372c49e7879916eea4a55d95_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTg3Mzg_4c9e61f7-7045-4a57-9510-ea21f1d7cf35"
      unitRef="usd">-4700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <mygn:IncreaseDecreaseInEarningsLossPerShare
      contextRef="ie2d0848b372c49e7879916eea4a55d95_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTkwNDU_2a46987c-af3e-430e-8a46-762aa4fb1ba0"
      unitRef="usdPerShare">-0.05</mygn:IncreaseDecreaseInEarningsLossPerShare>
    <us-gaap:CapitalizedContractCostGross
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMTk4MTI_6460ce29-18bb-4054-b323-a6f9dadb7ebb"
      unitRef="usd">0</us-gaap:CapitalizedContractCostGross>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1ODQ_7c5eeb6c-d0f4-4410-b7e7-7ad22f84a2e0">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Payment Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the fair value compensation cost relating to stock-based payment transactions in accordance with ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation &#x2013; Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee&#x2019;s requisite service period, which is generally the vesting period. The fair value of restricted stock units (RSUs) and performance restricted stock units (PSUs) that do not have market conditions is based on the number of shares granted and the quoted price of the Company&#x2019;s common stock on the grant date. The fair value of PSU awards that have market conditions is determined using the Monte Carlo Method. For PSUs, t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Company estimates the likelihood of achievement of the performance conditions at the end of each period. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeitures are recognized as a reduction of compensation expense in earnings in the period in which they occur. The fair value of shares issued under the Company's Employee Stock Purchase Plan is calculated using the Black-Scholes option-pricing model, based on assumptions including the risk-free interest rate, expected life, expected dividend yield and expected volatility. The average risk-free interest rate is determined using the U.S. Treasury rate. We determine the expected life based on the offering period of the Employee Stock Purchase Plan. The expected volatility is determined using the weighted average of daily historical volatility of the price of the Company's common stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <mygn:OtherIncomeExpensePolicyPolicyTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1ODU_d3d6126f-3d67-4a1e-a3c1-68cd377715ec">Other Income (Expense)The Company recognizes the gain or loss on its divestitures as Other income (expense) in the Consolidated Statement of Operations. During the year ended December&#160;31, 2021, the Company recognized a net gain on divestitures of $162.0 million. See Note 17 for additional information regarding these divestitures. In addition, during the fiscal year ended June 30, 2020, the Company received approximately $14.6 million from the Provider Relief Fund under the CARES Act to reimburse the Company for health care related expenses or lost revenues that were attributable to COVID-19, which was recognized as a component of Other income (expense) in the Consolidated Statements of Operations.</mygn:OtherIncomeExpensePolicyPolicyTextBlock>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfNTQ5NzU1ODQzNjkz_11112c90-235f-4439-9a3d-ee6cac25dd84"
      unitRef="usd">162000000</us-gaap:GainLossOnDispositionOfAssets>
    <mygn:CARESActOf2020ProviderReliefFundAmount
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjIyMDk_d11cb9dc-5036-4c6a-94e2-21401a7a1812"
      unitRef="usd">14600000</mygn:CARESActOf2020ProviderReliefFundAmount>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1ODY_d4d1e194-ec36-4e3f-b197-77b70b2ac14b">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal, state, and foreign income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company&#x2019;s filings, including the positions taken therein, are subject to audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the Company's consolidated financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1ODI_41bc9283-3c1f-42d5-a427-d08ab2a603ea">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share (EPS) is computed based on the weighted-average number of shares of common stock outstanding.&#160;&#160;Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding used to compute basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding and dilutive securities used to compute diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain outstanding options and RSUs were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive options and RSUs excluded from EPS computation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1NjU_340333f1-a600-4b14-bf2a-61a499c62ee5">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding used to compute basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average shares outstanding and dilutive securities used to compute diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfMy0xLTEtMS0xMTk0ODI_de58c89a-1169-4153-a7f0-58c8bd1e0677"
      unitRef="shares">80600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfMy0zLTEtMS0xMTk0ODI_0d9a1e81-777d-49bb-86e6-e1c8f2260fd5"
      unitRef="shares">78000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfMy01LTEtMS0xMTk0ODI_ee119907-5823-4d25-ac2f-3e630ebf3c4a"
      unitRef="shares">75000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfMy03LTEtMS0xMTk0ODI_cbcc44b3-e17a-44bd-b5de-d1b0d913eaa2"
      unitRef="shares">74300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfNC0xLTEtMS0xMTk0ODI_e22eb89e-8232-4dd0-bd31-52d7f96ea462"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfNC0zLTEtMS0xMTk0ODI_24b55a8d-1d06-4ae0-be22-6c46967e4937"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfNC01LTEtMS0xMTk0ODI_519525dc-f51d-461e-8f78-ef9f353d4033"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfNC03LTEtMS0xMTk0ODI_746c5edc-30f7-4d5c-9133-6164a3cd91eb"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfNS0xLTEtMS0xMTk0ODI_40558196-ba3a-45a2-bbfd-d579cd020de8"
      unitRef="shares">80600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfNS0zLTEtMS0xMTk0ODI_6d3062a4-ad12-4346-9e2f-eaa85bb1bab2"
      unitRef="shares">78000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfNS01LTEtMS0xMTk0ODI_2c030741-ade4-49fc-99bc-d589563b1656"
      unitRef="shares">75000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmM5Nzc2MmMzYmM4MjRiY2ViMThjNmI5NGViOTE1MWYxL3RhYmxlcmFuZ2U6Yzk3NzYyYzNiYzgyNGJjZWIxOGM2Yjk0ZWI5MTUxZjFfNS03LTEtMS0xMTk0ODI_e41f53b7-9e1b-4d63-b010-c16eb2ac8f1a"
      unitRef="shares">74300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1Njc_08fc8a98-24c7-40d5-bd51-77c66fac64c4">These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive options and RSUs excluded from EPS computation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmVjOGI0ZjQyYjViNjQ1M2E4ZjFmMTNmMGFlZDY4NjA2L3RhYmxlcmFuZ2U6ZWM4YjRmNDJiNWI2NDUzYThmMWYxM2YwYWVkNjg2MDZfMi0xLTEtMS0xMTk0ODI_274c63a1-abfb-4ab0-92e1-08b623456a20"
      unitRef="shares">4400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmVjOGI0ZjQyYjViNjQ1M2E4ZjFmMTNmMGFlZDY4NjA2L3RhYmxlcmFuZ2U6ZWM4YjRmNDJiNWI2NDUzYThmMWYxM2YwYWVkNjg2MDZfMi0zLTEtMS0xMTk0ODI_6b7ebc43-8301-480f-9d49-ea2345725d85"
      unitRef="shares">4500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmVjOGI0ZjQyYjViNjQ1M2E4ZjFmMTNmMGFlZDY4NjA2L3RhYmxlcmFuZ2U6ZWM4YjRmNDJiNWI2NDUzYThmMWYxM2YwYWVkNjg2MDZfMi01LTEtMS0xMTk0ODI_0d4f7554-93a2-416c-8c4f-552da94ae188"
      unitRef="shares">6600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmVjOGI0ZjQyYjViNjQ1M2E4ZjFmMTNmMGFlZDY4NjA2L3RhYmxlcmFuZ2U6ZWM4YjRmNDJiNWI2NDUzYThmMWYxM2YwYWVkNjg2MDZfMi03LTEtMS0xMTk0ODI_a7e2ffbb-6028-4b9a-b196-be0fd0ef72db"
      unitRef="shares">5500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1ODE_b197243b-dcb2-42d3-a8e7-d294e6bf8e5c">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company&#x2019;s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive loss as a separate component of Stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the cumulative translation adjustments included in Accumulated other comprehensive loss (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Period translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1Nzg_fc6fa889-53ff-455d-b7e7-0c8736f6b6a1">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the cumulative translation adjustments included in Accumulated other comprehensive loss (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Period translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmJmNGE0N2I5OGY4MDQwZmI4MjJiZjBlYTI3ZTVjOGEzL3RhYmxlcmFuZ2U6YmY0YTQ3Yjk4ZjgwNDBmYjgyMmJmMGVhMjdlNWM4YTNfMC0xLTEtMS0xMTk0ODI_84a770c0-0382-423f-83f4-ec80656239a4"
      unitRef="usd">-4900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmJmNGE0N2I5OGY4MDQwZmI4MjJiZjBlYTI3ZTVjOGEzL3RhYmxlcmFuZ2U6YmY0YTQ3Yjk4ZjgwNDBmYjgyMmJmMGVhMjdlNWM4YTNfMS0xLTEtMS0xMTk0ODI_28707e46-9da3-408d-b1c7-b0188471cc4f"
      unitRef="usd">-1300000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RhYmxlOmJmNGE0N2I5OGY4MDQwZmI4MjJiZjBlYTI3ZTVjOGEzL3RhYmxlcmFuZ2U6YmY0YTQ3Yjk4ZjgwNDBmYjgyMmJmMGVhMjdlNWM4YTNfMi0xLTEtMS0xMTk0ODI_3380b7d5-5674-4c47-a60b-eb57a7b60207"
      unitRef="usd">-6200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85MS9mcmFnOjQyZTlmOWIzMjcxYzQ0OWNhNTIzNTE2MzIxOWM0YTM5L3RleHRyZWdpb246NDJlOWY5YjMyNzFjNDQ5Y2E1MjM1MTYzMjE5YzRhMzlfMjU1NzU_d91426a3-038d-48d7-91b7-f984d5db6468">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies and adopted by the Company as of the specified effective date. During the year ended December 31, 2022, there have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the FASB that have or are expected to have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNjE2_be301806-b267-4a7f-8e93-badc487717a9">MARKETABLE INVESTMENT SECURITIES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value debt securities classified as available-for-sale securities by major security type and class of security at December&#160;31, 2022 and December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and maturities of debt securities classified as available-for-sale are as follows at December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2022 and 2021, the transition period ended December 31, 2020, and the fiscal year ended June 30, 2020, the Company sold $28.4 million, $8.3 million, $1.6 million, and $3.4 million of investments, respectively. The amount of gross realized gains and realized losses upon sales of investments were insignificant in all periods presented. As of December&#160;31, 2022, the Company had &lt;span id="i98f7445d1c2e464ba5eec17b1b0524ad_4604"/&gt;118 available-for-sale debt securities in a gross unrealized loss position of $2.7 million, with a fair market value of $111.6 million. As of December&#160;31, 2021, the Company had 100 available-for-sale debt securities in a gross unrealized loss position of $0.2 million, with a fair market value of $77.7 million. As of December 31, 2022 and December 31, 2021, the expected losses were determined to be immaterial and as such, the Company did not record an allowance for credit losses. The Company does not intend to sell these available-for-sale debt securities, and it is not more likely than not that it will be required to sell these securities prior to recovery of their amortized cost basis. Additional information relating to fair value of marketable investment securities can be found in Note 3.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNjE0_6dd6c77f-338d-4ca7-a762-6994568f0a73">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value debt securities classified as available-for-sale securities by major security type and class of security at December&#160;31, 2022 and December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia75f79427aab4f40a89a2217f2dc3335_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfMy0xLTEtMS0xMTk0ODI_7faef468-d895-483b-933c-79df6355b678"
      unitRef="usd">53600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia75f79427aab4f40a89a2217f2dc3335_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfMy03LTEtMS0xMTk0ODI_67478596-fcf4-446f-9ad3-19eb89a41e4a"
      unitRef="usd">53600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id0da8029be334899949f916d03b47e6e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfNC0xLTEtMS0xMTk0ODI_301f8b07-e5ee-4ca8-8b47-f2f62f1a7c23"
      unitRef="usd">3300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id0da8029be334899949f916d03b47e6e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfNC03LTEtMS0xMTk0ODI_c5422795-f6c6-473a-8bf4-454a80d26c0d"
      unitRef="usd">3300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfNS0xLTEtMS0xMTk0ODI_14644990-01a1-4ccb-a8fa-55eadfad8b74"
      unitRef="usd">56900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfNS03LTEtMS0xMTk0ODI_d7fbcb4f-d990-4ffa-8d95-c1bce3189036"
      unitRef="usd">56900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ieecccfa51e634b24b60447c9f26442d1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfNy0xLTEtMS0xMTk0ODI_b4ea1a13-52d8-4a79-b128-feee16bdbba1"
      unitRef="usd">66700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ieecccfa51e634b24b60447c9f26442d1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfNy0zLTEtMS0xMTk0ODI_eab52196-d158-4c50-8ecf-2fa9a9519efa"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ieecccfa51e634b24b60447c9f26442d1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfNy01LTEtMS0xMTk0ODI_a1c8fa66-448d-4a55-be0b-9475850871d4"
      unitRef="usd">1600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieecccfa51e634b24b60447c9f26442d1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfNy03LTEtMS0xMTk0ODI_b2f15b3d-8c40-46ce-babe-4a964f66bda8"
      unitRef="usd">65100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iea4bf30af38941b3b6938c631d1ce22e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfOC0xLTEtMS0xMTk0ODI_f51023fe-06eb-4147-80ce-b66315d0f731"
      unitRef="usd">16300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iea4bf30af38941b3b6938c631d1ce22e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfOC0zLTEtMS0xMTk0ODI_99600a84-02ae-4f43-8df4-494f965b3c18"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iea4bf30af38941b3b6938c631d1ce22e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfOC01LTEtMS0xMTk0ODI_d325999f-719c-4071-9ba4-13e958c992ab"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iea4bf30af38941b3b6938c631d1ce22e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfOC03LTEtMS0xMTk0ODI_cbaffeb4-9961-4600-8d16-3119311ddb10"
      unitRef="usd">16000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i33fcfcc4292d45c6b97cc255ecd96967_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfOS0xLTEtMS0xMTk0ODI_5a176c94-dc80-4f97-aa32-4307d8461ea7"
      unitRef="usd">20700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i33fcfcc4292d45c6b97cc255ecd96967_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfOS0zLTEtMS0xMTk0ODI_1228b742-fa60-4594-b882-73b2476df64c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i33fcfcc4292d45c6b97cc255ecd96967_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfOS01LTEtMS0xMTk0ODI_8b48cb8d-df76-49ea-901a-a32505840ed7"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i33fcfcc4292d45c6b97cc255ecd96967_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfOS03LTEtMS0xMTk0ODI_3f9d4147-9734-4670-8c9c-90643f4947fb"
      unitRef="usd">20000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib0e18392f2264c7ba9f8a25badbde19f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfMTAtMS0xLTEtMTE5NDgy_a725fecd-6e12-4d63-893a-5a3c198cca75"
      unitRef="usd">11800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib0e18392f2264c7ba9f8a25badbde19f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfMTAtMy0xLTEtMTE5NDgy_c9fdb3d9-242b-4bea-aa21-0facf8dba9bd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib0e18392f2264c7ba9f8a25badbde19f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfMTAtNS0xLTEtMTE5NDgy_f8810309-8cd9-45e9-9541-f1bf9d1400ad"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib0e18392f2264c7ba9f8a25badbde19f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfMTAtNy0xLTEtMTE5NDgy_3e3f696d-3e4f-490e-94f3-2dd3c982c88e"
      unitRef="usd">11700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <mygn:InvestmentsAndCashAmortizedCost
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfMTEtMS0xLTEtMTE5NDgy_1d40ee6a-d424-4307-8ec8-fc886cfd9421"
      unitRef="usd">172400000</mygn:InvestmentsAndCashAmortizedCost>
    <mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfMTEtMy0xLTEtMTE5NDgy_e949e4f3-e701-4ec2-b676-61ffc439a85e"
      unitRef="usd">0</mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax>
    <mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfMTEtNS0xLTEtMTE5NDgy_f6009565-99b7-4ddb-b379-a3a3b8784f5a"
      unitRef="usd">2700000</mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:InvestmentsAndCash
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjU0MjRiZmIwODcyZjQ3NTc5ZmRjNGQ2ZTYyZjVkZGM5L3RhYmxlcmFuZ2U6NTQyNGJmYjA4NzJmNDc1NzlmZGM0ZDZlNjJmNWRkYzlfMTEtNy0xLTEtMTE5NDgy_a57e8f6e-1a19-4266-acd4-f6f4a55bf69d"
      unitRef="usd">169700000</us-gaap:InvestmentsAndCash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic37ece6897254048a406c0b1fa7f3ad7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfMy0xLTEtMS0xMTk0ODI_584bfcc4-0938-4f3d-832b-63b6f14a5fed"
      unitRef="usd">194200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic37ece6897254048a406c0b1fa7f3ad7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfMy03LTEtMS0xMTk0ODI_1148d15b-4778-4598-9817-37d508d60604"
      unitRef="usd">194200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4a9bed5c63e84983966641b7a24d4bd5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfNC0xLTEtMS0xMTk0ODI_fa9d1a00-8dd8-49f0-8b5c-93a5c635e50d"
      unitRef="usd">63200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4a9bed5c63e84983966641b7a24d4bd5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfNC03LTEtMS0xMTk0ODI_96598fc2-7c0d-45f9-92b4-6839bf4860ab"
      unitRef="usd">63200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfNS0xLTEtMS0xMTk0ODI_2fe60af4-cd79-4c11-8e27-9e20240238d0"
      unitRef="usd">257400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfNS03LTEtMS0xMTk0ODI_8a2a50ca-441c-4d71-88c4-c9e2359ea935"
      unitRef="usd">257400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iffb0ffff83b34e97a987ed8e7389d515_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfNy0xLTEtMS0xMTk0ODI_afd67bf4-049b-4f3a-a25e-3200ab5756ac"
      unitRef="usd">105700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iffb0ffff83b34e97a987ed8e7389d515_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfNy0zLTEtMS0xMTk0ODI_e594d13b-0350-47c6-b29a-578c9347fb6a"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iffb0ffff83b34e97a987ed8e7389d515_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfNy01LTEtMS0xMTk0ODI_5584b335-78bb-47fd-a202-ea6ce875aa4c"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iffb0ffff83b34e97a987ed8e7389d515_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfNy03LTEtMS0xMTk0ODI_f9674e8f-c6d4-4bc7-8490-1fa6f05245a1"
      unitRef="usd">105600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i06c8acb8e4034c26bb0e7099f0eb44f5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfOC0xLTEtMS0xMTk0ODI_fbafe362-7b29-47bd-b682-d68965a6c68d"
      unitRef="usd">16100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i06c8acb8e4034c26bb0e7099f0eb44f5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfOC0zLTEtMS0xMTk0ODI_647bc425-2064-4303-a116-81b56b1bebfb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i06c8acb8e4034c26bb0e7099f0eb44f5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfOC01LTEtMS0xMTk0ODI_d78ecc11-7d7b-4281-b9fd-65d895d09b3f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i06c8acb8e4034c26bb0e7099f0eb44f5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfOC03LTEtMS0xMTk0ODI_d3131803-6554-4116-b515-f5b76cf0f7ff"
      unitRef="usd">16100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iae9580cce4d64144acfc341401d74a31_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfOS0xLTEtMS0xMTk0ODI_3b778d76-e2b9-4394-a23d-e92ef1f4465d"
      unitRef="usd">6800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iae9580cce4d64144acfc341401d74a31_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfOS0zLTEtMS0xMTk0ODI_ba0638dc-b533-477f-843d-4eb822006416"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iae9580cce4d64144acfc341401d74a31_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfOS01LTEtMS0xMTk0ODI_7388fa71-a00d-4857-b565-a637925e871c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iae9580cce4d64144acfc341401d74a31_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfOS03LTEtMS0xMTk0ODI_5ba770c8-6aac-473f-b3ff-e57f49a25119"
      unitRef="usd">6800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6fa40776bd48450d8df11ae05f802a71_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfMTAtMS0xLTEtMTE5NDgy_4f601390-a585-4190-ad6c-5c5dca6bc227"
      unitRef="usd">11900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6fa40776bd48450d8df11ae05f802a71_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfMTAtMy0xLTEtMTE5NDgy_2bcf3ed8-c18c-4db1-bbee-bb0ea07c3b63"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6fa40776bd48450d8df11ae05f802a71_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfMTAtNS0xLTEtMTE5NDgy_50782ae5-a982-4c12-b615-7c1242070ac0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6fa40776bd48450d8df11ae05f802a71_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfMTAtNy0xLTEtMTE5NDgy_fffea6d9-9fdd-432a-b086-59825aaac431"
      unitRef="usd">11900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <mygn:InvestmentsAndCashAmortizedCost
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfMTEtMS0xLTEtMTE5NDgy_27f4c5cc-b738-4a18-8250-960059bfec01"
      unitRef="usd">397900000</mygn:InvestmentsAndCashAmortizedCost>
    <mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfMTEtMy0xLTEtMTE5NDgy_69b741ab-204b-4f7a-91f5-7e89dc6799bb"
      unitRef="usd">100000</mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax>
    <mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfMTEtNS0xLTEtMTE5NDgy_dfe93dc6-5f91-4f6b-9ee9-80493619cdb9"
      unitRef="usd">200000</mygn:InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:InvestmentsAndCash
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOjNhNWU3NGY4NTMzNzQ3OWViNDJjNzhkNDViOGM0YTJlL3RhYmxlcmFuZ2U6M2E1ZTc0Zjg1MzM3NDc5ZWI0MmM3OGQ0NWI4YzRhMmVfMTEtNy0xLTEtMTE5NDgy_bb4f53c3-2312-48a7-8ce7-5db31128d3fb"
      unitRef="usd">397800000</us-gaap:InvestmentsAndCash>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNjE1_35792114-5a42-4389-b444-4b1c4bdfe9c1">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and maturities of debt securities classified as available-for-sale are as follows at December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia75f79427aab4f40a89a2217f2dc3335_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfMS0xLTEtMS0xMTk0ODI_e98807a8-ad40-4989-a041-bac91b297cf3"
      unitRef="usd">53600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia75f79427aab4f40a89a2217f2dc3335_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfMS0zLTEtMS0xMTk0ODI_f7449ddd-1a1b-4def-b2d5-34945f6808f8"
      unitRef="usd">53600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id0da8029be334899949f916d03b47e6e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfMi0xLTEtMS0xMTk0ODI_22a685dd-edc4-4482-bc4f-f53540ac0751"
      unitRef="usd">3300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id0da8029be334899949f916d03b47e6e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfMi0zLTEtMS0xMTk0ODI_946b95d1-75bc-4758-b84b-76b6b1c67d40"
      unitRef="usd">3300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfNC0xLTEtMS0xMTk0ODI_ebb7f2eb-cd9a-45a3-bccd-ba44717a81e4"
      unitRef="usd">58800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfNC0zLTEtMS0xMTk0ODI_9a82b475-042b-4fff-95c1-17bad00ea52e"
      unitRef="usd">58000000.0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfNS0xLTEtMS0xMTk0ODI_8ded9e9d-a296-438d-bc92-b760d45f3c88"
      unitRef="usd">56700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfNS0zLTEtMS0xMTk0ODI_5c1d6798-324d-4703-8c31-b176f9d84e92"
      unitRef="usd">54800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfNi0xLTEtMS0xMTk0ODI_d1d2b119-cf44-47a1-9991-37e404054ea3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfNi0zLTEtMS0xMTk0ODI_bd9799fe-92ec-48bb-836d-edaed64d0cc8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <mygn:InvestmentsAndCashAmortizedCost
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfNy0xLTEtMS0xMTk0ODI_ab7559b5-821b-4d17-86d2-0058c9775231"
      unitRef="usd">172400000</mygn:InvestmentsAndCashAmortizedCost>
    <us-gaap:InvestmentsAndCash
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RhYmxlOmE2OGI0YTZiZDhlZTQ4M2U4MTc0MGU4NmFiMjAzNDE2L3RhYmxlcmFuZ2U6YTY4YjRhNmJkOGVlNDgzZTgxNzQwZTg2YWIyMDM0MTZfNy0zLTEtMS0xMTk0ODI_49e0173f-c922-40aa-b392-8da97bd8ecd0"
      unitRef="usd">169700000</us-gaap:InvestmentsAndCash>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNTQ5NzU1ODE3Nzgx_4972544c-a727-4498-9528-81283f41e119"
      unitRef="usd">28400000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNTQ5NzU1ODE3Nzk2_283753cf-f81d-4b83-9c8b-9083a56fe038"
      unitRef="usd">8300000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNDM5ODA0NjUxNTY4MQ_67177035-80aa-4988-8b22-8f727b5c9cd2"
      unitRef="usd">1600000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNDM5ODA0NjUxNTY4NQ_96ce8b53-c37c-438e-b349-99487bdec213"
      unitRef="usd">3400000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNTQ5NzU1ODE2Njc3_eea11a09-08d5-4143-9589-ece27e52c76f"
      unitRef="position">118</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfMjE5OTAyMzI2MDM3OQ_e1ad7706-8364-4e22-8a37-0905d898b4ee"
      unitRef="usd">2700000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNTQ5NzU1ODE2NzUx_f8cc6099-f48d-4b06-b2f9-150bf3a61a2e"
      unitRef="usd">111600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNTQ5NzU1ODE3MzU0_ba2d0ca3-bf5b-4f73-b92f-6a265a6bac65"
      unitRef="position">100</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfMjE5OTAyMzI2MDM4NQ_41329496-e130-49b2-98de-9efbc2e88deb"
      unitRef="usd">200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85NC9mcmFnOjk4Zjc0NDVkMWMyZTQ2NGJhNWVlYzE3YjFiMDUyNGFkL3RleHRyZWdpb246OThmNzQ0NWQxYzJlNDY0YmE1ZWVjMTdiMWIwNTI0YWRfNTQ5NzU1ODE3NDI4_d8d48fdc-c637-4a11-8c5d-efa3d273d731"
      unitRef="usd">77700000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RleHRyZWdpb246MDUzYjcwZWZlZjU5NGUzZTljNmQzNDNkMjIwOGU3ZjZfMzE0Mw_6190ff23-761f-4765-ab22-4aa2693038cc">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#x2014;quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#x2014;observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&#160;Some of the Company&#x2019;s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#x2014;unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s financial instruments are valued using quoted prices in active markets or based on other observable inputs.&#160;&#160;For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information.&#160;&#160;For Level 3 contingent consideration related to the acquisitions of Sividon Diagnostics GmbH ("Sividon") and Gateway, the Company reassesses the fair value of each expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected contingent consideration liability.&#160;&#160;This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the expected measurement periods of approximately 12.5 and 2.3 years for Sividon and Gateway, respectively, utilizing various potential pay-out scenarios.&#160;&#160;Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the contingent consideration itself, the related projections, and the overall business.&#160;&#160;The contingent consideration liabilities are classified as components of Accrued liabilities and Other long-term liabilities in the Consolidated Balance Sheets.&#160;Changes to contingent consideration liabilities are reflected in Selling, general, and administrative expense in the Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.03pt"&gt;Money market funds are primarily comprised of exchange traded funds and accrued interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the change in the fair value of the contingent consideration during the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration recognized at acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value recognized in the statement of operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translation adjustments recognized in other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RleHRyZWdpb246MDUzYjcwZWZlZjU5NGUzZTljNmQzNDNkMjIwOGU3ZjZfMzE0NA_e51511fc-d5eb-4a25-a635-3d8b770ca4a7">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#x2014;quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#x2014;observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&#160;Some of the Company&#x2019;s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#x2014;unobservable inputs.&lt;/span&gt;&lt;/div&gt;All of the Company&#x2019;s financial instruments are valued using quoted prices in active markets or based on other observable inputs.&#160;&#160;For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information.&#160;&#160;For Level 3 contingent consideration related to the acquisitions of Sividon Diagnostics GmbH ("Sividon") and Gateway, the Company reassesses the fair value of each expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected contingent consideration liability.&#160;&#160;This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the expected measurement periods of approximately 12.5 and 2.3 years for Sividon and Gateway, respectively, utilizing various potential pay-out scenarios.&#160;&#160;Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the contingent consideration itself, the related projections, and the overall business.&#160;&#160;The contingent consideration liabilities are classified as components of Accrued liabilities and Other long-term liabilities in the Consolidated Balance Sheets.&#160;Changes to contingent consideration liabilities are reflected in Selling, general, and administrative expense in the Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company&#x2019;s financial statements.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm
      contextRef="i823a913a8ad749ad8b995c1f537650c7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RleHRyZWdpb246MDUzYjcwZWZlZjU5NGUzZTljNmQzNDNkMjIwOGU3ZjZfMTg5Mg_105b542b-9202-4819-9904-e88a1488fea2">P12Y6M</mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm>
    <mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm
      contextRef="i0aaca7c4dbe24675bb0115e449ba69fc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RleHRyZWdpb246MDUzYjcwZWZlZjU5NGUzZTljNmQzNDNkMjIwOGU3ZjZfNDM5ODA0NjUxNDQ2Nw_ceff012b-1495-4e9c-bf41-a7bae56a91db">P2Y3M18D</mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RleHRyZWdpb246MDUzYjcwZWZlZjU5NGUzZTljNmQzNDNkMjIwOGU3ZjZfMzE0NQ_85fff0c3-c72e-4359-8cc6-23a2a95ab384">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds and notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal agency issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26.03pt"&gt;Money market funds are primarily comprised of exchange traded funds and accrued interest.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iac2403f7ee104879ad98b6a6781a824e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfMi0xLTEtMS0xMTk0ODI_8b77093d-f792-41f6-9562-d5d481a643a6"
      unitRef="usd">3300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4956a5a0ff064149afbcc9ba2dfdc7e7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfMi0zLTEtMS0xMTk0ODI_26df4cab-2c67-4240-a7ee-9a5d07693c00"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6f3a3fbe29f8436db24dface84e90cf7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfMi01LTEtMS0xMTk0ODI_46a44e6e-af15-44ef-96e0-9c1723adb9ec"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i054731a368194949b2bfc357f58a8920_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfMi03LTEtMS0xMTk0ODI_44b27f06-9557-4ff5-90df-0f90132123ef"
      unitRef="usd">3300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if505b51f5d2949a79b80bf083731f945_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfMy0xLTEtMS0xMTk0ODI_14a0d25f-5955-47b3-afa5-57b8ab59d10b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2b9734be1f184d3ab68c6b578ec56321_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfMy0zLTEtMS0xMTk0ODI_3eee3a93-42eb-4666-9de4-9bd65763ad52"
      unitRef="usd">65100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic347427564244bcc8e0ff3d8c35f4333_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfMy01LTEtMS0xMTk0ODI_f3b3eefc-fe07-4a61-94a4-00a1921664cf"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieecccfa51e634b24b60447c9f26442d1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfMy03LTEtMS0xMTk0ODI_56d98a02-f41d-483a-8fbf-25e938541900"
      unitRef="usd">65100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib1a379dc7f4c475caaaa883ad45060a9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNC0xLTEtMS0xMTk0ODI_9eaaba73-9a8e-4568-9fb3-a20adcb83469"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i52834bd336224beaa3d88ac9bf176567_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNC0zLTEtMS0xMTk0ODI_3a6ccd71-e02b-4cce-b2d8-755d0f02a54c"
      unitRef="usd">16000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0531632a6ded481b8155d92ceea1b3ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNC01LTEtMS0xMTk0ODI_0e96a9a3-c03a-4104-a562-748df37fa10d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iea4bf30af38941b3b6938c631d1ce22e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNC03LTEtMS0xMTk0ODI_f37333ee-793d-4874-9e1b-4e101ed86baa"
      unitRef="usd">16000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8957a860dc7c44a8943b3e806ea2d496_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNS0xLTEtMS0xMTk0ODI_3b298753-7aaa-415e-9c7d-e09334d0db0a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i75e1560d14dc4c37a9651815e98123dd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNS0zLTEtMS0xMTk0ODI_ea412d18-35dc-4280-9b9b-822c5aec287b"
      unitRef="usd">20000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if528d1eea02f4c89b8cc2f9410d179e9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNS01LTEtMS0xMTk0ODI_402fdfd5-5333-4d38-8aa7-e3a9999ecbbc"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i33fcfcc4292d45c6b97cc255ecd96967_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNS03LTEtMS0xMTk0ODI_1c1ed4a1-364b-4581-b940-1b55cbd37155"
      unitRef="usd">20000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iabee9b04bba344d0a4676474f9fd0aa9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNi0xLTEtMS0xMTk0ODI_c8855641-84b5-4c10-b9ec-08b559428a1c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7f4ee512990746498f686969e753a8f7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNi0zLTEtMS0xMTk0ODI_80262068-b41d-4fdc-ae0e-96e77d3efa26"
      unitRef="usd">11700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4fa11b5293574a56b95e476c81a3cbca_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNi01LTEtMS0xMTk0ODI_1339a9f0-1e2d-47bd-b421-db287b3956bb"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib0e18392f2264c7ba9f8a25badbde19f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNi03LTEtMS0xMTk0ODI_0d290b86-25fa-4ac0-b8cf-1f0a1a289683"
      unitRef="usd">11700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5d313c46b56f4ea4811041efe14780de_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNy0xLTEtMS0xMTk0ODI_6dc89f55-2df0-4cfe-aa31-838d6f0bcb3b"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8776fe30d4b443b885e41cdae0f9a864_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNy0zLTEtMS0xMTk0ODI_d76f14dd-3c7d-463f-a4e7-fb8b18d526e6"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9a42cd3883284fccba2c6f45fdec7c5c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNy01LTEtMS0xMTk0ODI_034c02ad-54ff-4315-8b2d-97ea5d82a68d"
      unitRef="usd">6800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2617796d6b8d481c94ef7401da39b8d8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfNy03LTEtMS0xMTk0ODI_a3e44081-4d0b-4e91-b4b7-04a212022fe9"
      unitRef="usd">6800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueNetAssetLiability
      contextRef="ic168d5bc29fe42c6a375be189bffb89f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfOC0xLTEtMS0xMTk0ODI_c07afe53-2b50-4891-a66c-251b64584158"
      unitRef="usd">3300000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="ibae6823d4dfc48c78710aeb85ccacafb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfOC0zLTEtMS0xMTk0ODI_02bc0067-fdff-43be-a1ea-119ba09a7f39"
      unitRef="usd">112800000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i53c84ffe4852490b9b62069255f02f88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfOC01LTEtMS0xMTk0ODI_47863386-ab2f-4a9c-b3c5-40371c57ab9f"
      unitRef="usd">-6800000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjEwNWFhYTc1NDI1MzQyMGVhOWRlMjAzY2MxYTZiYmVlL3RhYmxlcmFuZ2U6MTA1YWFhNzU0MjUzNDIwZWE5ZGUyMDNjYzFhNmJiZWVfOC03LTEtMS0xMTk0ODI_080bf46a-44c6-4561-942b-d9ddd6ef9103"
      unitRef="usd">109300000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6f6de559c7f84f1ba22b6bde6e9505dc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfMi0xLTEtMS0xMTk0ODI_be04f438-4a28-45f1-97bf-bbb7b7fe9a97"
      unitRef="usd">63200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iba93170941f54ad4a6e9bd9506cadfec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfMi0zLTEtMS0xMTk0ODI_1f41a778-5a9e-4683-9b3c-8b504709a5a0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icf95e9b463a9489fba6e904f9b508bc0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfMi01LTEtMS0xMTk0ODI_adc379b3-be30-4708-b28b-234f1fd93b68"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if1f7a81ab4d546fa8363f6765db2ca47_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfMi03LTEtMS0xMTk0ODI_ce9ea390-f7c9-470a-91e6-452706791a8b"
      unitRef="usd">63200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3f4577ae6fc24714b12a9f4dae881ad9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfMy0xLTEtMS0xMTk0ODI_3c7a17ec-3c49-4819-95fe-d863937c99e6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia38de968e38b4dd0ad1104298f2e258f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfMy0zLTEtMS0xMTk0ODI_640c1ad2-654e-4984-bcf1-d07a6eb0a844"
      unitRef="usd">105600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib0493540df994c2f871795b87f29a7bc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfMy01LTEtMS0xMTk0ODI_d1ece127-b4f4-46fa-8721-695736d41721"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iffb0ffff83b34e97a987ed8e7389d515_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfMy03LTEtMS0xMTk0ODI_30f9a2fc-6dbb-4749-bdf6-fd22814acf75"
      unitRef="usd">105600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifdb7ac3fc3ba484292b559015692e497_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNC0xLTEtMS0xMTk0ODI_f4f3ce53-36d4-4d21-b710-00618c1d3aaf"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1763682428bf431f830915fa01ba4076_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNC0zLTEtMS0xMTk0ODI_7ffc7497-6afb-4cf8-9646-3ed8e489388a"
      unitRef="usd">16100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3cba5a8d0243495aaf7a24002f234432_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNC01LTEtMS0xMTk0ODI_41846e50-b933-4c73-a969-15e8bdf3c89b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i06c8acb8e4034c26bb0e7099f0eb44f5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNC03LTEtMS0xMTk0ODI_f934f5ad-849a-4502-8cc8-5fa940a038b9"
      unitRef="usd">16100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic69437fe4efd4416859e92172cc5790f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNS0xLTEtMS0xMTk0ODI_81ca80b1-733d-4b29-ad4d-923a0aeb33e3"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie95b38d0545844f98dede4b82126203f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNS0zLTEtMS0xMTk0ODI_6515a699-a27f-4d43-83c6-10192aad5ddf"
      unitRef="usd">6800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8e7d1835e2e34202be5a79f205d84bd9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNS01LTEtMS0xMTk0ODI_ba0f9104-add1-454f-8432-f2036f284ea8"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iae9580cce4d64144acfc341401d74a31_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNS03LTEtMS0xMTk0ODI_09eeae55-fcd8-47f1-8227-56d68a9bfd31"
      unitRef="usd">6800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4b14cf32d8ca4635ae65df760ee25e81_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNi0xLTEtMS0xMTk0ODI_e49f650a-7d6b-4c73-867a-62dcd131014c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ife394a441cff404aaae4b092a3d3bb46_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNi0zLTEtMS0xMTk0ODI_850c8bb0-0623-4d69-8dde-77cb337e8d87"
      unitRef="usd">11900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibe950e801781495697dc7289c421c614_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNi01LTEtMS0xMTk0ODI_aa221f46-188d-408e-bb03-c2e115c6ccb1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6fa40776bd48450d8df11ae05f802a71_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNi03LTEtMS0xMTk0ODI_130b2ce1-0899-4b37-b47f-2478bd2b49cd"
      unitRef="usd">11900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id59c003282bb4959a9f3ab119e181c6c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNy0xLTEtMS0xMTk0ODI_6f1453fe-03a4-404d-8311-73ca1858d253"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie1174c90b6ee4dc5b6d409ab036a9e96_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNy0zLTEtMS0xMTk0ODI_1ea5ee00-cfc3-4f7e-93d5-958d45763c2a"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i30e651fc58854e6d9587d0fd1ace6220_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNy01LTEtMS0xMTk0ODI_b676e1e1-ce6b-4ace-aa46-3a84284e24ef"
      unitRef="usd">8600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie511c7937db0407398aaef7ccbbae95e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfNy03LTEtMS0xMTk0ODI_5cb6428c-3d2d-45e7-bffc-0d0da6cce8ec"
      unitRef="usd">8600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i524f05cde0ab49718e7546d04f102aa5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfOC0xLTEtMS0xMTk0ODI_61ec6d67-95e8-4ce0-a526-977b4343fa4b"
      unitRef="usd">63200000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i50667905e6f44ea3bbc5d72c01cf8826_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfOC0zLTEtMS0xMTk0ODI_4ce34a94-e8fe-4ea6-b6eb-43a6caa8a6c8"
      unitRef="usd">140400000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i4d017fae949f44c49fe499f702ad7561_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfOC01LTEtMS0xMTk0ODI_69e54f98-c82f-44a6-b02f-8e8e9103a7f9"
      unitRef="usd">-8600000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOmNmODQ3MDJjOWZkZDRkOTI4OWNiYmQ3ZDEzNTgxMmRkL3RhYmxlcmFuZ2U6Y2Y4NDcwMmM5ZmRkNGQ5Mjg5Y2JiZDdkMTM1ODEyZGRfOC03LTEtMS0xMTk0ODI_94f527ba-4efb-436b-8fbb-6eeec9296598"
      unitRef="usd">195000000.0</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RleHRyZWdpb246MDUzYjcwZWZlZjU5NGUzZTljNmQzNDNkMjIwOGU3ZjZfMzE0Ng_442d278c-f2f1-49c7-96dc-c94c09a5e8e1">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the change in the fair value of the contingent consideration during the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration recognized at acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value recognized in the statement of operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translation adjustments recognized in other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMS0xLTEtMS0xMTk0ODI_5e494e48-380d-485d-bc85-d770539bd074"
      unitRef="usd">8600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMS0zLTEtMS0xMTk0ODI_1b03c53a-53aa-47db-bd04-272d7d4153de"
      unitRef="usd">10900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ideeefc606008446e85d0fd21a9515813_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMS01LTEtMS0xMTk0ODI_bbda7076-b7d9-4c80-a91b-19d30e8bbd8d"
      unitRef="usd">6800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if96afdd71e74449aa558f9c0f8968925_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMS03LTEtMS0xMTk0ODI_7d1a8abe-3f73-41af-85cb-c20bd4708796"
      unitRef="usd">13800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMi0xLTEtMS0xMTk0ODI_305f3ce4-c485-4b6a-b146-81934b35ebf8"
      unitRef="usd">3000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMi0zLTEtMS0xMTk0ODI_02a1562f-bea5-43d8-9c14-b03a1b5447a4"
      unitRef="usd">3300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMi01LTEtMS0xMTk0ODI_e01a4e5a-aa1f-409d-b22e-cb924e6d7e38"
      unitRef="usd">100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMi03LTEtMS0xMTk0ODI_f2702178-3a1f-4853-a8e5-e4a028f4737e"
      unitRef="usd">3900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMy0xLTEtMS0xMzM5MjE_d7dd2c69-a707-4070-97fb-50a1a81cf478"
      unitRef="usd">2100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMy0zLTEtMS0xMzM5MjE_7607a9dd-6504-48d8-9bce-83ce03f52e07"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMy01LTEtMS0xMzM5MjE_cec13f6f-99f2-46c0-aa68-d773d5725abe"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMy03LTEtMS0xMzM5MjE_4f52a823-c59d-4d43-8c93-26fcef50a7e0"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <mygn:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMy0wLTEtMS0xMTk0ODI_0360defe-fb8a-48dd-a915-4a3693d24d9e">Change in fair value recognized in the statement of operations</mygn:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMy0xLTEtMS0xMTk0ODI_ea3547e9-e800-469a-b68b-227b006a14b5"
      unitRef="usd">400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMy0zLTEtMS0xMTk0ODI_4e24a8fd-466a-40dd-af7e-5ddc61752f10"
      unitRef="usd">-1800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMy01LTEtMS0xMTk0ODI_ede3eb44-8995-479c-91f0-fa59729cdab8"
      unitRef="usd">-3500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfMy03LTEtMS0xMTk0ODI_0ff86c96-0d6b-4c8e-8a6a-94e8b95e876e"
      unitRef="usd">2800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfNC0xLTEtMS0xMTk0ODI_b1ff1adf-4f59-43bd-8b7c-7cc6ea6bc7b4"
      unitRef="usd">500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfNC0zLTEtMS0xMTk0ODI_dd821c4b-8639-4300-9fe6-d45a7e7b1ed7"
      unitRef="usd">800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfNC01LTEtMS0xMTk0ODI_bb4d4592-e238-4fd8-908c-589d10717f4a"
      unitRef="usd">-700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfNC03LTEtMS0xMTk0ODI_4ddd1a21-d2e3-4495-8ac9-72a81bb9ed6a"
      unitRef="usd">300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfNS0xLTEtMS0xMTk0ODI_28f9bcc6-2f7f-45a5-af3b-94e7cfbe44e5"
      unitRef="usd">6800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfNS0zLTEtMS0xMTk0ODI_0ed75eee-be3e-47a3-a386-178e7519a721"
      unitRef="usd">8600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfNS01LTEtMS0xMTk0ODI_cbbb9b1e-92cf-464e-afa7-07532cba0d2c"
      unitRef="usd">10900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ideeefc606008446e85d0fd21a9515813_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF85Ny9mcmFnOjA1M2I3MGVmZWY1OTRlM2U5YzZkMzQzZDIyMDhlN2Y2L3RhYmxlOjU0ZTllZTAzZmEyNzQ1NGI5MzMxZDE0ZmRlNDkwNGJlL3RhYmxlcmFuZ2U6NTRlOWVlMDNmYTI3NDU0YjkzMzFkMTRmZGU0OTA0YmVfNS03LTEtMS0xMTk0ODI_8aa89679-b3b3-4358-96f7-331136e07e68"
      unitRef="usd">6800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90ZXh0cmVnaW9uOjkzYjU4NWYzMTQzMTRlZDJiM2Y1MTkxM2FiZWU1OTljXzMxOQ_ee5d7ae3-fd3f-4fe5-bb7a-23d92f5377dc">PROPERTY, PLANT AND EQUIPMENT, NET&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The property, plant and equipment at December&#160;31, 2022 and December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2022, the Company ceased the use of certain leased Salt Lake City facilities and one of its South San Francisco facilities. As a result, the Company recognized a $3.9 million impairment on the property, plant and equipment associated with the leases, which consisted primarily of leasehold improvements.  See Note 13 for further discussion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, the Company completed the sales of Myriad RBM, Inc. and the Myriad Autoimmune business, which resulted in the disposition of $3.1 million of property, plant and equipment. See Note 17 for additional information regarding these divestitures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded depreciation during the respective periods as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90ZXh0cmVnaW9uOjkzYjU4NWYzMTQzMTRlZDJiM2Y1MTkxM2FiZWU1OTljXzMyMA_3920fffd-5d52-41bc-b89f-1e7689d60752">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The property, plant and equipment at December&#160;31, 2022 and December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded depreciation during the respective periods as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1b01cebc763e4599b78408e1e92b66b8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTo1YjgzZTc5NjI0NmU0OGQyOTFjODAyMDdjMmVlNWI5Ni90YWJsZXJhbmdlOjViODNlNzk2MjQ2ZTQ4ZDI5MWM4MDIwN2MyZWU1Yjk2XzItMS0xLTEtMTE5NDgy_592675cd-45f5-4887-b5e5-26bede22d775"
      unitRef="usd">67900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4a85a5fe1cfa49c0aaf2a1f85c315776_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTo1YjgzZTc5NjI0NmU0OGQyOTFjODAyMDdjMmVlNWI5Ni90YWJsZXJhbmdlOjViODNlNzk2MjQ2ZTQ4ZDI5MWM4MDIwN2MyZWU1Yjk2XzItMy0xLTEtMTE5NDgy_b13d65df-ba92-4b8f-92ac-60a5d6939cc8"
      unitRef="usd">38000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0bbbaf79da6c4e839df3a413fd2c8433_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTo1YjgzZTc5NjI0NmU0OGQyOTFjODAyMDdjMmVlNWI5Ni90YWJsZXJhbmdlOjViODNlNzk2MjQ2ZTQ4ZDI5MWM4MDIwN2MyZWU1Yjk2XzMtMS0xLTEtMTE5NDgy_5b0c64b9-21e3-43fd-831b-fad098d951e2"
      unitRef="usd">124700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7d090498adec48f5a5d9ada3ace9a11f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTo1YjgzZTc5NjI0NmU0OGQyOTFjODAyMDdjMmVlNWI5Ni90YWJsZXJhbmdlOjViODNlNzk2MjQ2ZTQ4ZDI5MWM4MDIwN2MyZWU1Yjk2XzMtMy0xLTEtMTE5NDgy_70a37e35-681a-495e-9efc-2309ee7b4e10"
      unitRef="usd">112400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTo1YjgzZTc5NjI0NmU0OGQyOTFjODAyMDdjMmVlNWI5Ni90YWJsZXJhbmdlOjViODNlNzk2MjQ2ZTQ4ZDI5MWM4MDIwN2MyZWU1Yjk2XzQtMS0xLTEtMTE5NDgy_2d61734c-0ef6-48f9-9231-adb4bb9da542"
      unitRef="usd">192600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTo1YjgzZTc5NjI0NmU0OGQyOTFjODAyMDdjMmVlNWI5Ni90YWJsZXJhbmdlOjViODNlNzk2MjQ2ZTQ4ZDI5MWM4MDIwN2MyZWU1Yjk2XzQtMy0xLTEtMTE5NDgy_c1435257-4f7f-442d-acdc-43aa023df44b"
      unitRef="usd">150400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTo1YjgzZTc5NjI0NmU0OGQyOTFjODAyMDdjMmVlNWI5Ni90YWJsZXJhbmdlOjViODNlNzk2MjQ2ZTQ4ZDI5MWM4MDIwN2MyZWU1Yjk2XzUtMS0xLTEtMTE5NDgy_a444551a-7ad9-46db-a574-9dbae4934de2"
      unitRef="usd">109200000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTo1YjgzZTc5NjI0NmU0OGQyOTFjODAyMDdjMmVlNWI5Ni90YWJsZXJhbmdlOjViODNlNzk2MjQ2ZTQ4ZDI5MWM4MDIwN2MyZWU1Yjk2XzUtMy0xLTEtMTE5NDgy_05ef87bc-7b09-4a38-9dfc-4a591489ea1a"
      unitRef="usd">106900000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTo1YjgzZTc5NjI0NmU0OGQyOTFjODAyMDdjMmVlNWI5Ni90YWJsZXJhbmdlOjViODNlNzk2MjQ2ZTQ4ZDI5MWM4MDIwN2MyZWU1Yjk2XzYtMS0xLTEtMTE5NDgy_b120f902-960f-490f-abc7-77797e743fca"
      unitRef="usd">83400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTo1YjgzZTc5NjI0NmU0OGQyOTFjODAyMDdjMmVlNWI5Ni90YWJsZXJhbmdlOjViODNlNzk2MjQ2ZTQ4ZDI5MWM4MDIwN2MyZWU1Yjk2XzYtMy0xLTEtMTE5NDgy_b5e53c9f-2afd-46d0-a7b2-d1acdba3d0cd"
      unitRef="usd">43500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="i87c0d4d014b8431486ad3d3075f0ca84_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90ZXh0cmVnaW9uOjkzYjU4NWYzMTQzMTRlZDJiM2Y1MTkxM2FiZWU1OTljXzExNTQ0ODcyMDkyODc0_b749a5e8-968a-4fd0-8629-09f1b5930d6b"
      unitRef="usd">3900000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="i2ed990c23f164e939a73f7223c4d3011_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90ZXh0cmVnaW9uOjkzYjU4NWYzMTQzMTRlZDJiM2Y1MTkxM2FiZWU1OTljXzIxMQ_24c572fa-3b96-4e5b-92bc-4ea2e04587b4"
      unitRef="usd">3100000</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:Depreciation
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTpmOWE3MGUyMTBkNDM0ZDExYWY2Mjg2NTk5MzU2ZGQyNC90YWJsZXJhbmdlOmY5YTcwZTIxMGQ0MzRkMTFhZjYyODY1OTkzNTZkZDI0XzItMS0xLTEtMTE5NDgy_7e6da233-0db7-4ada-87bb-03f15dac9924"
      unitRef="usd">11600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTpmOWE3MGUyMTBkNDM0ZDExYWY2Mjg2NTk5MzU2ZGQyNC90YWJsZXJhbmdlOmY5YTcwZTIxMGQ0MzRkMTFhZjYyODY1OTkzNTZkZDI0XzItMy0xLTEtMTE5NDgy_b78e0b2c-c719-47a4-b60c-6538eacb0db7"
      unitRef="usd">12100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTpmOWE3MGUyMTBkNDM0ZDExYWY2Mjg2NTk5MzU2ZGQyNC90YWJsZXJhbmdlOmY5YTcwZTIxMGQ0MzRkMTFhZjYyODY1OTkzNTZkZDI0XzItNS0xLTEtMTE5NDgy_c150999b-3af1-483a-aa37-a761c5e9090f"
      unitRef="usd">5000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDAvZnJhZzo5M2I1ODVmMzE0MzE0ZWQyYjNmNTE5MTNhYmVlNTk5Yy90YWJsZTpmOWE3MGUyMTBkNDM0ZDExYWY2Mjg2NTk5MzU2ZGQyNC90YWJsZXJhbmdlOmY5YTcwZTIxMGQ0MzRkMTFhZjYyODY1OTkzNTZkZDI0XzItNy0xLTEtMTE5NDgy_727502ee-93c8-4d5f-88d7-785358ba8d8c"
      unitRef="usd">11000000.0</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzQyNDU_40bed2b9-d275-47ff-9900-e494b0b56055">GOODWILL AND INTANGIBLE ASSETS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amount of goodwill for the year ended December&#160;31, 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired (see Note 16)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 1, 2022, the Company acquired Gateway. In connection therewith, the Company recognized $48.7 million of goodwill. See Note 16 for additional information on this acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed goodwill for impairment as part of its annual goodwill testing in accordance with the appropriate guidance (see Note 1) and determined none of its reporting units were impaired as of the annual testing date. The Company did not record an impairment of goodwill for the years ended December 31, 2022 and 2021, or the transition period ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fiscal year ended June 30, 2020, as a result of the effect of COVID-19 on expected future cash flows and a corresponding decline in the Company's market capitalization and enterprise value, the Company performed an interim quantitative impairment review of goodwill for the Myriad Mental Health, Myriad Autoimmune and Myriad International reporting units as of March 31, 2020. Based on this analysis, the Company recognized a goodwill impairment charge of $80.7&#160;million related to the goodwill from the Myriad Autoimmune reporting unit. The goodwill impairment charge is reflected in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations. On July 1, 2021, the Company completed the sale of Myriad RBM, Inc., and as a result the goodwill attributable to the Myriad RBM reporting unit is no longer held by the Company. In addition, on September 13, 2021, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;select operating assets and intellectual property, including the Vectra&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; test, from the Myriad Autoimmune business unit were sold. As a result of this divestiture, the goodwill attributable to the Myriad Autoimmune reporting unit is no longer held by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fiscal year ended June 30, 2020, the Company also recognized a $1.3 million impairment charge for goodwill allocated to the Clinic asset group that is included in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets have primarily consisted of amortizable assets of developed technologies, customer relationships, and trademarks as well as a non-amortizable intangible asset of in-process research and development.&#160;On November 1, 2022, the Company acquired Gateway. As part of the acquisition, the Company acquired customer relationships, trademarks, and developed technologies of $1.6 million, $6.1 million, and $10.1 million, respectively. See Note 16 for additional information on this acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's developed technologies have estimated remaining useful lives of 8 and 13 years. The Company's trademarks and customer relationships acquired have an estimated remaining useful life of approximately 10 years. Prior to the sale of Myriad RBM, Inc., the estimated useful life of acquired in-process research and development was also evaluated in conjunction with the annual impairment analysis of intangible assets.&#160;The classification of the acquired in-process research and development as an indefinite lived asset was deemed appropriate during prior years as the related research and development was not yet complete nor had it been abandoned. During the fiscal year ended June 30, 2020, the Company decided to abandon the development of one of its in-process research and development intangible assets, and as a result the Company recognized a charge of $17.7 million, which is reflected in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations. The Company concluded there was no impairment of long-lived intangible assets for the years ended December 31, 2022 and 2021 or the transition period ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the amounts reported as intangible assets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At December 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Useful Life &lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Useful Life &lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Useful Life &lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Useful Life &lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(212.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(212.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded amortization during the respective periods for these intangible assets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense of intangible assets as of December&#160;31, 2022 is estimated to be as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzQyNDY_7cd30b75-8639-4e70-a040-fb15a655552a">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amount of goodwill for the year ended December&#160;31, 2022 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired (see Note 16)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTpjZTM3NGNjYTUyMjY0Y2Y2OGEyYzVjYjJlZTk5NzJjOS90YWJsZXJhbmdlOmNlMzc0Y2NhNTIyNjRjZjY4YTJjNWNiMmVlOTk3MmM5XzEtMS0xLTEtMTE5NDgy_de1e25c5-f4c0-48e1-8858-3c82eabf257f"
      unitRef="usd">239200000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTpjZTM3NGNjYTUyMjY0Y2Y2OGEyYzVjYjJlZTk5NzJjOS90YWJsZXJhbmdlOmNlMzc0Y2NhNTIyNjRjZjY4YTJjNWNiMmVlOTk3MmM5XzItMS0xLTEtMTM0MDYx_1334c3db-ae57-4f5a-a077-0f55c0667149"
      unitRef="usd">48700000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTpjZTM3NGNjYTUyMjY0Y2Y2OGEyYzVjYjJlZTk5NzJjOS90YWJsZXJhbmdlOmNlMzc0Y2NhNTIyNjRjZjY4YTJjNWNiMmVlOTk3MmM5XzMtMS0xLTEtMTE5NDgy_242534e0-9e48-4319-a3be-f05db6ea112d"
      unitRef="usd">-1100000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTpjZTM3NGNjYTUyMjY0Y2Y2OGEyYzVjYjJlZTk5NzJjOS90YWJsZXJhbmdlOmNlMzc0Y2NhNTIyNjRjZjY4YTJjNWNiMmVlOTk3MmM5XzQtMS0xLTEtMTE5NDgy_3356db1a-edbe-431a-9c25-613014993600"
      unitRef="usd">286800000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzU0OTc1NTgyMDQ5MA_1334c3db-ae57-4f5a-a077-0f55c0667149"
      unitRef="usd">48700000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzM5NQ_9df03175-d4e3-4f54-8781-6a5af98397fd"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzM5NQ_a1aef03f-7abd-491d-8cea-33727dd365db"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzM5NQ_bdb9aeae-abc1-4e6b-a0a2-a4a35ae64763"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ia5e94090de30419c96fa1c05060afd64_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzEwMDY_cdd94d13-dca6-4cc2-af49-6528b15bdbf8"
      unitRef="usd">80700000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i39965e7109344a238233c9caa866cfb3_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzE3NjM_7b129449-1c95-4c38-9354-f90f6b605808"
      unitRef="usd">1300000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="id82e3f3eeb68492399f4153822f134df_D20221101-20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzQzOTgwNDY1MjE2MjA_9de1c87a-d79a-4636-9472-9862732c8b74"
      unitRef="usd">1600000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="if437534e60cb4439b2cd0da6651519aa_D20221101-20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzQzOTgwNDY1MjE2Mjg_f6a3442e-add3-4e5b-8ef2-2a2b122a19c5"
      unitRef="usd">6100000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="ic3c2906fb217491a8423ba010a090290_D20221101-20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzU0OTc1NTgyMTkxOA_f6d0a627-1a2b-4a31-bf8f-42a4b4ee96cf"
      unitRef="usd">10100000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic7975a4442d44d779f0f1bf53782120d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzI4NTk_9d2860b4-9b04-4ab8-979e-330ed74794e6">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ife7424d471c047f29674554074fafb8c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzI4NjY_d330aa62-920c-4234-818d-57694f787765">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i082547e446854663944c1f7d21ca67bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzU0OTc1NTgxOTg4MA_93a615f5-7c94-4b38-a10b-191a57b4369b">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzM1MTU_004e9700-34ca-4c5e-9d39-eb5068a5b21c"
      unitRef="usd">17700000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzM2Njg_a39e3b8e-6c2f-4852-8d58-6d9d051b31b4"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzM2Njg_a886a3f2-e5e9-4b7a-bfa6-0845dfd6b5e4"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzM2Njg_f4ebfc12-ed61-4235-b0f7-9a76c7270049"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzQyNDc_068752ff-5aab-4a41-beda-57e48f7dff59">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the amounts reported as intangible assets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At December 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Useful Life &lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Useful Life &lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Useful Life &lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Useful Life &lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(212.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(212.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzQyNDc_dd9a2c96-65c7-4988-8d75-4c2a64a45f9f">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the amounts reported as intangible assets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At December 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Useful Life &lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Useful Life &lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Useful Life &lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Useful Life &lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technologies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(212.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(212.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib6ebe315d6824fd7a89d2f7c74efcf31_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzEtMS0xLTEtMTE5NDgy_7b3b6726-a0da-4b64-b1fd-b6f34335c7ab"
      unitRef="usd">625000000.0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib6ebe315d6824fd7a89d2f7c74efcf31_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzEtMy0xLTEtMTE5NDgy_6c2a4cb3-d447-4d3f-bc46-02db3fe256d4"
      unitRef="usd">252900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib6ebe315d6824fd7a89d2f7c74efcf31_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzEtNS0xLTEtMTE5NDgy_b6b6abe0-693b-4ee4-90da-b1ea5411cf44"
      unitRef="usd">372100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i88103ecea9f2472aad40efe4318bcd91_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzEtNy0xLTEtMTQyODU0_8f548b5a-170a-49da-b2f8-b907279f5dad">P14Y4M24D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i88103ecea9f2472aad40efe4318bcd91_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzEtOS0xLTEtMTQyODU0_d264b9f6-80a9-458f-961f-cd59dc952545">P9Y1M6D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9aef28d53f8c47c8ab1d99d12cdd400f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzItMS0xLTEtMTMyNjk0_35d9e91b-5f3e-4b92-98ad-cd630c556282"
      unitRef="usd">1600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9aef28d53f8c47c8ab1d99d12cdd400f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzItMy0xLTEtMTMyNjk0_3bd753fb-cd5c-4287-a0b2-cd6db42c4938"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9aef28d53f8c47c8ab1d99d12cdd400f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzItNS0xLTEtMTMyNjk0_04ea54ac-9ba3-4715-abe9-691fb56eaffb"
      unitRef="usd">1600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i082547e446854663944c1f7d21ca67bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzItNy0xLTEtMTQyODU0_14a67255-9c85-4e3d-bb8b-37549c2cdde9">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i082547e446854663944c1f7d21ca67bf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzItOS0xLTEtMTQyODU0_f1b7cfb8-d148-4153-a5c2-e2d7d449269e">P9Y9M18D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id72ef2bad75948119bfd502da5931067_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzMtMS0xLTEtMTMyNjk0_5783a88c-d851-44be-a67d-a52f2a6eb74a"
      unitRef="usd">6100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id72ef2bad75948119bfd502da5931067_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzMtMy0xLTEtMTMyNjk0_3c47259d-71a0-4aa7-843e-c764f30d294f"
      unitRef="usd">100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id72ef2bad75948119bfd502da5931067_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzMtNS0xLTEtMTMyNjk0_a5f70b1c-71de-42fc-bfde-e60caa9ba89d"
      unitRef="usd">6000000.0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="idcc890f9cd184879a64c08e82dcbbc8f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzMtNy0xLTEtMTQyODU0_ba78d70e-7b28-4b7d-9d92-9e36bca85b64">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="idcc890f9cd184879a64c08e82dcbbc8f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzMtOS0xLTEtMTQyODU0_6e5f1419-9d7d-4bcb-9c05-735adfab8692">P9Y9M18D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzItMS0xLTEtMTE5NDgy_d3f3d058-6b22-464d-a0bc-255991b1922f"
      unitRef="usd">632700000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzItMy0xLTEtMTE5NDgy_c806868d-5214-400c-a212-aed03dbc1e24"
      unitRef="usd">253000000.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzItNS0xLTEtMTE5NDgy_90b3d44f-822e-466b-8a69-99cc6b41ae13"
      unitRef="usd">379700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzQtNy0xLTEtMTQyODU0_752c514d-69c5-44f8-9575-b4b28942deb4">P14Y4M24D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo1YWIxNDZjN2EwMjI0YWI0ODQ3MzdkNjAzMmJiODRjNi90YWJsZXJhbmdlOjVhYjE0NmM3YTAyMjRhYjQ4NDczN2Q2MDMyYmI4NGM2XzQtOS0xLTEtMTQyODU0_277be4ee-6ad9-487c-9fb4-2a503a84be80">P9Y1M6D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i73af76a4fce548948796425f49a1806c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTphMDc2YjYzMDc4MDc0NmNkYjUwZGFmNTlhMzUzMTZhYy90YWJsZXJhbmdlOmEwNzZiNjMwNzgwNzQ2Y2RiNTBkYWY1OWEzNTMxNmFjXzEtMS0xLTEtMTE5NDgy_7e68df1f-e6ab-4d57-8918-e02bc0df7f34"
      unitRef="usd">616600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i73af76a4fce548948796425f49a1806c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTphMDc2YjYzMDc4MDc0NmNkYjUwZGFmNTlhMzUzMTZhYy90YWJsZXJhbmdlOmEwNzZiNjMwNzgwNzQ2Y2RiNTBkYWY1OWEzNTMxNmFjXzEtMy0xLTEtMTE5NDgy_2b8f4ced-784c-4707-b1f7-bb21cda95bf5"
      unitRef="usd">212500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i73af76a4fce548948796425f49a1806c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTphMDc2YjYzMDc4MDc0NmNkYjUwZGFmNTlhMzUzMTZhYy90YWJsZXJhbmdlOmEwNzZiNjMwNzgwNzQ2Y2RiNTBkYWY1OWEzNTMxNmFjXzEtNS0xLTEtMTE5NDgy_cf415c96-8ba7-484a-8d9c-82a14fa74c0b"
      unitRef="usd">404100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i43ae1240cef14457931c317f4fd211b4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTphMDc2YjYzMDc4MDc0NmNkYjUwZGFmNTlhMzUzMTZhYy90YWJsZXJhbmdlOmEwNzZiNjMwNzgwNzQ2Y2RiNTBkYWY1OWEzNTMxNmFjXzEtNy0xLTEtMTQyODcw_f67738cf-4c8e-4852-804b-a65409242f88">P14Y7M6D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i43ae1240cef14457931c317f4fd211b4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTphMDc2YjYzMDc4MDc0NmNkYjUwZGFmNTlhMzUzMTZhYy90YWJsZXJhbmdlOmEwNzZiNjMwNzgwNzQ2Y2RiNTBkYWY1OWEzNTMxNmFjXzEtOS0xLTEtMTQyODcw_708e97f7-6049-4dea-a792-aae97af47963">P10Y2M12D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTphMDc2YjYzMDc4MDc0NmNkYjUwZGFmNTlhMzUzMTZhYy90YWJsZXJhbmdlOmEwNzZiNjMwNzgwNzQ2Y2RiNTBkYWY1OWEzNTMxNmFjXzctMS0xLTEtMTE5NDgy_3e461a05-5f97-4930-b9de-22d4b7e2e564"
      unitRef="usd">616600000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTphMDc2YjYzMDc4MDc0NmNkYjUwZGFmNTlhMzUzMTZhYy90YWJsZXJhbmdlOmEwNzZiNjMwNzgwNzQ2Y2RiNTBkYWY1OWEzNTMxNmFjXzctMy0xLTEtMTE5NDgy_a88d18c2-cea3-4b79-8f8e-fb41a96d5a12"
      unitRef="usd">212500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTphMDc2YjYzMDc4MDc0NmNkYjUwZGFmNTlhMzUzMTZhYy90YWJsZXJhbmdlOmEwNzZiNjMwNzgwNzQ2Y2RiNTBkYWY1OWEzNTMxNmFjXzctNS0xLTEtMTE5NDgy_f35cb530-d5b3-45ac-b1fb-eca2516fe749"
      unitRef="usd">404100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTphMDc2YjYzMDc4MDc0NmNkYjUwZGFmNTlhMzUzMTZhYy90YWJsZXJhbmdlOmEwNzZiNjMwNzgwNzQ2Y2RiNTBkYWY1OWEzNTMxNmFjXzctNy0xLTEtMTQyODc4_5f71135f-c006-43c3-9cf7-d4a07ae9c58f">P14Y7M6D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTphMDc2YjYzMDc4MDc0NmNkYjUwZGFmNTlhMzUzMTZhYy90YWJsZXJhbmdlOmEwNzZiNjMwNzgwNzQ2Y2RiNTBkYWY1OWEzNTMxNmFjXzctOS0xLTEtMTQyODc4_1fe90849-6eed-4209-99c6-fc1a708c3a89">P10Y2M12D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzQyNDk_b89fae9a-b860-48c1-ae20-b4de8363d145">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded amortization during the respective periods for these intangible assets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTowOTkwN2RjYTBhMDE0MmUxOTBhMTgyMThhODhkNTRiMS90YWJsZXJhbmdlOjA5OTA3ZGNhMGEwMTQyZTE5MGExODIxOGE4OGQ1NGIxXzItMS0xLTEtMTE5NDgy_3ec5ed25-c192-4c46-97af-d82fe2d104ed"
      unitRef="usd">41100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTowOTkwN2RjYTBhMDE0MmUxOTBhMTgyMThhODhkNTRiMS90YWJsZXJhbmdlOjA5OTA3ZGNhMGEwMTQyZTE5MGExODIxOGE4OGQ1NGIxXzItMy0xLTEtMTE5NDgy_4953c6c4-6c98-42b7-9ef6-2a3bafe73632"
      unitRef="usd">50700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTowOTkwN2RjYTBhMDE0MmUxOTBhMTgyMThhODhkNTRiMS90YWJsZXJhbmdlOjA5OTA3ZGNhMGEwMTQyZTE5MGExODIxOGE4OGQ1NGIxXzItNS0xLTEtMTE5NDgy_79a3e9e5-fb57-4a08-9f60-fc0e1e1e9dca"
      unitRef="usd">30800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTowOTkwN2RjYTBhMDE0MmUxOTBhMTgyMThhODhkNTRiMS90YWJsZXJhbmdlOjA5OTA3ZGNhMGEwMTQyZTE5MGExODIxOGE4OGQ1NGIxXzItNy0xLTEtMTE5NDgy_34ab52f5-69b7-4da1-a248-a06690b41d16"
      unitRef="usd">61000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90ZXh0cmVnaW9uOjE2NGMxZDNhMWI2YzRjNWI5MDcxN2VjMTZjYTJlMGUwXzQyNDg_55d60bc3-a8d2-42d5-81f5-4f9ae27436c2">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense of intangible assets as of December&#160;31, 2022 is estimated to be as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo2NDI4MjY5ZWFjNTc0NzhlODY0MmI3MDM4MjkwOTdjZC90YWJsZXJhbmdlOjY0MjgyNjllYWM1NzQ3OGU4NjQyYjcwMzgyOTA5N2NkXzEtMS0xLTEtMTE5NDgy_8f396fa1-d677-43e1-8cda-2815ca593c87"
      unitRef="usd">42800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo2NDI4MjY5ZWFjNTc0NzhlODY0MmI3MDM4MjkwOTdjZC90YWJsZXJhbmdlOjY0MjgyNjllYWM1NzQ3OGU4NjQyYjcwMzgyOTA5N2NkXzItMS0xLTEtMTE5NDgy_f6049e3c-a929-4c92-997e-17721019ecda"
      unitRef="usd">42800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo2NDI4MjY5ZWFjNTc0NzhlODY0MmI3MDM4MjkwOTdjZC90YWJsZXJhbmdlOjY0MjgyNjllYWM1NzQ3OGU4NjQyYjcwMzgyOTA5N2NkXzMtMS0xLTEtMTE5NDgy_0503b4bf-1100-4ea1-a403-e06fb0e66046"
      unitRef="usd">42800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo2NDI4MjY5ZWFjNTc0NzhlODY0MmI3MDM4MjkwOTdjZC90YWJsZXJhbmdlOjY0MjgyNjllYWM1NzQ3OGU4NjQyYjcwMzgyOTA5N2NkXzQtMS0xLTEtMTE5NDgy_daa301f2-0b96-4c18-b7f2-d6b3624bf0d6"
      unitRef="usd">42800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo2NDI4MjY5ZWFjNTc0NzhlODY0MmI3MDM4MjkwOTdjZC90YWJsZXJhbmdlOjY0MjgyNjllYWM1NzQ3OGU4NjQyYjcwMzgyOTA5N2NkXzUtMS0xLTEtMTE5NDgy_98b962a5-b2e0-4aab-9efd-38ce8f4aec02"
      unitRef="usd">42800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo2NDI4MjY5ZWFjNTc0NzhlODY0MmI3MDM4MjkwOTdjZC90YWJsZXJhbmdlOjY0MjgyNjllYWM1NzQ3OGU4NjQyYjcwMzgyOTA5N2NkXzYtMS0xLTEtMTE5NDgy_4d3d8f5e-b708-4454-98a8-27f828a363d6"
      unitRef="usd">165700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDMvZnJhZzoxNjRjMWQzYTFiNmM0YzViOTA3MTdlYzE2Y2EyZTBlMC90YWJsZTo2NDI4MjY5ZWFjNTc0NzhlODY0MmI3MDM4MjkwOTdjZC90YWJsZXJhbmdlOjY0MjgyNjllYWM1NzQ3OGU4NjQyYjcwMzgyOTA5N2NkXzctMS0xLTEtMTE5NDgy_db3e5702-06fc-451f-a704-6c1b55697fee"
      unitRef="usd">379700000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90ZXh0cmVnaW9uOjJmYWUxM2ZlZGEwNTRjZDhiMmU5MjNiODg3ZGMwMzA1XzI4_e8113f23-6942-4a31-9410-10ea5f8ceb3d">ACCRUED LIABILITIES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's accrued liabilities at December&#160;31, 2022 and December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal charges pending settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Refunds payable and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90ZXh0cmVnaW9uOjJmYWUxM2ZlZGEwNTRjZDhiMmU5MjNiODg3ZGMwMzA1XzI5_8fdb4878-aefe-4889-9728-f10f6e7cd7ca">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's accrued liabilities at December&#160;31, 2022 and December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal charges pending settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Refunds payable and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzItMS0xLTEtMTE5NDgy_5074a502-31af-4679-8bf7-a170fbb12c2e"
      unitRef="usd">41200000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzItMy0xLTEtMTE5NDgy_4fa1c6ac-0748-4119-8c3b-55d32a5b1b37"
      unitRef="usd">52800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzMtMS0xLTEtMTE5NDgy_0a0814e3-9a53-4e2d-956e-c938f3cc2321"
      unitRef="usd">0</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzMtMy0xLTEtMTE5NDgy_7b990666-e189-43bb-b286-ec97fb3959cd"
      unitRef="usd">62000000.0</us-gaap:LitigationReserveCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzQtMS0xLTEtMTE5NDgy_4bde8203-14f7-4160-9056-3498d8409d53"
      unitRef="usd">4800000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzQtMy0xLTEtMTE5NDgy_00839af3-910a-40c7-9287-7979ae7b03ac"
      unitRef="usd">4000000.0</us-gaap:TaxesPayableCurrent>
    <mygn:RefundsPayableAndReserveCurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzUtMS0xLTEtMTE5NDgy_22ed16d3-6aa7-41ee-bb8f-0322efe4b1e5"
      unitRef="usd">19300000</mygn:RefundsPayableAndReserveCurrent>
    <mygn:RefundsPayableAndReserveCurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzUtMy0xLTEtMTE5NDgy_032d38d4-fb6d-4b1a-b4f7-51ac5fb0d281"
      unitRef="usd">9800000</mygn:RefundsPayableAndReserveCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzYtMS0xLTEtMTE5NDgy_84b94c29-9423-459f-89e8-4215fb793118"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzYtMy0xLTEtMTE5NDgy_d069404e-2573-436b-a231-369123f9c71d"
      unitRef="usd">3200000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzctMS0xLTEtMTM2NzQx_d300ee4a-bb28-49e9-87d5-f5721f0522c0"
      unitRef="usd">600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzctMy0xLTEtMTM2NzQx_8c2a045d-e029-445e-8b16-3283749913e2"
      unitRef="usd">5200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzctMS0xLTEtMTE5NDgy_66c1c387-5fd5-4c24-b101-dc29312fe131"
      unitRef="usd">4800000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzctMy0xLTEtMTE5NDgy_bc9df50c-0f5c-45eb-b847-15b48ef137a3"
      unitRef="usd">5400000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzgtMS0xLTEtMTE5NDgy_307dbb12-5aad-4fe6-afbc-84e3b5f4c762"
      unitRef="usd">23600000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzgtMy0xLTEtMTE5NDgy_960060e0-adc6-4738-b9f4-ddac05ea8a51"
      unitRef="usd">19300000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzktMS0xLTEtMTE5NDgy_222881fb-b317-462d-8dd3-a9cc563098c8"
      unitRef="usd">94300000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDYvZnJhZzoyZmFlMTNmZWRhMDU0Y2Q4YjJlOTIzYjg4N2RjMDMwNS90YWJsZTphNjg5NzMxZGViMTY0Y2FlYjUzODEyNThjMjIyYTAwYS90YWJsZXJhbmdlOmE2ODk3MzFkZWIxNjRjYWViNTM4MTI1OGMyMjJhMDBhXzktMy0xLTEtMTE5NDgy_7f0c8a17-415d-4f6f-9cd9-168f7bd9e62c"
      unitRef="usd">161700000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzQ0MjA_3ec65fcb-9a33-45de-adb7-a07d6c9bb97b">LONG-TERM DEBT&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 23, 2016, the Company entered into a senior secured revolving credit facility (the &#x201c;Facility&#x201d;) as borrower, with the lenders from time to time party thereto. On July 31, 2018, the Company entered into Amendment No. 1 to the Facility, which effected an &#x201c;amend and extend&#x201d; transaction with respect to the Facility by which the maturity date thereof was extended to July 31, 2023 (the "Maturity Date") and the maximum aggregate principal commitment was increased from $300.0 million to $350.0 million.&#160;&#160;On May 1, 2020, the Company entered into Amendment No. 2 to the Facility, which waived the Company&#x2019;s compliance with certain covenants and modified the interest rate and other terms during the modification period from March 31, 2020 through June 30, 2021 (as modified, the "Modification Period&#x201d;). This amendment included a modification to the leverage covenant and the interest coverage ratio covenant, which were waived through March 31, 2021, as well as revisions to certain negative covenants of the Facility during the Modification Period. On February 22, 2021, the Company entered into Amendment No. 3 to the Facility, which waived compliance with the leverage ratio and the interest coverage ratio covenants through the quarter ended March 31, 2022 and also lowered the minimum liquidity covenant (which was added by Amendment No. 2) to $150&#160;million, and made it applicable through such quarter. Amendment No. 3 also restricted the Company from borrowing under the Facility if unrestricted cash, cash equivalents and marketable investment securities exceed $150.0&#160;million, unless such borrowings are in connection with permitted acquisitions, decreased the maximum aggregate principal commitment from $350.0&#160;million to $300.0&#160;million, with a further reduction in the maximum aggregate principal commitment from $300.0&#160;million to $250.0&#160;million by September 30, 2021, extended the Modification Period for an additional year through June 30, 2022, and revised certain negative covenants in connection with the extension. The amendments were accounted for as modifications pursuant to guidance in ASC 470-50, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. On July 26, 2022, the Company entered into Amendment No. 4 to the Facility (the "Amended Facility"), which extended the Modification Period through the Maturity Date, decreased the maximum aggregate principal commitment from $250.0&#160;million to $200.0&#160;million, with a further reduction to $150.0&#160;million as of December 31, 2022, waived compliance with the leverage ratio and interest coverage ratio covenants through the Maturity Date, and provided for monthly reporting of the Company's liquidity if the total revolving credit exposure is greater than $0, without giving effect to the dollar amount of any letter of credit exposure not in excess of $5.0&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Covenants in the Amended Facility impose operating and financial restrictions on the Company. These restrictions may prohibit or place limitations on, among other things, the Company&#x2019;s ability to incur additional indebtedness under the Amended Facility or otherwise, create certain types of liens, and complete mergers, consolidations, or change in control transactions. The Amended Facility may also prohibit or place limitations on the Company&#x2019;s ability to sell assets, pay dividends or provide other distributions to stockholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Facility contains customary loan terms, interest rates, representations and warranties, and affirmative and negative covenants, subject to customary limitations, exceptions and exclusions. The Amended Facility also contains certain customary events of default. Amendment No. 2 modified the Facility to increase the interest rate to be fixed at a spread of LIBOR plus 350 basis points on drawn balances and the undrawn fee was increased to 50 basis points during the Modification Period. Amendment No. 4 replaced the option to make Eurodollar borrowings, which bore interest by reference to the LIBOR rate, with term benchmark loans, which will bear interest by reference to the secured overnight financing rate ("SOFR"). Amendment No. 4 did not modify the applicable margins and undrawn fee amounts. The interest rate for term benchmark loans continues to be fixed at a spread of SOFR plus 350 basis points on drawn balances and undrawn fees continue to be 50 basis points. The SOFR floor was revised to 0.0%. The Company was in compliance with all applicable financial covenants at December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;During the year ended December 31, 2021, the Company made principal repayments totaling $226.4 million to pay off the remaining outstanding balances on the Amended Facility. As a result, the Company had no outstanding balances under the Amended Facility as of December 31, 2022.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i23aeff032bf24bb8a9d3d3bb253094dc_I20161223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzQ2Nw_3eec56b8-5624-430e-a7d6-115de2494c02"
      unitRef="usd">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia162acc4f40848918e001774e6a4f960_I20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzQ3Mw_74bc735a-ab31-45e7-9064-a228198cd811"
      unitRef="usd">350000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <mygn:DebtCovenantLiquidityCovenantMinimum
      contextRef="ia7185e4956c746a9b0f45493392d399d_I20210222"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgxNDg0NDU_f3a739a7-a276-412a-ade0-21444c1845c6"
      unitRef="usd">150000000</mygn:DebtCovenantLiquidityCovenantMinimum>
    <mygn:DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum
      contextRef="ia7185e4956c746a9b0f45493392d399d_I20210222"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgxNDg0NTk_0e0d1af6-dca9-42e2-ba95-e03e4584da48"
      unitRef="usd">150000000</mygn:DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ib45bd6e5ec9a4ed7a463e74534d19bab_I20210221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzk0MA_cccbd8b3-b05e-47c7-a6b5-41390c0753fb"
      unitRef="usd">350000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia7185e4956c746a9b0f45493392d399d_I20210222"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzk0Ng_39649a42-b749-4240-9c99-be785621039c"
      unitRef="usd">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia7185e4956c746a9b0f45493392d399d_I20210222"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzEwMjY_79595b45-b079-46d1-8899-d1003f073c2f"
      unitRef="usd">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i674b5e2ec7a24dd2868cf183995d5ed4_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzEwMzI_07d946cb-092e-44ae-9fa6-568674cd4e68"
      unitRef="usd">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i33356f53153c4a03be9389d7449cf3f6_I20220725"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMDE0MA_b3c83b34-c0ec-445b-9ead-a5e41b308733"
      unitRef="usd">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i843f20e91d9b42f9abab257be67b0fba_I20220726"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMDE1Ng_66cfe280-da7d-45b4-8ed2-63ba599c5c76"
      unitRef="usd">200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="icf8301cef485443f9fbd8a975ee8e8bf_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMDE3Mg_8808841d-461d-4b24-846f-e47a8de7324a"
      unitRef="usd">150000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <mygn:LineOfCreditFacilityCreditExposureThreshold
      contextRef="i8f459a7b8fd94d27b059f67e4c1866ff_D20220726-20220726"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMDE4OA_58a5c49a-2d0a-4815-a757-4e05db9ce060"
      unitRef="usd">0</mygn:LineOfCreditFacilityCreditExposureThreshold>
    <mygn:LineOfCreditFacilityCreditExposureThreshold
      contextRef="i262a62b1f2d845acbe48f9be412ca7bf_D20220726-20220726"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMDE5Mg_ca2b4c6e-86f7-4e51-8845-cfbeeab0a49d"
      unitRef="usd">5000000</mygn:LineOfCreditFacilityCreditExposureThreshold>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iaa57fda02bc54eccb40407c480ef96e1_D20200401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMjA5MQ_96d7494f-4505-454c-a501-57d9fab65ae0"
      unitRef="number">0.0350</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i60ba3c848587432396a389bd552eb846_D20200401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMjA5OQ_c1ed27eb-5a48-405a-af1b-40ee0d4dda00"
      unitRef="number">0.0050</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i58d539dc7d304c43a5fbc7a02678e86e_D20220726-20220726"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMjExNA_76236f30-c733-47ba-9c8a-e804c5de5eff"
      unitRef="number">0.0350</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i93a2ffa60cb1493fa939b40a6cd3610e_D20220726-20220726"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMjEwNg_e3279773-2b24-4b04-bc54-e94531293cea"
      unitRef="number">0.0050</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <mygn:DebtInstrumentFloorPercentage
      contextRef="i58d539dc7d304c43a5fbc7a02678e86e_D20220726-20220726"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMjEyNA_a70fd8b5-e641-435f-a63e-226a29e848d7"
      unitRef="number">0.000</mygn:DebtInstrumentFloorPercentage>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i1e2a786776cf421188638389979b41f0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzU0OTc1NTgyMzY5MA_7337cd07-4c83-4e65-a808-9c060018671a"
      unitRef="usd">226400000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:LongTermDebt
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMDkvZnJhZzpkNTg0NmQ3MDBkMjg0ZWU4OWJkNDRhNWNjODE1M2QxYi90ZXh0cmVnaW9uOmQ1ODQ2ZDcwMGQyODRlZTg5YmQ0NGE1Y2M4MTUzZDFiXzQyNzI_74a343e3-8d93-459c-9bcf-0900bd543c7c"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTIvZnJhZzphZTdjYjM3MDVkZDE0MmYxYmE5ZDM0ZWU0M2M2ZjdhNi90ZXh0cmVnaW9uOmFlN2NiMzcwNWRkMTQyZjFiYTlkMzRlZTQzYzZmN2E2XzYwOA_72a09403-c7d9-43b4-9ccb-428caa7a5fd6">OTHER LONG-TERM LIABILITIES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's other long-term liabilities at December&#160;31, 2022 and December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company&#x2019;s balance of other long-term liabilities as of December&#160;31, 2022 and 2021 consisted primarily of the long-term portion of contingent consideration related to the acquisitions of Sividon and Gateway and restricted cash related to the acquisition of Gateway. See Note 16 for additional information on the Gateway acquisition.</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTIvZnJhZzphZTdjYjM3MDVkZDE0MmYxYmE5ZDM0ZWU0M2M2ZjdhNi90ZXh0cmVnaW9uOmFlN2NiMzcwNWRkMTQyZjFiYTlkMzRlZTQzYzZmN2E2XzYwOQ_3976446c-a13e-4616-baa6-b1fe7023371b">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's other long-term liabilities at December&#160;31, 2022 and December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTIvZnJhZzphZTdjYjM3MDVkZDE0MmYxYmE5ZDM0ZWU0M2M2ZjdhNi90YWJsZTo1YmEzY2FiMGFlNmI0MTE2YmYwYmE5ZDg1MjZmYzIxZi90YWJsZXJhbmdlOjViYTNjYWIwYWU2YjQxMTZiZjBiYTlkODUyNmZjMjFmXzItMS0xLTEtMTE5NDgy_52747532-b7c7-4a55-ad03-a0665cce1d58"
      unitRef="usd">6800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTIvZnJhZzphZTdjYjM3MDVkZDE0MmYxYmE5ZDM0ZWU0M2M2ZjdhNi90YWJsZTo1YmEzY2FiMGFlNmI0MTE2YmYwYmE5ZDg1MjZmYzIxZi90YWJsZXJhbmdlOjViYTNjYWIwYWU2YjQxMTZiZjBiYTlkODUyNmZjMjFmXzItMy0xLTEtMTE5NDgy_0b8d88d7-ccff-4445-94bf-e98c8be64b05"
      unitRef="usd">5400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTIvZnJhZzphZTdjYjM3MDVkZDE0MmYxYmE5ZDM0ZWU0M2M2ZjdhNi90YWJsZTo1YmEzY2FiMGFlNmI0MTE2YmYwYmE5ZDg1MjZmYzIxZi90YWJsZXJhbmdlOjViYTNjYWIwYWU2YjQxMTZiZjBiYTlkODUyNmZjMjFmXzMtMS0xLTEtMTE5NDgy_865848ec-9cc0-41bc-8370-253b704088e0"
      unitRef="usd">7700000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTIvZnJhZzphZTdjYjM3MDVkZDE0MmYxYmE5ZDM0ZWU0M2M2ZjdhNi90YWJsZTo1YmEzY2FiMGFlNmI0MTE2YmYwYmE5ZDg1MjZmYzIxZi90YWJsZXJhbmdlOjViYTNjYWIwYWU2YjQxMTZiZjBiYTlkODUyNmZjMjFmXzMtMy0xLTEtMTE5NDgy_27269305-a385-43a9-80c6-6f2dff4de86d"
      unitRef="usd">200000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTIvZnJhZzphZTdjYjM3MDVkZDE0MmYxYmE5ZDM0ZWU0M2M2ZjdhNi90YWJsZTo1YmEzY2FiMGFlNmI0MTE2YmYwYmE5ZDg1MjZmYzIxZi90YWJsZXJhbmdlOjViYTNjYWIwYWU2YjQxMTZiZjBiYTlkODUyNmZjMjFmXzQtMS0xLTEtMTE5NDgy_68ad3d13-3ae8-43ab-9ae2-3d96c3784a0f"
      unitRef="usd">14500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTIvZnJhZzphZTdjYjM3MDVkZDE0MmYxYmE5ZDM0ZWU0M2M2ZjdhNi90YWJsZTo1YmEzY2FiMGFlNmI0MTE2YmYwYmE5ZDg1MjZmYzIxZi90YWJsZXJhbmdlOjViYTNjYWIwYWU2YjQxMTZiZjBiYTlkODUyNmZjMjFmXzQtMy0xLTEtMTE5NDgy_8ea171cc-43c0-4ab2-a711-763874681151"
      unitRef="usd">5600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzE2NjI_ba050c0f-42f8-4bde-9e37-da976a98275d">PREFERRED AND COMMON STOCKHOLDERS' EQUITY&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share.&#160;There were no shares of preferred stock outstanding at December&#160;31, 2022 and December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. There were 81.2&#160;million and 80.0&#160;million shares of common stock issued and outstanding at December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shares of common stock issued and outstanding&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning common stock issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock issued and outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company&#x2019;s Board of Directors authorized a share repurchase program of $200.0 million of the Company&#x2019;s outstanding common stock. The Company may repurchase its common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company&#x2019;s management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.&#160;&#160;As of December&#160;31, 2022, the Company had $110.7 million remaining on its current share repurchase authorization. No shares were repurchased during the years ended December&#160;31, 2022 and 2021 under this authorization.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzkx_82eb1e80-b928-4914-be60-d008f04691ad"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzkx_b4031ec7-cefe-4609-ae5f-f0e7ae706388"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzEzMQ_3b31072b-e2a6-474d-a8d2-5956f3ac9d0f"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzEzMQ_d9a7c5f4-8788-42e1-a9f9-d0b0935ea5e3"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzE1Ng_0804a2c9-9652-43e6-b163-427bfbe946ef"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzE1Ng_8b74d96c-10ad-43ed-8517-eae3e14a4b6c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzI0NA_2eca74f6-6ab3-4f76-9bf8-4f8269e7ba87"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzI0NA_436402ed-06ef-4cc5-ab50-60636281d170"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzI4MQ_2e2d644b-6c9c-44a2-b3c9-e824dbefc857"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzI4MQ_69cbed33-4520-4ee4-913b-92a0b15e7e16"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzU0OTc1NTgxNjM4NA_544291e6-000f-4298-bda9-dadd5e537fb7"
      unitRef="shares">81200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzU0OTc1NTgxNjM4NA_b18a1e92-626c-4aa4-821d-cf98f4765546"
      unitRef="shares">81200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzU0OTc1NTgxNjM3OQ_130e4922-7e4c-41cb-9093-1ad0d825b580"
      unitRef="shares">80000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzU0OTc1NTgxNjM3OQ_eafbadca-ef1e-419f-aec8-192b2fb222d8"
      unitRef="shares">80000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzE2NjA_f7149403-4f72-4e77-aa9e-f62a43645e61">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shares of common stock issued and outstanding&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning common stock issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock issued and outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzItMS0xLTEtMTE5NDgy_04938b83-ad93-40e6-987b-64a1fb202d7b"
      unitRef="shares">80000000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzItMS0xLTEtMTE5NDgy_df127af9-5a09-4bd5-916f-6c8f13bbd613"
      unitRef="shares">80000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzItMy0xLTEtMTE5NDgy_9d44d667-3abd-4703-bbad-77ce7ed59124"
      unitRef="shares">75400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzItMy0xLTEtMTE5NDgy_c5067c5c-949c-4b82-b463-198ca0b27774"
      unitRef="shares">75400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ideeefc606008446e85d0fd21a9515813_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzItNS0xLTEtMTE5NDgy_026d6b23-adc2-4a12-b5b6-d7e169391e9d"
      unitRef="shares">74700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ideeefc606008446e85d0fd21a9515813_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzItNS0xLTEtMTE5NDgy_d867a1c5-2af1-4a23-9b93-2e36424ebd02"
      unitRef="shares">74700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if96afdd71e74449aa558f9c0f8968925_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzItNy0xLTEtMTE5NDgy_800dc614-21b1-4644-858f-a059ae450405"
      unitRef="shares">73500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="if96afdd71e74449aa558f9c0f8968925_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzItNy0xLTEtMTE5NDgy_8c26711f-be0b-4141-8b39-87ed53791b75"
      unitRef="shares">73500000</us-gaap:CommonStockSharesIssued>
    <mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzMtMS0xLTEtMTE5NDgy_9f6490fe-f4c1-49f5-b2e2-bb8248d4b221"
      unitRef="shares">1200000</mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans>
    <mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzMtMy0xLTEtMTE5NDgy_f6aa58bf-33b6-4d08-8348-1a5221be1a4a"
      unitRef="shares">4600000</mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans>
    <mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzMtNS0xLTEtMTE5NDgy_7a48dde0-b64d-4252-a123-cac2a7243a18"
      unitRef="shares">700000</mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans>
    <mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzMtNy0xLTEtMTE5NDgy_a696a1aa-cc1c-40a8-b0f4-07e3ec3fd145"
      unitRef="shares">1200000</mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans>
    <us-gaap:CommonStockSharesIssued
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzUtMS0xLTEtMTE5NDgy_a811f2ff-3e8c-4bb9-bcb4-17ebf347340e"
      unitRef="shares">81200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzUtMS0xLTEtMTE5NDgy_f2f9ee8c-e396-43aa-832f-d2da3ff53bd3"
      unitRef="shares">81200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzUtMy0xLTEtMTE5NDgy_a79afe66-5bd6-4259-8255-1e2bbdee5aee"
      unitRef="shares">80000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzUtMy0xLTEtMTE5NDgy_ab97c595-3716-4e8b-9a51-e5c75b626595"
      unitRef="shares">80000000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzUtNS0xLTEtMTE5NDgy_7f2a8769-aa27-4f30-b56b-aa1c376df6f5"
      unitRef="shares">75400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzUtNS0xLTEtMTE5NDgy_b2da25d5-27f2-49c7-a1ef-6fed4baa20ea"
      unitRef="shares">75400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ideeefc606008446e85d0fd21a9515813_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzUtNy0xLTEtMTE5NDgy_7d13b29f-ebab-46a1-ae7d-448e4d4f16e9"
      unitRef="shares">74700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ideeefc606008446e85d0fd21a9515813_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90YWJsZTo4NjhlMjcxODcxZjI0Y2IzYTQwMWY2NDg0Njg3MGJkMi90YWJsZXJhbmdlOjg2OGUyNzE4NzFmMjRjYjNhNDAxZjY0ODQ2ODcwYmQyXzUtNy0xLTEtMTE5NDgy_dbb70726-7cb3-44e2-80cd-0724fdf85e1e"
      unitRef="shares">74700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i3f7f76edb655468cb01a3ed28231577b_I20160630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzUyNw_21677560-0090-448a-bdc7-10f3b3e9adaa"
      unitRef="usd">200000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzk4NQ_50e985db-2af3-4a41-bbc1-68712f22dfec"
      unitRef="usd">110700000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzU0OTc1NTgxNDE0MzU_4e01c85a-82b8-4807-8c20-2449e194d0ce"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTUvZnJhZzo4MDcxNTBhMjQ3YjE0ZWVhYTEwZmVjOWFlMTdhMGYxYS90ZXh0cmVnaW9uOjgwNzE1MGEyNDdiMTRlZWFhMTBmZWM5YWUxN2EwZjFhXzU0OTc1NTgxNDE0MzU_7d1e6b35-81bd-4af2-8749-4cc27c585afa"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzYyODI_c0c737f7-77b2-48b1-b020-b48eea34f6a1">STOCK-BASED COMPENSATION&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 30, 2017, the Company&#x2019;s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the &#x201c;2017 Plan&#x201d;).&#160;&#160;The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee of the Board of Directors, to make grants of restricted and unrestricted stock and stock unit awards to employees, consultants and directors.&#160;Stockholders have approved amendments to the 2017 Plan increasing the shares available to grant. As of December&#160;31, 2022, the Company had 1.9 million shares of common stock available for grant under the 2017 Plan. If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued or reacquired shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. To the extent that awards outstanding under the Company's prior equity plans expire or are cancelled without delivery of shares of common stock, the shares of common stock underlying these awards also will be available for issuance pursuant to the 2017 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of shares, terms, and vesting periods are generally determined by the Company&#x2019;s Board of Directors or a committee thereof on an award-by-award basis. RSUs granted to employees generally vest either ratably over four years or as a cliff vesting after three years either on the anniversary of the date on which the RSUs were granted or during the month in which such anniversary dates occur. The number of PSUs awarded to certain employees may be increased or may be reduced based on certain additional performance and market metrics. RSUs granted to non-employee directors vest in full upon the earlier of the completion of one year of service following the date of the grant or the date of the next annual meeting of stockholders following such grant. Options granted to the Company's President and Chief Executive Officer as an inducement to his employment expire seven years from the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance and market conditions associated with PSU awards granted during the year ended December&#160;31, 2022 include vesting that is based on revenue targets (34% weighting), adjusted earnings per share targets (33% weighting), and relative total stockholder return (33% weighting) measured against the Nasdaq Health Care Index (IXHC) using the 20-trading day averages at the beginning and end of the measurement period. The measurement period for these awards is January 1, 2022 through December 31, 2024. The Company estimates the likelihood of achievement of performance conditions at the end of each period. The portion of the awards pertaining to relative total stockholder return represent market conditions and, accordingly, the estimated fair value of such awards are recognized over the performance period. The Company has also assessed that as of December&#160;31, 2022, the performance conditions for the remaining two performance targets (revenue and adjusted earnings per share) are considered probable of being achieved and, accordingly, these portions of the awards are also being expensed over the performance period. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the transition period ended December 31, 2020, the Company granted stock-based awards to the Company's President and Chief Executive Officer as an inducement material to his commencement of employment and entry into an employment agreement with the Company. The inducement awards are included in the tables presented below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity under the Company's equity plans, and inducement awards for the year ended December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(number of shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of&lt;br/&gt;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no options granted during the years ended December 31, 2022 and 2021 and June&#160;30, 2020. During the transition period ended December&#160;31, 2020, 0.7&#160;million options were granted to the Company's President and Chief Executive Officer, with a weighted average grant fair value of $13.38 and as of December 31, 2022, these were the only options outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the RSU awards activity under the Company's equity plans and inducement awards, including PSU awards for the year ended December&#160;31, 2022, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(number of shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of&lt;br/&gt;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;grant date&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs unvested and outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs unvested and outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant-date fair value of RSUs granted during the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020, and the fiscal year ended June&#160;30, 2020 was $25.78, $29.83, $13.69 and $27.96, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of RSUs that vested during the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020, and the fiscal year ended June&#160;30, 2020 was $31.0 million, $22.6 million, $29.1 million and $32.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized and included in the Consolidated Statements of Operations was allocated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of testing revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there was $64.3 million of total unrecognized stock-based compensation expense that will be recognized over a weighted-average period of 2.0 years. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of options fully vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of options exercised was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intrinsic value of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has an Employee Stock Purchase Plan that was initially approved by stockholders in 2012 and was amended and approved by the Board of Directors of the Company on September 23, 2021 and the stockholders on June 2, 2022 (the &#x201c;Amended and Restated 2012 Purchase Plan&#x201d;), under which 4.0&#160;million shares of common stock were authorized. Shares are issued under the Amended and Restated 2012 Purchase Plan twice yearly at the end of each offering period and the number of shares that may be purchased by any participant during an offering period is limited to 5,000 shares. As of December&#160;31, 2022, 1.7 million shares of common stock were available for issuance under the Amended and Restated Purchase Plan. Shares purchased under, and compensation expense associated with, the Amended and Restated 2012 Purchase Plan for the periods reported are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares purchased under the plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of shares issued under the Amended and Restated 2012 Purchase Plan that was in effect for each period reported was calculated using the Black&#x2011;Scholes option-pricing model using the weighted-average assumptions below. Each of these inputs is subjective and its determination generally requires significant judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i5d254d84e7e9429fb9eb353fa0fe6727_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzYwOQ_452befe7-9cd7-4ab1-909b-faef8cdb43d9"
      unitRef="shares">1900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9757cc95b46f40a8a4d1310a7a341adf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzEzNTU_1dfe03b6-76b5-4ae5-b12f-1157d6d0d26a">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i801883d593c048cf8de2e2c90f49176b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzY1OTcwNjk3NzY4ODY_999692c9-6653-474a-9c31-29b12008bee2">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i12ca3a8a2ca341308119fa4fbac76272_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzE3MTE_003f0a3f-1aca-4e4b-92f2-0d3627b3de5f">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i662ff17b6ca34e25bba3e0323f9e924c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzIwNjY_c6c7b032-2bfe-4173-b89d-17999c8a5b2e">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i17cec0855d2440f9801f4db7e5a729b9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzU0OTc1NTgyMTcwMg_ea69948f-b9c4-4c39-8db6-cb289c62de76"
      unitRef="number">0.34</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i01fda04e6cb14149830711083c57c751_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzU0OTc1NTgyMTcyMA_07d63a66-8139-49f2-96e8-c2656fcb2232"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i8a3e0bd95e204ba5951ebd463f3b3a4c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzU0OTc1NTgyMTcxMQ_37a0f053-f5a5-4c6f-86f0-e3f41c462062"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzYyODY_be660370-760a-4599-a48e-29a6b7314ebf">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity under the Company's equity plans, and inducement awards for the year ended December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(number of shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of&lt;br/&gt;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzEtMS0xLTEtMTE5NDgy_b1eac592-d987-4a83-9595-bdd37ca8f34b"
      unitRef="shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzEtMy0xLTEtMTE5NDgy_dc411cda-51c7-45cb-8324-7bea17f107b8"
      unitRef="usdPerShare">20.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzQtMS0xLTEtMTE5NDgy_29509e59-1bac-4245-bcde-c24557d902d8"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzQtMy0xLTEtMTE5NDgy_f93086c0-8171-4b8d-8d46-29cab4bcb1d3"
      unitRef="usdPerShare">26.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzUtMS0xLTEtMTE5NDgy_96875192-b468-495e-8eee-01a0b9989b38"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzUtMy0xLTEtMTE5NDgy_f0407905-339a-4484-a47c-e26b7a09e556"
      unitRef="usdPerShare">26.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzYtMS0xLTEtMTE5NDgy_7119daeb-f2ed-4e42-8f9a-2cb7f859f4b1"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzYtMy0xLTEtMTE5NDgy_674a242e-b0d8-43cd-966c-58fe0bfb7941"
      unitRef="usdPerShare">13.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzYtNS0xLTEtMTE5NDgy_a7b6fb9b-7e27-492c-8785-91e49c54cdc5">P4Y7M13D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzctMS0xLTEtMTE5NDgy_e69a23ac-9ab8-4da8-be97-216976f2e6bb"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzctMy0xLTEtMTE5NDgy_3e109ccc-5918-4d87-a87b-5b0b47de5b3a"
      unitRef="usdPerShare">13.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzctNS0xLTEtMTE5NDgy_0e369235-856c-4fbf-8d48-41d22d5e7666">P4Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzgtMS0xLTEtMTE5NDgy_d001743f-c22c-4943-afe9-2ca7558a511b"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzgtMy0xLTEtMTE5NDgy_2d576a49-b6e1-410d-aa9c-50667a8452eb"
      unitRef="usdPerShare">13.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5OTQwNGMzMGMzNjU0YTE4OThlYjdiZTQzZmEwMzBjOS90YWJsZXJhbmdlOjk5NDA0YzMwYzM2NTRhMTg5OGViN2JlNDNmYTAzMGM5XzgtNS0xLTEtMTE5NDgy_c13a8905-f9c9-4b3d-80c8-fd0cd57e736c">P4Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzMyMTA_7346fdad-0184-4fdc-b0e9-81bd4860b793"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzMyMTA_78e87407-5919-4c48-83f8-832b8c254582"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzMyMTA_8cc65dcf-af48-4f8e-911b-eae3b5ad79d3"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i552292b1ed264bf49d505c379dad4c2b_D20200701-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzMzMTg_851d9579-9705-4278-b40c-e076cac2672a"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iaafdb3a4d0da4dec918d7e953639a791_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzM0NDI_c1c0204a-06f9-4f51-976e-e685871d28bc"
      unitRef="usdPerShare">13.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i552292b1ed264bf49d505c379dad4c2b_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzM0NDI_f27fd73c-413f-4c98-ac6d-316d3a8c814a"
      unitRef="usdPerShare">13.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzYyODA_fbc5261c-5117-4f88-9f2b-dab028f62d62">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the RSU awards activity under the Company's equity plans and inducement awards, including PSU awards for the year ended December&#160;31, 2022, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(number of shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of&lt;br/&gt;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;grant date&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs unvested and outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs unvested and outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie26285660df14abb951924a100df85e5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTpjYTlhM2QwYzhhYjM0NzY3YmUzMWZkMDg3NmIzMjNiNC90YWJsZXJhbmdlOmNhOWEzZDBjOGFiMzQ3NjdiZTMxZmQwODc2YjMyM2I0XzItMS0xLTEtMTE5NDgy_32b72b63-2025-4536-81c4-63b00b670e68"
      unitRef="shares">3100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie26285660df14abb951924a100df85e5_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTpjYTlhM2QwYzhhYjM0NzY3YmUzMWZkMDg3NmIzMjNiNC90YWJsZXJhbmdlOmNhOWEzZDBjOGFiMzQ3NjdiZTMxZmQwODc2YjMyM2I0XzItMy0xLTEtMTE5NDgy_9e13ea08-d603-4c16-b781-c1f8345a25b7"
      unitRef="usdPerShare">24.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id5d419cf4013469c83dd80d51c5ee579_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTpjYTlhM2QwYzhhYjM0NzY3YmUzMWZkMDg3NmIzMjNiNC90YWJsZXJhbmdlOmNhOWEzZDBjOGFiMzQ3NjdiZTMxZmQwODc2YjMyM2I0XzMtMS0xLTEtMTE5NDgy_a006d099-4bc9-495d-89f8-92605eab14b4"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id5d419cf4013469c83dd80d51c5ee579_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTpjYTlhM2QwYzhhYjM0NzY3YmUzMWZkMDg3NmIzMjNiNC90YWJsZXJhbmdlOmNhOWEzZDBjOGFiMzQ3NjdiZTMxZmQwODc2YjMyM2I0XzMtMy0xLTEtMTE5NDgy_9d19f7e0-4c67-49a0-a31a-15d7c05cc160"
      unitRef="usdPerShare">25.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="id5d419cf4013469c83dd80d51c5ee579_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTpjYTlhM2QwYzhhYjM0NzY3YmUzMWZkMDg3NmIzMjNiNC90YWJsZXJhbmdlOmNhOWEzZDBjOGFiMzQ3NjdiZTMxZmQwODc2YjMyM2I0XzUtMS0xLTEtMTE5NDgy_78a8c62a-9002-4fc6-99a4-d4ca91674ca8"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="id5d419cf4013469c83dd80d51c5ee579_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTpjYTlhM2QwYzhhYjM0NzY3YmUzMWZkMDg3NmIzMjNiNC90YWJsZXJhbmdlOmNhOWEzZDBjOGFiMzQ3NjdiZTMxZmQwODc2YjMyM2I0XzUtMy0xLTEtMTE5NDgy_35bf4e3b-516d-4c63-a3c5-b64db2543527"
      unitRef="usdPerShare">25.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="id5d419cf4013469c83dd80d51c5ee579_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTpjYTlhM2QwYzhhYjM0NzY3YmUzMWZkMDg3NmIzMjNiNC90YWJsZXJhbmdlOmNhOWEzZDBjOGFiMzQ3NjdiZTMxZmQwODc2YjMyM2I0XzYtMS0xLTEtMTE5NDgy_ce704cea-4a0b-4985-87c0-6dea5e015cbb"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="id5d419cf4013469c83dd80d51c5ee579_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTpjYTlhM2QwYzhhYjM0NzY3YmUzMWZkMDg3NmIzMjNiNC90YWJsZXJhbmdlOmNhOWEzZDBjOGFiMzQ3NjdiZTMxZmQwODc2YjMyM2I0XzYtMy0xLTEtMTE5NDgy_fda59d35-f0cd-490f-becf-6bb1358cb103"
      unitRef="usdPerShare">26.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i26ec50a211f240d3938bde3431435c8b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTpjYTlhM2QwYzhhYjM0NzY3YmUzMWZkMDg3NmIzMjNiNC90YWJsZXJhbmdlOmNhOWEzZDBjOGFiMzQ3NjdiZTMxZmQwODc2YjMyM2I0XzctMS0xLTEtMTE5NDgy_09188190-01df-4ca1-b22b-07a9dbe5f00a"
      unitRef="shares">3700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i26ec50a211f240d3938bde3431435c8b_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTpjYTlhM2QwYzhhYjM0NzY3YmUzMWZkMDg3NmIzMjNiNC90YWJsZXJhbmdlOmNhOWEzZDBjOGFiMzQ3NjdiZTMxZmQwODc2YjMyM2I0XzctMy0xLTEtMTE5NDgy_d217099f-d431-4b54-9685-b391f65e7319"
      unitRef="usdPerShare">25.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id5d419cf4013469c83dd80d51c5ee579_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzM5NTU_9d19f7e0-4c67-49a0-a31a-15d7c05cc160"
      unitRef="usdPerShare">25.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3dae6418ac5148938050aacb2ef5d508_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzM5NTk_9ff50eba-5eaf-4786-a3e5-f012ba3960cb"
      unitRef="usdPerShare">29.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i968d2e2144e34ee4916a9183d20c0063_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzM5NjM_18032661-3c6f-4503-9838-baf7ce91c807"
      unitRef="usdPerShare">13.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i00d66009a0f2488699d68deb116f85b0_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzM5NzA_01c353e4-2759-4cd1-9824-b4a2d9b2c8d4"
      unitRef="usdPerShare">27.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="id5d419cf4013469c83dd80d51c5ee579_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzQxMzQ_cf4dc6d3-1a4c-4bdb-832f-73caf4f4d44f"
      unitRef="usd">31000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i3dae6418ac5148938050aacb2ef5d508_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzQxMzg_0ea32ffa-5941-4435-928b-209404ede194"
      unitRef="usd">22600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i968d2e2144e34ee4916a9183d20c0063_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzQxNDI_5f6a79b8-89ce-4705-b355-6584406737c8"
      unitRef="usd">29100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i00d66009a0f2488699d68deb116f85b0_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzQxNDk_f9ee4d93-8d97-460d-b9e3-46f30e3f330d"
      unitRef="usd">32400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzYyODc_975da954-a2f8-4dcc-95a1-d21c911dfff7">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized and included in the Consolidated Statements of Operations was allocated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of testing revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="if6b55a5a308740858d157bc072e2ecaf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzItMS0xLTEtMTE5NDgy_6df75644-431e-47e7-89b4-2378e9680abf"
      unitRef="usd">1700000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie6834607b2374e2b81387c6f893f406a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzItMy0xLTEtMTI1ODkx_26ccee6f-65dc-4d4a-8051-fa45d5cc0657"
      unitRef="usd">1500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2868dacc9996425d84f6678061f8071d_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzItMy0xLTEtMTE5NDgy_3e095612-097b-4a5e-b780-81adcc2fad84"
      unitRef="usd">600000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i5e2d7d18c84e44c5a8a95712783d775b_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzItNS0xLTEtMTE5NDgy_df4b664d-156c-49ee-b5a7-ad4fcf8c44b8"
      unitRef="usd">1200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if34523c4b068408ca1452aea7567d7b8_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzMtMS0xLTEtMTE5NDgy_4da7501b-159f-4a8d-b7f5-82c1906d8f30"
      unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6f6f6d3b79734ce2bdb563e220afb94c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzMtMy0xLTEtMTI1ODkx_881f6f03-ee84-4801-9eec-5f904069c57a"
      unitRef="usd">100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i66dd3e15c00846fc81665b366c136737_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzMtMy0xLTEtMTE5NDgy_1738d55b-5093-43aa-b046-d616631d690e"
      unitRef="usd">100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id15d2c557b414206ada2d552b9b565a4_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzMtNS0xLTEtMTE5NDgy_5ff8d111-7537-4cfd-85c7-8660845e63bc"
      unitRef="usd">300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia04b5d1b8fa24d0fad862d180d2bd154_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzQtMS0xLTEtMTE5NDgy_e58c27dd-d11c-4f04-b94f-346dd9117fd5"
      unitRef="usd">5200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i87a0fc790ba34918898f41f810a4a2f1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzQtMy0xLTEtMTI1ODkx_ff4d583a-7388-452e-bf70-da942406f19b"
      unitRef="usd">4200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iaa289b04ec1840778fdb19aca12b8a05_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzQtMy0xLTEtMTE5NDgy_b28f5540-d7a2-4948-8663-dc062f2dcb78"
      unitRef="usd">2400000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iff363386463e4c7b99ce076eeb84919c_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzQtNS0xLTEtMTE5NDgy_47a53478-7cb6-4f51-9cb9-44e7e4cb6d04"
      unitRef="usd">5000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i249245e4ff6941f7be7f6d734b685a95_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzUtMS0xLTEtMTE5NDgy_fc56b9ae-26ec-4669-b359-24888e3b2162"
      unitRef="usd">31200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i86e699f1c66445bca22715a30a1f46ed_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzUtMy0xLTEtMTI1ODkx_6c9d028f-a300-4d8e-8625-e6142756ac8f"
      unitRef="usd">30500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i58532a67b1154bc58a0b382ff6c515d4_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzUtMy0xLTEtMTE5NDgy_f30e36b3-429a-4920-9736-84b46e1b5135"
      unitRef="usd">11800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id4d1d3c76ec0427db381fbba56a23a6d_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzUtNS0xLTEtMTE5NDgy_16b78b87-8c6b-4d9d-b5c7-229dfd039550"
      unitRef="usd">18700000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzYtMS0xLTEtMTE5NDgy_51d0eb12-0596-4e82-8db9-0e44b13c85d4"
      unitRef="usd">38100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzYtMy0xLTEtMTI1ODkx_d109a3ca-d4cd-405c-9b87-904e413f5c16"
      unitRef="usd">36300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzYtMy0xLTEtMTE5NDgy_a887cd56-10a1-4577-a420-c3ca42838063"
      unitRef="usd">14900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MzdlYTE0M2RiZTQ0NDIwYjY5ZTNlM2E0OGQ3MDdmYi90YWJsZXJhbmdlOjUzN2VhMTQzZGJlNDQ0MjBiNjllM2UzYTQ4ZDcwN2ZiXzYtNS0xLTEtMTE5NDgy_1291d413-8490-402e-8b3e-4d244c1a6dab"
      unitRef="usd">25200000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzQzMTc_f60c8a90-2cb5-452c-8393-e528b6eaefd9"
      unitRef="usd">64300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzQ0MzM_e07cd6fb-c4f0-43e4-96ce-246d067d2de4">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <mygn:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzYyODg_b0f7456d-8537-4300-83a4-3371e8aecbb7">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of options fully vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mygn:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MDU5YzUxY2UyMjE0ZmE3ODhhZTdkYjkwMWFhNzc3MS90YWJsZXJhbmdlOjUwNTljNTFjZTIyMTRmYTc4OGFlN2RiOTAxYWE3NzcxXzEtMS0xLTEtMTE5NDgy_1abd2c78-f988-470b-8ba1-2cc149a8d903"
      unitRef="usd">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MDU5YzUxY2UyMjE0ZmE3ODhhZTdkYjkwMWFhNzc3MS90YWJsZXJhbmdlOjUwNTljNTFjZTIyMTRmYTc4OGFlN2RiOTAxYWE3NzcxXzItMS0xLTEtMTE5NDgy_646b9d6a-3413-44b9-a4ba-f03839d262a8"
      unitRef="usd">400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i26ec50a211f240d3938bde3431435c8b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo1MDU5YzUxY2UyMjE0ZmE3ODhhZTdkYjkwMWFhNzc3MS90YWJsZXJhbmdlOjUwNTljNTFjZTIyMTRmYTc4OGFlN2RiOTAxYWE3NzcxXzMtMS0xLTEtMTE5NDgy_3a47a385-1abf-49dd-bca4-5489b7e576c3"
      unitRef="usd">54000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzYyODQ_bf73b0b2-60cd-464b-bcd1-33e1cf0e27f0">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of options exercised was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intrinsic value of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5MGM5NjU1MmZjNjA0MmZjYThlNzI2NjU3Mjc1NDQ1NC90YWJsZXJhbmdlOjkwYzk2NTUyZmM2MDQyZmNhOGU3MjY2NTcyNzU0NDU0XzItMS0xLTEtMTE5NDgy_551e6d52-5342-415a-8f3e-b05c9a3d8f6c"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5MGM5NjU1MmZjNjA0MmZjYThlNzI2NjU3Mjc1NDQ1NC90YWJsZXJhbmdlOjkwYzk2NTUyZmM2MDQyZmNhOGU3MjY2NTcyNzU0NDU0XzItMy0xLTEtMTE5NDgy_8bf6a082-3705-4dd0-b7a2-d0323c39d8de"
      unitRef="usd">29200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5MGM5NjU1MmZjNjA0MmZjYThlNzI2NjU3Mjc1NDQ1NC90YWJsZXJhbmdlOjkwYzk2NTUyZmM2MDQyZmNhOGU3MjY2NTcyNzU0NDU0XzItNS0xLTEtMTE5NDgy_a2881182-b3ff-49c7-bcfb-9077f8802c10"
      unitRef="usd">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTo5MGM5NjU1MmZjNjA0MmZjYThlNzI2NjU3Mjc1NDQ1NC90YWJsZXJhbmdlOjkwYzk2NTUyZmM2MDQyZmNhOGU3MjY2NTcyNzU0NDU0XzItNy0xLTEtMTE5NDgy_3e64fa4b-287f-48fa-9302-32417faacb95"
      unitRef="usd">8800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="iab27d0ec33e742d2977386c29c6a64ab_D20210923-20210923"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzUxNTM_7df693bf-5996-4222-ba91-cc1db50a0bcb"
      unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="iab27d0ec33e742d2977386c29c6a64ab_D20210923-20210923"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzU3Mzc_4e1fa98a-a834-46b4-aed4-73a5ec2144b3"
      unitRef="shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i15344703477a40f5b457a744eeee71b2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzU4NzY_56befbef-38c7-4f9e-8cd6-e78e8a775643"
      unitRef="shares">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzYyODU_72366ec9-d720-4692-8925-801ec73b0557">Shares purchased under, and compensation expense associated with, the Amended and Restated 2012 Purchase Plan for the periods reported are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares purchased under the plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="i15344703477a40f5b457a744eeee71b2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTphYjhiYTc2YjE3YTA0MGI0YWNmMzJmMzE0M2IxNWY1Zi90YWJsZXJhbmdlOmFiOGJhNzZiMTdhMDQwYjRhY2YzMmYzMTQzYjE1ZjVmXzItMS0xLTEtMTE5NDgy_5e977b1f-0ae7-4bed-aa34-53b541ee7af4"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="i3580a51b82cc466099d9eb0a57c378cd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTphYjhiYTc2YjE3YTA0MGI0YWNmMzJmMzE0M2IxNWY1Zi90YWJsZXJhbmdlOmFiOGJhNzZiMTdhMDQwYjRhY2YzMmYzMTQzYjE1ZjVmXzItMy0xLTEtMTE5NDgy_1aa00bbb-814c-47a8-ac54-e807361b63d8"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="i0f908585f461487aa148598b903a4f33_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTphYjhiYTc2YjE3YTA0MGI0YWNmMzJmMzE0M2IxNWY1Zi90YWJsZXJhbmdlOmFiOGJhNzZiMTdhMDQwYjRhY2YzMmYzMTQzYjE1ZjVmXzItNS0xLTEtMTE5NDgy_c2832ad3-0a03-422f-ac30-318cdc3663ed"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="id374269cc21d403aa573e11a92743d26_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTphYjhiYTc2YjE3YTA0MGI0YWNmMzJmMzE0M2IxNWY1Zi90YWJsZXJhbmdlOmFiOGJhNzZiMTdhMDQwYjRhY2YzMmYzMTQzYjE1ZjVmXzItNy0xLTEtMTE5NDgy_7fd62c6d-0e67-4698-8b29-33a77d280195"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="i15344703477a40f5b457a744eeee71b2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTphYjhiYTc2YjE3YTA0MGI0YWNmMzJmMzE0M2IxNWY1Zi90YWJsZXJhbmdlOmFiOGJhNzZiMTdhMDQwYjRhY2YzMmYzMTQzYjE1ZjVmXzMtMS0xLTEtMTE5NDgy_5d9d4bf3-1401-46c3-a6ea-de0848b181b9"
      unitRef="usd">1900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="i3580a51b82cc466099d9eb0a57c378cd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTphYjhiYTc2YjE3YTA0MGI0YWNmMzJmMzE0M2IxNWY1Zi90YWJsZXJhbmdlOmFiOGJhNzZiMTdhMDQwYjRhY2YzMmYzMTQzYjE1ZjVmXzMtMy0xLTEtMTE5NDgy_56ea7fce-bf28-4411-89a5-5dc4e667aaca"
      unitRef="usd">1500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="i0f908585f461487aa148598b903a4f33_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTphYjhiYTc2YjE3YTA0MGI0YWNmMzJmMzE0M2IxNWY1Zi90YWJsZXJhbmdlOmFiOGJhNzZiMTdhMDQwYjRhY2YzMmYzMTQzYjE1ZjVmXzMtNS0xLTEtMTE5NDgy_853a1ec3-f028-472f-ba5e-f799a1d26793"
      unitRef="usd">600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="id374269cc21d403aa573e11a92743d26_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZTphYjhiYTc2YjE3YTA0MGI0YWNmMzJmMzE0M2IxNWY1Zi90YWJsZXJhbmdlOmFiOGJhNzZiMTdhMDQwYjRhY2YzMmYzMTQzYjE1ZjVmXzMtNy0xLTEtMTE5NDgy_badc267d-0bdd-435c-acfc-4f872fc8d05d"
      unitRef="usd">1700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90ZXh0cmVnaW9uOmQxYmJmMzNlNjBhYTQ4NDhhNTcwMmIwNWQzOTBhZTc4XzYyODE_16355df4-9d13-41f5-80dc-8114b262ee79">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of shares issued under the Amended and Restated 2012 Purchase Plan that was in effect for each period reported was calculated using the Black&#x2011;Scholes option-pricing model using the weighted-average assumptions below. Each of these inputs is subjective and its determination generally requires significant judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i15344703477a40f5b457a744eeee71b2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzItMS0xLTEtMTE5NDgy_3bc0ef30-e814-4e70-929d-db14086d4cdd"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3580a51b82cc466099d9eb0a57c378cd_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzItMy0xLTEtMTE5NDgy_7046b411-f330-4be7-b687-54397153c636"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0f908585f461487aa148598b903a4f33_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzItNS0xLTEtMTE5NDgy_47140b4a-5d4d-46b7-99aa-13b70feb477a"
      unitRef="number">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id374269cc21d403aa573e11a92743d26_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzItNy0xLTEtMTE5NDgy_ba9f8442-cdee-453c-b9e1-33db497dd628"
      unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i15344703477a40f5b457a744eeee71b2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzMtMS0xLTEtMTE5NDgy_cfa02a30-c743-4845-836f-2eddd27033ae"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3580a51b82cc466099d9eb0a57c378cd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzMtMy0xLTEtMTE5NDgy_ae973ac7-553b-4242-b22e-760f30b4ba54"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0f908585f461487aa148598b903a4f33_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzMtNS0xLTEtMTE5NDgy_48bd4bca-7009-4cb6-8af4-9185648c0b09"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id374269cc21d403aa573e11a92743d26_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzMtNy0xLTEtMTE5NDgy_bc9da06d-505f-4e64-bb83-0d8c2eb05002"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i15344703477a40f5b457a744eeee71b2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzQtMS0xLTEtMTE5NDgy_b36361f4-4117-4e04-8ff5-66d1c0383982">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3580a51b82cc466099d9eb0a57c378cd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzQtMy0xLTEtMTE5NDgy_09e41ad8-5caa-4ea9-972b-408b64ed635f">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0f908585f461487aa148598b903a4f33_D20200701-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzQtNS0xLTEtMTE5NDgy_bc3eadb9-59c4-491e-a6be-a62b8ad982de">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id374269cc21d403aa573e11a92743d26_D20190701-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzQtNy0xLTEtMTE5NDgy_d802015d-5dfe-4b77-9837-773648b414b9">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i15344703477a40f5b457a744eeee71b2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzUtMS0xLTEtMTE5NDgy_489d570d-b4cd-4715-a983-2900fd5010b2"
      unitRef="number">0.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3580a51b82cc466099d9eb0a57c378cd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzUtMy0xLTEtMTE5NDgy_37b19809-d6e8-4873-97e5-b0de29cf29f2"
      unitRef="number">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0f908585f461487aa148598b903a4f33_D20200701-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzUtNS0xLTEtMTE5NDgy_30688d11-7e76-4f81-bd90-733a2d74bdf0"
      unitRef="number">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id374269cc21d403aa573e11a92743d26_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMTgvZnJhZzpkMWJiZjMzZTYwYWE0ODQ4YTU3MDJiMDVkMzkwYWU3OC90YWJsZToyMjBmN2U3YmYxMjE0MDIzOGQ5MmVhZjgwNDE1MWU2Yy90YWJsZXJhbmdlOjIyMGY3ZTdiZjEyMTQwMjM4ZDkyZWFmODA0MTUxZTZjXzUtNy0xLTEtMTE5NDgy_6a20ac8e-37eb-4912-8a01-ca669b216a8b"
      unitRef="number">0.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90ZXh0cmVnaW9uOmQ2YWEyZWE4YThhYzRlNzNhMzIzMGEwNDQ2ZjMyNDA4XzU0NDU_891f56d1-f0e4-4ae8-a50e-7084e134a393">INCOME TAXES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax benefit consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss before income taxes consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The differences between income taxes at the statutory federal income tax rate and income taxes reported in the Consolidated Statements of Operations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.404%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax expense at the statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incentive stock option and employee stock purchase plan expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CARES Act&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible meals and entertainment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible officer compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible legal settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions, dispositions, and contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;52.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company&#x2019;s deferred tax assets and liabilities were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 174 capitalized costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Tax Cuts and Jobs Act (TCJA), passed in 2017, amended Section 174 of the Internal Revenue Code to require that specific research and experimental (R&amp;amp;E) expenditures be capitalized and amortized over five years for U.S. R&amp;amp;E expenditures or 15 years for non-US R&amp;amp;E expenditures beginning in the Company&#x2019;s fiscal year ended December 31, 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although Congress has considered legislation that would defer, modify or repeal the capitalization and amortization requirement, there is no assurance that the provision will be deferred, repealed or otherwise modified.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the requirement is not modified, the Company may be required to utilize some of its federal and state tax attributes and there may be increases to state cash taxes or tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred a cumulative three-year loss. Pursuant to ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the negative evidence of a cumulative loss may be difficult to overcome. However, the Company will have significant future taxable income resulting from the reversal of taxable temporary differences. Primarily due to the availability of such expected future taxable income, the Company concluded that it is more likely than not that the benefits of the majority of its deferred income tax assets will be realized. However, for certain deferred tax assets a valuation allowance has been established, primarily due to limitations imposed by Section 382 of the Internal Revenue Code and certain jurisdictional limitations. For the year ended December&#160;31, 2022, the Company's valuation allowance increased by $3.9&#160;million, primarily due to the anticipated inability to utilize deferred tax assets related to state attributes and credits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the Company had the following net operating loss and research credit carryforwards (tax effected), with their respective expiration periods. Certain carryforwards are subject to the limitations of Section 382 and 383 of the Internal Revenue Code as indicated (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Subject to&lt;br/&gt;sections 382, 383&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expires&lt;br/&gt;beginning in year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Through&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal capital loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;No &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Utah net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;No&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;California net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other state net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign net operating losses (various jurisdictions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;No&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal research credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2042&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Utah research credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;No&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2036&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;California research credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;No&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the cumulative losses that have been incurred to date in foreign operations, the changes of the Tax Cuts and Jobs Act and the election to treat its foreign subsidiaries as disregarded entities, no deferred taxes related to the Company&#x2019;s foreign operations have been recorded. For those foreign entities for which an election has been made to be treated as disregarded for U.S. tax purposes, the appropriate U.S. jurisdiction deferred tax assets and liabilities have been recorded.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement criteria as set forth in ASC 740. As of December&#160;31, 2022, the Company had net unrecognized tax benefits of $31.9 million. The Company&#x2019;s gross unrecognized tax benefits as of the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020 and the fiscal year ended June 30, 2020, and the changes in those balances are as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at the beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross increases - current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross increases - prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross decreases - prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross decreases - settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross decreases - statute lapse&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest and penalties in year-end balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and penalties related to uncertain tax positions are included as a component of Income tax benefit and all other interest and penalties are included as a component of Other income (expense) in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files U.S. federal, foreign and state income tax returns in jurisdictions with various statutes of limitations. The Company is currently under audit by the state of California for years ended June 30, 2017 and 2018.&#160;&#160;Annual tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90ZXh0cmVnaW9uOmQ2YWEyZWE4YThhYzRlNzNhMzIzMGEwNDQ2ZjMyNDA4XzU0NDY_cabd2040-e198-4422-8694-7d0fc9f0aaab">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax benefit consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzMtMS0xLTEtMTE5NDgy_f79e7f62-3eda-44cd-93b7-303fc9dfe531"
      unitRef="usd">-500000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzMtMy0xLTEtMTE5NDgy_79a7a370-a4e4-4491-b4ce-27e55d9c0694"
      unitRef="usd">-1900000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzMtNS0xLTEtMTE5NDgy_a2deae49-20b3-4aeb-a5f5-c3892ab3144a"
      unitRef="usd">-75800000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzMtNy0xLTEtMTE5NDgy_1bfd5123-a080-40a5-bd0d-a6b8b9fad774"
      unitRef="usd">26600000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzQtMS0xLTEtMTE5NDgy_9273a71c-f1a5-4028-8b3c-ad5d3bbcd3e4"
      unitRef="usd">1900000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzQtMy0xLTEtMTE5NDgy_926a7782-d0c0-4f74-aa0e-196786363d5a"
      unitRef="usd">3600000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzQtNS0xLTEtMTE5NDgy_cf6ef515-3bea-4d8f-988f-2271881a6337"
      unitRef="usd">-600000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzQtNy0xLTEtMTE5NDgy_541e11d5-6e8b-4b30-8cf7-f96601fe32ca"
      unitRef="usd">4900000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzUtMS0xLTEtMTE5NDgy_a5479cd6-394c-476a-b520-b60b59d78012"
      unitRef="usd">500000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzUtMy0xLTEtMTE5NDgy_b95badab-ae52-4687-be72-feb430a66463"
      unitRef="usd">100000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzUtNS0xLTEtMTE5NDgy_fb7cfce2-e1c9-42a4-8b13-d8402307612c"
      unitRef="usd">200000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzUtNy0xLTEtMTE5NDgy_c2ebece7-a672-4a18-9c8b-c0e41ae0f945"
      unitRef="usd">500000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzYtMS0xLTEtMTE5NDgy_442da0a0-c922-4ab9-9862-6c60578a015a"
      unitRef="usd">1900000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzYtMy0xLTEtMTE5NDgy_41797bb2-8276-482b-9e23-f8bac9249b9b"
      unitRef="usd">1800000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzYtNS0xLTEtMTE5NDgy_a10ad688-e0ae-49ce-bf92-ba4789d274c1"
      unitRef="usd">-76200000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzYtNy0xLTEtMTE5NDgy_c431f681-aa18-43b8-b508-714f56fc587e"
      unitRef="usd">32000000.0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzgtMS0xLTEtMTE5NDgy_85fe8b1b-7f05-44da-b919-5807f2c67a4c"
      unitRef="usd">-25800000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzgtMy0xLTEtMTE5NDgy_539a03f2-047a-4106-957d-a4d67da8ebc2"
      unitRef="usd">-33700000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzgtNS0xLTEtMTE5NDgy_131986ee-fa59-47e7-9882-93fdc61abd57"
      unitRef="usd">39100000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzgtNy0xLTEtMTE5NDgy_c559dcde-1797-4d01-aaaa-744ddb48c859"
      unitRef="usd">-51500000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzktMS0xLTEtMTE5NDgy_e6ef0fca-b930-4c12-b53b-9bc1047cbbcd"
      unitRef="usd">-4800000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzktMy0xLTEtMTE5NDgy_1edcbbf8-69bf-4c80-a263-3b5642d4b4be"
      unitRef="usd">5100000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzktNS0xLTEtMTE5NDgy_bc20ec9b-cad4-4fd7-8a5e-5a20d23650e5"
      unitRef="usd">-3400000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzktNy0xLTEtMTE5NDgy_c1da0116-4c64-4b55-bfa1-97a8e6148467"
      unitRef="usd">-4100000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEwLTEtMS0xLTExOTQ4Mg_b26c89e7-d595-424b-a7f5-040946b94afe"
      unitRef="usd">-2900000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEwLTMtMS0xLTExOTQ4Mg_fc99a652-88ee-4461-bd1b-5fad068b2958"
      unitRef="usd">100000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEwLTUtMS0xLTExOTQ4Mg_0a0a6223-1e8b-4042-a5c8-64448e3e2b8e"
      unitRef="usd">-500000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEwLTctMS0xLTExOTQ4Mg_9ac4dc96-487c-4897-bd9d-5166b00f11a3"
      unitRef="usd">-3600000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzExLTEtMS0xLTExOTQ4Mg_93cadb49-3dd4-461c-b24a-60b3da3f253b"
      unitRef="usd">-3000000.0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzExLTMtMS0xLTExOTQ4Mg_71ebe5b4-6fb0-49a3-8fcb-7b40f42a8820"
      unitRef="usd">3200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzExLTUtMS0xLTExOTQ4Mg_ea3ea483-a162-4df8-9c59-71927ea70b93"
      unitRef="usd">0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzExLTctMS0xLTExOTQ4Mg_f833580e-ce26-479a-8fd3-3d546c15941c"
      unitRef="usd">-3500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEyLTEtMS0xLTExOTQ4Mg_74323e1d-50ba-4cf8-ab71-86796b69dd9e"
      unitRef="usd">-30500000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEyLTMtMS0xLTExOTQ4Mg_02fc30e3-0911-43bc-9f2f-dfa1baea437a"
      unitRef="usd">-31700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEyLTUtMS0xLTExOTQ4Mg_1cbf5e87-b9a5-495c-9be4-1b8b87f52618"
      unitRef="usd">35200000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEyLTctMS0xLTExOTQ4Mg_f8e6911a-f228-42c1-a3a8-2537723f05fb"
      unitRef="usd">-55700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEzLTEtMS0xLTExOTQ4Mg_8ba5356a-4f23-496f-87df-8c4d8a9392fb"
      unitRef="usd">-28600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEzLTMtMS0xLTExOTQ4Mg_8555e2be-be80-44f4-92e7-6e4fd94479a9"
      unitRef="usd">-29900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEzLTUtMS0xLTExOTQ4Mg_80999957-61a5-400a-9468-e2f4e2a608d0"
      unitRef="usd">-41000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTphYjk4Y2YwN2IxYzQ0ZmE2Yjc2NWYxMGEyMDk1N2UyOC90YWJsZXJhbmdlOmFiOThjZjA3YjFjNDRmYTZiNzY1ZjEwYTIwOTU3ZTI4XzEzLTctMS0xLTExOTQ4Mg_ffd88beb-b924-46fe-9a74-c3557e528413"
      unitRef="usd">-23700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90ZXh0cmVnaW9uOmQ2YWEyZWE4YThhYzRlNzNhMzIzMGEwNDQ2ZjMyNDA4XzU0NDc_8cefeb64-076b-421e-b424-e43a4c720738">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss before income taxes consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzItMS0xLTEtMTE5NDgy_4f6f0696-d86f-4ae8-abfe-b45ccf503ab0"
      unitRef="usd">-141300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzItMy0xLTEtMTE5NDgy_baf57618-fdf0-4adf-ab10-dba914c2f68b"
      unitRef="usd">-53800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzItNS0xLTEtMTE5NDgy_3e9a287d-1b3a-4d9c-9faf-63df163240f2"
      unitRef="usd">-101800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzItNy0xLTEtMTE5NDgy_d7b7d8ea-9cd1-4a98-a8be-5809ccc69d63"
      unitRef="usd">-240900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzMtMS0xLTEtMTE5NDgy_5b9360f9-ecfd-4ba6-b2f9-20b93c993851"
      unitRef="usd">700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzMtMy0xLTEtMTE5NDgy_e590f33a-a0e6-44a7-8984-a6e7afc61a50"
      unitRef="usd">-3300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzMtNS0xLTEtMTE5NDgy_32abbabb-1da9-49f3-aee5-e2f780d76d06"
      unitRef="usd">7700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzMtNy0xLTEtMTE5NDgy_ee30bc1c-e52e-40f7-82d4-92e43bc863f9"
      unitRef="usd">17600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzQtMS0xLTEtMTE5NDgy_6adbac88-bc2b-4d54-95f0-a3cb05049db1"
      unitRef="usd">-140600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzQtMy0xLTEtMTE5NDgy_7a163311-e2e7-4226-a27a-db381a7276e1"
      unitRef="usd">-57100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzQtNS0xLTEtMTE5NDgy_5e3b1ee2-3cee-4c37-9778-f7e74a966061"
      unitRef="usd">-94100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTo0Y2RjMjVkMTFhYjE0ZmI1ODlkZjZkNzY3ZjRjMDg0OC90YWJsZXJhbmdlOjRjZGMyNWQxMWFiMTRmYjU4OWRmNmQ3NjdmNGMwODQ4XzQtNy0xLTEtMTE5NDgy_77bff06a-6a10-45eb-b0fe-747328221b65"
      unitRef="usd">-223300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90ZXh0cmVnaW9uOmQ2YWEyZWE4YThhYzRlNzNhMzIzMGEwNDQ2ZjMyNDA4XzU0NDk_c397577e-dd54-43af-b68b-b0caeaf20ecd">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The differences between income taxes at the statutory federal income tax rate and income taxes reported in the Consolidated Statements of Operations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.404%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax expense at the statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incentive stock option and employee stock purchase plan expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CARES Act&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible meals and entertainment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible officer compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible legal settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions, dispositions, and contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;52.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzItMS0xLTEtMTE5NDgy_215215b1-f95a-481b-9ded-fade1f09b07a"
      unitRef="usd">-29500000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzItMy0xLTEtMTE5NDgy_19d06bf4-f597-4bb2-9a8d-a05ccd87d03f"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzItNS0xLTEtMTE5NDgy_71e5db84-eb8e-4f64-80f5-89c8f520e233"
      unitRef="usd">-12000000.0</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzItNy0xLTEtMTE5NDgy_a83ba05a-41c4-492d-bf7d-602db2577b29"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzItOS0xLTEtMTE5NDgy_64687b0b-bfde-4f3b-9ffd-ee1a5fe52008"
      unitRef="usd">-19800000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzItMTEtMS0xLTExOTQ4Mg_ca90184b-fab6-4351-a8a7-652cd4f4ac23"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzItMTMtMS0xLTExOTQ4Mg_cc34c2ce-4742-4c84-8662-d9b8ce024194"
      unitRef="usd">-46900000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzItMTUtMS0xLTExOTQ4Mg_2c23675e-98d4-426d-b7f4-01017aa94239"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzMtMS0xLTEtMTE5NDgy_d564473f-45eb-4310-bb72-09abffccdc0a"
      unitRef="usd">-3300000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzMtMy0xLTEtMTE5NDgy_de9f4aa0-38e6-4089-a101-daf8424db832"
      unitRef="number">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzMtNS0xLTEtMTE5NDgy_17936bef-c8b3-494f-803d-e6dcf0d2a524"
      unitRef="usd">-1800000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzMtNy0xLTEtMTE5NDgy_2dc883f9-38c9-46c8-880e-0c2f9c2a88f5"
      unitRef="number">0.032</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzMtOS0xLTEtMTE5NDgy_cd8fb898-1658-4ae6-bb99-cba394f77456"
      unitRef="usd">-1200000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzMtMTEtMS0xLTExOTQ4Mg_dd865833-ea3d-42ec-a36e-2867ea8bdb4d"
      unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzMtMTMtMS0xLTExOTQ4Mg_823be6c6-136f-4b7d-9d01-3d5e4073dc61"
      unitRef="usd">4000000.0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzMtMTUtMS0xLTExOTQ4Mg_e4e93169-75f7-4c7c-81a3-0bd5acbba320"
      unitRef="number">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzQtMS0xLTEtMTE5NDgy_0af79d7d-5ee5-4ad2-9094-b775c27e9dc0"
      unitRef="usd">3500000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzQtMy0xLTEtMTE5NDgy_1e9e9687-6128-4d88-b4fa-5c78a460dd30"
      unitRef="number">-0.025</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzQtNS0xLTEtMTE5NDgy_d1e60565-c0b1-40d6-b0e2-d2404d0d40a1"
      unitRef="usd">-2500000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzQtNy0xLTEtMTE5NDgy_da8a789b-4a98-457f-9bb1-91a4c4193e9a"
      unitRef="number">0.044</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzQtOS0xLTEtMTE5NDgy_65fa9998-9548-4f62-a0c1-d02f1086aaf8"
      unitRef="usd">1300000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzQtMTEtMS0xLTExOTQ4Mg_2d47a399-6f27-4e47-97ec-58b6b4d68bcd"
      unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzQtMTMtMS0xLTExOTQ4Mg_f2cace01-b294-4d99-bca6-fc60d799cb85"
      unitRef="usd">2800000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzQtMTUtMS0xLTExOTQ4Mg_91ed3e18-d0f3-4a19-9be2-f12e5bffe5fd"
      unitRef="number">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzUtMS0xLTEtMTE5NDgy_41d11f14-8392-4593-a6ce-eee6464f3ad3"
      unitRef="usd">600000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzUtMy0xLTEtMTE5NDgy_97726a53-34ba-4a96-9cef-e0fc368b8826"
      unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzUtNS0xLTEtMTE5NDgy_e5933cf6-48c1-4fef-b71d-fdae1c3685a0"
      unitRef="usd">-3000000.0</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzUtNy0xLTEtMTE5NDgy_3cb4b6ce-ee5d-424b-96fd-1689eb0a6314"
      unitRef="number">0.053</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzUtOS0xLTEtMTE5NDgy_d87a1810-ceef-4fbb-9fce-5a88a3a0eed3"
      unitRef="usd">600000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzUtMTEtMS0xLTExOTQ4Mg_5369899e-0917-421c-9046-581ac3af2dce"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzUtMTMtMS0xLTExOTQ4Mg_4036c3f2-7c37-48de-8b84-ee7196c1075a"
      unitRef="usd">1500000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzUtMTUtMS0xLTExOTQ4Mg_e87d0163-c2f7-459c-b82e-0e9988cd5a43"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzYtMS0xLTEtMTE5NDgy_018851de-58e9-4456-8b90-2a5056172c5e"
      unitRef="usd">2500000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzYtMy0xLTEtMTE5NDgy_434690cf-58ea-4794-8439-15761418457e"
      unitRef="number">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzYtNS0xLTEtMTE5NDgy_4b63ba6f-c97d-4566-b3d0-0bb141249275"
      unitRef="usd">700000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzYtNy0xLTEtMTE5NDgy_4668848a-8ae8-43c2-8415-1ee06480e662"
      unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzYtOS0xLTEtMTE5NDgy_96c3bc3d-e81a-4942-98ba-6943eb86d64a"
      unitRef="usd">2500000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzYtMTEtMS0xLTExOTQ4Mg_36abf3fd-9061-4200-8b7a-200435bdb14f"
      unitRef="number">-0.027</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzYtMTMtMS0xLTExOTQ4Mg_3bf80863-122d-4881-9f88-23b80a5e0de0"
      unitRef="usd">-200000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzYtMTUtMS0xLTExOTQ4Mg_c406a2ec-50ec-474d-a4bb-f846712254ae"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzctMS0xLTEtMTE5NDgy_cd919999-8a86-4ef5-943e-97231591971b"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzctMy0xLTEtMTE5NDgy_70465747-e989-49c9-91e1-f9673b1262a6"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzctNS0xLTEtMTE5NDgy_43960434-2c05-4024-b63f-886b001223f5"
      unitRef="usd">500000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzctNy0xLTEtMTE5NDgy_2b63ca22-6b85-42ef-8ac9-b86b5a9f38d6"
      unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzctOS0xLTEtMTE5NDgy_10e1763b-13da-44a0-9422-8909d5865031"
      unitRef="usd">-2100000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzctMTEtMS0xLTExOTQ4Mg_b3ee335f-86f3-4286-bc0c-14e0983e3c7b"
      unitRef="number">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzctMTMtMS0xLTExOTQ4Mg_9b84a52b-7759-4a24-9cbd-f7cfdabb9520"
      unitRef="usd">700000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzctMTUtMS0xLTExOTQ4Mg_8c28b352-3cf8-4b3d-b7f6-4670a5793759"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzgtMS0xLTEtMTE5NDgy_8e8d1a2c-c2a0-4cb4-b1ad-03eb09537ca1"
      unitRef="usd">2600000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzgtMy0xLTEtMTE5NDgy_32a059b9-30d8-4f8f-a843-549827636bd3"
      unitRef="number">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzgtNS0xLTEtMTE5NDgy_25cf384d-063d-4520-a17a-28354cc3b7d8"
      unitRef="usd">-3200000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzgtNy0xLTEtMTE5NDgy_5d224606-9275-42cf-b739-552c992bf0e5"
      unitRef="number">0.056</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzgtOS0xLTEtMTE5NDgy_40236b98-9269-47e2-aaef-0cdc0572e1ad"
      unitRef="usd">-300000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzgtMTEtMS0xLTExOTQ4Mg_a9f3abfe-9b12-4dcd-960f-e8d7292e45ed"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzgtMTMtMS0xLTExOTQ4Mg_c21aa163-d06f-4359-8f1f-1d8d9f83adf4"
      unitRef="usd">3500000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzgtMTUtMS0xLTExOTQ4Mg_c7097e2b-4450-410b-b09a-f8d88fe0a041"
      unitRef="number">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <mygn:IncomeTaxReconciliationCARESAct
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzktMS0xLTEtMTE5NDgy_4df2c7f6-8890-449d-8f07-498709531e7f"
      unitRef="usd">0</mygn:IncomeTaxReconciliationCARESAct>
    <mygn:EffectiveIncomeTaxRateReconciliationCARESAct
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzktMy0xLTEtMTE5NDgy_484658ed-5b7f-4b06-81a8-9ce3c4d08309"
      unitRef="number">0</mygn:EffectiveIncomeTaxRateReconciliationCARESAct>
    <mygn:IncomeTaxReconciliationCARESAct
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzktNS0xLTEtMTE5NDgy_a531f153-c939-464b-a118-6dc19e103e15"
      unitRef="usd">2700000</mygn:IncomeTaxReconciliationCARESAct>
    <mygn:EffectiveIncomeTaxRateReconciliationCARESAct
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzktNy0xLTEtMTE5NDgy_10627ca0-2196-4346-9c9c-871ddcd89942"
      unitRef="number">-0.047</mygn:EffectiveIncomeTaxRateReconciliationCARESAct>
    <mygn:IncomeTaxReconciliationCARESAct
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzktOS0xLTEtMTE5NDgy_8831c927-8163-4df1-8cc2-8ba94a60bdcd"
      unitRef="usd">-20700000</mygn:IncomeTaxReconciliationCARESAct>
    <mygn:EffectiveIncomeTaxRateReconciliationCARESAct
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzktMTEtMS0xLTExOTQ4Mg_10f28eb7-496e-4366-9181-d6e9704f7556"
      unitRef="number">0.220</mygn:EffectiveIncomeTaxRateReconciliationCARESAct>
    <mygn:IncomeTaxReconciliationCARESAct
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzktMTMtMS0xLTEyMjM0OA_b9ec247d-90ef-4d7a-a354-58ad3d29a6c3"
      unitRef="usd">0</mygn:IncomeTaxReconciliationCARESAct>
    <mygn:EffectiveIncomeTaxRateReconciliationCARESAct
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzktMTUtMS0xLTEyMjM0OA_821157df-2519-4550-927a-07d494f3a023"
      unitRef="number">0</mygn:EffectiveIncomeTaxRateReconciliationCARESAct>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEwLTEtMS0xLTExOTQ4Mg_c23cf641-27b8-441f-9c50-0ec58b2c0dd9"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEwLTMtMS0xLTExOTQ4Mg_4c1b3518-4742-48f3-9b7f-725f9c68077c"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEwLTUtMS0xLTExOTQ4Mg_5983dd33-5599-41b8-b751-196d74ebc2aa"
      unitRef="usd">100000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEwLTctMS0xLTExOTQ4Mg_984f946b-f9d2-4fd2-91ec-6021f159bcbb"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEwLTktMS0xLTExOTQ4Mg_5e171e90-fbe2-491d-bb4a-7a7b3567065f"
      unitRef="usd">500000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEwLTExLTEtMS0xMTk0ODI_970c3da5-d2b2-4e4a-85d0-856ab060531b"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEwLTEzLTEtMS0xMTk0ODI_dfe0db37-284c-4d07-a886-209dc99ccc95"
      unitRef="usd">1800000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEwLTE1LTEtMS0xMTk0ODI_9a1ff73f-37ce-4f97-be67-2d1bcaa6310c"
      unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment>
    <mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzExLTEtMS0xLTExOTQ4Mg_983ddf14-e55e-463c-92ea-068d9be4ad0f"
      unitRef="usd">3500000</mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation>
    <mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzExLTMtMS0xLTExOTQ4Mg_9f0e8616-2143-4529-99a1-1721a9617356"
      unitRef="number">-0.025</mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation>
    <mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzExLTUtMS0xLTExOTQ4Mg_d6b685fb-f736-4da1-8027-a75f5e010a46"
      unitRef="usd">3300000</mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation>
    <mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzExLTctMS0xLTExOTQ4Mg_74e2ff00-31f7-45b5-aeb8-962808adbfc4"
      unitRef="number">-0.058</mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation>
    <mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzExLTktMS0xLTExOTQ4Mg_130761fc-2858-42f8-b5d1-2748d81b979d"
      unitRef="usd">100000</mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation>
    <mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzExLTExLTEtMS0xMTk0ODI_a76b0365-9beb-4aeb-84dd-c74f3f8ebeb9"
      unitRef="number">-0.001</mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation>
    <mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzExLTEzLTEtMS0xMTk0ODI_7c095ea2-0b41-448e-bc85-9066145a7f93"
      unitRef="usd">1600000</mygn:IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation>
    <mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzExLTE1LTEtMS0xMTk0ODI_46e8fedf-bc52-4947-ac94-173772635fbc"
      unitRef="number">-0.007</mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation>
    <mygn:IncomeTaxReconciliationAssetImpairment
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEyLTEtMS0xLTExOTQ4Mg_6e58b68e-7eb5-4f41-9ae2-c1e28d81a1ab"
      unitRef="usd">0</mygn:IncomeTaxReconciliationAssetImpairment>
    <mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEyLTMtMS0xLTExOTQ4Mg_57c9bebb-df0c-4f84-a34a-4bfb1aa334c9"
      unitRef="number">0</mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment>
    <mygn:IncomeTaxReconciliationAssetImpairment
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEyLTUtMS0xLTExOTQ4Mg_c5e2fce5-91e9-4d80-8017-342f6882fabc"
      unitRef="usd">0</mygn:IncomeTaxReconciliationAssetImpairment>
    <mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEyLTctMS0xLTExOTQ4Mg_1b1187dd-15a2-40e2-aed1-ec387d776518"
      unitRef="number">0</mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment>
    <mygn:IncomeTaxReconciliationAssetImpairment
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEyLTktMS0xLTExOTQ4Mg_68c43be5-93d6-483f-8f31-eb24afd52aee"
      unitRef="usd">0</mygn:IncomeTaxReconciliationAssetImpairment>
    <mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEyLTExLTEtMS0xMTk0ODI_46cb1226-0fd4-4d67-97a7-d4a774769896"
      unitRef="number">0</mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment>
    <mygn:IncomeTaxReconciliationAssetImpairment
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEyLTEzLTEtMS0xMTk0ODI_2eabfc46-71e5-4b59-bf7b-c703a0e384c4"
      unitRef="usd">12600000</mygn:IncomeTaxReconciliationAssetImpairment>
    <mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEyLTE1LTEtMS0xMTk0ODI_3f3b7c5e-c893-477c-85c9-4ba38771e3df"
      unitRef="number">-0.056</mygn:EffectiveIncomeTaxRateReconciliationAssetImpairment>
    <mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEzLTEtMS0xLTExOTQ4Mg_18abb214-c53d-4737-a7ee-d38f3a788936"
      unitRef="usd">0</mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement>
    <mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEzLTMtMS0xLTExOTQ4Mg_38efb359-2294-42d1-b38d-79534bcb643b"
      unitRef="number">0</mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements>
    <mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEzLTUtMS0xLTExOTQ4Mg_e6d56b95-e8ec-47f8-9303-fd08c7b50447"
      unitRef="usd">2500000</mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement>
    <mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEzLTctMS0xLTExOTQ4Mg_eebd3963-29e6-4217-8b5e-495f2d20388b"
      unitRef="number">-0.045</mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements>
    <mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEzLTktMS0xLTExOTQ4Mg_7f4de322-b602-4d93-8e6e-ec62f680c1ef"
      unitRef="usd">0</mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement>
    <mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEzLTExLTEtMS0xMTk0ODI_4b67d23c-8918-413d-b69e-c64efd318bdc"
      unitRef="number">0</mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements>
    <mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEzLTEzLTEtMS0xMTk0ODI_513daed9-b437-4244-b590-02a6d4ec57a5"
      unitRef="usd">0</mygn:IncomeTaxReconciliationNonDeductibleLegalSettlement>
    <mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzEzLTE1LTEtMS0xMTk0ODI_c62426de-b6f0-48d7-9643-56e379387b45"
      unitRef="number">0</mygn:EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements>
    <mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE0LTEtMS0xLTExOTQ4Mg_bb5a2e92-f26d-472b-a60f-751477f224ee"
      unitRef="usd">-100000</mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration>
    <mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE0LTMtMS0xLTExOTQ4Mg_87c1dd16-bd93-41dc-8972-9d4a9d4d8082"
      unitRef="number">0.001</mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration>
    <mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE0LTUtMS0xLTExOTQ4Mg_064e695c-3b32-4ca6-9578-52ef9c4511b0"
      unitRef="usd">-23000000.0</mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration>
    <mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE0LTctMS0xLTExOTQ4Mg_a5a1b1fb-2cf2-44b9-befb-81e972639af5"
      unitRef="number">0.403</mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration>
    <mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE0LTktMS0xLTExOTQ4Mg_9ee9f2b1-7167-4bfd-b11a-37ba94fd75f8"
      unitRef="usd">700000</mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration>
    <mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE0LTExLTEtMS0xMTk0ODI_840d0dd2-943e-49b7-be7a-066ebdc32e22"
      unitRef="number">-0.007</mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration>
    <mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE0LTEzLTEtMS0xMTk0ODI_ac744d4a-3939-453e-9072-515845c659a9"
      unitRef="usd">-300000</mygn:IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration>
    <mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE0LTE1LTEtMS0xMTk0ODI_6a033e90-9fd3-46d2-854f-251e47125540"
      unitRef="number">0.001</mygn:EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE2LTEtMS0xLTExOTQ4Mg_781e6882-26c5-4efc-a97b-3753760f8289"
      unitRef="usd">-1400000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE2LTMtMS0xLTExOTQ4Mg_898a9b8f-b8e8-49d4-b72b-85d77734e745"
      unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE2LTUtMS0xLTExOTQ4Mg_24c2e134-d387-47da-b8c9-a2661cd4eb43"
      unitRef="usd">800000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE2LTctMS0xLTExOTQ4Mg_bc13da6f-c80c-434b-9f4e-b03bf51cbac2"
      unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE2LTktMS0xLTExOTQ4Mg_44769f86-1b35-4346-b6fd-9604af68ebd2"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE2LTExLTEtMS0xMTk0ODI_73187cde-9443-4036-be4e-bfebe433aed6"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE2LTEzLTEtMS0xMTk0ODI_d5bfdea2-1f48-408b-a8e3-a9762de500a4"
      unitRef="usd">800000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE2LTE1LTEtMS0xMTk0ODI_96384bb1-9fc5-450f-a97f-474914e35f10"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE3LTEtMS0xLTExOTQ4Mg_eb15e1fe-4bc0-4d00-ae35-f6a66b7c4314"
      unitRef="usd">-28600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE3LTMtMS0xLTExOTQ4Mg_b7f39e33-b93b-46f6-8e34-d496739756df"
      unitRef="number">0.203</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE3LTUtMS0xLTExOTQ4Mg_1d6fb008-0d49-401f-a3a3-e05b9bba4d38"
      unitRef="usd">-29900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE3LTctMS0xLTExOTQ4Mg_4edc0781-1fe6-49d8-8b39-e8032905291b"
      unitRef="number">0.523</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE3LTktMS0xLTExOTQ4Mg_75b93543-3d86-4ad8-8fdd-612211a109e9"
      unitRef="usd">-41000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE3LTExLTEtMS0xMTk0ODI_b9a56e9c-d799-4166-959e-47efeb4188b4"
      unitRef="number">0.435</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE3LTEzLTEtMS0xMTk0ODI_32348eb8-86cf-4d5d-8724-254bae47e69b"
      unitRef="usd">-23700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiZTg5MTMyZGY2OGQ0MjIzYWE4MmMyZDYwZmE0ZGE1NS90YWJsZXJhbmdlOmJlODkxMzJkZjY4ZDQyMjNhYTgyYzJkNjBmYTRkYTU1XzE3LTE1LTEtMS0xMTk0ODI_ceddd18a-7600-4052-a14d-2ecbe0b9e048"
      unitRef="number">0.106</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90ZXh0cmVnaW9uOmQ2YWEyZWE4YThhYzRlNzNhMzIzMGEwNDQ2ZjMyNDA4XzU0NTA_b29144b1-9de9-4958-93e6-0c457afeb060">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company&#x2019;s deferred tax assets and liabilities were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 174 capitalized costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzMtMS0xLTEtMTE5NDgy_a00994cf-fa71-4d98-9812-57aadb19c464"
      unitRef="usd">66600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzMtMy0xLTEtMTE5NDgy_dc1fa3b7-df81-4813-87d0-08af16d96fa0"
      unitRef="usd">67200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzQtMS0xLTEtMTE5NDgy_9526da02-dfa1-402b-9119-861de196802f"
      unitRef="usd">200000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzQtMy0xLTEtMTE5NDgy_fe7d99d2-342d-4acf-94bb-8d9b594a9c5b"
      unitRef="usd">1200000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzUtMS0xLTEtMTE5NDgy_82dbe4de-2db0-4427-b147-391d191a74fe"
      unitRef="usd">3600000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzUtMy0xLTEtMTE5NDgy_9372e021-d1b6-4e9f-bff5-da70cbb18212"
      unitRef="usd">4500000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzYtMS0xLTEtMTE5NDgy_d23ac52f-8dc9-45da-8cdc-3eb8369b3a40"
      unitRef="usd">19900000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzYtMy0xLTEtMTE5NDgy_d68f9ad4-9f0d-417c-ad0b-36b5388ce06d"
      unitRef="usd">17300000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <mygn:DeferredTaxAssetsLeaseLiabilities
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzctMS0xLTEtMTE5NDgy_375eff3f-6a15-4488-a4a2-60cf91e30f87"
      unitRef="usd">35200000</mygn:DeferredTaxAssetsLeaseLiabilities>
    <mygn:DeferredTaxAssetsLeaseLiabilities
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzctMy0xLTEtMTE5NDgy_f33ebfbb-d606-4a9d-9bae-0086a8e87bef"
      unitRef="usd">22400000</mygn:DeferredTaxAssetsLeaseLiabilities>
    <mygn:DeferredTaxAssetResearchAndExperimentalExpenseCapitalization
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzgtMS0xLTEtMTM0NDIw_4eb3aa3d-b9f4-486d-bfdb-f626086ebb67"
      unitRef="usd">21200000</mygn:DeferredTaxAssetResearchAndExperimentalExpenseCapitalization>
    <mygn:DeferredTaxAssetResearchAndExperimentalExpenseCapitalization
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzgtMy0xLTEtMTM0NDMz_febfe4a2-7d8d-498e-bf8e-1bb32d13e4ed"
      unitRef="usd">0</mygn:DeferredTaxAssetResearchAndExperimentalExpenseCapitalization>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzgtMS0xLTEtMTE5NDgy_83732c24-c39b-43a4-a453-6549633bb027"
      unitRef="usd">10800000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzgtMy0xLTEtMTE5NDgy_5a75baef-88fb-493b-b9c7-05bc28e89326"
      unitRef="usd">14200000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzktMS0xLTEtMTE5NDgy_b509e4ae-5c46-4f87-87c3-48b6d3696091"
      unitRef="usd">3400000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzktMy0xLTEtMTE5NDgy_dcac148b-cda9-4145-866c-0fb8108eeae2"
      unitRef="usd">4500000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzEwLTEtMS0xLTExOTQ4Mg_a6e514a3-2487-4862-bf15-d5374130bcec"
      unitRef="usd">160900000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzEwLTMtMS0xLTExOTQ4Mg_8bf1046b-345e-4a62-a98a-55950e7a4f8f"
      unitRef="usd">131300000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzExLTEtMS0xLTExOTQ4Mg_1b145362-8ac3-4dda-8eeb-384710a0fdcf"
      unitRef="usd">42400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzExLTMtMS0xLTExOTQ4Mg_95d83cb4-a050-4d4e-b241-71840c8dfdb3"
      unitRef="usd">38500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzEyLTEtMS0xLTExOTQ4Mg_c48659ce-0ac6-4850-9eee-7dd24c87717b"
      unitRef="usd">118500000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzEyLTMtMS0xLTExOTQ4Mg_5a95d6a0-5335-4a82-94bc-1e39c1d539dc"
      unitRef="usd">92800000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzE0LTEtMS0xLTExOTQ4Mg_f9fb6a2d-7d77-445e-8750-701b1dba48e4"
      unitRef="usd">93800000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzE0LTMtMS0xLTExOTQ4Mg_98ca9e53-83cb-448e-ae5b-4ac7796a0cea"
      unitRef="usd">104900000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <mygn:DeferredTaxLiabilitiesLeaseRightOfUseAssets
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzE1LTEtMS0xLTExOTQ4Mg_9839d82e-213a-4274-af90-ee63c2e3e197"
      unitRef="usd">25400000</mygn:DeferredTaxLiabilitiesLeaseRightOfUseAssets>
    <mygn:DeferredTaxLiabilitiesLeaseRightOfUseAssets
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzE1LTMtMS0xLTExOTQ4Mg_2ab4a3dc-f1e6-4818-8754-18013476d28c"
      unitRef="usd">20200000</mygn:DeferredTaxLiabilitiesLeaseRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzE2LTEtMS0xLTExOTQ4Mg_84efaeac-d3b5-4533-8f07-e6bbfd4e1783"
      unitRef="usd">2800000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzE2LTMtMS0xLTExOTQ4Mg_43099fe0-7f5c-4af9-99a0-496394702b8d"
      unitRef="usd">3500000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzE3LTEtMS0xLTExOTQ4Mg_ee9c1b98-3a0f-463d-ac39-dccbaac02ada"
      unitRef="usd">122000000.0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzE3LTMtMS0xLTExOTQ4Mg_3affb99c-5dc7-4d29-9f22-93be1eab0738"
      unitRef="usd">128600000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzE4LTEtMS0xLTExOTQ4Mg_8d995d8c-0ca6-4595-b8bf-c16971f496e8"
      unitRef="usd">3500000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTplMjQ1NTViNmZiZWE0ZDk0OWFhZmRhMGFjOTYzYWE3MC90YWJsZXJhbmdlOmUyNDU1NWI2ZmJlYTRkOTQ5YWFmZGEwYWM5NjNhYTcwXzE4LTMtMS0xLTExOTQ4Mg_fdfb18d1-6536-4267-8f08-a513ba38bd66"
      unitRef="usd">35800000</us-gaap:DeferredTaxLiabilities>
    <mygn:ValuationAllowanceIncreaseDecreaseDuringPeriod
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90ZXh0cmVnaW9uOmQ2YWEyZWE4YThhYzRlNzNhMzIzMGEwNDQ2ZjMyNDA4XzQ5NDc4MDIzMzA5ODc_f8474021-bcba-43a1-a37f-669a41af8c53"
      unitRef="usd">-3900000</mygn:ValuationAllowanceIncreaseDecreaseDuringPeriod>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90ZXh0cmVnaW9uOmQ2YWEyZWE4YThhYzRlNzNhMzIzMGEwNDQ2ZjMyNDA4XzU0NTE_580ab83e-8710-4d12-8f8c-542d57f37948">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the Company had the following net operating loss and research credit carryforwards (tax effected), with their respective expiration periods. Certain carryforwards are subject to the limitations of Section 382 and 383 of the Internal Revenue Code as indicated (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Subject to&lt;br/&gt;sections 382, 383&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expires&lt;br/&gt;beginning in year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Through&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal capital loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;No &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Utah net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;No&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;California net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other state net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign net operating losses (various jurisdictions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;No&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal research credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Yes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2042&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Utah research credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;No&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2036&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;California research credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;No&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ibc16948f5d7e4bd8969f02b7c60c2fc4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzEtMi0xLTEtMTE5NDgy_78b2fac5-2368-4383-80fb-e1e5ee270f5b"
      unitRef="usd">26600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="i8481cd3af014407fa42d2b6f5b5acbdf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzEtNC0xLTEtMTE5NDgy_ea7968bb-1ccd-44d2-a159-f4a1654f9fc2">Yes</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <mygn:OperatingLossCarryforwardsExpirationYear
      contextRef="idc38c0d48fe34cf9a4096e501b238ec1_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzEtNi0xLTEtMTE5NDgy_799f8663-33da-44d9-941c-8cf16e52aba5">2033</mygn:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i7acceb782b124009867513e1e395eb09_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzItMi0xLTEtMTE5NDgy_e9a87ada-4191-4a4c-9116-6f375468e78b"
      unitRef="usd">13500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="i8265cfaa4f6249e280c2c2cf4edf2b88_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzItNC0xLTEtMTE5NDgy_f161cdf1-1aa0-4257-a505-a1db848b8abc">No</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <mygn:TaxCreditCarryforwardsExpirationDate
      contextRef="i94684063e7f148b8b931a967f3ea2e9d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzItNi0xLTEtMTE5NDgy_542b76a2-05d6-48d7-9147-d2423bde757b">2026</mygn:TaxCreditCarryforwardsExpirationDate>
    <mygn:TaxCreditCarryforwardsExpirationDate
      contextRef="ie05625b5ce714586b315182123a0066c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzItOC0xLTEtMTE5NDgy_8549c862-6ebf-4a7d-9d37-ffecee0acb9f">2026</mygn:TaxCreditCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0e56caf70d6447518290386f81719ca9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzMtMi0xLTEtMTE5NDgy_531609d8-8a2e-4a05-b5b4-bfd51e3edf01"
      unitRef="usd">2800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="i94ef8507bf234538b9ed98fb0e389325_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzMtNC0xLTEtMTE5NDgy_12989380-cb8f-448f-80d8-4e11eedc9a52">No</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <mygn:OperatingLossCarryforwardsExpirationYear
      contextRef="i0bbddf290d464aadaa27acb940277180_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzMtNi0xLTEtMTE5NDgy_bf3736c2-3faf-41e5-b1e2-6fd6a30f0e73">2023</mygn:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ib3a2d7f8de3c427785c15b09085c84d6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzQtMi0xLTEtMTE5NDgy_4f0420aa-3a86-473f-b29f-ea13b80a56ce"
      unitRef="usd">4400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="i83f4a6d86c4f4eb39c69c44ec0b4f2fd_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzQtNC0xLTEtMTE5NDgy_e1676122-9485-4f0b-bf31-9f57fc45d83d">Yes</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <mygn:OperatingLossCarryforwardsExpirationYear
      contextRef="ib5f72eb0018746c886b57ce4f50c4db8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzQtNi0xLTEtMTE5NDgy_87fea002-66b5-4df3-b3ff-ac08e1b2e1e4">2029</mygn:OperatingLossCarryforwardsExpirationYear>
    <mygn:OperatingLossCarryforwardsExpirationYear
      contextRef="i491a5a05cb774a8fb1c3c42b73443667_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzQtOC0xLTEtMTE5NDgy_7cfa04a6-9089-4fac-b613-0754e799cca4">2041</mygn:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="iaef3f6c95fd94ce4b015ac7e3db94ae4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzUtMi0xLTEtMTE5NDgy_5dedb442-5564-413a-8149-0c8384881d31"
      unitRef="usd">7700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="ibea3c187441f480487b44a951451baba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzUtNC0xLTEtMTE5NDgy_2a8533a3-8353-4022-9373-d744be6c66f4">Yes</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:OperatingLossCarryforwards
      contextRef="if40585f71c3c463a9840bdd7070fc047_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzYtMi0xLTEtMTE5NDgy_2a823a0d-8492-4745-89b0-93bc88a3e81c"
      unitRef="usd">11600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="id2f519e64bc04789a7526a6bd09819a6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzYtNC0xLTEtMTE5NDgy_070fca1b-e916-4647-899a-60634bf745b0">No</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ia9e7946b9ce6498cab7885f8d675da90_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzctMi0xLTEtMTE5NDgy_2cbcd692-1d45-45f9-9ea7-598c99727990"
      unitRef="usd">8700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="ifb59e7c4e69149dd82d0501e71e1ce19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzctNC0xLTEtMTE5NDgy_94491ebc-2fc8-48b1-ad56-cc3c5eb7b639">Yes</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <mygn:TaxCreditCarryforwardsExpirationDate
      contextRef="iaf9dfcf78da842f5bad9f364f2105f81_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzctNi0xLTEtMTE5NDgy_f754668d-5426-4149-a607-7f2f52e71e01">2027</mygn:TaxCreditCarryforwardsExpirationDate>
    <mygn:TaxCreditCarryforwardsExpirationDate
      contextRef="i532ba0950b96453a85caae716fac82b6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzctOC0xLTEtMTE5NDgy_8f913600-d509-49e7-863e-2237e025a691">2042</mygn:TaxCreditCarryforwardsExpirationDate>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i1da4606ad7ed41209dfcdca23de08ed6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzgtMi0xLTEtMTE5NDgy_c5659152-16c7-45a1-8c0c-0e8fbb6932e3"
      unitRef="usd">6900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="ic667a4f90d994acbb20e3e566f84f92e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzgtNC0xLTEtMTE5NDgy_7087c8a6-702f-4cc7-b2e6-51ee7e6ee0b7">No</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <mygn:TaxCreditCarryforwardsExpirationDate
      contextRef="iea7482a897494be892bc46b821925654_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzgtNi0xLTEtMTE5NDgy_523e072f-4eb0-4004-9d1d-412b8a8606af">2023</mygn:TaxCreditCarryforwardsExpirationDate>
    <mygn:TaxCreditCarryforwardsExpirationDate
      contextRef="if99355023d8f4ac5ab1b42964f050f9e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzgtOC0xLTEtMTE5NDgy_dc574225-339e-482a-a138-6a00a7585ae2">2036</mygn:TaxCreditCarryforwardsExpirationDate>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i06d164c0b6e04a459e6a33b952092ab4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzktMi0xLTEtMTE5NDgy_4a2f35ec-62c7-475a-921d-d0f6f5d57067"
      unitRef="usd">4400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="i6df636aa6bd446ed8b2aea33d99d66a4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpjYTYzYzg5M2JiMzU0ZmI0YjQwNzY2YmU5YTQ2YzE0Ny90YWJsZXJhbmdlOmNhNjNjODkzYmIzNTRmYjRiNDA3NjZiZTlhNDZjMTQ3XzktNC0xLTEtMTE5NDgy_61d3ceae-67ef-4a15-8933-fabaa3dace21">No</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90ZXh0cmVnaW9uOmQ2YWEyZWE4YThhYzRlNzNhMzIzMGEwNDQ2ZjMyNDA4XzU0OTc1NTgxOTg2Nw_bd544ac0-64e7-47da-9f89-17b668fac928"
      unitRef="usd">31900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90ZXh0cmVnaW9uOmQ2YWEyZWE4YThhYzRlNzNhMzIzMGEwNDQ2ZjMyNDA4XzU0NDg_ac7935d9-c8be-4a17-82a2-9a33ff3fb93d">The Company&#x2019;s gross unrecognized tax benefits as of the years ended December 31, 2022 and 2021, the transition period ended December&#160;31, 2020 and the fiscal year ended June 30, 2020, and the changes in those balances are as follows:&#160;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at the beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross increases - current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross increases - prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross decreases - prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross decreases - settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross decreases - statute lapse&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest and penalties in year-end balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzItMS0xLTEtMTE5NDgy_d0b52d32-3328-4e28-ab68-7a5577d741b6"
      unitRef="usd">32100000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzItMy0xLTEtMTIyOTEx_065d3a56-c266-4e8a-89c6-2b56f7b109ab"
      unitRef="usd">37600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ideeefc606008446e85d0fd21a9515813_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzItMy0xLTEtMTE5NDgy_35619275-a9fe-400a-ab13-4d3622880620"
      unitRef="usd">23500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if96afdd71e74449aa558f9c0f8968925_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzItNS0xLTEtMTE5NDgy_feef172d-7036-468c-b336-508dcaa30c15"
      unitRef="usd">21700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzMtMS0xLTEtMTE5NDgy_7787263d-983a-43f6-9ebb-ded50feedc2f"
      unitRef="usd">900000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzMtMy0xLTEtMTIyOTEx_541ee85e-f441-445f-9395-4085bc203168"
      unitRef="usd">1400000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzMtMy0xLTEtMTE5NDgy_720e09f2-4ce5-4606-ad46-d85d96d20b9e"
      unitRef="usd">13900000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzMtNS0xLTEtMTE5NDgy_1e2e01fd-c24c-4833-b0b9-2c34926c5fec"
      unitRef="usd">1600000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzQtMS0xLTEtMTE5NDgy_0f34f6b9-6e53-4a3a-acfb-96e1fbc5efbc"
      unitRef="usd">1600000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzQtMy0xLTEtMTIyOTEx_d4543420-0528-4e84-af39-7bc15b5a9153"
      unitRef="usd">1100000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzQtMy0xLTEtMTE5NDgy_2955d16b-1a9e-4d17-a727-4d67223db650"
      unitRef="usd">1000000.0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzQtNS0xLTEtMTE5NDgy_a3fccb7a-c49d-458f-bfa1-9d302ad75647"
      unitRef="usd">700000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzYtMS0xLTEtMTE5NDgy_f326d196-2ee0-49c8-a651-76a732066882"
      unitRef="usd">2000000.0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzYtMy0xLTEtMTIyOTEx_6ecdda79-674f-4f03-a258-03b56b36a534"
      unitRef="usd">2800000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzYtMy0xLTEtMTE5NDgy_ca0da84b-0b25-466b-8e06-dbf587218650"
      unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzYtNS0xLTEtMTE5NDgy_9a3f8cbe-e35b-4f5c-af64-c5ece7460186"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzctMS0xLTEtMTE5NDgy_18d200bf-5da8-441f-bed8-d78d21863aa5"
      unitRef="usd">700000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzctMy0xLTEtMTIyOTEx_ec0dc735-cef3-4867-858a-6147c3b58607"
      unitRef="usd">5100000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzctMy0xLTEtMTE5NDgy_42afc3d9-a3a3-40cd-a808-1066435d0dd1"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzctNS0xLTEtMTE5NDgy_b26a2ccc-81e9-4095-aabd-af78fdf5f4b1"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzgtMS0xLTEtMTE5NDgy_7088797c-c97f-4d92-ae30-9d9801cdeade"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzgtMy0xLTEtMTIyOTEx_bc34d245-fdd8-40c5-ad42-9abdee04d9a7"
      unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzgtMy0xLTEtMTE5NDgy_bcf5e0b3-f23f-48c4-ad57-50c5f0c06f46"
      unitRef="usd">700000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzgtNS0xLTEtMTE5NDgy_ff4c1734-5922-495b-99c3-63e9336139a3"
      unitRef="usd">500000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzktMS0xLTEtMTE5NDgy_bd544ac0-64e7-47da-9f89-17b668fac928"
      unitRef="usd">31900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzktMy0xLTEtMTIyOTEx_16914b94-3d76-4f55-8bb8-a2145709fda2"
      unitRef="usd">32100000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzktMy0xLTEtMTE5NDgy_cac0c874-de9e-423c-af59-920b16604d02"
      unitRef="usd">37600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ideeefc606008446e85d0fd21a9515813_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzktNS0xLTEtMTE5NDgy_c8e35ba4-5457-4bf6-91ac-5de6da1be2cb"
      unitRef="usd">23500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzEwLTEtMS0xLTExOTQ4Mg_ad4368b9-08ba-4534-b1ac-b51c6ddb712f"
      unitRef="usd">4100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzEwLTMtMS0xLTEyMjkxMQ_8452b122-1695-4193-a9e4-79b93efb27ab"
      unitRef="usd">3300000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="id83f26d989d54298a0d5f2d84eba7095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzEwLTMtMS0xLTExOTQ4Mg_4184eb11-989e-4f1a-b770-04e255b3f713"
      unitRef="usd">2200000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ideeefc606008446e85d0fd21a9515813_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjEvZnJhZzpkNmFhMmVhOGE4YWM0ZTczYTMyMzBhMDQ0NmYzMjQwOC90YWJsZTpiMTg1ZjQ5ZWYxYWU0ZGM0OWRhNzg0MjBmOThlNzQ3OS90YWJsZXJhbmdlOmIxODVmNDllZjFhZTRkYzQ5ZGE3ODQyMGY5OGU3NDc5XzEwLTUtMS0xLTExOTQ4Mg_b7fddfa0-981e-41f5-bd62-cc0deef9c7e9"
      unitRef="usd">1400000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjQvZnJhZzo2N2RjOTI1NDk5YjI0YmI1YmFmMjY0NTdhMDE5YjczNy90ZXh0cmVnaW9uOjY3ZGM5MjU0OTliMjRiYjViYWYyNjQ1N2EwMTliNzM3XzEwMTIz_c376c0d5-f5fe-401f-87ac-8176274789c5">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is involved from time to time in various disputes, claims and legal actions, including class actions and other litigation, including the matters described below, arising in the ordinary course of business. Such actions may include allegations of negligence, product or professional liability or other legal claims, and could involve claims for substantial compensatory and punitive damages or claims for indeterminate amounts of damages. The Company is also involved, from time to time, in investigations by governmental agencies regarding its business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of the government or private payors. The Company has received subpoenas from time to time related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations or other laws.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to defend its current litigation matters, but cannot provide any assurance as to the ultimate outcome or that an adverse resolution would not have a material adverse effect on its financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses legal contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. When evaluating legal contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the proceedings may be in early stages, there may be uncertainty as to the outcome of pending appeals or motions, there may be significant factual issues to be resolved, and there may be complex or novel legal theories to be presented. In addition, damages may not be specified or the damage amounts claimed may be unsupported, exaggerated or unrelated to possible outcomes, and therefore, such amounts are not a reliable indicator of potential liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the Company has not recorded any material accrual for loss contingencies associated with legal proceedings or other matters or determined that an unfavorable outcome is probable and reasonably estimable in accordance with ASC 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. However, it is possible that the ultimate resolution of legal proceedings or other matters, if unfavorable, may be material to the Company's results of operations, financial condition or cash flows. Further, in the event that damages from an unfavorable resolution of one or more of these proceedings exceed the aggregate amount of the coverage limits of the Company&#x2019;s insurance, or if the Company&#x2019;s insurance carriers disclaim coverage, the amounts payable by the Company could also have a material adverse impact on the Company&#x2019;s results of operations, financial condition or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Securities Class Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 27, 2019, a class action complaint was filed in the U.S. District Court for the District of Utah, against the Company, its former President and Chief Executive Officer, Mark C. Capone, and its Chief Financial Officer, R. Bryan Riggsbee (Defendants). On February 21, 2020, the plaintiff filed an amended class action complaint, which added the Company's former Executive Vice President of Clinical Development, Bryan M. Dechairo, as an additional Defendant. This action, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;In re Myriad Genetics, Inc. Securities Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (No. 2:19-cv-00707-DBB), is premised upon allegations that the Defendants made false and misleading statements regarding the Company's business, operations, and acquisitions.&#160;&#160;The lead plaintiff seeks the payment of damages allegedly sustained by it and the purported class by reason of the allegations set forth in the amended complaint, plus interest, and legal and other costs and fees.&#160;On March 16, 2021, the U.S. District Court for the District of Utah denied the Company's motion to dismiss.&#160;On December 1, 2021, the U.S. District Court for the District of Utah granted plaintiff's motion for class certification. The parties currently are engaged in discovery.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stockholder Derivative Actions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 9, 2021, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Company's former President and Chief Executive Officer, Mark C. Capone, its Chief Financial Officer, R. Bryan Riggsbee, its former Executive Vice President of Clinical Development, Bryan M. Dechairo, and certain of the Company's current and former directors, Lawrence C. Best, Walter Gilbert, John T. Henderson, Heiner Dreismann, Dennis Langer, Lee N. Newcomer, S. Louise Phanstiel, and Colleen F. Reitan (collectively, the Individual Defendants), and the Company, as nominal defendant. The complaint is premised upon similar allegations as set forth in the securities class action, including that the Individual Defendants made false and misleading statements regarding the Company's business and operations. The plaintiff, Donna Hickock, asserts breach of fiduciary duty and unjust enrichment claims against the Individual Defendants and seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches, or disgorgement or restitution, from each of the Individual Defendants, plus interest. Plaintiff Hickock also seeks legal and other costs and fees relating to this action. On November 19, 2021, this action was stayed by the Delaware Court of Chancery pending the resolution of the securities class action lawsuit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 18, 2022, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and the Hickock stockholder derivative action. The plaintiff, Esther Kogus, asserts that the Individual Defendants breached their fiduciary duties and also asserts unjust enrichment and aiding and abetting breaches of fiduciary duty claims against the Individual Defendants. Plaintiff Kogus seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches and claims, and restitution from the Individual Defendants. On behalf of herself, plaintiff Kogus seeks legal and other costs and fees relating to this action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 3, 2022, the Delaware Court of Chancery consolidated the Hickock and Kogus derivative actions and stayed the consolidated action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 17, 2021, a stockholder derivative complaint was filed in the U.S. District Court in the District of Delaware against the Individual Defendants, and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the securities class action and Hickock stockholder derivative action. The plaintiff, Karen Marcey, asserts that the Individual Defendants violated U.S. securities laws and breached their fiduciary duties, and also asserts unjust enrichment, waste of corporate assets and insider trading claims against all or some of the Individual Defendants. Plaintiff Marcey seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged violations and restitution from the Individual Defendants, plus interest and, on behalf of herself, legal and other costs and fees relating to this action. On January 4, 2022, this action was stayed by the U.S. District Court for the District of Delaware pending the resolution of the securities class action lawsuit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 21, 2020, Ravgen, Inc. filed a lawsuit against the Company and its wholly owned subsidiary, Myriad Women's Health, Inc., in the U.S. District Court for the District of Delaware, alleging infringement of two Ravgen-owned patents. The lawsuit seeks monetary damages, enhancement of those damages for willfulness, injunctive relief, and recovery of attorney's fees and costs. Various third parties have filed challenges to the validity of the asserted patents with the U.S. Patent and Trademark Office, which challenges have been instituted for review. On March 14, 2022, the case was stayed pending the outcome of the first of these validity challenges. On February 13, 2022, the court lifted the stay and litigation of the case has resumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 3, 2022, a purported class action lawsuit was filed against the Company in the U.S. District Court in the Northern District of California by Ashley Carroll. Plaintiff alleges, among other things, that the Company made false statements about the accuracy of its Prequel prenatal screening test. The complaint seeks unspecified monetary damages and injunctive relief. On April 1, 2022, the Company filed a motion to dismiss the lawsuit. On May 2, 2022, the plaintiff amended her complaint. On June 2, 2022, the Company filed a motion to dismiss the amended complaint. On July 26, 2022, the court granted and denied in part the Company's motion to dismiss the amended complaint. As part of the court's order, plaintiff was granted leave to file a second amended complaint. The plaintiff filed a second amended complaint on August 16, 2022. On September 6, 2022, the Company filed a motion to dismiss the second amended complaint. On November 9, 2022, the Court granted and denied in part the Company's motion to dismiss the second amended complaint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber
      contextRef="i78b35c2904e342a2a22d1151ef8b25d8_D20201221-20201221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjQvZnJhZzo2N2RjOTI1NDk5YjI0YmI1YmFmMjY0NTdhMDE5YjczNy90ZXh0cmVnaW9uOjY3ZGM5MjU0OTliMjRiYjViYWYyNjQ1N2EwMTliNzM3XzIxOTkwMjMyOTkwMDY_3fd6d84f-b594-4183-a139-24f96c6cd70a"
      unitRef="patent">2</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzQ5MTc_8de37a19-8f91-4003-ac69-1c374ef98117">LEASES The Company leases certain office spaces and research and development laboratory facilities, vehicles, and office equipment with remaining lease terms ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzE4MA_55b83f90-88ae-4e25-9b41-229696ec6103"&gt;one&lt;/span&gt; to fifteen years. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options, which allows the Company to, at its election, renew or extend the lease for a fixed period of time. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. During the twelve months ended December&#160;31, 2022, in an effort to reduce its real estate footprint, the Company ceased the use of certain of its leased Salt Lake City facilities and one of its South San Francisco facilities. As a result, the Company recorded an impairment charge on ROU assets of $13.0 million and an impairment charge of $3.9 million on the related property, plant and equipment, which consisted primarily of leasehold improvements. The total $16.9 million impairment is included in Goodwill and long-lived asset impairment charges in the Consolidated Statement of Operations.&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the year ended December&#160;31, 2022, the Company incurred $22.1 million in lease costs which are included in operating expenses in the Consolidated Statements of Operations in relation to these operating leases. Of such lease costs, $3.2&#160;million was variable lease expense, which was not included in the measurement of the Company's operating ROU assets and lease liabilities. The variable rent expense is comprised primarily of the Company's proportionate share of operating expenses, property taxes, and insurance and is classified as lease expense due to the Company's election to not separate lease and non-lease components. For the year ended December&#160;31, 2021, the Company incurred $20.7 million in lease costs which are included in operating expenses in the Consolidated Statements of Operations in relation to these operating leases. Of such lease costs, $3.2 million was variable lease expense, which was not included in the measurement of the Company's operating ROU assets and lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2022, the Company entered into a non-cancelable operating lease for approximately 230,000 square feet in west Salt Lake City, Utah. The lease has a term of 15 years, which, along with rent payments, are expected to commence in the third quarter of 2023. The Company will take possession of the leased facility in phases, which began in the three months ended June 30, 2022. As a result, the Company has recognized the related lease balances for the phase, or portion, of the leased facility that the Company has taken possession of, and will recognize the additional phases of the leased facility as possession occurs. As of December&#160;31, 2022, the Company has recognized an approximately $13.9 million ROU asset and corresponding lease liability, net of tenant improvement allowance not yet received. Total future rent payments under the lease are approximately $78.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also took possession of a lease for approximately 63,000 square feet in South San Francisco, California with a term of 10 years, which, along with rent payments, are expected to commence in the third quarter of 2023. As a result, the Company recognized the related ROU asset and lease liability, net of tenant improvement allowance not yet received, of $30.7 million in the Consolidated Balance Sheets as of December&#160;31, 2022. Total future rent payments under the lease are approximately $58.8&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: leases not yet commenced&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current maturities of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the weighted average remaining lease term is 10.3 years and the weighted average discount rate used to determine the operating lease liability was 5.87%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the implicit rate in the Company's leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating the Company&#x2019;s incremental borrowing rates, the Company gives consideration to its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary. The lease term used may reflect any option to extend or terminate the lease when it is reasonably certain the Company will exercise such options. Lease expenses for the Company's operating leases are recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i4fa41121b7d143cfbc8e91a9ced3020a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzE4Ng_07d02409-f5e3-4814-bf7b-4e336c3a5d86">P15Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzExNTQ0ODcyMTAzNTI0_6f51713d-3c2e-4721-ba14-ff67898fb8f3"
      unitRef="usd">13000000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="i87c0d4d014b8431486ad3d3075f0ca84_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzExNTQ0ODcyMTAzNTMx_b749a5e8-968a-4fd0-8629-09f1b5930d6b"
      unitRef="usd">3900000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzEwOTk1MTE2MzkyMTc_bf84b7cd-01fe-41df-a896-fdfd05e0668b"
      unitRef="usd">16900000</us-gaap:AssetImpairmentCharges>
    <us-gaap:LeaseCost
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzI0Nzg_d0ca7cc5-2740-4dde-85ce-18ff38c98a4d"
      unitRef="usd">22100000</us-gaap:LeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzI2NDI_ceb8755e-c4c5-49d2-975d-0c8ef10e8491"
      unitRef="usd">3200000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyMTQwMg_761300f8-080f-4f2a-bc97-8b3647a711a5"
      unitRef="usd">20700000</us-gaap:LeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyMTQxMA_868ec9f0-6310-4311-bd53-ec3c6caf18d5"
      unitRef="usd">3200000</us-gaap:VariableLeaseCost>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i7ec137fde2704324b8c089d57adb90e5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyMzU1Ng_59d2187e-d72b-4856-af09-ba94b334c9b4"
      unitRef="sqft">230000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i7ec137fde2704324b8c089d57adb90e5_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyMzU0Ng_3f965ca1-9971-4109-9bbb-19171171f5f6">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib7c0bca71a544a8293274a98d8342a84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyNDU1OA_c7f075ae-6805-4348-936f-02dc87701431"
      unitRef="usd">13900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib7c0bca71a544a8293274a98d8342a84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyNDU1OA_d39e3d0f-1deb-496b-b081-8e9c66e40ade"
      unitRef="usd">13900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ib7c0bca71a544a8293274a98d8342a84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyMzYyOQ_769a8af0-cb0c-4075-a884-8cefc8914993"
      unitRef="usd">78000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i0d8e9e97f965410eb1e1d5fb7d188a69_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyNDQ2NA_b7b519a8-d749-4860-a321-94f8383ae6d4"
      unitRef="sqft">63000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i0d8e9e97f965410eb1e1d5fb7d188a69_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyNDQ4MA_fcae1aab-f849-40b1-aec7-0b5648a42b88">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0d8e9e97f965410eb1e1d5fb7d188a69_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyNDU3Nw_847ea305-2b6f-41e3-bf75-fc10c2c04a65"
      unitRef="usd">30700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i0d8e9e97f965410eb1e1d5fb7d188a69_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgyNDU3Nw_fb158110-c4d0-4cb7-86bc-490138ff318a"
      unitRef="usd">30700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i0d8e9e97f965410eb1e1d5fb7d188a69_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzU0OTc1NTgxNDk3NDI_ba641039-c5fa-4521-b152-8ffdfcee8604"
      unitRef="usd">58800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzQ5MTY_aba30366-2683-4ce1-991c-a756021576bd">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: leases not yet commenced&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current maturities of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzEtMS0xLTEtMTE5NDgy_076dbad9-4f71-4fe5-bec5-caa8ea95224e"
      unitRef="usd">20200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzItMS0xLTEtMTE5NDgy_a3c290e8-2834-47e4-bc8d-86af6e03faf4"
      unitRef="usd">23800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzMtMS0xLTEtMTE5NDgy_4d6ecbf4-b2af-4b09-8eb4-e4784ed69802"
      unitRef="usd">17900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzQtMS0xLTEtMTE5NDgy_f5315cba-9799-4b04-af90-ba10e54466a2"
      unitRef="usd">16300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzUtMS0xLTEtMTE5NDgy_712d24ca-0089-4e69-a571-b925cbe319fd"
      unitRef="usd">15000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzYtMS0xLTEtMTE5NDgy_07c89ac0-a8fb-48ad-9191-c708eccb5343"
      unitRef="usd">92600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzctMS0xLTEtMTE5NDgy_f613d85c-417b-4b88-9a8a-ebb0929d3955"
      unitRef="usd">185800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzgtMS0xLTEtMTE5NDgy_f899fa32-b5b5-4d07-81a0-2a00b174ea35"
      unitRef="usd">18900000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <mygn:OperatingLeaseLiabilityIncludingLeasesNotYetCommenced
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzktMS0xLTEtMTE5NDgy_2861381d-ab4f-4ec4-be7c-68e9764419d2"
      unitRef="usd">166900000</mygn:OperatingLeaseLiabilityIncludingLeasesNotYetCommenced>
    <mygn:OperatingLeaseLiabilityLeasesNotYetCommenced
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzEwLTEtMS0xLTExOTQ4Mg_b7eed224-ac8e-497b-8122-76d67470480b"
      unitRef="usd">21900000</mygn:OperatingLeaseLiabilityLeasesNotYetCommenced>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzExLTEtMS0xLTExOTQ4Mg_0ff69279-6703-4f03-9bc0-353046dee16b"
      unitRef="usd">14100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90YWJsZTpkOTc0NmY3MmFlZDg0ZTI2YjY3OGQ3ZjEyZWQzOGQ1Yy90YWJsZXJhbmdlOmQ5NzQ2ZjcyYWVkODRlMjZiNjc4ZDdmMTJlZDM4ZDVjXzEyLTEtMS0xLTExOTQ4Mg_bcfbf851-d71d-4c5c-a751-1bdbf6389288"
      unitRef="usd">130900000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzQxMTM_49c256f1-58a1-474a-851e-b736ca1fd5c7">P10Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMjcvZnJhZzowMGI3ZWI4Zjg0YTg0YWVhODFkYzRmZmRkYzUzYTUxZC90ZXh0cmVnaW9uOjAwYjdlYjhmODRhODRhZWE4MWRjNGZmZGRjNTNhNTFkXzQyMDc_7a03031c-12ab-43e4-8fab-cca24dbde347"
      unitRef="number">0.0587</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzAvZnJhZzpkNzUzNmNlODNiZDk0YTMwOTVlYzJkZWIzYmIwYTZiMS90ZXh0cmVnaW9uOmQ3NTM2Y2U4M2JkOTRhMzA5NWVjMmRlYjNiYjBhNmIxXzQ0OQ_5ed7bde7-b92f-4ffc-8d2a-f7925539fcbe">EMPLOYEE DEFERRED SAVINGS PLAN&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a deferred savings plan which qualifies under Section&#160;401(k) of the Internal Revenue Code. Substantially all of the Company&#x2019;s U.S. employees are covered by the plan. The Company makes matching contributions of 50% of each employee&#x2019;s contribution with the employer&#x2019;s contribution not to exceed 4% of the employee&#x2019;s compensation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s recorded contributions to the plan are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred savings plan contributions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzAvZnJhZzpkNzUzNmNlODNiZDk0YTMwOTVlYzJkZWIzYmIwYTZiMS90ZXh0cmVnaW9uOmQ3NTM2Y2U4M2JkOTRhMzA5NWVjMmRlYjNiYjBhNmIxXzI2Ng_78f8221f-961a-4468-bed0-3c05616565c4"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzAvZnJhZzpkNzUzNmNlODNiZDk0YTMwOTVlYzJkZWIzYmIwYTZiMS90ZXh0cmVnaW9uOmQ3NTM2Y2U4M2JkOTRhMzA5NWVjMmRlYjNiYjBhNmIxXzM0OA_83bda8b3-3788-46f8-a1c3-7a3214d4add4"
      unitRef="number">0.04</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanDisclosuresTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzAvZnJhZzpkNzUzNmNlODNiZDk0YTMwOTVlYzJkZWIzYmIwYTZiMS90ZXh0cmVnaW9uOmQ3NTM2Y2U4M2JkOTRhMzA5NWVjMmRlYjNiYjBhNmIxXzQ1MA_1ffb82a2-f568-412e-917c-dd38f04c0317">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s recorded contributions to the plan are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred savings plan contributions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DefinedContributionPlanDisclosuresTableTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzAvZnJhZzpkNzUzNmNlODNiZDk0YTMwOTVlYzJkZWIzYmIwYTZiMS90YWJsZTozNDgwN2UyMWUzZDc0NjZhYWNjZGQyNzg3MGRkYjg0OS90YWJsZXJhbmdlOjM0ODA3ZTIxZTNkNzQ2NmFhY2NkZDI3ODcwZGRiODQ5XzItMS0xLTEtMTE5NDgy_51f97f28-c642-4927-accd-90c1486afb7d"
      unitRef="usd">9000000.0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzAvZnJhZzpkNzUzNmNlODNiZDk0YTMwOTVlYzJkZWIzYmIwYTZiMS90YWJsZTozNDgwN2UyMWUzZDc0NjZhYWNjZGQyNzg3MGRkYjg0OS90YWJsZXJhbmdlOjM0ODA3ZTIxZTNkNzQ2NmFhY2NkZDI3ODcwZGRiODQ5XzItMy0xLTEtMTIxNTAz_23860edf-7a3f-4658-a14b-4a22109fcc8c"
      unitRef="usd">8400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzAvZnJhZzpkNzUzNmNlODNiZDk0YTMwOTVlYzJkZWIzYmIwYTZiMS90YWJsZTozNDgwN2UyMWUzZDc0NjZhYWNjZGQyNzg3MGRkYjg0OS90YWJsZXJhbmdlOjM0ODA3ZTIxZTNkNzQ2NmFhY2NkZDI3ODcwZGRiODQ5XzItMy0xLTEtMTE5NDgy_4500463c-e8dd-4330-beb2-d4e43b73060e"
      unitRef="usd">4000000.0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i3d0e08156cb641f29dd07ca3ce93941c_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzAvZnJhZzpkNzUzNmNlODNiZDk0YTMwOTVlYzJkZWIzYmIwYTZiMS90YWJsZTozNDgwN2UyMWUzZDc0NjZhYWNjZGQyNzg3MGRkYjg0OS90YWJsZXJhbmdlOjM0ODA3ZTIxZTNkNzQ2NmFhY2NkZDI3ODcwZGRiODQ5XzItNS0xLTEtMTE5NDgy_9a58222a-33c3-45dc-a908-d73de5148bdc"
      unitRef="usd">7100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90ZXh0cmVnaW9uOjVjM2M3NmU3OWI4ZTQ0NDA4YWEyYWRmYzY1NWYzOWYwXzEyOTI_f4234307-403d-403c-bdb6-17ca33e21ff7">SEGMENT AND RELATED INFORMATION&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s business is aligned with how the chief operating decision maker ("CODM") reviews performance and makes decisions in managing the Company. On July 1, 2021, the Company completed the divestiture of Myriad RBM, Inc., and, as a result, now operates a single reporting segment. Prior to the sale, the Myriad RBM, Inc. operating segment was included in the Company&#x2019;s previously reported "other" segment. The Company&#x2019;s remaining operations have been aggregated into a single reporting segment, which primarily provides testing that helps assess an individual&#x2019;s risk for developing disease or disease progression and guides treatment decisions across medical specialties where genetic insights can significantly improve patient health care and lower health care costs, and includes corporate services such as finance, human resources, legal and information technology. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. The CODM evaluates segment performance based on operating income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles assets by geographical region to total assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net equipment, leasehold improvements and property:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Total assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and marketable investment securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,320.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90ZXh0cmVnaW9uOjVjM2M3NmU3OWI4ZTQ0NDA4YWEyYWRmYzY1NWYzOWYwXzEyOTQ_e5411f65-a68b-41fb-bb35-b4acc9624773">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles assets by geographical region to total assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net equipment, leasehold improvements and property:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Total assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,029.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and marketable investment securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,320.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iabf0e35c76ce4737b597d4d31b6103bb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzMtMS0xLTEtMTE5NDgy_331f453b-bec9-438b-8dd3-62822ddb840e"
      unitRef="usd">81900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id0f83e0a22104fedb4e475de48140594_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzMtMy0xLTEtMTE5NDgy_f5272903-f430-48c1-b5f6-605b685c8ee9"
      unitRef="usd">41600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i03e3d05930c246f797d9ab7061985860_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzQtMS0xLTEtMTE5NDgy_f1ccc482-77ce-4054-8deb-4d451ff75a11"
      unitRef="usd">1500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0e82739b44cd45d7b099f422b6ae33cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzQtMy0xLTEtMTE5NDgy_61d604e6-c775-4295-a64e-fdb3637bcfb8"
      unitRef="usd">1900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4c8aad575c1d41c389544f11390b9d59_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzUtMS0xLTEtMTE5NDgy_e77d07e6-21cb-4356-b95c-bc15f9f309e3"
      unitRef="usd">83400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib0a06975e9204301b5cb15099574bcee_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzUtMy0xLTEtMTE5NDgy_5342beb5-69d4-4312-87b6-8203370d0d46"
      unitRef="usd">43500000</us-gaap:PropertyPlantAndEquipmentNet>
    <mygn:AssetsLessCashCashEquivalentsAndInvestments
      contextRef="iabf0e35c76ce4737b597d4d31b6103bb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzctMS0xLTEtMTE5NDgy_13f80ca2-b1b0-47e1-b31a-97dd884a3274"
      unitRef="usd">983400000</mygn:AssetsLessCashCashEquivalentsAndInvestments>
    <mygn:AssetsLessCashCashEquivalentsAndInvestments
      contextRef="id0f83e0a22104fedb4e475de48140594_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzctMy0xLTEtMTE5NDgy_784e1caf-5268-4be5-b6c3-b05c806ef1fd"
      unitRef="usd">870800000</mygn:AssetsLessCashCashEquivalentsAndInvestments>
    <mygn:AssetsLessCashCashEquivalentsAndInvestments
      contextRef="i03e3d05930c246f797d9ab7061985860_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzgtMS0xLTEtMTE5NDgy_5ee04cde-e08c-4a7f-a3ca-86cdd4272e9f"
      unitRef="usd">45600000</mygn:AssetsLessCashCashEquivalentsAndInvestments>
    <mygn:AssetsLessCashCashEquivalentsAndInvestments
      contextRef="i0e82739b44cd45d7b099f422b6ae33cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzgtMy0xLTEtMTE5NDgy_593abc11-a377-42d8-89d4-057dd6fdc4df"
      unitRef="usd">51100000</mygn:AssetsLessCashCashEquivalentsAndInvestments>
    <mygn:AssetsLessCashCashEquivalentsAndInvestments
      contextRef="i4c8aad575c1d41c389544f11390b9d59_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzktMS0xLTEtMTE5NDgy_ae939da5-d33d-40b2-acc0-b2b4b66d57a9"
      unitRef="usd">1029000000</mygn:AssetsLessCashCashEquivalentsAndInvestments>
    <mygn:AssetsLessCashCashEquivalentsAndInvestments
      contextRef="ib0a06975e9204301b5cb15099574bcee_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzktMy0xLTEtMTE5NDgy_8c2017bf-f284-4276-94ac-b3c9017d74fd"
      unitRef="usd">921900000</mygn:AssetsLessCashCashEquivalentsAndInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzEwLTEtMS0xLTExOTQ4Mg_e141f250-4060-437c-af21-9457bfb8524e"
      unitRef="usd">169700000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzEwLTMtMS0xLTExOTQ4Mg_54d94bd1-9bf2-426a-8f78-4e91f3f816e9"
      unitRef="usd">398800000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:Assets
      contextRef="ifb254f1abbe54bc896976a7ef3e19442_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzExLTEtMS0xLTExOTQ4Mg_a39428e0-7b41-4792-943d-1b69073145ac"
      unitRef="usd">1198700000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i29d9f082f6304b3c901b8a69a382c99f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzMvZnJhZzo1YzNjNzZlNzliOGU0NDQwOGFhMmFkZmM2NTVmMzlmMC90YWJsZTowYTgzNGMwNDJhODE0MjcwYjI5NmFlNWI2ZTY3NTAyMS90YWJsZXJhbmdlOjBhODM0YzA0MmE4MTQyNzBiMjk2YWU1YjZlNjc1MDIxXzExLTMtMS0xLTExOTQ4Mg_3c55e5f2-89b9-4bcd-8ba7-a0efaf0688ec"
      unitRef="usd">1320700000</us-gaap:Assets>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzkxOA_8a66adcf-ab74-430d-9d5a-cd23ba700fee">BUSINESS ACQUISITION&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 1, 2022, the Company acquired all of the membership interests of Gateway, a San Diego-based personal genomics company and developer of consumer genetic tests that give families insight into their future children.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition date fair value of the consideration transferred was $68.7&#160;million. Cash consideration amounted to $66.6&#160;million, of which $8.5&#160;million was deposited for general representation and warranty and working capital adjustment purposes in an escrow account, legally owned by the Company. The remaining consideration included contingent cash consideration with a fair value of $2.1&#160;million. The contingent consideration is classified as a liability and has a maximum value of up to $32.5&#160;million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;based on the achievement of certain performance-based targets.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The acquisition date fair value of the contingent consideration was based on the Monte Carlo Method, utilizing various pay-out scenarios that factor in forecasted revenue, earnings before interest, taxes, depreciation and amortization ("EBITDA"), and Prequel and FirstGene test volumes that directly result from the sale of the SneakPeek Gender DNA Test relative to targets for fiscal 2023 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition is being accounted for under the acquisition method of accounting in accordance with ASC Topic 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The consideration transferred was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date. Management estimated the fair value of tangible and intangible assets and liabilities in accordance with the applicable accounting guidance for business combinations and utilized the services of third-party valuation consultants. The significant assumptions used in the model to estimate the value of the intangible assets included projected cash flows, discount rates, net working capital and long-term growth rate. The initial allocation of the consideration transferred is based on a preliminary valuation and is subject to adjustments. Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible), liabilities assumed, as well as tax-related matters. During the measurement period, the Company may record adjustments to the provisional amounts recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management estimated that consideration paid exceeded the fair value of the net assets acquired. Therefore, goodwill of $48.7&#160;million was recorded. The goodwill recognized is primarily attributable to the expected synergies to be achieved from the business combination and is deductible for income tax purposes. The following table summarizes the estimated fair value of identified assets acquired and liabilities assumed at the date of acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of Purchase Price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Identifiable Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the identifiable intangible assets and related useful lives were determined using an income approach discounting expected future cash flows to present value at a discount rate of 15.5%. The discount rate was based on the estimated internal rate of return for the acquisition and represents the rate that market participants might use to value the intangible assets. The Company will amortize the intangible assets on a straight-line basis over their estimated useful lives. The estimated useful life of the customer relationships and trademarks is 10 years and the estimated useful life of the developed technology is 8 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transactions Separate From the Business Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the business acquisition, the Company also recognized certain transactions which were accounted for separately from the acquisition of assets and assumptions of liabilities in the business acquisition. Compensation expense of $1.9&#160;million was paid at the closing of the transaction pursuant to a retention arrangement with Gateway employees that was negotiated in connection with their retention by the Company. Receipt of the additional amounts available under the retention arrangement is contingent upon future service from the employees and the achievement of certain performance-based targets related to revenue and EBITDA. The $1.9&#160;million of compensation expense is recognized in Selling, general, and administrative expense in the Consolidated Statement of Operations for the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also incurred approximately $3.1&#160;million of acquisition-related costs in connection with the acquisition of Gateway, which has been recognized as an expense in Selling, general, and administrative expense in the Consolidated Statement of Operations in the period incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pro Forma Information (Unaudited)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited pro forma results presented below include the effects of Gateway acquisition as if it had been consummated as of January 1, 2021, with adjustments to give effect to pro forma events that are directly attributable to the acquisition, which includes adjustments related to the amortization of acquired intangible assets, interest income and expense, and depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited pro forma results do not reflect any operating efficiency or potential cost savings that may result from the consolidation of Gateway with the Company. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operation of the combined company would have been if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations and are not necessarily indicative of results that might have been achieved had the acquisition been consummated as of January 1, 2021. The Company did not have any material, nonrecurring pro forma adjustments directly attributable to the business acquisition included in the reported pro forma earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;709,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue and net loss from Gateway included in the Company's Consolidated Statements of Operations since the acquisition date through December 31, 2022 is $3.3 million and $2.8 million, respectively. Of the $2.8 million net loss recognized, $1.9&#160;million is the compensation expense paid at the closing of the transaction discussed above.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i871418f253134efc9cceceeafbb4c291_D20221101-20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzQ5NDc4MDIzNDI2MTY_529d2386-09ee-4f96-ae45-db9ae952e7d4"
      unitRef="usd">68700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i871418f253134efc9cceceeafbb4c291_D20221101-20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMxOTI_e9999dfa-554a-4f20-97c0-da2809dd3b33"
      unitRef="usd">66600000</us-gaap:PaymentsToAcquireBusinessesGross>
    <mygn:BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments
      contextRef="i871418f253134efc9cceceeafbb4c291_D20221101-20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzczMTc_63ebee01-1dee-48fa-9769-0c7f11e3b5c4"
      unitRef="usd">8500000</mygn:BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="i871418f253134efc9cceceeafbb4c291_D20221101-20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMyMDc_1ecb331d-4976-4f51-beeb-7a93faba9f53"
      unitRef="usd">2100000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMyMjE_ecc0c80b-bfca-4cf2-879f-d5d8846bb4e1"
      unitRef="usd">32500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:Goodwill
      contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMyMzY_246540dc-5151-4fe1-8a92-6c70d271300a"
      unitRef="usd">48700000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzQ5NDc4MDIzNDM2ODQ_dfd529f5-0441-4586-84d7-75e08db8b714">The following table summarizes the estimated fair value of identified assets acquired and liabilities assumed at the date of acquisition. &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of Purchase Price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
      contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzEtMS0xLTEtMTMwMzI2_742e18ea-9702-461f-88be-0d77d2ee6250"
      unitRef="usd">1053000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzItMS0xLTEtMTMwMzI2_5c0d7a40-6031-4e61-884b-f3a76fdbb59f"
      unitRef="usd">1900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ic41e7d1ebb214f6792a964d2daa1b432_I20221101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzUtMS0xLTEtMTM2NTk5_a44ada57-c1f1-4d78-9854-df32917d19b7"
      unitRef="usd">10100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ibd5b839397f4403ca413620e5ce1dffc_I20221101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzYtMS0xLTEtMTM2NTk5_b0b9da08-2ca4-4f23-af91-76af01ae93fb"
      unitRef="usd">6100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i789e41c2063b4e77b952b8700cc045f7_I20221101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzctMS0xLTEtMTM2NTk5_980b1114-4148-47c1-a82c-d833b1affaa5"
      unitRef="usd">1600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzgtMS0xLTEtMTM3MjUz_06629387-8092-4387-8741-be982eb0bbb3"
      unitRef="usd">17800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzUtMS0xLTEtMTMwMzI2_5620d883-9649-4554-8a7b-a4fdb5095d34"
      unitRef="usd">161000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzExLTEtMS0xLTEzODU2OA_c73d8fee-d585-41ff-8385-a48219b00427"
      unitRef="usd">20914000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzYtMS0xLTEtMTMwMzI2_0fe2a4d5-e3c1-462a-9d27-df501923a848"
      unitRef="usd">246000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzctMS0xLTEtMTMwMzI2_de105a3b-a595-4e6b-b1f2-74dd176780e5"
      unitRef="usd">693000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzgtMS0xLTEtMTMwMzI2_f1ff2b79-3016-45ed-a228-dbe7ec255567"
      unitRef="usd">939000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzE2LTEtMS0xLTEzODU3OA_198fabf5-8c5e-426c-9087-2ebc304e798f"
      unitRef="usd">19975000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzExLTEtMS0xLTEzNjQ3MA_1e2e6adc-0784-4eb2-a617-052f5b67ccad"
      unitRef="usd">48723000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTo4MzllNGE1MzlmYjg0ZjEyYmYzZjU3NTFiMjY1N2VkZS90YWJsZXJhbmdlOjgzOWU0YTUzOWZiODRmMTJiZjNmNTc1MWIyNjU3ZWRlXzExLTEtMS0xLTEzMDMyNg_9bf6daee-48fc-44c6-8463-e85506f69bc7"
      unitRef="usd">68698000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <mygn:BusinessCombinationIntangibleAssetsMeasurementInput
      contextRef="i75436f77b2804ab3bbcc97fe20a6f36c_D20221101-20221101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMyOTQ_64c2382b-b7dc-43ec-b51a-a3dc94ede252"
      unitRef="number">0.155</mygn:BusinessCombinationIntangibleAssetsMeasurementInput>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="id82e3f3eeb68492399f4153822f134df_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMzMDA_38d7e33a-56b5-42fb-8849-d72a77914614">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if437534e60cb4439b2cd0da6651519aa_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMzMDA_c0422a72-3c37-45c0-956b-45d348da1995">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ic3c2906fb217491a8423ba010a090290_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMzMTQ_ff13d72a-c0e9-4168-a27e-2e5d89c6006b">P8Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="i7a2ff25d850940a7bc40bed0d8065631_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMzMjc_dffe71b0-852e-4bca-9b6a-02b1497ce391"
      unitRef="usd">1900000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="i7a2ff25d850940a7bc40bed0d8065631_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMzNDE_96de7982-b9df-462d-b87d-027e7340f314"
      unitRef="usd">1900000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i7a2ff25d850940a7bc40bed0d8065631_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzIxOTkwMjMyNzMzNTU_7a72a39e-b923-445c-b4f1-d7c5923764a4"
      unitRef="usd">3100000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzQ5NDc4MDIzNDM2ODU_b74bfa6c-83f8-4e52-8090-1dcc6b1aa504">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;709,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i7a2ff25d850940a7bc40bed0d8065631_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTpiOTQ4YThkNjJhNDY0OWNjOWVkYTY4MDdmZjFmYmQxOC90YWJsZXJhbmdlOmI5NDhhOGQ2MmE0NjQ5Y2M5ZWRhNjgwN2ZmMWZiZDE4XzMtMS0xLTEtMTMwMzYy_170bf0db-3825-48b7-bbb0-12db48fba014"
      unitRef="usd">695632000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i673ce123e2a44d4598692c845966f939_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTpiOTQ4YThkNjJhNDY0OWNjOWVkYTY4MDdmZjFmYmQxOC90YWJsZXJhbmdlOmI5NDhhOGQ2MmE0NjQ5Y2M5ZWRhNjgwN2ZmMWZiZDE4XzMtMy0xLTEtMTMwMzYy_c037e776-afc5-43a1-9555-97cc471be93b"
      unitRef="usd">709132000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i7a2ff25d850940a7bc40bed0d8065631_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTpiOTQ4YThkNjJhNDY0OWNjOWVkYTY4MDdmZjFmYmQxOC90YWJsZXJhbmdlOmI5NDhhOGQ2MmE0NjQ5Y2M5ZWRhNjgwN2ZmMWZiZDE4XzQtMS0xLTEtMTMwMzYy_68b9b4bd-5847-44f8-bbe0-18ef73349762"
      unitRef="usd">-112185000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i673ce123e2a44d4598692c845966f939_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90YWJsZTpiOTQ4YThkNjJhNDY0OWNjOWVkYTY4MDdmZjFmYmQxOC90YWJsZXJhbmdlOmI5NDhhOGQ2MmE0NjQ5Y2M5ZWRhNjgwN2ZmMWZiZDE4XzQtMy0xLTEtMTMwMzYy_0b4d14e3-8f8a-45c7-ad5a-ef4c39cf35e6"
      unitRef="usd">-28686000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="i42ace60aa6e54d01b61af32b6f5812e2_D20221101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzQzOTgwNDY1MjgzODk_147483a9-4b84-42c3-9483-ac08cf85aeca"
      unitRef="usd">3300000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="i42ace60aa6e54d01b61af32b6f5812e2_D20221101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzQzOTgwNDY1Mjg0MDQ_a3ddcba4-904e-4a56-884d-5eef2c43d6a7"
      unitRef="usd">-2800000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="i42ace60aa6e54d01b61af32b6f5812e2_D20221101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzQzOTgwNDY1MjkxNTM_a3ddcba4-904e-4a56-884d-5eef2c43d6a7"
      unitRef="usd">-2800000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="i7a2ff25d850940a7bc40bed0d8065631_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDIvZnJhZzpiYjdhNzY5ODE5NWE0NzA4ODA2Y2UxYTgwZWU5OTA0NS90ZXh0cmVnaW9uOmJiN2E3Njk4MTk1YTQ3MDg4MDZjZTFhODBlZTk5MDQ1XzQzOTgwNDY1MjkxNjg_96de7982-b9df-462d-b87d-027e7340f314"
      unitRef="usd">1900000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzE4NDQ_6cd37162-86cc-47a5-8a6f-fc796b45155f">DIVESTITURES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 28, 2021, the Company completed the sale of the Myriad myPath, LLC laboratory to Castle Biosciences, Inc. for cash consideration of $32.5&#160;million. The transaction was accounted for as a sale of assets and the Company recognized a gain of $31.2&#160;million, net of transaction costs of $1.3&#160;million, in Other income (expense) in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 1, 2021, the Company completed the sale of Myriad RBM, Inc., then a wholly owned subsidiary of the Company, to IQVIA RDS, Inc., for cash consideration of $197.0&#160;million. The transaction was accounted for as a sale of a business and the Company recognized a gain of $121.0&#160;million, net of transaction costs of $4.8&#160;million, in Other income (expense) in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 13, 2021, the Company completed the sale of select operating assets and intellectual property, including the Vectra test, from the Myriad Autoimmune business unit to Laboratory Corporation of America Holdings for cash consideration of $150.0&#160;million. The transaction was accounted for as a sale of a business and the Company recognized a loss of $0.6&#160;million, net of transaction costs of $4.4&#160;million, in Other income (expense) in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating results of these businesses do not qualify for reporting as discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the divestiture transactions, the Company recognized losses of $5.2&#160;million and $6.5&#160;million for a non-cancelable inventory purchase commitment and inventory, respectively, during the year ended December 31, 2021, as t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Company no longer had use for the goods. Both of these losses are included in Other income (expense) in the Consolidated Statements of Operations for the year ended December, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table details the amounts recognized in Other income (expense) for the year ended December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of Myriad RBM, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of the Myriad myPath, LLC laboratory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on sale of Myriad Autoimmune assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i32039b626a934562bee22c0bff60b59d_D20210528-20210528"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzE2MQ_ea8babfc-7f80-4197-af3f-7fa220962fa4"
      unitRef="usd">32500000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <mygn:GainLossOnDispositionOfAssetsNetOfTransactionFees
      contextRef="i32039b626a934562bee22c0bff60b59d_D20210528-20210528"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzI1Ng_67ae0b38-2c6b-4219-b355-2804db1c24c5"
      unitRef="usd">31200000</mygn:GainLossOnDispositionOfAssetsNetOfTransactionFees>
    <mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts
      contextRef="i32039b626a934562bee22c0bff60b59d_D20210528-20210528"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzI4OA_f9f9a31b-0b69-4fdf-89d0-e04fc62c214a"
      unitRef="usd">1300000</mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts>
    <us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries
      contextRef="if94a3c16ec0f40b79d3e7cd2713c4a83_D20210701-20210701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzUzNg_6897c532-6c9e-477c-b104-63c804155230"
      unitRef="usd">197000000</us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="if94a3c16ec0f40b79d3e7cd2713c4a83_D20210701-20210701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzYzNQ_4b1b247b-b133-4e25-8cf9-94c02da5957e"
      unitRef="usd">121000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts
      contextRef="if94a3c16ec0f40b79d3e7cd2713c4a83_D20210701-20210701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzY2Nw_cca63351-d690-4aa3-9007-933085b41dd2"
      unitRef="usd">4800000</mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts>
    <us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries
      contextRef="i754115245e57408994525a98aed1283a_D20210913-20210913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzEwMDI_525feefb-464b-4409-a5ea-bfca0c2ce0e1"
      unitRef="usd">150000000</us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i754115245e57408994525a98aed1283a_D20210913-20210913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzExMDE_9c5a6bf1-c7b8-46e4-b19c-d1e52bf8fb99"
      unitRef="usd">-600000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts
      contextRef="i754115245e57408994525a98aed1283a_D20210913-20210913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzExMzM_25e581f4-8391-4725-8dfb-6410848f60a8"
      unitRef="usd">4400000</mygn:DisposalGroupNotDiscontinuedOperationTransactionCosts>
    <us-gaap:InventoryFirmPurchaseCommitmentLoss
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzE0MTA_1fdc811c-388d-4092-8746-29e4f91678c4"
      unitRef="usd">5200000</us-gaap:InventoryFirmPurchaseCommitmentLoss>
    <us-gaap:InventoryWriteDown
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzE0MTc_afd48829-6ff7-4790-a3b0-766bade2087d"
      unitRef="usd">6500000</us-gaap:InventoryWriteDown>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90ZXh0cmVnaW9uOmI3ZDA0ZGQzM2M3YjRiZjM5YjBlZDY2ZTUyZjFjNGUwXzE4NDU_63a42862-9ea4-4635-8654-74f067d14cd8">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table details the amounts recognized in Other income (expense) for the year ended December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of Myriad RBM, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of the Myriad myPath, LLC laboratory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on sale of Myriad Autoimmune assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i11ee8a7e07b6457b867d5750561f27de_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90YWJsZTpkMjI2YWFjOTdkNDc0NWJkODVhNWNlZTVkNmM0MGUwZi90YWJsZXJhbmdlOmQyMjZhYWM5N2Q0NzQ1YmQ4NWE1Y2VlNWQ2YzQwZTBmXzEtMS0xLTEtMTE5NDgy_7fd79b2d-61c6-4c4b-bc52-7fb351f06ae2"
      unitRef="usd">121000000.0</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i2ba75a9ef71348d3b90148f91f146b36_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90YWJsZTpkMjI2YWFjOTdkNDc0NWJkODVhNWNlZTVkNmM0MGUwZi90YWJsZXJhbmdlOmQyMjZhYWM5N2Q0NzQ1YmQ4NWE1Y2VlNWQ2YzQwZTBmXzItMS0xLTEtMTE5NDgy_552bd60d-398f-496f-b936-5bbf8b2e73bb"
      unitRef="usd">31200000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <mygn:DisposalGroupNotDiscontinuedOperationGainLossOnInventory
      contextRef="i7b99a13c827f4f10ad3b6af0f22ddd25_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90YWJsZTpkMjI2YWFjOTdkNDc0NWJkODVhNWNlZTVkNmM0MGUwZi90YWJsZXJhbmdlOmQyMjZhYWM5N2Q0NzQ1YmQ4NWE1Y2VlNWQ2YzQwZTBmXzMtMS0xLTEtMTE5NDgy_7b768c2f-feda-48ac-875b-586b81414096"
      unitRef="usd">-11700000</mygn:DisposalGroupNotDiscontinuedOperationGainLossOnInventory>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="ie73f9b8455314405972aa71faee08793_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90YWJsZTpkMjI2YWFjOTdkNDc0NWJkODVhNWNlZTVkNmM0MGUwZi90YWJsZXJhbmdlOmQyMjZhYWM5N2Q0NzQ1YmQ4NWE1Y2VlNWQ2YzQwZTBmXzQtMS0xLTEtMTE5NDgy_e78f5daa-e9f1-434e-8f9d-1ec2ac05a90a"
      unitRef="usd">-600000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <mygn:DisposalGroupNotDiscontinuedOperationGainLossOther
      contextRef="i7b99a13c827f4f10ad3b6af0f22ddd25_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90YWJsZTpkMjI2YWFjOTdkNDc0NWJkODVhNWNlZTVkNmM0MGUwZi90YWJsZXJhbmdlOmQyMjZhYWM5N2Q0NzQ1YmQ4NWE1Y2VlNWQ2YzQwZTBmXzUtMS0xLTEtMTE5NDgy_e1f7c9b6-ef3b-44b2-a04c-e001e9658934"
      unitRef="usd">-600000</mygn:DisposalGroupNotDiscontinuedOperationGainLossOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xMzkvZnJhZzpiN2QwNGRkMzNjN2I0YmYzOWIwZWQ2NmU1MmYxYzRlMC90YWJsZTpkMjI2YWFjOTdkNDc0NWJkODVhNWNlZTVkNmM0MGUwZi90YWJsZXJhbmdlOmQyMjZhYWM5N2Q0NzQ1YmQ4NWE1Y2VlNWQ2YzQwZTBmXzYtMS0xLTEtMTE5NDgy_392d293a-007f-40a7-8c12-b46e5e0d68ca"
      unitRef="usd">139300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90ZXh0cmVnaW9uOmNlOTdjNWQyZGM4ZjRkMTRiZTUzYTNkYWY5NjM2YTk5XzQ0_12b8d58a-427f-48cb-ba79-433c8c51ddbf">SUPPLEMENTAL CASH FLOW INFORMATION&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's supplemental cash flow information for the respective periods are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received for income tax receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash investing and financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Establishment of operating lease right-of-use assets and lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tenant improvement allowance not yet received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of property, plant and equipment in accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities and other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90ZXh0cmVnaW9uOmNlOTdjNWQyZGM4ZjRkMTRiZTUzYTNkYWY5NjM2YTk5XzQ1_eed38525-992f-477c-913b-b9ac3cfd8098">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's supplemental cash flow information for the respective periods are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six-month Transition Period Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received for income tax receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash investing and financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Establishment of operating lease right-of-use assets and lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tenant improvement allowance not yet received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of property, plant and equipment in accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities and other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:IncomeTaxesPaid
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzItMS0xLTEtMTE5NDgy_84457a13-0952-45bd-9955-905ebeeb513d"
      unitRef="usd">1800000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzItMy0xLTEtMTE5NDgy_0b1847c7-1b4f-4721-88fc-0ba6978da1e8"
      unitRef="usd">4600000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzItNS0xLTEtMTE5NDgy_f7bdb96c-e4b1-485d-b646-d61173edb497"
      unitRef="usd">1800000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzItNy0xLTEtMTE5NDgy_26fafe26-c948-4999-bafb-8073673346f2"
      unitRef="usd">1000000.0</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzMtMS0xLTEtMTE5NDgy_d7135b41-1fce-4926-9ad8-81be84300c53"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzMtMy0xLTEtMTE5NDgy_5205b386-4937-4e3d-8d14-1d38b8344a8c"
      unitRef="usd">4400000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzMtNS0xLTEtMTE5NDgy_2ae8339b-b0d1-437d-b965-08f6bef8706f"
      unitRef="usd">5200000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzMtNy0xLTEtMTE5NDgy_ff0d851c-13cb-4653-8449-1dc38e4fa8f8"
      unitRef="usd">9500000</us-gaap:InterestPaidNet>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzQtMS0xLTEtMTE5NDgy_eb050973-a8dc-40a9-9beb-0b817853e59a"
      unitRef="usd">0</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzQtMy0xLTEtMTE5NDgy_9ce88cb8-c5dd-499e-b8f8-c02a134ff8e9"
      unitRef="usd">90000000.0</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzQtNS0xLTEtMTE5NDgy_9a99f300-87aa-470b-820c-f3c4a1c0367a"
      unitRef="usd">0</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzQtNy0xLTEtMTE5NDgy_e2bc1272-1baa-431a-a8a3-7cc4a313c338"
      unitRef="usd">0</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzctMS0xLTEtMTE5NDgy_82c9a9d7-3734-4884-9c8f-d884e41adbae"
      unitRef="usd">46900000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzctMy0xLTEtMTE5NDgy_15e1c3ce-f150-4348-a8ce-a4f9b3e57753"
      unitRef="usd">41800000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzctNS0xLTEtMTE5NDgy_e27e3b88-ee03-4ae4-b327-bc1d24da5a2b"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzctNy0xLTEtMTE5NDgy_728827a7-7458-4c4e-a901-0ee49762c920"
      unitRef="usd">74500000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <mygn:OperatingLeaseLiabilityEstablished
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzgtMS0xLTEtMTE5NDgy_7782f3a9-705e-4533-8ff8-1221f656c4d1"
      unitRef="usd">46900000</mygn:OperatingLeaseLiabilityEstablished>
    <mygn:OperatingLeaseLiabilityEstablished
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzgtMy0xLTEtMTE5NDgy_3545ae74-42b4-439f-b72e-8e77ef19a942"
      unitRef="usd">48100000</mygn:OperatingLeaseLiabilityEstablished>
    <mygn:OperatingLeaseLiabilityEstablished
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzgtNS0xLTEtMTE5NDgy_4a8c4f68-962e-41c4-8c4b-38a3c6becb7a"
      unitRef="usd">0</mygn:OperatingLeaseLiabilityEstablished>
    <mygn:OperatingLeaseLiabilityEstablished
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzgtNy0xLTEtMTE5NDgy_8f1d7a80-ea76-45aa-99f4-c6d47945336e"
      unitRef="usd">78800000</mygn:OperatingLeaseLiabilityEstablished>
    <mygn:TenantImprovementAllowanceNotYetReceived
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzktMS0xLTEtMTMzMzk2_3a8eaf65-f369-44f5-8440-56c539338bb0"
      unitRef="usd">22900000</mygn:TenantImprovementAllowanceNotYetReceived>
    <mygn:TenantImprovementAllowanceNotYetReceived
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzktMy0xLTEtMTMzNDA0_ceeddabc-6b53-4c47-bd55-277f6bad4906"
      unitRef="usd">0</mygn:TenantImprovementAllowanceNotYetReceived>
    <mygn:TenantImprovementAllowanceNotYetReceived
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzktNS0xLTEtMTMzNDEy_8ff060db-8bf2-4d09-a639-65d748755521"
      unitRef="usd">0</mygn:TenantImprovementAllowanceNotYetReceived>
    <mygn:TenantImprovementAllowanceNotYetReceived
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzktNy0xLTEtMTMzNDIw_b91fa1be-9a9c-400d-88bc-5a4e16e51b54"
      unitRef="usd">0</mygn:TenantImprovementAllowanceNotYetReceived>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzEwLTEtMS0xLTEzMzM5Ng_fbeca70a-6c77-47ab-878c-2ad3e401840f"
      unitRef="usd">10000000.0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzEwLTMtMS0xLTEzMzQwNA_21eaaf6e-df9e-4a93-927b-96d23ede0e97"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzEwLTUtMS0xLTEzMzQxMg_d54ab61b-3023-4325-89e1-af2b58b92372"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzEwLTctMS0xLTEzMzQyMA_441dcb0b-5396-4d52-a94d-7fbc0a93bcba"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <mygn:LeaseRelatedExpendituresIncurredButNotYetPaid
      contextRef="iedfe917262044462b9e1ce9927a372cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzktMS0xLTEtMTE5NDgy_a193b642-cf07-40e0-be37-c2e7dfa9930e"
      unitRef="usd">0</mygn:LeaseRelatedExpendituresIncurredButNotYetPaid>
    <mygn:LeaseRelatedExpendituresIncurredButNotYetPaid
      contextRef="ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzktMy0xLTEtMTE5NDgy_6540a3e2-5985-49ba-885d-5b211b93e04f"
      unitRef="usd">0</mygn:LeaseRelatedExpendituresIncurredButNotYetPaid>
    <mygn:LeaseRelatedExpendituresIncurredButNotYetPaid
      contextRef="i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzktNS0xLTEtMTE5NDgy_a842de92-06b1-4035-99ba-bf5ca5b3626d"
      unitRef="usd">0</mygn:LeaseRelatedExpendituresIncurredButNotYetPaid>
    <mygn:LeaseRelatedExpendituresIncurredButNotYetPaid
      contextRef="i41fe705e06544ea8b5e1a828cfe5dbad_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlMDc5MzA5MGNmODQyMjc5NDQyNzdkNDYwZDM5YTRkL3NlYzo3ZTA3OTMwOTBjZjg0MjI3OTQ0Mjc3ZDQ2MGQzOWE0ZF8xNDgvZnJhZzpjZTk3YzVkMmRjOGY0ZDE0YmU1M2EzZGFmOTYzNmE5OS90YWJsZTozMTllODBiNjJlODg0MzkxYmM0Nzk3NDZjMTliOGFkNC90YWJsZXJhbmdlOjMxOWU4MGI2MmU4ODQzOTFiYzQ3OTc0NmMxOWI4YWQ0XzktNy0xLTEtMTE5NDgy_cbd81926-8f42-470b-b149-15005817d118"
      unitRef="usd">4300000</mygn:LeaseRelatedExpendituresIncurredButNotYetPaid>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>111
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "M#858'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  K0V%6!TH1!NX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)OITW10^CVLN))07!!\18FL[O!I@W)2+MO;QIWNX@^@)!+9OY\
M\PVD1:]P#/0<1D^!+<6;V?5#5.@WXLCL%4#$(SD=RY084G,_!J<Y7<,!O,8/
M?2"0574'CE@;S1H68.%7HNA:@PH#:1[#&6]PQ?O/T&>80:">' T<H2YK$-TR
MT9_FOH4K8($Q!1>_"V168J[^B<T=$.?D'.V:FJ:IG)J<2SO4\/;T^)+7+>P0
M60](Z56TBD^>-N(R^;79WN\>1"<KV115.O6N;I2\595\7UQ_^%V%W6CLWOYC
MXXM@U\*O?]%] 5!+ P04    "  K0V%6F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M "M#8596VB@VY@<  ,TO   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9K]<Z(X&,?_E8RW<[<[4RLO:FVO=<9BN^=NV_5J]W9Z-_=#A*A,@;@A].6_
MOR>@()T0X2;VAXK \R7YF(3G"\_Y"V5/\8H0CE[#((HO6BO.UV>=3NRN2(CC
M8[HF$1Q94!9B#E_9LA.O&<%>&A0&'<LP^IT0^U%K>)[NF[+A.4UXX$=DRE"<
MA"%F;Y<DH"\7+;.UW7'O+U=<[.@,S]=X26:$?U]/&7SKY"J>'Y(H]FF$&%E<
MM$;FV=@^$0'I&7_YY"7>V4:B*W-*G\27B7?1,D2+2$!<+B0P?#P3AP2!4()V
M_-R(MO)KBL#=[:WZ==IYZ,P<Q\2AP0_?XZN+UJ"%/++ 2<#OZ<L?9-.AGM!S
M:1"G_]%+=FZWVT)N$G,:;H*A!:$?99_X=0-B)V!@5 18FP#K78!9=05[$V"_
M#^A5!'0W =V43-:5E,,8<SP\9_0%,7$VJ(F-%&8:#=WW(_&[SSB#HS[$\:%#
MGPE#;?1]-D8?/WPZ[W 0%8<Z[D;@,A.P*@1,"]W2B*]B=!5YQ"L+=* U>9.L
M;9,N+:7BF+C'R#:/D&58EJ1!CCK\FLR/D66GX;8D?*P._Y)$<'5#=O52;^P<
ML)WJV4K _XSF,6<PR/^5$<X4NG(%,?//XC5VR44+IG9,V#-I#7_]Q>P;O\OH
MZ!0;:Q(KD>OFY+HJ]>&8N@FL,!P]O*V)#)LZW#3:7V5\E%%-^6@2*_'IY7QZ
M]?B,HBC! ;HG:\JX#)1:A[-$AM=11C4%I4FL!*J?@^K7 S4ES*>>6*@0+);2
M,;5':;LT5:Y-ROBFT#2)E:"=Y-!.E%UU$L8$LVL_=F%P/1+,E.#4:NVV:;5M
M4T9,&=B4F":Q$K%!3FQ0<[UB&/*B-*VIGI-JK04.8NFD5(8UI:5)K$3K-*=U
MJNSA5<1]_@;#*R#H+@GGA,DHJ36,MM7O=Z7S4!G8E),FL1(GTR@R-*,.J7NR
M]$4. 0/L#H?2.;A'Z/;Q?C(:H\]7=U</$V=VA"9WSK$,GEJG*3U=:F5\.PFN
M60??)'(I@\F(Q;P\0C,.ZQBB##DTB3A[@T]/SE2M/KZ2 E0&-0:H2:T,T"H
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MW<Y'>TNZ[A2U@:KTU;E1:&O=3PO;7$$[![N_50J/ACN@:=?)7U!+ P04
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M1WY<?R@*;OK+L"5-!V#,:Y33-8<MZFR8.;A,4KM[XK0#V@SDN:BC<^2G,Y1
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M*T9!O#& WQ="Z*<+\XYI_TYQ_B]02P,$%     @ *T-A5HC %A#- @  BPD
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M'N7N"]3SZ5N]1')=_I-=%3L<."39:"/S&L81Y$Q43_I<KT,+"*(C0%@#X:E
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MQGB8B#'AB:9'"F6W<G=*]V)<>EH2S]/<F\53-V2RE>VXFMFW\@$K3]?LOE4
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MV<1&2.=J=Q(4CV12\3@IFC\I6C 56C\?K7@D:O%X%^;Q&KV-4Q2)GAEFG<2
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M^K/$3A64-<#_*RG-\\ NT/6^T^]02P,$%     @ *T-A5BU!L!FK!@  W2X
M !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6S-6FUOVS80_BN$5VP-4-L2
M9<MREQA8;0GK@&Y%LFX?AGU@)"86JA=7HI/TW^\HJY(HTHR$$NV^)))]]QQY
MSY&\._/R,2\^EGM*&7I*DZR\FNP9.[R>S\MP3U-2SO(#S>";N[Q("8/7XGY>
M'@I*HDHI3>;8LMQY2N)LLKFL/GM?;"[S(TOBC+XO4'E,4U)\?D.3_/%J8D^^
M?' =W^\9_V"^N3R0>WI#V8?#^P+>Y@U*%*<T*^,\0P6]NYK\8K\.\(HK5!)_
MQ?2Q[#PC/I7;//_(7]Y&5Q.+CX@F-&0<@L"_![JE2<*18!R?:M!)8Y,K=I^_
MH ?5Y&$RMZ2DVSSY.X[8_FKB35!$[\@Q8=?YXZ^TGM"2XX5Y4E9_T6,M:TU0
M>"Q9GM;*,((TSD[_R5/MB(Z"[9Q1P+4"'JK@U I.3P%<J598U J+GH)S3F%9
M*RQ["HMSDW9K!;?R_<E9E:=WA)'-99$_HH)+ QI_J.BJM,'!<<8CZX85\&T,
M>FRSS;,R3^*(,!JA&P;_(&Q8B?([>,O#C_L\B6A1_H3\3\>8?493].%FAUZ^
MN$ O4)RA=W&20("4EW,&@^&0\[ V_.9D&)\Q_&?.2*)0V^K5MGF:0D"6?&P*
M[9U>^Y<HBGE DP0=2!Q-808A.<3JD?C/8(7A,3TFE>-RMJ<%"O,45O>>+[L'
MBI*\5+DET*->4P;; 4!24F1Q=E^BEZ1C"-9,',;L0@2> ^D-\[AA'E>6%F<L
MO:'W<<9-P,I,2!921!CZ[9C-D&.]0MBRURI23YBK"I/O6@\;V_*\&<@^=$F4
MQ:S92I39G626 I3KB4*^##1=SA:B4" +X>7,;80$]SB->YQ*RSGCGK=9"#MU
M2='+'3T]7?" 5RZ*?Z[S)$&PTSV2(OI7Y39'1P4_/5Z7!Q+2JPD$4$F+!SK9
M_/B#[5H_JU:(2;"=23#?)%A@"$Q@?]&PO] NCK=E>:S6!.R#86?+0<<,F#\]
M3_F)%E6K'I8\J0[* ZRD\A7*("4 S7)/8&B(/H5[DMV#+&0"L+^S/0\@OO(8
M>5)%RVEL7B>>G7[,;[7C'QL$ PSZ)@T&AL $;I<-MTLMMS<=\@[D,S_O@"+.
M(561L91\ YL+[K&AM3B6C2$6?9,6 T-@ AUN0X>KI>-W6"MGSLHWKN2)J;U>
MSY8][VL-C/6^23#?)%CPK#<$_Z\:_Z^T_K^F84+*,H;$XK2'0?W!-R\R(+]!
MQP,HP)>0F(1-)EF!  "4*[=E',50L:C(74G3L69VCUGMT,<R:Q+,'S#ZP)!!
M@5:OH=73TOJ'@K(X@W?(:#AU%\TI=>80\@;0HQW"6'I,@OD#1A\8,BC0LV[H
M66OI\;/H?.J-+14A:VE*:]N33B)92LZ\91G;6KN=C/GD0UEL*IU#@4+(7CF=
M@D!PCVVU=:GU#?/OVIBA!-PHVLXHFF\4+3"%)@9!ISEA_X_3\'IP8FQ+I:Y"
M2MIJ=K60VX7J9W1Z7XQFSA":R%S;7+#UW86127:-)FQ)"]G56INCU]T0F[Y1
MFX$I-)&5MJ=A:XMF;:Y=JXK;O2,=^7H+HSDPVGXPBA8\ZQ"1A+:U8.M["U^=
MF=ERN8[EM6*T06 4S1\R@<"429&EMDE@Z[L$<H(&>0@D:/;Y!*U&[&[RGB>M
M'[FZMV9>_[B0A6Q(T?J%KZ^0F^*9T_>D/*XIQJLS<=S6[;;[+3,TDZ7RUBC:
MSBB:;Q0M,(4F!D';/+#UW8/OG*')5;AG]>-_JY_"Z& 88M,W:C,PA2:2W+82
M;'TO86PR)Q??CBLU[?0V1[,RQ*9OU&9@"DUDI>T@V/H6@C:94Y3E>"4U"_06
M1G-@$LTWBA8\ZQ#Q-]2V38&U%?#7)W,U?N\([R4$6_THQA)E%,T?-(/ E$V1
MI[:3@/6=!'TZ9RN9D0O[M;N2J5'5__V$3B%D8^Q*QX9";KJ4&I<J*;Q<G(WF
MSI4 _ U3.FRR=-X:1=L91?.-H@6FT,0@:)L$6-\D^+XI'594W0LII=-/870P
M#+'I&[49F$(326Z;$%C?A!B9TF'%#0%/Z@WI;8YF98A-WZC-P!2:R$K;=,#Z
MIH,NI<.**MZV^QF=WL!H"DRB^4;1@N?\(5+0=C6P_CK"UR=TBI_I'3EK,-J@
M,(KF#YI!8,JFR%/;>,#ZQH,^H<-*9DZ(W7N"GK>4J9'%% F=+&1C5_KAQU?(
M3:7KDH%*RG%=*:&;=R[Z\HO?[TAQ'V<E2N@=*%JS%:R)XG27^O3"\D-U]_<V
M9RQ/J\<])7",<P'X_B[/V9<7?IVXN=&^^0]02P,$%     @ *T-A5M91?)\Y
M"@  %S,  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6RMFVUSVS82Q[\*
M1M>Y26<BB02IIYSM&4>D4]\TCB=.TM<P"5FX4*1*0G;<3W\+DA9%[A)R6N5%
MK(<_EMK% OAA09X]9?GW8BVE9C\V25J<#]9:;]^-QT6TEAM1C+*M3.&;599O
MA(:W^<.XV.92Q&6C33+FCC,=;X1*!Q=GY6>W^<59MM.)2N5MSHK=9B/RY_<R
MR9[.!^[@Y8//ZF&MS0?CB[.M>)!W4G_=WN;P;KRW$JN-3 N5I2R7J_/!I?LN
M]'W3H%1\4_*I.'C-C"OW6?;=O+F.SP>.^44RD9$V)@3\>91+F23&$OR./VNC
M@_TU3</#UR_6KTKGP9E[4<AEEORA8KT^'\P'+)8KL4OTY^SI-UD[-#'VHBPI
MRO_94ZUU!BS:%3K;U(WA%VQ46OT5/^I '#0 .W0#7C?@W0;3G@9>W<#K-O![
M&OAU _^U#29U@]+U<>5[&;A :'%QEF=/+#=JL&9>E-$O6T.\5&H2Y4[G\*V"
M=OIBF:5%EJA8:!FS.PU_( MTP;(56XIBS:X@DPHV9%_O O;FEU_9+TRE[*-*
M$NCEXFRLX2<80^.HOMS[ZG*\YW)3]C%+];I@81K+F&B_M+=WN<7 &'S?!X"_
M!. ]MUH,9#1BGON6<8<[U ]Z?7-.- ]>W]PEFH?VYO_=I=#<H7Y\*QC>/AN\
MTI[7EPV7=[^QJ]\__7''KCY_^L@^W8:?+[]<WWQ@E\LOU]^NOUR'=^^H7J_,
M^K19,]F]*[8BDN<#F,T*F3_*P<6__^5.G?]0$3^EL>"4QL(3&6OUC;_O&]]F
M_>(&5HTD*PHFM,[5_4Z+^T0RG;&/S[D2,?L@4ZE55+QEURDD%<P<T?=UEL0R
M)\=I=;%9>3&SFCQ>#"?>"'+P\; K*M7D4.6ZO"T*"%-\-NJH0D+E+A:CR5[6
MBLID'Y6)-6,OX__!)%G-61"+7$99&BD(3/H2+OC4O([,;+;-LT<%\P:[?V:P
MUN9"J_2A6JR45K(@<WMRRMP^I;'@E,;"$QEK]>)TWXM3:VX'$HQ&2E3LD,9,
M;+)<J[_*#Z@^J<S-#Y+)FXSFG>3%H@D?S3K)BT53WK445J+I@6C&Z;R=[3V>
MV4=SE@[+E%2IEA!0S>0/@+]"4M[.T&]T1G['6:QQD:^49M)QE;I6SQB=[WV=
MO\[71 +2V1R=X\Y CF*-BSTE1+A7YZA7'=K1Q=[1A=71+S(5J69J8^:9$J28
M2 "@1!I),S5)8&(*>MXO++^D\AHKW(X[P5$CH4W1<MAU&GQTK"[?F65F:% ]
M9E&V,3U;C6)++]<F6[WCCQ8=CPF5-^\N4 &EFHZ\CN.$BD]&/4/8/6!G]\BT
MM9)Y#IZK%'R'Q5C\D#04N^CZOM]=(9>$:N@YW;0-2!GO1B:D9)/#2;+M-&^<
MYE:GOZ9FD7U(U5_@.'C,[@$\5DK3CG/T(V8(,@C1T,4]3:CX:-KU&JL.9X>V
MSPT6NU:R.YBM-[ &:K,[@CTZ;$)3V*-!!J31,].Y@-POM[]T*#PT^H8H$ECC
M=,-P5!):)>T(-/#IVNGS=X-2,*Q5^@C36I8_DR[Z1^>QXY*@EK17@>XR9;73
M]K%!2=?*.!?7T+DJ+Z=MZ."'+(N?8*-;\DB2I0_#Q$S?3!2%[$GVR7'W)S@]
MI]VI+Z!4:/4B1(#3?:G>D)AK1[$/ C;XT-&% (B&,-SO"E" ST4%9OW>8TA"
MWA^5!(1DZ$Z[>PE2U>-Y0V3NS+[Y78OT =P$_RLOJYY7XEXE_;L#U\IY/[L]
M.*FUX*36PE-9:W=/ Y&NG2)O<PG#,WX!BZIW,KV6>3T':UMR8B#$FUU"Y'87
MF( 0#:=X&<(JWKOT-GCI'N'+7,02MJM1MC/[W8HH31F ='E!K)<NPFE*YCI=
M@@HHV7PT=P[_(0+!O#GUZ1CP!CBY'3BO;0L0)S@/818A I#HSL&$"B5#>$34
M=K'!2F['RI=,[\5)3J"=Z\Q1WQ(Z!VV5"-%\,5K8.I9H CC=,P'SABRYG2P_
ME8.Y?Q!SD@"]KM.$RL'=2Z@\W+_\M93!&Y;D=I:\?!F^6_'<-W9K$QTB1HE,
MJ+PN*06$:C%R%ZU_7;>IRSM];,$;B.1VB 37\YULK:FD]Q@ H0>1]X1JCH(4
M$++II#L(0D+EC_KFJ@8HN1TH]_O#7,*DM:.[&F,<Y2Q&RR'J:,(2QTL3(?/Z
M^[;A1F[GQANJQOIF5Y2[XU_):BL9#ER/&\Z\;G\M*9GKH(U_0.C<.0X)403L
M#TD#E/P(4'9.4ZYOOH5WKSE-X2=ERI-:"TYJ+3R5M78/-4S)[4RY%%NE15(Q
M9:ST+N_)2@+Z9JAB1:G\"<Y)7'<<=HMY(67+=?I*5KQ!2&Y'R,OHSYTJ5%FE
M>%L>C, >KQRWPGR3T_5)?KQ R0E G*!3H."XI= J:1]K-M3HV:GQ-L\B*>."
MK?)L@_:V1W:VM6V;]\<E@4=4*F<+5+8C9$#M7D\ &J;TCC#E+H_6PFR;P.^-
MR+_+ZOS0U'.J\S-62-A']4[,M7UK$$@L]5 .D#I_ABH<E&[J]&VCO(8S/3MG
MMI-A(W3M=ID&)C?^?I P57H3-$\0*I?/<9BP;(K*HJ&'$76ZZ(G0P6T 1^J=
M]L6\BL?QQ=S#A4C>/:3S"-:<S1#%$C(^\[L[GI"0N8O>T=. J^?_U$I^=7US
M>;-\S7T15B#^Z1LC3FDM.*FU\%36VCW4H+9G1^WVF(ZRS<;4,,WA%%-%838=
MNS2&W671=UZU301=M_=>48Q=$B(,HX1H@>NZU/6\WA1N^-RS\_FM>'ZI;)M#
MFR>EUVN9Q.8<X[3A(LC<P_$B^1T5VT@9/K.F9(O>XE0[@ W->_83^X, 1EEJ
M9C_S#EX6,$'F550.3L:$KHBJ8BTR4OBH'79^W:)DK6K1(DHLPI*'#D%I5=]:
MT3"T9V?H*VE6SJ+(S/T;X+C)+',+J4I%&IDU @(&^]\L>31O(B!,I=E*1*8
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M."W3Z@: Z6U8IHX()-NW!-.2B%A9&;)L"$*!ABD\5P33K$E9T-",:&*":F/
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MXGYR)(][,J;6J4OA!#Q]8;3P9#6?2]AFA+0GE2GDMGW#UE,XBY6@@F('N1V
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M2Q/P/C?&=P^T07]+?/(74$L#!!0    ( "M#85;HJL6(E (  ,H%   9
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M5V-G<7OO2^TT873H*FXTX5BF4N*04AIA(%G3HC)E"^\>_>'7\I[EFK]TFU:
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M.NW).G%]9I2AWBA1Z(C!\\DY.J3TX%@TK>?\%H<>BF&MVY6RI?6IWU KJLD
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M% R$2_B",SS?$>0A+P7IUR+(QXZMVL 1:4!8OH/1$H@C9^#\5E1$WJ@VXAL
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MY$U?6#WO&7)FT2D\FDW^Q,^N"$ VHV(-*2/!'8U&:Y>QLF2)V9L[(M7@&NL
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M^$@;'@J;\X?1A2W0$O#/M4(+X&@#UI<6@3,^T 7UE_*+_P%02P,$%     @
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MLG35]H\9?=N@=@8TOU#*;EY<@/IK:?PW4$L#!!0    ( "M#858#@."AM ,
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M[?#\-*BR76^L*GQGF2M+?<HO,_HQ0.T$Z/M2*5MOG('F5V/X-U!+ P04
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MBZ6T->PE"%*#9H,^R (?R!BE I](HFMF?CK"UE-<F,]5O:EI]**D+0 Z!#K
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MCUTS@&5XN'MQ-L8O7UA^^6*<PRE/H0_O'$\98I:_<ZA ^T;&1L8?,J,U6$A
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M[<Y?XLFCXWYFF=_/UH2^.+F86 6']*IKFRE IMRUS<G6I$UY3!,WR;%._M#
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M8*E8\3*S=^KQ!U$%%*.]1&6&CNRQZNL-6%(:J_)J,"#(9>%:_KE*Q&L&!-6
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MA0;*B45PF!CV'01CA@R8(_*ET,2>'\M"L- [84=@(Y=9!M&88R(5'GP\>.Y
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M@MK7F'9^E$: ^ M!=[H\& ?5?Q'C?P%02P,$%     @ *T-A5F6YLEVE!
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M:\R8]F2.@G:64F7,T%2MNCI7R!)'E*7=T/>C;L:XZ$S';NU23<>R,"D7>*E
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M<'N^8?_D8Z=8YLS@I1(_>6GK:7 <0(D5ZX2]4\O/N(YGY/@*)8S_PK*WS;(
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MK>F_@=H9T'FEE-TLG(/A3S3["U!+ P04    "  K0V%6'EEL$X<"  ##!0
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M2V=:U:!=-+&YA2_5HTD<E^Y2[JVF74XXFWZS!6JX5G+[886ZA&O.UEQPR]'
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MFXL([STB_\35.CWRR]$/^DY,NP[H?/_IX\E1T.ZQ9Q*_ T8ZN;I^=R.N,M>
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MQ)3<KZC)#\6_.%(8.0TU/BM.Z_>$[+2G!\<Q'S-1'<9\--C7QFBE39,NB4=
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MV)GM4/CW.SMI5J32+Q>_W#WW7'S/33=*/YD2T<)+):29!:6U]20,359BQ<Q
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MARIBB)R1!S'/Q4PD+-?D.DGD.M<BGY,[F8E$\()\)+\PI9CQ-#F)N68B*S[
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M&:>'4,*DQ]D6<(U6:KIATF78RF!,=6%-)%>C6/%D\ITO(,7_8)YF.@.3O,(
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M)6'OA@1^X-L<>CD\L,#CE\-[%OC\.OS33B#<MSE_%HRP2:FPY LO\,TR*C9
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M!XFP)XEO(3&#1F(&@(>)0?MXKZ.JVT9=50VJ+J'0#B2Z1V]"Z!==;C%_I(5
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M:YPQ_20.OY*2T(WQ%PNF\E]T*&T]!\69TB(MP1!!2GGQC[^70M0 47@&$)2
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M2Z0Q@.]K(?1Q8":H&N3I?U!+ P04    "  K0V%6)8Z^U <#  #_"P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6RU5EU/VS 4_2M6AB:0(-]-6]9&
M&NVF(<%4@=@>ICV8Y+:U<.)@.RW\^]E)" D-'6QM'UK;N>?TW.-KYX[6C-^)
M)8!$#PE-Q=A82IF=6I:(EI!@8;(,4O5DSGB"I9KRA24R#C@N0 FU7-L.K 23
MU A'Q=J,AR.62TI2F'$D\B3!_/$,*%N/#<=X6K@BBZ74"U8XRO "KD'>9#.N
M9E;-$I,$4D%8BCC,Q\9GYW3B%( BX@>!M6B,D4[EEK$[/3F/QX:M%0&%2&H*
MK'Y6, %*-9/2<5^1&O5_:F!S_,3^M4A>)7.+!4P8_4EBN1P; P/%,,<YE5=L
M_0VJA'J:+V)4%-]H7<7:!HIR(5E2@96"A*3E+WZHC&@ '/\5@%L!W+<"O K@
M%8F6RHJTIECB<,39&G$=K=CTH/"F0*ML2*JW\5IR]90HG QG7%4$EX_':$9Q
M*A%.8_3E/B>9VBIYC+ZK0CI!9U@]BT"@PRE(3*@X4HLWUU-T>'"$#A!)T26A
M5.V*&%E2B=+45E0)."L%N*\(F$)D(L\Y1J[MNAWPR=OA3AMN*2MJ/]S:#[?@
M\_[%#_3K0H6C<PF)^-V5:LGM=W/K$WDJ,AS!V%!'3@!?@1%^_. $]J>NQ'=$
MUK+!JVWPMK$W;,AJ&^"Y+!:<B<Z]+EG[!:N^05:A,W3-8&2MFIEU1/5LTZ^C
M6I+]6K*_5?(%"*%NA2A/<HHEQ.HP*V,B@O5UT:6UI!LT5)PX]M!T7XCM# O,
M8;?:7JVV]S\&IR"[)/<VM P\T[<;'^>%^DV$[YF];NU!K3WXB]/JWEPR&B.2
M9)RM0&ON+(>M/.\]#SLB:Z7<KU/N[_%:Z._2AAV1M6P8U#8,]G(M##:J,.B;
MPVUU6R*"!L(;=%?ML-8^W*J]WJXN@5NA[]VA'9&ULG3LYQ>ZO<=2K<AWY,2N
MV-I6-'H;9R_E6M&V7E"N;_9?U&A7F.-NO,>L1G>F6^-+S!<D%8C"7.%LLZ_N
M:%YVF^5$LJQHV&Z95.U?,5RJ#AVX#E#/YXS)IXGN >N>/_P#4$L#!!0    (
M "M#859$%%8)[ (  -T)   9    >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM
M;+5646_:,!#^*U9639W$" 0*K .D IV&5"K4JMO#M >3',2J8Z>V ^V_W]D)
M*500K1-[2>R+[_-]G^_BZV^D>M0Q@"'/"1=ZX,7&I)>^K\,8$JKK,@6!7Y92
M)=3@5*U\G2J@D7-*N!\T&AT_H4QXP[ZSS=6P+S/#F8"Y(CI+$JI>1L#E9N U
MO:WACJUB8PW^L)_2%=R#>4CG"F=^B1*Q!(1F4A %RX%WU;P<]^QZM^ '@XW>
M&1/+9"'EHYU,HX'7L $!A]!8!(JO-8R!<PN$83P5F%ZYI77<'6_1OSGNR&5!
M-8PE_\DB$P^\GD<B6-*,FSNY^0X%GPN+%TJNW9-LBK4-CX29-C(IG#&"A(G\
M39\+'78<FITC#D'A$+QU:!]Q:!4.+4<TC\S1FE!#AWTE-T39U8AF!TX;YXUL
MF+"G>&\4?F7H9X9SA0FAS$N-S#D5AE 1D>NGC*5X4J9&;C&//I-;JA2U<I/S
M"1C*N/Z$UH?["3D_^T3."!-DQCC'8]%]WV!4%ML/BPA&>03!D0B: 9E)86)-
MKD4$T3Z CW1*3L&6TRBH1)Q 6">M9HT$C2 X$-#X[]V;%>&T2HE;#J]]!&_V
MHAB-R-UH5B-3@=A6X\)XE1G)DB030!:91D=]4,'*#6RA7^J4AC#PL)(UJ#5X
MPX\?FIW&UT/L3P2VIT6[U*+MT%O_DF[DUPTN)U,#B?Y]2(;V*64X$=B>#!>E
M#!>5*?$J0UK* *4,6O+(F2((L:0D9Q$U;RLC5Z1RF_<JDH-U'9C]^Z^'K3H6
MP/H T4Y)M%-)] ;P%QM;/BQ)E5R#)7@PQ2MQWLOD1&![E+LEY>Y_3/'N*64X
M$=B>#+U2AE[ER4^3E#+E.(<Q52LXQ+9W(..^E!F7DZC<YKTD_)V;,@&,RC80
MFH0R$R:_8$IKV:-<N:OYC7V$O4O>:KS"Y(W/#,DRH0F')4(VZETL*Y4W$_G$
MR-3=QPMI\'9WPQC[+U!V 7Y?2FFV$[M!V=$-_P!02P,$%     @ *T-A5M??
M5@NB @  T@<  !D   !X;"]W;W)K<VAE971S+W-H965T-3DN>&ULK55M3]LP
M$/XK5H8FD%CSTA<FUD:"IA.;Q%2!V#Y,^^ FU\;"L8/MM/#O=W;2T+)0H8DO
MB<]^GL=WY[-OO)'J7N< ACP67.B)EQM3GON^3G,HJ.[)$@2N+*4JJ$%3K7Q=
M*J"9(Q7<CX)@Y!>4"2\>N[FYBL>R,IP)F"NBJZ*@ZND2N-Q,O-#;3MRP56[L
MA!^/2[J"6S!WY5RAY;<J&2M :"8%4;"<>!?A^6Q@\0[PD\%&[XR)C60AY;TU
MOF43+[ . 8?46 6*OS5,@7,KA&X\-)I>NZ4E[HZWZE]=[!C+@FJ82OZ+92:?
M>)\]DL&25MS<R,T5-/$,K5XJN79?LFFP@4?22AM9-&3TH&"B_M/')@\[!-3I
M)D0-(7I)&+U"Z#>$_DO"X!7"H"$,WDH8-@07NE_'[A*74$/CL9(;HBP:U>S
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M)8/>&3JDZ@Y2&T:6[HE<2(,/KAOFV'1!60"N+Z4T6\-NT+;Q^"]02P,$%
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MHS88_E<L=IIZTC5@DT#2)9'2=+M5NDY5N^XT3?O@@I.@ L[93G+=7S\;"(1
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M(,M26P)4$3 '#8ZZ53;(/:^/PL)B0*V,-Q+:#&I85EK4&QWG6C?N;;&%A2F
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M8DH.5T1J&5,#Y/T%I6)_HB;(=RZG_P-02P,$%     @ *T-A5N,&GUBK @
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M!@&'W%@%BI\U3(!S*X1F_&XTO?9(2]P=;]4_.]_1EQG5,)'\!RM,.?+./%+
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M#M4,J&9"-0NJV;4V8%[D0#MVH9J'TKK#05OG)HL+W;XDJ\Q_2,B:4O*.IWC
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MID$U':H94,V$:A94LZ&: ]5<J.:AM.[XT-;%*=C+N2G0.CBHID(U#:KI4,V
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M'<^J)RS=E;>0NDL92^/RX9;Z*YH5#?CWUVG*GIX4'33WG5O^"U!+ P04
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M>B& YDD"R8]G%./]7#.U0\&G:!LR4: O9AG<HC5BG[,7PL_TFA)$"4IIA%-
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M'64]S/%7!2AK@.^74IKMQ&[0_4Z9_@]02P,$%     @ *T-A5M[<_E4$"0
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M<IAB2PK2!.#SI1!Z/S$O:)K<\!]02P,$%     @ *T-A5D$>=D_^ P  )1$
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M65X#U/,-8_*UH3OHOHPL_P=02P,$%     @ *T-A5A$%:_3U @  FPD  !D
M  !X;"]W;W)K<VAE971S+W-H965T-SDN>&ULK59=;]HP%/TK5E9-K;3FF] R
MB#0(TSJM4E76[=DD%XB:V,PVT/W[V4[(0G"C/I0'8COG'-]S[=AW?*#LF6\
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M1E9/P!1 OE]1*HX=-4%3C\7_ %!+ P04    "  K0V%63":,@7$'   7*
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M!<-6^X6]4_!.T>YV="2S@GR5YNA>,@I8/ZQ.1@$0)L 1 Y6V34,UPI\UUBD
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MZJ0X7"HY5UE^@_O^1FO[<))74&YKG_X/4$L#!!0    ( "M#85;_BUJ$UP,
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M1/A9UPN!&:LOP;;0V@PWM"K\,8:CF,_I1CZ$9#'M*E16 &%C6+I#=^1W%M7
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M \IW4\=W]H8[LBF4,;AQ5.$-K$#=5TNA=VZGDI$2F"2<(0'YU+GQKQ>AP5O
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M"\( ]/><<[7?F .Z*1[_ U!+ P04    "  K0V%6U:.:PBX"  "U!   &0
M 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX;6R%5-N.TS 0_17+2 @DV+3I!532
M2.T6Q#[LJFH%/" >G&2:6.O8P9XTNW^/+VDH4K>\Q!Y[SIDSDQDGG=*/I@)
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M=T!"$,9 O]]RKAYOS)FS_(]A\1]02P,$%     @ *T-A5I'BKQ@N!@  42T
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M>GZW>J-%7CZ@>BNT2:;ERQTS$SII=S"?;X30]V_L ,U3U*O_ 5!+ P04
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MV7Z%L>=+7I<WFKD_[DF3*$G=!I9Y7]=G]MQU>Z5XM=FMOMEI__XG4$L#!!0
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M4$L! A0#%     @ *T-A5@=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  K0V%6!TH1!NX    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M"  K0V%6F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( "M#8596VB@VY@<  ,TO   8
M      " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M"  K0V%6L<'(N#L"  "Z!0  &               @($I$   >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ *T-A5GGQS_.4!@  7QP  !@
M             ("!FA(  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( "M#85:(P!80S0(  (L)   8              " @609  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  K0V%6XXSY1'('  #_
M*   &               @(%G'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ *T-A5@1M]7V) P  !PL  !@              ("!#R0
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( "M#858M0; 9
MJP8  -TN   8              " @<XG  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    "  K0V%6UE%\GSD*   7,P  &
M@(&O+@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ *T-A
M5M.SX30>*0  !H4  !@              ("!'CD  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( "M#85:G?2\PX00  ,8,   9
M      " @7)B  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ *T-A5N\\>^>."   =!8  !D              ("!BF<  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  K0V%6,NR,NS@$  #,"0
M&0              @(%/<   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( "M#85:KJ2_$JP@  #89   9              " @;YT  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ *T-A5HTT?I4'
M P  E 8  !D              ("!H'T  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    "  K0V%6@F?J&Q8(   Q%@  &0
M@('>@   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( "M#
M85;HJL6(E (  ,H%   9              " @2N)  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ *T-A5@Z\OLFB!   = L  !D
M         ("!]HL  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    "  K0V%6M/LF?X,,  #Q)0  &0              @('/D   >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( "M#859S0*LD.@T  #\D
M   9              " @8F=  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ *T-A5DD;,W<8#@  P"H  !D              ("!^JH
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  K0V%6":U[
ME' '  !;%   &0              @(%)N0  >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( "M#858Q8A%62 ,  $X'   9
M  " @?#   !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
M*T-A5C1]BH\4!0  ^ H  !D              ("!;\0  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    "  K0V%6@&33PY@+   U'P  &0
M            @(&ZR0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( "M#85:6.\0@UP0  #D-   9              " @8G5  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ *T-A5@. X*&T P
M=@@  !D              ("!E]H  'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    "  K0V%6]8,&'P@J  ";C@  &0              @(&"
MW@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( "M#858J
MEY==- @  (D;   9              " @<$( 0!X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ *T-A5F1\9\EP!   40P  !D
M     ("!+!$! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M"  K0V%69;FR7:4$   G#   &0              @('3%0$ >&PO=V]R:W-H
M965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( "M#858N5NQ0%0,  "T'   9
M              " @:\: 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L!
M A0#%     @ *T-A5N2<YO2_!   !A   !D              ("!^QT! 'AL
M+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  K0V%6*L&GY@ #
M  "5!@  &0              @('Q(@$ >&PO=V]R:W-H965T<R]S:&5E=#,S
M+GAM;%!+ 0(4 Q0    ( "M#858>66P3AP(  ,,%   9              "
M@2@F 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ *T-A
M5DGIY0;M @  J08  !D              ("!YB@! 'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    "  K0V%6SPVP [,&   )%0  &0
M        @($*+ $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( "M#8585>/]WE D  (4;   9              " @?0R 0!X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ *T-A5E_<&$7U @  D08
M !D              ("!OSP! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    "  K0V%6 /+TZ*4"  #/!0  &0              @('K/P$
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( "M#85;#GV\(
M!P,  'T&   9              " @<=" 0!X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ *T-A5M]<]$6D P  B @  !D
M ("!!48! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  K
M0V%6XZE!IND"  !4!@  &0              @('@20$ >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( "M#85;>(]VRG@,  &@(   9
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M 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ *T-A5G.
M*MCE"@  5',  !D              ("!06,! 'AL+W=O<FMS:&5E=',O<VAE
M970T-RYX;6Q02P$"% ,4    "  K0V%6<HFC$(\#  "["P  &0
M    @(%=;@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (
M "M#858/ID)'> ,  (,+   9              " @2-R 0!X;"]W;W)K<VAE
M971S+W-H965T-#DN>&UL4$L! A0#%     @ *T-A5L[4A>^7 @  & 8  !D
M             ("!TG4! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"
M% ,4    "  K0V%6@$M??OD&  #,.@  &0              @(&@> $ >&PO
M=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( "M#858'X7L[^P0
M ,TC   9              " @=!_ 0!X;"]W;W)K<VAE971S+W-H965T-3(N
M>&UL4$L! A0#%     @ *T-A5CNUASIJ P  5PP  !D              ("!
M H4! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    "  K0V%6
MQ['<C*\"  #4!P  &0              @(&CB $ >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;%!+ 0(4 Q0    ( "M#85:/L*DL0 @  /E1   9
M      " @8F+ 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%
M  @ *T-A5OXV_O,P!   + \  !D              ("! )0! 'AL+W=O<FMS
M:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    "  K0V%6)8Z^U <#  #_"P
M&0              @(%GF $ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+
M 0(4 Q0    ( "M#859$%%8)[ (  -T)   9              " @:6; 0!X
M;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ *T-A5M??5@NB
M @  T@<  !D              ("!R)X! 'AL+W=O<FMS:&5E=',O<VAE970U
M.2YX;6Q02P$"% ,4    "  K0V%6AZJ@YZ<"  !6!@  &0
M@(&AH0$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( "M#
M859YI<;(G0<  -M5   9              " @7^D 0!X;"]W;W)K<VAE971S
M+W-H965T-C$N>&UL4$L! A0#%     @ *T-A5O.?,>H'!0  Q1P  !D
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M=#8V+GAM;%!+ 0(4 Q0    ( "M#85;%[U+K<@(  $X&   9
M  " @>?# 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @
M*T-A5@SUJ&I<!   W1H  !D              ("!D,8! 'AL+W=O<FMS:&5E
M=',O<VAE970V."YX;6Q02P$"% ,4    "  K0V%6S]?]")(#  "S#   &0
M            @($CRP$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4
M Q0    ( "M#85;>W/Y5! D  /=4   9              " @>S. 0!X;"]W
M;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ *T-A5G=5#0W% P
MY0\  !D              ("!)]@! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX
M;6Q02P$"% ,4    "  K0V%6PP/5WR@$  "'%@  &0              @($C
MW $ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( "M#85;R
M5#_@+@0  .,8   9              " @8+@ 0!X;"]W;W)K<VAE971S+W-H
M965T-S,N>&UL4$L! A0#%     @ *T-A5I_'2$ER @  T08  !D
M     ("!Y^0! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "M#8581!6OT]0(  )L)   9              "
M@3CU 0!X;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ *T-A
M5DPFC(%Q!P  %R@  !D              ("!9/@! 'AL+W=O<FMS:&5E=',O
M<VAE970X,"YX;6Q02P$"% ,4    "  K0V%6'J-;IE $   '$   &0
M        @($,  ( >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0
M   ( "M#859W<0*8V0(  /<)   9              " @9,$ @!X;"]W;W)K
M<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @ *T-A5L OU1D!!@  XBX
M !D              ("!HP<" 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q0
M2P$"% ,4    "  K0V%6_XM:A-<#  "X#@  &0              @(';#0(
M>&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    ( "M#859M/&,P
M,0(  .($   9              " @>D1 @!X;"]W;W)K<VAE971S+W-H965T
M.#4N>&UL4$L! A0#%     @ *T-A5G(UK9=)!@  TRH  !D
M ("!410" 'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6Q02P$"% ,4    "  K
M0V%6B8NRA'(#  #5#0  &0              @('1&@( >&PO=V]R:W-H965T
M<R]S:&5E=#@W+GAM;%!+ 0(4 Q0    ( "M#85;=P_VT90(  (X%   9
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M970Y,BYX;6Q02P$"% ,4    "  K0V%67WF$-0X%  !2(   &0
M    @(&V, ( >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;%!+ 0(4 Q0    (
M "M#859IG:SQE0(  '4&   9              " @?LU @!X;"]W;W)K<VAE
M971S+W-H965T.30N>&UL4$L! A0#%     @ *T-A5OV[?SWI!0  FS,  !D
M             ("!QS@" 'AL+W=O<FMS:&5E=',O<VAE970Y-2YX;6Q02P$"
M% ,4    "  K0V%6.[1)W^D$  "H)0  &0              @('G/@( >&PO
M=V]R:W-H965T<R]S:&5E=#DV+GAM;%!+ 0(4 Q0    ( "M#85;+;NX** 0
M '<0   9              " @0=$ @!X;"]W;W)K<VAE971S+W-H965T.3<N
M>&UL4$L! A0#%     @ *T-A5D4OC.@T P  R!,   T              ( !
M9D@" 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  K0V%6EXJ[',     3 @
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8;6Q02P4&     &D :0#6'   _U@"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>352</ContextCount>
  <ElementCount>493</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>80</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Marketable Investment Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/MarketableInvestmentSecurities</Role>
      <ShortName>Marketable Investment Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Property, Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PropertyPlantandEquipmentNet</Role>
      <ShortName>Property, Plant and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Other Long-Term Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OtherLongTermLiabilities</Role>
      <ShortName>Other Long-Term Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Preferred and Common Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquity</Role>
      <ShortName>Preferred and Common Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Employee Deferred Savings Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/EmployeeDeferredSavingsPlan</Role>
      <ShortName>Employee Deferred Savings Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Segment and Related Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SegmentandRelatedInformation</Role>
      <ShortName>Segment and Related Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Business Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/BusinessAcquisition</Role>
      <ShortName>Business Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/Divestitures</Role>
      <ShortName>Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Supplemental Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>Supplemental Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Marketable Investment Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/MarketableInvestmentSecuritiesTables</Role>
      <ShortName>Marketable Investment Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/MarketableInvestmentSecurities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/FairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Property, Plant and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PropertyPlantandEquipmentNetTables</Role>
      <ShortName>Property, Plant and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/PropertyPlantandEquipmentNet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/AccruedLiabilities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Other Long-Term Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OtherLongTermLiabilitiesTables</Role>
      <ShortName>Other Long-Term Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/OtherLongTermLiabilities</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Preferred and Common Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables</Role>
      <ShortName>Preferred and Common Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/PreferredandCommonStockholdersEquity</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/StockBasedCompensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/IncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/Leases</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Employee Deferred Savings Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/EmployeeDeferredSavingsPlanTables</Role>
      <ShortName>Employee Deferred Savings Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/EmployeeDeferredSavingsPlan</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Segment and Related Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SegmentandRelatedInformationTables</Role>
      <ShortName>Segment and Related Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/SegmentandRelatedInformation</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Business Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/BusinessAcquisitionTables</Role>
      <ShortName>Business Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/BusinessAcquisition</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Divestitures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/DivestituresTables</Role>
      <ShortName>Divestitures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/Divestitures</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Supplemental Cash Flow Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SupplementalCashFlowInformationTables</Role>
      <ShortName>Supplemental Cash Flow Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.myriad.com/role/SupplementalCashFlowInformation</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Organization and Summary of Significant Accounting Policies - Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRestrictedCashDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Organization and Summary of Significant Accounting Policies - Revenue by Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Revenue by Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Organization and Summary of Significant Accounting Policies - Revenue by Geographical Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Revenue by Geographical Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Organization and Summary of Significant Accounting Policies - Reconciliation of Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Reconciliation of Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Organization and Summary of Significant Accounting Policies - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Organization and Summary of Significant Accounting Policies - Foreign Currency Cumulative Translation Adjustments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesForeignCurrencyCumulativeTranslationAdjustmentsDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Foreign Currency Cumulative Translation Adjustments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails</Role>
      <ShortName>Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Marketable Investment Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails</Role>
      <ShortName>Marketable Investment Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails</Role>
      <ShortName>Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Property, Plant and Equipment, Net - Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails</Role>
      <ShortName>Property, Plant and Equipment, Net - Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Property, Plant and Equipment, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails</Role>
      <ShortName>Property, Plant and Equipment, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Property, Plant and Equipment, Net - Depreciation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails</Role>
      <ShortName>Property, Plant and Equipment, Net - Depreciation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Goodwill and Intangible Assets - Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Long Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/LongTermDebtDetails</Role>
      <ShortName>Long Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Other Long-Term Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/OtherLongTermLiabilitiesDetails</Role>
      <ShortName>Other Long-Term Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/OtherLongTermLiabilitiesTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Preferred and Common Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails</Role>
      <ShortName>Preferred and Common Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Preferred and Common Stockholders' Equity - Shares of Common Stock Issued and Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/PreferredandCommonStockholdersEquitySharesofCommonStockIssuedandOutstandingDetails</Role>
      <ShortName>Preferred and Common Stockholders' Equity - Shares of Common Stock Issued and Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Stock-Based Compensation - Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Stock-Based Compensation - Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Stock-Based Compensation - Aggregate Intrinsic Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails</Role>
      <ShortName>Stock-Based Compensation - Aggregate Intrinsic Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Stock-Based Compensation - Intrinsic Value of Options Exercised (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationIntrinsicValueofOptionsExercisedDetails</Role>
      <ShortName>Stock-Based Compensation - Intrinsic Value of Options Exercised (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Stock-Based Compensation - Shares Purchased and Compensation Expenses for ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails</Role>
      <ShortName>Stock-Based Compensation - Shares Purchased and Compensation Expenses for ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Stock-Based Compensation - Valuation Assumptions for ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails</Role>
      <ShortName>Stock-Based Compensation - Valuation Assumptions for ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Income Taxes - Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Income Taxes - Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Income Taxes - Statutory Federal Income Tax Rate and Income Taxes Reported (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails</Role>
      <ShortName>Income Taxes - Statutory Federal Income Tax Rate and Income Taxes Reported (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Income Taxes - Net Operating Loss and Research Credit Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Net Operating Loss and Research Credit Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/CommitmentsandContingencies</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Employee Deferred Savings Plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/EmployeeDeferredSavingsPlanNarrativeDetails</Role>
      <ShortName>Employee Deferred Savings Plan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - Employee Deferred Savings Plan - Contributions to Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/EmployeeDeferredSavingsPlanContributionstoPlanDetails</Role>
      <ShortName>Employee Deferred Savings Plan - Contributions to Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - Segment and Related Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails</Role>
      <ShortName>Segment and Related Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - Segment and Related Information - Assets by Geographical Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails</Role>
      <ShortName>Segment and Related Information - Assets by Geographical Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - Business Acquisition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails</Role>
      <ShortName>Business Acquisition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - Business Acquisition - Schedule of Estimated Fair Value of Identified Assets acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Business Acquisition - Schedule of Estimated Fair Value of Identified Assets acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - Business Acquisition - Schedule of Pro Forma Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/BusinessAcquisitionScheduleofProFormaInformationDetails</Role>
      <ShortName>Business Acquisition - Schedule of Pro Forma Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - Divestitures - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/DivestituresNarrativeDetails</Role>
      <ShortName>Divestitures - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0000096 - Disclosure - Divestitures - Other Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/DivestituresOtherIncomeDetails</Role>
      <ShortName>Divestitures - Other Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="mygn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>0000097 - Disclosure - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.myriad.com/role/SupplementalCashFlowInformationDetails</Role>
      <ShortName>Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.myriad.com/role/SupplementalCashFlowInformationTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:LesseeOperatingLeaseRemainingLeaseTerm, us-gaap:NumberOfReportableSegments, us-gaap:PropertyPlantAndEquipmentUsefulLife -  mygn-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="mygn-20221231.htm">mygn-20221231.htm</File>
    <File>mygn-20221231.xsd</File>
    <File>mygn-20221231_cal.xml</File>
    <File>mygn-20221231_def.xml</File>
    <File>mygn-20221231_lab.xml</File>
    <File>mygn-20221231_pre.xml</File>
    <File>mygn-20221231ex211.htm</File>
    <File>mygn-20221231xexx231.htm</File>
    <File>mygn-20221231xexx311.htm</File>
    <File>mygn-20221231xexx312.htm</File>
    <File>mygn-20221231xexx32.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mygn-20221231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1386">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>117
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mygn-20221231.htm": {
   "axisCustom": 1,
   "axisStandard": 33,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 1386,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 352,
   "dts": {
    "calculationLink": {
     "local": [
      "mygn-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mygn-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mygn-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mygn-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mygn-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mygn-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 745,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 4,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 8
   },
   "keyCustom": 52,
   "keyStandard": 441,
   "memberCustom": 29,
   "memberStandard": 51,
   "nsprefix": "mygn",
   "nsuri": "http://www.myriad.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.myriad.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Marketable Investment Securities",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.myriad.com/role/MarketableInvestmentSecurities",
     "shortName": "Marketable Investment Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.myriad.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Property, Plant and Equipment, Net",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNet",
     "shortName": "Property, Plant and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Goodwill and Intangible Assets",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Accrued Liabilities",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.myriad.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Long-Term Debt",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.myriad.com/role/LongTermDebt",
     "shortName": "Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Other Long-Term Liabilities",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.myriad.com/role/OtherLongTermLiabilities",
     "shortName": "Other Long-Term Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Preferred and Common Stockholders' Equity",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquity",
     "shortName": "Preferred and Common Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.myriad.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.myriad.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.myriad.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.myriad.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.myriad.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Employee Deferred Savings Plan",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.myriad.com/role/EmployeeDeferredSavingsPlan",
     "shortName": "Employee Deferred Savings Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Segment and Related Information",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.myriad.com/role/SegmentandRelatedInformation",
     "shortName": "Segment and Related Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Business Acquisition",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.myriad.com/role/BusinessAcquisition",
     "shortName": "Business Acquisition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Divestitures",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.myriad.com/role/Divestitures",
     "shortName": "Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Supplemental Cash Flow Information",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.myriad.com/role/SupplementalCashFlowInformation",
     "shortName": "Supplemental Cash Flow Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "27",
     "role": "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Organization and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Marketable Investment Securities (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.myriad.com/role/MarketableInvestmentSecuritiesTables",
     "shortName": "Marketable Investment Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.myriad.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.myriad.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Property, Plant and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNetTables",
     "shortName": "Property, Plant and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Accrued Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.myriad.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Other Long-Term Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.myriad.com/role/OtherLongTermLiabilitiesTables",
     "shortName": "Other Long-Term Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Preferred and Common Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables",
     "shortName": "Preferred and Common Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.myriad.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.myriad.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.myriad.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Employee Deferred Savings Plan (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.myriad.com/role/EmployeeDeferredSavingsPlanTables",
     "shortName": "Employee Deferred Savings Plan (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.myriad.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Segment and Related Information (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.myriad.com/role/SegmentandRelatedInformationTables",
     "shortName": "Segment and Related Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Business Acquisition (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.myriad.com/role/BusinessAcquisitionTables",
     "shortName": "Business Acquisition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Divestitures (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.myriad.com/role/DivestituresTables",
     "shortName": "Divestitures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Supplemental Cash Flow Information (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.myriad.com/role/SupplementalCashFlowInformationTables",
     "shortName": "Supplemental Cash Flow Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "id83f26d989d54298a0d5f2d84eba7095_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Organization and Summary of Significant Accounting Policies - Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRestrictedCashDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Organization and Summary of Significant Accounting Policies - Revenue by Type (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Revenue by Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Organization and Summary of Significant Accounting Policies - Revenue by Geographical Region (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Revenue by Geographical Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i35dea8de7d5247b6af91e476fc730262_D20200701-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ideeefc606008446e85d0fd21a9515813_I20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Organization and Summary of Significant Accounting Policies - Reconciliation of Deferred Revenue (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Reconciliation of Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mygn:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Organization and Summary of Significant Accounting Policies - Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i29d9f082f6304b3c901b8a69a382c99f_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Organization and Summary of Significant Accounting Policies - Foreign Currency Cumulative Translation Adjustments (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesForeignCurrencyCumulativeTranslationAdjustmentsDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Foreign Currency Cumulative Translation Adjustments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i29d9f082f6304b3c901b8a69a382c99f_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails",
     "shortName": "Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
     "shortName": "Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Marketable Investment Securities - Narrative (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails",
     "shortName": "Marketable Investment Securities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i823a913a8ad749ad8b995c1f537650c7_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i823a913a8ad749ad8b995c1f537650c7_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mygn:BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
     "shortName": "Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ideeefc606008446e85d0fd21a9515813_I20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails",
     "shortName": "Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "if96afdd71e74449aa558f9c0f8968925_I20190630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Property, Plant and Equipment, Net - Balances (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails",
     "shortName": "Property, Plant and Equipment, Net - Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i2ed990c23f164e939a73f7223c4d3011_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisposals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Property, Plant and Equipment, Net - Narrative (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails",
     "shortName": "Property, Plant and Equipment, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i2ed990c23f164e939a73f7223c4d3011_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisposals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Property, Plant and Equipment, Net - Depreciation Expense (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails",
     "shortName": "Property, Plant and Equipment, Net - Depreciation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i29d9f082f6304b3c901b8a69a382c99f_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Goodwill and Intangible Assets - Future Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails",
     "shortName": "Goodwill and Intangible Assets - Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.myriad.com/role/AccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLinesOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Long Term Debt (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.myriad.com/role/LongTermDebtDetails",
     "shortName": "Long Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Other Long-Term Liabilities (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails",
     "shortName": "Other Long-Term Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Preferred and Common Stockholders' Equity - Narrative (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails",
     "shortName": "Preferred and Common Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ideeefc606008446e85d0fd21a9515813_I20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Preferred and Common Stockholders' Equity - Shares of Common Stock Issued and Outstanding (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquitySharesofCommonStockIssuedandOutstandingDetails",
     "shortName": "Preferred and Common Stockholders' Equity - Shares of Common Stock Issued and Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "if96afdd71e74449aa558f9c0f8968925_I20190630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "if96afdd71e74449aa558f9c0f8968925_I20190630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i29d9f082f6304b3c901b8a69a382c99f_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Stock-Based Compensation - Stock Options Activity (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i29d9f082f6304b3c901b8a69a382c99f_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ie26285660df14abb951924a100df85e5_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Stock-Based Compensation - Restricted Stock Units Activity (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "id5d419cf4013469c83dd80d51c5ee579_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i2868dacc9996425d84f6678061f8071d_D20200701-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mygn:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Stock-Based Compensation - Aggregate Intrinsic Value (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails",
     "shortName": "Stock-Based Compensation - Aggregate Intrinsic Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mygn:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Stock-Based Compensation - Intrinsic Value of Options Exercised (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.myriad.com/role/StockBasedCompensationIntrinsicValueofOptionsExercisedDetails",
     "shortName": "Stock-Based Compensation - Intrinsic Value of Options Exercised (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0f908585f461487aa148598b903a4f33_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Stock-Based Compensation - Shares Purchased and Compensation Expenses for ESPP (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails",
     "shortName": "Stock-Based Compensation - Shares Purchased and Compensation Expenses for ESPP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0f908585f461487aa148598b903a4f33_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0f908585f461487aa148598b903a4f33_D20200701-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Stock-Based Compensation - Valuation Assumptions for ESPP (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails",
     "shortName": "Stock-Based Compensation - Valuation Assumptions for ESPP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0f908585f461487aa148598b903a4f33_D20200701-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Income Taxes - Income Tax Benefit (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails",
     "shortName": "Income Taxes - Income Tax Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Income Taxes - Loss Before Income Taxes (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.myriad.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails",
     "shortName": "Income Taxes - Loss Before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Income Taxes - Statutory Federal Income Tax Rate and Income Taxes Reported (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails",
     "shortName": "Income Taxes - Statutory Federal Income Tax Rate and Income Taxes Reported (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "mygn:ValuationAllowanceIncreaseDecreaseDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.myriad.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "mygn:ValuationAllowanceIncreaseDecreaseDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ibc16948f5d7e4bd8969f02b7c60c2fc4_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Income Taxes - Net Operating Loss and Research Credit Carryforwards (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails",
     "shortName": "Income Taxes - Net Operating Loss and Research Credit Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ibc16948f5d7e4bd8969f02b7c60c2fc4_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ideeefc606008446e85d0fd21a9515813_I20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i78b35c2904e342a2a22d1151ef8b25d8_D20201221-20201221",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPatentsAllegedlyInfringedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.myriad.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i78b35c2904e342a2a22d1151ef8b25d8_D20201221-20201221",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPatentsAllegedlyInfringedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.myriad.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Employee Deferred Savings Plan - Narrative (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.myriad.com/role/EmployeeDeferredSavingsPlanNarrativeDetails",
     "shortName": "Employee Deferred Savings Plan - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DefinedContributionPlanDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - Employee Deferred Savings Plan - Contributions to Plan (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.myriad.com/role/EmployeeDeferredSavingsPlanContributionstoPlanDetails",
     "shortName": "Employee Deferred Savings Plan - Contributions to Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DefinedContributionPlanDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "iedfe917262044462b9e1ce9927a372cc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - Segment and Related Information - Narrative (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails",
     "shortName": "Segment and Related Information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - Segment and Related Information - Assets by Geographical Region (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails",
     "shortName": "Segment and Related Information - Assets by Geographical Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - Business Acquisition - Narrative (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails",
     "shortName": "Business Acquisition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i871418f253134efc9cceceeafbb4c291_D20221101-20221101",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ifb254f1abbe54bc896976a7ef3e19442_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - Business Acquisition - Schedule of Estimated Fair Value of Identified Assets acquired and Liabilities Assumed (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails",
     "shortName": "Business Acquisition - Schedule of Estimated Fair Value of Identified Assets acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i8ef3dc9ee255434a9ee4f9ac735c9aba_I20221101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i7a2ff25d850940a7bc40bed0d8065631_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - Business Acquisition - Schedule of Pro Forma Information (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://www.myriad.com/role/BusinessAcquisitionScheduleofProFormaInformationDetails",
     "shortName": "Business Acquisition - Schedule of Pro Forma Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i7a2ff25d850940a7bc40bed0d8065631_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFirmPurchaseCommitmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - Divestitures - Narrative (Details)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://www.myriad.com/role/DivestituresNarrativeDetails",
     "shortName": "Divestitures - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "ia68997c1c35b433b8f9ebc3d8a32eccb_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFirmPurchaseCommitmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000096 - Disclosure - Divestitures - Other Income (Details)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://www.myriad.com/role/DivestituresOtherIncomeDetails",
     "shortName": "Divestitures - Other Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i7b99a13c827f4f10ad3b6af0f22ddd25_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mygn:DisposalGroupNotDiscontinuedOperationGainLossOnInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000097 - Disclosure - Supplemental Cash Flow Information (Details)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://www.myriad.com/role/SupplementalCashFlowInformationDetails",
     "shortName": "Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mygn-20221231.htm",
      "contextRef": "i0cc2515a3c2a40d48164835d5b8e33e0_D20200701-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 80,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r775",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r775",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r775",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "verboseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r775",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "verboseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "verboseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r775",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.myriad.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mygn_AmendmentToCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to Credit Agreement [Member].",
        "label": "Amendment To Credit Agreement [Member]",
        "terseLabel": "Amended facility"
       }
      }
     },
     "localname": "AmendmentToCreditAgreementMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_AssetsLessCashCashEquivalentsAndInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets, Less Cash, Cash Equivalents, And Investments",
        "label": "Assets, Less Cash, Cash Equivalents, And Investments",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AssetsLessCashCashEquivalentsAndInvestments",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.myriad.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mygn_AutoimmuneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Autoimmune",
        "label": "Autoimmune [Member]",
        "terseLabel": "Autoimmune"
       }
      }
     },
     "localname": "AutoimmuneMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Warranty And Working Capital Adjustments",
        "label": "Business Combination, Consideration Transferred, Warranty And Working Capital Adjustments",
        "terseLabel": "Warranty and working capital adjustment"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredWarrantyAndWorkingCapitalAdjustments",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Liability, Measurement Input, Term",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input, Term",
        "terseLabel": "Measurement period for earn out liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mygn_BusinessCombinationIntangibleAssetsMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Intangible Assets, Measurement Input",
        "label": "Business Combination, Intangible Assets, Measurement Input",
        "terseLabel": "Estimated net cash flows discount rate"
       }
      }
     },
     "localname": "BusinessCombinationIntangibleAssetsMeasurementInput",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mygn_CARESActOf2020MedicarePaymentAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act of 2020 medicare payment amount.",
        "label": "CARES Act Of 2020 Medicare Payment Amount",
        "terseLabel": "Advance Medicare payments to provide relief from economic impacts of COVID-19"
       }
      }
     },
     "localname": "CARESActOf2020MedicarePaymentAmount",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_CARESActOf2020ProviderReliefFundAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act of 2020 Provider Relief Fund amount.",
        "label": "C A R E S Act Of2020 Provider Relief Fund Amount",
        "terseLabel": "Provider fund relief under CARES Act"
       }
      }
     },
     "localname": "CARESActOf2020ProviderReliefFundAmount",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_ChangeInContractWithCustomerLiabilityCurrentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract with Customer, Liability, Current",
        "label": "Change In Contract with Customer, Liability, Current [Roll Forward]",
        "terseLabel": "Change In Contract with Customer, Liability, Current [Roll Forward]"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityCurrentRollForward",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_ClinicReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinic Reporting Unit",
        "label": "Clinic Reporting Unit [Member]",
        "terseLabel": "Clinic reporting unit"
       }
      }
     },
     "localname": "ClinicReportingUnitMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration.",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Asset, Adjustment To Revenue For Expanded Coverage, Previously Constrained",
        "label": "Contract With Customer, Asset, Adjustment To Revenue For Expanded Coverage, Previously Constrained",
        "terseLabel": "Revenue recognized due to expanded local coverage determination for which revenue was previously constrained"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_ContractWithCustomerLiabilityDivestitures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Divestitures",
        "label": "Contract With Customer, Liability, Divestitures",
        "negatedTerseLabel": "Divestitures"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDivestitures",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Including New Contract, Revenue Recognized",
        "label": "Contract With Customer, Liability, Including New Contract, Revenue Recognized",
        "negatedLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_ContractWithCustomerLiabilityPrepayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer, liability, prepayments.",
        "label": "Contract With Customer Liability Prepayments",
        "terseLabel": "Prepayments"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityPrepayments",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_CostOfOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about the cost of pharmaceutical and clinical services expense have been included.",
        "label": "Cost Of Other Revenue [Member]",
        "terseLabel": "Cost of other revenue"
       }
      }
     },
     "localname": "CostOfOtherRevenueMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_CostOfTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about the cost of molecular diagnostic testing expense have been included.",
        "label": "Cost Of Testing [Member]",
        "terseLabel": "Cost of testing revenue"
       }
      }
     },
     "localname": "CostOfTestingMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_DebtCovenantLiquidityCovenantMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant, Liquidity Covenant Minimum",
        "label": "Debt Covenant, Liquidity Covenant Minimum",
        "terseLabel": "Minimum liquidity covenant"
       }
      }
     },
     "localname": "DebtCovenantLiquidityCovenantMinimum",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum",
        "label": "Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum",
        "terseLabel": "Minimum unrestricted cash and cash equivalents threshold per covenant"
       }
      }
     },
     "localname": "DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DebtInstrumentFloorPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Floor Percentage",
        "label": "Debt Instrument, Floor Percentage",
        "terseLabel": "SOFR floor (percent)"
       }
      }
     },
     "localname": "DebtInstrumentFloorPercentage",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mygn_DeferredTaxAssetResearchAndExperimentalExpenseCapitalization": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset, Research And Experimental Expense Capitalization",
        "label": "Deferred Tax Asset, Research And Experimental Expense Capitalization",
        "terseLabel": "Section 174 capitalized costs"
       }
      }
     },
     "localname": "DeferredTaxAssetResearchAndExperimentalExpenseCapitalization",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease right-of-use asset.",
        "label": "Deferred Tax Assets, Lease Liabilities",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DeferredTaxLiabilitiesLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax lease liability.",
        "label": "Deferred Tax Liabilities, Lease Right-Of-Use Assets",
        "terseLabel": "Lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeaseRightOfUseAssets",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DisposalGroupNotDiscontinuedOperationGainLossOnInventory": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Not Discontinued Operation, Gain (Loss) On Inventory",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) On Inventory",
        "terseLabel": "Loss on inventory"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnInventory",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DisposalGroupNotDiscontinuedOperationGainLossOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Not Discontinued Operation, Gain (Loss) Other",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOther",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_DisposalGroupNotDiscontinuedOperationTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Not Discontinued Operation, Transaction Costs",
        "label": "Disposal Group, Not Discontinued Operation, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationTransactionCosts",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_EarningsPerShareBasicAndDilutedEPSAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share, Basic And Diluted EPS",
        "label": "Earnings Per Share, Basic And Diluted EPS [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedEPSAbstract",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Acquisitions, Dispositions, And Contingent Consideration",
        "label": "Effective Income Tax Rate Reconciliation, Acquisitions, Dispositions, And Contingent Consideration",
        "terseLabel": "Acquisitions, dispositions, and contingent consideration"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAcquisitionsDispositionsAndContingentConsideration",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mygn_EffectiveIncomeTaxRateReconciliationAssetImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation asset impairment.",
        "label": "Effective Income Tax Rate Reconciliation Asset Impairment",
        "terseLabel": "Asset impairment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAssetImpairment",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mygn_EffectiveIncomeTaxRateReconciliationCARESAct": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation CARES Act",
        "label": "Effective Income Tax Rate Reconciliation CARES Act",
        "terseLabel": "CARES Act"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationCARESAct",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation non deductible legal settlements.",
        "label": "Effective Income Tax Rate Reconciliation Non Deductible Legal Settlements",
        "terseLabel": "Non-deductible legal settlement"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNonDeductibleLegalSettlements",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mygn_EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation non-deductible officer compensation.",
        "label": "Effective Income Tax Rate Reconciliation Non Deductible Officer Compensation",
        "terseLabel": "Non-deductible officer compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNonDeductibleOfficerCompensation",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mygn_EmployeeStockPurchasePlanTwentyTwelveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan Twenty Twelve [Member]",
        "label": "Employee Stock Purchase Plan Twenty Twelve [Member]",
        "terseLabel": "2012 Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanTwentyTwelveMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails",
      "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag",
        "label": "Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag",
        "terseLabel": "Fair value, recurring basis, unobservable input reconciliation, gain (loss), statement of income"
       }
      }
     },
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Disposition of Assets, Net Of Transaction Fees",
        "label": "Gain (Loss) On Disposition of Assets, Net Of Transaction Fees",
        "terseLabel": "Net gain on sale of assets adjusted for transaction fees"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssetsNetOfTransactionFees",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_GatewayGenomicsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gateway Genomics, LLC",
        "label": "Gateway Genomics, LLC [Member]",
        "terseLabel": "Gateway Genomics, LLC"
       }
      }
     },
     "localname": "GatewayGenomicsLLCMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails",
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofProFormaInformationDetails",
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_GoodwillAndIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets.",
        "label": "Goodwill And Intangible Assets [Line Items]",
        "terseLabel": "Goodwill And Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsLineItems",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_GoodwillAndIntangibleAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets.",
        "label": "Goodwill And Intangible Assets [Table]",
        "terseLabel": "Goodwill And Intangible Assets [Table]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsTable",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_HereditaryCancerTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular diagnostic hereditary cancer testing.",
        "label": "Hereditary Cancer Testing [Member]",
        "terseLabel": "Hereditary Cancer"
       }
      }
     },
     "localname": "HereditaryCancerTestingMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Reconciliation, Acquisitions, Dispositions, And Contingent Consideration",
        "label": "Income Tax Reconciliation, Acquisitions, Dispositions, And Contingent Consideration",
        "terseLabel": "Acquisitions, dispositions, and contingent consideration"
       }
      }
     },
     "localname": "IncomeTaxReconciliationAcquisitionsDispositionsAndContingentConsideration",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_IncomeTaxReconciliationAssetImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation asset impairment.",
        "label": "Income Tax Reconciliation Asset Impairment",
        "terseLabel": "Asset impairment"
       }
      }
     },
     "localname": "IncomeTaxReconciliationAssetImpairment",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_IncomeTaxReconciliationCARESAct": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Reconciliation CARES Act",
        "label": "Income Tax Reconciliation CARES Act",
        "terseLabel": "CARES Act"
       }
      }
     },
     "localname": "IncomeTaxReconciliationCARESAct",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_IncomeTaxReconciliationNonDeductibleLegalSettlement": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation non-deductible legal settlement.",
        "label": "Income Tax Reconciliation Non Deductible Legal Settlement",
        "terseLabel": "Non-deductible legal settlement"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNonDeductibleLegalSettlement",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation nondeductible expense officers compensation.",
        "label": "Income Tax Reconciliation Nondeductible Expense Officers Compensation",
        "terseLabel": "Non-deductible officer compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOfficersCompensation",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_IncreaseDecreaseInEarningsLossPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in earnings (loss) per share.",
        "label": "Increase Decrease In Earnings Loss Per Share",
        "terseLabel": "Change in earnings (loss) per share (in dollars per share)"
       }
      }
     },
     "localname": "IncreaseDecreaseInEarningsLossPerShare",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mygn_IncreaseDecreaseInUnrecognizedTaxBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in unrecognized tax benefits.",
        "label": "Increase Decrease In Unrecognized Tax Benefits",
        "negatedLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInUnrecognizedTaxBenefits",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_IntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets.",
        "label": "Intangible Assets [Line Items]",
        "terseLabel": "Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IntangibleAssetsLineItems",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 1.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments And Cash, Accumulated Gross Unrealized Gain, before Tax",
        "label": "Investments And Cash, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized holding gains"
       }
      }
     },
     "localname": "InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 2.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments And Cash, Accumulated Gross Unrealized Loss, before Tax",
        "label": "Investments And Cash, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross unrealized holding losses"
       }
      }
     },
     "localname": "InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_InvestmentsAndCashAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments And Cash, Amortized Cost",
        "label": "Investments And Cash, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "InvestmentsAndCashAmortizedCost",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_LeaseArrangementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangement",
        "label": "Lease Arrangement [Axis]",
        "terseLabel": "Lease Arrangement [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementAxis",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_LeaseArrangementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangement [Domain]",
        "label": "Lease Arrangement [Domain]",
        "terseLabel": "Lease Arrangement [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementDomain",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_LeaseRelatedExpendituresIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Related Expenditures Incurred But Not Yet Paid",
        "label": "Lease Related Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Accrued liabilities and other long-term liabilities"
       }
      }
     },
     "localname": "LeaseRelatedExpendituresIncurredButNotYetPaid",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_LineOfCreditFacilityCreditExposureThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Credit Exposure Threshold",
        "label": "Line Of Credit Facility, Credit Exposure Threshold",
        "terseLabel": "Line of credit facility, credit exposure threshold"
       }
      }
     },
     "localname": "LineOfCreditFacilityCreditExposureThreshold",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MyriadAutoimmuneAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Myriad Autoimmune Assets",
        "label": "Myriad Autoimmune Assets [Member]",
        "terseLabel": "Myriad Autoimmune Assets",
        "verboseLabel": "Loss on sale of Myriad Autoimmune assets"
       }
      }
     },
     "localname": "MyriadAutoimmuneAssetsMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MyriadAutoimmuneReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Myriad Autoimmune Reporting Unit",
        "label": "Myriad Autoimmune Reporting Unit [Member]",
        "terseLabel": "Myriad Autoimmune reporting unit"
       }
      }
     },
     "localname": "MyriadAutoimmuneReportingUnitMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MyriadMyPathLLCLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Myriad My Path LLC Laboratory",
        "label": "Myriad My Path LLC Laboratory [Member]",
        "terseLabel": "Myriad myPath LLC laboratory",
        "verboseLabel": "Gain on sale of the Myriad myPath, LLC laboratory"
       }
      }
     },
     "localname": "MyriadMyPathLLCLaboratoryMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MyriadRBMIncAndMyriadAutoimmuneBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Myriad RBM, Inc. And Myriad Autoimmune Business",
        "label": "Myriad RBM, Inc. And Myriad Autoimmune Business [Member]",
        "terseLabel": "Myriad RBM, Inc. and Myriad Autoimmune business"
       }
      }
     },
     "localname": "MyriadRBMIncAndMyriadAutoimmuneBusinessMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_MyriadRBMIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Myriad RBM, Inc",
        "label": "Myriad RBM, Inc [Member]",
        "terseLabel": "Myriad RBM, Inc.",
        "verboseLabel": "Gain on sale of Myriad RBM, Inc."
       }
      }
     },
     "localname": "MyriadRBMIncMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_NonCashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash interest expense.",
        "label": "Non Cash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpense",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_NonEmployeeDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non employee director.",
        "label": "Non Employee Director [Member]",
        "terseLabel": "Non-Employee Director"
       }
      }
     },
     "localname": "NonEmployeeDirectorMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_OperatingLeaseLiabilityEstablished": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liability Established",
        "label": "Operating Lease Liability Established",
        "negatedLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityEstablished",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_OperatingLeaseLiabilityIncludingLeasesNotYetCommenced": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Liability, Including Leases Not Yet Commenced",
        "label": "Operating Lease, Liability, Including Leases Not Yet Commenced",
        "terseLabel": "Present value of future lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityIncludingLeasesNotYetCommenced",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_OperatingLeaseLiabilityLeasesNotYetCommenced": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Liability, Leases Not Yet Commenced",
        "label": "Operating Lease, Liability, Leases Not Yet Commenced",
        "negatedTerseLabel": "Less: leases not yet commenced"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityLeasesNotYetCommenced",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiration Year",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss, expiration in year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "mygn_OptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options and Restricted Stock Units.",
        "label": "Options And Restricted Stock Units [Member]",
        "terseLabel": "Options and RSUs"
       }
      }
     },
     "localname": "OptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Table]",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_OtherIncomeExpensePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other income policy text block.",
        "label": "Other Income (Expense) Policy [Policy Text Block]",
        "terseLabel": "Other Income (Expense)"
       }
      }
     },
     "localname": "OtherIncomeExpensePolicyPolicyTextBlock",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mygn_OtherStateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other State.",
        "label": "Other State [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherStateMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_OtherTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular diagnostic other testing.",
        "label": "Other Testing [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherTestingMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_PerformanceObligationEstimatedTransactionPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Obligation Estimated Transaction Price",
        "label": "Performance Obligation Estimated Transaction Price [Member]",
        "terseLabel": "Performance Obligation Estimate"
       }
      }
     },
     "localname": "PerformanceObligationEstimatedTransactionPriceMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_PharmacogenomicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmacogenomics",
        "label": "Pharmacogenomics [Member]",
        "terseLabel": "Pharmacogenomics"
       }
      }
     },
     "localname": "PharmacogenomicsMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_PrenatalTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular diagnostic Prenatal testing.",
        "label": "Prenatal Testing [Member]",
        "terseLabel": "Prenatal"
       }
      }
     },
     "localname": "PrenatalTestingMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_RaygenIncVersusMyriadWomensHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Raygen, Inc Versus Myriad Women's Health, Inc.",
        "label": "Raygen, Inc Versus Myriad Women's Health, Inc. [Member]",
        "terseLabel": "Raygen, Inc Versus Myriad Women's Health, Inc."
       }
      }
     },
     "localname": "RaygenIncVersusMyriadWomensHealthIncMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification From Accumulated Other Comprehensive Loss, Deconsolidation Of Subsidiary",
        "label": "Reclassification From Accumulated Other Comprehensive Loss, Deconsolidation Of Subsidiary",
        "terseLabel": "Reclassification out of accumulated other comprehensive loss upon the deconsolidation of a subsidiary"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_RefundsPayableAndReserveCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refunds Payable And Reserve, Current",
        "label": "Refunds Payable And Reserve, Current",
        "terseLabel": "Refunds payable and reserves"
       }
      }
     },
     "localname": "RefundsPayableAndReserveCurrent",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_ScheduleOfIntangibleAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Intangible Assets [Table]",
        "label": "Schedule Of Intangible Assets [Table]",
        "terseLabel": "Schedule Of Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsTable",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mygn_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Share-Based Compensation Arrangement By Share-Based Payment Award, Aggregate Intrinsic Value",
        "label": "Schedule Of Share-Based Compensation Arrangement By Share-Based Payment Award, Aggregate Intrinsic Value [Table Text Block]",
        "terseLabel": "Schedule of Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueTableTextBlock",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mygn_SividonDiagnosticsGmbHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sividon Diagnostics GmbH",
        "label": "Sividon Diagnostics GmbH [Member]",
        "terseLabel": "Sividon Diagnostics GmbH"
       }
      }
     },
     "localname": "SividonDiagnosticsGmbHMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_SouthSanFranciscoCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "South San Francisco, California",
        "label": "South San Francisco, California [Member]",
        "terseLabel": "South San Francisco, California"
       }
      }
     },
     "localname": "SouthSanFranciscoCaliforniaMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans",
        "label": "Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans",
        "terseLabel": "Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquitySharesofCommonStockIssuedandOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mygn_TaxCreditCarryforwardsExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforwards Expiration Date",
        "label": "Tax Credit Carryforwards Expiration Date",
        "terseLabel": "Tax credit, expiration in year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardsExpirationDate",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "mygn_TenantImprovementAllowanceNotYetReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant Improvement Allowance Not Yet Received",
        "label": "Tenant Improvement Allowance Not Yet Received",
        "terseLabel": "Tenant improvement allowance not yet received"
       }
      }
     },
     "localname": "TenantImprovementAllowanceNotYetReceived",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_TestingRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molecular diagnostic testing.",
        "label": "Testing Revenue [Member]",
        "terseLabel": "Testing revenue"
       }
      }
     },
     "localname": "TestingRevenueMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_TumorProfilingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tumor Profiling",
        "label": "Tumor Profiling [Member]",
        "terseLabel": "Tumor Profiling"
       }
      }
     },
     "localname": "TumorProfilingMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand seventeen employee director and consultant equity incentive plan.",
        "label": "Two Thousand Seventeen Employee Director And Consultant Equity Incentive Plan [Member]",
        "terseLabel": "2017 Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mygn_UnrecognizedTaxBenefitsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Net",
        "label": "Unrecognized Tax Benefits, Net",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsNet",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_ValuationAllowanceIncreaseDecreaseDuringPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance, Increase (Decrease) During Period",
        "label": "Valuation Allowance, Increase (Decrease) During Period",
        "negatedTerseLabel": "Decrease in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceIncreaseDecreaseDuringPeriod",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mygn_WestSaltLakeCityLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "West Salt Lake City Lease",
        "label": "West Salt Lake City Lease [Member]",
        "terseLabel": "West Salt Lake City Lease"
       }
      }
     },
     "localname": "WestSaltLakeCityLeaseMember",
     "nsuri": "http://www.myriad.com/20221231",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "President and Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r311",
      "r348",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r364",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r437",
      "r439",
      "r441",
      "r442",
      "r829",
      "r830"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r311",
      "r348",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r364",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r437",
      "r439",
      "r441",
      "r442",
      "r829",
      "r830"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r370",
      "r750",
      "r833",
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r430",
      "r508",
      "r676",
      "r696",
      "r724",
      "r725",
      "r746",
      "r760",
      "r770",
      "r831",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails",
      "http://www.myriad.com/role/LeasesNarrativeDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r430",
      "r508",
      "r676",
      "r696",
      "r724",
      "r725",
      "r746",
      "r760",
      "r770",
      "r831",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails",
      "http://www.myriad.com/role/LeasesNarrativeDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r370",
      "r750",
      "r833",
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r366",
      "r679",
      "r748",
      "r768",
      "r826",
      "r827",
      "r833",
      "r900"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r366",
      "r679",
      "r748",
      "r768",
      "r826",
      "r827",
      "r833",
      "r900"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r430",
      "r501",
      "r508",
      "r538",
      "r539",
      "r540",
      "r652",
      "r676",
      "r696",
      "r724",
      "r725",
      "r746",
      "r760",
      "r770",
      "r822",
      "r831",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails",
      "http://www.myriad.com/role/LeasesNarrativeDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r430",
      "r501",
      "r508",
      "r538",
      "r539",
      "r540",
      "r652",
      "r676",
      "r696",
      "r724",
      "r725",
      "r746",
      "r760",
      "r770",
      "r822",
      "r831",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails",
      "http://www.myriad.com/role/LeasesNarrativeDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ReportableGeographicalComponentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reportable Geographical Components [Member]",
        "terseLabel": "Reportable geographical components"
       }
      }
     },
     "localname": "ReportableGeographicalComponentsMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r263",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r336",
      "r389",
      "r390",
      "r578",
      "r605",
      "r606",
      "r607",
      "r608",
      "r632",
      "r644",
      "r645",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r263",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r336",
      "r389",
      "r390",
      "r578",
      "r605",
      "r606",
      "r607",
      "r608",
      "r632",
      "r644",
      "r645",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": {
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r322",
      "r323",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Error Correction, Adjustment [Member]",
        "terseLabel": "Immaterial Prior Period Medicare Claims"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r367",
      "r368",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r749",
      "r769",
      "r833"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r367",
      "r368",
      "r708",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r749",
      "r769",
      "r833"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r801",
      "r887"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_UT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH",
        "terseLabel": "Utah"
       }
      }
     },
     "localname": "UT",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r25",
      "r767"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails",
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r30",
      "r731"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r130",
      "r271"
     ],
     "calculation": {
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r280",
      "r282",
      "r283",
      "r284",
      "r616"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesForeignCurrencyCumulativeTranslationAdjustmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r276",
      "r692",
      "r702",
      "r706"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r39",
      "r42",
      "r201",
      "r645",
      "r697",
      "r698",
      "r785",
      "r786",
      "r787",
      "r795",
      "r796",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Estimated useful lives (in years)"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r547",
      "r548",
      "r549",
      "r795",
      "r796",
      "r797",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r162",
      "r163",
      "r510"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based payment expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r67",
      "r113",
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive options and RSUs excluded from EPS computation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of real estate property"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r67",
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Goodwill and long-lived asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r224",
      "r243",
      "r275",
      "r307",
      "r352",
      "r356",
      "r362",
      "r387",
      "r431",
      "r432",
      "r434",
      "r435",
      "r436",
      "r438",
      "r440",
      "r442",
      "r443",
      "r597",
      "r601",
      "r617",
      "r767",
      "r829",
      "r830",
      "r888"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets",
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r266",
      "r279",
      "r307",
      "r387",
      "r431",
      "r432",
      "r434",
      "r435",
      "r436",
      "r438",
      "r440",
      "r442",
      "r443",
      "r597",
      "r601",
      "r617",
      "r767",
      "r829",
      "r830",
      "r888"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FairValueNetAssetLiability",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized holding gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross unrealized holding losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r378",
      "r396"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]",
        "terseLabel": "Available-for-sale:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 4.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Available-for-sale, Due after five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r100",
      "r381",
      "r690"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Available-for-sale, Due after five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Available-for-sale, Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r100",
      "r380",
      "r689"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Available-for-sale, Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]",
        "terseLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Available-for-sale, Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r100",
      "r379",
      "r688"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Available-for-sale, Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r97",
      "r377",
      "r396",
      "r683"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r513",
      "r514",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails",
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Financial Statement Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r592",
      "r758",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails",
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofProFormaInformationDetails",
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r180",
      "r181",
      "r592",
      "r758",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails",
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofProFormaInformationDetails",
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails",
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofProFormaInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r872",
      "r873"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r590",
      "r591"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r590",
      "r591"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition-related costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r189",
      "r190",
      "r193"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Business acquisition consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r188",
      "r191",
      "r595"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r188",
      "r192"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Short-term contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r188",
      "r192"
     ],
     "calculation": {
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r194",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "BUSINESS ACQUISITION"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "negatedLabel": "Business combination, pro forma information, loss of acquiree since acquisition date, actual"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Business combination, pro forma information, revenue of acquiree since acquisition date, actual"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Total identifiable assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedTerseLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
        "negatedTerseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r182",
      "r183"
     ],
     "calculation": {
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedTotalLabel": "Total liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r182",
      "r183"
     ],
     "calculation": {
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Net identifiable assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Total fair value of Purchase Price"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.",
        "label": "Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized",
        "terseLabel": "Business combination, separately recognized transactions, expenses and losses recognized"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value",
        "terseLabel": "Business acquisition, contingent cash fair value"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of California.",
        "label": "California Franchise Tax Board [Member]",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property, plant and equipment in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLossCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deductions derived from capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year.",
        "label": "Capital Loss Carryforward [Member]",
        "terseLabel": "Capital loss"
       }
      }
     },
     "localname": "CapitalLossCarryforwardMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAmortization1": {
     "auth_ref": [
      "r256",
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for amortization of capitalized computer software costs.",
        "label": "Capitalized Computer Software, Amortization",
        "terseLabel": "Amortization expense for capitalized software"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAmortization1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareNet": {
     "auth_ref": [
      "r726"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.",
        "label": "Capitalized Computer Software, Net",
        "terseLabel": "Unamortized software costs"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostGross": {
     "auth_ref": [
      "r807"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Gross",
        "terseLabel": "Capitalized costs incurred to obtain or fulfill contract"
       }
      }
     },
     "localname": "CapitalizedContractCostGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r69",
      "r269",
      "r728"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      },
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Amortized cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]",
        "terseLabel": "Cash and cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InvestmentsAndCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Estimated fair value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r70",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r784"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and marketable investment securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r63",
      "r69",
      "r75"
     ],
     "calculation": {
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of the period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of the period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r63",
      "r216"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]",
        "terseLabel": "Establishment of operating lease right-of-use assets and lease liabilities"
       }
      }
     },
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "SUPPLEMENTAL CASH FLOW INFORMATION"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r82",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r82",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Contract with Customer, Liability [Abstract]",
        "terseLabel": "Reconciliation of Deferred Revenue"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r35",
      "r231",
      "r251"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r135",
      "r424",
      "r425",
      "r711",
      "r828"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r795",
      "r796",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending common stock issued (in shares)",
        "periodStartLabel": "Beginning common stock issued (in shares)",
        "terseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquitySharesofCommonStockIssuedandOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending common stock outstanding (in shares)",
        "periodStartLabel": "Beginning common stock outstanding (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquitySharesofCommonStockIssuedandOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19",
      "r767"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value, 81.2 and 80.0 shares outstanding at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r146",
      "r147",
      "r149",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "EMPLOYEE DEFERRED SAVINGS PLAN"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/EmployeeDeferredSavingsPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r43",
      "r287",
      "r289",
      "r295",
      "r684",
      "r693"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r84",
      "r85",
      "r214",
      "r215",
      "r370",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r84",
      "r85",
      "r214",
      "r215",
      "r370",
      "r707",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r84",
      "r85",
      "r214",
      "r215",
      "r370",
      "r710",
      "r903"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r240",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r84",
      "r85",
      "r214",
      "r215",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk (in percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r84",
      "r85",
      "r214",
      "r215",
      "r370",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Reconciliation of Deferred Revenue Balances"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r747"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Revenue increase (decrease) due to changes in estimated transaction price due to contractual adjustments"
       }
      }
     },
     "localname": "ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r487",
      "r488",
      "r499"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "periodEndLabel": "Deferred revenue - ending balance",
        "periodStartLabel": "Deferred revenue - beginning balance",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r755",
      "r757",
      "r902"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds and notes",
        "verboseLabel": "Corporate bonds and notes"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r47",
      "r679"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Costs and expenses"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CumulativeTranslationAdjustmentSummaryRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Cumulative Translation Adjustment Summary [Roll Forward]",
        "terseLabel": "Cumulative Translation Adjustment Summary [Roll Forward]"
       }
      }
     },
     "localname": "CumulativeTranslationAdjustmentSummaryRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesForeignCurrencyCumulativeTranslationAdjustmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r794",
      "r868",
      "r870"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r794",
      "r868"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r174",
      "r574",
      "r582",
      "r794"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r794",
      "r868",
      "r870"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r138",
      "r305",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r460",
      "r467",
      "r468",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "LONG-TERM DEBT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r225",
      "r228",
      "r242",
      "r311",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r456",
      "r457",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r631",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r33",
      "r311",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r456",
      "r457",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r631",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r33",
      "r140",
      "r141",
      "r142",
      "r143",
      "r217",
      "r218",
      "r220",
      "r239",
      "r311",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r456",
      "r457",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r469",
      "r631",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r384",
      "r397",
      "r738"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Available-for-sale securities, gross unrealized loss, fair market value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r385",
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTerseLabel": "Debt securities, available-for-sale, unrealized loss position, accumulated loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r386",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Debt securities, available-for-sale, in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r794",
      "r869",
      "r870"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r174",
      "r794",
      "r869"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r67",
      "r174",
      "r575",
      "r581",
      "r582",
      "r794"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r16",
      "r17",
      "r226",
      "r241",
      "r568"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r555",
      "r556"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Long-term deferred taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r794",
      "r869",
      "r870"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r172",
      "r867"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r172",
      "r867"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r866"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r172",
      "r867"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r172",
      "r867"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r172",
      "r867"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r172",
      "r867"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses and liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r166",
      "r866"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r172",
      "r867"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r172",
      "r867"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosuresTableTextBlock": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Contributions to the Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/EmployeeDeferredSavingsPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Deferred savings plan contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/EmployeeDeferredSavingsPlanContributionstoPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Company matching contribution as percentage of employee contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/EmployeeDeferredSavingsPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Company matching contribution, maximum as percentage of employee compensation"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/EmployeeDeferredSavingsPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r67",
      "r128"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r67",
      "r128"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technologies"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r498",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r833"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Type"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r512",
      "r543",
      "r544",
      "r546",
      "r551",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]",
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r127",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposed of by Sale"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r421",
      "r790",
      "r819"
     ],
     "calculation": {
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "terseLabel": "Gain (loss) on sale of subsidiary"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r11",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "DIVESTITURES"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/Divestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r758",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r296",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r328",
      "r330",
      "r332",
      "r333",
      "r334",
      "r336",
      "r607",
      "r608",
      "r685",
      "r694",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r296",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r330",
      "r332",
      "r333",
      "r334",
      "r336",
      "r607",
      "r608",
      "r685",
      "r694",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r622"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of foreign exchange rates on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r558"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total income tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r309",
      "r558",
      "r584"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal income tax expense at the statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r864",
      "r871"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r864",
      "r871"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment": {
     "auth_ref": [
      "r864",
      "r871"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to meals and entertainment expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Percent",
        "terseLabel": "Non-deductible meals and entertainment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r864",
      "r871"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r863",
      "r864"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "terseLabel": "Incentive stock option and employee stock purchase plan expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r863",
      "r864"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "terseLabel": "Incentive stock option and employee stock purchase plan expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r864",
      "r871"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": {
     "auth_ref": [
      "r864",
      "r871"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r864",
      "r871"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedLabel": "Research and development credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-Based Compensation Expense [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r545"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period for recognition (years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r139",
      "r262",
      "r291",
      "r292",
      "r293",
      "r312",
      "r313",
      "r314",
      "r316",
      "r323",
      "r326",
      "r338",
      "r388",
      "r486",
      "r547",
      "r548",
      "r549",
      "r577",
      "r578",
      "r606",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r645",
      "r697",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r609",
      "r610",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r205",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r458",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r610",
      "r649",
      "r650",
      "r651",
      "r742",
      "r743",
      "r755",
      "r756",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r458",
      "r502",
      "r507",
      "r610",
      "r649",
      "r755",
      "r756",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r458",
      "r502",
      "r507",
      "r610",
      "r650",
      "r742",
      "r743",
      "r755",
      "r756",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r458",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r610",
      "r651",
      "r742",
      "r743",
      "r755",
      "r756",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r208",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Change in Fair Value of Contingent Consideration"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r612"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedTerseLabel": "Change in fair value recognized in the statement of operations"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "auth_ref": [
      "r613"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "negatedTerseLabel": "Translation adjustments recognized in other comprehensive income (loss)"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Consideration recognized at acquisition"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Payment of contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r458",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r649",
      "r650",
      "r651",
      "r742",
      "r743",
      "r755",
      "r756",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Fair Value, Net Asset (Liability)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FairValueNetAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r382",
      "r383",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r400",
      "r401",
      "r402",
      "r469",
      "r484",
      "r603",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r738",
      "r802",
      "r803",
      "r804",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Weighted-Average Useful Life (in Years)",
        "verboseLabel": "Estimated remaining useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r273",
      "r419"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Recorded Amortization for Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r416",
      "r418",
      "r419",
      "r420",
      "r680",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Future Amortization Expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r119",
      "r681"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross carrying amount, amortizable"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r114",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r119",
      "r680"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total net, amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsFutureAmortizationExpenseDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Weighted-Average Remaining Useful Life (in Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-Lived Intangible Assets Acquired",
        "terseLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r618",
      "r619",
      "r620",
      "r621"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Non-cash impact of foreign currency transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r790",
      "r819",
      "r821"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedLabel": "Gain on sale of businesses and assets",
        "terseLabel": "Net gain on divestiture"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r272",
      "r408",
      "r682",
      "r740",
      "r767",
      "r808",
      "r815"
     ],
     "calculation": {
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Carrying amount at end of period",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails",
      "http://www.myriad.com/role/ConsolidatedBalanceSheets",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r410",
      "r740"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill acquired (see Note 16)"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Goodwill and long-lived asset impairment charges",
        "verboseLabel": "Impairment of goodwill and long-lived assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "GOODWILL AND INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r414",
      "r415",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets and Other Long-Lived Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Translation adjustments"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r67",
      "r409",
      "r411",
      "r414",
      "r740"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "verboseLabel": "Goodwill impairment charge"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GovernmentContractsConcentrationRiskMember": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. Risk is the materially adverse effects of termination of a significant contract or group of contracts or from future loss of a significant portion of business with a specified political body or unit thereof, such as Department of Defense, US Navy, New York City.",
        "label": "Government Contracts Concentration Risk [Member]",
        "terseLabel": "Government Contracts Concentration Risk"
       }
      }
     },
     "localname": "GovernmentContractsConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r67",
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r308",
      "r583"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r44",
      "r221",
      "r232",
      "r254",
      "r352",
      "r355",
      "r361",
      "r364",
      "r686",
      "r737"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.myriad.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r308",
      "r583"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Income (loss) before income taxes:"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r758",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Disposal of Subsidiary [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r309",
      "r559",
      "r566",
      "r573",
      "r579",
      "r585",
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r310",
      "r325",
      "r326",
      "r351",
      "r557",
      "r580",
      "r586",
      "r695"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax benefit",
        "totalLabel": "Total income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails",
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Amount"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r290",
      "r553",
      "r554",
      "r566",
      "r567",
      "r572",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r864"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r864"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r558"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Federal income tax expense at the statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment": {
     "auth_ref": [
      "r864"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount",
        "terseLabel": "Non-deductible meals and entertainment"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r864"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r864"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "auth_ref": [
      "r864"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r864"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesStatutoryFederalIncomeTaxRateandIncomeTaxesReportedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r64",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r677",
      "r789"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r789"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidTaxes": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Taxes",
        "negatedLabel": "Prepaid taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquitySharesofCommonStockIssuedandOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Gross carrying amount, total"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r112",
      "r117"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangibles, net",
        "totalLabel": "Net, total"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r219",
      "r234",
      "r294",
      "r350",
      "r630"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r300",
      "r303",
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryFirmPurchaseCommitmentLoss": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss recognized on firm purchase commitment for inventory.",
        "label": "Inventory, Firm Purchase Commitment, Loss",
        "terseLabel": "Loss on non-cancelable purchase commitment"
       }
      }
     },
     "localname": "InventoryFirmPurchaseCommitmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r278",
      "r729",
      "r767"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r268",
      "r277",
      "r337",
      "r403",
      "r405",
      "r407",
      "r678",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Loss on inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/DivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r49",
      "r349"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAndCash": {
     "auth_ref": [
      "r252"
     ],
     "calculation": {
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": {
       "order": 3.0,
       "parentTag": "mygn_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.",
        "label": "Investments and Cash",
        "terseLabel": "Estimated fair value",
        "totalLabel": "Total, Estimated fair value"
       }
      }
     },
     "localname": "InvestmentsAndCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAndCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments and Cash [Abstract]",
        "terseLabel": "Total:"
       }
      }
     },
     "localname": "InvestmentsAndCashAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r110",
      "r222",
      "r238",
      "r255",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "MARKETABLE INVESTMENT SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r641",
      "r766"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r886"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r642"
     ],
     "calculation": {
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total future lease payments",
        "totalLabel": "Total future lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails",
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r642"
     ],
     "calculation": {
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r642"
     ],
     "calculation": {
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r642"
     ],
     "calculation": {
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r642"
     ],
     "calculation": {
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r642"
     ],
     "calculation": {
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r642"
     ],
     "calculation": {
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r642"
     ],
     "calculation": {
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: amounts representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r884"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r885"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease extension term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r885"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r29",
      "r307",
      "r387",
      "r431",
      "r432",
      "r434",
      "r435",
      "r436",
      "r438",
      "r440",
      "r442",
      "r443",
      "r598",
      "r601",
      "r602",
      "r617",
      "r736",
      "r829",
      "r888",
      "r889"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r230",
      "r249",
      "r767",
      "r793",
      "r805",
      "r880"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r32",
      "r267",
      "r307",
      "r387",
      "r431",
      "r432",
      "r434",
      "r435",
      "r436",
      "r438",
      "r440",
      "r442",
      "r443",
      "r598",
      "r601",
      "r602",
      "r617",
      "r767",
      "r829",
      "r888",
      "r889"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FairValueNetAssetLiability",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "negatedTerseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum aggregate principal commitment"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Undrawn fee (percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r35",
      "r823"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Legal charges pending settlement"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Legal charges pending settlement"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Assets by Geographical Region"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r14",
      "r228",
      "r245",
      "r457",
      "r471",
      "r742",
      "r743"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Outstanding balances"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r136",
      "r137",
      "r426",
      "r427",
      "r428",
      "r824",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": {
     "auth_ref": [
      "r824",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of another entity's patents that the entity has allegedly infringed.",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number",
        "terseLabel": "Number of patents allegedly infringed"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable investment securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Long-term marketable investment securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Investment Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r879"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r879"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Measurement input, expected term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r37",
      "r229",
      "r248",
      "r307",
      "r387",
      "r431",
      "r434",
      "r435",
      "r436",
      "r442",
      "r443",
      "r617"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r835"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds",
        "verboseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r63",
      "r65",
      "r68"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r45",
      "r68",
      "r233",
      "r253",
      "r265",
      "r285",
      "r288",
      "r293",
      "r307",
      "r315",
      "r317",
      "r318",
      "r320",
      "r321",
      "r325",
      "r326",
      "r331",
      "r352",
      "r355",
      "r361",
      "r364",
      "r387",
      "r431",
      "r432",
      "r434",
      "r435",
      "r436",
      "r438",
      "r440",
      "r442",
      "r443",
      "r608",
      "r617",
      "r737",
      "r829"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss attributable to Myriad Genetics, Inc. stockholders",
        "totalLabel": "Net loss attributable to Myriad Genetics, Inc. stockholders",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r199",
      "r203",
      "r285",
      "r288",
      "r325",
      "r326",
      "r787"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of world"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r352",
      "r355",
      "r361",
      "r364",
      "r737"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r883"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Loss due to abandonment of facility"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Maturities of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r634"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease, liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current maturities of operating lease liabilities",
        "terseLabel": "Current maturities of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets",
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Noncurrent operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets",
      "http://www.myriad.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r633"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets",
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r790"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r640",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r639",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.",
        "label": "Operating Loss Carryforwards, Limitations on Use",
        "terseLabel": "Net operating loss subject to sections 382,383"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r77",
      "r78",
      "r89",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities",
        "verboseLabel": "Accrued liability for Medicare refund"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "auth_ref": [
      "r790",
      "r820"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.",
        "label": "Other Asset Impairment Charges",
        "terseLabel": "Impairment charge"
       }
      }
     },
     "localname": "OtherAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r274"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Change in foreign currency translation adjustment, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r197",
      "r198",
      "r200",
      "r286",
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r281",
      "r282"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]",
        "terseLabel": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other liabilities.",
        "label": "Other Liabilities Disclosure [Text Block]",
        "terseLabel": "OTHER LONG-TERM LIABILITIES"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OtherLongTermLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Total other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets",
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Long-Term Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OtherLongTermLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/DivestituresOtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesNoncurrent": {
     "auth_ref": [
      "r15",
      "r227",
      "r244"
     ],
     "calculation": {
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.",
        "label": "Other Sundry Liabilities, Noncurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payment of contingent consideration recognized at acquisition"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "auth_ref": [
      "r55",
      "r58"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Payments for (Proceeds from) Tenant Allowance",
        "negatedTerseLabel": "Tenant improvement allowance received"
       }
      }
     },
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtRestructuringCosts": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage.",
        "label": "Payments of Debt Restructuring Costs",
        "negatedLabel": "Fees associated with refinancing of revolving credit facility"
       }
      }
     },
     "localname": "PaymentsOfDebtRestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Payment of tax withheld for common stock issued under stock-based compensation plans"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r56",
      "r96",
      "r297"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of marketable investment securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r57",
      "r594"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash purchase price paid"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r298",
      "r874",
      "r875",
      "r876"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails",
      "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails",
      "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r784"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidTaxes": {
     "auth_ref": [
      "r730",
      "r739",
      "r806"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Taxes",
        "terseLabel": "Prepaid taxes"
       }
      }
     },
     "localname": "PrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or the sale of investment in consolidated subsidiaries (generally greater than 50 percent).",
        "label": "Proceeds from Divestiture of Interest in Consolidated Subsidiaries",
        "verboseLabel": "Proceeds from sale of business"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "auth_ref": [
      "r65",
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes.",
        "label": "Proceeds from Income Tax Refunds",
        "terseLabel": "Cash received for income tax receivables"
       }
      }
     },
     "localname": "ProceedsFromIncomeTaxRefunds",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r59",
      "r160"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from common stock issued under stock-based compensation plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities and sales of marketable investment securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r52",
      "r96",
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Investment sold"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from sale of assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/DivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": {
     "auth_ref": [
      "r788"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Proceeds from Sales of Business, Affiliate and Productive Assets",
        "terseLabel": "Proceeds from sale of business and assets"
       }
      }
     },
     "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r834"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r265",
      "r285",
      "r288",
      "r301",
      "r307",
      "r315",
      "r325",
      "r326",
      "r352",
      "r355",
      "r361",
      "r364",
      "r387",
      "r431",
      "r432",
      "r434",
      "r435",
      "r436",
      "r438",
      "r440",
      "r442",
      "r443",
      "r596",
      "r599",
      "r600",
      "r608",
      "r617",
      "r686",
      "r737",
      "r764",
      "r765",
      "r787",
      "r829"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r134",
      "r712",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY, PLANT AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Disposals",
        "terseLabel": "Property, plant and equipment sold and deconsolidated"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisposals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r129",
      "r270"
     ],
     "calculation": {
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r131",
      "r250",
      "r691",
      "r767"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails",
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r131",
      "r712",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r60",
      "r792"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "negatedLabel": "Repayment of revolving credit facility",
        "terseLabel": "Principal repayment"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r413",
      "r414",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [
      "r413",
      "r414",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r165",
      "r257",
      "r896"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research credit"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r782",
      "r791",
      "r897",
      "r899"
     ],
     "calculation": {
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r782",
      "r791"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash, current"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r709",
      "r783",
      "r791"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash, non current"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails",
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r144",
      "r247",
      "r701",
      "r706",
      "r767"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r262",
      "r312",
      "r313",
      "r314",
      "r316",
      "r323",
      "r326",
      "r388",
      "r547",
      "r548",
      "r549",
      "r577",
      "r578",
      "r606",
      "r697",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r347",
      "r348",
      "r354",
      "r359",
      "r360",
      "r366",
      "r367",
      "r370",
      "r497",
      "r498",
      "r679"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "negatedTerseLabel": "Reduced revenues",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyGeographicalRegionDetails",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuebyTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r500",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Geographical Region"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r638",
      "r766"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r370",
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r42",
      "r881",
      "r882"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Cumulative Translation Adjustments Included in Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Dilutive Common Shares"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r101",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r180",
      "r181",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails",
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofProFormaInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/SupplementalCashFlowInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in common stock outstanding.",
        "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]",
        "terseLabel": "Summary of Shares of Common Stock Issued and Outstanding"
       }
      }
     },
     "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Income Tax Benefit"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recognized in Other Income"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/DivestituresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Differences Between Statutory Federal Income Tax Rate and Income Taxes Reported"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r158",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r114",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Amortizable Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r740",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Changes in Carrying Amount of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r794"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Loss Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r122",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Non-amortizable Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails",
      "http://www.myriad.com/role/PropertyPlantandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Estimated Fair Value of Identified Assets acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r75",
      "r223",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year.",
        "label": "Schedule of Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value [Table Text Block]",
        "terseLabel": "Schedule of Intrinsic Value of Options Exercised"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r509",
      "r511",
      "r513",
      "r514",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails",
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails",
      "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of employee stock purchase plan activity.",
        "label": "Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]",
        "terseLabel": "Schedule of Shares Purchased and Compensation Expenses for ESPP"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r150",
      "r151",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions for ESPP"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r763",
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Future Amortization Expense of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r877"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "SOFR"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r352",
      "r353",
      "r358",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT AND RELATED INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/SegmentandRelatedInformationAssetsbyGeographicalRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general, and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general, and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Service period for award vesting (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "RSUs canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "RSUs canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "RSUs granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs granted (in dollars per share)",
        "verboseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "RSUs unvested and outstanding, ending (in shares)",
        "periodStartLabel": "RSUs unvested and outstanding, beginning (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "RSUs unvested and outstanding, ending (in dollars per share)",
        "periodStartLabel": "RSUs unvested and outstanding, beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "RSUs vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r532"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of restricted stock units that vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "RSUs vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Valuation Assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails",
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails",
      "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee",
        "terseLabel": "Maximum number of shares per participant per offering period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted average remaining contractual life (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r532"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationIntrinsicValueofOptionsExercisedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Options canceled or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options canceled or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, ending (in shares)",
        "periodStartLabel": "Options outstanding, beginning (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, ending (in dollars per share)",
        "periodStartLabel": "Options outstanding, beginning (in dollars per share)",
        "terseLabel": "Options outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued under the plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "auth_ref": [
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award",
        "terseLabel": "Shares purchased under the plans (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r513",
      "r514",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails",
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.myriad.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Achievement levels based on EPS Targets"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Relative Total Stockholders Return"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Performance based on Nasdaq Healthcare Provider Index"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r516",
      "r535",
      "r536",
      "r537",
      "r538",
      "r541",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Payment Expense"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting weight (in percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount",
        "terseLabel": "Plan compensation expense"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationSharesPurchasedandCompensationExpensesforESPPDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Aggregate intrinsic value of RSUs outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Award expiration period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options fully vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationAggregateIntrinsicValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, Weighted average remaining contractual life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and expected to vest, Weighted average remaining contractual life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Options outstanding, Weighted average remaining contractual life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r36",
      "r139",
      "r262",
      "r291",
      "r292",
      "r293",
      "r312",
      "r313",
      "r314",
      "r316",
      "r323",
      "r326",
      "r338",
      "r388",
      "r486",
      "r547",
      "r548",
      "r549",
      "r577",
      "r578",
      "r606",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r645",
      "r697",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r338",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r139",
      "r144",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r144",
      "r152"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Stock repurchase program, remaining repurchase authorization"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r18",
      "r19",
      "r139",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "verboseLabel": "Shares repurchased (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r22",
      "r23",
      "r95",
      "r767",
      "r793",
      "r805",
      "r880"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Myriad Genetics, Inc. stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r195",
      "r196",
      "r202",
      "r262",
      "r263",
      "r292",
      "r312",
      "r313",
      "r314",
      "r316",
      "r323",
      "r388",
      "r486",
      "r547",
      "r548",
      "r549",
      "r577",
      "r578",
      "r606",
      "r623",
      "r624",
      "r628",
      "r645",
      "r698",
      "r699",
      "r793",
      "r805",
      "r880"
     ],
     "calculation": {
      "http://www.myriad.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedBalanceSheets",
      "http://www.myriad.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r145",
      "r306",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "PREFERRED AND COMMON STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/PreferredandCommonStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "terseLabel": "Schedule of Net Operating Loss and Research Credit Carryforwards (Tax Effected)"
       }
      }
     },
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the limitation related to use of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Limitations on Use",
        "terseLabel": "Tax credit subject to sections 382,383"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNetOperatingLossandResearchCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.myriad.com/role/AccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Accrued taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r374",
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Trade Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/BusinessAcquisitionNarrativeDetails",
      "http://www.myriad.com/role/BusinessAcquisitionScheduleofEstimatedFairValueofIdentifiedAssetsacquiredandLiabilitiesAssumedDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.myriad.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r382",
      "r383",
      "r469",
      "r484",
      "r603",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r802",
      "r803",
      "r804",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease": {
     "auth_ref": [
      "r40",
      "r881"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cumulative translation adjustment, after tax, from translating foreign currency financial statements into the reporting currency.",
        "label": "Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease)",
        "verboseLabel": "Period translation adjustments"
       }
      }
     },
     "localname": "TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesForeignCurrencyCumulativeTranslationAdjustmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r734",
      "r755",
      "r898"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government securities",
        "verboseLabel": "U.S. government securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r687",
      "r755",
      "r902"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "Federal agency issues",
        "verboseLabel": "Federal agency issues"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails",
      "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r552",
      "r561"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized tax benefits at end of year",
        "periodStartLabel": "Unrecognized tax benefits at the beginning of period",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesNarrativeDetails",
      "http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r562"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Gross decreases - prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r564"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedLabel": "Gross decreases - settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r560"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Interest and penalties in year-end balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r563"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Gross increases - current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r562"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Gross increases - prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r565"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Gross decreases - statute lapse"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r339",
      "r340",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r637",
      "r766"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/LongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r798"
     ],
     "calculation": {
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Effect of dilutive stock option and RSUs (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r329",
      "r334"
     ],
     "calculation": {
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average shares outstanding and dilutive securities used to compute diluted EPS (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r328",
      "r334"
     ],
     "calculation": {
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average shares outstanding used to compute basic EPS (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations",
      "http://www.myriad.com/role/OrganizationandSummaryofSignificantAccountingPoliciesEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted average shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.myriad.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1,2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128487-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4578-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "https://asc.fasb.org/topic&trid=2134446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r771": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r772": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r773": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r774": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r775": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r776": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r777": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r778": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r779": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e777-108305",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r904": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r905": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r906": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r907": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r908": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r909": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>118
<FILENAME>0000899923-23-000011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000899923-23-000011-xbrl.zip
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MK#O5!&.3 XLAB@(&@M9!9<V!R<RMLB-72UK,.RVJT6=KH6Z %A%,S)8,I8!
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M[/QU'8)6ZDR'JI2:2<#!(0AT,8&(E$7VPAJKV["8;GZZ??/Y(M9I%A9*DT*
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M(AX\V=S?V5A=6UE_MO5L;^/I[M]7-K:>/IR?SA.N-V3\[ S39,J!E6%9&7W
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M$'4-^48:PS168W%QO8<IH%_\FQKY59U@=!.H7K2J'H8@T]()2Y^^1MTG"SA
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M]#HMV<A#H3TIW'#[ J93@HYP\)8CK?92-%JXC&PUV*1(@,5!5(H]9QJW!DE
M.!: S=<0@>@8W K/E?.X;*B+$YW5\>"X,W&AQ RGI"QF(U+S\[S0A"D[T34<
MA95H9^^KLXNH%'L^+ 8SMHX1E"M'<4Z/D8'3BIEI5LPMUM. ;'U>/^^>L$-Q
M4ZQX%"AHK-(%MX.@QMF0I4VS=5%5'H?UEICA$%:JV#>E,=%',\=5L3VT9'B-
M8RRW'&?>;?O(#D8J"6+BFP _^X1R V(>WT5O\P$G%W>B7\A2S/^KTIB"7/A:
M(-(TS!#NK%:1C-G6:RP4&URPMW)8R+:>WX$U &R1>8\X#;C 3(-;CJG'%DG+
MPO@PB=F<9#MD'F%SU(W*4A2UQ_"Q1/VRB.% K0QO7>#&81)1%T\G*N.4%YTC
M;WSTA?JL#^AF7(3F]@W;J%KNJL:E"#.-U"E).F>.,,[*KT$QJVF6V!9AZ4/$
M$3OJ=D&9[4[TP]QF#JJ%:P;CK@BD$&V0ILMN:2Q<@(?A<3 Z%A$5+ACZ8T;&
MI2Y\."5U20>9Z:4A.A(YG-%QK>>:$%_51! ,7DO42HJW3!3HL#;]M!.,K^,A
MM2S3\<GI+(K <D8@/!H#\(#Q;CTEX1&1MP<DC479V]W;[SA\8Q#)+)>P>5$F
M4DR#(XDW!Y$V>E)',#R= P>HLYP0P5">+D 7D4693@2*-DUF3+TB>I^]?G_Q
MW"942+8#/&F\B"+,:1\SCQTJ9X2/DD0)0@PKT37&DL419-]+W35S%<>-%J6P
M9@>S5B('7&-RXE3%06!GC"-FVJD8.^UR*CWWP;:EM85F2:M!.LW8Q^8Q@OEV
M9D1ZJ%)P=.:_E50%9T.L :9A<<NY1IQ+Q+."M&_4_5J>X1%;-9=U&Y6&#W)*
M-WG@J]6$MQY(J82""K&MBC;BW;^)2'50>&EI/63858]6J7IKG'/0ZYH/BL.2
M9DUVZ*OZ U6VPZHS@)I@'RB!NAL9K3L=%T4BWOUJ6D@U ^-,>\ 8(JT9&*\.
M8NDY3I5>5IJY@L;C:&L>K9QIP:.&T2(E765:S*H B9I1:THS L^;\PD2'6))
M<..'C%1DU12^J!C?9));HV"K$/_N2:.YY\B.&'(9\X"S/@*CB47_DCEDB\%(
MX2':3])XE!>5-6.#R$9XB&Z*\J,%LBH# @;!ZJ&R;[W%D;RQ6]E4P9YV0]^Q
M! S="V[GP'MN,%0K^3@6Q86QEFL$=%!R<I"ST04 FM2N6M$C.2/0&A);N&D-
MS7YC]\P9AEYC#UJ4C(L;;^LA:U1-1E*-8@!UJV8D)ZXR(L_JM$N&'!A_;(.3
M&EG":=SHG5S?-":0+$Z,:SL#E]/LI0U9':+.D9UP_0#AL5S#8[_AO).ELAYQ
MD#<<J;@$W0?9N'"!+NCH70:2FI(PLW^\($E-AL#\NS3G60MJN@Y*HV,K4H7X
M=?*S1GV.>SNG>Z<(_&B_07VQQH1V."9D^]0U?MO?V]G;WU_[\^Y.;^UO3_78
M@WL]]H[NB\N%5H.CY'38>Z%[)=5'TQHL,$TB$+G]B:FE^<LM??Z41%9V^ONB
MA^GDSMR>PUOC<\[IX$[+^KZ&[>HMKMZ"E^;KKJ$PHS_5^C:D>7-Y[SKICT*2
MPHZ?J#^G9'C?A^;:M7C 6GSM8_:DZ^32Y;_06=JNV2]6.OP^>MFNN6OQQM<[
M(I_3#?L/L[IAQ<R?B:I<S4]+5U_IU$JATY^)IEQU6$M37V5]@QJY+T-6C57<
ME'U21\KJEVW_)MH +I=PWG\;/WM5[K_'#W[%YQ' M^PV:Q/3V5=ZV,*L;,98
MVASS6W+,%_SN3W16+DPU*-.I:_I<-)($XDJ##M5W#RTB/B=&T"_3=:/KW2]J
MM,F!FC4A-_:]V.+K)< !+NE_VDC<5WXY/_$[9$VF@_L0X)NSJ((QKJT&4 _-
MB=TN5FLSI"6X._8K*D'<(//XJ;)J%%V"Q\Z%:#XKX+:<EZ6I^/09""9 /Q37
M9._$.7+L,E2#<G*;(95U8NJ2$^XF),ASF@8*8+F+*2EE7"_*16T2W![%B( /
M_()]&$O[-)OY4T4')[0+**>K;1H0$O.*PF;S9)@')\5,9K9'/*=!3-%&W>>G
MX4/0<2^;1V-:+#LUND/"E*X:TN4 +V8-A:6%#O_)30#0/31D&:F&/FG^)F.V
MQ66Y%HM)8J,N&3-+.80\X_1;K:<O,@;"GR,C$8F8*W:&(]$Q]STQ.0H7;SAU
MD;^*N3"7Q9=[#6-VHBJ 5\J^R2X34N<D9Q/K;6*2-*:TKY(* TY8DEQ[F\LD
MN4VES=6TJ4Z6=HS 40Z,[*\2I8+.,-^)W@N$$B?]RL^O?:[?AZ+(OLI)^H-#
M;1"]3T@<H3#=55P4@Q3@35RB@3N$!#BQ4E*?+27<2&ZM37"PAPM$R.5 KE!E
MJDG^ C;*\Z"C57'^KR."';NM<585-C>@\E@QC[2]JR3C]FZOEAD%F40[?D5#
MI+<J/...RX-3.+8@#%Y2#SL+V]A1++OTUYFK;NC8M\Z[4C6/BG26#0V1P17J
M916F!W-R9%@8,J0E[\Z!K<-5/.G0H&&/REF;[+NF&JGQ2I[9W@LI"I>:ZJ$;
MYD:GUJS6V-;%0;;MD#R2&K1Z$4G.E!-\'9V[O,D+GS?9:KUW:[TV#<ZKC#B-
M$UI K3Z1"A &(!%4+E^R BE"*F$,I8^6>TE]#'X+U<2B;/RB2J-E+?S44/63
MA@(H?3!)XX>1W?P?WI^?1?+2^HD5\_>* *I&[>(I5_V7.#B#^L6<T1ZG@N9D
MD\0;-4&,V4@GCSO)LT;7S"+^>>=J)WJ%#'8PV(MR-HK.$I245+4X%:)GKR[.
MG@/* C4=Q*F+;-X]NWA''+=?(%>=/D]H=U%P\N[L_;OG0&])^RF$Q4YT+F#C
MV;QCV[>!/+B,)2@%$GTBC^A-7?<B9U19]!0%(/%:+2F/AL$SY)XXJSR,!CV*
MB[)D6Y4X.LODYG[Q%.:^:E0E+=!98(ZD6E= ND]=%F'B-0DC!!0=YI;5J!DZ
MLY:*0*<X2_YV1J*-RQ)MR9*E2V<PH$\6-\?@O%2@X]EZP11EPOFWYA/=V>>Z
M)^YVJA)RLW@)SESO27DK5FSSUF3O2==$3%,I[Z2_BPD1,;B^0S)2]!W8GOT,
M7(,+0HB=5-QM59@LP+CJ,8V<[DAC"(6:#/\X'D@Z](#XU;.7%Q_.GF^AWF6S
M!+95WWI2=0L2;+VFM6&GL69D55%RX#-R&DX5C8L),FZA1) ,*B;]5+HIT350
M>$@_FD?/_O;^XCF#-,VT?7BH]C3ETLZ3'GH&V5L6O5#KJ@"BPL._*8KWA+8O
MK<E6AX1QI<:T9E #O!9@E;^=B%;$+4CEUS-1AE/?,"2EF1I.R%=8N(<[\5O)
M]2>47$I7?%+I_(')<*F]VBO&ZU'L2"#Q OTQ+LM8FU1JX>*/*O4N\\K6^W+K
M-'KVLQ\OKY[[AX-D;<^\,6BY^&T^ F<&AJK)"E**N?@G(_X[B-))/\YB5_7,
M ^A6Q*=-)&HE"<A<H1@L% J#2#*DN@CC)H"%=DGEDFC'@)S360\/*Z?BC\:P
M2S,F40VU\R;F7D\3TH'A5?9'LQ.1!"&#*3(IUQ[!I1UG]-\M%-:+J5>ML'Z
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M,&M:-5GV*3?2/Q0[B*$)V&YMAO&D%VR ,348FTGAN%XX$N5<HM0V<5/4)ZO
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M)UT-Q[G48VN1#IHM6X="%:AA97X=UMO$_6)6:VK.Q!W7BM.OM,M[E* 6-T[
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M0;>>_1GNT9PU4*IZ:2,?MH/L]BE.5Z18"JV\AAJZG5T ?T$H4%LV2OQI6J:
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M=[W*:ET6QA,+FM':A"<MZ]$*1>+XHF9(W4T$>U?:=Q/[045EV++:MG _2WP
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MYQ+Q>/;SA]<79^?GF\B$GZS(;R4G+N7$K^+#NH;W9\4MR,SOJ+[[V_N+S:_
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M0L[)54&"BB[.HU<E[1VP.3K1.2T_O31/8UZT<%%DG>VA&*>,3$(;;SYAP^[
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M.$<5)F@W%[!O.@4\PP/WX6FP7_0YR6K:D_,1*% R!>^\#AN>5/QF06JC8X2
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M(@YOQD8=I T:@<;3-QQ0$<>B$PDH!0*LK+Z&F3A<&BRR!<*3;'ZK6[Y# VZ
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M+)8U1KW%2[MF'6O<B&*/"FFBR\8WCK$X81=?:4,"O9-=60ZG."2:E$VOED2
MK!ZSQI7F+E0?,=9E^!9$%\C&,>5.]+_.P]U41LI;G UALKC_I7&<M<1(ZJBE
M*CRY3BL65F268Z>U=BPQ63SW)F)5N4@KLBBTH7%1"W A_XZ[(.U) ;_F1 )4
M_E:VQ%W*(_,B&LV@K-![UI.&X'[20]BHU@+7G>CE-2K2A^X;O\U<HYYJDMV2
ME\9KN>N,>YRDA4%P*1N^ VO-@B;6'*X-?/.A:NBJ 1:3,]2N\9DA-@:KGB6;
M\V$KR/CM8IZ(TF;- Z4X5_5K-?FZ*9A:;W_#VW_<>OLW8RRMMW_K2L>^^=XC
M9#%8! G9.,<'GTNYO?F3G$=E-4GUB2[[UN/%[&+.QJTJ2<-VSM05 >29P%<!
M<(.,.[PH4==V&4_-#,]3(Z_34&I5G5YQG4A'GW;#Z?IJ0*"XR:8!AX:TYD@,
MW-8%TUET*T.]6_ LC69IPGI14@QF[!-SY2BJJ']E"/;/S/9](F!X'L.MYV0Q
MIR2$W(+I5]5VKSC9EC=1H8VT'&7]3E;.XENZ?04UN8(<SA;71%M'M$'@Z[87
MWTW_JD?BC3N1EFA:JO)JG*WWNYM<&Z5^ BLGOO9J.1OZRQ]5?UC8QTO&)VMB
M,5=[(84C&L0,I(=<?K6PF_:.PNA)B*$1OKMMTE;Q4] 26]EH#S_[M66QE[:Y
MHYJQ]R9^NR*8&9$%!_=A'D_,$O_AYS?3#AG7PQ&)9U!<>.@B++SC9S1H;M^[
M*^6#TYE4>20N-6N!URRRF M/Q]BWGU25CEQJ_VT'3@VX*SO4'TEKGOKH&BW:
MVQR<833'UKHIO]/5:YQ7\VF*LCU[6&A[8Z6;VS9 :(9=,^+ #[BJ<XHZ$\OO
MRF*E"^,UVKFS;K1)G-?RB2?EO+<RQR -*[ 5Y4CPYDUF69V2Q1<E*+2C'>BG
M+HVML$3BCY7DL/I3Z7F#5.L$T?F0+*R<%Q^P5B5)#-KF? 4@>%QK1M8TU\K=
MP2,D;K!*<0C):)K%%GT.%>$ +T'2FO*M=:J'1*"J!0ZY=DBV/,K7/'O??&XX
M<9V62P'N3+[@8U*<2-9$) :[EC>\(S-[@$V3,W->+-2&0:#<@TU83KJ"!3@.
M4#!,I H@=>4HVS*!^%ZU>KKG+JK@OZ#E#\1TO';ML6<#6>KY;2O?@,.\8^TV
M@J\6%KT4<DWXJ&=R^7)MGV3HZ)-7LMOM,T4:"KAC2[:44AC%=,K =&OC9NI-
MYW,4ALPT;*?U_+=R2*8=A.H*8P,3V6+-0J5EH4$Y_YHW"B9$0[O,0' ,38VR
M!'A[M>:RTVR\T4@N#L(+MZJ%V@_%)68\,!]C;3W8]I'3I:V36[%:;,):[FQK
M8]F1CP0@#9Y8X.2$SK:4_[N"+]DPXH0.2L-?#@8X8LBO!0#FN)SX-+,L_6BR
M^4(!3QPM!GS"C#R;2K\0W['3\$GS'Y;MZ+OH9O$AJX#EP[J]RXN7S7PJ<1/P
M\:R+A2%*EOKJF54^*+:P/9:40^[&*@GGB=>S1*"#1UJ7W%!K&*=" !ROC8M7
M53;KJ;%^'$*<&%-+A3VO%LU.ZNB;83+.C^,A!,[Z9Y=O+IXOE K]8E3[T77)
MYW?N@-<1&F8-O\[9JKQ-@CG@(CJ-G 3UUBQ,44,[8"6<Q -U@*;(3^,$/$7H
MUO!1$N8$+D5<)03P\,JBS>$,OQA;56H%_UHF4=VV&UYKX?/=)ZX_ID,>#YA8
M%0:/G1"^5I3S')R7BKD*/WG=G1 &[\[>OZ.7,11P408=@4)L]P*ER3%Q(GCP
M]?@HG!*8>VE!9)O:):0$3<8XJ<'0ENH%L#!#D![ANKA<%D$.84VP=G5^:;.&
MA\MB'/RTN"A"7A"Z*VA19G73 X,5IY&?+0R'7X<DL[')IE;Y=,LAH?J1PO)*
M/O7<#D*%K4*B,A=FU:'D_#SX91CM@O,*<IJBQR@A-F0!-GP0+BB\[C0F0\I
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M=&T&UE;T<R%8"(9"WFKJLALKQEKI/5Y2*#FQ8@2G@@"K$PQZ^+VG^76E85K
M(01*\^U:;PY#.!_:HA1:UT$4S2"O0BMTTO[E79*5\!XT(\ACAG/4V*U?X\@^
M,".-LC\2V?O2<DC7P"[5HH\T<NY][^O]C/M_0^K!!(U 8_!=Q<T!]_*UKSV\
M=U]E+J^B86?H/^@TC8W,'A@36$F$=5R.H7<:*08DO8MT$71P8-+I<!;LCDD?
M(G[D5OVJ+8X0B&_#=SS?-AJW"BEQ-NUY7FO9L)L]>G7Z^K%N_IUE.$+2J5FR
M>PL*KBT=)*XJY%*<8@X<NH*JX32O#D@JSQ>Q6*NME'Z%WR%EF->R2]BA]IKN
M1(8QJ03-E2!O]I3$,J2G0A)'IT !<IQJUZ?5WO%C13PL.:T3RO-KZ5>.7W\?
M+OPO/P 5_@E$!_<M[:</DDGZLV,> 5:'4E0&YR\$[Z3I7Z_]YC-6?"2G&VH_
M(_QAKGZCN;)<Y;("[W_%(EP2 CB?YS /=SX/W"("'ZNJ36!4XI2 Y8MVS.<I
MV<MF\\NM=6P70_ARF+<[GS>=%8EYV&B)'TI1[%ISL@AD^<!EZ"6=4H=YN?MY
MH2AKP]4 T8V5F<EYFDSA%$X9 Q!2 E=-M%PO.'&8I[N?)VVT;QORID,]F)L)
MO4=_/P.Q:Z?BV1A(,L)^MRUJ0R%<\60#^95XXK)Z-06C/P:B,878:S7^X/+>
M^3+.)=33>4$*,\@X!_?74@_B<<6 #919IZ\/9\('F"2)I=%<M3^4_I8^/\S%
M7<^%VPD/T(*_(:>!4679B(SCR\_^RWJW6L"3!LY.EDHIN3\M] #'X&4].Z$7
M6JE2]BF%[]RML,D9<L/%L8AS.5$<>Q/S4]JP@9_/'KTY>17[-0+;;S?,N1J%
MN-2U@N+:5RRQHS] 160CV- I8- VYO:DG\&>(:!V T#YA_B;%V4Y.UM<E 7@
M[X].?WAQ]OAXAN=,FDJ;.N6*>?*U)K&U[I><WBZ)R.0SOM!GBZ/B+KS@A\[:
MT-MVV:R&=02C5:&1#C]'TTHL P7DJ6'3'6G2:;->TU._L80;_8&=$>6A7#2,
MT4T%X[DDI4+E-$P+)IF8Y3-9(:H.E]?)0PM&&RE'_'(LB$X7BA47H<@LXMK
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MR-<R7KHB)U]'*3<0"(5$,<Z!3KDF6Y,%CT> I ^UD2/)-'W ;H^GGSU9/OU
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M+(0Z+L+BHK'90<S126P8NS@&O;!)U&4;N7');ER9"EK4%N9J;@00M9'[M&U
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MDO\3X8Q!:9G )>?EQ;"60&'%,)U?V1$;E+!#,0IH4*E]H!Y<),7&.E<-:;=
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M-'XFC9]?'1H_[\>S'!H_/XK&S]]&MNU#OM][GIKW1@WM'JR)O8KM\W(ELE\
M/6FH)\09.(J%SI'Y@3?JQKOC+V'84):6B=%C''6H3&]H)X8>!W4#$OZZ##\H
M?]UH,JKA(9>KAQ])6E(X\"8NH*P+-F>[I MA%H]G?VZN0$*SCT7DFN62[5TO
MK&[#M#/6?^MOC[^%!\AVUQ'+<(^HWT8WD'*] 9C:\.">USZ GL@'NJB08N.^
MD);1!H5\)V"<W+*.E8?-"LQ6<+CRNJ[FD3LE/(U)<R EN&Q65<,9G:6#WT#0
MO-."9F?]5*[G:6D\&_IN[JH=/#5']'(,?6FZ=XZ2:P9.3TX,K!LF ?+P!B!C
M($ ]]!6>&7RD"TX]V.KCV18)FU)[9R$VHAV!<G-=>6&]3AH!9,1:0'^X0A<'
M/RP;72O';%US[=M.T63\/3P<%_@Q]/FJ"_D,KXTC+YP UB3QP1,M]]A4FW)5
M"9>O/2<F4 FSLC 7+ZJVZP$UX 7ZAGQ1T(>_>OLLXP&D-[O,F4@73ORY+!-'
M\90);VN"K40^$27JK?1';BFTZ]Q&E(VY'M!"B8/X'/N\!V;K,M)$&5>*"9&K
M^QY5R0+YBIL0W-+9&%O);3.<"Z9=5D*"LDA:Z9K1OZ]*WZ1E$A&RW[DU]'CV
MG&9 E;+L,>2^'*)$JJ(!:+-IXY+^#COOCX<*V <,8%F[:I=+&F5S:  5>5LP
M1=1^_,6W#R;E\!#G9TSAQ5W8TA/%QTNR90.H[3 G=SDG^653%=8HS:<V)^9C
M&[W6=V!EV5(>IN-.IX,%.D.78O L%!P]YI(Y3,9=3@:Y6>S+!Q!OGA!9KG#<
M&VV[N,9\[* CX5OZ\V%N[GYN)F+6Z]B,[G/HSHYTC$\=$L?R&0X4DG)7>N>5
M1T0()&0\#"N^&\9O+K8=LMMUIQ@T#A.2*$D5(M6SW1?^3OGK_T0$_D!R,.^9
MM_I(9-[O\]9)%4[+7\O%P"N=LUSYGM&GD5*>G]+5ND%+O)+1TB];W!DS0"[;
M(X$H[P&*:459DC,(G/AHVEZH.RKH>;%XX<+2LY+K6?*N8WHVO^6T[(9:DJ3.
M!(?LTPR!-2[I7J/OUQ> =NFF]QR[^4;LA7G718G*E#P[7LES-#=%N3)\T"\-
MW?#WW>S/TH_'N>5Z(20G44=1TA6:<]0C,[ [ZU!*_I&7'E<%-3.I$;R;'*_>
M$O4XZ1E<NE*FN91)YC073ZMAK>V;>O'(T\'ZYLQ=-OO[4"W>:5.Z9RM& BFL
M&9J+OS&)'EN^"&.8D,!VZHNH82Y*$;&-[6-YBJ::6I87>:<;'T( @M")2H"C
MO)1\D6-:>S(G7((Z>]/&"??8/9. IJ"WD68S]^UL1[BR:<_S6C,N$.'M6U#>
MMY:=M>1DH8E.GN(X<3(*NB]O&H"0>6(QJA936WNSN&,.53*11P&. $,5R$E6
MGE]G4&U'DRDK^S")EJ<4#(*!WS0G#$YB9-CTIYJ^TEL6DACK5LW5:KOSH-<T
M<_Q'5GR_/E1\[\>S'"J^][OB.[U__AR*/JOMI&9C641W;NO=B *<>* T8 QX
M-1<C;$HV@W@7R0&12R7%U]/8L80!T3J "3/  H?[)T\5'^8Z#_;VONFHDW7V
M)FC",[.>"A R!">6O90?PH=32@BP6P -SG1T1NRH8-J:",C_PS7^M@Z\X]HU
M#\WU"L&Y$8=_V= )?$4SL+]6L'<)_NG_S-L__.F09[C#/ /K,"]I!B4'.D'G
MS/R4C#!K8Q&7/=!U,]16@J4_;#E.09F2HW#!U8Z\=]IBS; )/\U7=+D"MZJ*
M3/":-&L]W%Z*!&C.N&B7%W0>5NQ-52R5PN4MH1Y<,CV "QQBQ9#]O5D^]!=D
M5OYAPL+QMX?DXETNK.@R"YTH+:X)%4PP:@UKV,#0?2PH G5:#W/T8>:(#JFN
MJ>M2B3U$_6TK4W>8@[N<@V;<%W=1M:55#V'.R.S1A0J4>)=+GSAPLL<!FQLW
M$4?/H3M;NO.E$U):XMC#07-,:7%B1+*SBA!C;<*Z."R"#[H(%*I=ET@@H4P9
MQ(2%#T<-*0Y9%>4]&,Q_QSP%U-HF@L20B%SHYPS94'"<??=@4#_L'-T SF0'
M=0\V\S!3=SU3$PEO#5PGLZ>'"?DP_J"@";G*0L=-L\U7Y@U&D@4W=2%7P)4&
MH7"Y1HU ,3>2[-KNDGV9^,MAMN\48A!K/3O3!'04&-VN/-Y0,VI(_FLZRK/U
M3('C$YK !6)^D,,=IO7.,SJ_;JHV3QK9==*XK&H[SL#CAPFYZPEQW+YP-GHM
M>=,6@D<2J: /,W&7,[$)&?4&5<6R6S!_B^_&.$S OR/.Y<RO1E(.IN$TM ]S
M].](W$HSD[%'@K@8$Z&]<]U%WI:'N;C+N3A?-7-1*A UBW+1U,V:0J) \W[8
M#!]H,R2LEZZ(A)UQF(*[['HRZ0.GDJ>1:%?VO0#/-"S]VU"<\S\?(,[SIY1
M]8,5ZQ<J WD;G8E8(@C:N]E[B$]D3GDB0XGV"FVLVFAK5#E[6;/NYYS^$VCI
MB0%34-Z48$>@T%X.+==,QQ2&45G &'T73=O4^675#MT,N<\21P9JX?56ZZZI
MTHQ)4;A^V?LYV-=NH)-Z&\:(@BP&V?%@GK[^GY?/CIY\,WL4BV?"^DE+O>XY
MTUC5W>-TB.P2TO0-#CCN+BZJSMK8;QS$+-U<]G!QDT6QJ#T;+=D\DQNMV4-?
M.6H_=THTZ>,REP]=,T7XEJKW%Y"]ADOEON[&M>W;%[*95Z_@TM1B:.<"A-X
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M#.W*VE\G8CY516&.5&'AP#@J6X<[GP-U/M:)RH<-M>5[11N]UKG=0%YY81(
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MFA?L"B*L!,=;RNA80#FRA*=8#DU;5SDG8Y=E@:'B;PKJ$4&%/54H:UA["ZT
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M+ Y^<;/E4E0;;<8*3P[?0/&^[+M;C.8JK6Q4HI $=[&I5Y%%)\I4':*:4^+
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MLFH'KN:L8;O:I):'.6G6\E?S-X5[DVR=.9?&TV,.@!"3\O66-$32SMM..:6
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M+#+X2'2"$83^O_1!_[R[ABSF97O2E2$WZIC>U=",#HAKDH$&"Y,\N_02B*!
M0J<_1R9*@XY$3\"^'MJ^H2K9M+W##@!) GKC_=1JH?T["\^CRW##=#1:W9ST
MW^T<X$C'*H+*CS6%F\^%PV(WVK3C1%C?=ZA2)_2EKPW5WQ-+\S##^"3YR!FX
MR"&06MG8 Q&9#^*IN"-1M1W;0,>*%U-\,?@.!P2.,HD<$;FN=KJ0Y>_\M;15
M1BS*Q7;>5H5\['GC ,>R%UMAZ7;N8NK6+)CK*^V@<E+SPC&/0;'M;LQ&JZ;J
M@]<2$&J,B@POJ# 3YK_JA@X4$94:\0WYC!=6L&3J?PA"TYHI17X"(,GUYB."
MF5R52;OK2'LNK*FJOL5YFP+@QD[UU!:.7M N[.U^CO -NWAR>!Z]_.EQ8+D;
M:A-%"4=\JSJ-6.#"#=[N0&F]>=-4T<N?=B_:A:O:V9'6UX=ZL7.*:5G8QUBL
M#L+_Q1Q:_=8:Y#)W.,FA)#M%;B9G&__N5@<4/KO-,>,H31 4:H5814E4A]/*
M2>)@*I<8K[MAM:2G\OCD\ ZF]=&-Z>!<72X,O/UZ:MQC&N_U#=^(VEV)X9&3
M,O/1#;OS%T-?-%<Q1-HP-JZAH_1<\'-M<252H,R7UDF_\8!6N1"6N; M?!CB
MMQ[XPN1!XZ7HYZ:^ 5!TCS.DV6@$)T9^J%7POE8&]5N,0) P2]HS73P(QKD5
M"M^L)-)UUN6W#(LN*#V440-J1\Q![A=IB$)"6%'Y^,>PH?\L5*I#OK^N]%,Y
MN@1A0.%ZIP'4#G8UD:5("?90+&JX+\DRO2.KBL5V[6"I@J>0]8@-II$R_U=%
M*V(N6US(M@NBY)5DT/L=9]X3\$F].:4QX8WD3@/V1J1373K4WZ/6,D)@=^,*
ME-M:]MY3CTMQ=F2KU3I0$A_ZP(8!>TLI.XSR/_,24Z)%]T%@'$U:@HAZHIFG
M=DD&U;^^:\Q@IDEE^TI&,)Z C?>'@SK2>W;]@9R5/*Q_[<@ZI.R3E/T7AY3]
M_7B60\K^GJ;LWS/$>*ZJ:E'5L>K,U13()6*.^ASS5X>Z=0 *;Q$))V$<2\1H
MZB:>K4EJUK!A,3,S=%&N,T*01SRSH:PK@.WH]TVDEK5,R\+0Y?F@)%Z*T</@
MD4N[VL:NI >LAO!+&?02\]GI#R]/CH":%EY=G1SFFC_+Z?S[ 66-4P9B0#_7
MZUJN.4/M5L*WN]=S\XXKDIM[0=>M9R\@:026F\Q1DON+XZ(OX(@R[![KQ, ^
MX5:ZRG:7%M_K%*%:30[X]R7HGK>)(J?@#-C;Q(V>UT7SQD1DD=I[5]WB;5Z!
M,#*;O;ZHFO&3?T^QSQD_.2[WK:SST<]_R&=_ 3KANA&X!A4EF$_3#P8#E1(?
MU\RRGVR+FX<^XX^>5>5Y.B-2):,1F5H,$ADD=[(R2>CG@AO-FS5],;$<5Y8M
MB*3EC((5M]QRCE-MKJ+2JBZ[_X%01&^5_+Q4Q4X$:"PD7-5L!1B,?*;T2\W.
M2X#1K5DPL(DFH)5XE8'-_07=X!VB,SPLJYIJ48(3:>><QM2$!\*SJVI5+"MK
MVUT"ATVK5B1( X:<2P]U,YM3"#=LQ)<LZ-!A%].6M!O <FR"V1OG80^5"?<Q
M([R"T0U!#0I/,W0+89'/=)$O@AMNK*C&6^@_5U74A71V MF):_KWAD0M+=5U
MM1"MV_IHG1<<Y;'*BN0W*?I$<<,*!- O#".,F ( ?;IT+@(*-GC93/46NS+7
M=&.F3RNP0FGJM3SV8E6A2L,X6\3C2;PM/8-T2%BY@'.U85G&=M)01AV!L 31
MVIF(AV'I.Z<3JG#1*,,0YQ3#?,E:%8CI@U:AYE!Q@I5EA#Y2#(WZFN1*T\0>
MPM.F,-7KM# =3L&H)-<8Z-V?Q;Y=,\"NW"$<?IX90[J!:0M:),R &8O> ?:'
MRDC(::M*8K7<N;VL((F:F"N&(OB^I<"M&$6:6-NCQYIB>8_16QYBXMBS[,1+
MI9ZQHT/'&8#TNF7KDAJLV]S?PCW@_%8BW\0FFE<$6 /CF7N'ACJD7X1FH YH
M!G=KE:EW[E,SYV6#$0]F8(.N@YZ+@PLE059Q6&<<Q@&T*WM(FH$QYF.7[EU9
M;J 0&5I89+D+-8%+"!I,,,672D.DH:6%KGS4$BEK#H>C>VW#C&HW7]+0=B]=
MN_>G\9=,J+A[AN[W[495Z[ )3;O3TBM^UI& 8GRZA&5U8N,V3<%Y@ JH_J5\
MN>/M).-O?[(3F6QLX$& 76L=:532_926JDY?_\_+9T=/OA'AVP DX6:+"&M0
M9 ':GWNH@D]W 204XMY+"3GOIIV6E. QA<FE'\YSJ'WC<5B0^GZNGIL"@^B4
MQ!"A6\.*QQ7C5L#[K!:G;"_\_#708.32DY%#AU-<2 L)G&=EW5:+"X$*Q$_7
M($8!(:L<-FRA5&K=+\9FWIBM4!$T%%IWEZASRL/2#.9N(@?MO2I=:#?5179[
M#.,P"WB(/4[=FO2@TA1[Z8;/&ILFWC!YI[3_-;R0]<P,D2HE/:&NNVY4L[7+
MQ2YT[E>+&U@":\,;DU=0]VIF>T_=S\> U^6-CI8>.E<7',>4L.&^9MPFPQ.C
M#/C,^MRBA!V<$G[HK12DQR]$<XBH+RCHVONQ0(F]!N\%A'J2'!#1@EURPH"R
M"\H'6.%:U5>;8NOFZKHJ:>+N^)Q^OF=O31S==D/VQ/?\*A'&M1K&Y7Y%X/TH
MF?3M,JU][*TA?)00C[0;L2/W)"_&YY0T)MLGXU/K?-7,>;6IQ+AH*TT/(3W[
M@ [A(:@!ZC*G**<BY_5-WD84C]()2)BJ__!?3^+=AN^6*TZMX<80UZ0O5H[,
M/?.S((G6U+Q] GQN/_34B=BYDME[GNOC@ST"(\<:J.-'2%$1$#=D)-,RV,RI
MDX!Q)M$VNHZ]]'(L4VTXY5"M9L]T=,P$7]NY79.#@*;K3[_Y]M8N#LUZLQ)L
M=#8JN&< ^E7=*O[#2E:<Z<0;6_V1^PCENKCLS4^BL-D=>(^N,!OH;J<2;N5F
M$T+A<1#R);4QR='J*H^J+^;GR*W$1 @L;I0R115\[-[G?K#-?V09\,M#&?!^
M/,NA#/AQE %?&W E> ;!+$DC;Z>=O-&!C*>-$+'K4>7(&+,1J3"-/7,X&4"V
M8P GW!0.Q8J4<KH9^HZCRZ4G##KKI2'AX?F7)]TT<##V,-&!8@<#I]G\='A9
M.15RE)"2D4$.RDF_U!)9)BE'Y87Y2XYWCJ4R*0Q,_2Z6H0)Q4WFKIO[WX7L*
M/$]&_70]WY.R']!=R(94H-?<T6Y0/\34X-P7M".9735=5#LK2BCK\#KH"RDN
M@T1A.@T\W,>S9\UN8MT17RD<K$LX&@X";O].AG1+,W$Z:DE&,61\N)+$/?7Y
ME8F81\2 UP42 6[8P[8WKB#\9XOB1F7 7:<[+3_8X:2(%Z55^/SGV??/WKSU
M]C31''>YK=AK X,*H-UEOA)*8F3QA<)-$_G?[K>0A^7TKR\G2\Z@*;!SB2X?
M@MD$L56R_%5;5NLY*"!X@2PUC>!HA ./56#\,RMXD+VXRQFE+QE5L.,Q6N3@
M0CXG0V#477T3,G/@?;(#B:T):!WGL#$T\TO12=64-<U!7DG*<8- 4"#5$P>,
MGO.'N;[+N4X4/"$S1/\<B[X#-D]#ZKR+PYS<Z0%M V\GM;1@C@PF,#EK9)]<
MWZGCA^G*U?*(_FTH]<.4W>64)4J*G$GV2@<P;WPH"H&:\"YH6ZBT"EMB<)(^
MZ#!U=SEU8,='SG_7X1U'Y5"^W7BZM= ]'=.IH_[5T#\8>C.Z2 #"373*6@H0
MB[_.&,4+U^@U\QG#.WJA%OE$Z,M/I>/-^<?I2=JC;V@&<HJ#];[[]51Q!%+M
MZ+QMP,6M*8VI?$84>V#]$6OSU<YX<891S**P^C"#=QK11)U;2518D*JJ772J
M\FF[V"Y64OX)/I0Q$0NI,<*53D4'>#[9X".)J-5L\ZP$-;% [4W0G,+!N5S!
MC!Q<KKN?\I"U3;.S8!X/=(W1.%_ETHZ*=LZJ6RMN+UQBJ%NFXFV&GFLN3%<I
M-;1L-F^VBZ;O^3Q AB]T^XJ1CB8\I-1\3N60R[C39>!S%EI[U4-8\O2,-A)F
M4-^&$SG,^Q%A)%]$#F>6/8[=JSXSK"SD#E@E=T*>=PF(&EP HP,:VLN*1L!J
M 9!5,'?@M&$([^P--]W24Y^ Y>?GO\Z^HSN5]%+\;T"7CG09QDR?+#K^;-$$
M##(^/FA6WOFRX\7E&&<9).Q !8M\4-ZM]ZS//T#PT8GT>"1B 8K%<(T!'I*>
MNE,IEX?0>#,8LS?=*P98#Z4Y_%.8K5UHOL.@L5G8[G37"?C$!1$P(\U\Q23-
M$3T.23'I(ZA&DA*10%^.&IP60Q\\0J\QY5LDC%<F4WJI"5J*0#"5A"KK#2T\
MD707.BU:'E4Q<")]646(7_@M[5]N"5]:YA^I_(K>F^&Q9?4/[69'H+06HB@=
MXG"  =IAI:W(TNH I2>KKLG&J+]_;<33SGR'T HP,C7%9K+52L>G>GB[:+>*
M[?9%Y+)QC4WB>/*JE&*-."0N(,X$Z^4HBBP1%;^A5575)9>U: 1H 0)E]8#,
M%6!% D4)67R>2U*1EH6&91#MM!R=*W0VYLP6PN]ZE)2%:%I!(*+TB<&DV'O>
MB@OB-3,D"-'3N+3)-/W2@L!8<92TLPE];X5.6YE,"#Y2%JJH$1 IK6(.GH'@
M*A^YDYQ5C8]P@LM94ADWC!9,9D$P!LR@C7O#%[ZKF-G4IJ\(7T0AM?NX ?75
MTTHZ;*?K$),G$O=J!,05*-K51;,J[^>&>]]^<O+9& <2S932=-&11#:PWCGR
MM?9EHEU3_(;<V3OJ'Y).R7LY9-?:J.^=.!F6,CA>V[R"IU/N'3N(@W(CPWG>
M%BI(P>7D%E>.?;J1?87'-?09R&&@J;I(>/M]4E 6FA9VQ'G@I2-(GR @/,D5
M9SQ0:/L*N-/RINEL4FDVMFR,X;RHYE4?FUO=]S8 ]'>&4.134<]1GV2,6VVU
MU9IJTVEOAG7COJN;*\XYH%68GIR_G)EYM+6)#<_-R,;Z* W)2^UY9H4J)HB'
M7@H+7C :&FN:+#H<$]2"@2/)3+%.DUA,?EDMI5C?=>"5^E9ZF8.LA]YG/$;*
M+.7VCZV"DM9SI39WR3V\R]*W0VB'Y_%,=^7D=@RWIZE:#5R9Y/A*-QO'6)#P
M97]I&6B[(&30=]8RBR?BQ)U\T:7[ETU"=4@#55[:."6G3FARQ2JR7>(9VWYL
MZB,0"(GGQW^BT(XWD'F#3#*D_@XK,0F,9QE5$=*>6</93J[7;+9NBJ2)NBU[
M978*_-7+LF!:-/(>4G,EK,#>:HWF-2@*A#-G__Y/UR?O._$.K U'7S,""+3K
M?"&;,O;L6MXU,:/9K*SX"4:DGW+TU7N.O.O9/YOW[@SYCT0R?W5 ,M^/9SD@
MF3\.)+.CPW&]BSBM*N9<8*'(;6SJ@1=J=<G9O&+=\ 4;2O'W Y=YVM<?.C7D
M+.SZ(U.>AVFNZU(BQL"-L'OC47-*RDZ@8FC(]CQ(A7&$D OP]X97<@2>HU#Q
M[T.U>*<C25,'"-76QBN5^M29<*)W--O]=B.B=T'H>F(6A63#&HOS?C^+E:6=
M"^:W7'J9S2#.K<[A\>R92U=6]<XD@X*PE&RE-JT)%^9\:X$J+\KP;<DT) (*
M\[R(G"ECLA57C^$&96U%0_.6Z\F2=E<DJY0A)\3$.XUV"?O^GEP!MU^ORUIY
M.KE*M(=H7?0.P/4CF(%DX[A=PD*-2AR::C_A4T0NF$>69_6L'H'M80^-9371
MD)PHC IF$P-0<))Q=Y,F5B1M'89BI[8.1_%W6ZE*(CO5$&S@^G_>2MU*>MRK
M-B:<H<A-%->OV^O21('7U^A$BC&O_OO.\OTT;^]_[# G_'1KRRU*W;=@:]U9
M9O=SY&YFJQ,SG<^PFEU*.BE1 ,6W\PULU=K49&1,N:N#[1R%^UYU'61LCHZ*
ML?9#JVGVLRN*P<F@4]@B?^#V&!S46^MYQE^_0SZDNZ#'(!^+0M38-IJ9:4%M
ME.9<V%/VSBX9@_X*),S"TY,B(#S36O+LR8I0*9*0S0D-X4D%9SF^"M*L97V.
MCM6H*[[[ #(*;&-6>8QPN1PUQFL4G-BH)8F'7T2V8W);8N&!7%0E"DIF-BYC
MFTXZ2*7U'<_P_[/W+LQM'$F7Z%]!>.?;D2*:M$@]+%EW-X)#239G]."*\OA^
M<>/&C2:Z";35Z,;T@Q3FU]_*DYE568T&'QI+(FULQ+=C$4!WO2L?)\]9$44;
MT_V\<"L%Y3,/]Y+)_H/]_4$J"R1.53Z#>TAU-\@R"649A<(^Z<7QE[T'NX_^
MY__8>_+@^8(HT E^UH^C4>RT^<*C09%O?7;6DO,M?O':,R3=A;T?Z)*TW7AJ
M5N.A@3J$)0G=I9QGLUA"%V%JMQ!G6%7#=V'U(3LA$2;#=!TB[Y_S5(V.F=\L
MP()(#<]+#L/DNC'7\#V7[ 84WG-B4)BSP2'")B!.4%Y]1/-Y841GZFJ&RBL.
MVJ-C8 T4B!$5>5&$SAUVE+00'NQX(%!K'CJ41BH= E^21*$7>KS5Y^SX??0>
MH_@^#K6_L'PVKN.'WO0H_NTW/9GN'[S@/8R)0_=?!92@;N5 ?$:MJZ^RL10_
M9J.K(+;;ER$E!>I#]Q5B,G1+90X"H"@I'4RY]?"<&JOP:&KA'P]</K#%Z6K$
M85"F?36=,W>>5#1F4?NL41HH!V[U0MUH$&B_T \A'<;H#@G:+QU?$_[<-+RC
MHXJJ+1IVW#RM\D:$@UF6"$*V[P;R\I;LP:8\IV9GJ;G+;)#KB5P +9BOCI>E
MMAD*3?+0T.+$,,"!5).\6T:,;*M+OQ&6:9T_RJU=B;TOB(@8=Q'D(SH-&55M
MOS!48+C^NU4<Q1>KT%V#YHZBXF2A.Z6#*/]4<)[(!_ZU>GJQ9/B 9TFI?:QA
MBZS]FNM!#BL] ECUIA/A5)Z:@GF>V9"1"27SJ0(?KG5B^!#3=7)5' "G&R%N
M.1*SQ=)^Y8- ]<JEHN6TJ >2KTN*\:;3O._TE'!=$?-\\XTB7R,WIDAG5=UV
M/M$L-<4%_O\F7>+)DZSI9X+!=?\UF7J+;GL0?,GU %#&K,G9]T#<MVBR'0(L
MK+1P$0@# 7_9G"P\E:GSEN54D!2\AF_)UY:@@((5%%)]P2I?E<1@;60V7<6I
M7W;%Z%EE\9$\Y7F>GA?@L% T --P$]A!G^\<^Z*%(X>V8VD:ZY;!T]_7S79I
M?>&E%4WTF9DI@%4DH,!HS_B4\+&EM%HC[ ?D;]F0==U:1$%%A&8BJY#B#5#/
M.O6U(HAG"/T;H#4$ZL.O\\P ;15#R&>;H#6X3D3R7B!Y%L9QBZ/C PU$ZW-F
MF$]G;G.U+7EG3+1V9A\HVF#"XD[*)IY)FC65J2]WT&?Z$,'$F5# '0VG;9=2
M<9: A]55V@ 124(>Z"*@/<BI@7?1]O0X-CE]C&515SFSGCO+DQCW-,E"ZRAS
M/ZT]81UC<3?Z2OBNOO?:(BQ_2HC(TRU$Y':T90L1N:40D1M)-P_87C<3?L<5
M%LX9*\L<('KF_,;9A1IV1K&R@ $K'<1/F8Z%6<G;BV-5P<U[531M1Q!(_/RX
M(7,KG[QY_X+9O45M)Y_DU9R/]<9?IU?%,"EQ)G^?=(QO@6A*""<F/L[I'F-R
M[Q O@2V1MPB<=6[&\TY=6.:\(<*;TYS[Q&(I YYPL3>EN!\#("2IZ,DBIZ*9
M >NKF[X&U>#(?0E^U/>":,7C/A@M:D-F-YCWB*N"F2PZ34'Y9]N9!,?S"O-&
MJ3X>>L^FAU&+V( PBJ%4D@$?Z@X6"/8JYX*O>W1#1[IK<NL*VF6L,>/+RDVS
MZW>[.SD<^XVPBK63DB9.F.G8;E1J!X%V2!'9F6B!4)X_R'6H?A.>@F(6Z.6
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M:;$(W"J^\EB%8;4:T(97B%(3<. L7:# %^/K'-K2UQG*26P5Z*+$*O^C"&$
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ML*5C59*Y)C5U73"<%Y9Y5?=(,Q<: %$_7'>IMWO]DI!:U>ZBGF2-NPT#DT.
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M>?#ZZ,5]H'KGJ+;U&]43/$XC4$_;+XGQ87="SK1$S7B3X5%X$A_ITSHC@C9
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MQZ5\&%ZJK;&KZP,J(IE<LHJS8X.!,9.%J)F/[A,2#H:H._K=?Q)VF##^!/Y
MO1IEB_<?[/_@"POW'SQ\FJCSSN$I$)M7^07-Y)*=>_I;OX37DD?%C7C!'726
M;[)Z]_;VDB</K[-ZZ][-_8GKS2L* I)+D4P.77?=\%5%&B_G>-$FFS7%M%*)
M5N6.+-<\B\3@Q.>Y="GN7KW&UIN_>:&UJ!N1!;%IF3VVR^SAGW.9 >*@*\PO
ME3?$@IE,WLV+6@H$XC6W_RAQ+9,5:1:>3ZE30)DQ7?2X@W[F^DE#_FAW0@<]
MQ1-.X!2B%M6=.)O/(/:Y-RZO.S_LM%3IJ&\7A"7F:(#O?$3>(Y1 />4!N9C\
M3#.DYCX\I,._RA,WR(W[]NJ6!I2O&J'3O 3QBT]V^H/ F@(4;?M77\A11"E=
M@L9H=H16$Z>+9G6=32[JYB-SO$@H &:"O@@9)P'8#5[!F S"NTAD9.PLHB_2
M7UX4^2P^6)$RIG4^9JK$R9<T<]U!)#-U>Q%WZ25I]%>:[3 T%7IN8G%E*CK(
M5:IY/OGN+=4B[#W<><VGK,1'Z:\([CA+VCFIT([()J]\].0D,(Y\][E1DH=[
M?\PHR<.-]OCKES\=O)XXJ_SPY<L71V]_NH-F^2OD3</J8H(S["))M>B>*=TG
MI<VQ1 MN?V<')=L=D^#0ECA$:G2F% M?<2$^^F,NQ$<;%^*;H[<O)R<'KUY^
M^._)BZ.3P]?O3GYY?Q>]Q/%8';?E?_]?I\WW_WL;R+.!O$>_1R#OX0_;0-[M
MCX']V0)Y7W^/C1^]QP?O/TR.CC[W,GKTX(]Y&3W>?!D=O/_'RP^35^_>3]Z_
M_.GHY,/[@[<?_GJ"#-*[MY.7_^>7HP__G;C/7A]\0'KIW>$_?G[W^L7+]Y,W
M!Q\^O'Q_,CEX^V)R='+RB_O3\2_O#W\^.'EY,GGW2GX[.7EY^,O[H^O&09]\
MLX%BUIG)4;"O[MZ-_&X(U",T!*&_,H7G"='.3V5]2@9<3GKH0K@C$4V@)U:+
MT[J<?/?FOW]ZN_N=72^W>4S&Y_7$8(-N<^LW</>U?(M\@7+L9]?S.?+3ID^;
M%4___D,P_#W\(@VZYI HE!)(BC@4]NR)K=0@R4V&9*_7;%!LDR(W;A-4/<@+
M*5!I"\/<UIDYBZK#EDB%%#M\5QYNR\@X.$0%)/8YA,>D8(AAQ>&*M,EIW]&G
M%';B D- H?(248VV:RAX7*6+G" VITW]4=_#V LJ_JQRCLUJ52!AE&YU#&Y\
MB[Z0DH#)L7,RIZO;W(&-(3*$O"L*'TI-!IVY5))19&,%&5I-(Q4 LBJO*"FA
M:EBE A=]/E4:'9::$/%2OV1F7^+K#H2L2.#!A><R A8P6DLE#,I/+/@ZKA#:
MT#%["WV;ZA//'6F+4 ;I.?W)9(F5Y^LK%FGVGU6B]$N0U+HQF,4%(QZF-T9?
M/5JX,EZE N"[G& Z*/P00\=>$Q=&-U:V<NV*E=N\&<=/DU\JP\-YHIJ)@;OP
M-O?H<T!1MZ#9&UP/JB!M)L=6!O$E5X[>Y=EXAZTS9@&=IM./[CAU!_..-.8,
M_^_YUVK:VGXF' ,)G!1UWY:>)_/?;F.PH$80J91DZE_V'SS8?3!Q;2O-@5?W
M'?3O.&%C*YR]<-Y?]O8>[/[@?_@M#<2"++ BNBSCKL:TU6S9*G>UIR@T8Z4\
MJ7F72XV3?Y0FK=TI7FG)5%1ZC*N/OP,<[M0=K W+N<Z9PM<_RYW7LR9=)-".
M)Q3Y-&7Z:R)0_N1V3,<9V:!$XA/XYHXZ1:JIKN+*T1$A3%,%D_@2F/@JL?7;
M*6-<5NN7"5O3ZQW1DHZV;Y=\C3,(6\NP,LL2@LPVE1FY!M5DW9*0R+4/O6]V
M,,LH6K%7^"4P(-BA#A5'(T-DI%% WL?CM&%I;L/I-IS^>,M7=3O:LHV,WP#B
M>J49\Q6-B$L"9I-CQ@#!3?RI29?SNV>H?8!WZYI.RESD?!+$S3FX%RR%P\(X
M5"4&H3/#&!2XC1F'LNCY&%6,E6&39.J+4:]7CO949 7P8>Y%1P:B&7L_,'Z&
M;2SS>7P%3.XYVV61IT1PC](K.+#TDWL']\5;/1->$]?7[H*0G;B 8&Q(R2O[
MM7F5><#@J?.8JDK*GR%PQ>] *$#:[]YV[V_W-SWM&D^X'VCFU\94Q_',1JF)
MMHSNI7QRY/;II\F]H__[Z/"^;[1\2\"+A]0D_[V?W?=D E"YQ"V(TB ^:$-T
M 5>$:2*;ER%$(1J"J-_PEZHBGA-#-*TK&T!8ALVUANKUY%.I#/-0;-"9MVSC
M48R!1[.LVT!,O\QU@MQ:^5=?=]>+_LM7RK3MO#68I9[@%M9).Z\OUG'(O,=H
M_]':A#*"< 'A5SNTT$#\$I&8N.,6KX_49W7),LB+\";MVNMX\X(?CVKHZ<#X
MB[NG)Q=I*SQ W.'U'5:,[%+!I&G5IH:I9C43AF>0L]O<A);'1*>;AX(/&01]
MPT3-"R(H E^?ZU?*P;Y4"(Z$[RVJ3#>+9/-+*";M!M,-MK/T79,0-P1T&-J
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MR?5LE[O3I;W'>[M/]OY<CH:<_9LR5G^.J_W/Y'(\>[S[]$_B<NSM/]A]?)W
MWQ^AKX^?[#Z]3E#H#]'7O=W]/XG706MXX&'A3OH>F;=; $,<1^P03\./-D=M
MBA@G?1OR_YPYID0Y4V(3N1E$H8@SZOW)\>0#P!CO&8R!JXFX2E*5F1!ZEDQ
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M_FX[4X%75D[Z7W4+GCG[4)+R=I"R[MGW[6@I25F2<I<6?@_ T*>BY!>?T+E
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M-H>%'9,'=Q&&V/W;J.'NMLJ;&>[]D&71=8+)3[#!'[/T7!W CD;*+J84*0=
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M 5<-_HK6/"3HE/$?#RO,*'N(TWT)VU747V;A>CQ4W)D ?1#<9A=;Q/$_Q73
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MT)6.?F'\<7;)L\.PIPU\N]61IOU%GF227V:\I=<H'X>XR-ZT$ERZ5.NOSA7
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M5]&'_UK1?_X<?#,&5\'W3#O[>?#S[&<T./[P_L?AUS,-WAT<GQY=P'=^'GZ
MWWT]^/GM*ZSCO6<>_@5$JKNA'@5JZ-F6"B1,U  .5=7T,-*=* QH&.V\M8Q_
M_=8B@[>_KD/8WRJ#YEBBK+1Q\44@A=-JPLGQ%MS:\E;I\,&9S,9<V'"4M/SD
ME4^,.=S@+_JZ%#7)N\]* J[VM+P[]3[W4>@F A*U71+\9_*@UW+0SA2O+^S6
M6P98SRC)G]Q[ML[E%AL]>V5_;D1BH]>TV;/GV'2;O(#JTM[4%?#"FXU>PBFF
M^O 2]$^\H'RCE\.EU$8O85K$:A60SLNX!\5-\N<XI8JI\25*U?U%:'3N(AM,
MFMT=/CC_5E6\C92QN9('5HDP'QN]@!=R"?@;;0SY"XVA#;8G?&Y/;#9_HSW1
MF[V!IJ]^X<^1[ISU[OYFFT+^/%-H/IMK+T@?]Z4^_H)9TC6D/MZ1N2Q_<)YQ
MJSY^@N@Z%]D *PO^*?HEMH11L4@[:0?*-G5K>IM[R>#TX91NU5#F1*&D/%S7
MYK\@9R<NY\6K)[A(J9Z\6'9T31GI?_D';=_N7L2.1.\9X,?+$%GV)CNW</9S
MU,?-7L]&SWZ3<RS8_#<Z38'1#W,K,LGTDO1'>^.#Y;B$EZS\VE+Y?<$ZD6M)
MWUQ'YK+"P7D[;['](>MV<&?G0\FI+^+ 7?LV3OV-E33?7C!M5L;DVW\%^6^+
MO7];V0?#74<?#*SZD7TPGF$NL@_&"GTPGI[G%K4JOF?Q[E+]++K3ZNN4MV8Z
MN2 Y%3$SWF\<?OA'AHV\L*(LR6E8 C0+5/,/-,5&6$4/H4PZW>-L_@$?7R9I
M4L)%T@7:27<7M;!Q&^^0CL75-!(8:MCQDJ03UMROJ9&U6FXN/MNR-5^11 G)
ML9'5:][6FHWZZU358;L[7Q51+1$X!@++L3&-HN7NK%N,]>:TZNS!T\WH+H=H
MGH([;Z'"%(LZA4U-K4ANE"%L\$4)&W<+VKA6L4B).\,:/#;?:QFDO>KY<@-2
MIB*_QB8PO(\OZY)<H@EDN*?X. *%&-KO=_;49\_IO__:AP/CD,F<NGLEZM[M
MK_/>E"GON3I@B-<*[^,FVNS#KQ%?1N"H-/#JA2Y5-KT3-('M6^^DAWI+JE;\
MV/NWV6(.6Z-B\]LNGRSKE,GP9)$067]#UMWO''@(F^%-D 'I)6M+VVS*SII_
M#NB&MH>L>P\*4=.;U]":[7[5]%G0B+@X2U)I7*#'B.6 WQ$WS^LO:5+%0XI?
M16.*7WM-4OMG [6(02)G PZ86Q-I#0AYFZ3JU4!,89XPNF_TM>6M^<L/O>,?
M4O$'YSFW;G,RI-=9_H-WHHX$E@5.<X@=O9E.=W*)G,CZ&![GYR058+#5UIR"
M(AZ!_LW?*ABXS&M#TTULV<B'_Y41*.]QR#04SM6'"!C$%\378V*'Q1P!M['%
ML#).61-NUK)9R 8.VYZEG2; ^7?W'U5C87&+=WD)"_0NUAAWKC FHF$P"EUL
M^RWZ^K9%[#^+!C(U[\0^]7S"7#"""I &LK;&(P826%3%_+E4/($4QUB=M[W$
M.1+EDK-R0Z[%H -C!]A22Z[$ .\IPZ" FI!J)9Y;K6*+'K)%B0C;O%86B!@F
M;TN<HT:O80;/5<IS<GD)<V7653X>T!*HIT8^$OM[TFA3#D_LEV $#98LAV1K
MZC3[+)3?V&IZS!JAU@>[O 1GZU8X8%O]6W&HO*OX-=R: R+Z0=,<[T=^# RI
M"$&0 M:R%H&6LI0(0/)QSCY-@FP\PK;GK WM C1!SBAQSD5KI:K@(96/]*HQ
M1#]7T*\R!A( \G0<<;:I%B\P6,1L!71*2*-QSKV9"/!4<+V, UPL^FRY3_/1
MCVZ=4J^Y8=-3P'WE3"[0WK.B LDX&8<7S8>KY7!H.X8:AZ2KC&C9F;VG4-:#
M/J2B9W,%@\Z@%SC]([;Z@.$NU.#)<Y;5VDJF'-03$ A:%<;Z'"4(@=IY*_PF
MJ%D-GS?$?N9PH]8BKX>7^34%)17^._6)L@VQT&I)4T.=/_FO-1(6V^4&4X@F
MU;!S#5*M.]LWE.WE)('7I8OT'4HZ;&;-NG&!%@&:2KYY @V14<)R*5S"#-E2
MT((<CE,$7T"5C"$?) 4'$,-?@SG+H$89-APSE7@?YPHZG(UU"^D(84>*]I=8
MZ_W6%=?ZM;C6^.AAI2'R>X6,WBBO]5^%J<@E#^<9AG719$CV<92"E1@JD=?G
MBDL8_K7Q*[:^SP970O2SBS9A=@I<=&"-,N3+7MG:&^WNC&-F#.A-!4G'@4$:
MBVIPV/R#B#*8+W;*)@/\)P/& 7,)=-T&!Y6JR1(8<B/R@Z8<9.WZ(AL(A,MK
M6F*%]E!<-.8G1,/\R3'"Z E69X8"J!&7A/7PGY[:W %0$*1-\39[5)G 7$A&
MY<EVMI.L[_==S;U/(UG=Z5N^?:]&LK?_SC;-M;>G]6!8U[A_>UI_;F32L_H&
M[+(R)TI9MG&^L\%I0,(?YSEVY%>%"(W9_WY_"EB[F9N"Q7@.X?(#0J[4&\I1
M<$6C_27:I)KK:9/ZT$<?(W>@,T>W"+>VA1"(4FKJHE_K=J\A/#]?FWB*K5VT
MD3K*B=LA**;=2?-L["FV88K#*\?U:N0)!G:#%\>8N6[@GA1@DN7M>O?56"O)
M#0VZ!1+>P%9#AT$D/*Y"54$(R>2*PVA-3Y@;S?SO23$#4B6<I6B\,$,N"P8(
M=\' > JA18SH+3 7W2>".]"KN[\ INJ7=#R<$NM+TFRI#R(YE#HA4&$#ZV6.
M'8=44&G%0-@E]F_;[!0:-7 #5YM9@(3RC$5*0('"^; X!T*\(0@5R3FSE<3.
M85 K&B4,&EA OA3%>'C)_3UE* 8A$LD$@YL%VM"XNAHGG?T&>/.F)_Y:1FQX
M?$I8"\"LH#TQ<R,=Y0018@;E4BO,8X'+G=#*N3(>B G7@Y:62))'*JYO(N;6
M7SFY9BL39;S%B3(RYZ6SZ2);G/,BS;L.F7=3HG--P [28EG%8F'"]3_9-;ID
M=Z-(1#!KFP4O970U,RVF6P;,RN[19U<%OU(1ABF#Q)A4@_$<Y@(47G6Q_1%%
ME8[[*$'3$C^M8:(I4[- L4@9$F!<1N,Y*N!<S;)4TH05P?0?%L) 2-[WJ._=
M$-0S&<2G^&A[U-K4:0Z:P.X(9;:IAC:5/Q)D5U1@[UZ.1R( @;D<9!"RD*!0
M2DNE,FJKIPRS<;%^VMRF.7.L%H$@F;@I&$WE6B.H>]Q;6UEA',+["@&>!ZR/
M!0U)P=-)8+L14%<I$S*F]X@MJA4V:7ZQZ>_&^5XDH,7FS+D)YB6IMF1(?DSO
M!H]]E/9<R@/,+,%E#.KO.B%^GY-'*B1N[NMM1-<6DO2TL51&P5K FF@.L%@B
M/GE50>=R:&A8UGD9?!YF$4+^EL14GL+=1(U/<3V&9?W5QUEGI90!=1:P2\E@
M4B0BM(]HK5$;X;J@#2HOIX)'4X4R./7.&$(*FGA\7$%VT3WX<I:$:PMMWBF4
M7X=7T8?/TM:F+*JFS34"%HB$C<:13\%( NG'$N)8WBO?&'9F8@$-9BFIOG+1
M8+I:PTZL&.DV&<B/FL^A]:$6DR&\=X2,4F$/UQR).._C$:)-STR A4D$PBP\
MUMS\ZJ (#!D)8[6QO3/;Q',MIRWD@%X0$%'Y?5P[\RH^5JL>>:Z@ZGR)\5OQ
MVQ, )QW!#YX7-LD\?%?")IU;WX8'QK>]+Y.S[^<_C[[_91]^_6(=?_V<'.X=
MP/C?+N!W/P^-0^NC^7E __-Y\NUK=!D8EG.\=S$\^_[MQ]'IG\GQWJ%QM/?C
MYMOIN?WMP\'UX??!Q='P/?SN\.?9SXL8_KP^^NMOWS:I2W1'M3W;42TM<%3?
MU"W5U70:T)C&$8UWWN[G*=S#_P\4B-^5,[@_SI6/'S]-(QEM7JB[S/!&#&WA
MHITC50BG$>!T=#89FN9L8)K2X_/0QXR'KK>1CW;_MD+B.(85J*8>NJKEAZ;J
M!X&GVDYL.U9,-,^U=]Z>$+@T/I(?0&2@:_:4+Z=+,U%G*&DV.U;6%S;=IOY:
MZ@M-65_8?3?EMOE:NU)/N!J4=%=FS4&[_S@YV#O8_7RP?]*A"<\79;>@XW5^
M[J_1U\*S # W]P:KAC":KA07S$'$LW)_74J1FXNL_/21!J_O>-9](@V.V?=-
M=_V(Y$Y?\QXC@&'ZRT4:5I[L6N'3%SK!YZ>R+07//4RB:$#7S3+3"-WSD]+:
M'=AF4] >$Y;[]Y5WBK/&\^P4QUZX,UIR]VJW:LOT58AJUE,=AI2"-K5B7.EQ
MUGSWA<\6O7MRLG]ZL@RE+%KMZCCV]]S.AXRQ^B17/GP1INCFX<\/N[XK@T%%
M ?K2FWM1P=2R[W5(CSW&FAB9IW@;+-V[V^>*\8"J10*FI5V10:O!15N_6&H#
MM'D9[IU;^JL'+;&Y--8RK%-K$_[1]SF/TBGC-.'>T7$1[;3=I7%@V%:LDR"@
MMA6$GN_XKD-<&IM41P/[[X/:2PKF>3(D@^+?.ZI=^DS'A7I.R.4;I*3=-,+_
M[-=DM#MZ1_(<(XW_)8,QV/(%[!"\Y3RW7W4B_*K#/[^?_3R?')V^_W[T]?#F
MZ/M?U]^&A];QAS/[[.O9SV^G!_#NX<_#GU'RT?Q\<3:\&1Q_WX6??;D^^OKG
M\/CTV_#;Z5_6F?'?"WC/_/9]\./PZY\_#H>'&KPS+-^!;XV_&5^<PSV8^^FN
M?C8\LX^&WP9'>Q??OWU]/SR#9X^__G5S-OQK<O;SKY]'QK?XZ)UV\_%T?W1X
MHMT<GO[0CO<._@Y,PX8#LE2BZ[9JA4&D^IY&5">T COP(MTRM)VWMM/W2U=L
M20/3V<GW(/I2L*U _.N\Q:4(>J$BR/ C/]8\(W9,S0K,T-?TP"..3TS/"'T_
M9B)(ER+H6430SVD1I#FN8U/;4:D?^*JE@_3Q-9>H+G%<*S0B0@UL76V[?:M#
M,FA-2OK&*':')/]!N4LO2:\H3PMI=,!8J,$;J^W)7$&[T=)H70I1?0)UWQ!A
M1DD9M(H,.IE5@RR+N,3RB*K94:!:KNNJ 0T=-?8MFVJ.H04& 37(ZVL/%4&W
MB(''4H.6M7&WGE/7I3=(3ET;I\YH"]0A$8UTHL:Z!]H"=4(UT&U/]8A.8T>S
MS= R=]YZ^L.5A35RZK9Y@4YS;*)3]:?@^>7(#_?2$I8UQS9:]JQ+2Q ]#HO/
MU9X?T9$4/O<0/LD<-2&T#<<*-35P"0@?,%M 32"VJH=6X&JAHQF:N_-6U_2^
MTR%39=U!CZWGU77I"9)7U\>K,XJ"3JS8#S2BAL0*5<N*3948/E$M6[,USS7]
M.#9VWOIZW^P0JVZ;5^$@O0):S_*)=!\\MF)0;37(&"E<5A$NDUE%P#<\ZE@T
M4@W+=< *,1T5Q(VG^J87NI:#Z>X$TSKZ>H>L$.DOZ*@>(%GS_JPY<^\[FJ<Y
MGNVKD:U%JF4XD>JACNZ04+.]V#>=P $=W7[XO2\=!/=FLD\YO21)I(S(S3U#
M!UMA:*SK[A?;?8J[+07,"@+F>$[*A!-'5(M=0S5LVU.M6*-P[8.H\:TXMDS7
M\S5+!P'C2A_ 2V;-==W]DC7OSYHS=W] +2/TS%@U#=-5+<=P5<\,-=4CQ":N
M"2?%6-.3F00=N/NQ16%:B/8CO!=&V,H*ECZ!)](+]OE)[*;1,1[#+MM]Z8>\
MATR:DUI@8*Q ,WS5",, [!'/5CU0']0H\#S0&/R Q"9S%70I8"E=!=U6%R3'
MKH]C9[0(PPVI[3F&&@<:<"SU C4PB*X:3N@1S?9)Z 7 L7JGDH'6Z4$PW8ZK
M$*?9B'4 >["VL$J-ULL43&O+.Y BZ)XBZ/!TEXD?)H9.]V'MYY._(\^-[,#W
M54<+--7R0D<EQ/54UPX\'>20'3D&R"#76IN786D>V" 7Q!;S]=IR%"1?/X2O
M)]-\'<6QZT6Z2N/  MTB(JH7$U_5'=>.+2]PB!GMO+4\J^]M"E]O0[GR<=5[
M>$ )0T*$WZE9K(X+N@9OQ7)M#%Z>D%J7\E$=ST<\G<\XF>/X"]A'>#)2:*TD
MM/9GE9'0(J;F^!0+(SS5LB)7#0++4V/3U@*?F@[UT:VJF0^O$EV)(3;(N[&M
M'+XN-41R^%HY?%HMH8X1Q8%-U<@/?=6*/4WU0P\4%,O079-HGN<&K*KBP5K)
MDS#XRVJ?,Y\)/V;IN8HMSY7A8Y1F;D40]S%+,X^R-)16TSW$T\&L J(1.S!M
M/U+U,(Y4BX26ZL>^KX:4N&806A$)S9VW]OJ,I@WU=[QL;GW,\DS)K??GUFEE
M(HQ\ _[GJL2)09D(?*)ZAFVJMD=HH+N:$VD><*O_\/A)][(P.JTR?,H10PD[
MJU\.B$#BP19=EZ@P])24+D:YVOH [OI2+O@9?,(3V$VC_7+_9>[WJJ+G<(ZB
M8#DD(K:K:H&KJ59(+=5S;$-U#0LT!X^XAH9VC"F3+5XRKZXOV4+RZOIX=5I-
M,$)#-^W84X$Q+5 3:*P&NF>JH,L'#G6TP(HP%&+V[0[QZC9X%@[2$4G/$]"/
MB_LK!5MAD:RO-K/<<1YN!?FR?X-H?K!U'[(L0HAR*7!6$CA_S2H'KJ^[H6MB
MDR<[4"W-B57?=D+5M2AU+-]VW3C<>6NZ?M_MD&$BW0@=U0XDTSX&T\XX$TRB
M@3 EJNGKAFK%CJ\&V/[)-"U"=%/3(]T#+4&S'EYJ+;T)*[%<2>/29_#8ZH&4
M)O>2)E]F50!=LP//=TU5U]#F\.Q0]:W 42U=-W47I$OHZCMO#<]96Z!3.@@Z
MR)CK4@$D8]Z7,6>= 1J(2N*IGN-H*IR)HWJA2573L4TS\JCOD@@8T_3[1H<8
M<QN\ :S : TU%B];HJPMD[$NYY(AR7N*E[,YIG^DN4$0F"JQL!F<J?LJ 6M?
M#0BAIFWXA/HF:PKS8%^CM/R[RZ1K2T:43+H.)IW6 1PW<'S? QV QJ #.)&N
M!H%GJ[8>6R!%33?0XYVWWHMMV+@A99?S58%[)WPNE0/=N:U8'FEGY?6_&'&[
MWM+2'27.\B$9P< WHS?I>*A&&0/XQO>D\%U)^(:S&A*)/2!"0U/=4'-4RX]M
MU0LB7W4,/PAC6W= 30(-J:?[WL/#(ZORQ#,[3J1LD[+M4<MKI6Q;JVR;5BSM
M@(:V;1JJ[A*0;9@:YD6Q#GJF&\0:B=TXQOJUGFEHFR/;7I;O:3Y$],>#W3\.
M/AZ<'NR?*+M'>\K)Z?&[__O/\<>]_<\G_U3V__IR<'JV)@!I$XXARL981+,R
M"/D3P4<O-<5MB#R6X-&#A 3)@.7O2P3IE](:N 3%4"[)9!YDT(-=6)U;L41M
M?10$I$^<?F3KDGMH4=_GM"3R IT:+EB(FD=#U8J(K_JFZZLF"0TWAN,* L0\
M\%YB$9X4.B]4Z*P;RDD*G8<)G9G&!+IC&YX;J!2.6K5\/0"A$[JJ&46N$?C$
M-UD?-+]3S=:WK:,S$'\^IE%3'Y=)@4^@YN"F?ZSW7 J=^PB=.?V.#$<+3=N/
M5>+;NFH99JP&MN>H(0D#&E/=U4QKYZUO=0I"1B8)=E<UD(RZ'D:=U@X")P#!
MZ1BJ'GF!:@5>C)T&7#5P8S>R21181K3S5G?TM;EU.^2YW1CUH'37#<E(=-M0
MLEC)IEHJ/E1YV(H,IL=IF%B*IHD43/<13',:%GD!B8GCF6JLQ396%X#9$CH$
M_B":34)-]X@-@JE;14LRW["C&H3DUO5RZTR-H0_:@AY@0)AB)P*"Q0<643V'
MQ*$?&*&)-8:Z^1(;%FU2YF$X&_=[E*[+2Z7M;+1D6I<>(8V:!TJC.6T*0C=T
M0ML.52.BOFHYL8NZ@ZOJQ'6LT(\]JA.41N[:2J$V)0]/,O>3JAV2N1_.W-.J
M!IR'00/35P.#J1J&IA+/]577 7$;1:&OAPZBP:W/MR@3T=; ?5_2G(;9>0JO
M,-!J): IC1.).O5,^L=P HMM'LHIN?E#'(ELSK:JG)K3*,$!@TBW_$B%\[%5
M2_-#U;-BD%@:]4,_TEW-QF2/-?1)D/!3+Y'!'ZJ#2 9?,X//A$X,QS>)IJF@
M<X"58<:!ZH-UH6IN;/M^$+LQH0@P]W!(%XE#]1B@#Q&-*>CD3!N1Z1:/[^G8
M$_M]D(;9D((T:EA'4B"M*I#FM&B(/=,P?<U6-<MS5"N,+-73=4\UO-!R ],,
M+6+LO.U6-UB9<]$QM4%RZR-QZ[3Z8/I&Y,9.H,9N!-QJ4*IZ4>BID0?_%]EA
M;% /N-7N5!^U.S2$*"DN!V2"DZ6W<_A3/;D-KI6Z@XI,">E@2HAL<'-/H7D^
MJ^($;DB)H^FJX>M$M0+LL:#%IFHY7F#9D4>)AEVH3&UM1M>&.DY>-L<^<EJ(
MY-C[<^Q,9HBC!UI@!JKOA*YJ41<;5/I$#>)(TQW?M@V-[+QU_9?8DZK36@/O
M2CFHW"&R].2IFU0V+2HI<>XG<7[,Z5#MQ!J(%5VE$0E52P?UP'<,HA+/# ,O
M],PHIBQS5/I!7C"GKK53I>34M7#J3,OJV/-,+]94HD54M3S=5OTHBE0M(%X0
MNYX=VPA*^_#*U(Z6GFQ(TNB:G A;',M]A&11*7U6D3X_YW3C\&TC,/304@/J
M@?0Q:: 2U]-5WS*HHUN&:=CZSEM3-S8G@"LS-#91Q9!<_0"NGM8I8J*'F@[J
MOD[< /%I'#4(S4"U(R.@%/%I3 R"VAO$U=O@C7B7#8?)")%A"P:JC8P&<Z=I
M>)O6L<0F+'4ZI0!\G!O]IDC>I,G@WSNC?$RGF;^Q\-TT>M=<MA0!2XB .<TG
M?!I:H8OE'[YCJA8U(M5#Z#O=LF(CU#4*E@;RUA3W/UO3PD<BT56N)TFBCTNB
MT[>4YL:ZK8':&9NH>U(W5DGL6*H3FZ&A^:$9&<9"$MV&F/;)* M_7&0#8(SB
M__W#,W3W=X7^;YR,)O?K4[K&?K*/-L93W_-1<E6.+890\?DW?CE&DD; ]&]4
MG\WQN=2"#+\*U-!37MTF_3[1_.2"Y'0MIO?!T?MY4C!+&5U^(OEQ?C(B(QK]
MEPS&M/ZTT-XU*1>7D(N'H\-W;;D(XPWH?SY/OGV-+@/#<@Y/_X*Y?$Z.][[H
MW_;VKX\^?)E\&QY,CCY\3@Z- ]BS;]_AY\;1\,_X\/3\;RN*?-/28]70[%BU
M'"=0O=BSU=BU \VBH>TYUNUWZ (JNI^I)ZEH(ZG(TR,0#3ZB*.D^-B\+5#AH
M6P7!31RJ:ZZE@?ZH];79UB,S/U N2:Y<X?'VE(5T5^"Q%X_D,VQ0'".OXG@\
M*D9@8X&\E^Z&YR2UGP=_.[X3Z*89JSYU,9\)Z,VCGJEZQ->UP(IC73=WWGKZ
MG$)U9B:O1E+K<EA)DNHL2?WXFQJ@*.J&J\+M%ZJ6%_FJ[T2.B@8'U8/8#!PD
M*6U.*Q:%4XV2U<>ID)&R1T,Z#&BNF'I/0:'#2 ])I:? XY<4WKZB@TFEF(-B
M*4/2CQ<%:K ?4QPDRZW*<M,>(].BL:<[L1K:Z#3V31UN?%W')#4#I+/A!FZ,
M-WZ74O%EQDA'PSF2/1_*GM/>,H]&8>336"618:D6:.!JH&F!2@+?"7T]]C3/
M[!I[;EN+TEV8-FXY&8#)DT1JDBHAN4Q&9" +3QZ]D7FU]Y]@ZP_2=WSC&X)(
MPN.M3T#-:3CFVZ9+M=!6G9""_D! 2@4!*A&>9\9P@V@&M@+0>X:CR7ZE+YFC
MU];Q7'+TTW+T3',/W_7-R A50LU8M4P_5KTX(BK(:S\&LC!]DW.TX;S$RI7-
M43O"<#P<#]")KF2LHB7,AI<YO:!ID5Q199 5VU;.\OI)-) "U@E_FP/54)X'
MRYQ_USP-WDO@(QS)$1T=QZ?D1@JJE035G#9C)+!UW0Q,U=%TL(UL$\PB.$E5
MUXD)0HKAK>R\]>9DN_TJO18O@87OKW)(%GX>%I[6-2(G-$SB4S7R+*):5NBJ
MGAM35:.&$SJV[NIAA&4PLY;#L[#PUGDV&BI&1.,D3$9;YM)X5HWB,QT1F%&T
M3_(4]JUH',<>/PTI@5:20',ZAT6&;T>^[ZFZ[1JJ%7J&ZOMVK/HA&#Z^YA!J
M!#MO3<>9$X=>7@9)QT6'^7;M:H3DV_7S[;3F +J![9IVH 8:Q33B(%!]V_-!
M^3?@H#P3#A%;D-I65_AV"R%7#B=Y0B+E TTIS*SH*:!"]WE&J\AO_J?(;'X4
M))9-E%O/$$)IYIOOL].0TFDEZ13.:=:E.8Y//4N-, ?7"@U7)9[EJ-35?-^Q
M=&)9_LY;SUM?B\/EN&"#?!>RNO;!H13)V0_G[&F]P[4(G DQU# .@+.M (&>
M?5\-=%T/J:%9KA;NO/4=]_$Y^]F*;#?<JW&4I2KR6YX-!ICGF0#KY;38-M?&
M,Z@:ATF:Y2"&#L2.MR.Y<7)#(_4GS3,IIE824_.ZA0;$U2/#5&,CBE5+AS\\
M&@6J8_BN1V(S=D-MYRTK+S1^[U 05WHW.JI+2-9]+-:=:0WFZ(%%(T?5#**I
M%O9)!]8U58<8GA;$H1Y'5A=9=PL='$_FRGCY-L_C>3,.TG PQIW[E.4XB]W1
M*$^"\8@$ WJ:85/#6A>LI9N48BM(L3FM2%W/=8TXBE37CYA_5@<[R?/AGUC?
M%Q//Q'KD)_& 2"?()@J$QW."2('P% )A6JWQ3<.*W=A40Q^[H8>^@Z$;0XWL
M(-2)[@1VX&RQXV1#-)Y&0U16"ELL;%9SSUYR?(UO3-B6*!L#1W(G]L,$8><V
M\]5S[<Z+N1X>H:_L;AK-\YC+8H/UW I'>W,ZT48T)@@+K"*5@YH(?PN(ZZIV
M2 ++-HCM6 2+#73?Z[OK[5KY4%YZ9A>7E*=2GG90W9;R]$GEZ4SQEF788:2[
M:@A&MFK9/E$)C4)5\VPW\N+0]R(?Y:EI:"]%GC(M_#=FO94-6!KM_88D/T]2
M_ODI*192-.Z>GC4-UN614H6$6+%%T@E&(=-L!*./,F1+MDDLZSI.4I*&"?,U
MP@]8)])^N]M,8['B"Y;1=S$(>YD5K)3R34X'!!O5_'Z=1*.+4C@T7A1GI]6O
MD  F,1XM?J4K&^EJ4\UW&G_B=)D<<:GF^J;F:V'L68;AHH;HNI'E:)'I$ROZ
MVW5VRI<N\KHUY#E5@YR2'RJ)885OR.":3(J=W]H4!N0UM?'3>[9P9^+XT7:&
M4SH(U@QQWN!$@7%ICD_!G$AGYJ)<Y'C__&.)(P(;%)E<R6+E7[^1C5T$=A%&
M-F9KF$.Z"X27]RS"RYW+<X=GGP]V]Y0/^T?[IP?O3GK*P=&[Q5*I*[/>/=I3
M3K[\<7*P=[#[^6#_I$,3GB_:WC5O@I-*_B,#"/A&>*#SJWB=I H,.\#)]A1Z
M$U*XZ&'ZO.6:0H:@4HR*7Q>NH\$$-K. V%5?WUQ,O8#%#,AE0=^4?_F]A$1.
M4C8E]M+O8BQQW:&HGE(MV*;Q7]=2O*]Q22Y<?>++XM=]]JLI78G_SM;ZGK;X
MUUI?7_B[VX;5M;[MV_<:]O;?V6:G)OLL>V!ZUF-,UM&6F] =+N4[8TK^S*-S
MS'<N#I[&4O7N$LV,0<XHR0ME'R[4J-5S<8F&YQNUSI/D1AW"4Q?*:0ZC,%5;
M^01#9='#5K]$1_:-VB@D"+$C?XY3JIA:>S<>RB<-Q]NRB?/=WC#T=J^77E8Q
MW#N_-_HRT DOAA*T)Z*$#=^8;4 3.:4%8M8H.;VBZ9@^&L+7RXX3;%,DP-2\
MP/-TTX\=UPH#S0]L+R:>0:EE1IIO_+V'=XVF:[JZ7(CU,R>]]WDV1-\'3N%K
M,KIX-RY@/VB^?R/2<7:+@L+_1UWJK'*4B$# ][.;;]_/]./3?>OL],S^MO?Y
M^]'IH?7M>S@YW,,Y[/X\.[T8'G_X?%$' KY<G_T\FWS;^V$>#M\/OGW_RSPZ
M/;"./QR:AWL_X+V+X=%7;&%^ID\' HY@;D??__QQ?!I.SK[^=WBT%^J'W\^M
MLY\AS/O@^OC#F?YM>/3CZ/M_X\-$! %.M)O#TQ_:\=[!W[IKN,36#(3_\C")
MF*A^&.FJK>FNKU,WUM#CZ;A>W]H4+,"GC9M*B;<]$L_UK="RJ!O$=F#9CN?'
MIFD1-PH-XH2AKC.)IY<2;XD@J)1XCR[Q?C8DGG&T]^5OJH>A%F%A)EQ>JN4:
M5/4LTU>C,**V'E-#\RR0>(ZS41)/2BLIK::DE6V904@BW[!M#Z24[?FNZQJ^
M[V,J%34IDU::YG)II4EIU3%IQ?2SR+ IU4BDZC325,NCFAH0S5$U-W0LN'Q
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M],!Z!PM.ZRV2\8R!Q/D>$9W!Y:ILC Q-=%((;YI 0J.'C0HD-'JX+7JX7I1
M+BQ%PT&SQ  #:?"VA$>L1$HFL)*@UF:>+::'!NV-+B5HT!X$M.?Y3D9GF7?
ME5* )D2P+&0@PZSV2A?*3EL-[>;YM[BR<0.B:(2P%"%T"B!1\.@P>M#)U"H(
M,V"=DF Q%ZKP*G)GJYCY*A7.+9-GV,[RQ^'[Z9CBZ(<T2>5B9]^,"I+NE:L[
M#:]>GIZ4&]]IEEAO]79P=^Z_U_?^=X?;U]<8\@FW-]Y>BK</NR4<*[27AA$P
MKJO&97#@N96@O9>1T-<]Z7>N-^3&[^-.T]FN<MGZ.F :EZW$99UZDY99:33@
MA2= 21I(& .2LY H4&1J_4TP??%8BZI:5+5!C=+&1'TQT7FO?XF=F,\@4]"
MP68H@98$J:1RQ7K2W;V&GT9HC=!NJ038"&U)0NM*L)9 "GW6H!A'0),Y6.\4
M6*:3DU*AX/*\OTEM :/=J?ZF-VDZFKVD:?KVLQU,7_'6K]A$EKL>3]_6>N%U
MHWSV**2/XY25KG+-+[\=-^&S5WG75@E_1[-Q&-$DCN+XY.U9BJMLF=K1>&17
M0HX?T_1II;]^*]3BLY''(YI.RGV;7?[=A^=/V(<8A+48Y"MBD&?=4K406L?R
M9 **6,L[AH/7.D @;U(4)F7KOMR@<MN/PIQVVH.PZH.@;%2DE0%&D@%2,. S
MLZ"E]E901I%470(JNWHS.[46M#FI77=2*QX]-&9:,S-]<@+QC/^J F;M@P,I
MK !4/H$-9"!Q$VSY"AV&&[FHC3T(+5KIZ5'01#GJ)(&"PQ*MZ/(HZ.A+\)*M
MQA)&9.]K0Y3L%DP&XZ2:@]EU![/BB5)S,!MDE1KZ<H79*F00L&0^Z+0'BPJA
MFLO8K)@V-\N!-O8@- ?3TZ. J>8Y/((VY0.ZNOO0GD<=F )&&22K#L9TSQ@'
MXV!:%M2<U%]STXJGA(V;ULU-7:U#8JYXB 3!RP1H/('GSH N69 1AD2JTP!#
M?A1:O-++@^"5BCSZ6'(?8ZJ3LF"SUR",X<%8&;R7>_OBGAYJJ>XO3L;B>/;F
MA-[7ZTQ?]FMWXR?OPLGZS_,O4AQ1N2IZD<Y/UV>CT[=GLS.:S-_'*D?M0SE'
MWOG7:*?>*\C>;N%PZF?CC7, KUNXYI(W[I_3QM';USY-'^=YN#%[_)$\/@T]
M6LO:UX0>+Q8<%_N<D5, YI,##,*!1Q9!"!^U]IQT^E*IY%:?B8M$I/-HM*=B
MU:?"&QFBDQJRJ)E)8@Z<\ I,U(IY[K,5=9?\HCW*J\H8#*]TTOA^G4I$C>_7
MBNSK!V[,I*B-C2!-87DT/ /)DFJ2,3$Z%-SAEVH.M_I,-+Y?UU-1_+(662?@
MV=9)G$A@H^40)#<.0T9'?F_?V 7CS0/E^\;5:Y"6:KC<("[G/7PHLR)A0'HL
MN*P(=3H&,*B<BHP%SK[4*7.K3T7SX.MY)C)YK9U%\,91[?(5Y9D0&IP+:(RP
M3.E8N%IM#U>WV+P?ON]A3K A>W/([AP#<<,*MIT%4]>>(2\)MV<B G&+M183
M6:"A/A,M!EC74V$I1.>U@BP" W32%.:ORYX#D\XD2PYYX7M<L'U^0'S?3@B7
M/R'\QUQNKOQ_'/^^_S_EP^5OO*;IB_%D/KNH/W5A(56MQLU[*U&]U=.41A3"
MZ>ORM]_7I0"3T[/RZF>GE9+F\\E4#P3S>$*3,*:3<GWE'UZ72Y[=^_!,7G^O
M%W\!Q3U33X[>G,[&]5'^=II.Z&S\>_KG'^-X]O+27U[YQ?/G[UOV\5?(EXLH
M+/797QG*C:S-:%=OQ]6/]7+G1&H2,TXRQT*V*$3)TU$8$U&S*!UA_'7>XWC^
M2R^GEV_A3>%L\--$KX!R>8??TLD?]'ZV]X]/'[#R=%V[\=?OV6?O3,YKNS/G
M3WKQ3J=3FENT<%6:UI\JUT2#N9;1RVGUO?_U%2;:VS^>2TJ>YM'__(.V]DT\
MJ"%'@?'\/2QX=&\58V8AQ@Z?/SFX_W#TPZ.C1\<'#YY^,SHX>O!Y%AK*5=\_
M>CAZ^NR[IP</#^X_.7CT=$ 7O)C*'EQE_J<?^+X^\ ^*HYBFEVDR*S0^^O?5
M!;-#?3=_&T]&Y65/"E1F?__LU5YQSVJ>K9[+QG[P2W/A@7+))_1FEKZ]_.2?
MEW' >#+_P_-?^N?%:UTXLTK$U\*L^:TY__9'CK['SGGZ(N"Z^,L7W[XW_]:U
MX._\>TK=DU)\]MOL'O_L][[TLNZ>L)__[I=>]<O?4_)FK]JN]<O?DQ;7<JU?
M]ZI_D2K\92G(=7YT0:WGG$8V4^RQ?T7M<[ ^3S2=C1X5!QQ'#U-(-:\>2?[-
M5S3)+='[M56WY.GX';PN/_5R=#PMKS*/XD<_EI<ZC>U&77]V+N[(O]Y.TDBR
M3^_&JI"Z4J']6D7/8=^PVG?T-=VG?_EN[]0MX_U";!D%L\'?&[:A>[/E-^8N
MM+YO8FM$+YMQ!G?GOGZF;^GW/^R#OK8UXO,G-X^?7I[<'+P_+*]Q]-LK=?CS
M 2NO+^=_]_@%_O+P^Y-?7O]K7+X61W\>J(\G-_]Z_?CX%7_\PZ/W]82G_L[1
MGR_4X<,GKX^.OW]U],/WKX_$\W(=S]GUDYO#U\_5X^-G^/SX7Z_+:Y:_%^3C
MAZ_^./KA.3_\^2?V_.?G\I??[JNCWY[DP_'%J<U3]N[P^!5[_/#@5V.$D$8R
M4#H+J&?S0%P$2-PYEYTE]&SUI1%;MO;KQN_C3K/9KE+975L:L254]N<5*L/R
M<[_&8)QW08-%Z0"38N"+ P*3HPH\!9;)KKPS8BD0-!IK-#88&KMK&R>VD,;F
M$1F7,C-#)01CJ !5RN"3TA +M2F-G'-K5EXXT6BLT=APWG7;,['U-,:OTQC5
ML0 M)+CRI$(Q%0=R48&6*5H47MAY8KGBFHF-\-@MB N4=W)+6'PVF:9R#7^F
M.'I!X\GH;[5(^/=1 27]3N.36B6$?#J%&=5N@13>3L=GXS3[9C1)9[5AXHS>
MW3$M@F&4Q1Z?O4S33[I5SLGLHSW_]_2DWMH?BE4KPSV>//U@O?O3\:Q\ZV'Y
M<O+B_.RRL.'C?$SO&A$N0X3ONQ4VG8SV.B-HD2*@#1Y<5AZTH<RY0UT"\:J;
MU,.VG3;S,D3,KZ]^U# _#,QW2E'*6A:BL<"MSE6:(H%3(4.QL2^I=Q(AZKK6
MH(=%S WS0\3\^HHM#?/#P_QYW29:IB@)"%D(P.+SP9E<G'W@/GFK;,QSE?CF
MY[<(\YLM3#2D#Q'IW=)&"+E@W(**Q &-T^"I?+ 938$Z]VC.Y;K;:./N_V1/
MO6+;41QZ\)(F+])H/!GETVGYQF14^&::)N']Z*PV/Y_,![1&%'][.SNK,S0K
MEX46W*TM<1W#+@M5?_']N0T?7)APWKY^?JWW)_'XHSWO?S!G<R$W<"$?AN6O
MN!#IR2I.5,QI5&V[XD V$NA0OE,>!!9PGB!VQ^67KHT/Z"2O(?X6BT(-\9M$
M?*<D)#&I9%!!L)H 2QX A"J!\5X80=D08D6\;8C?'L1OMB+4<#YLG,\]>^3:
M,6("1"('&'D$5Z(X*#3O'#H?G"Z>7=[#59/#!O8!N_?U=:DTV \!]IV:D$U8
M#"HD6&D04$@)/B<)L<!=>8W!)5%K0ETM\EMQ[SVUM RX4O&);L?)5=V.KZRZ
M7?0478A:R'*CX^G;.B-W>?%W=JRM_QNT.\2_ODK. LYO['T3]EXP!1=2#M$F
M!CJHVJQH'%!=^YUBD"BSY,E2G8)3*Z5GO>-FX.LZ&X,V!AU29:PQ:&\,VBEO
M:65,4)) 1Q%J05N!C24+)F.S%3P9;V5)>UD?+4^-0!N!-@*]A=ZS1J!K(=#S
M]K$@;&#>@E!* 0KRX%WY+&D,+'$=BSWW]A5;:7JY$6@CT$:@MU>\;03:&X%V
M*K Z"^9%2."LLH"1 CBA/-AD>,"8,&9]/G#8/7K90@9MXON7%W\GQ??%I[?C
M9N+[5C3Q_>'KUM\U\?TKW,7MK9!7$^,?IAC_TRLBE/_OOZS@YI^C1__W=GSV
M?O#O:M=%^9'?X^IF4NY?%F17YF92_[<A=&_US23I-W^MO/RB,EMRL=MT8\NU
M?N4#VY_<^5:)+9<4^/7IY'_\]!_[<TWA.RR(?[]<:XVIZ&1^.][0.,+X_-8$
M>C,^*_]^AV]."&]?OSVI4<#\CIS6OK?S>_.7K3UWZ#8]26=4_O'\'B6:3LJ5
MS^9?_(VNW<&8\CB,SSJUCCMTM\ZUS>=WXU-]\_D_+0@OSV_KIR'F!A7B-]$_
MM_A.?7?_W_>/'CQZ.KI_//K7LZ-'=5O'J)8][XSX^^+[<@?$WQ>_\64.("V3
MAD*,*68,,I+3/A@>(F/*21-^/9C7S_]R /XJ'L_3O +5D[?UCOUX.ITW,E_9
M77!\>G0ZJ=<Q+6E1^9&#2CYI=C:4PCH>?ECN^Y^7OSP\>GGT\! /_XSU[[P[
M.OY)/9__?AP?/CQDAW]^]_KH.(X_%M8?R</CG_#HMU_&1W]^/S[\\\FKPY\?
MX2\__.?D\</[[WYY^$H<'O^G+@;^HU-8/P[OCAZ^$$>O#^3ASP=_'OWPT[OG
MQR]?_?+S,SQ\^/VKQ\?/WQW]_.R/PX??Y:,% E9!\T0^9@@B&4!3FYRUS^#1
M"2V#K%)^B\?=+[%R&P<^-YNF&,S!Y[HT41OK[BKK$BIO5&'8\OY1&6F=2#8;
MI<DSFREOFG7SZ?0UG94+>W?V[>3M:XBG\SIR_;N-DI>CY.Z0F8N>"VMKBX@$
M%#Z UU)#9CI;5#HBJ\.DWS!M%S3<-5INM-QH>94WODPW21:.ET XHR>+P207
MI<W(A#:<(F?F\[S\F2:2%A;?!@=W^DV"-%PP88&*CP5$R\ G1\ X&A<YUS&H
MO7VU4K=)H[]&?P.DOV78S[-H*^%A#*BR=M8J7T(4Q7D@IU.K!0R9].1UTDO,
M9QT40=;< +J8P!++D ,37C)?3%T"3Z$6S#FWJ+/1;J/=3=&NTY1C-#P91'1$
M2MGL LO6:>N$:L6 K>5D=9V3'7,2,THPQ>: R27P.@1@)2;E7DC&A9T7 ZR]
MYQHM#T8<XU;G(0YFL[<T"?.^TC!OR1C-VS%&\_[.\\_!TRS56_#Z39K,SJ4]
MWYR4/_I!U7/VD@J^1^E=F N#QHKST1_CLY<OSY6)5]T&LYKG&MX4ROQ46?SS
M9C+ @PE'>I0$WS4#+Z,4(A1%XBF@)8R9.4Y,^NA$]%HDF9?6"Y_[ZHKK%*_*
M?O^'3MZFIQ6HWU4X/[B"YN9ZEW"]CQ]TZ_ "$Y/:1X@V.$ 9.5"4#K0RCDGI
MF."I%[&W1@%;0P&-XYN!FX&WV<"WN?2C.?%U._%._HR!I.<J@>3:EOS9FN+$
M10*G0XG/6 %[CEOEQ'>H.74Q0)]>R4[?T/LZ'U9RT(J(=,>63-S,%S7IX.%Z
ME-[3PH]BO[/CTX\C)S_2.!Y,'IS/F<P]B[_N69[4QO?9^"P]3=/?QR&=NZ(G
M*9R^F,Q?9>Z5FO]9QO\L4 QW@46C! -MH@#D',$6^T.D1,8;1S[E^9E:5_FG
MX7[8N&_TW,S4S+0+>5GSHL/RHITLS@O+>>:RCJ64+,Z6+,ZBD,"]MS)897.(
M@_.B.R_#?Y3.OCRANYMK8U<J$6YI%;"9J9FIF>D.FVDIC6*GK1 )F6(!@W64
M0K9<I\"(1^N^ILKQF>F(XG$^+D1J4=424=7A\?VS#_._QX_*>W_Q_E=D(::(
M'A@F!X@H@9AD$#,2"]IQ<NY<5;/MM=]1K*Y/#K=A=16L/GYZ#:N1:9)*$'CG
M"9#K $Y2[0M-CHQ-1FDQ**QNZ*#J5I%6$OT3FLW&N5S0'&FG;^>MDU?4>49S
M;:-15]=H]/9-^87RS0JG#[*(\Q<I+S":O?6S<1S3]'T[]6KUNF:F9J9UEU6]
M(R<2Y\F:@%EPXH(I;[CP,AER]JO+JJ_?EW=]G1J_GYZ^OB+[UMUT6L.$AY\R
MX>/\] ,+M@ABJ0CBT=G1]0A""[(9%0-F58GV2UX&CC@O'U)2(?AL J]2/WQ
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MB6V7*''OO.&2#8U]=^B\Z:^U^QX^>O#H\+M'3T:2KZ#?M_6]SBN/EU.AI_(
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MEW'V_?3T];F][E^:J-'4$C3U^,&5JL!O]_G1P_ K9\:5)U2 B $! U/@3.+
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M>&T1=55+BJ^TE:IA=KCMWVOKMO@\9-L&FYZA?%E%X3Z9; /(7)=@ID!@O=-
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M(S[AHLO,BEP8#;TLJ3'WEK0C:45P+O]ZL($<J-'74O3UTX*^$I.,<#*#LX2
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M>1R4NE)S$W?K5\Z>ZMKVFFV.55W,,OQ0$][OF<G'@C#CARU>+]1AXP?/GE/
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M44FO+PV WK'RWK@-P_>MG-=&0]8G,:]HN3JRTFT]S!]JB/MM. Q9OMP;A!=
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MU?WEB\$QU%[DA?Q"%PQAWOVCQC_=[DB3?679_MBH&$V7,*YY+I$+QC,;]&Q
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M'9?"26Z!BK$GH X8+9$-QB(FF0\$=#O/Y<X3:FYJ#NM(^2Z1<E3,)Y*(AL/
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M]53;8&+20DC\G1*\=P"Q&8!8]:W$@(.2@B&%=<H%I (R B<4M4M>&RL8EQU
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M^-,-1=Y4X5 V4FYC9"YG#D;I7%(NLI2U#^H,KUT)JX9$"^KQ)TJY25;G?.
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MW&,GP,:H\Q-6$P?>SN( %X#A/C(4?*Y<AH5%3C&/#&'4R\""CH #0LM-LRY
ML*1S$"L=*RG./MPI1E)-^AE#&!$.BR02H01SYZ+5%'.1 OSGN4ZX=HZL'(3M
MSH=)F, !E!8/)HQV8-$(C1S% EGL#<@F(P7QH,@L+S-C9129):9M/&<4X$SK
M@*5C3G+I@N$X:>5M IV&4U>CP$JBP&R@Q%"!>: &F2@$ L,T(2-D0E$"EH-=
MZH)RRTS/JD'@28$ HR:9Q(5-7G"33U9I3@(% ]E+%T6H06 %06 N3B*E-IY%
MB7"0&'&A+,J5UQ'FQ@ALN%5)%JK LO*MUPX%:B2Y]S")T)&'?,Q:>TZX=3GK
M@DMN L-*X]HOLHI(,A<FH?"?B,(@!]"!P#C$R/*DD1?6V(PQC."-+;:$]LSK
MBB0U"ER9?26$\]X9)1VHGSR")9$4IB;FKK AU2BPBBBP($HBB8HI1HR"R^47
M@O)(TT01)Q'TQ B_R["Q19:0@EGCP%/$ 94HD2E*$H%>8K1.6Y>5 :$#R87@
M:AQ821R8BY+HQ"VUS((J0&G^X9$31" 1!-76,N-,3IL@=^\+_5 X\'P.E%P2
M)+EFF*J<P$L&RQQZ9ZX=Q[MP-UA;N<7ZKT=<H">#]TR$:'7(%5\I5T[:9$CD
M*E=X89C*NM_&ZN']V_F0$G8B88T!Z&EPB.O D9:<(,(%DSX&ZG+];JK$W<V_
MI?/2(V?/U*A:H^KRNQAA,)^3)#IZDQ.,#&:2@3Y&F?=!\0=J?5*CZLU0=39$
M!R0/MHZ)R#KF$>>8(YNT1F <"<R)E ;KXBQ3#:HUJ-:@>N]E:;RG8,):YFGN
M*L$UD3F/,PBG8VY44H/J"H+J7,@S*<X#L1(9K0%4:?X4?4+YU)\DS%CN3.XU
MO_3S'.N/JC4RU\B\DLBLB2,D)$MXM%QS"=8F<8I[;7F2U-8G[581F>="R%8D
MJ5UDB(E<,$P&AISQ'"E!L,$16T[4QI8P\N[9*$\-F6M4K5%U^:$XT':33CJX
M2#G13GNGG?>,:XH!84.-JBN(J@M"\L[80(+A*.J<Z9M;(EOG+.+61IP[(EC,
M-K8XK=T(-:S6L'KOL,I)B@J+B*7@H*]J)R*QFFJ?HLA),S6LKB2LSF4X&!.P
M%QA(GON$. =UU3#+4;#&Z!0Q%B%N;$FFEUUCYA%QM<B!^&-HX:5;Q:0R9;>Z
M9[:8U7_^"*WO6_^!'Z.I=&S_J-4M!T0O@ML)D&<KG3\2OW[LPD(UMC^\:D@L
M7S1&.W%/0RF>^+(UA)G[:PRN8NA& HYNC%AZT/@!3-T8<?7@GH=\Y0 ;_\K=
M52C^LUK XC?RY[]?-& L$2AB>-[H1]\[ZL)#!Z-\DL:P!SAVVO+#QO 8?NO#
M"!+L0B\U3F&F+8"FQE&O%P:-7K\!(_O>\O!E^)(?S;G1ZN8WV XP1WZ('<*S
M4SOFU<F/!&H<M&!C"W+,W_QQW/+'Q:5J5/'G:7EWK^&J/[;AM?#<^-,?V^Y1
MS%U[X!N]09P?S&;C ![UJM>!-3]OG,9^[O #HX(']AQ0M:VP/].6+5 _[URY
M<78\C88[SQ.&YPURV=9<OG4 T\HJ2Z<#@L/;HIQKL49P#:8X.&L/+Z[$B[DA
M7YQ[03K%DE3?N#CT8ULN6,'RQ6*TVNUB'I.U/CO-:UBL:N>T'8O'YJTJ9VV[
M/DY-NIS \/AL )@$N];M#0L*Z(?),E@0/L/!9HE]^][; 7S1MMOG+Z;>VK'?
M8N/4GG=@;P:P3*V\&[UB'-7@_WMP<0RI''?UEC/;GAY6];;/QS'/I07[Y/U9
M7KZI!U8#'4QO6;ME84DRQ<!*[40@TSZ0R8B06]WJ^]T"8NT0KOUEV\5X/AS'
M/,O&SEE_M(NIE:5MXSS:/I!<@)O_/NO&!L,O&EG"SPTFMK[#/?84B.0G2/WA
M(E:_5$@\% ;$]GGCOQY#[>F<@_1XM?U^]\.V'^ZG?/->#, U_?BNI)OM A\N
M]M_JGG50Z U1]<1U5X#:\?^^/__R.9PZRF5SY^_V_N=#4&;V8$RO3V!LXK!0
M@/;(WL$A/&]7'/YZ?[SW*RLS_Y#]G<.OR@GIJ;+(%AD[QDKD@@LH:!JQ$880
M4X1!+LW/!))JYRW/D/R8LBA\+]AN1 (3[ #4  ;Z#I@(/-5NQ30!1>#W+@@<
MWV@!SV5Q "#R:O_3VQU$3*/7G>;'$C=M^9:PX#4_(OP&O IO )X]LJTN0/98
M>E5(!9=<!$VHFR$!5FP;@*V=F9]4P%]H47 7T"U<*$ #6#L#8/S>ZIT-VE/
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MA^3U.</?&(FQU1QA:D'+2)PA'7(.H>')2-!$/-%+,_QK=E]EP_^1^;TV_._
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MI9-,Z=XF65(1H$\N;YLW!P@W]O-=,":[,F-I'/<SI/Z?EHI8&88-]DD7;9
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M/R(@MITIR-F6;?O%17^\;-/<ZRQWL*ASS.>RSA*9XNXF[(Q,<8=[.W76^-
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M-BRPZ _:T/+]9J[-X*%GG2,@Z>&^" \Z:![WAA(3[.4A9@6LTEI.8EYF>>N
M!8[&W]*<:%]E@VTCD!)\WGY@IXF5NC,TUU;MJ++(#R77.SAMUB_MRI4-]]*B
M?LV=U_7RLH=OQELW,4KS:E1!T\@2B]%)S0T%"D^<"*!NF@CC(0TM3.3"P@2_
MW,S9[X$+0/S*R)X\VGCN"B*%P:\YQW6VO;-_ NTF=;BO?KC^S81(O%86!64L
MXI))9+BBR&A)%:->.Y43TLW(1W?.YF_F6@Z),Y7C?23VCG-F'/4!!RNE(((8
M:\MR>,+EL/\M20NB%8T(E#8VK)>A8Z*(6@K;/K7$>+&R)F^HES'DCGF6A&>>
M&BR3HZ!?&&(UI\Q93+#%!L,W94D\C8=XY_O/[758$0%;X )$8 GDXL($N:03
MXM1RQV,T('GGXL(W+HG+*AZMT]?K(_[OWG5[:B7"9)7SJ))!N[ --ZNC7X->
M3(-6+:_E:N>]Z<RS5T:)7."=!LZ#4B;A1%P23&D*;0FW./,\1,Y?,Y#SI6K(
M7\T4KR '1L6_#8-NUOY>'5:V>&/G.^R@5$OL.#(.<P"( WU(F8@8PS$HK@QL
M=BMK>C*&J*+)FZ8S1<4I#UP1C[E*U$C%A>!8\623T[<YPEZF<\[I/-S]%F#>
M+! >,A1[8#G&D28Z(*&DX4EII23L@(1-S6?E1+L2+@%X']<:VM>)WI>B><4#
MP%$W4D&J[+I50,C/ZBI0>FY:2%A3P57D7&K!I62@O'N25*#$6ZE<*@OIH?;0
MGR!>\3H(V<Q*(I) RAN@",<TL@0[1$#:$<IQ)HW+>^AU:^KO;C-[X#J_,.Q7
M#LB+E3.Y7L[7V"V4T=I)5FVSJ2YF;Z(=.3=@51T.VD-Y[C(P:1@S-![H-'+8
M#37?"6U]I.=6&1=:\%$S-;T]K[1WH;_>MIVYF=FC&6*J5FAMW."3.Q%BK-R>
M8]%3H^)BQ]68#CW?<.&PUEAKA+D;AJ7=Z<-=_0MO"WS0!=Q">_LU%V.[9AW<
MUFG'L%J[JY4TBZ%A:/X:/6U8EW"L*3!:8P%>MQFKJ:F8[0F:Z6"]FS-UX;D"
M+\VTVVE2LM_\.7*^7$9^%PE_9MP)J>]\^88QCT9AC!CWH/=[$9$)S*#H!);:
M"E#&<J) =4/@YWGYS$?V@>Y<<7F>FW^K8.4*H$\:SG:/%3HC*.H5+D[:.-S_
M9IF)#.8 24]!T]2"(AV$1C*8@ 5QC.2JG4\:B%HF>B$3K;6T+%$4130@&"F+
M7+(28<U%2$'"CC'?1"\^GK%,]"(F.O'HDB<PT4&2K%4)Y'!2R%@EO:*P$>5S
M!G>*<YP(;AS;<*8DGCD#'N\;[UBRTDYFI5779Z4M^667-C7KJ\@O.S/9YBV2
M9SY6$LJM"R5WEAFF5\W1ZTY0Z;^!YJ($30D):[.O@A/D8K!(J,AU4B$E8:82
M5#[6!%YO0RN3ER<O!&.I-Q))X14"M&D0^G->7E#.),RE ,P]V^RBPPR@E3$H
MSW6OUAL<Y7B5LS@T>E6Y%LX/Z@W/Y$U++U<2/[Y]);E$F5[%^F[UTI^D1#O3
M#Y#XM#2V-+9JK,1L$?EO%Y6FYF&RBIA;98I=[T^K;F]OD0[W+GU?OCRY'[J=
M7J_VOZ[[VV7&GO5J%UG$$-RFO/2+&,9U[P='@Z';9WT4Q9G%_S*(<PQB(Y9%
M-\]X?:W^B &M0Z/L?JP-G>BU[$4?0CI+>CD3]JWR>Y>!O79@/UU$3]QVB!\I
MS^03EY:?%816THN7].+7^E6<C"XR(H+4E*>@K#:!)N45C\DG1FZ;ENT&(T@E
MT3Q[1\DP75N'['[=^MG8V#MLT,T3> ]\OH6AC:R>VW:X?E8_^K.YO?'IL-&<
M2-=V^,_![N$FAO>PW9UUZ-,G^/LC;VSXLP:%-F[43W>/MGCC0YW.3#NN''-2
M48DL#A9Q)SER) 7D9&*<,>&5=2MKDBZBFNECI!V_(P^7^O*OL[[\/ F$'X'4
MQO2+<?6BT-R\-#=9Z%3FD!WO& J<*\0#2\AY+A&FP;$4J9"!KZQ105?-_1,'
M+T^]YD)RA>2637 #];_PV9Q\-E6"WDDGK8L82<,<XC%R9+( YTBT@A/B$P<^
M8XK..&>U8+%MR4AMGF?,TZ=G ?&9;FFM"6;11VL2Y8KF0J XIL@9T<X'0\J!
MCN7 ^(7,\O%T>^,+_J:3X-H)BXC"H)J9#&^:-'(&*ZI,$L'F4@=\E5];%[;@
MZKGBJG=ABQQ7!(;IJDF!VOV@MOUY FJ!2NY,DDAC:Q 7.B$C24(^"!.\$51P
ML;)F+C?3F4A[UE[4V];[F'DDL10[NTZ@-C8FJH-@27NNO+:.!&,"H3X 7>!4
M+*%/P@%7ZIR=-@Z_XV],!!,-<4@D%A'00<YJ8F&U!LFP%T)236>G-GFZ,F>+
M]O 5N#X\7*^U\;W0LR"/#NS326"[H&!"7=[-\Q%]K9#%CF9@!\>IYX;IG*XR
MI[WXO8"[@+L8MQX5L(W)G1CS;,2R'AEG&>**"&1=-$@:DIR0T:;D7OI.?#^U
M86EA6C*./&.<3AJH"(?IH4(@X[5 /+* G-,.,26X\9E5HZER?4UE*EGB,+4"
MG6*#>@PT3=F@$G'*)Z=1(+FR+1$,6>$IBC2HP+FATL1L@YI*#?;J A)W+K)D
MO;)RU_/DT544A%UG0?4Q7!-B7 H"TV"%801+5>Q.3X+[^K3=22C-K-8>!2T(
MXMQ%!-0= /PT42NC4]S.SJ%Z-T?N,OIJ7R9<YPDN>P2\EN"R!2%XRL#D.8C!
M)B!%+$;<6H4T9Q%Y)7EB.%##T\K:K)2W3U*3OH#W^>VUQ:XT/TZG[$I6)(4=
M\8#3$!&GR2.8J8AR=GEKC<O!;GFG752D^S*"]7ZJP-+"=*9R'+S7!B?C ]%<
M*V,E]UA'38-WSNMB5UH2G$[:E9Q5.B@<D7)4YS1O 9F0W;&12>>M%D[R!=J5
M"G0>&3K%KO2 :)JR*\DH$N'$ (8 2-QYAXS' BDF;$C6:6GH ]B5;O"M$+;L
M!J9.ORHN,9%19UZ_TB@,<I3Y!CI="YU!?EQUVNW5GJY8\.@\"Y*]5:TC1P5/
MQ#H7!<!4&VF4M"HF%DE.47=;-6*FG6Y&[M&B3MPQ8&QT!B.PQ +.>88=I8A+
M'G)<B4=4"&.((X924/LEH]<6'GXBR#RQC[O09J'-19I.%\6;Q73ZB+%Y(P[U
M&DLM<[T<2CB"M>"1A:E"-@;,@O,DTNI<+IMAE+F]\?19TN?-K2WD6LCU&<ND
MC=@O$NGB B=';&JP8X'SA#2E$212Z9"V$C1_X[UTG-A(6#X5;(I$6D+'%I"M
MNEC''QKD'Z>MXTI0+P@HF])X@0#M&AFA!'+<46TX#3%7NUG8L> "G4>&3K&.
M/R":IJSC5"D7>8Q(VF 0U\HCDQQ'U K,K.8N:GS+D[^_5?G.2X;UUY%:NS2V
M-+9D6/]%AG52,JR7#.LEPWK)L+[<XU4RK)<,ZR\XP_I+-]Z_WG2=BMFDI.7)
M1\&UR9%ZDE.1N+%$8^DK\_Q4?>)7>\KK^ #:1G</=\_@7P[_X<91X_ONX9>3
MO0_OCQH[K8/ZV9>S^L[>P>[IA)WA:/.D<;;7;!S6X=]]^.\C//]3L['SQ_?=
MK[L$VG?6V*G_;!R]/YR=9SU*'1))*,I<:S (A;0A&D5,G<<AJ<3XRIHD\OY9
M#9Y9PLY":Z^#UN8)Z7@$7GO9(1V/R'23(1W4Z<0]R'Q*<X^XPBI7E( ?CA(?
MK!$NB94U2NBJ**G6"\F]+));+HY[.:<&'X_/IH(J?.)$Y$+#VEF%N.86Y<K>
M2%-+>+**>^Q6UCCF)=7ZJT\)S9F-A'+L8R*<"V48\8RHQ%, *#M>.8;)N6.8
ME)B*)\+XE9@*?_(M2:68]@EQKR-@7%"D,7?(2L&QH9PFK:N8"KEL)PX+KNZ-
MJU<8</%X4+L:< %04UA'HT ?D)@;Q$.TR"I#D;7PL4T<I"!6'>ZE]SF/>!XG
M ;?'FY%5KGSX*\MD/:,KRV0]HRO+9#VC*\MD/:,K?S%9KR&O03DJMKA!>!:Z
MUVW,EM0$D["F23+0D)DWF+A\R,@R3;TQZ;9FRU>5I>"Q]"T_[7AFD4MBL4 B
M&86X81@Y$R*B-'"G(HU"WM'QO(Q'OW[E?RF4]EHH;1YW\Z(XK;B;'Y[?)MW-
M5NM M*?(QUPLQ"F#=-(1I7S>U<@@+*%SNYN7D=H6T*C"BJ^=%9= T'O!1_\?
MCP:GO-2)">\$"'=!.*!!87V.NG$H>DL%D2DJ;N[FI5Y&+IS#<_9B?&!6:F.4
M)YX)QQES.IGH/ O:,AJ]=\6WO!S(O.I;YM]$4H0PD9#'6"+./$/&)X4"MUC9
M:+S0Z<Z^Y0*$!0.A.(,?$!L3SF#^C:1HL.8&R1@#XA17N6HD2IY8A;5G5IO;
M.H.O'K^?NGSB[R?+[C"^K#9_'L=V+^[DAN_ ^_]H=?SW9[J6]OY]@/W1/VW[
MU0RV#S=IXT/]Y]Y&XZ#^=8ONGGTZ;'S=$M#NGPWZSR&LI</=G3];]0]?3OY]
M!NW>^/[-:9. #2UR6F+$M2?(1HJ1XR%J)ED@'$3+"'+B,0QTOSO(EOIYDRP\
M,I71RNA^$&OO.D?PYM-:-_HL,(6:'5L%-2"1?"*N#Q=V8^\X@E3V(]:.*\[I
M9<K)7_7BM.$>_H&O6ZW.2>_RH/4-V2=$M4>\^DP3;%40\UQ2##RKQH)V@>_V
MV*<967J[3!.W] 5>*X29VPAARW=ZMSJ-6]ML9\(:S^SP:'+I\@W)Y^9/= 17
M'=1VNO"49L7?0^FP#-3DVAF-R)^#=JPQ_&:>^+VE.+U]T=/J@6^;?7B9OXWK
MH=FNP7M:L#9NER_@.B/*\SKLGX7AA?3V-O'0+V;(R&))XN4,#"X#<YN!F3\_
M1DHX^6>5'V-<9ZYUTCTJLY3CEJ_UN.6=K#HW^;7&%^5VFC3SO!"/5@?>\?VD
M03\=[N[\<5#?V,3UHR\_M_/O._NG]9V#@^V-@^^-G4_-^N?)S)SK(C][[T/C
MH/YA\R3;_/9V-J&/FS^W-[9^;G_8Y-L?/I+&AZV?,\NKL.A%#%0@3PQ%W'.)
M\@$1%#1-D090-&-86>/D!1Z[O,K0MS]+/KSO]9+;O/U_,>1V)Y=((;?'([?)
MJ"5N!//2<R2]T8A3IY")22)JF;,I*B8975D3^/Z)^N<%12&W0F[+16[8>RJ(
ML,Q3RW'@FDBNF0C"Z<A8Q!6Y8:R&Y(8+N3TRN4W%(BEC6311H.2$0MQBC4R2
M&"6/(X'_F^#MRAK#ER5'"[D5<GN=Y,8)[/981"P%Y]%J)R*QFFJ?H@C.ADQN
MQ%R0&Y8,%W)[3'*;E-P8MT[0)) T(+3Q8 FRE&MDL90&.TX"D?D\S8R"=4M*
M;K>(GGG8:)G/_B"&02MVT@UQ,^\'_4$WENB96=$S^]^$"!*#QH>L#A3TB2"0
M)K!(>3(V4L69]/191L\,I_UJO$P<3OQ,2W .B8'/S[VP0\B-JA'06K,'8] '
M[LSIY?N=FHMC(32U*WZ[6P74O(!R+LJL:O, T15JU6"YR.B*9U !8P$!$T_L
MA+IEI8]Q-(YH^-4E;0="8<7O5/Q.2U"=>EHH:L#[=TYBZT>LYVBE%R/WT\;&
M%J\?[HJ]K^\/&SL>-\X.6ML;NR#_;S%X-GSW'=H1#O?>3<K]<,WA_FGCL-7:
M_5HGC;./;/O#%]XX_'BZ>^A/ZF?[I_!NT:"-[S,3N.O$C$P@[0>I0.Z'V4/:
M!XNH)L);89C7:F6-TP48-1[)'?6L2U+=GJ3YM;LOG:^O,SFY<-/<W)2EI)V3
M3J&DN2AIAH<\Y12*D7ED#36(>T.1,2HBHE1V]ID(_+082IJ-_,=AG><I&HH[
ML<Z,OA;662#K''1C++PS%^_4IWD'"\P<=PD1F'O$8S:!<LQ0Q#(Y'"70DERH
M*%2DG5OSCBS2SO+QSOO.H%MH9R[:^3A-.\%:ADFB"#LC0=PA&CD%?P;IF*3
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M@\)SCCX>_N=\DS:.MO:=Q0)[G!"G"=Q6%R(RD2D4; XQ&$V5"#.5%S&.(<J
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M\@+3M^4:4UCFX$[GKT\/F_YPM&P.HRPC; )AFPBRE(5_FJ-;^B?P8_+!^8F
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MI?@\C_ARAL/(KBXD%I6&\476QD*B75F&>TW0BF'8*^_BQ8X?:^5$&*P$E &
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MN<6^X.-N52P@HCR4\4]PX:"_U2GW*(J_-JHP\VR8^?.^2XHY["B2.*=82NY
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M@\'HO1N&^[97WPF__K>+:7AX,0L7_(24]' R2=/9E#T=/CS%8:^\=$M>^K#
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ME]-7;U^*Y[__<GI\^C,_?AM/CW_$9WC\L_C/IZ?M=BXBJTR451"-RB!<*L?
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M]Z#JX(8+->[CD"U3J'&I .4JH[:+ [>6*H[W8FSV/C/ZAW8<(LU:=[1C%B5
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M36W[6X17U;0LQ%N]X)+-PCD"W)26+,18<&7NHBMU,D3TAC/43 L@OI62[YT
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M#2*?)02]0WWA$?G2V<Q-;(J@V7K0J"J*G>@T<[LB:%5;K)EA6@DHE"2J%?=
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M?HR#M"7K_V*$8]3K-_CL3=V'GD_#E/NMU(Z_>W8_&L<TAMFT/N#X]'%T7OI
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M. CC5>3**F)I2<1<.8Q:PQ;=!>GF#H!6D'X-2-MG/5V@B$@(T95R[4*"42H
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M].1B=^S2!^?^'_GK(\ZCMX<W<^-'+AGXD JBMV3?K;PV0)?^/!E?W,V9>Y/
M(X+>@<MXLP_<X+W[.#GX]JJ(005S;0RO/_Z-#YGSQAYR)J80UVBRFLE!/SZ-
MR[OPGEQG[J6'&@JY\;_Z.A%M.;$D(.X8TR7@KG44BD2.>(M_:)1EC;E$B_#/
M;]W./L2C8A*&Y6@//L."57@-JS,>YKF4_DB!H?$0!B_L7.32,>L9P__DYWWK
M>11D#8;G:N3NU_-3Y+"/S_/SLU2>?_CF)U1FC]QX_!'MR7LWCI,7^'W?#T;A
MW;VS'2_)\8LG?TA#G#>\')*EI6P496#02( 4+$J=.:X&<X"""+WH0H7C\W2P
M&][0P^DR:@DU7^,DHKXH.J3(Z6&:]D87ZV4FY8N5^AR FIDK]!POK:+>/QK7
M$05VD<K_^PUJT^E)N6Z_A")*$&OF,'PXZ\]PV#MK= T:O4=S)7CU>@XU\^3<
MO\4/7MC>R[(3V>2RW"SWQPW_&]E9/$*4FHTM_@=^X]S43_[WP3*^KKQI<INP
MYE_FM8FCXB0/W-DD/;CXX;O8GYP-W,<'_6$S5<V'OIM??FZ3RS=<W\HO7SA[
M^2_[=$AF-FJ>23#_YOG+A\U+UX+"L]>D/"3BYI?)(?W*UR3_NJM^Z6;-H1%?
M>S]W?:_V4&JV,_<JF-J1>S6'FBQW/W^367/+!)K-[/"9I:K77#'.2U2LN47I
MF"^,PDS7=VD<'IZ.SK]P'&K_!^#7S];OGW[\[=%D9NXFQ=Y]4XS=/1Z:)T5&
MI$DS+E?VFTJDZ!Z/RXN3<=D\NC("7WL.XC;)D-U-2/QAOD?2UK2K% .[=>K.
M6K*N=S@_Y];/W^TDG%M$CWU)<A,FRZB3\+%D)V;"O Z*!):#6#8[\68'?N>C
MO_,\G+>O2I[-IS?R&?M7_QEZYZ]/GY)7^)[C3Z_8J].7>%_HW7]Z0HX_7L_#
M.3XY?GO\]OGC=Y]>G3[]=/SBE]-7;W_IHY?/C]^^[K]^,3@Y?HQ^_XN?^7\^
M/9D^ZU]K<J6-9]D%"8PK P)M*QB2/22:9$I,DRS]P1%3NY-HWJ7R@W]C+^[2
MBMX.W@N#<D88&B)WF5 AB,Y.L,B\PA4B7? Q+Q&4NQG*/_T5X7@^?#E)%=!+
M ?KXT35 )Z>M,MX##2&"$)&!H])"%HXJ*;+-@1T<O2I[Z=>RT#8@"BJ(6B"*
M@9M (IK%Q$7(U@EB59*$>L9-"O0+(&KV3F]&T)// <97Z I4_"R'GY9!M#8;
MI3AP'EW!CP4K:  3,L5Y8LX[6>K&<%X!M#$ /1W&E/NH+--J_MRNG2&[<-GF
M:8M?[ZS5RAQ+^BC:(7J\-LQ3AA>S1FE)>2KUS67RQ"[KH[QP'QXU>T.7*7D6
MQZM.RJTX^6G;24G6&>T*'5-+03@1P%*J0&6NI5 FH1=36N1UJ@C'NJ&Z&L]U
MD.2_Z&HP)4-V3F3%A$W,D,#P_[)(,3-OS!*NQD)$5B_CJQ#9\C)0"Z$KF"E0
M5VKA,*G!22+1U8@>W41OG \'1\>CZQJIMU%K=J\@8I'X!%$\Z5RZE!MO.756
MZ<R38\G&OW,D%N+CDA/QV$TK/):$QW6#)07S6CD&1,92?#)J-%A"0V2"<1^3
MEJ4C$DZ+6HL34?&Q*(6,2,6DER%I*J11GE-)3<&!(T2I+Z6057RL%Q_/KYL/
M(X4-I8VY2CZCH-,1;.0:2@Y52L0%;_,2^-C[.F<OI^[DCO;O:K7G"^(@2:K@
MLB91":$+9UC"C<J&:FJ#6]HEK-M6:R*09VV/4')TZVPT8%#K((&@]/32"_ Y
M2O3=T4L@="U553M<EGTUHMLQ:VY%RD82[3/C0G)4NRE:DSU)W%C.9-U[NGM4
MMKQ"RBQ.AB$0O,FE5TL&0Q"D(E&:4@S62;;(*]QVY'Q_8$*\CS&CP8I"">>B
M<TP7-24(TYH:4G>7[A8AU^V6SUQS%1CP[! A-*'=H@EU<([*<9))TKP1OIW;
M7=HMC-S7#:1'> .(V&'?K<MMJ#M)RV:[<<>BSB8F'LH9.B,#E9Y8@C\8$55U
M&^Z8?G]NNPTB$\&(<\"=42 TS^"9S9 <Y=X0AXY?.C@2JW=SJOM(W=!#AF?A
M5#0JB"R2YS8H&X1(@7B16?Y2D+RZ#1M"93MEC2JM:"EO+(P$Q*A'/YY3L%GJ
M'(2,AL?UI:Q5G"S B9=9L^0)H48+%8Q17NJ01)8DB.B_M-]:_88-0.2ZX3(Z
M)T<(.@JJ=!&*F8/G.8,+Q"3J6:*EL3%.C:T8V11&A*5..B*#UUHXDST-1>EY
MS87@2NF*D3O%2&M328?L"%I[0,EMT8RX %Y1#D1+D;2U(;@&(X+>[TVEYZ4N
MWKP:3]U;NELGT:7,LPI6YF@%VE=/J'1!)QZ]%2[5(U%WS2,O%^PMQ12]$ RD
M5 )$:?QKJ+! @N%&&$,CSLZ1/M1U;VD_#+M/CH<B? 7-PA!A-$Z_LY(*2;WS
MKCJ)=X_*EI/(G)&<.PZ&2PZ"--UP-(>(T^:3"DIET<ES3;N%D]_<N#\ZWZP*
MN!>#MO=;#3^,QOC/X0()B=_QCS]G0W*EQNFD5;>_[D"L4UQF0:2163=^J>+.
M&D%\C)IHD@,1NHK+.S9CK]KB$LU824"-8(1E(+208*PGI;-;,,;Q9&@X.*)T
M]?/V=0NB&^HRLBRI34KX@D%CG99,.>4CL89:IZJZO'M8MM1E0Y&.>DB6*A!*
M:(2E=:"(XL)GA*DG:\M<NK<P645<UD&[3S'*BX/0UPJOUN#D1H.3-FDKE+<!
MK94UP7EM4$^:J+2,SI)Z%OJN+558(""##U&A=J01M:.0V8)-3H/$";-6,VTM
M6BI3HY.[Q/%?TH_92\1E$$E9*FR,AD4B"4V:EI+HU-:CT'<*R)9TM$)8FGP
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M227E<L[O+'F6)\'5[[.XJA)GC),!X"H%7*4N(LK$(=$Z@!UVJ4YLNLS&I2N
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MP5P:1UI2 J*3$DZ!'%*E%*%@D%'X?Q>Y>.T]C6;/]O,3_P**,34%@YV+2!G
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M"%:/E^<#^Z[\Y7^QJV];7KW+NG[R_DO_6SR^"-K&-_S$;A* 9\5;_ OSRY,
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MG@1<!&KM?4AK'>O9H,B7#^T.9U)1;DD[>6-G?L]A$=X 4Q_RK:J!Z6' =+D
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M\ FA(!%A- ,D[$%#(QL!V68.OM$=PG2R#DX(TQSA>UV<"#SA!&[LYP39[ET
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M]XWZ(MC^-PI">S23O[)A;&[XOHR-7ETT6[FBV0_%A'4J4I\^_//X2_?\<V_
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M?0\^!LP,-A^FQI;PJE(GLHB3X,GQV!8C&#W,!FUI=C$:V2:0''N2SS[)NTV
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MDX!68@'3SQ8P"3*4G9!G#I1(GM&</'Y"'F)%LGDH\08^:(D15KU%P9H;P;@
M6N<#&+^CN2F\\+M\:9=FV-ICD5]/S;*5"BL5#*F'DI2A&2K+O,YQV(09\"N>
MHE':% @;$MD#2>B[>-C3R =;0 3)D2??H@$0",5'H,A>\$$OV%.DV W@H \"
M/</G8AJF:NJK:^-/ _S4+EH0%PNJD&Y=0OV]W @ _0O#G/TS> (;K :\*$@6
MW02%#]/@+! A+AFL!UDOL=8'.Y0LR '*C^?C6Q?^#7AX?]/BSX=X#?QEW?)9
M!BMPN9+%>24R4X_O,5O4-M<@_ -]5R85>$/F-/OD@X]YZ_G?V5M#TVOO*J\]
M^L?<<C)D'K$1O2?I!OY2MNM*V_&Y8$ZN#@Z1$AF_BQF;$/,&#XW2!8L2K0^2
M(6E99$3K:5;@<T4-C>WYPNR@/KI^*<;*)RSP<0#6KP#%#P9?*%FLY[M!R'[A
MD^D']A=H_QMV>GJ)[B=#<PKW9Z7??&,'(;'E- + -K-8,;+]B43>D*?H8/OQ
ML&(+$QX()Q"W8S3E\0_;_6F+;T7 =HM&8&VI$7@%TF#9<QF]],4/VXL"@-:K
MQ$4XXX0"#OM#\._( X5DXR?J>W3I? &6W#6_ X2"ON4F<R'G]JB(3I(ENHV7
M"#G^:6+JRP2(Q!^SZ:YL%@)UR$PDU([]268C0\_=0^C:%3)G(U7^BT8@]@C-
MX+5 !I<"S[$M^A[8T\!E/C!<KJ4HM<< C3Q4'ZRFD>;04\WAQQPLK J8(N2V
MFF@;4AC%LBTJO9>8NG,#'OD<Z"_=44D:&CRZ S 9) .90!Z&K$*I^N+C]V @
MFV0%V^XT@B%&06I_YI)-.MRQ_XL9^MRIL#_&Z,_+;\COHV-@VL*%SI-APV@B
M1]8"8&@Z)71):#I-Q16>1O=IFT?1TK)O@O)T+&E8R,_*63W\\+UY9F8FJQ6
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M.[>K>@T#SYV#I<#*'=9[D69547.OF^Y-L=BT3*STS7IWPHQP1X1=C$:V*?R
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M2P(>%A[!"!Y@7!_>FF(D!GZ46"=\8;'+:.C8)NN:IA>Y(6;P?K+]"7O;\UW
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MJLJBF9.CNEY;I,?"GT//FL%?XW#B?/Q_4$L#!!0    ( "M#85;U:-UDL!<
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M8R"$<U2C"L#*S:MM;E(T1<H:#VG #O$" RN/B7]-\80&-8:3 CDK"Z^W64A
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MI_N^ZB)MX<W) G_ZY?\!4$L#!!0    ( "M#85;TF81 [C,  )4@ @ 5
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M;8JW3'A7<FR\N!^!U">WI]5*;RF%KA-)OT_&::6-I"L"M98@$]EK%0O!LBF
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MFK,9B:Y*0S!10&"1!JBS3IMEJ^U,D"60[SS91S.=6/%70=4[J"4N,E:M8RQ
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M:$WPTI9@4K(RW;!)6Z2$KL7SF%V2YO(^_CN_WW!R,@V?/]'OC=[C"3WC8#>
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M6'=LNE7<NC--=7!WN!'808S(O!8&,*I$?D0M>:'(2LK)2R,MF4GM.SAL NP
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M?/@K KD+G;+)1&44D&U)6Q#J %Y8"RD*YH3P@>G6QW[W(WK.)&JHJR[O(__
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M$_8:H.4ITR:0.KKKN /.8>XQ]E34?6K?0\H]$8"\IQ!K1TVCL%8@KZV:(DI
MSD/23++0O 9I;XI_X!J@>[UO(]QN3N,OSWVOX5L=_J(VY!/I&O*=Z[E+@5HM
M%9S7UDF/4>IMSN#O?5G_)^][:^3VJ7H[<38\QCHO#T^?#M-=J+S,PFADD'U!
M0D7[8K3%0!36:\TL.39B(R6O?<4C5VT;T75VYG3GF=C/WWX/_S69OAR%V?EE
MHX_91%DT!"XM*,<2!,L96.36Q<B%TST>4=Z$]_2LNZYTT^M1U.P2Z)6;QTW@
M=M5==3NH!ZN5WXWJ-Z=8,[WUNVK="5M(1KLD"[10FP@JTP"B*C4#C?D0E"'O
MO'DK]&.@V<.%[H^29=NHJP-VO3R;S2>G.'V/H_.0B4_#SZM8!J^Q^,P$%!;K
M.8\(X,EFAQR53(A986P=&'\/G /T2^Q2E3>KD3?20P?7N1^G(>-IF/[S,L9%
M\F!E!#2>+$,D!\_K2+/%9Z&X9$7<##5JT6?C&H:G38:])-Y%W&3MWSGYC/DC
MID_CR6AR\NW]\.3316R^H@73>I7 "F>7AI]. HRS,I.?SZQK70[U 4A/FQ\M
M]='00)Y-YX/W-/+S/"&?E4[>%4CH8^V@4,OC20;!%&'0R!+41JD,]-0KA*#O
M+LEP[85/QR?:78X-+U(O0*PVH0U@;./%;*+6]G/Y8:]D#^'?5-\>DFNXB-^$
M@S9K9H6%$E,]E*5_HBNT.$3OO&2)\[#1[GUH!:ZQ]]OK;QN!-=;;[R2IT[/3
M)9"$,3-#=J 2D=?8X@*>:PE.>1<Q1,7X1MOL YJ[]M+^-M*]Q#YI(;.&MO,"
M2/AZ!4@H&8W.9+IS01L!>@7>T ZCT2E3:CNUTF([O/;21ZB\G676@=F["NU?
M!,'-SB6W2$2I97V8YF"-(VL\!@\^.0^<HRLI"4L676-S=PV4IV/SM)1YPQB@
M^V"=AT9>I+AM +"C4]X'P1WF7+>)*C>@Q_YZZ&GMN XT6EZK&@JPS(FZ1&9P
M%6A)/!J%+F79.JGP0$1YX&3V,#S91ORM8PE^"W/\*WS[#<>3TV&:O7GS<KGA
MZ:)4[:T*.=>@6>MIR-5DT62G*,^2$.5&J:UUP81KWM#_N4AC34Q:B_' 27@W
MO^\F%V_=6[I,R=MH9#<S\\BN$UH[GK-3 E544=(B8*531 EE[LO,6_>^/>;I
M^A!8(:.49.*"S"S7[)D"05L%F6P?FV4RL:2-)FIGJ7@/)@!9KC :F4 F;Z'V
MER,3/42@64>3D0F:E*TCU8XL":N->K?.O-I&\/UFYUWI@'2UT]& 69J$,1<0
M=5%5R=> ;Z4A&1M-D0;;EPS='N53)T\+Y?0;GE!;'CGR^H4)BZ:6"90QA;9B
M8<")X(I.)"K630K?.D1/G2;;"KV# *D[E[W;:3W>"I5C=%"CA,E*XPR\0$F@
M0PC(K5*E]:WA9LB>!$4Z4$(7:7JWV7L;HQ/D"JCBP&I?4Y65HA6."0@E.!3>
MQJ1:][#>!->3I,G>"NC@\&VC?%--7IU/R8))EHALZB5/%"0)EVD[%,IHT;I*
M]1'F_O:]W>RH@-LDT1W:(>^Q"HX(?:U])TZ'D\P'J%Q@@3G(MG:98=R17&2
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MH=$@ZS^J2!IAHA4GYQ2S*,$DU]K N/K^IZ'JG25Z6[NNK6EY'G!!VTHBBS>
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MZ'NQ2"#[D_2RZMQE4"F%F0,G1/4DSP#9P1I<BJ7$P'.R^CKWUI3NV.1M1^C
M=*[429<:Z2"QYRYD[S_\N4H;E09K&3,@FR/2!/,$SHL (>MH&)-.-,\0OQ=0
MS]WNVROP5NF_5M+O8/.[N&2HT,Y%L1HRTTSHFJ\>M *EH@7/50":#A')BTK)
MMZX"M1;,4Z-$&ZDWS#R93>>#C\/Y>5OV//PRS&=AM-A^@^=11AI<3G5A5$I
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MHZFQ04+ [C=K,\%R]=T[]JV7JS":2&UQJPZ.;GJ">Z-+E"*+K ,C(=7NG7L
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M9\5&&0U=P;L?A/5UX_(/=[..A@E*M<@<;6N)3J'P7(!1495FL-QZRU!RM2,
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MH#<#( !@8&+XRP'\\\%PY"#&8\S'3["P'AB4G@2.,# R'CG*^"OJ@[/P@_/
M42ZF4Q=OJAP[K?.<^9(CM]2[L.3C0O<*&WB>_,1=OO7BM?<)EC.\9_G."5^Y
M>NVZB+2,K-SM._*JOZFI:]S7?/#T=UT]J/XS U,S<PM+*VL;)V>7-ZYN[AX^
M[WW]_ ,"@\(C/D5&17^.B4U)34O/R,S*SBDJ+BDM*Z^HK&IL:FYIQ7YK:^_I
M[>L?&!P:'IF>F9V;7UA<6E[!;VWO[!+VB/ND7WDQ (P,_^/X5_/B.LCKR-&C
MC$>9?^7%<,3UEP'74::+-X^=4M%A?NYX^I+4N^/<]\*2"QM."-UZ@N-Y\?HG
MRYG+TM/"^%^I_26S_[/$O/]=F?W/Q/Z:UPC QLAP\.,Q<@%@@'H&-^FWODN^
M;F]O'J^U$+E_UJG^SAWF1%L8C8>61 >4\C&;Z71@QHJ(I ,7K#&KTY@=GOS8
MMW>2B% 2DD*HH@-UT70@,/5OS6TS4@Y-#DT.30Y-#DT.30Y-#DT.30Y-#DT.
M30Y-#DT.30Y-#DT.30Y-_MN9*'HK= 3TB4 N75O*F6,18;G&^$,91 >^G7,@
M$1VH3+89^9;3=(#R+H,.H/WHP ^]*AO@6DK0(0[Q'P)\[+64MTJ,_^LUMH#X
MFXOPRY&@:X<XQ'\(./E2@@YI[A!_3QS2W"'^SOCWT5SE9 ""KQ:?Y%T*YX3T
M+_RPWTS>>OJD_&C;L?MMC_D>.8;UN7QAZJ-=<GNJUJ?<D.46IU%0]WVR:!S6
M<KYR->1K_< :+]?XO0C52UW<07R70WQ$&7]XRP?M]T*HWLJ\HTMYMIZ"N5DK
M')F(3.'5R]4H/5V=8O3#[+TN1V1A""UO"AD,.DD[ \G2S+8B*6C*Y'Y[+63V
M6?W-]M8FQPF=UM_)<XRK=EH&O3MF&GT2>5]UOG/E6^@W@50J/O1S$A_5R-$!
MU6.1=.!=(1*ONX5<W\Y4S7-;G3X3YU(Q,CX^IB*2^\>ZNUUDX=(KVQ_(:6\$
M-[([(_? ?)W&S;"C5-L,?:6A>"KMQ[?DGOM#4D6)*D==>" &^#.1T]4Z3KDK
M;SQT"Q5^&RP_P6+9>^-NC@='8+J7 @Z>&&/!GH]*'3G>V_FBY5*(1[C[5<8K
M=4I$8=P"YPBY-5&$Z#^[5]E7 W9X,R!O$K%8<]^'P7O^N @7W^TG<K=.P>N5
MVW]XZ:80<\8S?[H$L[]@:C4KJ-3L,S,S2U;*?5+'3Z3BRKH)VGC(>YH014G.
MP"1V,-<<F0%/G@]I95WK"&\Q?G)7];0W]P?!)'OKO1\KL?#2]6*'\HI BY#"
M#[F "B4$T/^*.NG6I(*+M[Y2F;<\(G5;V/!Q=2C@.,CT+6?RI**QPQ2(<;5.
MJ(H_N??&7.4P=2OG 7KF%?C<OAS!D9HD/8F*Y=EKQ@1=66PN'^EO]AY@KHSB
M#I5^G5[,?[UUJCV'HY^U-Q%0;NF1Z5)H/N.]JH4I[<O3%+E2'&/^,#3U=;C(
MNI?J#(15C0Q"_)S@K,&-]_>7>WL]O3J<7[(O+'7I>?]YL[D"B)3<D]=-"WP7
MXDF\ZWEXQF<EA3AT4S?;A*;E5[<RG&''Y1NZ[X4CC]B??[LQ>WN%R_^>%>.$
M,#%R^KB,Q-JRHFZ*1I;]*$&][_FIQ0NF%FN+ESD25E.9A83"8'?4R,<HDC!F
M\6CAA%%;F.70R,QXN_"V8Z>W&,WD%D7!PS%^6W^RD#FDU"T5[]_D<-*XS14Y
MK=7$4WU?BR= 01WO[3Z2'V]9//5*$E#./+BI@$,<XM\ 8ZO5 8_N</K3@:UC
M<;0Z?CJ@8K"<&_._U..P',B!OR+?= ;:S'YKVN'=+HS;5O!Y8>\L6]OQCF^=
M#3K<'L52*)7XQ&N,HK/0EO6K4^AW#BY4[?Y%%M.BHG'_JGA4)'/Y&Z6W5T=J
MR@ER1&@.$:DV4 .?\7T^@SRK3<"&JC6IG;!P#!NJOOE" 4C8$FVD,.-5&S!G
ME87!S9P?E*\5%Y?WSHFFN$$[8N]_ ;P%",E'S3AJJMGBK[$@JG#(=5[<++;N
M0OE/:1"/P<JYO'I3]B*LR*WU)UW>[0P7CC@FMKZ] QHQ)+CUU\G9F'#U.=MY
M3-ZK^6$6J^89\##FQD^IHMFJSR3!2K0L'GOPG5@E>7NP#P:N49!VLV*BCX[-
M;'U?^*GU&<KT.5?\S=L3"D8G&81J/;N#P%821]Q K5W3L).KUBDK2$NM2-MF
M\W?]P0R!-TNXRHF%?::*@W&('Z!22!,5/!V*R5BJHF8&N.3IM=KR&QK?J9DZ
M]_OUVJ$C7\37IN+C_^"\RQ&L0JP%M3H,^S>;7"\M)POC?Z*G*TJ/AO$TWB5[
M)VTDGO64W#3JIIRFZB(8YATC<HVB2.LHTHM2C#GHO2N"BYIXS!]]E^ JOS<B
MGF_7UAQV^1N7"O-&>53._;5'G'?0EZB?$"++2,!%X@Q%$K\[LR1WIBIBS-!X
MW+N@4B2KOASG][O&$[>+*"4IAB4Z4$Z$$1\C)?EH V6C24::O;@N3XU&B[ Z
M'J)T%ZUBJ4R-#DQLG0;G>>61(13-7K!5]TDWU6F'M^AC%;TV6BYPN%5Z\GLF
MT8]#34S0L*'08\Q/ZTD.,U=1)9"W=(#=\!FFO"KZ0:^0WX""IQHTLDA/6J?B
MW7(XY"[B$T,[;7!+$[0V.?N4=V+K(C.UU_$D.%D&O/8Y!U.,]CXR"S(UQ:)C
M]ZDV\!>+$&HZQC)/W9C;2,5V1D#>O,0P_<2E!U\;5-_>G[F/>P416&T!FX%'
M^)N4.8F>=.#XU1"9:Y2;>59RM^[E9B\(.UOSM4<I,NM9/,D4.';K.R! !YA8
MQLI@' 8GE7MD[GAAC&:4DT+!#\!6%I;4$F7.UBEW48%J<60M(1#98'MUYFI@
M"1T8J2:@<'+^->(]-@A>7$?I1G)6Z_O?)N6E/U^&]\Y?.K9A-!MJ^X5:(2V@
MVN2Q^%;Y^G+9EC$GQZ1ZM%6JKXY(&Y=RD+Y\N&=5Z [#;KJ7#UEQ S:J.LO2
M"KS%OC)TT)ZT"@:AQ$P*)DOW&DMQ*,(>1?@,'5CY+6FX OQR_,,^ FH\/ MV
MG3P_F$!K1O#VN02CSWOI]*^;E<:UR&T,!% LA(3NK]7E&'O[T(&'70!<5XW[
M,<,O/(89*>6E%6NP&LFS!0SF>CIG+WWAL*2=RM.@O>6%$??H )<&1=@ 107$
M,?A-VJ4JFVN,,73@?:X.'?C"-$A3H@/-!\T3>JETX"XKFG+P!0?DQP8!"\AI
MD3[D$H,+'4 A\=S(1MVL R5W9)4."-*!&=%_FO9[4 HB <;(V4F*&@@7:0/>
M :KH !9##%K..@SB,(C#( Z#. SB,(C#( Z#. SB,(C#( Z#. SB,(C#( Z#
M^'\+X@BV&3H(=52]$N)H'_K*S&X(AJPVW-&YR\3]5PC>4N-^S/S%"TP'/DI/
M[N(F22R#VD;=371@GU&;#L#8#W+(<^X#=-2X_R?T7 ,4%=*)Q?>3'@PXD^%/
MM2M&%T;&U2^'X!K\?L<W -2[>>>N,7Y'3L?3> \R\OV"G&)#3AN8"! EIL G
M;' V57+OG>&WGOBX1KK86@5>LG^2R79,745H2?O-I\?,-V<E_)1/$]\7HDZY
MN3X:,+@9,%==KA?&G(*98!PZA\4EU8/]$<QU?GN_X?RBS3U/C//\].^,NK62
MOW^![&-,Y0:@0K.H]PAV8OA/3&"-7.;*MGKU*?>9YIP:2HJ*'V-$J\>VL0LW
M0P?QZC3R?=UYK C1LFD$\<'B;)26_MUPE:%;U!FEP#S(*3=+37QHL&/:J@>\
M+CMCS+2KM.KNTM %'Y^QD\>5 O(>7#OBYY]L/<'78U=2>Z6=7>%1F?''D=$+
M]V?YO@."<TFME3 ^+W8<9[. ZCKM BXC+AMVDM%8VE#8RY0AX97A60'-V: -
MJR]L$L>)O$UU#+TCV*98L:A@&ZP3UI(%6T,J/%^X=T<&[6YY+-E6IK2/:VST
MH=^=BS&,J=EG1>IQ*@(AVFJ ^P=8L41CA8M$.?J=,Q+\9CWOV(OOFG1 []%W
M6N3RJR:!DIM-;+;<.EF_A0 L.<< P)F;]*?/N1_B'QO_KF<BASC$OQ^*%K\J
M(.[^[156F?2W5V#6GWUC'.*_#PY)[A!_9QR2W"'^OC@DN?^^$.U6=,+W-DXP
M;U_TQ*PKJ;F1!<(X5.B ==T*S9V 3O1R(M\CIK8*FIWI1;ZP7L>&630K<!+2
M5I!LC,LPN<^.QU@9W"J=M(H&-STENK^1/E3[.P[[IJ6V<6SU;AAB.CI)&E@0
MG^+-*4F\R21KW"X=B.9_J"D.YX^7H!P/VM]NG2Q!!WK=7^?XI/[./%'1I^J-
MX(8'LOXN*79+V;BZ^/3NE5JY!G#Q9%#-']F.THQJA<_#9' 71ZE#M+V95TJK
M4[:+SS(<P::^P4'K K37=,!/8\E92C%3V#LO.#QB4ZQ.AP[X6ZK@<@DA?<Y:
M\T5X[<ZJJ)CK]=6.5;9.*YY5I-#4\F12Z/<M=O4!T=QGJ15E,:K8&R_YGD'N
M'5^%'24V-51EOBO-=NXR&&N2WPJ]HPDMOKC!20?0L6O*)RG6&**C6UFTX:;S
M"4,I0TNQ$THFBCO*N3_(@K;%5V=8*D22?N^4,$^?P.]N44)OK/I?F\VF.HF5
MWX(6C9@DG*: L@EV/*JJ@R\5-=,;LI;+K[M:RF]HFBK".9,%&N9T2=0G4A]F
MTGF=N[_-\]U[)*5G=2TE*.7>?]D:XT/\XR+N<B";W>4/64%2G5B 82P6<+EX
M4>7R%,L63 #18\*/P\0X9)Q&3Z+/EK^\FSGQB [@3B)2ZMSQV%;(:>)V9Q"!
M.*HO1ZD8L;A=N#0VCYGZ;;#=XKRF=X.)I-?66ME^;=UJ$BSZ5:N"@'67YVU7
M3TH4'8"CTFI<R/?<8 TTLS/;2+L5T;"Y9P77,G^F+8'9DFSV%[%@ :^GLTBI
M,]6TSMXX5.'PJ;<H=8>:R42EW'>EI;&DF=MBR>$S[AQ]0<(W.N' ^0B3EBF'
M893)8$UUPAN=Y.%$KQ3&,4DZX)I"NRK44W<FPS3.LM@YZTKJB+Q$'!V0<Q#:
M7#:/ 7,VZ#9+ST\88#XAVV"=^*Q9]S3]67574U]=OLLD!I/B*=AP>7/BU:T-
MF;O2_,<:Z,!]H^]-(\J3N$O*?G4?<;#&;G;B,1E:>V_ONGZ3"83<-DH[Z@'G
M91RI&B&Q8=Y;-_:V=L00#+TFZ( +*K[3K3UMDXW-';JM1-,RWZYL(H*F)OT4
MCYTR%.5R0F"VJ*Z!PMTY>%\Z\/:=<0LW=/)Q4T^3RM-4'IXYA#N,RY!'[DE-
M?/IX_"1*D3&-<N^G(:3_8AN?E?WIP(L.F]=IILGH$,0E+[G^.O[58]V/49WE
M'R,<W,]2QSK6ES1<5I0_7]U8:<-K^.Y,GK7:7O;(*QH;:9<7Y.,OOK[6-%#G
M>>?;LD78(JI:YR5Y'[R]!+^BD=3?GKFVN/G$,W_"EE)%N]J*9%,664EBVX5(
MC<4ER%J K O?-&+(6M2!/<HVS)0(;I6'A4KKERI=F=)FQ+6[N<55W5[3H -&
M9M!O()ZZDP?]QJY 5]6V1DRA@T<N'0@%IR+\LS:.2;REP'.]% >B'_<LU+^\
M,; 9<7Z5.@#ZMLN#&[:P"_RVJB@H)1'FO%(S&$V15R9+M^$J=YE"&C2=ZFJ%
MY\C@EI>4NIV42HA_$M=.4N"YV[6]:</R@/B-.7"-;RUGEE)<,FF.(Q]CF&J0
M>"DV5W-"P@(A9Q#R4$GCP5<[X:KG:MQZK1?_1P7?GP3F#S_5N!F60 >]RQR[
M'-5+CN9=V@N]A:,#M+N]R,$FY)*HL0S K:-VB']HZ):R/^C5+ E?(2SP:UFU
MFEB/79+HB]7.RJWUBX@H,HBR$<W->FDWE[A@M3[UP=[=_(^<U+Z(>C07OGM=
M,VW9Q+S<;ST4_?HV^??Z-!:X_X3##\_8_;U6$)>BRFPNZI9^GWG%A_/I50D?
M,W\R@U P#R*E*4C23:L1M2D\7SY)@RH/BD\_M)?J19,K]C?WD FHU .6?60E
MSQQCE]SJ,MJ C4U+KTK:JRJ?DH3;+F+.47['2Z#2'-:U5>HZXO,2,!M3,.+Q
MU=V721[U/W>45)OEVBPSGD'@SN.7WK&"LK$J&V[HUSBYM3Q7E_DQ8L;>FN,N
MF3WNV$?RK:U47'<?M+GC=!S^:/SUS+9A:U#<ZK;##W+6\]?VYX,2U"O)M694
M7DBXR4M<B()V=?^F4$EA:>S6@NI[OZ/BZSM':M'UF**)W!QW5^7+5>>T"QO(
M-XXJKBF=(&?3 13H.>PW(JS!XZKW&JTKU?K'\,6SEBK1R+WX+>1I0Y==/N2)
M'ZG6L\+?R6*\^YCZ?47LAYL\:#9N=U[7 Y(1)I+B)WUH@F[(^C*:"2I3S>'B
M64\__HP#]VVB,R$_/$AT([LG4YV%>R;<^(Q_O6[>DYKQ!T6O(U9V?U%#ALH_
MWZ),VH::Q8/2^VL2Z[/5Q0EO--E\1)HH>^LP(2]3(L@=1YK1UGATRL0-/AHH
M7UNHQ$.MY<<I[I)/I5:4!VV<N) H'<O'G8J]Y*?W1%*%.0O-*M-^S>)3I65:
M5'?Y/EIHLOU6[+ZVB94M<XTG'8C85@9PF" 7"6;;DS8>NAV&QK]YOLZO[?=W
M48XD2#1B@JLLF[L46,NZ]7V='%]T=9.75S!9FT-)W,1^W#$8FSMIT?^%^TZH
MB:=*E"?LB4(1(K5.0ZAU)\%@^U[?'YC>#;.2FG?E6&E+)LC^^@1&IG'V9HU<
MH+-H;L-&%?@V'3"!=.R>-V%E;#FK&Y LJOV2A+XNL5JU365/J4%/+6)9P0%Z
MRYDVQQ0D3JK78..%OPD\4Z)"\><M!;-A^<\=G1U+(FU.U<!V+1<0<A\:!NH'
MG$5;>V#]@Q]UU'@&''VY__;9X=\3_Y[GE(?X1X(YT:=Y!.K[4GL!C63RQ5C$
M%.B3KJU@AX[8"-_N#?XT'BY^,E+SFHIQ74!?CGQK9281T;(IH_#MI=W3K\45
M.CM\*W!?-]Y0I$V!8H<#R]!B^>AF]*X^'<@%-=;P-RM?ZZ]YYF6_"[_GN4^6
M[OI8UU[+[0DP>>D];]$W4IKV,^F!O2:3*'7;&T4;7"TS=HI/"8[K-74;2> *
M$B\65JJ=D!EC.VT++NOX1G:9B0SPS($O4!QW9*:4K^/+*F>UNDMLY3\,?N70
M/3LC?2 (F1EQW <*V& R1$*Y.]6ZUZ3BMJ5.0"]U49&S>;".R$O0*RG=VO!Z
MZDX8EJ?Z=06U*L4038FF*[9SX&G3 //!B(T@.@!N2;*D \=KY 3CZ8#7Y#[B
M^/YFTP3OKT1N[(0H>Y)]^I\;^>Y9+*6.?12=4&0GBQQD6X77W<,,W8C;L0:G
MH%IKR1H_=N@ IWYZ8HPY4TC.3M!1%N5, 4CE AHZ.$\1]6T:<8M>%QZUHHXC
MD([X&!3O"[R<'X_G[;T)&!(2/6%.1#:2(+XWU!+#,AN>V\M_%?6>6/,HW+L<
MVY<21-:_)SV3RF16#6*]TYX6O[ QJ7?053[[UT30$:XP;RG114A(4O$DB>K9
M6#:!=LKX#7P*S[F B4Z'\ZFYQ_C!5*52UW+1&OT>@OG&,2^DJMI+F5>J9!80
M+@V* ZY<76RHHWA)L[ 3>NK,%WR&?&!/*#Q$*F_0T7.@@/3[,J&G6,L:TP>_
M*$72 =711!:*#9'IX.0ONCPX>4"7OEIHQR4ZD$S:AMWH/CH /:4J[7 4?Q,:
MTG#PAD>Y#M[P$QTH?]4J40,;%R:!.[H<2)MD9I[G"MK(*1UD#M)IRQ,1I .[
M0^&F)H/[K)1%*G:T[!ZI[M_(W)=;7(6I^82%?4/W%U%:_<PU1GX@<G,0EG//
M0@T#VE?E9093EP8_ENBH>5A^^K,$C%O7+Y)\][>RTPG\-ZKT3]7)A_C7P//=
MK7J&UY_"ZK!@>^Z3WG?U)V,"/9B?S& 4Q*,]75\G.$'S<C0T.4]$5[3K:3KO
M=>5@/6>7P!G4.:M$MF+RH^*LIA>?VW/+C.G N$H'XDC=&_S@NE:.3>*!',U3
MC[!W(_\^I3CGR5F%(>+W>&9BHS)=OYIHNL)=9.8[_26D-XSC5K2]9)^W?+HV
M<?;V=MVF&LT!MZM,!\2G*&JV$'YQM6$;.M"&4/:O)JX2LJNJML6\Q"P)]TGP
M*KSJ?7B_/"<6K&+"_W6U"A6 3MQ^6AM+6J[J4(@"JR3Z#.GM>=>=<8O ]ESO
MV2&0Q5\-1M VF.C .T&,6AL!G7S 9S>7Y#FCG?(?',C;[D\J6B[@C5V'YBD2
MM /+?B!&/ZW(M8TO@\)7MR!]I+87!V(TV%>ZDBQF1H5!XDSN[W<<C.DY*+_4
MM81&;_J!NE9J8O^8V=\-\H?9D)CK)XLF(M-_:=)*^=)OBVL%ISY>WU.\1?,9
MJ:T;&.#G=YLJ\U-P$^)_<NV32-8.\$K$@&R$\<6Y:3TJWQ1>+!^GN2KSWIRI
ML9?")1\H<H<].A 9-(*(LTX;QMJ:VK(GE)B>8#O.Q;O$].R *(]^THW"MMRY
MHU#;&'0MX\+_;FH>+4ILP2EWS_!4K\B[A78T<Z%/F9YX!4R;[>TXU,^9"F:K
MO7Y1\,FQ).$<_D"+N2R\>7XSLD FTN-42?2NY1S"W69$>\$WJ_MYEJ&FM3OC
MRW"^8RQ)VY.UGJ &&*J':-203 R")MV?OE#]LGB$++B6E+6.91Q%B%"$>A%7
MK"OA91[-HL&>\R;(,:0N54-G#!1:HS-M!VFH:AZQR'TY,*@#RJDBF"LU[**_
MX?45'=AG=#TX<)[*J';88.P6->)$2#U>F6=Z-5?;O@J]J48'C).2)@?VN(Q'
ML8JG+O^/Y?AA'U4$5+)%9S$^F/,2RH+?8]]\,:O%D<MO[GJ^AMQ(G,@EAGI0
MG=)6!CP6DIBHOLVN;YSRB0L?YO61B>.Y.U]SY9)CGRSXA1OF3R[4='<4>\76
M/85&>32LBQ\0&B7864?-,_/M(<\>XG_'K\W$V5E>/\6C@@JKTXY>F*U9ZT#A
M[N1%5CIPY%)!7D"ZGT^VP0/1:OEKSU=?9&3_"/Y4+526#VE-XJZ1F[HV2H8^
M5G'ZD!</JDG 3 EE]A<HK2[0 0%$#^(R7B[&(=WT;J$]^.?HK8*]B'+*4<YL
MM' 4-%$]7,/ZLFEE3*CFU4H9W!U_WJ>^T]ZH6QN$?3$:&90\/\;_Y$VBO%'N
MOAX=D"O:-R(XG*?UCFS4+AA:Z;!S=.(7S92:./>J)*:DE&RQXNBKF(KPF05K
M<?'+"HG/C(IO[E[>LJW#R=5CN(FS'3%BX&+IA<7UZ"]?A/JAFW+S* \2?_UD
M\:0O!33?[<A)F$BIV=\+8KF^JT_BQ%Z=J$,D&L=9%NO:EJ5.&$B$'XRQMY5#
M\\TC<!2!&_*/C%-S]SLHXQ14G!<GSJ&9IGA=+#*PK,!A'U'=Z6C:[]:!K%=!
M)WNQDF6)#HTTX]8,#@RB9F':\4B2%9D.U >26'8+CKP%ZKE+]YXAV:<*]#X-
M*E;7UFDYU"W66RA"0K$F)Q'?!:(.TL:,/R]L_=A:V)H3D,J2(PD(O,W448,_
MV_J__H6-T,T2_N<@S2'GAU=NKB5(V6T*@6I\:S6RE :325.A.4&MI>?<@NPC
M]2<DG.W42Q\JJ>E]RA,NUFA *.(X\G#;!G;@W_T9BGZ,77GH)+%W(!%O]NEU
M-Z*#JY*:E'YC$G--[1RN*+*8I>[L./S86],8$I3 (:)G0\X8W](K/WV7DLLA
M>&5MR9.+#@S<X<%CF^F KT%FD]+3CHICB]HQJ&%TV"LTK0/I4HNY,3@7D_@T
M\-OJ#0L.2)C+2DU2-.46V*R]^(,L7&VJL-!H,U/3/;^[8Z&FKA.'"7*>/+N$
M6_'0;?\UTQO*QU]5L*:1;@MM!',J7[:99-]]YYFIN7"7R'OF-6B\L\[_1VCG
M'=!#'P+T+06>1E']"7W<,]]V]EG>9.!%AXT"FD8RNK*MN/U9VIVK&WV&^31;
M2A6(,=&,YW4V^;YG7V)W>00=4,[45..&]H&N_.-3JJZ+]I-NU=Y\AUW6K)<O
M[3YVR+0TO0^5$7CV&<=D\!7)ZP;1P@_Z;98(V(R-+[NVS7<??Z.]^M&Q\K[0
M1_ES (YJ2, 1=3)60JP%-M*SU#./;?0T[RL3QW11?1(]M?[3F\UH=LKO/WCU
M<:W99S+-JTW7F4RNMCZ0/\E2KG1\CX\[%M8XR;Q4Q??S:XU$6D-ZD;N#39GC
M)T?:@$8G_+MFEU<I^<)RH9L#(9Q8GK*DYN^[;J _(/-"QUC\37/EIJ_46\AM
M;H9=UU!%]R]><CC*R&2@S&WG/-E+W!WBFA9*/+\?Z<0R^Q[%P46;US .,%\Y
MCQ0#I8%<V].RDV7:+[S"-MX4OD36V[XGKIO3 =940CW.LJGK;C'12:N,;-Q?
M-G/T@TZ&URRY/>QJV:.;L20H-HF%HC"[><28:+"G56+(7&Z5%_G'8S%^D!#V
MW5;D;44/TW3 F622;9UG/3!(@G="RZ WOQ:,W9WN^4WHXJ?0XY=J>F?*U^6F
M.'VJWO:6CC_1=+%+_I[TG"O6[(D4Z\[OWQH8 BZ?G^69G2SH/M 5(&^:>*_+
MR>Z#@6U"<['(Z?;F;SW<=*"NY^D!X^;0@0*TSW.\%^(:,7WF>&J?ET;62K@J
M>W/[V9:W1?>7.,>%DP2_7#G&,,<X2..A]<,X$1*VC/=_[O+ER5@>;3'/5IVK
MJ6=+\!?6GTVH_,YP>VH0/?@-7![MO>YU*Y-H.J,7:,?C'^!,U;N67O5.MN2+
M7[B<EXL(_BTG+$DP<M?2SR4-?]5O)\]$>%B F@9]4/F=\<L?8 .@!\U+#".;
M>,D23?.Z4U?.I9'\LNU'Q<5**A1G65WU7MS;$!B\(U"?WS2+_&"O#*((X2TP
M5J,2-[Y>MG5M?=/>]-(NE&CQE @-0S2!V9S7F:>5T,&999H4%73;C2V3!W+M
MA3<^!+U#W7T3=7NU.M$'$(S 11."<.#6Z%A.CA4(-95E/]QZ,.QSYHEX>\:/
M39?-LF]_^RXE6HUG#BCI/K%4[E%6".=(R!C)C)'I:K+[3>".<MH40U\X@/X(
MMM$^TS&%QJ+],%S2HO=+MCW?_+2Y.9H9%;YNQM',(:?XNBJ"]MU=!DVVG3 F
M]F(GV1!G&Q14S+_";NS%/9(ZIQ;(23G*]TCI_LX7CB*'T=GIA_+^PU&+>K$"
MHXBAJ*-J**-3(!#N/!E:[09MB06'2O-KVZKT7>S;J4X?Y^ED%G%O."JHPNQ]
M_"B7M\A[)+N7&*\/;Z/IO2('CJ_*&D/G+IB*?C#;&Z<-&FW'#W9.%FIWTIB)
M,7B-Z;C[/</6T6@G*_WM]Y\:NPXN#=AEVL%-0?T39QC_^^+]E!E.M+/&B:SB
M!FN8,#L)H99F28 LB_[0@9"?P'\2S5 /YIIGLOZ87A?M4G.G P8)GXT$A?C
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MF)[6O=#L%G[E(+NJBC6D:I]%>>YNCLM% Y9T.6>"Y6SI]>\?QN6#>@PS#FY
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M \$_-ZK JZE@1>GQ!ZL:&&]"ZXR68<5912?U5^UP-;@USF$V/1/U'*75;Z
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MJ?K0]% Z_^7PX^&&T9 KL9DJ*KIC7]-#SX?\A_F!\T%%&(=Q4*F2:MSRU7O
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MR+S^Y;-XR-E?H!FGZ\+O"A5F;T5;%S8=Q/)^.JXB(@38K0NEC-2CC]/TIHQ
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M,6G<"]H3,ZR2/52?ZXUN[8,U"5XP_G &LH*$,P%XG&7I3C/M'$D1MBH7:\V
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MM@JZXU9"7Z[8//4BFSXM,XL2H,%(L/#M9M><TH@D9&M!T-/K&H<[YFBZ?#\
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M^+LY[28+H"!\")Z#UUJ_!+/1)Q;E%_"1S<^+\-++D%'@C?0WEN1 HHY\!*;
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M@Q+N',NF_?B"<KL!5$?^O(F;#1QE 8;L)UD [7:K<6(V4\\K$+?*X\ "I)W
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MYT>;9#;JZO;A![+3/G:T^5].-T2IZ97$2*B9GV;&WH>&,(4_7T(>6T*J/;I
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M^A[;[8,KO=ZJ\.3G+OEB8T\OURNG7*8$\_Q) (."G.DX#[_/C !39#VN7+C
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MWRUY(60DC<D"4 X92L??18?03VX&AS*T:RE'B/,TKX2I0@&OE_Y)RF&;(X?
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MSQS_M?CB2>0[R>8:>=LJA!T0%A0=MB&!A3&%ZU.L0^M!=W\Q:Q@L '%A]:
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MW8.2F^5J^32_J0EMWS'CUN(::>[VN*OCHC3 #.8Z]'&/+9I=M6G*)QOL5S*
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M#L-) SAA&>"036=T;_/[/#1D)SDMPE%V:4802F4\L<L]1/?1_JD)$)_N@IE
M48G &:N>(G-VN0 3+\0-WXL_\N92JT'GB$DD7F)7_:3[8&A%DZ7K+ WPL; C
M6X1P9A-9=T*RV_R9C66GO9?X]Y^*5EV"[K!LDR]93\]NG$(4_.DF7JC3<!4\
M"1=:'-=X17)T8:Q,GE-!N!'Q)O[FHT"A.%>2)B_7W=#,Z#C%M0I2.3D.U>A
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M0+UX&MOI*5[7OWTU?*TEC!S56 (D"@P-LC@?O<YJP&IWP6M.HN=%75W+IV,
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M5:H(UFRO+Q9[O6HCYGFJPG3(7!7R\.T9[$.F];JLQ0BH;B@_66RB.B[IXEJ
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M)#2EI[>\<9/"X\P^A7$F&"L:A7REU3X?L!I*-L1!+Y EI[P78D^!Z;ZBM<C
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M00 J%<ZYB,288E<C2ZL$S_6T6P2_=VJPC=&HU-\:"/C.WB>19CWUCQ*<Y)F
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MF9#=<&[\V(5(F/=)\+Z48O^=V1T5$\UT/9,7?H"G@;]INS)I1\.6AQ123T7
M1AK*_L+OWGGW5PZ]4!YHBJ1,(,]1KL!MB%O9RG$GR$"L@=:5>6:MK8W^^,&T
M%6[#)3$;1XAO:'P6$(Y->K/?@D$NV:.[P#S334EA7L5TA*TXV257Y3OQZN7:
M#I#.5IFY9Z932CL%92B\D:T+<W65%AL:'<&EBHVQ?:)#3:4M  #=DG,45G0B
M*#SO%(@(JZ'NO.5,C7!$E,@MNTH(.*(,7P+X_Z]G+_P?'C6B.JIU_D\6M-O
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M.$L._7]C[SVCFHJV=N$@"BHETCM!04 1$*6WJ"A%Q&"AEX@T,501B+0@TJN
M@-*" B+2I",E 4(5$:FA"81>)4$(@;0;SSN^;]QSSCON&&>,>^^O^X,?[+'7
MW'/-N=:SGF=G[;E(IW '3SIF-T]/U77FSO1_=Z513](!U@#BE-Q2\LM,[H;M
M5H*;L($3611YP3%)NH%YMX^R 9F6:]=$O_*C,B^"(X5OCM9:)'$8\>8H:Z'T
M':@S58G1WIMK)H 0UULOS$O(>O# GGD#RJ6)7*>JU)]&)TI\6BL@W^0'R3?N
ME/1<*]SC6P55!6!^6>U171>0<>=3O<Z0ZB87_EQ1G<K\U2SVJOZDV+'/CN6
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M,P1L)BF7< R#\PK;1_(^O=9:CP2^/7>?*;WO=$IX4 T?*#&8@1SS/0E@6+\
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MQ/K[E ):-=-'OHPX<IM[9=C,HX)WR3 GP?,^4\\#J YMD)] T:*6MAC,(T[
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M)S4CWF^4A!0_J5%6"_A4W/<MW__B7&>^>$$2YU43DB,AO@,A6*;HI7VA1+6
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M8C#:/ZI[=W_Z-[<+J- ?",;=TL#_\OGUX2"-'Q*/7G,;1^,=&"2,SX!R"2F
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M!;OC.G,(K[\.,K^GEE;*__T:/6B^?&R4,&VCY\>>.G UXN:]YQ$U2O, K2P
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M;B:6*WA4_#:7/EEV6WU&_^%[>P- N)9%.GQD(2.68$P<(OGZXM:M#^Z,.-L
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M*!5T'H[>WB^>@+N:X<$)>T'C(Q0_CKDT]_H-]K1.I/HSK:UG!2F#V4ECFW1
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M*\UUQZ$&]K7R8*6]PZ*>/3!S5=C31O2PQ3U[@+)7X+///7I7Q&\BT#:)D>M
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M!Z%1G.[%FHS-3[H7==]*$&8(L)6FZMUE)TNK.!X=@^WNH3#W[HIU0N]J0Z[
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M%L0'90R[SCUEYM[R]>27+ZPY*"I-)Y-<D(@@*6$F$J1<"8HAC>-$O>98!DG
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M.:G&/]-:6SJTYW$W/!QVB:;O@^$+@;0_$C8%Q]5Q\%EYPQX%FYJ_=PQL?.$
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M5(?JY#JF(X>*H&)*HQ#ED95_=$;>V(A(IR\T^H*NPE?M_G*OXJKG(#?C'X=
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MP> =!>[*@JTZO)(H8C)"(8QPIK.J*864R!"*.,-Y&."(,B.GO+<&8YL$.C:
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MI%&>01IB2B*29%E ;!: I\6-S5UKU0+/9-$6@])1?!O.ZEG+TA#[/),YY9&
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MW)Q(*G&6(09YC A$0<YACK&$"4J96O9%F.96N?J.]1L;-2J5U)!T>A(UG:4
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MG_O!-INQWG8(/4]0G1%K3:DWRNN(]4;_>M2Z!GD-_/ 'MJLRA>X5'+;"H3>
M]XHC^I/D*Q7S03TDJP3 .,P4_><9Q%QRB'C$82XHAY(D<1CD6"1VQSA6TL=&
M\M_$*JBOCDVY7ZC1T%V>=-&W;V*Q+ UK\_4;BHM6%I<#/. :X60V9JW^F^1C
M'@!NL(S,KNPQN-ZG8;'/RCQTDYY!<GO=3M\K*E6/T"3G04*(<FA91G516(E@
MGDL*D8S3& 4Y"YA58OE126/CK8M;(!_'E&(9"Z(FA"Q/(XC22,\4,8,9CXA
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M/F#=2VCP(J3?[/%E.2M8\4*F[^8S7K7UHS')2!I1!!/!<[4L)@&D>8A@D/(
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M\*_@[<99RZC+ 22!^^:8\KH[IHYP9O9=^:"%T68=67)14F2X?GT#'"3*DBB
M BEFKU.5$6&3W'M_(#]L 'O(J?C^]O/=@C=%O1 2)"()Q%Q@B$@<0X;UWX(D
M#2A'))-VVUTGGC\UCJXT!%I%\Q7S_["CZE/@16E$<1!G$*<QT:N ,#/UCPC4
MBWN&$Q)31HC=^MX#?.,L[W^C^0(L%]OBZ7X![9ZU/( T\'SS"HWSA86L4!%+
MOC'[5B6##(G.GJ#14+I\$CUC>C7]F8O*.2V,XK"<UT[=-LJ,=$;G9BXY=]E
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M3%-V!7K6N@&U+(PC4RKKS#%[$%J325]@AF>-4C-@5#-%F!NJ>$>?<\W 50G
M^B+3T;@IX7QK>MZ7<;)>N>083/Y(8^_I8[/#,=..T,#1RWH>_/)'*39S^54U
M!+(+@D6)(ER&,8PCJ=<R"1&0Q(F "@4!HBG1WH?3JJ9#UM1XH%'5>.3O'LT9
M0)F>\*YQ06Y+%\3\MC'%\>RT W;+HTT_8 Y]\MC"<;L;4NTC#=,BTP(67^=U
M'9+&/4X[;_+!:9?%+?WXY ,M3.6SU3=9-"G#.9]Q1/6*)1.0X3B!R%1PIW'
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M?\\DBY.(TQC&7$40!<3D61$&@R1,XRR5,4O<FJ]=K-+4)HS&(I/V6VI?1]R
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M13(=%3/J\H.U9_K2,%>U"[YT8?[>PKQ1'ER=A[E/ R1+Q-QU/C(5/'3+(TM
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MIDA#<46<Y!"%00QIFA,814)*DL4D3HTB<@_??FR>V59#O9DMP ^MI&$N\Q$
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MGZ"'E3L[!WVN[]GBCA3+JM3N9T'TMJU^^'1[SN_S!=7Y9GINN9T_KW5T1C>
M6?VV7BZ+^6,5,+A)#VPS6=529;;F>A*[(4M=<K&<9CFE.94Q%"1F4$T/!!+.
M4LAR*N(L$D$>1].Y>-2IAP\6??&&,L#H-<;U:_S&#(]['G6,5S$'4I=-?JG*
M)B^W=7?5'U8_!2@WD<W*@5V<C]EZYX?%;*TQKK$?J+G?ICCV!'3,KKLB=PT'
MM>5OTE(VQH/*^IT&RMT" BT*^@EJ<7#8%'#HH7/50G PO8=M.#CT<+QI3SBX
M CU#U[LS<UTOLG$>,YD%+,QT'VD:093C&%*>9S"3H8@E3Z(LM6HT>%32V%9
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M8)3B;*ONQ77IG8^Z&7N-91#?L\;]UF#0M;CQE$!K<Y5%UC$.-&9O8C&[?YR
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M6TD?VPNN<TSG3*E81PZH1_N#D&*ISZ"^BA<Q/W'Z[V HS)P(;P![9HM:;^U
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M&/(P94)$L<A19-,3QU8!*T(>8!=[HV'5-\>.<*W!-^-5GY .L9FSU74"-K9
MN5A";<T$;"&_/@6Y-8?VQ<T155J+'Y01^X*S3WR][^,R):L33_/;Z_8K3;C-
ME<[-K5,D2J6E%,5*L7'3GZBHV_Z6M_,O51?VOXOB\>=*\*L7L22/XN9/L61%
M*;XL"R:F!-% A"2! B,&$8\E5(XNA:E(\B0669!%5FOS=[5F;*YP8Q-@1#W
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MP58KEVQ65=+"5LT):=5C[SX_CM5K9M'88#TQ,+F?23G6EK=T?UK&ST!EOK]
MS@DU3S&>7=NCAG].L)Q&AFX/<1N!FA3L]T+=0A9?R<]&$:JIJSP/,.,<$PDQ
M1FI^2+(8XC#6^QF8IJ&(XCRU.CUQH[VIC3*-G78L=0M3,U[RB-3 3-18"AI3
M+]>(]T<]AL!X(IM;K8U*+X:NGQ**Z6U]=D,?-RHDKL18R4)K6S]^$V*C)K9W
MG%=R(63QMBC98J5K1)1O7FHA$;+X=;W:/I?[,][ZFI4*LY=;P9OSX*ME4Y^%
M92D+4L)5^(L91$BK$T6IWA&)">.*J!@3]ENK@]L]-4K;>0!J%]HB"6TOP,$-
MM\(\8[T6-KO!D^KL@5EY@'YVW',>#76O&]C#6_T*N^&C=<7EK?7QFK<;RJI3
MB>N7^>^/<YS%&6,!@P2%:JH?1$2%OIS!$&>2QTRPE!J-,H='3FT ^'U9Z&EC
MU1>&.^0M?+KIULWK@9GP]X\/7]_IVIIW7]\]]B>W<Q\[5CR;BVO::7XY,$[K
M4:.0P;GIN^_TPK^X18.[W>#[U7=:+*M/\_-Z]7ZU_DX>EE+_IU(7)>NE^I++
M3^M*5T[>L?_>%FLA'@ME?_5++3*G<VCOJJS:>8C#@.EJ\1*I22C*D@021BD4
M8<9#EL21Q)8BH$.9:O3JCZH?NO-4K\7M7)V!Y_4*5&Z"XN#N#"CZK?(Z2.,H
M*+6G]:^-JB-7-L] G>YL%Q4.]GJ8A8&OVN7CL-V^K^_;?:V\!)6;X*'=USM/
M09597/?[W7&_M_RMCCE4"M-=_6X=)0[=*9["PL','#4.'!KLT\!O\/;<AJF/
M"JVJ]$$E[UN5JGROS%LR]?.#BE'+O2B2$"(- T)@&$8<(HEB2'2NC)!9$"&4
M!P@SFV4'XY:G%C>V:K@TIE<)(G)GO!X/M#)X(6Q%J<P[PXSE!X%X8-IN; 8/
M1^#NS0:5W8-H5UFCY8E/S=L=E2"MX3AE//L'.&[=K+Y_+PX)1-6,^$FH9D0Y
MCW*.6"Q"]<%R731%36 IICD,2483&C.>Y[G5MLWUMJ9&4RU3JT^(M8VUW,CI
M0-AP$\</;D-OX)Q =F\$F?W&S6TP?&W:=+0T[H;-;9?/-FL,;G&26J]6R=0C
MORA:6A=,S3JKVAYZ.:C\3>@]YGD@,X(SAJ"D.(,(IVJ.':0,QFDHLQC'".'$
M0EG]=HM3(X]=>5;]%7QY_-U.,MT X&[6& 2V@;ECA]B=1FQO<%.:J#(9_%$;
M;;A_9 ZFE=BY7U!'TS9OO8X7P?6E F,#T V]<H,'C2E/;N[7B1JYQ8WV"=N-
M@L?+NY_LFRYCJ@\:SBD/>,1D#%.DI4IC@2#.$(=Y&O,L(WF<2VZ:L7VI@:FQ
M[<Y&L#.R.OEJGK-]$<1NBO4!S<",:HF*5=IVE^M.>=L7'SA:XG:7.^W,[<[K
M',M<]BQ*W,KCZRRISIAD>89S*)"((4*9@'E(<LA30G$<AHPR;%7^<AR[IT8U
MNY&TG:"LTY#Y:K$@ZQ(\BW6=DFR9D3S6:R 9B;(L#B"5-("(J1@]SQ&%& NA
M#_0D(HKGSU4UZ\<-66_^95^&4Q]&?25F@(JG8KG\5WL[DBB/]?0,"J)KY$8T
MAR3C(>0XBR2)L$QQT+P=[Y:&NZ.3?3=V'HS\9HA_/=(P6Z.:8$</'6%=*:T+
M6DYKJ;?V=8WCH/)\!AK?9\>'+,[.9.P0 !4$'NOOCMMGONKRCF3UN/5ZQ^V*
MLSJ^(S?O6INCVL_5&R'%1GPH?@C^L%3-/FE]TUHBXJ3UWTLAMXL/A50A,)=A
MG) (9A%3(3!/5>S#L("<QB0.XSA+I=4.;!]CIA;7'F0,MI6-8*$+UE:CU(M0
M8Y3ER-2KG\R&F['0'W@,V;D!:C]@Y0@X>+(O.70V)M3N .V/SX(C_5'U5I:D
MARDC%R_I#]IYB1,/SW0CV4^;;V*]JYM8B/*02[W/GT@)B0C/(IBB)(1(AFJB
MD.<A#"07C)"$T-Q*->=VDU,CS,IBT#(9'&PV2:]P1=Z,'/WB.?363T\HK4G.
M'!U/5&;0X*B$90[ *2U9W.E&/N])L?Z;%E%J'^VH#FZHR++)?R&+_0&0>U*'
MGQ^*I:B28N882YI%)(&""+V&$5*8BR"&(@BHP"@D:6RT^>'+H*D1E_8'5 [I
MP_R52Z#R">R< G]HX^M,,4L"Z]U[9O0V9I\,3'ZWNV,&]AZ!O4M@YY-99UE3
MI"^$/1%H;W-&I5=?X)V2K[?G.N3]_+I:\3^+Q>)N>1:''K[>-"1AG","1:C%
M%--$0!PP#G,4TIQ$>1AB(S5YXQ:G1JX[FZLTEK-)G .QFF-OD!+D&]&!J?$5
MP;1("?(-ZD@I07MP=4Y0<0"W%CSVE0YD TYG.I#1@\9+![+QZR@=R.I&MPCZ
MD&>DQ2!W-7<I"4DL> @ECA*($D$@X93KXR<(2RQP$%EE<E]L96ITW,IU8U45
M)7:C0*\%H&:1:F^8!N;8%D)-G2G?)8P[$? 4'EYN8]28K]/-TT"N^V+GV@#/
M8KUY^:SZ5VLAZ%IASWH@.8QJ<1+C% <2QB++M-9U"$F 0L@BP@G/:)S2S+(,
MP(TFIT8(.XMGH+*Y&OSV5O>8]QJ ;\87?B$=F#P\H.DBV6\(D#]U_EL-CBW$
M;PC !<U]TSM=(X\?8KD56M-_5\?L/XN-XK=RL_HNUN]^-L(K.MY1_^-?R<]Y
M1.,H9CR&)-=BM"**H I0,(R#B =I&F>2&Y5+[F'#U$BJ4I8'Z]H1VU#%H0>"
M*!$BQ# -A)JTYTD$:9:DD-&,I)@',F#A3A#CZ^MWQ+'@Q==1HDB^92I :GK$
M\O"?2Y>8QI:#ONJ#1YZ5]741F)W]X$_E -AY, -['\#.":T*Z3,X=8;06^AJ
M;\'(@:TS1.=AK_NC7&L9_*=8+/YCN?IS^2A(N5H*_E"66[&>(YRS,$HCB*B0
M.A\>JW$G1&K<2=5L..*2YD;)0#=;FMKHTHCY:VOA/[2Y8&<OJ VVK75P#>%N
M$O.*V\!4Y0Z90RV$&W#TJ(IP[<DCUT>XX>!YI81;-SCL9CP6/PJ^6KXMR--R
M56X*5O[ZG?Y[<QXTC_*084)AJE5B$=/'(VC 8)BBF*N_RR"-C'<QNEJ:&C4T
MMH*6L4!;:[&ZW@FLP1:%+[@&9H1K2+F<4>Z$S&(CPA=T(VU 6+]L=CL/)FAT
M[CAT/F"\G083/XYV&(QN<)O?OQ6R6(I*2V)=T&VEP:7Z]-WWY\7J1:Q_(QOV
M385O1_\NU.NRW'R2U3_.LSS2DA )S$6&M/9V"G.J2#8*<B0"DL:AM#J%V-NB
MJ5&P3KXGRQ?PO;&\DIW9F0Y(=59(FZ\3@%<2B-I1<729W?RT?Z>:S59'[:J!
MZ;_Q!;2-K=9 U8RU\0?L'#JZ: 8:GW3G55?XF\MZ ]C3S+:_/:/.<[W!=SKK
M]?=@AT!W7XKZB] X5(55];F>@Q1B6:MC%SN9BKU2T$;]5!:\T<6>9U&.:9Q)
MB%DF((JIT+5<U-0Y5XP>8"YRLT*I?LV:&G^W/9@!WO)A=JPBMM$_'ORPB!?]
M=:E!//XJ'34P>]<^5>5ECKV:@>/N>WO4?7=M1;,-N'_U[K.8&[Q*-XXTD1BS
M.^WF(-Y1[YRP^&MMO-F-=X2.ID+^G^XP N\DB=68OCM 6S#5U-MBL=T(_N[S
MX_YL3R;3 +,@@B2DU4Y< '.4(!CR*$NSF$D6&1U=L&QW:F/H1[&IQ>/WN@B&
M.L"V>!N,?\.@./1Z]4Z-75E=BP\T=1LKTFM,KRIHVAY4LT788H@:!NF1QB!C
MQ#V-+/9@=0X=%H\;;VRP]_&(_!UNM]]CO%_]$.O]VQYS(5'.4ICD7%>6RS%4
M4Z8$,IZE41:HEP@;;1R</7EJ#%T99TT>YX#=WB)TAF%@BC5&P&H'\**W3CM^
MQT\:;8?OH@/M';W+%[@N1]/-PU(]JF+XNHI?E%)& H8@DB2#*,XII)B%,*-9
M$ 52?9RAE<;'A3:F]C$^LF^";Q?5>O"'U?()JD:_ VTX.%CN6'SQ$L2FR[V]
M@!MZ_^X4LZ].F#FLT5Y%Q=NJZWD+(Z^C7G7Q?&7T^J5NE/!!YPV)#X*4HOR\
M6A3LY:OXN7FC[/O'G&*, HEC& =:E%P$*<1$Z^/FJ:(()@@G1J+D!FU-C2)J
M(^T^_2XHS2C $T #4T%MY0S4=H(_:DN!-A54MGK\_ T0\40#72V-2@<&+I_2
M@LDM/<4E'I;/VTWY0?P0B[C)M" HDP&5#%(4QQ"%NBPTYAGD:8A0&M*$(:.S
MRP9M38\>E&T@=I1ZN("E&3]X0FA@?F@+--2&:JZH +N=[>.NNW =$]^2"A=:
M>AVUA.LN7Q5"Z+C%-6'X;ZO%=KDAZY?WQ4)]>_,TYBQ.$PXESB5$2<P@CM,
MYH2%C/*0INIVJT3ADQ:FQ@9-MNO>2E";:9L6?(KC[;E^;W2&7E:U!,8A^?>*
M\SV2?D^?.'*R[Q6'SI-\KUWH-M#OCMD_?']65%&=<5N5Y9Q$F4@1%C"5D5Z@
M$S',,Y[ &%.9H)BE <;S'V)-5Z:C_.6&;%[:=G/#O;M[N8=B;RA@W\CZR?*
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MS.:(<;6%R8N-KOJA6%5O\?,W6ZVP^'>Q^4P*/D\2RB7/U9PZXHK6. XA)6$
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MI7 -8)8!S2,<YS".,L7!(5$(J] (HB"C(4I(EB!IHS'H'>81% >5C3-0-30
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MH5B*<![GF/  !5 (O<*)>0A5-);"+,U$A$C($VZ4.MK9RM3HKC84-";.=C\
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MFT_R*_DY#T/*F:!J)H%)!)&@$M*0,YBQ).=Q$M.,62U!#&7HU&CFX ]X4IZ
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MM;_U!>J&7XHEX*O%@JQ+\*SBL%*C=/U$["1>GC[,.HE78D3*=JQ1OJ]"7J,
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MC#CYV4BL0V= *P]+#!W=PF:F31+ 8R)1!$?PMCZ#1*F8=%'JDD[+>NZL=A@
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M=6O:FQ0,>X"UT/?=N.]H"0]X/*V6Z]J.)5^D-1VSN/PZ3?CBVW0U"<9@\+Q
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MF+3EK:]A]A(R3.*\5Y4O6LM_A"#:RFA"9')GO0,1 ^TW(QD$;P*89$W01J:
MK1-6]Y R3"Y]2" =HX,10.EO.#W[3'2_^(K+<(:_7=1G8>_*G:876_9>35=I
MMEA=+#<6_GJ6MC,V8!V!KFLS6(HPP<? P))K)WRQDC6?==B&\L,LWH_RJF8
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MT3YC^E0JASW&GQV]_6EP!);X^JY]]6EQ3Z3><1IO<_H!2=2KZ1JW7>DWHOF
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M72,XHV_&?KD$#-Z0K\RZ9N+>5M]"01%:.:\L8\V+=4;T3+-O;3\8=C]%]"/
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M>RE=MAK;S &KW6UJ[T]96X_G+.K,\63 ,\?!E5QO'I((MG72\@GD#3NK9C2
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MX?-+3M;;.(W:G@:"1]BR^]H0GF;"'J.ME9.U:5*YVJ1'EQ=A=NV])QZ#*2R
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M]&))[NYM5@W''&4B!@TYN!X3^! E8";OVB#W2;1^_G\"N:-]'G@*)I]+?2-
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MF$/#XM/%^6))^Z5,9]<,6":RHL@/BI)D*85TX+(@PVE*4"PFJ_AAG87V?7W
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MD,QM%8N$P&26JG@C?(O-?H\2,-X[92/%SEM+>42HK$_=Q??)7Q\F1D3)G2A
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MQBTC*&XYG?62 ]?<(>-<I<$+#UOPT7]P<B#L]JH_. $&.K"#W9HEG(R"*V'
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M/BJM3HZ(#H*D#<\/;1"*JI!ATWF1:YV["G7.?BP"M'6A%*V9,JV]U$>)Z:0
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MTS/>;B66D',KE9200S76B!F<KA,HO"!W4QJK?.N^UQ?Q3+ 7% YX)MA'+QU
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M#(\V%2D*D^Z$N:FG2.VV+JL[].ZMV+/$[YOYY6+B$R*+00-Q4UM"*=(-5D5
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MW*!H_;*["UWC)K*&PEYSC72 LFUX_7[^/5S<#C@\"RZ5NF'+9'(7?41P1FE
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ME^"*273<Q>AT"$SG%I5!/WQTO$?2)HH_6'X=Q+_/WHF/78EOK]>\V6 B\U)
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MR G(+ER%$^O^G-'^[/*%ZX'8MSOX<\ DF#)06/%U]F@ ;W*&[+%PKH5'ULU
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M4TXSI]T@^=Y_/[D?>16>6/?GC/8[8>>;^6+]VQ/I,OG"R8$V=:J5S(:LW0I
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M&OU^]^*Q%AG@+-WXTP_Y?+Y8'34@J\V#V\;,K21P@HA:).68*K72P]03%YX
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MB@_@9IGC__D\__9O]>LN,5-_^X&5S6-Z\Y6/Q,(APNO AKS$LREMU+,I_K;
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M=?"0F2\\DA-H<ZYS"24)(PL)4EHON>?*I1;],O9KD30@$AJI[][V2/O(L@<
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M^[00O![!Z)0)-AD-/@E% C4,@G41;,F*:1553G8 [.X\./,).R8G1^W>"NW
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M<7L0G<"R#:>$X3M@;#ZH/P)Q\?_^/_\74$L#!!0    ( "M#858BJY^.&04
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M1.ML8B(?\EOP!=SNJ0662-D:FLUM0!#8_-B'?5+5.@+ZI&U@JC4OG!PN+HY
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M2P$"% ,4    "  K0V%6]6C=9+ 7   P& $ $0              @ $W9 0
M;7EG;BTR,#(R,3(S,2YX<V102P$"% ,4    "  K0V%6])F$0.XS  "5( (
M%0              @ $6? 0 ;7EG;BTR,#(R,3(S,5]C86PN>&UL4$L! A0#
M%     @ *T-A5I^T[$V(=   [#@% !4              ( !-[ $ &UY9VXM
M,C R,C$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( "M#85:*4NR#A9T! -_3 @ 4
M              "  ?(D!0!M>6=N+3(P,C(Q,C,Q7V<Q+FIP9U!+ 0(4 Q0
M   ( "M#859/B?Z#FFL! !WY#@ 5              "  :G"!@!M>6=N+3(P
M,C(Q,C,Q7VQA8BYX;6Q02P$"% ,4    "  K0V%6>#39RYO8  #@^0D %0
M            @ %V+@@ ;7EG;BTR,#(R,3(S,5]P<F4N>&UL4$L! A0#%
M  @ *T-A5B*KGXX9!0  ;$8  !8              ( !1 <) &UY9VXM,C R
M,C$R,S%E>#(Q,2YH=&U02P$"% ,4    "  K0V%6- E)WY,$  !<%   &
M            @ &1# D ;7EG;BTR,#(R,3(S,7AE>'@R,S$N:'1M4$L! A0#
M%     @ *T-A5@ 2HP'E!P  L"4  !@              ( !6A$) &UY9VXM
M,C R,C$R,S%X97AX,S$Q+FAT;5!+ 0(4 Q0    ( "M#85:OI8F2W@<  +$E
M   8              "  749"0!M>6=N+3(P,C(Q,C,Q>&5X>#,Q,BYH=&U0
M2P$"% ,4    "  K0V%6B\$.UJ4$  !O%   %P              @ &)(0D
M;7EG;BTR,#(R,3(S,7AE>'@S,BYH=&U02P4&      P #  G P  8R8)

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
